EANM26
WORLD LEADING MEETING



FINAL PROGRAMME

VIENNA

OCTOBER 17-21, 2026

eanm26.eanm.org

TABLE OF CONTENTS

WORDS OF WELCOME 4

GENERAL INFORMATION

Board & Scientific Programme Representatives 8
Session Coordinators 9
EANM'26 Reviewers 10
EANM'26 Chairpersons 14
EANM National Societies: Delegates / Deputies 16
UEMS/EBNM National Societies: Delegates / Deputies 18
UEMS/EBNM Committees 20
General Information 22
Floorplans 28
Programme Overview 31

SCIENTIFIC & TECHNOLOGISTS' PROGRAMME

Plenary Sessions 41
Continuing Medical Education – CME Sessions 42
Special Track 43
Joint Symposia 45
Special Symposia 46
EU Policy Symposia 46
Learn & Improve Professional Skills (LIPS) Track 47
Clinical Oncology Track 48
Theranostics Track 49
Cutting Edge Science Track 50
M2M–The 13th 'From Molecule to Man' Track 51
Further Oral Presentations & Case Report Sessions 52
e-Posters Presentations 54
Technologists' Track 56
Awards 58

ABSTRACTS

Oral Presentations 60
e-Poster Presentation Sessions 156
e-Posters 185

INDUSTRY EXHIBITION

Satellite Symposia 336
List of Exhibitors (A-Z) 347
List of Exhibitors (Booth number) 354
Exhibition Halls 360
Company Profiles 370

CORPORATE MEMBERS 466

USEFUL CONTACTS 468

IMPRINT 469

WORLD LEADING MEETING — EANM'26
OCTOBER 17–21, 2026
TABLE OF CONTENTS | FINAL PROGRAMME

WORDS OF WELCOME

by the Congress Chair



VALENTINA GARIBOTTO

EANM SCIENTIFIC EVENTS COUNCIL, CHAIR

Dear Colleagues,

It is a great pleasure to invite you to the 39th Annual Congress of the European Association of Nuclear Medicine (EANM'26), which will take place in Vienna on October 17–21, 2026.

At a time when nuclear medicine is evolving at an unprecedented pace, the EANM Annual Congress is increasingly established as key moment to pause, reflect, and collectively define the directions that will shape our field. Like in previous congress editions, EANM'26 is being designed not only to present the latest advances, but also to foster critical dialogue on how innovation, evidence, and collaboration can be translated into meaningful impact for patients and healthcare systems worldwide.

The scientific programme of the congress is developed under a renewed governance model. As Chair of the EANM Scientific Events Council Chair, I oversee the programme together with seven distinguished experts. This newly created EANM Council, launched in January 2026, reflects our commitment to diversity of expertise, openness of perspectives, and scientific excellence. The result is a programme that is both rigorous and forward-looking, shaped by collective intelligence rather than individual vision.

EANM'26 will highlight outstanding research across the full spectrum of nuclear medicine, from breakthrough developments in theranostics and radiopharmaceutical sciences to innovative imaging technologies, quantitative approaches, and clinical translation. As always, the strength of the congress lies in the quality of the science you bring — your research, your curiosity, and your willingness to challenge established paradigms.

Beyond scientific content, the congress aims to stimulate interaction across disciplines, professional backgrounds, and generations. Engaging and empowering younger colleagues remains a strategic priority, as they will drive the next transformations of our specialty. Creating spaces for dialogue, mentorship, and exchange is essential to ensure that progress remains sustainable and inclusive; and we will make sure to embrace this aspect again during our congress.

I truly look forward to welcoming you to Vienna, home of the EANM Executive Office and a city where scientific excellence meets rich artistic and cultural heritage. From architecture to music and philosophy, Vienna embodies the creativity, rigour, and innovation that thrive when disciplines intersect.

In this inspiring setting, I invite you to engage, exchange, and co-create the future of nuclear medicine with us!

Warm regards,

Valentina Garibotto
EANM Scientific Events Council, Chair

WORDS OF WELCOME

by the Chair of the Technologists Committee



LUÍSA ROLDÃO PEREIRA

EANM TECHNOLOGISTS COMMITTEE, CHAIR

Dear fellow Technologists,

It is both a privilege and a genuine pleasure to invite you to the EANM'26 Annual Congress in Vienna, Austria, on behalf of the EANM Technologists Committee.

In Vienna, tradition meets innovation, classical foundations harmonise with forward-thinking ideas. It is, perhaps, the perfect metaphor for Nuclear Medicine today. We are a discipline grounded in strong scientific principles, yet constantly evolving through technological advances, exciting Theranostics paths, stepping into artificial intelligence, and personalised care. At the centre of this evolution stand the patients we care for, but also multidisciplinary teams, of which you, the Nuclear Medicine Technologists, are such a significant part.

Each EANM Congress has its own character, but what never changes is the remarkable energy of our community. Passionate, interested, and ever curious - Technologists are the steady force behind safe, high-quality imaging and therapy. We are the frontline engine, problem-solvers, patient advocates, and increasingly, critical connectors.

At EANM'26, we will once again present a comprehensive and dynamic Technologists' Track, carefully designed to reflect the real priorities of our profession. As such, we will:

- Provide practical, applicable guidance that supports everyday clinical excellence around new working practices and flexible working; offer a focus on radiation protection, dosimetry, paediatrics; and launch our yearly Technologist Guide.

- Offer Mini Courses and sessions designed to sharpen skills and boost confidence in daily practice.

Collaboration continues to be omnipresent in our programme, which was built together with colleagues from other committees and partner societies, reflecting the true interdisciplinary nature of Nuclear Medicine.

As a Portuguese Technologist beginning my first year as Chair of the Technologists Committee, I feel a sense of meaning knowing that the street leading to our congress bears the name of Aristides de Sousa Mendes - a symbol of courage and principled leadership in difficult times. His legacy reminds us that leadership, in any field, is grounded in responsibility, integrity, and service to others - values that are fundamental to our roles.

May Vienna inspire us not only to connect and collaborate, but also to reflect more deeply on our own professional impact - on our patients, our teams, and the future of Nuclear Medicine - while taking time to experience the beauty and spirit of this remarkable city. Join us in Vienna: to learn, to lead, to collaborate, and to enjoy being part of this extraordinary community!

I very much look forward to welcoming you to EANM'26.

Luísa Roldão Pereira,
EANM Technologists Committee, Chair

BOARD & SCIENTIFIC PROGRAMME REPRESENTATIVES

EANM BOARD

President 2025-2026
Paola Anna Erba (Italy)

President Elect 2025-2026
Felix Mottaghy (Germany)

Internal Groups Officer 2025-2026
Val Lewington (United Kingdom)

Secretary/Treasurer 2026-2027
Pierre-Yves Salaun (France)

Scientific Liaison Officer 2025-2026
Michel Koole (Belgium)

SCIENTIFIC PROGRAMME REPRESENTATIVES

Scientific Events Council, Chair
Valentina Garibotto (Switzerland)

AI Committee
Dimitris Visvikis (France), Margarita Kirienko (Italy)

Bone & Joint Committee
Davina Mak (United Kingdom), Franceso Dondi (Italy)

Cardiovascular Committee
Olivier Lairez (France), Fabien Hyafil (France)

Dosimetry Committee
Emmanuel Deshayes (France), Johannes Tran-Gia (Germany)

Inflammation & Infection Committee
Domenico Albano (Italy), Olivier Gheysens (Belgium)

Neuroimaging Committee
Antoine Verger (France), Igor Yakushev (Germany)

Oncology & Theranostics Committee,
Wolfgang Fendler (Germany), Valentina Ambrosini (Italy)

Paediatrics Committee
Julian Rogasch (Germany), Pinar Kiratli (Türkiye)

Physics Committee
Laetitia Imbert (France), Ana Denis-Bacelar (United Kingdom)

Radiation Protection Committee
Uta Eberlein (Germany), Ioannis Iakovou (Greece)

Radiopharmaceutical Sciences Committee
Eleni Gourni (Switzerland), Verena Pichler (Austria)

Thyroid Committee
Alfredo Campennì (Italy), Michael Kreissl (Germany)

Translational Molecular Imaging & Therapy Committee
Peter Laverman (Netherlands), Tessa Buckle (Netherlands)

Technologist Committee
Luisa Roldao Pereira (United Kingdom),
Angelo Rafael Felgosa Cardoso (Switzerland)

SESSION COORDINATORS

SESSION COORDINATORS

EANM thanks all Session Coordinators for their huge engagement in organising the session details and speakers.

Daniela Oprea-Lager (Netherlands)
Matthias Brendel (Germany)
Olivier Gheysens (Belgium)
Johannes Tran-Gia (Germany)
Fabien Hyafil (France)
Valentina Ambrosini (Italy)
Peter Laverman (Netherlands)
Wolfgang Fendler (Germany)
Davina Mak (United Kingdom)
Petra Petranović Ovčariček (Croatia)
Elena Prieto (Italy)
Laszlo Papp (Austria)
Margarita Kirienko (Italy)
Julian Rogasch (Germany)
Floris van Velden (Netherlands)
Christophe Deroose (Belgium)
Samantha Terry (United Kingdom)
Matteo Bauckneht (Italy)
Samia Massalha (Israel)
Lucia Leccisotti (Italy)
Ayah Nawwar (United Kingdom)
Francesco Giammarile (Austria)
Michael Kreissl (Germany)
Donatienne Van Weehaeghe (Belgium)
Dimitris Visvikis (France)
Eleni Gourni (Switzerland)

Antoine Verger (France)
Federico Caobelli (Switzerland)
Alfredo Campennì (Italy)
Domenico Albano (Italy)
Karolien Goffin (Belgium)
Nelleke Tolboom (Netherlands)
Mattias Sandström (Sweden)
Uta Eberlein (Germany)
Ana Denis-Bacelar (France)
Thomas Wendler (Germany)
Kuangyu Shi (Switzerland)
Nathalie L. Albert (Germany)
Francesco Cicone (Italy)
Valentina Ambrosini (Italy)
Francesco Fraioli (Italy)
Eric Guedj (France)
Paola Anna Erba (Italy)
Olivier Lairez (France)
Marta Coelho (Portugal)
Luísa Roldão Pereira (United Kingdom)
Tania Oliveira Hackl (Austria)
Ângelo Cardoso (Switzerland)
Paolo Turco (Italy)
John Sunderland (United States of America)
Iva Hristova (Bulgaria)

EANM'26 REVIEWERS

Abgral, R. (France)
Acampa, W. (Italy)
Adam, J. (Netherlands)
Ahmadzadehfar, H. (Germany)
Akdemir, U. Ö. (Türkiye)
Albano, D. (Italy)
Albert, N. L. (Germany)
Aloj, L. (United Kingdom)
Altini, C. (Italy)
Ambrosini, V. (Italy)
Ametamey, S. (Switzerland)
Annunziata, S. (Italy)
Antunovic, L. (Italy)
Armstrong, I. (United Kingdom)
Atay Kapucu, L. Ö. (Türkiye)
Baldari, S. (Italy)
Balkay, L. (Hungary)
Ballinger, J. (Canada)
Balogova, S. (Slovakia)
Bar-Sever, Z. (Israel)
Barthel, H. (Germany)
Bauckneht, M. (Italy)
Beer, A. (Germany)
Beheshti, M. (Germany)
Ben-Haim, S. (Israel)
Bernhardt, P. (Sweden)
Berti, V. (Italy)
Biassoni, L. (United Kingdom)
Bilgin, B. E. (Türkiye)
Bogović Crnčić, T.
Booij, J. (Netherlands)
Botelho, M. F. R. (Portugal)
Bozkurt, M. F. (Türkiye)
Brendel, M. (Germany)
Brenner, W. (Germany)
Buchert, R. (Germany)
Buckle, T. (Netherlands)
Burroni, L. (Italy)
Buvat, I. (France)
Cai, W. (United States of America)
Carrilho Vaz, S. (Portugal)
Castell Conesa, J. (Spain)
Castellucci, P. (Italy)
Ceci, F. (Italy)
Chakravartty, R. (United Kingdom)
Cook, G. J.R. (United Kingdom)
Costa, G. M. L. M. (Portugal)
Cremonesi, M. (Italy)
Cuocolo, A. (Italy)
Dalm, S. (Netherlands)
Daou, D. (France)
De Geus-Oei, L.-F. (Netherlands)
de Keizer, B. (Netherlands)
De Palma, D. (Italy)
de Swart, J. (Netherlands)
de Vries, E. F.J. (Netherlands)
Deandreis, D. (Italy)
Delgado-Bolton, R. C. (Spain)
Denis-Bacelar, A. M. (United Kingdom)
Deuther-Conrad, W. (Germany)
Dickson, J. (United Kingdom)
Dierickx, L. O. (France)
Drzezga, A. (Germany)
Eberlein, U. (Germany)
Ertay, T. (Türkiye)
Etchebehere, E. (Brazil)
Evangelista, L. (Italy)
Everaert, H. (Belgium)
Farolfi, A. (Italy)
Farsad, M. (Italy)
Fernández Léon, A. (Spain)
Ferrari, C. (Italy)
Flamen, P. (Belgium)
Flotats Giralt, A. (Spain)
Fragoso-Costa, P. (Germany)
Fraioli, F. (United Kingdom)
Franceschi, M. (Croatia)
Franzius, C. (Germany)
Gaberšček, S. (Slovenia)
Gabriel, M. (Austria)
Gallowitsch, H.-J. (Austria)
Georgoulias, P. (Greece)
Gheysens, O. (Belgium)
Giammarile, F. (France)
Gimelli, A. (Italy)
Glatting, G. (Germany)
Glaudemans, A. (Netherlands)
Gnanasegaran, G. (United Kingdom)
Goffin, K. (Belgium)
Gourni, E. (Switzerland)
Grana, C. M. (Italy)
Gratz, S. (Germany)
Groheux, D. (France)
Grötzinger, C. (Germany)
Guedj, E. (France)
Guillet, B. (France)
Haberkorn, U. (Germany)
Halldin, C. (Sweden)
Hartman, N. (United Kingdom)
Hatt, M. (France)
Herrmann, K. (Germany)
Heskamp, S. (Netherlands)
Hess, S. (Denmark)
Hesse, S. (Germany)
Hindorf, C. (Sweden)
Hofman, M. (Australia)
Holm, S. (Denmark)
Howell, R. (United States of America)
Hyafil, F. (France)
Iakovou, I. (Greece)
Jamar, F. (Belgium)
Jehanno, N. (France)
Kampen, W. U. (Germany)
Kirac, S. (Türkiye)
Kirienko, M. (Italy)
Kiss, O. (Germany)
Kobe, C. (Germany)
Konijnenberg, M. W. (Netherlands)
Koranda, P. (Czech Republic)
Kostkiewicz, M. (Poland)
Koutsikos, J. (Greece)
Kráčmerova, T. (Czech Republic)
Kraeber-Bodéré, F. (France)
Krämer, S. (Switzerland)
Kreissl, M. (Germany)
Kresnik, E. (Austria)
Kunikowska, J. (Poland)
Kurth, J. (Germany)
Lairez, O. (France)
Langsteger, W. (Austria)
Lassmann, M. (Germany)
Lavelli, V. (Italy)
Laverman, P. (Netherlands)
Leccisotti, L. (Italy)
Lodi, F. (Italy)
Lubberink, M. (Sweden)
Lugato, B. (Austria)
Mada, M. (United Kingdom)
Maes, A. (Belgium)
Maffioli, L. (Italy)
Maina-Nock, T. (Greece)
Maldonado, A. (Spain)
Manevska, N. (North Macedonia)
Manrique, A. (France)
Mapelli, P. (Italy)
Marafi, F. (Kuwait)
Marengo, M. (Italy)
Marie, P.-Y. (France)
Mihailovic, J. (Serbia)
Mikolajczak, R. (Poland)
Milan, E. (Italy)
Mindt, T. L. (Austria)
Minguez Gabiña, P. (Spain)
Mitjavila Casanovas, M. (Spain)
Monteiro, M. (Switzerland)
Morbelli, S. (Italy)
Morigi, J. J. (Australia)
Mu, L. (Switzerland)
Mudun, A. (Türkiye)
Någren, K. A. (Denmark)
Nekolla, S. (Germany)
Niculae, D. (Romania)
Nock, B. A. (Greece)
Nonnekens, J. (Netherlands)
Noriega Alvarez, E. (Spain)
Ocak, E. M. (Türkiye)
Oebro Fosbøl, M. (Denmark)
Oprea-Lager, D.-E. (Netherlands)

EANM'26 REVIEWERS

Orlhac, F. (France)
Orlova, A. (Sweden)
Ozcan, Z. (Türkiye)
Ozgen Kiratli, P. (Türkiye)
Palmedo, H. (Germany)
Panagiotidis, E. (Greece)
Papathanasiou, N. (Greece)
Pappata, S. (Italy)
Pascual, T. (Austria)
Paycha, F. (France)
Payoux, P. (France)
Petranović Ovčariček, P. (Croatia)
Piciu, D. (Romania)
Poeppel, T. (Germany)
Rabiner, I. (United Kingdom)
Rajkovaca, Z. (Bosnia and Herzegovina)
Rausch, I. (Austria)
Redondo, F. (Chile)
Rodríguez-Fraile, M. (Spain)
Roelants, V. (Belgium)
Rogasch, J. (Germany)
Rominger, A. (Switzerland)
Rossetti, C. (Italy)
Rouzet, F. (France)
Santos, A. I. (Portugal)
Sattler, B. (Germany)
Schäfer, N. (Switzerland)
Schmidt, M. (Germany)
Schottelius, M. (Switzerland)
Sciagrà, R. (Italy)
Seimbille, Y. (Netherlands)
Semah, F. (France)
Sestini, S. (Italy)
Shagera, Q. (Belgium)
Shi, K. (Switzerland)
Siclari, G. (Italy)
Slart, R. (Netherlands)
Smith, G. (United Kingdom)
Sollini, M. (Italy)
Stevens, H. (Netherlands)
Stokke, C. (Norway)
Stokkel, M. (Netherlands)
Strigari, L. (Italy)
Sunderland, J. (United States of America)
Svegborn, S. (Sweden)
Terry, S. (United Kingdom)
Terwinghe, C. (Belgium)
Testanera, G. (United Kingdom)
Todde, S. (Italy)
Tolboom, N. (Netherlands)
Tolmachev, V. (Sweden)
Tran-Gia, J. (Germany)
Treglia, G. (Switzerland)
Tuncel, M. (Türkiye)
Turco, P. (Italy)
Türkmen, C. (Türkiye)
Vaccaro, I. (Italy)
Van der Bruggen, W. (Netherlands)
van Dongen, G. (Netherlands)
van Essen, M. (Sweden)
van Lith, S. (Netherlands)
van Velden, F. H. P. (Netherlands)
Vanhove, C. (Belgium)
Varmenot, N. (France)
Verberne, H. J. (Netherlands)
Verburg, F. (Germany)
Verger, A. (France)
Vidal Sicart, S. (Spain)
Vlajkovic, M. (Serbia)
Vrachimis, A. (Cyprus)
Vriens, D. (Netherlands)
Walz, J. (France)
Weber, W. (Germany)
Weiler-Sagie, M. (Israel)
Windhorst, A. D. (Netherlands)
Yakushev, I. (Germany)
Zerizer, I. (United Kingdom)
Zhang-Yin, J. (France)
Ziegler, S. I. (Germany)



MEET THE EXPERT - JOIN US AT OUR BOOTH

^{225}Ac Production via Medium-Energy Cyclotrons: Actineer's Path Towards Increasing Production Capacities

Dr. Neil Quigley
Senior Global Product Manager

Monday, October 19th
10:30 - 10:50, CET
ITM Booth, Hall X4, #415

This presentation will cover the technological and operational developments that Actineer, a joint venture between ITM & CNL, has made to support sustainable ^{225}Ac manufacturing. Quantitative ^{225}Ac production & ^{226}Ra management will be discussed, highlighting the Actineer production cycle and how it was designed to offer greater supply-chain security and facilitate ^{225}Ac manufacturing scaling.

itm-radiopharma.com

itm PASSION FOR PRECISION

M-GL-ITM-0049

EANM'26 CHAIRPERSONS

(AS PER SEPTEMBER 18, 2026)

Aguiar, P. (Spain)
Albano, D. (Italy)
Albert, N. (Germany)
Antunovic, L. (Italy)
Bailly, C. (France)
Bajuk Studen, K. (Slovenia)
Bauckneht, M. (Italy)
Behe, M. (Switzerland)
Boellaard, R. (Netherlands)
Boreel, D. (Netherlands)
Brendel, M. (Germany)
Bridoux, J. (Belgium)
Brink, A. (Austria)
Brosch-Lenz, J. (Germany)
Bucerius, J. (Austria)
Bundschuh, R. (Germany)
Burger, I. (Switzerland)
Campenni, A. (Italy)
Caobelli, F. (Switzerland)
Cardoso, A. (Switzarland)
Castellucci, P. (Italy)
Cavinato, L. (Italy)
Chiti, A. (Italy)
Cicone, F. (Italy)
Cleeren, F. (Belgium)
Collarino, A. (Italy)
Constantino, C. (Portugal)
Cornelissen, B. (Netherlands)
Costa, P. (Portugal)
Dalm, S. (Netherlands)
Danieli, R. (Belgium)
de Blois, E. (Netherlands)
de Geus-Oei, L. (Netherlands)
De Keizer, B. (Netherlands)
Denis-Bacelar, A. (United Kingdom)
Deroose, C. (Belgium)
Dickson, J. (United Kingdom)
Eberlein, U. (Germany)
Eder, M. (Germany)
Eilsberger, F. (Germany)
Elsinga, P. (Netherlands)
Elvas, F. (Belgium)
Emmett, L. (Australia)
Erba, P.A. (Italy)
Evangelista, L. (Italy)
Evangelista, L. (Italy)
Farolfi, A. (Italy)
Fendler, W. (Germany)
Fenwick, A. (United Kingdom)
Fiz, F. (Italy)
Fraiolii, F. (United Kingdom)
Garibotto, V. (Switzerland)
Garrigue, P. (France)
Geist, B. (Austria)
Georgoulias, P. (Greece)
Gheysens, O. (Belgium)
Giammarile, F. (Austria)
Gillings, N. (Denmark)
Goffin, K. (Belgium)
Gormsen, L. (Denmark)
Gotthardt, M. (Netherlands)
Gourni, E. (Switzerland)
Grozdic Milojevic, I. (Serbia)
Guglielmo, P. (Italy)
Hatt, M. (France)
Hautzel, H. (Germany)
Hendrikse, H. (Netherlands)
Heskamp, S. (Netherlands)
Hess, S. (Denmark)
Hoberueck, S. (Germany)
Hyafil, F. (France)
Imbert, L. (France)
Kaiser, L. (Germany)
Keinänen, A. (Finland)
Kersting, D. (Germany)
Kiratli, P. (Türkiye)
Kirienko, M. (Italy)
Kiß, O. (Germany)
Koehner, M. (Germany)
Koole, M. (Belgium)
Kopka, K. (Germany)
Kraeber-Bodéré, F. (France)
Kreissl, M. (Germany)
Kunikowska, J. (Poland)
Küper, A. (Germany)
Kurth, J. (Germany)
Lam, M. (Netherlands)
Liberini, V. (Italy)
Maccora, D. (Italy)
Manrique, A. (France)
Marner, L. (Denmark)
Martins, A. (Portugal)
Massalha, S. (Israel)
Maurer, A. (Germany)
Mautone, V. (Italy)
Mendes, F. (Portugal)
Mikail, N. (Switzerland)
Mileva, M. (Belgium)
Mingels, C. (Switzerland)
Morbelli, S. (Italy)
Morgat, C. (France)
Nawwar, A. (United Kingdom)
Neglia, D. (Italy)
Niculae, D. (Romania)
Nikolopoulou, A. (United States)
Nonnekens, J. (Netherlands)
Noordzij, W. (Netherlands)
Noriega-Álvarez, E. (Spain)
Oliveira Hackl, T. (Austria)
Orlova, A. (Sweden)
Oyen, W. (Italy)
Papp, L. (Austria)
Petranovic Ovcaricek, P. (Croatia)
Philippe, C. (Austria)
Piccardo, A. (Italy)
Pichler, V. (Austria)
Portillo, M. (Argentina)
Poty, S. (France)
Prakash, V. (United Kingdom)
Preusser, M. (Austria)
Preusser, M. (Austria)
Prieto, E. (Spain)
Prieto Azcárate, E. (Spain)
Rasul, S. (Austria)
Ripa, R. (Denmark)
Rodríguez- Alfonso, B. (Spain)
Rogasch, J. (Germany)
Roldão Pereira, L. (United Kingdom)
Sachpekidis, C. (Germany)
Sandhu, S. (Australia)
Sandström, M. (Sweden)
Santoro, L. (France)
Sarnelli, A. (Italy)
Sattler, B. (Germany)
Schottelius, M. (Switzerland)
Seifert, S. (Germany)
Seimbille, Y. (Netherlands)
Shi, K. (Switzerland)
Slart, R. (Netherlands)
Sollini, M. (Italy)
Spreckelmeyer, S. (Germany)
Stokke, C. (Norway)
Strigari, L. (Italy)
Tavares, A. (United Kingdom)
Terry, S. (United Kingdom)
Tolboom, N. (Netherlands)
Treglia, G. (Switzerland)
Tuncel, M. (Türkiye)
Turco, P. (Italy)
Ulaner, G. (United States)
Valente, S. (Portugal)
Vallis, K. (United Kingdom)
van Velden, F. (Netherlands)
Van Weehaeghe, D. (Belgium)
Varrone, A. (Sweden)
Vaz, S. (Portugal)
Velikyan, I. (Sweden)
Verger, A. (France)
Vergnaud, L. (France)
Visvikis, D. (France)
Voltin, C. (Germany)
Vrachmis, A. (Cyprus)
Vriens, D. (Netherlands)
Vugts, D. (Netherlands)
Walz, J. (France)
Wendler, T. (Germany)
Windhorst, A. (Netherlands)
Yakushev, I. (Germany)
Ziegler, S. (Germany)
Zoubenko, E. (Israel)
Zucchetta, P. (Italy)

EANM NATIONAL SOCIETIES:
DELEGATES / DEPUTIES

SOCIETY	DELEGATE	DEPUTY
Armenian Society of Nuclear Medicine	V. Barsegian	M. Artashesyan
Austrian Society of Nuclear Medicine and Theranostics	T. Traub-Weidinger	C. Uprimny
Azerbaijan Society of Nuclear Medicine	F. Novruzov	A. Aliyev
Belgian Society of Nuclear Medicine	S. van Hecke	A. Deleu
Bosnian Society of Nuclear Medicine	A. Šadija	S. Zarac Bobic
British Nuclear Medicine Society	S. Dizdarevic	S. Redman
Bulgarian Society of Nuclear Medicine	V. Hadzhiyska	Z. Dancheva
Croatian Society of Nuclear Medicine	A. Barić Žižic	A. Golubic
Cyprus Society of Nuclear Medicine	D. Kyprianou	O. Demetriadou
Czech Society of Nuclear Medicine	M. Simanek	P. Koranda
Danish Society of Clinical Physiology and Nuclear Medicine	P. Hovind	M. Reichkendler
Estonian Nuclear Medicine Society	I. Muoni	T. Karner
Finnish Society of Nuclear Medicine	K. Timonen	J. Schlidt
French Society of Nuclear Medicine	F. Courbon	F. Cachin
Georgian Nuclear Medicine Specialists Association	N.Shengelia de Lange	K. Shamatava
German Society of Nuclear Medicine	M.Luster	M. Schäfers
Hellenic Society of Nuclear Medicine and Molecular Imaging	S. Chatziioannou	V. Valotassiou
George de Hevesy Hungarian Society of Nuclear Medicine	T. Györke	G. Trencsenyi
Icelandic Society of Nuclear Medicine	to be nominated	to be nominated
Irish Nuclear Medicine Association	R. Killeen	K. O'Regan
Israeli Society of Nuclear Medicine	Z. Bar-Sever	Z. Keidar
Italian Society of Nuclear Medicine Molecular Imaging and Therapy	A. Campennì	S. Nuvoli
Latvian Society of Nuclear Medicine	M. Kalnina	J. Kedrova
Lithuanian Society of Nuclear Medicine	S. Šedienė	N. Jurkienė
Luxembourg Society of Nuclear Medicine	J. Zhang-Yin	C. Als
Maltese Association of Radiologists and Nuclear Medicine Physicians	M. Aquilina	A.Mallia
Dutch Society of Nuclear Medicine	S. Jap-A-Joe	S. Veldhuijzen van Zanten
Macedonian Society of Nuclear Medicine	V. Majstorov	N. Manevska
Norwegian Society of Nuclear Medicine and Molecular Imaging	O.H. Kvernenes	T.C.H. Adamsen
Polish Society of Nuclear Medicine	A. Mazurek	I. Wenzel-Duszyńska
Sociedade Portugesa de Medicina Nuclear	I. Patrocínio Carvalho	P. Gouveia
Romanian Society of Nuclear Medicine and Molecular Imaging	M. Gherghe	C.R. Stolniceanu
Serbian Nuclear Medicine Society	M. Radulovic	I. Grozdic Milojevic
Slovak Society of Nuclear Medicine and Radiation Hygiene	L. Kaliska	E. Takascova
Slovenian Society of Nuclear Medicine	L. Ležaić	M. Glogovsek
Spanish Society of Nuclear Medicine and Molecular Imaging	J.R. García Garzón	M. J. Garcia-Velloso
Swedish Society of Nuclear Medicine	S. Strandberg	E. Trägårdh
Swiss Society of Nuclear Medicine	F. Forrer	M. Wissmeyer
Turkish Society of Nuclear Medicine	L.Ö. Atay	C. Soydal
Ukrainian Society of Nuclear Medicine	Y. Kmetyuk	V. Danylenko

UEMS/EBNM NATIONAL SOCIETIES: DELEGATES / DEPUTIES

COUNTRY	DELEGATE	DEPUTY
AUSTRIA	Rainer Lipp	Siroos Mirzaei
BELGIUM	Stijn Van Hecke	Anna-Leen Deleu
BULGARIA	Elena Piperkova	Antonia Dencheva Tzonevska
CROATIA	Drazen Huic	Sanja Kusačić Kuna
CYPRUS	Rena K. Demetriadou	
CZECH REPUBLIC	Pavel Koranda	Milan Šimánek
DENMARK	Julie Bjerglund Andersen	Tatiana Kristensen
ESTONIA	Eve Kelk	Anne Poksi
FINLAND	Kirsi Timonen	Jukka Kemppainen
FRANCE	Eric Gremillet	Jean-Louis Pelletier
GERMANY	Winfried Brenner	Martin Gotthardt
GREECE	Sophia Koukouraki	Ioannis Iakovou
HUNGARY	Laszlo Pavics	Istvan Szilvasi
ITALY	Giuseppe Rubini	Desirè Deandreis
LATVIA	Marika Kalnina	Jelena Kedrova
LITHUANIA	Donatas Vajauskas	Nemira Jurkienė
LUXEMBOURG	Patrick Paulus	Christian Picard
MALTA	Mark Anthony Aquilina	Andrew Mallia

COUNTRY	DELEGATE	DEPUTY
THE NETHERLANDS	Lenka Pereira Arias Bouda	Wim J. G. Oyen
NORWAY	Tom Christian Holm Adamsen	Rune Sundset
POLAND	Miroslaw Dziuk	Bozena Birkenfeld
PORTUGAL	Antonio Luis Ferreira dos Santos	Rudolfo Pinto da Silva
ROMANIA	Gabriel Andries	Raluca Mititelu
SERBIA	Vera Artiko	Jasna Mihailovic
SLOVAKIA	Andrej Vondrak	Lucia Kaliska
SLOVENIA	Luka Lezaic	Damjana Hrastnik
SPAIN	Gomez Caminero	Pena Viloria
SWEDEN	Jesus Lopez Urdaneta	Kristian Valind
SWITZERLAND	Ariane Boubaker	John Prior
TÜRKIYE	Gulay Altun	Zehra Ozcan
UNITED KINGDOM	Humayun Bashir	Yong Du

Nominated by UEMS Observer Countries

ISRAEL	Adam Steinmetz	Michael Reuben Quastel
JORDAN	Akram Al-Ibraheem	
TUNISIA	Aymen Bettaieb	

UEMS/EBNM COMMITTEES

EXECUTIVE COMMITTEE

President	J. Prior (Switzerland)
Secretary & Treasurer	R. Hustinx (Belgium)
Member	A. Boubaker (Switzerland)

AUDITOR(S)

	R. W. Lipp (Austria)

FELLOWSHIP EXAMINATION COMMITTEE - FEBNM

Chair	I. Kulakiene (Lithuania)
Members	J. Ramón García Garzón (Spain)
	H. Bashir (United Kingdom)
	A.T. Golubic (Croatia)
	M.F. Bozkurt (Türkiye)
	A. Boubaker (Switzerland)

UEMS/EBNM EDUCATION AND SYLLABUS COMMITTEE - ESC

Chair	H. B. Sayman (Türkiye)
Members	J. Darcourt (France)
	T.V. Bogsrud (Norway)
	D. Huic (Croatia)
	M. Mitjavila Casaonova (Spain)
	P. Castellucci (Italy)

UEMS/EBNM CME ACCREDITATION COMMITTEE - CME

Chair	M. Farsad (Italy)
Members	E. Lopci (Italy)
	A. Haug (Austria)
	S. Sillanmäki (Finland)

UEMS/EBNM ACCREDITATION COMMITTEE - AC

Chair	R. Mititelu (Romania)
Committee Members	J. Prior (Switzerland)
	A. García-Burillo (Spain)
	N. Mutlukoca (Norway)
	P. van Boxem (Belgium)
	M.L. Hall (United Kingdom)
	S. Mirzaei (Austria - Ex Officio)
	M. Bajic (Sweden- Ex Officio)
Corresponding Members:	F. Giesel (Germany)
	A. Jiménez Heffernan (Spain)
	I.E. Sippo-Tujunen (Finland)
	N.G. Hartman (United Kingdom)
	S.E. Bouyoucef (Algeria)
	A. Ciarmiello (Italy)
	L. Torres (Cuba)
	I. Iakovou (Greece)
	S.R. Zakavi (Iran)

EUAffairs
by the European Association of Nuclear Medicine

EU Affairs at EANM'26

→ Dedicated booth in the EANM Village

→ 2 Policy Symposia

→ EU Track showcasing ongoing projects

→ EU-funded projects

eanm.org/eu



Find more details:

GENERAL INFORMATION

AUDIO & VIDEO RECORDINGS

Audio and/or video recordings during the congress are strictly prohibited and must not be made without prior written permission from the EANM Executive Office.

CERTIFICATE OF ATTENDANCE

Your certificate of attendance will be available in your myEANM-Area after the congress. Please be aware that you will need to fill out a congress evaluation form.

CLOSING SESSION & FAREWELL COCKTAIL

All registered participants and accompanying persons are cordially invited to the Closing Ceremony and Farewell Cocktail, which will take place on Wednesday, October 21, 2026, from 11:25 to 12:15.

The Closing Ceremony will be held at the Hall A of the Austria Center Vienna (ACV), and the subsequent Farewell Cocktail in Foyers of Level 2 (red level).

Austria Center Vienna (ACV)
Bruno-Kreisky-Platz 1
1220 Vienna, Austria
www.acv.at/en/

CME CREDITS AND CERTIFICATES

The EANM'26 – 39th Annual Congress of the European Association of Nuclear Medicine, Vienna, Austria 17/10/2026 – 21/10/2026, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 25.5 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

The CME Sessions during EANM'26 – 39th Annual Congress of the European Association of Nuclear Medicine, Vienna, Austria 18/10/2025 – 21/10/2025, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 26.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

To acquire CME credits, attendees must scan their congress badge upon first arrival at the congress venue and upon entering each CME session. For CME sessions, an evaluation form for each session attended and the overall congress evaluation must be completed.

CME Sessions will be streamed live and are also available on-demand after the congress until December 23, 2026 (23:59 CEST).

To obtain your CME certificate(s), please visit your myEANM area. In the section EANM'26 > Certificates, the certificate(s) will be available within 24 hours after you have scanned your congress badge and completed the evaluations.

CONGRESS APP

Enhance your congress experience with the EANM'26 Congress App! Access all the essential information right at your fingertips, ranging from the comprehensive Scientific Programme to the Exhibitors' List, the Venue Maps, and much more.

Personalise your congress schedule effortlessly and evaluate sessions conveniently on your smart device, ensuring a smooth process to receive your CME credits.

The Congress App will be available for download from all common platforms two weeks before the start of the EANM'26.

CONGRESS e-POSTER AREA

Explore all the e-Posters uploaded for the EANM'26 in the e-Poster Area. You can easily find specific posters by searching for the author's name, topics, or keywords. The onsite e-Poster Area is located in the Gallery on Level 1. The e-Posters can also be accessed online via the virtual congress platform, with online access remaining open until December 21, 2026 (23:59 CET).

CONGRESS LANGUAGE

The congress language is English. Please note that simultaneous translation will not be provided.

CONGRESS OFFICE

The congress office at the Austria Center Vienna (ACV) will be open during the following days and times:

Saturday, October 17, 2026:	07:30 - 18:00
Sunday, October 18, 2026:	07:30 - 18:00
Monday, October 19, 2026:	07:30 - 18:00
Tuesday, October 20, 2026:	07:30 - 18:00
Wednesday, October 21, 2026:	07:30 - 12:00

CONGRESS SELF CHECK-IN

To ensure a swift badge collection without long queues, please come prepared with your QR code and a valid photo ID to our self-check-in stations, located in the EANM Registration Area (Entrance Hall).

CONGRESS VENUE

The EANM'26 will take place in the ACV – Austria Center Vienna.

Austria Center Vienna (ACV)
Bruno-Kreisky-Platz 1
1220 Vienna, Austria
www.acv.at/en/

The ACV is within 2 minutes walking distance from the metro station Kaisermühlen VIC, right behind the Vienna International Center and the United Nation's headquarters. The Metro U1 (red line) is the only one connecting the city centre with the ACV.

DATES & DEADLINES

October 6, 2026:	Advanced Registration Deadline (from October 7, on-site registration fee)
October 17, 2026:	Opening Ceremony and Welcome Reception
October 21, 2026:	Closing Ceremony and Farewell Cocktail

EANM EXECUTIVE OFFICE

Should you have any questions or requests ahead of EANM'26, feel free to reach out to the EANM Executive Office!

EANM Executive Office
Schmalzhofgasse 26
1060 Vienna, Austria
Phone: +43 1 890 44 27
Fax: +43 1 890 44 27-9
office@eanm.org
www.eanm.org

EANM MEMBERS' ASSEMBLY

The EANM Members' Assembly will be held on Saturday, October 17, 2026, from 12:00–13:30 (Hall F2, Level 0).

Please note: Only EANM members in good standing - with settled 2026 membership dues - are eligible to attend.

EXPERTS TRAINING LAB

Are you interested in Nuclear Cardiology? Don't miss this unique opportunity to join the EANM and ASNC (American Society of Nuclear Cardiology) Experts Training Lab and deepen your knowledge of PET Myocardial Perfusion Imaging!

Following the success of last years' Training Labs, the programme is back as a fixed point on the agenda. This year, participants can choose between two introductory sessions, offering an introduction to PET Myocardial Perfusion Imaging, and a dedicated advanced session designed for those looking to further expand their knowledge and expertise.

Session times:

Sunday, October 18, 2026:	13:15–14:45
Monday, October 19, 2026:	13:15–14:45
Tuesday, October 20, 2026:	13:15–14:45

Location:
Level 1, Room 1.14

Registration Details:
- Free of charge for all congress participants
- Seating will be available on a first-come, firstserved basis until the room is full
- No online registration is necessary, just join us in person!
- Save the date and do not miss out on this exclusive learning opportunity!

EANM TV

Whether you're attending EANM'26 in person or online, join TV speaker Roy Sheppard and expert guests for two live EANM TV shows each day at 08:00 and 17:30, featuring the latest developments in nuclear medicine.

The YouTube link will be shared via our communication channels shortly before the congress. Stay tuned!

EANM VILLAGE

Come by the EANM Village to discover what's happening across EANM and meet the team behind it!

Explore the different booths, each showcasing a key area of EANM's work, from education, publications and accreditation to EU affairs and community initiatives.

And don't forget to grab your EANM'26 Miniguide! Collect stamps as you explore each Village booth and attend one of the two EU Symposia. Once your EANM Village Pass is completed, bring it to the EANM Get Involved! Booth to receive a prize.

Entrance Hall | Open daily throughout the congress.

FOOD AND BEVERAGE

We are pleased to offer a variety of food and beverage outlets conveniently located throughout the congress venue. Please note, only cashless payment is accepted.

VIENNA INFORMATION DESK

The Vienna Information Desk in the registration area at Level 0 of the ACV will be opened as follows:

Saturday, October 17, 2026:	11:00 - 17:00
Sunday, October 18, 2026:	10:00 - 16:00
Monday, October 19, 2026:	10:00 - 16:00

INSURANCE AND LIABILITY

The EANM Executive Office, the congress organisers, and the venue will not accept liability for any personal injury, loss or damage to property incurred during the EANM'26. You are strongly encouraged to arrange your own travel and health insurance.

INTERNET CORNER

Internet access and limited printing facilities will be provided at dedicated stations located in the Gallery on Level 1.

LIVE STREAM

All ticket holders for the online access will automatically get access to the online content. Onsite congress ticket holders (except Day Ticket holders, Exhibitors and Accompanying Persons) will also be granted full online access. The following sessions will be live-streamed and will also be available on-demand until December 21, 2026: Opening Ceremony, incl. all 14 CME Sessions (incl. CME credits collection), all 7 CTE Sessions, and the Closing Ceremony. All live streamed Satellite Symposia will also be included (approx. 8 symposia).

The credits for the CME sessions can be collected on-demand (for online and onsite participants).

LOST AND FOUND

A lost and found service will be provided at the EANM Registration Desk for the duration of the congress.

MEDIA

Please note that photographs and video recordings will be taken during EANM'26. By registering for and attending the event, you agree that EANM may photograph or record you and use these recordings for documentation, communication, and promotional purposes, in any media format, including its websites, social media, newsletters, and printed materials, without further approval or payment.

If you do not wish to be photographed or filmed, please contact the EANM Executive Office in advance at communications@eanm.org. Requests for removal will be assessed and implemented where technically and reasonably feasible. Images used in printed materials cannot be withdrawn. Please note that unless you explicitly state otherwise via e-mail, EANM will assume you accept our photo and video policy.

MEDICAL FACILITIES

Medical assistance and ambulance service will be available throughout the congress.

MOBILE PHONES

Out of respect for other participants, you are requested to refrain from making phone calls in a lecture room. Your mobile device should always be on silent mode when you are in the congress centre.

NAME BADGES

Badges for the congress will be issued on-site between October 17 and October 21, 2026. The badges must be collected in person. A confirmation e-mail, including a QR code, will be issued upon successful completion of registration. With this QR, along with a valid photo ID, the name badge can be printed onsite in the registration area.

OPENING CEREMONY & WELCOME RECEPTION

All registered participants and accompanying persons are cordially invited to the Opening Ceremony and the Welcome Reception, which will be held on Saturday, October 17, 2026, from 18:00-21:45.

The Opening Ceremony will be held at the Hall A of the ACV – Austria Center Vienna and the subsequent Welcome Reception will be in the Foyers on Level 2 (red level).

Austria Center Vienna (ACV)
Bruno-Kreisky-Platz 1
1220 Vienna, Austria

PARKING

Private vehicles can be parked in the Austria Center Vienna parking facilities for an additional fee: €19.40 for one day, €32.80 for two days, €45.80 for three days, or €58.80 for a weekly card. Further information is available on the ACV website.

REGISTRATION DESK

The Registration Desk at the entrance level of the ACV will be open:

Saturday, October 17, 2026:	07:30-21:45
Sunday, October 18, 2026:	07:30-18:00
Monday, October 19, 2026:	07:30-18:00
Tuesday, October 20, 2026:	07:30-18:00
Wednesday, October 21, 2026:	07:30-12:00

REVIEW CENTRE

The Review Centre offers participants the opportunity to view PowerPoint presentations from sessions already held during the EANM'26 Congress, allowing those who missed a session to review the corresponding slides afterwards. The Review Centre is located in the Gallery on Level 1.

SOCIAL MEDIA & NEWSLETTERS

Follow our social media channels and subscribe to the EANM Congress Newsletters to get regular and exclusive updates about EANM'26!

Bluesky	@eanm.org
Facebook	@officialEANM
Flickr	@officialEANM
Instagram	@eanm_nucmed
LinkedIn	@officialEANM
X	@EANM_NucMed
YouTube	@officialEANM

You can subscribe to the EANM Congress Newsletter here: www.eanm.org/publicpress/newsletter/.

VISA

All foreign visitors entering Austria must hold a valid passport. For EU citizens, a valid photo ID is sufficient.

Please check the current visa requirements with the nearest Austrian consulate/embassy in your country before travelling to Austria. Registered congress participants may request a visa confirmation letter through myEANM-Area. Please note that visa invitation letters are issued in accordance with applicable legal requirements.

WI-FI

Complimentary WiFi will be available throughout the congress venue at EANM'26.

Login credentials:
Network: EANM
Password: eanm2026

YOUNG PROFESSIONALS LOUNGE

The EANM Young Professionals Lounge (YPL) welcomes congress participants up to 38 years of age. It's a dedicated space for students and early-career attendees to enjoy a quiet area to relax, work, and network during the EANM Annual Congress.

Open daily, Level 1, Hall L1+L2

LEVEL 2

Lecture Halls


Hall A	Opening Ceremony, CME Sessions, Plenary Sessions, Closing Session
Hall B	Cutting Edge Science Track
Hall C	Clinical Oncology Track

Foyer A B C

Welcome Reception Area

Foyer A B C

Delegates Catering Area, Farewell Drink



LEVEL 0

Entrance Hall

Registration, Self Check-In, **EANM Village,** Meeting Point

Cloakroom

0.14–0.16

Lecture Halls

Hall E1	Learn & Improve Professionals Skills (LIPS) Track
Hall E2	M2M Track
Hall F1	TROP / Featured Sessions
Hall F2	TROP / Featured Sessions, Joint Symposia

EU Affairs Track

0.11–0.12

Speaker Preview Room

0.94–0.95

Meeting Rooms

0.42, 0.45, 0.96–0.97

EANM Congress Office

Suite F

Industry Hospitality Suite


0.90

Exhibition Halls

X4, X5

Catering

MOTTO Cafe



LEVEL 1

Gallery

Societies Village

Foyer L1

e-Poster Area, Internet Corner, Review Centre

Hall L1 + L2

Young Professionals Lounge

Hands-on Workshop


Raum 1.14

EANM Committee & Council Meetings

1.15 - 1.96

Meeting Room

1.34



LEVEL –2

EANM Arena

Hall D	Special Track (Debates, Challenge the Experts, Round Table, Joint Symposia)

Lecture Halls

Hall G1	Theranostics Track, EU Policy Symposia, Special Symposia
Hall G2	e-Poster Sessions
Hall K	Technologists' Track

Meeting Rooms


-2.11 - -2.15, -2.81, -2.82

Industry Hospitality Suites

-2.31 - -2.62, -2.66, -2.77, -2.92 - -2.94

Exhibition Halls

X2, X3, Catering Area
EANM Immersive Cinema



EMUC26 | BRUSSELS, BELGIUM 5 - 8 November 2026

The largest GU cancer congress in Europe



www.emuc26.org

ESUR EUROPEAN SOCIETY OF RADIOLOGY | EANM European Association Nuclear Medicine | ESTRO European SocieTy for Radiotherapy & Oncology | eau European Association of Urology

PROGRAMME OVERVIEW
SATURDAY, OCTOBER 17, 2026

Location/ Time	Hall A	Hall F2			Location/ Time
08:00–08:30					08:00–08:30
08:30–09:00					08:30–09:00
09:00–09:30					09:00–09:30
09:30–10:00					09:30–10:00
10:00–10:30					10:00–10:30
10:30–11:00					10:30–11:00
11:00–11:30		**EANM Delegates' Assembly** (11:00–11:45)			11:00–11:30
11:30–12:00					11:30–12:00
12:00–12:30		**EANM Members' Assembly** (12:00–13:30)			12:00–12:30
12:30–13:00					12:30–13:00
13:00–13:30					13:00–13:30
13:30–14:00					13:30–14:00
14:00–14:30					14:00–14:30
14:30–15:00		**EANM Advisory Council Meeting** (14:15–15:30)			14:30–15:00
15:00–15:30					15:00–15:30
15:30–16:00				**EANM Committee Meetings** (15:30–17:45)	15:30–16:00
16:00–16:30					16:00–16:30
16:30–17:00					16:30–17:00
17:00–17:30					17:00–17:30
17:30–18:00					17:30–18:00
18:00–18:30	*101* **Opening Ceremony Including Awards Ceremony** (18:00 – 19:15)				18:00–18:30
18:30–19:00					19:30–20:30
19:30–20:00	**Welcome Reception** (19:15 – 21:15)				20:30–21:00
20:00–21:30					21:00–21:30
21:30–22:00					21:30–22:00

WORLD LEADING MEETING — EANM'26
OCTOBER 17–21, 2026

PROGRAMME OVERVIEW

SUNDAY, OCTOBER 18, 2026

Location/ Time	Hall A	Hall D – Arena	Hall E1	Hall E2	Hall B	Hall C	Hall F1	Hall F2	Hall G2	Hall K	Hall G1	Location/ Time
	LIVE STREAM									LIVE STREAM		
08:00–08:30	*201* **CME 1** Oncology & Theranostics Committee **The Alpha Era in Prostate Cancer: Progress, Challenges, and Next Steps**	*202* **Special Track** Oncology & Theranostics Committee **Debate: From Innovation to Recommendation: Introducing FAPI in Clinical Guidelines**	*203* **LIPS Track** Neuroimaging Committee **Neuroimaging Brain Metastases: Updates on Diagnosis and Therapy**	*204* **M2M Track TROP Session** Radiopharmaceutical Sciences Committee **Making Radiotracers Better**	*205* **Cutting Edge Science Track TROP Session** Physics Committee **Advanced PET Imaging: Methods and Applications**	*206* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Gastro-Intestinal Malignancy**	*207* **TROP Session** Thyroid Committee **Nuclear Medicine Imaging in Endocrine Disease: Present and Future Perspective**	*208* **TROP Session** Cardiovascular Committee **The New Age of Myocardial Perfusion SPECT**	*209* **e-Poster Presentations Session 1** Dosimetry Committee **Dosimetry e-Posters**	*210* **Technologists' Track Opening CTE 1** Technologists Committee + SNMMI **Technologists' Guide Launch**	*211* **Special Symposium 1** EARL **New Image Quality and Sensitivity Methods for NEMA NU 2 and IEC 61675-1 PET Standards**	08:00–08:30
08:30–09:00												08:30–09:00
09:00–09:30												09:00–09:30
09:30–10:00	*301* **CME 2** Neuroimaging Committee **Assessment, Staging and Monitoring of Alzheimer's Disease Neuropathological Changes in the Era of Disease-Modifying Therapies with PET**	*302* **Special Symposium 2** EARL **Clinical Implications of EARL PET/CT Accreditation Standards 3, LAFOV Brain and a ^{177}Lu SPECT/CT Accreditation for NaI and CZT: Results, Specifications, and Future Directions**	*303* **LIPS Track** Cardiovascular Committee **Tips and Tricks to Set Up a Cardiac PET Programme on MPI**	*304* **M2M Track TROP Session** Radiopharmaceutical Sciences Committee **^{161}Tb vs ^{177}Lu, and the Winner Is...**	*305* **Cutting Edge Science Track TROP Session** AI Committee **AI and Monte Carlo Based Quantitative SPECT Imaging**	*306* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Neuroendocrine Imaging**	*307* **TROP Session** Dosimetry Committee **Advanced Dosimetry Methodology: Virtual Validation, Simplified Kinetics and Patient-Specific Marrow Modelling**	*308* **Joint Symposium 1** Oncology & Theranostics Committee / EAU **Changing Care: Highlights on Level I Therapy Trials in Prostate Cancer**	*309* **e-Poster Presentations Session 2** Cardiovascular Committee **A Journey Through the Cardiovascular System**	*310* **Technologists' Track CTE 2** Technologists Committee + EFRS **New Working Practices in Nuclear Medicine: Innovation, Safety and Emerging Responsibilities**	*311* **Special Session** Oncology & Theranostics Committee **Intra-Arterial and Locoregional Radionuclide Therapy**	09:30–10:00
10:00–10:30												10:00–10:30
10:30–11:00												10:30–11:00
11:00–11:30												11:00–11:30
11:30–12:00	*401* **Plenary 1** **THERANOSTICS: The Next Level**											11:30–12:00
12:00–12:30												12:00–12:30
12:30–13:00												12:30–13:00
13:00–13:30	**Lunch Break**	*402* **Joint Symposium 1A** Translational Molecular Imaging & Therapy Committee / ESRR **Attracting and Educating Young Scientists in the Field of Radiopharmacy**	**Satellite Symposium**	**Satellite Symposium**	**Satellite Symposium**	**Satellite Symposium**	**Satellite Symposium**	**Satellite Symposium**	**Satellite Symposium**	**Satellite Symposium**	**Satellite Symposium**	13:00–13:30
13:30–14:00												13:30–14:00
14:00–14:30												14:00–14:30
14:30–15:00												14:30–15:00
15:00–15:30	*501* **CME 3** Inflammation & Infection Committee **Immune Cell Imaging**	*502* **Special Track** Translational Molecular Imaging & Therapy Committee **Challenge the Expert: Combination Therapies, the Emerging Role of Radiobiology**	*503* **LIPS Track** Thyroid Committee **Getting "It" Right: The Right Indication and Best Imaging Approach for Diagnostics in Hyperparathyroidism**	*504* **M2M Track TROP Session** Radiopharmaceutical Sciences Committee **Radiosynthesis and Radionuclide Production**	*505* **Cutting Edge Science Track TROP Session** AI Committee **Segmentation in PSMA Imaging/Therapy**	*506* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Renal Cell Cancer and Novel Targets**	*507* **TROP Session** Neuroimaging Committee **Movement Disorders, Epilepsy, Encephalitis and Inflammation**	*508* **Joint Symposium 2** Oncology & Theranostics Committee / EORTC **Design and Conduct of Clinical Trials - How to Generate Evidence for RLTs**	*509* **e-Poster Presentations Session 3** Oncology & Theranostics Committee **Oncology & Theranostic e-Posters**	*510* **Technologists' Track Oral Presentations 1** Technologists Committee **Nuclear Medicine Across the Spectrum: Education, Professional Issues, Conventional Imaging, and Paediatrics**	*511* **Special Symposium 3** EANM Journals **The EANM Journal Landmark Lecture & Alavi-Carlsen Award. Fifty Years of FDG: From Discovery to the Future of Precision Medicine**	15:00–15:30
15:30–16:00												15:30–16:00
16:00–16:30												16:00–16:30
16:30–17:00	*601* **CME 4** Dosimetry Committee **Dosimetry in Practice: Choosing the Right Level of Complexity**	*602* **Special Track** Oncology & Theranostics Committee **Debate: Is There a Role for Radium-223 in the Era of PSMA RLT?**	*603* **LIPS Track** Inflammation & Infection Committee **Diagnostic Utility and Clinical Challenges of ^{18}F-FDG PET/CT for Infection Imaging in Special Populations**	*604* **M2M Track TROP Session** Translational Molecular Imaging & Therapy Committee **Radiolabeled Peptides, From Development to Application**	*605* **Cutting Edge Science Track TROP Session** AI Committee **AI Based Quantitative Imaging**	*606* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Breast**	*607* **Featured Session** Neuroimaging Committee **Neuro-Oncology Imaging**	*608* **TROP Session** Thyroid Committee **Integrated Diagnostic Approach for Radioiodine Avid and Non-Avid Differentiated Thyroid Carcinoma**	*609* **e-Poster Presentations Session 4** Physics Committee **Physics e-Posters**	*610* **Technologists' Track CTE 3** Technologists + Paediatrics Committee **[^{18}F]FDG for PET/CT and PET/MRI: the Focus on Paediatric Patients**	*611* **Theranostics Track** Oncology & Theranostics Committee **Neuroendocrine Therapy**	16:30–17:00
17:00–17:30												17:00–17:30
17:30–18:00												17:30–18:00
18:00–18:30												18:00–18:30

FINAL PROGRAMME | PROGRAMME OVERVIEW

WORLD LEADING MEETING — EANM'26
OCTOBER 17–21, 2026

PROGRAMME OVERVIEW

MONDAY, OCTOBER 19, 2026

Location/ Time	Hall A	Hall D – Arena	Hall E1	Hall E2	Hall B	Hall C	Hall F1	Hall F2	Hall G2	Hall K	Hall G1	Location/ Time
	LIVE STREAM									LIVE STREAM		
08:00–08:30	*701* **CME 5** Cardiovascular Committee **Looking at Inflammation Within the Heart, What's Hot?**	*702* **Special Track** AI Committee **Round Table: My AI Project - Methods, Challenges and Success Solutions**	*703* **LIPS Track** Oncology & Theranostics Committee **Current and Emerging Imaging Applications in Breast Cancer**	*704* **M2M Track TROP Session** Translational Molecular Imaging & Therapy Committee **First-In-Human PET Tracers**	*705* **Cutting Edge Science Track TROP Session** Physics Committee **PET/SPECT for Therapy Optimisation**	*706* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Colorectal and Prostate Imaging**	*707* **TROP Session** Neuroimaging Committee **Targeted Radionuclide Therapy for Brain Tumours**	*708* **Joint Symposium 3** Dosimetry Committee / ESTRO **Understanding Radiobiological Parameters for Dose–Response Correlations**	*709* **e-Poster Presentations Session 5** Radiopharmaceutical Sciences Committee **The Science of Radiopharmaceutical Preparation**	*710* **Technologists' Track Oral Presentations 2** Technologists Committee **PET and Radiopharmacy: Science, Technology, and Clinical Applications**	*711* **TROP Session** Bone & Joint Committee **New Insights into Musculoskeletal Imaging and Theranostics**	08:00–08:30
08:30–09:00												08:30–09:00
09:00–09:30												09:00–09:30
09:30–10:00	*801* **CME 6** Oncology & Theranostics Committee **PRRT Beyond GEP**	*802* **Special Track** Cardiovascular Committee **Challenge the Expert: Myocardial Blood Flow in Practice: Challenge the Experts**	*803* **LIPS Track** Paediatrics Committee **The Evolving Role of Bone Scintigraphy in Paediatric Imaging: Current Indications and Challenges**	*804* **M2M Track TROP Session** Translational Molecular Imaging & Therapy Committee **LET's Do Therapy!**	*805* **Cutting Edge Science Track TROP Session** Dosimetry Committee **Radioembolisation and Locoregional Radionuclide Therapy Dosimetry**	*806* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Prostate Cancer Therapy**	*807* **TROP Session** Neuroimaging Committee **From Amyloid Imaging to Anti-Amyloid Therapy**	*808* **TROP Session** Thyroid Committee **Radioiodine Therapy: A Timeless Paradigm for Differentiated Paediatric and Adult Thyroid Carcinoma**	*809* **e-Poster Presentations Session 6** Bone & Joint Committee **Bone & Joint e-Posters**	*810* **Technologists' Track CTE 4** Technologists + Inflammation & Infection Committee **Imaging of Foreign Body Associated Inflammation and Infections : Pearls and Pitfalls**	*811* **Special Symposium 4** EARL **Unlock Precision in Imaging — Discover the Clinical Benefits of EARL PET Accreditation**	09:30–10:00
10:00–10:30												10:00–10:30
10:30–11:00												10:30–11:00
11:00–11:30												11:00–11:30
11:30–12:00	*901* **Plenary 2** **From Treatment to Prevention: The Evolving Role of Nuclear Medicine in Early Diagnosis**											11:30–12:00
12:00–12:30												12:00–12:30
12:30–13:00												12:30–13:00
13:00–13:30	**Lunch Break**			**Satellite Symposium**	**Satellite Symposium**	**Satellite Symposium**	**Satellite Symposium**	**Satellite Symposium**		**Satellite Symposium**	**Satellite Symposium**	13:00–13:30
13:30–14:00												13:30–14:00
14:00–14:30												14:00–14:30
14:30–15:00												14:30–15:00
15:00–15:30	*1001* **CME 7** Translational Molecular Imaging & Therapy Committee **How Can You Monitor the Immune System Activity in Patients?**	*1002* **Special Track** **EANM Sanjiv Sam Gambhir Young Investigator Award – Compete and Win!**	*1003* **LIPS Track** Neuroimaging + Paediatric Committee **Improving Diagnostics and Management of Paediatric Brain Tumours: The Role of PET and Theranostics**	*1004* **M2M Track TROP Session** Cardiovascular Committee **Inside the Diseased Heart: A Molecular Journey**	*1005* **Cutting Edge Science Track TROP Session** AI Committee **LLMs and Other Innovative DL Approaches**	*1006* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Lung**	*1007* **TROP Session** Inflammation & Infection Committee **Cardiovascular Infection and Inflammation: Heart and Vessels under Attack!**	*1008* **Joint Symposium 4** Oncology & Theranostics Committee / ENETS **PRRT and Systemic Therapy Options for NET**	*1009* **e-Poster Presentations Session 7** Thyroid Committee **Nuclear Medicine in Endocrine Disorders: Current Diagnostic and Therapeutic Landscapes**	*1010* **Technologists' Track Technologists' e-Poster Presentations Session** Technologists Committee **Technologists' e-Posters**	*1011* **Theranostics Track** Oncology & Theranostics Committee **Prostate Cancer Therapy I**	15:00–15:30
15:30–16:00												15:30–16:00
16:00–16:30												16:00–16:30
16:30–17:00	*1101* **CME 8** Oncology & Theranostics Committee **The Evidence Shift: Impact of Prospective Imaging Trials in Oncology**	*1102* **Special Track** Inflammation & Infection Committee + Young Professionals Council **Round Table: Clinical and Research Challenges in Infection Imaging: Where to Invest or Let it Go**	*1103* **LIPS Track** AI Committee **Metrics for AI**	*1104* **M2M Track TROP Session** Translational Molecular Imaging & Therapy Committee **Advances in Combination Therapies**	*1105* **Cutting Edge Science Track TROP Session** Physics Committee **Dynamic PET Imaging and Kinetic Analysis**	*1106* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Image-Guided Interventions**	*1107* **Featured Session** Paediatrics Committee **Intelligence in Imaging Paediatrics from Diagnosis to Therapy**	*1108* **Joint Symposium 5** Neuroimaging Committee / EPA **What Can Nuclear Medicine Offer in Psychiatry?**	*1109* **e-Poster Presentations Session 8** Translational Molecular Imaging & Therapy Committee **Translational Imaging and Therapy**	*1110* **Technologists' Track CTE 5** Technologists + Thyroid Committee **NM Applications for Benign Thyroid Diseases**	*1111* **Theranostics Track** Oncology & Theranostics Committee **Prostate Cancer Therapy II**	16:30–17:00
17:00–17:30												17:00–17:30
17:30–18:00												17:30–18:00
18:00–18:30												18:00–18:30

FINAL PROGRAMME | PROGRAMME OVERVIEW

WORLD LEADING MEETING — EANM'26
OCTOBER 17–21, 2026

PROGRAMME OVERVIEW
TUESDAY, OCTOBER 20, 2026

Location/ Time	Hall A	Hall D – Arena	Hall E1	Hall E2	Hall B	Hall C	Hall F1	Hall F2	Hall G2	Hall K	Hall G1	Location/ Time
	LIVE STREAM									LIVE STREAM		
08:00–08:30	*1201* **CME 9** Paediatrics Committee **The Evolving Role of Nuclear Medicine in Paediatric Epilepsy: From Seizure Focus Localisation to Prognostic Imaging**	*1202* **Joint Symposium 6** EANM / ESR **Meet the Radioembolisation Team**	*1203* **LIPS Track** Dosimetry Committee **Clinical Dosimetry: How Do I Start?**	*1204* **M2M Track TROP Session** Radiopharmaceutical Sciences Committee **Non-Oncological Tracers**	*1205* **Cutting Edge Science Track TROP Session** AI Committee **AI Segmentation Methodologies**	*1206* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Gynaecological and Abdominal Malignancy**	*1207* **TROP Session** Neuroimaging Committee **Tau PET and Beyond: Imaging Neurodegeneration**	*1208* **Special Session** Oncology & Theranostics Committee **Imaging Companions for Non-Radioactive Targeted Therapy: Is There a Role?**	*1209* **e-Poster Presentations Session 9** Radiation Protection Committee **Radiation Protection e-Posters**	*1210* **Technologists' Track CTE 6** Technologists + TMI&T Committee **Behind the Scenes in Translational Nuclear Medicine**	*1211* **EU Policy Symposium 1** Policy & Regulatory Affairs Council **Radioligand Therapy in Europe: Regulation, Readiness and Patient Acces**	08:00–08:30
08:30–09:00												08:30–09:00
09:00–09:30												09:00–09:30
09:30–10:00	*1301* **CME 10** Thyroid Committee **Beyond Iodine: The New Era of Targeted Radiopharmaceutical Therapy for Thyroid Disease**	*1302* **Special Track** Physics Committee / IAEA **Debate: Towards Green Nuclear Medicine and Theranostics**	*1303* **LIPS Track** Oncology & Theranostics Committee **FDG PET in Theranostics: Friend or Foe?**	*1304* **M2M Track TROP Session** Radiopharmaceutical Sciences Committee **Upcoming Targets and Their Tracers**	*1305* **Cutting Edge Science Track TROP Session** AI Committee **AI Based Modeling for Patient Classification**	*1306* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Radioembolisation and New Applications**	*1307* **TROP Session** Paediatrics Committee **Shaping the Future: New Tracers and Emerging Applications in Nephrology**	*1308* **Featured Session** Radiation Protection Committee **Radiation Protection in Everyday Practice**	*1309* **e-Poster Presentations Session 10** Inflammation & Infection Committee **Best e-Posters on Inflammation & Infection Imaging**	*1310* **Technologists' Track Oral Presentations 3** Technologists Committee **Advancing Theranostics: Innovations in Therapy and Dosimetry**	*1311* **Special Symposium 5** EANM Journals **Publishing in the AI Era: How Young Researchers Can Build Their Scientific Career**	09:30–10:00
10:00–10:30												10:00–10:30
10:30–11:00												10:30–11:00
11:00–11:30												11:00–11:30
11:30–12:00	*1401* **Plenary 3** **Our Path to Sustained Scientific Success: How to Prepare for 2040**											11:30–12:00
12:00–12:30												12:00–12:30
12:30–13:00												12:30–13:00
13:00–13:30	**Lunch Break**	**Special Lunch Session** Young Professional Council **Theranostic Survival Guide: Everything You Need to Know Before Getting Started**		**Satellite Symposium**	**Satellite Symposium**	**Satellite Symposium**	**Satellite Symposium**	**Satellite Symposium**		**Satellite Symposium**	**Satellite Symposium**	13:00–13:30
13:30–14:00												13:30–14:00
14:00–14:30												14:00–14:30
14:30–15:00												14:30–15:00
15:00–15:30	*1501* **CME 11** Radiation Protection Committee **Artificial Intelligence and Radiological Protection: Rethinking Justification and Decision-Making in the Era of Smart Nuclear Medicine**	*1502* **Special Track** Thyroid Committee **Challenge the Expert: Overdiagnosis in Thyroid Cancer: Balancing Early Detection with Clinical Significance**	*1503* **LIPS Track** Bone & Joint Committee **Joint EANM/ESNR/ Eurospine Guideline on Bone SPECT/CT in Suspected Facet Joint Arthropathy and Non-Infectious Post Operative Spine Conditions**	*1504* **M2M Track TROP Session** Radiopharmaceutical Sciences Committee **Advances in Theranostic Tracers**	*1505* **Cutting Edge Science Track TROP Session** Dosimetry Committee **From Clinical Dosimetry to Treatment Adaptation in [^{177}Lu] Therapy**	*1506* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Prostate Cancer Staging**	*1507* **TROP Session** Case Report Session 1 **Cases Worth Telling**	*1508* **Joint Symposium 7** Cardiovascular Committee / EACVI **Stiff Heart, Think Amyloidosis**	*1509* **e-Poster Presentations Session 11** AI Committee **AI Data and Image Analysis, Dynamic Imaging**	*1510* **Technologists' Track CTE 7** Technologists Committee / ESTRO **Theranostics: Bridging Nuclear Medicine and Radiotherapy for Better Cancer Treatment**	*1511* **EU Policy Symposium 2** Policy & Regulatory Affairs Council **Accelerating Clinical Trials in Nuclear Medicine: From Regulation to Implementation**	15:00–15:30
15:30–16:00												15:30–16:00
16:00–16:30												16:00–16:30
16:30–17:00	*1601* **CME 12** AI Committee **Large Language Models in NM**	*1602* **Special Track** Neuroimaging Committee **Debate: Early Amyloid and Tau Perfusion vs FDG PET**	*1603* **LIPS Track** Radiation Protection Committee **What Would You Do if...? Radiation Protection Issues in Special Cases of Everyday Practices**	*1604* **M2M Track TROP Session** Radiopharmaceutical Sciences Committee **Making the Most of a FAP-ulous Target**	*1605* **Cutting Edge Science Track TROP Session** Physics Committee **Quantitative PET: Harmonisation and Robustness**	*1606* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Prostate Cancer: New Imaging Applications**	*1607* **TROP Session** Thyroid Committee **The Power of Nuclear Medicine Imaging in Targeting Parathyroid Disorders**	*1608* **Round Table** Oncology & Theranostics Committee Young Professionals Council **Residents for Residents 2026**	*1609* **e-Poster Presentations Session 12** Radiopharmaceutical Sciences Committee **Modern Approaches to Drug Development in Nuclear Medicine**	*1610* **TROP Session** Cardiovascular Committee **Amyloid Hunters: New Weapons**	*1611* **Special Symposium 6** Dosimetry Committee **Round Table: Single-Time Point Dosimetry: A Step Forward or a Step Too Far?**	16:30–17:00
17:00–17:30												17:00–17:30
17:30–18:00												17:30–18:00
18:00–18:30												18:00–18:30

FINAL PROGRAMME | PROGRAMME OVERVIEW

WORLD LEADING MEETING — EANM'26
OCTOBER 17–21, 2026

PROGRAMME OVERVIEW
WEDNESDAY, OCTOBER 21, 2026

Location/ Time	Hall A	Hall D – Arena	Hall E1	Hall E2	Hall B	Hall C	Hall F1	Hall F2	Hall G2	Hall K	Hall G1	Location/ Time
	LIVE STREAM									LIVE STREAM		
08:00–08:30	*1701* **CME 13** Bone & Joint Committee **Diagnosis and Treatment of Joint Diseases**	*1702* **Special Track** AI Committee **Debate: Digital Twins in Nuclear Medicine**	*1703* **LIPS Track** Physics Committee **Understanding Your Measurements: Practical Guide to Uncertainty Quantification**	*1704* **M2M Track TROP Session** Radiopharmaceutical Sciences Committee **Advances in Radiopharmaceutical Development**	*1705* **Cutting Edge Science Track TROP Session** Dosimetry Committee **Emerging Radiopharmaceuticals, Alpha Therapy and Biology-Guided Dosimetry**	*1706* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Head and Neck**	*1707* **TROP Session** Inflammation & Infection Committee **Heterogeneous Infectious and Inflammatory Diseases**	*1708* **TROP Session** Thyroid Committee **Management of Benign and Malignant Thyroid Disorders: From Diagnosis to Therapy**	*1709* **e-Poster Presentations Session 13** Neuroimaging Committee **Neuroimaging e-Posters**	*1710* **Technologists' Track Mini Courses** Technologists Committee *1710a* **Mini Course 1** (08:00-09:00) **Radiation Protection in Patients Undergoing Radioligand Therapy** *1710b* **Mini Course 2** (09:05-10:05) **Instrumentation and Dosimetry** *1710c* **Mini Course 3** (10:15-11:15) **Therapeutic Radioisotopes and Their Radioligands - The Overview of Daily Radiochemical Practice**	*1711* **TROP Session** Case Report Session 2 **Cases Worth Telling**	08:00–08:30
08:30–09:00												08:30–09:00
09:00–09:30												09:00–09:30
09:30–10:00	*1801* **CME 14** Physics + Dosimetry Committee **Quantitative Imaging & Dosimetry Using Total-Body PET Imaging**	*1802* **Special Track** Radiopharmacy Committee **Round Table: Pairing for Precision: The Ideal Theranostic Combination for Radiometal-Based Therapy**	*1803* **LIPS Track** Translational Molecular Imaging & Therapy + AI Committee **Multimodal Therapeutic Planning in Times of AI Innovations**	*1804* **M2M Track TROP Session** Translational Molecular Imaging & Therapy Committee **Animal Models and In Vitro Alternatives**		*1806* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Lymphoma and Myeloma**	*1807* **TROP Session** Neuroimaging Committee **Neuroimaging: Novel Tracers and Emerging Clinical Applications**	*1808* **Featured Session** Cardiovascular Committee **Going with the Flow: New Horizons in Quantitative Nuclear Cardiology**	*1809* **e-Poster Presentations Session 14** Paediatrics Committee **Paediatrics e-Posters**		*1811* **TROP Session** Other Clinical Studies Session **What Doesn't Fit Anywhere Else (But Absolutely Should)**	09:30–10:00
10:00–10:30												10:00–10:30
10:30–11:00												10:30–11:00
11:00–11:30	*1901* **Closing Session** (11:25-11:45) **Farewell Drink** (11:45-12:15)											11:00–11:30
11:30–12:00												11:30–12:00
12:00–12:30												12:00–12:30

- Plenary Sessions
- CME Sessions
- Special Track
- Learn & Improve Professional Skills (LIPS) Track
- Joint Symposia
- M2M Track
- Cutting Edge Science Track
- Clinical Oncology Track
- Special Symposium
- Featured/TROP Session
- e-Poster Presentations
- Technologists' Track Session
- Continuing Medical Education
- Highlighted for Young Professionals

FINAL PROGRAMME | PROGRAMME OVERVIEW



SCIENTIFIC PROGRAMME

INVITED SPEAKER SESSIONS

PLENARY SESSIONS

1

Sunday, October 18, 2026 | 11:30 - 13:00 | Hall A

THERANOSTICS: The Next Level

- **Emma Aneheim (Gothenburg, Sweden)**: Exciting New Isotopes for Therapy– Just a Trend?
- **Thomas Hope (San Francisco, United States of America)**: Rethinking FAPTargeted Theranostics
- **Xiaoli Lan (Wuhan, China)**: Integrin Directed Theranostics – Ready to Be a Success Story?
- **Wolfgang Fen dler (Essen, Germany)**: RLT and Chemo – Combination or Competition?
- **Shahneen Sandhu (Melbourne, Australia)**: RLT + Immunotherapy: Unlocking Immune Synergies with Radioligands
- **Constantinos Zamboglou (Limassol, Cyprus)**: RLT + EBRT: Combining Systemic and Focal Radiation for Synergistic Tumour Control

2

Monday, October 19, 2026 | 11:30 - 13:00 | Hall A

From Treatment to Prevention: The Evolving Role of Nuclear Medicine in Early Diagnosis

Chairpersons: Jan Bucerius (Graz, Austria), Valentina Garibotto (Geneva, Switzerland)

- **Ken Hermann (Essen, Germany)**: Prevention and Early Diagnosis in Oncology
- **Marcus Hacker (Vienna, Austria)**: Preventing Cardiovascular Diseases the Nuclear Medicine Way
- **Massimo Filippi (Milan, Italy)**: PET Imaging and the Prevention of Alzheimer's Disease
- **Paola Anna Erba (Milan, Italy)**: EANM Perspective to Move from Treatment to Prevention
- **Panel Discussion – All speakers**

3

Tuesday, October 20, 2026 | 11:30 - 13:00 | Hall A

Our Path to Sustained Scientific Success: How to Prepare for 2040

Chairpersons: Martin Gotthardt (Nijmegen, Netherlands)

- Introduction by the chairs
- Will Nuclear Medicine Break Its Own Neck? How to Overcome Toxic Leadership
- **Margret Schottelius (Lausanne, Switzerland)**: Are We Producing Results— Or Just Noise? How Standardisation Strengthens Nuclear Medicine Research
- **Roslyn Francis (Crawley, WA, Australia)**: Fragmentation of Research: Nuclear Medicine Is Talking to Itself
- **Nathalie Albert (Munich, Germany)**: Increasing Intellectual Output: Attenuation Correction for Female Contributions
- Collaboration of Academia and Industry: Essential for Avoiding Extinction
- **Panel Discussion (All speakers and invited experts)**: Felix Mottaghy (Germany); Johannes Czernin (Los Angeles, United States)

CONTINUING MEDICAL EDUCATION (CME) SESSIONS

1
Sunday, October 18, 2026 | 08:00 - 09:30 | Hall A
Oncology & Theranostics Committee
The Alpha Era in Prostate Cancer: Progress, Challenges, and Next Steps

2
Sunday, October 18, 2026 | 09:45 - 11:15 | Hall A
Neuroimaging Committee
Assessment, Staging and Monitoring of Alzheimer's Disease Neuropathological Changes in the Era of Disease-Modifying Therapies with PET

3
Sunday, October 18, 2026 | 15:00 - 16:30 | Hall A
Inflammation & Infection Committee
Immune Cell Imaging

4
Sunday, October 18, 2026 | 16:45 - 18:15 | Hall A
Dosimetry Committee
Dosimetry in Practice: Choosing the Right Level of Complexity

5
Monday, October 19, 2026 | 08:00 - 09:30 | Hall A
Cardiovascular Committee
Looking of Inflammation Within the Heart: What's Hot?

6
Monday, October 19, 2026 | 09:45 - 11:15 | Hall A
Oncology & Theranostics Committee
PRRT Beyond GEP

7
Monday, October 19, 2026 | 15:00 - 16:30 | Hall A
Translational Molecular Imaging & Therapy Committee
How Can You Monitor the Immune System Activity in Patients?

8
Monday, October 19, 2026 | 16:45 - 18:15 | Hall A
Oncology & Theranostics Committee
The Evidence Shift: Impact of Prospective Imaging Trials in Oncology

9
Tuesday, October 20, 2026 | 08:00 - 09:30 | Hall A
Paediatrics + Neuroimaging Committee
The Evolving Role of Nuclear Medicine in Paediatric Epilepsy: From Seizure Focus Localisation to Prognostic Imaging

10
Tuesday, October 20, 2026 | 09:45 - 11:15 | Hall A
Thyroid Committee
Beyond Iodine: The New Era of Targeted Radiopharmaceutical Therapy for Thyroid Disease

11
Tuesday, October 20, 2026 | 15:00 - 16:30 | Hall A
Radiation & Protection Committee
Artificial Intelligence and Radiological Protection: Rethinking Justification and Decision-Making in the Era of Smart Nuclear Medicine

12
Tuesday, October 20, 2026 | 16:45 - 18:15 | Hall A
AI Committee
Large Language Models in NM

13
Wednesday, October 21, 2026 | 08:00 - 09:30 | Hall A
Bone & Joint Committee
Diagnosis and Treatment of Joint Diseases

14
Wednesday, October 21, 2026 | 09:45 - 11:15 | Hall A
Physics Committee
Quantitative Imaging & Dosimetry Using Total-Body PET Imaging

SPECIAL TRACK

1
Sunday, October 18, 2026 | 08:00 - 09:30 | Hall D – Arena
Oncology & Theranostics Committee
Debate:
From Innovation to Recommendation: Introducing FAPI in Clinical Guidelines

2
Sunday, October 18, 2026 | 09:45 - 11:15 | Hall D – Arena
Oncology & Theranostics Committee
Intra-Arterial and Locoregional Radionuclide Therapy

3
Sunday, October 18, 2026 | 15:00 - 16:30 | Hall D – Arena
Translational Molecular Imaging & Therapy Committee
Challenge the Expert:
Combination Therapies, the Emerging Role of Radiobiology

4
Sunday, October 18, 2026 | 16:45 - 18:15 | Hall D – Arena
Oncology & Theranostics Committee
Debate:
Is There a Role for Radium-223 in the Era of PSMA RLT?

5
Monday, October 19, 2026 | 08:00 - 09:30 | Hall D – Arena
AI Committee
Round Table:
My AI Project - Methods, Challenges and Success Solutions

6
Monday, October 19, 2026 | 09:45 - 11:15 | Hall D – Arena
Cardiovascular Committee
Challenge the Expert:
Myocardial Blood Flow in Practice: Challenge the Experts

7
Monday, October 19, 2026 | 15:00 - 16:30 | Hall D – Arena
EANM Sanjiv Sam Gambhir Young InvestigatorAward - Compete and Win!

8
Monday, October 19, 2026 | 16:45 - 18:15 | Hall D – Arena
Inflammation & Infection Committee + Young Professionals Council
Round Table:
Clinical and Research Challenges in Infection Imaging: Where to Invest or Let it Go

9
Tuesday, October 20, 2026 | 08:00 - 09:30 | Hall F2
Oncology & Theranostics Comittee
Imaging Companions for Non-Radioactive Targeted Therapy: Is There a Role?

10
Tuesday, October 20, 2026 | 09:45 - 11:15 | Hall D – Arena
Physics Committee
Debate:
Towards Green Nuclear Medicine and Theranostics

11
Tuesday, October 20, 2026 | 15:00 - 16:30 | Hall D – Arena
Thyroid Committee
Challenge the Expert:
Overdiagnosis in Thyroid Cancer: Balancing Early Detection with Clinical Significance

12
Tuesday, October 20, 2026 | 16:45 - 18:15 | Hall D – Arena
Neuroimaging Committee
Debate:
Early Amyloid and Tau Perfusion vs FDG PET

12a
Tuesday, October 20, 2026 | 16:45 - 18:15 | Hall F2
Oncology & Theranostics Committee + Young Professionals Council
Round Table:
Residents for Residents 2026

13
Wednesday, October 21, 2026 | 08:00 - 09:30 | Hall D – Arena
AI Committe
Debate:
Digital Twins in Nuclear Medicine

14
Wednesday, October 21, 2026 | 09:45 - 11:15 | Hall D – Arena
Radiopharmacy Committee
Round Table:
Pairing for Precision – Is There an Ideal Theranostic Combination for Radiometal-Based Therapy?

JOINT SYMPOSIA

1
Sunday, October 18, 2026 | 09:45 - 11:15 | Hall F2
Oncology and Theranostics Committee / EAU
Changing Care: Highlights on Level I Therapy Trials in Prostate Cancer

1a
Sunday, October 18, 2026 | 13:15 - 14:45 | Hall D – Arena
EANM / ESRR
Attracting and Educating Young Scientists in the Field of Radiopharmacy

2
Sunday, October 18, 2026 | 15:00 - 16:30 | Hall F2
Oncology & Theranostics Committee / EORTC
Design and Conduct of Clinical Trials – How to Generate Evidence for RLRs

3
Monday, October 19, 2026 | 08:00 - 09:30 | Hall F2
Dosimetry Committee / ESTRO
Understanding Radiobiological Parameters for Dose-Response Correlations

4
Monday, October 19, 2026 | 15:00 - 16:30 | Hall F2
Oncology & Theranostics Committee / ENETS
PRRT and Systemic Therapy Options for NET

5
Monday, October 19, 2026 | 16:45 - 18:15 | Hall F2
Neuroimaging Committee / EPA
What Can Nuclear Medicine Offer in Psychiatry?

6
Tuesday, October 20, 2026 | 08:00 - 09:30 | Hall D – Arena
EANM / ESR
Meet the Radioembolisation Team

7
Tuesday, October 20, 2026 | 15:00 - 16:30 | Hall F2
Cardiovascular Committee / EACVI
Stiff Heart, Think Amyloidosis



SPECIAL SYMPOSIA

1
Sunday, October 18, 2026 | 08:00 - 09:30 | Hall G1
EARL / NEMA
New Image Quality and Sensitivity Methods for NEMA NU 2 and IEC 61675-1 PET Standards

2
Sunday, October 18, 2026 | 09:45 - 11:15 | Hall D – Arena
EARL
Clinical Implications of EARL PET/CT Accreditation Standards 3, ^{177}Lu SPECT/CT Accreditation for NaI and CZT: Results, Specifications, and Future Directions

3
Sunday, October 18, 2026 | 15:00 - 16:30 | Hall G1
EANM Journals
The EANM Journal Landmark Lecture & Alavi-Carlsen Award. Fifty Years of FDG: From Discovery to the Future of Precision Medicine

4
Monday, October 19, 2026 | 09:45 - 11:15 | Hall G1
EARL
Unlock Precision in Imaging — Discover the Clinical Benefits of EARL PET Accreditation

5
Tuesday, October 20, 2026 | 09:45 - 11:15 | Hall G1
EANM Journals
Publishing in the AI Era: How Young Researchers Can Build Their Scientific Career

6
Tuesday, October 20, 2026 | 16:45 - 18:15 | Hall G1
Dosimetry Committee
Round Table: Single-Time Point Dosimetry: A Step Forward or a Step Too Far?

EU POLICY SYMPOSIA

1
Tuesday, October 20, 2026 | 08:00 - 09:30 | Hall G1
Policy & Regulatory Affairs Committee
Radioligand Therapy in Europe: Regulation, Readiness and Patient Access

2
Tuesday, October 20, 2026 | 15:00 - 16:30 | Hall G1
Policy & Regulatory Affairs Committee
Accelerating Clinical Trials in Nuclear Medicine: From Regulation to Implementation

LEARN & IMPROVE PROFESSIONAL SKILLS (LIPS) TRACK

1
Sunday, October 18, 2026 | 08:00 - 09:30 | Hall E1
Neuroimaging Committee
Neuroimaging Brain Metastases: Updates on Diagnosis and Therapy

2
Sunday, October 18, 2026 | 09:45 - 11:15 | Hall E1
Cardiovascular Committee
Tips and Tricks to Set Up a Cardiac PET Programme on MPI

3
Sunday, October 18, 2026 | 15:00 - 16:30 | Hall E1
Thyroid Committee
Getting 'It' Right: The Right Indication and Best Imaging Approach for Diagnostics in Hyperparathyroidism

4
Sunday, October 18, 2026 | 16:45 - 18:15 | Hall E1
Inflammation & Infection Committee
Diagnostic Utility and Clinical Challenges of [^{18}F]-FDG PET/CT for Infection Imaging in Special Populations

5
Monday, October 19, 2026 | 08:00 - 09:30 | Hall E1
Oncology & Theranostics Committee
Current and Emerging Imaging Applications in Breast Cancer

6
Monday, October 19, 2026 | 09:45 - 11:15 | Hall E1
Paediatrics Committee
The Envolving Role of Bone Scintigraphy in Paediatric Imaging: Current Indications and Challenges

7
Monday, October 19, 2026 | 15:00 - 16:30 | Hall E1
Neuroimaging + Paediatric Committee
Improving Diagnostics and Management of Paediatric Brain Tumours: The Role of PET and Theranostics

8
Monday, October 19, 2026 | 16:45 - 18:15 | Hall E1
AI Committee
Metrics for AI

9
Tuesday, October 20, 2026 | 08:00 - 09:30 | Hall E1
Dosimetry Committee
Clinical Dosimetry: How Do I Start?

10
Tuesday, October 20, 2026 | 09:45 - 11:15 | Hall E1
Oncology & Theranostics Committee
FDG PET in Theranostics: Friend or Foe?

11
Tuesday, October 20, 2026 | 15:00 - 16:30 | Hall E1
Bone & Joint Committee
Joint EANM/ESNR/Eurospine Guideline on Bone SPECT/CT in Suspected Facet Joint Arthropathy and non Infectious Post Operative Spine Conditions

12
Tuesday, October 20, 2026 | 16:45 - 18:15 | Hall E1
Radiation Protection Committee
What Would You Do if...? Radiation Protection Issues in Special Cases of Everyday Practices

13
Wednesday, October 21, 2026 | 08:00 - 09:30 | Hall E1
Physics Committee
Understanding Your Measurements: Practical Guide to Uncertainty Quantification

14
Wednesday, October 21, 2026 | 09:45 - 11:15 | Hall E1
Translational Molecular Imaging Therapy + AI Committee
Multimodal Therapeutic Planning in Times of AI Innovations

CLINICAL ONCOLOGY TRACK

206
Sunday, October 18, 2026 | 08:00 – 09:30 | Hall C
Oncology & Theranostics Committee – TROP Session
Gastro-Intestinal Malignancy

306
Sunday, October 18, 2026 | 09:45 – 11:15 | Hall C
Oncology & Theranostics Committee – TROP Session
Neuroendocrine Imaging

506
Sunday, October 18, 2026 | 15:00 – 16:30 | Hall C
Oncology & Theranostics Committee – TROP Session
Renal Cell Cancer and Novel Targets

606
Sunday, October 18, 2026 | 16:45 – 18:15 | Hall C
Oncology & Theranostics Committee – TROP Session
Breast

706
Monday, October 19, 2026 | 08:00 – 09:30 | Hall C
Oncology & Theranostics Committee – TROP Session
Colorectal and Prostate Imaging

806
Monday, October 19, 2026 | 09:45 – 11:15 | Hall C
Oncology & Theranostics Committee – TROP Session
Prostate Cancer Therapy

1006
Monday, October 19, 2026 | 15:00 – 16:30 | Hall C
Oncology & Theranostics Committee – TROP Session
Lung

1106
Monday, October 19, 2026 | 16:45 – 18:15 | Hall C
Oncology & Theranostics Committee – TROP Session
Image-Guided Interventions

1206
Tuesday, October 20, 2026 | 08:00 – 09:30 | Hall C
Oncology & Theranostics Committee – TROP Session
Gynaecological and Abdominal Malignancy

1306
Tuesday, October 20, 2026 | 09:45 – 11:15 | Hall C
Oncology & Theranostics Committee – TROP Session
Radioembolisation and New Applications

1506
Tuesday, October 20, 2026 | 15:00 – 16:30 | Hall C
Oncology & Theranostics Committee – TROP Session
Prostate Cancer Staging

1606
Tuesday, October 20, 2026 | 16:45 – 18:15 | Hall C
Oncology & Theranostics Committee – TROP Session
Prostate Cancer: New Imaging Applications

1706
Wednesday, October 21, 2026 | 08:00 – 09:30 | Hall C
Oncology & Theranostics Committee – TROP Session
Head and Neck

1806
Wednesday, October 21, 2026 | 09:45 – 11:15 | Hall C
Oncology & Theranostics Committee – TROP Session
Lymphoma and Myeloma

THERANOSTICS TRACK

611
Sunday, October 18, 2026 | 16:45 – 18:00 | Hall G1
Oncology & Theranostics Committee
Neuroendocrine Therapy

1011
Monday, October 19, 2026 | 15:00 – 16:30 | Hall G1
Oncology & Theranostics Committee
Prostate Cancer Therapy I

1111
Monday, October 19, 2026 | 16:45 – 18:00 | Hall G1
Oncology & Theranostics Committee
Prostate Cancer Therapy II

CUTTING EDGE SCIENCE TRACK

205
Sunday, October 18, 2026 | 08:00 – 09:30 | Hall B
Physics Committee – TROP Session
Advanced PET Imaging: Methods and Applications

305
Sunday, October 18, 2026 | 09:45 – 11:15 | Hall B
AI Committee – TROP Session
AI and Monte Carlo Based Quantitative SPECT Imaging

505
Sunday, October 18, 2026 | 15:00 – 16:30 | Hall B
AI Committee – TROP Session
Segmentation in PSMA Imaging/Therapy

605
Sunday, October 18, 2026 | 16:45 – 18:15 | Hall B
AI Committee – TROP Session
AI Based Quantitative Imaging

705
Monday, October 19, 2026 | 08:00 – 09:30 | Hall B
Physics Committee – TROP Session
PET/SPECT for Therapy Optimisation

805
Monday, October 19, 2026 | 09:45 – 11:15 | Hall B
Dosimetry Committee – TROP Session
Radioembolisation and Locoregional Radionuclide Therapy Dosimetry

1005
Monday, October 19, 2026 | 15:00 – 16:30 | Hall B
AI Committee – TROP Session
LLMs and Other Innovative DL Approaches

1105
Monday, October 19, 2026 | 16:45 – 18:15 | Hall B
Physics Committee – TROP Session
Dynamic PET Imaging and Kinetic Analysis

1205
Tuesday, October 20, 2026 | 08:00 – 09:30 | Hall B
AI Committee – TROP Session
AI Segmentation Methodologies

1305
Tuesday, October 20, 2026 | 09:45 – 11:15 | Hall B
AI Committee – TROP Session
AI Based Modeling for Patient Classification

1505
Tuesday, October 20, 2026 | 15:00 – 16:30 | Hall B
Dosimetry Committee – TROP Session
From Clinical Dosimetry to Treatment Adaptation in [^{177}Lu] Therapy

1605
Tuesday, October 20, 2026 | 16:45 – 18:15 | Hall B
Physics Committee – TROP Session
Quantitative PET: Harmonisation and Robustness

1705
Wednesday, October 21, 2026 | 08:00 – 09:30 | Hall B
Dosimetry Committee – TROP Session
Emerging Radiopharmaceuticals, Alpha Therapy and Biology-Guided Dosimetry

M2M TRACK

204
Sunday, October 18, 2026 | 08:00 – 09:30 | Hall E2
Radiopharmaceutical Sciences Committee – TROP Session
Making Radiotracers Better

304
Sunday, October 18, 2026 | 09:45 – 11:15 | Hall E2
Radiopharmaceutical Sciences Committee – TROP Session
^{161}Tb vs ^{177}Lu, and the Winner Is...

504
Sunday, October 18, 2026 | 15:00 – 16:30 | Hall E2
Radiopharmaceutical Sciences Committee – TROP Session
Radiosynthesis and Radionuclide Production

604
Sunday, October 18, 2026 | 16:45 – 18:15 | Hall E2
Translational Molecular Imaging & Therapy Committee – TROP Session
Radiolabeled Peptides, From Development to Application

704
Monday, October 19, 2026 | 08:00 – 09:30 | Hall E2
Translational Molecular Imaging & Therapy Committee – TROP Session
First-In-Human PET Tracers

804
Monday, October 19, 2026 | 09:45 – 11:15 | Hall E2
Translational Molecular Imaging & Therapy Committee – TROP Session
LET's Do Therapy!

1004
Monday, October 19, 2026 | 15:00 – 16:30 | Hall E2
Cardiovascular Committee – TROP Session
Inside the Diseased Heart: A Molecular Journey

1104
Monday, October 19, 2026 | 16:45 – 18:15 | Hall E2
Translational Molecular Imaging & Therapy Committee Committee – TROP Session
Advances in Combination Therapies

1204
Tuesday, October 20, 2026 | 08:00 – 09:30 | Hall E2
Radiopharmaceutical Sciences Committee – TROP Session
Non-Oncological Tracers

1304 Tuesday, October 20, 2026 | 09:45 – 11:15 | Hall E2
Radiopharmaceutical Sciences Committee – TROP Session
Upcoming Targets and Their Tracers

1504 Tuesday, October 20, 2026 | 15:00 – 16:30 | Hall E2
Radiopharmaceutical Sciences Committee – TROP Session
Advances in Theranostic Tracers

1604 Tuesday, October 20, 2026 | 16:45 – 18:15 | Hall E2
Radiopharmaceutical Sciences Committee – TROP Session
Making the Most of a FAP-ulous Target

1704 Wednesday, October 21, 2026 | 08:00 – 09:30 | Hall E2
Radiopharmaceutical Sciences Committee – TROP Session
Advances In Radiopharmaceutical Development

1804 Wednesday, October 21, 2026 | 09:45 – 11:15 | Hall E2
Translational Molecular Imaging & Therapy Committee – TROP Session
Animal Models and In Vitro Alternatives

FURTHER ORAL PRESENTATIONS & CASE REPORTS

207 Sunday, October 18, 2026 | 08:00 – 09:30 | Hall F1
Thyroid Committee – TROP Session
Nuclear Medicine Imaging in Endocrine Disease: Present and Future Perspective

208 Sunday, October 18, 2026 | 08:00 – 09:30 | Hall F2
Cardiovascular Committee – TROP Session
The New Age of Myocardial Perfusion SPECT

307 Sunday, October 18, 2026 | 09:45 – 11:15 | Hall F1
Dosimetry Committee – TROP Session
Advanced Dosimetry Methodology: Virtual Validation, Simplified Kinetics and Patient-Specific Marrow Modelling

507 Sunday, October 18, 2026 | 15:00 – 16:30 | Hall F1
Neuroimaging Committee – TROP Session
Movement Disorders, Epilepsy, Encephalitis and Inflammation

607 Sunday, October 18, 2026 | 16:45 – 18:15 | Hall F1
Neuroimaging Committee – Featured Session
Neuro-Oncology Imaging

608 Sunday, October 18, 2026 | 16:45 – 18:15 | Hall F2
Thyroid Committee – Trop Session
Integrated Diagnostic Approach for Radioiodine Avid and Non-Avid Differentiated Thyroid Carcinoma

707 Monday, October 19, 2026 | 08:00 – 09:30 | Hall F1
Neuroimaging Committee – TROP Session
Targeted Radionuclide Therapy for Brain Tumours

711 Monday, October 19, 2026 | 08:00 – 09:30 | Hall G1
Bone & Joint Committee – TROP Session
New Insights into Musculoskeletal Imaging and Theranostics

807 Monday, October 19, 2026 | 09:45 – 11:15 | Hall F1
Neuroimaging Committee – TROP Session
From Amyloid Imaging to Anti-Amyloid Therapy

808 Monday, October 19, 2026 | 09:45 – 11:15 | Hall F2
Thyroid Committee – TROP Session
Radioiodine Therapy: A Timeless Paradigm for Differentiated Paediatric and Adult Thyroid Carcinoma

1007 Monday, October 19, 2026 | 15:00 – 16:30 | Hall F1
Inflammation & Infection Committee – TROP Session
Cardiovascular Infection and Inflammation: Heart and Vessels Under Attack!

1107 Monday, October 19, 2026 | 16:45 – 18:15 | Hall F1
Paediatrics Committee – Featured Session
Intelligence In Imaging Paediatrics From Diagnosis to Therapy

1207 Tuesday, October 20, 2026 | 08:00 – 09:30 | Hall F1
Neuroimaging Committee – TROP Session
Tau PET and Beyond: Imaging Neurodegeneration

1307 Tuesday, October 20, 2026 | 09:45 – 11:15 | Hall F1
Paediatrics Committee – TROP Session
Shaping the Future: New Tracers and Emerging Applications in Nephrology

1308 Tuesday, October 20, 2026 | 09:45 – 11:15 | Hall F2
Radiation Protection Committee – Featured Session
Radiation Protection in Everyday Practice

1507 Tuesday, October 20, 2026 | 15:00 – 16:30 | Hall F1
Case Report Session 1 – TROP Session
Cases Worth Telling

1607 Tuesday, October 20, 2026 | 16:45 – 18:15 | Hall F1
Thyroid Committee – TROP Session
The Power of Nuclear Medicine Imaging in Targeting Parathyroid Disorders

1610 Tuesday, October 20, 2026 | 16:45 – 18:15 | Hall K
Cardiovascular Committee – TROP Session
Amyloid Hunters: New Weapons

1707 Wednesday, October 21, 2026 | 08:00 – 09:30 | Hall F1
Inflammation & Infection Committee – TROP Session
Heterogeneous Infectious and Inflammatory Diseases

1708 Wednesday, October 21, 2026 | 08:00 – 09:30 | Hall F2
Thyroid Committee – TROP Session
Management of Benign and Malignant Thyroid Disorders: From Diagnosis to Therapy

1711 Wednesday, October 21, 2026 | 08:00 – 09:30 | Hall G1
Case Repost Session 2 – TROP Session
Cases Worth Telling

1807 Wednesday, October 21, 2026 | 09:45 – 11:15 | Hall F1
Neuroimaging Committee – TROP Session
Neuroimaging: Novel Tracers and Emerging Clinical Applications

1808 Wednesday, October 21, 2026 | 09:45 – 11:15 | Hall F2
Cardiovascular Committee – Featured Session
Going with the Flow: New Horizons in Quantitative Nuclear Cardiology

1811 Wednesday, October 21, 2026 | 09:45 – 11:15 | Hall G1
Other Clinical Studies Session – TROP Session
What Doesn't Fit Anywhere Else (But Absolutely Should)

e-POSTER PRESENTATION SESSIONS

209 Sunday, October 18, 2026 | 08:00 – 09:30 | Hall G2
Dosimetry Committee
Dosimetry e-Posters

309 Sunday, October 18, 2026 | 09:45 – 11:15 | Hall G2
Cardiovascular Committee
A Journey Through the Cardiovascular System

509 Sunday, October 18, 2026 | 15:00 – 16:30 | Hall G2
Oncology & Theranostics Committee
Oncology & Theranostic e-Posters

609 Sunday, October 18, 2026 | 16:45 – 18:15 | Hall G2
Physics Committee
Physics e-Posters

709 Monday, October 19, 2026 | 08:00 – 09:30 | Hall G2
Radiopharmaceutical Sciences Committee
The Science Of Radiopharmaceutical Preparation

809 Monday, October 19, 2026 | 09:45 – 11:15 | Hall G2
Bone & Joint Committee
Bone & Joint e-Posters

1009 Monday, October 19, 2026 | 15:00 – 16:30 | Hall G2
Thyroid Committee
Nuclear Medicine in Endocrine Disorders: Current Diagnostic and Therapeutic Landscapes

1109 Monday, October 19, 2026 | 16:45 – 18:15 | Hall G2
Translational Molecular Imaging & Therapy Committee
Translational Imaging and Therapy

1209 Tuesday, October 20, 2026 | 08:00 – 09:30 | Hall G2
Radiation Protection Committee
Radiation Protection e-Posters

1309 Tuesday, October 20, 2026 | 09:45 – 11:15 | Hall G2
Inflammation & Infection Committee
Best e-Posters on Inflammation & Infection Imaging

1509 Tuesday, October 20, 2026 | 15:00 – 16:30 | Hall G2
AI Committee
AI Data and Image Analysis, Dynamic Imaging

1609 Tuesday, October 20, 2026 | 16:45 – 18:15 | Hall G2
Radiopharmaceutical Sciences Committee
Modern Approaches to Drug Development in Nuclear Medicine

1709 Wednesday, October 21, 2026 | 08:00 – 09:30 | Hall G2
Neuroimaging Committee
Neuroimaging e-Posters

1809 Wednesday, October 21, 2026 | 09:45 – 11:15 | Hall G2
Paediatrics Committee
Paediatrics e-Posters

TECHNOLOGISTS' TRACK

PLENARY SESSIONS

1
Sunday, October 18, 2026 | 11:30 - 13:00 | Hall A
THERANOSTICS: The Next Level

2
Monday, October 19, 2026 | 11:30 - 13:00 | Hall A
From Treatment to Prevention: The Evolving Role of Nuclear Medicine in Early Diagnosis

3
Tuesday, October 20, 2026 | 11:30 - 13:00 | Hall A
Our Path to Sustained Scientific Success: How to Prepare for 2040

INVITED SPEAKER SESSIONS (CTE SESSION)

1
Sunday, October 18, 2026 | 08:00 - 09:30 | Hall K
Technologists Committee + SNMMI
Technologists' Guide Launch

2
Sunday, October 18, 2026 | 09:45 - 11:15 | Hall K
Technologists Committee + EFRS
New Working Practices in Nuclear Medicine: Innovation, Safety and Emerging Responsibilities

3
Sunday, October 18, 2026 | 16:45 - 18:15 | Hall K
Technologists + Paediatrics Committee
[^{18}F]FDGFDG for PET/CT and PET/MRI: the Focus on Paediatric Patients

4
Monday, October 19, 2026 | 09:45 - 11:15 | Hall K
Technologists + Inflammation & Infection Committee
Imaging of Foreign Body Associated Inflammation and Infections : Pearls and Pitfalls

5
Monday, October 19, 2026 | 16:45 - 18:15 | Hall K
Technologists + Thyroid Committee
NM Applications for Benign Thyroid Diseases

6
Tuesday, October 20, 2026 | 08:00 - 09:30 | Hall K
Technologists Committee + TMI&T Committee
Behind the Scenes in Translational Nuclear Medicine

7
Tuesday, October 20, 2026 | 15:00 - 16:30 | Hall K
Technologists Committee / ESTRO
Theranostics: Bridging Nuclear Medicine and Radiotherapy for Better Cancer Treatment

MINI COURSES

1710a
Wednesday, October 21, 2026 | 08:00 - 09:00 | Hall K
Technologists Committee + Radiation Protection Committee
Radiation Protection in Patients Undergoing Radioligand Therapy

1710b
Wednesday, October 21, 2025 | 09:05 - 10:05 | Hall K
Technologists Committee + Physics Committee
Instrumentation and Dosimetry

1710c
Wednesday, October 21, 2026 | 10:15 - 11:15 | Hall K
Technologists Committee + Radiopharmaceutical Sciences Committee
Therapeutic Radioisotopes and Their Radioligands - The Overview of Daily Radiochemical Practice

PROFFERED PAPER SESSIONS (ORAL PRESENTATIONS)

510
Sunday, October 18, 2026 | 15:00 – 16:30 | Hall K
Technologists' Committee – TROP Session
Nuclear Medicine Across the Spectrum: Education, Professional Issues, Conventional Imaging, and Paediatrics

710
Monday, October 19, 2026 | 08:00 – 09:30 | Hall K
Technologists' Committee – TROP Session
PET and Radiopharmacy: Science, Technology, and Clinical Applications

1010
Monday, October 19, 2026 | 15:00 – 16:30 | Hall K
Technologists' Committee – e-Poster Presentation Session
Technologist' e-Posters

1310
Tuesday, October 20, 2026 | 09:45 – 11:15 | Hall K
Technologists' Committee – TROP Session
Advancing Theranostics: Innovations in Therapy and Dosimetry

AWARDS

EANM will bestow several awards throughout the EANM'26.

EANM MARIE CURIE AWARD

Each year EANM is awarding the best rated abstract with the prestigious Marie-Curie Award. The Award is bestowed during the EANM Congress Opening Ceremony by the EANM Scientific Events Council Chair.

EANM YOUNG AUTHORS' AWARD

(Kindly supported by United Imaging Healthcare)

EANM is offering an award to young authors of very good quality abstracts accepted for presentation at the EANM Annual Congress. This award aims to encourage young and talented nuclear medicine investigators to submit their results to the EANM Annual Congress and to have financial aid to attend the meeting and present their work.

EANM SANJIV SAM GAMBHIR YOUNG INVESTIGATOR AWARD

(Kindly supported by Telix Pharmaceuticals)

This award will fund a 3 months visitorship at Stanford University. Six jury picked candidates will compete in an award session for this recognition.
Details: Monday, October 19, 2026 – 15:00-16:30 in Hall D – Arena.

EANM TECHNOLOGISTS' AWARD

(Kindly supported by United Imaging Healthcare)

The purpose of the EANM Technologists' Award is to encourage Nuclear Medicine Technologists to present the abstract of their research project at the EANM Annual Congress.
A total of 4 awards will be handed over at the EANM'26.

EANM YOUNG SCIENTIST NETWORK (YSN) AWARD

(Kindly supported by Advanced Accelerator Applications (ADACAP), a Novartis company)

The YSN aims to support early-career researchers and clinicians from diverse disciplines conducting innovative research in alpha radioligand therapy (α-RLT). By fostering promising small to mid-size projects, the YSN seeks to accelerate high-quality research with clear translational and clinical relevance

EANM ALAVI CARLSEN AWARD

Recognising excellence and supporting the next generation of scientists. The EANM Alavi-Carlsen Award celebrates outstanding research by young scientists and supports their continued scientific development and training. Discover the award and celebrate this year's winners at EANM'26!
Details: Tuesday, October 20, 2026 – 13:15 - 14:45 in Hall G2

European Association Nuclear Medicine
ELSEVIER

One year of bridging disciplines and advancing research—join us and contribute.



Discover more about the EANM Journals

THE EANM journal
EANM innovation

Oral Sessions

OC

Saturday, October 17, 2026, 18:00 - 19:30

Hall A

Opening Ceremony including Awards Ceremony

OP-001

Opening Ceremony
V. Garibotto;
Geneva University and Geneva University Hospitals, Geneva, SWITZERLAND.

201

Sunday, October 18, 2026, 08:00 - 09:30

Hall A

CME 1 - Oncology & Theranostics Committee: The Alpha Era in Prostate Cancer: Progress, Challenges, and Next Steps

OP-006

What are the Most Promising Alpha-Emitters?
A. Kjær;
University of Copenhagen, Department of Biomedical Sciences, Copenhagen, DENMARK.

OP-007

Why is TAT Relevant for Prostate Cancer?
M. Eiber;
Department of Nuclear Medicine, TUM University Hospital, Munich, GERMANY.

OP-008

How to Properly Select and Monitor Patients Treated with TAT?
L. Emmet;
St Vincent's Hospital, Department of Theranostics and Nuclear Medicine, Sydney, AUSTRALIA.

OP-009

TAT-Challenges and Future Directions
T. Brabander;
Erasmus Medisch centrum, Department of Nuclear medicine, Rotterdam, NETHERLANDS.

202

Sunday, October 18, 2026, 08:00 - 09:30

Hall D (Arena)

Special Track 1 - Oncology & Theranostics Committee: Debate: From Innovation to Recommendation: Introducing FAPI in Clinical Guidelines

OP-010

Point of View: FAPI PET on Trials: Is Survival Data Essential for Clinical Adoption?
S. Veldhuijzen van Zanten;
Erasmus Medical Centre, Department of Radiology and Nuclear Medicine, Rotterdam, NETHERLANDS.

OP-011

Point of View: Beyond the Hype: Are We Ready to Expand FAPI Indications in Oncology?
W. Fendler;
Clinical University, Dept. of Nuclear Medicine, Essen, GERMANY.

203

Sunday, October 18, 2026, 08:00 - 09:30

Hall E1

LIPS Session 1 - Neuroimaging Committee: Neuroimaging Brain Metastases: Updates on Diagnosis and Therapy

OP-012

Current Clinical Management and New Therapies
M. Preusser;
Medicine University of Vienna, Vienna, AUSTRIA.

OP-013

Diagnostic Imaging of Brain Metastases
A. Verger;
University Hospital of Nancy, Nancy, FRANCE.

OP-014

PET RANO BM Criteria – New Avenues for Clinical Trials
N. Albert;
LMU Hospital, Ludwig Maximilians University, Munich, GERMANY.

OP-015

Targeted Radionuclide Rherapy for Brain Metastases
N. Tolboom;
Medical Centre Utrecht, Utrecht, NETHERLANDS.

204

Sunday, October 18, 2026, 08:00 - 09:30

Hall E2

M2M Track: TROP Session - Radiopharmaceutical Sciences Committee: Making Radiotracers Better

OP-016

Photoacid-Activated ^{64}Cu-Doped Metal-Organic Frameworks Potentiate Radionuclide-Integrated Cuproptosis
Y. Feng*, X. Zhang, X. Wang, X. Lan;*
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Scien, Wuhan, CHINA.

OP-017

Shattering Pretargeting Pre-conceptions with an in vivo Stable Trans Cyclooctene (TCO)
N. Straathof*[1], S. Delaney[1], M. Zabrocki[1], J. A. Plischke[1], Y. Yang[1], G. M. Knudsen[2], U. M. Battisti[1], M. M. Herth[1];*
[1]Copenhagen University, Copenhagen, DENMARK,
[2]Copenhagen University Hospital, Copenhagen, DENMARK.

OP-018

Structural drivers of SST_2/SST_5 agonism or antagonism by DOTA-NOC derived ligands
F. Spinnler*[1], L. Del Pozzo[1], L. Bohrmann[1], S. Zanger[1], N. Blum[2], M. Brendel[2], S. Schulz[2], R. Mansi[1], M. Fani[1];*
[1]Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, SWITZERLAND,
[2]Institute of Pharmacology and Toxicology, University Hospital Jena, Jena, GERMANY.

OP-019

Novel Bispecific RDC+ADC Theranostics Targeting HER2 & TF
E. Wu, ***Z. Qu****;*
Nanolattix, Taiyuan, CHINA.

OP-020

A linker-optimised PSMA-targeting scaffold enables systematic fluorescent dye library evaluation for dual-labelled fluorescence-guided surgery
P. Minges*[1,2,3], J. Matthias[4], L. Domogalla[1,2], B. Thomas[5], N. Steinacker[1,2], H. Müller[5], A. Dietzel-Schaarschmidt[6], P. Meyer[1,2], M. Eder[1,2], A. Eder[1,2];*
[1]University Medical Center Freiburg, Freiburg im Breisgau, GERMANY,
[2]Division of Radiopharmaceutical Development, DKTK Partner Site Freiburg and DKFZ Heidelberg, GERMANY,
[3]Faculty of Biology, University of Freiburg, Freiburg, GERMANY,
[4]Abberior GmbH, Göttingen, GERMANY,
[5]Xion GmbH, Berlin, GERMANY,
[6]Henke-Sass, Wolf GmbH, Tuttlingen, GERMANY.

OP-021

Modular Glyco-Engineering of HER2-Targeting Affibody for Radiotheranostics
W. Wang*[1], M. Huang[1], R. Wang[1], Y. Wang[2], R. Tian[1];*
[1]Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA,
[2]Department of Nuclear Medicine and Clinical Nuclear Medicine Research Lab, West China Hospital, Sichuan University, Chengdu, CHINA.

OP-022

AI-driven De novo Design of GPC3-binding Macrocycles as Radiotracers for Hepatic Carcinoma
R. En;
Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA.

OP-023

A novel site-specific decoupled labeling platform enables scalable TROP-2 targeted antibody radiotheranostics
K. Bratteby*[1], K. Pettersson Palm[1], M. Godzwon[2], K. Åkerberg Schriever[3], N. Thalén[3], P. I. Arvidsson[1], J. Ytterberg[4], L. Dahllund[3], M. Ohlin[2], R. Altena[1], J. Siikanen[1], T. A. Tran[1];*
[1]Karolinska Institutet, Stockholm, SWEDEN,
[2]Lund University, Lund, SWEDEN,
[3]Royal Institute of Technology, Stockholm, SWEDEN,
[4]Uppsala University, Uppsala, SWEDEN.

OP-024

Development and Preclinical Evaluation of an Affinity-Optimized Biparatopic Anti-EGFR Antibody for Targeted Radionuclide Therapy of EFGR-Positive Colorectal Cancer (CRC)
D. Fon*[1], E. Nwangele[1], F. Njotu[1], J. Ketchemen[1], C. Bimela[1], L. Athili[1], A. Ngong[1], K. Bato[1], M. Uppalapati[2], H. Fonge[1];*
[1]Université Laval, Quebec City, QC, CANADA,
[2]University of Saskatchewan, Saskatoon, SK, CANADA.

205

Sunday, October 18, 2026, 08:00 - 09:30

Hall B

Cutting Edge Science Track: Physics Committee: Advanced PET Imaging: Methods and Applications

OP-025

First-in-human simultaneous $Na^{124}I$/^{18}FFDG dual-tracers PET imaging based on prompt gamma emissions
X. Li*[1], L. He[2], M. Niu[1], Y. Liu[2], J. Ren[2], R. Yang[1], W. Yang[1], J. Wang[1], F. Kang[1];*
[1]Department of Nuclear Medicine, Xijing Hospital, Xi'an, CHINA,
[2]United Imaging Healthcare, Shanghai, CHINA.

OP-027

Simulation-Based Imaging Performance and Experimental Motion Quantification of a Bed-Adapted Walk-Through PET

R. Aziz[1], *B. Vervenne*[1], *M. Abi Akl*[1], *J. Maebe*[1], *N. Withofs*[2], *C. Vanhove*[1], *S. Vandenberghe*[1];
[1]*Ghent University, Ghent, BELGIUM,*
[2]*CHU of Liege, Liege, BELGIUM.*

OP-028

Fast and Fitting-Free Ortho-Positronium Lifetime Tomography Without Prior Assumptions on Branching Ratios

J. Qi;
UC Davis, Davis, CA, UNITED STATES OF AMERICA.

OP-029

Brain PET Prototype Using TOF-DOI Detectors Aiming 1-mm Resolution

K. Narita[1],[2], *G. Akamatsu*[1], *Y. Iwao*[1], *E. Yoshida*[1], *H. Tashima*[1], *M. Takahashi*[1], *T. Yamaya*[1];
[1]*National Institutes for Quantum Science and Technology (QST), Chiba, JAPAN,*
[2]*Graduate School of Science and Engineering, Chiba University, Chiba, JAPAN.*

OP-030

The Impact of 178 ps TOF Time Resolution: Effects on Image Quality and Detectability of Hot and Cold Spheres Under Scatterering Conditions

K. Inuzuka[1], *Y. Yamashita*[2], *S. Awamoto*[2], *S. Yoshidome*[2], *Y. Masaki*[1], *S. Kamitamari*[1], *K. Yamada*[3], *S. Baba*[4];
[1]*Division of Medical Quantum Science, Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JAPAN,*
[2]*Division of Radiology, Department of Medical Technology, Kyushu University Hospital, Fukuoka, JAPAN,*
[3]*Department of Radiological Technology, School of Health Sciences, Faculty of Medicine, Kyushu University, Fukuoka, JAPAN,*
[4]*Division of Medical Quantum Science, Department of Health Sciences, Faculty of Medicine, Kyushu University, Fukuoka, JAPAN.*

OP-031

Fast-acquisition PET-CT using a long-axial field-of-view (LA-FOV) total body PET scanner: results from the EQUIP Study

C. Pain[1], *A. Corlett*[1,2], *P. Jackson*[1,2], *R. Alipour*[1,2], *G. Kong*[1,2], *A. Wong*[1,2], *J. P. Buteau*[1,2], *T. Akhurst*[1,2], *S. L. Stuckey*[1,3], *D. Fernando*[1], *M. S. Hofman*[1,2];
[1]*Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA,*
[2]*University of Melbourne, Melbourne, AUSTRALIA,*
[3]*Monash University, Melbourne, AUSTRALIA.*

OP-032

Validation of the equivalence of ultra-long axial field-of-view PET/CT without CT attenuation correction reconstruction in the diagnosis and treatment of lymphoma: A new strategy for reducing radiation dose

M. Li, *Z. Wang, H. Pang;*
The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

OP-033

One Scan, One System: single subject networks as a novel biomarker

A. Grentner, *B. Geist;*
Medical University of Vienna, Division of Nuclear Medicine, Vienna, AUSTRIA.

206

Sunday, October 18, 2026, 08:00 - 09:30

Hall C

Clinical Oncology Track: Gastro-Intestinal Malignancy

OP-034

[68Ga]Ga-FAPI-46 PET/CT vs [18F]FDG PET/CT for Primary Staging of Gastric and Gastroesophageal Adenocarcinomas: Results from A Danish Prospective Trial

M. Bentestuen[1,2], *I. Makieva*[1], *T. B. Andersen*[1], *M. Ladekarl*[3,2], *S. Dikinis*[4,2], *M. Borrisholt*[5], *S. B. Jensen*[1,6], *L. R. Soro*[1], *O. Thorlacius-Ussing*[4,2], *H. D. Zacho*[1,2];
[1]*Department of Nuclear Medicine and Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, DENMARK,*
[2]*Department of Clinical Medicine, Aalborg University, Aalborg, DENMARK,*
[3]*Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, DENMARK,*
[4]*Department of Gastrointestinal Surgery and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, DENMARK,*
[5]*Department of Pathology, Aalborg University Hospital, Aalborg, DENMARK,*
[6]*Department of Chemistry and Bioscience, Aalborg University, Aalborg, DENMARK.*

OP-035

Whole-body HER2 PET/CT reveals spatial heterogeneity of HER2 expression in advanced gastroesophageal adenocarcinoma.

A. Tzortzakakis[1], *L. Liu*[1], *M. Zeinali*[1], *G. Ahlgren*[1], *T. Nilsson*[1], *M. Holstensson*[1], *K. Bratteby*[1], *F. Y. Frejd*[2], *I. Rouvelas*[1], *M. Lindblad*[1], *F. Klevebro*[1], *M. Nilsson*[1], *T. A. Tran*[1], *R. Axelsson*[1];
[1]*Karolinska Institutet, Stockholm, SWEDEN,*
[2]*Uppsala University, Uppsala, SWEDEN.*

OP-036

ELEGANCE: Prospective pilot study, assessing imaging performance of 89Zirconium-labelled Girentuximab [89Zr]Zr-girentuximab PET/CT in Patients with Hepatocellular Carcinoma, Biliary Tract Cancer or Gastro-Entero- Pancreatic Neuroendocrine Neoplasms

C. Bailly[1], *R. Bardy*[1], *F. Lelan*[1], *C. Ansquer*[1], *C. Francois*[1], *R. Metz*[1], *A. Lugat*[1], *M. Barbaud*[1], *A. Menard*[1], *C. Dubegny*[1], *V. Vilgrain*[2], *R. Lebtahi*[2], *F. Kraeber-Bodere*[1], *T. Carlier*[1], *Y. Touchefeu*[1];
[1]*CHU Hotel Dieu, Nantes, FRANCE,*
[2]*AP-HP Nord, Beaujon Hospital, Clichy, FRANCE.*

OP-037

Phenotypic approach integrating Dmax and TMTV from baseline FDG-PET in gastrointestinal cancers correlated with ctDNA analysis

P. de Priester, *K. Amrane, Y. Cras, A. Boilève, A. Italiano, M. Ducreux, A. Hollebecque, C. Massard, T. Henry, D. Déandreis;*
Institut Gustave Roussy, Villejuif, FRANCE.

OP-038

Real-World Evidence in a Large Cohort Supporting FAPI PET/CT as a Preferred Modality over FDG PET/CT for Hepatopancreatobiliary Cancer Diagnosis

M. Veenstra[1], *S. Batchu*[2], *D. de Jong*[1], *M. Jayanthi*[2], *E. Vegt*[1], *S. F. Memon*[2], *A. Tyagi*[2], *D. Bos*[1], *S. Lakhtakia*[2], *M. Bruno*[1], *N. D. Reddy*[2], *H. Rughwani*[2], *M. Thomeer*[1];
[1]*Erasmus MC, Rotterdam, NETHERLANDS,*
[2]*AIG Hospitals, Hyderabad, INDIA.*

OP-039

Diagnostic Performance and Clinical Value of [68Ga]GaFAPI46 PET/CT and [18F]FDG PET/CT for Post Neoadjuvant Chemotherapy Staging of Gastric and Gastroesophageal Junction Adenocarcinoma

M. Bentestuen[1,2], *I. Makieva*[1], *T. B. Andersen*[1], *M. Ladekarl*[3,2], *S. Dikinis*[4], *M. Borrisholt*[5], *S. B. Jensen*[1,6], *L. R. Soro*[1], *O. Thorlacius-Ussing*[4,2], *H. D. Zacho*[1,2];
[1]*Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, DENMARK,*
[2]*Department of Clinical Medicine, Aalborg University, Aalborg, DENMARK,*
[3]*Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, DENMARK,*
[4]*Department of Gastrointestinal Surgery and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, DENMARK,*
[5]*Department of Pathology, Aalborg University Hospital, Aalborg, DENMARK,*
[6]*Department of Chemistry and Bioscience, Aalborg University, Aalborg, DENMARK.*

OP-040

PSMA Pet/Ct In Hepatocellular Carcinoma: A Potential Game-Changer In Management?

P. Guglielmo[1], *S. Damiani*[2], *M. Rodari*[1], *G. Torzilli*[1], *T. Pressiani*[3], *L. Evangelista*[1];
[1]*Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ITALY,*
[2]*Humanitas University, Pieve Emanuele, Milan, ITALY,*
[3]*Hepatopancreatobiliary Oncology Unit, IRCCS Humanitas Research Hospital, Milan, ITALY.*

OP-041

HIMIKO: [68Ga]Ga-PSMA-11 PET/CT in Hepatocellular carcinoma: impact of multiparametric dynamic whole-body imaging and kinetic modeling

C. Bailly[1], *R. Bardy*[1], *Y. Touchefeu*[1], *F. Lelan*[1], *C. Francois*[1], *R. Metz*[1], *M. Barbaud*[1], *N. Taheri*[1], *A. Menard*[1], *C. Dubegny*[1], *R. Lebtahi*[2], *V. Vilgrain*[2], *F. Kraeber-Bodere*[1], *T. Carlier*[1];
[1]*CHU Hotel Dieu, Nantes, FRANCE,*
[2]*AP-HP Nord, Beaujon Hospital, Clichy, FRANCE.*

OP-042

Head-to-Head Comparison of [68Ga]Ga-FAPI PET/CT and [18F]FDG PET/CT In Treatment Naive Gastric Carcinoma and the Clinical Utility of FAP-RADS for Structured Interpretation

A. Anirudh, *H. Goyal, D. Halanaik, S. Sureshkumar, P. Sai Krishna, S. Ananth Kumar;*
Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, INDIA.

207

Sunday, October 18, 2026, 08:00 - 09:30

Hall F1

Thyroid Committee: Nuclear Medicine Imaging in Endocrine Disease: Present and Future Perspective

OP-043

Full quantitative assessment of hepatic free fatty acid metabolism using [18F]FTHA-PET in MAFLD and its associations with liver enzymes

U. Ustsinau[1,2], *T. Saari*[1,3], *M. Monfort Pires*[1,3], *R. Aarnio*[1,4], *M. U-Din*[1,3], *F. M. Acosta*[1,4], *A. K. Kirjavainen*[1,5], *C. Philippe*[2], *P. Nuutila*[1,3], *K. A. Virtanen*[1,3];
[1]*Turku PET Centre, University of Turku, Turku, FINLAND,*
[2]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, AUSTRIA,*
[3]*Turku PET Centre, Turku University Hospital, Turku, FINLAND,*
[4]*InFLAMES Research Flagship, University of Turku, Turku, FINLAND,*
[5]*Turku PET Centre, Radiopharmaceutical Chemistry Laboratory, University of Turku, Turku, FINLAND.*

OP-044

Evaluation of Metabolic, Volumetric, and Clinical Parameters of Brown Adipose Tissue with Fluorodeoxyglucose Positron Emission Tomography / Computed Tomography

M. Dasar[1], *G. Koca*[1], *N. M. Arslan*[1], *H. Eroğlu Elden*[2], *K. Demirel*[1], *M. Korkmaz*[1];
[1]*University Of Health Sciences, Ankara Training And Research Hospital, Department Of Nuclear Medicine, Ankara, TÜRKIYE,*
[2]*Kahramanmaraş Necip Fazıl City Hospital, Kahramanmaraş, TÜRKIYE.*

OP-045

The Changing Landscape of PET in Functioning Pituitary Disease To Influence Treatment Outcomes: A Systematic Review

A. Nashikkar[1], *R. Brewster*[2], *D. Llewellyn*[2], *M. Yakubu*[2], *R. Srinivasan*[3], *S. Chicklore*[3], *S. Gould*[2], *P. Carroll*[3], *A. Velusamy*[3], *G. Cook*[2], *A. Hammers*[2], *R. Senanayake*[4];
[1]*Kings College London, London, UNITED KINGDOM,*
[2]*King's College Hospital, London, UNITED KINGDOM,*
[3]*Guy's & St Thomas' NHS Foundation Trust, London, UNITED KINGDOM,*
[4]*Guy's & St Thomas' NHS Foundation Trust/King's College Hospital, London, UNITED KINGDOM.*

OP-046

Development and Prospective Validation of a Noninvasive Model for Adrenalectomy without Adrenal Venous Sampling in Patients with Primary Aldosteronism Based on ^{68}Ga-Pentixafor PET/CT

Y. Yang, *Y. Yang, J. Yang, T. Long, S. Hu;*
Xiangya Hospital, Central South University, Changsha, CHINA.

OP-047

Delta ^{68}Ga-Pentixafor PET/CT Radiomics Models for the Detection of Surgically Curable Primary Aldosteronism

R. Zuo, *Z. Wang, H. Pang;*
the First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

OP-048

Diagnostic performance of ^{68}Ga-Pentixafor PET imaging in the prospective PENTALON study using adrenal vein sampling as gold standard.

A. Cottereau[1], *J. Riancho*[2], *E. Piekarski*[1], *Q. Nguyen*[3], *A. Arnoux*[3], *E. Snobbert*[1], *T. Rusu*[4], *Y. Mouraeff*[1], *L. Amar*[2], *F. Hyafil*[5];
[1]*Cochin, Nuclear Medicine, Paris, FRANCE,*
[2]*Hôpital Européen Georges-Pompidou, Endocrinology, Paris, FRANCE,*
[3]*Hopital Européen Georges-Pompidou, Biostatistics, Paris, FRANCE,*
[4]*Tenon Hospital, Radiopharmacy department, Paris, FRANCE,*
[5]*Hopital Européen Georges-Pompidou, Nuclear Medicine department, Paris, FRANCE.*

OP-049

Diagnostic Value of Multiparametric ^{68}Ga-Pentixafor PET/MR for Identification and Subtyping of Functional Adrenocortical Adenomas

X. Chen[1], *R. Zhang*[1], *Q. Ji*[2], *Y. Hu*[2], *J. Zhao*[1], ***Y. Xing***[1];
[1]*Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA,*
[2]*Shanghai United Imaging Healthcare Co., Ltd., Shanghai, CHINA.*

OP-050

Accuracy of ^{11}C-Metomidate PET/CT for Identifying Unilateral Aldosterone-Producing Adrenal Adenomas in Primary Aldosteronism: A Single-Center Pilot Study

S. Cheung, *S. Chen, Y. Wong, K. Wu, Y. Yip, K. Cheng, M. Cheung, C. Ho;*
Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.

OP-051

Comparison of ^{68}Ga-Septixafor and ^{68}Ga-Pentixafor PET/CT in the Diagnostic Efficacy for Subtyping Primary Aldosteronism

W. Zhengjie[1], *Z. Rui*[1], *L. Xiang*[2], *P. Hua*[1];
[1]*The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA,*
[2]*Medical University of Vienna, Vienna, AUSTRIA.*

208

Sunday, October 18, 2026, 08:00 - 09:30

Hall F2

Cardiovascular Committee: The New Age of Myocardial Perfusion SPECT

OP-052

2013 vs. 2019 ESC Pre-Test Probability Models of Obstructive Coronary Artery Disease and Their Relationship with Stress Myocardial Perfusion SPECT Findings: A Real-World Analysis

F. Silva-Ribeiro, *B. Martins, C. V. Pinto, V. C. Sousa;*
Unidade Local de Saúde de Loures / Odivelas, Lisboa, PORTUGAL.

OP-053

Relationship between myocardial blood flow measured by dynamic SPECT and CT-derived fractional flow reserve in coronary artery disease

A. Maltseva, *A. Mochula, A. Dasheeva, V. Shipulin, A. Tsygikalo, K. Zavadovsky;*
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

OP-054

Evaluation of Coronary Microvascular Disease and Prognostic Value Using D-SPECT-derived Myocardial Flow Reserve in Patients after Percutaneous Coronary Intervention

R. Wang[1], *W. Dong*[2], *H. Wang*[1], *P. Xie*[1];
[1]*Gansu Provincial Hospital, Lanzhou, CHINA,*
[2]*Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA.*

OP-055

Optimization of Assessment of Myocardial Perfusion Studies on Discovery NM 530c Camera - Myocardial Flow Reserve Values Combined with Static SPECT Data

P. Cichocki, *J. Kusmierek, A. Plachcinska, Z. Adamczewski;*
Department of Nuclear Medicine, Medical University of Lodz, Lodz, POLAND.

OP-056

Inferior myocardial wall ischemia (IMWI) score: how to improve multi-pinhole CZT myocardial perfusion imaging specificity for IMWI

F. Vauchot[1], *H. Boukrouma*[1], *J. Sagnes*[1], *C. Vauchot*[2], *T. Paunet*[1], *J. Dubois*[1];
[1]*CHU Montpellier, Montpellier, FRANCE,*
[2]*Clinique du Millénaire, Montpellier, FRANCE.*

OP-057

Clinical Evaluation of Myocardial Flow Reserve Values Calculated using Different Kinetic Models in SPECT Studies, Based on Invasive Coronary Angiography Data

P. Cichocki, *A. Plachcinska, J. Kusmierek, Z. Adamczewski;*
Department of Nuclear Medicine, Medical University of Lodz, Lodz, POLAND.

OP-058

Enhanced Coronary Territory-Based Diagnostic Accuracy of Myocardial Perfusion SPECT/CT Using a Novel Multifocal Collimator with Integrated Corrections

S. Watanabe[1], *K. Nakajima*[1], *T. Shibutani*[1], *S. Yoshida*[1], *F. Massanes*[2], *T. Shimizu*[3], *A. H. Vija*[2];
[1]*Kanazawa university hospital, Kanazawa, JAPAN,*
[2]*Siemens Medical Solutions USA, Inc., Hoffman Estates, IL, UNITED STATES OF AMERICA,*
[3]*Siemens Healthcare K.K., Tokyo, JAPAN.*

OP-059

Replacing spatial filtering with deep-learning noise reduction improves low-dose gated SPECT myocardial perfusion imaging

P. Marbaix[1], *M. Perrin*[1], *M. Claudin*[1], *R. Baavour*[2], *Y. Lamash*[2], *L. Imbert*[1], *P. Marie*[1];
[1]*CHRU-Nancy, Department of Nuclear Medicine and Nancyclotep Imaging platform, Nancy, FRANCE,*
[2]*Spectrum Dynamics Medical, Caesarea, ISRAEL.*

OP-060

Beyond the Septal Perfusion Defect: Lateral Wall Entropy on Gated SPECT Phase Analysis Captures Mechanical Risk in Left Bundle Branch Block

G. Kaya[1], *B. Soydaş-Turan*[2];
[1]*Republic of Türkiye, Ministry of Health, Yozgat City Hospital, Dept. of Nuclear Medicine, Ankara, TÜRKIYE,*
[2]*Kastamonu Training and Research Hospital, Kastamonu, TÜRKIYE.*

210

Sunday, October 18, 2026, 08:00 - 09:30

Hall K

CTE 1 - Technologists Committee / SNMMI: Technologists' Guide Launch

OP-061

Paediatric Patients are Not Small Adults - Communication Considerations

A. Grilo;
Department of Exact Sciences, Life Sciences, Social Sciences and Humanities, Lisbon, PORTUGAL.

OP-062

Achieving Diagnostic Confidence in Paediatric PET/MRI: Technical and Procedural Considerations

A. Capotosto;
Azienda Ospedale Università of Padova, Padua, ITALY.

OP-063

Diagnostic Radiopharmaceuticals - Promising Agents in Paediatric Patients

L. Rimanic;
Faculty British Columbia Institute of Technology (BCIT), School of Health Sciences, Nuclear Medicine Technology Program, Burnaby, CANADA.

211

Sunday, October 18, 2026, 08:00 - 09:30

Hall G1

Special Symposium 1 - EARL: New Image Quality and Sensitivity Methods for NEMA NU 2 and IEC 61675-1 PET Standards

OP-064

Introduction to new NEMA NU 2 and IEC 61675-1 PET Sensitivity and Image Quality Standards

G. Wells;
University of Ottawa Heart Institute, Division of Cardiac Imaging, Ottawa, CANADA.

OP-065

A New ^{22}Na Point Source Methodology for NEMA and IEC PET System Sensitivity Measurement

J. Yap;
University of Utah, Department of Radiology and Imaging Sciences, UNITED STATES OF AMERICA.

OP-066

Introduction of a New NEMA Image Quality Phantom with Modified Acquisition and Analysis Methodology

T. Turkington;
Duke University, Department of Radiology, Durham, UNITED STATES OF AMERICA.

OP-067

The New NEMA Image Quality Phantom: Applications Beyond Acceptance Testing and System Characterization

J. Sunderland;
University of Iowa, Department of Radiology, Iowa, UNITED STATES OF AMERICA.

301

Sunday, October 18, 2026, 09:45 - 11:15

Hall A

CME 2 - Neuroimaging Committee: Assessment, Staging and Monitoring of Alzheimer's Disease Neuropathological Changes in the Era of Disease-Modifying Therapies with PET

OP-068

Treatment Stratification and Monitoring of Anti-Amyloid Treatment with Quantitative Amyloid PET

L. Collij;
Lund University, Lund, SWEDEN.

OP-069

Specific Staging of Alzheimer's Disease Neuropathology with Tau PET
N. Franzmeier;
LMU Hospital, Munich, GERMANY.

OP-070

Assessment of Neurodegeneration Patterns in Alzheimer's Disease and Related Disorders
C. Boccalini;
University of Geneva, Geneva, SWITZERLAND.

OP-071

Real World Experience with PET Imaging for Inclusion and Monitoring of Anti-Amyloid Treatment
F. Agosta;
San Raffaele University, Milan, ITALY.

302

Sunday, October 18, 2026, 09:45 - 11:15

Hall D (Arena)

Special Symposium 2 - EARL: Clinical Implications of EARL PET/CT Accreditation Standards 3, ^{177}Lu SPECT/CT Accreditation for NaI and CZT: Results, Specifications, and Future Directions

OP-123

EARL PET/CT Accreditation Standards 3 and LAFOV Brain: Enhancing Diagnostic Quality and Patient Outcomes
R. Boellaard;
Amsterdam University Medical Center, Amsterdam, NETHERLANDS.

OP-124

^{177}Lu SPECT/CT Accreditation for Scintillation Scanners: Results, Specifications, and Points of Learning
L. Vávrová;
Universitätsklinikum Würzburg, Würzburg, GERMANY.

OP-125

^{177}Lu SPECT/CT Accreditation for CZT Scanners: Initial Results, and Future Directions
L. Imbert;
Centre Hospitalier Universitaire de Nancy, Nancy, FRANCE.

303

Sunday, October 18, 2026, 09:45 - 11:15

Hall E1

LIPS Session 2 - Cardiovascular Committee: Tips and Tricks to Set Up a Cardiac PET Programme on MPI

OP-076

The Physician Point of View
F. Hyafil;
Hôpital européen Georges-Pompidou AP-HP, Service de Médecine Nucléaire, Paris, FRANCE.

OP-077

The Technician Point of View
M. Coelho;
University Hospital Essen, Department of Nuclear Medicine, Essen, GERMANY.

OP-078

The Physicist Point of View
M. Lubberink;
Uppsala University, Department of Surgical Sciences, Uppsala, SWEDEN.

OP-079

The Radiopharmacist Point of View
T. Bregaint;
Hôpital européen Georges-Pompidou AP-HP, Service de Pharmacie, Paris, FRANCE.

304

Sunday, October 18, 2026, 09:45 - 11:15

Hall E2

M2M Track: TROP Session - Radiopharmaceutical Sciences Committee: ^{161}Tb vs ^{177}Lu, and The Winner Is...

OP-080

Development and preclinical characterization of [^{161}Tb]Tb-ART-101 as a next-generation PSMA radiotherapeutic
M. Bio Idrissou, *H. Comas Rojas, J. Munson, L. Lambert, A. Pinchuk, R. Hernandez;*
University of wisconsin-Madison (UW-Madison), Madison, WI, UNITED STATES OF AMERICA.

OP-081

Optimising CD38-Targeted Radioimmunotherapy in Aggressive Lymphoma with Repeated Lutetium-177 Isatuximab and Terbium-161 Benchmarking
B. Collin[1,2], *C. Petitot*[2,3], *A. Kownacka*[2,3], *D. Vivier*[1], *M. Moreau*[1], *S. Poty*[1,2], *F. Denat*[1], *A. Cochet*[1,2], *C. Rossi*[3,4], *F. Girodon*[3,4], *P. Bellaye*[2,3], *A. M. M. Dias*[1,2];
[1]*ICMUB UMR CNRS 6302, Dijon, FRANCE,*
[2]*IMATHERA, UMS INSERM 58 (BioSanD, Centre GF Leclerc), Dijon, FRANCE,*
[3]*CTM UMR INSERM 1231, Dijon, FRANCE,*
[4]*CHU François Mitterrand, Dijon, FRANCE.*

OP-082

Evaluation of the therapeutic efficacy of ^{161}Tb versus ^{177}Lu anti-CD30 radioimmunotherapy in a disseminated T-cell lymphoma mouse model
E. Rioja Blanco[1], *L. Rahunathen*[1], *Y. Banz*[2], *C. Schlapbach*[3], *U. Novak*[4], *T. Chiorazzo*[1], *P. Grundler*[1], *A. N. Moiseeva*[1], *N. van der Meulen*[1], *M. Grzmil*[1], *R. Schibli*[1], *M. Behe*[1];
[1]*PSI Center for Life Sciences, Villigen PSI, SWITZERLAND,*
[2]*Institute of Tissue Medicine and Pathology, University of Bern, Bern, SWITZERLAND,*
[3]*Department of Dermatology, Inselspital, Bern University Hospital, Bern, SWITZERLAND,*
[4]*Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, SWITZERLAND.*

OP-083

Preclinical Evaluation of Site-Specifically Radiolabeled Anti-CD70 Antibody [^{177}Lu]Lu- and [^{161}Tb]Tb-RDT-008 for The Treatment of Clear Cell Renal Cell Carcinoma
A. Yamaguchi, *J. Han, G. Ma, A. R. Sump, M. Lin, E. Subramani, J. K. Allen, C. Shi, H. C. Manning;*
The University of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

OP-084

Preclinical Evaluation of PNABased Affibody-mediated Pretargeting for targeting HER2: A direct comparison between Tb-161 and Lu-177
M. Oroujeni[1], *K. Westerlund*[2], *J. Clinton*[2], *A. Elshazli*[1], *E. Papalanis*[1], *I. Zelepukin*[1], *A. Vorobyeva*[1], *A. Olrova*[1], *A. Eriksson Karlström*[2], *V. Tolmachev*[1];
[1]*Uppsala University, Uppsala, SWEDEN,*
[2]*KTH Royal Institute of Technology, Stockholm, SWEDEN.*

OP-085

Enhancing Prostate Cancer Care Through Tandem PSMA- and GRPR-targeted Radionuclide Treatment
L. Bokhout[1], *C. M. Ntihabose*[1,2], *G. J. L. H. van Leenders*[3], *C. H. M. van Deurzen*[3], *E. H. de Blois*[1], *S. U. Dalm*[1];
[1]*Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS,*
[2]*Department of Hospital Pharmacy, Erasmus MC, Rotterdam, NETHERLANDS,*
[3]*Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, NETHERLANDS.*

OP-086

^{3}D radiobiology, a toolbox to study radionuclide therapy in PDX-derived prostate cancer organoids
D. Boreel, *S. Margis, N. Mehra, G. Verhaegh, F. Nijsen, S. Heskamp;*
Radboudumc, Nijmegen, NETHERLANDS.

OP-087

One Chelator, Three Radionuclides: First Head-to-Head Comparison of ^{177}Lu/^{161}Tb/^{225}Ac-PYTA-PE-panitumumab for Radioimmunotherapy of Pancreatic Adenocarcinoma
S. Poty[1,2], *M. Cheveau*[1,3], *L. Carter*[4], *M. Moreau*[1], *F. Boschetti*[3], *F. Denat*[1];
[1]*Université Bourgogne Europe, ICMUB, Dijon, FRANCE,*
[2]*Centre Georges François Leclerc, Dijon, FRANCE,*
[3]*CheMatech, Dijon, FRANCE,*
[4]*Memorial Sloan Kettering Cancer Centre, New York, NY, UNITED STATES OF AMERICA.*

OP-088

Comparative Preclinical Assessment of Lutetium-177 and Terbium-161 Labeled GRPR Antagonist for Prostate Cancer: Tumor Retention and SPECT Imaging
N. Kumar[1,2], *A. Bilinska*[1,2,3], *E. Menéndez*[1,2], *A. Rominger*[1,2], *E. Gourni*[1,2];
[1]*Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND,*
[2]*Department of Biomedical Research, University of Bern, Bern, SWITZERLAND,*
[3]*Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, SWITZERLAND.*

305

Sunday, October 18, 2026, 09:45 - 11:15

Hall B

Cutting Edge Science Track: AI Committee: AI and Monte Carlo Based Quantitative SPECT Imaging

OP-089

Toward Quantitative ^{212}Pb-SPECT with Torch Monte Carlo-Based Reconstruction
L. Polson[1], *F. J. Wilson*[1], *N. Culala*[2], *S. Graves*[3];
[1]*Voximetry, Madison, WI, UNITED STATES OF AMERICA,*
[2]*Perspective Therapeutics, Seattle, WA, UNITED STATES OF AMERICA,*
[3]*University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA.*

OP-090

A Generalizable Deep Learning-based Partial Volume Correction for Lu-177 SPECT/CT using Scanner Domain Conditioning
S. Kamrani[1,2], *A. Gehring*[1], *M. Salas Ramirez*[1], *J. Leube*[1], *P. Sheikhzadeh*[3], *J. Gustafsson*[4], *J. Tran-Gia*[1];
[1]*Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,*
[2]*Department of Medical Radiation Engineering, Shahid Beheshti University, Tehran, IRAN, ISLAMIC REPUBLIC OF,*
[3]*Department of Nuclear Medicine, IKHC, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,*
[4]*Medical Radiation Physics, Lund University, Lund, SWEDEN.*

OP-091

A Full Monte Carlo Reconstruction Algorithm for Improved Precision via Dual-Photopeak Lu-177 SPECT Imaging
L. Polson[1], *F. J. Wilson*[1], *S. Graves*[2];
[1]*Voximetry, Madison, WI, UNITED STATES OF AMERICA,*
[2]*University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA.*

OP-092

Enhanced image quality and quantitative accuracy in Ac-225 SPECT imaging via Monte Carlo-based reconstructions: a simulation and phantom study

C. Li[1,2], *P. Esquinas*[1,3,4], *J. Fowler*[1,2], *X. Hou*[3], *A. Rahmim*[1,2,3], *C. Uribe*[2,3,4];
[1]*Department of Physics & Astronomy, University of British Columbia, Vancouver, BC, CANADA,*
[2]*Department of Basic & Translational Research, BC Cancer Research Institute, Vancouver, BC, CANADA,*
[3]*Department of Molecular Imaging & Therapy, BC Cancer, Vancouver, BC, CANADA,*
[4]*Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.*

OP-093

Experimental and Monte Carlo-based assessment of collimator-induced X-rays in ^{177}Lu SPECT energy spectra

M. Koole[1], *B. Laurent*[2], *D. Visvikis*[2];
[1]*KU Leuven, Leuven, BELGIUM,*
[2]*INSERM, Brest, FRANCE.*

OP-094

Simulation-driven training of deep-learning models for Iodine-131 imaging before first patient acquisition

O. Ziv, *B. Yuzefovich, A. Devir-Wolfman, G. Rabin, R. Zananiri, J. Sachs;*
GE HealthCare, Haifa, ISRAEL.

OP-095

A Deep-Learning Approach to Reconstruction-Based Scatter Compensation in Multi-Pinhole SPECT

C. Steele[1], *G. Wells*[2];
[1]*Carleton University, Ottawa, ON, CANADA,*
[2]*University of Ottawa Heart Institute, Ottawa, ON, CANADA.*

OP-096

SPECT-driven AI attenuation correction maps bridge the gap between attenuation correction methods for DaT scan quantification.

Z. Wilson[1,2], *A. Sohlberg*[1,3,4], *J. Lilja*[3,1], *H. McMeekin*[3], *K. Bradley*[1], *D. McGowan*[1,2];
[1]*Oxford University Hospital NHS FT, Oxford, UNITED KINGDOM,*
[2]*University of Oxford, Oxford, UNITED KINGDOM,*
[3]*Hermes Medical Solutions, Stockholm, SWEDEN,*
[4]*Lahti Central Hospital, Lahti, FINLAND.*

OP-097

Evaluation of Reduced Acquisition Times in ^{123}I-FP-CIT SPECT (DaTscan) Imaging

D. Hescheler, *N. Bischoff, J. Mitura, H. Wissel, J. Wybranska, M. C. Kreissl;*
Department of Radiology and Nuclear Medicine, University Hospital Magd, Magdeburg, GERMANY.

306

Sunday, October 18, 2026, 09:45 - 11:15

Hall C

Clinical Oncology Track: Neuroendocrine Imaging

OP-098

Impact of68Ga-DOTATOC PET/CT-Based miTNM Staging on Implemented Management in Patients with Neuroendocrine Tumours

L. Yang[1], *W. Fendler*[2], *K. Herrmann*[2], *F. Weber*[3], *H. Lahner*[4], *D. Kersting*[2], *H. Hautzel*[2], *I. Ciuciulkaite*[2];
[1]*Department of Nulcear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA,*
[2]*Department of Nuclear Medicine, West German Cancer Center, DKTK and NCT site, University Hospital Essen, Essen, GERMANY,*
[3]*Department of Endocrine Surgery, West German Cancer Center, DKTK and NCT site, University Hospital Essen, Essen, GERMANY,*
[4]*Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, German Cancer Consortium, West German Cancer Center, Essen, GERMANY.*

OP-099

Hybrid SSTR-PET/CT criteria ouperfom RECIST 1.1 or SSTR-PET criteria alone in GEP-NET undergoing PRRT

C. Dascalescu, *F. L. Herr, C. Smith, V. Fusch, R. Ebner, M. L. Schnitzer, M. Heimer, J. Rübenthaler, K. Klimek, A. Holzgreve, R. A. Werner, C. C. Cyran;*
LMU Hospital, Munich, GERMANY.

OP-100

Quantitative Analysis of ^{177}Lu Urinary Excretion in PRRT Using a Novel Automated ^{177}Lu Removal System: Correlation with Tumour Burden and the 'Tumour Sink Effect'

S. Watanabe[1,2], *K. Hirata*[1,2], *Y. Sugawara*[3], *Y. Kikuchi*[3], *J. Takenaka*[1,2], *N. Wakabayashi*[1,2], *K. Oguri*[1,4], *K. Kudo*[1,4];
[1]*Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, JAPAN,*
[2]*Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, JAPAN,*
[3]*Advanced Medical Science-Planning, Inc, Tokyo, JAPAN,*
[4]*Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, JAPAN.*

OP-101

Three-Dimensional AI-Based Body Composition Analysis as a Prognostic Imaging Biomarker in NET Patients Undergoing PRRT

T. Ruhwedel[1], *J. Rogasch*[1], *N. Beetz*[2], *M. Galler*[1], *D. Geisel*[1], *W. Brenner*[1], *H. Amthauer*[1], *T. Walter-Rittel*[1], *I. Schatka*[1];
[1]*Charité Universitätsmedizin Berlin, Berlin, GERMANY,*
[2]*University Hospital Zurich (USZ), Zurich, SWITZERLAND.*

OP-102

Ga-68 DOTATATE PET/CT Deep Learning Approach to Predicting Prolonged Disease Control After Lu-177 DOTATATE Therapy

D. Dawson[1], *M. Milantoni*[2], *D. Laidley*[1], *R. Wong*[3], *S. Mattonen*[2];
[1]*London Health Sciences Centre, London, ON, CANADA,*
[2]*Department of Medical Biophysics, Western University, London, ON, CANADA,*
[33]*Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, CANADA.*

OP-103

[^{68}Ga]Ga-DOTA-Exendin-4 PET/CT for the Localization of Insulinoma: Results of an International, Dual-Center, Retrospective, Open-Label Real-World Imaging Study

J. Fricke[1], *K. Laubner*[2], *M. Schildmeijer*[1], *C. Wojsa*[1], *L. Menz*[2], *P. T. Meyer*[2], *J. Seufert*[2], *E. Christ*[1], *M. T. Freitag*[2], *D. Wild*[1];
[1]*University Hospital Basel, Basel, SWITZERLAND,*
[2]*University Hospital Freiburg, Freiburg, GERMANY.*

OP-104

Incremental value of ^{18}F-AIF-NOTA-JR11 PET/MR in detecting liver metastases in patients with neuroendocrine Tumours

X. Jin[1], *Q. Xie*[1], *X. Ding*[1], *B. Yu*[1], *Y. Zhang*[1], *X. Su*[2], *C. Yuan*[3], *M. Lu*[1], *Z. Yang*[1], *J. Yu*[1];
[1]*Peking University Cancer Hospital & Institute, Beijing, CHINA,*
[2]*Beijing United Imaging Healthcare Technology Development Co., Ltd., Beijing, CHINA,*
[3]*Peking University Third Hospital, Beijing, CHINA.*

OP-105

^{68}Ga-NJR-11 versus ^{68}Ga-DOTANOC PET/CT in neuroendocrine Tumours: a prospective head-to-head comparison study

M. K. Taggar[1], *S. A. Shamim*[1], *G. Arora*[1], *C. R*[1], *S. Rastogi*[1], *M. Verma*[2];
[1]*All India Institute Of Medical Sciences, New Delhi, INDIA,*
[2]*Maulana Azad Medical College, New Delhi, INDIA.*

OP-106

Next-Generation SSTR2-Targeted Antagonist [^{68}Ga] Ga-AG1001: A First-in-Human Study on Tracer Uptake, Biodistribution and Dosimetry

X. Yao[1], *W. Wu*[1], *P. Zhang*[1], *L. Xu*[1], *Q. Meng*[1], *R. Tian*[1], *Z. Zheng*[2], *P. Wang*[2], *J. Yue*[2], *Y. Jin*[2], *J. Yan*[2], *M. Liao*[2], *F. Wang*[1];
[1]*Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, CHINA,*
[2]*AlphaGen Therapeutics, Shanghai, CHINA.*

307

Sunday, October 18, 2026, 09:45 - 11:15

Hall F1

Dosimetry Committee: Advanced Dosimetry Methodology: Virtual Validation, Simplified Kinetics and Patient-Specific Marrow Modelling

OP-107

In-Silico Validation of the ^{177}Lu Dosimetry Chain: The Potential of Monte Carlo Benchmarking

K. Onuma[1], *T. Ogino*[1], *S. Ito*[1], *F. Sasaki*[2], *T. Kita*[2], *H. Sagara*[1], *H. Daisaki*[1];
[1]*Gunma Prefectural College of Health Sciences, Maebashi, JAPAN,*
[2]*Graduate School of Radiological Technology, Gunma Prefectural College of Health Sciences, Maebashi, JAPAN.*

OP-108

A Virtual Human Twin for Enhancement of Quantitative SPECT/CT Imaging

A. Gehring[1], *E. Yousefzadeh-Nowshahr*[2], *G. Glatting*[2], *J. Gustafsson*[3], *J. Tran-Gia*[1];
[1]*Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,*
[2]*Department of Nuclear Medicine, Ulm University, Ulm, GERMANY,*
[3]*Medical Radiation Physics, Lund, Lund University, Lund, SWEDEN.*

OP-109

Automated and explainable lesions dosimetry in ^{177}Lu-PSMA therapy

H. Baldau[1], *A. Sanchez-Lajusticia*[2], *D. Sarrut*[1,2], *L. Vergnaud*[1,3];
[1]*CREATIS; CNRS UMR5220; Inserm U1294; INSA-Lyon; Université Lyon 1, Lyon, FRANCE,*
[2]*LUMEN Nuclear Medicine Department, Centre Léon Bérard, Lyon, FRANCE,*
[3]*Autorité de sûreté nucléaire et de radioprotection (ASNR), Direction de la recherche et de l'expertise en santé/SDOS/LEDI, Fontenay-aux-Roses, FRANCE.*

OP-110

Population-based single-time-point kidney TIA calculation in [^{177}Lu]Lu-PSMA-617 therapy: A multicenter study

G. Glatting[1], *S. Aminah*[2], *E. Yousefzadeh-Nowshahr*[1], *S. M. B. Peters*[3], *A. R. Hakim*[2], *T. M. Z. Y. Polem*[2], *I. Budiansah*[2], *U. Nemer*[4], *F. Kind*[4], *P. T. Meyer*[4], *B. M. Privé*[3], *J. Nagarajah*[3], *L. Ferrer*[5], *M. Konijnenberg*[6], *N. Varmenot*[7], *M. Mix*[8], *D. Hardiansyah*[2];
[1]*Universität Ulm, Ulm, GERMANY,*
[2]*Universitas Indonesia, Depok, INDONESIA,*
[3]*Radboud University Medical Centre, Nijmegen, NETHERLANDS,*
[4]*Medical Centre – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY,*
[5]*ICO René Gauducheau, St-Herblain, FRANCE,*

[6]Erasmus Medical Centre, Rotterdam, NETHERLANDS,
[7]Nantes University, Nantes, FRANCE,
[8]Stellenbosch University, Cape Town, SOUTH AFRICA.

OP-111

Single- and Dual-Time-Point Dosimetry for Radioligand Therapy: A Unified Framework Validated Across Short- and Long-Circulating Agents

J. Li[1,2], T. Zhao[1,2], J. Huang[3], Y. Hua[1,2,4], J. Zhang[1,2,5];
[1]Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,
[2]Theranostics Center of Excellence, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,
[3]Department of Diagnostic Imaging, National University Hospital, Singapore, SINGAPORE,
[4]Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, Wuxi, CHINA,
[5]Clinical Imaging Research Centre, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.

OP-112

A population-based bayesian pharmacokinetic modelling of [^{177}Lu]Lu-PSMA-617 for whole-body single-time-point dosimetry

A. Terro[1], T. Zaragori[2,3], C. Boursier[4], P. Vera[1,5], P. Decazes[1,5], L. Imbert[3,4], T. Dufflot[6], A. Dieudonné[1,5];
[1]QuantIF-AIMS, Rouen University, Rouen, FRANCE,
[2]CIC,Inserm, University of Lorraine, CHRU Nancy, Nancy, FRANCE,
[3]IADI, U1254, Inserm, University of Lorraine, Nancy, FRANCE,
[4]Department of Nuclear Medicine, Nancyclotep Imaging Platform, University of Lorraine, CHRU Nancy, Nancy, FRANCE,
[5]Department of Nuclear Medicine, Henri Becquerel Center, Rouen, FRANCE,
[6]Univ Rouen Normandie, Normandie Univ, INSERM U1096, CHU Rouen, Department of Pharmacology and Inserm CIC-CRB 1404, Rouen, FRANCE.

OP-113

Towards a Personalised S-value Library: Cellularity-Dependent Red Marrow Absorbed Fractions from Human Vertabral µCT

H. Foss[1], E. Dall'Ara[2,3], M. Palanca[4], P. Bernhardt[1], J. Hemmingsson[1];
[1]Department of Medical Radiation Sciences, Institute of Clinical Sciences, The Sahlgrenska Academy, Gothenburg, SWEDEN,
[2]Insigneo Institute, The University of Sheffield, Sheffield, UNITED KINGDOM,
[3]Division of Clinical Medicine, The University of Sheffield, Sheffield, UNITED KINGDOM,
[4]Department of Industrial Engineering, Alma Mater Studiorum - University of Bologna, Bologna, ITALY.

OP-114

Personalised S Values created from segmented trephine bone marrow biopsy samples in a cohort of patients undergoing treatment for haematological malignancies

E. Morris[1,2], S. Michopoulou[2,3], K. Orchard[2,3], P. Schneider[2], A. Dickinson[2];
[1]Barts Health NHS Trust, London, UNITED KINGDOM,
[2]University of Southampton, Southampton, UNITED KINGDOM,
[3]University Hospital Southampton, Southampton, UNITED KINGDOM.

OP-115

Microenvironment heterogeneity-adjusted relative biological effectiveness reveals hidden marrow toxicity in SSTR2-targeted PRRT

J. Hong[1], S. Kossatz[2], K. Pandya[1], R. Seifert[1], H. Choi[3], S. Bae[3], K. Zeimpekis[1], E. Zan[4], P. Knoll[5], V. Gershan[5], A. Afshar[1], A. Rominger[1], W. Weber[6], K. Shi[1];
[1]Department of Nuclear Medicine, Inselspital, University of Bern, Bern, SWITZERLAND,
[2]Technical University Munich, Munich, GERMANY,
[3]Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,
[4]Department of Nuclear Medicine, Cleveland Clinic, Cleveland, OH, UNITED STATES OF AMERICA,
[5]IAEA, Vienna, AUSTRIA, [6]the Department of Nuclear Medicine, Klinikum Rechts der Isar, Munich, GERMANY.

308

Sunday, October 18, 2026, 09:45 - 11:15

Hall F2

Joint Symposium 1 - Oncology & Theranostics Committee / EAU: Changing Care: Highlights on Level I Therapy Trials in Prostate Cancer

OP-116

Highlights on Alpha Therapy: The New Kid on the Block?

J. Calais;
University of California, Los Angeles (UCLA), Los Angeles, UNITED STATES OF AMERICA.

OP-117

Highlights on Beta Therapy: How Will This Impact Future Management?

D. Deandreis;
Gustave Roussy, Paris, FRANCE.

OP-118

Combination RLT Is Coming: ENZAp, AlphaBet and More

L. Emmett;
St. Vincent's Hospital & University of New South Wales, Sydney, AUSTRALIA.

OP-119

How to Put This in Clinical Context?

B. Tombal;
Cliniques Universitaires Saint-Luc, Brussels, BELGIUM.

310

Sunday, October 18, 2026, 09:45 - 11:15

Hall K

CTE 2 - Technologists Committee + EFRS: New Working Practices in Nuclear Medicine: Innovation, Safety and Emerging Responsibilities

OP-120

Beyond the Console: Remote Scanning and the Future of Nuclear Medicine Practice

A. Geão;
CUF Descobertas, Lisbon, PORTUGAL.

OP-121

Remote Technical Support in Nuclear Medicine: Safety, Risk Mitigation and Workforce Adaptation

A. Sheahan Quinsten;
University Hospital Essen, Institute for Diagnostic and Interventional Radiology and Neuroradiology, Essen, GERMANY.

OP-122

Governance Models for Remote Nuclear Medicine Practice: Ethical, Legal and Professional Implications

D. Fonseca Ribeiro;
King's College Hospital NHS Foundation Trust, Radiology Care Group, London, UNITED KINGDOM.

311

Sunday, October 18, 2026, 09:45 - 11:15

Hall G1

Special Session – Oncology & Theranostics Committee: Intra-Arterial and Locoregional Radionuclide Therapy

OP-072

Intra-Arterial Radiopharmaceutical Therapy for Liver Tumours

M. Lam;
UMC Utrecht, Department of Nuclear Medicine and Radiology, Utrecht, NETHERLANDS.

OP-073

Intra-Arterial Radionuclide Therapy for Brain Tumours: Interventional Radiology and Radioprotection Aspects

V. Da Ros;
University Hospital of Rome "Tor Vergata", Rome, ITALY.

OP-074

Intra-Arterial Peptide Receptor Radionuclide Therapy for Meningioma

A. Braat;
Netherlands Cancer institute Amsterdam, Department of Nuclear Medicine, Amsterdam,NETHERLANDS.

OP-075

Locoregional Radiopharmaceutical Therapy for Brain Tumours

J. Kunikowska;
Medical University of Warsaw, Department of Nuclear Medicine; Warsaw, POLAND.

401

Sunday, October 18, 2026, 11:30 - 13:00

Hall A

Plenary 1: THERANOSTICS: The Next Level

OP-126

Exciting New Isotopes for Therapy – Just a Trend?

E. Aneheim;
University of Gothenburg, Gothenburg, SWEDEN.

OP-127

Rethinking FAP-Targeted Theranostics

T. Hope;
Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, UNITED STATES OF AMERICA.

OP-128

Integrin Directed Theranostics – Ready to Be a Success Story?

X. Lan;
Nuclear Medicine and PET Center Union Hospital, Tongji Medical College, HUST, Wuhan, CHINA.

OP-129

RLT and Chemo – Combination or Competition?

W. Fendler;
Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY.

OP-130a

RLT + Immunotherapy: Unlocking Immune Synergies with Radioligands

S. Sandhu;
Peter MacCallum Cancer Centre, Victoria, AUSTRALIA.

OP-130b

RLT + EBRT: Combining Systemic and Focal Radiation for Synergistic Tumor Control

C. Zamboglou;
Department of Radiation Oncology Medical Center - University of Freiburg, Freiburg, GERMANY.

402

Sunday, October 18, 2026, 13:15 - 14:45
Hall D (Arena)

Joint Symposium 1A - Translational Molecular Imaging & Therapy Committee / ESRR: Attracting and Educating Young Scientists in the Field of Radiopharmacy

OP-131

ESRR: Joining Forces in Radiopharmaceutical Education
F. Elvas;
University of Antwwrp, Department of Nucelar Medicine, Antwerp, BELGIUM.

OP-132

Inspire by EANM: How to Secure the Future Nuclear Medicine Workforce
K. Lückerath;
University Hospital Essen, Clinic for Nuclear Medicine, Essen, GERMANY.

OP-133

The Road to a New Radiopharmaceutical Educational Program – Best Practice
M. van Wijk;
Radboud Univerity Medical Center, Department of Medical Imaging, Nuclear Medicine, Nijmegen, NETHERLANDS.

501

Sunday, October 18, 2026, 15:00 - 16:30
Hall A

CME 3 - Inflammation & Infection Committee: Immune Cell Imaging

OP-134

Cellular Targeting in Cancer and Inflammation
C. Buckley;
Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Oxford, UNITED KINGDOM.

OP-135

Imaging the Immune Response in Cancer: New Frontiers in Immuno-Oncology
L. Evangelista;
Humanitas University, Department of Nuclear Medicine, Milan, ITALY.

OP-136

Advancing Preclinical Imaging for Translational Research
J. Sosabowski;
Barts Cancer Institute - Queen Mary University of London, Center of Cancer Biomarkers and Biotherapeutics, London, UNITED KINGDOM.

OP-137

Immune Cell Imaging in Inflammation & Infection: Mapping the Immune Landscape
C. Lauri;
Department of Medical-Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Nuclear Medicine Unit, University Hospital Sant' Andrea, Rome, ITALY.

502

Sunday, October 18, 2026, 15:00 - 16:30
Hall D (Arena)

Special Track 3 - Translational Molecular Imaging & Therapy Committee: Challenge the Expert: Combination Therapies, the Emerging Role of Radiobiology

OP-138

Combining with Immunotherapies
S. Heskamp;
Radboud University Medical Center, Nijmeden, NETHERLANDS.

OP-139

Combining with Epigenetic Modulators
R. Hernandez;
University of Wisconsin-Madison, Madison WI, UNITED STATES OF AMERICA.

OP-140

Team 'Synergy Skeptics'
M. Sabatella;
Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, NETHERLANDS.

OP-141

Team 'Synergy Skeptics'
T. Mohajershojai;
Karolinska Institutet, Stockholm, SWEDEN.

OP-142

Team 'Synergy Skeptics'
E. O'Neill;
University of Oxford, Oxford, UNITED KINGDOM.

OP-143

Team 'Synergy Skeptics'
S. Schmitl;
Medical University of Vienna, Vienna, AUSTRIA.

503

Sunday, October 18, 2026, 15:00 - 16:30
Hall E1

LIPS Session 3 - Thyroid Committee: Getting 'It' Right: The Right Indication and Best Imaging Approach for Diagnostics in Hyperparathyroidism

OP-144

Parathyroid Ultrasound as Gatekeeper: Adenoma, Carcinoma, and the Thyroid you Cannot Afford to Miss
P. Petranovic Ovcaricek;
University Hospital Center Sestre Milosrdnice, Zagreb, CROATIA.

OP-145

To Perform or Not to Perform [^{99m}Tc]Tc-MIBI Scintigraphy? Why, Who, and How
A. Campennì;
University of Messina, Messina, ITALY.

OP-146

^{18}F-Fluorocholine PET/CT and PET/MR – Rationals for Their Use in Parathyroid Imaging
M. Huellner;
University Hospital of Zurich, Zurich, SWITZERLAND.

504

Sunday, October 18, 2026, 15:00 - 16:30
Hall E2

M2M Track: TROP Session - Radiopharmaceutical Sciences Committee: Radiosynthesis and Radionuclide Production

OP-147

Inorganic materials as Th-229 generators for Ac-225 production
A. Cosby, *L. Lilley, E. Yalcintas Bethune;*
TerraPower, Seattle, WA, UNITED STATES OF AMERICA.

OP-148

Development of F-18 Indirect Labeling reagent 3-[^{18}F]TDBFB using the Suzuki Coupling
Y. Yagi[1], *M. Ando*[2], *M. Omokawa*[3], *H. Kimura*[4], *T. Higuchi*[3,5];
[1]*Kyoto University of Medical Science, Nantan, JAPAN,*
[2]*Kanazawa University, Kanazawa, JAPAN,*
[3]*Okayama University, Okayama, JAPAN,*
[4]*Kyoto University, Kyoto, JAPAN,*
[5]*University Hospital Würzburg, Würzburg, GERMANY.*

OP-149

Batchless and Boundless: The Next Generation of Continuous Sequential Radiosynthesis Modules.
D. Graf[1], *W. Zhang*[2], *D. Mallik*[1], *C. Kellner*[1], *M. Organ*[1], *A. Shuhendler*[1];
[1]*University of Ottawa, Ottawa, ON, CANADA,*
[2]*York University, Toronto, ON, CANADA.*

OP-150

Production and Characterization of ^{228}Th to Support ^{212}Pb/^{212}Bi Targeted Alpha Therapy Research and Development
D. Rotsch, *P. Kankanamalage, D. W. Stracener, M. Duggin, H. Hernandez Noyola, V. Bautista, J. Griswold, R. Copping;*
Oak Ridge National Laboratory, Oak Ridge, TN, UNITED STATES OF AMERICA.

OP-151

An Optimized Automated Strategy for High-Purity ^{68}Ga-Trivehexin Production for PET Imaging of αvβ6 integrin
A. Gagliardi, *A. Guercio, M. Scarlattei, G. Baldari, L. Ruffini, S. Migliari;*
Nuclear Medicine Division, University Hospital of Parma, Parma, ITALY.

OP-152

Fully automated radiosynthesis of [^{177}Lu]Lu-FO-004 for therapeutic targeting of FAP in multi-centre clinical trials
C. Wichmann[1], *Z. Cao*[1], *B. Nguyen*[2], *K. Young*[2], *A. Joannidis*[2], *E. Goyne*[2], *A. Veamatahau*[2], *N. Guo*[1], *S. McCluskey*[2], *J. Kaufmann*[3], *A. Scott*[1];
[1]*Olivia Newton-John Cancer Research Institute, Heidelberg, AUSTRALIA,*
[2]*Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, AUSTRALIA,*
[3]*B Pharmaceuticals GmbH, Berlin, GERMANY.*

OP-153

A multi-radionuclide automated platform for small molecules and peptides radiolabelling
J. Masset[1], *A. Dubart*[1], *C. Vanasschen*[1], *M. Hawotte*[1], *E. Duray*[1], *R. Veronesi*[1], *C. Renon*[2], *P. Auzeloux*[2], *S. Levesque*[3], *M. Ragot*[3], *C. Warnier*[1];
[1]*Trasis, Ans, BELGIUM,*
[2]*UMR1240 Inserm, Clermont Ferrand, FRANCE,*
[3]*Centre Jean Perrin, Clermont Ferrand, FRANCE.*

OP-154

First Synthesis of [^{18}F]Aroyl Fluoride from Nucleophilic Radiofluorination of S-aryl Benzothioates
K. Lu, *W. Chen;*
West China Hospital, Sichuan University, Chengdu, CHINA.

505

Sunday, October 18, 2026, 15:00 - 16:30
Hall B

Cutting Edge Science Track: AI Committee: Segmentation in PSMA Imaging / Therapy

OP-155

Total Tumour-Burden Dosimetry in Patients Undergoing ^{177}Lu-PRRT
S. Curkic Kapidzic[1,2], *J. Gustafsson*[1], *E. Larsson*[2], *C. Warfvinge*[3,4], *P. Asp*[3,4], *A. Gålne*[5], *K. Sjögreen Gleisner*[1];
[1]*Medical Radiation Physics Lund, Lund University, Lund, SWEDEN,*

[2]Radiation Physics, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, SWEDEN,
[3]Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, SWEDEN,
[4]Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, SWEDEN,
[5]Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund, SWEDEN.

OP-156

From Physiological Uptake to Metastatic Burden in PSMA PET/CT

N. Abdallah[1], *L. Imbert*[2], *M. Koole*[3], *D. Visvikis*[4], *J. Bert*[1];
[1]University Hospital of Brest, LaTIM, INSERM, U1101, Brest, FRANCE,
[2]CHU de Nancy Brabois, Nancy, FRANCE,
[3]KU Leuven, Leuven, BELGIUM,
[4]LaTIM, INSERM, U1101, Brest, FRANCE.

OP-157

AI-assisted CT organ segmentation and its impact on absorbed dose uncertainty in Lu-177 dosimetry

V. Nuttens[1], *C. Spielvogel*[2], *W. Deckers*[3], *M. Koole*[3];
[1]AZORG, Aalst, BELGIUM,
[2]Medical University of Vienna, Vienna, AUSTRIA,
[3]KU Leuven, Leuven, BELGIUM.

OP-158

PSMASegmentator: Open-source, AI-based software for automatic segmentation and biomarker extraction from PSMA PET/CT

J. Noble[1,2], *M. Hiwase*[3,4,5], *N. Barry*[6,2], *P. Rowshanfarzad*[1,2], *M. Ebert*[1,6,2], *J. Ong*[7], *M. O'Callaghan*[3,5,8], *C. Sweeney*[3,4,9], *M. To*[10,11,12], *J. Kendrick*[1,2];
[1]The University of Western Australia, Perth, AUSTRALIA,
[2]Centre for Advanced Technologies in Cancer Research (CATCR), Perth, AUSTRALIA,
[3]Adelaide University, Adelaide, AUSTRALIA,
[4]Central Adelaide Health Network, Adelaide, AUSTRALIA,
[5]Southern Adelaide Health Network, Adelaide, AUSTRALIA,
[6]Sir Charles Gairdner Hospital, Perth, AUSTRALIA,
[7]Fiona Stanley Hospital, Perth, AUSTRALIA,
[8]South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCOCC), Adelaide, AUSTRALIA,
[9]South Australian ImmunoGENomics Cancer Institute (SAiGENCI), Adelaide, AUSTRALIA,
[10]Flinders University, Adelaide, AUSTRALIA,
[11]South Australian Medical Imaging, Adelaide, AUSTRALIA,
[12]Australian Institute for Machine Learning, Adelaide, AUSTRALIA.

OP-159

Can [68Ga]Ga-PSMA PET Data Improve the Automatic Tumour Segmentation in Multi-Timepoint [177Lu]Lu-PSMA SPECT?

L. Castelbranco Silva, *C. S. Constantino, P. Ferreira, Â. F. Silva, D. Rombo, F. P. M. Oliveira, D. C. Costa;*
Champalimaud Foundation, Lisbon, PORTUGAL.

OP-160

Clinical Feasibility of TTV Quantification on PSMA PET/CT and SPECT/CT Leveraging Deep-learning Auto-segmentation of CT Organs

K. Ngai, *A. S. Nelson, N. Dwivedi;*
MIM Software, a GE HealthCare Company, Cleveland, OH, UNITED STATES OF AMERICA.

OP-161

LUCID: Fully Automated nnU-Net-Based Total Tumor Volume Segmentation in Longitudinal SPECT/CT for Radiopharmaceutical Therapy

R. Hamidpour Badoe[1,2], *F. Yousefirizi*[1,2], *S. Kurkowska*[2,3], *N. Colpo*[4], *C. Williams*[4], *C. Dellar*[5], *W. Parulekar*[5],
D. Juneau[6], *F. Saad*[6], *K. Chi*[7], *K. Zukotynski*[8], *J. Beauregard*[9,10], *M. Soleimani*[11], *D. Wilson*[4], *A. Rahmim*[1,2], *F. Benard*[2,4,1], *C. Uribe*[1,2,4];
[1]University of British Columbia, Vancouver, BC, CANADA,
[2]Department of Basic and Translation Research, BC Cancer Research Institute, Vancouver, BC, CANADA,
[3]Department of Nuclear Medicine, Pomeranian Medical University, Szczecin, POLAND,
[4]Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, BC, CANADA,
[5]Canadian Cancer Trials Group, Kingston, ON, CANADA,
[6]University of Montreal Hospital Center, Montreal, QC, CANADA,
[7]Department of Medical Oncology, BC Cancer, Vancouver, BC, CANADA,
[8]McMaster University, Hamilton, ON, CANADA,
[9]Nuclear Medicine, Department of Medical Imaging, CHU de Quebec, Quebec City, QC, CANADA,
[10]Department of Radiology and Nuclear Medicine, Universite Laval, Quebec City, QC, CANADA,
[11]Department of Medicine, Devision of Medical Oncology, University of British Columbia, Vancouver, BC, CANADA.

OP-162

Automated whole-body lesion segmentation and tumour-burden quantification on prostate-specific membrane antigen positron emission tomography/computed tomography using cascaded deep learning

S. Zhong[1], *J. Lv*[1], *J. Zhang*[1], *Y. Shao*[2], *Y. He*[1], *Y. Yi*[2], *J. Liu*[2], *Y. Gao*[2], *X. Wang*[1], *Y. Fu*[1];
[1]Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CHINA,
[2]R&D Department, Shanghai United Imaging Intelligence Co., Ltd, Shanghai, CHINA.

OP-163

Automated Multi-Threshold PSMA PET Quantification in mCRPC: Validation and Comparison with a Commercial Auto-Segmentation Platform

C. Garcia[1], *P. Jehanno*[2], *Y. Cras*[3], *J. Donoso*[1,4], *H. Noamen*[1], *A. Dujardin*[2], *A. Daverio*[1], *M. Borsali*[1], *K. Trabelsi*[1], *L. Agrigoroaie*[1], *D. Deandreis*[1];
[1]Nuclear Medicine Dpt. Gustave Roussy, Villejuif, FRANCE,
[2]PAIRE, Paris, FRANCE,
[3]Radiophysics Dpt. Gustave Roussy, Villejuif, FRANCE,
[4]Nuclear Medicine Section. Hospital Clinico. Universidad de Chile, Santiago de Chile, CHILE.

506

Sunday, October 18, 2026, 15:00 - 16:30

Hall C

Clinical Oncology Track: Renal Cell Cancer and Novel Targets

OP-164

[68Ga]Ga-DPI-4452 (CA-IX peptide) PET/CT for Imaging Clear Cell Renal Cell Carcinoma: Interim Results from a Bicentre Registry

A. Küper[1], *V. Grünwald*[2], *K. M. Pabst*[1], *D. Kersting*[1], *F. Barbato*[1], *B. M. Schaarschmidt*[3], *C. Darr*[2], *M. Nader*[4], *F. Zarrad*[4], *K. Herrmann*[1], *W. Fendler*[1], *L. Au*[5], *J. P. Buteau*[5], *R. Eapen*[5], *G. Guduguntla*[5], *M. Haskali*[5], *D. Moon*[5], *D. G. Murphy*[5], *S. Siva*[5], *M. S. Hofman*[5], *S. M. Levy*[5];
[1]Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY,
[2]Department of Urooncology, University Hospital Essen, Essen, GERMANY,
[3]Department of Radiology, University Hospital Essen, Essen, GERMANY,
[4]Department of Radiopharmacy, University Hospital Essen, Essen, GERMANY,
[5]Department of Oncology, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

OP-165

First-in-Human Phase I Trial on [68Ga]Ga-OncoCAIX PET/CT in Clear Cell Renal Cell Carcinoma: Final Results on Safety and Diagnostic Performance

F. Gelardi[1], *M. Sollini*[1,2], *C. Pini*[1,2], *L. Antunovic*[1], *E. Busnardo*[1], *A. Larcher*[1,2], *U. Capitanio*[1], *R. Bertini*[1], *A. Briganti*[1,2], *A. Salonia*[1,2], *F. Montorsi*[1,2], *A. Maielli*[1], *R. Petrelli*[1], *G. Bonfitto*[1], *A. Tudda*[1], *M. Minotti*[1], *J. Mock*[3], *S. Cazzamalli*[3], *S. Oehler*[3], *M. Muller*[3], *D. Neri*[3], *A. Alessi*[4], *P. Erba*[5,6], *A. Chiti*[1,2];
[1]IRCCS Ospedale San Raffaele, Milan, ITALY,
[2]Vita-Salute San Raffaele University, Milan, ITALY,
[3]Philochem AG, Otelfingen, SWITZERLAND,
[4]Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, ITALY,
[5]ASST Papa Giovanni XXIII Hospital, Bergamo, ITALY,
[6]University of Milano-Bicocca, Milan, ITALY.

OP-166

Diagnostic Performance of 18F-NYM124, a Novel Small-Molecule CAIX-Targeted Probe, in Clear Cell Renal Cell Carcinoma: A Prospective Head-to-Head Comparison with 18F-FDG PET/CT

P. Fang[1], *B. Li*[2], *N. Zhang*[2], *Z. Zhu*[2], *Z. Huang*[1], *G. Cheng*[1], *S. Yang*[1], *G. Yang*[2], *Z. Wang*[2];
[1]Norroy bioscience Co., Ltd, Wuxi, CHINA,
[2]The Affiliated Hospital of Qingdao University, Qingdao, CHINA.

OP-167

Diagnostic Accuracy of 68Ga-NYM096 PET/CT for Clear Cell Renal Cell Carcinoma: An imaging-histopathology correlation study

W. Zhu[1], *M. Liu*[1], *X. Yan*[1], *J. Wang*[1], *H. Zhuo*[1], *X. Li*[1], *C. Bai*[1], *G. Zheng*[1], *Y. Zhang*[1], *M. Ma*[2], *X. Gao*[2], *O. Sartor*[3], *L. Huo*[1];
[1]Peking Union Medical College Hospital, Beijing, CHINA,
[2]Peking University First Hospital, Beijing, CHINA,
[3]LCMC Health, Metairie, LA, UNITED STATES OF AMERICA.

OP-168

Investigating the Potential of Carbonic Anhydrase IX as a Diagnostic Imaging Target in Von Hippel-Lindau Disease: Preliminary Results from the CAT-VHL Phase 2 Trial

F. Gelardi[1], *A. Larcher*[1], *L. Antunovic*[1], *F. Cei*[1], *L. Salerno*[1], *C. Re*[1], *F. Belladelli*[1], *G. Guazzarotti*[1], *G. Brembilla*[1], *F. De Cobelli*[1,2], *S. Calloni*[1], *A. Falini*[1,2], *N. Tenace*[1], *M. Ponzoni*[1,2], *A. Cigliola*[1], *P. Guerriero*[3], *P. Verzè*[3,4], *R. Bertini*[1], *A. Briganti*[1,2], *M. Sollini*[1,2], *F. Montorsi*[1,2], *U. Capitanio*[1], *A. Salonia*[1,2], *A. Chiti*[1,2];
[1]IRCCS Ospedale San Raffaele, Milan, ITALY,
[2]Vita-Salute San Raffaele University, Milan, ITALY,
[3]Ospedale San Giovanni di Dio e Ruggi d'Aragona, Salerno, ITALY,
[4]Università di Salerno, Baronissi (SA), ITALY.

OP-169

One-stop-shop imaging for VHL syndrome using 68Ga-NYM096 PET/CT

W. Zhu[1], *X. Yan*[1], *J. Wang*[1], *M. Liu*[1], *M. Liu*[1], *H. Zhuo*[1], *Y. Cheng*[1], *X. Li*[1], *A. Tong*[1], *C. Bai*[1], *G. Zheng*[1], *Y. Zhang*[1], *L. Huo*[1], *O. Sartor*[2];
[1]Peking Union Medical College Hospital, Beijing, CHINA,
[2]LCMC Health, Metairie, LA, UNITED STATES OF AMERICA.

OP-170

Phase 3 study to assess the safety and efficacy of [177Lu]Lu-girentuximab in advanced, relapsed or recurrent ccRCC (LUTEON)

J. Roetman[1], *G. Tlili*[2], *A. Scott*[3], *T. Faivre*[1], *D. Cade*[1], *S. Pal*[4];
[1]Telix Pharmaceuticals, North Melbourne, AUSTRALIA,
[2]CHU Bordeaux, Bordeaux, FRANCE,
[3]Austin Health, Heidelberg, AUSTRALIA,
[4]City of Hope, Duarte, CA, UNITED STATES OF AMERICA.

OP-171

CD2-targeted T-Cell Imaging with the Novel Radioligand [68Ga]Ga-NOTA-CD2-sdAb: A Case Series

N. Dreher[1,2,3], *M. Lutz*[4,2,3], *A. Reichart*[5,2,3], *J. S. Enke*[1,2,3], *D. Gosmann*[6,7], *L. Russelli*[8,7], *J. Brosch-Lenz*[1,2,3], *W. A. Weber*[8,3], *A. Richter*[8,3], *C. Lapa*[1,2,3];
[1]Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY,
[2]National Center for Tumor Diseases (NCT), NCT WERA, Augsburg, GERMANY,

[3]Bavarian Cancer Research Center (BZKF), Munich, GERMANY,
[4]Department of Hematology and Oncology, Faculty of Medicine, Augsburg, GERMANY,
[5]Department of Gastroenterology, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY,
[6]Department of Medicine III, TUM University Hospital, Technical University of Munich, Munich, GERMANY,
[7]TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, GERMANY,
[8]Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, School of Medicine and Health, Munich, GERMANY.

OP-172

Preliminary results from the ongoing first-in-human clinical trial of anti-CD44v6 agent [177Lu]Lu-AKIR001

J. N. Nilsson[1,2], *L. de Petris*[1,2], *M. Zupancic*[1,2], *J. Yachnin*[1,2], *T. A. Tran*[1,2], *K. Bratteby*[1,2], *C. Jonsson Pranér*[2], *P. Grybäck*[1,2], *P. Bernhardt*[3,4], *C. C. Juhlin*[1,2], *A. C. L. Mortensen*[5,1], *J. Zedenius*[1,2], *F. Frejd*[5], *R. Bränström*[1,2], *M. Nestor*[5];
[1]Karolinska Institutet, Stockholm, SWEDEN,
[2]Karolinska University Hospital, Stockholm, SWEDEN,
[3]Gothenburg University, Gothenburg, SWEDEN,
[4]Sahlgrenska University Hospital, Gothenburg, SWEDEN,
[5]Uppsala University, Uppsala, SWEDEN.

507

Sunday, October 18, 2026, 15:00 – 16:30

Hall F1

Neuroimaging Committee: Movement Disorders, Epilepsy, Encephalitis and Inflammation

OP-173

Assessment of the Novel Neuronal Synuclein Disease Staging System in Dementia with Lewy Bodies Patients

G. Rovera[1], *M. Gonzalez*[2], *P. Hoede*[3], *A. Lemstra*[4], *D. Tovar-Rios*[2], *J. Booij*[5], *J. van Alphen*[4], *D. Alcolea*[6], *I. Santana*[7], *J. Durães*[7], *M. Kramberger*[8], *A. Pilotto*[9], *J. Hort*[10], *Z. Nedelska*[10], *A. Rongve*[11], *A. Delva*[12], *R. Vandenberghe*[12], *P. Donaghy*[13], *J. Taylor*[13], *K. Rejdak*[14], *E. Papuc*[14], *S. O'Dowd*[15], *S. Fullam*[15], *A. Lathuilière*[16], *A. Isik*[17], *C. Chafer*[18], *D. Ferreira*[19], *C. Teunissen*[3], *D. Aarsland*[2,20], *S. Morbelli*[1];
[1]Nuclear Medicine Unit, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, ITALY,
[2]Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, NORWAY,
[3]Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, NETHERLANDS,
[4]Alzheimer Center Amsterdam, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, NETHERLANDS,
[5]Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, NETHERLANDS,
[6]Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN,
[7]Neurology Department, Coimbra University Hospital Centre, Coimbra, PORTUGAL,
[8]Department of Neurology, University Medical Centre Ljubljana, Ljubljana, SLOVENIA,
[9]Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, ITALY,
[10]Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, CZECH REPUBLIC,
[11]Department of Clinical Medicine, University of Bergen, Bergen, NORWAY,
[12]Department of Neurology, University Hospitals Leuven, Leuven, BELGIUM,
[13]Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UNITED KINGDOM,
[14]Department of Neurology, Medical University of Lublin, Lublin, POLAND,
[15]Tallaght Institute of Memory and Cognition, Tallaght University Hospital, Dublin, IRELAND,
[16]Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, SWITZERLAND,
[17]Unit for Aging Brain and Dementia, Department of Geriatric Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, TÜRKIYE,
[18]Alzheimer's Disease Research Group, Health Research Institute La Fe, Valencia, SPAIN,
[19]Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, SWEDEN,
[20]Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UNITED KINGDOM.

OP-174

NonInferiority of [18F]LBT999 PET versus [123I]FPCIT SPECT for Dopamine Transporter Imaging in the Differential Diagnosis of Parkinson's Disease and Essential Tremor: Results from the DATTEP Study

P. Payoux[1,2], *A. Hitzel*[1], *A. Verger*[3], *C. Bouvet*[4], *P. Remy*[5], *F. Lejeune*[6], *M. Chafai*[7], *A. Flaus*[8], *L. Defebvre*[9], *G. Tlili*[10], *J. Corvol*[11], *G. Castelnovo*[12], *P. Damier*[13], *M. Ribeiro*[14], *T. Horowitz*[15], *E. Cassol*[1], *P. Gantet*[1], *C. Thalamas*[16], *A. Sommet*[16], *T. Carlier*[17], *A. Drif*[16], *L. Chabbert*[16], *M. Simonetta-Moreau*[18], *C. Brefel Courbon*[19,2], *A. Salabert*[20,2], *O. Rascol*[19,21,2];
[1]Department of Nuclear Medicine, University Hospital of Toulouse, Toulouse, FRANCE,
[2]Univ Toulouse, INSERM, ToNIC, Toulouse, France, Toulouse, FRANCE,
[3]Department of Nuclear Medicine, University Hospital of Nancy, Nancy, FRANCE,
[4]Department of Nuclear Medicine, Centre Jean Perrin, Clermont Ferrand, FRANCE,
[5]Department of Neurology, University Hospital of Créteil, Créteil, FRANCE,
[6]Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, FRANCE,
[7]Department of Nuclear Medicine, Centre Georges-François Leclerc, Dijon, FRANCE,
[8]Department of Nuclear Medicine, University Hospital of Lyon, Lyon, FRANCE,
[9]Department of Neurology, University Hospital of Lille, Lille, FRANCE,
[10]Department of Nuclear Medicine, University Hospital of Bordeaux, Bordeaux, FRANCE,
[11]Department of Neurology, University Hospital of La Pitié Salpétrière, Paris, FRANCE,
[12]Department of Nuclear Medicine, University Hospital of Nîmes, Nîmes, FRANCE,
[13]Department of Neurology, University Hospital of Nantes, Nantes, FRANCE,
[14]Department of Nuclear Medicine, University Hospital of Tours, Tours, FRANCE,
[15]Department of Nuclear Medicine, University Hospital of Marseille, Marseille, FRANCE,
[16]Clinical Investigation Center CIC1436, University Hospital of Toulouse, Toulouse, FRANCE,
[17]Department of Nuclear Medicine, University Hospital of Nantes, Nantes, FRANCE,
[18]Department of Neurology, University Hospital of Toulouse, Toulouse, FRANCE,
[19]Department of Clinical Pharmacology and Neurosciences, University Hospital of Toulouse, Toulouse, FRANCE,
[20]Department of Radiopharmacy, University Hospital of Toulouse, Toulouse, FRANCE,
[21]Clinical Investigation Center CIC1436, Toulouse Parkinson Disease Reference Center, NS-PARK Network, Toulouse, FRANCE.

OP-175

First-in-Human Evaluation of [18F]ACI-15916, a New α-Synuclein PET Radioligand, in Healthy Volunteers and Individuals with α-Synucleinopathies

M. Monir[1], *P. Plavén Sigray*[1], *J. Svensson*[1], *A. Forsberg Morén*[1], *M. Bolin*[1], *Y. Khani Meynaq*[1], *M. Cortes Gonzalez*[1], *S. Nag*[1], *V. Jelic*[2], *M. Andréasson*[3], *P. Svenningsson*[3], *A. Pfeifer*[4], *K. M. Scott*[4], *F. Capotosti*[4], *A. Varrone*[1];
[1]Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, SWEDEN,
[2]Department of Neurobiology, Karolinska Institutet, Stockholm, SWEDEN,
[3]Center for Neurology, Academic Specialist Center, Stockholm, SWEDEN,
[4]AC Immune SA, Lausanne, SWITZERLAND.

OP-176

Brain-periphery metabolic coupling in Parkinson's disease identified by integrated multimodal FDG-PET/MRI

J. Wang, *Y. Zhu, M. Tian, C. Zuo;*
Department of Nuclear Medicine/PET center, Huashan Hospital, Fudan University, Shanghai, CHINA.

OP-177

Repeated [18F]FDG-PET in the Presurgical Workup of Drug-Resistant Epilepsy: A Multicenter Study

G. Nottet[1], *T. Horowitz*[2], *S. Bouvard*[3], *F. Cotton*[1], *M. Hermier*[1], *H. Catenoix*[1], *C. Haegelen*[1], *M. Janier*[1], *J. Julien*[1], *S. Rheims*[1], *E. Guedj*[2], *S. Lagarde*[2], *L. Maillard*[4], *K. Ostrowsky-Coste*[1], *A. Hammers*[5], *A. Verger*[4], *F. Bartolomei*[2], *A. Flaus*[1];
[1]Hospices Civils de Lyon, Lyon, FRANCE,
[2]Assistance Publique-Hopitaux de Marseille, Marseille, FRANCE,
[3]Université Claude Bernard Lyon [1], Lyon, FRANCE,
[4]Hôpital Universitaire de Nancy, Nancy, FRANCE,
[5]School of Biomedical Engineering and Imaging Sciences, King's College London, London, UNITED KINGDOM.

OP-178

Brain Metabolism Pattern in Anti-IgLON5 Disease

D. Barcola[1], *A. Kas*[2,3], *K. Smolik*[4], *F. Cotton*[5,6,7], *G. Criton*[5,6,7], *D. Psimaras*[8], *J. Honnorat*[4], *A. Farina*[4], *P. Payoux*[9,10], *M. Rafiq*[11], *F. Semah*[12], *T. Alberto*[13], *B. Joubert*[4,14], *A. Flaus*[1,15];
[1]Department of Nuclear Medicine, Hospices Civils de Lyon, Lyon, FRANCE,
[2]Service de Médecine Nucléaire, Sorbonne Université, 47-83 Boulevard de l'Hôpital, 75013, Paris, FRANCE,
[3]U1146 Inserm, SU, UMR 7371 CNRS, Laboratoire d'imagerie Biomédicale, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, FRANCE,
[4]Centre de Référence des Syndromes Neurologiques Paranéoplasiques et Encéphalites Auto-immunes, Hospices Civils de Lyon - MeLiS CNRS UMR 5284 - INSERM U1314, Université Claude Bernard Lyon 1, Lyon, FRANCE,
[5]Department of Radiology, Hospices Civils de Lyon, Lyon, FRANCE,
[6]Université Claude Bernard Lyon 1, Villeurbanne, FRANCE, [7]Laboratoire CREATIS, CNRS UMR 5220, Inserm U1296, INSA Lyon, Villeurbanne, FRANCE,
[8]Service de Neurologie 2 - Mazarin, Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, 75013, Paris, FRANCE,
[9]Department of Nuclear Medicine, Toulouse University Hospital, 2 Rue Charles Viguerie, 31300, Toulouse, FRANCE,
[10]Toulouse NeuroImaging Center, ToNIC, Inserm, UPS, University of Toulouse, Place du Dr Joseph Baylac, 31024, Toulouse, FRANCE,
[11]Department of Cognitive Neurology, Epilepsy and Movement Disorders, Centre Hospitalier Universitaire de Toulouse, Toulouse, FRANCE,
[12]Nuclear Medicine Department, University Hospital, Inserm, CHU Lille, U1172-LilNCog—Lille, F-59000, Lille, FRANCE,
[13]Department of Neurology, French Competence Center on Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes, Lille University Hospital, F-59000, Lille, FRANCE,
[14]Department of Neurology, Groupe Hospitalier Sud, Hospices Civils de Lyon, Lyon, FRANCE,
[15]Lyon Neuroscience Research Center, CNRS UMR5292, INSERM U1028, Université Claude Bernard Lyon 1, Lyon, FRANCE.

OP-179

Long-term value of brain [18F]-FDG PET in the clinical trajectory of patients with post-COVID-19 condition and neurocognitive disorders

S. Heyer[1], *E. Laruelle*[2], *P. Schaefer*[3], *F. Goehringer*[2], *A. Verger*[1];
[1]Department of Nuclear Medicine, CHRU Nancy, Nancyclotep Imaging Platform, IADI, INSERM, U1254, Université de Lorraine, Nancy, FRANCE,
[2]Department of Infectious Diseases, Centre Hospitalier Regional Universitaire de Nancy, Nancy, FRANCE,
[3]Department of Nuclear Medicine, CHRU Nancy, Nancyclotep Imaging Platform, Nancy, FRANCE.

OP-180

Comparative Study of TSPO PET and susceptibility-sensitive MRI for Detecting Chronic Active Lesions in Multiple Sclerosis

M. Zhang[1], *M. Pan*[1], *P. Fu*[1], *X. Zhu*[1], *Y. Zhang*[1], *H. Ju*[1], *Y. Bai*[1], *Q. Zhou*[2], *S. Chen*[2], *B. Li*[1];
[1]Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA,
[2]Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.

OP-181

Neuroinflammation Beyond Aging: Evidence for Age-Invariant [18F]F-DED PET Signal in Alzheimer's Disease

G. Bischof[1], *M. Zeinaki*[2], *B. Rauchmann*[3,4,5], *J. S. Dornreich*[6], *L. Tagnin*[6], *L. Vogler*[6], *J. S. Gnörrich*[6], *A. Gesenhues*[6], *D. Dhoqina*[6], *G. U. Höglinger*[7,8,9], *R. A. Werner*[6], *L. Frontzkowski*[10,11], *G. Salvadó*[12,13], *D. Vállez-Garcia*[12,13], *F. Hirsch*[11], *D. Janovitz*[11], *K. Bürger*[14,11], *J. Vögelein*[14,8,15], *S. Stöcklein*[16], *S. Lindner*[6], *J. Levin*[7], *R. Perzneczky*[17,14], *N. Koglin*[1], *A. Müller*[1], *N. Franzmeier*[8,11], *A. Stephens*[1], *M. Brendel*[2];
[1]*Lantheus GmbH, Germany, Berlin, GERMANY,*
[2]*University Hospital, LMU Munich, Department of Nuclear Medicine, Munich, GERMANY,*
[3]*University Hospital, LMU Munich, Institute of Neuroradiology, Munich, GERMANY,*
[4]*University Hospital, LMU Munich, Department of Psychiatry and Psychotherapy, Munich, Germany, Munich, GERMANY,*
[5]*German Center for Neurodegenerative Diseases, DZNE, Munich, GERMANY,*
[6]*University Hospital, LMU Munich, Department of Nuclear Medicine, Munich, GERMANY,*
[7]*German Center for Neurodegenerative Diseases, DZNE, Munich, GERMANY,*
[8]*Munich Cluster for Systems Neurology, SyNergy, Munich, GERMANY,*
[9]*University Hospital, LMU Munich, Department of Neurology, Munich, GERMANY,*
[10]*University Hospital, LMU Munich, Department of Nuclear Medicine, Munich, GERMANY,*
[11]*University Hospital, LMU Munich, Institute for Stroke and Dementia Research (ISD), Munich, GERMANY,*
[12]*Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain, Barcelon, SPAIN,*
[13]*Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain, Barcelona, SPAIN,*
[14]*German Center for Neurodegenerative Diseases, DZNE, Munich, GERMANY,*
[15]*University Hospital, LMU Munich, Department of Neurology, Munich, GERMANY,*
[16]*University Hospital, LMU Munich, Department of Radiology, Munich, GERMANY,*
[17]*University Hospital, LMU Munich, Department of Psychiatry and Psychotherapy, Munich, Munich, GERMANY.*

508

Sunday, October 18, 2026, 15:00 - 16:30

Hall F2

Joint Symposium 2 - Oncology & Theranostics Committee / EORTC: Design and Conduct of Clinical Trials - How to Generate Evidence for RLTs

OP-182

Current RLT Activities of the EORTC

C. Deroose;
UZ Leuven, Leuven, BELGIUM.

OP-183

Evidence-Based Evaluation of RLT Targets: THERASCORE

N. Albert;
LMU University Hospital, Munich, GERMANY.

OP-184

Challenges and Opportunities of Multinational Trial Conduct

M. Preusser;
Medical University of Vienna, Vienna, AUSTRIA.

OP-185

Appropriate Endpoints for RLT Trials

M. Hofman;
Peter MacCallum Cancer Centre, Victoria, AUSTRALIA.

510

Sunday, October 18, 2026, 15:00 – 16:30

Hall K

Technologists' Track Oral Presentations 1 - Technologists Committee: Nuclear Medicine Across the Spectrum: Education, Professional Issues, Conventional Imaging, and Paediatrics

OP-186

Beyond planar imaging: 2D reprojections from 3D SPECT for split renal function evaluation

A. Bouzidi, *M. Hesse, F. Dupont, F. Jamar, O. Gheysens, V. Depoortere;*
Cliniques universitaires Saint-Luc, Bruxelles, BELGIUM.

OP-187

Optimization of SPECT Renal Dynamic Imaging Workflow Using a Bi-LSTM Model with anchor-pointConstraints

L. Jicheng, *J. Liu;*
Lanzhou University, Lanzhou, CHINA.

OP-188

Workflow Optimization in Positron Emission Tomography/Computed Tomography (PET/CT) Using Artificial Intelligence (AI) Software: A Technologist's Perspective

E. Aroni, *E. Skoura, G. Thiveos, G. Georgoulas, I. Papantoniou, A. Kokkini, I. Koutsikos, I. Datseris;*
Henry Dunant Hospital Center, Athens, GREECE.

OP-189

Coupled Dynamical System Approach for Noise Reduction in Nuclear Medicine Imaging

R. Kasai, *T. Yoshinaga;*
Institute of Biomedical Sciences, Tokushima University, Tokushima, JAPAN.

OP-190

Demonstrating the Complementary Roles of Radiographers and Consultants in Nuclear Medicine Registrar Training: A Workflow-Based Case Analysis

H. Chandler, *N. Gandy, T. Beaconsfield;*
London North West University Healthcare NHS Trust, Harrow, London, UNITED KINGDOM.

OP-191

Paediatric PET-CT Under General Anaesthetic on a Long Axial Field of View Scanner - from Admission to Discharge at the PET Centre

I. Vaitkute, *G. Testanera, J. John, S. Gould, G. Krokos, C. Stopher;*
King's College London and Guy's and St Thomas's NHS Foundation Trust, London, UNITED KINGDOM.

OP-192

Optimising Sentinel Lymph Node Radiopharmaceutical Administration Using 29G Insulin Syringes: A Prospective Quality Improvement Project in Nuclear Medicine

C. Rodrigues, *J. Dias;*
The Royal Marsden Hospital NHS Foundation Trust, London, UNITED KINGDOM.

OP-193

Impact of Two Decades of PET/CT Technological Evolution on Image Quality, Quantification and Patient Dose

A. Martins[1,2], *I. Rodrigues*[1,2], *M. Vieira*[1], *J. Oliveira*[1], *S. Carmona*[1], *P. Almeida*[1,3], *L. Oliveira*[1];
[1]*Nuclear Medicine Department, Joaquim Chaves Saúde, Lisbon, PORTUGAL,*
[2]*CrossI&D Lisbon Research Center, Escola Superior de Saúde da Cruz Vermelha Portuguesa - Lisboa, Lisbon, PORTUGAL,*
[3]*Faculty of Sciences, University of Lisbon, Lisbon, PORTUGAL.*

OP-194

Incorporating 99mTc-sestaMIBI SPECT/CT in the characterization of kidney lesions: A Single Centre Pictorial Review

C. Pina, *L. Collins, M. Dwyer, H. Bashir, I. Munir;*
East Kent Hospitals University Foundation NHS Trust, Canterbury, UNITED KINGDOM.

511

Sunday, October 18, 2026, 15:00 - 16:30

Hall G1

Special Symposium 3 - EANM Journals: The EANM Journal Landmark Lecture & Alavi-Carlsen Award. Fifty Years of FDG: From Discovery to the Future of Precision Medicine

OP-195

The Alavi-Carlsen Award and The EANM Journal Landmark Lecture

G. Ninatti;
University of Milano-Bicocca, Milan, ITALY.

OP-196a

EANM Innovation Alavi-Carlsen Award Winner Presentation

OP-196b

The EANM Journal Alavi-Carlsen Award Winner Presentation

OP-197

Fifty Years of FDG: From Discovery to the Future of Precision Medicine

S. Fanti;
IRCCS Azienda Ospedaliero-Universitaria di Bologna and University of Bologna, Bologna, ITALY.

OP-198

Looking Back, Looking Forward: Reflections on Fifty Years of FDG

A. Alavi;
Perelman School of Medicine at the University of Pennsylvania, Pennsylvania, UNITED STATES OF AMERICA.

601

Sunday, October 18, 2026, 16:45 - 18:15

Hall A

CME 4 - Dosimetry Committee: Dosimetry in Practice: Choosing the Right Level of Complexity

OP-199

What Levels of Dosimetry Are There? A Fit-For-Purpose Framework

C. Stokke;
Division of Radiology and Nuclear Medicine, Oslo, NORWAY.

OP-200

When Is Comprehensive Dosimetry Needed? Exploratory and First-in-Human Studies
F. Westerbergh;
Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN.

OP-201

Optimising Dosimetry for Clinical Trials: Enabling Multicentre Studies
E. Deshayers;
Institut de Cancérologie de l'Ouest (ICO), Anger, FRANCE.

OP-202

Routine Practice with Approved Radiopharmaceuticals: From Verification to Evidence Generation
J. Tran-Gia;
University Hospital Würzburg, Würzburg, GERMANY.

602

Sunday, October 18, 2026, 16:45 - 18:15
Hall D (Arena)

Special Track 4 - Oncology & Theranostics Committee: Debate: Is There a Role for Radium-223 in the Era of PSMA RLT?

OP-203

Point of View: Yes, There Is Still a Role for Radium-223
D. Oprea-Lager;
Radboud University Medical Center, Nijmegen, NETHERLANDS.

OP-204

Point of View: No, There Is No Role for Radium-223 at Present
S. Fanti;
IRCCS Azienda Ospedaliero-Universitaria di Bologna and University of Bologna, Bologna, ITALY.

OP-205

The Medical Oncologist's Perspective
F. Turco;
EOC - Istituto Oncologico della Svizzera Italiana, Bellinzona, ITALY.

OP-206

Take-Home Messages: What We Have Learned Today
M. Bauchneth;
IRCCS Azienda Ospedaliera Metropolitana Genova and University of Genoa, Genoa, ITALY.

603

Sunday, October 18, 2026, 16:45 - 18:15
Hall E1

LIPS Session 4 - Inflammation & Infection Committee: Diagnostic Utility and Clinical Challenges of [^{18}F]FDG PET/CT for Infection Imaging in Special Populations

OP-207

Critically Ill Patients
D. Albano;
Università degli studi di Brescia, ASST Spedali Civili, Nuclear Medicine Department, Brescia, ITALY.

OP-208

Solid Organ Transplantation and Immunocompromised Patients
B. Rodriguez;
Hospital Puerta de Hierro Majadahonda, Madrid, SPAIN.

OP-209

Paediatrics
M. Øbro Fosbøl;
Rigshospitalet Hospital/Institute, Copenhagen, DENMARK.

604

Sunday, October 18, 2026, 16:45 - 18:15
Hall E2

M2M Track: TROP Session - Translational Molecular Imaging & Therapy Committee: Radiolabeled Peptides, from Development to Application

OP-210

Development and Preclinical Evaluation of ^{68}Ga-P15-3:A Novel DLL3-Targeted Peptide Tracer for Broad-Spectrum PET Imaging of Pan-cancer Malignancies
Z. Deng[1,2], *T. Liu*[1], *Z. Yang*[1,2];
[1]*Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, CHINA,*
[2]*Institute of Molecular Medicine and National Biomedical Imaging Center, College of Future Technology, Peking University, Beijing, CHINA.*

OP-211

Peptide-Based Quantification of EpCAM Expression in Triple Negative Breast Cancer
L. Kovacs dos Santos, *L. Wagner, M. Schäfer, M. Benešová-Schäfer;*
German Cancer Research Center (DKFZ), Heidelberg, GERMANY.

OP-212

Cost analysis and process validation of ^{68}Ga PSMA production from cyclotron produced ^{68}Ga
D. Szikra, *D. Szűcs, I. Jószai, G. Farkasinszky;*
University of Debrecen, Division of Nuclear Medicine, Medical Imaging Department, Debrecen, HUNGARY.

OP-213

High affinity in vivo stable GRPR-targeting antagonist NOTA-PKB for PET imaging
A. Orlova, *K. Obeid, H. Fakhro, E. Bezverkhniaia, V. Tolmachev, P. Kanellopoulos;*
Uppsala University, Uppsala, SWEDEN.

OP-214

Impact of PSMA Density, Intracellular Trafficking and Apparent Specific Activity on [^{212}Pb]Pb-AB001 Binding and Internalization in Three Prostate Cancer Cell Lines
R. Liukaityte[1,2], *R. Wangen-Riise*[1], *A. Juzeniene*[1,2];
[1]*Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, NORWAY,*
[2]*Department of Physics, University of Oslo, Oslo, NORWAY.*

OP-215

Prostate Cancer Theranostics: Preclinical Characterization Of PSMA/GRPR-Targeting Heterodimer Labeled With ^{68}Ga And ^{177}Lu
E. Bezverkhniaia, *P. Kanellopoulos, K. Obeid, O. Andersson, A. Gazsó, U. Rosenström, V. Tolmachev, A. Orlova;*
Uppsala university, Uppsala, SWEDEN.

OP-216

UtilizingNear-infrared Light to Shield Normal Organs from Radiation in PSMA-targeted Radiotherapy
X. Ma, *Q. Wang, H. Zhang, W. Zhao, J. Welfare, N. Archer, H. Wang, S. Cheng, L. Pan, J. Frank, Z. Wu, D. Lawrence, Z. Li;*
University of North Carolina, Chapel Hill, Chapel Hill, NC, UNITED STATES OF AMERICA.

OP-217

Acoustic Cluster Therapy (ACT) enhanced PET/MRI guided uptake of [^{68}Ga] Ga-PSMA-617 radioligand in a murine Glioblastoma model
E. Arshad[1], *S. Figenschau*[1], *P. Suwattananuruk*[2], *R. Berzaghi*[3], *A. Moldes-Anaya*[2], *M. Mühlenpfordt*[4], *M. S. Wigen*[4], *M. Kranz*[1];
[1]*Tumor Biology Research Group, Department of Medical Biology, UiT-The Arctic University of Norway, Tromsø, NORWAY,*
[2]*PET Imaging Center, University Hospital Northern Norway, Tromsø, NORWAY,*
[3]*Nuclear Medicine and Radiation Biology, Department of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, NORWAY,*
[4]*Exact Therapeutic AS, Oslo, NORWAY.*

OP-218

Discordant PSMA11 Imaging and GCPII Biology in Breast Cancer: Implications for Clinical Translation
T. Ebenhan[1,2], *M. M. Sathekge*[3,2], *J. Kleynhans*[4,5], *F. Cleeren*[4], *J. Mahapane*[1,2], *M. M. Tshabalala*[1,2];
[1]*University of Pretoria, Pretoria, SOUTH AFRICA,*
[2]*Nuclear Medicine Research Infrastructure - NuMeRI NPC, Pretoria, SOUTH AFRICA,*
[3]*University of Pretoria & Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA,*
[4]*Katholieke Universiteit Leuven, Leuven, BELGIUM,*
[5]*Czech Technical University in Prague, Prague, CZECH REPUBLIC.*

605

Sunday, October 18, 2026, 16:45 - 18:15
Hall B

Cutting Edge Science Track: AI Committee: AI Based Quantitative Imaging

OP-219

Fast Reconstruction With Novel Deep Learning-Based FastPET Method for ECG-Gated Cardiac ^{82}Rb-PET Functional Imaging: A Clinical Validation Study
S. Dreier[1], *F. Aghapour Zangeneh*[1], *Y. Zheng*[2], *N. Gözlügöl*[1], *P. Schleyer*[2], *D. Bharkhada*[2], *V. Panin*[2], *M. Conti*[2], *A. Rominger*[1], *W. A. Bosbach*[1], *H. Sari*[1,3];
[1]*Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND,*
[2]*Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA,*
[3]*Siemens Healthineers International AG, Zurich, SWITZERLAND.*

OP-220

Dose-Aware Diffusion Models for Standardizing Cross-Institutional PET Image Quality: A Solution for External Referrals
G. Kim, *S. Lee, M. Yun;*
Yonsei University, Seoul, KOREA, REPUBLIC OF.

OP-221

Deep Learning based Axial Field of View Extension of CT in TotalBody PET/CT
A. Mehranian[1], *S. Wollenweber*[2], *F. Kotasidis*[3], *Z. Chalampalakis*[4], *A. Lulinsky*[5], *H. Ratner*[5], *R. Johnsen*[2], *G. Kovalski*[5];
[1]*GE HealthCare, Oxford, UNITED KINGDOM,*
[2]*GE HealthCare, Waukesha, WI, UNITED STATES OF AMERICA,*
[3]*GE HealthCare, Zurich, SWITZERLAND,*
[4]*GE HealthCare, Buc, FRANCE,*
[5]*GE HealthCare, Haifa, ISRAEL.*

OP-222

PseudoEARL-Net: a deep learning-based harmonization tool for retrospective EARL harmonization of multicenter FDG PET/CT
A. Kebaili[1], *T. Carlier*[2], *A. Girard*[3], *A. Devillers*[4], *O. Humbert*[5,6], *S. Hapdey*[1,7], *C. Boucherie*[8], *F. Orlhac*[9], *P. Decazes*[1,7];
[1]*AIMS, QuantIF, University of Rouen-Normandy, Rouen, FRANCE,*
[2]*Department of Nuclear Medicine, Nantes University Hospital, Nantes University, University of Angers, INSERM, CNRS, CRCI²NA, Nantes, FRANCE,*
[3]*Department of Nuclear Medicine, Amiens University*

Hospital, Amiens, FRANCE,
[4]Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, FRANCE,
[5]Department of Nuclear Medicine, Centre Antoine Lacassagne, University of Côte d'Azur, Nice, FRANCE,
[6]University of Côte D'Azur, INSERM, CNRS, iBV, Nice, FRANCE,
[7]Department of Nuclear Medicine, Centre Henri Becquerel, Rouen, FRANCE,
[8]INSA Rouen, Rouen, FRANCE,
[9]IRIS, Institut Curie, Inserm, CNRS, University of Versailles Saint-Quentin, PSL University, Orsay, FRANCE.

OP-223

A universally robust deep-learning framework for CT-free, ultra-low-dose PET/CT across heterogeneous clinical domains

H. Wang[1], *X. Qiao*[1], *R. Guo*[1], *Q. Huang*[2], *B. Li*[1];
[1]Department of Nuclear Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA,
[2]Macao Polytechnic University, Macao, CHINA.

OP-224

Optimizing Acquisition Time and Injected Dose in ^{18}F-FDGPET/CT Imaging Using Deep Learning: Enhancing Image Protocol Efficiency and Safety

Y. Zeng, *X. Mu, W. Chong, B. Mo, J. Qin, W. Fu;*
The First Affiliated Hospital of Guilin Medical University, Guangxi Guilin, CHINA.

OP-225

Impact of AI-Based Attenuation Correction (AC) TruCorr on Global and Vessel-Associated Reversible Ischaemic Burden in CZT-Based Myocardial SPECT

D. Schäfer[1], *D. Knollmann*[2], *W. Schäfer*[2];
[1]University of Cologne, Cologne, GERMANY,
[2]Nuklearmedizin der Kliniken Maria Hilf, Mönchengladbach, GERMANY.

OP-226

Deep learning time-of-flight enhancement algorithm performance evaluation for a digital BGO-based long axial field-of-view PET/CT system

Z. Chalampalakis[1], *J. M. Mostert*[2], *S. D. Wollenweber*[3], *R. Johnsen*[3], *H. Ratner*[4], *A. Mehranian*[5], *F. A. Verburg*[2], *M. Segbers*[2], *F. Kotasidis*[6];
[1]GE Healthcare, Buc, FRANCE,
[2]Erasmus MC, Department of Radiology and Nuclear Medicine, Rotterdam, NETHERLANDS,
[3]GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA,
[4]GE Healthcare, Haifa, ISRAEL,
[5]GE Healthcare, Oxford, UNITED KINGDOM,
[6]GE Healthcare, Zurich, SWITZERLAND.

OP-227

Real-world Clinical Evaluation of a Deep Learning-based Respiratory Motion Correction Algorithm of ^{18}F-FDG PET/CT in Lung Lesions: A Three-year Follow-up Study

J. Wang[1], *J. Wang*[2], *F. Kang*[1], *J. Wang*[1];
[1]Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, CHINA,
[2]United Imaging Healthcare, No. [2258] Chengbei Road, Shanghai, CHINA.

606

Sunday, October 18, 2026, 16:45 - 18:15
Hall C

Clinical Oncology Track: Breast

OP-228

Impact of [^{18}F]Fluoroestradiol (FES) PET/CT on Second-Line Treatment Decision in Patients with ER+ HER2- Metastatic Breast Cancer: Results from the ESTROTIMP Trial

A. Cochet[1,2], *S. Ladoire*[1], *S. Maria van de Ven*[3], *F. Bidard*[4], *J. Alberini*[1,2], *A. Bellesoeur*[4], *S. Parisse Di-Martino*[5], *O. Humbert*[6], *T. Cassou-Mounat*[7], *E. Deshayes*[8], *L. Djaileb*[9], *K. Kerrou*[10], *E. Deluche*[11], *R. Seban*[4];
[1]Centre Georges-Francois Leclerc, Dijon, FRANCE,
[2]ICMUB UMR CNRS [6]302, Dijon, FRANCE,
[3]GE HealthCare, Chicago, IL, UNITED STATES OF AMERICA,
[4]Institut Curie, Paris, FRANCE,
[5]Centre Léon Bérard, Dijon, FRANCE,
[6]Centre Antoine Lacassagne, Nice, FRANCE,
[7]Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, FRANCE,
[8]Institut du Cancer de Montpellier, Montpellier, FRANCE,
[9]Centre Hospitalier Universitaire de Grenoble, Grenoble, FRANCE,
[10]Hopital Tenon, Paris, FRANCE,
[11]Centre Hospitalier Universitaire de Limoges, Limoges, FRANCE.

OP-229

Head-to-head comparison of ^{68}Ga-FAPI-46 and ^{18}F-FDG PET/CT for the initial staging of invasive lobular breast cancer: a prospective study

F. Hugonnet[1], *N. Balamoutoff*[1], *S. Mihailescu*[1], *A. Bafghi*[1], *J. Barrière*[2], *F. Berthier*[1], *M. Blouet*[1], *T. Darnaud*[3], *C. Dugourd*[1], *A. Ferran*[3], *M. Kogay*[1], *W. Lescaut*[1], *M. Masse*[3], *M. Missana*[1], *F. Mocquot*[1], *C. Montemagno*[4], *I. Monticelli*[1], *M. Niederoest*[2], *B. Paulmier*[1], *B. Serrano*[1], *V. Nataf*[1], *M. Faraggi*[1];
[1]CHPG, Monaco, MONACO,
[2]Polyclinique Saint Jean, Cagnes-sur-Mer, FRANCE,
[3]Centre Antoine Lacassagne, Nice, FRANCE,
[4]Centre Scientifique de Monaco, Monaco, MONACO.

OP-230

Prognostic Value of PERCIST Metabolic Response After Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Results from the TRINE PET Multicenter Study

L. Urso[1], *S. Panareo*[2], *D. Albano*[3], *A. Iudicello*[4], *L. Filippi*[5], *P. Guglielmo*[6], *A. Mazzoletti*[7], *S. Taralli*[8], *A. Annovazzi*[9], *L. Fantini*[10], *F. Garrou*[11], *L. Evangelista*[12];
[1]University of Ferrara, Ferrara, ITALY,
[2]University Hospital of Modena, Modena, ITALY,
[3]University of Brescia, Brescia, ITALY,
[4]University Hospital of Ferrara, Ferrara, ITALY,
[5]University of Rome Tor Vergata, Rome, ITALY,
[6]Humanitas Gavazzeni, Bergamo, ITALY,
[7]Poliambulanza Hosptial, Brescia, ITALY,
[8]Policlinico Gemelli, Rome, ITALY,
[9]IRCCS Regina Elena National Cancer Institute, Rome, ITALY,
[10]IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola, ITALY,
[11]Hospital of Novara, Novara, ITALY,
[12]Humanitas University, Pieve Emanuele, ITALY.

OP-231

Predicting Pathological Complete Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer Using Radiomic Analysis

M. Geffroy[1,2], *N. Normand*[1], *O. Kerdraon*[3], *S. Miet*[3], *S. Ourguiti*[3], *J. Frénel*[2,3], *M. Campone*[2,3], *J. Bertin-Ciftci*[3], *N. Varmenot*[2,3], *C. Rousseau*[2,3], *L. Ferrer*[2,3];
[1]Images Perception Interaction, Laboratoire des Sciences du Numériques de Nantes, Nantes, FRANCE,
[2]Nantes Université, Inserm U[1307], CNRS U[6075], Université d'Angers, CRCI[2]NA, Nantes - France, Nantes, FRANCE,
[3]Institut de Cancérologie de l'Ouest, Unicancer, Saint-Herblain, FRANCE.

OP-232

Whole-Body [^{18}F]FDG PET Radiomic Features Significantly Enhance Prognostic Stratification of Metastatic Breast Cancer

J. Auriac[1], *N. Hovhannisyan-Baghdasarian*[1], *C. Nioche*[1], *R. Seban*[1,2], *N. Jehanno*[2], *M. Luporsi*[1], *F. Bidard*[3], *I. Buvat*[1], *F. Orlhac*[1];
[1]Institut Curie, PSL, Université Versailles Saint-Quentin, Inserm, CNRS, Université Paris-Saclay, IRIS, Orsay, FRANCE,
[2]Institut Curie, Department of Nuclear Medicine, Paris-St-Cloud, FRANCE,
[3]Institut Curie, Department of Medical Oncology, Paris-St-Cloud, FRANCE.

OP-233

FirstinHuman Evaluation of a SiteSpecifically Labelled [^{89}Zr]ZrS2Trastuzumab for HER2Targeted PET Imaging

T. Michaelsdóttir[1], *K. B. Elkington*[1], *M. Loft*[1], *C. Christensen*[2], *L. Falborg*[3], *J. Madsen*[3], *N. Gillings*[3], *K. B. V. Døssing*[2], *M. B. Mogensen*[4], *M. V. Maraldo*[5], *M. Mau-Soerensen*[4], *K. S. Rohrberg*[4], *A. Loft*[3], *M. M. Clausen*[1], *A. Kjaer*[1];
[1]Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital - Rigshospitalet & Cluster for Molecular Imaging, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, DENMARK,
[2]Cluster for Molecular Imaging, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, DENMARK,
[3]Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DENMARK,
[4]Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DENMARK,
[5]Department of Oncology, Zealand University Hospital - Næstved, Copenhagen, DENMARK.

OP-234

Prognostic Value of F-18 FDG PET/CT Metabolic Parameters at Primary Staging in Locally Advanced Breast Cancer

S. Ceylan[1], *B. Demirel*[1], *S. Demirtaş Şenlik*[1], *M. Doğan*[2], *G. Uçmak*[1];
[1]Ankara Oncology Training and Research Hospital Nuclear Medicine Clinic, Ankara, TÜRKIYE,
[2]Ankara Oncology Training and Research Hospital Medical OncologyClinic, Ankara, TÜRKIYE.

OP-235

Multiparametric Machine Learning Using ^{18}F-FDG PET/CT Radiomics for Prediction of Axillary Lymph Node Metastasis in Breast Cancer

S. Ozdemir[1], *G. Koca*[2], *M. Dasar*[2], *H. Eroglu Elden*[3], *A. Akbulut*[2], *K. Demirel*[2], *M. Korkmaz*[2];
[1]Hatay Training and Research Hospital, Nuclear Medicine Department, Hatay, TÜRKIYE,
[2]University of Health Sciences, Ankara Training and Research Hospital, Nuclear Medicine Department, Ankara, TÜRKIYE,
[3]Kahramanmaras Necip Fazil City Hospital, Nuclear Medicine Department, Kahramanmaraş, TÜRKIYE.

OP-236

Prognostic Impact of an FDG PET/CT and DW-MRI Combined Cellularity-Adjusted Metabolic Index with Whole-Body Tumor Burden in De Novo Stage IV Breast Cancer

S. Jeong[1], *J. Shin*[2], *J. Kim*[2], *H. Ahn*[2], *Y. Park*[2], *J. Ahn*[2], *J. Lee*[3], *H. Lee*[1,4];
[1]Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KOREA, REPUBLIC OF,
[2]Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KOREA, REPUBLIC OF,
[3]Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KOREA, REPUBLIC OF,
[4]Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, KOREA, REPUBLIC OF.

607

Sunday, October 18, 2026, 16:45 - 18:15
Hall F1

Neuroimaging Committee: Neuro-Oncology Imaging

OP-237

Application of PET RANO 1.0 criteria and associations with prognosis in a retrospective single-center cohort of IDH-mutant glioma

M. Mair[1,2], *T. Aras-Brendler*[2], *J. Reis*[3], *I. von Polenz*[2], *L. Wiegand*[2], *R. Stürzl*[2], *E. Barci*[2], *K. J. Müller*[4], *J. Weller*[5], *S. Katzendobler*[5], *R. A. Werner*[2], *M. Preusser*[1], *S. Schönecker*[6], *P. N. Harter*[7,8], *N. Thon*[5,9], *L. von Baumgarten*[8,4,5], *N. L. Albert*[8,2];
[1]Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, AUSTRIA,
[2]Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY,
[3]Institute of Neuroradiology, LMU University Hospital, LMU Munich, Munich, GERMANY,
[4]Department of Neurology, LMU University Hospital, LMU Munich, Munich, GERMANY,
[5]Department of Neurosurgery, LMU University Hospital,

LMU Munich, Munich, GERMANY,
[6]Department of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, GERMANY,
[7]Center of Neuropathology and Prion Research, Faculty of Medicine, LMU Munich, Munich, GERMANY,
[8]Bavarian Cancer Research Center (BZKF), Partner Site Munich and German Cancer Consortium (DKTK), Partner Site Munich, Munich, GERMANY,
[9]Department of Neurosurgery, Knappschaft University Hospital Bochum, Bochum, GERMANY.

OP-238

Histopathological correlates of O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography uptake and joined impact on survival in recurrent glioblastoma, isocitrate dehydrogenase wildtype

P. Ahle Erichsen[1,2], *Z. Majed Yasin[1], T. Urup[3], A. Bashir[4], J. Skjøth-Rasmussen[5], O. Mølby Henriksen[2], I. Law[2],*
B. Winther Kristensen[1];
[1]Department of Pathology, The Bartholin Institute, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DENMARK,
[2]Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, [2100] Copenhagen, Denmark, Copenhagen, DENMARK,
[3]Danish Comprehensive Cancer Center Brain Tumor Center, Copenhagen, Denmark, Copenhagen, DENMARK,
[4]Department of Neurosurgery, St. Mary's and Charing Cross Hospitals Imperial College Hospital Foundation NHS trust, Greater London, United Kingdom, Greater London, UNITED KINGDOM,
[5]Department of Neurosurgery, Neuroscience Center, Copenhagen University Hospital – Rigshospitalet, Denmark Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark, Copenhagen, DENMARK.

OP-239

Dynamic amino acid PET at initial diagnosis of non-contrast-enhancing brain MRI lesions: preliminary results from the multicenter prospective KING study

A. Verger[1], *A. Flaus[2], S. Querellou[3], A. Kas[4], N. De Leiris[5], V. Roch[1], L. Imbert[1], G. Gauchotte[6], T. Zaragori[1];*
[1]CHRU Nancy, Nancy, FRANCE,
[2]CHU Lyon, Lyon, FRANCE,
[3]CHU Brest, Brest, FRANCE,
[4]APHP, Paris, FRANCE,
[5]CHU Grenoble, Grenoble, FRANCE,
[6]CHRU Nancy, histopathology, Nancy, FRANCE.

OP-240

Impact of FET-PET and MRI versus MRI derived adjuvant radiotherapy treatment volumes and dosimetry: Preliminary findings from the prospective multisite FET-PET in Glioblastoma (FIG) Trial (TROG 18.06).

A. Scott[1], *R. Francis[2], S. Lee[1], E. Lau[3], E. Thomas[4], I. Ruisi[5], M. Pinkham[6], S. Ng[1], M. Back[7], N. Bucknell[4], A. Whitehead[8], R. Dykyj[8], O. Cook[8], A. Moore[8], M. Ebert[4], L. Holloway[5],*
J. Descallar[5], M. Fay[9], N. Barry[4], H. Gan[1], E. Barnes[10], E. Koh[5,11];
[1]Austin Health and ONJCRI, Melbourne, AUSTRALIA,
[2]Royal Brisbane and Womens Hospital, Brisbane, AUSTRALIA,
[3]Austin Health, Melbourne, AUSTRALIA,
[4]Sir Charles Gairdner Hospital, Perth, AUSTRALIA,
[5]Liverpool Hospital, Sydney, AUSTRALIA,
[6]Princess Alexandria Hospital, Brisbane, AUSTRALIA,
[7]Royal North Shore Hospital, Sydney, AUSTRALIA,
[8]TROG Cancer Research, Newcastle, AUSTRALIA,
[9]University of Newcastle, Newcastle, AUSTRALIA,
[10]NHMRC Clinical Trials Centre, University of Sydney, Sydney, AUSTRALIA,
[11]University of New South Wales, Sydney, AUSTRALIA.

OP-241

Impact of 68Ga-DOTA-TOC PET/CT on Radiotherapy Target Delineation in Intracranial Meningiomas: A Prospective Evaluation

M. Usmani, *K. Al Riyami, S. Hashmi, A. Jain, S. Al Saifi, S. Kheruka;*
Sultan Qaboos Comprehensive Cancer Care and Research Center (SQCCCRC), University Medical City, Muscat, OMAN.

OP-242

Correlation of [18F]SiTATE-PET-tracer with somatostatin receptor expression in meningiomas: An ex vivo histological pilot study

R. Gerdes[1], *J. Schittenhelm[2], S. Singer[3], G. Reischl[4], H. Becker[5], M. Tatagiba[5], S. Castaneda-Vega[1], C. la Fougère[1], B. Bender[6], N. Trautwein[1];*
[1]University Hospital Tuebingen, Department of Nuclear Medicine and Clinical Molecular Imaging, Tuebingen, GERMANY,
[2]University Hospital Tuebingen, Institute of Neuropathology, Department of Pathology and Neuropathology, Tuebingen, GERMANY,
[3]University Hospital Tuebingen, Department of General and Molecular Pathology and Pathological Anatomy, Tuebingen, GERMANY,
[4]University Hospital Tuebingen, Department of Preclinical Imaging and Radiopharmacy, Tuebingen, GERMANY,
[5]University Hospital Tuebingen, Department of Neurosurgery, Tuebingen, GERMANY,
[6]University Hospital Tuebingen, Department of Neuroradiology, Tuebingen, GERMANY.

OP-243

Optimization of static reconstruction time interval in dynamic 18F-FET PET-CT for glioma imaging: toward a shortened protocol

N. Vikhrova, *D. Kalaeva, I. Pronin;*
National Medical Research Center for Neurosurgery named after N.N. Burdenko, Moscow, RUSSIAN FEDERATION.

OP-244

Comparing FAPI and FET PET in Gliomas and Brain Metastases: Early Insights into Tumor Microenvironment Imaging from an Italian Multicenter Study

A. Martini[1], *E. Landi[2], I. Laghai[2], G. Bianciardi[2,3], M. Dona[2], A. Leo[2], P. Caroli[4], M. Monti[4], V. Di Iorio[4], L. Fedeli[5],*
S. Sestini[2];
[1]Nuclear Medicine Unit, Department of Diagnostic Imaging, N.O.P. - S. Stefano, U.S.L. Toscana Centro, PRATO, ITALY,
[2]Nuclear Medicine Unit, Department of Diagnostic Imaging, N.O.P. - S. Stefano, U.S.L. Toscana Centro, Prato, ITALY,
[3]Nuclear Medicine Unit, Alma Mater Studiorum University of Bologna, Bologna, ITALY,
[4]Nuclear Medicine Unit, IRCCS -IRST, Meldola, ITALY,
[5]Department Medical Physics, N.O.P. - S. Stefano, U.S.L. Toscana Centro, Prato, ITALY.

OP-245

Evaluation of NMN-BBB score-based subgroup outcomes in newly diagnosed glioblastoma: a retrospective single-center analysis

R. Stürzl[1], *K. J. Müller[2], J. Reis[3], T. Schabhüttl[1,4], I. von Polenz[1], L. Kaiser[1], M. J. Mair[1,4], L. von Baumgarten[2,5,6], P. Harter[7,5,6], S. Schönecker[8], R. Werner[1], D. Kalasauskas[9], F. Ringel[9], J. Blobner[9], M. Preusser[4], N. L. Albert[1,5,6];*
[1]Department of Nuclear Medicine, LMU University Hospital, Munich, GERMANY,
[2]Department of Neurology, LMU University Hospital, Munich, GERMANY,
[3]Department of Neuroradiology, LMU University Hospital, Munich, GERMANY,
[4]Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, AUSTRIA,
[5]Bavarian Cancer Research Center (BZKF), Partner Site Munich, Munich, GERMANY,
[6]German Cancer Consortium (DKTK), Partner Site Munich, Munich, GERMANY,
[7]Center for Neuropathology and Prion Research, Faculty of Medicine, LMU Munich, Munich, GERMANY,
[8]Department of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, GERMANY,
[9]Department of Neurosurgery, LMU University Hospital, Munich, GERMANY.

608

Sunday, October 18, 2026, 16:45 - 18:15
Hall F2

Thyroid Committee: Integrated Diagnostic Approach for Radioiodine Avid and Non-Avid Differentiated Thyroid Carcinoma

OP-246

A Clinicopathological and Biochemical Prediction Model for Predicting Locoregional/Distant Metastasis in Patients with Differentiated Thyroid Carcinoma: The LDM Score

I. Ak Sivrikoz, *E. Ilhan, S. Aslan;*
ESOGU School of Medicine Department of Nuclear Medicine, Eskisehir, TÜRKIYE.

OP-247

Prognostic Value of TTF-2 and FOXE1 Alterations in Papillary Thyroid Carcinoma: Linking Immunohistochemistry to Genetic Insights

F. Aras, *F. Çam, A. Tan, H. S. Mavili;*
Manisa Celal Bayar University Medical Faculty, Manisa, TÜRKIYE.

OP-248

Comparative evaluation of Trop2-targeted 68Ga-MY6349 PET/CT with standard-of-care imaging for presurgical staging and clinical management in thyroid cancer: a prospective, histopathology-based study

W. Guo, *H. Chen;*
The first affiliated hospital of Xiamen University, Xiamen City, CHINA.

OP-249

Evaluation of [18F]SiTATE PET/CT in advanced oncocytic thyroid carcinoma using SSTR-RADS

P. Dahlmann[1], *S. C. Siegmund[1], R. A. Werner[1,2], C. Spitzweg[3,4];*
[1]Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY,
[2]The Russell H Morgan Department of Radiology and Radiological Sciences, Division of Nuclear Medicine and Molecular Imaging, Johns Hopkins School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA,
[3]Department of Medicine IV, Division of Endocrinology, Diabetes and Metabolism, LMU Univeristy Hospital Munich, LMU Munich, Munich, GERMANY,
[4]Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, UNITED STATES OF AMERICA.

OP-250

68Ga-labeled PET tracers versus 18F-FDG for metastatic detection in thyroid cancer patients after 131I therapy: a comparative analysis of 68Ga-PSFA, 68Ga-FAPI and 68Ga-PSMA

S. Liu, *H. Pang;*
The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

OP-251

Prognostic Value of Baseline Thyroglobulin with Complementary FDG PET Stratification in BRAF V600E-Mutant Radioiodine-Refractory Papillary Thyroid Carcinoma Treated with Dabrafenib plus Trametinib

Y. Chang;
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TAIWAN, PROVINCE OF CHINA.

OP-252

Exploration of Chemokine Receptor 4 Targeted 68Ga-Pentixafor PET/CT in Radioiodine-Refractory Differentiated Thyroid Cancer

Y. Liu, *H. Dai, C. Sun, Y. Sun, T. Tian, R. Huang;*
Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA.

OP-253

Early Risk Stratification of Radioiodine-Refractory Differentiated Thyroid Cancer Using Clinical and FDG-PET Parameters

Z. LI[1], *S. Watanabe[1,2,3], K. Hirata[1,2,3], J. Takenaka[1,2,3], N. Wakabayashi[1,2,3], K. Kudo[1,2,3];*
[1]Department of Diagnostic Imaging, Faculty of Medicine, Hokkaido University, Sapporo, JAPAN,
[2]Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, JAPAN,
[3]Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, JAPAN.

OP-254

^{68}Ga-NODAGA-RGD PET/CT Predicts Efficacy of Neoadjuvant Therapy in Newly Diagnosed Locally Advanced Thyroid Cancer

L. Shi[1], F. Yu[1], J. Pan[2], W. Wu[1], J. Wang[2], S. Li[3], F. Wang[1];
[1]*Nanjing First Hospital, Nanjing Medical University, Nanjing, CHINA,*
[2]*Affiliated Hospital of Integrated Traditional Chinese and Western Medicine of Nanjing University of Chinese Medicine, Nanjing, CHINA,*
[3]*Medical University of Vienna, Vienna, AUSTRIA.*

610

Sunday, October 18, 2026, 16:45 - 18:15

Hall K

CTE 3 - Technologists + Paediatrics Committee: [^{18}F]FDG for PET/CT and PET/MRI: The Focus on Paediatric Patients

OP-255

Clinical Indications of [^{18}F]FDG PET in Paediatric Patients

C. Olianti;
Careggi University Hospital, Florence, ITALY.

OP-256

Image Interpretation and Pitfalls of [^{18}F]FDG PET in Paediatric Patients

M. Luporsi;
Hôpital de Libramont, Libramont, BELGIUM.

OP-257

Optimizing [^{18}F]FDG PET/CT and PET/MRI in Children: Balancing Time, Dose Reduction and Image Quality

L. Borgwardt;
Rigshospitalet, Copenhagen, DENMARK.

611

Sunday, October 18, 2026, 16:45 - 18:15

Hall G1

Theranostics Track: Neuroendocrine Therapy

OP-258

Imaging and dosimetric predictors of response and survival in ^{177}Lu-DOTATATE treatment for neuroendocrine neoplams

C. Schmidt[1], S. Spink[2], R. Manavaki[1], C. Abeywickrama Batagodage[2], D. Gillett[2], S. Alsadik[2], D. Inchiappa[3], V. Stokes[3], I. Harper[2], J. Ang[4], R. Casey[3], S. Heard[2], L. Aloj[1];
[1]*Department of Radiology, University of Cambridge, Cambridge, UNITED KINGDOM,*
[2]*Department of Nuclear Medicine, Cambridge University Hospitals, Cambridge, UNITED KINGDOM,*
[3]*Department of Endocrinology, Cambridge University Hospitals, Cambridge, UNITED KINGDOM,*
[4]*Department of Oncology, Cambridge University Hospitals, Cambridge, UNITED KINGDOM.*

OP-259

Dosimetry-guided radioligand therapy in neuroendocrine Tumours: Interim safety analysis of the DUONEN trial

M. Kolodziej[1], M. Opalinska[2], R. Mikołajczak[3], A. Hubalewska-Dydejczyk[2], A. Kowalska[4], M. Dedecjus[5], P. Garnuszek[3], M. Saracyn[1], I. Cieszykowska[3], J. Januszkiewicz-Caulier[5], D. Gasior-Perczak[4], K. Jozwik-Plebanek[1], W. Lenda-Tracz[2], K. Kacperski[1], W. Chalewska[5], G. Kamiński[1];
[1]*Military Institute of Medicine - National Research Institute, Warsaw, POLAND,*
[2]*Jagiellonian University Medical College, Krakow, POLAND,*
[3]*National Centre for Nuclear Research, Otwock, POLAND,*
[4]*Jan Kochanowski University, Kielce, POLAND,*
[5]*National Institute of Oncology - National Research Institute, Warsaw, POLAND.*

OP-260

^{177}Lu-DOTATATE Retreatment in Progressive Well-Differentiated NETs: Outcomes from the LUTHREE Prospective Study

M. Sansovini, S. Nicolini, I. Grassi, M. Celli, I. Marini, D. Valentina, A. Sarnelli, M. Monti, E. Giani, L. Vizza, F. Foca, P. Caroli, F. Matteucci;
IRST, Meldola (Fc), ITALY.

OP-261

177LuDOTATATE Rechallenge from the SEPTRALU-SEMNIM Registry: Timing, Selection, Efficacy and Safety

M. Mitjavila Casanovas[1], A. García Burillo[2], V. Pubul[3], S. Prado[4], J. Hernando[2], A. Prieto[1], Z. Noguerada[5], T. Aroui[6], M. Castellón[7], R. Valverde[8], F. Pena[9], B. Llana[10], M. Nevares[11], M. Velasco[12], L. Garcia-Cañamaque[13], J. Ardila[14], J. Arbizu[15], D. Balaguer[16], M. Orduña[17], A. Repetto[18], M. de la Rubia[19], M. Antón Leal[20], J. Vercher-Conejero[21], P. Jimenez-Fonseca[10], A. Carmona-Bayonas[22];
[1]*Hospital Universitario Puerta de Hierro Majadahonda, Madrid, SPAIN,*
[2]*Hospital Universitario Vall d'Hebron, Barcelona, SPAIN,*
[3]*Hospital Clínico Universitario de Santiago, Santiago de Compostela, SPAIN,*
[4]*Hospital Universitari i Politècnic La Fe, Valencia, SPAIN,*
[5]*Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, SPAIN,*
[6]*Hospital Universitario Virgen de las Nieves, Granada, SPAIN,*
[7]*Hospital Universitario Virgen de la Arrixaca, Murcia, SPAIN,*
[8]*Hospital Universitario de Cruces, Barakaldo, SPAIN,*
[9]*Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN,*
[10]*Hospital Universitario Central de Asturias, Oviedo, SPAIN,*
[11]*Hospital Universitario de Burgos, Burgos, SPAIN,*
[12]*Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN,*
[13]*Hospital H.M. Sanchinarro, Madrid, SPAIN,*
[14]*Hospital Universitario Gregorio Marañón, Madrid, SPAIN,*
[15]*Clínica Universidad de Navarra, Pamplona, SPAIN,*
[16]*Hospital Universitario Doctor Peset, Valencia, SPAIN,*
[17]*Hospital Universitario Ramón y Cajal, Madrid, SPAIN,*
[18]*Hospital Universitario Son Espases, Palma de Mallorca, SPAIN,*
[19]*Hospital Universitario de Getafe, Madrid, SPAIN,*
[20]*Hospital Universitario San Juan de Alicante, Alicante, SPAIN,*
[21]*ICO-Bellvitge, L'Hospitalet de Llobregat, SPAIN,*
[22]*Hospital Universitario Morales Meseguer, Universidad de Murcia, Murcia, SPAIN.*

OP-262

Comparison of Tumour- and Organ Absorbed Doses in ^{177}Lu SSTR Agonist and Antagonist PRRT for NETs across alternating treatment cycles: A single center experience

N. Hammersen[1,2], W. Jentzen[1,2], P. Fragoso Costa[1,2], W. Fendler[1,2], K. Herrmann[1,2], A. Küper[1,2], F. Zarrad[1,2], H. Lahner[3], A. Mathew[3], D. Führer-Sakel[3], C. Lapa[4], D. Kersting[1,2];
[1]*Department of Nuclear Medicine, West German Cancer Center, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY,*
[2]*German Cancer Consortium (DKTK), partner site Essen, a partnership between German Cancer Research Center (DKFZ) and University Hospital Essen, Essen, GERMANY,*
[3]*Department of Endocrinology, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,*
[4]*Nuclear Medicine, Medical Faculty, University Augsburg, Augsburg, GERMANY.*

OP-263

Tandem [^{90}Y]Y/[^{177}Lu]Lu-DOTATATE therapy in neuroendocrine Tumours: The largest long-term real-world experience from Poland

M. Kolodziej[1], A. Zemczak[2], K. Pełka[3], D. Pawlak[4], K. Jozwik-Plebanek[1], G. Kamiński[1], L. Królicki[3], B. Kos-Kudła[2], J. Kunikowska[3];
[1]*Military Institute of Medicine - National Research Insitute, Warsaw, POLAND,*
[2]*Medical University of Silesia, Katowice, POLAND,*
[3]*Medical University of Warsaw, Warsaw, POLAND,*
[4]*National Centre for Nuclear Research, Otwock, POLAND.*

OP-264

Real-world safety and efficacy of antagonist PRRT using [^{177}Lu]Lu-DOTA-JR11 in patients with advanced neuroendocrine neoplasms

B. Menz[1], J. Meister[1], H. R. Kulkarni[1,2], D. Müller[1,3], S. Wiessalla[1], F. C. Robiller[1], T. Langbein[1];
[1]*Department of Nuclear Medicine, Zentralklinik Bad Berka, GERMANY,*
[2]*Bold Advanced Medical Future (BAMF) Health, Grand Rapids, MI, UNITED STATES OF AMERICA,*
[3]*ABX-Advanced Biochemical Compounds Gmbh, Dresden, GERMANY.*

OP-265

BETA PLUS Study Phase 0b: Effect of Peptide Mass on Safety, Dosimetry, and Preliminary Efficacy of [^{161}Tb]Tb-DOTA-LM3 in Metastatic GEP-NET (G1-2)

J. Fricke[1], F. Westerbergh[2], L. McDougall[1], G. P. Nicolas[1], E. Christ[1], D. E. Schmid[3], C. Galvao[1], M. Fani[1], P. Bernhardt[2], N. P. van der Meulen[3], C. Müller[3,4], R. Schibli[3,4], D. Wild[1];
[1]*University Hospital Basel, Basel, SWITZERLAND,*
[2]*University of Gothenburg, Gothenburg, SWEDEN,*
[3]*Paul Scherrer Institute, Villigen-PSI, SWITZERLAND,*
[4]*ETH Zürich, Zürich, SWITZERLAND.*

OP-266

[^{177}Lu]Lu-DOTA-TATE versus Temozolomide-Capecitabine in Gastroenteropancreatic Neuroendocrine Tumours: A Real-World Retrospective Cohort Study

M. Kappenstein[1], N. Ninosu[2], A. Hamm[3], K. Klimek[4], V. Koehler[5], C. Koch[5], J. Bojunga[5], R. Werner[6], N. von Bubnoff[7], D. Groener[1];
[1]*Department of Nuclear Medicine, Clinic for Radiology and Nuclear Medicine, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, GERMANY,*
[2]*Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, GERMANY,*
[3]*Medical Center, Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, GERMANY,*
[4]*Department of Nuclear Medicine, LMU University Hospital, Munich, GERMANY,*
[5]*Medical Clinic [1], University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, GERMANY,*
[6]*Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY,*
[7]*Medical Center, Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Lübeck, Frankfurt, GERMANY.*

701

Monday, October 19, 2026, 08:00 - 09:30

Hall A

CME 5 - Cardiovascular Committee: Looking at Inflammation Within the Heart, What's Hot?

OP-267

Patient Preparation: The Fatter, the Better

K. Wechalekar;
Royal Brompton and Harefield Hospitals, Department of Nuclear Medicine, London, UNITED KINGDOM.

OP-268

Cardiac Sarcoidosis: The Best Example

L. Leccisotti;
Policlinico Gemelli, Department of Nuclear Medicine, Rome, ITALY.

OP-269

Myocarditis: How Far Can We Go with PET ?

P. Marie;
CHU Nancy, Department of Nuclear Medicine, Nancy, FRANCE.

OP-270

New Tracers, New Kids on the Block for Cardiac Inflammation?

R. Büchel;
Universitätsspital Zürich, Zurich, SWITZERLAND.

702

Monday, October 19, 2026, 08:00 - 09:30
Hall D (Arena)

Special Track 5 - AI Committee: Round Table: My AI Project - Methods, Challenges and Success Solutions

OP-271

My AI Project - Methods, Challenges and Success Solutions
C. Constantino;
Champalimaud Foundation, Lisbon, PORTUGAL.

OP-272

My AI Project - Methods, Challenges and Success Solutions
C. Spielvogel;
Medical University of Vienna, Vienna, AUSTRIA.

OP-273

My AI Project - Methods, Challenges and Success Solutions
A. Boukhari;
University Brest, INSERM, Brest, FRANCE.

OP-274

My AI Project - Methods, Challenges and Success Solutions
E. Doering;
Fonrschungszentrum Jülich – University Köln, Cologne, GERMANY.

703

Monday, October 19, 2026, 08:00 - 09:30
Hall E1

LIPS Session 5 - Oncology & Theranostics Committee: Current and Emerging Imaging Applications in Breast Cancer

OP-275

FDG
S. Carrilho Vaz;
Champalimaud Foundation, Lisbon, PORTUGAL.

OP-276

FES & HER2
G. Gebhart;
Hopital Universitaire de Bruxelles, Brussels, BELGIUM.

OP-277

FAPI
P. Backhaus;
University Hospital Münster, Münster, GERMANY.

OP-278

SSTR and GRPR
D. Kersting;
Universitätsklinikum Essen, Essen, GERMANY.

704

Monday, October 19, 2026, 08:00 - 09:30
Hall E2

M2M Track: TROP Session - Translational Molecular Imaging & Therapy Committee: First-In-Human PET Tracers

OP-279

Trop2 immuno-PET/CT imaging ofprostate cancer: aproof-of-concept translational study
X. Long[1], *S. Cheng*[1], *W. Wei*[2], *X. Lan*[1], *D. Jiang*[1];
[1]*Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA,*
[2]*Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shangai, CHINA.*

OP-280

Bicyclic peptide-based EphA2-targeted PET in pancreatic cancer: first-in-human safety, biodistribution and dosimetry
A. Eder[1,2], *C. Wielenberg*[1], *M. A. Omrane*[1,2], *M. El Fakiri*[1,2], *A. Klotsotyra*[1], *K. Brüggemann*[1], *H. Becker*[1], *M. Quante*[1], *M. Mix*[1], *M. Eder*[2,1,3], *P. T. Meyer*[1,2], *M. T. Freitag*[1];
[1]*University Medical Center, Freiburg, GERMANY,*
[2]*German Cancer Consortium, Freiburg, GERMANY,*
[3]*German Cancer Research Center, Heidelberg, GERMANY.*

OP-281

PepMimic-Enabled De Novo Design of a TROP-2-Targeting Peptide Tracer for Precision PET Imaging
Z. Wang[1], *Z. Lin*[2], *W. Miao*[2], *J. Lu*[1];
[1]*Xuanwu Hospital Capital Medical University, Beijing, CHINA,*
[2]*The First Affiliated Hospital of Fujian Medical University, FuZhou, CHINA.*

OP-282

Development and Preclinical Evaluation of ^{18}F-CYNB: A CD103-targeted Nanobody Based Radio-tracer for Visual Prediction of Response to Cancer Immunotherapy
Z. Wang, *Y. Li, M. Yang, X. Zhang;*
Department of Nuclear Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, CHINA.

OP-283

First-in-Human PET Imaging and Dosimetry of [^{68}Ga]Ga-FC516, an ACP3-Targeted Radiotracer for Prostate Cancer
Y. Zhong[1], *H. Tai*[1], *H. Liu*[1], *S. Wu*[1], *S. Shi*[1], *Z. Yin*[1], *M. Sun*[1], *X. Yuan*[1], *L. Wang*[2], *N. Xi*[1];
[1]*Findcure Biosciences (Zhongshan) Co., Ltd., Zhongshan, CHINA,*
[2]*Center of Cyclotron and PET Radiopharmaceuticals (CCPR), Department of Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, CHINA.*

OP-284

Development of a Novel High-Affinity TROP2-Targeting Antibody Lead and Its Application as [^{6464}Cu]Cu-HX090302-NOTA for ImmunoPET Imaging of Breast Cancer: From Bench to First-in-Human Results
C. Li[1], *H. Liu*[1], *P. Zhang*[2], *X. Wang*[2], *R. Wang*[1];
[1]*Department of Nuclear Medicine, The First Medical Center of Chinese PLA General Hospital, Beijing, CHINA,*
[2]*Beijing Hexin Pharmaceutical Technology CO., LTD., Beijing, CHINA.*

OP-285

[^{11}C]-4′-O-Methylpyridoxine, a PET Tracer to Predict Chemoresistance in Non-Small Cell Lung Cancers and Visualise T Cell Activation in Autoimmune Diseases
C. Kellner[1,2], *D. Graf*[1,2], *A. A. Torrens*[1], *T. Kaur*[3], *H. Zhao*[4], *A. F. Brooks*[3], *P. J. H. Scott*[3], *C. L. Addison*[4,5,6], *A. J. Shuhendler*[1,2,7];
[1]*University of Ottawa, Department of Chemistry and Biomolecular Sciences, Ottawa, ON, CANADA,*
[2]*University of Ottawa, Heart Institute, Ottawa, ON, CANADA,*
[3]*University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA,*
[4]*Ottawa Hospital Research Institute, Ottawa, ON, CANADA,*
[5]*University of Ottawa, Department of Medicine, Ottawa, ON, CANADA,*
[6]*University of Ottawa, Department of Biochemistry, Microbiology, and Immunology, Ottawa, ON, CANADA,*
[7]*University of Ottawa, Brain and Mind Research Institute, Ottawa, ON, CANADA.*

OP-286

A Novel FAP Targeting Peptide for Radioligand Diagnosis and Therapy: from Preclinical to First-in-human
X. Mu, *Y. Lu, L. Zhang, J. Li, W. Fu;*
Department of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, CHINA.

OP-287

Development of ^{68}Ga/^{131}I-labeled Anti-nectin-4 DimericNanobodies for Tumor Radiotheranostics: From Preclinical Evaluation to First-in-Human Application
X. Long, *X. Zhang, R. An, Y. Zhang, X. Lan, D. Jiang;*
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

705

Monday, October 19, 2026, 08:00 - 09:30
Hall B

Cutting Edge Science Track: Physics Committee: PET/SPECT for Therapy Optimisation

OP-288

^{88}Y PET imaging of glass microsphere distribution using a dBGO LAFOV PET/CT system
M. Segbers, *F. A. Verburg, R. M. van Haaren, D. Rook, J. M. Mostert;*
Erasmus Medical Center, Rotterdam, NETHERLANDS.

OP-290

From Calibration to Clinic: Province-Wide Implementation of Quantitative ^{177}Lu SPECT/CT for Post-treatment Imaging in British Columbia
X. Hou[1], *P. EsquinasFernandez*[1], *M. Gonzalez*[2], *E. Dahlen*[3], *J. Curtis*[4], *D. Worsley*[5], *G. Sexsmith*[6], *C. Mohamed*[2], *S. Tyldesley*[1], *D. Schellenberg*[1], *M. Soleimani*[1], *D. Wilson*[1], *S. Graves*[7], *C. Uribe*[1];
[1]*BC Cancer, Vancouver, BC, CANADA,*
[2]*Interior Health, Kelowna, BC, CANADA,*
[3]*Fraser Health, Vancouver, BC, CANADA,*
[4]*Vancouver Island Health Authority, Victoria, BC, CANADA,*
[5]*Vancouver Coastal Health, Vancouver, BC, CANADA,*
[6]*Providence Health Care, Vancouver, BC, CANADA,*
[7]*University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA.*

OP-291

Building the Traceability Backbone for Radiopharmaceutical Therapy: First Results from the PDIB Secondary Standards Laboratory Network
S. Graves[1], *L. Verheyen*[2], *B. D. Wright*[3], *X. Hou*[4], *E. Jamieson*[4], *B. E. Zimmerman*[5], *J. J. Sunderland*[1], *R. Galea*[6], *A. Fenwick*[7], *C. S. Vargas*[2], *S. E. Lapi*[3], *C. Uribe*[4];
[1]*University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA,*
[2]*Belgian Nuclear Research Centre (SCK-CEN), Mol, BELGIUM,*
[3]*University of Alabama Birmingham, Birmingham, AL, UNITED STATES OF AMERICA,*
[4]*BC-Cancer, Vancouver, BC, CANADA,*
[5]*National Institute of Standards and Technology (NIST), Gaithersburg, MD, UNITED STATES OF AMERICA,*
[6]*National Research Council of Canada, Metrology Research Center, Ottawa, ON, CANADA,*
[7]*UK National Physical Laboratory, London, UNITED KINGDOM.*

OP-292

Evaluation of scatter correction for quantitative ^{177}Lu SPECT/CT using a CZT-based system.
R. Danieli[1], *F. Dupont*[2], *T. Assoignon*[3], *C. Marin*[1], *N. Reynaert*[1], *B. Vanderlinden*[1], *M. Hesse*[2];
[1]*Hôpital Universitaire de Bruxelles, Brussels, BELGIUM,*
[2]*Nuclear Medicine Department, Cliniques Universitaires Saint-Luc, Brussels, BELGIUM,*
[3]*UCLouvain, Woluwe-Saint-Lambert, BELGIUM.*

OP-293

Towards reduced acquisition times for ^{177}Lu and ^{131}I imaging using a dual-side CZT-based full-ring SPECT/CT system

E. Emond[1], *H. Devendranath*[2], *N. Hammersen*[2], *J. Kertscher*[2], *V. Ferri*[3];
[1]*GE HealthCare GmbH, Düsseldorf, GERMANY,*
[2]*Department of Nuclear Medicine, University Hospital Essen, West German Cancer Center (WTZ), Essen, GERMANY,*
[3]*GE Medical Systems Italia S.p.A, Milan, ITALY.*

OP-294

Optimising SPECT/CT for Alpha Emitters: Phantom Validation and Calibration of [^{211}At] Imaging

R. van Rooij[1], *N. Falzone*[2], *S. Bhagwat*[2], *D. B. Divlianska*[2], *D. L. Yokell*[2], *B. van der Wildt*[1], *A. J. Poot*[1], *A. J. A. T. Braat*[1];
[1]*University Medical Center Utrecht, Utrecht, NETHERLANDS,*
[2]*Telix Pharmaceuticals Pty Ltd, Melbourne, AUSTRALIA.*

OP-295

Harmonised multicentre crosscalibration of ^{211}At for preclinical and clinical studies within the EU-HORIZON-JU-IHI Accelerate.EU project

H. Levillain[1,2], *C. Marin*[1], *S. Rodriguez Pérez*[3], *S. Humpert*[4], *B. Neumaier*[4], *S. Genouel*[5], *R. Garcia*[6], *W. Delbart*[1], *G. Doumont*[2], *K. Tabury*[3], *L. Ferrer*[7,8], *N. Varmenot*[7,8], *B. Vanderlinden*[1];
[1]*Institut Jules Bordet (IJB), Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Brussels, Belgium., Brussels, BELGIUM,*
[2]*Numix-CMMI, Université Libre de Bruxelles (ULB), Charleroi (Gosselies), BELGIUM,*
[3]*Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM,*
[4]*Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Jülich, GERMANY,*
[5]*GIP Arronax, Saint-Herblain, FRANCE,*
[6]*TetraKit Technologies ApS, University of Copenhagen, Copenhagen, DENMARK,*
[7]*Institut de Cancérologie de l'ouest (ICO), Nantes, FRANCE,*
[8]*CRCI2NA, UMR 1307 Inserm-UMR 6075 CNRS, Nantes University, Nantes, FRANCE.*

OP-296

Patient-Specific Recovery Coefficients for SPECT: Using Patient Anatomy and Uptake Context to Correct Partial Volume Effect

A. Ocampo Suarez[1,2], *S. Kurkowska*[2], *P. Esquinas Fernandez*[3], *X. Hou*[3], *J. Fowler*[1,2], *M. Soleimani*[4], *D. Wilson*[3], *F. Benard*[3,2,1], *S. Graves*[5], *J. Tran-Gia*[6], *C. Uribe*[3,2,1];
[1]*Departments of Physics and Astronomy, University of British Columbia, Vancouver, BC, CANADA,*
[2]*Department of Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC, CANADA,*
[3]*Molecular Imaging and Therapy, BC Cancer, Vancouver, BC, CANADA,*
[4]*BC Cancer Agency, Vancouver, BC, CANADA,*
[5]*Department of Radiology, University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA,*
[6]*Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacherstr, Würzburg, GERMANY.*

706

Monday, October 19, 2026, 08:00 - 09:30
Hall C

Clinical Oncology Track: Colorectal and Prostate Imaging

OP-297

PDGFRβ PET/CT for In Vivo Characterisation of Tumour Stroma in Liver Neoplasia: Preliminary Results from the IMAGINE-1 Study

A. Tzortzakakis[1], *M. Ferrat*[1], *M. M. Moein*[1], *E. Jussing*[1], *A. Lindvall*[1], *M. Holstensson*[1], *C. Hindorf*[1], *A. Abrahamsson*[1], *A. Östman*[1], *J. Engstrand*[1], *M. Gerling*[1], *O. Eriksson*[2], *T. A. Tran*[1], *R. Axelsson*[1];
[1]*Karolinska Institutet, Stockholm, SWEDEN,*
[2]*Uppsala University, Uppsala, SWEDEN.*

OP-298

The role of [^{68}Ga]Ga-FAPI-46 PET/CT in exploring tumour-stroma interactions and histopathological growth patterns in colorectal cancer liver metastases: first results from the FOAM trial (NCT07109440)

I. Vierasu, *L. Verset, W. Delbart, A. Veron Sanchez, F. Sclafani, A. Boisson, Z. Wimana, S. Cerfontaine, M. Gomez-Galdon, C. Marin, H. Levillain, P. Kristanto, L. Taraji, N. Benhima, K. Willard-Gallo, J. L. Van Laethem, V. Lucidi, A. Bohlok, V. Donckier, P. Flamen; Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, BELGIUM.*

OP-299

Hybrid PET-MRI Response Modeling Outperforms Individual Biomarkers in Predicting Pathological Response in Locally Advanced Rectal Cancer

P. Shinkar[1], *M. Vamsy*[1], *D. Kumar*[2], *V. Varshney*[2], *P. Wadhwa*[2], *L. Somepalli*[1], *V. R. Parapati*[3];
[1]*Omega Hospital, Hyderabad, INDIA,*
[2]*United Imaging Healthcare, Shanghai, CHINA,*
[3]*Omega Cancer Hospital, Hyderabad, INDIA.*

OP-300

Prospective Randomized intra-patient Comparison of Diagnostic Performance and Clinical Impact of Total-Body vs Short-Axial Field-of-View [^{68}Ga] Ga-PSMA-11 PET/CT in Biochemical Recurrent Prostate Cancer: the VAULT Study

A. Di Giorgio[1], *M. Di Franco*[2], *G. Cuzzani*[1], *M. Rapa*[3], *C. Nanni*[4], *P. Castellucci*[4], *A. Farolfi*[4], *S. Fanti*[1,4];
[1]*Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,*
[2]*Department of Radiology, University of California-Davis, Davis, CA, UNITED STATES OF AMERICA,*
[3]*Nuclear Medicine, University of Brescia, Italy; Nuclear Medicine, ASST Spedali Civili di Brescia, Brescia, ITALY,*
[4]*Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

OP-301

Diagnostic Benefit of Dual Time-Point [^{64}Cu] Cu-NODAGA-PSMA-617 PET/CT after Negative [^{68}Ga]Ga-PSMA-11 or [^{18}F]F-PSMA-1007 PET/CT in Early Biochemically Recurrent Prostate Cancer

S. Hoberück[1], *M. von Müller*[1], *J. Müller*[1], *T. Hölscher*[2], *F. Hofheinz*[3], *I. Apostolova*[4], *E. Michler*[1], *C. Furth*[5], *M. Galler*[5], *A. Braune*[1,3,6], *M. Pretze*[1], *F. Brandt*[1], *C. Mamat*[3], *M. Miederer*[1,7], *K. Kopka*[3,7,8], *R. A. Bundschuh*[1];
[1]*Department of Nuclear Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Fetscherstraße 74, 01307 Dresden, Germany, Dresden, GERMANY,*
[2]*Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Fetscherstraße 74, 01307 Dresden, Germany, Dresden, GERMANY,*
[3]*Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Dresden, GERMANY,*
[4]*Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany., Hamburg, GERMANY,*
[5]*Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany., Berlin, GERMANY,*
[6]*Technische Universität Dresden, Carl Gustav Carus Faculty of Medicine, 01307 Dresden, Germany, Dresden, GERMANY,*
[7]*Department of Translational Imaging in Oncology, National Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zent, Dresden, GERMANY,*
[8]*TUD Dresden University of Technology, School of Science, Faculty of Chemistry and Food Chemistry, Dresden, Germany., Dresden, GERMANY.*

OP-302

Prospective comparison of 64Copper [^{64}Cu]SAR-bisPSMA vs 68Gallium[^{68}Ga] PSMA-11 PET/CT for biochemical recurrence of prostate cancer following radical prostatectomy(Co-PSMA trial).

L. Emmett[1], *N. Papa*[1], *A. Nguyen*[2], *N. Ayati*[2], *K. Wong*[2], *K. DeVitt*[2], *S. Sharma*[2], *B. Ho*[2], *J. Chen*[2], *S. Khan*[2];
[1]*390 Victoria St, Sydney, AUSTRALIA,*
[2]*St Vincent's Hospital, Sydney, AUSTRALIA.*

OP-304

Dual-tracer PET/CT Imaging of CD8+ T cell Infiltration and Granzyme B Activation Enhances Response Prediction to Combined Radiotherapy and PD-l inhibitor

Z. Hong[1], *S. Ge*[2], *Y. Zhu*[1], *Y. Kong*[1], *M. Xu*[1], *J. Zhang*[1], *P. Xing*[1], *S. Deng*[2], *L. Zhang*[1];
[1]*The second affiliated hospital of Soochow university, Suzhou, CHINA,*
[2]*The first affiliated hospital of Soochow university, Suzhou, CHINA.*

OP-305

Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer with68Ga-FAPI-04 PET and ^{18}F-FDG PET: A Prospective Study

Z. Huang[1], *Y. An*[2], *G. Lin*[2], *Z. Zhu*[3], *R. Cui*[1];
[1]*Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CHINA,*
[2]*Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CHINA,*
[3]*Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Beijing, CHINA.*

707

Monday, October 19, 2026, 08:00 - 09:30
Hall F1

Neuroimaging Committee: Targeted Radionuclide Therapy for Brain Tumours

OP-306

Invited Speaker

N. Tolboom;
Medical Centre Utrecht, Utrecht, NETHERLANDS.

OP-307

Radionuclide Therapy with [^{177}Lu]Lu-DOTATATE in Refractory Meningiomas: Results from the French Multicenter MELUTE Cohort

N. Garabedian[1], *T. Zaragori*[2], *E. Tabouret*[3], *L. Taillandier*[4], *C. Ansquer*[5], *S. Boughdad*[6], *C. Bund*[7], *C. Cheze-Le-Rest*[8], *J. Darcourt*[9], *G. Delaby*[10], *I. Dygai-Cochet*[11], *E. Deshayes*[12], *A. Edet-Sanson*[13], *A. Flaus*[14], *T. Fidani*[15], *T. Horowitz*[16], *P. Meneret*[17], *E. Quak*[18], *S. Querellou*[19], *G. Tlili*[20], *L. Vija*[21], *G. Hossu*[2], *L. Imbert*[22], *B. Salgues*[6], *E. Guedj*[16], *M. Peyre*[23], *T. Graillon*[24], *C. Boursier*[22], *A. Verger*[22];
[1]*Chru Nancy, Department of Nuclear Medicine, Nancyclotep Imaging Platform, Nancy, FRANCE,*
[2]*Université de Lorraine, Iadi, Inserm U1254, Cic 1433, Innovation Technologique, Nancy, FRANCE,*
[3]*Aix-Marseille University, Aphm Cnrs, Inp, Institute of Neurophysiopathology, Neuro-Oncology Department, Timone University Hospital, Marseille, FRANCE,*
[4]*Université de Lorraine, Department of Neuro-Oncology, Cran Umr 7039, Cnrs, Nancy, FRANCE,*
[5]*Nantes Université, Nantes University Hospital, Department of Nuclear Medicine, Inserm, Cnrs, Crci²na, Nantes, FRANCE,*
[6]*Sorbonne University, Department of Nuclear Medicine and Molecular Imaging, Pitié-Salpêtrière Hospital, Ap-hp, Inserm, Cnrs, Laboratoire d'Imagerie Biomédicale, Paris, FRANCE,*
[7]*Institut Strauss, Department of Nuclear Medicine and Molecular Imaging, Strasbourg, FRANCE,*
[8]*University Hospital of Poitiers, Department of Nuclear Medicine, Poitiers, France, Latim Umr 1101, Inserm, Poitiers, FRANCE,*
[9]*Université Côte d'Azur/Cea, Department of Nuclear Medicine, Centre Antoine Lacassagne, Tiro-Umr E4320, Nice, FRANCE,*

[10]Lille University Hospital, Department of Nuclear Medicine, Claude Huriez Hospital, Lille, FRANCE,
[11]Université Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, Department of Nuclear Medicine, Dijon, FRANCE,
[12]Université de Montpellier, Department of Nuclear Medicine, Institut du Cancer de Montpellier, Inserm U1194, Montpellier, FRANCE,
[13]Rouen University, Department of Nuclear Medicine, Centre Henri Becquerel;
Quantlf-Aims, Rouen, FRANCE,
[14]Hospices Civils de Lyon;
Department of Nuclear Medicine, Lyon Neuroscience Research Center, Cnrs Umr 5292, Inserm U1028, Lyon, FRANCE,
[15]Montpellier University, Department of Nuclear Medicine, Inserm U1046/Cnrs Umr 9214 Phymedexp, Chru Montpellier, Montpellier, FRANCE,
[16]Aix Marseille Univ Department of Nuclear Medicine, Aphm, Cnrs, Centrale Marseille, Institut Fresnel, Hôpital de La Timone, Cerimed, Marseille, FRANCE,
[17]Centre Eugène Marquis Department of Nuclear Medicine, Inserm Umr 1099, Rennes, FRANCE,
[18]Centre François Baclesse, Department of Nuclear Medicine and Thyroid Unit, Caen, FRANCE,
[19]Brest University Hospital, Department of Nuclear Medicine, Inserm UMR 1304 Getbo, Université de Bretagne Occidentale, Brest, FRANCE,
[20]Bordeaux University Hospital, Department of Nuclear Medicine, Bordeaux, FRANCE,
[21]Université de Toulouse, Department of Nuclear Medicine, Oncopole Claudius Regaud, Toulouse, FRANCE,
[22]Chru Nancy, Department of Nuclear Medicine, Nancyclotep Imaging Platform, Université de Lorraine, Iadi, Inserm U1254, Nancy, FRANCE,
[23]Sorbonne University, Department of Neurosurgery, Ap-hp, Pitié-Salpêtrière Hospital, Paris, FRANCE,
[24]Aix-Marseille University, Aphm, Inserm, Mmg (U1251), Department of Neurosurgery, Timone University Hospital, Marseille, FRANCE.

OP-308

Peptide Receptor Radionuclide Therapy with Lu-177- and Y-90-Labeled Somatostatin Analogues in Progressive Meningioma: Survival Outcomes from a Bicentric Retrospective Analysis

I. Ciuciulkaite[1], T. Telli[1], L. I. Frommann[1], S. Kebir[2,3], K. Herrmann[1], W. P. Fendler[1], H. Hautzel[1], P. Fragoso Costa[1], L. Umutlu[4,5], M. Müther[6], L. Stegger[7], K. Rahbar[7], M. Schäfers[7], D. Kersting[1], W. Roll[7], C. Backhaus[7];
[1]Department of Nuclear Medicine, West German Cancer Center, DKTK and NCT site, University Hospital Essen, Essen, GERMANY,
[2]Department of Neurology, University Medicine Essen, University Duisburg-Essen, Essen, GERMANY,
[3]DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), University Medicine Essen, University Duisburg-Essen, Essen, GERMANY,
[4]Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, GERMANY,
[5]German Cancer Consortium (DKTK), Partner Site, Essen-Düsseldorf, Partnership Between DKFZ and University Hospital Essen, Essen, GERMANY,
[6]Department of Neurosurgery, West German Cancer Center, University Hospital Münster, Münster, GERMANY,
[7]Department of Nuclear Medicine, West German Cancer Center, University Hospital Münster, Münster, GERMANY.

OP-309

Real-world efficacy and safety of ^{177}Lu-DOTATATE in recurrent and inoperable meningiomas: early outcomes from a large single-centre cohort

G. Sipka[1], K. Apro[1], A. Dobi[2], K. Hideghety[2], M. Balazsfi[3], P. Barzó[3], A. Bakos[1], I. Farkas[1], S. Nagy[1], N. Friedrich[1], B. Revesz[1], B. Bardoczi[1], R. Nemet[1], V. Zsiros[1], F. Timar[1], L. Pavics[1], Z. Besenyi[1];
[1]University of Szeged, Department of Nuclear Medicine and Theranostics, Szeged, HUNGARY,
[2]University of Szeged, Department of Oncotherapy, Szeged, HUNGARY,
[3]University of Szeged, Department of Neurosurgery, Szeged, HUNGARY.

OP-310

Response, dosimetry and predictive factors of [^{177}Lu] Lu-DOTATATE treatment in recurrent/progressive meningioma: a retrospective single-center study

M. Mair[1,2], B. E. Vindstad[2], A. Celiku[2], A. Delker[2], K. J. Müller[3], V. Stoecklein[4], L. Wiegand[2], A. C. Wehn[4], V. Wenter[2], M. Zacherl[2], R. A. Werner[2], L. von Baumgarten[3,4,5], M. Preusser[1], M. Brendel[2], P. N. Harter[5,6], G. Böning[2], C. Schichor[4], N. L. Albert[5,2];
[1]Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, AUSTRIA,
[2]Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY,
[3]Department of Neurology, LMU University Hospital, LMU Munich, Munich, GERMANY,
[4]Department of Neurosurgery, LMU University Hospital, LMU Munich, Munich, GERMANY,
[5]Bavarian Cancer Research Center (BZKF), Partner Site Munich and German Cancer Consortium (DKTK), Partner Site Munich, Munich, GERMANY,
[6]Center of Neuropathology and Prion Research, LMU University Hospital, LMU Munich, Munich, GERMANY.

OP-311

Iodofalan (^{131}I) in recurrent high-grade gliomas: evaluation of safety and efficacy

A. El Ghalbouni[1], T. A. J. Sturre[1], A. J. A. T. Braat[1], J. Dankbaar[1], F. Y. F. L. De Vos[2], P. A. J. T. Robe[3], A. Claes[4], T. J. Snijders[3], N. Tolboom[1];
[1]Department of Radiology and Nuclear Medicine, UMC Utrecht, Utrecht, NETHERLANDS,
[2]Department of Medical Oncology, UMC Utrecht, Utrecht, NETHERLANDS,
[3]Department of Neurology and Neurosurgery, UMC Utrecht, Utrecht, NETHERLANDS,
[4]Department of Radiotherapy, UMC Utrecht, Utrecht, NETHERLANDS.

OP-312

IPAX BrIGHT: Pivotal Study of [^{131}I]Iodofalan ith or without lomustine vs lomustine alone for treatment of patients with radiographically confirmed recurrent glioblastoma at first recurrence

J. Roetman[1], A. A. J. A. Braat[2], N. Tolboom[2], A. M. Scott[3], H. K. Gan[3], J. Pichler[4], W. Pullin[5], D. Divlianska[1], D. Cade[1], J. de Groot[6];
[1]Telix Pharmaceuticals, North Melbourne, AUSTRALIA,
[2]University Medical Centre Utrecht, Utrecht, NETHERLANDS,
[3]Austin Health, Heidelberg, AUSTRALIA,
[4]Kepler University Hospital, Linz, AUSTRIA,
[5]Gold Coast University Hospital, Southport, AUSTRALIA,
[6]University of California San Francisco, San Francisco, CA, UNITED STATES OF AMERICA.

OP-313

Targeted Alpha Therapy for Recurrent Glioblastoma Multiforme with [^{225}Ac]-PSMA: A new theranostic approach

K. Saglam[1], H. B. Sayman[1], O. Aras[2], M. V. Hekim[1], E. Akgün Kaymak[3], F. Öner Dinçbaş[1];
[1]Istanbul University-Cerrahpasa, Istanbul, TÜRKIYE,
[2]Innovative Body Scan, LLC, Dallas, Texas [75211], TX, UNITED STATES OF AMERICA,
[3]University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, TÜRKIYE.

OP-314

Non-Neoplastic Cellular Binding of PSMA-Targeted Probes Limits Radiation Dose Delivery and Therapeutic Efficacy in Glioma

R. Yang, K. Guo, G. Li, J. Ye, K. Yu, T. Ma, J. Wang, Y. Guo, F. Kang, J. Wang;
Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

708

Monday, October 19, 2026, 08:00 - 09:30
Hall F2

Joint Symposium 3 - Dosimetry Committee / ESTRO: Understanding Radiobiological Parameters for Dose–Response Correlations

OP-315

Core Radiobiological Parameters for Dose Comparisons: RPT vs. EBRT

A. Sarnelli;
Medical Physics Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY.

OP-316

Dose–Effect Correlations in Radiation Therapies: Identifying Which Dose Metrics Predict Outcome Best?

A. McWilliam;
Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, United Kingdom;
The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM.

OP-317

A Roadmap for Dose-Effect Correlations in RPT: Let's Make a Better Use of What is Available!

C. Stokke;
Oslo University Hospital, Division of Radiology and Nuclear Medicine, Oslo, NORWAY.

OP-318

A Roadmap for Dose-Effect Correlations in RPT: Let's Make a Better Use of What is Available!

F. Cicone;
Unit of Nuclear Medicine, "Renato Dulbecco" University Hospital, Magna Graecia University of Catanzaro, Catanzaro, ITALY.

710

Monday, October 19, 2026, 08:00 - 09:30
Hall K

Technologists' Track Oral Presentations 2 - Technologists Committee: PET and Radiopharmacy: Science, Technology, and Clinical Applications

OP-319

Rethinking Paediatric PET: Age and Sex Shape [^{18}F] FDG Biodistribution

I. Tjio, E. C. R. Chocolaad, D. Divyanshi, J. H. Van Snick, R. H. J. A. Slart, A. W. J. M. Glaudemans, O. V. Ivashchenko;
University Medical Center Groningen, Groningen, NETHERLANDS.

OP-320

JiT-PET: A Dose-Adaptive Flow Matching Model via Direct Image Prediction for Multi-Manifold Ultra-Low-Dose PET Denoising

F. Li[1], F. Shang[1], L. Huo[2], S. Liu[3];
[1]School of Medical Science and Engineering, Beijing Institute of Technology, Beijing, CHINA,
[2]Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, CHINA,
[3]Institute of Artificial Intelligence, University of Science and Technology Beijing, Beijing, CHINA.

OP-321

Clinical Validation of Motion Correction Techniques for Quantitative Amyloid, Tau and Metabolism PET in Alzheimer's Disease

J. Li, Z. Zhang, W. Zhengjie, P. Hua;
The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

OP-322

Reduced Acquisition Duration or [^{18}F]FDG Activity in Brain PET/CT examinations: Evaluation of performance and diagnostic robustness from the RADFAB study

M. Rode, P. Dolliner, J. Damgaard Mortensen, P. Christian Holdgaard;
University Hospital of Southern Denmark, Vejle, DENMARK.

OP-323

Clinical Optimisation of Acquisition Time in [^{18}F]-FDG-PET for Brain Imaging

R. Klausen, P. Braad;
Department of Radiology, Hospital of Southern Denmark, Aabenraa, DENMARK.

OP-324

Spatial Distribution of Myocardial Fibroblast Activation after Myocardial Infarction: A Multimodal FAPI PET and Accelerated T2-Weighted Dark-Blood MRI Study

X. Wang[1], *Y. Bian*[1], *X. Su*[2], *Y. Yang*[2], *C. Yang*[1], *X. Du*[1], *H. Feng*[1], *S. Zhang*[1];
[1]*First Affiliated Hospital of Dalian Medical University, Dalian, CHINA,*
[2]*Beijing United Imaging Healthcare Technology Development Co., Ltd., Beijing, CHINA.*

OP-325

Exploring PET-based Radiomic Models for Early Treatment Response Prediction to Neoadjuvant Chemotherapy in Breast Cancer

P. Dwivedi[1,2,3], *M. Mhatre*[1,2], *S. Barage*[2], *V. Kumar*[4], *S. Ghosh*[1,3], *A. Agrawal*[1,3];
[1]*Advanced Centre for Treatment Research and Education In Cancer,Tata Memorial Centre, Mumbai, INDIA,*
[2]*Amity University, Mumbai, INDIA,*
[3]*Homi Bhabha National Institute, Mumbai, INDIA,*
[4]*Indian Institute of Technology, Mumbai, INDIA.*

OP-326

Beyond the Vein: Technologist-Led Development of a Low-Dose Oral [18F]FDG Protocol on Long-axial Field-of-view PET/CT

N. Colpo, *C. Williams, A. M. Weppler, P. Ravi, A. Rahmim, C. Uribe, F. Bénard, I. Alberts;*
BC Cancer, Vancouver, BC, CANADA.

OP-327

Experiences and Achievements with a LAFOV Scanner-Reflections from a Paediatric Team.

B. Kragh Faelled, *S. Hansen;*
Aarhus University hospital, Aarhus, DENMARK.

711

Monday, October 19, 2026, 08:00 - 09:30

Hall G1

Bone & Joint Committee: New Insights Into Musculoskeletal Imaging and Theranostics

OP-328

Ga-68 PSMA PET/CT in Treatment-Naïve Osteosarcoma: Baseline Tumour Characterisation, Metastatic Staging, and Correlation with Histopathological Response to Neoadjuvant Chemotherapy

R. Karna, *K. J. Das, A. Singhal, L. Kapoor, V. S. Kumar, S. A. Khan, A. W. Barwad, A. R. Mridha, J. K. Meena, D. Pushpam, S. Bakhshi, R. Kumar;*
All India Institute of Medical Sciences, New Delhi, INDIA.

OP-329

A Head-to-Head Comparative Study of 68Ga-DOTA-IBA and 18F-NaF PET/CT in Bone Metastases

H. Liu, *Y. Liu, L. Liu, X. Shang, L. Qiu, Y. Chen;*
the Affiliated Hospital of Southwest Medical University, Luzhou, CHINA.

OP-330

Phase I Dose-Escalation Study of [177Lu]Lu-P15-073 in Patients with Bone Metastases: Safety, Preliminary Antitumor Activity, and PET-Based Dose Individualization

J. Lv[1], *M. Ke*[1], *M. Li*[2], *J. Zhang*[1], *W. Liang*[3], *X. Lin*[4], *H. Zhong*[1], *R. Zhao*[1], *X. Wang*[1];
[1]*Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CHINA,*
[2]*Department of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CHINA,*
[3]*Department of Thoracic Oncology and Surgery, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CHINA,*
[4]*State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, CHINA.*

OP-331

Comparison of FDG PET/CT Parameters and CT Radiomics for Prediction of Metastatic Disease in Newly Diagnosed Ewing Sarcoma Patients

C. Simsir, *M. F. Bozkurt;*
Department of Nuclear Medicine, Hacettepe University Faculty of Medicine, Ankara, TÜRKIYE.

OP-332

[18F]F-FAPI-74 PET/CT for Assessment of Fibroblast-Driven Remodeling in Shoulder Joints

M. Eichinger[1], *F. J. Gildehaus*[1], *T. Higuchi*[2], *F. L. Giesel*[3], *R. A. Werner*[1,4], *S. C. Siegmund*[1];
[1]*Department of Nuclear Medicine, LMU University Hospital, Ludwig-Maximilians-Universität München, Munich, GERMANY,*
[2]*Department of Nuclear Medicine and Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, GERMANY,*
[3]*Department of Nuclear Medicine, University Hospital Düsseldorf, Düsseldorf, GERMANY,*
[4]*Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM, ENETS Certified Center of Excellence), LMU University Hospital, Ludwig-Maximilians-Universität München, Munich, GERMANY.*

OP-333

[68Ga]Ga -FAPI-46 PET/CT for Soft-Tissue Tumor Characterization: A Prospective exploratory Study with Immunohistochemical Correlation

J. Enke[1,2], *K. Kimura*[1], *E. Kimura*[1], *Y. Arias Gonzalez*[1], *A. T. Nguyen*[1], *L. Theus*[1], *S. Lira*[1], *R. Nabong*[1], *C. Mona*[1], *L. Unterrainer*[1,3], *F. C. Eilber*[4], *J. G. Crompton*[4], *A. Holzgreve*[1,5], *A. S. Singh*[6], *S. Dry*[7], *J. Czernin*[1], *J. Calais*[1];
[1]*Department of Nuclear Medicine and Theranostics, University of California Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA,*
[2]*Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY,*
[3]*Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, GERMANY,*
[4]*Division of Surgical Oncology, University of California Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA,*
[5]*Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY,*
[6]*Department of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA,*
[7]*Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA.*

OP-334

Location Matters: Metabolic Heterogeneity of Paediatric Rhabdomyosarcoma on 18F-FDG PET/CT

E. Isik, *D. Arslan, Z. Ozkan, S. Kuyumcu, Y. Sanli;*
Istanbul University Istanbul Faculty of Medicine Nuclear Medicine Department, Istanbul, TÜRKIYE.

OP-335

Can Ultrafast SPECT/CT Replace Standard SPECT/CT as Add-On to Planar Bone Scintigraphy in Breast Cancer Patients: A Prospective Study

M. Jorgensen[1], *J. Wichman*[2], *J. Ejlersen*[3], *J. Fledelius*[4], *H. D. Zacho*[5,6];
[1]*Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, DENMARK,*
[2]*Department of Clinical pharmacology, Aalborg University Hospital, Aalborg, DENMARK,*
[3]*Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK,*
[4]*Department of Nuclear Medicine, Aarhus University Hospital, Aarhus, DENMARK,*
[5]*Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, DENMARK,*
[6]*Department of Clinical Medicine, Aalborg University, Aalborg, DENMARK.*

OP-336

Metabolic Tumour Burden and Prognosis in Ewing Sarcoma: An Analysis of FDG PET/CT Findings

E. Cansu Çay, *T. Bilgücü Arıcı, B. Demirel, G. Uçmak, S. Demirtaş Şenlik;*
Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, TÜRKIYE.

801

Monday, October 19, 2026, 09:45 - 11:15

Hall A

CME 6 - Oncology & Theranostics Committee: PRRT Beyond GEP

OP-337

Paraganglioma/Pheochromocytoma

T. Brabander;
Erasmus MC, Rotterdam, NETHERLANDS.

OP-338

Lung Carcinoids

A. Kjæe;
Copenhagen University Hospital-Rigshospitalet Department of Biomedical Sciences, Copenhagen, DENMARK.

OP-339

Meningioma

A. Buck;
University Hospital Würzburg, Würzburg, GERMANY.

OP-340

Medullary Thyroid Cancer

D. Deandreis;
Gustave Roussy Institute, Villejuif, FRANCE.

802

Monday, October 19, 2026, 09:45 - 11:15

Hall D (Arena)

Special Track 6 - Cardiovascular Committee: Challenge the Expert: Myocardial Blood Flow in Practice: Challenge the Experts

OP-341

Is the Physician Always Right?

A. Manrique;
Centre Hospitalier Universitaire de Caen, Nuclear medicine, Caen, FRANCE.

OP-342

In Case of Doubt, Ask the Physicist

L. Paulsen Tolbod;
Aarhus University Hospital, Nuclear medicine, Aarhus, DENMARK.

OP-343

SPECT Clinical Cases

C. Nappi;
Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY.

OP-344

PET Clinical Cases

M. Bailly;
Centre Hospitalier Régional d'Orléans, Orléans, FRANCE.

803

Monday, October 19, 2026, 09:45 - 11:15

Hall E1

LIPS Session 6 - Paediatrics Committee: The Evolving Role of Bone Scintigraphy in Paediatric Imaging: Current Indications and Challenges

OP-345

Paediatric Bone Scan as a Localisation Study

H. Nadel;
Lucile Packard Children's Hospital at Stanford, Department of Radiology, Stanford, CA, UNITED STATES OF AMERICA.

OP-346

One Scintigraphy in the Assessment of the Limping Child

M. Carmen Gerganese;
IRCCS Bambino Gesù Paediatric Hospital, Diagnostic Imaging Department – Nuclear Medicine, Rome, ITALY.

OP-347

Advances in Peadiatric Bone Scintigraphy Using a 360° Total Body SPECT/CT Camera

Z. Bar-Sever;
Schneider Children's Medical Center, Department of Nuclear Medicine, Tel-Aviv, ISRAEL.

804

Monday, October 19, 2026, 09:45 - 11:15

Hall E2

M2M Track: TROP Session - Translational Molecular Imaging & Therapy Committee: First-In-Human PET Tracers: LET's Do Therapy!

OP-348

Advancing ^{119}Sb Auger Radiotherapy: Production, Purification, Novel Chelation, and Preliminary Therapeutic Evaluation in Colorectal Cancer

A. Mirzaei[1,2], *S. Ait-Mohand*[1], *S. Tremblay*[1], *V. Dumulon-Perreault*[2], *É. Rousseau*[1,2,3], *B. Guérin*[1,2,3];
[1]*Department of Medical Imaging and Radiation Sciences, Université de Sherbrooke, Sherbrooke, QC, CANADA,*
[2]*Sherbrooke Molecular Imaging Center (CIMS), Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CRCHUS), Sherbrooke, QC, CANADA,*
[3]*Institut de Recherche sur le Cancer de l'Université de Sherbrooke (IRCUS), Sherbrooke, QC, CANADA.*

OP-349

[^{225}Ac]Ac-DOTA-Panitumumab-F(ab')2 Are Highly Cytotoxic to Human Triple-Negative Breast Cancer (TNBC) Cells In Vitro and Increase Median Survival In Vivo in NCG Mice with Metastatic TNBC Tumours

A. Chu[1], *C. Chan*[1], *M. Cai*[1], *Z. Cai*[1], *V. Radchenko*[2], *R. M. Reilly*[1];
[1]*Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, CANADA,*
[2]*Life Sciences Division, TRIUMF, University of British Columbia, Vancouver, BC, CANADA.*

OP-350

Experimental targeted radiotherapy in PC-3 bearing mice using the recently developed [^{225}Ac]Ac-PKB3

P. Kanellopoulos[1], *A. Lebedev*[2], *E. Papalanis*[3], *K. Obeid*[1], *E. Bezverkhniaia*[1], *C. Byrne*[2], *T. Pack*[2], *V. Tolmachev*[3], *A. Orlova*[1], *S. Selivanova*[2];
[1]*Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN,*
[2]*Canadian Nuclear Laboratories, Chalk River, ON, Canada, Chalk River, ON, CANADA,*
[3]*Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, Uppsala, SWEDEN.*

OP-351

^{67}Cu-labelled CXCR4 Radiopharmaceuticals with Enhanced Tumour Uptake in Neuroendocrine Prostate Cancer

I. Astiazaran-Rascon[1,2], *M. Jaraquemada-Pelaez*[1], *M. Ligeour*[1], *H. Merkens*[1], *P. Ng*[1], *K. Lin*[1,2], *J. Lau*[1,2], *F. Benard*[1,2];
[1]*BC Cancer, Vancouver, BC, CANADA,*
[2]*University of British Columbia, Vancouver, BC, CANADA.*

OP-352

CDCP1 as a Theranostic Target in Radioresistant Non-Small Cell Lung Cancer: From immunoPET Imaging to Targeted Radionuclide Therapy

S. Xu[1], *B. Li*[2], *S. Wang*[1], *K. Zhao*[1], *J. Yu*[1], *X. Chen*[3], ***J. Liu***[3,1];
[1]*Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CHINA,*
[2]*Henan University of Science and Technology, Luoyang, CHINA,*
[3]*Center for Nuclear Medicine and Molecular Imaging, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CHINA.*

OP-353

Antitumor Efficacy and Safety of Locoregional [^{177}Lu] Lu-RM26 Radionuclide Therapy in Glioblastoma

L. Wang[1], *D. Li*[1], *X. Chen*[2], *Z. Zhu*[3], *J. Zhang*[4];
[1]*Beijing Tiantan Hospital, Beijing Tiantan Hospital, Capital Medical University, Beijing, CHINA,*
[2]*Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,*
[3]*Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, CHINA,*
[4]*Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.*

OP-354

Investigation of MicroRNAs as Predictors of Radioligand Therapy Response in Gastroenteropancreatic Neuroendocrine Tumours

F. Scalorbi[1], *E. Garanzini*[1], *C. Marzi*[2], *M. Gariboldi*[1], *G. Calareso*[1], *M. Baccini*[2], *G. Sabella*[1], *S. Pusceddu*[1], *A. Marchiano*[1], *L. Roz*[1], *M. Milione*[1], *M. Maccauro*[1];
[1]*Istituto Nazionale Tumori Milano, Milan, ITALY,*
[2]*Department of Statistics, Computer Science, Applications "G. Parenti", University of Florence, Florence, ITALY.*

OP-355

Targeting ALDH1A1 for the non-invasive detection and treatment of therapy-resistant cancers

T. Witney[1,2], *S. dos Santos*[1,2], *R. Edwards*[1,2], *R. Pereira*[1], *M. George*[1], *A. Emmanuelli*[1], *L. Vass*[1], *E. Hards*[1], *O. Vilhelmsson Timmermand*[1], *H. Hammad Rattu*[1], *H. Greenwood*[1], *M. Tanc*[1,2];
[1]*King's College London, London, UNITED KINGDOM,*
[2]*Nuclide Therapeutics, London, UNITED KINGDOM.*

OP-356

Antitumor Efficacy and Mechanism of a Novel Hypoxia-Responsive Fibroblast Activation Protein Radioligand

Z. Ruiyue[1], *Y. Deng*[1], *X. Wang*[1], *L. Zhu*[2], *H. F. Kung*[3];
[1]*The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CHINA,*
[2]*Beijing Normal University, Beijing, CHINA,*
[3]*University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.*

805

Monday, October 19, 2026, 09:45 - 11:15

Hall B

Cutting Edge Science Track: Dosimetry Committee: Radioembolisation and Locoregional Radionuclide Therapy Dosimetry

OP-357

Comparative voxel-based dosimetry between pre-treatment SPECT/CT and post-treatment Total-Body ^{90}Y PET/CT in SIRT

M. Santoro[1], *G. Della Gala*[1], *P. Mantineo*[1], *A. Golemi*[2], *E. Lodi Rizzini*[3], *A. G. Morganti*[3,4], *S. Fanti*[2,4], *L. Strigari*[1];
[1]*Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[2]*Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[3]*Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[4]*Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, ITALY.*

OP-358

Impact of Y-90 SPECT-Based Tumor Dosimetry Methods for Radioembolization in Early Stage Renal Cell Carcinoma

I. Azrour[1], *F. Hao*[2], *C. E. Mona*[1], *B. M. Shuch*[3], *P. K. Gupta*[1], *S. A. Padia*[2], *C. A. Meyer*[1];
[1]*Department of Nuclear Medicine and Theranostics, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, UNITED STATES OF AMERICA,*
[2]*Division of Interventional Radiology, Department of Radiology, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, UNITED STATES OF AMERICA,*
[3]*UCLA Institute of Urologic Oncology David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, UNITED STATES OF AMERICA.*

OP-359

A Physics-Informed Neural Network Approach to Hepatic Haemodynamics for Y-90 Radioembolization Treatment Planning

E. Taatizadeh, *N. Panneerselvam, E. Roncali;*
University of California, Davis, Davis, CA, UNITED STATES OF AMERICA.

OP-360

Optimizing ^{90}Y PET/CT for Small-Volume Dosimetry: Phantom Validation of Reconstruction and Noise Performance

A. Sarnelli[1], *D. Bruno*[1], *E. Mezzenga*[1], *M. D'Arienzo*[2], *G. Feliciani*[1], *V. Mautone*[1], *P. Caroli*[1], *M. Sansovini*[1];
[1]*Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, ITALY,*
[2]*ASL Roma 6, Roma, ITALY.*

OP-361

Effects of dose heterogeneity on tumor response after ^{90}Y resin SIRT for hepatocellular carcinoma

H. Xi, *X. Zheng, A. W. J. M. Glaudemans, J. v. Sluis, S. J. S. Ruiter, R. J. de Haas, M. Kater, O. V. Ivashchenko, W. Noordzij;*
University Medical Center Groningen, Groningen, NETHERLANDS.

OP-362

Lung Dose Verification Following Y90-Radioembolization Therapy: An Inter-modality Comparison

S. Kappadath, *B. Lopez;*
University of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

OP-363

Dosimetry audit of lung side-effects after Y90 SIRT

J. Boucek[1], *S. Abraham*[2], *T. Randell*[1], *M. Chin*[1], *E. Her*[2];
[1]*Royal Perth Hospital, Perth, AUSTRALIA,*
[2]*Fiona Stanley Hospital, Perth, AUSTRALIA.*

OP-364

Monte Carlo investigation of dose modelling and application variability in rhenium-188 epidermal radionuclide therapy

I. Quin[1], *L. Käselau*[1], *D. Bolst*[2];
[1]*OncoBeta gmbh, Munich, GERMANY,*
[2]*University of Woolongong, Woolongong, AUSTRALIA.*

OP-365

Avidination for Radionuclide Therapy in Nonpalpable Breast Cancer (ARTHE): model-based Monte Carlo dosimetry of ^{90}Y-DOTA-biotin locoregional therapy

A. Sarnelli[1], *M. Cremonesi*[2], *E. D'Andrea*[3], *F. Botta*[4], *M. Sansovini*[1], *P. Sanna*[5], *M. Amadori*[5], *I. Grassi*[1], *P. Caroli*[1], *I. Marini*[1], *S. Nicolini*[1], *M. Belli*[1], *L. Fabbri*[1], *E. Scarpi*[1], *M. Monti*[1], *V. Di Iorio*[1], *O. Nanni*[1], *G. Paganelli*[1], *F. Falcini*[5], *F. Matteucci*[1];
[1]*Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, ITALY,*
[2]*Istituto Europeo di Oncologia, Milano, ITALY,*
[3]*Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, ITALY,*
[4]*ASST Sette Laghi, Varese, ITALY,*
[5]*Morgagni-Pierantoni Hospital, Forlì, ITALY.*

806

Monday, October 19, 2026, 09:45 - 11:15
Hall C

Clinical Oncology Track: Prostate Cancer Therapy

OP-366

Efficacy of [^{177}Lu]-PSMA-617 Therapy in Patients with de novo Metastatic Prostate Cancer treated by a triplet scheme

M. Borsali, *H. Noamen, K. Trabelsi, A. Daverio, Y. Cras, M. Rey-Cardenas, A. FUEREA, A. Patrikidou, C. Pobel, M. Dipalma, J. Uliano, N. Naoun, R. Flippot, Y. Loriot, A. Bernard-Tessier, C. Garcia, D. Deandreis; Gustave Roussy, Villejuif, FRANCE.*

OP-367

Impact of VISION and TheraP Imaging Criteria on Outcomes of ^{177}Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer

N. Hasan[1], *M. Krim[1], D. Vallot[1], J. Texier[2], M. Bros[1], L. Vija[1], T. Cassou-Mounat[1], C. Lamesa[1], F. Courbon[1];*
[1]IUCT ONCOPOLE, Toulouse, FRANCE,
[2]CHU Toulouse, Toulouse, FRANCE.

OP-368

MIRROR: Multimodal AI-based Registry for Response and Outcome in ^{177}Lu-PSMA Radioligand Therapy

D. Pizzuto[1], *H. Levillain[2], K. Zormpas Petridis[3], E. Csernai[4], J. Dhont[2], H. Kalisch[5], H. Roisse[6], C. Artigas[2], L. Ferrer[6],*
S. Calvo[7], A. Radics[4], S. Annunziata[1];
[1]Nuclear Medicine Unit, GSteP Radiopharmacy Direzione Scientifica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY,
[2]Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B.), Bruxelles, BELGIUM,
[3]Department of Radiology and Radiotherapy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS;
Università Cattolica del Sacro Cuore, Rome, ITALY,
[4]GE Healthcare, Budapest, HUNGARY,
[5]Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY,
[6]ICO René Gauducheau, F-[44800] Saint-Herblain, Nantes Université, Univ Angers, INSERM, CNRS, CRCI[2]NA, F-[44000], Nantes, FRANCE,
[7]GE Healthcare, Philadelphia, PA, UNITED STATES OF AMERICA.

OP-369

Visual RECIP 1.0 on post-therapy [^{177}Lu]Lu-PSMA SPECT/CT for treatment response evaluation in Metastatic Castration-Resistant Prostate Cancer: Inter-reader performance in a Multicenter retrospective Study

A. Mercier[1], *L. Unterrainer[2,3,4], E. Jacquet[5], M. Unterrainer[2,6], A. Delker[2], L. Hempel[2], Z. Ells[2,4], S. Kunte[2], J. Zahner[2], A. Holzgreve[2,4], M. Zacherl[2], G. Sheikh[2],*
J. Casuscelli[7], K. Pienta[8], M. Laramas[5], M. Faure[9], H. Ilhan[2,6], A. Gafita[10,11], L. Djaileb[9];
[1]Nuclear Medicine Department, University Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, Grenoble, FRANCE,
[2]Department of Nuclear Medicine, University Hospital LMU Munich, Munich, GERMANY,
[3]Bavarian Cancer Research Center, Partner Site Munich, Munich, GERMANY,
[4]Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA, UNITED STATES OF AMERICA,
[5]Université Grenoble Alpes, Medical Oncology Department, CHU Grenoble Alpes, Grenoble, FRANCE,
[6]Department of Radiology, University Hospital LMU Munich, Munich, GERMANY,
[7]Department of Urology, University Hospital LMU Munich, Munich, GERMANY,
[8]Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA,
[9]Université Grenoble Alpes, Nuclear Medicine Department, INSERM, CHU Grenoble Alpes, LRB, Grenoble, FRANCE,
[10]Division of Nuclear Medicine and Molecular Imaging; The Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA,
[11]Johns Hopkins Theranostics Center, Baltimore, MD, UNITED STATES OF AMERICA.

OP-370

Spatial Transcriptomic Profiling of the Tumour Immune Microenvironment in Prostate Cancer: Associations with ^{177}Lu-PSMA Therapy Response and Survival

K. Pandya[1], *S. Bae[2], J. Hong[1], C. Lapa[3], A. Rominger[1], A. Afshar Oromieh[1], K. Shi[1], H. Choi[4,2], R. Seifert[1];*
[1]Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND,
[2]Portrai Inc., Seoul, KOREA, REPUBLIC OF,
[3]Department of Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY,
[4]Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF.

OP-371

[^{18}F]FDG PET/CT as a predictor for PSA-response during [^{177}Lu]Lu-PSMA treatment for metastatic castration-resistant prostate cancer

H. Corveleyn[1], *K. Muylle[2], A. Bracke[1], L. De Ceuninck[2], S. Bourgeois[1], E. Vranken[2], M. De Bock[2], H. Everaert[1];*
[1]UZ Brussel, Jette, BELGIUM,
[2]AZ Delta, Roeselare, BELGIUM.

OP-372

Nephrotoxicity pofile in prostate cancer patients, treated with Lutetium-177 PSMA: a long-term follow up analysis

L. Wirth, *G. Santo, L. Rossetti, K. Merther, F. Scherbauer, G. Bletzacher, P. Lehmann, G. Di Santo, I. Virgolini;*
Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA.

OP-373

Automatic RECIP 1.0 Response Evaluation on ^{68}Ga-PSMA PET/CT in mCRPC Patients after ^{177}Lu-PSMA Therapy

M. Khateri[1], *H. Nasrollahi[1], A. Soliman[2], B. Spottiswoode[2], M. Beheshti[1];*
[1]Division of Molecular Imaging and Theranostics, University Hospital Salzburg, Salzburg, AUSTRIA,
[2]Siemens Medical Solutions USA, Knoxville, TN, UNITED STATES OF AMERICA.

OP-374

Dual-Target PSMA and Bisphosphonate [^{177}Lu] Lu-P17-079: First-in-Human Dosimetry of a Therapeutic Agent for Metastatic Prostate Cancer

K. Lin[1], *W. Jin[1], J. Wang[1], Y. Wang[1], X. Ma[1], L. Zhu[2], H. Kung[3], Z. Zhu[1];*
[1]Peking Union Medical College Hospital, Beijing, CHINA,
[2]Beijing Normal University, Beijing, CHINA,
[3]University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.

807

Monday, October 19, 2026, 09:45 - 11:15
Hall F1

Neuroimaging Committee: From Amyloid Imaging to Anti-Amyloid Therapy

OP-375

Shorter early perfusion amyloid-PET protocol to improve prognostic stratification and correlation with Tau load

G. Garelli[1,2], *L. Sofia[3,2], C. Boccalini[2], G. Rovera[1,4], S. DeKeyser[5], V. De Ridder[5], Y. Brackenier[5], M. Zotta[1,4], I. Rainero[6,7], G. B. Frisoni[8,9], E. Rubino[6,7], F. Roveta[6,7], M. Bauckneht[3,10], S. Raffa[10], M. Pardini[11,12], D. E. Peretti[2], S. Morbelli[1,4], V. Garibotto[2,13,14];*
[1]Department of Medical Sciences, University of Turin, Turin, ITALY,
[2]Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, SWITZERLAND,
[3]Department of Health Sciences (DISSAL), University of Genoa, Genoa, ITALY,
[4]Nuclear Medicine Unit, Città della Salute e della Scienza di Torino, Turin, ITALY,
[5]Nuclivision, Ghent, BELGIUM,
[6]Department of Neuroscience "Rita Levi-Montalcini", University of Turin, Turin, ITALY,
[7]Center for Cognitive Disorders and Dementias, Department of Neuroscience and Mental Health, Città della Salute e della Scienza di Torino, Turin, ITALY,
[8]Geneva Memory Centre, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, SWITZERLAND,
[9]Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, SWITZERLAND,
[10]Nuclear Medicine Unit, IRCCS Azienda Ospedaliera Metropolitana, Genoa, ITALY,
[11]Department of Neuroscience, University of Genoa, Genoa, ITALY,
[12]Clinical Neurology Unit, IRCCS Azienda Ospedaliera Metropolitana, Genoa, ITALY,
[13]Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, SWITZERLAND,
[14]CIBM, Centre for Biomedical Imaging, University of Geneva, Geneva, SWITZERLAND.

OP-376

The Limbic-to-Neocortical Transition as the Critical Tipping Point for Amyloid-Associated Clinical Progression: A Dual-Phase [^{18}F]Florbetaben PET Study

S. Kang, *H. Chang, J. Jeong, B. Kim;*
Ewha Womans University Seoul hospital, Seoul, KOREA, REPUBLIC OF.

OP-377

Longitudinal Effects of Lecanemab on Aβ Clearance and Multimodal Brain Network Coupling Stratified by Baseline Tau Burden in Mild Cognitive Impairment and Early Alzheimer's Disease

Y. Chang, *R. Wang;*
Chinese PLA General Hospital, Beijing, CHINA.

OP-378

AmyTex: A Quantitative Texture Biomarker Framework for Amyloid PET Across Scanners and Tracers

D. Ufton[1], *A. Drzezga[1], S. Minoshima[2];*
[1]University Hospital of Cologne, Department of Nuclear Medicine, Cologne, GERMANY,
[2]University of Utah;
Department of Radiology and Imaging Sciences, Salt Lake City, UT, UNITED STATES OF AMERICA.

OP-379

Integrating β-Amyloid and Tau Biomarkers in a Tertiary Memory Clinic: Real-World Performance of Visual PET Reads, Quantitative PET, and CSF

J. Gnörich[1], *K. Probst[1], H. Eyob[1], L. Frontzkowski[2], C. Palleis[3], A. Jäck[3], A. Bernhardt[3], S. Roemer-Cassiano[3], S. Katzdobler[3], F. Schöberl[3], A. Zwergal[3], J. Levin[3], S. Stöcklein[4], G. Höglinger[3], R. Werner[1], N. Franzmeier[2], M. Brendel[1];*
[1]LMU University Hospital, Department of Nuclear Medicine, Munich, GERMANY,
[2]Institute for Stroke and Dementia Research, Munich, GERMANY,
[3]LMU University Hospital, Department of Neurology, Munich, GERMANY,
[4]LMU University Hospital, Department of Radiology, Munich, GERMANY.

OP-380

Real-world translation from diagnostic workup to anti-amyloid treatment eligibility in tertiary care settings: the biological shift captured by amyloid PET

C. Poggio[1], *F. Roveta[2], E. Rubino[2], M. Losa[3], M. Laudadio[2], C. Luppi[4], M. Zotta[1], G. Rovera[1], A. Lesca[1], S. Raffa[5], L. Sofia[5], F. Massa[6], M. Massaia[4], D. Imperiale[7], L. Roccatagliata[8], I. Rainero[2], M. Bozzali[2], M. Pardini[3], S. Morbelli[1];*
[1]Nuclear Medicine Department, University of Turin, Turin, ITALY,

[2]Department of Neuroscience "Rita Levi-Montalcini", University of Turin, Turin, ITALY,
[3]Clinical Neurology Unit, IRCCS Azienda Ospedaliera Metropolitana, Genoa, ITALY,
[4]Center for Cognitive Disorders and Dementia, Section of Geriatrics, Citta' della Salute e della Scienza di Torino, Turin, ITALY,
[5]Nuclear Medicine Unit, IRCCS Azienda Ospedaliera Metropolitana, Genoa, ITALY,
[6]Clinical Neurology Unit, IRCCS Azienda Ospedaliera Metropolitana, Genoa, ITALY,
[7]Unit of Neurology, Maria Vittoria Hospital, ASL Città Di Torino, Turin, ITALY,
[8]Neuroradiology Department, University of Genoa, Genoa, ITALY.

OP-381

Different spatial distribution of brain amyloid in Alzheimer's disease and Lewy Body disease: a comparative PET analysis

D. Cecchin[1], *A. Cagnin*[2], *A. Antonini*[2], *E. Fiorenzato*[3], *S. Mozzetta*[2], *F. Serani*[1], *A. Bertoldo*[4], *M. Facca*[4];
[1]University of Padova - Dipartimento di Medicina -DIMED, Padova, ITALY,
[2]University of Padova - Dipartimento di Neuroscience, Padova, ITALY,
[3]University of Padova - Dipartimento di Psicologia Generale, Padova, ITALY,
[4]University of Padova - Dipartimento di Ingegneria dell'Informazione, Padova, ITALY.

OP-382

Agreement between visual and semi-quantitative amyloid-β, tau, and neurodegeneration PET biomarkers in Alzheimer's disease

V. Megens[1,2], *E. G. Müller*[3], *L. Eikenes*[1,4], *A. K. Håberg*[5,6], *K. Van Laere*[2,7];
[1]Department of Circulation and Medical Imaging, NTNU, Trondheim, NORWAY,
[2]Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM,
[3]Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY,
[4]Department of Radiology and Nuclear Medicine, St. Olavs Hospital, Trondheim, NORWAY,
[5]Department of Neuromedicine and Movement Science, NTNU, Trondheim, NORWAY,
[6]MiDT National Research Center, St. Olavs Hospital, Trondheim, NORWAY,
[7]Division of Nuclear Medicine, UZ Leuven, Leuven, BELGIUM.

OP-383

Lecanemab treatment promotes imaging-defined resolution of neuroinflammation in early Alzheimer's disease: a longitudinal [18F]DPA-714 PET/MR study

L. Xiao, *Y. Tang, S. Hu;*
Xiangya Hospital Central South University, Changsha, CHINA.

808

Monday, October 19, 2026, 09:45 - 11:15
Hall F2

Thyroid Committee: Radioiodine Therapy: A Timeless Paradigm for Differentiated Pediatric and Adult Thyroid Carcinoma

OP-384

Evaluating the utility of [18F]-FDG PET/CT in guiding treatment decisions in thyroid cancer

H. Chitluri[1], *A. Agrawal*[2], *V. Rangarajan*[1], *N. Purandare*[1], *S. Shah*[1], *A. Puranik*[1], *S. Choudhury*[2], *S. Ghosh*[2], *I. Dev*[2];
[1]Tata Memorial Hospital, Mumbai, INDIA,
[2]ACTREC, TMC, Mumbai, INDIA.

OP-385

Iodine-131 Abstention or De-Escalation Strategy in Low-Risk Differentiated Thyroid Cancer Without Molecular Profiling: Feasibility and Safety of a Dynamic Reclassification Approach in a Resource-Limited Setting

D. Mouas, *B. F. P. Agboton, S. R. Rahabi, A. Talbi, O. Arar, M. Hemaz, M. C. Zounma, Y. F. Zinsou, A. Amimour;*
CHU Lamine Debaghine, Alger, ALGERIA.

OP-386

Reliability of the De-escalation Strategy in Low-Risk Differentiated Thyroid Cancer: A Comparison of Low-Dose (30 mCi) and High-Dose (100 mCi) Radioiodine Ablation

B. Düsova, *G. Mütevelizade, M. Ebrahimpoortajdar, U. Balaman, E. Bilgin;*
Celal Bayar Üniversitesi Hafsa Sultan Hastanesi, Izmir, TÜRKIYE.

OP-387

Clinical Predictors of Excellent Response to 100 mCi ^{131}I Therapy and Validation of the 2025 ATA Risk Stratification in Intermediate- and High-Risk DTC

J. Xin, *J. Wang, W. Ma;*
Department of Nuclear Medicine, Xijing Hospital, FourthMilitary Medical University, Xi'an, CHINA.

OP-388

The Illusion of Excellent Response: Predictors of Early Recurrence in Intermediate-Risk Papillary Thyroid Carcinoma and the Impact of Biochemical Re-stratification

S. Medina-Ornelas;
Instituto Nacional de Ciencias Médicas y Nutricion "Salvador Zubiran", Mexico City, MEXICO.

OP-389

Nearly Excellent Response after Repeated RAI Treatment for Progressive rrDTC Patients post Redifferentiation Therapy

D. Shen[1,2,3], *H. Chan*[1], *F. Tsai*[1], *Y. Chiu*[1], *T. Liang*[1], *Y. She*[1], *S. Li*[1];
[1]Kaohsiung Veterans General Hospital, Kaohsiung, TAIWAN, PROVINCE OF CHINA,
[2]Cheng Shiu University, Kaohsiung, TAIWAN, PROVINCE OF CHINA,
[3]Tri-Service General Hospital, Taipei, TAIWAN, PROVINCE OF CHINA.

OP-390

Outcomes of Pediatric Thyroid Cancer Patients Aged <15 years after Radioactive Iodine Therapy

B. Yoo[1], *J. Paeng*[1], *Y. Lee*[2], *Y. Kim*[1], *G. Cheon*[1];
[1]Seoul National University Hospital, Department of Nuclear Medicine, Seoul, KOREA, REPUBLIC OF,
[2]Seoul National University Hospital, Department of Pediatrics, Seoul, KOREA, REPUBLIC OF.

OP-391

Disease-free survival and therapy response in pediatric metastatic papillary thyroid cancer.

m. mehesen[1], *O. Zakzok*[2], *S. Abdelhamid*[2], *D. Mustafa*[3], *M. Elsahfiey*[4], *S. Shaker*[5], *I. Zaky*[6], *R. Mostafa*[7];
[1]National Cancer Institute, Cairo university, Cairo, EGYPT,
[2]Pediatric oncologist, Pediatric oncology department, CCHE-57357, Cairo, EGYPT,
[3]Clinical research senior associate, Clinical research department, CCHE57357, Cairo, EGYPT,
[4]Senior Surgical Oncology Senior consultant, Surgery department, CCHE- 57357, Cairo, EGYPT,
[5]Surgical Oncology P.T Consultant, Surgery department, CCHE-57357, Cairo, EGYPT,
[6]Radiological consultant, radiology department, CCHE-57357, Cairo, EGYPT,
[7]Nuclear Medicine P.T Doctor, Nuclear Medicine department, CCHE57357, Cairo, EGYPT.

OP-392

Prognostic Value of the Number of Metastatic Nodes in Pediatric Papillary Thyroid Cancer Patients: A Real-Life Multicenter Study

L. Xiao, *B. Liu;*
West China Hospital of Sichuan University, Chengdu, CHINA.

810

Monday, October 19, 2026, 09:45 - 11:15
Hall K

CTE 4 - Technologists + Inflammation & Infection Committee: Imaging of Foreign Body Associated Inflammation and Infections: Pearls and Pitfalls

OP-393

SPECT/CT: Following the Infection and Inflammation Trail

M. Oliviera;
Nuclear Medicine, Santo António Hospital, Porto, PORTUGAL.

OP-394

Imaging the Fire: PET/CT Applications in Inflammatory and Infection States

M. Casanova Martins;
Nuclear Medicine, Singleton Hospital, Swansea, UNITED KINGDOM.

OP-395

Pathogen-Targeted Imaging: What's Next?

G. R. Bonfitto;
Department of Nuclear Medicine and Molecular Imaging, IRCCS Ospedale San Raffaele, Milan, ITALY.

811

Monday, October 19, 2026, 09:45 - 11:15
Hall G1

Special Symposium 4 - EARL: Unlock Precision in Imaging — Discover the Clinical Benefits of EARL PET Accreditation

OP-396

The Reliability of Centiloids in Non-Harmonised Versus Harmonised Datasets: Enhancing Diagnostic Quality and Patient Outcomes

R. Boellaard;
Amsterdam University Medical Center, Amsterdam, NETHERLANDS.

OP-397

Clinical and Research Benefits of the EARL Brain Accreditation

E. van der Giessen;
Amsterdam University Medical Center, Amsterdam, NETHERLANDS.

OP-398

PET Data Harmonisation and Standardisation in the Context of Total Metabolic Tumour Volume (TMTV)

A. Segolene Cottereau;
Cochin Hospital, Universite de Paris, Paris, FRANCE.

OP-399

Which SUV is More Stable for PSMA-Positivity Thresholding? EARL-Harmonised Lesional SUV Versus Reference Tissue SUV

A. Nikiforuk;
P. Hertsen Moscow Oncology Research Institute - branch of the NMRRC of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

OP-400

Impact of EARL Harmonisation on Inter-Scanner Variability of MTV and TLG (Phantom and Patients Study- with the Emphasis on the Patients' Study

A. Khalimon;
P. Hertsen Moscow Oncology Research Institute - branch of the NMRRC of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

901

Monday, October 19, 2026, 11:30 - 13:00

Hall A

Plenary 2: From Treatment to Prevention: The Evolving Role of Nuclear Medicine in Early Diagnosis

OP-401

Prevention and Early Diagnosis in Oncology

K. Hermann
Universitätsklinikum Essen, Essen, GERMANY.

OP-402

Preventing Cardiovascular Diseases the Nuclear Medicine Way

***M. Hacker**;*
Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA.

OP-403

PET Imaging and the Prevention of Alzheimer's Disease

***M. Filippi**;*
Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, ITALY.

OP-404a

EANM Perspective to Move from Treatment to Prevention

***P. A. Erba**;*
Department of Medicine and Surgery, University of Milan Bicocca, Milan, ITALY.

OP-404b

Panel Discussion – All speakers

1001

Monday, October 19, 2026, 15:00 - 16:30

Hall A

CME 7 - Translational Molecular Imaging & Therapy Committee: How Can You Monitor the Immune System Activity in Patients?

OP-405

Fundamentals of Tumour Microenvironment and Immune Response

***M. Ansems**;*
Radboud University Medical Center, Nijmegen, NETHERLANDS.

OP-406

Imaging of the Tumour Microenvironment: Key Breakthroughs and Remaining Hurdles

***T. Groof**;*
Vrije Universiteit Brussel, Brussels, BELGIUM.

OP-407

PET Imaging of the Immune Response in Cancer Immunotherapy

***J. Schwenck**;*
University Hospital of Tuebingen, Tuebingen, GERMANY.

OP-408

Immune Therapy Tracers – Ready for Prime Time? View from the Clinician

***W. Menke**;*
Amsterdam University Medical Center, Amsterdam, NETHERLANDS.

1002

Monday, October 19, 2026, 15:00 - 16:30

Hall D (Arena)

Award Session/Special Track 7 - EANM Sanjiv Sam Gambhir Young Investigator Award - Compete and Win!

1003

Monday, October 19, 2026, 15:00 - 16:30

Hall E1

LIPS Session 7 - Neuroimaging + Paediatrics Committee: Improving Diagnostics and Management of Paediatric Brain Tumours: The Role of PET and Theranostics

OP-413

Clinical Challenges and Current Management of Pediatric CNS Tumours

***S. Plasschaert**;*
Princess Máxima Center for Pediatric Oncology, Utrecht, NETHERLANDS.

OP-414

Imaging of CNS Tumours with PET

***D. Cecchin**;*
University-Hospital of Padova, Padova, ITALY.

OP-415

New Advances in Paediatric Neuroimaging: PET-MR and Total-Body PET

***I. Law**;*
Copenhagen University Hospital Rigshospitalet, Copenhagen, DENMARK.

OP-416

Theranostic Potential in Pediatric CNS Tumours

***N. Tolboom**;*
Department of Radiology and Nuclear Medicine, Utrecht, NETHERLANDS.

1004

Monday, October 19, 2026, 15:00 – 16:30

Hall E2

Cardiovascular Committee: Inside the Diseased Heart: A Molecular Journey

OP-417

Cancer-induced myocardial metabolic shift: the relationship between total metabolic tumour volume and left ventricular glucose uptake patterns

***A. Msoune**, A. Benlemlih, Y. Lasry, A. Bakraoui Samlali, R. Bouchikhi, Z. Ouassafrar, A. Guensi;*
CHU Ibn Rochd, Casablanca, MOROCCO.

OP-418

Enhanced Myocardial Suppression on ^{18}F-FDG PET/CT in Suspected Cardiac Sarcoidosis with an 18-Hour Fasting Protocol

***H. Santema**[1], D. Vriens[2], H. Siebelink[1], F. Esser[1], L. Stoger[3], J. Goeman[1], J. Torremans[1], M. Tjong Joe Wai[1], P. Dibbets-Schneider[1], M. Geelhoed[4], F. Stevens[1], M. Ninaber[1], **L. de Geus-Oei**[1];*
[1]LUMC, Leiden, NETHERLANDS,
[2]Radboudumc, Nijmegen, NETHERLANDS,
[3]UMCU, Utrecht, NETHERLANDS,
[4]St. Antonius Hospital, Nieuwegein, NETHERLANDS.

OP-419

FDG-PET-based Risk Stratification for Ventricular Tachyarrhythmias in Patients with Cardiac Sarcoidosis

***C. Backhaus**, L. Drage, L. Eckardt, D. Korthals, W. Roll, L. Stegger, S. Hermann, M. Schaefers, D. Ventura;*
University Hospital Muenster, Muenster, GERMANY.

OP-420

Macrophagetargeted PET imaging in cardiac sarcoidosis: Temporal agreement between ^{64}CuDOTATATE and ^{18}FFDG

***R. Ripa**[1], A. Yafasova[2], E. Fosbøl[2], N. Noory[2], P. Hasbak[2], K. Rossing[2], J. Butt[2], L. Køber[2], A. Kjaer[2], F. Gustafsson[2];*
[1]Copenhagen University Hospital - Bispebjerg, Copenhagen, DENMARK,
[2]Copenhagen University Hospital - Rigshospitalet, Copenhagen, DENMARK.

OP-421

Fibroblast Activation Imaging by [^{18}F]F-FAPI PET Predicts Recurrence After Atrial Fibrillation Ablation: A Pilot Study

***M. Zhao**[1], C. Zhou[1], J. Xu[1], R. Shi[2], X. Li[3];*
[1]Third Xiangya Hospital of Central South University, Changsha, CHINA,
[2]Xiangya Hospital of Central South University, Changsha, CHINA,
[3]Vienna General Hospital, Medical University of Vienna, Vienna, AUSTRIA.

OP-422

Preserved risk stratification of lethal arrhythmic events using a ^{123}I-MIBG-based risk model in patients with and without ICD/CRTD

***K. Nakajima**[1], T. Doi[2], T. Nakata[3], T. Nakahashi[4], H. Tada[1], H. Wakabayashi[1], H. J. Verberne[5];*
[1]Kanazawa University, Kanazawa, JAPAN,
[2]Teine Keijinkai Hospital, Sapporo, JAPAN,
[3]Hokodate-Gryoukaku Hospital, Hakodate, JAPAN,
[4]Takaoka Municipal Hospital, Takaoka, JAPAN,
[5]University of Amsterdam, Amsterdam, NETHERLANDS.

OP-423

Pixelwise Biparametric Mapping of Uptake and Washout Enables Absolute Characterisation of Myocardial Metabolic Phenotypes in 123IBMIPP SPECT

***H. Miyauchi**[1], K. Hoshi[2], R. Ono[1], Y. Kobayashi[1];*
[1]Chiba University Graduate School of Medicine, Chiba, JAPAN,
[2]National Center for Child Health and Development, Tokyo, JAPAN.

OP-424

[^{18}F]MC225 PET Imaging for Functional Evaluation of Cardiac P-Glycoprotein in Healthy Volunteers and Patients with Parkinson's Disease: A Feasibility Study

***W. Liu**, J. Somsen, R. H. J. A. Slart, G. Luurtsema;*
University Medical Center Groningen, Groningen, NETHERLANDS.

OP-425

[^{18}F]F-AraG PET imaging detects early myocardial responses to cancer therapy

***H. Chae**[1], U. Shrestha[2], M. Das[3,4], M. S. Vasanawala[3,4], D. Behl[5], D. Davar[6], S. Srinivas[7], A. D. Colevas[3], J. B. Sunwoo[3], N. Del Mar[3], M. Pierini[5], M. Guillen[3], J. Garcia[2], N. Omidvari[8], N. Gupta[9], J. Kim[2], H. Cabrera[1], J. Blecha[2], D. M. Wilson[2], S. R. Cherry[8], H. VanBrocklin[2], R. R. Flavell[2], J. Moslehi[2], Y. Seo[2], J. Levi[1];*
[1]CellSight Technologies Inc., San Francisco, CA, UNITED STATES OF AMERICA,
[2]University of California, San Francisco, San Francisco, CA, UNITED STATES OF AMERICA,
[3]Stanford University, Stanford, CA, UNITED STATES OF AMERICA,
[4]Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, UNITED STATES OF AMERICA,
[5]Sutter Medical Center, Sacramento, CA, UNITED STATES OF AMERICA,
[6]University of Pittsburgh, Pittsburgh, PA, UNITED STATES OF AMERICA,
[7]University of California, Irvine, Irvine, CA, UNITED STATES OF AMERICA,
[8]University of California, Davis, Davis, CA, UNITED STATES OF AMERICA,
[9]Oregon Health & Science University, Portland, OR, UNITED STATES OF AMERICA.

1005

Monday, October 19, 2026, 15:00 – 16:30
Hall B

Cutting Edge Science Track: AI Committee: LLMs and Other Innovative DL Approaches

OP-426

Automated Assessment of Structured Reporting Adherence in Tc-99m DMSA Renal Cortical Scintigraphy Using a Locally Deployed Large Language Model: A Retrospective Study

S. Rayamajhi, *A. K. Pandey, H. Prasad, C. D. Patel, R. Kumar;*
All India Institute Of Medical Sciences, New Delhi, INDIA.

OP-427

Auditable Multi Agent Workflows Outperform Standard Large Language Models in Neuroendocrine Tumor Board Decisions

P. Koller[1], *C. Clement*[1], *A. Lazar*[2,1], *L. Müller*[3], *A. Orlando*[4], *M. Haissaguerre*[5], *C. M. Gana*[6], *J. Hernando*[7], *W. Bosbach*[1], *A. van Eijk*[8], *J. Capdevilla*[7], *R. Trepp*[3], *A. Chiti*[2], *A. Rominger*[1], *K. Shi*[1,9,10], *R. Seifert*[1];
[1]*Department of Nuclear Medicine Bern University Hospital, University of Bern, Bern, SWITZERLAND,*
[2]*Università Vita-Salute San Raffaele, Milano, ITALY,*
[3]*Department of Diabetology, Endocrinology, Nutritional Medicine & Metabolism (UDEM), Bern University Hospital, University of Bern, Bern, SWITZERLAND,*
[4]*Istituto Europeo di Oncologia, Via Giuseppe Ripamonti, Milano, SWITZERLAND,*
[5]*Department of Endocrinology and Endocrine Oncology. University Hospital of Bordeaux and University of Bordeaux., Pessac, FRANCE,*
[6]*Terapia Radiometabolica, Divisione Medicina Nucleare, IRCCS Istituto Europeo di Oncologia, Milano, ITALY,*
[7]*Vall d'Hebron Institute of Oncology, Barcelona, SPAIN,*
[8]*ITM Radiopharma, Garching, GERMANY,*
[9]*Department of Nuclear Medicine, Technical University Munich, Munich, GERMANY,*
[10]*Chair for Computer-aided Medical Procedure, School of Computation, Information & Technology, Technical University Munich, Munich, GERMANY.*

OP-428

Assessment of Large Language Model Performance in the Selection of Appropriate Tracers and Protocols for PET/CT Imaging

C. Backhaus, *P. Schindler, D. Ventura, M. Rust, P. Brueggemann, O. Platte, L. Stegger, K. Rahbar, D. Heider, M. Schaefers, L. Plagwitz, W. Roll;*
University Hospital Muenster, Muenster, GERMANY.

OP-429

Vision-Language Stable Diffusion for Synthetic Multi-View Data Augmentation in Scintigraphy Imaging

G. Hajianfar[1], *P. Mohammadi Kazaj*[2], *Y. Hu*[1], *A. Saberi Manesh*[1], *H. Zareian*[3], *N. Amiri*[4], *S. Bagheri*[5], *A. Aghaee*[6], *Y. Salimi*[1], *A. Sanaat*[1], *I. Shiri*[2], *H. Zaidi*[1];
[1]*Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, SWITZERLAND,*
[2]*Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND,*
[3]*Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,*
[4]*Department of Medical Physics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IRAN, ISLAMIC REPUBLIC OF,*
[5]*Department of Nuclear Medicine, Children Medical Center, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,*
[6]*Department of Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.*

OP-430

Inherently explainable spatial AI

A. Boukhari[1], *L. Papp*[2], *M. Hatt*[1];
[1]*Laboratory of medical information processing (LaTIM), Brest, FRANCE,*
[2]*Medical University of Vienna, Vienna, AUSTRIA.*

OP-431

Analysis of F-18 FDG PET/CT Images Using DenseNET Neural Networks in Breast Cancer and Prediction of Clinical and Histopathological Features

B. Demir[1], *M. Atalay*[1], *H. K. Yurtcu*[2], *F. Ertek*[1], *A. Aytac*[3], *H. I. Ellez*[3], *E. Z. Tarini*[4];
[1]*Sanliurfa Mehmet Akif Inan Training and Research Hospital, Department of Nuclear Medicine, Sanliurfa, TÜRKIYE,*
[2]*Harran University Medical School Department of Nuclear Medicine, Sanliurfa, TÜRKIYE,*
[3]*Sanliurfa Mehmet Akif Inan Training and Research Hospital, Department of Medical Oncology, Sanliurfa, TÜRKIYE,*
[4]*Sanliurfa Mehmet Akif Inan Training and Research Hospital, Department of Pathology, Sanliurfa, TÜRKIYE.*

OP-432

Interpretable Dual-Tracer [^{68}Ga]Ga-PSMA and [^{68}Ga]Ga-RM26 PET/CT Radiomics Enables Virtual Biopsy and Prognostic Stratification in Treatment-Naïve Prostate Cancer

Y. Li[1], *Y. Chen*[2], *Y. Tang*[1], *A. Rominger*[2], *K. Shi*[2], *S. Hu*[1];
[1]*Xiangya Hospital, Central South University, Changsha, CHINA,*
[2]*Inselspital, University Hospital Bern, Bern, SWITZERLAND.*

OP-433

Semi-supervised and Unsupervised Deep Learning Combination for Automated PD-L1 Status Prediction in Lung Cancer Using Multi-modal PET/CT Fusion

R. Da-ano[1], *O. Tankyevych*[2], *M. Berraho*[2], *C. Cheze Le Rest*[2], *D. Visvikis*[1];
[1]*INSERM - DR GRAND OUEST/ LaTIM U*[1101], *Brest, FRANCE,*
[2]*Nuclear Medicine, University of Poitiers, Poitiers, FRANCE.*

OP-434

Can Foundation-Model Embeddings Simplify DAT-SPECT Analysis? A Feasibility Study Using BrainIAC in PD, Controls, and SWEDD

M. Inglese[1], *S. P. Caminiti*[2], *R. Malito*[3], *N. Toschi*[1];
[1]*University of Rome Tor Vergata, Rome, ITALY,*
[2]*University of Pavia, Pavia, ITALY,*
[3]*IRCCS Mondino Foundation, Pavia, ITALY.*

1006

Monday, October 19, 2026, 15:00 – 16:30
Hall C

Clinical Oncology Track: Lung

OP-435

Assessing the clinical acceptability of ultra-low dose PET/CT and CT-less PET using a long axial field-of-view PET/CT system: a single-centre, single-blinded method agreement study

I. Alberts[1,2], *B. Nolet*[1], *C. Mingels*[2], *A. Rominger*[2], *H. Sari*[3,4];
[1]*BC Cancer Agency, Vancouver, BC, CANADA,*
[2]*Inselspital, Bern, SWITZERLAND,*
[3]*University of Bern, Bern, SWITZERLAND,*
[4]*Siemens Healthineers, Zurich, SWITZERLAND.*

OP-436

Metabolic Response Patterns on ^{18}F-FDG PET/CT in Metastatic Non-Small Cell Lung Cancer: Frequency and Prognostic Value under First-Line Chemo-Immunotherapy Compared with Immunotherapy Alone

S. Boumedine[1], *M. Masse*[1], *J. Darcourt*[1], *D. Chardin*[2], *R. Schiappa*[1], *T. Pace-Loscos*[1], *S. Contu*[1], *R. Boujnah*[1], *O. Humbert*[1];
[1]*Centre Antoine Lacassagne, Nice, FRANCE,*
[2]*CHU de l'Archet, Nice, FRANCE.*

OP-437

Dual-Tracer [18]FDG- and [^{68}Ga]FAPI-PET/CT Supports Safe Discontinuation of Long-Term Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer

A. Valitova[1], *N. Berenbrok*[2,3], *M. Collienne*[2,3,4], *S. Loges*[2,3,5], *K. Kapadocha*[6], *B. Wängler*[7], *H. Rudolf*[7], *G. Davarci*[7], *J. Kappes*[6], *C. Cotarelo*[8], *F. Grawe*[1,9];
[1]*DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Heidelberg, GERMANY,*
[2]*Department of Personalized Oncology, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, GERMANY,*
[3]*Division of Personalized Medical Oncology (A*[420]*), German Cancer Research Center (DKFZ), Heidelberg, GERMANY,*
[4]*German Center for Lung Research (DZL), Heidelberg, GERMANY,*
[5]*DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, GERMANY,*
[6]*Department of Pulmonary Medicine, Theresienkrankenhaus, Mannheim, GERMANY,*
[7]*Molecular Imaging and Radiochemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, Mannheim, GERMANY,*
[8]*Institute of Pathology, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY,*
[9]*Department of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY.*

OP-438

Dynamic ^{18}F-FDG-PET CT studies with a Long Axial Field of View (LAFOV) PET-CT in patients with confirmed lung cancer stage IV prior combined immuno-chemotherapy

I. Federmann[1], *I. Schoinas*[1], *L. Pan*[1], *C. Sachpekidis*[1], *P. Christopoulos*[2], *M. Thomas*[2], *A. Dimitrakopoulou-Strauss*[1];
[1]*German Cancer Research Center, Heidelberg, GERMANY,*
[2]*Thoraxklinik Heidelberg University Hospital, Heidelberg, GERMANY.*

OP-439

Pre-treatment normal lung [^{18}F]FDG uptake as a biomarker of clinical radiation pneumonitis after thoracic radiotherapy

C. Constantino[1,2], *F. P. Oliveira*[1], *C. Matos*[1], *S. Vieira*[1], *J. C. Castanheira*[1], *A. Canudo*[1], *R. Teixeira*[1], *J. Kociolek*[1], *N. Pimentel*[1], *S. Vinga*[2], *D. C. Costa*[1];
[1]*Champalimaud Foundation, Lisbon, PORTUGAL,*
[2]*INESC-ID, Instituto Superior Tecnico, University of Lisbon, Lisbon, PORTUGAL.*

OP-440

Artificial intelligence-assisted metabolic response assessment on serial fluorodeoxyglucose positron emission tomography/computed tomography in lung cancer

S. Kheruka, *A. Jain, K. Al Riyami, N. Al-Maymani, N. Al-Makhmari, R. ALSukaiti;*
Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City, Muscat, OMAN.

OP-441

AI-Driven Prognostic Assessment in NSCLC Patients Treated with First-Line Immunotherapy Using Baseline [^{18}F]FDG PET and Clinical Data

A. Lazar[1], *F. R. Ogliari*[2], *M. De Salazar*[3], *M. De Maria*[4], *L. Papotto*[2], *L. Mollica*[2], *M. Sollini*[1,5], *M. Reni*[1,2], *A. Bulotta*[1,2], *P. Vizza*[3], *P. Veltri*[3], *A. Chiti*[1,5], *L. Antunovic*[5,6];
[1]*Vita-Salute San Raffaele University, Milan, ITALY,*
[2]*Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, ITALY,*
[3]*University of Calabria, Rende, ITALY,*
[4]*Mediterranea University, Reggio Calabria, ITALY,*
[5]*Department of Nuclear Medicine, IRCCS San Raffaele Hospital, Milan, ITALY,*
[6]*Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, Milan, ITALY.*

OP-442

First-in-human translation of the c-MET-targeting theranostic ligand FL-261 for imaging in NSCLC

Y. Song[1], *X. Zhang*[1], *Y. Gai*[1], *Y. Gao*[1], *K. Zhu*[1], *D. Barton*[2], *N. Wong*[2], *X. Lan*[1];
[1]*Wuhan Union Hospital, Wuhan, CHINA,*
[2]*Full-Life Technologies, Shanghai, CHINA.*

OP-443

PFS and OS prediction in a prospective trial on resectable NSCLC: Dual time-point ^{18}FDG PET/CT before and after short term preoperative immune checkpoint inhibition outperforms pathological response assessment

H. Hautzel[1], *M. Wiesweg*[2], *T. Plönes*[3,4], *D. Theegarten*[5], *D. M. Kersting*[1], *C. Aigner*[3,6], *K. Herrmann*[1], *M. Schuler*[2];
[1]*Department of Nuclear Medicine, University Hospital Essen, University Duisburg - Essen, Essen, GERMANY,*
[2]*Department of Medical Oncology, University Hospital Essen, University Duisburg - Essen, Essen, GERMANY,*
[3]*Department of Thoracic Surgery, University Hospital, Essen University Duisburg - Essen, Essen, GERMANY,*
[4]*Department of Surgery, Division of Thoracic Surgery, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, GERMANY,*
[5]*Institute for Pathology, University Hospital Essen, University Duisburg - Essen, Essen, GERMANY,*
[6]*General Hospital Vienna, Department of Thoracic Surgery, Medical University Vienna, Vienna, AUSTRIA.*

1007

Monday, October 19, 2026, 15:00 – 16:30

Hall F1

Inflammation & Infection Committee: Cardiovascular Infection and Inflammation: Heart and Vessels Under Attack!

OP-444

Diagnostic Performance of VOI-Based Quantification in [^{99m}Tc]Tc-HMPAO-Labelled Leukocyte SPECT/CT for Vascular Prosthesis Infection

P. Negrete Montiel[1], *B. M. Jaramillo López*[1], *Á. R. Suazo Montero*[1], *R. D. C. Zambrano Infantino*[1], *N. Álvarez Mena*[1], *F. Sebastián Palacid*[1], *S. Pena Vaquero*[1], *G. M. Melo*[2];
[1]*Hospital clínico Univeristario De Valladolid, Valladolid, SPAIN,*
[2]*NOVA Medical School, Lisboa, PORTUGAL.*

OP-445

Predictive Value of ^{18}F-FDG-PET/CT for Aortic Dilation in Giant Cell Arteritis

P. Sobole[1], *P. Nunes*[1], *G. Constantin*[1], *V. Colin*[2], *A. Cochet*[1], *M. Samson*[2], *J. Alberini*[1];
[1]*Centre George François Leclerc, Dijon, FRANCE,*
[2]*CHU Dijon Bourgogne, Dijon, FRANCE.*

OP-446

Beyond visual analysis: added value of MIV and liver-normalised TBR in FDG PET/CT assessment of large vessel vasculitis

C. Habachi[1,2], *R. Ghannem*[1,2], *A. Ezzine*[1,3], *H. Boudriga*[1,3], *M. Ben Fredj*[1,3], *K. Chatti*[1,2];
[1]*University hospital Sahloul of Sousse, Nuclear medicine department, sousse, TUNISIA,*
[2]*University of Monastir, Monastir, TUNISIA,*
[3]*University of Sousse, Sousse, TUNISIA.*

OP-447

Uptake of ^{18}F-FDG in the aortic wall in HIV infection: a comparison with inflammatory biomarkers

P. Plaza López, *I. Arrieta Aldea, J. Gispert, E. Cañas, S. García Anselmo, R. Valhondo, B. Patrut, R. Güerri; Hospital del Mar Barcelona, Barcelona, SPAIN.*

OP-448

Beyond SUV: dynamic FDG PET may improve lesion characterization in complex infectious and inflammatory cardiovascular scenarios

S. Capitanio[1], *G. Muti*[2], *A. Franchini*[1], *A. Spataro*[1], *L. Airò Farulla*[1], *A. Scarale*[1], *E. Gay*[1], *G. Cabrini*[1], *M. Cuomo*[1], *F. Firinu*[1], *C. Rossetti*[1];
[1]*Nuclear Medicine Unit, Dipartimento Ematologia, Oncologia e Medicina Molecolare, ASST Niguarda Hospital, Milano, ITALY,*
[2]*Medical Physics Department, ASST Niguarda Hospital, Milano, ITALY.*

OP-449

Beyond the Graft: ^{18}F-FDG PET/CT Mapping of Inflammatory Activity After Complex Aortic and Cardiothoracic Surgery

I. Znamenskiy[1,2], *M. Beregov*[1], *D. Mosin*[1], *D. Kharina*[1], *A. Kondakov*[2];
[1]*Petrovsky National Research Centre of Surgery, Moscow, RUSSIAN FEDERATION,*
[2]*Pirogov Russian National Research Medical University, Moscow, RUSSIAN FEDERATION.*

OP-450

Somatostatin receptor PET versus [^{18}F]FDG PET for the detection of infective endocarditis: a pilot study

T. Larive, *E. Chevalier, B. Lefevre, C. Boursier, P. Marie; CHRU Brabois, rue du Morvan, Vandœuvre-lès-Nancy, FRANCE.*

OP-451

Utility of Total Lesion Glycolysis Score on ^{18}F-FDG-PET/CT for Diagnosis and Prognosis in Polymyalgia Rheumatica

B. Liu[1,2,3], *E. H. J. G. Aarntzen*[2,4], *K. S. M. van der Geest*[5], *E. Brouwer*[5], *R. H. J. A. Slart*[2,6,7];
[1]*Department of Rheumatology, Austin Health, University of Melbourne, Melbourne, AUSTRALIA,*
[2]*Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS,*
[3]*Department of Nuclear Medicine and PET, Royal Melbourne Hospital, Melbourne, AUSTRALIA,*
[4]*Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS,*
[5]*Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS,*
[6]*Department of Biomedical Photonic Imaging, Faculty of Science and Technology, University of Twente, Enschede, NETHERLANDS,*
[7]*Department of Medicine and Surgery, University of Milan Bicocca, Milan, ITALY.*

OP-452

Whole-body ^{18}F-FDG PET networks reveal BMI-dependent nonlinear inflammatory aging

Z. Shi[1], *X. Li*[2], *M. Hacker*[2], *S. Xue*[2], *X. Li*[2], *Z. Huang*[1];
[1]*Department of Nuclear Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA,*
[2]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, AUSTRIA.*

1008

Monday, October 19, 2026, 15:00 - 16:30

Hall F2

Joint Symposium 4 - Oncology & Theranostics Committee / ENETS: PRRT and Systemic Therapy Options for NET

OP-453

How to Sequence Systemic Therapy in NET Talk

M. Pavel;
Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, GERMANY.

OP-454

PRRT: Patients' Selection and Toxicities

A. Braat;
University Medical Center Utrecht, Utrecht, NETHERLANDS.

OP-455

Response Assessment to PRRT

C. Deroose;
University Hospitals Leuven & Nuclear Medicine and Molecular Imaging, Leuven, BELGIUM.

OP-456

Antagonists-Based Theranostics

J. Fricke;
University Hospital Basel, Basel, SWITZERLAND.

1011

Monday, October 19, 2026, 15:00 – 16:30

Hall G1

Theranostics Track: Prostate Cancer Therapy I

OP-457

PSMA-REACH: Real-world effectiveness and treatment patterns of [^{177}Lu]Lu-PSMA-617 in patients with mCRPC

F. Courbon[1], *C. Bailly*[2], *A. Flechon*[3], *A. Giraudet*[3], *P. Blanchard*[4], *G. Fiard*[5], *M. Pouriel*[6], *E. Duperray*[6], *P. Barthelemy*[7], *G. Roubaud*[8];
[1]*IUCT-Oncopole Toulouse, Toulouse, FRANCE,*
[2]*Nantes University Hospital, Nantes, France, Nantes, FRANCE,*
[3]*Léon Berard Center, Lyon, France, Lyon, FRANCE,*
[4]*Radiation Oncology Department, Gustave Roussy Cancer Campus, INSERM 1018 CESP, University Paris-Saclay, Villejuif, France, PARIS, FRANCE,*
[5]*Grenoble University Hospital, Grenoble, France, Grenoble, FRANCE,*
[6]*Novartis Pharma SAS, Rueil-Malmaison, France, Rueil-Malmaison, FRANCE,*
[7]*Strasbourg University Hospital, Strasbourg, France, Strasbourg, FRANCE,*
[8]*Institut Bergonié Cancer Center, Bordeaux, France, Bordeaux, FRANCE.*

OP-458

Personalized [^{177}Lu]Lu-PSMA Radioligand Therapy: Efficacy and Safety of Reduced Dosing

L. Widjaja[1], *J. Hornfeck*[1], *P. J. Dahlmann*[1], *S. C. Siegmund*[1], *F. J. Gildehaus*[1], *A. Delker*[1], *N. Schmidt-Heegemann*[2], *M. J. Zacherl*[1], *F. L. Giesel*[3], *K. Klimek*[1], *J. Casuscelli*[4], *C. G. Stief*[4], *R. A. Werner*[1];
[1]*Department of Nuclear Medicine, LMU University Hospital, Munich, GERMANY,*
[2]*Department of Radiation Oncology, LMU University Hospital, Munich, GERMANY,*
[3]*Department of Nuclear Medicine, Medical Faculty, University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, GERMANY,*
[4]*Department of Urology, LMU University Hospital, Munich, GERMANY.*

OP-459

Lu-177 PSMA Rechallenge Therapy: Patient Selection and Assessment of Treatment Efficacy

K. Aslaner[1], *D. Arslan*[1], *M. Basaran*[2], *B. Arca*[1], *E. Isik*[1], *Y. Sanli*[1];
[1]*Istanbul University Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[2]*Istanbul University Faculty of Medicine, Department of Medical Oncology, Istanbul, TÜRKIYE.*

OP-460

[^{177}Lu]Lu-PSMA-I&T radioligand therapy in hormone-sensitive prostate cancer with biochemical recurrence: interim clinical outcomes from a prospective trial

H. Einspieler[1], *S. Schmitl*[1], *I. K. Langrate*[1], *D. Muin*[1], *O. Kulterer*[1], *A. Göllner*[1], *G. Kramer*[2], *M. Hacker*[1], *P. Rajwa*[2], *S. Shariat*[2], *S. Rasul*[1];
[1]*Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA,*
[2]*Department of Urology, Medical University of Vienna, Vienna, AUSTRIA.*

OP-461

Prognostic Value of [^{177}Lu]Lu-PSMA SPECT and Timing of RECIP Assessment in mCRPC

A. Bekkhoucha[1], *T. Zaragori*[2], *P. Olivier*[1], *M. Claudin*[1], *P. Marie*[1], *J. kunsch*[1], *A. Verger*[1], *S. Heyer*[1], *L. Imbert*[1], *C. Boursier*[1];
[1]*Nancy University Hospital of Lorraine, Vandoeuvre-lès-Nancy, FRANCE,*
[2]*CHRU-Nancy, Inserm, Université de Lorraine, CIC 1433, Innovation Technologique, Nancy, FRANCE.*

OP-462

Initial Safety and Efficacy of ^{177}Lu-NYM032 in Progressive mCRPC: A Phase I/II Study

O. Sartor[1], *Y. Wang*[2], *L. Hou*[2], *Q. Xu*[2], *X. Xue*[3,4], *J. Pan*[5], *X. Lin*[5], *P. Fang*[5], *P. Mozley*[5], *C. Yu*[2,6];
[1]*LCMC Health, New Orlean, CA, UNITED STATES OF AMERICA,*
[2]*Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, Wuxi, CHINA,*
[3]*Department of Nuclear Medicine, The First People's Hospital of Yancheng, Yancheng, CHINA,*
[4]*Department of Nuclear Medicine, The Yancheng Clinical College of Xuzhou Medical University, Yancheng, CHINA,*

[5]Norroy bioscience Co., Ltd, Wuxi, CHINA,
[6]Wuxi School of Medicine, Jiangnan University, Wuxi, CHINA.

OP-463

Evaluation of the safety and efficacy of ^{225}Ac-PSMA-CY313 in metastatic castration-resistant prostate cancer: interim analysis

S. Li[1], *Y. Shi*[1], *R. Gao*[2], *F. Wang*[3], *H. Zhang*[1], *Q. Geng*[2], *J. Liu*[4], *Y. Wu*[4];
[1]*Department of Nuclear Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, CHINA,*
[2]*Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xian, CHINA,*
[3]*Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, CHINA,*
[4]*C-ray Therapeutics (Chengdu) Co., Ltd., Shanghai, CHINA.*

OP-464

Safety and Efficacy of [^{161}Tb]Tb-PSMA-I&T (9.5 GBq) Radioligand Therapy for mCRPC: Results from the Expanded VIOLET Phase I/II Study

M. Hofman, *L. Kostos, J. Xie, P. Jackson, L. McIntosh, R. Alipour, T. Akhurst, B. Emmerson, G. Ghosh, M. B. Haskali, R. Kashyap, N. Kovaleva, G. Kong, S. Levy, J. McKenzie, D. G. Murphy, J. Saghebi, S. Sandhu, B. Tran, C. Martin, M. Vermeulen, A. A. Azad, J. P. Buteau;*
Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

OP-465

First-in-human dose escalation of [^{161}Tb]Tb-SibuDAB in mCRPC: results from the PROGNOSTICS Phase Ib study

A. Chirindel[1], *G. Nicolas*[1], *F. Westerbergh*[2], *L. McDougall*[1], *D. Schmid*[3], *S. Geistlich*[3], *A. Bauman*[4], *A. Fokkema*[5], *N. Aceto*[5], *P. Bernhardt*[2], *N. van der Meulen*[6], *C. Müller*[3], *R. Schibli*[3], *D. Wild*[1];
[1]*University Hospital of Basel, Division of Nuclear Medicine, Basel, SWITZERLAND,*
[2]*Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN,*
[3]*PSI Center for Life Sciences, Villigen-PSI, SWITZERLAND,*
[4]*University Hospital of Basel, Division of Radiopharmaceutical Chemistry University Hospital Basel, Basel, SWITZERLAND,*
[5]*Department of Biology, Institute for Molecular Health Sciences, ETH Zurich, Zurich, SWITZERLAND,*
[6]*PSI Center for Nuclear Engineering and Sciences, Villigen-PSI, SWITZERLAND.*

1101

Monday, October 19, 2026, 16:45 - 18:15
Hall A

CME 8 - Oncology & Theranostics Committee: The Evidence Shift: Impact of Prospective Imaging Trials in Oncology

OP-466

FAP Imaging in Oncology

L. Unterrainer;
LMU Hospital, Department of Nuclear Medicine, Munich, GERMANY.

OP-467

FDG PET-Guided Randomized Trials

G. Gebhart;
Institute Jules Bordet – Hopital Universitaire de Bruxelles (H.U.B), Brussels, BELGIUM.

OP-468

Molecular Imaging Biomarkers of Outcome: PSMA, FAP, FDG, SSTR and more

C. Civan;
Istanbul University, Istanbul, TÜRKIYE.

OP-469

Novel Imaging in Phase I/II: CA9, GRPR and New Cancer Targets

A. Farolfi;
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

1102

Monday, October 19, 2026, 16:45 - 18:15
Hall D (Arena)

Inflammation & Infection Committee + Young Professionals Council: Round Table: Clinical and Research Challenges in Infection Imaging: Where to Invest or Let it Go

OP-470a

All talks: Round Table Participant

O. Gheysens;
Department of Nuclear Medicine, Cliniques universitaires Saint-Luc, Brussels, BELGIUM.

OP-470b

Round table participant

A. Glaudemans;
Department of Nuclear Medicine, University Medical Center Groningen, Groningen, NETHERLANDS.

OP-470c

Round table participant

T. Van den Wyngaert;
University of Antwerp and Department of Nuclear Medicine at Antwerp University Hospital, Antwerp, BELGIUM.

OP-470d

Round table participant

D. Simankova;
Karlovy Vary Hospital, Nuclear Medicine Department, Karlovy Vary, CZECH REPUBLIC.

OP-470e

Round table participant

E. Romano Gargarella;
Università Cattolica del Sacro Cuore, Nuclear Medicine Department, Rome, ITALY.

OP-470f

Round table participant

M. Vaillant;
Hospital Clinico San Carlos, Nuclear Medicine Department Madrid, SPAIN.

1103

Monday, October 19, 2026, 16:45 - 18:15
Hall E1

LIPS Session 8 - AI Committee: Metrics for AI

OP-474

State-of-the-Art on Performance Metrics for AI in Nuclear Medicine

L. Cavinato;
Politecnico di Milano, Milan, ITALY.

OP-475

How to Evaluate AI in Relation to Patient Outcomes and Clinical Decision-Making

P. Slomka;
Medicine Research Center Cedars-Sinai, David Geffen School of Medicine University of California, Los Angeles, UNITED STATES OF AMERICA.

OP-476

How to Assess Trustworthiness of AI Tools in Nuclear Medicine?

M. Hatt;
LaTIM INSERM, Brest, FRANCE.

1104

Monday, October 19, 2026, 16:45 - 18:15
Hall E2

M2M Track: TROP Session - Translational Molecular Imaging & Therapy Committee: Advances in Combination Therapies

OP-477

CDK4/6i are synergistic in combination with [^{177}Lu]Lu-DOTATATE and [^{177}Lu]Lu-PSMA

E. O'Neill[1], *F. Amoroso*[1], *M. Mosley*[1], *B. Cornelissen*[2];
[1]*University of Oxford, Oxford, UNITED KINGDOM,*
[2]*University Medical Center Groningen, Groningen, NETHERLANDS.*

OP-478

Comparative evaluation of [^{225}Ac]Ac- and [^{177}Lu]Lu-DOTA-hG250 targeted radionuclide therapy and combination with PD1 blockade in a preclinical renal cell carcinoma model

T. van der Werff[1], *S. Kleinendorst*[2], *S. Wenker*[2], *G. Franssen*[2], *E. Oosterwijk*[1], *M. Konijnenberg*[3], *S. Muselaers*[1], *M. Wheatcroft*[4], *K. Twumasi-Boateng*[4], *S. Heskamp*[2];
[1]*Radboud University Medical Center, Dpt. Urology, Nijmegen, NETHERLANDS,*
[2]*Radboud University Medical Center, Dpt. Medical Imaging, Nijmegen, NETHERLANDS,*
[3]*Radboud University Medical Center, Dpt. Medical Imaging / Erasmus University Medical Center, Dpt. Radiology and Nuclear Medicine, Nijmegen/Rotterdam, NETHERLANDS,*
[4]*Telix Pharmaceuticals, Melbourne, AUSTRALIA.*

OP-479

Antitumour efficacy of actinium (^{225}Ac) felivotide mopaxetan (^{225}Ac-PSMA-Trillium, BAY3563254) in combination with androgen receptor pathway inhibitors in preclinical models of prostate cancer

U. Hagemann[1], *V. Cruciani*[2], *S. Zitzmann-Kolbe*[1], *S. Hammer*[1], *D. Purwin*[1], *S. Osterberg*[1], *A. N. Hosein*[3], *E. Gasal*[4];
[1]*Bayer AG, Berlin, GERMANY,*
[2]*Bayer AS, Oslo, NORWAY,*
[3]*Bayer HealthCare Pharmaceuticals, Whippany, NJ, UNITED STATES OF AMERICA,*
[4]*Bayer Consumer Care AG, Basel, SWITZERLAND.*

OP-480

Transketolase Inhibition Sensitizes PSMA-Targeted ^{177}Lu Radioligand Therapy in PSMA-Positive Tumor Models

Q. Wu[1,2], *T. Zhao*[1,2], *R. P. Baum*[3], *J. Zhang*[1,2,4];
[1]*Departments of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapo, Singapore, SINGAPORE,*
[2]*Theranostics Center of Excellence (TCE), Yong Loo Lin School of Medicine, National University of Singapore, [11] Biopolis Way, Helios, Singapore 138667, Singapore, Singapore, SINGAPORE,*
[3]*Curanosticum Wiesbaden-Frankfurt, Department of Molecular Radiotherapy, ICPO Center of Excellence, DKD HELIOS Klinik, Wiesbaden, Germany, Wiesbaden,*

GERMANY,
[4]Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore, Singapore, SINGAPORE.

OP-481

Olaparib Potentiates ^{177}Lu-PSMA-617 Radioligand Therapy in Prostate Cancer through Glycolytic Suppression

Q. Wu[1,2], *L. Luo*[3], *R. P. Baum*[4], *J. Zhang*[1,2,5];
[1]Departments of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,
[2]Theranostics Center of Excellence (TCE), Yong Loo Lin School of Medicine, National University of Singapore, [11] Biopolis Way, Helios, Singapore 138667, Singapore., Singapore, SINGAPORE,
[3]The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China, Xi'an, CHINA,
[4]Curanosticum Wiesbaden-Frankfurt, Department of Molecular Radiotherapy, ICPO Center of Excellence, DKD HELIOS Klinik, Wiesbaden, Germany., Wiesbaden, GERMANY,
[5]Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore, SINGAPORE.

OP-482

Targeted Killing of Tumor Associated Macrophages with a Novel [^{177}Lu]Lu-Nanomedicine Prolongs Survival and Unlocks Checkpoint Inhibition in an Orthotopic Pancreatic Cancer Model

S. Minami[1], *S. A. Nørgaard*[2], *K. T. Thrane*[2], *N. Łopuszyńska*[2], *N. Nielsen*[2], *A. Lindberg*[2], *B. Lu*[1], *J. Yoshihara*[1], *W. Thomas*[1], *J. L. Cleland*[1,3];
[1]Programmable Medicine, Redwood City, CA, UNITED STATES OF AMERICA,
[2]Minerva Imaging, Ølstykke, DENMARK,
[3]Ironfist Therapeutics, Redwood City, CA, UNITED STATES OF AMERICA.

OP-483

EphA3-directed stromal radioimmunotherapy potentiates chemotherapy and immunotherapy in pancreatic cancer

Z. Cao[1,2,3], *C. Wichmann*[1,2,3], *L. Osellame*[1,2], *N. Guo*[1], *F. Scott*[1,2], *I. Burvenich*[1,2], *P. Janes*[1,4], *A. Scott*[1,2,3];
[1]Olivia Newton-John Cancer Research Institute, Heidelberg, AUSTRALIA,
[2]School of Cancer Medicine, La Trobe University, Bundoora, AUSTRALIA,
[3]Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, AUSTRALIA,
[4]School of Cancer Medicine, La Trobe Univeristy, Bundoora, AUSTRALIA.

OP-484

Multi-Target HDAC Inhibitor CUDC-101 Enhances PSMA Expression and Improves Radioligand Therapy in PSMA-Low Prostate Cancer

H. Jung[1,2,3], *K. Kang*[1,2,3], *H. Youn*[1,3,4];
[1]Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,
[2]Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF,
[3]Cancer Research Institute, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF,
[4]Cancer Imaging Center, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

OP-485

Evaluation of Treatment Efficacy in Combined Radiation Therapy and Immunotherapy by Immune Cell-Targeted PET Imaging

N. Kobayashi[1], *Y. Shimizu*[1], *N. Kondo*[2], *T. W. Nobashi*[1], *K. Ishimatsu*[1], *R. Sadahiro*[3], *S. Ohira*[4], *N. Tanaka*[5], *Y. Nakamoto*[1];
[1]Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, JAPAN,
[2]Division of Particle Radiation Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, JAPAN,
[3]Department of Psycho-Oncology, National Cancer Center Hospital National Cancer Center Japan, Tokyo, JAPAN,
[4]Department of Radiological Science, Graduate School of Human Health Science, Tokyo Metropolitan University, Tokyo, JAPAN,
[5]Department of Urology, Keio University School of Medicine, Tokyo, JAPAN.

1105

Monday, October 19, 2026, 16:45 - 18:15
Hall B

Cutting Edge Science Track: Physics Committee: Dynamic PET Imaging and Kinetic Analysis

OP-486

Multi Tracer Spectral Analysis of Dynamic Large Axial Field of View PET/CT Studies

C. Smith[1], *N. Tolboom*[2], *D. Visser*[1], *R. B. Henrar*[1], *G. J. C. Zwezerijnen*[1], *M. E. den Hollander*[1], *C. Menke-van der Houven van Oordt*[1], *I. Bahce*[1], *M. Yaqub*[1], *R. Boellaard*[1];
[1]Amsterdam UMC, Amsterdam, NETHERLANDS,
[2]UMC Utrecht, Utrecht, NETHERLANDS.

OP-487

Towards Clinically Compatible Dynamic PET: Enabling Kinetic Analysis with 20-Minute Acquisitions

I. Incicco[1], *D. Dall'Olio*[1], *I. Brusa*[2], *R. Mei*[2], *A. Farolfi*[2], *C. Nanni*[2], *B. A. Spencer*[3], *G. Wang*[3], *L. Nardo*[3], *S. Fanti*[2,4], *G. Castellani*[1,5];
[1]Department of Medical and Surgical Sciences, University of Bologna, Bologna, ITALY,
[2]Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,
[3]Department of Radiology, University of California-Davis, Davis, CA, UNITED STATES OF AMERICA,
[4]Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,
[5]IRCCS Azienda Ospedaliero-Universitaria di Bologna S.Orsola, 40138, Bologna, ITALY.

OP-488

Validation of ^{18}F-Flutemetamol PET for the Assessment of Cerebrospinal Fluid Dynamics

D. Peretti[1], *K. van Laere*[2,3], *M. Veronese*[4,5], *F. Turkheimer*[5], *J. Schubert*[5];
[1]University of Geneva, Geneva, SWITZERLAND,
[2]University Hospitals Leuven, Leuven, BELGIUM,
[3]KU Leuven, Leuven, BELGIUM,
[4]University of Padua, Padua, ITALY,
[5]King's College London, London, UNITED KINGDOM.

OP-489

From Tracer Uptake to Tissue Physiology: Quantification of Dynamic PET using a Novel Kinetic Model

Z. Czelusniak[1], *P. K. Cramon*[1], *T. L. Andersen*[1,2], *I. Law*[1,2];
[1]Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet – Copenhagen University Hospital, Copenhagen, DENMARK,
[2]Departement of Clinical Medicine, Copenhagen University, Copenhagen, DENMARK.

OP-490

Kinetic Evaluation and Quantification of the Novel α-Synuclein PET Tracer ^{18}F-FD4 in Synucleinopathies

L. Lopes[1], *F. Liu*[2], *R. Ni*[1], *J. Hong*[1], *Y. Chen*[1], *Y. Yang*[3], *J. Bian*[4,5], *J. Lu*[3], *Y. Zhao*[2], *Q. Jiang*[3], *D. Li*[4,5], *J. Ge*[3], *J. Wang*[2], *C. Liu*[6,7], *C. Zuo*[3], *K. Shi*[1];
[1]Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND,
[2]Department of Neurology, National Center for Neurological Disorders, and National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, CHINA,
[3]Department of Nuclear Medicine/PET Center, National Research Center for Aging and Medicine, National Center for Neurological Disorders, and State Key Laboratory of Brain Function and Disorders, Huashan Hospital, Fudan University, Shanghai, CHINA,
[4]Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, CHINA,
[5]Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai, CHINA,
[6]Interdisciplinary Research Center on Biology and Chemistry, State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, CHINA,
[7]Shanghai Academy of Natural Sciences (SANS), Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, CHINA.

OP-491

From Black Box to Physical Interpretation: A ^{3}D-Printed Dynamic Phantom for Kinetic-Modelling Validation in Total-Body PET

L. Strigari[1], *D. Conti*[2], *A. Proto*[3], *F. Zagni*[2], *G. Cicoria*[2], *A. Taibi*[3], *M. Santoro*[2];
[1]IRCCS AOUBO, Bologna, ITALY,
[2]IRCCS Azienda Ospedaliero Universitario di Bologna, Bologna, ITALY,
[3]University of Ferrara, Ferrara, ITALY.

OP-492

A Comprehensive Multi-Organ Examination of Perfusion and Glucometabolic Features and Crosstalk in Healthy Subjects and patients with diabetes

M. Eldevik[1,2], *J. B. Løhde*[3,4], *A. H. Dias*[1,2], *S. Hvidsten*[5], *L. C. Gormsen*[1,2], *O. L. Munk*[1,2];
[1]Department of Nuclear Medicine, Aarhus University Hospital, Aarhus, DENMARK,
[2]Department of Clinical Medicine, Aarhus University, Aarhus, DENMARK,
[3]Steno Diabetes Center Aarhus, Aarhus, DENMARK,
[4]Department of Biomedicine, Aarhus University, Aarhus, DENMARK,
[5]Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK.

OP-493

Are regions of resistant intracranial metastatic disease associated with reduced oxygenation? A multiparametric ^{18}F-FPIA PET/MRI study

M. Inglese[1], *S. Islam*[2], *L. McLeavy*[2], *F. Mauri*[2], *T. M. Barwick*[3], *A. D. Waldman*[2], *K. O'Neill*[2], *M. Williams*[2], *E. O. Aboagye*[2], *N. Toschi*[1];
[1]University of Rome Tor Vergata, Rome, ITALY,
[2]Imperial College London, London, UNITED KINGDOM,
[3]Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.

OP-494

Development of a dynamic phantom with exchange and trapping for quantitative kinetic PET imaging

F. Zagni[1], *G. Cicoria*[1], *I. Brusa*[2], *D. Dall'Olio*[3], *M. Santoro*[1], *C. Nanni*[2], *A. Farolfi*[2], *R. Mei*[2], *I. Corazza*[3], *G. Castellani*[3], *S. Fanti*[2], *L. Strigari*[1];
[1]Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,
[2]Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,
[3]Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, ITALY.

1106

Monday, October 19, 2026, 16:45 - 18:15
Hall C

Clinical Oncology Track: Image-Guided Interventions

OP-495

Novel Hybrid Image-Guided Surgery Techniques: LiDAR-Registered Freehand SPECT combined with NIR Fluorescence

G. Pisano[1,2], *R. W. A. Verdijk*[1,3], *M. N. van Oosterom*[1,3], *D. D. D. Rietbergen*[1,4], *O. R. Brouwer*[3], *H. G. van der Poel*[3,5], *F. W. B. van Leeuwen*[1,3];
[1]Interventional Molecular Imaging Laboratory, Leiden University Medical Centre, Leiden, NETHERLANDS,
[2]Nuclear Medicine Unit, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,
[3]Department of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS,

[4]Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS,
[5]Department of Urology, Amsterdam University Medical Centers, VUmc, Amsterdam, NETHERLANDS.

OP-496

Molecular Surgery in Pancreatic and Hepatic Cancer: PET Radiopharmaceuticals to Address the Critical Challenge of Margin Assessment and Intraoperative Lesion Localisation

J. Orozco Cortes[1], *J. Sabater Sancho*[2], *L. Sabater Orti*[3,4], *M. Romero Otero*[5], *E. Muñoz Forner*[3], *M. Garces Albir*[3], *M. Redal peña*[2], *H. Rodriguez*[2], *T. Mut Dolera*[2];
[1]*Hospital Universitario Dr. Peset, Nuclear Medicine, Valencia, SPAIN,*
[2]*Hospital Clinico Universitario, Nuclear Medicine, Valencia, SPAIN,*
[3]*Hospital Clinico Universitario, Hepatobiliary and Pancreatic Surgery Unit, Valencia, SPAIN,*
[4]*INCLIVA (Instituto de Investigación Sanitaria), Valencia, SPAIN,*
[5]*Hospital Clinico Universitario, Radiopharmacy, Valencia, SPAIN.*

OP-497

Tomographic visualization of radiotracer-avid lesions during prostate cancer surgery via gantry-free robotic SPECT

F. van Leeuwen[1], *A. Berrens*[2], *K. Prikovets*[3], *S. Azargoshasb*[3], *L. J. Slof*[3], *B. A. Cakal*[4], *P. J. van Leeuwen*[2], *M. Sinaasappel*[2], *T. Wendler*[5], *H. G. van der Poel*[2], *M. N. van Oosterom*[3];
[1]*Leiden University Medical Center, Interventional Molecular Imaging Laboratory, Leiderdorp, NETHERLANDS,*
[2]*Netherlands Cancer Institute, Amsterdam, NETHERLANDS,*
[3]*Leiden University Medical Center, Interventional Molecular Imaging Laboratory, Leiden, NETHERLANDS,*
[4]*Surgiceye, Munich, GERMANY,*
[5]*University of Augsburg, Augsburg, GERMANY.*

OP-498

Using Signal-to-Background feedback to Enhance PSMA-Radioguided Surgery

B. Cakal[1,2,3], *V. A. Ottens*[1,4], *K. Pirkovets*[1,4], *D. van Tuil*[1,4], *L. Zuur*[4], *M. Sinaasappel*[4], *G. Gandaglia*[5,6], *A. Briganti*[5,6], *H. G. van der Poel*[4], *P. J. van Leeuwen*[4], *F. W. B. van Leeuwen*[1,4];
[1]*Leiden University Medical Centre, Leiden, NETHERLANDS,*
[2]*University Hospital Augsburg, Augsburg, GERMANY,*
[3]*Crystal Photonics GmbH, Berlin, GERMANY,*
[4]*Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NCI-AVL), Amsterdam, NETHERLANDS,*
[5]*IRCCS Ospedale San Raffaele, Milan, ITALY,*
[6]*Vita-Salute San Raffaele University, Milan, ITALY.*

OP-499

Iodine-125 Seed-Guided Surgery for Occult Lesion Localisation: A Multicentre Spanish Experience with Over 1,600 Procedures

J. Orozco Cortes[1,2], *A. Gadea Castillo Simon*[3], *R. Alvarez Perez*[4], *J. Sabater Sancho*[5,6], *M. Lara Martinez*[7], *C. Sampol Bas*[8], *S. Vidal Sicart*[9], *C. Castillo Arias*[5], *F. Cavagna Matti*[10], *A. García Ruíz* [3], *M. Miguel Martínez*[3], *C. Rodriguez Vergara*[4], *L. Brero Sanchez*[4], *S. Romero Acevedo*[7], *E. Martel Gimeno*[7], *A. Guerra Velastegui*[8], *P. Abreu Sánchez*[10], *G. Bonino*[10], *J. Infante de la Torre*[10], *J. Ribera Perianes*[9], *E. Caballero Calabuig*[11], *R. Martinez García*[12,2], *E. Buch Villa*[13,6];
[1]*Hospital Universitario Dr Peset, Medicina Nuclear, Valencia, SPAIN,*
[2]*FISABIO (Fundació per al Foment de la Investigació Sanitària i Biomèdica de la Comunitat Valenciana), Valencia, SPAIN,*
[3]*Hospital Universitario De Burgos, Medicina Nuclear, Burgos, SPAIN,*
[4]*Hospital Universitario Virgen del Rocio, Medicina Nuclear, Sevilla, SPAIN,*
[5]*Hospital Clinico Universitario, Nuclear Medicine, Valencia, SPAIN,*
[6]*INCLIVA (Instituto de Investigación Sanitaria), Valencia, SPAIN,*
[7]*Complejo Hospitalario Universitario de Canaria, Medicina Nuclear, Tenerife, SPAIN,*
[8]*Hospital Universitari Son Espases, Palma de Mallorca, SPAIN,*
[9]*Hospital Clinic de Barcelona, Barcelona, SPAIN,*
[10]*Hospital Universitario Dr Peset, Valencia, SPAIN,*
[11]*Hospital Universitario Dr. Peset, Nuclear Medicine, Valencia, SPAIN,*
[12]*Hospital Universitario Dr Peset, Breast Surgery Unit, Valencia, SPAIN,*
[13]*Hospital Clinico Universitario, Breast Surgery Unit, Valencia, SPAIN.*

OP-500

Radioguided Localisation of Non-palpable Breast Lesions Using I-125 Radioactive Seeds vs. Hookwire Localisation

P. Paez Vargas, *R. Salvador-Arthur, A. M. Paguay-Moina, G. Martínez-Arias, M. Parra-Rina, A. Tardin-Cardoso, D. Nogueira-Souto, P. Razola-Alba, L. Cáncer-Garza, T. Escalera-Temprado, M. Delgado-Castro, A. Andres-Gracia;*
Hospital Clinico Universitario Lozano Blesa, Zaragoza, SPAIN.

OP-501

Multimodal Angiography-PET-MRI Reveals Vascular Determinants of Intra-Arterial Radioligand Delivery in Brain

I. Pruis, *M. Allaoui, P. J. van Doormaal, S. A. Cornelissen, L. van Dijk, F. G. te Nijenhuis, T. van Walsum,*
S. E. M. Veldhuijzen van Zanten;
Erasmus MC, Rotterdam, NETHERLANDS.

OP-502

Intrathyroidal Indocyanine Green for Near-Infrared Lymphatic Mapping in Differentiated Thyroid Cancer: Initial Feasibility Experience.

C. Furtado Prieto[1,2,3], *B. Martinucci*[2], *C. Guarneri*[4], *U. Parada*[4], *M. Cabrera*[3], *X. Camacho*[3], *M. Tassano*[3], *O. Alonso*[2], *G. Burroso*[5], *A. Rodriguez*[5], *P. Cabral*[3], *J. P. Gambini*[5];
[1]*Hospital Central de las Fuerzas Armadas, Montevideo, URUGUAY,*
[2]*Unidad Académica de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, URUGUAY,*
[3]*Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, URUGUAY,*
[4]*Unidad Académica Clínica Quirúrgica A, Hospital de Clínicas Dr. Manuel Quintela, Facultad de Medicina, UdelaR, Montevideo, URUGUAY,*
[5]*Centro Uruguayo de Imagenología Molecular, Montevideo, URUGUAY.*

OP-503

Ultra-low dose PET/CT for staging and diagnosing pregnant and breastfeeding women - an assessment of performance and clinical outcome

M. Stolberg[1], ***F. E. Høi-Hansen***[1], *E. Lundholm*[1], *K. Madsen*[1], *F. L. Andersen*[1,2], *K. Korsholm*[1,2];
[1]*Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, DENMARK,*
[2]*Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DENMARK.*

1107

Monday, October 19, 2026, 16:45 - 18:15
Hall F1

Paediatrics Committee: Intelligence in Imaging Paediatrics from Diagnosis to Therapy

OP-504

Invited Speaker

J. Rogasch;
Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Berlin, GERMANY.

OP-505

Baseline ^{18}F-FDG PET/CT Radiomics in Lymphoma: Can Low Metabolic Activity and Homogeneity Predict Local Chemoresistance?

H. Gencer, *N. Köylüce;*
Kayseri City Hospital, Kayseri, TÜRKIYE.

OP-506

Interim PET Radiomics for Risk Stratification in Pediatric Lymphoblastic Lymphoma

G. Kaya[1], *B. Volkan-Salancı*[2], *B. Aydın*[3], *P. Kıratlı*[2];
[1]*Republic of Türkiye, Ministry of Health, Yozgat City Hospital and Hacettepe University Faculty of Medicine Depts. of Nuclear Medicine, Ankara, TÜRKIYE,*
[2]*Hacettepe University Faculty of Medicine, Dept. of Nuclear Medicine, Ankara, TÜRKIYE,*
[3]*Hacettepe University Faculty of Medicine, Dept. of Pediatric Oncology, Ankara, TÜRKIYE.*

OP-507

Less is more: AI-enabled dose reduction in pediatric PET imaging

M. Larmuseau[1], *V. De Ridder*[1], *Y. Cras*[2], *S. DeKeyser*[1], *K. Braeckman*[1], *J. Maes*[3], *C. Carron*[3], *P. Berlanga*[2], *N. Gaspar*[2], *L. Agrigoroaie*[2], *D. Deandreis*[2];
[1]*Nuclivision, Ghent, BELGIUM,*
[2]*Gustave Roussy Hospital, Paris, FRANCE,*
[3]*AZ Groeninge, Kortrijk, BELGIUM.*

OP-508

Baseline PET Radiomics and Metabolic Tumour Burden Enhance Prognostic Stratification Beyond Interim Response in Paediatric Hodgkin Lymphoma

F. Yousefirizi[1], *C. Strahlendorf*[2], *A. Lo*[3], *Y. Mbithi*[1], *C. Uribe*[3], *A. Rahmim*[1], *C. Gowdy*[2];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,*
[2]*BCCH, Vancouver, BC, CANADA,*
[3]*BC Cancer, Vancouver, BC, CANADA.*

OP-509

Quantifying the Invisible: A Novel PET Severity Score for Paediatric MOGAD Linking Metabolism to Disability in the Largest ^{18}F-FDG PET-CT Series (n=30)

D. Palivela[1], *S. Taywade*[2], *D. Datta*[1], *L. Saini*[1], *S. Tiwari*[1], *R. Kumar*[1];
[1]*All India Institute of Medical Sciences, Jodhpur, INDIA,*
[2]*All India Institute of Medical Sciences, Nagpur, INDIA.*

OP-510

Survival Stratification in Paediatric High- and Low-Grade Gliomas: The Added Value of Multimodal [^{18}F] F-DOPA PET and FLAIR MRI Radiomics

M. Mureddu[1], *R. Trò*[1], *A. Rossi*[2], *A. Ramaglia*[2], *A. Verrico*[3], *C. Milanaccio*[3], *G. Morana*[4], *A. Piccardo*[5], *F. Fiz*[5], *M. M. Fato*[1];
[1]*Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), University of Genoa, Genoa, ITALY,*
[2]*NeuroRadiology Unit, IRCCS Istituto Giannina Gaslini, Genoa, ITALY,*
[3]*Neuro-Oncology Unit, IRCCS Istituto Giannina Gaslini, Genoa, ITALY,*
[4]*Department of Neurosciences, University of Turin, Turin, ITALY,*
[5]*Nuclear Medicine Unit, Ente Ospedaliero Ospedali Galliera, Genoa, ITALY.*

OP-511

Longitudinal Quantitative and Radiomic PET Features for Predicting Progression-Free Survival in Paediatric Hodgkin Lymphoma

F. Yousefirizi[1], *C. Strahlendorf*[2], *A. Lo*[3], *Y. Mbithi*[2], *C. Uribe*[3], *A. Rahmim*[1], *C. Gowdy*[2];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,*
[2]*BCCH, Vancouver, BC, CANADA,*
[3]*BC Cancer, Vancouver, BC, CANADA.*

OP-512

Comparison of [^{18}F]mFBG PET and [^{123}I]mIBG Scintigraphy for Detecting Bone and Bone Marrow Involvement in Neuroblastoma

M. Fosbøl[1], *J. Brok*[2], *T. N. Winther*[2], *K. F. Andersen*[3], *C. B. Johnbeck*[2], *L. H. Enevoldsen*[2], *K. B. Larsen*[2], *H. H. Johannesen*[2], *F. L. Andersen*[2,4], *L. Borgwardt*[2];
[1]*Copenhagen University Hospital - Rigshospitalet, Copenhagen, DENMARK,*
[2]*Copenhagen University Hospital -Rigshospitalet, Copenhagen, DENMARK,*
[3]*Copenhagen University Hospital - North Zealand, Hilleroed, DENMARK,*
[4]*University of Copenhagen, Copenhagen, DENMARK.*

1108

Monday, October 19, 2026, 16:45 - 18:15
Hall F2

Joint Symposium 5 - Neuroimaging Committee / EPA: What Can Nuclear Medicine Offer in Psychiatry

OP-513

PET Psychiatry: The Psychiatrist's Perspective
U. Müller;
University of Cambridge / Government of Jersey, Department of Psychiatry / Adult ADHD & Autism Service, Cambridge/St Helier, United Kingdom/Jerse, Cambridge/St Helier, UNITED KINGDOM.

OP-514

The Use of Nuclear Medicine Imaging in Biological Research and Clinical Practice of Psychiatric Disorders
S. Hesse;
University of Leipzig Medical Center, Department of Nuclear Medicine / Integrated Research and Treatment Center (IFB) Adiposity Diseases, Leipzig, GERMANY.

OP-515

Disorders of the Brain: the Future of Neuroimaging for Diagnosing and Treating Psychiatric Disorders in the Age of AI
F. Coutts;
Centre for Addiction and Mental Health / University of Toronto, Krembil Centre for Neuroinformatics / Department of Psychiatry, Toronto, CANADA.

1110

Monday, October 19, 2026, 16:45 - 18:15
Hall K

CTE 5 - Technologists + Thyroid Committee: NM Applications for Benign Thyroid Diseases

OP-517

Radioiodine Therapy in Patients with Thyroid Disorders: 85 Years of an Effective, Safe and Theragnostic Therapy
A. Campennì;
University of Messina, Messina, ITALY.

OP-518

Non-Toxic Nodular Goiter And Radioiodine Therapy: Why, Who, When, And How
M. Kreissl;
Division of Nuclear Medicine, University Hospital Magdeburg, Magdeburg, GERMANY.

OP-519

Governance Models for Remote Nuclear Medicine Practice: Ethical, Legal and Professional Implications
B. Emmerson;
Peter MacCallum Cancer Centre, Department Cancer Imaging, Melbourne, AUSTRALIA.

1111

Monday, October 19, 2026, 16:45 - 18:15
Hall G1

Theranostics Track: Prostate Cancer Therapy II

OP-520

Prospective multicentre real-world outcomes of [^{177}Lu]Lu-PSMA-I&T in mCRPC: results from a Swiss registry
A. Chirindel[1], *G. Nicolas*[1], *M. Tissier*[2], *M. del Sol Pérez Lago*[3], *F. Forrer*[4], *A. Afshar-Oromieh*[5], *S. Beintner-Skawran*[6], *A. Bauman*[7], *M. Coslovsky*[8], *V. Klotzbücher*[8], *A. Zander*[3], *O. Maas*[4], *I. Engel-Bicik*[6], *A. Lorch*[9], *C. Rentsch*[10], *F. Stenner*[11], *A. Templeton*[12], *E. Nitzsche*[13], *N. Schaefer*[2], *D. Wild*[1];
[1]*Division of Nuclear Medicine, University Hospital of Basel, Basel, SWITZERLAND,*
[2]*Department of Nuclear Medicine, University Hospital of Lausanne, Lausanne, SWITZERLAND,*
[3]*Department of Nuclear Medicine, Cantonal Hospital of Lucerne, Lucerne, SWITZERLAND,*
[4]*Department of Nuclear Medicine, Cantonal Hospital of St. Gallen, St. Gallen, SWITZERLAND,*
[5]*Department of Nuclear Medicine, Inselspital Bern, Bern, SWITZERLAND,*
[6]*Department of Nuclear Medicine, University Hospital of Zurich, Zurich, SWITZERLAND,*
[7]*Division of Radiopharmaceutical Chemistry, University Hospital of Basel, Basel, SWITZERLAND,*
[8]*Department Clinical Research, University of Basel and University Hospital of Basel, Basel, SWITZERLAND,*
[9]*Department of Medical Oncology and Haematology, University Hospital Zurich, Zurich, SWITZERLAND,*
[10]*Department of Urology, University Hospital of Basel, Basel, SWITZERLAND,*
[11]*Department of Medical Oncology, University Hospital of Basel, Basel, SWITZERLAND,*
[12]*Department of Medical Oncology, St. Claraspital, Basel, SWITZERLAND,*
[13]*Department of Nuclear Medicine, Cantonal Hospital of Aarau, Aarau, SWITZERLAND.*

OP-521

SPECT/CT + PSA triage: a PET-sparing strategy during 177LuPSMA radioligand therapy
M. Kassas, *P. Kristanto, P. Flamen, C. Artigas;*
Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, BELGIUM.

OP-522

^{177}Lu-PSMA Rechallenge in a Real-World Cohort: Safety, Efficacy, and Paired PET Biomarkers
M. Kassas, *R. Soussi, Z. Noordally, P. Flamen, C. Artigas;*
Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, BELGIUM.

OP-523

Interim results from PTherpan-Lu trial: [^{177}Lu] Lu-DOTA-HYNIC-panPSMAradionuclide therapy for patients with metastatic castration-resistant prostate cancer
J. Roetman[1], ***Y. Omar***[2], *Y. Atteya*[2],[3], *M. Elkanawaty*[2],[4], *A. Ahmed*[5], *G. Elhusseiny*[5], *M. El Shazly*[5], *A. Ameen*[5];
[1]*Telix Pharmaceuticals, North Melbourne, AUSTRALIA,*
[2]*Nuclear Medicine Department, Misr Radiology Center, Cairo, EGYPT,*
[3]*Radiology and Nuclear Medicine Department, Helwan University, Helwan, EGYPT,*
[4]*Radiology Department, Benha University, Benha, EGYPT,*
[5]*Department of Oncology and Nuclear Medicine, Alexandria University, Alexandria, EGYPT.*

OP-524

A Single-Arm, Low-Dose, Prospective Study of ^{225}Ac-LNC1011 in Patients with Metastatic Castration-Resistant Prostate Cancer
G. Wang[1], *J. Zang*[1], *X. Chen*[2], *J. Zhang*[3], *W. Miao*[1];
[1]*the First Affiliated Hospital, Fujian Medical University, Fuzhou, CHINA,*
[2]*Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CHINA,*
[3]*National University of Singapore, Singapore, SINGAPORE.*

OP-525

First-In-Human Phase 1 Study of ATNM-400, Actinium-225 Antibody Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
J. Cardaci[1], *A. Singh*[1], *T. Michele*[2], *N. Lenzo*[3], *G. Ghosh*[3], *J. Gibson*[4], *M. Roy*[4], *A. Kamal*[4], *J. Kim*[4];
[1]*GenesisCare Murdoch, Murdoch WA, AUSTRALIA,*
[2]*GenesisCare St. Andrews, Adelaide SA, AUSTRALIA,*
[3]*ICON Hollywood, Nedlands WA, AUSTRALIA,*
[4]*Actinium Pharmaceutical, Inc., New York, NY, UNITED STATES OF AMERICA.*

OP-526

First-in-Human Preliminary Study of Low-Dose [^{161}Tb]Tb-NYM032, a PSMA-Targeted Radiopharmaceutical, in Patients with mCRPC
L. Xiao[1], *R. Luo*[1], *F. Liu*[1], *Z. Zhao*[1], *L. Cao*[1], *R. Wang*[2], *Z. Zhu*[2], *Z. Chen*[1];
[1]*Mianyang Central Hospital, Mianyang, CHINA,*
[2]*Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CHINA.*

OP-527

FDG Uptake as a Determinant of Lesion Dosimetry and Outcomes in PSMA Radioligand Therapy for mCRPC
S. Wen[1], *S. Xue*[1], *A. A. Nikolic*[2], *S. Dintner*[3], *R. A. Bundschuh*[4], *M. Hacker*[5], *X. Li*[6], *C. Lapa*[2];
[1]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna Gene, Vienna, AUSTRIA,*
[2]*Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY,*
[3]*Pathology, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY,*
[4]*Department of Nuclear Medicine, University Hospital Carl Gustav Carus at the TU Dresden, Dresden, GERMANY,*
[5]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna, AUSTRIA,*
[6]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna, AUSTRIA.*

OP-528

FDG PET/CT for Detection of Early Treatment Failure After Two Cycles of ^{177}Lu-PSMA Radioligand Therapy
M. Kassas, *R. Poenaru, M. Zekri, P. Flamen, C. Artigas;*
Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, BELGIUM.

1201

Tuesday, October 20, 2026, 08:00 - 09:30
Hall A

CME 9 - Paediatrics Committee: The Evolving Role of Nuclear Medicine in Paediatric Epilepsy: From Seizure Focus Localisation to Prognostic Imaging

OP-774

Paaediatric Epilepsy: The Neurosurgeon's View
C. Dorfer;
Department of Neurosurgery, Medical University of Vienna, Vienna, AUSTRIA.

OP-775

Functional Neuroimaging with PET in Paediatric Epilepsy: Current Status and Future Directions
E. Ergün;
Hacettepe University Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.

OP-776

SPECT in Childhood Epilepsy: Focus Localisation and Clinical Decision-Making
I. Roca Bielsa;
Hospital St Joan de Déu, Department of Nuclear Medicine, Barcelona, SPAIN.

1202

Tuesday, October 20, 2026, 08:00 - 09:30
Hall D (Arena)

Joint Symposium 6 - EANM / ESR: Meet the Radioembolisation Team

OP-577

The Radiologist's Role
I. Bargellini;
Department of Diagnostic and Interventional Radiology, AOU Città della Salute e della Scienza di Torino, Turin, ITALY.

OP-578

The Nuclear Medicine Physician's Role

M. Finessi;
Division of Nuclear Medicine, Department of Medical Sciences, University of Turin, AOU Città della Salute, Turin, ITALY.

OP-579a

Case-Based Presentation and Discussion

M. Seidensticker;
Großhadern Klinik und Poliklinik für Radiologie, LMU Klinikum, Munich, GERMANY.

OP-579b

Case-Based Presentation and Discussion

M. Zacherl;
Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY.

1203

Tuesday, October 20, 2026, 08:00 - 09:30

Hall E1

LIPS Session 9 - Dosimetry Committee: Clinical Dosimetry: How Do I Start?

OP-537

General Introduction on What to Think About When Starting Clinical Dosimetry

M. Sandström;
Uppsala University Hospital, Medical Physics, Uppsala, SWEDEN.

OP-538

The Dosimetry Chain for Clinical Dosimetry

L. Santoro;
NSERM U1194 (Radiobiology & Targeted Radiotherapy), Montpellier, FRANCE.

OP-539

How Do I Optimise the Acquisition Protocols for Y-90 When Starting Clinical Dosimetry?

V. Mautone;
IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori" Meldola, ITALY.

1204

Tuesday, October 20, 2026, 08:00 - 09:30

Hall E2

M2M Track: TROP Session - Radiopharmaceutical Sciences Committee: Non-Oncological Tracers

OP-542

Advancing presynaptic GABA imaging: in vivo PET/CT evaluation of a novel ^{18}F-labelled lipophilic nipecotic acid-derived tracer for GAT1- imaging in rat brain

A. Florea[1,2], *N. Knippenberg*[3], *B. Altunay*[1], *O. Schijns*[4], *G. Hoogland*[4], *M. Sadeghzadeh*[1], *V. Ornelis*[3], *B. van Grinsven*[3], *H. Diliën*[3], *F. M. Mottaghy*[1,2], *M. Bauwens*[2];
[1]*Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, GERMANY,*
[2]*Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre+ (MUMC+), Maastricht, NETHERLANDS,*
[3]*Sensor Engineering Department, Faculty of Science and Engineering, Maastricht University, Maastricht, NETHERLANDS,*
[4]*Department of Neurosurgery, Maastricht University Medical Centre+ (MUMC+), Maastricht, NETHERLANDS.*

OP-543

PET/MRI imaging in an intracranial tumour model to assess uptake of ^{89}Zr-Df-ifabotuzumab-pyrrolobenzodiazepine across the blood brain barrier

I. Burvenich[1,2], *S. Menon*[1,2], *A. Rigopoulos*[1], *D. Cao*[1], *Z. Cao*[1,2], *C. W. Wichmann*[1,2], *P. W. Janes*[1,2], *H. K. Gan*[1,2,3], *A. M. Scott*[1,2,3];
[1]*Olivia Newton-John Cancer Research Institute, Heidelberg, AUSTRALIA,*
[2]*La Trobe University, Bundoora, AUSTRALIA,*
[3]*Austin Health, Heidelberg, AUSTRALIA.*

OP-544

In vivo evaluation of [^{11}C]UCB-1A: the first PET radioligand for imaging synaptic vesicle glycoprotein 2C (SV2C)

S. Nag[1], *V. Sousa*[1], *A. Morén*[1], *P. Datta*[1], *M. Tóth*[1], *Y. Khani Meynaq*[1], *R. Zou*[1], *A. Valade*[2], *C. Vermeiren*[2], *P. Motte*[2], *J. Mercier*[2], *H. Ågren*[3], *C. Halldin*[1,4], *A. Varrone*[1];
[1]*Karolinska Institutet, Stockholm, SWEDEN,*
[2]*UCB Biopharma, Braine l'Alleud, BELGIUM,*
[3]*Uppsala University, Uppsala, SWEDEN,*
[4]*Semmelweis University Dept. Biophysics and Radiation Biology, Budapest, HUNGARY.*

OP-545

Decoding microglia glucose metabolism by an in vivo snapshot of cellular glucose uptake in distinct microglia activation states

S. Wagner[1], *L. M. Bartos*[1,2], *V. Zenatti*[3], *D. Prtvar*[3], *S. Fixemer*[3], *C. Klaus*[3], *K. Nalbach*[3,4], *S. Müller*[3,4], *S. Lichtenthaler*[3,4,5], *J. Herms*[3,6,5], *L. Paeger*[3,6,5], *M. Prestel*[3], *R. A. Werner*[1], *J. Gnörich*[1], *L. von Baumgarten*[7,8], *N. L. Albert*[1], *S. Tahirovic*[3], *M. Brendel*[1,5,3];
[1]*Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY,*
[2]*Institute of Clinical Neuroimmunology, LMU Hospital, LMU Munich, Munich, GERMANY,*
[3]*German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, GERMANY,*
[4]*Neuroproteomics, School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich, Munich, GERMANY,*
[5]*Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY,*
[6]*Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität, Munich, GERMANY,*
[7]*University Hospital Munich (LMU), Faculty of Medicine and LMU University Hospital, Department of Neurosurgery, Munich, GERMANY,*
[8]*Bavarian Cancer Research Center (BZKF), Munich, GERMANY.*

OP-546

Evaluation of [^{11}C]CJ1-34 - a Promising CNS PET Agent for Imaging Mitochondrial Dysfunction in Alzheimer's Disease

L. Reichert, *A. Delparente, C. V. M. L. Jie, M. Schläppi, H. Guo, C. Keller, R. Schibli, L. Mu;*
ETH, Zurich, SWITZERLAND.

OP-547

Suppression of epileptic seizures by intracranial administration of astatine-labeled gold nanoparticles

H. Kato[1], *Y. Kadonaga*[2], *N. Shimada*[3], *D. Katayama*[4], *K. Ooe*[2], *X. Huang*[5], *Y. Kon*[6], *Y. Xiaojie*[7], *H. Haba*[7], *K. Kabayama*[5], *A. Toyoshima*[5], *K. Fukase*[5];
[1]*Department of Advanced Radioisotope Medicine, The University of Osaka Graduate School of Medicine, Suita, Osaka, JAPAN,*
[2]*Institute for Radiation Sciences, The University of Osaka, Suita, Osaka, JAPAN,*
[3]*Faculty of Medicine, The University of Osaka, Suita, Osaka, JAPAN,*
[4]*Department of Radiology, The University of Osaka Graduate School of Medicine, Suita, Osaka, JAPAN,*
[5]*Institute for Radiation Sciences, The University of Osaka, Toyonaka, Osaka, JAPAN,*
[6]*Research Center for Nuclear Physics, The University of Osaka, Suita, Osaka, JAPAN,*
[7]*Nishina Center for Accelerator-Based Science, RIKEN, Tokyo, JAPAN.*

OP-548

Evaluation of the Efficacy of FAP-Targeted CAR-Tregs in Improving Ventricular Remodeling Following Myocardial Infarction via Directed Immune Modulation

Z. Zhou, *C. Qin, D. Zheng, S. Wei, Y. Lv, Z. Dai, X. Lan;*
the Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, CHINA.

OP-549

Early Assessment of Doxorubicin-induced Myocardial injury Using D-SPECT, ^{18}F-FAPI PET, and Acetylcholine Provocation in a Porcine Model

J. Bai, *Y. Tian, N. Nan, H. Wang, J. Liu, H. Mi, W. Dong;*
Beijing Anzhen Hospital, Beijing, CHINA.

1205

Tuesday, October 20, 2026, 08:00 - 09:30

Hall B

Cutting Edge Science Track: AI Committee: AI Segmentation Methodologies

OP-550

A Generalized ^{3}D nnU-Net for Cross-Scanner Rodent Anatomical Segmentation in Micro-CT

R. Janssen[1], *G. T. Mastrorocco*[1], *L. De Smet*[2], *S. Vandenberghe*[1], *F. De Vos*[2], *C. Vanhove*[1], *B. van der Heyden*[1];
[1]*MEDISIP-INFINITY, Department of Electronics and Information Systems, Ghent University, Ghent, BELGIUM,*
[2]*Department of Pharmaceutical Analysis, Ghent University, Ghent, BELGIUM.*

OP-551

^{3}D nnU Net Deep Learning Segmentation of Ga 68 PSMA 11 PET/CT: Automated Prognostic Biomarker Extraction in Metastatic Castration Resistant Prostate Cancer

J. Mikolajczak, *A. Szabo, D. Waldmannstetter, D. Schmidt, J. Moosbauer, D. Weidt, D. Hellwig;*
University Hospital Regensburg, Regensburg, GERMANY.

OP-552

Learning When a Segmentation Is Good Enough: Physician-Acceptance and Correction-Effort Modeling for AI-Clinician Interactive Segmentation

N. Bayasi[1,2], ***F. Yousefirizi***[1,2], *A. Rahmim*[1,2];
[1]*University of British Columbia, Vancouver, BC, CANADA,*
[2]*BC Cancer Research Institute, Vancouver, BC, CANADA.*

OP-553

Translating FDG and PSMA PET Reports into Segmentation Constraints via Large Language Model-Based Lesion Extraction

L. Di Palma[1], *A. Macula*[2], *S. Gonella*[2], *M. Ali*[1,2], *F. Tedoldi*[2], *D. Fazzini*[1], *P. Gandolfo*[1,2];
[1]*CDI Centro Diagnostico Italiano, Milan, ITALY,*
[2]*Bracco Imaging S.p.A., Milan, ITALY.*

OP-554

Multicentre validation of a deep learning model for Paget's disease of bone lesion segmentation in bone scintigraphy

I. Correia[1,2], *F. P. M. Oliveira*[1], *R. S. Silva*[3], *C. S. Constantino*[1], *L. C. Silva*[1], *J. C. Castanheira*[1], *Â. F. Silva*[1], *N. Matela*[4,2], *D. C. Costa*[1];
[1]*Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, PORTUGAL,*
[2]*Faculdade de Ciências da Universidade de Lisboa, Lisbon, PORTUGAL,*
[3]*Nuclear Medicine Department, Centro Hospitalar Universitário de Santo António, Porto, PORTUGAL,*
[4]*Instituto de Biofísica e Engenharia Biomédica, Lisbon, PORTUGAL.*

OP-555

AI aided, human-in-the-loop, TMTV calculation in lymphoma research studies: The experience from the BIDIFLY-LYSA consortium.

S. Malmon[1], *Y. Al Tabaa*[2], *G. Henique*[3], *N. Taleb*[1], *T. Reichert*[4], *R. Metz*[5], *P. Viau*[6], *L. Vercellino*[7], *N. Deleval*[8], *D. Bessac*[9], *A. Cottereau*[10], *C. Antoine*[11], *I. Buvat*[3], *G. Cartron*[12], *C. Sarkozy*[13], *S. Kanoun*[1];
[1]*Pixilib, Toulouse, FRANCE,*
[2]*Scintidoc - Nuclear Medicine Center, Montpellier, FRANCE,*
[3]*Institut Curie - LITO, Paris, FRANCE,*
[4]*Nuclear Medicine Center - Institut Paoli-Calmettes, Marseille, FRANCE,*
[5]*Nuclear Medicine Center - CHU Nantes, Nantes, FRANCE,*
[6]*Nuclear Medicine Center - CHU Nice, Nice, FRANCE,*
[7]*Nuclear Medicine Center - CHU Saint-Louis, Paris, FRANCE,*
[8]*Nuclear Medicine Center - Institut Curie, Paris, FRANCE,*

[9]Nuclear Medicine Center - CHU Strasbourg, Strasbourg, FRANCE,
[10]Nuclear Medicine Center - CHU Cochin, Paris, FRANCE,
[11]Lysarc, Créteil, FRANCE,
[12]Hematology Department - CHU Montpellier, Montpellier, FRANCE,
[13]Hematology Department - Institut Curie, Paris, FRANCE.

OP-556

Automated Multi-Organ Segmentation in the Era of Total-Body Imaging: Evaluation of TotalSegmentator, CADS and MOOSE on Standard CT and LAFOV PET/CT Datasets

Q. Chen[1], *S. Gutschmayer*[2], *G. Cook*[3], *C. Duan*[4], *Z. Chang*[4], *M. Antonelli*[4], *A. Hammers*[5];
[1]King's College London, London, UNITED KINGDOM,
[2]QIMP Team, Medical University of Vienna, Vienna, AUSTRIA,
[3]School of Biomedical Engineering and Imaging Sciences, King's College London & PET Imaging Centre, Guy's and St Thomas' NHS Foundation Trust, London, UNITED KINGDOM,
[4]School of Biomedical Engineering and Imaging Sciences, King's College London, London, UNITED KINGDOM,
[5]School of Biomedical Engineering and Imaging Sciences, King's College London & PET Imaging Centre, Guy's and St Thomas' NHS Foundation Trust, London, UNITED KINGDOM.

OP-557

Unified Centiloid quantification via Contrast-agnositic Brain Segmentation

T. Sun[1], *M. Zhao*[2], *K. Guo*[3], *Y. Chen*[1], *F. Kang*[3], *F. Shi*[1], *D. Shen*[1,4];
[1]Department of Research and Development, United Imaging Intelligence, Shanghai, CHINA,
[2]Department of Nuclear Medicine, Peking University Third Hospital, Beijing, CHINA,
[3]Xijing Hospital, The Fourth Military University, Xi'An, Shaanxi, CHINA,
[4]School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, Shanghai Tech University, Shanghai, CHINA.

OP-558

Multicenter assessment of an automated AI-based lesion segmentation tool for detecting lymphoma on whole-body FDG PET/CT.

T. Masogo[1,2], *N. Zholshybek*[3,4], *P. Wadhwa*[4], *C. Kaoma*[1,2], *F. Bayembayev*[3], *K. Dileep*[4], *Y. Seebarruth*[5], *M. Sathekge*[1,2], *K. Ramonaheng*[1,2];
[1]Nuclear Medicine Research Infrastructure, Pretoria, SOUTH AFRICA,
[2]University of Pretoria & Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA,
[3]Nuclear Medicine Unit of the University Medical Center, Astana, KAZAKHSTAN,
[4]United Imaging Healthcare, Shanghai, CHINA,
[5]Jawaharlal Nehru Hospital, Rose Belle, MAURITIUS.

1206

Tuesday, October 20, 2026, 08:00 - 09:30
Hall C

Clinical Oncology Track: Gynaecological and Abdominal Malignancy

OP-559

First-in-human evaluation of [89Zr]Zr-DFO-B43.13 for CA125-targeted PET imaging of high-grade serous ovarian cancer: Preliminary results

H. Baker[1], *D. G. H. Hulse*[1], *R. Manavaki*[1], *L. Beer*[1], *V. Bura*[1], *T. D. Fryer*[1], *A. N. Priest*[1,2], *E. Crowe*[1], *C. Schmidt*[1], *A. Chhabra*[2], *L. M. T. Lechermann*[1], *J. Field-Rayner*[1], *L. C. Buckingham*[1], *V. C. Lupson*[1], *M. Wylot*[1], *M. J. Zamora Morales*[1], *S. Freeman*[2], *F. I. Aigbirhio*[1], *C. A. Parkinson*[1], *E. Sala*[1], *J. D. Brenton*[1], *D. J. Vugts*[3], *J. Ang*[2], *L. Aloj*[1];
[1]University of Cambridge, Cambridge, UNITED KINGDOM,
[2]Cambridge University Hospitals NHS Foundation Trust, Cambridge, UNITED KINGDOM,
[3]Amsterdam UMC, Amsterdam, NETHERLANDS.

OP-560

Comparative Evaluation of [68Ga] Ga-FAPI-04 PET Scan, CECT and Diagnostic Laproscopy for Peritoneal Carcinomatosis Detection in Ovarian Carcinoma: A Multimodal Imaging Study

P. HJ[1], *S. S. Prasanna*[1], *E. R. Shanbhag*[1], *V. Joshi*[1], *N. S. Verma*[1], *R. K. Chandrashekhar*[1], *P. Wadhwa*[2], *K. Aggarwal*[1], *M. K. Kallur*[1], *V. K. Ahuja*[1], *A. K. Rajgopal*[1];
[1]Aster Hospital, Banglore, INDIA,
[2]United Imaging Healthcare, Delhi, INDIA.

OP-561

F-18-FDG PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis in Ovarian Cancer: Preliminary Results from an International IAEA Multicenter Study

M. Jreige[1], *S. Sina*[2], *J. Gambini*[3], *S. Adnan*[4], *A. Golubic*[5], *H. Singh*[6], *N. Ali*[7], *M. Mititelu*[8], *F. Görtan*[9], *V. Artiko*[10], *K. Huseynzade*[11], *A. Aliev*[11], *D. Paez*[12], *F. Giammarile*[12], *O. Rollgeiser*[12], *A. Brink*[12], *P. Mathevet*[1], *J. Prior*[1], *M. Nicod Lalonde*[1], *F. Novruzov*[11];
[1]Lausanne University Hospital, Lausanne, SWITZERLAND,
[2]Shiraz University, Shiraz, IRAN, ISLAMIC REPUBLIC OF,
[3]University of Uruguay, Montevideo, URUGUAY,
[4]Institute of Nuclear Medicine and Oncology, Lahore, PAKISTAN,
[5]University Hospital Center Zagreb, Zagreb, CROATIA,
[6]Chandigarh University, Chandigarh, INDIA,
[7]Putrajaya National Cancer Institute, Putrajaya, MALAYSIA,
[8]Central Clinical Emergency Military Hospital, Bucharest, ROMANIA,
[9]Ankara City Hospital, Ankara, TÜRKIYE,
[10]University of Belgrade Faculty of Medicine, Belgrade, SERBIA,
[11]National Centre of Oncology, Baku, AZERBAIJAN,
[12]International Atomic Energy Agency, Vienna, AUSTRIA.

OP-562

Predictive Value of Fluorine-18 Fluoroestradiol PET/CT for Estrogen Receptor Expression in Endometrial Cancer Compared with Fluorine-18 Fluorodeoxyglucose PET/CT

M. Çidemal[1], *Ç. Soydal*[1], *G. Ç. Şendur*[1], *A. Gökçe*[1], *C. C. Ersöz*[1], *D. Enneli*[1], *S. Taşkın*[2], *M. Araz*[1], *N. Ö. Küçük*[1];
[1]Ankara University Faculty of Medicine, Ankara, TÜRKIYE,
[2]Memorial Göztepe Hospital, Istanbul, TÜRKIYE.

OP-563

Prognostic Significance of Metabolic Parameters in Patients with Vulvar Carcinoma Evaluated by Pre-Treatment F-18 FDG PET/CT

S. Kubat[1], *A. Dursun*[1], *C. Engür Uyanık*[1], *E. Tatcı*[1], *S. Baydemir*[2], *Ö. Özmen*[1];
[1]Health Sciences University, Ankara Etlik City Hospital, Nuclear Medicine Department, Ankara, TÜRKIYE,
[2]Health Sciences University, Ankara Etlik City Hospital, Gynecologic Oncology Department, Ankara, TÜRKIYE.

OP-564

[68Ga]Ga-FAPI-46 PET/CT for Assessment of Neoadjuvant Chemotherapy Response in Peritoneal Carcinomatosis: A Prospective Translational Study

A. Arçay Öztürk[1], *G. Liberale*[2], *J. Noel*[3], *W. Delbart*[4], *A. Deleu*[4], *E. Woff*[4], *R. Poenaru*[4], *L. Polastro*[5], *L. Theunissen*[4], *P. Kristanto*[6], *S. Vercauteren*[4], *C. Marin*[7], *L. Taraji*[4], *P. Flamen*[4];
[1]Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Anderlecht, BELGIUM,
[2]Department of Digestive Surgery and Digestive Surgical Oncology,Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Anderlecht, BELGIUM,
[3]Department of Pathology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Anderlecht, BELGIUM,
[4]Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Anderlecht, BELGIUM,
[5]Department of Medical Oncology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Anderlecht, BELGIUM,
[6]Clinical Biostatistics Unit, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Anderlecht, BELGIUM,
[7]Department of Medical Physics, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Anderlecht, BELGIUM.

OP-565

Optimized Threshold-Based Segmentation Approach for Response Assessment in SiTATE-PET/CT Response Assessment in GEP-NET Under Somatostatin Analogs

C. Dascalescu, *F. L. Herr, R. Ebner, L. A. Reichert, M. Fauter, I. Indzhiev, M. L. Schnitzer, M. M. Heimer, C. J. Auernhammer, J. Rübenthaler, L. Kumar Shiyam Sundar, J. Ricke, R. A. Werner, A. Holzgreve, C. C. Cyran;*
LMU Hospital, Munich, GERMANY.

OP-566

Molecular imaging and Long-term Clinical Outcomes of Type 1 Gastric Neuroendocrine Tumours

K. Saglam[1], *G. Beydağı*[2], *L. Kabasakal*[1], *O. Şahin*[1], *K. Akçay*[2], *S. Ergün*[1], *N. Alan*[2], *T. Toklu*[2], *S. Pekmezci*[1];
[1]Istanbul University-Cerrahpasa, Istanbul, TÜRKIYE,
[2]Yeditepe University Medical Faculty, Istanbul, TÜRKIYE.

OP-567

Head-to-head comparison of [18F]AlF-NOTA-JR11 and [68Ga]DOTA-JR11 PET imaging in neuroendocrine neoplasms

X. Ding[1], *X. Meng*[1], *Q. Xie*[1], *X. Jin*[1], *X. Su*[2], *J. Yu*[1];
[1]Peking University Cancer Hospital & Institute, Beijing, CHINA,
[2]Beijing United Imaging Healthcare Technology Development Co., Ltd, Beijing, CHINA.

1207

Tuesday, October 20, 2026, 08:00 - 09:30
Hall F1

Neuroimaging Committee: Tau PET and Beyond: Imaging Neurodegeneration

OP-568

Tau PET Fill States as Spatial Biomarkers for Alzheimer's Disease Staging and Differential Diagnosis

E. Doering[1], *G. Bischof*[2], *T. van Eimeren*[1], *N. Franzmeier*[3], *L. Frontzkowski*[3], *K. Giehl*[1], *J. Gnörich*[3], *G. Höglinger*[3], *J. Levin*[3], *R. Perneczky*[3], *M. Brendel*[3], *A. Drzezga*[1];
[1]Research Center Juelich, Juelich, GERMANY,
[2]University Hospital Cologne, Cologne, GERMANY,
[3]Department of Nuclear Medicine, University Hospital of Munich, Munich, GERMANY.

OP-569

Reproductive-Endocrine Factors Influence Medial Temporal Tau Pathology Burden and Accumulation in Women

M. Hoenig[1,2], *M. Seto*[2], *C. Birkenbihl*[2], *M. Cuppels*[2], *J. Brown*[2], *D. Townsend*[2], *T. Betthauser*[3], *C. Gleason*[3], *M. Bilgel*[4], *S. Resnick*[4], *S. O'Bryant*[5], *J. Caldwell*[3], *K. Cody*[3], *M. Properzi*[2], *A. Schultz*[2], *B. Hanseeuw*[2], *J. Manson*[6], *L. Mosconi*[7], *H. Joffe*[8], *M. Hickey*[9], *K. Johnson*[2], *R. Sperling*[2], *S. C. Johnson*[3], *R. Buckley*[2], *G. Coughlan*[2];
[1]Research Center Juelich, Juelich, GERMANY,
[2]Massachusetts General Hospital, Boston, MA, UNITED STATES OF AMERICA,
[3]University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, UNITED STATES OF AMERICA,
[4]Laboratory Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, UNITED STATES OF AMERICA,
[5]University of North Texas Health Science Center, Fort Worth, TX, UNITED STATES OF AMERICA,
[6]Brigham and Women's Hospital, Boston, MA, UNITED STATES OF AMERICA,
[7]Departments of Neuroscience, Neurology, and Radiology, Weill Cornell Medicine, New York, NY,

UNITED STATES OF AMERICA,
[8]Beth Israel Deaconess Medical Center, Boston, MA, UNITED STATES OF AMERICA,
[9]Royal Women's Hospital, The University of Melbourne, Parkville, AUSTRALIA.

OP-570

A Harmonized Visual Reading Framework for Tau PET Staging in Alzheimer Disease

***E. Van de Giessen**[1], E. Ruppert[2], M. R. Vermeiren[1], M. Scop Medeiros[2], G. Povala[2], C. Soares[2], A. Rocha[2], M. Scarpatto Rodrigues[2], M. Oliveira[2], R. Mroue[2], P. L. Ferreira[2], L. Amaral[2], G. Bauer-Negrini[2], F. Z. Lussier[2], B. Bellaver[2], J. Masdeu[3], D. L. Todurascu[2], T. Karikari[2], W. Jagust[4], D. N. Soleimani-Meigooni[5], J. Fortea[6], V. Lowe[7], H. Oh[8], B. Pascual[3], B. A. Gordon[9], P. Rosa-Neto[10], S. Baker[4], R. Ossenkoppele[1], T. A. Pascoal[2];*
[1]Amsterdam UMC, Amsterdam, NETHERLANDS,
[2]University of Pittsburgh, Pittsburgh, PA, UNITED STATES OF AMERICA,
[3]Houston Methodist Research Institute, Houston, TX, UNITED STATES OF AMERICA,
[4]Lawrence Berkeley National Laboratory, Berkeley, CA, UNITED STATES OF AMERICA,
[5]University of California San Francisco, Memory and Aging Center, San Francisco, CA, UNITED STATES OF AMERICA,
[6]Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN,
[7]Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA,
[8]Brown University, Providence, RI, UNITED STATES OF AMERICA,
[9]Washington University in St. Louis, St. Louis, MO, UNITED STATES OF AMERICA,
[10]McGill University, Montreal, QC, CANADA.

OP-571

Added value of semi-quantification on Tau-PET visual assessment in routine memory clinic practice

***L. Sofia**[1,2], G. Garelli[2,3], C. Steenhout[2,4], G. Mathoux[5], L. Mu[6], M. Scheffler[7], H. Zetterberg[8,9,10], N. J. Ashton[8,11,12], K. Blennow[8], G. Sambuceti[1], G. B. Frisoni[13,14], S. Morbelli[3], C. Boccalini[2], V. Garibotto[2,5,15];*
[1]Department of Health Sciences (DISSAL), University of Genoa, Genoa, ITALY,
[2]Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, SWITZERLAND,
[3]Department of Medical Sciences, University of Turin, Turin, ITALY,
[4]Division of Nuclear Medicine and Oncological Imaging, Department of Medical Physics, CHU of Liege, Liege, BELGIUM,
[5]Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, SWITZERLAND,
[6]Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, SWITZERLAND,
[7]Division of Radiology, Geneva University Hospitals, Geneva, SWITZERLAND,
[8]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, SWEDEN,
[9]Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, SWEDEN,
[10]Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, UNITED STATES OF AMERICA,
[11]Banner Alzheimer's Institute, Phoenix, AZ, UNITED STATES OF AMERICA,
[12]Banner Sun Health Research Institute, Sun City, AZ, UNITED STATES OF AMERICA,
[13]Geneva Memory Centre, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, SWITZERLAND,
[14]Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, SWITZERLAND,
[15]CIBM, Centre for Biomedical Imaging, University of Geneva, Geneva, SWITZERLAND.

OP-572

Hippocampal and basal ganglia tau deposition across the Alzheimer's disease continuum in Down syndrome

***P. Stefaneli Mormandi**[1,2], L. Vaqué-Alcázar[3,4,5], M. Franquesa-Mullera[3,6], M. Calls-Calahorro[1], Y. Delisau-Gil[1], P. Zaragoza-Ballester[1], M. Carmona-Iragui[3,7,8], S. Asadurova[1], J. Fortea[3,7,8], V. Camacho[1,2], A. Flotats[1,2];*
[1]Nuclear Medicine Department, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, Facultat de Medicina-Universitat Autònoma de Barcelona, Barcelona, SPAIN,
[2]Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, SPAIN,
[3]Sant Pau Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN,
[4]Department of Medicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Barcelona, SPAIN,
[5]Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SPAIN,
[6]Institut de Neurociències, Universitat Autònoma de Barcelona, Barcelona, SPAIN,
[7]Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, SPAIN,
[8]Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, SPAIN.

OP-573

Optimisation of the time window for quantification of early phase tau PET

***D. Peretti**[1], C. Boccalini[1], G. B. Frisoni[2,1], V. Garibotto[2,1];*
[1]University of Geneva, Geneva, SWITZERLAND,
[2]Geneva University Hospitals, Geneva, SWITZERLAND.

OP-574

Tau Deposition Across Braak Stages Drives Microstructural White Matter Damage in Alzheimer's Disease: A Multimodal PET/MRI Investigation

***G. Huang**[1], Y. Zhang[1], H. Shao[1], M. Xin[1], S. Gao[1], L. Qi[2], J. Hao[2], J. Liu[1], C. Zhang[1];*
[1]Department of Nuclear Medicine, Renji Hospital,Shanghai Jiaotong University School of Medicine, Shanghai, CHINA,
[2]United Imaging Healthcare, Shanghai, CHINA.

OP-575

Cerebrospinal fluid biomarkers of synaptic damage and neuroinflammation in the Alzheimer's disease continuum

***A. Agosti**[1], L. Bonino[2], S. Boschi[2], A. Chiarandon[2], G. Brodini[2], E. Piella[2], A. Cermelli[2], M. Zotta[1], G. Rovera[1], E. Rubino[2], I. Rainero[2], F. Roveta[2], S. Morbelli[1];*
[1]Nuclear Medicine Unit, AOU Città della Salute e della Scienza, University of Turin, Turin, ITALY,
[2]Aging Brain and Memory Clinic, Department of Neuroscience "Rita Levi-Montalcini", University of Turin, Turin, ITALY.

OP-576

Comparison of AMPA Receptor Density Across Tau Accumulation Using CenTauRz in MCI and Alzheimer's Diseases

***K. Tachibana**[1], M. Hatano[1], Y. Fujimoto[1], S. Tsugawa[1], W. Nakajima[1], T. Arisawa[1], S. Ichijo[1], A. Sano[1], Y. Katsuno[1], K. Takahata[2], M. Higuchi[2], H. Abe[1], T. Takahashi[1];*
[1]Department of Physiology, Yokohama City University, Yokohama City, JAPAN,
[2]Advanced Neuroimaging Center, National Institute of Radiological Sciences, National Institutes for Quantum Science and Technology, Chiba City, JAPAN.

1208

Tuesday, October 20, 2026, 08:00 - 09:30

Hall F2

Special Session - Oncology & Theranostics Committee: Imaging Companions for Non-Radioactive Targeted Therapy: Is There a Role?

OP-533

PET Imaging Companions for Antibody-Drug Conjugates and Other Targeted Agents: Current Evidence and Future Perspectives

C. Deroose;
University Hospitals Leuven, Nuclear Medicine, Leuven, BELGIUM.

OP-534

PET Imaging in Lymphoma and Myeloma Patients Treated with Chimeric Antigen Receptor T-Cells

F. Kraeber-Bodéré;
University Hospital Nantes, Nuclear Medicine Department, Nantes, FRANCE.

OP-535

Estrogen Receptor (ER)-Targeted PET for Guiding ER-Targeted and Endocrine Therapy

G. Ulaner;
Hoag Family Cancer Institute, Molecular Imaging and Therapy, Irvine, California, UNITED STATES OF AMERICA.

OP-536

HER-2 PET: A Promising Companion for Anti HER-2 Therapy

G. Gebhart;
Institute Jules Bordet, Nuclear Medicine, Brussels, BELGIUM.

1210

Tuesday, October 20, 2026, 08:00 - 09:30

Hall K

CTE 6 -Technologists + TMI&T Committee: Behind the Scenes in Translational Nuclear Medicine

OP-581

The Bridge Between Research and Patient Care in Nuclear Medicine

T. Buckle;
Leiden University Medical Center, Interventional Molecular Imaging Laboratory, Leiden, NETHERLANDS.

OP-582

Keeping Research Safe: Regulatory Insights for Translational Nuclear Medicine

L. Wendlinger;
Werner Siemens Imaging Center, Eberhard Karls University of Tübingen, Department of Preclinical Imaging and Radiopharmacy, Tübingen, GERMANY.

OP-583

How NMTs Turn Research Into Clinical Reality

M. Rosaria Ruggiero;
Fondazione Policlinico Universitario A. Gemelli IRCCS & Medipass Ergèa Group, GSTeP Radiopharmacy, Rome, ITALY.

1211

Tuesday, October 20, 2026, 08:00 - 09:30

Hall G1

EU Policy Symposium 1 - Policy & Regulatory Affairs Council: Radioligand Therapy in Europe: Regulation, Readiness and Patient Access

OP-584

Opening Keynote - The Strategic Importance of Radioligand Therapy for Europe's Health Systems

OP-585

State of Play - Preparing Healthcare Systems for the RLT Era

A.Chiti;
Humanitas University, Milan, ITALY.

OP-586

Regulation and Clinical Practice: Are We Getting the Balance Right?

C. Decristoforo; *EANM Policy & Regulatory Affairs Council member, Innsbruck, AUSTRIA.*

OP-587

RLT Angels: Building Excellence and Readiness Across Europe

1301

Tuesday, October 20, 2026, 09:45 - 11:15

Hall A

CME 10 - Thyroid Committee: Beyond Iodine: The New Era of Targeted Radiopharmaceutical Therapy for Thyroid Disease

OP-588

Radioiodine Therapy: Still Going Strong

A. Campenni;
University of Messina, Messina, ITALY.

OP-589

Understanding and Overcoming Radioiodine Resistance

F. Eilsberger;
Philipps University Marburg, Marburg, GERMANY.

OP-590

Theranostics in Medullary Thyroid Carcinoma: Where Are We Now?

M. Tuncel;
Hacettepe University Faculty of Medicine, Ankara, TÜRKIYE.

OP-591

Emerging Radiopharmaceuticals Beyond I-131: NIS and Alternative Targets

D. Deandreis;
Institute Gustave Roussy, Villejuif, FRANCE.

1302

Tuesday, October 20, 2026, 09:45 - 11:15

Hall D (Arena)

Special Track 10 - Physics Committee + IAEA: Debate: Towards Green Nuclear Medicine and Theranostics

OP-592

Green Healthcare Cannot Be Green Everywhere: Regional Realities Must Shape the Transition

D. Paez;
IAEA, Vienna, AUSTRIA.

OP-593

Green Healthcare Must Be Green Everywhere: Nuclear Medicine Must Accelerate Its Sustainability Transition

R. Hustinx;
University Hospital of Liège, Liège, BELGIUM.

1303

Tuesday, October 20, 2026, 09:45 - 11:15

Hall E1

LIPS Session 10 - Oncology & Theranostics Committee: FDG PET in Theranostics: Friend or Foe?

OP-594

Advantages and Pitfalls of FDG PET in Thyroid Cancer Theranostics

D. Deandreis;
Gustave Roussy, Villejuif, FRANCE.

OP-595

Advantages and Pitfalls of FDG PET in Neuroendocrine Neoplasms Theranostics

R. Laudicella;
Messina University, Messina, ITALY.

OP-596

Advantages and Pitfalls of FDG PET in Prostate Cancer Theranostics

I. Burger;
University of Zurich, Zurich, SWITZERLAND.

1304

Tuesday, October 20, 2026, 09:45 - 11:15

Hall E2

M2M Track: TROP Session - Radiopharmaceutical Sciences Committee: Upcoming Targets and Their Tracers

OP-597

High-contrast PET imaging of urothelial carcinoma and triple-negative breast cancer using Nectin-4-directed radiolabelled bicyclic peptides

R. Wodtke[1], *J. Trommer*[1], *T. Krönke*[1], *M. Ullrich*[1], *M. Laube*[1], *S. Hoberück*[2], *C. Thomas*[2], *M. Miederer*[2], *R. A. Bundschuh*[2], *S. Stadlbauer*[1], *K. Kopka*[1], *J. Pietzsch*[1];
[1]*Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY,*
[2]*University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, GERMANY.*

OP-598

Development and Preliminary Evaluation of a Dual-Target (PSMA/RET) PET Molecular Probe for Full-Stage Diagnosis of Prostate Cancer

L. Tang, *W. Wang, M. Zhou, S. Hu;*
XiangYa Hospital, Central South University, Changsha City, Hunan Province, CHINA.

OP-599

Preclinical Evaluation of ^{177}Lu-Labelled CD44v6-Targeted Full-Length and scFv Antibodies for Bladder Cancer Radioimmunotherapy

I. Lodewijk[1], *T. Xu*[1], *S. Rinne*[1], *M. Dueñas*[2,3,4], *M. Nestor*[1];
[1]*Department of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala University, Uppsala, SWEDEN,*
[2]*Cellular and Molecular Oncology and Genitourinary Tumor Group, Instituto de Investigación Sanitaria Hospital [12] de Octubre (imas[12]), Madrid, SPAIN,*
[3]*Molecular and Translational Oncology Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, SPAIN,*
[4]*Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, SPAIN.*

OP-600

Preclinical Evaluation of the Novel LRRC15-Targeted Nanobody Probe [^{68}Ga]Ga-NOTA-VHH92 for Immuno-Positron Emission Tomography Imaging Across Multiple Tumour Models

M. Li[1], *Z. Pan*[2], *Q. Cui*[1], *H. Yin*[2], *Y. Feng*[1], *X. Zhang*[1], *Y. Song*[1], *X. Wang*[1], *Y. Liu*[1], *Y. Gai*[1], *D. Jiang*[1], *J. Zhu*[3], *X. Lan*[1];
[1]*Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA,*
[2]*Asclevi Incorporated, Shanghai, CHINA,*
[3]*Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmaceutical Science, Shanghai Jiao Tong University, Shanghai, CHINA.*

OP-602

Preparation of a Novel ^{18}F-Labeled Bicyclic Peptide Imaging Agent and Its Application in Targeted Tumor MT1-MMP PET Imaging

J. Yang, *L. Qiu;*
The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China, CHINA.

OP-603

Exploration of Pentraxin-3 as a novel imaging target for inflammatory activity

X. Zhou, *W. Yang, F. Kang, J. Wang;*
department of nuclear medicine, Xi'an, CHINA.

OP-604

Trem2-Targeted PET for Pre-Treatment Stratification to Improve Anti-PD-1 Therapy Efficacy in Non-Small Cell Lung Cancer

X. Wang, *Y. Liu, Y. Feng, Z. Lin, W. Hu, H. Fang, J. Rong, X. Lan;*
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

OP-605

Optimization of the Arg8-Arg9 Cleavage Site in Neurotensin(6-13) Analogs for NTSR1-targeted PET Imaging of Cancer

S. Kaur[1,2], *S. Pathania*[1,2], *K. Yee*[1], *F. Cookson*[1], *P. Ng*[1], *H. Merkens*[1], *F. Benard*[1,2], *K. Lin*[1,2], *J. Lau*[1,2];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,*
[2]*The University of British Columbia, Vancouver, BC, CANADA.*

1305

Tuesday, October 20, 2026, 09:45 - 11:15

Hall B

Cutting Edge Science Track: AI Committee: AI Based Modeling for Patient Classification

OP-606

Effect of Encoding Classical Data to Quantum States on the Predictive Performance of Quantum AI Models in Cancer Classification

L. Papp[1], *D. Visvikis*[2], *M. Sollini*[3], *K. Shi*[4], *M. Kirienko*[5];
[1]*Medical University of Vienna, Vienna, AUSTRIA,*
[2]*INSERM, UMR [1101], LaTIM, University of Brest, Brest, FRANCE,*
[3]*IRCCS Ospedale San Raffaele, Milan, ITALY,*
[4]*University of Bern, Bern, SWITZERLAND,*
[5]*Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, ITALY.*

OP-607

Optimising [^{177}Lu]Lu-DOTATATE Therapy: Virtual Trials of Dosimetry-Guided and Adaptive Dosing Strategies

M. Macsuka[1], *B. Driscoll*[2,3], *I. W. T. Yeung*[4], *U. Metser*[5], *R. K. S. Wong*[2,6], *D. R. McGowan*[1,7], *K. A. Vallis*[1];
[1]*Department of Oncology, University of Oxford, Oxford, UNITED KINGDOM,*
[2]*Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CANADA,*
[3]*Techna Institute, University Health Network, Toronto, ON, CANADA,*
[4]*Southlake Regional Health Centre, Newmarket, ON, CANADA,*
[5]*Joint Department of Medical Imaging, University Health Network, Toronto, ON, CANADA,*
[6]*Department of Radiation Oncology, University of Toronto, Toronto, ON, CANADA,*
[7]*Department of Medical Physics and Clinical Engineering, Oxford University Hospitals NHS, Oxford, UNITED KINGDOM.*

OP-608

Towards Fully Automated PET RANO Parameter Extraction in Glioma

H. Lamprecht[1], *A. J. Zounek*[1], *R. Stürzl*[1], *E. Barci*[1], *E. Istrefi*[1], *J. Isakaj*[1], *K. J. Müller*[2], *V. Ruf*[3], *R. A. Werner*[1], *M. Brendel*[1], *L. von Baumgarten*[4], *S. Ziegler*[1], *L. Kaiser*[1], *N. L. Albert*[1],
L. K. S. Sundar[5];
[1]*Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY,*
[2]*Department of Neurology, LMU University Hospital, LMU Munich, Munich, GERMANY,*
[3]*Center for Neuropathology and Prion Research, Faculty of Medicine, LMU Munich, Munich, GERMANY,*
[4]*Department of Neurosurgery, LMU University Hospital, LMU Munich, Munich, GERMANY,*
[5]*Department of Radiology, LMU University Hospital, LMU Munich, Munich, GERMANY.*

OP-609

A Multi-Network Consensus Framework for Reliable and Reproducible Deep Radiomics in PET-Based Lung Cancer Survival Prediction

M. Luo[1,2], *A. Rahmim*[1,2,3], *M. R. Salmanpour*[1,2];
[1]*Faculty of Medicine, The University of British Columbia, Vancouver, BC, CANADA,*
[2]*Department of Basic and Translational Research, BC Cancer Research Centre, Vancouver, BC, CANADA,*
[3]*Departments of Physics and Biomedical Engineering, The University of British Columbia, Vancouver, BC, CANADA.*

OP-610

AIDriven Automated Deauville Scoring on FDG-PET/CT: A Transparent DecisionSupport Tool

E. Woff[1], *S. Bidgoli*[1], *A. Amrani*[2], *A. Gjukaj*[1], *M. Zekri*[1], *P. Flamen*[1], *O. Debeir*[2], *J. Dhont*[1];
[1]*Hôpital Universitaire de Bruxelles, Anderlecht, BELGIUM,*
[2]*Ecole Polytechnique de Bruxelles, Bruxelles, BELGIUM.*

OP-611

Artificial IntelligenceBased Lesion Detector Supports DecisionMaking Regarding the Need for Bone SPECT/CT Based on Planar Bone Scintigraphy

P. Czina[1], *C. Csikos*[1], *D. Csáki*[2], *S. Barna*[1,3], *Á. Budai*[1,3], *A. Balogh*[4], *B. Husztik*[4], *F. Nagy*[4], *I. Garai*[1,3];
[1]*University of Debrecen Clinical Centre, Institute of Nuclear Medicine, Debrecen, HUNGARY,*
[2]*University of Debrecen Faculty of Medicine, Debrecen, HUNGARY,*
[3]*Scanomed Ltd., Debrecen, HUNGARY,*
[4]*Mediso Ltd., Budapest, HUNGARY.*

OP-612

Automated quantitative analysis of FDG-PET/CT using AI-assisted PERCIST for response monitoring in metastatic breast cancer

M. Naghavi-Behzad[1,2,3], *N. M. Jakobsen*[1,3], *M. Vogsen*[4,2,1], *O. Gerke*[1,2], *E. Trägårdh*[5], *M. G. Hildebrandt*[1,2], *L. Edenbrandt*[6];
[1]*Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK,*
[2]*Department of Clinical Research, University of Southern Denmark, Odense, DENMARK,*
[3]*Shared first authorship, Odense, DENMARK,*
[4]*Department of Oncologi, Odense University Hospital, Odense, DENMARK,*
[5]*Department of Translational Medicine, Lund University, Malmö, SWEDEN,*
[6]*Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, SWEDEN.*

OP-613

Integration of Spatial Analysis and Deep Learning for Enhanced Tumour Classification in Total-Body PET/CT Imaging:Using Residual Deep Learning with Spatial Feature Augmentation and Cross-Validated Ensemble Learning

D. Han[1], *S. Wail*[2];
[1]*Telix Pharmaceuticals, Sydney, AUSTRALIA,*
[2]*Telix Pharmaceuticals, Melbourne, AUSTRALIA.*

OP-614

Artificial Intelligence Outperforms Semi-Quantitative Analysis in Detecting Coronary Artery Disease on Myocardial Perfusion Scintigraphy

H. Yildiz[1], *S. Karaçavuş*[1], *A. E. Yetkin*[2], *G. Ergün*[3], *F. Demir*[1], *H. Gençer*[1];
[1]*University of Health Sciences, Kayseri Faculty of Medicine, Department of Nuclear Medicine, Kayseri, TÜRKIYE,*
[2]*Boğaziçi University, Biomedical Engineering, Istanbul, TÜRKIYE,*
[3]*University of Health Sciences, Kayseri Faculty of Medicine, Department of Cardiology, Kayseri, TÜRKIYE.*

1306

Tuesday, October 20, 2026, 09:45 - 11:15

Hall C

Clinical Oncology Track: Radioembolisation and New Applications

OP-615

From Prediction to Proof in Y-90 Radioembolization: Tc-99m MAA Planning, Extrahepatic Traps, and Post-Therapy Imaging Findings

G. Kaya[1], *B. Volkan-Salanci*[2], *F. Çay*[3], *F. Eldem*[3], *M. Bozkurt*[2];
[1]*Republic of Türkiye, Ministry of Health, Yozgat City Hospital and Hacettepe Faculty of Medicine Depts. of Nuclear Medicine, Ankara, TÜRKIYE,*
[2]*Hacettepe University Faculty of Medicine, Dept. of Nuclear Medicine, Ankara, TÜRKIYE,*
[3]*Hacettepe University Faculty of Medicine, Dept. of Radiology, division of Vascular Interventional Radiology, Ankara, TÜRKIYE.*

OP-616

DOORwaY90 (NCT04736121): Selective Internal Radiation Therapy using SIR-Spheres Y-90 Resin Microspheres as first-line treatment for unresectable Hepatocellular Carcinoma patients

N. Kokabi[1], *A. Sarwar*[2], *G. Nadolski*[3], *E. Wehrenberg-Klee*[4], *D. Murrey*[5], *R. Gandhi*[6], *A. Mahvash*[7], *S. Kappadath*[7];
[1]*University of North Carolina, Chapel Hill, NC, UNITED STATES OF AMERICA,*
[2]*University of Pittsburgh Medical Center, Pittsburgh, PA, UNITED STATES OF AMERICA,*
[3]*Hospital of the University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA,*
[4]*Massachusetts General Hospital, Boston, MA, UNITED STATES OF AMERICA,*
[5]*Inland Imaging, Spokane, WA, UNITED STATES OF AMERICA,* [6]*, Miami Cancer Institute, Miami, FL, UNITED STATES OF AMERICA,*
[7]*The University of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.*

OP-617

ALBIomics: Integration of ^{18}F-FDG PET/CT Radiomics and ALBI Grade Predicts Outcome in Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization

E. Kaya[1], *M. Kaya*[1], *Ç. Erdim*[2], *A. Dablan*[2], *H. Özgül*[2], *D. Manalı*[3], *A. B. Dere*[4], *F. Gür*[5], *C. Şin*[6], *H. B. Kapucu*[1], *B. Esen Akkaş*[1];
[1]*Basaksehir Cam and Sakura City Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[2]*Basaksehir Cam and Sakura City Hospital, Department of Radiology, Istanbul, TÜRKIYE,*
[3]*Eastern Mediterranean University, Department of Electrical & Electronic Engineering, Famagusta, CYPRUS,*
[4]*Ağrı Training and Research Hospital, Department of Nuclear Medicine, Ağrı, TÜRKIYE,*
[5]*Osmaniye Training and Research Hospital, Department of Nuclear Medicine, Osmaniye, TÜRKIYE,*
[6]*Bagcılar Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE.*

OP-619

Initial Outcomes from the OSPREY Registry of Patients with Unresectable Locally Advanced Pancreatic Cancer Treated with EUS-Guided Phosphorus-32 Microparticles plus Gemcitabine-Based Chemotherapy in Routine Clinical Practice

S. Prado Wohlwend[1], *E. Tsaousidis*[2], *V. Pubul*[3], *V. Peiró-Valgañón*[4], *P. Oliván Sasot*[5], *G. Ventroni*[6], *F. Matteucci*[7], *A. Staudenherz*[8], *E. V. Caballero Calabuig*[9];
[1]*Hospital Universitario y Politécnico La Fe, Valencia, SPAIN,*
[2]*General Anticancer Oncological Hospital of Athens "Agios Savvas", Athens, GREECE,*
[3]*Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago de Compostela, SPAIN,*
[4]*Hospital Universtiario de Fuenlabrada, Madrid, SPAIN,*
[5]*Hospital Clínico Universitario de Valencia, Valencia, SPAIN,*
[6]*Azienda Ospedaliera San Camillo-Forlanini Hospital, Rome, ITALY,*
[7]*Azienda Unità Sanitaria Localle (AUSL) della Romagna, Forli-Cesena, ITALY,*
[8]*Universitätsklinikum St. Pölten, St. Pölten, AUSTRIA,*
[9]*Hospital Universitario Dr Peset, Valencia, SPAIN.*

OP-620

PRECISE: a pilot study of transarterial radioembolisation in recurrent glioblastoma

G. Ninatti[1,2], *H. Asadi*[1], *A. Owen*[1], *L. Cher*[1,2], *S. Ng*[1,2], *M. Brooks*[1], *K. Wilkie*[2], *A. Braat*[3], *A. M. Scott*[1,2], *H. Gan*[1,2];
[1]*Austin Health, Melbourne, AUSTRALIA,*
[2]*Olivia Newton-John Cancer Research Institute, Melbourne, AUSTRALIA,*
[3]*UMC Utrecht, Utrecht, NETHERLANDS.*

OP-621

Contribution of [^{18}F]AIF-FAPI-74 PET/CT in Clinically Challenging Oncologic Situations: Interim Analysis of a Prospective Multicenter Trial (FAPIDO)

J. Maes[1], *S. Stroobants*[2], *D. Van Weehaeghe*[3], *K. De Man*[3], *L. Boeckxstaens*[1], *W. Storms*[4], *K. Geboes*[3], *F. Cleeren*[4], *C. M. Deroose*[1];
[1]*UZ Leuven, Leuven, BELGIUM,*
[2]*UZ Antwerpen, Antwerpen, BELGIUM,*
[3]*UZ Gent, Gent, BELGIUM,*
[4]*KU Leuven, Leuven, BELGIUM.*

OP-622

Not All Lutetium Ticks the Same Clock: Disease-Specific Optimization of Post-Treatment SPECT/CT Timing in ^{177}Lu Theranostics

J. Koutsikos[1], *I. Papantoniou*[1], *G. Thiveos*[1], *A. Kokkini - Paschou*[1,2], *M. Stathopoulou*[1], *V. Pantzou*[1], *S. Bacalis*[2], *T. Petropoulos*[1], *E. Skoura*[1], *A. Velidaki*[3], *I. Datseris*[1];
[1]*Henry Dunant Hospital Center, Athens, GREECE,* [2401] *General Military Hospital of Athens, Athens, GREECE,*
[3]*Laiko General Hospital of Athens, Athens, GREECE.*

OP-623

Rhenium-188 epidermal brachytherapy for non-melanoma skin cancer in elderly patients: feasibility and results.

T. Gallanti, *J. M. Cordero García, R. de Moraes Souza, J. M. Busto Leis, M. Mayor Arenal, D. Monachello Araujo, S. Rizkallal Monzon, P. P. Portilla Merino, J. Otero Gonzalez, S. Soca, A. Mayor Ibarguren, C. Escabias Del Pozo, M. C. Lancha Hernandez, M. Coronado Poggio, S. Rodado Marina, L. Dominguez Gadea;*
Hospital Universitario La Paz, Madrid, SPAIN.

1307

Tuesday, October 20, 2026, 09:45 - 11:15

Hall F1

Paediatrics Committee: Shaping the Future: New Tracers and Emerging Applications in Nephrology

OP-624

Beyond FDG: CAIX-Targeted PET Achieves Near-Complete Tumor Detection in Renal Cell Carcinoma

E. Arslan[1], *H. Kömek*[2], *C. Can*[2], *E. Akgün*[1], *T. F. Çermik*[3], *R. Kılıç*[2], *Z. Urakçı*[4], *N. Akdeniz*[4], *A. R. Kural*[5];
[1]*University of Health Sciences, Istanbul Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[2]*University of Health Sciences, Diyarbakır Gazi Yaşargil Training and Research Hospital, Department of Nuclear Medicine, Diyarbakır, Türkiye, Diyarbakir, TÜRKIYE,*
[3]*Acibadem Maslak Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[4]*University of Health Sciences, Diyarbakır Gazi Yaşargil Training and Research Hospital, Department of Medical Oncology, Diyarbakır, TÜRKIYE,*
[5]*Acıbadem Maslak Hospital, Department of Urology, Istanbul, TÜRKIYE.*

OP-625

Revealing Kidney Fibrosis Activity Beyond Renal Tracer Retention with CTR-FAPI

L. Kang, *Y. Qiu, Y. Lei, J. Zhang, T. Wang, Q. Yang, Z. Chen;*
Dept. of Nuclear Medicine, Peking University First Hospital, Beijing, CHINA.

OP-626

Diagnostic Performance of ^{68}Ga-JH120061 PET/CT for Renal Cell Carcinoma

J. Zang, *G. Wang, Y. Lai, Y. Peng, W. Miao;*
The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, CHINA.

OP-627

[^{89}Zr]Zr-Girentuximab PET/CT for Characterization of Indeterminate Renal Masses: Diagnostic Performance and Clinical Impact in a Real-World Cohort

S. Rasul, *I. Resch-Huebner, I. Langrate, E. Patronas, S. Shariat, M. Schmidinger, M. Hacker;*
Medical University of Vienna, Vienna, AUSTRIA.

OP-628

Beyond Bosniak Classification: CA9-Targeted68Ga-NYM096 PET/CT for Characterizing Cystic Renal Masses

X. Yan[1], *J. Wang*[1], *M. Liu*[1], *H. Zhuo*[1], *G. Zheng*[2], *Y. Zhang*[2], *O. Sartor*[3], *D. Dong*[2], *W. Zhu*[1], *L. Huo*[1];
[1]*Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CHINA,*
[2]*Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CHINA,*
[3]*LCMC Health, Metairie, LA, UNITED STATES OF AMERICA.*

OP-630

Treatment Response and Recurrence in Paediatric Thyroid Cancer: A 45-Year Single-Centre Experience

D. Ozarslan, *F. Tamer, Z. Burak, Z. Ozcan;*
Ege University, Izmir, TÜRKIYE.

OP-631

Impact of post-therapy iodine-131 whole-body scintigraphy on disease staging and management in pediatric differentiated thyroid carcinoma: a single-center experience

N. Vasconcelos, *D. Silva, R. Marão, R. Lopes, L. Violante, F. Leite, A. Magalhães Ferreira, I. Lucena Sampaio;*
Instituto Português de Oncologia do Porto, Porto, PORTUGAL.

1308

Tuesday, October 20, 2026, 09:45 - 11:15

Hall F2

Radiation Protection Committee: Radiation Protection in Everyday Practice

OP-632

Invited Speaker

M. Vandecapelle;
Medical Applications, Federal Agency for Nuclear Control, Brussels, BELGIUM.

OP-633

Patient release after therapy with Lu-177 radiopharmaceuticals in HERCA member states

M. Vandecapelle[1,2], *N. Stritt*[1,3], *T. Bradshaw*[4], *A. Coniglio*[1,5], *J. Dalmo*[1,6], *M. Ditto*[7], *R. Elek*[1,8], *D. Fenton*[9], *A. Fremout*[2], *C. Fynbo*[1,10], *B. Godthelp*[1,11], *R. Hesselmann*[3], *J. Høiness*[1,12], *L. Ideström*[6], *L. McEneaney*[9], *P. Papirnik*[1,13], *M. Petcu*[1,14], *N. Pétursdóttir*[1,15], *M. Ramirez Vera*[1,16], *C. Salmon*[17], *M. Siegfried*[1,18], *J. Subina*[1,19], *A. Svobodova*[1,13], *S. Kaijaluato*[1,20];
[1]*Heads of European Radiological protection Competent Authorities (HERCA), Paris, FRANCE,*
[2]*Federal Agency for Nuclear Control (FANC), Brussels, BELGIUM,*
[3]*Federal Office for Public Health (BAG), Bern, SWITZERLAND,*
[4]*Care Quality Commission (CQC), London, UNITED KINGDOM,*
[5]*Ministry of Health, Rome, ITALY,*
[6]*Swedish Radiation Safety Authority (SSM), Stockholm, SWEDEN,*
[7]*Ministry of Health, Vienna, AUSTRIA,*
[8]*Hungarian Atomic Energy Authority (OAH), Budapest, HUNGARY,*
[9]*Environmental Protection Agency (EPA), Dublin, IRELAND,*
[10]*Danish Health Authority Radiation Protection (SIS), Copenhagen, DENMARK,*
[11]*Authority for Nuclear Safety and Radiation Protection (ANVS), The Hague, NETHERLANDS,*
[12]*Norwegian Radiation and Nuclear Safety Authority (DSA), Oslo, NORWAY,*
[13]*State Office for Nuclear Safety (SUJB), Prague, CZECH REPUBLIC,*
[14]*National Commission for Nuclear Activities Control (CNCAN), Bucharest, ROMANIA,*
[15]*Icelandic Radiation Safety Authority (GR), Reykjavik, ICELAND,*
[16]*Nuclear Safety Council (CSN), Madrid, SPAIN,*
[17]*Nuclear Safety and Radiation Protection Authority (ASNR), Paris, FRANCE,*
[18]*The Federal Ministry for the Environment, Climate Action, Nature Conservation and Nuclear Safety, Berlin, GERMANY,*
[19]*Estonian Environmental Board, Talinn, ESTONIA,*
[20]*Radiation and Nuclear Safety Authority (STUK), Helsinki, FINLAND.*

OP-634

Machine learning for discharge-time prediction in patient with differentiated thyroid cancer treated with ^{131}I

L. Garau[1,2], *R. Bologna*[1], *D. Capobianco*[1], *S. Schiattarella*[1], *M. Rensi*[1], *N. Ortolan*[1], *V. Rosso*[3], *L. Bastianutti*[1], *F. Di Gregorio*[1], *C. Cusano*[2];
[1]*Nuclear Medicine Unit, University Hospital, UDINE, ITALY,*
[2]*Department of Electrical, Computer and Biomedical Engineering, Pavia, ITALY,*
[3]*Medical Physics, University Hospital, UDINE, ITALY.*

OP-635

Early bedside count-rate monitoring to derive composite operational thresholds for bedside vigilance and urgent imaging in [^{177}Lu]Lutetium radioligand therapy

C. Garcia[1], *Y. Cras*[2], *A. Ndoumbe*[1], *E. Wattelet*[1], *A. Elima*[1], *K. Trabelsi*[1], *H. Noamen*[1], *M. Borsali*[1], *A. Daverio*[1], *L. Ferreol*[3], *P. Lacassagne*[3], *D. Deandreis*[1];
[1]*Nuclear Medicine Dpt. Gustave Roussy, Villejuif, FRANCE,*
[2]*Radiophysics Dpt. Gustave Roussy, Villejuif, FRANCE,*
[3]*Radiopharmacy. Gustave Roussy, Villejuif, FRANCE.*

OP-636

Can Administered I-131 Activity and Day-1 External Dose Rate Predict Isolation Duration After Radioiodine Therapy? Identifying Optimal Cut-offs

R. Wijaya, *R. Hanifatunnisa, F. Tarigan, R. Shintawati, T. As'ad, A. Gozian, A. Latuheru, P. Pratamadinata, B. Darmawan, H. Budiawan, A. Achmad, A. Kartamihardja;*
Faculty of Medicine, Universitas Padjadjaran, Bandung, INDONESIA.

OP-637

Optimization of Acquisition Time of Na[^{18}F]fluoride PET/CT in Patients with Fibrous Dysplasia

K. van Duuren[1], *L. A. Kloosterboer*[1], *P. Dibbets-Schneider*[1], *D. E. P. Muylaert*[1], *L. Heijmen*[1], *F. Smit*[2], *J. J. Goeman*[1], *N. M. Appelman-Dijkstra*[1], *L. de Geus-Oei*[1,3,4], *F. H. P. van Velden*[1];
[1]*Leiden University Medical Center, Leiden, NETHERLANDS,*
[2]*Alrijne Hospital, Leiderdorp, NETHERLANDS,*
[3]*University of Twente, Enschede, NETHERLANDS,*
[4]*Delft University of Technology, Delft, NETHERLANDS.*

OP-638

γ-H2AX Tracks for the Early Detection of Internal Exposure to α-emitters in Human Blood

I. Strobel[1], *H. Scherthan*[2], *S. Schumann*[1], *M. Salas-Ramirez*[1], *K. Blaurock*[1], *L. Göring*[1], *M. Lassmann*[1], *U. Eberlein*[1];
[1]*Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,*
[2]*Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, GERMANY.*

OP-639

Optimization of cerebral intra-arterial administration in radioligand therapy

E. Daru, *A. Flaus, C. Bolot, E. Levigoureux-Gervais, V. El-Jammal, C. Lachachi, M. Janier, V. Breant, S. Chaib;*
Hospices Civils de Lyon, Groupement Hospitalier Est, Lyon, FRANCE.

1310

Tuesday, October 20, 2026, 09:45 - 11:15

Hall K

Technologists' Track Oral Presentations 3 - Technologists Committee: Advancing Theranostics: Innovations in Therapy and Dosimetry

OP-640

Comparative Evaluation of Renal Dosimetry in Lutetium-177 DOTATATE and PSMA Therapies

R. Mishra[1], *A. Nazar*[2], *P. Pradhan*[2], *A. Kumar*[2];
[1]*Kamala Nehru Memorial Hospital, Prayagraj, INDIA,*
[2]*Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, INDIA.*

OP-641

Combination of [^{177}Lu]Lu-PSMA-617 and [^{177}Lu]Lu-TBM in Prostate Cancer: A Comparative Study of Safety and Survival Outcomes

Y. Liu, *Y. Chen, Z. Liu;*
Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, CHINA.

OP-642

Evaluation of Time-Point Selection Using a Prior-Information Approach for Single-Time-Point Dosimetry in ^{177}Lu-DOTATATE Therapy

A. Komatsu[1], *N. Miyaji*[1], *T. Yamao*[1], *K. Wachi*[1], *N. Akiya*[1], *M. Masubuchi*[1,2], *T. Horikawa*[1], *Y. Ogane*[1], *O. Kanno*[1], *S. Mashiko*[1], *A. Oishi*[3], *M. Morimoto*[3], *Y. Yamamoto*[4], *Y. Nishiyama*[4], *K. Miwa*[1];
[1]*Fukushima Medical University, Fukushima, JAPAN,*
[2]*National Cancer Center Japan, Kashiwa, JAPAN,*
[3]*Kagawa University Hospital, Kagawa, JAPAN,*
[4]*Kagawa University, Kagawa, JAPAN.*

OP-643

Optimal Reconstruction Parameters for Quantitative ^{177}Lu SPECT/CT Imaging in Absorbed Dose Estimation

N. Akiya[1], *N. Miyaji*[1], *T. Yamao*[1], *K. Wachi*[1], *M. Masubuchi*[1,2], *A. Komatsu*[1], *T. Horikawa*[1], *Y. Ogane*[1], *O. Kanno*[1], *S. Mashiko*[1], *A. Oishi*[3], *M. Morimoto*[3], *Y. Yamamoto*[4], *Y. Nishiyama*[4], *K. Miwa*[1];
[1]*Fukushima Medical University, Fukushima, JAPAN,*
[2]*National Cancer Center Japan, Kashiwa, JAPAN,*
[3]*Kagawa University Hospital, Kagawa, JAPAN,*
[4]*Kagawa University, Kagawa, JAPAN.*

OP-644

Dual PET Imaging in Neuroendocrine Tumor Patients Treated with [^{225}Ac]Ac-DOTATATE: The NETPET Score as a Prognostic Biomarker

Y. Liu, *T. Xu, Y. Chen;*
Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, CHINA.

OP-645

Implementation-Dependent Variability in Monte Carlo-Based Dosimetry for ^{177}Lu Targeted Radionuclide Therapy

M. Masubuchi[1,2], *K. Miwa*[2,3], *N. Miyaji*[3], *T. Yamao*[3], *N. Akiya*[2], *K. Wachi*[2], *A. Komatsu*[2], *T. Horikawa*[2], *M. Yoshimoto*[1], *A. Inaki*[1];
[1]*Division of Functional Imaging, Exploratory Oncology and Clinical Trial Center, National Cancer Center Japan, Kashiwa, JAPAN,*
[2]*Department of Radiological Sciences, Graduate School of Health Sciences, Fukushima Medical University, Fukushima, JAPAN,*
[3]*Department of Radiological Sciences, School of Health Sciences, Fukushima Medical University, Fukushima, JAPAN.*

OP-646

Impact of PET Reconstruction Protocols on ^{90}Y-SIRT Dosimetry Accuracy: A Monte Carlo Validation Study Using LAFOV PET

H. Zhang, *L. Huo;*
Peking Union Medical College Hospital, Beijing, CHINA.

OP-647

Analysis of image quality by regulating beta function of BSREM reconstruction algorithm and comparison with conventional reconstructions in NET

P. Sharma, *D. Jangid, A. Thombre, R. S. Meena, T. K. Jain, B. R. Mittal;*
Mahatma Gandhi Medical College and Hospital, Jaipur, INDIA.

OP-648

Comparison of two peristaltic pump-based infusion methods for [^{177}Lu]Lu-lutetium vipivotide tetraxetan administration

K. Tomsic, *K. Zaletel, D. Šfiligoj Planjšek, L. Jensterle;*
University medical centre Ljubljana, Ljubljana, SLOVENIA.

1311

Tuesday, October 20, 2026, 09:45 - 11:15

Hall G1

Special Symposium 5 - EANM Journals: Publishing in the AI Era: How Young Researchers Can Build Their Scientific Career

OP-649

What Editors Really Look for in a Manuscript

S. Minoshima;
The University of Utah, Department of Radiology and Imaging Sciences, Salt Lake City, UNITED STATES OF AMERICA.

OP-650

How to Use AI Without Compromising Scientific Integrity

M. Kirienko;
Foundation IRCCS National Cancer Institute, Milan, ITALY.

OP-651

From Reviewer to Editorial Board: Building Your Academic Reputation

L. Unterrainer;
LMU Hospital, Department of Nuclear Medicine, Munich, GERMANY.

1401

Tuesday, October 20, 2026, 11:30 - 13:00

Hall A

Plenary 3: Our Path to Sustained Scientific Success: How to Prepare for 2040

OP-653

Will Nuclear Medicine Break Its Own Neck? How to Overcome Toxic Leadership

OP-654

Are We Producing Results— Or Just Noise? How Standardisation Strengthens Nuclear Medicine Research

M. Schottelius;
Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne (UNIL), Depts. of Nuclear Medicine and of Oncology, Lausanne, SWITZERLAND.

OP-655

Fragmentation of Research: Nuclear Medicine Is Talking to Itself

R. J. Francis;
Australian Centre for Quantitative Imaging, University of Western Australia, Crawley, WA, AUSTRALIA.

OP-656a

Increasing Intellectual Output: Attenuation Correction for Female Contributions

N. Albert;
Ludwig Maximilian University Munich, Department of Nuclear Medicine, Munich, GERMANY.

OP-656b

Collaboration of Academia and Industry: Essential for Avoiding Extinction

D. Niepel;
Head Medical Affairs Int, Vice President, Paris, FRANCE.

OP-656c

Panel Discussion

E. Zan;
Cleveland Clinic, Division of Nuclear Medicine, Cleveland, Ohio, UNITED STATES OF AMERICA.

OP-656d

Panel Discussion

J. Czernin;
University of California at Los Angeles, Los Angeles County, California, UNITED STATES OF AMERICA.

1501

Tuesday, October 20, 2026, 15:00 - 16:30

Hall A

CME 11 - Radiation Protection Committee: Artificial Intelligence and Radiological Protection: Rethinking Justification and Decision-Making in the Era of Smart Nuclear Medicine

OP-657

Smarter Images, Safer Patients: How AI Enables Ultra-Low Dose PET and SPECT

C. Tsoumpas;
University Medical Center Groningen, Groningen, NETHERLANDS.

OP-658

Rethinking Justification: How AI Challenges Traditional Risk-Benefit Decisions

R. Seifert;
Universitätsspital Bern, Bern, SWITZERLAND.

OP-659

AI in Therapy Planning and Response Assessment: Decision Support or Decision Driver?

I. Buvat;
Institut Curie, Orsay, FRANCE.

OP-660

Trust and Robustness in AI-Driven Segmentation and Decision Support

A. Depeursinge;
CHUV (Centre Hospitalier Universitaire Vaudois), Lausanne, SWITZERLAND.

1502

Tuesday, October 20, 2026, 15:00 - 16:30

Hall A

Special Track 11 - Thyroid Committee: Challenge the Expert: Overdiagnosis in Thyroid Cancer: Balancing Early Detection with Clinical Significance

OP-661

Finding the Bad One: How to Diagnose (Clinically Relevant) Thyroid Cancer

A. Aghaee;
Qaem Academic Medical Center (Teaching, Research, and Clinical Care), Mashhad University of Medical Sciences, Nuclearmedicine Research Center, Mashhad, IRAN.

OP-662a

Challengers' Team

F. Eilsberger;
University Hospital Marburg, Department of Nuclear Medicine, Marburg, GERMANY.

OP-662b

Challengers' Team

P. Mossel;
Leiden University Medical Center (LUMC), Radiology/ Nuclear Medicine and Molecular Imaging, Leiden, NETHERLANDS.

OP-662c

Challengers' Team

I. Marín-Melero;
Clinique Notre-Dame de Grâce (CNDG), Department of Nuclear Medicine, Charleroi, BELGIUM.

OP-662d

Challengers' Team

A. Thies;
University Hospital Magdeburg, Division of Nuclear Medicine, Magdeburg, GERMANY.

OP-662e

Challengers' Team

L. Elshof;
University Medical Centre Utrecht, Radiology & Nuclear Medicine, Utrecht, NETHERLANDS.

1503

Tuesday, October 20, 2026, 15:00 - 16:30

Hall E1

LIPS Session 11 - Bone & Joint Committee: Joint EANM/ESNR/Eurospine Guideline on Bone SPECT/CT in Suspected Facet Joint Arthropathy and Non-Infectious Post Operative Spine Conditions

OP-665

Facet Joints

T. Van den Wyngaert;
Antwerp University Hospital, Department of Nuclear Medicine, Antwerp, BELGIUM.

OP-666

Post Operative Spine

R. Graham;
Royal United Hospitals Bath NHS Foundation Trust, Department of Nuclear Medicine and Radiology, Bath, UNITED KINGDOM.

OP-667

The Spine Surgeon's Perspective – What do They Want to Know?

F. Wong;
Guy's & St. Thomas's NHS Foundation Trust, Spinal Surgery Department, London, UNITED KINGDOM.

1504

Tuesday, October 20, 2026, 15:00 - 16:30

Hall E2

M2M Track: TROP Session - Radiopharmaceutical Sciences Committee: Advances in Theranostic Tracers

OP-669

A Novel ACP3-Targeted Radiotracer ^{68}Ga/^{177}Lu-NY129 for Molecular Imaging of Prostate Cancer

P. Fang, *Z. Huang, X. Lv, G. Cheng, C. Fan, S. Yang;*
Norroy bioscience Co., Ltd, Wuxi, CHINA.

OP-670

A B7-H3-Targeted Antibody-Drug Conjugate-Based Theranostic Platform for Lung Cancer: Integration of ^{89}Zr-ImmunoPET and ^{177}Lu-Targeted Radionuclide Therapy

Z. Chen, *T. Kang, L. Kang;*
Peking University First Hospital, Beijing, CHINA.

OP-671

A Novel GPC3-Targeting Peptide for HCC Radiotheranostics: Preclinical Evaluation

P. Fang, *Z. Huang, X. Lv, S. Yang;*
Norroy bioscience Co., Ltd, Wuxi, CHINA.

OP-672

Development and preclinical evaluation of TT331, a novel TROP2-targeted monoclonal antibody for ^{89}Zr/^{161}Tb theranostics in solid Tumours

K. Pettersson Palm[1], *J. Siikanen*[1], *M. Godzwon*[2], *J. Andréll*[3], *K. Åkerberg Schriever*[3], *N. Thalén*[3], *J. Ytterberg*[4], *L. Dahllund*[3], *M. Ohlin*[5], *A. Roos*[3], *P. I. Arvidsson*[3], *R. Altena*[1], *T. Foukakis*[1], *K. Bratteby*[1], *T. A. Tran*[1];
[1]*Karolinska Institutet, Solna, SWEDEN,*
[2]*SciLifeLab, Lund, SWEDEN,*
[3]*SciLifeLab, Solna, SWEDEN,*
[4]*SciLifeLab, Uppsala, SWEDEN,*
[5]*Karolinska Institutet, Lund, SWEDEN.*

OP-673

Preclinical Evaluation of a ^{68}Ga/^{177}Lu-Labeled CD38-Targeted Cyclic Peptide for Radiopharmaceutical Imaging and Therapy of Multiple Myeloma

Y. Wang, ***M. Zheng****, S. Ge, Q. Liu, L. Miao;*
First Affiliated Hospital of Soochow University, Suzhou, CHINA.

OP-674

Development of Theranostic Radiopharmaceutical FC516 Targeting ACP3 for Prostate Cancer

Y. Zhong[1], *Z. Yin*[1], *C. Xi*[2], *H. Fu*[2], *L. Chen*[2], *H. Tai*[1], *H. Liu*[1], *Y. Zhang*[1], *S. Wu*[1], *S. Shi*[1], *M. Sun*[1], *X. Yuan*[1], *N. Xi*[1], *C. Yu*[2];
[1]*Findcure Biosciences (Zhongshan) Co., Ltd., Zhongshan, CHINA,*
[2]*Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, Wuxi, CHINA.*

OP-675

Theranostic Potential of VHH Domains (Nanobodies) Targeting MUC16 Expression in Pancreatic Cancer

C. Bimela[1], *A. Kankanamge*[2], *E. Nwangele*[1], *D. Fon*[1], *T. Mercado*[2], *J. Broqueza*[2], *F. Njotu*[1], *J. Pougoue Ketchemen*[1], *M. Khosravifarsani*[1], *K. Bato*[1], *A. Ngong*[1], *L. Athili*[1], *H. Fonge*[1], *M. Uppalapati*[2];
[1]*Université Laval, Quebec City, QC, CANADA,*
[2]*University of Saskatchewan, Saskatoon, SK, CANADA.*

OP-676

Novel nastorazepide-based radioligands demonstrate excellent Cholecystokinin-2 Receptor targeting and theranostic potential

L. Bohrmann[1], *D. Novak*[2,3], *R. H. Gaongkar*[1], *M. Kroselj*[2,3], *M. Fani*[1], *P. Kolenc*[2,3], *M. Anderluh*[3], *R. Mansi*[1];
[1]*University Hospital Basel, Basel, SWITZERLAND,*
[2]*University Medical Centre Ljubljana, Ljubljana, SLOVENIA,*
[3]*University of Ljubljana, Ljubljana, SLOVENIA.*

OP-677

Carbostyril-attached bifunctional chelators for Tb-based radio-luminescent dual-modality theranostics

D. Zhang[1,2], *J. Mang*[1,2], *S. McNeil*[1,2], *H. Meeres*[1,3], *L. Wharton*[1], *M. Bergamo*[1], *C. Rodriguez-Rodriguez*[4], *H. Merkens*[5,6], *F. Bénard*[5,6], *H. Yang*[1,2,7];
[1]*Life Sciences Division, TRIUMF, Vancouver, BC, CANADA,*
[2]*Department of Chemistry, University of British Columbia, Vancouver, BC, CANADA,*
[3]*Interdisciplinary Oncology, University of British Columbia, Vancouver, BC, CANADA,*
[4]*Center for Comparative Medicine, University of British Columbia, Vancouver, BC, CANADA,*
[5]*Department of Molecular Oncology, BC Cancer, Vancouver, BC, CANADA,*
[6]*Department of Radiology, University of British Columbia, Vancouver, BC, CANADA,*
[7]*Department of Chemistry, Simon Fraser University, Burnaby, BC, CANADA.*

1505

Tuesday, October 20, 2026, 15:00 – 16:30

Hall B

Cutting Edge Science Track: Dosimetry Committee: From Clinical Dosimetry to Treatment Adaptation in ^{177}Lu Therapy

OP-678

Dose-response Analysis in Patients with Gastroenteropancreatic Neuroendocrine Tumours Receiving ^{177}Lu-edotreotide

A. Flaus[1], *H. Amthauer*[2], *E. Martínez Albero*[3], *E. Deshayes*[4], *J. B. Ćwikła*[5], *N. Mulholland*[6], *J. L. Vercher-Conejero*[7], *R. Lebtahi*[8], *G. Kong*[9], *A. Kluge*[10], *E. Huber*[11], *L. Kaiser*[11], *A. García Burillo*[12];
[1]*Hopital Louis Pradel, Bron, FRANCE,*
[2]*Charité - Universitätsmedizin Berlin, Berlin, GERMANY,*
[3]*Hospital Universitario 12 de Octubre, Madrid, SPAIN,*
[4]*Institut du Cancer de Montpellier Val d'Aurelle, Montpellier, FRANCE,*
[5]*GAMMED Centrum Diagnostyczno-Lecznicze, Warszawa, POLAND,*
[6]*King's College Hospital, London, UNITED KINGDOM,*
[7]*Bellvitge University Hospital, Barcelona, SPAIN,*
[8]*Hôpital Beaujon, Université Paris-Cité, Clichy, FRANCE,*
[9]*Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA,*
[10]*ABX-CRO advanced pharmaceutical services, Dresden, GERMANY,*
[11]*ITM Oncologics GmbH, Garching, GERMANY,*
[12]*Vall Hebron Institute of Oncology, Barcelona, SPAIN.*

OP-679

Analysis of Cycle-by-Cycle and Total Lesional Absorbed Dose (AD) vs. Change in Tumor Size 6 Months Post-therapy in GEP-NET Patients Treated with ^{177}Lu-DOTATATE: Importance of High AD in Early Cycles

F. Lin[1], *J. del Rivero*[1], *J. Zou*[1], *I. Shamis*[1], *L. Lindenberg*[1], *E. Mena-Gonzalez*[1], *I. B. Turkbey*[1], *T. Magee*[1], *Y. Teng*[2], *C. Millo*[3], *P. Herscovitch*[3], *R. Maass-Moreno*[3], *S. Adler*[1], *P. Choyke*[1], *J. Carrasquillo*[1,4];
[1]*National Cancer Institute, Bethesda, MD, UNITED STATES OF AMERICA,*
[2]*American Association of Colleges of Osteopathic Medicine, Bethesda, MD, UNITED STATES OF AMERICA,*
[3]*National Institutes of Health, Bethesda, MD, UNITED STATES OF AMERICA,*
[4]*Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.*

OP-680

Time Dependent Red Marrow-to-Blood Activity Concentration Ratios Challenge Blood-Based Dosimetry in [^{177}Lu]Lu-DOTA-TATE Therapy

T. Monserrat Fuertes[1], *J. Hemmingsson*[2], *P. Mínguez Gabiña*[3], *A. Álvarez Amigo*[1], *C. Díaz Aviñó*[1], *G. V. P. Prado*[1], *D. P. Suárez*[1], *M. A. Peinado Montes*[1], *P. Bernhardt*[2,4];
[1]*Hospital Universitario Central de Asturias, Oviedo, SPAIN,*
[2]*Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg, SWEDEN,*
[3]*Hospital Universitario Cruces/Gurutzeta, Bilbao, SPAIN,*
[4]*Sahlgrenska University Hospital, Gothenburg, SWEDEN.*

OP-681

Accounting for partial volume effects makes baseline tumoral SUVmean from ^{177}Lu-PSMA SPECT prognostically comparable to ^{68}Ga-PSMA PET

S. Heyer[1], *C. Boursier-Joppin*[1], *A. Zouaoui*[2], *S. Melki*[2], *P. Olivier*[1], *M. Claudin*[2], *P. Marie*[1], *L. Imbert*[1];
[1]*Department of Nuclear Medicine, CHRU Nancy, Nancyclotep Imaging Platform and IADI, INSERM, U*[1254]*, Nancy, FRANCE,*
[2]*Department of Nuclear Medicine, CHRU Nancy, Nancyclotep Imaging Platform, Nancy, FRANCE.*

OP-682

Modeling Lesion Dynamics in [^{177}Lu]Lu-PSMA RPT: Contributions of Systemic Clinical Covariates

N. Cavedini[1,2], *V. Zolkina*[2], *A. Riznychenko*[2], *U. Nemer*[3], *W. Noordzij*[2], *A. Marques da Silva*[4], *C. Moriguichi Jeckel*[1], *M. Mix*[3], *O. Ivashchenko*[2];
[1]*Graduate Program of Biomedical Gerontology, School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, BRAZIL,*
[2]*Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, NETHERLANDS,*
[3]*Department of Nuclear Medicine, Faculty of Medicine, University of Freiburg Medical Center, Freiburg, GERMANY,*
[4]*Hospital das Clínicas, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, BRAZIL.*

OP-683

Biology-informed pre-therapy dose mapping for [^{177}Lu]Lu-PSMA therapy with dual-tracer PSMA/FDG PET

S. Xue[1], *s. wen*[1], *A. A. Nikolic*[2], *S. Dintner*[3], *R. A. Bundschuh*[4], *M. Hacker*[5], *X. Li*[6], *C. Lapa*[2];
[1]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna Gene, Vienna, AUSTRIA,*
[2]*Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY,*
[3]*Pathology, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY,*
[4]*Department of Nuclear Medicine, University Hospital Carl Gustav Carus at the TU Dresden, Dresden, GERMANY,*
[5]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna, AUSTRIA,*
[6]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna, AUSTRIA.*

OP-684

Cycle-to-Cycle Prediction of Absorbed Dose in [^{177}Lu]Lu-PSMA-617 Therapy Using Radiomic and Dosiomic Features from Prior SPECT/CT Imaging

P. Geramifar[1], *E. Yazdani*[1,2], *I. Klyuzhin*[1,3], *A. Dhalla*[1], *F. Farhadi*[3], *B. Saboury*[3,4], *C. Uribe*[1,4,5], *A. Rahmim*[1,4,5], *P. Esquinas*[1,4,5];
[1]*Ascinta Technologies Inc., Vancouver, BC, CANADA,*
[2]*Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,*
[3]*Institute of Nuclear Medicine, Bethesda, MD, UNITED STATES OF AMERICA,*
[4]*BC Cancer, Vancouver, BC, CANADA,*
[5]*University of British Columbia, Vancouver, BC, CANADA.*

OP-685

From Population to Patient: Can Cycle 1 ^{177}Lu-PSMA-617 Dosimetry Guide Individual Therapy? Results from Pan-Canadian PR21 trial (NCT04663997)

S. Kurkowska[1], *P. L. Esquinas*[2], *X. Hou*[2], *N. Colpo*[1], *C. Williams*[1], *C. Dellar*[3], *W. Parulekar*[3], *F. Saad*[4], *K. Zukotynski*[5], *K. Chi*[2], *J. M. Beauregard*[6,7], *F. Benard*[1], *C. Uribe*[1];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,*
[2]*BC Cancer Agency, Vancouver, BC, CANADA,*
[3]*Canadian Cancer Trials Group, Kingston, ON, CANADA,*
[4]*University of Montreal Hospital Center, Montreal, QC, CANADA,*
[5]*McMaster University, Hamilton, ON, CANADA,*
[6]*Department of Radiology and Nuclear Medicine, Université Laval, Quebec City, QC, CANADA,*
[7]*Division of Nuclear Medicine, Department of Medical Imaging, CHU de Québec - Université Laval, Quebec City, QC, CANADA.*

OP-686

Correlation-Informed Residual Learning for Pretherapy Prediction of Voxel-Wise Time-Integrated Activity Maps in [^{177}Lu]Lu-PSMA-617 Radioligand Therapy

Y. Chen, *J. Hu, R. Seifert, A. Rominger, A. Afshar-Oromieh, K. Shi;*
Department of Nuclear Medicine, Inselspital, University of Bern, Bern, SWITZERLAND.

1506

Tuesday, October 20, 2026, 15:00 – 16:30

Hall C

Clinical Oncology Track: Prostate Cancer Staging

OP-687

Use of PSMA PET/CT for primary metastatic staging of prostate cancer in routine clinical practice: a nationwide analysis.

C. C. Loeff[1,2], *P. J. van Leeuwen*[3], *I. G. Schoots*[4,5], *K. K. H. Aben*[2,6], *D. E. Oprea-Lager*[1], *B. L. Heesterman*[2];
[1]*Department of Medical Imaging, Radboud university medical center, Nijmegen, NETHERLANDS,*
[2]*Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, NETHERLANDS,*
[3]*Department of Urology, Netherlands Cancer Institute*

- Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS,
[4]Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, NETHERLANDS,
[5]Department of Radiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS,
[6]Science department IQ Health, Radboud university medical center, Nijmegen, NETHERLANDS.

OP-688

A Dual Tracer PET Imaging Analysis of the Prospective Exploratory Biodistribution Trial NCT04457232: FAP vs. PSMA in Patients with Prostate Cancer

A. Holzgreve[1,2], *K. Kimura*[2], *Y. M. Arias Gonzalez*[2], *S. Lira*[2], *A. T. Nguyen*[2], *L. M. Unterrainer*[2,3], *C. E. Mona*[2], *K. Flores*[4], *A. E. Sisk Jr.*[4], *M. B. Rettig*[5,6], *J. Czernin*[2], *J. Calais*[2];
[1]Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY,
[2]Department of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine at UCLA, Los Angeles, CA, UNITED STATES OF AMERICA,
[3]Department of Nuclear Medicine, TUM Munich, Munich, GERMANY,
[4]Department of Pathology, University of California Los Angeles (UCLA), Los Angeles, CA, UNITED STATES OF AMERICA,
[5]Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, UNITED STATES OF AMERICA,
[6]Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA, UNITED STATES OF AMERICA.

OP-689

Segmentation Threshold Determines Reconstruction Sensitivity of PSMA-PET/CT Volumetry in mCRPC

E. Schötz, *D. Ufton, J. Weindler, M. Schmidt, K. S. Roth, A. Drzezga, C. Kobe;*
University Hospital of Cologne, Department of Nuclear Medicine, Cologne, GERMANY.

OP-690

Evaluation of Diagnostic Performance and Safety of Flotufolastat F-18 (XTR020) PSMA-Targeted PET Imaging in Biochemically Recurrent Prostate Cancer After Prior Therapy: A Single-arm, Multicenter Phase III Trial

R. Wang[1], *X. Zhang*[1], *Y. Liu*[1], *H. Zhou*[1], *S. Niu*[1], *J. Yang*[2], *B. Long*[3], *Z. Wang*[3], *X. Wang*[4], *D. Gu*[4], *B. Han*[5], *J. Zhao*[5], *S. Xu*[6], *L. Jiang*[7], *Y. Wang*[8], *Z. Zhang*[9], *F. Li*[9], *J. Zhou*[10], *W. Xue*[11], *J. Liu*[11], *Y. Wang*[12];
[1]The First Medical Center, Chinese PLA General Hospital, Beijing, CHINA,
[2]Beijing Friendship Hospital, Capital Medical University, Beijing, CHINA,
[3]Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, CHINA,
[4]The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CHINA,
[5]Shanghai General Hospital, Shanghai, CHINA,
[6]Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, CHINA,
[7]Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, CHINA,
[8]The Second Hospital of Tianjin Medical University, Tianjin, CHINA,
[9]The Second Affiliated Hospital of Anhui Medical University, Hefei, CHINA,
[10]The First Affiliated Hospital of Anhui Medical University, Hefei, CHINA,
[11]Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA,
[12]Medical Department, Sinotau Pharmaceutical Group, Beijing, CHINA.

OP-691

Intra-patient comparison of osseous lesions without morphological correlate in [^{18}F]PSMA-1007 PET/CT to [^{18}F]piflufolastat in prostate cancer patients

W. Bosbach, *A. D. Sidandy, A. Rominger, A. Afshar-Oromieh;*
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Swi, Bern, SWITZERLAND.

OP-692

Bone metastases on ^{18}F-sodium fluoride PET/CT in newly diagnosed prostate cancer: is imaging needed in intermediate-risk disease?

C. Madsen[1], *H. D. Zacho*[2], *R. Bisbjerg*[3], *D. Fuglø*[4], *P. B. Østergren*[3];
[1]Department of Nuclear Medicine, Copenhagen University Hospital Herlev and Gentofte, Herlev, DENMARK,
[2]Department of Nuclear Medicine and Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, DENMARK,
[3]Department of Urology, Copenhagen University Hospital Herlev and Gentofte, Herlev, DENMARK,
[4]Department of Nuclear Medicine, Herlev Hospital, Herlev, DENMARK.

OP-693

Whole-Prostate ^{68}Ga-PSMA PET/CT Radiomics With XGBoost Improves Multicenter Detection of Clinically Significant Prostate Cancer: a Multicenter Study

Y. Tang[1], *L. Xiao*[1], *J. Yang*[1], *Y. Li*[1], *K. Shi*[2], *S. Hu*[1];
[1]Xiangya Hospital Central South University, Changsha, CHINA,
[2]Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.

OP-694

^{99}mTc-MIP-1404 SPECT/CT for primary staging of prostate cancer (PROSTAMIP): a prospective randomized phase III trial

S. Malaspina[1], *M. Seppänen*[2], *T. Noponen*[3], *M. Anttinen*[4], *L. Eklund*[4], *T. Tommila*[5], *K. Timonen*[6], *J. Raiko*[1], *J. Kemppainen*[1], *J. Schildt*[7], *L. Nummelin*[1], *M. Högerman*[8], *I. Rinta-Kiikka*[9], *J. Ronkainen*[9], *E. Saukko*[10], *I. Kohonen*[10], *P. Boström*[5], *O. Ettala*[5];
[1]Turku PET Centre,University of Turku and Turku University Hospital, Turku, FINLAND,
[2]Department of Clinical Physiology, Nuclear Medicine and Turku PET Centre,University of Turku and Turku University Hospital, Turku, FINLAND,
[3]Department of Medical Physics and Nuclear Medicine, University of Turku and Turku University Hospital, Turku, FINLAND,
[4]Department of Urology, University of Turku and Turku University Hospital, Turku, FINLAND,
[5]Department of Urology, University of Turku and Turku University Hospital, Turku, FINLAND,
[6]Department of Clinical Physiology and Nuclear Medicine, Central Hospital of Central Finland, Jyväskylä, FINLAND,
[7]Department of Clinical Physiology and Nuclear Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, FINLAND,
[8]Department of Biostatistics, University of Turku, Turku, FINLAND,
[9]Department of Radiology, Tampere University and Tampere University Hospital, Tampere, FINLAND,
[10]Department of Diagnostic Radiology, University of Turku and Turku University Hospital, Turku, FINLAND.

OP-695

^{99}mTc PSMA SPECT/CT is superior to bone scan, SPECT or SPECT/CT at detecting bone metastases from prostate cancer

M. Baehr[1], *J. Borggrefe*[1], *T. M. Hoang*[2], *K. Liepe*[3];
[1]Ruhr University Bochum, Minden, GERMANY, [2]free statistician, Duesseldorf, GERMANY,
[3]General Hospital Frankfurt (Oder), Frankfurt (Oder), GERMANY.

1507

Tuesday, October 20, 2026, 15:00 – 16:30
Hall F1

Case Report Session 1: Cases Worth Telling

OP-696

Radioembolization in PediatricOnset Sporadic Medullary Thyroid Carcinoma: A Rare Case Report

N. Vasconcelos, *D. Silva, R. Marão, R. Lopes, M. Arantes, F. Leite, L. Violante, I. Lucena Sampaio;*
Instituto Português de Oncologia do Porto, Porto, PORTUGAL.

OP-697

Superiority of PSMA PET/CT in identification of brain metastasis in TNBC patient

M. Mehesen[1], *R. Shera*[1], *D. Deif*[1], *T. ElMaghraby*[2];
[1]National Cancer Institute, Cairo university, Cairo, EGYPT,
[2]Faculty of medicine, Cairo university, Cairo, EGYPT.

OP-698

Partial Splenic Embolisation as a Bridging Strategy to Peptide Receptor Radionuclide Therapy in Pancreatic Neuroendocrine Tumour With Left-Sided Portal Hypertension-Related Thrombocytopenia

C. Turkan[1], *E. B. İman*[1], *F. Çay*[2], *S. Yalçın*[3], *M. Tuncel*[1];
[1]Hacettepe University, Department of Nuclear Medicine, Ankara, TÜRKIYE,
[2]Hacettepe University, Department of Radiology, Ankara, TÜRKIYE,
[3]Hacettepe University, Department of Medical Oncology, Ankara, TÜRKIYE.

OP-699

Hormone receptor targeted PET/CT with [^{18}F] Fluoroestradiol and gastrin releasing peptide receptor agonist in recurrent metastatic hormone receptor-positive breast cancer

L. Fenzl[1], *J. S. Enke*[1,2], *L. Glanschtnig*[1], *C. Lapa*[1], *D. Nina*[3,4], *R. A. Werner*[5], *M. Zacherl*[5], *A. Holzgreve*[5], *J. Brosch-Lenz*[1], *A. Dierks*[1];
[1]Department of Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY,
[2]Department of Nuclear Medicine and Theranostics, David Geffen School of Medicine, University of California, Los Angeles, CA, UNITED STATES OF AMERICA,
[3]Gynecology, Obstetrics and Senology, Faculty of Medicine, University of Augsburg, Breast Center, University Hospital Augsburg, CCC Alliance WERA, Augsburg, GERMANY,
[4]Bavarian Cancer Research Center (BZKF), Augsburg, GERMANY,
[5]Department of Nuclear Medicine, LMU University Hospital, Munich, GERMANY.

OP-700

[^{68}Ga]Ga-SSA PET/CT reveals an unexpected breast metastasis in malignant insulinoma.

D. J. Tamayo-Ossa, *A. Bagán-Trejo, J. L. Vercher-Conejero, J. J. Martín-Marcuartu, J. L. Díaz-Moreno, B. Hervás-Sanz, M. Zamorano-Rivas, M. Cortés-Romera;*
Nuclear Medicine-PET (IDI) Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

OP-701

FDG PET/CT detection of neurolymphomatosis in relapsed Burkitt lymphoma with excellent early response to intrathecal and systemic therapy

B. Alencar, *M. Osmak, T. Agnello, B. Amorim, C. Ramos, E. Etchebehere, M. Lima;*
Unicamp, Campinas, São Paulo, Brazil, BRAZIL.

OP-702

Agonist Trap Unmasked -DOTANOC Fibroid Mimicry Resolved by NODAGA-JR11 Antagonist PET

M. K. Taggar, *S. A. Shamim, G. Arora;*
All India Institute Of Medical Sciences, New Delhi, INDIA.

OP-703

Dual-Tracer PET Assessment of Complete Amyloid and Tau Clearance in a Male Patient With Alzheimer Disease

Y. Chang, *R. Wang;*
Chinese PLA General Hospital, Beijing, CHINA.

OP-704

Subtle FDG PET/CT Findings in a Catastrophic Case of Intravascular Large B-Cell Lymphoma

W. Wong;
Queen Elizabeth Hospital, Hong Kong, HONG KONG.

1508

Tuesday, October 20, 2026, 15:00 - 16:30
Hall F2

Joint Symposium 7 - Cardiovascular Committee / EACVI: Stiff Heart, Think Amyloidosis

OP-705

From the Clinical Points of View, What Else Do We Need?
D. Neglia;
Fondazione Toscana Gabriele Monasterio, Cardiovascular Department, Pisa, ITALY.

OP-706

Do We Need Signal Quantification?
S. Ben-Heim*;*
Hadassah Medical Center, Jerusalem, ISRAEL.

OP-707

Improved Phenotyping

OP-708

Treatments and the Role of Imaging in Follow-Up

1510

Tuesday, October 20, 2026, 15:00 - 16:30
Hall K

CTE 7 - Technologists Committee / ESTRO: Theranostics: Bridging Nuclear Medicine and Radiotherapy for Better Cancer Treatment

OP-709

Theranostics: Principles and the Role of Nuclear Medicine in Precision Oncology
M. Cuzzocrea*;*
Ente Ospedaliero Cantonale (EOC), Tessin, SWITZERLAND.

OP-710a

Theranostics in Clinical Trial Quality Assurance: Multidisciplinary Collaboration and Future Directions
E. Miles*;*
East And North Hertfordshire Teaching NHS Trust, Hertfordshire, UNITED KINGDOM.

OP-710b

NMTIC - Theranostics Consortium
K. Pathmaraj;
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, AUSTRALIA.

1511

Tuesday, October 20, 2026, 15:00 - 16:30
Hall G1

EU Policy Symposium 2 - Policy & Regulatory Affairs Council: Accelerating Clinical Trials in Nuclear Medicine: From Regulation to Implementation

OP-711

ACT EU: Building a More Efficient and Harmonised Environment for Clinical Trials in Europe
M. Lunzer*;*
Chair of the European Medicines Agency Clinical Trials Coordination Group, Vienna, AUSTRIA.

OP-712

Breaking Down Barriers: Advancing Non-Commercial Clinical Trials in Nuclear Medicine Across Europe
L. Evangelista*;*
EANM Representative to ACT EU, Milan, ITALY.

OP-713

From Protocol to Patient: Practical Lessons from Multinational Academic Trials in Europe
W. Van der Graaf*;*
European Organisation for Research and Treatment (EORTC) President, Amsterdam, NETHERLANDS.

OP-714

Moderated Multi-Stakeholder Panel Discussion - Turning ambition into action: What will it take to accelerate nuclear medicine trials in Europe?
N. Albert;
LMU Hospital, Ludwig Maximilians University, Munich, GERMANY.

1601

Tuesday, October 20, 2026, 16:45 - 18:15
Hall A

CME 12 - AI Committee: Large Language Models in Nuclear Medicine

OP-715

Principles of LLMs
C. Hinge*;*
Technical University of Denmark, Copenhagen, DENMARK.

OP-716

Enhancing Nuclear Medicine Education with LLMs for Clinicians and Patients
P. Koller*;*
University Bern, Bern, SWITZERLAND.

OP-717

LLMs for Report Generation in Nuclear Medicine
M. Kassar*;*
University Bern, Bern, SWITZERLAND.

OP-718

LLMs Across the Research Workflow
W. Roll*;*
University Clinic Münster, Münster, GERMANY.

1602

Tuesday, October 20, 2026, 16:45 - 18:15
Hall D (Arena)

Special Track 12 - Neuroimaging Committee: Debate: Early Amyloid and Tau Perfusion vs FDF PET

OP-719

Point of View: Early Amyloid and Tau Perfusion Imaging Can Be Reliably Used as a Proxy for FDG
S. Morbelli*;*
AOU Citta' della Salute e della Scienza di Torino, Turin, ITALY.

OP-720

Point of View: Early Amyloid and Tau Perfusion Imaging Cannot Be Substitute of FDG
H. Barthel*;*
Municipal Hospital Dessau, Dessau-Roßlau, GERMANY.

1603

Tuesday, October 20, 2026, 16:45 - 18:15
Hall E1

LIPS Session 12 - Radiation Protection Committee: What Would You Do if...? Radiation Protection Issues in Special Cases of Everyday Practices

OP-721

How to Handle Huge Contaminations
A. Stenvall*;*
Radiation Physics, Skåne University Hospital, Lund, SWEDEN.

OP-722

Dosimetry in Case of Extravasation
S. Medici*;*
Lausanne University Hospital, Lausanne, SWITZERLAND.

OP-723

Waste Management: What Would You Do if Radioactive Waste of the Clinic Were Found in a Landfill?
J. Allmann*;*
Department of Nuclear Medicine, Technical University Munich, Munich, GERMANY.

OP-724

Radiation Exposure and Risk Communication to Caregivers, Relatives, Accompanying Persons, or Non-Exposed Workers.
P. Covens*;*
Department of Molecular Imaging and Therapy, University of Brussel - VUB, Brussel, BELGIUM.

1604

Tuesday, October 20, 2026, 16:45 - 18:15
Hall E2

M2M Track: TROP Session - Radiopharmaceutical Sciences Committee: Making the Most of a FAP-ulous Target

OP-725

Heterobivalent Radioligands Improve Tumor Volume Control in Fibroblast-Activation Protein α (FAP) Positive Tumours
T. Bailly*, J. Millul, M. Fani;*
Universitätsspital Basel, Division of Radiopharmaceutical Chemistry, Basel, SWITZERLAND.

OP-726

Extraction, Radiolabeling and Preclinical Evaluation of Novel [^{177}Lu]Lu-KRT83/31 for FAP-Targeted Radioligand Theranostics of Solid Tumor
S. Das[1,2]*, M. Guleria*[2,3]*, R. Bhattacharya*[1]*, T. Das*[2,3]*, S. Dhara*[1]*;*
[1]*Indian Institute of Technology Kharagpur, Kharagpur, INDIA,*
[2]*Bhabha Atomic Research Center, Mumbai, INDIA,*
[3]*Homi Bhabha National Institute, Mumbai, INDIA.*

OP-727

Advancing FAPI-Based Theranostics: Comparative Preclinical Evaluation of Two Homodimeric Constructs
N. Kumar[1,2]*, A. Bilinska*[1,2,3]*, E. Menendez*[1,2]*, F. Rösch*[4]*, A. Rominger*[1,2]*, E. Gourni*[1,2]*;*
[1]*Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND,*
[2]*Department of Biomedical Research, University of Bern, Bern, SWITZERLAND,*
[3]*Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, SWITZERLAND,*
[4]*Department of Chemistry–TRIGA site, Johannes Gutenberg-University Mainz, Mainz, GERMANY.*

OP-729

[^{161}Tb]Tb-FAPI theranostics guided by [^{68}Ga]Ga-FAPI PET/CT for myocardial fibrosis in a pressure-overload mouse model
W. Wang*, J. Zhang, M. Zhou, J. Liu, R. Shi, S. Hu;Xiangya Hospital of Central South University, Changsha, CHINA.*

OP-730

Design, Synthesis, Preclinical Characterization and First-in-Human Evaluation of [^{68}Ga]GaNYM052, a Novel Fibroblast Activation Protein-Targeted Radiotracer

J. Li, *W. Chong, L. He, Y. Mo, L. Zhang, X. Mu, W. Fu;*
Affiliated Hospital of Guilin Medical University, Guilin, CHINA.

OP-731

FAP-Targeted Radioligand Therapy Combined with PD-L1 Blockade in Immune-Excluded Melanoma Is Associated with Interferon-γ-Linked Antigen Presentation Signatures, Including NLRC5-Associated Genes

S. So[1,2,3], *H. Oh*[1,3,2], *J. Lee*[2], *J. Zhang*[4], *X. Chen*[4], *K. Kang*[2,5,3], *H. Youn*[2,3,6], *G. Cheon*[2,3,7];
[1]*Seoul Nation University, Seoul, KOREA, REPUBLIC OF,*
[2]*Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,*
[3]*Cancer Research Institute, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF,*
[4]*Department of Diagnostic Radiology, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore, SINGAPORE,*
[5]*Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, KOREA, REPUBLIC OF,*
[6]*Cancer Imaging Center, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,*
[7]*Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, Seoul, KOREA, REPUBLIC OF.*

OP-732

A novel dual-targeted FAP/TROP2 PET probe, [^{68}Ga] Ga-FAPI-TTP, for enhanced tumor imaging across heterogeneous epithelial malignancies

Y. Pei, *X. Guo, Z. Yang;*
Peking University Cancer Hospital & Institute, Department of Nuclear Medicine, Beijing, CHINA.

OP-733

Early Visualization and Prognostic Evaluation of Radiation-Induced Heart Injury Using the Dual-Targeted Tracer FAPI-RGD

J. Pei, *Y. Pang, S. Wang, J. Liu, J. Yu;*
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Me, Jinan, CHINA.

1605

Tuesday, October 20, 2026, 16:45 - 18:15

Hall B

Cutting Edge Science Track: Physics Committee: Quantitative PET: Harmonisation and Robustness

OP-734

Standardization of image quality and activity quantification in a multi-centre PET imaging study (Ex-PET)

J. Lagerstedt[1], *J. Siikanen*[1], *E. Ilan*[2], *S. Kvernby*[3], *A. Kistner*[1], *T. Tran*[1], *O. Wiklander*[1], *R. Altena*[4], *C. Hindorf*[1];
[1]*Karolinska University Hospital, Stockholm, SWEDEN,*
[2]*Akademiska Sjukhuset, Uppsala, SWEDEN,*
[3]*Skåne University Hospital, Lund, SWEDEN,*
[4]*Karolinska Institutet, Stockholm, SWEDEN.*

OP-735

Anthropomorphic STEP BRAIN phantom: an intercomparison across Italian PET scanners

L. Fedeli[1], *A. Martini*[2], *B. Alfano*[3], *M. Quarantelli*[4], *D. Cecchin*[5], *M. Pirozzi*[6], *S. Rossella*[5], *S. Fanti*[7], *V. Berti*[8], *F. Magnani*[9], *D. Donner*[9], *P. Bertolaccini*[10], *U. Guerra*[11], *L. Mansi*[12], *S. Sestini*[2];
[1]*USL Toscana Centro, -, ITALY,*
[2]*USL Toscana Centro, Prato, ITALY,*
[3]*Human Shape Technologies, Naples, ITALY,*
[4]*IBB, CNR, Naples, ITALY,*
[5]*NM Unit, DIMED, UNIPA, Padua, ITALY,*
[6]*Dept. Advanced Medical Surgical Sciences, UNICA, Naples, ITALY,*
[7]*NM, IRCCS AOUB, UNIBO, Bologna, Italy, Bologna, ITALY,*
[8]*NM Unit, AUOC, UNIFI, Firenze, ITALY,*
[9]*NM Unit, S. Chiara Hospital, Trento, ITALY,*
[10]*NM Unit, AUSLNO, Massa Carrara, ITALY,*
[11]*NM, Fond. Poliambulanza, Brescia, ITALY,*
[12]*CIRPS, Roma, ITALY.*

OP-736

Optimisation of [^{18}F]FDG dosage for quantitative whole-body PET: ensuring image quality anthropometric independency and EARL harmonisation

I. Baltabaev[1,2], *A. Khalimon*[1], *A. Nikiforuk*[1], *M. Khodzhibekova*[1], *I. Pylova*[1], *T. Lazutina*[1], *D. Khodakova*[1], *A. Leontev*[1], *E. Bezumova*[2];
[1]*P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION,*
[2]*N.N. Blokhin National Medical Research Centre of Oncology of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.*

OP-737

Robustness of Long Axial Field of View PET to Defective Detector Blocks: Impact on Quantitative Accuracy and Clinical Tolerability

K. Vrakidis[1,2], *W. Lan*[3], *D. Bharkhada*[4], *P. M. Linder*[3], *M. Yaqub*[1,2], *C. la Fougère*[3,5], *R. Boellaard*[1,2], *F. P. Schmidt*[3,6];
[1]*Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS,*
[2]*Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, NETHERLANDS,*
[3]*Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tübingen, Tübingen, GERMANY,*
[4]*Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA,*
[5]*Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, GERMANY,*
[6]*Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tübingen, Tübingen, GERMANY.*

OP-738

Preliminary Investigation of the Impact of Detector Gaps on Spatial Resolution in a Long Axial FOV PET System

I. Torres Espallardo[1], *S. Dietrich*[2], *C. González Avilés*[3], *M. E. Strugari*[2], *Á. Anreus*[3], *V. Bernabeu Rodriguez*[4], *R. Díaz Expósito*[4], *L. Martí Bonmatí*[4], *A. J. González*[3];
[1]*Clinical Area of Medical Imaging, Valencia, SPAIN,*
[2]*Research Institute La Fe, Valencia, SPAIN,*
[3]*Instituto de Instrumentación para Imagen Molecular (I*^{3}*M), Valencia, SPAIN,*
[4]*Clinical Area of Medical Imaging, H La Fe, Valencia, SPAIN.*

OP-739

Digital-BGO vs. digital-LSO PET/CT image noise and contrast: Does higher NEMA sensitivity meet or surpass the 'effective sensitivity' of TOF?

J. Kennedy, *T. Palchan Hazan, Z. Keidar;*
Rambam - Health Care Campus, Haifa, ISRAEL.

OP-740

The impact of learning-based reconstruction algorithms on quantitative features of PET/MR images

X. Meng[1], *X. Su*[2], *Y. Yang*[2], *Z. Yang*[1];
[1]*Peking University Cancer Hospital, Beijing, CHINA,*
[2]*Beijing United Imaging Healthcare Technology Development Co., Ltd., Beijing, CHINA.*

OP-741

A Multi-Center Harmonization Initiative for Total-Body [^{18}F]FDG-PET/CT of Healthy Controls

M. Eldevik[1,2], *C. Loisel*[3], *C. Hinge*[4], *S. Gutschmayer*[5], *M. Pires*[5], *A. H. Dias*[1,2], *I. Buvat*[3], *O. L. Munk*[1,2], *F. L. Andersen*[4,6], *T. Beyer*[5];
[1]*Department of Nuclear Medicine, Aarhus University Hospital, Aarhus, DENMARK,*
[2]*Department of Clinical Medicine, Aarhus University, Aarhus, DENMARK,*
[3]*IRIS Inserm, CNRS, Institut Curie, PSL University, Versailles Saint-Quentin University, Orsay, FRANCE,*
[4]*Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, DENMARK,*
[5]*QIMP Team, Medical University of Vienna, Vienna, AUSTRIA,*
[6]*Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DENMARK.*

OP-742

Population-Based Mapping of Metastatic Distribution in Prostate Cancer Using PSMA PET/CT and SPECT/CT

F. Yousefirizi[1], *P. Yazdi*[1], *P. L. Esquinas*[2], *C. Uribe*[2];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,*
[2]*BC Cancer, Vancouver, BC, CANADA.*

1606

Tuesday, October 20, 2026, 16:45 - 18:15

Hall C

Clinical Oncology Track: Prostate Cancer: New Imaging Applications

OP-743

Standardized PSMA-PET Enables Reproducible Imaging-Based Risk Stratification: External Validation of PPP3 Nomograms

G. Alcin[1], *W. P. Fendler*[1], *M. J. Karpinski*[1,2], *C. Civan*[1], *S. Hoberück*[3], *A. Vrachimis*[4], *W. Tao*[5], *M. Sathekge*[6], *F. Mattana*[7], *A. Maman*[8], *D. F. Arslan*[9], *A. Kibar*[10], *W. Wei*[11], *K. Herrmann*[1], *B. Hadaschik*[12], *K. Rahbar*[2], *T. Maurer*[13];
[1]*Department of Nuclear Medicine, DKTK and NCT University Hospital Essen, Essen, GERMANY,*
[2]*Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY,*
[3]*Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, GERMANY,*
[4]*Department of Nuclear Medicine, German Medical Institute, European University Cyprus, Limassol, CYPRUS,*
[5]*Department of Nuclear Medicine, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, CHINA,*
[6]*Department of Nuclear Medicine, University of Pretoria, Pretoria, SOUTH AFRICA,*
[7]*Division of Nuclear Medicine and Theranostics, IEO European Institute of Oncology, IRCCS, Milano, ITALY,*
[8]*Department of Nuclear Medicine, Faculty of Medicine, Ataturk University, Erzurum, TÜRKIYE,*
[9]*Department of Nuclear Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, TÜRKIYE,*
[10]*Department of Nuclear Medicine, Faculty of Medicine, Trakya University, Edirne, TÜRKIYE,*
[11]*Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA,*
[12]*Department of Urology, University Hospital Essen, Essen, GERMANY,*
[13]*Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, GERMANY.*

OP-744

Added Prognostic Value of FDG PET over PSMA PET in Metastatic Castration-Resistant Prostate Cancer

J. Passoni[1], *G. Rovera*[2,3,4], *L. Sofia*[1], *C. Garcia*[4], *A. Di Giorgio*[5], *M. Donegani*[6], *S. Raffa*[6], *A. Farolfi*[7], *R. Piva*[6], *S. Chiola*[6], *V. Pau*[6], *S. Ratti*[6], *G. Sambuceti*[1,6], *S. Morbelli*[2,3], *D. Deandreis*[4], *G. Marra*[3], *M. Bauckneht*[1,6];
[1]*Department of Health Sciences (DISSAL), University of Genova, Genoa, ITALY,*
[2]*Nuclear Medicine Unit, AOU Città della Salute e della Scienza di Torino, Turin, ITALY,*
[3]*Department of Medical Sciences, University of Turin,*

Turin, ITALY,
[4]Nuclear Medicine Department, Institute Gustave Roussy, Villejuif, FRANCE,
[5]Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,
[6]IRCCS Azienda Ospedaliera Metropolitana, Genoa, ITALY,
[7]Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria Di Bologna, Bologna, ITALY.

OP-745

Baseline PSMA/FDG Dual-Tracer PET Lesion Phenotypes Predict Prognosis in HSPC Patients Treated with ADT

H. Zhang[1], *Y. Jia*[1], *M. Hacker*[1], *X. Li*[1], *J. Liu*[2], *X. Zhou*[2], *S. Xue*[1];
[1]Medical University of Vienna, Vienna, AUSTRIA,
[2]Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.

OP-746

Impact of Specific Activity on Physiological Standardised Uptake Values in ^{18}F-Flotufolastat Positron Emission Tomography: A Post-hoc Analysis of the LIGHTHOUSE and SPOTLIGHT Trials

R. Penny[1], *J. O'Doherty*[2], *S. Rahman*[1], *E. Teoh*[1];
[1]Blue Earth Diagnostics, Oxford, UNITED KINGDOM,
[2]Blue Earth Diagnostics, Needham, MA, UNITED STATES OF AMERICA.

OP-747

Intra-patient Comparison of PSMA-PET Imaging with ^{64}Cu-RAX301 and ^{68}Ga-PSMA-11 in Prostate Cancer Diagnosis

G. Chen[1], *F. Chen*[2], *M. Hong*[1], *J. Li*[2], *G. Han*[1], *Z. Li*[2], *S. Liu*[1], *S. Li*[2];
[1]RadAlliance Therapeutics Inc, San Diego, CA, UNITED STATES OF AMERICA,
[2]Department of Nuclear Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, CHINA.

OP-748

Impact of [^{68}Ga]Ga-PSMA-11 PET/CT in the diagnosis of prostate cancer in men with equivocal or non-suspicious findings on multi-parametric MRI (PRIMARY2): a multi-centre, phase III, randomised trial

M. Hofman[1], *J. P. Buteau*[1], *D. Moon*[2], *M. T. Fahey*[1], *M. J. Roberts*[3], *N. Ayati*[4], *N. Papa*[1], *D. G. Murphy*[1], *V. Kasivisvanathan*[5], *Y. T. Du*[6], *A. C. Hutton*[7], *G. Jack*[8], *S. Lee*[1], *S. Lee*[8], *S. Leslie*[9], *S. M. Levy*[1], *E. Link*[1], *C. Mitchell*[1], *J. J. Morigi*[10], *A. Nguyen*[4], *M. I. Patel*[9], *D. A. Pattison*[3], *J. Yaxley*[11], *J. Thompson*[7], *L. Emmett*[4];
[1]Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA,
[2]University of Melbourne, Melbourne, AUSTRALIA,
[3]Royal Brisbane and Women's Hospital, Brisbane, AUSTRALIA,
[4]St Vincent's Hospital, Sydney, AUSTRALIA,
[5]University College London, London, UNITED KINGDOM,
[6]Royal Adelaide Hospital, Adelaide, AUSTRALIA,
[7]University of New South Wales, Sydney, AUSTRALIA,
[8]Austin Health, Melbourne, AUSTRALIA,
[9]University of Sydney, Sydney, AUSTRALIA,
[10]Royal Darwin Hospital, Darwin, AUSTRALIA,
[11]University of Queensland, Brisbane, AUSTRALIA.

OP-749

Comparative Evaluation of mpMRI, PSMAPET, and PSMAPET/mpMRI for Intraprostatic Lesion Detection and their Associations with Immunohistochemical Biomarkers

M. Zarei[1], *E. Nilsson*[1], *J. Grefve*[1], *S. Strandberg*[2], *J. Jonsson*[1], *K. Sandgren*[1], *A. Keeratijarut Lindberg*[3], *A. Bergh*[3], *K. Söderkvist*[4], *C. Thellenberg Karlsson*[4], *L. Nedar*[5], *V. Berg Løgager*[6], *E. Thimansson*[7,8], *E. Trägårdh*[8,9], *J. Bengtsson*[10,11], *E. Hvittfeldt*[9,10], *J. Axelsson*[1], *K. Riklund*[2], *A. Josefsson*[12], *T. Nyholm*[1], *E. Wallsten*[1];
[1]Department of Diagnostics and Intervention, Radiation Physics, Umeå University, Umeå, SWEDEN,
[2]Department of Diagnostics and Intervention, Diagnostic Radiology, Umeå University, Umeå, SWEDEN,
[3]Department of Medical Biosciences, Pathology, Umeå University, Umeå, SWEDEN,
[4]Department of Diagnostics and Intervention, Oncology, Umeå University, Umeå, SWEDEN,
[5]Department of Nuclear Medicine and Hospital Physics, Karolinska University Hospital, Stockholm, SWEDEN,
[6]Department of Radiology, Copenhagen University Hospital in Herlev, Herlev, DENMARK,
[7]Department of Translational Medicine, Diagnostic Radiology, Lund University, Malmö, SWEDEN,
[8]Department of Radiology, Helsingborg Hospital, Helsinborg, SWEDEN,
[9]Department of Translational Medicine, Wallenberg Centre for Molecular Medicine, Lund University, Malmö, SWEDEN,
[10]Department of Medical Imaging and Physiology, Skåne University Hospital, Lund, SWEDEN,
[11]Department of Clinical Sciences, Diagnostic Radiology, Lund University, Lund, SWEDEN,
[12]Department of Diagnostics and Intervention, Urology and Andrology, Umeå University, Umeå, SWEDEN.

OP-750

Diagnostic Performance of [^{68}Ga]Ga-P16-093 PET/MRI versus mpMRI in Newly Diagnosed Prostate Cancer, with Histopathology as the Reference Standard

J. Zang[1], *G. Wang*[1], *L. Zhu*[2], *H. Kung*[3], *W. Miao*[1];
[1]The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, CHINA,
[2]Beijing Normal University, Beijing, CHINA,
[3]University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.

OP-751

PSMA PET/MRI-guided prostate biopsies - head-to-head clinical testing against systematic selected-site biopsies and validation of the PRIMARY score using [^{18}F]PSMA-1007

M. Jochumsen[1,2], *L. Medrud*[1], *A. H. Dias*[1,2], *M. A. Pedersen*[1,2], *C. Stilling*[1], *K. Bouchelouche*[1,2], *P. Iversen*[1,2], *J. Fledelius*[1], *L. P. Tolbod*[1,2], *L. F. Grønnemark*[1], *J. Bjærre*[1], *S. Vind-Kezunovic*[1], *M. H. Andersen*[1], *K. D. Berg*[3,2];
[1]Aarhus University Hospital, Aarhus, DENMARK,
[2]Aarhus University, Aarhus, DENMARK,
[3]Gødstrup Hospital, Herning, DENMARK.

1607

Tuesday, October 20, 2026, 16:45 - 18:15
Hall F1

Thyroid Committee:The Power of Nuclear Medicine Imaging in Targeting Parathyroid Disorders

OP-752

Positive Sestamibi SPECT/CT alone is sufficient without routine Ultrasound for pre-operative Parathyroid adenoma localisation in Primary Hyperparathyroidism

R. Burhan, *I. Rahim, P. Patil, N. Tyagi, N. Gandy;*
London North West University Healthcare NHS Trust, London, UNITED KINGDOM.

OP-753

Diagnostic accuracy of [^{18}F]F-choline PET/CT in the localization of parathyroid pathology.

G. Mera, *J. Ardila, S. Salcedo, S. Alvarez, Y. Ascanio, V. Castillo, J. Ardila, L. Reguera, I. Gomez, J. Orcajo, A. Mari, J. Guzman, D. Zamudio, J. Alonso;*
Hospital General Universitario Gregorio Marañon, Madrid, SPAIN.

OP-754

^{18}F-fluorocholine (FCH) PET/CT vs. ultrasonography for detecting abnormal parathyroid glands in patients harbouring a renal transplant

J. Talbot[1], *C. Aveline*[1], *M. Tassart*[1], *K. Kerrou*[1], *J. Zhang-Yin*[1], *E. Blanc*[1], *B. Jonca*[1], *E. Poiseau*[1], *S. Perié*[2], *I. Wagner*[1], *J. Haymann*[1], *J. Boffa*[1], *S. Balogova*[1], *F. Montravers*[1];
[1]Hopital Tenon, Paris, FRANCE,
[2]Clinique Arthmann, Neuilly, FRANCE.

OP-755

^{18}F-Fluorocholine PET/CT for Parathyroid Localization in Primary Hyperparathyroidism after Inconclusive Conventional Imaging in a Large Tertiary Center

D. Juneau, *Y. A. Lucinian, M. Léger, F. Mercier, J. DaSilva;*
CHUM, Montreal, QC, CANADA.

OP-756

Optimal timing of ^{18}F-FCH PET/CT in preoperative localization of parathyroid adenoma: a comparative assessment of 10 versus 60 minutes acquisition

I. El Moatassim[1,2], *R. Ciappuccini*[1], *C. Jaudet*[1], *A. Lasne-Cardon*[1], *M. Cavarec*[3], *F. Jegoux*[4], *C. Guery*[5], *A. Devillers*[5], *J. Grellard*[1], *B. Clarisse*[1], *F. Christy*[1], *E. Quak*[1];
[1]Centre François Baclesse, Caen, FRANCE,
[2]Mohammed V Military Teaching Hospital, Rabat, MOROCCO,
[3]University Hospital, Brest, FRANCE,
[4]University Hospital, Rennes, FRANCE,
[5]Eugene Marquis Cancer Institute, Rennes, FRANCE.

OP-757

Added Value of Dual-Time-Point ^{68}Ga-Trivehexin PET in Parathyroid Adenoma Localization

A. Sadeq[1], *S. Dashti*[2], *A. Sayed Ali*[3], *F. Marafi*[1];
[1]Jaber AlAhmad center for Molecular Imaging, Shuwaikh medical area, KUWAIT,
[2]Al-Amiri hospital, Alassima medical area, KUWAIT,
[3]Mubarak Al-Kabeer hospital, Hawalli medical area, KUWAIT.

OP-758

Comparative Performance of ^{11}C-Methionine and ^{11}C-Choline PET/CT in Primary Hyperparathyroidism: Impact of Adenoma Weight.

L. García Belaústegui[1], *M. de la Higuera*[1], *J. de Abajo-Larriba*[1], *A. Basanta Mota*[2], *S. Peralta Benitez*[2], *A. Aguilar Pinto*[2], *J. Arbizu*[2];
[1]CUN Madrid, Madrid, SPAIN,
[2]Clínica Universidad de Navarra, Pamplona, SPAIN.

OP-759

Head-to-head Comparison of68Ga-DOTANOC PET/CT and ^{99}mTc-MIBI with SPECT/CT for Localization of MEN-associated Primary Hyperparathyroidism: A Paired Analysis

C. Shiva, *N. A. Damle, A. Tyagi, S. L.S, C. Ganapathy, K. Vengadesan, R. Khadgawat, M. Bhatt, E. Nahid, S. Chumber, P. Ranjan, G. Puri, K. Kataria, S. Dixit;*
All India Institute of Medical Sciences (AIIMS), New Delhi, INDIA.

OP-760

Diagnostic Performance and Comparison of [^{18}F] FDG and [^{18}F]fluorocholine PET/CT in the Evaluation of Parathyroid Carcinoma

A. Bekkhoucha[1], *M. Borsali*[2], *M. Longo*[2], *S. Moog*[2], *J. Pinigina*[2], *J. Hadoux*[2], *L. Lamartina*[2], *E. Baudin*[2], *D. Deandreis*[2];
[1]Nancy University Hospital of Lorraine, Vandoeuvre-lès-Nancy, FRANCE,
[2]Institut Gustave-Roussy, Villejuif, FRANCE.

1608

Tuesday, October 20, 2026, 16:45 - 18:15
Hall F2

Round Table - Oncology & Theranostics Committee + Young Professionals Council: Residents for Residents 2026

OP-761

FDG PET Cases

M.L. Acosta Pereira;
Hospital de Clinicas – UDELAR, Montevideo, URUGUAY.

OP-762

PSMA PET Cases

A. A. Al-Marrani;
University of Cape Town, Cape Town, SOUTH AFRICA.

OP-763

SSTR PET Cases

A. Thies;
Otto von Guericke University Magdeburg, Magdeburg, GERMANY.

OP-764

Other PET Tracers Cases

A. Agosti;
AOU Città della Salute e delle Scienza di Torino, Turin, ITALY.

1610

Tuesday, October 20, 2026, 16:45 - 18:15

Hall K

Cardiovascular Committee: Amyloid Hunters: New Weapons, New Targets

OP-765

DPD SPECT/CT-Based Evaluation of Right Ventricular Involvement in ATTR-CM: Correlation with Cardiac Ultrasound Parameters

M. Vaillant[1], *C. Wakfie*[1], *M. Zapardiel*[1], *A. Espinoza*[2], *M. Restrepo-Córdoba*[2], *G. Cuesta*[1], *P. Daudén*[1], *P. Nespral*[1], *M. Romero*[1], *L. Carreño Mancilla*[1], *A. Ortega*[1], *C. Rodríguez Rey*[1], *M. Cabrera*[1];
[1]*Nuclear Medicine Department, Hospital Clínico San Carlos, Madrid, SPAIN,*
[2]*Cardiology Department, Hospital Clínico San Carlos, Madrid, SPAIN.*

OP-766

Soft Tissue-to-Bone Ratio: An Opportunistic Imaging Biomarker for Cardiometabolic Risk on Routine Bone Scintigraphy

C. Spielvogel[1], *K. Kluge*[2], *K. Kumpf*[2], *C. Nitsche*[2], *C. Hengstenberg*[2], *P. J. Slomka*[3], *M. Hacker*[2];
[1]*Medical University of Vienna / Cedars-Sinai Medical Center, Vienna, AUSTRIA,*
[2]*Medical University of Vienna, Vienna, AUSTRIA,*
[3]*Cedars-Sinai Medical Center, Los Angeles, CA, UNITED STATES OF AMERICA.*

OP-767

^{99}mTc-PYP SPECT/CT and ^{11}C-PIB PET/CT for the Differentiation of Cardiac Amyloidosis Subtypes in Guiding Precision Therapy

Y. Yip, *S. Chen, S. Cheung, I. Ho, Y. Wong, K. Wu, K. Cheng, C. Ho;*
Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.

OP-768

Right Ventricular Involvement in Cardiac Amyloidosis Assessed by Dynamic [^{18}F]Florbetaben PET: Quantitative Correlation with Left Ventricular Amyloid Burden and Clinical Outcome

J. von Hinten[1], *M. J. Hügle*[1], *C. Lapa*[1], *K. Hermann*[2], *T. Jedamzik*[3], *A. Buck*[3], *L. Kessler*[4], *C. Morbach*[5], *L. Umutlu*[6], *S. Settelmeier*[7,8], *T. Rassaf*[7,8], *D. Kersting*[2], *K. Michalski*[3];
[1]*Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY,*
[2]*Nuclear Medicine, Faculty of Medicine, University of Essen, Essen, GERMANY,*
[3]*Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,*
[4]*Department of Radiology, University of Essen, Essen, GERMANY,*
[5]*Dpt. Clinical Research and Epidemiology, Comprehensive Heart Failure Center& Department Medicine I, University Hospital Würzburg, Würzburg, GERMANY,*
[6]*Department of Cardiology, University of Essen, Essen, GERMANY,*
[7]*West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine, University Hospital Essen, Essen, GERMANY,*
[8]*West German Amyloidosis Center, University Hospital Essen, Essen, GERMANY.*

OP-769

AL and ATTR Cardiac Amyloidosis Identified by 18 F-florbetaben-PET Detection of Cardiac and Multi-Organ Involvement

T. Sprauel[1], *E. Itti*[2], *L. Imbert*[1], *T. Zaragori*[3], *M. Doyen*[1], *V. Roch*[4], *A. Verger*[1], *O. Huttin*[1], *C. Jacquet*[5], *E. Donal*[6], *F. Lejeune*[7], *N. Veran*[1], *J. Picolli*[1], *O. Lairez*[8], *A. Hitzel*[8], *E. Cariou*[8], *B. Chambert*[9], *C. Soullier*[9], *A. Zaroui*[10], *T. Damy*[10], *P. Marie*[1];
[1]*Université de Lorraine, Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy, Vandœuvre-lès-Nancy, FRANCE,*
[2]*APHP Henri Mondor, Créteil, FRANCE,*
[3]*CHRU Nancy, Nancyclotep, Vandœuvre-lès-Nancy, FRANCE,*
[4]*Nancyclotep, Vandœuvre-lès-Nancy, FRANCE,*
[5]*CHRU Nancy, Vandœuvre-lès-Nancy, FRANCE,*
[6]*CHU Rennes, Rennes, FRANCE,*
[7]*Centre Eugène Marquis, Rennes, FRANCE,*
[8]*CHU Toulouse, Toulouse, FRANCE,*
[9]*CHU Nimes, Nimes, FRANCE,*
[10]*CHU Henri Mondor, Créteil, FRANCE.*

OP-770

Prognostic Value of ^{18}F-FAPI Positron Emission Tomography in Predicting Amyloid Light-Chain Cardiac Amyloidosis

X. Han, *W. Dong;*
Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, CHINA.

OP-771

Dual-Tracer68Ga-FAPI-04 and ^{18}F-Florbetapir PET Reveals Distinct Pathologic Patterns and Prognostic Value in Light-Chain Cardiac Amyloidosis

Y. Zhang, *X. Wang, L. Huo;*
Peking Union Medical College Hospital, Beijing, CHINA.

OP-772

Tracer-Specific Biodistribution Profiles in Cardiac Amyloidosis: Implications for Visual Phenotyping and Diagnostic Grading

A. Di Giorgio[1], *G. Battisti*[2], *N. Bonazzi*[2], *S. Prisco*[3], *V. Berti*[4], *M. Starace*[4], *F. Cappelli*[5], *S. Longhi*[6], *S. Fanti*[1,7], *R. Bonfiglioli*[7];
[1]*Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,*
[2]*Nuclear Medicine Division, Azienda Unità Sanitaria Locale Istituto di Ricerca e Cura a Carattere Scientifico of Reggio Emilia, Reggio Emilia, ITALY,*
[3]*Nuclear Medicine Unit, Hospital Care Department of Radiology, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, ITALY,*
[4]*Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Firenze, ITALY,*
[5]*Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Firenze, ITALY,*
[6]*Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[7]*Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

OP-773

Quantitative ^{99}mTc-Pyrophosphate SPECT/CT Imaging for Monitoring Therapeutic Response in Transthyretin Cardiac Amyloidosis: The Role of SUVratios

O. Bourogianni[1], *D. Korela*[2], *N. Kapsoritakis*[1], *E. Papadaki*[1], *M. Stathaki*[1], *E. Foukarakis*[3], *S. Koukouraki*[1];
[1]*Nuclear Medicine Department, University Hospital of Crete, Heraklion, GREECE,*
[2]*Cardiology Department, Venizelion General Hospital of Heraklion, Heraklion, GREECE,*
[3]*Department of Cardiology, Venizelio General Hospital of Heraklion, [71409] Heraklion, Greece., Heraklion, GREECE.*

1611

Tuesday, October 20, 2026, 16:45 - 18:15

Hall G1

Special Symposium 6: Dosimetry Committee: Round Table: Single-Time Point Dosimetry: A Step Forward or a Step Too Far?

OP-773a

Round Table Participant

E. Deshayes; *Montpellier Cancer Institute, Montpellier University, Montpellier, FRANCE.*

OP-773b

Round Table Participant

M. Mileva;
Department of Nuclear Medicine, The Brussels University Hospital, Brussels, BELGIUM.

OP-773c

Round Table Participant

Y. Dewaraja; *Department of Radiology, University of Michigan, Ann Arbor, UNITED STATES OF AMERICA.*

OP-773d

Round Table Participant

F. Cicone;
Department of Experimental and Clinical Medicine, Magna Græcia University of Catanzaro, Calabria, ITALY.

OP-773e

Round Table Participant

C. Uribe;
Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, CANADA.

1701

Wednesday, October 21, 2026, 08:00 - 09:30

Hall A

CME 13 - Bone & Joint Committee: Diagnosis and Treatment of Joint Diseases

OP-529

Radiological Assessment of Joint Diseases: MRI and Ultrasound

D. Mak;
Guy's & St. Thomas's NHS Foundation Trust, Radiology Department, London, UNITED KINGDOM.

OP-530

Nuclear Medicine Imaging of Joint Disease

J. Zhang Yin;
Clinque Sud Luxembourg, Department of Nuclear Medicine, Arlon, BELGIUM.

OP-531

Radiosynoviorthesis

K. Liepe;
Klinikum Frankfurt (Oder), Department of Nuclear Medicine, Frankfurt (Oder), GERMANY.

OP-532

DMARDs

R. Byng-Maddick;
Rheumatology Department, Guy's & St. Thomas's NHS Foundation Trust, London, UNITED KINGDOM.

1702

Wednesday, October 21, 2026, 08:00 - 09:30

Hall D (Arena)

Special Track 13 - AI Committee: Debate: Digital Twins in Nuclear Medicine

OP-777

Point of View: The Light Side of Digital Twins

L. Cavinato;
Politecnico di Milano, Milano, ITALY.

OP-778

Point of View: The Dark Side of Digital Twins

D. Visvikis;
INSERM, LaTIM, Brest, FRANCE.

1703

Wednesday, October 21, 2026, 08:00 - 09:30
Hall E1

LIPS Session 13 - Physics Committee: Understanding Your Measurements: Practical Guide to Uncertainty Quantification

OP-781

Measurement Traceability in Nuclear Medicine: What it Is, Why it Matters and When it Is Needed
A. Denis-Bacelar;
National Physical Laboratory, Teddingtonn, UNITED KINGDOM.

OP-782

Accurate Activity Measurements with Radionuclide Calibrators and Gamma Counters
S. Rodriguez Perez;
Belgian Nuclear Research Centre, Mol, BELGIUM.

OP-783

Activity, Activity Concentration, and Absorbed Dose: Uncertainty in Image-Based Dosimetry
J. Gustaffson;
Lund University, Lund, SWEDEN.

OP-784

Navigating Compliance and Clinical Implementation: The UK MPACE Accreditation Experience
J. Scuffham;
Royal Surrey NHS Foundation Trust, Guildford, UNITED KINGDOM.

1704

Wednesday, October 21, 2026, 08:00 - 09:30
Hall E2

M2M Track: TROP Session - Radiopharmaceutical Sciences Committee: Advances in Radiopharmaceutical Development

OP-785

In vitro evaluation of designed ankyrin repeat protein (DARPin)-peptide nucleic acid (PNA) chimeras, created by microbial transglutaminase ligation for radionuclide pretargeting
A. Elshazli[1], *K. Westerlund*[2], *J. Clinton*[2], *A. Orlova*[3], *A. E. Karlström*[2], *M. Oroujeni*[1], *V. Tolmachev*[1];
[1]*Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN,*
[2]*Department of Protein Science, KTH Royal Institute of Technology, Stockholm, SWEDEN,*
[3]*Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN.*

OP-786

Visualization of Heart-Brain-Gut Axis Inflammation and the Ameliorative Effect of FMT in Heart Failure Rats using ^{18}F-DPA-714 PET/CT
L. Yang, *Y. Jia, X. Luo, Y. Wen, Z. Xiang, S. Li;*
Department of Neclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, CHINA.

OP-787

Inhibition of FcRn-Mediated Antibody Recycling as a Strategy to Alleviate Hematologic Toxicity of Radioimmunoconjugates.
M. Altai[1], *W. Zedan*[1], *B. Salerno*[2], *E. Ulmert*[1], *C. Yuen*[3], *S. Geres*[1], *M. Trajkovic-Arsic*[4], *G. Semenova*[5], *K. Sjöström*[6], *D. Thorek*[2], *K. Lückerath*[7], *T. Gräslund*[8], *D. Ulmert*[1,3];
[1]*Division of Oncology and Pathology, Clinical Sciences, Lund, SWEDEN,*
[2]*Department of Radiology, Washington University School of Medicine, St. Louis, MO, UNITED STATES OF AMERICA,*
[3]*Department of Molecular & Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA, UNITED STATES OF AMERICA,*
[4]*Bridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, Essen, GERMANY,*
[5]*Division of Hematology/Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, Los Angeles, CA, UNITED STATES OF AMERICA,*
[6]*Innovagen AB, Lund, SWEDEN,*
[7]*Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,*
[8]*Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, SWEDEN.*

OP-788

Development and first-in-Human evaluation of a novel CAIX-targeting radiotracer for clear cell renal cell carcinoma precision theranostics
S. Cheng, *Y. Song, R. An, Y. Zhang, X. Lan, D. Jiang;*
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

OP-789

Development of a Compact Three-Armed Linker for Bimodal Nuclear and Optical Imaging with Single-Domain Antibodies
N. Mammadbayli[1,2], *L. Schäfer*[1], *M. Sadeghzadeh*[1], *B. Altunay*[1], *A. Morgenroth*[1], *S. Lütje*[1,3], *F. M. Mottaghy*[1,2,3];
[1]*Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, GERMANY,*
[2]*Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, NETHERLANDS,*
[3]*Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Aachen, GERMANY.*

OP-790

Levothyroxine improves vestibular neuroplasticity mechanisms measured with [^{18}F]FDG and behavioral tests after unilateral chemical labyrinthectomy
I. Fuxjäger[1], *M. Antons*[2], *G. Leschiutta*[1], *G. Palumbo*[3], *K. Wind-Mark*[3], *S. Lindner*[3], *S. I. Ziegler*[3,4], *M. Brendel*[3,5,6], *R. A. Werner*[3], *A. Zwergal*[1,7];
[1]*German Center for Vertigo and Balance Disorders, LMU University Hospital, LMU Munich, München, GERMANY,*
[2]*Department of Radiology, LMU University Hospital, LMU Munich, München, GERMANY,*
[3]*Department of Nuclear Medicine, LMU University Hospital, LMU Munich, München, GERMANY,*
[4]*Clinic for Nuclear Medicine, Hannover Medical School (MHH), Hannover, GERMANY,*
[5]*German Center for Neurodegenerative Diseases (DZNE), München, GERMANY,*
[6]*Munich Cluster for Systems Neurology (SyNergy), München, GERMANY,*
[7]*Department of Neurology, LMU University Hospital, LMU Munich, München, GERMANY.*

1705

Wednesday, October 21, 2026, 08:00 - 09:30
Hall B

Cutting Edge Science Track: Dosimetry Committee: Emerging Radiopharmaceuticals, Alpha Therapy and Biology-Guided Dosimetry

OP-791

Real-Time Evaluation of Ac-225 Radiolabelling and Daughter Retention via Direct Alpha Spectroscopy
J. Bailey[1], *J. R. Brown*[2], *C. A. Diget*[2,1], *K. Staunton-Mann*[2,3], *A. Coates*[2], *Z. Ghose*[2], *A. Mercado-Quintero*[2], *E. Timakova*[1], *K. Ortner*[1], *T. Deakin*[3];
[1]*TRIUMF, Vancouver, BC, CANADA,*
[2]*University of York, York, UNITED KINGDOM,*
[3]*LabLogic Systems Limited, South Yorkshire, UNITED KINGDOM.*

OP-792

A click-based fluorine-18 radiolabelling platform for rapid and modular synthesis of receptor-targeted pet tracers
S. Otaru[1], *A. Paulus*[1], *K. Elbadri*[2], *M. Sarparanta*[1], *A. Roivainen*[3], *A. Airaksinen*[3];
[1]*Radiochemistry, Department of Chemistry, University of Helsinki, Helsinki, FINLAND,*
[2]*Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, FINLAND,*
[3]*Turku PET Centre, University of Turku, Turku, FINLAND.*

OP-793

Glycosylated Multivalent RGD Radiotracer Enables Blood-Brain Barrier Penetration for High-Contrast Glioma Imaging
M. Huang[1], *W. Wang*[1], *R. Wang*[1], *Y. Wang*[2], *R. Tian*[1];
[1]*The Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Chengdu, CHINA,*
[2]*Department of Nuclear Medicine and Clinical Nuclear Medicine Research Lab, West China Hospital, Sichuan University, Chengdu, China, Chengdu, CHINA.*

OP-794

First in-human dosimetry of [^{177}Lu]Lu-OncoACP3-DOTA and [^{177}Lu]Lu-RYZACP3-DOTA Radiopharmaceutical Therapy of Advanced Prostate Cancer
J. Brosch-Lenz[1], *K. Seifert*[2], *F. Büther*[2], *F. Schaeg*[2], *A. J. Schrader*[2], *M. Rust*[2], *M. Claesener*[2], *F. Landau*[2], *P. Schindler*[2], *D. Ventura*[2], *K. Rahbar*[2], *M. Schäfers*[2], *P. Backhaus*[2];
[1]*University of Augsburg, Augsburg, GERMANY,*
[2]*University of Münster, Münster, GERMANY.*

OP-795

Biodistribution and Dosimetry of [^{161}Tb]Tb-DOTAGA-Glu-(FAPI)2 in Advanced-Stage Solid Tumours: First-in-Human Experience
D. Kersting[1], *W. Jentzen*[1], *N. Hammersen*[1], *I. A. Mavroeidi*[2], *I. Čiučiulkaitė*[1], *M. Nader*[1], *J. T. Siveke*[2], *M. Schuler*[2], *K. Herrmann*[1], *R. Hamacher*[2], *W. P. Fendler*[1], *P. Fragoso Costa*[1];
[1]*Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,*
[2]*Department of Medical Oncology, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY.*

OP-796

Radiobiological Dose-Effect Comparison of [^{161}Tb]Tb- and [^{177}Lu]LuPSMAI&T in Prostate Cancer
M. Sabatella[1,2], *R. Brandt*[1,2], *G. Garrido Hernandez*[1,2], *C. Ntihabose*[1,3], *E. de Blois*[1,3], *J. Nonnekens*[1,2];
[1]*Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiology and Nuclear Medicine, Rotterdam, NETHERLANDS,*
[2]*Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Molecular Genetics, Rotterdam, NETHERLANDS,*
[3]*Erasmus MC, Department of Clinical Pharmacy, 3015 GD, Rotterdam, NETHERLANDS.*

OP-797

Limited sensitivity of patient-derived CAFs to ^{212}Pb-FAP-targeted radionuclide therapy: implications for stromal targeting in radiopharmaceutical therapy
S. Kvarsvik Kristiansen[1,2], *I. Z. Martinez*[3], *A. Juzeniene*[1,2];
[1]*Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, NORWAY,*
[2]*University of Oslo, Oslo, NORWAY,*
[3]*The Arctic University of Norway, Tromsø, NORWAY.*

OP-798

Radiobiological and immunomodulatory effects of different radiation types in a hypoxic B16F10-OVA tumor model

R. Wuestenenk, *S. T. M. Wenker, J. D. M. Molkenboer-Kuenen, G. M. Franssen, M. Boswinkel, K. de Roode, S. Kleinendorst, P. Rijken, M. van Erp, H. Peters, P. N. Span, M. Ansems, J. Bussink, S. A. M. van Lith, S. Heskamp;*
Radboudumc, Nijmegen, NETHERLANDS.

OP-799

Bridging radiopharmaceutical therapy modelling and immuno-oncology using a quantitative systems pharmacology framework

T. McColl[1,2], *T. I. Yusufaly*[3], *A. Farrokhi*[4], *J. Fowler*[1,5], *C. Uribe*[6,2,7], *A. Rahmim*[2,1,5];
[1]*Department of Basic and Translational Sciences, BC Cancer Research Institute, Vancouver, BC, CANADA,*
[2]*Department of Radiology, University of British Columbia, Vancouver, BC, CANADA,*
[3]*Department of Radiology and Radiological Sciences, Johns Hopkins, Baltimore, MD, UNITED STATES OF AMERICA,*
[4]*Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, CANADA,*
[5]*Department of Physics & Astronomy, University of British Columbia, Vancouver, BC, CANADA,*
[6]*Department of Radiology, BC Cancer Research Institute, Vancouver, BC, CANADA,*
[7]*Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, BC, CANADA.*

OP-800

Pharmacological BRD4 Degradation to Augment Targeted Alpha Therapy Efficacy in Advanced Prostate

M. Bio Idrissou, *D. Cai, C. Li, N. Hawkins, H. Comas Rojas, W. Tang, G. Iyer, R. Hernandez;*
University of Wisconsin-Madison (UW-Madison), Madison, WI, UNITED STATES OF AMERICA.

OP-801

DW-MRI-informed cell-level microdosimetry for targeted alpha therapy: impact of tumor microstructure and activity heterogeneity

V. Onecha[1], *J. Marchant*[2,3], *B. Rosen*[2,3], *A. Bertolet*[1];
[1]*Center for Nuclear Medicine Research and Theranostics Sciences (CNMTS), Department of Radiology, Mass General Brigham, Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA,*
[2]*Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, UNITED STATES OF AMERICA,*
[3]*Harvard-MIT Program in Health Science and Technology, Massachusetts Institute fo Technology, Cambridge, MA, UNITED STATES OF AMERICA.*

OP-802

Quantitative Astatine-211 SPECT Imaging for Novel Targeted Alpha Therapy Applications

Z. Lu[1], *K. Fitzpatrick*[1], *J. Niedbala*[1], *D. Hubers*[1], *M. Ljungberg*[2], *A. Gupta*[1], *N. Varmenot*[3], *L. Ferrer*[3], *S. Miller*[1], *B. Viglianti*[1], *P. Scott*[1], *Y. Dewaraja*[1];
[1]*University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA,*
[2]*Lund University, Lund, SWEDEN,*
[3]*Institut de Cancerologie de l'Ouest; CRCI²NA, UMR 1307 Inserm-UMR 6075 CNRS, Nantes University, Nantes, FRANCE.*

1706

Wednesday, October 21, 2026, 08:00 - 09:30

Hall C

Clinical Oncology Track: Head and Neck

OP-803

[68Ga]Ga-FAPI-46 PET/CT for Staging H&N Cancer Patients: Diagnostic Performance and Potential Impact on Treatment Approach

E. Fortunati[1], *G. Siepe*[2], *G. Cuzzani*[3], *I. Brusa*[1], *S. Emiliani*[1], *C. Nanni*[1], *P. Castellucci*[1], *R. Mei*[1], *M. Fermi*[4], *M. Olive*[4], *C. Martoni*[4], *A. Farolfi*[1], *S. Fanti*[1,3];
[1]*Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[2]*Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[3]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,*
[4]*Department of Otorhinolaryngology-Head and Neck Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

OP-804

FDG-PET and Liquid Biopsy as Complementary Non-Invasive Biomarkers of Disease Burden and prognosis in relapsed/metastatic HNSCC patients

E. Romano Gargarella[1], *L. Agrigoroaie*[2], *F. Dall'Olio*[2], *C. Bou-Orm*[2], *R. Ibrahim*[2], *D. Deandreis*[2];
[1]*Section of Nuclear Medicine, Department of Radiological Sciences and Hematology, Sacred Heart Catholic University, Rome, ITALY,*
[2]*Gustave Roussy Cancer Campus, Villejuif, FRANCE.*

OP-805

Evaluation of Tumour Growth Rate and Hypoxia in p16- Head and Neck Squamous Cell Carcinomas using 18F-FDG and 18F-MISO PET/CT

P. Koranda[1], *P. Karhan*[2], *L. Quinn*[1], *G. Horňák*[1], *J. Cincibuch*[3], *M. Doležel*[3], *M. Kamínek*[1];
[1]*Department of Nuclear Medicine, University Hospital and Palacký University, Olomouc, CZECH REPUBLIC,*
[2]*Department of Physics and Radiation Protection, University Hospital and Palacký University Olomouc, Olomouc, CZECH REPUBLIC,*
[3]*Department of Oncology, University Hospital and Palacký University, Olomouc, CZECH REPUBLIC.*

OP-806

Integrated 68Ga-DOTATATE PET Imaging and Genetic Profiling in Head and Neck Paragangliomas: Toward a Radiogenomic Approach

A. Gagliardi[1], *M. Scarlattei*[1], *M. Falcioni*[2], *E. Ambrosini*[3], *G. Vitetta*[3], *V. Giannatiempo*[4], *K. Fessi*[4], *A. Guercio*[1], *S. Migliari*[1], *G. Bertoli*[2], *G. Baldari*[1], *T. Graziani*[1], *B. Altieri*[4], *L. Ruffini*[1];
[1]*Nuclear Medicine Division, University Hospital of Parma, Parma, ITALY,*
[2]*Otoneurosurgery and Microsurgery Unit, University Hospital of Parma, Parma, ITALY,*
[3]*Medical Genetics, University Hospital of Parma, Parma, ITALY,*
[4]*Division of Endocrinology and Diabetes, University Hospital of Parma, Parma, ITALY.*

OP-807

Shared Metabolic Signatures of Aggressive Disease: Cross-Cancer FDG-PET Radiomics in Lung and Head and Neck Malignancies

M. Salmanpour[1,2,3], *A. Fathi Jouzdani*[4], *A. Gorji*[4,1], *A. Rahmim*[1,2];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,*
[2]*University of British Columbia, Vancouver, BC, CANADA,*
[3]*Technological Virtual Collaboration Company (TECVICO CORP.), Vancouver, BC, CANADA,*
[4]*Hamadan University of Medical Sciences, Hamedan, IRAN, ISLAMIC REPUBLIC OF.*

OP-808

Can 68Ga Trivehexin PET/CT help differentiate post treatment changes from residual and recurrent head and neck squamous cell carcinoma? - initial results from a Prospective study

S. Choudhury, *A. Agrawal, S. Ghosh, I. Dev, M. Manikanakan, S. Nair, P. Joshi, S. Sinha, A. Kumar, K. Tanwar, D. Rawat, P. Chaturvedi;*
ACTREC, Tata Memorial Centre, Navi Mumbai, INDIA.

OP-809

Baseline [18F]FDG PET-Derived Metabolic Tumour Volume as a Predictor of Event-Free Survival in Head and Neck Cancer Treated with Definitive Radiotherapy

D. Silva, *N. Vasconcelos, R. Marão, R. Lopes, I. Miguel, A. Soares, I. Lopo, J. P. Teixeira, H. Duarte, I. L. Sampaio;*
Instituto Português de Oncologia do Porto Francisco Gentil, Porto, PORTUGAL.

OP-810

Multiparametric PET/MR Habitat Radiomics Combined with Peritumoral Analysis for Detection of Recurrence in Head and Neck Cancer

W. Zhou[1], *H. Ye*[1], *J. Dai*[1], *Y. Guo*[2];
[1]*The Affiliated Cancer Hospital of Xiangya School of Medicine/Hunan Cancer Hospital, Central South Un, Changsha, CHINA,*
[2]*Shenzhen United Imaging Healthcare Co., Ltd., Shenzhen, CHINA.*

OP-811

Prognostic Value of FDG PET/CT-Based Immunometabolic Phenotypes on Survival in Laryngeal Squamous Cell Carcinoma

I. Ak Sivrikoz[1], *E. Ilhan*[1], *S. Çiler*[1], *U. Toprak*[2];
[1]*ESOGU School of Medicine Department of Nuclear Medicine, Eskisehir, TÜRKIYE,*
[2]*ESOGU School of Medicine Department of Radiology, Eskisehir, TÜRKIYE.*

1707

Wednesday, October 21, 2026, 08:00 - 09:30

Hall F1

Inflammation & Infection Committee: Heterogeneous Infectious and Inflammatory Diseases

OP-812

Intrahospital transport safety of critically ill patients for PET/CT imaging

C. P. van Stee[1], *B. van Leer*[1], *J. H. Snick*[1], *A. W. J. M. Glaudemans*[1], *M. W. N. Nijsten*[1], *R. H. J. A. Slart*[1,2], *J. Pillay*[1];
[1]*University Medical Center Groningen, Groningen, NETHERLANDS,*
[2]*Biomedical Photonic Imaging Group, Faculty of Science and Technology, University of Twente, Enschede, NETHERLANDS.*

OP-813

Quantification and patterns of intracranial metabolism on FDG PET-CT in paediatric tuberculous meningitis

C. Burger[1], *P. Dupont*[2,1], *J. Warwick*[1], *J. Seddon*[3,1], *A. Doruyter*[1];
[1]*Stellenbosch University, Cape Town, SOUTH AFRICA,*
[2]*KU Leuven, Leuven, BELGIUM,*
[3]*Imperial College London, London, UNITED KINGDOM.*

OP-814

Beyond the Cavity: Pre-operative TMIV and Immunometabolic Phenotyping as Synergistic Predictors of 2-Year Survival in patients undergoing lung resection for drug resistant tuberculosis

S. More, *T. Mefane, M. Makhele, A. Al-marrani, N. Jacobs, M. Rivombo, K. Hlongwa;*
University of Cape Town, Cape Town, SOUTH AFRICA.

OP-815

FDG PET/CT in RelapsingPolychondritis: Whole-Body Cartilage Mapping, Disease Activity Assessment, and Diagnostic Utility — A Single-Centre Experience

A. S Babu, *M. Umar, K. Bangkim Chandra, R. Kumar;*
All India Institute of Medical Sciences, New Delhi, INDIA.

OP-816

Kinetic Modeling of Total-Body [18F]FDG-PET/CT for Crohn's Disease: Preliminary Results of the CRODYNO Study

A. Di Giorgio[1], *D. Dall'Olio*[2], *I. Brusa*[3], *M. Binetti*[2,4], *M. Di Giovanni*[5], *M. Papendieck*[2,4], *A. Tiano*[2,4], *C. Nanni*[3], *N. Dussias*[2,6], *F. Rizzello*[2,6], *S. Cardelli*[2,4], *F. Rosini*[7], *B. A. Spencer*[8], *L. Nardo*[8], *P. Gionchetti*[2,6], *M. Rottoli*[2,4], *T. Beyer*[9], *S. Fanti*[1,2,3], *V. Lucidi*[5], *G. Calini*[2,4], *A. Farolfi*[3];
[1]*Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,*
[2]*Department of Medical and Surgical Sciences, University of Bologna, Bologna, ITALY,*
[3]*Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[4]*Surgery of Alimentary Tract, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*

FINAL PROGRAMME | ABSTRACTS

[5]Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,
[6]IBD Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,
[7]Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,
[8]Department of Radiology, University of California-Davis, Davis, CA, UNITED STATES OF AMERICA,
[9]QIMP Team, Medical University of Vienna, Vienna, AUSTRIA.

OP-817

[18F]FDG PET/CT for the Diagnosis of Sternal Wound Infection and Development of a PET-Based Assessment Score, a retrospective case-control study

M. Badarna[1], *S. Schwartz*[2], *Z. Keidar*[1], *N. Ganem-Zoubi*[3];
[1]Department of Nuclear Medicine, Rambam Healthcare Campus, Haifa, ISRAEL,
[2]Technion - the Israeli Institute of Technology, Haifa, ISRAEL,
[3]Infectious Diseases Unit, Rambam Health Care Campus, Haifa, ISRAEL.

OP-818

Comparative Evaluation of [68Ga]Ga-NOTA-Ubiquicidin(29-41) PET/CT and [18F]FDGPET/CT Findings in Patients with Acquired Immunodeficiency Syndrome: Preliminary Analysis Results

A. Ozturk[1], *B. Koc*[2], *I. Baydemir*[1], *B. Yilmaz Bildik*[1], *M. C. Baloglu*[1], *Z. Tosunoglu*[1], *G. Alcin*[1], *E. Arslan*[1], *E. Zerdali*[3], *N. D. Sari*[2], *E. Akgun*[1];
[1]Istanbul Training and Research Hospital Nuclear Medicine Department, Istanbul, TÜRKIYE,
[2]Istanbul Training and Research Hospital Department of Infectious Diseases and Clinical Microbiology, Istanbul, TÜRKIYE,
[3]Haseki Training and Research Hospital Department of Infectious Diseases and Clinical Microbiology, Istanbul, TÜRKIYE.

OP-819

[18F]FDG PET/CT Revealing Predilection of Clinically Unrecognized Infective Site in Group B Streptococcal Bacteraemia

H. Cheung, *S. Wong, P. Tsoi, H. Lam, W. Ngai, P. Choi; Pamela Youde Nethersole Eastern Hospital, Hong Kong, HONG KONG.*

OP-820

FAPI PET/CT in Rhematological Interstitial Lung Disease Patients

A. Guarneri[1], *E. Perrone*[1], *E. De Lorenzis*[2], *G. Alonzi*[2], *M. D'Agostino*[3], *S. Bosello*[3], *A. Cancellieri*[4], *S. Baroni*[5], *M. Calcagni*[6], *L. Leccisotti*[6];
[1]Unit of Nuclear Medicine Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Rome, ITALY,
[2]Unit of Rheumatology and Clinical Immunology Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Rome, ITALY,
[3]Unit of Rheumatology and Clinical Immunology Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy, Rome, ITALY,
[4]Unit of Pathology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Rome, ITALY,
[5]Department of Laboratory and Infectious Sciences, Fondazione Policlinico Universitario Agostino Gemelli Rome, Italy, Rome, ITALY,
[6]Unit of Nuclear Medicine Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy, Rome, ITALY.

1708

Wednesday, October 21, 2026, 08:00 - 09:30

Hall F2

Thyroid Committee: Management of Benign and Malignant Thyroid Disorders: From Diagnosis to Therapy

OP-821

Noninvasive imaging of PD-L1 in thyroid Nodules with a 99mTc-labeled nanobody: histopathologic correlation in a first-in-human cohort

B. Kreppel[1], *M. Essler*[1], *L. Pallos*[1], *M. Toma*[1], *N. Veit*[1], *M. Marinova*[1], *A. Türler*[2], *J. Küppers*[1];
[1]University Hospital Bonn, Bonn, GERMANY,
[2]Johanniter Kliniken Bonn, Bonn, GERMANY.

OP-822

Complementary Activity Assessment of Thyroid-Associated Ophthalmopathy using Integratedl8F-FAPI-04 PET/MRI with FAPI uptake and T2WI

X. Yang[1], *M. Wu*[1], *X. Shi*[1], *L. Gan*[1], *H. Xing*[1], *Y. Zhang*[1], *Z. Hao*[1], *Z. Huang*[1], *E. Li*[2], *L. Huo*[1];
[1]Peking Union Medical Collage Hospital, Beijing, CHINA,
[2]Shanghai United Imaging Healthcare Co., Ltd., Shanghai, CHINA.

OP-823

Radioiodine Testing and Therapy in an Iodine-Deficient Population: Disease-Specific Functional Profiles and Outcomes in a Large Single-Center Cohort

J. Mommsen[1], *K. Hansen*[1], *B. Adams*[1], *A. von Werder*[2], *K. Knorr*[1], *M. Eiber*[1,3], *M. Gammel*[1];
[1]Department of Nuclear Medicine, TUM Klinikum, Rechts der Isar, Technical University of Munich, (TUM), School of Medicine and Health, Munich, GERMANY,
[2]Klinik und Poliklinik für Innere Medizin II, TUM Klinikum, Rechts der Isar, Technical University of Munich (TUM), School of Medicine and Health, Munich, GERMANY,
[3]Bavarian Cancer Research Center (BZKF), Erlangen, GERMANY.

OP-824

Biochemical vs dosimetric predictors of success in radioiodine therapy for benign thyroid disease: A retrospective cohort study

J. Mendes, *P. Ferreira, T. Faria;*
Hospital de São João, Porto, PORTUGAL.

OP-825

What is the most effective method for the treatment of Graves' Disease with radioiodine, dosimetric or empirical approach? A PRISMA guided review.

K. Mangion, *S. Agius;*
University of Malta, Msida, MALTA.

OP-826

Comparison of 131I Therapy and Percutaneous Microwave Thermal Ablation (PMWT) in the Treatment of Large Toxic Nodular Goiter (LTNG)

B. Criscuoli, *S. Alborino, C. Manni, f. salvatori, f. chiumiento, g. follacchio, c. mincarelli, F. Capoccetti; AST Macerata, Macerata, ITALY.*

OP-827

Comparison of [68Ga]Ga-CTR-FAPI PET-CT with Conventional Imaging in Recurrent/Metastatic Medullary Thyroid Carcinoma

Y. Qi[1], *S. Liu*[2], *Z. Li*[3], *Y. Nie*[1], *M. Xu*[4], *J. Chen*[5], *X. Zhang*[2], *R. Li*[2], *P. Liu*[4], *C. Wang*[4], *S. Liu*[1], *Z. Liu*[3,4,5], *Y. Lin*[2], *Z. Kong*[1];
[1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA,
[2]Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA,
[3]Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, CHINA,
[4]Changping Laboratory, Beijing, CHINA,
[5]Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Key Laboratory of Bioorganic Chemistry and Molecular, Beijing, CHINA.

OP-828

Dynamic [18F]F-DOPA LAFOV-PET/CT Evaluation of Medullary Thyroid Carcinoma Lesions: Optimizing the Acquisition Window for Lesions Detection

E. Fortunati[1], *I. Brusa*[1], *L. Calderoni*[1], *E. Greco*[2], *G. Bianciardi*[2], *S. Chillotti*[3,4], *D. Dall'Olio*[4], *F. Lodi*[1], *M. Assenza*[5], *S. Civollani*[6], *E. Tabacchi*[1], *S. Fanti*[1,2], *V. Ambrosini*[1,2];
[1]Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,
[2]Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,
[3]Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,
[4]Department of Medical and Surgical Sciences, University of Bologna, Bologna, ITALY,
[5]Professional Development and Implementation of Research in Health Professional Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,
[6]Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-829

Tumor burden at 18F-DOPA PET/CT and ctDNA in medullary thyroid cancer

C. Nappi[1,2], *M. Borsali*[1], *H. Noamen*[1], *M. Longo*[1], *S. Moog*[1], *I. Pinigina*[1], *Y. Menu*[1], *A. Italiano*[1], *B. Bonnet*[1], *E. Baduin*[1], *D. Hartl*[1], *I. Breuskin*[1], *L. Lamartina*[1], *J. Hadoux*[1], *D. Deandreis*[1];
[1]Institute Gustave Roussy, Villejuif, FRANCE,
[2]IRCCS Synlab SDN, Naples, ITALY.

1710a

Wednesday, October 21, 2026, 08:00 - 09:00

Hall K

Mini Course 1 - Technologists Committee: Radiation Protection in Patients Undergoing Radioligand Therapy

OP-830

Radiation Protection in Radioligand Therapy: Practical Principles for Technologists and Nurses

S. Schumann;
University Hospital of Würzburg, Department of Nuclear Medicine, Würzburg, GERMANY.

OP-831

Optimising Patient and Staff Safety During 177Lu Radioligand Therapy: From Theory to Clinical Workflow

P. Exadaktylou;
AHEPA University Hospital, 2nd Nuclear Medicine Department, Thessaloniki, GREECE.

OP-832

Managing Radiation Exposure and Contamination in Radioligand Therapy: Challenges and Practical Solutions

S. Stienaers;
University Hospitals Leuven, Leuven, BELGIUM.

1710b

Wednesday, October 21, 2026, 09:05 - 10:05

Hall K

Mini Course 2 - Technologists Committee: Instrumentation and Dosimetry

OP-833

From Detector to Image: Understanding Nuclear Medicine Instrumentation

C. Vanhove;
Institute Biomedical Technology, Ghent, BELGIUM.

OP-834

Radiation Dose in Nuclear Medicine: Principles and Practical Dosimetry

M. Stam;
Leiden University Medical Center, Leiden, NETHERLANDS.

OP-835

Dose Optimisation and Radiation Safety: The Technologist's Role

V. Mautone;
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY.

1710c

Wednesday, October 21, 2026, 10:15 - 11:15

Hall K

Mini Course 3 - Technologists Committee: Therapeutic Radioisotopes and Their Radioligands - The Overview of Daily Radiochemical Practice

OP-836

Common Theranostic Radioligands in Daily Practice: Radiochemistry Overview and Radiation Protection Challenges

C. Morgat;
Department of Radiopharmacy & Nuclear Medicine, University Hospital of Bordeaux, Bordeaux, FRANCE.

OP-837

From Radioligand Preparation to Patient Care: Radiation Protection Skills in Theranostic Nuclear Medicine

L. Rotteveel;
UMC Utrecht, Department Radionuclide Apotheek, Utrecht, NETHERLANDS.

OP-838

From Radioligand Preparation to Patient Care: Radiation Protection Skills in Theranostic Nuclear Medicine

K. Alkayal;
University Medical Center (UMC), Utrecht, NETHERLANDS.

1711

Wednesday, October 21, 2026, 08:00 - 09:30

Hall G1

Case Report Session 2: Cases Worth Telling

OP-839

Beyond the Orbit: ^{18}F-FDG PET/CT Mapping Extensive Multifocal Chloromatous and Intramedullary Deposits in an infant with Acute Erythroid Leukemia(M6)

A. S K, *M. L. Narayan, U. K. Nath, R. Shah, C. Puranicmath, V. Jain, N. Nagpal;*
All India Institute of Medical Sciences, Rishikesh, INDIA.

OP-840

Intraspinal Paraganglioma in a Complex Patient: a Challenge for Current Therapeutic Strategies

A. Bagán-Trejo[1], *J. Vercher-Conejero*[1], *J. Martín-Marcuartu*[1], *V. Carrero-Vasquez*[1], *J. Ruffinelli*[2], *I. Peiró*[3], *F. Guerrero-Pérez*[4], *C. García-Alcober*[5], *A. Dacosta-Escobar*[1], *S. Orts-Expósito*[5], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine-PET (IDI) Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN,*
[2]*Oncology Department, Institut Català d'Oncologia, Barcelona, SPAIN,*
[3]*Clinical Nutrition Unit, Institut Català d'Oncologia, Barcelona, SPAIN,*
[4]*Endocrinology Department, Hospital Universitari de Bellvitge, Barcelona, SPAIN,* [5]*Radiopharmacy Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN.*

OP-841

Added Value of Contrast-Enhanced SPECT/CT in [^{99m}Tc]Tc -Albumin Scintigraphy for Protein-Losing Enteropathy in Complex Postoperative Anatomy.

Ó. Hernández Cristancho, *M. Rubio Alvarez, A. Palomar-Muñoz, M. Diez, M. Barios-Profitós, N. Calviño, M. Marusso Fizzani, S. Martinez Rosales, D. Urbina Jaramillo, C. Gámez Cenzano;*
Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.

OP-842

High-Grade Pulmonary Mucoepidermoid Carcinoma Beyond Classical Demographics: A Rare Case Report

L. Bejinariu[1], *A. Marin*[1], *M. Alexa*[1], *V. Mazilu*[1], *R. M. Mititelu*[1,2];
[1]*Clinic of Nuclear Medicine, Central Universitary Emergency Military Hospital Dr. Carol Davila, Bucharest, ROMANIA,*
[2]*Department of Nuclear Medicine, University of Medicine and Pharmacy Carol Davila, Bucharest, ROMANIA.*

OP-843

Large Vessel Vasculitis Incidentally Diagnosed on ^{18}F-FDG PET/CT: A Case Presenting with Unexplained Systemic Inflammation

N. Arslan, *M. Daşar, G. Koca, K. Demirel, M. Korkmaz;*
Ankara Research and Training Hospital, Ankara, TÜRKIYE.

OP-844

Same-day dual radiopharmaceutical imaging on a long-axial-field-of-view PET/CT - a paediatric case study

P. Kench[1], *H. Kertesz*[1], *G. Angelis*[1], *K. London*[1,2];
[1]*The University of Sydney, Sydney, AUSTRALIA,*
[2]*The Children's Hospital at Westmead, Sydney, AUSTRALIA.*

OP-845

PET-CT for the Diagnosis, Staging and Monitoring of Metastatic Disease from a Malignant Meningioma

A. Gutierrez[1], *A. Quon*[2], *M. Benz*[3], *M. Allen-Auerbach*[2], *J. Czernin*[2];
[1]*UCLA Medical Center, Santa Monica, CA, UNITED STATES OF AMERICA,*
[2]*UCLA Medical Center, Los Angeles, CA, UNITED STATES OF AMERICA,*
[3]*Kantonspital Aarau, Aarau, SWITZERLAND.*

OP-846

^{68}Ga-FAPI PET/CT as a Game-Changer in the Differential Diagnosis of Complex Brain Lesions: A Case Report

G. Bianciardi[1,2], *A. L. Martini*[1], *I. Laghai*[1], *E. Landi*[1], *A. Leo*[1], *S. Valente*[1], *S. Sestini*[1];
[1]*Nuclear Medicine Unit, Department of Diagnostic Imaging, N.O.P. - S. Stefano, U.S.L. Toscana Centro, Prato, ITALY,*
[2]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY.*

OP-847

^{18}F-FDG and ^{68}Ga-PSMA-Avid Bone Metastases with Unremarkable Renal Findings in Renal Cell Carcinoma with Elevated PSA Mimicking Prostate Cancer

Y. Li, *Y. Tang, S. Hu;*
Xiangya Hospital, Central South University, Changsha, CHINA.

1801

Wednesday, October 21, 2026, 09:45 - 11:15

Hall A

CME 14 - Physics + Dosimetry Committee: Quantitative Imaging & Dosimetry Using Total-Body PET Imaging

OP-848

Challenges for Quantitative Imaging in TB-PET

O. Ivashchenko;
University Medical Center Groningen, Groningen, NETHERLANDS.

OP-849

Parametric Imaging with TB-PET

S. Ziegler;
MHH Medical School Hannover, Hannover, GERMANY.

OP-850

Theranostics with TB-PET

L. Filippi;
Fondazione PTV Policlinico Tor Vergata University Hospital, Rome, ITALY.

OP-851

A New Era for ^{177}Lu Radioligand Therapy

A. Rominger;
University Hospital Bern, Bern, SWITZERLAND.

1802

Wednesday, October 21, 2026, 09:45 - 11:15

Hall D (Arena)

Special Track 14 - Radiopharmacy Committee: Round Table: Pairing for Precision – Is There an Ideal Theranostic Combination for Radiometal-Based Therapy?

OP-852

Who Are Our Real Competitors? Positioning Radiometal Theranostics in Today's Oncology

N. Schaefer;
Service de médecine nucléaire et imagerie moléculaire-CHUV, Lausanne, SWITZERLAND.

OP-853

The Vector Is the Key – Ligand Design Ultimately Defines Theranostic Success

Y. Seimbille;
University Medical Center Rotterdam, Rotterdam, NETHERLANDS.

OP-854

The Chelator Can Provide True Precision, Including Optimal Radiometal Coordination

M. Ma;
School of Biomedical Engineering and Imaging Sciences, King's College London, London, UNITED KINGDOM.

OP-855

The Radionuclide Duo Defines the Biology – Physics and Dosimetry Derive Precision and Efficacy

A. Ashfaq;
Universitätsklinikum Giessen und Marburg GmbH, Klinik für Nuklearmedizin, Marburg, GERMANY.

1803

Wednesday, October 21, 2026, 09:45 - 11:15

Hall E1

LIPS Session 14 - Translational Molecular Imaging & Therapy + AI Committee: Multimodal Therapeutic Planning in Times of AI Innovations

OP-856

Radiation Therapy – How Nuclear Medicine Imaging Informs RT Planning and What AI Changes

G. Heilemann;
Medical University of Vienna, Radiation Oncology, Vienna, AUSTRIA.

OP-857

SIRT – AI-Supported Dosimetry and Planning in Radioembolisation

E. Roncali;
University of California Davis, Biomedical Engineering & Radiology, Davis, UNITED STATES OF AMERICA.

OP-858

Radioguided Surgery – Molecular Imaging and AI in Surgical Planning

J. Orozco;
Hospital Universitario Doctor Peset, Nuclear Medicine, Valencia, SPAIN.

OP-859

Image-Guided Interventions – And the Future of AI-Driven Therapeutic Planning

F. van Leeuwen;
Leiden University Medical Center (LUMC), Interventional Molecular Imaging Laboratory, Leiden, NETHERLANDS.

1804

Wednesday, October 21, 2026, 09:45 - 11:15

Hall E2

M2M Track: TROP Session - Translational Molecular Imaging & Therapy Committee: Animal Models and in Vitro Alternatives

OP-860

Humanized Mouse Models for CXCR4 Radiopharmaceutical Development in Cancer

I. Astiazaran-Rascon[1,2], *D. Ghosh*[3], *M. Ligeour*[1], *E. Friesen*[1,2], *H. Merkens*[1], *P. Ng*[1], *M. Koh*[3], *K. Lin*[1,2], *J. Lau*[1,2], *A. Karsan*[3,2], *F. Benard*[1,2];
[1]*BC Cancer, Vancouver, BC, CANADA,*
[2]*University of British Columbia, Vancouver, BC, CANADA,*
[3]*Genome Sciences Center, Vancouver, BC, CANADA.*

OP-861

An improved animal model to assess bone marrow and systemic toxicity of CXCR4-targeting radiopharmaceuticals

E. Friesen[1,2], *I. Astiazarán-Rascón*[1,2], *F. Cookson*[2], *P. Ng*[2], *H. Merkens*[2], *J. Zeisler*[2], *J. Pan*[3], *I. Alberts*[3], *J. Lau*[1,2], *K. Lin*[1,2], *F. Bénard*[1,2,3];
[1]*University of British Columbia, Vancouver, BC, CANADA,*
[2]*BC Cancer Research Institute, Vancouver, BC, CANADA,*
[3]*BC Cancer Agency, Vancouver, Vancouver, BC, CANADA.*

OP-862

Translational Preclinical Characterization of Radioligand Therapy in Fully Characterized Prostate Cancer PatientDerived Xenograft Models

D. Beckford Vera, *M. Farshbaf, G. Llerena, M. Denton, K. Monger, K. Cotton, E. Kosmowski, S. Meanhout, D. Paraboschi, D. Tabaa, P. Heverly, M. Mancini;*
Champions Oncology, Rockville, MD, UNITED STATES OF AMERICA.

OP-863

Preclinical Evaluation of Xenograft Models with Distinct PSMA Expression as a Basis for Individualised Radioligand Therapy

B. Sun[1,2], *M. Elbahloul*[2,3], *D. Werner*[1], *G. Costa*[4,5], *A. Wurzer*[1], *F. Schilling*[1], *W. A. Weber*[1], *R. Eichner*[2,3], *G. Glatting*[4,5], *S. Kossatz*[1,2];
[1]*Department of Nuclear Medicine, TUM University Hospital, TUM School of Medicine and Health, Bavarian Cancer Research Center (BZKF), Munich, GERMANY,*
[2]*Central Institute for Translational Cancer Research (TranslaTUM), Technical University of Munich, Munich, GERMANY,*
[3]*Department for Internal Medicine III, TUM University Hospital, School of Medicine and Health, Technical University of Munich, Munich, GERMANY,*
[4]*Department of Nuclear Medicine, Ulm University, Ulm, GERMANY,*
[5]*Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, GERMANY.*

OP-864

Construction and Mechanism of Action of a Novel Strategy for PDAC Treatment Using NIS Gene-Modified Oncolytic Virus Combined with ^{131}I Internal Radiation Therapy

X. Su, *S. Yu, W. Wang;*
Zhejiang University School of Medicine, Hangzhou, CHINA.

OP-865

Glioblastoma-brain assembloids are a physiologically relevant ^{3}D model for evaluating PSMA-targeted radioligand therapy

R. Quintens[1], *S. Waelkens*[1,2], *C. Segers*[3], *V. Bogaerts*[3], *T. Opsomer*[3], *A. Vaniqui*[4], *F. De Smet*[2];
[1]*Radiobiology Unit, Nuclear Medical Applications Institute, SCK CEN, Mol, BELGIUM,*
[2]*Laboratory of Precision Cancer Medicine, Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM,*
[3]*TRT-Radiopharmaceuticals Unit, Nuclear Medical Applications Institute, SCK CEN, Mol, BELGIUM,*
[4]*Radiation Protection Unit, Nuclear Medical Applications Institute, SCK CEN, Mol, BELGIUM.*

OP-866

Longitudinal Evaluation of [^{18}F]FDG- and [^{18}F]FAPI-PET/CT for Immunotherapy Response Assessment in a Murine Model of Colorectal Cancer

M. Antons[1], *F. Herr*[1], *H. Hirner-Eppeneder*[1], *G. Palumbo*[2], *J. Stock*[1], *S. Lindner*[2], *G. Sheikh*[2], *J. Toms*[2], *M. Brendel*[2,3,4], *J. Ricke*[1], *R. A. Werner*[2,5], *C. C. Cyran*[1];
[1]*Department of Radiology, LMU University Hospital, Munich, GERMANY,*
[2]*Department of Nuclear Medicine, LMU University Hospital, Munich, GERMANY,*
[3]*Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY,*
[4]*German Cancer Research Center (DKFZ), Heidelberg, GERMANY,*
[5]*The Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA.*

OP-867

Terbium-161 PSMA Radioligand Therapy Induces M1 Macrophage Polarization in Prostate Cancer Models

Z. Ming, *A. Kurniawan, I. Farinha Antunes, E. de Vries, B. Cornelissen;*
UMCG, Groningen, NETHERLANDS.

OP-868

Treatment of Orthotopic U251-Luc Human Glioblastoma Tumours in Mice Using Gold-198 Nanoparticles Administered by Convection-Enhanced Delivery

M. Brown[1], *Z. Cai*[1], *R. Reilly*[1,2];
[1]*University of Toronto, Toronto, ON, CANADA,*
[2]*University Health Network, Toronto, ON, CANADA.*

1806

Wednesday, October 21, 2026, 09:45 - 11:15

Hall C

Clinical Oncology Track: Lymphoma and Myeloma

OP-869

Metabolic tumour volume at baseline calculated with RECOMIA AI-based tool can predict progression-free survival in lymphoma patients examined with FDG-PET/CT

M. Sadik[1], *J. Lopez Urdaneta*[1], *P. Andersson*[2], *O. Enqvist*[3], *E. Trägårdh*[4], *L. Edenbrandt*[1];
[1]*Medicine, Gothenburg, SWEDEN,*
[2]*Medicine and Haematology, Gothenburg and Borås, SWEDEN,*
[3]*Electrical Engineering and Eigenvision AB, Gothenburg and Lund, SWEDEN,*
[4]*Clinical Physiology and Nuclear Medicine and Translational Medicine and Wallenberg Center for Molecular Medicine, Malmö, SWEDEN.*

OP-870

AI-based PET Lesion Segmentation in Follicular Lymphoma: An extensive Benchmark Study Integrating Technical Accuracy and Prognostic Performance.

G. Henique[1], *S. Kanoun*[2], *S. Malmon*[2], *T. Reichert*[3], *R. Metz*[4], *P. Viau*[5], *L. Vercellino*[6], *N. Deleval*[1], *D. Bessac*[7], *A. Cottereau*[6], *C. Antoine*[8], *G. Cartron*[9], *Y. Al Tabaa*[10], *C. Sarkozy*[1], *I. Buvat*[1];
[1]*Institut Curie, Paris, FRANCE,*
[2]*Pixilib, Toulouse, FRANCE,*
[3]*Institut Paoli-Calmettes, Marseille, FRANCE,*
[4]*CHU-Nantes, Nantes, FRANCE,*
[5]*CHU-Nice, Nice, FRANCE,*
[6]*AP-HP, Paris, FRANCE,*
[7]*NHC - Strasbourg, Strasbourg, FRANCE,*
[8]*Lysa, Lyon, FRANCE,*
[9]*CHU Montpellier, Montpellier, FRANCE,*
[10]*Scintidoc, Montpellier, FRANCE.*

OP-871

Modified Deauville Score including Personalized Residual TMTV improves identification of poor outcomes patients in First Line FL patients: a Bidifly-Lysa Study

Y. Al Tabaa[1], *S. Malmon*[2], *T. Reichert*[3], *R. Metz*[4], *P. Viau*[5], *L. Vercellino*[6], *N. Deleval*[7], *D. Bessac*[8], *A. Cottereau*[9], *C. Antoine*[10], *G. Henique*[11], *I. Buvat*[12], *G. Cartron*[13], *C. Sarkozy*[14], *S. Kanoun*[2];
[1]*Scintidoc Nuclear Medicine Center, Montpellier, FRANCE,*
[2]*Pixilib, Toulouse, FRANCE,*
[3]*Nuclear Medicine, Insitut Paoli Calmettes, Marseille, FRANCE,*
[4]*Nuclear Medicine, CHU Nantes, Nantes, FRANCE,*
[5]*Nuclear Medicine, CHU Nice, Nice, FRANCE,*
[6]*Nuclear Medicine Center, CHU Saint Louis, Paris, FRANCE,*
[7]*Nuclear Medicine, Insititut Curie, Paris, FRANCE,*
[8]*Nuclear Medicine, CHU Strasbourg, Strasbourg, FRANCE,*
[9]*Nuclear Medicine, CHU Cochin, Paris, FRANCE,*
[10]*LYSARC, Créteil, FRANCE,*
[11]*Laboratoire d'imagerie translationnelle en oncologie (U^{1288}), Institut Curie, Paris, FRANCE,*
[12]*Laboratoire d'imagerie translationnelle en oncologie (U^{1288}), Insitut Curie, Paris, FRANCE,*
[13]*Hematology Department, CHU Montpellier, Montpellier, FRANCE,*
[14]*Hematology, Institut Curie, Paris, FRANCE.*

OP-872

Is True Whole-Body ^{18}F-FDG PET/CT Required in Multiple Myeloma Assessment?

Y. Yechiel[1], *R. Gill*[1], *Z. Keidar*[1,2];
[1]*Rambam Health Care Campus, Haifa, ISRAEL,*
[2]*Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, ISRAEL.*

OP-873

Diagnostic performance and management impact of ^{3}T whole-body MRI and [^{18}F]FDG PET/CT in high-risk smouldering and symptomatic multiple myeloma: a patient-level analysis

D. Bezzi[1], *A. Rossi*[2], *I. Azzali*[3], *A. Prochowski Iamurri*[2], *M. Celli*[4], *F. Matteucci*[4], *G. Feliciani*[5], *V. Rossetti*[6], *C. Cerchione*[7], *P. Caroli*[4];
[1]*Ospedale M. Bufalini, AUSL Romagna, Cesena, ITALY,*
[2]*Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY,*
[3]*Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy., Meldola, ITALY,*
[4]*Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY,*
[5]*Medical Physics Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY,*
[6]*Nuclear Medicine Unit, AUSL Romagna, Meldola, ITALY,*
[7]*Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY.*

OP-874

[^{68}Ga]Ga-PSMA-11 PET/CT Outperforms [^{18}F]FDG in Predicting Progression-Free Survival and Early Treatment Failure in Newly Diagnosed Multiple

Myeloma: A Prospective Prognostic Analysis
M. Di Franco[1], D. Bezzi[2], M. Talarico[3], E. Zamagni[3], S. Fanti[4,5], C. Nanni[5];
[1]Department of Radiology, University of California, Davis, Davis, CA, UNITED STATES OF AMERICA,
[2]Nuclear Medicine Unit, AUSL Romagna, Romagna, ITALY, Romagna, ITALY,
[3]Seràgnoli Institute of Hematology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,
[4]Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,
[5]Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-875

Promising performance of [^{68}Ga]Ga-PentixaFor PET/CT for initial staging and therapeutic evaluation of multiple myeloma patients in first line treatment or relapse: interim analysis.
C. François[1,2], C. Touzeau[2,3], L. Garderet[4], C. Mesguich[5], C. Aveline[6], C. Bailly[1,2], B. Jamet[1,2], F. Kraeber-Bodéré[1,2], C. Bodet-Milin[1,2];
[1]Nuclear Medicine Department, CHU Nantes, Nantes Université, Nantes, FRANCE,
[2]Nantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI^{2}NA, Nantes, FRANCE,
[3]Hematology Department, CHU Nantes, Nantes Université, Nantes, FRANCE,
[4]Hematology Department, Hôpital Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, FRANCE,
[5]Nuclear Medicine Department, CHU Bordeaux, Bordeaux, FRANCE,
[6]Nuclear Medicine Department, Hôpital Tenon, Assistance Publique Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, FRANCE.

OP-876

Clinical translation of a novel ^{18}F-labelled C-X-C chemokine receptor 4 radioligand: A prospective Phase I study
I. Alberts[1], S. Harsini[1], S. Kurkowsa[1], C. Sachepekidis[2], D. Villa[1], C. Venner[1], M. Chan[1], E. Rousseau[3], D. Wilson[1], H. Saprunoff[1], N. Colpo[1], C. Williams[1], M. Pourghiasian[1], P. Ravi[1], C. Uribe[1], D. Kwon[1], K. Lin[1], F. Benard[1];
[1]BC Cancer Agency, Vancouver, BC, CANADA,
[2]Department of Nuclear Medicine, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece, Alexandropoulis, GREECE,
[3]University of Sherbrooke, [2500] boul. de l'Université, Sherbrooke, Quebec, Canada, Sherbrooke, QC, CANADA.

OP-877

A Phase 1 Study Investigating the Safety, Biodistribution, and Dosimetry of [^{68}Ga]Ga-A9-6217 in Participants with Select Advanced or Metastatic Solid Tumours: Case series of selected patients.
R. Meehan[1], R. Hicks[2], J. Kabunda[3], J. Callahan[2], K. Ramonaheng[3], Z. S. Mohammadi[4], S. Sibiya[3], C. Davis[3], B. Vaughan[4], V. Miakushko[1], M. Dornan[1], P. Patel[1], J. Roncal[1], S. Hull[1], M. Sathekge[3];
[1]Alpha^9 Oncology, Boston, MA, UNITED STATES OF AMERICA,
[2]Melbourne Theranostic Innovation Centre, Melbourne, AUSTRALIA,
[3]Nuclear Medicine Research Infrastructure, Pretoria, SOUTH AFRICA,
[4]Royal North Shore Hospital, Sydney, AUSTRALIA.

1807

Wednesday, October 21, 2026, 09:45 - 11:15

Hall F1

Neuroimaging Committee: Neuroimaging: Novel Tracers and Emerging Clinical Applications

OP-878

Astrocyte-PET in Alzheimer's Disease Amyloid Cascade: Results from the ASTEROID cohort
M. Zeinaki[1], B. S. Rauchmann[2,3,4], J. S. Dorneich[1], L. Tagnin[1], L. Vogler[1], J. S. Gnörich[1], A. Gesenhues[1], D. Dhoqina[1], G. U. Höglinger[4,5,6], R. A. Werner[1], L. K. Frontzkowski[1,7], G. Salvadó[8,9,10], D. Vállez-García[8,9], F. Hirsch[7], D. Janowitz[7], K. Bürger[4,7], J. Vöglein[4,5,6], S. Stöcklein[11], S. Lindner[1], J. Levin[4,5,6], G. N. Bischof[12,13], N. Franzmeier[5,7], R. Perneczky[3,4], M. Brendel[1,4,5];
[1]Department of Nuclear Medicine, University Hospital LMU, Munich, GERMANY,
[2]Institute of Neuroradiology, University Hospital LMU, Munich, GERMANY,
[3]Department of Psychiatry and Psychotherapy, University Hospital LMU, Munich, GERMANY,
[4]German Center for Neurodegenerative Diseases, DZNE, Munich, GERMANY,
[5]Munich Cluster for Systems Neurology, SyNergy, Munich, GERMANY,
[6]Department of Neurology, University Hospital LMU, Munich, GERMANY,
[7]Institute for Stroke and Dementia Research, ISD, University Hospital LMU, Munich, GERMANY,
[8]Barcelonaβeta Brain Research Center, BBRC, Pasqual Maragall Foundation, Barcelona, SPAIN,
[9]Hospital del Mar Medical Research Institute, IMIM, Barcelona, SPAIN,
[10]Clinical Memory Research Unit, Department of Clinical Sciences Malmö, University, Lund, SWEDEN,
[11]Department of Radiology, University Hospital LMU, Munich, GERMANY,
[12]Department of Nuclear Medicine, University Hospital, Cologne, GERMANY,
[13]Life Molecular Imaging, LMI, Berlin, GERMANY.

OP-879

Neocortical [^{18}F]SMBT-1 Uptake Correlates with Plasma GFAP and pTau-217 Across the Alzheimer's Disease Continuum
N. Okamura[1], A. Ishiki[1], K. Hiraoka[2], R. Kobayashi[3], N. Tomita[1], B. Mesfin[2], Y. Wu[2], R. Harada[1], A. Kikuchi[2], K. Furukawa[1], H. Watabe[2], S. Mugikura[4], S. Kawakatsu[5], S. Furumoto[2], M. Tashiro[2];
[1]Tohoku Medical and Pharmaceutical University, Sendai, JAPAN,
[2]Research Center for Accelerator and Radioisotope Science, Tohoku University, Sendai, JAPAN,
[3]Yamagata University Hospital, Yamagata, JAPAN,
[4]Tohoku University Hospital, Sendai, JAPAN,
[5]Fukushima Medical University, Aizuwakamatsu, JAPAN.

OP-880

TSPO-PET Identifies a Clinically Actionable Predictor in Depression: DLPFC-AdjacentSkull-Meninges Inflammation Linking Antidepressant Response to Single-CellMechanisms
L. Xu[1], X. Song[2], K. Liao[1], P. Zheng[2], H. Pang[1];
[1]Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA,
[2]Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

OP-881

First Dual-Tracer PET Study of Mu and Kappa Opioid Receptor Availability in Alcohol Use Disorder
G. Emvalomenos[1], S. Kim[2], M. Grasso[2], G. Stanley[1], J. Gallezot[1], K. Fontaine[1], S. Najafzadeh[1], H. Gao[1], D. Labaree[1], X. Papademetris[1,3], S. Krishnan-Sarin[2], K. P. Cosgrove[1,2,4], E. D. Morris[1,2,5];
[1]Radiology and Biomedical Imaging, Yale University, New Haven, CT, UNITED STATES OF AMERICA,
[2]Psychiatry, Yale University, New Haven, CT, UNITED STATES OF AMERICA,
[3]Biomedical Informatics & Data Science, Yale University, New Haven, CT, UNITED STATES OF AMERICA,
[4]Neuroscience, Yale University, New Haven, CT, UNITED STATES OF AMERICA,
[5]Biomedical Engineering, Yale University, New Haven, CT, UNITED STATES OF AMERICA.

OP-882

Noradrenergic control of neurobehavior in human binge-eating disorder and obesity
S. Hesse[1,2], M. Rullmann[1], F. Zientek[1], A. Haddenhorst[3,2], H. Vöhringer[3,2], L. Okhof[3,2], G. A. Becker[1], A. Schildan[1], A. S. Juarascio[4], G. K. W. Frank[5,6], O. Sabri[1], A. Hilbert[3,2];
[1]Department of Nuclear Medicine, University of Leipzig Medical Center, Leipzig, GERMANY,
[2]Integrated Research and Treatment Center (IFB) Adiposity Diseases, University of Leipzig Medical Center, Leipzig, GERMANY,
[3]Behavioral Medicine Research Unit, Department of Psychosomatic Medicine and Psychotherapy, University of Leipzig Medical Center, Leipzig, GERMANY,
[4]Department of Psychology, Drexel University, Philadelphia, PA, UNITED STATES OF AMERICA,
[5]University of California San Diego, UCSD Eating Disorder Center, San Diego, CA, UNITED STATES OF AMERICA,
[6]Rady Children's Hospital San Diego, San Diego, CA, UNITED STATES OF AMERICA.

OP-883

Longitudinal [^{11}C]K-2 PET Reveals Synaptic Plasticity Underlying Auditory-Language Recovery after Cochlear Implantation in Living Human Brain
T. Sahara[1,2], H. Abe[2], W. Nakajima[2], M. Hatano[2], A. Kashio[1], Y. Arai[3], N. Oridate[3], K. Kondo[1], T. Takahashi[2];
[1]Department of Otorhinolaryngology and Head and Neck Surgery, Faculty of Medicine, University of Tokyo, Tokyo, JAPAN,
[2]Department of Physiology, Yokohama City University Graduate School of Medicine, Yokohama, JAPAN,
[3]Department of Otolaryngology, Yokohama City University Hospital, Yokohama, JAPAN.

OP-884

Synaptic Redistribution and Network Reorganization in Classic Trigeminal Neuralgia: A [^{18}F]SynVesT-1 PET Study with Exploratory Post-MVD Follow-up
H. Jiang[1], L. Xiao[1], J. Yang[1], A. Rominger[2], K. Shi[2], Y. Tang[1], S. Hu[1];
[1]Xiangya Hospital, Central South University, Changsha, CHINA,
[2]Department of Nuclear Medicine, Inselspital, Bern, SWITZERLAND.

OP-885

Impact of Socioeconomic Status on Brain Glucose Metabolism in a Large-scale ^{18}F-FDG PET Study
K. Pak[1], S. Shin[2], H. Nam[3];
[1]Pusan National University Hospital, Busan, KOREA, REPUBLIC OF,
[2]Samsung Changwon Hospital, Changwon, KOREA, REPUBLIC OF,
[3]Changwon Fatima Hospital, Changwon, KOREA, REPUBLIC OF.

OP-886

Clinical Performance of the Brain-Dedicated NeuroLF System in Amyloid PET Imaging of Alzheimer's Disease
H. Barthel[1,2], M. Shriver[3], M. Rullmann[2], S. Tiepolt[2], J. Fischer[4], I. Sacco[4], C. Hoorvash[4], M. Hüllner[5], P. Kaufmann[5], V. Treyer[5], B. Sattler[2], O. Sabri[2];
[1]Municipal Hospital Dessau, Dessau-Roßlau, GERMANY,
[2]Leipzig University Medical Centre, Leipzig, GERMANY,
[3]ProScan/NCH, Naples, FL, UNITED STATES OF AMERICA,
[4]Positrigo AG, Zurich, SWITZERLAND,
[5]University of Zurich Medical Centre, Zurich, SWITZERLAND.

1808

Wednesday, October 21, 2026, 09:45 - 11:15

Hall F2

Cardiovascular Committee: Going with the Flow: New Horizons in Quantitative Nuclear Cardiology

OP-887

Invited Speaker
F. Hyafil;
Hopital Européen Georges-Pompidou, Nuclear Medicine department, Paris, FRANCE.

OP-888

Stress Myocardial Blood Flow as the Key Prognostic Parameter in Patients with Diabetes Mellitus
M. Havel[1], M. Kaminek[2], G. Hornak[2], L. Quinn[2], G. Havlova[1], V. Kincl[3];
[1]University of Ostrava and University Hospital Ostrava, Department of Nuclear Medicine, Ostrava, CZECH REPUBLIC,
[2]Palacky University Olomouc and University Hospital Olomouc, Department of Nuclear Medicine, Olomouc, CZECH REPUBLIC,
[3]International Clinical Research Centre, St. Anne ś University Hospital, Faculty of Medicine, Masaryk University, Brno, CZECH REPUBLIC.

OP-889

Head-to-head Comparison of Multiple Cardiac Magnetic Resonance Parameters for the Detection of CMVD in Patients with INOCA: Validation with Integrated PET/MRI Scanner

R. Wen, *Q. Xie, M. Ni, B. Pan, X. Meng, X. Wang;*
The First Affiliated Hospital of University of Science and Technology of China., Hefei, CHINA.

OP-890

Females Have Higher Myocardial Perfusion Assessed by [15O]H2O PET Across Comorbidities and Left Ventricular Function: A Heterogeneous 701-Patient Referral Cohort

J. Larsson[1], *P. D. Mark*[1], *R. Haahr*[1], *M. Krakauer*[1], *R. Ripa*[1,2];
[1]*Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital – Bispebjerg and Frederiksberg Hospital, Copenhagen, DENMARK,*
[2]*Department of Clinical Medicine, University of Copenhagen, Copenhagen, DENMARK.*

OP-891

Determination of the Shortest Acquisition Time Window for Quantitative ^{18}F-Flurpiridaz Myocardial Perfusion Imaging and Characterization of Tracer Redistribution in Ischemic Myocardium

Y. Wen[1,2,3], *H. Song*[1,2,3], *Z. Xiang*[1,2,3], *R. Shen*[1,2,3], *Z. Qin*[1,2,3], *J. Zhao*[1,2,3], *Y. Jia*[1,2,3], *Y. Hou*[4], *M. Yang*[5], *Y. Wang*[6], *H. Wang*[1,2,3], *P. Wu*[1,2,3], *S. Li**[1,2,3];
[1]*Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, CHINA,*
[2]*Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, Taiyuan, Shanxi, CHINA,*
[3]*CAEA Center of Excellence on Nuclear Technology Applications for Diagnosis, Treatment & Transformation of Nuclear Medicine, Taiyuan, Shanxi, CHINA,*
[4]*Department of Radiation Oncology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, CHINA,*
[5]*Department of Nuclear Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, CHINA,*
[6]*Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, CHINA.*

OP-892

Pushing the limits in myocardial perfusion LAFOV PET/CT - how low can rubidium activity be? A pilot study

C. Bregenzer[1], *K. Chandrasekaran*[1], *A. O. Rominger*[1], *Â. R. Felgosa Cardoso*[1], *H. Sari*[1,2], *F. Caobelli*[1];
[1]*Department of Nuclear Medicine, Inselspital, University Hospital Bern, University of Bern, Bern, SWITZERLAND,*
[2]*Siemens Healthineers International AG, Zürich, SWITZERLAND.*

OP-893

Exploring a Novel Paradigm: Prospective Comparison of ^{18}F-Flurpiridaz and ^{18}F-FDG PET/CT for Imaging Malignant Tumours

H. Song[1,2,3], *J. Zhao*[1,2,3], *Z. Xiang*[1,2,3], *K. Zhou*[1,2,3], *Y. Wen*[1,2,3], *H. Li*[1,2,3], *Q. Lian*[1,2,3], *Y. Wang*[4,5], *Z. Qin*[1], *Y. Hou*[6], *Z. Wu*[1,2,3], *P. Wu*[1,2,3], *S. Li*[1,2,3];
[1]*Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, CHINA,*
[2]*Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Taiyuan, CHINA,*
[3]*CAEA Center of Excellence on Nuclear Technology Applications for Diagnosis, Treatment & Transformation of Nuclear Medicine, Taiyuan, CHINA,*
[4]*United Imaging Healthcare Co., Ltd., Shanghai, CHINA,*
[5]*ShanghaiTech University, Shanghai, CHINA,*
[6]*Department of Radiation Oncology, First Hospital of Shanxi Medical University, Taiyuan, CHINA.*

OP-894

Relationship Between Epicardial Adipose Tissue and Coronary Vascular Function by Rubidium-82 PET/CT

A. D'Antonio, *T. Mannarino, E. Zampella, R. Assante, S. Azizi, F. Ingallinella, Y. Natale, E. Di Donna, A. Cuocolo, W. Acampa;*
Department of Advanced Biomedical Sciences, University of Naples "Federico II", Napoli, ITALY.

OP-895

Simultaneous Assessment of Myocardial and Renal perfusion by cardiac ^{82}Rb-PET/CT Reveals Heterogeneous Cardio-Renal Microvascular Patterns

B. Siadari[1,2], *M. den Haan*[2], *F. Smit*[2,3], *S. de Boer*[3], *K. Bogaard*[3], *H. Lamb*[2], *E. Comans*[1], *T. Ruytenberg*[2], *F. van Velden*[2], *L. d. Geus-Oei*[2], *I. Dekkers*[1];
[1]*Amsterdam university medical centre, Amsterdam, NETHERLANDS,*
[2]*Leiden university medical centre, Leiden, NETHERLANDS,*
[3]*Alrijne Leiderdorp Ziekenhuis, Leiderdorp, NETHERLANDS.*

1811

Wednesday, October 21, 2026, 09:45 - 11:15

Hall G1

Other Clinical Studies: What Doesn't Fit Anywhere Else (But Absolutely Should)

OP-896

Prospective Evaluation of Diagnostic Performance of Multi-cancer Early Detection Test of Markers Apo10+TKTL in Circulating Macrophages in Adult Patients with Suspected or Confirmed Macroscopic Solid Premalignant or Malignant Lesion(s) Referred to FDG PET/CT and in Healthy Adults: PanTumPET Study

S. Balogova[1], *I. Jaksic*[1], *L. Noskovicova*[1], *B. Duchaj*[1], *P. Musil*[1], *D. Sutovska*[1], *P. Zahorcova*[2], *K. Cillikova*[2], *J. Kovacs*[2], *L. Hunakova*[1], *R. Hruby*[2], *L. Lukac*[1];
[1]*Comenius University of Bratislava, Bratislava, SLOVAKIA,*
[2]*Bory Hospital a.s., Bratislava, SLOVAKIA.*

OP-897

Choosing wisely after PET/CT: turning incidental findings into guideline-concordant next steps

P. C. Holdgaard, *M. D. Rasmussen, J. B. Medhus, J. B. Espesen;*
Lillebaelt Hospital - University Hospital of Southern Denmark, Vejle, DENMARK.

OP-898

Patient preferences and experience with total-body and long-axial field-of-view PET/CT: A prospective, multi centre cross-sectional study

I. Alberts[1], *P. Ravi*[1], *S. Perreira*[2], *M. Assenza*[3], *N. Colpo*[1], *C. Williams*[1], *R. Mei*[3], *S. Fanti*[3], *F. Benard*[1], *S. Chicklore*[2], *G. Cook*[2];
[1]*BC Cancer, Vancouver, BC, CANADA,*
[2]*Guy's and St Thomas' NHS Foundation Trust, London, UNITED KINGDOM,*
[3]*IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

OP-899

Biodistribution Evaluation to Reduce Administered Radiopharmaceutical Dose on LOng Axial Field of VieW PET Scanners (BELOW) Trial: Preliminary Results of [^{18}F]FDG Cohort

M. Steemers - de Boer[1], *E. A. Aalbersberg*[1], *J. J. M. A. Hendrikx*[1], *W. V. Vogel*[1], *A. J. A. T. Braat*[1,2], *B. J. de Wit - van der Veen*[1];
[1]*Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, NETHERLANDS,*
[2]*University Medical Center Utrecht, Utrecht, NETHERLANDS.*

OP-900

Whole-Body [^{18}F]F-AraG PET Imaging in Individuals Without Malignancy: Subclinical Immune-Metabolic Activity with Oncological Implications

J. Levi[1], *T. Nobashi*[2], *U. Shrestha*[3], *H. Cabrera*[1], *J. Blecha*[3], *H. Vanbrocklin*[3], *R. Flavell*[3], *Y. Seo*[3], *H. Chae*[1];
[1]*CellSight Technologies, San Francisco, CA, UNITED STATES OF AMERICA,*
[2]*Kyoto University Hospital, Kyoto, JAPAN,*
[3]*University of California San Francisco, San Francisco, CA, UNITED STATES OF AMERICA.*

OP-901

Variability of body composition and metabolism in healthy controls undergoing test/retest [^{18}F]FDG-PET/CT imaging with 1-year intervals: A Multi-Scanner Validation

C. Vu[1,2], *X. Yang*[1,3], *N. Akatani*[1], *J. Taki*[4], *S. Takeda*[4], *T. Yamase*[5], *K. Yokoyama*[5], *M. Pires*[6], *S. Gutschmayer*[6], *D. Ferrara*[6], *T. Beyer*[6], *H. Wakabayashi*[1];
[1]*Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, JAPAN,*
[2]*Division of Advanced Preventive Medical Science, Graduate School of Advanced Preventive Medical Sciences, Kanazawa University, Kanazawa, Ishikawa, JAPAN,*
[3]*Department of Nuclear Medicine, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Ishikawa, JAPAN,*
[4]*PET Center, Kanazawa Advanced Medical Center, Kanazawa, Ishikawa, JAPAN,*
[5]*Public Central Hospital of Matto Ishikawa, Hakusan, Ishikawa, JAPAN,*
[6]*Quantitative Imaging Medical Physics (QIMP) Team, Medical University of Vienna, Vienna, AUSTRIA.*

OP-902

Gallium-68 FAPI PET/CT for Non-Invasive Assessment of Liver Fibrosis: Association with Fibrosis Indices

C. Soydal, *M. Çidemal, M. Araz, N. Ö. Küçük;*
Ankara University Medical Faculty, Ankara, TÜRKIYE.

OP-903

AI-Assisted Detection of Incidental Pulmonary Embolism in PET/CT: Impact on Workflow and Reporting Time

M. Orevi, *S. Ben Haim, J. Sosna;*
Hadassah Medical Center, Jerusalem, ISRAEL.

OP-904

Comprehensive comparison of [^{68}Ga]Ga-FAPI-46 and [^{18}F]FAPI-74 PET/CT in a prospective study: Physiological biodistribution and malignant lesion uptake

W. Tao[1,2], *A. Küper*[1], *K. Pabst*[1], *R. Hamacher*[1], *N. Hammersen*[1], *M. Nader*[1], *H. Hautzel*[1], *F. Barbato*[1], *L. Umutlu*[1], *M. Schuler*[1], *K. Herrmann*[1], *W. Fendler*[1], *D. Kersting*[1];
[1]*Department of Nuclear Medicine, West German Cancer Center, German Cancer Consortium and National Center for Tumor Diseases site, University Hospital Essen, Essen, GERMANY,*
[2]*Department of Nuclear Medicine, The Affiliated Huaian No. [1] People's Hospital of Nanjing Medical University, Huai'a, CHINA.*

1901

Wednesday, October 21, 2026, 11:25 - 11:45

Hall A

Closing Ceremony

OP-903

Closing Ceremony

V. Garibotto; *Geneva University and Geneva University Hospitals, Geneva, SWITZERLAND.*

e-Poster Presentation Sessions

209

Sunday, October 18, 2026, 08:00 - 09:30

Hall G2

Dosimetry e-Poster

EPS-001

[^{18}F]FDG Uptake and Dosimetry Measurements of the Healthy Fetus from LAFOV PET/IdCT Imaging

K. Madsen[1], *S. Holm[1], E. Lundholm[1], F. E. Høi-Hansen[1], M. M. K. Stolberg[1], F. L. Andersen[1,2], K. Korsholm[1];*
[1]Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, DENMARK,
[2]Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen, DENMARK.

EPS-002

First in-human dosimetry of [^{68}Ga]Ga-CPCR4A-L for CXCR4-directed PET imaging

J. Brosch-Lenz[1], *N. Dreher[1], L. Stopper[2], J. Enke[1], A. Casini[2], C. Lapa[1];*
[1]University of Augsburg, Augsburg, GERMANY,
[2]Technical University of Munich, Munich, GERMANY.

EPS-003

Absorbed dose threshold for soft tissue lesion complete response of differentiated thyroid cancer metastases treated with radioiodine: comparison between tumour control probability assessed with RECIST and ^{124}I PET

C. Chiesa[1], *G. Tognolini[2], M. G. Bruno[1], G. Carletti[1], G. Gorgoni[3], F. Rubino[1], O. Laura[3], M. Poli[3], F. Severi[3], A. Lorenzoni[1], A. Alessi[1], D. Scienza[1], L. Grappeja[4], B. Parducci[4], E. Mesiani[4], M. Salgarello[3], M. Maccauro[1];*
[1]Foundation IRCCS Istituto Nazionale Tumori, Milano, ITALY,
[2]Postgraduate Specialisation School in Medical Physics, University of Milan, Milan, ITALY,
[3]IRCCS Sacro Cuore Don Calabria, Negrar, ITALY,
[4]Postgraduate Specialisation School in Nuclear Medicine, University of Milan, Milano, ITALY.

EPS-004

Quantitative Evaluation of Hematologic Toxicity and Organ Dosimetry Following [^{177}Lu] Lu-DOTATATE

S. Barna[1], *P. Czina[2], B. Hanna[2], Á. Budai[1], A. Kovács[2], C. Csikos[2], I. Garai[1];*
[1]Scanomed, Debrecen, HUNGARY,
[2]University of Debrecen, Debrecen, HUNGARY.

EPS-005

Quantifying the Tumor Sink Effect in [^{177}Lu] LuPSMA617 Therapy: Implications for Personalized Dosimetry

S. Bagheri[1], *A. Ebrahimifard[1], D. Librizzi[2], F. Eilsberger[1], M. Luster[1], B. Hooshyar Yousefi[1];*
[1]Department of Nuclear Medicine, School of Medicine, Philipps University Marburg, Marburg, GERMANY,
[2]Department of Nuclear Medicine, Bethel Evangelical Clinic, University Hospital OWL, Bielefeld, Germany, Bielefeld, GERMANY.

EPS-006

Impact of misregistration on parotid gland dosimetry in ^{177}Lu-PSMA therapy: A multicentric study

L. Vergnaud[1,2], *J. Gasteuil[3], M. Koulibaly[3], L. Marage[3], S. Contu[4], E. Seutin[4], J. Badel[5,2], A. Giraudet[5], A. Sanchez-Lajusticia[5], C. Garcia[6], D. Deandreis[6], Y. Cras[7], N. Anizan[8], P. Schwartz[9], D. Sarrut[2], S. Lamart[1];*
[1]Autorité de sûreté nucléaire et de radioprotection (ASNR), Direction de la recherche et de l'expertise en santé/SDOS/LEDI, Fontenay-aux-Roses, FRANCE,
[2]CREATIS; CNRS UMR 5220; INSERM U 1044; University of Lyon; INSA Lyon; University Lyon 1, Lyon, FRANCE,
[3]Department of Nuclear Medicine, Centre Antoine Lacassagne University of Côte d'Azur, Nice, FRANCE,
[4]Department of Epidemiology, Biostatistics and Health Data, Centre Antoine Lacassagne University of Côte d'Azur, Nice, FRANCE,
[5]Lumen Nuclear Medicine Department, Centre Léon Bérard, Lyon, FRANCE,
[6]Department of Nuclear Medicine, Gustave Roussy, Villejuif, FRANCE,
[7]Department of Medical Physics, Gustave Roussy, Villejuif, FRANCE,
[8]Department of Medical Physics, Institut Bergonié, Bordeaux, FRANCE,
[9]Department of Nuclear Medicine, Institut Bergonié, Bordeaux, FRANCE.

EPS-007

Biomarker-Enhanced Early Single-Time-Point Dosimetry for Lu-177-PSMA Therapy Using Deep Learning

Y. Liu[1], *A. Afshar-Oromieh[2], A. Rominger[2], K. Shi[2], G. Mok[1];*
[1]Biomedical Imaging Laboratory (BIG), Department of Electrical and Computer Engineering, Faculty of Science and Technology, Macao, MACAO,
[2]Department of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, SWITZERLAND.

EPS-008

Comparison of small-volume sampling with whole-kidney segmentation for renal dosimetry based on ^{177}Lu quantitative SPECT/CT in PRRT and PSMA-RLT

M. Aanounou[1], *A. S. Demers[1], A. Beaulieu[1], F. Arsenault[1], G. April[1], F. A. Buteau[1], F. Pouliot[2], J. M. Beauregard[1];*
[1]Department of Radiology and Nuclear Medicine, Université Laval;
Division of Nuclear Medicine, Department of Medical Imaging, CHU de Québec - Université Laval, Quebec City, QC, CANADA,
[2]Department of Surgery, Université Laval ;
Division of Urology, Department of Surgery, CHU de Québec - Université Laval, Quebec City, QC, CANADA.

EPS-009

A Decade of SIRT: Lung Shunt, Activity Delivery and Agreement Between Planning and Post-Treatment Dosimetry

D. Gillett[1], *F. Leek[1], R. Crawford[1], I. Harper[1], D. Hulse[1], E. Shin[1], S. Heard[1], N. Shaida[1], T. See[1], N. Hilliard[1], M. Hoare[1], L. Aloj[2];*
[1]Cambridge University Hospitals NHSFT, Cambridge, UNITED KINGDOM,
[2]University of Cambridge, Cambridge, UNITED KINGDOM.

EPS-010

Quantitative Actinium-225 SPECT/CT Reconstruction: Insights from the ACTI-QUANT AAPM Grand Challenge 2025

O. Ivashchenko[1], *E. Hippeläinen[2], M. Sandström[3], J. Tran-Gia[4], J. O'Doherty[5];*
[1]University Medical Center Groningen, Groningen, NETHERLANDS,
[2]University of Helsinki, Helsinki, FINLAND,
[3]Uppsala University, Uppsala, SWEDEN,
[4]University Hospital Würzburg, Würzburg, GERMANY,
[5]Medical University of South Carolina, Charleston, SC, UNITED STATES OF AMERICA.

EPS-011

Feasibility of predictive and post-treatment dosimetry using 203/^{212}Pb as a theranostic pair for targeted alpha therapy

D. Kästner[1], *E. Michler[1], M. Pretze[1], J. Müller[1], H. Hartmann[1], F. Brandt[1], R. Freudenberg[1], M. K. Schultz[2], C. Brogsitter[1], R. A. Bundschuh[1];*
[1]Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, GERMANY,
[2]Perspective Therapeutics Inc., Coralville, IA, UNITED STATES OF AMERICA.

EPS-012

Radiological impact of impurities from ^{212}Pb-Chloride production for targeted radionuclide therapy

G. Sandker, *Y. Buchatskaya, J. Garousi, G. de With, R. Bouwman;*
NRG Pallas, Petten, NETHERLANDS.

EPS-013

Multicenter DEQCT-Based Quantification of Bone and Water Mass Fractions in a ^{3}D-Printed Metastatic Vertebral Phantom

M. Salas Ramirez[1], *A. Theisen[1], J. Leube[1], A. Gehring[1], L. Pieper[2], A. Noto[3], W. Claeys[4], A. Delker[3], M. Koole[4], J. Tran-Gia[1];*
[1]Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,
[2]Department of Radiation Oncology, University Hospital Erlangen, Erlangen, GERMANY,
[3]Department of Nuclear Medicine, Ludwig Maximilian University Hospital, Munich, GERMANY,
[4]Nuclear Medicine & Molecular Imaging, KU Leuven, Leuven, BELGIUM.

EPS-014

MyeloDose: A Software Tool for Red Marrow Dosimetry Using Skeletal S-Factors

J. Blakkisrud[1], *C. Stokke[1,2];*
[1]Division for Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY,
[2]Department of Physics, University of Oslo, Oslo, NORWAY.

EPS-015

A microdosimetric analysis correlating DNA damage and apoptosis in LNCaP cells following treatment with [^{177}Lu]Lu-PSMA-617

P. Hawarihewa[1], *S. Resch[1], M. Rumiantcev[1], H. Scherthan[2], M. Zacherl[1], F. Lindheimer[1], G. Böning[1], R. A. Werner[1,3], S. I. Ziegler[4], M. Brendel[1,5,6], A. Delker[1];*
[1]LMU University Hospital, Munich, GERMANY,
[2]Bundeswehr Institute of Radiobiology affiliated to the Univ. of Ulm, Munich, GERMANY,
[3]Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Sciences, Division of Nuclear Medicine and Molecular Imaging, Baltimore, MD, UNITED STATES OF AMERICA,
[4]Department of Nuclear Medicine, Hannover Medical School (MHH), Hannover, GERMANY,
[5]SyNergy, University of Munich, Munich, GERMANY,
[6]DZNE - German Center for Neurodegenerative Diseases, Munich, GERMANY.

EPS-016

Spheroid-based binding kinetics, diffusion and dosimetry of radiopharmaceuticals

S. Lundsten Salomonsson[1,2], *G. Garrido-Hernandez[3,4], H. Ögren[1], M. Konijnenberg[3], J. Nonnekens[3,4];*
[1]Ridgeview Instruments, Uppsala, SWEDEN,
[2]Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN,
[3]Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, NETHERLANDS,
[4]Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, NETHERLANDS.

EPS-017

Dose-dependent senolytic window defines navitoclax efficacy as an adjuvant to targeted alpha- and beta-emitting radiopharmaceutical therapy

M. Lindsey, *A. Smith, M. Bio Idrissou, Y. Medina-Guevara, L. Wehner, J. Cabahug, J. Munson, H. Comas-Rojas, A. Pinchuk, L. Lambert-Lepesevich, O. Kwon, B. Bednarz, R. Hernandez;*
University of Wisconsin-Madison, Madison, WI, WI, UNITED STATES OF AMERICA.

EPS-018

Improving Biological Mechanism and Cellular Dosimetry in Targeted Radiotherapy of Prostate Cancer by Combining ^{64}Cu-iPSMA-iCS-GRP78 and ^{177}Lu-iPSMA-iCS-GRP78

D. Trujillo Benítez[1], *E. Azorin-Vega[1], L. Meléndez-Alafort[2], G. Ferro-Flores[1];*
[1]instituto Nacional de Investigaciones Nucleares, La Marquesa, México, MEXICO,
[2]Veneto Institute of Oncology IOV–IRCCS, Via Gattamelata [64], [35128] Padova (Padua), ITALY.

EPS-019

The radiosensitizing potential of DNA-PK inhibitors in breast cancer targeted radiotherapy

D. Niculae[1], *D. A. Niculae[2], R. Serban[1], D. Cocioaba[1], A. Necsoiu[1], R. Leonte[1];*
[1]Horia Hulubei National Institute for Physics and Nuclear Engineering, Magurele, ROMANIA,
[2]University of Medicine and Pharmacy Carol Davila, Bucharest, ROMANIA.

EPS-020

Development and multicenter evaluation of a patient-specific ^{3}D-printed vertebral phantom for quantitative SPECT/CT imaging

A. Theisen[1], *J. Leube*[1], *A. Gehring*[1], *L. Pieper*[1], *A. Noto*[2], *A. Delker*[2], *M. Koole*[3], *W. Claeys*[3], *M. Salas-Ramirez*[1], *J. Tran-Gia*[1];
[1]*Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,*
[2]*LMU University Hospital, Munich, GERMANY,*
[3]*Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM.*

EPS-021

Histological Analysis of SSTR2 Expression in Normal Bone Marrow Biopsies: Frequency, Spatial Distribution and Cell Size

J. Hemmingsson[1], *S. Gharaghani*[2], *P. Johansson*[2], *K. Smits*[1], *E. Brynjarsdóttir*[3], *A. Hallqvist*[3], *P. Bernhardt*[1];
[1]*University of Gothenburg - Inst. of Clinical Sciences - Dept. of Medical Radiation Sciences, Gothenburg, SWEDEN,*
[2]*University of Gothenburg - Institute of Biomedicine - Dept. of Laboratory Medicine, Gothenburg, SWEDEN,*
[3]*University of Gothenburg - Inst. of Clinical Sciences - Dept. of Oncology, Gothenburg, SWEDEN.*

309

Sunday, October 18, 2026, 09:45 - 11:15
Hall G2

A Journey Through the Cardiovascular System

EPS-022

^{18}F-FDG PET/CT for Multidimensional Clinical Evaluation of Aortic Dissection and Aneurysm: A Retrospective Cohort Study

H. Zhan, *C. Qin, Y. Lv, X. Ren, S. Wei, D. Zheng, Z. Zhou, Z. Dai, X. Liu, X. Lan;*
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EPS-023

Molecular Imaging of Vascular Fibroblast Activation using [F18]F-FAPI-74 PET/CT: Association with Aortic Calcification rather than Aortic Diameter

C. Kreuer[1], *S. C. Siegmund*[1], *M. Brendel*[1,3], *S. M. Berthold*[1], *K. Stark*[2,3,4], *T. Higuchi*[5], *F. L. Giesel*[6], *R. A. Werner*[1,3,7], *S. C. Siegmund*[1];
[1]*Department of Nuclear Medicine, LMU University Hospital, Ludwig-Maximilians-Universität München, Munich, GERMANY,*
[2]*Medical Clinic I, Department of Cardiology, LMU University Hospital, Ludwig-Maximilians-Universität München, Munich, GERMANY,*
[3]*Interfaculty Center for Endocrine and Cardiovascular Disease Network Modelling and Clinical Transfer (ICONLMU), Ludwig-Maximilians-Universität München, Munich, GERMANY,*
[4]*German Center for Cardiovascular Research (DZHK), Munich Heart Alliance (MHA), Partner Site Munich, Munich, GERMANY,*
[5]*Department of Nuclear Medicine and Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, GERMANY,*
[6]*Department of Nuclear Medicine, University Hospital Düsseldorf, Düsseldorf, GERMANY,*
[7]*Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM, ENETS Certified Center of Excellence), LMU University Hospital, Ludwig-Maximilians-Universität München, Munich, GERMANY.*

EPS-024

Molecular Imaging of Activated Fibrotic Pathogenesis in Calcified Atherosclerosis: A Biomarker of Cardiovascular Risk

C. Kreuer[1], *S. C. Siegmund*[1], *M. Brendel*[1,2], *H. Eyob*[1], *S. M. Berthold*[1], *Z. I. Kolabas*[1], *S. Fiedler*[2,3], *F. Jaudas*[4,5], *E. Wolf*[2,4,5], *A. Blutke*[2,3], *F. L. Giesel*[6], *T. Higuchi*[7], *K. Stark*[2,8,9], *S. T. Kunte*[3,10], *M. G. Fischer*[8], *R. A. Werner*[1,2,11];
[1]*Department of Nuclear Medicine, LMU University Hospital, Ludwig-Maximilians-Universität München, Munich, GERMANY,*
[2]*Interfaculty Center for Endocrine and Cardiovascular Disease Network Modelling and Clinical Transfer (ICONLMU), Ludwig-Maximilians-Universität München, Munich, GERMANY,*
[3]*Institute of Veterinary Pathology, Center for Clinical Veterinary Medicine, Ludwig-Maximilians-Universität München, Munich, GERMANY,*
[4]*Chair of Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, Munich, GERMANY,*
[5]*Center for Innovative Medical Models (CiMM), Ludwig-Maximilians-Universität München, Munich, GERMANY,*
[6]*Department of Nuclear Medicine, University Hospital Düsseldorf, Düsseldorf, GERMANY,*
[7]*Department of Nuclear Medicine and Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, GERMANY,*
[8]*Medical Clinic I, Department of Cardiology, LMU University Hospital, Ludwig-Maximilians-Universität München, Munich, GERMANY,*
[9]*German Center for Cardiovascular Research (DZHK), Munich Heart Alliance (MHA), Partner Site Munich, Munich, GERMANY,*
[10]*Small Animal Clinic, Center for Clinical Veterinary Medicine, Ludwig-Maximilians-Universität München, Munich, GERMANY,*
[11]*Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM, ENETS Certified Center of Excellence), LMU University Hospital, Ludwig-Maximilians-Universität München, Munich, GERMANY.*

EPS-025

Longitudinal [^{18}F]FDG PET/MR Assessment of Arterial Inflammation in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

S. Xue[1], *C. Hu*[2], *L. Li*[3], *H. Einspieler*[1], *A. Kiss*[4], *B. K. Podesser*[4], *J. B. Klein*[5], *M. Hacker*[1], *X. Li*[1], *X. Zhou*[6], *j. Liu*[7];
[1]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna Gene, Vienna, AUSTRIA,*
[2]*Ludwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research and Translational Surgery, Vienna, AUSTRIA,*
[3]*Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Shanghai, CHINA,*
[4]*Ludwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research and Translational Surgery, Medical University of Vienna, Vienna, AUSTRIA,*
[5]*Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, AUSTRIA,*
[6]*Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, CHINA,*
[7]*Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA.*

EPS-026

Vascular Patterns of Incidental Thrombosis on PET/CT in Oncology: Insights from a Retrospective Study

M. Vaillant[1], *C. Rodríguez Rey*[1], *A. Ortega*[1], *R. Cano*[1], *C. Wakfie*[1], *L. García-Belaustegui*[1], *G. Cuesta*[1], *P. Daudén*[1], *P. Nespral*[1], *P. Bascuñana*[2], *M. Romero*[1], *L. Carreño Mancilla*[1], *M. Cabrera*[1];
[1]*Nuclear Medicine Department, Hospital Clínico San Carlos, Madrid, SPAIN,*
[2]*Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid Hospital Clínico San Carlos, Madrid, SPAIN.*

EPS-027

Habitat-based quantification of carotid plaque heterogeneity withintegrated ^{18}F-FDG PET/MR for metabolic activity assessment and cardiovascular risk stratification

R. Qin[1], *C. Zheng*[1], *Z. Liu*[2], *Y. Yang*[3], *J. Lu*[1];
[1]*Xuanwu Hospital, Capital Medical University, Beijing, CHINA,*
[2]*Beijing United Imaging Research Institute of Intelligent Imaging, Beijing, CHINA,*
[3]*Beijing United Imaging Healthcare Technology Development Co., Ltd., Beijing, CHINA.*

EPS-028

Go with the Flow: Prognostic Value of CZT-SPECT Myocardial Flow Reserve Quantification

M. Marusso Fizzani, *M. J. Díez-Castro, A. Palomar-Muñoz, S. Bondia-Bescós, N. Calviño, D. Sánchez-Artuñedo, A. Roque, M. N. Pizzi, C. Gamez-Cenzano;*
Hospital Universitario Vall d'Hebron, Barcelona, SPAIN.

EPS-029

Normative Modeling of Whole-Body Metabolic Coordination from FDG-PET Reveals Systemic Dysregulation in HFrEF

X. Li[1], *Z. Shi*[2], *J. Ding*[3,4], *Z. Wang*[1], *O. C. Kulterer*[1], *F. Kiefer*[5], *C. Philippe*[1], *B. Geist*[1], *S. Wen*[1], *X. Zhang*[2], *J. Zhao*[3,4], *M. Hacker*[1], *S. Xue*[1], *X. Li*[1];
[1]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna, AUSTRIA,*
[2]*Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA,*
[3]*Department of Nuclear Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, CHINA,*
[4]*State Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, CHINA,*
[5]*Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Vienna, AUSTRIA.*

EPS-030

Association of gSPECT-Derived Entropy with Left Ventricular Remodelling in Patients with Left Bundle Branch Block

T. Klarica Gembic[1], *J. Anicic*[2,3], *J. Nekic*[1,3];
[1]*Clinical Hospital Center Rijeka, Department of Nuclear Medicine, Rijeka, CROATIA,*
[2]*Clinical Hospital Center Rijeka, Clinic for Cardiovascular Diseases, Rijeka, CROATIA,*
[3]*University of Rijeka, Faculty of Medicine, Rijeka, CROATIA.*

EPS-031

Reduced left ventricular ejection fraction is independently associated with decreased myocardial blood flow: Findings from a heterogeneous population examined with [^{15}O]H2O PET

P. Mark[1,2], *J. Larsson*[1], *R. Haahr*[1,3], *M. Krakauer*[1], *R. Ripa*[1,4];
[1]*Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital - Bispebjerg Frederiksberg Hospital, Copenhagen, DENMARK,*
[2]*Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DENMARK,*
[3]*Department of Cardiology Y, Copenhagen University Hospital – Bispebjerg and Frederiksberg Hospital, Copenhagen, DENMARK,*
[4]*Department of Clinical Medicine, University of Copenhagen, Copenhagen, DENMARK.*

EPS-032

Clinical Factors and Imaging Characteristics of Abnormal Myocardial FAPI Uptake in Cancer Patients: A New Perspective for Visualizing Subclinical Myocardial Remodeling

Y. Lyu, *C. Qin, D. Zheng, Z. Zhou, S. Wei, Z. Dai, X. Liu, H. Zhan, X. Lan, Z. Gao;*
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Scien, Wuhan, CHINA.

EPS-034

Myocardial uptake volume in ^{68}Ga-DOTATOC PET/CT: Effects of respiratory gating, reconstruction parameters and segmentation threshold

K. Johnsrud[1,2], *H. Fretheim*[1,3,4], *A. G. Sherwani*[2], *L. Gridset*[2], *E. G. Müller*[2], *M. Revheim*[1,5], *T. Hjørnevik*[1,6,7];
[1]*Institute of Clinical Medicine, University of Oslo, Oslo, NORWAY,*
[2]*Department of Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY,*
[3]*Department of Rheumatology, Oslo University Hospital, Oslo, NORWAY,*
[4]*Lillehammer Hospital for Rheumatic Diseases, Lillehammer, NORWAY,*
[5]*The Intervention Centre, Oslo University Hospital, Oslo, NORWAY,*
[6]*Institute for Experimental Medical Research, Oslo University Hospital, Oslo, NORWAY,*
[7]*Department of Physics and Computational Radiology, Oslo University Hospital, Oslo, NORWAY.*

EPS-035

^{131}Iodine-metaiodobenzylguanidine(MIBG) Myocardial Scintigraphy Profile and its Association with Heart Rate Variability(HRV) and Autonomic Symptoms in Patients with Parkinson's Disease: A Pilot Cross-Sectional Study

V. Balgi, *N. Pandit, R. Sugumaran, S. Velkumary, H. Kumar KT;*
Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, INDIA.

EPS-036

Early-phase ^{99}mTc-DPD scintigraphy in suspected cardiac amyloidosis:Analysis ofsemi-quantitativeparameters

L. Ferber[1], *L. Kessler*[1], *C. Rischpler*[1], *S. Settelmeier*[2], *T. Telli*[1], *Z. Varasteh*[1], *A. Carpinteiro*[3], *C. Spielvogel*[4], *T. Hagenacker*[5], *L. Michel*[2], *K. Herrmann*[1], *T. Rassaf*[2], *M. Sraieb*[1], *D. Kersting*[1], *W. Fendler*[1];
[1]*Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,*
[2]*Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, GERMANY,*
[3]*Department of Hematology, West German Tumor Center, University Hospital Essen, Essen, GERMANY,*
[4]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA,*
[5]*Department of Neurology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, Essen, GERMANY.*

EPS-037

Myocardial ^{99}mTc-DPD Uptake Changes in Tafamidis-Treated Transthyretin Cardiac Amyloidosis. Preliminary Results from an Ongoing Research Project

M. Zapardiel[1], *C. Wakfie Corieh*[1], *A. Restrepo Córdoba*[2], *J. Goirigolzarri Artaza*[2], *A. Ortega Candil*[1], *A. Berardinelli Isea*[1], *M. Vaillant López*[1], *M. Romero Porras*[1], *L. Carreño Mancilla*[1], *M. Cabrera Martin*[1];
[1]*Department of Nuclear Medicine, Hospital Clínico San Carlos, Madrid, SPAIN,*
[2]*Department of Cardiology, Hospital Clínico San Carlos, Madrid, SPAIN.*

EPS-038

Lung Ventilation-Perfusion PET/CT using Galligas and Gallium-68-MAA for the diagnosis of pulmonary embolism: a prospective diagnostic accuracy study versus CT pulmonary angiography

P. Le Roux, *F. Blanc-Beguin, B. Dissaux, S. Hennebicq, P. Lissillour, C. Tromeur, R. Le Pennec, D. Simon, F. Couturaud, G. Le Gal, P. Robin, P. Salaun;*
Brest University Hospital, Brest, FRANCE.

EPS-039

Quantitative Lung Perfusion in Pulmonary Vascular Diseases: A Comparative Study of V/Q SPECTand Phase-Resolved Functional Lung MRI

R. Ma, *P. He, L. Li, P. Han, H. Li, L. Fu;*
China-Japan Friendship Hospital, Beijing, CHINA.

EPS-040

Quantitative SPECT/CT Ventilation-Perfusion Imaging to Assess the Effects of Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension

R. Ma, *P. He, L. Li, P. Han, H. Li, L. Fu;*
China-Japan Friendship Hospital, Beijing, CHINA.

EPS-041

Feasibility study of pulmonary perfusion analysis using early dynamic ^{18}F-NaF PET/CT acquisitions

A. Auxillion[1], *M. Savanovic*[2], *S. Masson*[1], *P. D'abadie*[1], *K. Fard*[1];
[1]*Institut Caribéen d'Imagerie Nucléaire, Centre Hospitalier Universitaire de Martinique, Fort de France, MARTINIQUE, Fort de France, MARTINIQUE,*
[2]*Siemens Healthineers, Courbevoie, FRANCE.*

EPS-042

Calculation of Myocardial Ischaemic Burden (%) on a Dedicated CZT D-SPECT Camera Based on SSS, SRS, and SDS

D. Knollmann, *D. Schuelgen, W. M. Schaefer;*
Kliniken Maria Hilf, Moenchengladbach, GERMANY.

509

Sunday, October 18, 2026, 15:00 – 16:30

Hall G2

Oncology & Theranostics e-Poster

EPS-043

Peripheral Uptake Suppression with Increasing Metastatic Burden in Breast Cancer

M. Rusticali[1], *K. Tehlan*[2,1], *L. Förner*[2,1], *N. Ditsch*[2], *C. Lapa*[2], *T. Wendler*[2,1];
[1]*Technical University of Munich, Munich, GERMANY,*
[2]*Universitätsklinikum Augsburg, Augsburg, GERMANY.*

EPS-044

Clinicopathological Factors Associated with Multiple Intramammary ^{18}F-FES Uptake on dbPET

K. Miyake[1], *Y. Shimizu*[2], *Y. Kitano*[2], *S. Yasumura*[2], *T. Oishi*[2], *K. Itagaki*[3], *M. Kataoka*[4], *M. Kawashima*[5], *N. Masuda*[5], *Y. Nakamoto*[2];
[1]*Department of Advanced Medical Imaging Research, Kyoto University Graduate School of Medicine, Kyoto, JAPAN,*
[2]*Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, JAPAN,*
[3]*Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, JAPAN,*
[4]*Preemptive Medicine and Lifestyle-related Disease Research Center, Kyoto University Hospital, Kyoto, JAPAN,*
[5]*Department of Breast Surgery, Kyoto University Hospital, Kyoto, JAPAN.*

EPS-045

Visualizing HER2-Positive Tumor via a Tunable Antibody Fragment with Optimized Plasma Half-Life: From Bench to First-in-Human Imaging

Y. Hua[1], *B. Li*[2], *Y. Xu*[1], *J. Zhang*[3], *X. Chen*[4], *C. Yu*[1];

[1]*Affiliated Hospital of Jiangnan University, Wuxi, CHINA,*
[2]*Henan University of Science and Technology, Luoyang, CHINA,*
[3]*National University of Singapore, Singapore, SINGAPORE,*
[4]*Shandong Cancer Hospital and Institute, Shandong, CHINA.*

EPS-046

Predictive Value of Baseline [^{18}F]FDG PET/CT for Pathological Complete Response in Triple-Negative Breast Cancer

N. Vasconcelos, *D. Silva, R. Marão, R. Lopes, S. Fontão de Castro, L. Violante, H. Duarte, I. Lucena Sampaio;*
Instituto Português de Oncologia do Porto, Porto, PORTUGAL.

EPS-047

Investigating LAFOV Dynamic PET/CT and Total-Body Kinetic Parameters for the Early Identification of Immunotherapy Responders in Metastatic Melanoma: Initial Data from the DYNAMO Study

A. Di Giorgio[1], *I. Brusa*[2], *D. Dall'Olio*[3], *P. Marchese*[4], *F. Comito*[4], *G. Siepe*[5], *C. Nanni*[2], *G. Castellani*[2,3], *S. Fanti*[1,2], *A. Farolfi*[2];
[1]*Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,*
[2]*Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[3]*Department of Medical and Surgical Sciences, University of Bologna, Bologna, ITALY,*
[4]*Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[5]*Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

EPS-048

Evolution of Intra-lesional FDG Metabolic Heterogeneity During Immunotherapy in Metastatic Melanoma

L. Förner[1,2], *J. Enke*[1], *C. Sulski*[1], *J. Welzel*[1], *C. Lapa*[1], *K. Tehlan*[1,2], *T. Wendler*[1,2];
[1]*University Hospital Augsburg, Augsburg, GERMANY,*
[2]*Technical University of Munich, Munich, GERMANY.*

EPS-049

^{18}F-FDG PET/CT in Rectal Cancer Management: Impact on Staging and Prognosis

C. Ortiz Muñoz, *J. Rodríguez Gómez, D. Martínez Osorio, J. Gatón Ramírez, N. Almeida Romera, F. López-Bermejo García, F. Pena Pardo, G. Molina Mendoza, P. Bravo Torrivilla, M. Contreras Ameduri, L. Fermin Ledesma, C. Lucas Lucas, M. Talavera Rubio, V. Poblete García;*
Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN.

EPS-050

Diagnostic, Therapeutic, and Economic Impact of the Protocolized Use of ^{68}Ga-DOTATOC PET/CT in Patients with Neuroendocrine Tumours (IMDOTA-NETs Study).

M. Cruz Montijano, *M. Casallas Cepeda, J. Bonilla Plaza, I. García Megías, M. Meneses Navas, J. Montalva Pastor, L. García Zoghby, S. Guzmán Ortiz, A. García Vicente;*
Complejo Hospitalario de Toledo, Toledo, SPAIN.

EPS-051

Baseline TotalMITV-to-SUVmean Ratio as an Independent Prognostic Marker in NET Patients Undergoing PRRT

E. Fortunati[1], *G. Lamberti*[2], *E. Andrini*[3], *V. Allegri*[1], *E. Lodi Rizzini*[4], *A. Monte*[2], *M. Di Franco*[5], *C. Mosconi*[2,6], *A. Morganti*[4,7], *D. Campana*[2], *S. Fanti*[1,5], *V. Ambrosini*[1,5];
[1]*Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[2]*Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, ITALY,*
[3]*Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[4]*Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[5]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,*
[6]*Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, ITALY,*
[7]*DIMES, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY.*

EPS-052

Measuring What Matters: Volumetric SSTR-PET Tumor Burden in GEP-NET Prognosis

C. Battisti[1], *C. Ferrari*[1], *A. Di Palo*[1], *D. Candido*[1], *A. R. Pisani*[1], *A. G. Nappi*[1], *D. Rubini*[2], *E. Lauricella*[3], *M. Bacalim*[3], *M. Cives*[3], *G. Rubini*[1];
[1]*Nuclear Medicine Unit, DIM, University-Policlinico, Bari, ITALY,*
[2]*Radiology Unit, DIM, University-Policlinico, Bari, ITALY,*
[3]*Division of Medical Oncology, DIM, University-Policlinico, Bari, ITALY.*

EPS-053

PSMA PET Nodal Burden Identifies Optimal Candidates for Androgen Deprivation Therapy in Oligorecurrent Prostate Cancer Treated with Metastasis-Direct Therapy

C. Pini[1,2], *P. Zaurito*[1,3], *L. Quarta*[1,3], *A. Viti*[1,3], *P. Scilipoti*[1,3], *A. Santangelo*[1,3], *A. Cosenza*[1,3], *M. Brancaccio*[1,3], *A. Galdieri*[1,3], *A. Occhi*[1,3], *F. Barletta*[1,3], *S. Scuderi*[1,3], *V. Cucchiara*[1,3], *A. Stabile*[1,3], *C. Mercinelli*[1,4], *A. Necchi*[1,4], *M. Roupret*[5], *F. Montorsi*[1,3], *G. Gandaglia*[1,3], *A. Briganti*[1,3], *M. Sollini*[1,2], *A. Chiti*[1,2];
[1]*Vita-Salute San Raffaele University, Milan, ITALY,*
[2]*Department of Nuclear Medicine, IRCCS San Raffaele Hospital, Milan, ITALY,*
[3]*Department of Urology, IRCCS San Raffaele Hospital, Milan, ITALY,*
[4]*Department of Oncology, IRCCS San Raffaele Hospital, Milan, ITALY,*
[5]*GRC 5 Predictive Onco-Uro Research Group, Department of Urology, Pitié Salpêtrière Hospital, Sorbonne University, Paris, FRANCE.*

EPS-054

Staging and Theranostic Potential of [^{18}F]PSMA-1007 PET/CT in Clear Cell Renal Cell Carcinoma: A Prospective Head-to-Head Comparison with Standard-of-Care CECT and Evaluation of PSMA-RLT Applicability

V. Bobrov, *A. Khalimon, D. Khodakova, A. Lokhova, M. Khodzhibekova, G. Khamadeeva, A. Nikiforuk, T. Lazutina, I. Pylova, A. Kalpinskiy, A. Leontev;*
P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

EPS-055

CrossTumor Evidence Mapping of PSMA Expression: Ranked Scoping Analysis of 171 Human Studies

T. Ebenhan[1,2], *W. Cordier*[1], *C. A. Gouws*[1,2], *M. M. Sathekge*[3,2], *M. T. Tshabalala*[1,2];
[1]*University of Pretoria, Pretoria, SOUTH AFRICA,*
[2]*Nuclear Medicine Research Infrastructure - NuMeRI NPC, Pretoria, SOUTH AFRICA,*
[3]*University of Pretoria & Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA.*

EPS-056

Synchronous Renal Masses Detected on PSMA PET/CT in Patients with Prostate Cancer: Imaging, Pathologic Features, and Clinical Implications

K. Kimura[1], *A. Kaba*[2], *T. J. Choi*[1], *J. Czernin*[1], *B. Shuch*[2], *J. Calais*[1];
[1]*Department of Nuclear Medicine and Theranostics, David Geffen School of Medicine at UCLA, Los Angeles, CA, UNITED STATES OF AMERICA,*
[2]*Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, UNITED STATES OF AMERICA.*

EPS-057

Association of Staging F-18 FDG PET/CT Parameters with Overall Survival and Mortality in Bladder Cancer

D. Yildiz Colak, *S. Demirtas Senlik, B. Demirel, G. Ucmak;*
University of Health Sciences Türkiye, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Clinic of Nuclear Medicine, Ankara, TÜRKIYE.

EPS-058

[^{68}Ga]-FAPI PET/CT for Early Treatment Response Assessment in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin plus Pembrolizumab

H. Menold[1], *C. Weigel*[2], *A. Valitova*[2], *S. Zschäbitz*[3], *B. Wängler*[4], *G. Davarci*[4], *H. Rudolf*[4], *P. Cieslik*[4], *F. Wessels*[1], *K. Kowalewski*[1], *F. Grawe*[5,2];
[1]*Department of Urology and Urological Surgery, University Medical Center Mannheim, GERMANY,*
[2]*DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Heidelberg, GERMANY,*
[3]*Department of Medical Oncology, National Center for Tumor Diseases, University Hospital, Heidelberg, GERMANY,*
[4]*Molecular Imaging and Radiochemistry, Clinic of Radiology and Nuclear Medicine, University Medical Center Mannheim, GERMANY,*
[5]*Department of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, GERMANY.*

EPS-059

Head-to-Head Comparison of ^{68}Ga-FAPI and ^{18}F-FDG PET/CT Across a Heterogeneous Oncologic Cohort Using Near-Simultaneous Imaging

M. Haidar, *J. Rizkallah, O. El Sardouk, N. Saliba, F. Zeineddine, A. Shamseddine, A. Tfayli, H. Assi, S. Temraz, A. S. Abi-Ghanem;*
American University of Beirut, Beirut, LEBANON.

EPS-060

The Added Value of [^{68}Ga]Ga-FAPi PET/CT for Peritoneal Cancer Index Assessment in Peritoneal Metastases

G. Beydagi[1], *P. Yesilkaya*[2], *K. Akcay*[2], *A. Gormez*[3], *N. Köksal*[4], *F. Sen*[5], *N. Alan*[2];
[1]*Department of Nuclear Medicine, University of Health Sciences Turkey, Istanbul Training and Research Hospital, Istanbul, TÜRKIYE,*
[2]*Yeditepe University, Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[3]*Yeditepe University, Department of Radiology, Istanbul, TÜRKIYE,*
[4]*Yeditepe University, Department of General Surgery, Istanbul, TÜRKIYE,*
[5]*Avrasya Hospital, Department of Medical Oncology, Istanbul, TÜRKIYE.*

EPS-061

Clinical Evaluation of [^{68}Ga]Ga-LNTH-1363S FAP-Targeted PET in Refractory and Relapsed Cancer: Comparison with [^{18}F]FDG PET and Morphological Imaging

J. Enke[1,2,3], *F. Aghapour Zangeneh*[4], *A. Lazar*[4], *J. Baessler*[2], *A. Rominger*[4], *F. Caobelli*[4], *K. Shi*[4], *J. W. Babich*[5], *L. Fenzl*[2,3], *N. Dreher*[2,3], *A. Dierks*[2,3], *C. Lapa*[2,3], *R. Seifert*[4];
[1]*Department of Nuclear Medicine and Theranostics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA,*
[2]*Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY,*
[3]*Bavarian Cancer Research Centre (BZKF), Augsburg, GERMANY,*
[4]*Department of Nuclear Medicine, Inselspital, University Hospital Bern, University of Bern, Bern, SWITZERLAND,*
[5]*Ratio Therapeutics, Boston, MA, UNITED STATES OF AMERICA.*

EPS-062

The AI Paradox in Renal Cell Carcinoma Radiomics: Traditional Machine Learning Outperforms Neural Networks in Multi-Endpoint Dual-Phase ^{18}F-FDG PET Analysis with Exploratory Delta Radiomics

D. Palivela[1], *S. Taywade*[2], *D. Datta*[1], *R. Kumar*[1];
[1]*All India Institute of Medical Sciences, Jodhpur, INDIA,*
[2]*All India Institute of Medical Sciences, Nagpur, INDIA.*

EPS-063

Theranostic Algorithm: Correlation Between Molecular Imaging and Tissue Biomarkers

I. Mavroeidi[1], *P. Fragoso Costa*[1], *I. Pretzell*[1], *S. Kreutzfeldt*[2], *S. Theurer*[1], *S. Fröhling*[2], *E. Wardelmann*[3], *M. Schuler*[1], *K. Herrmann*[1], *J. Siveke*[1], *W. Fendler*[1], *R. Hamacher*[1], *D. Kersting*[1];
[1]*Essen University Hospital, Essen, GERMANY,*
[2]*NCT Heidelberg, Heidelberg, GERMANY,*
[3]*Institut for Pathology, Münster University Hospital, Münster, GERMANY.*

EPS-063a

A Machine Learning Approach for Personalized ^{177}Lu-PSMA therapy: Pretherapeutic Response Classification via PSMA PET Radiomics

H. Nasrollahi[1], *M. Hajian*[2], *M. Khateri*[1], *G. Rendl*[1], *G. Schweighofer-Zwink*[1], *B. Spottiswoode*[3], *C. Pirich*[1], *M. Farsad*[4], *F. Zini*[2], *M. Beheshti*[1];
[1]*Division of Molecular Imaging and Theranostics, University Hospital Salzburg, Salzburg, AUSTRIA,*
[2]*Department of Computer Science, Free University of Bozen-Bolzano, Bolzano, ITALY,*
[3]*Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA,*
[4]*Regional Hospital of Bolzano, Bolzano, ITALY.*

609

Sunday, October 18, 2026, 16:45 - 18:15

Hall G2

Physics e-Poster

EPS-064

Assessment of Phantom and Patient Image Quality in a PET System with DOI-Sensitive Detectors

A. Blomgren[1], *B. Brunt*[2], *M. Palm*[2], *C. Vallgren*[2], *K. Zeimpekis*[3], *M. Viscione*[3], *A. Rominger*[3], *K. Shi*[3];
[1]*Department of Nuclear Medicine, Bern, SWITZERLAND,*
[2]*Terapet SA, Geneva, SWITZERLAND,*
[3]*Department of Nuclear Medicine, Inselspital, Bern, SWITZERLAND.*

EPS-065

Phantomless Quality Assurance and Continuous Calibration of PET Systems Using Intrinsic Background Radiation from LYSO Scintillators

A. Cohen[1,2], *V. Barbulescu*[2], *F. Jansen*[2,2,2];
[1]*GE Healthcare, Milwaukee, WI, UNITED STATES OF AMERICA,*
[2]*GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA.*

EPS-066

Accurate image-derived input functions using few-second imaging on Siemens Quadra LAFOV PET-CT

H. Buschhold[1], *P. Marsden*[2], *G. Krokos*[2];
[1]*King's College London, London, UNITED KINGDOM,*
[2]*King's College London & Guy's & St Thomas' PET Centre, London, UNITED KINGDOM.*

EPS-067

A Pilot Study of Brain Glucose Metabolism and Network Reorganization in Kallmann Syndrome Based on FDG PET

c. zhou, *M. Zhao;*
the Third Xiangya Hospital, Central South University, Changsha, CHINA.

EPS-068

Regional Brain PET Quantification Under Low Dose Scanning on Biograph Vision 600 and Biograph Vision.X

Y. Salimi[1], *A. Sanaat*[1], *H. Sari*[2], *V. Garibotto*[1], *H. Zaidi*[1];
[1]*Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, SWITZERLAND,*
[2]*Siemens Healthineers International AG, Zürich, SWITZERLAND.*

EPS-069

Small-lesion detectability and reconstruction optimisation on the Biograph Vision X vs Vision 600: a whole-body anthropomorphic phantom study

D. Bourhis, *C. Robert Le Guen, M. Pavoine, R. Abgral, P. Salaün;*
CHU Brest, Médecine nucléaire, Brest, FRANCE.

EPS-070

Preclinical Evaluation of GD2-Targeted peptide as PET Tracers for Neuroblastoma

J. Chu, *P. Wang, C. Wang, E. Ren, X. Su;*
Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA.

EPS-071

Fluorinated radiopharmaceuticals sorption onto plasticized polyvinyl chloride automated injector tubings: implications for patient dosing

L. Kazek[1], *P. Tylski*[2], *A. Flaus*[3], *C. Bolot*[1], *E. Levigoureux*[1], *Y. Le Basle*[4], *E. Feschet-Chassot*[5], *B. Mailhot-Jensen*[5], *A. Durand*[6], *A. Chabanse*[7], *P. Chennell*[4], *S. Chaïb*[1,8,9];
[1]*Hospices Civils de Lyon, Hôpital Louis Pradel, Service Pharmaceutique, Radiopharmacie, Bron, FRANCE,*
[2]*Hospices Civils de Lyon, Hôpital Louis Pradel, Service de Physique Médicale et Radioprotection, Bron, FRANCE,*
[3]*Hospices Civils de Lyon, Hôpital Louis Pradel, Service de Médecine Nucléaire, Bron, FRANCE,*
[4]*Université Clermont Auvergne, CHU Clermont-Ferrand, CNRS, Clermont Auvergne INP, ICCF, F-^{63000}, Clermont-Ferrand, FRANCE,*
[5]*Université Clermont Auvergne, CNRS, Clermont Auvergne INP, ICCF, F-^{63000}, Clermont-Ferrand, FRANCE,*
[6]*Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'oncologie médicale, Lyon, FRANCE,*
[7]*Groupe Hospitalier de la région de Mulhouse et Sud-Alsace, service pharmaceutique, Radiopharmacie, Mulhouse, FRANCE,*
[8]*Département Biophysique, Institut des Sciences Pharmaceutiques et Biologiques, Université Claude Bernard Lyon [1], Lyon, FRANCE,*
[9]*Lyon Cancer Research Center, CNRS, INSERM, Lyon, FRANCE.*

EPS-072

Development of a Vertex-to-Thighs Anthropomorphic Phantom for Quantitative PET and SPECT Imaging

A. Gunawan[1], *I. McKay*[1], *K. Eng*[1], *M. Yu*[1], *R. Khan*[1], *T. Chowdhury*[1], *C. Li*[2,3], *R. Bahr*[4], *A. Rahmim*[2,3,5], *C. F. Uribe*[3,4,5], *J. Fowler*[2,3];
[1]*Department of Mechanical Engineering, University of British Columbia, Vancouver, BC, CANADA,*
[2]*Department of Physics & Astronomy, University of British Columbia, Vancouver, BC, CANADA,*
[3]*Department of Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC, CANADA,*
[4]*Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, BC, CANADA,*
[5]*Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.*

EPS-073

Comparison of Lesion Detectability in CZT-based SPECT/CT Between Tc-99m and Y-90 Using an Anthropomorphic Phantom

D. Campizes, *F. Miguéis, C. Barros, P. Gil, V. Sousa, J. Isidoro;*
ULS de Coimbra, Coimbra, PORTUGAL.

EPS-074

Multi-center Performance Evaluation of a Dual Collimator CZT Based Ring SPECT/CT System

Y. Hazan[1], *H. Aravinth Devendranath*[2], *A. Averill*[1], *V. Ferri*[1], *N. Hammersen*[2], *C. Hruska*[3], *J. Kennedy*[4], *T. Palchan Hazan*[4], *G. Rabin*[1], *G. Reiter*[1], *D. Wedeleit*[2], *R. Zananiri*[1];
[1]*GE Healthcare, Haifa, ISRAEL,*
[2]*University Hospital Essen, Essen, GERMANY,*
[3]*Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA,*
[4]*Rambam Health Care Campus, Haifa, ISRAEL.*

EPS-075

Towards a Standardized Radiotheranostic Workflow: Integration of Dosimetry and Treatment Verification Inspired by Radiotherapy

M. Savio Salas, *E. Quinteros, M. Bastianello, A. Bordón, R. Ruggeri;*
Integral Oncology Center - Leben Salud, Neuquen, ARGENTINA.

EPS-076

CZT Tail characterization of ^{3}D-ring camera for improved scatter correction in Lu-177 SPECT reconstruction.

F. Dupont[1], *T. Assoignon*[2], *R. Danieli*[3,4], *M. Hesse*[1];
[1]*Cliniques universitaires Saint-Luc, Bruxelles, BELGIUM,*
[2]*UCLouvain, Bruxelles, BELGIUM,*
[3]*Hôpital Universitaire de Bruxelles, Bruxelles, BELGIUM,*
[4]*Université Libre de Bruxelles, Bruxelles, BELGIUM.*

EPS-077

Quantitative ^{177}Lu SPECT Reconstruction Differences: SSIM & Radial Profile Metrics

L. Vávrová[1], *A. Denis-Bacelar*[2], *J. Kurth*[3], *I. Hristova*[4], *R. Boellaard*[5], *D. Ferrara*[4], *M. Lassmann*[1], *J. Dickson*[6], *J. Tran-Gia*[1];
[1]*Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,*
[2]*National Physical Laboratory, Teddington, UNITED KINGDOM,*
[3]*Rostock University Medical Center, Rostock, GERMANY,*
[4]*EANM Forschungs GmbH, Vienna, AUSTRIA,*
[5]*Amsterdam UMC, Amsterdam, NETHERLANDS,*
[6]*University College London Hospitals, London, UNITED KINGDOM.*

EPS-078

Comparison of ^{131}I-Imaging Performance of a Dual-Collimator CZT full-ring and Conventional NaI SPECT/CT systems

H. Devendranath[1,2], *Y. Hazan*[3], *J. Kertscher*[1,2], *W. Jentzen*[1,2], *E. Emond*[4], *R. Zananiri*[3], *G. Reiter*[4], *V. Ferri*[5], *K. Herrmann*[1,2], *N. Hammersen*[1,2];
[1]*Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,*
[2]*German Cancer Consortium (DKTK), partner site Essen, a partnership between German Cancer Reseearch Center (DKFZ) and University Hospital Essen, Essen, GERMANY,*
[3]*GE HealthCare, Haifa, ISRAEL,*
[4]*GE HealthCare GmbH, Düsseldorf, GERMANY,*
[5]*GE Medical Systems Italia S.p.A, Milan, ITALY.*

EPS-079

Quantitative SPECT/CT Imaging of Actinium-225: Development and Validation of a Calibration Framework for Patient-Specific Dosimetry in Targeted Alpha Therapy

A. Ashfaq, *F. Eilsberger, M. Luster;*
Philipps University Marburg, Marburg, GERMANY.

EPS-080

Patient-Informed Synthetic Lesion Insertion for PET/SPECT Reconstruction Optimisation: An Observer Study

N. Aghakhanolia[1,2], *A. Shariftabrizi*[3], *O. Gharibi*[2,4], *J. Fowler*[2,4], *F. Yousefirizi*[2,5], *A. Rahmim*[1,2,5], *P. Esquinas*[5,6];
[1]*School of Biomedical Engineering, University of British Columbia, Vancouver, BC, CANADA,*
[2]*Department of Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC, CANADA,*
[3]*Division of Nuclear Medicine, Department of Radiology, University of Iowa Carver College of Medicine, Iowa, IA, UNITED STATES OF AMERICA,*
[4]*Department of Physics & Astronomy, University of British Columbia, Vancouver, BC, CANADA,*
[5]*Department of Radiology, University of British Columbia, Vancouver, BC, CANADA,*
[6]*Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, BC, CANADA.*

EPS-081

Do networks from whole-body [^{18}F]FDG-PET/CT reflect the metabolic regulation of glucose?

C. Loisel[1], *M. Pires*[2], *M. Kirkeli Eldevik*[3,4], *C. Hinge*[5], *S. Gutschmayer*[2], *F. Orlhac*[1], *F. Littrup Andersen*[5,6], *O. Lajord Munk*[3,4], *T. Beyer*[2], *I. Buvat*[1];
[1]*Institut Curie, Orsay, FRANCE,*
[2]*QIMP Team, Medical University of Vienna, Vienna, AUSTRIA,*
[3]*Department of Nuclear Medicine, Aarhus University Hospital, Aarhus, DENMARK,*
[4]*Department of Clinical Medicine, Aarhus University, Aarhus, DENMARK,*
[5]*Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, DENMARK,*
[6]*Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DENMARK.*

EPS-082

Optimisation of Parathyroid Imaging using a Digital CZT-Based SPECT/CT System: Clinical Evaluation of a Simultaneous Dual-Tracer [^{123}I]I/[^{99m}Tc]Tc-Sestamibi Protocol

F. Serani[1], *E. Celadin*[2], *S. Zampieri*[1], *P. Zucchetta*[3], *R. Simeone*[3], *V. Bodanza*[3], *G. Grassetto*[3], *L. Turk*[3], *D. Cecchin*[1];
[1]*Nuclear Medicine Unit, Department of Medicine DIMED, University of Padova;*
Nucleare Medicine Unit, DIDAS, University Hospital of Padova, Padova, ITALY,
[2]*Department of Medicine DIMED, University of Padova, Padova, ITALY,*
[3]*Nucleare Medicine Unit, DIDAS, University Hospital of Padova, Padova, ITALY.*

EPS-083

Opposing bias of Ga-68 PSMA-PET/CT and mpMRI for intraprostatic tumour extent: prospective comparison with whole-mount histopathology in the DEPROMP trial

B. Kreppel[1], *M. Ritter*[1], *C. Schmidt*[1], *G. Kristiansen*[1], *F. C. Gärtner*[1], *J. Luetkens*[1], *U. Attenberger*[1], *C. Ohlmann*[2], *S. Hauser*[1], *J. Ellinger*[1], *P. Krausewitz*[1], *M. Anspach*[2], *M. Essler*[1];
[1]*University Hospital Bonn, Bonn, GERMANY,*
[2]*Johanniter Kliniken Bonn, Bonn, GERMANY.*

EPS-084

Performance characterisation of a novel ultra-high resolution CZT gamma camera with DOI sensitivity

A. Cherlin, *M. Exley, I. Baistow, N. Atkins;*
Kromek Ltd, Sedgefield, UNITED KINGDOM.

EPS-085

Sequential Positive-then-Negative Dual-Tracer PET Imaging Strategy: Enabling Precise Lesion Quantificationand One-Stop MultidimensionalCharacterization

R. Shen[1,2,3], *Z. Xiang*[1,2,3], *S. He*[4], *H. Song*[2,3], *Y. Wen*[2,3], *Y. Jia*[2,3], *J. Zhao*[1,2,3], *Z. Qin*[1,2,3], *H. Wang*[1,2,3], *M. Yang*[5], *Z. Wu*[1,2,3], *Y. Wang*[6], *S. Li*[1,2,3], *P. Wu**[1,2,3];
[1]*Department of Nuclear Medicine,First Hospital of Shanxi Medical University, Taiyuan, Shanxi, CHINA,*
[2]*Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, Taiyuan, Shanxi, CHINA,*
[3]*CAEA Center of Excellence on Nuclear Technology Applications for Diagnosis, Treatment & Transformation of Nuclear Medicine, Taiyuan, Shanxi, CHINA,*
[4]*Department of Radiology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, CHINA,*
[5]*Department of Nuclear Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, CHINA,*
[6]*Chinese Military Medical School, National Clinical Research Center for Geriatric Diseases, The Second Medical Center, Chinese PLA General Hospital, Beijing, CHINA.*

709

Monday, October 19, 2026, 08:00 - 09:30
Hall G2

The Science of Radiopharmaceutical Preparation

EPS-086

^{68}Ga-kits can be simple - Gallium is a "friendly" metal after all

G. Claude[1], *S. Shafei*[2], *M. Balzer*[1], *P. De Jong*[2], *C. Njiki Noufelé*[3], *W. Brenner*[1], *S. Spreckelmeyer*[1];
[1]*Charité – Universitätsmedizin Berlin, Klinik für Nuklearmedizin, Berlin, GERMANY,*
[2]*Freie Universität Berlin, Berlin, GERMANY,*
[3]*Vivantes, Klinik für Nuklearmedizin, Berlin, GERMANY.*

EPS-087

Towards a Distributed and Future-Proof Supply of Medical Isotopes: the DANTE Compact Fusion Neutron Source

T. Verdier[1], *S. Fehér*[2];
[1]*DANTE Fusion ApS, Birkerød, DENMARK,*
[2]*Frontiers in Energy Innovations GmbH, Garching, GERMANY.*

EPS-088

A Multi-Radionuclide Platform for Immunoconjugate Radiolabeling

J. Masset, *A. Dubart, C. Vanasschen, M. Hawotte, R. Veronesi, E. Duray, C. Warnier;*
Trasis, Ans, BELGIUM.

EPS-089

Ensuring Secure Supply of Enriched Stable Isotopes for the Growing Radiopharmaceutical Market

A. Watson, *M. Essa, A. Ceruso;*
Urenco Isotopes, Almelo, NETHERLANDS.

EPS-090

Synthesis and evaluation of aTerbium-161-RM2 radiopharmaceutical for Radionuclide Therapy

S. Sibiya[1,2,3], *S. Maus*[4], *M. Shungube*[1,2], *S. Mdanda*[1,2,3], *Y. Mzizi*[1,3,2], *A. Mokoena*[1], *Q. Zikhali*[1], *L. Mohlala*[1], *K. Ramonaheng*[1,2,3], *M. Qebetu*[1,2,3], *T. Ratsakatika*[1], *S. du Plessis*[5], *J. Zeevart*[6,1], *M. Sathekge*[1,2,3];
[1]*NuMeRI NPC, Pretoria, SOUTH AFRICA,*
[2]*Department Of Nuclear Medicine, Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA,*
[3]*University Of Pretoria, Pretoria, SOUTH AFRICA,*
[4]*Universitaetsklinikum des-Saarlandes, Homburg, GERMANY,*
[5]*IsoNexus, Pretoria, SOUTH AFRICA,*
[6]*Nuclear Energy Corporation South Africa, Pretoria, SOUTH AFRICA.*

EPS-091

A Generator-Compatible Production of n.c.a. ^{166}Ho for Targeted Radionuclide Therapy

Z. Talip[1], *E. Renaldin*[1], *U. Köster*[2], *C. Hillhouse*[1], *N. van der Meulen*[1], *R. Eichler*[1];
[1]*Paul Scherrer Institut, Villigen, SWITZERLAND,*
[2]*Institut Laue-Langevin, Grenoble, FRANCE.*

EPS-092

Adverse Reactions To Radiopharmaceuticals From 2020 To 2025

C. Piedelobo Vaquero[1], *L. Cebollada Cameo*[1], *L. Sanz Vazquez*[1], *E. Dobra Neacsu*[1], *S. G. Horcas Villaverde*[2], *J. Pérez Iruela*[1];
[1]*Servicio de Radiofarmacia. Hospital Universitario Ramón y Cajal., Madrid, SPAIN,*
[2]*Servicio de Medicina Nuclear. Hospital Universitario Ramón y Cajal., Madrid, SPAIN.*

EPS-093

Optimized Manufacturing of [^{18}F]DPA714: A GMPReady Process for Clinical TSPOPET

A. Humblot-Negri, *P. Novelli, L. Trump, C. Warnier;*
Trasis, Ans, BELGIUM.

EPS-094

Copper filters or calibration nightmares? Measuring I-123 and In-111 with confidence

A. Fenwick, *A. Ogunjimi, N. Ramirez, E. Bendall;*
National Physical Laboratory, Teddington, UNITED KINGDOM.

EPS-095

The Tracer Factory: Advancing Knowledge Exchange and Harmonisation in Radiopharmaceutical Manufacturing

N. Van Camp[1], *S. Zullino*[2], *A. D. Windhorst*[3];
[1]*Laboratory of Advanced PET Imaging, MIRCen - Neuratris, Biological Institute Jacob, CEA, Fontenay aux Roses, FRANCE,*
[2]*Tracer Factory Workgroup & Experts, https://eatris.eu/tracer-factory/ ,EATRIS, Amsterdam, NETHERLANDS,*
[3]*Department Radiology & Nuclear Medicine, Amsterdam UMC, Amsterdam, NETHERLANDS.*

EPS-096

Scaling Up Ac-225 Production from the Ra-226(p,2n)Ac-225 Reaction: Can we Automate the Separation of Actinium-225 from Radium-226 Using a Commercial Radiochemistry Module?

A. Yordanov, *M. Stika, S. Phillips, S. Jannetti, M. Leuschner;*
Ionetix Corporation, Lansing, MI, UNITED STATES OF AMERICA.

EPS-097

Multivariate Optimisation of an HPLC-DAD method for identification and radiochemical purity assessment of [^{18}F]PSMA-1007

G. Camillo Gomes de Oliveira, *C. Lino Dos Santos Costa, M. Bicalho Silveira;*
Nuclear Technology Development Center, Belo Horizonte, BRAZIL.

EPS-098

A228Th/^{224}Ra generator based on citrate solution for production of high-purity ^{224}Ra for radiopharmaceuticals

K. Fure[1], *R. G. Li*[1], *A. L. Brandsnes*[1], *S. Kling*[2,1], *J. R. Karlson*[1];
[1]*Oncoinvent Solutions AS, Oslo, NORWAY,*
[2]*MedtechByrån, Linköping, SWEDEN.*

EPS-099

Process, Analytical and Stability Validation of [^{18}F]F-SiTATE and [^{177}Lu]Lu-DOTATATE: Implementation of a Cyclotron-based Theragnostic Platform

J. Franco[1], *J. Giglio*[2];
[1]*Universidad de la República de Uruguay/Ciclotrón Colombia, Medellin, COLOMBIA,*
[2]*Universidad de la República de Uruguay/CUDIM, Montevideo, URUGUAY.*

EPS-100

Scaling PSMA PET in ResourceLimited Settings: KitBased Performance, Cost and Radiation TradeOffs

T. Ebenhan[1,2,3], *L. Mohlala*[2], *J. Kleynhans*[4], *B. Marjanovic-Painter*[3], *J. Wagener*[3], *C. Davis*[5,2], *J. Mahapane*[5], *L. Smith*[2], *J. Zeevaart*[3], *J. Suthiram*[3], *M. M. Sathekge*[5,2];
[1]*University of Pretoria, Pretoria, SOUTH AFRICA,*
[2]*Nuclear Medicine Research Infrastructure - NuMeRI NPC, Pretoria, SOUTH AFRICA,*
[3]*South African Nuclear Energy Corporation (necsa), Pelindaba, SOUTH AFRICA,*
[4]*Czech Technical University in Prague, Prague, CZECH REPUBLIC,*
[5]*University of Pretoria & Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA.*

EPS-101

Presenting An Innovative Automated Synthesis Module System Dedicated To Astatine- 211 Labelled Radiopharmaceuticals

L. Metello[1], *M. Capoulas*[1], *V. Gupta*[2], *A. Uhlending*[3], *V. Hugenberg*[3], *L. Cunha*[1], *D. Jolly*[1];
[1]*IsoPor Group, Portugal, PORTUGAL,*
[2]*German Cancer Research Center (DKFZ), Heidelberg, GERMANY,*
[3]*Herz und Diabeteszentrum NRW - HDZ, Univ der Ruhr - Univ. Bochum, Bad Oeynhausen, GERMANY.*

EPS-102

Medical Radionuclide Cyclotron Production: Focus on ^{67}Cu and ^{67}Ga

N. Zhutova[1], *S. A. Brühlmann*[1], *M. Walther*[1], *K. Kopka*[1,2], *M. Kreller*[1];
[1]*Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY,*
[2]*Technische Universität Dresden, School of Science, Faculty of Chemistry and Food Chemistry, Dresden, GERMANY.*

EPS-103

Human-Ready GMP ^{68}Ga/^{177}Lu-RAFT-RGD Enables αvβ3-Targeted Theranostics in Aggressive Brain Tumours

B. Bogdanovic[1], *S. Bacot*[1], *L. Dumas*[1], *F. Raes*[1], *M. Debiossat*[1], *C. André*[1], *E. N'Guessan*[1], *E. Launay*[1], *J. Leenhardt*[1,2], *D. Fagret*[1], *C. Montemagno*[1,3], *C. Ghezzi*[1];
[1]*Univ. Grenoble Alpes, INSERM*[1039]*, LRB, Grenoble, FRANCE,*
[2]*Univ. Grenoble Alpes, CHU Grenoble Alpes, Department of Nuclear Medicine, Grenoble, FRANCE,*
[3]*Centre Scientifique de Monaco, Biomedical Department, Monaco, MONACO.*

EPS-104

One-step Synthesis of ^{18}F-Labeled Isothiocyanate Derivatives for PET tracer development

Z. Li, *W. Chen;*
Department of Nuclear Medicine and Clinical Nuclear Medicine Research Lab, West China Hospital, Sichuan University, Chengdu, CHINA.

EPS-105

Ensuring radiolabelling performance: Quality evaluation of Actinium-225 precursors

E. Chilug, *F. Bruchertseifer, B. Lynch, M. Weis, A. Morgenstern;*
European Commission, Joint Research Centre, Karlsruhe, GERMANY.

EPS-106

First-Year Operational and Quality Review of IRCCS IRST Radiopharmaceutical Therapy Factory

V. Di Iorio[1], *E. Brugugnoli*[1], *C. Cuni*[1], *M. Solari*[1], *S. Boschi*[2], *A. Colamartini*[1], *M. Monti*[1], *M. Sansovini*[1], *A. Sarnelli*[1];
[1]*Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l., Meldola (FC), ITALY,*
[2]*University of Bologna, Bologna, ITALY.*

809

Monday, October 19, 2026, 09:45 - 11:15
Hall G2

Bone & Joint e-Poster

EPS-107

Utility of SPECT/CT with ^{99m}Tc-MDP in the Diagnostic and Therapeutic Approach to a Giant Pelvic Chondrosarcoma Causing Renal Obstruction: A Case Report

G. dos Santos[1,2], *L. Acosta*[1], *E. Silvera*[1], *O. Alonso Nuñez*[1,2];
[1]*Hospital de Clinicas, Montevideo, URUGUAY,*
[2]*CUDIM -Uruguayan Centre of Molecular Imaging, Montevideo, URUGUAY.*

EPS-108

Severe Osteoporosis with Multiple Fractures - a Misleading Presentation of Tumor-Induced Osteomalacia

R. Pichova, *S. Batek, M. Chovanec, L. Brunerova;*
University Hospital Kralovske Vinohrady, Prague [10]*, CZECH REPUBLIC.*

EPS-109

Diagnostic Value of Locoregional Lymph Node Metabolism on FDG PET/CT in Suspected Periprosthetic Joint Infection

B. Van den Broeck[1], *K. De Man*[1], *F. Gemmel*[2], *D. Huis in 't Veld*[1], *W. Huysse*[1], *J. Neyt*[1], *R. Waterschoot*[1], *D. Van Weehaeghe*[1];
[1]*UZ Gent, Gent, BELGIUM,*
[2]*AZ Oudenaarde, Oudenaarde, BELGIUM.*

EPS-110

Recurrent Myxofibrosarcoma of the Pectoralis Major Mimicking Breast Carcinoma With Synchronous Lung Adenocarcinoma: Role of ^{18}F-FDG PET/CT

M. Mihaylova, *E. Piperkova, L. Chavdarova, M. Zaharinov;*
USHATO "Prof. Ivan Chernozemski", Department of Nuclear medicine, Sofia, BULGARIA.

EPS-111

Quantitative Bone SPECT/CT for the Detection of Knee Chondral Lesions: Compartment-Specific Diagnostic Concordance with MRI

D. Bucur, *P. Omoumi, N. Schaefer, J. Prior, M. Nicod Lalonde, M. Jreige;*
CHUV, Lausanne, SWITZERLAND.

EPS-112

Acute Multifocal Osteomyelitis with Visceral Extension: Contribution of ^{18}FDG PET/CT in Diagnosis, Assessment of Extent, and Therapeutic Follow-up

Z. Missaoui, *A. Ezzine, M. Ben Fredj, R. Sfar, R. Mehri, G. Baazoug, Z. Jemni, H. Boudrigua, K. Chatti;*
Department of Nuclear Medicine, Sahloul University Hospital Center, Sousse, TUNISIA.

EPS-113

Phase-Specific Roles of SPECT in Dual SPECT/CT Radiomics for Predicting MRONJ Healing

S. Choi[1], *J. Park*[2], *D. Yoon*[2], *J. Hwang*[3,4], *J. Kim*[5], *D. Klm*[6], *S. Ahn*[7,8], *J. Kim*[2,9], *H. Yoon*[1,5];
[1]*Department of Computational Medicine, Ewha Womans University College of Medicine, Seoul, KOREA, REPUBLIC OF,*
[2]*Department of Oral and Maxillofacial Surgery, Research Institute for Intractable Osteonecrosis of the Jaw, Ewha Womans University College of Medicine, Seoul, KOREA, REPUBLIC OF,*
[3]*Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF,*
[4]*Yonsei Institute for Digital Health, Yonsei University, Seoul, KOREA, REPUBLIC OF,*
[5]*Department of Nuclear Medicine, Ewha Womans University College of Medicine, Seoul, KOREA, REPUBLIC OF,*
[6]*Department of Emergency Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF,*
[7]*Department of Biomedical Engineering, Ewha Medical Research Institute, Ewha Womans University, Seoul, KOREA, REPUBLIC OF,*
[8]*Ewha Medical Artificial Intelligence Research Institute, Ewha Womans University College of Medicine, Seoul, KOREA, REPUBLIC OF,*
[9]*Project for Korean National Cohort for Osteonecrosis of the Jaw, Seoul, KOREA, REPUBLIC OF.*

EPS-114

Prognostic Significance of Preoperative ^{18}F-FDG PET/CT Metabolic and Morphological Parameters in Bone and Soft Tissue Sarcomas

G. Aymandir, *G. Mütevelizade, H. Tosyalı, K. Erdem, E. Bilgin;*
Celal Bayara Üniversitesi Hafsasultan Hastanesi, Manisa, TÜRKIYE.

EPS-115

Impact of Serial ^{18}F-FDG PET/CT on Restaging and Local Treatment Planning in Unusual Bilateral Breast Metastatic Relapse from Embryonal Rhabdomyosarcoma

C. Mas Pascasio, *B. Ruiz de Almirón de Andrés, E. Ramos Moreno, S. Sanz Viedma;*
Hospital Clínico Universitario Virgen de la Victoria, Málaga, SPAIN.

EPS-116

Comparison of Whole-Body Scintigraphy and Multifield Bone SPECT/CT in the Differential Evaluation of Metastases in Cancer Patients

P. Korol[1], *O. Shcherbina*[1], *M. Ivakh*[1], *V. Ivchuk*[1], *M.*

Firsova[1], M. Kostylev[2], M. Tkachenko[3];
[1]Shupik National University Healthcare of Ukraine, Kyiv, UKRAINE,
[2]Shalimov National Scientific Center of Surgery and Transplantation, Kyiv, UKRAINE,
[3]Bogomolets National Medical University of Ukraine, Kyiv, UKRAINE.

EPS-117

Clinical impact of manual SPECT/CT fusion using MIM software in oncologic patients with solitary bone lesions

***M. Agolti**, E. Formenti, M. Gutierrez, L. Solari;*
Centro de Medicina Nuclear Clinica Modelo, Parana, ARGENTINA.

EPS-118

Correlation Between Diffusion-Weighted MRI and Bone Scintigraphy in Primary Malignant Bone Tumours: A Segment-Based Analysis - Prospective Observational Study

*K. Yadav, **V. K. Dhingra**, M. Dhingra, S. Saran, A. Sehrawat;*
All India Institute of Medical Sciences, Rishikesh, INDIA.

EPS-119

An AI-Derived Bone Scan Index Reflects Clinically Relevant Skeletal Tumor Burden in Patients with Bone Metastases

***C. Csikos**[1], P. Czina[1], K. Elek[1], S. Barna[1,2], I. Mihovk[1], Z. Seress[3], M. Szolikovà[3], Á. Kovács[3], I. Garai[1,2];*
[1]Division of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY,
[2]Scanomed Ltd., Debrecen, HUNGARY,
[3]Mediso Ltd., Debrecen, HUNGARY.

EPS-120

Clinical Application of ^{99}mTc-MDP SPECT/CT for the Diagnosis of Enostosis. A Pilot Study in Ukraine

***P. Korol**[1], O. Shcherbina[1], M. Kostylev[2], M. Tkachenko[3], V. Ivchuk[1], M. Ivakh[1], M. Firsova[1];*
[1]Shupik National University Healthcare of Ukraine, Kyiv, UKRAINE,
[2]Shalimov National Scientific Center of Surgery and Transplantation, Kyiv, UKRAINE,
[3]Bogomolets National Medical University of Ukraine, Kyiv, UKRAINE.

EPS-121

Early diagnosis of heterotopic ossification using ^{99}mTc-Methylene Diphosphonatethree-phase bone scintigraphy and SPECT/CT in the setting of inconclusive conventional imagingconventional imaging

***G. dos Santos**[1,2], M. Iraheta[1], E. Silvera[1], O. Alonso Nuñez[1];*
[1]Hospital de Clínicas "Dr. Manuel Quintela", Montevideo, URUGUAY,
[2]CUDIM -Uruguayan Centre of Molecular Imaging, Montevideo, URUGUAY.

EPS-122

Impact of SPECT/CT Bone Scintigraphy on Diagnostic Confidence and Management Decisions in Oncogeriatric Patients

***A. Khelifa**, D. Meziane, L. Mellaz, Z. Khen;*
Draa Ben Khedda Oncologic Center, Tizi Ouzou, ALGERIA.

EPS-123

Resolving the diagnostic uncertainty in bone metastases: The Role of ^{18}F-NaF PET/CT- A pilot study

***N. Bozhinovska**[1], S. Besliev[2], S. Tasevski[2], A. Jankulovska[1], B. Stoilovska Rizova[1], S. Stojanoski[1], T. Makazlieva[1], N. Manevska[2], A. Ugrinska[1];*
[1]Institute of Pathophysiology and Nuclear Medicine "Isaac Tadzer", Skopje, NORTH MACEDONIA,
[2]Institute of Positron emission tomography, Skopje, NORTH MACEDONIA.

EPS-124

"Functional biomarkers in ^{99}mTc-MIBI quantitative SPECT/CT and their relationship with radiologicalaggressiveness inGCTB"

***F. Lemus Ramírez**[1], D. Arguelles Perez[1], M. Hernández Hernández[1], A. Lopez Mendez[2];*
[1]Instituto Nacional De Rehabilitación Luis Guillermo Ibarra Ibarra, México, MEXICO,
[2]Instituto Mexicano del Seguro Social, México, MEXICO.

EPS-125

Comparison of the diagnostic performance of bone scintigraphy, CT and SPECT/CT for detection of bone metastases in the staging of newly diagnosed breast cancer. A utility and justification study of supplementary SPECT/CT.

***E. Stølsmark**;*
Stavanger Universitetssjukehus, Stavanger, NORWAY.

1009

Monday, October 19, 2026, 15:00 – 16:30

Hall G2

Nuclear Medicine in Endocrine Disorders: Current Diagnostic and Therapeutic Landscapes

EPS-126

Oncocytic Thyroid Carcinoma: A SEER-Based Analysis of Lymph Node Involvement and Relative Survival With and Without Radioiodine Therapy

***H. Weis**[1,2], H. Alakus[3], K. Schmidt[1], L. Van Heek[1], H. Golbarg[4], M. C. Kreissl[2], M. Schmidt[1], C. Chiapponi[5];*
[1]Department of Nuclear Medicine, Faculty of Medicine and University Hospital of Cologne, Cologne, GERMANY,
[2]Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, GERMANY,
[3]Department of Surgery, University Hospital Cologne, Cologne, GERMANY,
[4]Department of Nuclear Medicine, Klinikum Stuttgart, Stuttgart, GERMANY,
[5]Department of Surgery, School of Medicine and Health, TUM Klinikum rechts der Isar, Technical University of Munich, Munich, GERMANY.

EPS-127

Preablative stimulated thyroglobulin for predicting response to131I therapy in high-risk differentiated thyroid carcinoma

***J. Tong**;*
Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, CHINA.

EPS-128

Determinants of Iodine-131 Elimination Kinetics in Differentiated Thyroid Cancer: A Multivariate Analysis of External Dose Rate at 18 and 42 Hours Post-Therapy

***R. Wijaya**, R. Hanifatunnisa, F. Tarigan, R. Shintawati, T. As'ad, A. Gozian, N. Indiarti, A. Latuheru, P. Pratamadinata, B. Darmawan, H. Budiawan, A. Achmad, A. Kartamihardja;*
Faculty of Medicine, Universitas Padjadjaran, Bandung, INDONESIA.

EPS-129

Ga-68 Trivehexin PET/CT as a First-Line and rescue imaging modality in Primary Hyperparathyroidism: Comparative Analysis with 99m Tc-Sestamibi and the Novel Incidental Detection of Concomitant Breast Malignancy

***P. HJ**[1], P. Wadhwa[2];*
[1]Aster Hospital, Banglore, INDIA,
[2]United Imaging Healthcare, Shanghai, CHINA.

EPS-130

Machine learning using T12 body composition and clinical variables to predict ^{131}I therapy efficacy in DTC

***W. Chong**, Z. Jiang, W. Fu, L. Zhang, J. Qin, Y. Zeng, X. Mu;*
Guilin Medical University Affiliated Hospital, Guilin, CHINA.

EPS-131

How Many Lymph Nodes Are Needed for Accurate Staging of Differentiated Thyroid Carcinomas?

***M. Heinrich**, T. Jedamzik, P. Kohnle, A. K. Buck, N. Schlegel, K. Michalski;*
Universitätsklinikum Würzburg, Würzburg, GERMANY.

EPS-132

Recurrence Risk of Differentiated Thyroid Cancer Treated with Total or Hemithyroidectomy. Updated Systematic Review and Meta-analysis

***F. Fiz**[1], A. Piccardo[1], G. Bottoni[1], G. Treglia[2], P. Trimboli[2];*
[1]Ospedale Galliera, Genova, ITALY,
[2]Università della Svizzera Italiana, Lugano, SWITZERLAND.

EPS-133

Specificity of parathyroid hormone measurement in ultrasound-guided aspirates of suspected parathyroid adenomas

***M. Biermann**[1], K. J. Bruun[2], C. Bravo[2], T. Haslerud[3], K. Brauckhoff[4];*
[1]Nuclear Medicine/PET-senter, Haukeland University Hospital, Bergen, NORWAY,
[2]Nuclear Medicine/PET-senter, Haukeland University Hospital, Bergen, Norway, Bergen, NORWAY,
[3]Nuclear Medicine, Stavanger University Hospital, Bergen, NORWAY,
[4]Dept. of Endocrine and Breast Surgery, Bergen, NORWAY.

EPS-135

Pediatric Graves' Disease: could radioactive iodine be a safe and well tolerated definitive treatment strategy?

***L. Antunovic**[1,2], G. Tarantola[3], G. Vincenzi[3], J. Jandric[2], M. Rodari[2], C. Rossetti[4], R. Maggiore[5], M. Vigone[3], A. Chiti[1,6];*
[1]Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY,
[2]Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, ITALY,
[3]Endocrine Unit, Department of Pediatrics, IRCCS San Raffaele Scientific Institute, Milan, ITALY,
[4]Functional Department for Higher Education, Research, and Development, Interhospital Functional Department of Nuclear Medicine, ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY,
[5]Department of Surgery, Endocrine Surgery Unit, IRCCS San Raffaele Scientific Institute, Milan, ITALY,
[6]Vita-Salute San Raffaele University, Milan, ITALY.

EPS-136

Dosimetry-based radioiodine therapy in Graves' disease with concomitant functioning nodules (Marine-Lenhart Syndrome)

***J. Baumgarten**, C. Happel, N. Mader, C. Keskin, S. A. Schenke, K. Klimek, A. Sabet, F. Grünwald, D. C. L. Gröner;*
Universitätsklinikum Frankfurt, Frankfurt, GERMANY.

EPS-137

Analysis of the circulating proteome associated with invasiveness in papillary thyroid carcinoma

***W. Zhang**, H. Liu;*
Department of Nuclear Medicine, The First Hospital of Shanxi Medical University, Taiyuan, CHINA.

EPS-138

Sex-specific circulating proteomic signatures under TSH stimulation in thyroid cancer patients after total thyroidectomy

***Y. Li**, H. Liu;*
First Hospital of Shanxi Medical University, Taiyuan, CHINA.

EPS-139

^{68}Ga-Trivehexin PET/CT for Localization of Parathyroid Adenomas

***M. Elkanawaty**[1], Y. Atteya[2], N. Taha[3], Y. Omar[1];*
[1]MISR Radiology Center, Cairo, EGYPT,
[2]Capital University, Cairo, EGYPT,
[3]Ain Shams University, Cairo, EGYPT.

EPS-140

Immunosuppressive Therapy for Graves' Ophthalmopathy: The Role of ^{99}mTc-DTPA SPECT/CTId in Assessing Inflammatory Activity

C. Stolniceanu[1], *I. Grierosu[1], C. Preda[1], S. Mogos[1], C. Cristea[2], W. Jalloul[1], C. Stefanescu[1];*
[1]University of Medicine and Pharmacy "Grigore T Popa" Iasi, Iasi, ROMANIA, [2]"Sf Spiridon" Clinical Hospital Iasi, Iasi, ROMANIA.

EPS-141

Prognostic performance of ATA 2015 and ATA 2025 risk stratification systems after radioiodine therapy in patients with differentiated thyroid cancer

C. Nappi[1,2], *E. Caiazzo[3], D. Origlia[4], D. Deandreis[2], M. Petretta[1], M. Klain[4], A. Cuocolo[4,1];*
[1]IRCCS Synlab SDN, Naples, ITALY,
[2]Institute Gustave Roussy, Villejuif, FRANCE,
[3]Nuclear Medicine Unit, University Hospital Federico II, Naples, ITALY,
[4]Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY.

EPS-142

Correlation between 4hour and 24hour Na[^{123}I]I thyroid uptake for therapeutic activity calculation in hyperthyroidism

O. Silva, *S. Carmona, A. Prata, J. G. Santos, H. Calqueiro, I. C. Ferreira, V. Sousa, A. I. Santos;*
Centro de Responsabilidade Integrada de Medicina Nuclear, Unidade Local de Saúde de Almada-Seixal, E.P.E., Almada, PORTUGAL.

EPS-143

A whole-body PET-derived metabolic aging clock identifies coordinated organ-level remodeling and disease-associated age acceleration

Z. Wang[1], *S. Xue[1], J. Ding[2], X. Li[1], O. Kulterer[1], Z. Shi[3], F. Kiefer[4], C. Philippe[1], B. K. Geist[1], S. Wen[1], X. Zhang[5], M. Hacker[1], J. Zhao[2], X. Li[1];*
[1]Medical University of Vienna Department of Biomedical Imaging and Image-guided Therapy, Vienna, AUSTRIA,
[2]Department of Nuclear Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, CHINA,
[3]Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical UniversityMedical University of Vienna Department of Biomedical Imaging and Image-guided Therapy, Beijing, CHINA,
[4]Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Vienna, AUSTRIA,
[5]Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical Universit, Beijing, CHINA.

EPS-144

[^{161}Tb]Tb-CP04 for CCK2R-Targeted Radioligand Therapy in Advanced Medullary Thyroid Carcinoma: First-in-Human Study Design (Acronim MTC-Tb)

M. Opalinska[1], *W. Lenda-Tracz[2], B. Głowa[3], I. Cieszykowska[4], D. Handkiewicz-Junak[5], A. Kowalska[6], W. Wojdowska[4], P. Garnuszek[4], R. Mikołajczak[4], A. Hubalewska-Dydejczyk[1];*
[1]Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND,
[2]Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, POLAND,
[3]University Hospital in Krakow, Krakow, POLAND,
[4]National Centre for Nuclear Research, Radioisotope Centre POLATOM, Otwock, POLAND,
[5]Maria Skłodowska-Curie National Institute of Oncology, Gliwice Branch, Gliwice, POLAND,
[6]Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, POLAND.

EPS-146

Prospective assessment of the Thyroid Imaging Reporting and Data System (Kwak-TIRADS) and shear wave elastography in autonomously functioning thyroid nodules before and after radioiodine therapy, and identification of predictors of therapeutic success

M. Čepel[1], *S. A. Schenke[1], J. Wüstemann[1], A. Lux[2], G. Ulrich[3], M. C. Kreißl[1];*
[1]Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University of Magdeburg, Magdeburg, GERMANY,
[2]Institute for Medical Data Science, University of Magdeburg, Magdeburg, GERMANY,
[3]Practice for Radiology Sudenburg, Magdeburg, GERMANY.

1010

Monday, October 19, 2026, 15:00 – 16:30

Hall K

Technologists e-poster

TEPS-001

Impact of different algorithm and parameter settings on quantitative accuracy in data-driven respiratory-gated PET/CT

N. Miyaji[1], *T. Yamao[1], K. Nitta[2], R. Inatsuki[2], H. Nishino[3], Y. Suzuki[3], A. Komuro[4], H. Nosaka[5], Y. Ogane[1], K. Miwa[1];*
[1]Fukushima Medical University, Fukushima, JAPAN,
[2]Southern TOHOKU Research Institute for Neuroscience Southern TOHOKU General Hospital, Koriyama, JAPAN,
[3]Takeda General Hospital, Aizuwakamatsu, JAPAN,
[4]Shirakawa Kosei General Hospital, Shirakawa, JAPAN,
[5]Ibaraki Prefectural University of Health Sciences, Ami, JAPAN.

TEPS-002

Impact of CZT technology on123I-ioflupaneSPECT:intra-patient comparison and workflowoptimisation

R. Benito, *A. Olmo, V. Vallejos, C. Pons, M. Caro, J. Molina, J. Riba, M. Diaz, N. Torres, J. Cordero, S. Lafuente, E. Gallardo, J. Latorre, P. Caresia, G. Moragas;*
Hospital Germans Trias I Pujol, Barcelona, SPAIN.

TEPS-003

Evaluation of Centiloid Values in ^{18}F-Flutemetamol Amyloid PET: Comparision Between OSEM and Hyper Iterative Recostructions at Reduced Acquisition Times

K. Shyli, *F. Firinu, A. Sotgiu, F. Casaburo, C. Serra, M. Mantovani, F. S. Oliverio, A. Lomartire, S. Fraschina;*
ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY.

TEPS-004

AI-Based Motion Management and Motion Correction vs. Respiratory-Gated Acquisition in Long Axial Field-of-View PET/CT: A Qualitative and Semiquantitative Comparison

K. Shyli, *F. Firinu, F. Casaburo, A. Sotgiu, S. Fraschina, C. T. Serra, A. Lomartire, M. Mantovani, F. S. Oliverio;*
ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY.

TEPS-005

Optimization of Image Reconstruction Parameters for Striatal Dopamine Transporter SPECT Using a Multifocal Collimator

D. Watanabe[1], *T. Shibutani[1,2], K. Fujiwara[1,3], T. Kawaguchi[1], T. Konishi[4], H. Yoneyama[4], M. Onoguchi[2], J. Komatsu[5], T. Shimizu[6], F. Massanes[7], A. H. Vija[7], K. Nakajima[8];*
[1]Department of Quantum Medical Technology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, JAPAN,
[2]Department of Quantum Medical Technology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, JAPAN,
[3]Department of Radiology, National Cerebral and Cardiovascular Center, Suita, Osaka, JAPAN,
[4]Department of Radiological Technology, Kanazawa University Hospital, Kanazawa, JAPAN,
[5]Department of Neurology, Kanazawa University, Kanazawa, JAPAN,
[6]Molecular Imaging Department, Siemens Healthcare K.K., Tokyo, JAPAN,
[7]Molecular Imaging, Siemens Medical Solutions USA, Inc., Hoffman Estates, IL, UNITED STATES OF AMERICA,
[8]Department of Nuclear Medicine, Kanazawa University, Kanazawa, JAPAN.

TEPS-006

Surfactant-Enhanced Pulmonary Distribution Assessed by [^{18}F]FDG PET Imaging in Neonatal Rats

K. Chang;
Taipei Medical University, Taipei, TAIWAN, PROVINCE OF CHINA.

TEPS-007

Autonomous patient release by nuclear medicine technologists (NMT) in PET/CT: safety and efficiency of an ISO9001-formalized organizational model

B. Maraviglia, *A. Gonfiantini, S. Gamannossi Degl'innocenti, T. Tognerelli, C. Costanza, G. Bruni, P. Galardini, E. Longo, S. Montalbano, S. Sestini, C. Mazzeo;*
SOC Medicina Nucleare, Ospedale Santo Stefano - Azienda USL Toscana Centro, Prato, ITALY.

TEPS-008

Prospective quality assurance study of tin filter for PET/CT attenuation correction

C. Hansen, *C. Sunde, M. Askløf, K. Korsholm, F. Andersen;*
Rigshospitalet, København, DENMARK.

TEPS-009

One-Pot Radio-Fluorosulfonylation of Amines: Development and Primary Preclinical Evaluation with Myocardial Perfusion PET Imaging

Y. Huang[1], *J. Wang[2], Y. He[1], Q. Cheng[2], Z. Xiao[1];*
[1]Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, CHINA,
[2]Hubei Research Center of Fundamental Science-Chemistry, Engineering Research Center of Organosilicon Compounds & Materials, Ministry of Education, College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, CHINA.

TEPS-010

Automated Regional SUV Quantification in Bone SPECT/CT Using Deep Learning-Based Segmentation: An Operator-Independent Framework Toward a 60-Region Normative Database

M. Shiga[1,2], *H. Yoshida[2], S. Fukai[2], N. Shimada[2], K. Takatsu[2], T. Terauchi[2], H. Sagara[1], M. Sato[1], H. Daisaki[1];*
[1]Graduate School of Radiological Technology, Gunma Prefectural College of Health Sciences, Gunma, JAPAN,
[2]The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JAPAN.

TEPS-011

The usefulness of data-driven respiratory gating correction in ^{201}TI myocardial perfusion SPECT using a multifocal collimator

T. Shibutani[1,2], *M. Ishida[3], K. Fujiwara[2,4], T. Kawaguchi[2], T. Konishi[5], H. Yoneyama[5], S. Watanabe[6], M. Onoguchi[1], T. Shimizu[7], M. Francesc[8], H. Vija[8], K. Nakajima[6];*
[1]Department of Quantum Medical Technology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, JAPAN,
[2]Department of Quantum Medical Technology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, JAPAN,
[3]Department of Radiological Technology, Kanazawa Medical University Hospital, Uchinada, JAPAN,
[4]Department of Radiology, National Cerebral and Cardiovascular Center, Suita, JAPAN,
[5]Department of Radiological Technology, Kanazawa University Hospital, Kanazawa, JAPAN,
[6]Department of Nuclear Medicine, Kanazawa University, Kanazawa, JAPAN,
[7]Molecular Imaging Department, Siemens Healthcare K.K., Tokyo, JAPAN,
[8]Molecular Imaging, Siemens Medical Solutions USA, Inc., Hoffman Estates, IL, UNITED STATES OF AMERICA.

TEPS-012

Formulation and Optimization of one-step lyophilized kit for CXCR4 targeting and it's comparative assessment of labeling efficiency with ^{68}Ga

S. Paunikar[1,2], *V. Vajarkar[1,2], S. Rawool[1,2], A. Chandak[3], A. Agrawal[1,2,4];*
[1]Advanced Centre for Treatment, Research and Education in Cancer-TMC, Navi-Mumbai, INDIA,
[2]Homi Bhabha National Institute, Mumbai, INDIA,
[3]Board of Radiation and Isotope Technology, Vashi-Navi-Mumbai, INDIA,
[4]Tata Memorial Hospital-TMC, Mumbai, INDIA.

TEPS-013

Opportunistic Coronary Calcium Scoring from Low Dose Attenuation Correction CT in a Fast-Track Outpatient Pathway: Comparison with Dedicated ECG-Gated Calcium Scoring CT

N. Balegh[1], *B. A. de Vries*[1], *S. M. Euser*[2], *P. T. Bot*[1], *J. J. Boer*[1];
[1]*Spaarne Gasthuis, Haarlem, NETHERLANDS,*
[2]*Regional Laboratory of Public Health Kennemerland, Haarlem, NETHERLANDS.*

TEPS-014

[177Lu]Lu-PSMA-I&T and [177Lu]Lu-DOTATATE post administration measurements to detect extravasation.

C. Terwinghe, *K. Goffin, N. Ahmadi Bidakhvidi, L. Boeckxstaens, J. Crama, S. Stienaers, C. M. Deroose; University Hospitals Leuven, Leuven, BELGIUM.*

TEPS-015

Integrated Quantitative ATN Assessment for Continuous Staging of Alzheimer's Disease

K. Wachi[1], *T. Yamao*[1], *N. Miyaji*[1], *N. Akiya*[1], *M. Masubuchi*[1,2], *T. Horikawa*[1], *A. Komatsu*[1], *S. Mashiko*[1], *Y. Ogane*[1], *O. Kanno*[1], *K. Miwa*[1];
[1]*Fukushima Medical University, Fukushima, JAPAN,*
[2]*Division of Functional Imaging, Exploratory Oncology and Clinical Trial Center, National Cancer Center Japan, Kashiwa, JAPAN.*

TEPS-016

Ketone body measurement in sarcoidosis patients: a quality assurance evaluation of a point-of-care ketone device and determination of a clinically applicable cut-off value for ketone levels

A. Cheikha;
Rigshospitalet, Clinic Physiology & nuclear medicine, PET, Ishøj, DENMARK.

TEPS-017

Optimization of [18F]FDG activity for digital PET/CT scanner.

M. Borsukiewicz[1], *K. Osińska*[1], *M. Tulik*[1,2], *K. Pełka*[1,2], *J. Kunikowska*[1,2];
[1]*Department of Nuclear Medicine, Central Clinical Hospital, Clinical Center of the Medical University of Warsaw, Warsaw, POLAND,*
[2]*Department of Nuclear Medicine, Medical University of Warsaw, Warsaw, POLAND.*

TEPS-018

Workflow Implementation and Dynamic PET/CT Imaging Experience with 11C-Metomidate in a Clinical Research Institution

M. Bin Mohamed Zam Zam[1,2], *J. Siew Chengyi*[1], *F. Huijing*[1];
[1]*National University Singapore - Centre for Imaging Research, Singapore, SINGAPORE,*
[2]*Singapore Institute of Technology, Singapore, SINGAPORE.*

TEPS-019

Gamification in Nuclear Medicine Technologist education: application of an escape room for radiopharmacy training

P. Costa, *M. Correia, R. Sousa, D. Vieira, J. Lemos; Nuclear Medicine Department, ESS, Polytechnic of Porto, Porto, PORTUGAL.*

TEPS-020

Expanding the Role of PhD Nuclear Medicine Technologists in Clinical Nuclear Medicine and University Education: Opportunities in Bosnia and Herzegovina

N. Salkica, *S. Hadžimusić;*
Clinic of nuclear medicine, Sarajevo, BOSNIA AND HERZEGOVINA.

TEPS-021

Attitudes and Practices of Infection Prevention and Control Among Nuclear Medicine Technologists: A Cross-Sectional Survey

P. Kench, *D. Abu Awwad, S. Hill, Y. Jimenez;*
The University of Sydney, Sydney, AUSTRALIA.

1109

Monday, October 19, 2026, 16:45 - 18:15

Hall G2

Translational Imaging and Therapy

EPS-147

PARP1-targeted alpha theranostics using [211At]PTT with [18F]FTT PET and [211At]SPECT in biologically distinct prostate cancer xenograft models

H. Babazada, *Y. Zhu, P. Martorano, H. Lee, S. B. Gitto, E. Blankemeyer, J. R. Kuchta, S. D. Metzler, D. A. Mankoff, R. H. Mach, M. D. Farwell;*
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.

EPS-148

Navitoclax synergy with radiopharmaceutical therapy reveals the dependence on BCL-xL signaling for survival in radiation-induced senescent prostate cancer cells

M. Lindsey, *A. Smith, M. Bio Idrissou, Y. Medina-Guevara, L. Wehner, J. Cabahug, J. Munson, H. Comas-Rojas, A. Pinchuk, L. Lambert-Lepesevich, O. Kwon, B. Bednarz, R. Hernandez;*
University of Wisconsin-Madison, Madison, WI, WI, UNITED STATES OF AMERICA.

EPS-149

ATNM-400 Elicits Durable Anti-tumor Responses in KRAS- and ALK-Driven NSCLC Models in a Mutation-Agnostic Manner

A. Kamal, *S. Mukherjee, J. Li, K. Peregrina, D. Lewis, L. Lumkong, V. Chavez, K. Subramanian, A. S. Chin, M. Roy, J. Kim, S. Kazerounian;*
Actinium Pharmaceuticals, New York, NY, UNITED STATES OF AMERICA.

EPS-150

Assessing FAP expression in vulvar squamous cell carcinoma using 18F-FAPI autoradiography

A. Florit[1,2], *D. Nardi*[3], *M. Ruggiero*[3], *S. Fragomeni*[4], *A. Piermattei*[5], *T. Pasciuto*[6,7], *E. Martinelli*[8], *F. D. Alcaro*[4], *A. Santoro*[5,9], *G. Zannoni*[5,9], *L. Alic*[10], *L. de Geus-Oei*[1,11,12], *S. Annunziata*[2], *F. H. P. van Velden*[11], *A. Fagotti*[4,8], *V. Rufini*[2,13], *C. Nero*[4], *G. Garganese*[4,8], *A. Collarino*[2];
[1]*Biomedical Photonic Imaging Group, University of Twente, Enschede, NETHERLANDS,*
[2]*Nuclear Medicine Unit, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,*
[3]*PET/CT Centre, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,*
[4]*Gynaecologic Oncology Unit, Department of Woman and Child's Health Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,*
[5]*General Anatomic Pathology Unit, Department of Laboratory and Haematological Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,*
[6]*Research Core Facility Data Collection G-STeP, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,*
[7]*Section of Hygiene, Department of Life and Public Health Sciences, Università Cattolica del Sacro Cuore, Rome, ITALY,*
[8]*Section of Obstetrics and Gynaecology, Department of Life and Public Health Sciences, Università Cattolica del Sacro Cuore, Rome, ITALY,*
[9]*Institute of Pathology, Università Cattolica del Sacro Cuore, Rome, ITALY,*
[10]*Magnetic Detection & Imaging Group, University of Twente, Enschede, NETHERLANDS,*
[11]*Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS,*
[12]*Department of Radiation Science and Technology, Delft University of Technology, Delft, NETHERLANDS,*
[13]*Section of Nuclear Medicine, Department of Radiological Sciences and Haematology, Università Cattolica del Sacro Cuore, Rome, ITALY.*

EPS-151

Impact of immobilisation techniques on in ovo [18F] FDG uptake

R. Abdelaziz[1,2], *T. Wanek*[3], *C. Kuntner*[3,4], *E. Lamprou*[5], *E. Fysikopoulos*[5], *M. Hacker*[1], *T. Balber*[1,2];
[1]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, AUSTRIA,*
[2]*Joint Applied Medicinal Radiochemistry Facility, Vienna, AUSTRIA,*
[3]*Preclinical Imaging Lab (PIL), Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA,*
[4]*Research Platform Medical Imaging (RPMI), Medical University of Vienna, Vienna, AUSTRIA,*
[5]*Bioemtech, Athens, GREECE.*

EPS-152

Preparation and preclinical investigation of 18F-labeled folate-RGD heteromeric ligand for PET imaging of triple-negative breast cancer.

S. Okarvi;
Cyclotron & Radiopharmaceutical;
King Faisal Specialist Hospital and Research Centre, Riyadh, SAUDI ARABIA.

EPS-153

Population Modeling of Pharmacokinetics and Dosimetry of a Novel PSMA-Targeting mAb in mCRPC: Toward Dose Optimization of Radioligand Therapy

F. Audy[1], *E. Routits*[1], *A. Adam*[2,1], *M. Hennion*[1], *H. Doddihal*[2], *K. Vadali*[2], *N. Lenzo*[3], *K. O'Byrne*[4], *L. Kriegler*[5], *S. Nagi*[6], *D. Cade*[7];
[1]*Cencora – PharmaLex US Corporation, Conshohocken, PA, UNITED STATES OF AMERICA,*
[2]*Telix Pharmaceuticals, Herstal, BELGIUM,*
[3]*Genesis Care, Alexandria, AUSTRALIA,*
[4]*Princess Alexander Hospital, Queensland, AUSTRALIA,*
[5]*GenesisCare North Shore, New South Wales, AUSTRALIA,*
[6]*Medical Oncology, Princess Alexandra Hospital, Queensland University of Technology, Translational Research Institute, Woolloongabba, AUSTRALIA,*
[7]*Telix Pharmaceuticals, Sidney, AUSTRALIA.*

EPS-154

PET Reporter Gene Imaging Enables Quantitative Tracking of Human Cardiac Progenitor Cells in Physiologically Relevant Cardiac Tissue Models

S. Seyfi[1,2,3], *T. Dorn*[3], *C. M. Poch*[4,2], *M. Grashei*[1], *V. Morath*[1], *V. Fricke*[3], *K. Fritschle*[1], *A. Skerra*[5], *M. Schwaiger*[1], *C. Kupatt*[3,2], *K. Laugwitz*[3,2], *A. Moretti*[3,2,6], *W. Weber*[1];
[1]*Department of Nuclear Medicine, TUM University Hospital Rechts der Isar, Munich, GERMANY,*
[2]*Centre for Cardiovascular Research (DZHK), Munich Heart Alliance (MHA), Partner Site Munich, Munich, GERMANY,*
[3]*First Department of Medicine, TUM University Hospital Rechts der Isar, Munich, GERMANY,*
[4]*Firs Department of Medicine, TUM University Hospital Rechts der Isar, Munich, GERMANY,*
[5]*Lehrstuhl für Biologische Chemie, School of Life Sciences, Technical University of Munich, Freising, GERMANY,*
[6]*Centre for Organoid Systems (COS), Technical University of Munich, Garchin, GERMANY.*

EPS-155

EphA2-targeted Theranostics in Triple-Negative Breast Cancer: A Preclinical Proof-of-Concept Study

T. Watabe[1], *T. Iwasawa*[2], *H. Kimura*[3], *Y. Shirakami*[1], *S. Naka*[4], *T. Kobayashi*[1], *K. Kato*[5];
[1]*The University of Osaka, Suita, JAPAN,*
[2]*Institute of Life Innovation Studies, Toyo University, Tokyo, JAPAN,*
[3]*Kyoto University, Kyoto, JAPAN,*
[4]*The University of Osaka Hospital, Suita, JAPAN,*
[5]*Toyo University, Tokyo, JAPAN.*

EPS-156

Next-Generation PSMA-Targeted 64Cu Terpyridine Theranostic: From Enhanced Tumor Targeting to In Vivo Efficacy in Prostate Cancer

H. Talebian[1], *S. Ait-Mohand*[1], *É. Rousseau*[2], *P. Mercy Ignatius Arokia Doss*[1], *L. Sanche*[1], *B. Guérin*[1];
[1]*Université de Sherbrooke, Sherbrooke, QC, CANADA,*
[2]*University de Sherbrooke, Sherbrooke, QC, CANADA.*

EPS-157

Targeting DLL3 with Zirconium-89 ImmunoPET: A Translational scFv-Fc Platform for Small Cell Lung Cancer

T. Lemaitre[1], *S. Illouz*[1], *M. Hussien*[1], *S. Tendler*[2], *C. M. Rudin*[1,2,3], *J. S. Lewis*[1,2,3];
[1]*Sloan Kettering Institute, New York, NY, UNITED STATES OF AMERICA,*
[2]*Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA,*
[3]*Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA.*

EPS-158

Establishing Gastroenteropancreatic Neuroendocrine Tumor Organoids as a Potential Tool for Prediction of Response to Peptide Receptor Radionuclide Therapy

D. Arbuznikova[1,2], L. Klaas[3], L. Schoemig[3], E. Dopfer[4], P. Bronsert[4], M. Eder[1,2], P. T. Meyer[1], M. Freitag[1], R. Thimme[3], M. Quante[3], A. Eder[1,2];
[1]*Department of Nuclear Medicine, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY,*
[2]*Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), partner site Freiburg, and German Cancer Research Centre (DKFZ), Freiburg and Heidelberg, GERMANY,*
[3]*Department of Internal Medicine II, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY,*
[4]*Department of Pathology, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY.*

EPS-159

Analysis of cooperative internalization of DARPins at HER2 receptor

I. Zelepukin, *A. Elshazli, V. Tolmachev;*
Uppsala University, Uppsala, SWEDEN.

EPS-160

Biological Validation of Human Glioma PET/MRI Phenotypes through Cross-Species Machine Learning and Light-Sheet Microscopy

S. Castaneda Vega[1,2], A. Mannel[1,2], E. Calderon[1], R. Kushwaha[3], L. Kuebler[3], B. Bender[4], J. Schittenhelm[5], U. Ernemann[4], I. Gonzalez-Menendez[5], L. Quintanilla-Martinez[5], B. Weigelin[3], C. la Fougère[1];
[1]*University Hospital Tübingen, Departmenf of Nuclear Medicine and Clinical Molecular Imaging, Tübingen, GERMANY,*
[2]*Eberhard Karls University Tuebingen, Werner Siemens Imaging Center, Tuebingen, GERMANY,*
[3]*Eberhard Karls University Tuebingen, Werner Siemens Imaging Center, Tübingen, GERMANY,*
[4]*University Hospital Tübingen, Department of Neuroradiology, Tübingen, GERMANY,*
[5]*University Hospital Tübingen, Department of Pathology and Neuropathology, Tübingen, GERMANY.*

EPS-161

Optimization of Size and Surface-Coating to Increase the Uptake of [^{198}Au]AuNPs and 197gHgAuNPs as Well as Radiation Absorbed Doses in Human Breast Cancer Tumours After Intravenous Injection

Z. Cai[1], *M. K. Brown[1], Y. Ganga-Sah[2], V. Radchenko[2,3], K. M. Nielsen[4], R. M. Reilly[1,5,6];*
[1]*Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, CANADA,*
[2]*Life Sciences Division, TRIUMF, Vancouver, BC, CANADA,*
[3]*Department of Chemistry, University of British Columbia, Vancouver, BC, CANADA,*
[4]*Nuclear Operations and Facilities, McMaster University, Hamilton, ON, CANADA,*
[5]*Department of Medical Imaging, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, CANADA,*
[6]*Joint Department of Medical Imaging and Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CANADA.*

EPS-162

Kinetic and Internalization Profiling of Pep-[1]L as an IL13Rα2-Targeted Peptide Radiotracer in Glioblastoma

M. Ejtema[1], *N. K. Ahmed[1], P. Kanellopoulos[2], D. Spiegelberg[1];*
[1]*Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN,*
[2]*Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN.*

EPS-163

Development of radiolabeled PTK7-directed single domain antibodies for breast cancer imaging

B. Altunay[1], *J. Reck[1], A. Florea[1], M. Sadeghzadeh[1], A. T. J. Vogg[1], L. Meszaros[2], A. Morgenroth[1], F. M. Mottaghy[1,3];*
[1]*Uniklinik RWTH Aachen, Aachen, GERMANY,*
[2]*Radiopharm Theranostics Ltd, Carlton South, AUSTRALIA,*
[3]*Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, NETHERLANDS.*

EPS-164

Advancing PARP-Targeted Radiotheranostics for the Treatment of Triple-Negative Breast Cancer

S. Lum, *C. Lord, A. Tutt, K. Tan, C. Y. Chan;*
The Institute of Cancer Research, London, UNITED KINGDOM.

1209

Tuesday, October 20, 2026, 08:00 - 09:30

Hall G2

Radiation Protection e-Poster

EPS-166

Mitigating Ac-227 Concerns for Ac-225 Clinical Sites

W. Peters, *A. Bakken, M. Burba;*
Niowave, Lansing, MI, UNITED STATES OF AMERICA.

EPS-167

Initial findings from launching a national incident learning system for nuclear medicine in the UK

A. Powell, *U. Findlay, E. Fower, L. Fraser, Y. Kinsella, N. Kirk;*
UK Health Security Agency, Oxford, UNITED KINGDOM.

EPS-168

Tube Current Modulation in Whole-Body CT: The Influence of Organ Characteristics on Delivered Dose

J. Terzic[1], *P. C. Holdgaard[1], J. K. Fuglsang[2], L. R. Østergaard[2], N. A. Bebbington[3];*
[1]*University Hospital of Southern Denmark, Vejle, DENMARK,*
[2]*Aalborg University, Aalborg, DENMARK,*
[3]*Siemens Healtcare A/S, Aarhus, DENMARK.*

EPS-169

Clinical Applications of Real-Time Patient Monitoring using Novel Ceiling Monitors in MRT facilities

J. Mohammed-Gayle[1], *E. Crick[1], H. Buschhold[1,2], R. Fernandez[1];*
[1]*Guy's and St Thomas' NHS Trust, London, UNITED KINGDOM,*
[2]*King's College London, London, UNITED KINGDOM.*

EPS-170

Large Language Model-Assisted Development of Bespoke Radiation Protection Training in Nuclear Medicine

C. Sibley-Allen, *R. Fernandez, J. Mohammed-Gayle;*
Guy's and St Thomas' NHS Foundation Trust, London, UNITED KINGDOM.

EPS-171

Radiation exposure of lung perfusion SPECT/CT versus CT pulmonary angiography

J. Foukal, *H. Kašpárková;*
University Hospital Brno, Brno, CZECH REPUBLIC.

EPS-172

Radiation Dose Indices from the CT Component of SPECT/CT Examinations: Departmental Data and Comparison with International Diagnostic Reference Levels (DRLs)

J. Koutsikos, *G. Thiveos, V. Pantzou, T. Petropoulos, M. Stathopoulou, I. Papantoniou, A. Kokkini - Paschou, E. Skoura, I. Datseris;*
Henry Dunant Hospital Center, Athens, GREECE.

EPS-174

Radiation Protection and staff dose for specimen PET-CT tumour resection in theatres

L. Rowley[1,2], *C. Pickles[2], S. Kallioinen[3,4], O. Adesanya[2];*
[1]*Institute for Precision Diagnostics & Translational Medicine, Coventry, UNITED KINGDOM,*
[2]*University Hospital Coventry and Warwickshire NHS Trust, Coventry, UNITED KINGDOM,*
[3]*University Hospitals of Coventry and Warwickshire NHS Trust, Coventry, UNITED KINGDOM,*
[4]*Warwick Medical School, The University of Warwick, Warwick, UNITED KINGDOM.*

EPS-176

Cutting Dose, Not Quality: Optimizing CT Protocols in PET/CT examinations

C. Battisti[1], *D. Rubini[2], C. Ferrari[1], A. R. Pisani[1], G. D. Arnese[1], C. Morelli[2], C. Dipalma[2], O. A. Moscatelli[2], G. Lorusso[2], N. Maggialetti[2], G. Rubini[1];*
[1]*Nuclear Medicine Unit, DIM, University-Policlinico, Bari, ITALY,*
[2]*Radiology Unit, DIM, University-Policlinico, Bari, ITALY.*

EPS-177

The Impact of Superficial Body Contamination on Measured Radiation Dose Rates Following ^{131}I Therapy: A Quantitative Evaluation of The Contribution of Hygiene Practices to Dose Rate Reduction

F. Çakir[1], *S. Demirtaş Şenlik[2], S. Kubat[1], A. Çınar[1], E. Tatcı[1], Ö. Özmen[1];*
[1]*Department of Nuclear Medicine, Ankara Etlik City Hospital, Ministry of Health, Ankara, TÜRKIYE,*
[2]*Department of Nuclear Medicine, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, TÜRKIYE.*

EPS-178

Radiological assessment of novel radiopharmaceuticals: implications for nuclear security

W. Ciecior, *T. Wirthgen, K. Voigt, S. Jansen, A. Jahn, K. Großmann, H. Lösch;*
VKTA – Radiation Protection, Analytics & Disposal Rossendorf Inc., Dresden, GERMANY.

EPS-179

Environmental Dose Monitoring in Nuclear Medicine Departments

M. Sultana, *S. Agius;*
University of Malta, Msida, MALTA.

EPS-180

The impact of the Administration of Radioactive Substances Advisory Committee in the UK

L. Fraser, *A. Powell, N. Parkar, M. A. Richardson;*
UK Health Security Agency, Didcot, UNITED KINGDOM.

EPS-181

Review of Family and Social Contact Restrictions for Patients Following Lu-177 Treatment

M. Serrano Campillo, *O. Rosas Lozano, C. González Navarro, M. Catalá Espí, Á. García Aliaga, F. García Cases;*
Hospital Universitario San Juan de Alicante, San Juan de Alicante, SPAIN.

EPS-182

Radionuclide-specific optimization of hot cell shielding and lead glass window thickness

M. Marengo[1], *L. Pompignoli[2], A. Infantino[3];*
[1]*Veneto Institute of Oncology IOV – IRCCS, Padova, ITALY,*
[2]*Tema Sinergie SpA, Faenza, ITALY,*
[3]*European Organization for Nuclear Research (CERN), Meyrin (Geneva), SWITZERLAND.*

1309

Tuesday, October 20, 2026, 09:45 - 11:15

Hall G2

Best e-Poster on Inflammation & Infection Imaging

EPS-183

Standardized Quantitative Assessment of Large-Vessel Vasculitis Using Semi-Automated PET/CT Analysis: Moving Beyond Visual Scoring

J. Cardoso Suarez, *M. Arjona Muñoz, F. Gari Martinez, M. Bermúdez Morales, M. Martínez Del Valle Torres, D. Becerra Garcia;*
Hospital Universitario Clinico San Cecilio, Granada, SPAIN.

EPS-184

The Utility of ^{18}F-FDG PET/MRI in the Evaluation of Large-Vessel Vasculitis

B. Hervás-Sanz[1], *P. C. Notta*[1], *G. Burcet-Rodríguez*[2], *I. E. Sánchez-Rodríguez*[1], *L. M. Gràcia-Sánchez*[1], *F. J. Narváez-García*[3], *E. Claver-Garrido*[4], *S. A. Bolívar-Cuevas*[2], *A. Aubanell-Creus*[2], *J. L. Díaz-Moreno*[1], *P. Maymó-Paituvi*[3], *A. Bagán-Trejo*[1], *M. Zamorano-Rivas*[1], *C. García-Alcober*[5], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,*
[2]*Radiology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,*
[3]*Rheumatology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,*
[4]*Cardiology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,*
[5]*Radiopharmacy Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN.*

EPS-185

^{18}F-FDG uptake in non-infective prosthetic vascular grafts and endografts

D. Pursanova, *I. P. Aslanidis, O. V. Mukhortova, I. V. Shurupova, D. D. Zubkov, K. S. Dudukin;*
A.N. Bakulev Scientific Center for Cardiovascular Surgery of the Ministry of Health of the Russian F, Moscow, RUSSIAN FEDERATION.

EPS-186

FDG PET/CT in Adult-Onset Still's Disease: Whole-Body Metabolic Characterisation, Lymphoma Differentiation, and Treatment Response Monitoring

M. Umar, *A. Babu, H. Khairwa, K. Chandra, R. Kumar;*
AIIMS, New Delhi, INDIA.

EPS-187

Clinical Indications for Investigating Infective Endocarditis using18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (^{18}F-FDG PET/CT): A Single-Center Experience

A. Kiousi[1], *S. Gavriilidis*[1], *M. Skylakaki*[2], *P. Rontogianni*[1], *Z. Delichas*[1], *N. Pianou*[1];
[1]*Nuclear Medicine Department, Evangelismos General Hospital, Athens, GREECE,*
[2]*Radiology Department, Evangelismos General Hospital, Athens, GREECE.*

EPS-188

A retrospective analysis of [^{18}F]FDG PET/CT in the diagnosis and management of suspected prosthetic and native valve endocarditis

A. Tan[1], *A. Bahuguna*[1], *M. Naik*[2];
[1]*Imperial College London, London, UNITED KINGDOM,*
[2]*Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.*

EPS-189

Unsuspected extrapulmonary involvement detected by Positron Emission Tomography / Computed Tomography in newly diagnosed sarcoidosis.

X. Valverde, *A. Caresia Aroztegui, V. Vallejos Arroyo, R. Ferrándiz Hervella, J. Mora Sospedra, N. Canchumanya Huatuco, S. Lafuente-Carrasco, M. Solà Suarez, M. Salcedo Pujantell, P. Hinojosa Salas, J. Deportós Moreno, M. Boronat de Ferrater, G. Moragas Freixa, J. Vidal Ripoll, C. Gutiérrez Domenech, I. Casafont Sole, S. Ruiz Llama, M. Lopez Gomez, A. Olmo Crespo;*
Hospital Universitari Germans Trias i Pujol, Badalona, SPAIN.

EPS-190

Distribution of Disease in ^{18}F Florbetaben PET Scans in Patients with Suspected Systemic Amyloidosis

S. Jo, *M. Dimitri, N. Ayars, S. Thoo, N. Horvath, D. Bartholomeusz;*
Royal Adelaide Hospital, Adelaide, AUSTRALIA.

EPS-191

Detection of low-grade inflammation of adipose tissue in elderly cancer patients with sarcopenia and sarcopenic obesity

A. Yurchenko[1], *M. Beregov*[1,2], *A. Filimonova*[1], *I. Znamenskiy*[1,3];
[1]*Petrovsky NRCS, Moscow, RUSSIAN FEDERATION,*
[2]*FSBI FCBRN of the FMBA, Moscow, RUSSIAN FEDERATION,*
[3]*FSAEI HE N.I. Pirogov RNRMU of MOH of Russia (Pirogov University), Moscow, RUSSIAN FEDERATION.*

EPS-192

Impact of Recent Surgical and Interventional Procedures on CXCR4 PET/CT Uptake: A Quantitative and Dual-Tracer Analysis

S. Serfling[1], *Y. Zhi*[2], *T. Higuchi*[1], *P. E. Hartrampf*[1], *A. K. Buck*[1], *R. A. Werner*[3];
[1]*Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,*
[2]*Department of Otorhinolaryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, University Hospital Würzburg, Würzburg, GERMANY,*
[3]*Department of Nuclear Medicine, LMU University Hospital, Munich, GERMANY.*

EPS-193

Utility of [^{18}F]FDG PET/CT for the detection of cyst infection in patients with renal or hepatorenal polycystic disease

M. Zamorano Rivas[1], *L. Gràcia Sánchez*[1], *B. Dacosta Escobar*[1], *D. J. Tamayo Ossa*[1], *J. Robles Barba*[1], *M. Suárez Piñera*[1], *M. Hueso Val*[2], *N. Estrada Choque*[2], *I. Grau Garriga*[3], *M. Cortés Romera*[1], *I. Sánchez Rodríguez*[1];
[1]*Nuclear Medicine- PET Department (ICS-IDI). Hospital Universitari de Bellvitge - IDIBELL, Barcelona, SPAIN,*
[2]*Nephrology Department. Hospital Universitari de Bellvitge, Barcelona, SPAIN,*
[3]*Infectious Diseases Department. Hospital Universitari de Bellvitge, Barcelona, SPAIN.*

EPS-194

^{18}F-FDG PET/CT Detects Occult Inflammation in CK-negative Dermatomyositis

A. Bagán-Trejo[1], *L. Gràcia-Sánchez*[1], *D. Ramírez-Muñoz*[1], *P. Notta-González*[1], *I. Sánchez-Rodríguez*[1], *B. Hervás-Sanz*[1], *E. Ricart-Paredes*[2], *M. Argelés-Colet*[1], *S. Orts-Expósito*[2], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine-PET (IDI) Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN,*
[2]*Radiopharmacy Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN.*

EPS-195

The Silent Culprit: ^{18}F-FDG PET/CT Identifies Disseminated Infective Primary Myositis as the Source of Infection in Pyrexia of Unknown Origin(PUO) —An Uncommon Etiological Spectrum

R. Shah, *M. L. Narayan, K. Vidhya, V. K. Saini, P. K. Panda, V. Jain, C. Puranicmath, S. Ajith;*
All India Institute Of Medical Science, Rishikesh, INDIA.

EPS-196

^{18}F-FDG PET/CT Findings in DRESS Syndrome Mimicking Lymphoma: A Case Report

A. Giarratana, *T. Romero Garcia, D. T. Yang;*
University of Wisconsin - Madison, Madison, WI, UNITED STATES OF AMERICA.

EPS-197

Added Value of SPECT/CT in the Evaluation of Persistent Pain After Total Hip Arthroplasty

A. Jankulovska[1], *S. Talevska*[1], *B. Stoilovska Rizova*[1], *N. Kolovcevska Bozhinovska*[1], *N. Stojanoska*[2], *T. Makazlieva*[1], *N. Manevska*[1,3], *S. Stojanoski*[1];
[1]*Institute of pathophysiology and nuclear medicine "Acad. Isak Tadzer", Faculty of Medicine, Skopje, NORTH MACEDONIA,*
[2]*Institute of Histology and Embryology, Faculty of Medicine, Skopje, NORTH MACEDONIA,*
[3]*Institute of positron emission tomography, Skopje, NORTH MACEDONIA.*

EPS-198

Correlation Between Infection Parameters and Triple-Phase Bone Scintigraphy Results in Children with Hematogenous Osteomyelitis

P. Korol[1], *O. Shcherbina*[1], *M. Tkachenko*[2], *M. Kostylev*[3];
[1]*Shupik National University Healthcare of Ukraine, Kyiv, UKRAINE,*
[2]*Bogomolets National Medical University of Ukraine, Kyiv, UKRAINE,*
[3]*Shalimov National Scientific Center of Surgery and Transplantation, Kyiv, UKRAINE.*

EPS-199

Study on the Resectability and Resection Scope of Hepatic Alveolar Echinococcosis in High-Altitude Regions Using PET-CT

Y. Yan, *B. Li, H. Guo, Y. Liu;*
Qinghai Provincial People's Hospital, Xining City, Qinghai Province, CHINA.

1509

Tuesday, October 20, 2026, 15:00 – 16:30

Hall G2

AI Data and Image Analysis, Dynamic Imaging

EPS-200

Automated AHA 17-Segment Myocardial Segmentation and Viability Analysis on Oncological FDG-PET/CT

S. Asa[1], *M. Isenkul*[2], *M. Cagan*[1], *B. Ocal*[1], *S. Biyikoglu*[1], *S. Sager*[1];
[1]*Istanbul University Cerrahpasa Medical Faculty Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[2]*Istanbul University Cerrahpasa Faculty of Engineering Department of Computer Engineering, Istanbul, TÜRKIYE.*

EPS-201

What is the Impact of Small, Distant Lesions on the Performance of a PET Prediction Model in Lymphoma?

A. L. Bes[1], *S. E. Wiegers*[1], *M. W. Heymans*[2], *E. Wallsten*[3], *J. J. Eertink*[4], *P. J. Lugtenburg*[5], *G. J. C. Zwezerijnen*[1], *J. M. Zijlstra*[4], *R. Boellaard*[1];
[1]*Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, NETHERLANDS,*
[2]*Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, NETHERLANDS,*
[3]*Department of Diagnostics and Intervention, Radiation Physics, Umea University, Umea, SWEDEN,*
[4]*Department of Hematology, Amsterdam UMC, Amsterdam, NETHERLANDS,*
[5]*Department of Hematology, Erasmus MC, Rotterdam, NETHERLANDS.*

EPS-202

The Impact of Segmentation Method for Baseline ^{18}F-FDG PET-CT Uptake Features in Follicular Lymphoma Patients.

A. Nijman, *S. Wiegers, G. J. C. Zwezerijnen, L. Verweij, Y. W. S. Jauw, M. Kersten, M. W. Heymans, J. M. Zijlstra, R. Boellaard;*
Amsterdam UMC, Amsterdam, NETHERLANDS.

EPS-203

Transformer-Based Positron Emission Tomography/Computed Tomography Fusion Model for Preoperative Prediction of Spread Through Air Spaces in Lung Adenocarcinoma: A Multicentre Validation

X. Zhu, *W. Fu;*
The First Affiliated Hospital of Guilin Medical University, Guilin, CHINA.

EPS-204

Automated TNM Staging of Breast Cancer from ^{18}F-FDG PET-CT: Multi-Class Deep Learning Segmentation, SUVmax Quantification, and Radiomic Imaging Signatures with External Validation

D. Prakash[1], *P. Kulkarni*[2], *V. Rangarajan*[2], *M. Kumar*[3];
[1]*Advanced Centre for Treatment, Research, and Education in Cancer, Tata Memorial Centre, Mumbai, Homi Bhabha National Institute, Mumbai and Amity University Uttar Pradesh, Noida, INDIA,*
[2]*Advanced Centre for Treatment, Research, and Education in Cancer, Tata Memorial Centre, & Homi Bhabha National Institute, Mumbai, INDIA,*
[3]*Amity University, Uttar Pradesh, Noida, INDIA.*

EPS-205

First Total-Body Kinetic Modeling and Parametric Imaging of Dynamic ^{68}Ga-PSFA-01 PET in Prostate Cancer

L. Guan, *H. Pang, Y. Li, X. Zhang;*
The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EPS-206

Whole-body [18F]FDG-PET/CT enables an organ-based assessment of the resting metabolic rate

C. Loisel[1], *M. Pires*[2], *C. Hinge*[3], *J. Auriac*[1], *S. Gutschmayer*[2], *F. Orlhac*[1], *R. Seban*[4], *F. Littrup Andersen*[3,5], *T. Beyer*[2], *I. Buvat*[1];
[1]*Institut Curie, Orsay, FRANCE,*
[2]*QIMP Team, Medical University of Vienna, Vienna, AUSTRIA,*
[3]*Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, DENMARK,*
[4]*Institut Curie, Saint Cloud, FRANCE,*
[5]*Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DENMARK.*

EPS-207

Assessment of metabolic and structural ageing across organs in healthy Japanese adults undergoing longitudinal [18F]FDG-PET/CT imaging

S. Gutschmayer[1], *M. Pires*[1], *C. H. M. Vu*[2,3], *X. Yang*[2,4], *N. Akatani*[2], *J. Taki*[5], *S. Takeda*[5], *T. Yamase*[6], *K. Yokoyama*[6], *H. Wakabayashi*[2], *T. Beyer*[1];
[1]*QIMP Team, Medical University of Vienna, Vienna, AUSTRIA,*
[2]*Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN,*
[3]*Division of Advanced Preventive Medical Science, Graduate School of Advanced Preventive Medical Sciences, Kanazawa University, Kanazawa, JAPAN,*
[4]*Department of Nuclear Medicine, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, JAPAN,*
[5]*PET Center, Kanazawa Advanced Medical Center, Kanazawa, JAPAN,*
[6]*Public Central Hospital of Matto Ishikawa, Hakusan, JAPAN.*

EPS-208

Acceleration of SPECT imaging using generation of synthetic intermediate projections

M. Parvin[1], *A. Gehring*[1], *J. Leube*[1], *J. Gustafsson*[2], *M. Salas-Ramirez*[1], *J. Tran-Gia*[1];
[1]*University Hospital Würzburg, Würzburg, GERMANY,*
[2]*Lund University, Lund, SWEDEN.*

EPS-209

Deep Learning-Based Super-Resolution of PET and CT Images Using SwinUNETR-v2

B. Demir;
Mehmet Akif Inan Education and Research Hospital, Sanliurfa, TÜRKIYE.

EPS-210

Fusion of Habitat and Deep Learning Features from PET/CT Predicts High-Risk Cytogenetics in Multiple Myeloma: A Multicenter Study

H. Chen, *Q. Luo;*
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, shanghai, CHINA.

EPS-211

Radiuma: Zero-Code Generation of Shareable and Reproducible Medical Imaging Workflows

M. Salmanpour[1,2,3], *M. Oveisi*[2,3], *I. Shiri*[4], *A. Rahmim*[1,2];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,*
[2]*University of British Columbia, Vancouver, BC, CANADA,*
[3]*Technological Virtual Collaboration Company (TECVICO CORP.), Vancouver, BC, CANADA,*
[4]*University of Bern, Bern, SWITZERLAND.*

EPS-212

PET-to-PET Modality Translation for Imputing Missing Functional Neuroimaging Data

L. Cavinato, *L. Caldera;*
Politecnico di Milano, Milano, ITALY.

EPS-213

Preoperative prediction of IDH status in adult glioma using integrated 18F-FET PET/MR: a comparative evaluation of image fusion algorithms

K. Zheng[1], *Q. Han*[1], *T. Li*[1], *Z. Liu*[2], *E. Li*[2], *Y. Yang*[3], *J. Liu*[1], *W. Ma*[1], *Y. Wang*[1], *H. You*[1], *L. Huo*[1];
[1]*Peking Union Medical College Hospital, Beijing, CHINA,*
[2]*Shanghai United Imaging Healthcare Co., Ltd., Shanghai, CHINA,*
[3]*Beijing United Imaging Healthcare Technology Development Co., Ltd., Beijing, CHINA.*

EPS-214

Developing a new reconstruction for dynamic spect - take one, perfusion

P. Benyovszki[1], *B. Kari*[2], *O. Partos*[2], *A. Szucs*[3];
[1]*Budapest University of Technology and Economics, Budapest, HUNGARY,*
[2]*Semmelweis University, Budapest, HUNGARY,*
[3]*Eotvos Lorand University, Budapest, HUNGARY.*

EPS-215

Optimization of Bolus-to-Infusion Ratio for Stable Arterial Input Function in 18F-FDG PET Activation Studies

V. Turmacu[1], *J. Bastijns*[1], *G. Vanderlinden*[1], *M. Koole*[1], *K. Van Laere*[1,2];
[1]*KU Leuven, Leuven, BELGIUM,*
[2]*UZ Leuven, Leuven, BELGIUM.*

EPS-216

Impact of MRI Slice Thickness on 18F-Florbetapir PET Quantification: A Head-to-Head Validation of Deep Learning-Based Structural Reconstruction

Y. Zhang[1], *M. Wang*[1], *R. Ni*[2], *A. Rominger*[2], *K. Shi*[2], *C. Zuo*[3], *J. Jiang*[1];
[1]*Shanghai University, Shanghai, CHINA,*
[2]*University of Bern, Bern, SWITZERLAND,*
[3]*Huanshan Hospital, Shanghai, CHINA.*

EPS-217

Automated whole-body composition assessment from routine PET/CT using multi-level machine learning: validation and prognostic value in a pan-cancer cohort

P. Decazes;
Henri Becquerel Cancer Center, Rouen Cedex[1], *FRANCE.*

EPS-218

Toward Robust and Reproducible Deep Radiomics: Deep PET/CT Tensor Radiomics in Machine Learning Model Selection for Lung Cancer Survival Prediction

M. Luo[1,2], *A. Rahmim*[1,2,3], *M. R. Salmanpour*[1,2];
[1]*Faculty of Medicine, The University of British Columbia, Vancouver, BC, CANADA,*
[2]*Department of Basic and Translational Research, BC Cancer Research Centre, Vancouver, BC, CANADA,*
[3]*Departments of Physics and Biomedical Engineering, The University of British Columbia, Vancouver, BC, CANADA.*

EPS-219

AI model using nnU-Net for automatic detection of 18F-FDG-avid lesions in PET/CT and generation of PET-fusible probability maps

E. Marino[1,2], *G. Peña*[3], *M. Di Natale*[3];
[1]*FUESMEN (Fundación Escuela de Medicina Nuclear), Mendoza, ARGENTINA,*
[2]*CNEA(Comisión Nacional de Energía Atómica), Buenos Aires, ARGENTINA,*
[3]*Fuesmen, Mendoza, ARGENTINA.*

1609

Tuesday, October 20, 2026, 16:45 - 18:15
Hall G2

Radiopharmaceutical Sciences Committee: Modern Approaches to Drug Development in Nuclear Medicine

EPS-220

A Novel [64Cu]Cu-Nanomedicine Radiotracer for Imaging Neuroinflammation

S. Minami[1], *B. Lu*[1], *W. Thomas*[1], *X. Li*[1], *J. L. Cleland*[1,2];
[1]*Programmable Medicine, Redwood City, CA, UNITED STATES OF AMERICA,*
[2]*ENIAC Imaging, Inc., Redwood City, CA, UNITED STATES OF AMERICA.*

EPS-221

Development of [225Ac]Ac PSMA nanodelivery system utilising poly (lactic-co-glycolic) acid-chitosan-folic acid functionalised nanoparticles for targeted alpha therapy of prostate cancer

Y. Mzizi[1,2], *B. Witika*[3], *H. Ndlovu*[4], *M. Shungube*[1], *P. Makoni*[3], *S. Sibiya*[1,2], *A. Malophane*[4], *M. Sathekge*[1,2], *S. Mdanda*[1,2];
[1]*Nuclear Medicine Research Infrastructure, Pretoria, SOUTH AFRICA,*
[2]*Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA,*
[3]*School of Pharmacy: Department of Pharmaceutical Sciences, Sefako Makgatho Health Sciences University, Ga-Rankuwa, SOUTH AFRICA,*
[4]*Department of Nuclear Medicine, University of Pretoria, Pretoria, SOUTH AFRICA.*

EPS-222

Preclinical imaging with click chemistry-based FAPi-dimers as diagnostic companions for halogen radioligand therapy

D. Beyer[1,2], *M. Martin*[1,2], *M. Müller*[1,2], *J. Schichler*[1,2], *U. Battisti*[1,2], *L. Hvass*[2], *V. Shalgunov*[1,3], *A. Miranda*[4], *F. Elvas*[4], *A. Jensen*[1], *A. Kjaer*[2], *M. Herth*[1,2,5];
[1]*Tetrakit Technologies ApS, Copenhagen, DENMARK,*
[2]*University of Copenhagen, Copenhagen, DENMARK,*
[3]*Rigshospitalet, Copenhagen, DENMARK,*
[4]*University of Antwerp, Antwerp, BELGIUM,*
[5]*Rigshospitalet, København, DENMARK.*

EPS-223

Modular Molecular Design of B7H3Targeting Affibody Molecules for Radionuclide Therapy: Biodistribution-Driven Selection and Therapy

M. Oroujeni[1], *Y. Liu*[1], *E. Recasens Pérez-Vera*[1], *E. Papalanis*[1], *E. Bezverkhniaia*[1], *E. Gunneriusson*[2], *S. Klint*[2], *E. Ryer*[2], *M. Carlqvist*[2], *A. Orlova*[1], *F. Y. Frejd*[2], *V. Tolmachev*[1];
[1]*Uppsala University, Uppsala, SWEDEN,*
[2]*Affibody AB, Solna, SWEDEN.*

EPS-224

Beyond Plaques: Targeting Soluble Amyloid-β Oligomers with a novel 64Cu PET Tracer

F. Raccah[1], *O. Sarrhini*[2], *S. Ait-Mohand*[1], *P. Doss*[1], *R. Lebel*[1], *D. Sikpa*[1], *K. Fernandes*[1], *M. Lepage*[1], *S. Gandy*[3], *S. Rahimipour*[4], *W. Lubell*[5], *B. Guérin*[1];
[1]*Université de Sherbrooke, Sherbrooke, QC, CANADA,*
[2]*Centre d'imagerie moléculaire de Sherbrooke (CIMS), Centre de Recherche du CHUS, Sherbrooke, QC, CANADA,*
[3]*Mount Sinai Alzheimer's Disease Research Center, New York City, NY, UNITED STATES OF AMERICA,*
[4]*Bar-Ilan University, Ramat-Gan, ISRAEL,*
[5]*Université de Montréal, Montréal, QC, CANADA.*

EPS-225

A DualSurface ADAPT Scaffold Protein Enables Selective and Specific Targeting of Folate ReceptorAlpha with Simultaneous HalfLife Extension

M. Din[1], *E. Larsson*[2], *A. Bitzios*[1], *E. Recasens Perez-Vera*[1], *A. Orlova*[1], *V. Tolmachev*[1], *S. Hober*[2], *A. Vorobyeva*[1];
[1]*Uppsala University, Uppsala, SWEDEN,*
[2]*KTH Royal institute of Technology,Stockholm, Sweden, Stockholm, SWEDEN.*

EPS-226

MD-Based Identification of New GRPR-Targeting Radioligands with Improved Therapeutic Efficacy and Tumor-to-Background Contrast

Y. Tao[1], *C. Li*[2], *J. Zhang*[1], *J. Liu*[2], *X. Chen*[2];
[1]*National University of Singapore, Singapore, SINGAPORE,*
[2]*Shandong First Medical University Affiliated Tumor Hospital (Shandong Cancer Hospital and Institute), Jinan, Shandong, CHINA.*

EPS-227

Understanding the radiobiology of therapeutic radionuclides on prostate cancer cell lines

M. Chandrashekhar[1], *T. Pack*[1], *C. Byrne*[1], *K. Wyszatko*[1], *S. Selivanova*[2];
[1]*Canadian Nuclear Laboratories, Chalk River, ON, CANADA,*
[2]*Universite Laval, Quebec City, QC, CANADA.*

EPS-228

C-terminal Leu13 modifications of neurotensin-based PET tracers to enhance NTSR1 binding and tumor uptake

S. Kaur[1,2], *M. Paladino*[1], *S. Pathania*[1,2], *P. Ng*[1], *H. Merkens*[1], *F. Benard*[1,2], *K. Lin*[1,2], *J. Lau*[1,2];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,*
[2]*The University of British Columbia, Vancouver, BC, CANADA.*

EPS-229

PET imaging of PD-L1 with a ^{43}Sc/^{44}Sc-labelled minibody

M. Richard[1], *D. Viertl*[2], *T. Demartinécourt*[3], *N. P. van der Meulen*[4], *Z. Talip*[4], *S. Huclier*[3], *C. Truillet*[1], *B. Kuhnast*[1];
[1]*CEA, Orsay, FRANCE,*
[2]*University of Lausanne, Lausanne, SWITZERLAND,*
[3]*GIP Arronax, Nantes, FRANCE,*
[4]*PSI Center for Nuclear Engineering and Sciences, Villigen, SWITZERLAND.*

EPS-230

Albumin binding improves the pharmacokinetics and therapeutic efficacy of a ^{177}Lu-labeled HER2 Fab radioconjugate

P. Liu[1], *Y. Pang*[1], *J. Liu*[1], *X. Chen*[1], *J. Zhang*[2];
[1]*Center for Nuclear Medicine and Molecular Imaging, Shandong Cancer Hospital and Institute, Jinan, CHINA,*
[2]*Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.*

EPS-231

Laser Ablation ICP-MS vs Autoradiography for Microscale Renal Mapping of Terbium-DOTA-TATE

J. Henriot[1,2], *T. Opsomer*[1], *C. Bouvier-Capely*[3], *T. Van Helden*[4], *I. Basabe Mendizabal*[4], *D. Suhard*[3], *T. van Acker*[4], *L. Struelens*[1], *M. Koole*[2], *C. Saldarriaga Vargas*[1];
[1]*Belgian Nuclear Research Center (SCK CEN), Mol, BELGIUM,*
[2]*KU Leuven, Leuven, BELGIUM,*
[3]*Autorité de Sûreté Nucléaire et de Radioprotection (ASNR), Fontenay-aux-Roses, FRANCE,*
[4]*Ghent University, Ghent, BELGIUM.*

EPS-232

CXCR4-PET imaging of systemic leukocyte dynamics in experimental atherosclerosis

M. Murillo Angarita[1], *P. Schots*[1], *P. Suwattananuruk*[2], *V. Berg*[1], *R. Sundset*[2,1];
[1]*UiT The Arctic University of Norway, Tromsø, NORWAY,*
[2]*University Hospital of Northern Norway, Tromsø, NORWAY.*

EPS-233

^{225}Ac-PYTA-Sacituzumab: A New Radiopharmaceutical for Targeted Radionuclide Therapy (TRT) of TROP-2 expressing Metastatic Triple Negative Breast Cancer (TNBC)

S. Vallabhajosula[1], *N. A. Thiele*[2], *K. J. Son*[1], *V. Navarro*[1], *A. Brown*[1], *M. Islam*[2], *N. H. Bander*[1], *P. W. Kantoff*[1];
[1]*Convergent Therapeutics, Cambridge, MA, UNITED STATES OF AMERICA,*
[2]*Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, TN, UNITED STATES OF AMERICA.*

EPS-234

Development of a dual cyclic peptide analogue for the targeting of Desmoglein-2: a novel target for tumor theranostics

M. Zhang;
Xijing Hospital, Xi'an, CHINA.

EPS-235

[^{68}Ga]Ga-NOTA-PEG2-RM26 PET/CT Enables In Vivo GRPR Characterisation and Complementary Biological Profiling in Prostate and ER-Positive Breast Cancer

A. Tzortzakakis[1], *S. a. Burén*[1], *J. Yachnin*[1], *C. Li*[1], *R. Altena*[1], *C. Hindorf*[1], *A. Bjäreback*[1], *E. Jussing*[1], *T. A. Tran*[1], *C. F. Moro*[1], *A. Orlova*[2], *R. Axelsson*[1];
[1]*Karolinska Institutet, Stockholm, SWEDEN,*
[2]*Uppsala University, Upsalla, SWEDEN.*

EPS-236

ARK-T-01: A Zwitterionic Peptide Platform Enabling Hydration Barrier-Mediated Enhancement of Targeting and Pharmacokinetics in Radioligand Therapy

J. H. Chang;
Klayon Therapeutics, Inc., Carmel, IN, UNITED STATES OF AMERICA.

EPS-237

Development of Bicyclic Peptide PET Tracers Targeting Urokinase-type Plasminogen Activator Receptor

S. Pu, *J. Xie, Z. Luo;*
shanghaitech University, Shanghai, CHINA.

EPS-239

A Novel Probe for Salivary Gland Uptake in PSMA-Targeted Theranostic

Y. Tan[1,2], *L. Tang*[3], *M. Zhou*[3];
[1]*Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,*
[2]*Theranostics Center of Excellence, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,*
[3]*Xiangya Hospital, Central South University, Changsha, CHINA.*

1709

Wednesday, October 21, 2026, 08:00 - 09:30

Hall G2

Neuroimaging e-Poster

EPS-240

Association between baseline ^{18}F-FDG-PET/TC regional metabolism and 5-year cognitive evolution in initially asymptomatic individuals

L. Cabrera Portillo, *M. Botanch-Domingo, S. López, A. Clavijo-Umbarila, P. Andrade-Mejía, C. Lage, F. Martínez, A. Pozueta, N. Carvalho-Duarte, F. Rodríguez-Izquierdo, M. Bravo, M. García, A. Corrales, N. Martínez-Amador, F. Gómez de la Fuente, A. Sanchez-Salmón, I. Martínez-Rodríguez, B. Lucas-Velazquez, D. Hernandez-Serrano, S. Cabrera-Zuñiga, V. Mendi-Barcina, R. Quirce, E. Rodríguez, J. Jiménez-Bonilla;*
Hospital Universitario Marqués de Valdecilla, Santander, SPAIN.

EPS-241

In vivo metabolic progression subtypes of multiple system atrophy identified by FDG-PET reveal hidden heterogeneity within the parkinsonian phenotype

J. Wang, *M. Tian, C. Zuo;*
Department of Nuclear Medicine/PET center, Huashan Hospital, Fudan University, Shanghai, CHINA.

EPS-242

Systemic Brain-Body Metabolic Coupling Patterns in Amyotrophic Lateral Sclerosis: A Whole-Body [^{18}F] Fluorodeoxyglucose PET/CT Study Across Clinical Phenotypes

H. Jiang[1], *L. Xiao*[1], *J. Yang*[1], *A. Rominger*[2], *K. Shi*[2], *Y. Tang*[1], *S. Hu*[1];
[1]*Xiangya Hospital, Central South University, Changsha, CHINA,*
[2]*Department of Nuclear Medicine, Inselspital, Bern, SWITZERLAND.*

EPS-243

Beyond Seronegative Ambiguity: 18f-FDG-PET Illuminates What MRI Cannot in Pediatric Autoimmune Encephalitis — Insights from a Single Centre Study

M. L Narayan, *P. K.Panda, S. Ajith, R. Shah, I. Sharawat;*
All India Institute of Medical Sciences (A.I.I.M.S) Rishikesh, Rishikesh, Dehradun, INDIA.

EPS-244

The Role of Quantitative ^{18}F-FDG PET/CT in the Differential Diagnosis of NBIA Subtypes: Atlas-Based Phenotyping

B. Arca[1], *E. G. Isik*[1], *D. Has Simsek*[1], *Z. G. Ozkan*[1], *Z. Yapici Obuz*[2], *Y. Sanli*[1];
[1]*Istanbul University, Istanbul Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[2]*Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, TÜRKIYE.*

EPS-245

Beyond Visual Assessment: Asymmetry in FDG-PET as an Objective Tool for Enhanced Epileptogenic Zone Localisation in Drug-Resistant Epilepsy.

S. Seth, *P. Srimathi, M. Tripathi, A. Suresh, R. Upadhyaya, A. Chaturvedi, J. Parihar, N. A. Damle, M. Tripathi;*
All India Institute Of Medical Sciences, New Delhi, INDIA.

EPS-246

Data-Driven Triple-Tracer PET Phenotypes in Progressive Supranuclear Palsy

C. Jia, *M. Liang, R. Cui;*
Peking Union Medical College, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, CHINA.

EPS-247

Role of florzolotau (^{18}F) positron emission tomography in the diagnosis of progressive supranuclear palsy

J. Lu[1], *X. Li*[2], *K. Chan*[2], *F. Liu*[2], *J. Wang*[2], *C. Zuo*[1], *the Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI);*
[1]*Department of Nuclear Medicine &PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA,*
[2]*Department and Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, CHINA.*

EPS-248

Dissociated Metabolic Networks in Patients with Co-Pathology of Limbic-Predominant Age-Related TDP-43 Encephalopathy and Alzheimer's Disease: The IAEA Neuroimaging Consortium

T. Thientunyakit[1], *J. Arbizu*[2], *M. Garcia-Granero*[2], *D. Cross*[3], *A. Damián*[4], *J. Warwick*[5], *". Jamsek*[6], *J. Reimand*[7], *M. Tripathi*[8], *M. Trošt*[9], *N. Sultana*[10], *O. Pellet*[11], *D. Paez*[11], *S. Minoshima*[3];
[1]*Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, THAILAND,*
[2]*Clinica Universidad de Navarra, Pomplona, SPAIN,*
[3]*The University of Utah, Salt Lake City, UT, UNITED STATES OF AMERICA,*
[4]*Centro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, URUGUAY,*
[5]*Stellenbosch University, Stellenbosch, SOUTH AFRICA,*
[6]*UMC Ljubljana, Ljubljana, SLOVENIA,*
[7]*North Estonia Medical Centre, North Estonia Medical Centre, ESTONIA,*
[8]*All India Institute of Medical Sciences, New Delhi, INDIA,*
[9]*University Medical Centre, Ljubljana, SLOVENIA,*
[10]*National Institute of Nuclear Medicine & Allied Sciences Bangladesh Atomic Energy Commission, Dhaka, BANGLADESH,* [11]*the International Atomic Energy Agency, Vienna, AUSTRIA.*

EPS-249

[^{11}C]K-2 PET Reveals Asymmetry of glutamate AMPA Receptor Density in Refractory Medial Temporal Lobe Epilepsy

W. Nakajima[1], *M. Hatano*[1], *H. Abe*[1], *T. Arisawa*[2], *Y. Takada*[1], *Y. Kimura*[3], *T. Takahashi*[1];
[1]*Department of Physiology, Yokohama City University School of medicine, Yokohama, JAPAN,*
[2]*Radioisotope Research Center, Yokohama City University Graduate School of Medicine, Yokohama, JAPAN,*
[3]*Faculty of Informatics, Cyber Informatics Research Institute, Kindai University, Higashi-Osaka, JAPAN.*

EPS-250

Hemispheric Tau Asymmetry Predicts Accelerated Multidomain Cognitive Decline in Alzheimer's disease

J. Wang[1], *J. Lu*[2], *C. Li*[2], *Y. Wei*[3], *Y. Chen*[1], *J. Wang*[2], *Y. Yang*[4], *S. Yan*[1], *H. Zhang*[2], *W. Bao*[2], *L. Zheng*[1], *X. Liang*[1], *Y. Guan*[2,5], *C. Zuo*[2,5], *Q. Zhao*[1,5,6], *Shanghai Memory Study (SMS), Alzheimer's Disease Neuroimaging Initiative (ADNI);*
[1]Department and Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, CHINA,
[2]Department of Nuclear Medicine and PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA,
[3]United Imaging Healthcare Co., Ltd., Shanghai, CHINA,
[4]Beijing United Imaging Healthcare Co., Ltd, Beijing, CHINA,
[5]National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, CHINA,
[6]National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, CHINA.

EPS-251

[18F]FET-PET enables non-invasive prediction of CDKN2A/B status and WHO grade in IDH-mutant astrocytoma

K. Mueller[1], *M. Mair*[2], *J. Werner*[3], *M. Müther*[4], *W. Roll*[5], *A. Chaban*[6], *J. Reis*[7], *T. Schabhüttl*[8], *J. Hilgers*[9], *K. Ciantar*[10], *P. Lohmann*[11], *P. Harter*[12], *L. von Baumgarten*[1], *C. Delbridge*[13], *I. Yakushev*[6], *J. Hainfellner*[14], *G. Widhalm*[15], *M. Hacker*[16], *N. Galldiks*[3], *M. Preusser*[2], *N. Albert*[8];
[1]Department of Neurology, University Hospital of Munich, LMU, Munich, GERMANY,
[2]Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, AUSTRIA,
[3]Department Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, GERMANY,
[4]Department of Neurosurgery, University Hospital Münster, Münster, Münster, GERMANY,
[5]Department of Nuclear Medicine, University Hospital Münster, Münster, Münster, GERMANY,
[6]Department of Nuclear Medicine, Technical University Hospital of Munich, Munich, GERMANY,
[7]Department of Neuroradiology, University Hospital of Munich, LMU, Munich, GERMANY,
[8]Department of Nuclear Medicine, University Hospital of Munich, LMU, Munich, GERMANY,
[9]Institute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich (FZJ), Juelich, Juelich, GERMANY,
[10]Institute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich, Juelich, GERMANY, [119] Institute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich (FZJ), Juelich, Juelich, GERMANY,
[12]Center for Neuropathology and Prion Research, LMU University Hospital, LMU Munich, Munich, GERMANY,
[13]Institute of Pathology, Department of Neuropathology, Technical University Hospital of Munich, Munich, GERMANY,
[14]Department of Neurology, Medical University of Vienna, Vienna, Vienna, AUSTRIA,
[15]Department of Neurosurgery, Medical University of Vienna, Vienna, Vienna, AUSTRIA,
[16]Division of Nuclear Medicine, Medical University of Vienna, Vienna, Vienna, AUSTRIA.

EPS-252

Diagnostic accuracy of long-axial-field-of-view [18F]FET PET/CT in high-grade glioma - new semi-quantitative cutoff values for tumour detection

M. Amon[1], *A. Lazar*[2], *J. Penner*[1], *P. Radojewski*[3], *A. Rominger*[1], *H. Sari*[1,4], *C. Mingels*[1];
[1]Universitätsklinik für Nuklearmedizin, Bern, SWITZERLAND,
[2]Vita-Salute San Raffaele University, Milan, ITALY,
[3]University Institute of Diagnostic and Interventional Neuroradiology, Bern, SWITZERLAND,
[4]Advanced Clinical Imaging Technology, Siemens Healthcare AG, Zurich, SWITZERLAND.

EPS-253

Metabolic Tumor Volume (MTV) Measurement in Brain Gliomas Using Amino Acid PET/CT: Prognostic Value and Comparison of Segmentation Methods

D. Kalaeva, *N. Vikhrova, I. Pronin;*
N. N. Burdenko National Medical Research Center of Neurosurgery, Moscow, RUSSIAN FEDERATION.

EPS-254

Reconstruction-dependent bias in semiquantitative FET PET: combined clinical and phantom evidence with implications for glioma imaging

A. Chaban, *J. Ni, S. Nekolla, I. Yakushev;*
Klinik und Poliklinik für Nuklearmedizin, Klinikum rechts der Isar, Technische Universität München, München, GERMANY.

EPS-255

External Validation of an Interpretable O-(2-[18F]fluoroethyl)-L-tyrosine Positron Emission Tomography and Magnetic Resonance Classifier for Differentiating True Progression from Treatment-related Changes in Post-treatment Diffuse Glioma

H. Dang, *S. Zhang, Y. Guan, J. Lu;*
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, CHINA.

EPS-256

Identification of Subregions Associated with Survival Risk in High-Grade Gliomas Using Hybrid 18F-FET PET/MR

J. Bai[1], *B. Cui*[1], *N. Li*[2], *Z. Liu*[2], *J. Lu*[1];
[1]Xuanwu Hospital, Beijing, CHINA,
[2]Beijing United Imaging Research Institute of Intelligent Imaging, Beijing, CHINA.

EPS-257

Cerebellar Microglial Metabolic-Inflammatory Coupling Drives Network Progression in Temporal Lobe Epilepsy: Multimodal PET and Targeted FOS Inhibition

Y. Tang[1], *L. Xiao*[1], *M. Zhou*[1], *J. Yang*[1], *K. Shi*[2], *S. Hu*[1];
[1]Xiangya Hospital Central South University, Changsha, CHINA,
[2]Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.

EPS-258

Individualized Metabolic Deviation Networks Enable Interpretable Prediction of MCI-to-AD Progression

T. Sun, *S. Hou, S. Wang;*
Paul C. Lauterbur Research Center for Biomedical Imaging, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, CHINA.

EPS-259

Functional-Metabolic Decoupling in Autoimmune Encephalitis A Multimodal PET/MRI Brain Network Study

H. Shao[1], *G. Huang*[1], *Y. Wang*[1], *L. Qi*[2], *J. Hao*[2], *J. Liu*[1];
[1]Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanhgai, CHINA,
[2]United Imaging Healthcare, Shanhgai, CHINA.

EPS-260

Molecular imaging of fibroblast activation protein on PET/MRI:association with carotid plaque

F. Fu[1], *M. Zhang*[2], *Y. M. Pan*[2], *B. Li*[2];
[1]Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CHINA,
[2]Department of Nuclear Medicine & Institute for medical imaging technology, Ruijin hospital, shanghai Jiaotong University, Shanghai, CHINA.

1809

Wednesday, October 21, 2026, 09:45 - 11:15
Hall G2

Paediatrics e-Poster

EPS-261

Impact of 18F PSMA PET/CT on the Clinical Management of Patients with Metastatic Castration-Resistant Prostate Cancer

O. Rosas Lozano, *C. González Navarro, M. Catala Espí, A. Palazón Vives, A. Martínez Esteve, J. Clavel Claver, J. Verdú Rico, T. Díaz Capilla, M. Anton Leal, A. Martínez Caballero;*
Hospital Univeristario San Juan de Alicante, Alicante, SPAIN.

EPS-262

Predictive value of the MAG-SOS scale for surgical intervention in Pyeloureteral Junction Obstruction (UPJO).

O. Rosas Lozano[1], *C. Abril Sánchez*[2], *M. Catala Espí*[1], *C. González Navarro*[1], *J. Clavel Claver*[1], *N. Albertos Mira-Marcell*[2], *A. Martínez Esteve*[1], *M. Anton Leal*[1], *A. Martínez Caballero*[1], *J. Verdú Rico*[1];
[1]Hospital Univeristario San Juan de Alicante, Alicante, SPAIN,
[2]Hospital General Univeristario Dr. Balmis, Alicante, SPAIN.

EPS-263

Residual syringe activity in paediatric nuclear medicine: quantification and associated factors

M. Vivar Pérez, *E. Durand Galíndez, M. Villar Pulido, N. Aguado de la Fuente, A. Puig Colom, M. Ruiz Santaella, A. Guerra Velastegui, S. Chamizo Ruiz, A. Luján Colas, F. Vega Martínez, C. Peña Villoria;*
Son Espases University Hospital, Palma de Mallorca, SPAIN.

EPS-264

123I-mIBG scintigraphy with whole-body SPECT/CT vs [18F]-FDOPA PET/CT in pediatric patients with neuroblastoma

E. Kireeva, *K. Chaurasiya, M. Dunaykin, T. Shamanskaya, Y. Likar;*
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, RUSSIAN FEDERATION.

EPS-265

Diuresis renography in the evaluation and management of pediatric ureteropelvic junction: What have we learned?

R. Belakroum;
Regional University Military Hospital, Constantine, ALGERIA.

EPS-266

[18F]FDG PET/CT as a Whole Body Quantitative Biomarker in Pediatric Langerhans Cell Histiocytosis: from Diagnosis to Prognosis and Treatment Monitoring

A. Khelifa[1], *A. Chihani*[2], *R. Bouteraa*[3], *C. Mahmoudi*[2], *I. Bechlaghem*[4];
[1]Draa Ben Khedda Oncologic Center, Tizi Ouzou, ALGERIA,
[2]Centre de Diagnostic Chahids Mahmoudi, Algiers, ALGERIA,
[3]Hopital Chahids Mahmoudi, Tizi Ouzou, ALGERIA,
[4]Centre de Médecine Nucléaire d'Oran, Oran, ALGERIA.

EPS-268

Motion-informed quantification after brain motion correction in paediatric and young-adult epilepsy 18F-FDG PET/CT.

A. Losiewicz[1], *J. Baran*[2,1], *A. Sliwinska*[1], *K. Kotulska-Jozwiak*[1];
[1]The Children's Memorial Health Institute, Warsaw, POLAND,
[2]Siemens Healthcare Sp. z o.o., Warsaw, POLAND.

EPS-269

Examining the Effects of Reconstruction Methods on Quantitative [18F]FET PET/CT Imaging Parameters in Pediatric Brain Tumours

T. Antonevskaya, *M. Yadgarov, Y. Likar;*
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, RUSSIAN FEDERATION.

EPS-270

Diagnostic utility of ^{99}mTc MAG3 renal scintigraphy for chemotherapy-induced nephrotoxicity in children

B. Abundiz López;
Secretaria de Salud Publica, Mexico, MEXICO.

EPS-271

Radioiodine Therapy Outcomes in Pediatric Differentiated Thyroid Cancer: A Single Center Experience

N. Saber Zenagui[1], *A. Khelifa*[2], *A. Medjahedi*[1];
[1]*University of Abou Bekr Belkaid, Tlemcen, ALGERIA,*
[2]*Faculty of Medicine, University of Algiers*[1]*, Algiers, ALGERIA.*

EPS-272

Effect of Donor and Recipient Characteristics on Dynamic Changes in Glomerular Filtration Rate After Living Donor Kidney Transplantation

M. Rai, *S. Barai, P. Pradhan;*
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, INDIA.

EPS-273

Diagnostic Value of [^{99m}Tc]Tc-Albumin Scintigraphy with SPECT/CT in the Localisation of Protein-Losing Enteropathy

Ó. Hernández Cristancho, *M. Rubio Alvarez, M. Diez, A. Palomar-Muñoz, J. Suils-Ramón, A. Cardozo-Saavedra, M. Hernández Fructuoso, D. Urbina Jaramillo, S. Martinez Rosales, N. Calviño, L. Nunez Lemos, E. Otero Ruiz, C. Gámez Cenzano;*
Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.

EPS-274

Radiomics-Enhanced Quantification of Tc-99m MDP Bone Scintigraphy in Pediatric Osteomyelitis: Integrating Phase-Specific Metrics with Multimodal Correlation

A. Pandey[1], *J. Chaudhary*[1], *P. D. Sharma*[2], *R. Mittal*[1], *R. Kumar*[1];
[1]*All India Institute of Medical Sciences, New Delhi, INDIA,*
[2]*SGTB Khalsa College, University of Delhi, Delhi, INDIA.*

EPS-275

Quantification of Patient Motion during Anaesthesia-Free LAFOV PET/CT in Paediatric Imaging

P. De Vries[1], *J. H. Van Snick*[2], *K. P. Koopmans*[2], *A. W. J. M. Glaudemans*[2], *O. V. Ivashchenko*[2];
[1]*Faculty of Science and Engineering, University of Groningen, Groningen, NETHERLANDS,*
[2]*Department of Nuclear Medicine and Molecular Imaging, University Medical Center of Groningen, Groningen, NETHERLANDS.*

EPS-276

Validation of simulated ultra low dose ^{18}F-FDG PET/CT in Paediatric protocols using Artificial Intelligence-Based Reconstruction

E. Marino[1,2], *L. M. Hehn*[3], *G. A. Peña*[1];
[1]*FUESMEN (Fundación Escuela de Medicina Nuclear), Mendoza, ARGENTINA,*
[2]*CNEA (Comisión Nacional de Energía Atómica), Buenos Aires, ARGENTINA,*
[3]*Instituto Balseiro - Universidad Nacional de Cuyo, San Carlos de Bariloche, ARGENTINA.*

EPS-277

The Role of ^{99}mTc-MAG3 Renal Scintigraphy in Detecting the Incidence of Asymptomatic Nephroptosis (A Pilot Study in Ukraine)

P. Korol[1], *O. Shcherbina*[1], *M. Kostylev*[2];
[1]*Shupik National University Healthcare of Ukraine, Kyiv, UKRAINE,*
[2]*Shalimov National Scientific Center of Surgery and Transplantation, Kyiv, UKRAINE.*

EPS-278

Whole-body ^{18}F-FDG PET/MR in paediatric Langerhans cell histiocytosis: staging, CNS-risk assessment and management impact

R. De Teresa Herrera[1], *P. Recarte Ortega*[2], *C. Gonzalez Roiz*[3], *A. Lancharro Zapata*[2], *M. Osuna Marco*[2], *M. Camacho Arias*[2], *B. Lopez-Ibor Aniño*[2];
[1]*Hospital de la Defensa Gómez Ulla, Madrid, SPAIN,*
[2]*Grupo HM Hospitales, Madrid, SPAIN,*
[3]*Hospital Universitario Clínico San Carlos, Madrid, SPAIN.*

EPS-279

Predicting Surgery in Antenatal Hydronephrosis with Preserved or Equivocal Drainage: the Overlooked Value of Baseline [^{99m}Tc]Tc-MAG3 Renography

J. Rei da Cruz Escaleira[1,2,3], *P. Matos*[4], *R. Sá e Silva*[1], *R. Teixeira*[1], *F. Ribeiro*[1], *S. Iria*[1], *T. Costa*[4], *L. Costa*[1], *L. Correia-Costa*[4,5];
[1]*Department of Nuclear Medicine, Unidade Local de Saúde (ULS) de Santo António, Porto, PORTUGAL,*
[2]*Unit for Multidisciplinary Research in Biomedicine (UMIB), Porto, PORTUGAL,*
[3]*Laboratory for Integrative and Translational Research in Population Health (ITR), Porto, PORTUGAL,*
[4]*Pediatric Nephrology Department, Centro Materno-Infantil do Norte, ULS Santo António, PORTO, PORTUGAL,*
[5]*EPIUnit ITR, Instituto de Saúde Pública da Universidade do Porto, Universidade do Porto, Porto, PORTUGAL.*

e-Posters

EP-01

A: Preclinical and Translational Studies → A1 Medical Preclinical → A11 In Vitro Studies

EP-0001

Nanotheranostic approach based on177Lu labeled extracellular vesicles for targeted drug delivery

L. Iturmendi[1,2], *M. I. González*[3], *M. J. Serramía*[1], *M. González-Arjona*[1], *C. Kitzberger*[4], *M. Desco*[1,2], *S. Kossatz*[4,5], *B. Salinas*[1,6];
[1]*Instituto de Investigación Sanitaria Gregorio Marañón, Unidad de Medicina y Cirugía Experimental, Madrid, SPAIN,*
[2]*Universidad Carlos III de Madrid, Departamento de Bioingeniería, Madrid, SPAIN,*
[3]*Unidad de Imagen Avanzada, Centro Nacional de Investigaciones Cardiovasculares (CNIC) Carlos III, Madrid, SPAIN,*
[4]*Department of Nuclear Medicine, TUM University Hospital, TUM School of Medicine and Health, Technical University Munich, Munich, GERMANY,*
[5]*Central Institute for Translational Cancer Research (TranslaTUM), Technical University Munich, Munich, GERMANY,*
[6]*Universidad Carlos III de Madrid, Departamento de Ciencia e ingeniería de materiales e ingeniería química, Madrid, SPAIN.*

EP-0002

Nanoparticulated radioactive DAPI derivatives can be used as therapeutic agents for Auger electron nuclear medicine

A. Makino[1,2], *M. Ueda*[3,4], *T. Mori*[2], *C. Suzuki*[1], *H. Watanabe*[2], *H. Okazawa*[2], *Y. Kiyono*[2];
[1]*Hamamatsu University School of Medicine, Hamamatsu, JAPAN,*
[2]*University of Fukui, Yoshida, JAPAN,*
[3]*Tokyo Metropolitan University, Hachioji, JAPAN,*
[4]*RIKEN Center for Sustainable Resource Science, Wako, JAPAN.*

EP-0003

In vitro evaluation of Affibody molecules targeting B7-H3 for radionuclide therapy of neuroblastoma

M. Oroujeni[1], *E. Recasens Pérez-Vera*[1], *E. Ryer*[2], *E. Gunneriusson*[2], *S. Klint*[2], *F. Y. Frejd*[1], *V. Tolmachev*[1];
[1]*Uppsala University, Uppsala, SWEDEN,*
[2]*Affibody AB, Solna, SWEDEN.*

EP-0004

Rosmarinic Acid-Cerium Nanocatalysts Enable Oxygenation-Enhanced ROS Neutralization and PET Imaging-Guided Therapy for Acute Kidney Injury

L. Hao[1], *Y. Zhao*[1], *P. Liu*[1], *S. Hu*[1], *W. Cai*[2];
[1]*Central South University, Changsha, Hunan, CHINA,*
[2]*University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.*

EP-0005

Development of NDUFS1 and RANKL Targeting Ligand for Inhibition of Triple-Negative Breast Cancer Proliferation

M. Al-Maslamani[1], *S. Moon*[2], *S. Nam*[2], *J. Park*[2], *K. Kim*[2], *S. Woo*[2];
[1]*Korea Institute of Radiological & Medical Sciences (KIRAMS), SEOUL, KOREA, REPUBLIC OF,*
[2]*Korea Institute of Radiological & Medical Sciences (KIRAMS), Seoul, KOREA, REPUBLIC OF.*

EP-0006

The impact of Tryptophan in human Prostate cancer

Y. Zhao[1], *A. Alfteimi*[1], *B. Zlatopolskiy*[2], *A. Helm*[1], *K. Aden*[3], *U. Lützen*[1], *M. Zuhayra*[1];
[1]*Department of Nuclear Medicine, University Hospital of S, Kiel, GERMANY,*
[2]*Institute of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, Cologne, GERMANY,*
[3]*Department of Inner Medicine I, University Hospital of S, Kiel, GERMANY.*

EP-0007

In Vitro Evaluation of Dose Rate Effects on 5-Aminolevulinic Acid-Mediated Radiosensitization Using Yttrium-90

B. Xu[1,2], *R. Eelkema*[2], *A. G. Denkova*[1];
[1]*Department of Radiation Science and Technology, Delft University of Technology, Delft, NETHERLANDS,*
[2]*Depatment of Chemical Engineering, Delft University of Technology, Delft, NETHERLANDS.*

EP-0008

Iodine-131-labelled gold nanoparticles targeting glucose-regulated protein 78 for liver cancer therapy

M. Zhang[1], *T. Qiao*[2], *W. Yi*[2], *Z. Lv*[1];
[1]*Department of Nuclear Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai, CHINA,*
[2]*Clinical Nuclear Medicine Center, Imaging Clinical Medical Center, Institute of Nuclear Medicine, Institute of Clinical Mass Spectrometry Applied Research Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, CHINA.*

EP-02

A: Preclinical and Translational Studies → A1 Medical Preclinical → A12 Preclinical Cardiology and Neurology

EP-0009

[^{161}Tb]Tb-FAPI Targeted Radionuclide Therapy for Early Post-MI Myocardial Fibrosis: Added Benefit of Valsartan

W. Wang, *J. Zhang, M. Zhou, S. Hu;*
Xiangya Hospital of Central South University, Changsha, CHINA.

EP-0010

^{18}F-Labeled TREM2-Targeting Peptide for PET Imaging in Alzheimer's Disease Mice

W. Liu, *K. Ding, Y. Bai, N. Guo, J. Zhao, Z. Luo;*
ShanghaiTech University, Shanghai, CHINA.

EP-0011

Subanaesthetic Ketamine Alters Sleep-Wake Architecture and Cerebral Metabolism in the Rat Brain

C. Pascovich[1], L. Reyes[2], M. Bentura[2], J. Castro[1], L. Osorio[1], A. Damián[2], E. Savio[2], ***R. Ferrando***[2]*, A. Costa[1], P. Torterolo[1];*
[1]Universidad de la República, Montevideo, URUGUAY,
[2]Centro Uruguayo de Imagenología Molecular, Montevideo, URUGUAY.

EP-0012

Alterations in a7nAChR and VAChT in the Alzheimer's disease brain and associations with amyloid-β, tau pathology and astrogliosis

M. Wadsak[1]*, M. Ye[2], E. N. Celik[3], D. Zhang[2], K. Pandya[1], D. Gozzi[1], J. Wang[1], P. Gillberg[4], K. Shi[1], A. Rominger[1], A. Nordberg[4], R. Nitsch[5], C. Hock[5], R. Ni[1,3];*
[1]Department of Nuclear Medicine, Bern University Hospital, University of Bern, Bern, SWITZERLAND,
[2]Kunming Institute of Zoology, Kunming, CHINA,
[3]Institute for Regenerative Medicine, University of Zurich, Institute for Biomedical Engineering, University of Zurich & ETH Zurich, Zurich, SWITZERLAND,
[4]Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, SWEDEN,
[5]Institute for Regenerative Medicine, University of Zurich, Zurich, SWITZERLAND.

EP-0013

^{18}F-AlF-NOTA-FAPI-04 PET/CT for Early Detection of Subclinical Myocardial Injury in Doxorubicin-induced Cardiotoxicity: Comparison with CMR-LGE in a Porcine Model

J. Liu[1]*, J. Bai[1], Y. Xu[1], H. Xie[1], N. Zhang[1], H. Mi[1], W. Dong[1], X. Song[2];*
[1]Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA,
[2]Beijing Friendship Hospital, Capital Medical University, Beijing, CHINA.

EP-0014

The study of glymphatic-associated ventricular CSF clearance in chronic ischemic stroke

B. Cui[1]*, T. Zhao[2], Y. Shan[1], C. Huang[2], J. Lu[1];*
[1]Xuanwu Hostpital, Beijing, CHINA,
[2]Emory University School of Medicine, Atlanta, GA, UNITED STATES OF AMERICA.

EP-0015

Characterizing Synergistic Myocardial Fibrosis Induced by Nanoplastic Pollution and Diabetes Using [^{18}F]F-FAPI-42 PET/CT as a Public Safety Nuclear Medicine Tool

C. Zhai[1]*, D. Zhang[2], G. Zhang[2];*
[1]The Third Affiliated Hospital of Southern Medical University, Guangzhou, CHINA,
[2]Southern Medical University, Guangzhou, CHINA.

EP-0016

[^{18}F]DPA-714 PET/MRI Characterisation of Chronic Aluminium-Induced Neuroinflammation and Behavioural Alterations

K. Szigeti[1,2,3]*, A. Vizbel[1], I. Horváth[1,4], L. Forgách[1,2], N. Kovács[1,2], M. Nacsa[1], B. Horváth[1], P. Hajdrik[1,2], V. Nevezi[1], Z. Varga[1,3], R. Bergmann[1], C. Halldin[1,3], D. Máthé[1,3,4];*
[1]Semmelweis University, Budapest, HUNGARY,
[2]HCEMM, In Vivo Imaging Advanced Core Facility, Budapest, HUNGARY,
[3]HUN-REN Supported Research Groups, Budapest, HUNGARY,
[4]CroMed Ltd., Budapest, HUNGARY.

EP-0017

Multimodal Molecular Imaging of Systemic Inflammatory Dynamics and Prognostic Value After Myocardial Ischemia-Reperfusion

Y. Dou[1,2]*, Y. Jia[1,2], J. Hao[3], S. He[4], Z. Qin[1,2], K. Zhou[1,2], Q. Lian[1,2], H. Song[1,2], Z. Xiang[1,2], G. Liang[5], J. Gao[6], H. Wang[1,2], M. Yang[7], J. Jin[1], J. Li[6], S. Li[1,2], P. Wu[1,2];*
[1]Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, CHINA,
[2]Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Key Laboratory of Molecular Imaging, Taiyuan, CHINA,
[3]Department of Anesthesiology, First Hospital of Shanxi Medical University, Taiyuan, CHINA,
[4]Department of Radiology, First Hospital of Shanxi Medical University, Taiyuan, CHINA,
[5]Department of Pathology, First hospital of Shanxi Medical University, Taiyuan, CHINA,
[6]China Institute For Radiation Protection, Taiyuan, CHINA,
[7]Department of Nuclear Medicine, Peking University First Hospital, Beijing, CHINA.

EP-0018

Establishment of a rat model of infective endocarditis for evaluation of ^{18}F-FDG PET imaging

I. Dawoodi[1]*, J. van Krimpen Mortensen, J. Straarup Madsen, T. Binderup, A. Kjaer;*
Department of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital – Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, DENMARK.

EP-03

A: Preclinical and Translational Studies → A1 Medical Preclinical → A13 Preclinical Oncology

EP-0019

Evaluation of MT1-MMP-targeted bicyclic peptides for PET imaging and pharmacokinetics in HT1080 tumours: identifying a lead candidate for sustained tumour retention

M. Sulewska[1]*, A. R. Regupathy[2], L. Domogalla[1], N. Steinacker[1], B. Blakeman[2], F. Wood[2], P. T. Meyer[3], M. Eder[1], G. E. Mudd[2], A. Eder[1];*
[1]German Cancer Consortium (DKTK) / University Medical Center Freiburg, Freiburg, GERMANY,
[2]BicycleTx Limited, Cambridge, UNITED KINGDOM,
[3]University Medical Center Freiburg, Freiburg, GERMANY.

EP-0020

Preclinical Evaluation of PSMA-Venadaparib Drug Conjugate with High Potency for Prostate Cancer Treatment

N. Holzleitner, *A. Daoud Ghadieh, B. Ludwig, W. Weber, S. Kossatz;*
Department of Nuclear Medicine, TUM University Hospital, School of Medicine and Health, Technical University of Munich, Munich, GERMANY.

EP-0021

Preclinical Evaluation of [^{89}Zr]Zr-DFO-STEAP1 Antibody as a Promising Theranostic Target for Prostate Cancer

J. Cabahug, *H. Comas Rojas, M. Idrissou, J. C. Mixdorf, J. W. Engle, R. Hernandez;*
University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

EP-0022

Uptake of radiolabeled-mIBG in neuroblastoma cells, spheroids, and xenograft model

T. Xu[1]*, I. Lejona Ugarte[1], S. L. Salomonsson[2], M. Nestor[1];*
[1]Department of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala, SWEDEN,
[2]Ridgeview Instruments AB, Uppsala, SWEDEN.

EP-0023

Development and Evaluation of a BCMA-Targeted Bicyclic Peptide Imaging Probe for Multiple Myeloma Detection

L. Kang, *L. Song, Q. Yang, Y. Qiu, J. Zhang, T. Wang, Z. Chen;*
Dept. of Nuclear Medicine, Peking University First Hospital, Beijing, CHINA.

EP-0024

Development of a ^{211}At-Tetrazine-PSMA Radioconjugate for Targeted α-Therapy

J. Schichler[1]*, U. M. Battisti[1,2], L. Hvass[3], C. Poulie[1,2], V. Shalgunov[1,4], N. R. Bom Pedersen[1,2], T. K. Gustavsson[2], S. Stotz[2], N. Billesborg Pedersen[2], L. A. Vázquez[2], A. I. Jensen[1], A. Kjaer[3], M. M. Herth[1,2];*
[1]TetraKit Technologies ApS, Copenhagen, DENMARK,
[2]Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DENMARK,
[3]Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, DENMARK,
[4]Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen, DENMARK.

EP-0025

Beyond Glycolysis: A CD44v6-Specific Peptide PET Tracer for FDG-PET Negative Malignancies

X. Chen;
The First Affilated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA.

EP-0026

HT547, a novel DOTA-conjugated bicyclic peptide targeting uPAR for radionuclide theranostics in solid Tumours

J. Gao[1]*, W. Li[1], D. Lin[1], S. Pu[2], J. Xie[2], Z. Luo[2], X. Zhang[1];*
[1]Hangzhou Healthytide Biotechnology Co., LTD, Hangzhou, CHINA,
[2]ShanghaiTech University, Shanghai, CHINA.

EP-0027

A Novel Theranostic Approach for TF-Targeting: Integrated RDC and ADC Development

Z. Qu, *E. Wu;*
Nanolattix, Taiyuan, CHINA.

EP-0028

A bivalent CAIX and hypoxia-targeting strategy amplifies tumor uptake in clear cell renal cell carcinoma

S. Cheng, *Y. Song, R. An, Y. Zhang, X. Lan, D. Jiang;*
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0029

A Site-Specifically Glycan-Conjugated TROP2 Theranostic Probe with Improved Tumor Targeting and Therapeutic Efficacy in Triple-Negative Breast Cancer

J. Liu, *X. Guo, H. Zhu, Z. Yang;*
Peking University Cancer Hospital & Institute, Beijing, CHINA.

EP-0030

Spatially delayed architecture enables tunable uptake and imaging window in PSMA-targeted near-infrared probes

T. Han[1]*, L. Xue[2], S. Zhu[2], S. Chen[1], J. Zhang[1];*
[1]NUS, Singapore, SINGAPORE,
[2]JiLin University, Changchun, CHINA.

EP-0031

PI3K inhibition with alpelisib and idelalisib enhances mIBG uptake in a preclinical neuroblastoma model

M. El Fakiri[1]*, R. Mansi[1], L. Bohrmann[1], K. Abid[2], M. Fani[1];*
[1]University Hospital Basel, Basel, SWITZERLAND,
[2]Lausanne University Hospital, Lausanne, SWITZERLAND.

EP-0032

Synthesis and Evaluation of a Novel ^{18}F-Labeled EGFR Tyrosine Kinase Inhibitor for Non-Small Cell Lung Cancer PET Imaging

Q. Xu, *F. Xiong, Y. Yang, B. Zhang, P. Wang, Q. Chen, X. Zhu, B. Yu;*
Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0033

Early assessment of tumor response to particle irradiation using sequential [^{18}F]FLT-PET and cellular uptake studies

Y. Kiyono[1], *A. Makino*[2,1], *K. Kume*[3], *T. Mori*[1], *H. Okazawa*[1];
[1]*University of Fukui, Yoshida-Gun, JAPAN,*
[2]*Hamamatsu University School of Medicine, Hamamatsu, JAPAN,*
[3]*The Wakasa Wan Energy Research Center, Tsuruga, JAPAN.*

EP-0034

Reinforced diagnostic efficacy prospects for [^{68}Ga] Ga-BZH3 via in-situ stabilization approaches

T. Maina-Nock[1], *P. Kanellopoulos*[1], *A. C. López Bularte*[2], *C. Liolios*[3], *A. Dimitrakopoulou-Strauss*[4], *K. Kopka*[5,6], *B. A. Nock*[1];
[1]*Molecular Radiopharmacy, INRaSTES, NCSR Demokritos, Athens, GREECE,*
[2]*Radiopharmacy División, Argentina Atomic Energy Commission (CNEA), C*[1429]*BNP, CABA, ARGENTINA,*
[3]*Department of Pharmacy, National and Kapodistrian University of Athens (NKUA), Panepistimioupolis-Zografou,* [15771]*, Athens, GREECE,*
[4]*Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ),* [69210]*, Heidelberg, GERMANY,*
[5]*Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR),* [01328]*, Dresden, GERMANY,*
[6]*TUD Dresden University of Technology, School of Science, Faculty of Chemistry and Food Chemistry,* [01062]*, Dresden, GERMANY.*

EP-0035

Development of FL-261 as a theranostic RDC vector for the diagnosis and treatment of c-MET positive cancers

J. Yang, *L. Zhao, J. Xia, J. Zhang, F. Liu;*
Full-Life Technologies, Shanghai, CHINA.

EP-0036

Synthesis and Preclinical Evaluation of a new Bis-PSMA ligand for targeting prostate cancer

S. Okarvi;
Cyclotron & Radiopharmaceutical;
King Faisal Specialist Hospital and Research Centre, Riyadh, SAUDI ARABIA.

EP-0037

The Study on the Therapeutic Efficacy of Anthracycline and ^{90}Y Nuclide-Loaded Montmorillonite Nanoclays for Pancreatic Cancer Models

W. Wang, *X. Su, S. Yu;*
Zhejiang University School of Medicine, Hangzhou, CHINA.

EP-0038

Application of ^{68}Ga-labeled HER2-targeted nanobody in tumor PET imaging

L. Kang, *Q. Yang, L. Song, X. Sun, J. Zhang, T. Wang, Z. Chen;*
Dept. of Nuclear Medicine, Peking University First Hospital, Beijing, CHINA.

EP-0039

Quantitative ^{89}Zr-DFO-NK1.1 PET Imaging of NK Cell Recruitment for Early Prediction of Therapeutic Response After PEI Ablation in Hepatocellular Carcinoma

Q. Chen, *P. Wang, F. Xiong, B. Zhang, Y. Yang, Q. Xu, X. Zhu, B. Yu;*
Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0040

DLL3 targeting monocyclic peptides for theranostic radiopharmaceuticals

W. Liu[1], *X. Gao*[1], *Y. Bai*[1], *K. Ding*[1], *J. Gao*[2], *D. Lin*[2], *Z. Luo*[1];
[1]*ShanghaiTech University, Shanghai, CHINA,*
[2]*Hangzhou Healthytide Biotechnology Co., Ltd., Hangzhou, CHINA.*

EP-0041

^{89}Zr- and ^{177}Lu-labeled anti-Trop2 antibody-conjugated drugs for theranostics in pancreatic cancer models

L. Kang, *X. Sun, T. Wang, Q. Yang, J. Zhang, Z. Chen;*
Dept. of Nuclear Medicine, Peking University First Hospital, Beijing, CHINA.

EP-0042

A New Platform for Imaging Alpha Emitting Radiopharmaceuticals in Pre Clinical Cancer Models

M. Batey, *E. Snay, J. Suchy, K. Duval, J. Tavares, C. Tavares, D. Patel, K. Lohith;*
Perceptive Discovery, Needham, MA, UNITED STATES OF AMERICA.

EP-0043

Theranostic Potential of [^{64}Cu]Cu-Labeled Nanoparticle Albumin-bound Paclitaxel by SPARC-specific Tumor Uptake

J. Kim[1,2,3], *J. Park*[1,3,4], *S. Lee*[1], *H. Jung*[1,2,3], *Y. Lee*[1,5,6], *G. Cheon*[1,3], *H. Youn*[1,3,5], *K. Kang*[1,2,3];
[1]*Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,*
[2]*Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, KOREA, REPUBLIC OF,*
[3]*Cancer Research Institute, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF,*
[4]*Research Institute for Convergence Science, Seoul National University, Seoul, KOREA, REPUBLIC OF,*
[5]*Cancer Imaging Center, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,*
[6]*Radiation Medicine Research Institute, Medical Research Center, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF.*

EP-0044

Stability-dependent profile of the GRPR-antagonist [^{111}In]In-SB11 in prostate cancer cell and mice models

T. Maina-Nock, *E. Lymperis, A. Kaloudi, B. A. Nock;*
Molecular Radiopharmacy, INRaSTES, NCSR Demokritos, Athens, GREECE.

EP-04

A: Preclinical and Translational Studies → A1 Medical Preclinical → A14 Preclinical Therapy

EP-0045

[^{198}Au]-Gold Nanoparticle Depot Combined with Doxorubicin Inhibits Primary Tumour Growth and Increases Median Survival in NCG Mice with Metastatic 231/LM2-4-Luc+ Human Triple-Negative Breast Cancer (TNBC) Tumours

M. Cai[1], *Z. Cai*[1], *A. Chu*[1], *C. Chan*[1], *K. M. Nielsen*[2], *R. M. Reilly*[1,3,4];
[1]*Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, CANADA,*
[2]*Nuclear Operations & Facilities, McMaster University, Hamilton, ON, CANADA,*
[3]*Department of Medical Imaging, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, CANADA,*
[4]*Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CANADA.*

EP-0046

Sensitizing Cold Melanoma to PD-1 Blockade: A Preclinical Study of Fractionated ^{131}I-5-IPN Targeted Radionuclide Therapy

T. Liu, *B. Qu, Z. Lin, X. Zhang, X. Lan;*
Department of Nuclear Medicine, Union Hospital, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0048

Immune Resetting of Radiopharmaceutical for Systemic Lupus Erythematosus

S. Qiao[1], *Z. Liu*[1,2];
[1]*Changping Laboratory, Beijing, CHINA,*
[2]*Peking University, Beijing, CHINA.*

EP-0049

A Glucose-Modified Albumin Nanocomplex for Theranostic Platform in Pulmonary Fibrosis

M. Kim[1,2], *S. Ma*[3], *K. Kim*[1], *J. Kim*[4], *Y. Park*[4], *Y. Oh*[4], *Y. Lee*[5], *K. Lee*[5], *R. Yoo*[1,3], *Y. Lee*[1,2,3];
[1]*Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF,*
[2]*Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF,*
[3]*Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,*
[4]*Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, KOREA, REPUBLIC OF,*
[5]*Division of RI application, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul, South Korea, Seoul, KOREA, REPUBLIC OF.*

EP-0050

Toward combination radiotheranostics: preclinical assessment of anti-VEGF treatment with FAP-targeted radiopharmaceutical therapy

T. Zhao[1], *Y. Pang*[2], *R. P. Baum*[3], *J. Zhang*[1];
[1]*National University of Singapore, Singapore, SINGAPORE,*
[2]*Shandong Cancer Hospital and Institute, Jinan, CHINA,*
[3]*ICPO Center of Excellence, DKD HELIOS Klinik, Wiesbaden, GERMANY.*

EP-0051

Intraperitoneal Targeted Alpha Therapy with Astatine-211-Labelled Trastuzumab on Nude Mice with SKOV-3 Cells

A. Andelin[1], *C. Ytterbrink*[1], *E. Aneheim*[1], *H. Jensen*[2], *L. Persson*[3], *T. Bäck*[1], *S. Palm*[1];
[1]*University of Gothenburg, Gothenburg, SWEDEN,*
[2]*Rigshospitalet Copenhagen University Hospital, Copenhagen, DENMARK,*
[3]*Swedish Radiation Safety Authority, Stockholm, SWEDEN.*

EP-0052

Imaging Mass Cytometry Maps Immune Remodeling After PSMA α- and β-Radioligand Therapy in Prostate Cancer

C. Mona, *J. J. Liang, I. Fajnorova, B. Louis, B. Comin-Anduix;*
UCLA, Los Angeles, CA, UNITED STATES OF AMERICA.

EP-0053

Generating Transgenic Mouse Model for Preclinical Investigation of Targeted Radionuclide Therapy and Immunotherapy of Cancer

T. Mohajershojai[1], *V. Valkovskaia*[1], *N. Pelo*[1], *M. Nestor*[2], *A. Espinosa*[1];
[1]*Karolinska Institute, Stockholm, SWEDEN,*
[2]*Uppsala University, Uppsala, SWEDEN.*

EP-0054

PET Imaging of rTMS-Induced Dopaminergic Modulation in Parkinsonian Primates: Implications for Neuromodulation-Based Theranostics

K. Ma, *C. Chen, C. Chen, S. Yeh, J. Shih;*
National Defense Medical University, Taipei, TAIWAN, PROVINCE OF CHINA.

EP-0055

[^{177}Lu]Lu-PSMA-617-Mediated Endoradiotherapy of Triple-negative Breast Cancer by Targeting PSMA Expression on Tumor-Associated Neovasculature

Y. Chen;
Shanghai Pulmonary Hospital, Shanghai, CHINA.

EP-0056

Alpha-Emitters disrupt mitochondrial homeostasis to drive senescence and combine with senolytic drugs Dasatinib and Quercetin to enhance anti-tumor immunity

X. Luan, *J. Zhang, F. Yu;*
Department of Nuclear Medicine, Shanghai Tenth People's Hospital and Institute of Nuclear Medicine, School of Medicine, Tongji University. No. [301] *Yanchangzhong Road, Shanghai,* [200072]*, CHINA.*

EP-0057

Longitudinal Multimodal Imaging of MSC-Mediated Interruption of Deleterious Inflammatory-Senescent Crosstalk in Inflamed Muscle

C. Meng, *X. Chen, L. Zhou, Y. Xia, X. Li, W. Fu, Y. Long, X. Ma;*
Department of Nuclear Medicine, The Second Xiangya Hospital, Central South University, Chang Sha, CHINA.

EP-0058

Experimentally Calibrated Simulations Reveal Optimized Dosing Strategies for [^{177}Lu]Lu-PSMA-617 Therapy

M. Ryhiner[1,2], *I. Fajnorova*[2], *I. C. Azrour*[2], *A. M. Fakharpour*[2], *J. Czernin*[2], *A. Rominger*[1], *C. A. Meyer*[2], *C. E. Mona*[2], *K. Shi*[1];
[1]*Bern University Hospital, Inselspital, Bern, SWITZERLAND,*
[2]*University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA.*

EP-05

A: Preclinical and Translational Studies → A1 Medical Preclinical → A15a Preclinical Dosimetry

EP-0059

Assessment of patient absorbed doses based on a preclinical biodistribution study with ^{225}Ac-PSMA-I&T

J. Ni[1], *K. Hürkamp*[2], *A. Wurzer*[1], *S. Nekolla*[1], *W. Li*[2], *C. D'Alessandria*[1];
[1]*Nuclear Medicine Department, TUM Universitäts Klinikum, Munich, GERMANY,*
[2]*Molecular Targets and Therapeutics Center, Helmholtz Munich, Neuherberg, GERMANY.*

EP-0060

SPECT/CT or gamma counting? Quantitative agreement for lutetium-177 and terbium-161 preclinical radiopharmaceutical therapy

S. Rodriguez Perez, *M. Crabbé, M. Beltrami, K. Spoormans, J. Henriot, M. Andersson, A. Zerguit, L. Struelens, C. Saldarriaga Vargas;*
SCK-CEN, Mol, BELGIUM.

EP-0061

Assessing Isotope- and Scale-Dependent Differences in Renal Dose-Rate Heterogeneity from Microscale to Clinical Image-Based Activity Distribution

I. Martin[1,2], *E. Jamieson*[1,2], *H. Merkens*[1], *M. Ligeour*[1], *M. Andersson*[1,2], *B. Miller*[3], *E. Roncali*[4], *P. Esquinas*[5,2], *F. Benard*[1,2], *C. Uribe*[1,2];
[1]*BC Cancer Research Centre, Vancouver, BC, CANADA,*
[2]*The University of British Columbia, Vancouver, BC, CANADA,*
[3]*The University of Arizona, Tucson, AZ, UNITED STATES OF AMERICA,*
[4]*University of California Davis, Davis, CA, UNITED STATES OF AMERICA,*
[5]*BC Cancer, Vancouver, BC, CANADA.*

EP-0062

[^{225}Ac]-PSMA-I&T vs [^{177}Lu]Lu-PSMA-I&T: Preclinical comparison in PSMA positive tumour model

A. Zerguit[1,2], *M. W. Konijnenberg*[2], *C. Saldarriaga Vargas*[1], *B. Baselet*[1], *T. Opsomer*[1], *M. Ooms*[1], *V. Bogaerts*[1], *C. Segers*[1], *M. Neefs*[1], *S. U. Dalm*[2], *L. Struelens*[1], *S. Rodriguez Pérez*[1];
[1]*Belgian Nuclear Research Center (SCK CEN), Mol, BELGIUM,*
[2]*Erasmus MC, Rotterdam, NETHERLANDS.*

EP-0063

Preclinical dosimetry of [^{68}Ga]Ga-NOTA-pamidronic acid using biodistribution-based time-activity modelling

M. H. Hassan[1], *M. F. Othman*[2], *W. H. Wan Kamal*[3], *S. Mohamad*[3], *A. S. Sued*[3], *S. S. Md Izah*[3], *N. Yen*[3], *S. A. Muhamad*[3], *H. R. Abdul Razak*[4];
[1]*Universiti Putra Malaysia, Serdang, MALAYSIA,*
[2]*Universiti Teknologi MARA, Bandar Puncak Alam, MALAYSIA,*
[3]*Malaysian Nuclear Agency, Kajang, MALAYSIA,*
[4]*University of Exeter, Exeter, UNITED KINGDOM.*

EP-0064

Impact of realistic geometries of LNCaP cells on cellular dosimetry and RBE after therapy with [^{177}Lu] Lu-PSMA-I&T and [^{225}Ac]Ac-PSMA-I&T

S. Resch[1], *P. Hawarihewa*[1], *J. Brosch-Lenz*[2], *R. A. Werner*[1,3], *B. Matthias*[1,4,5,5], *G. Böning*[1], *A. Delker*[1];
[1]*LMU Klinikum Großhadern, München, GERMANY,*
[2]*Universitätsklinikum Augsburg, Augsburg, GERMANY,*
[3]*Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Sciences, Division of Nuclear Medicine and Molecular Imaging, Baltimore, MD, UNITED STATES OF AMERICA,*
[4]*SyNergy, University of Munich, Munich, GERMANY,*
[5]*DZNE – German Center for Neurodegenerative Diseases, Munich, GERMANY.*

EP-0065

Clinical feasibility of dried blood spot sampling for ^{177}LuPSMA blood activity assessment

K. Doornhof, *S. Koolen, H. Hendrikse, T. Dirks;*
Erasmus MC, Rotterdam, NETHERLANDS.

EP-0066

Preclinical Biodistribution Data Processing Framework for Time-Integrated Activity Calculations: Correction of Interindividual Injection Variability

A. Alvers[1], *A. K. Mapanao*[2], *C. Müller*[2,3], *F. Y. Frejd*[4], *M. Nestor*[4], *P. Bernhardt*[1,5];
[1]*Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN,*
[2]*Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, SWITZERLAND,*
[3]*Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, SWITZERLAND,*
[4]*Department of Immunology, Genetics, and Pathology, Science for Life Laboratories, Uppsala University, Uppsala, SWEDEN,*
[5]*Department of Medical Physics and Biomedical Engineering (MFT), Sahlgrenska University Hospital, Gothenburg, SWEDEN.*

EP-0067

QDOSE Allometry-Guided Human Dosimetry of [^{211}At]APA: Impact of Administration Route on Maximum Tolerated Activity

N. Falzone, *S. Kimiaei, L. Li, D. Yokell, D. B. Divlianska, S. Bhagwat;*
Telix Pharmaceuticals, Melbourne, AUSTRALIA.

EP-0068

Tissue-Scale Activity Mapping of ^{225}Ac and Daughter Redistribution in Anti-GD2 Targeted Alpha Therapy: Towards Spatially Informed Dosimetry in a Neuroblastoma Model

E. Timakova[1,2], *K. Ortner*[2], *I. Martin*[1,3], *M. Ghavami*[4], *C. Rodriguez-Rodriguez*[5], *J. Bailey*[2], *H. Ghaffari-Nazari*[4], *J. Lim*[1,4], *K. Schultz*[4,1], *G. Reid*[4,1], *C. Uribe*[3], *P. Schaffer*[2,1];
[1]*University of British Columbia, Vancouver, BC, CANADA,*
[2]*TRIUMF, Vancouver, BC, CANADA,*
[3]*BC Cancer Research Centre, Vancouver, BC, CANADA,*
[4]*BC Children's Hospital Research Institute, Vancouver, BC, CANADA,*
[5]*UBC Centre for Comparative Medicine, Vancouver, BC, CANADA.*

EP-0069

Tumour sink effect in [^{177}Lu]Lu-rhPSMA-10.1 preclinical radioligand therapy: a physiologically based pharmacokinetic model investigation

G. Costa, *E. Yousefzadeh-Nowshahr, V. Vasic, A. J Beer, G. Glatting;*
Univesität Ulm, Ulm, GERMANY.

EP-0070

Uptake heterogeneity effects on dose and LETd distributions in microlesion-scale targeted radionuclide therapy with Actinium-225, Lead-212, Astatine-211, and Lutetium-177.

G. Garrido-Hernandez[1], *M. Konijnenberg*[1,2], *J. Nonnekens*[1];
[1]*Erasmus Medical Center, Rotterdam, NETHERLANDS,*
[2]*Radboud University Medical Center, Nijmegen, NETHERLANDS.*

EP-0071

Microdosimetric Modelling of Heterogeneous Ra-223 Distributions in ^{3}D Tumour-Bone Co-Culture Systems

V. Sorokin, *E. McGregor, E. O'Neill, M. A. Hill;*
University of Oxford, Oxford, UNITED KINGDOM.

EP-0072

Radiation Dosimetry, Chemistry and Formulation of a Novel [^{64}Cu]Cu-Nanomedicine Radiotracer that Selectively Targets Tumor Associated Macrophages

J. Cleland[1], *N. P. Holland*[2], *T. K. Nielsen*[2], *A. Romani*[2], *N. Nielsen*[2], *A. Lindberg*[2], *B. Lu*[3], *J. Yoshihara*[3], *W. Thomas*[3], *S. Minami*[3];
[1]*Ironfist Therapeutics, Redwood City, CA, UNITED STATES OF AMERICA,*
[2]*Minerva Imaging, Olstykke, DENMARK,*
[3]*Programmable Medicine, Redwood City, CA, UNITED STATES OF AMERICA.*

EP-0073

Comparison of ^{111}In Human Dosimetry Estimates Derived from Preclinical ^{111}In Single Photon Emission Tomography Imaging and Gamma Counting

A. Friedman[1], *P. Gawne*[2], *K. Gresco*[1], *J. Heimann*[1], *S. Chu*[3], *J. Kim*[2], *J. Cleaver*[2], *J. Sosabowski*[2], *F. Mota*[3];
[1]*Perceptive Discovery, Needham, MA, UNITED STATES OF AMERICA,*
[2]*Barts Cancer Institute, London, UNITED KINGDOM,*
[3]*Perceptive Discovery, London, UNITED KINGDOM.*

EP-0074

Do Mouse Kidney Shape Distortions Matter for µPET/CT Quantification? A Custom ^{3}D-Printed Phantom Study

E. Jamieson[1,2], *I. Martin*[1,2], *J. Jeffrey*[3], *B. Cox*[3], *F. Benard*[1,2,4], *P. L. Esquinas*[2,4], *C. Uribe*[4,2,1];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,*
[2]*University of British Columbia, Vancouver, BC, CANADA,*
[3]*Phantech, Madison, WI, UNITED STATES OF AMERICA,*
[4]*BC Cancer, Department of Functional Imaging, Vancouver, BC, CANADA.*

EP-06

A: Preclinical and Translational Studies → A1 Medical Preclinical → A15b Preclinical Radiobiology

EP-0075

A Promising GPC3-Targeting Cyclic Peptide HL7037 Based Radiotherapeutic Agent for Hepatocellular Carcinoma (HCC)

J. Shi, *H. Cui, X. Gu, H. Sun;*
HighsLab Therapeutics, Shenzheng, CHINA.

EP-0076

Metabolic Heterogeneity in HCC: Insights into Proton Beam Therapy Resistance and Biomarker Identification Assessed by [^{18}F]FP-GLU, [^{18}F]FDG, and [^{1}H] NMR.

Y. Chung[1], *C. Weng*[2];
[1]*Chang Gung Memorial Hospital, Taoyuan, TAIWAN, PROVINCE OF CHINA,*
[2]*Chang Gung University, Taoyuan, TAIWAN, PROVINCE OF CHINA.*

EP-0077

Transcriptomic Analysis Reveals the Dose-Dependent Antitumor Mechanisms of ^{225}Ac in LLC Cells

X. Luan;
Department of Nuclear Medicine, Shanghai Tenth People's Hospital and Institute of Nuclear Medicine, School of Medicine, Tongji University. No. 301 Yanchangzhong Road, Shanghai, 200072, CHINA.

EP-0078

Cyclotron-Produced ^{206}Bi Enables Evaluation of Remediation Strategies to Reduce Radio-bismuth Renal Redistribution During Targeted Alpha Therapy

L. Wehner, *E. Aluicio-Sarduy, M. Bio Idrissou, H. Comas Rojas, L. Batley, B. Bednarz, J. W. Engle, R. Hernandez;*
University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

EP-0079

Correlation Between G-6-Pase Expression and ^{18}F-FDG Uptake: A Comparison of Lung Cancer and Inflammatory Pulmonary Nodules

Y. Luo, *Z. Chen, Z. Cui, J. Liu;*
The Second Hospital of Lanzhou University, Lanzhou, CHINA.

EP-0080

Dose scheduling drives tumor compositional shift and PSMA-targeted selection pressure in a heterogeneous prostate cancer model: integrating dosimetry, imaging, and transcriptomics

I. Fajnorova[1], *M. Ryhiner*[2], *I. C. Azrour*[1], *A. Fakharpour*[1], *J. Czernin*[1], *A. Rominger*[2], *K. Shi*[2], *C. A. Meyer*[1], *C. E. Mona*[1];
[1]*UCLA, Los Angeles, CA, UNITED STATES OF AMERICA,*
[2]*Bern University Hospital, Bern, SWITZERLAND.*

EP-0081

Analysis of Oral Microbiota Changes and Microecological Characteristics Associated with Lutetium-177 Treatment

L. Jicheng, *J. Liu;*
Lanzhou University, Lanzhou, CHINA.

EP-0082

A mathematical model for optimizing targeted alpha therapy combined with immunotherapy

M. Yang[1,2], *M. Ryhiner*[2], *G. Yang*[1], *Y. Jin*[1], *K. Wang*[1], *K. Shi*[2], *F. Yu*[1];
[1]*Department of Nuclear Medicine, Shanghai Tenth People's Hospital and Institute of Nuclear Medicine, School of Medicine, Tongji University, Shanghai, CHINA,*
[2]*Department of Nuclear Medicine, Inselspital Bern University Hospital, Bern, SWITZERLAND.*

EP-0083

Deciphering DNA Repair Mechanisms Across Targeted Radionuclide Therapy and Other Radiotherapy Modalities via a CRISPR/Cas9 DNA Repair Gene Knockout Screen

R. Winter[1], *Ö. Sercin*[2], *U. Bauder-Wüst*[1], *M. Schäfer*[1], *Y. Remde*[1], *M. Roscher*[1], *M. Benešová-Schäfer*[1];
[1]*German Cancer Research Center, Heidelberg, GERMANY,*
[2]*German Aerospace Center (DLR), Köln, GERMANY.*

EP-0084

The radiobiological effects of FAP-targeted radionuclide therapy on patient-derived cancer-associated fibroblasts

M. Moers, *K. Raaijmakers, M. Boswinkel, S. Heskamp, H. Westdorp, M. Ansems, S. van Lith;*
Radboud University Medical Center, Nijmegen, NETHERLANDS.

EP-0085

Dynamic FAP biology shapes FAPI uptake and challenges preclinical models

A. Bilinska[1], *N. Kumar*[1], *E. Menéndez*[1], *F. Rösch*[2], *A. Rominger*[1], *E. Gourni*[1];
[1]*Department of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, SWITZERLAND,*
[2]*Department of Chemistry–TRIGA site, Johannes Gutenberg-University Mainz, Germany, Mainz, GERMANY.*

EP-0086

L-Dihydroroate Combined with DHODH/Calcoco2 as a Novel Multimodal Biomarker Panel for Predicting Response to Targeted Alpha Therapy

J. Zhang, *F. Yu;*
Department of Nuclear Medicine, Shanghai Tenth People's Hospital and Institute of Nuclear Medicine, School of Medicine, Tongji University, Shanghai, CHINA.

EP-07

A: Preclinical and Translational Studies → A1 Medical Preclinical → A16 New Radiopharmaceuticals - SPECT

EP-0087

Synthesis of a targeted FGFR4 peptide probe ^{99}mTc-HYNIC-Ile-Arg-Pro-Asp-Gly-Tyr-Asn-Val and its application in hepatocellular carcinoma

H. Hao[1], *Q. Zhao*[2], *Z. Ma*[2], *T. Pan*[3], *B. Lv*[3];
[1]*College of Basic Medical Sciences,Ningxia medical university, Yinchuan, CHINA,*
[2]*Nuclear Medicine Department, General Hospital of Ningxia Medical University, Yinchuan, CHINA,*
[3]*The First Clinical Medical College, Ningxia Medical University, Yinchuan, CHINA.*

EP-0088

Evaluation of99mTc-labeled AMD070 derivatives as novel CXCR4 molecular probes

X. Zhang, *X. Xiang, L. Xu, H. Pang;*
The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EP-0089

^{131}I-Labeled Aging-Targeted Extracellular Vesicles: A First-in-Monkey SPECT Imaging Study

K. Yu, *J. Ye, C. Xu, W. Yang, F. Kang;*
The First Affiliated Hospital of Air Force Medical University, Xi'an, Shaanxi, CHINA.

EP-0091

Technetium-99m labelled Photosensitizers for Synergistic and Theranostic Applications

J. Staudinger[1,2], *R. Gao*[3], *Y. Wang*[3], *M. Petrik*[4,5,6], *G. Gasser*[3], *T. L. Mindt*[1,7];
[1]*University of Vienna, Faculty of Chemistry, Institute of Inorganic Chemistry, Wien, AUSTRIA,*
[2]*University of Vienna, Vienna Doctoral School in Chemistry, Wien, AUSTRIA,*
[3]*Chimie ParisTech, PSL University, CNRS, Institute of Chemistry for Life and Health Sciences, Paris, FRANCE,*
[4]*Palacky University, Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Olomouc, CZECH REPUBLIC,*
[5]*Palacky University, Czech Advanced Technology and Research Institute, Olomouc, CZECH REPUBLIC,*
[6]*University Hospital Olomouc, Olomouc, CZECH REPUBLIC,*
[7]*University of Vienna and Medical University of Vienna, Joint Medicinal Radiochemistry Facilities, Vienna, AUSTRIA.*

EP-0093

Development and Validation of an MRC2-Specific Monoclonal Antibody SPECT Molecular Imaging Probe

S. Wei, *C. Qin, Y. Lv, D. Zheng, Z. Zhou, Z. Dai, X. Liu, H. Zhan, X. Lan;*
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Scien, Wuhan, China, CHINA.

EP-0094

In Vivo SPECT/CT Imaging of a Radiolabeled Novel Long-Acting FAPI in a Solid Tumor Model

L. Chen, *W. Lo, M. Chen;*
National Atomic Research Institute, Taoyuan City, TAIWAN, PROVINCE OF CHINA.

EP-08

A: Preclinical and Translational Studies → A1 Medical Preclinical → A17 New Radiopharmaceuticals - PET

EP-0095

CD38-Targeted ImmunoPET for Multiple Myeloma: Translational Assessment and AI-Driven Quantitative Analysis

Z. Chen, *T. Wang, L. Kang;*
Peking University First Hospital, Beijing, CHINA.

EP-0096

β-Gal-Targeted PET Molecular Imaging of Cellular Senescence for Monitoring Osteoarthritis Progression and Anti-Senescence Therapy

X. Yutong, *X. Li, Y. Long, L. Zhou, C. Meng, X. Chen, W. Fu, X. Ma;*
The Central South University, Changsha,Hunan, CHINA.

EP-0097

^{18}FLabeled DABTA Tracers for PET Imaging of αSynuclein Pathology: Synthesis, Binding, and Preclinical Evaluation

A. Hojjat Shamami[1], *S. Bagheri*[1], *B. Uzuegbunam*[2], *F. Geibl*[3], *M. Henrich*[3], *W. Oertel*[3], *W. Weber*[2], *M. Luster*[1], *D. Librizzi*[4], *B. Hooshyar Yousefi*[1];
[1]*Department of Nuclear Medicine, Philipps University Marburg, Marburg, GERMANY,*
[2]*Department of Nuclear Medicine, Technical University of Munich, Munich, GERMANY,*
[3]*Department of Neurology, Philipps University Marburg, Marburg, GERMANY,*
[4]*Department of Nuclear Medicine, University Hospital OWL, Bethel Evangelical clinic, Bielefeld, GERMANY.*

EP-0098

Preclinical evaluation and preliminary clinical study of Al^{18}F-NOTA for PET/CT imaging of renal function

X. Zhang, *X. Su;*
Zhejiang university, Hang zhou, CHINA.

EP-0099

Development of a Novel Extra Domain B of Fibronectin Targeted Probe for Prostate Cancer Risk Stratification

Z. Ruiyue, *M. Xu, X. Wang;*
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CHINA.

EP-0100

Application of B7-H3-Targeted PET Imaging in Postoperative Assessment of Liver Transplantation

B. Mei, *L. Xia, Z. Yang;*
Peking University Cancer Hospital & Institute, Beijing, CHINA.

EP-0101

^{68}Ga-Labeled Hypoxia-Responsive ACP3-Targeted Probe for Precision PET/CT Imaging of Prostate Cancer

Y. Xi[1], *X. Wang*[2], *J. Hu*[1], *B. Li*[1];
[1]*Shanghai Jiaotong University affiliated Ruijin Hospital, Shanghai, CHINA,*
[2]*Fudan University Shanghai Cancer Center, Shanghai, CHINA.*

EP-0102

A Pilot Study of Semi-Quantitative Analysis on ^{18}F-mGluR4 micro-PET Brain Metabolism Imaging

L. Zhang, *W. Chong, J. Yang, Y. Mo, J. Li, X. Mu, J. Li, W. Fu;*
Guilin Medical University Affiliated Hospital, Guilin, CHINA.

EP-0103

Dual-Tracer PET Imaging Reveals Decoupled Fibroblast Activity and Collagen Deposition Across Organs

J. Byun[1], *J. Paeng*[1], *Y. Kim*[1,2], *J. Kim*[1,3], *Y. Lee*[1,2], *K. Kang*[1,2], *G. Cheon*[1,2,3];
[1]*Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,*
[2]*Cancer Research Institute, Seoul National University, Seoul, Republic of Korea, Seoul, KOREA, REPUBLIC OF,*
[3]*Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, Seoul, KOREA, REPUBLIC OF.*

EP-0104

Gallium-68-labelled melanocortin-1 receptor-targeted peptide tracers for melanoma imaging

Q. Chen, *X. Lan, D. Jiang;*
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0105

Synthesis and preclinical evaluation of ^{18}F-labeled hydroxyphenethylguanidines for norepinephrine transporter imaging

Y. Cao, *W. Chen;*
Department of Nuclear Medicine and Clinical Nuclear Medicine Research Lab, West China Hospital, Chengdu, Sichuan, China, CHINA.

EP-0106

Development of C-11 Labeled Rapamycin Analogs for mTORC1 Imaging and Evaluation in Non-Human Primates Using PET

K. Jia, *S. Nag, J. Svensson, P. Data, A. Varrone, P. Sigray;*
Karolinska Institutet, Stockholm, SWEDEN.

EP-0107

Focused ultrasound-mediated blood-brain barrier opening to visualize postsynaptic density in vivo

S. Stotz[1], *V. Andrianopoulou[1], T. E. Wuensche[1], G. M. Knudsen[2], U. M. Battisti[1], K. Strømgaard[1], M. M. Herth[1];*
[1]University of Copenhagen, Department of Drug Design and Pharmacology, Copenhagen, DENMARK,
[2]Neurobiology Research Unit and Institute for Clinical Medicine, Copenhagen University Hospital Rigshospitalet and University of Copenhagen, Copenhagen, DENMARK.

EP-0108

Evaluation of ^{68}Ga-DOTA-Folate PET/CT in Ovarian Tumours: A Comparative Study with ^{18}F-FDG

X. Ma[1], *J. Xiang[1], H. Sui[2], G. Cheng[3], W. Jin[1], K. Lin[1], Y. Wang[1], Z. Zhu[1], H. Sui[2];*
[1]Peking Union Medical College Hospital, Beijing, CHINA,
[2]epartment of Nuclear Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, CHINA,
[3]FUWAI Hospital, Beijing, CHINA.

EP-0109

Development of a novel PET probe for neural oxytocin receptor imaging

C. Suzuki[1], *S. Nishiyama[2], S. Yamamoto[2], Y. Tomonari[2], M. Kanazawa[2], H. Oba[2], N. Harada[2], A. Makino[1], H. Yamasue[1], Y. Magata[1];*
[1]Hamamatsu University School of Medicine, Hamamatsu, JAPAN,
[2]Hamamatsu Photonics K.K., Hamamatsu, JAPAN.

EP-0110

Comparative Evaluation of [^{18}F]FMISO PET and [^{18}F] FDG PET for Predicting Neoadjuvant Treatment Response and Prognosis in Patients with Locally Advanced Colorectal Cancer

I. Mesci[1], *M. Araz[1], C. Soydal[1], C. Akyol[2], M. A. Koç[3], G. Utkan[4], P. A. Gunduz[1], N. Ö. Küçük[1];*
[1]Ankara University Medical School Nuclear Medicine Department, Ankara, TÜRKIYE,
[2]Ankara University Medical School General Surgery Department, Ankara, TÜRKIYE,
[3]Ankara University Medical School Generel Surgery Department, Ankara, TÜRKIYE,
[4]Ankara University Medical School Medical Oncology Department, Ankara, TÜRKIYE.

EP-0111

B7H3-Targeted PET Imaging Probe for Pan-Tumor Imaging: A Clinical Study

L. Xia*;*
Peking University Cancer Hospital, Beijing, CHINA.

EP-0112

Matrix metalloproteinase-responsive peptide nanoprobes for enhanced ^{68}Ga retention and PET imaging of invasive Tumours

Z. Chen, *H. Wu, Y. Liu, H. Wang;*
Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA.

EP-0113

[^{68}Ga]Ga-NOTA-ADH-1 PET/CT for non-invasive diagnosis of low/undifferentiated thyroid carcinoma

Z. Xie, *Z. Li, X. Su;*
Department of Nuclear Medicine, The First Affiliated Hospital of Zhejiang University, School of Medicine, Zhejiang University, Hangzhou, [310003]., HangZhou, CHINA.

EP-0114

Preclinical Evaluation of ^{68}Ga-NYM184, a Novel CXCR4-Targeted Radiotracer for PET Imaging

P. Fang, *W. Lv, G. Cheng, S. Yang;*
Norroy bioscience Co., Ltd, Wuxi, CHINA.

EP-0115

AI-driven De novo Design of Targeted Peptide Radiotracers for Clear Cell Renal Cell Carcinoma

X. Zhang, *X. Su;*
Zhejiang university, Hang zhou, CHINA.

EP-0116

A novel ^{18}F-labelled aldosterone synthase tracer for positron emission tomography imaging of aldosterone-producing adenomas

S. Furumoto[1], *Y. Shimizu[1], Y. Yamazaki[2], Y. Tezuka[3], T. Tanaka[1], G. Takao[1], T. Otaka[1], R. Hosaka[1], Y. Ono[3], Y. Toyama[1], R. Harada[4], R. Iwata[1], F. Satoh[2], H. Katagiri[3], T. Suzuki[2], H. Sasano[1], T. Kaneta[5], K. Takase[6];*
[1]Research Center for Accelerator and Radioisotope Science, Tohoku University, Sendai, JAPAN,
[2]Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, JAPAN,
[3]Department of Diabetes, Metabolism, and Endocrinology, Tohoku University Hospital, Sendai, JAPAN,
[4]Division of Pharmacology, Tohoku Medical and Pharmaceutical University, Sendai, JAPAN,
[5]Department of Diagnostic Image Analysis, Tohoku University Graduate School of Medicine, Sendai, JAPAN,
[6]Department of Diagnostic Radiology, Tohoku University Hospital, Sendai, JAPAN.

EP-0117

Development of fluorine-18 analogs of metoclopramide for P-gP PET imaging at the blood-brain barrier

S. Huvelle[1], *P. Deniel[2], B. Hosten[2], S. Chasseigneaux[3], N. Tournier[1], L. Breuil[4], F. Caillé[1];*
[1]Laboratoire d'Imagerie Biomédicale Multimodale (BIOMAPS), Université Paris-Saclay, CEA, CNRS, Inserm, orsay, FRANCE,
[2]Service Pharmacie, Assistance Publique - Hôpitaux Paris, Hôpital Saint-Louis, Paris, FRANCE,
[3]Inserm UMR-S [1144], Faculté de Pharmacie de Paris, Université Paris-Cité, Paris, FRANCE, [45].Service Pharmacie, Assistance Publique - Hôpitaux Paris, Hôpital Cochin, orsay, FRANCE.

EP-0118

Non-Invasive Monitoring of BRAF-MEK Inhibitor Therapy in a Human Melanoma Mouse Model using [^{18}F]-ML-10 PET/CT

J. Stock[1], *F. Herr[1], M. Antons[1], H. Hirner-Eppeneder[1], S. Kloiber[1], R. Werner[2], F. Gildehaus[2], M. Brendel[2], J. Ricke[1], W. Kunz[1], A. Klose[1], M. Heimer[1], P. Kazmierczak[1], C. Cyran[1];*
[1]Department of Radiology, LMU University Hospital, Munich, GERMANY,
[2]Department of Nuclear Medicine, LMU University Hospital, Munich, GERMANY.

EP-0119

Preclinical development of ^{68}Ga-SFB6-ZN01 as a novel radiotracer targeting the cancer integrin αvβ6

Y. Wang[1], *Z. Xiao[1], Y. Huang[1], K. Xu[1], H. Wu[1], Y. Gai[2], P. Lei[3], Y. Jiang[1], Y. He[1];*
[1]Department of nuclear medicine, Zhongnan Hospital of Wuhan University, Wuhan, CHINA,
[2]Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA,
[3]Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0120

^{68}Ga-Labelled Ketobenzothiazole-Derived Peptidomimetics for PET Imaging of Matriptase Activity in Epithelial Cancer

A. Buchler[1,2], *F. Cookson[1], H. Merkens[1,2], M. Ligeour[1], E. Friesen[1,2], J. Zeisler[1], P. Ng[1], J. Lau[1,2], K. Lin[1,2], F. Bénard[1,2];*
[1]BC Cancer, Vancouver, BC, CANADA,
[2]University of British Columbia, Vancouver, BC, CANADA.

EP-0121

Development of a new PET radiotracer targeting adenosine kinase: from synthesis to in vivo evaluation

C. Sire, *E. Pincemail, C. Denis, A. Winkeler, B. Kuhnast, M. Richard;*
Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), CEA, CNRS, Inserm, Université Paris-Saclay, Orsay, FRANCE.

EP-0122

Head-to-Head Comparison of ^{18}F-FDG and ^{68}Ga-FAPI PET/CT in Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer: A Prospective Analysis

N. Harrish, *S. Sharma, A. Arya, M. Ora, P. Pradhan;*
Sanjay Gandhi Postgraduate Institue of Medical Sciences, Lucknow, INDIA.

EP-0123

GMP (CMC) validation and human radiation dosimetry of the novel SV2C PET radioligand [^{11}C] UCB-^{1}A for clinical translation

S. Nag, *M. Bolin, P. Datta, A. Morén, A. Varrone;*
Karolinska Institutet, Stockholm, SWEDEN.

EP-0124

Exploring a novel copper-64 labeled radioligand for PET imaging of EGFR-positive cancers

L. Plaza[1,2], *S. Bak[1], M. Danielsen[3], M. Skavenborg[3], N. Langkjær[1], C. Mckenzie[3], H. Thisgaard[1,2];*
[1]Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK,
[2]Department of Clinical Research, University of Southern Denmark, Odense, DENMARK,
[3]Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense, DENMARK.

EP-0125

Clinical Value of ^{18}F-(^{2}S,^{4}R)-4-Fluoroglutamine PET/CT in Lung Cancer

X. Xu, *F. Liu, Q. Xie, S. Liu, N. Li, Z. Yang;*
Peking University Cancer Hospital, Beijing, CHINA.

EP-0126

Radiolabeling and Preclinical Development of a Novel ^{18}F-Labeled PET Ligand for Monoacylglycerol Lipase

A. Haider[1], *Y. Li[2], T. Zhao[2], Z. Song[2], J. Chen[2], M. B. Wittwer[1], U. Grether[1], X. Zhou[2], S. H. Liang[2];*
[1]F. Hoffmann-La Roche Ltd., Basel, SWITZERLAND,
[2]Emory University, Atlanta, GA, UNITED STATES OF AMERICA.

EP-0127

Development of Non-Peptidic Neuropeptide Y1 Receptor Radiopharmaceuticals for Targeting Ewing Sarcoma

K. Yee[1], *P. Ng[1], F. Cookson[1], J. Zeisler[1], H. Merkens[1], K. Lin[1,2], F. Bénard[1,2], J. Lau[1,2];*
[1]Department of Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC, CANADA,
[2]Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.

EP-0128

Dual Targeting CCK2R/SSTR2 Radiopharmaceutical for Small Cell Lung Cancer: Synthesis and Preclinical Evaluation of a Theranostic Probe

Y. Tan[1,2], *B. Chen[3], J. Zhang[1,2,4];*
[1]Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,
[2]Theranostics Center of Excellence, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,
[3]Xiangya Hospital, Central South University, Changsha, CHINA,
[4]Clinical Imaging Research Centre, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.

EP-0129

Preclinical Evaluation of a [^{68}Ga]Ga-Labeled Cyclic PTP for PET Imaging of Plectin-1 in Pancreatic Ductal Adenocarcinoma

H. Huang, *J. Li, Q. Xu, X. Su;*
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA.

EP-0130

A Nanobody-Based PET/CT Tracer Targeting Glycoprotein A33 for Early Detection of Colorectal Cancer

W. Li, *S. Cheng, X. Lan, D. Jiang;*
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0131

Phage display-based screening of B7-H3-targeted peptides for the construction, optimisation, and application of a radiotracer

Y. Zhang[1], *Z. Yang*[2], *L. Xia*[2], *H. Zhu*[2];
[1]*Peking University Cancer Hospital Yunnan Hospital, Beijing, CHINA,*
[2]*Peking University Cancer Hospital, Beijing, CHINA.*

EP-0132

Voxelbased PET/CT imaging of αsynucleinopathies in a mouse model of Parkinson's disease with novel 18Flabeled tracers

B. Hooshyar Yousefi[1], *S. Bagheri*[1], *F. Geibl-Henrich*[2], *M. Henrich*[2], *B. Uzuegbunam*[3], *W. Oertel*[4], *M. Luster*[1], *D. Librizzi*[5];
[1]*Nuclear Medicine Department, Philipps University of Marburg, Marburg, GERMANY,*
[2]*Dept. of Psychiatry and Psychotherapy, Philipps University of Marburg, Marburg, GERMANY,*
[3]*Nuclear Medicine Department, Technical University of Munich, Munich, GERMANY,*
[4]*Dept. of Neurology, Philipps University of Marburg, Marburg, GERMANY,*
[5]*Nuclear Medicine Department, University Hospital OWL, Bethel Evangelical Hospital, Bielefeld, GERMANY.*

EP-0133

Automated synthesis of click prosthetic groups for pretargeting application and protein labeling using [^{18}F]fluoroethylamine as a small building block

S. Specklin[1], *A. Fumanal Idocin*[1], *B. Kuhnast*[1], *F. Taran*[2];
[1]*Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'imagerie biomédicale multimodale (BIOMAPS), Orsay, FRANCE,*
[2]*CEA, Service de Chimie Bio-organique et Marquage, DMTS, Université Paris-Saclay, Gif-Sur-Yvette, FRANCE.*

EP-0134

Preclinical Evaluation of a Novel ^{89}Zr-labeled Anti-STEAP1 Monoclonal Antibody for Pan-cancer Immuno-PET Imaging

Z. Deng[1,2], *T. Liu*[1], *Z. Yang*[1,2];
[1]*Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, CHINA,*
[2]*Institute of Molecular Medicine and National Biomedical Imaging Center, College of Future Technology, Peking University, Beijing, CHINA.*

EP-0135

A Novel GD2-Targeted Radionuclide Probe ^{89}Zr-TD-hu3F8 for Melanoma Diagnosis

Q. Tan[1], *H. Cao*[1], *H. Zhu*[2];
[1]*Medical School of Guizhou University, Guiyang, CHINA,*
[2]*Peking University Cancer Hospital & Institute, Beijing, CHINA.*

EP-0136

Immuno-PET Imaging with ^{89}Zr-Labeled GDF15-Targeted Antibody for Tumor Lesion Detection and Cancer Cachexia Assessment

J. Tao, *H. Zhu;*
Peking University Cancer Hospital & Institute, Beijing, CHINA.

EP-0137

Preclinical Evaluation of Zirconium-89-Labeled Plant-Produced Atezolizumab for PD-L1 ImmunoPET Imaging Across Multiple Solid Tumours

S. Sriwongta[1,2,3], *S. Yaset*[2,4,5], *S. Hao*[6,7], *Z. Yang*[6,7], *P. Rojsitthisak*[2,3,8], *Z. Hua*[6,7], *O. Vajragupta*[3,8];
[1]*Faculty of Radiological Technology, Rangsit University, Pathum Thani, THAILAND,*
[2]*Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, THAILAND,*
[3]*Molecular Probes for Imaging Research Network, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, THAILAND,*
[4]*National Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, THAILAND,*
[5]*Molecular Probes for Imaging Research Network, Faculty of Pharmaceutical Sciences, Chulalongkorn Universit, Bangkok, THAILAND,*
[6]*GuiZhou University Medical College, Guizhou, CHINA,*
[7]*Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, CHINA,*
[8]*Center of Excellence in Natural Products for Ageing and Chronic Diseases, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, THAILAND.*

EP-0138

Dual-Chelator Conjugates for [^{68}Ga]Ga- and [^{177}Lu]Lu-Based PSMA Radiotheranostics

W. Jin[1], *Y. Luo*[2], *Z. Zhu*[1], *L. Zhu*[2], *H. Kung*[3];
[1]*Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CHINA,*
[2]*Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing, CHINA,*
[3]*Department of Radiology, University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.*

EP-0139

Synthesis, Preclinical Evaluation, and Clinical Translation of a Long-Acting Dual-Targeting FAP/Integrin αvβ3 Heterodimeric Theranostic Radiotracer

T. Zhao[1], *R. Wang*[2], *X. Chen*[3], *J. Zhang*[1];
[1]*National University of Singapore, Singapore, SINGAPORE,*
[2]*Peking Union Medical College, Beijing, CHINA,*
[3]*Shandong Cancer Hospital and Institute, Jinan, CHINA.*

EP-0140

Mitochondria-targeted tumor PET imaging with novel peptide-based probe [^{68}Ga]MTP-NOTA

H. Wu, *Y. Liu, J. Wu, C. Lu, H. Wang;*
NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA.

EP-0141

^{68}Ga-Labeled Mesothelin-Binding Peptide for Accurate Diagnosis of MSLN-Expressing Lesions

N. Liu;
The First Affilated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA.

EP-0142

A Novel CD44v6-Targeting Peptide Probe for PET Imaging of Malignant Tumours

F. Wenhao;
Department of Nuclear Medicine, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, CHINA.

EP-0143

Allosteric modulation of neurotensin receptor 1 improves binding affinity and PET performance of a ^{68}Ga-labeled neurotensin analog

S. Kaur[1,2], *J. Zeisler*[1], *W. Lau*[1], *F. Cookson*[1], *P. Ng*[1], *H. Merkens*[1], *F. Benard*[1,2], *K. Lin*[1,2], *J. Lau*[1,2];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,*
[2]*The University of British Columbia, Vancouver, BC, CANADA.*

EP-0144

Engineering Anti-Integrin αvβ6 Antibodies Towards Improved PET Imaging and Radioimmunotherapy

Y. Hua, *Y. Xu, J. Sheng, X. Shao, J. Wang, H. Fu, Y. Chunjing;*
Affiliated Hospital of Jiangnan University, Wuxi, CHINA.

EP-0145

Radiofluorination of cucurbit[7]uril for supramolecular labeling of antibodies

L. Bancheri[1], *V. Goncalves*[1], *S. Specklin*[2], *P. Bellaye*[3], *Z. Bonnefoy*[1];
[1]*Université Bourgogne Europe, Dijon, FRANCE,*
[2]*Université Paris-Saclay, Inserm, CEA, Laboratoire d'Imagerie Biomédicale Multimodale Paris-Saclay (BioMaps), Orsay, FRANCE,*
[3]*Centre Georges-François Leclerc, Service de Médecine Nucléaire, Plateforme d'Imagerie et de Radiothérapie Précliniques, Dijon, FRANCE.*

EP-0146

CD276TargetedAntibody-Drug Conjugate Theranostic Platform in Prostate Cancer

T. Gu, *Y. Qiu, L. Kang;*
Peking University First Hospital, Beijing, CHINA.

EP-0147

Novel cyclic peptide PET tracer for non-invasive ROR1 imaging in a preclinical colorectal cancer model

X. Nian[1], *M. Cheng*[2], *Z. Gao*[1], *X. Lan*[1], *D. Jiang*[1];
[1]*Huazhong University of Science and Technology, Wuhan, CHINA,*
[2]*Zhejiang University, HangZhou, CHINA.*

EP-0148

Non-Invasive Imaging of Fibrotic Burden in Myelofibrosis: Preclinical Evaluation of ^{68}Ga-DOTA-ECL1i PET Targeting CCR2

A. Guercio[1], *S. Migliari*[1], *S. Valtorta*[2,3], *L. M. Pasini*[4], *P. Rainone*[2,3], *A. Gagliardi*[1], *G. Pozzi*[5], *M. Scarlattei*[1], *A. Coliva*[3], *F. Martelli*[6], *F. De Nuccio*[7], *M. Vitale*[8], *C. Carrubbi*[5], *A. R. Migliaccio*[9,10], *R. M. Moresco*[2,3,11], *L. Ruffini*[1], *E. Masselli*[4,5];
[1]*Nuclear Medicine Division, University Hospital of Parma, Parma, ITALY,*
[2]*IBSBC-CNR, Milano, ITALY,*
[3]*Nuclear Medicine Division, IRCCS San Raffaele Hospital, Milano, ITALY,*
[4]*Hematology and BMT Unit, University Hospital of Parma, Parma, ITALY,*
[5]*Anatomy Unit, Department of Medicine and Surgery (DiMeC), University of Parma, Parma, ITALY,*
[6]*National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Roma, ITALY,*
[7]*Department of Medicine and Surgery, Unisalento, Lecce, ITALY,*
[8]*Faculty of Medicine and Surgery, Vita-Salute University-San Raffaele, Milano, ITALY,*
[9]*Institute of Nanotechnology, National Research Council (Cnr-NANOTEC), c/o Campus Ecotekne, Roma, ITALY,*
[10]*Altius Institute for Biomedical Sciences, Seattle, WA, UNITED STATES OF AMERICA,*
[11]*Department of Medicine and Surgery, University of Milan Bicocca, Milano, ITALY.*

EP-0149

Noninvasive Assessment of Colitis Activity by Targeted Imaging of Neutrophil Elastase with [^{68}Ga]Ga-POL6014

M. Niu, *X. Wang, Y. Guo, J. Wang, F. Kang;*
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

EP-0150

Development of ^{68}Ga-Labeled σ2 Receptor-Targeted Probes for PET Imaging of Tumor Proliferation

C. Xu, *J. Ye, K. Yu, W. Yang, F. Kang, J. Wang;*
Air Force Medical University, Xi'an, CHINA.

EP-0151

^{68}Ga-anti-integrin peptide as a theranostic agent in glioblastoma

F. Alves da Silva[1,2], *J. Carron*[1], *G. Melo*[3], *A. Ali*[1], *F. Alves*[3], *M. Amaro Santos*[1], *V. Castro Rodrigues*[4], *J. Carvalho*[5], *A. Gois Ruiz*[5], *L. Fuscaldi*[3], *L. Malavolta*[3], *C. Passos Lima*[1,6];
[1]*Laboratory of Cancer Genetics, School of Medical Sciences, University of Campinas, Campinas, São Paulo, BRAZIL,*
[2]*Nuclear and Energy Research Institute (IPEN), Radiopharmacy Center, Sao Paulo, Sao Paulo, BRAZIL,*
[3]*Santa Casa de São Paulo School of Medical Sciences, São Paulo, São Paulo, BRAZIL,*
[4]*Division of Nuclear Medicine, Department of Radiology and Oncology, School of Medical Sciences, University of Campinas, Campinas, São Paulo, BRAZIL,*
[5]*School of Pharmaceutical Sciences, University of Campinas, Campinas, São Paulo, BRAZIL,*
[6]*Division of Clinical Oncology, Department of Radiology and Oncology, Campinas, Sao Paulo, BRAZIL.*

EP-0152

Development and evaluation of [^{68}Ga]Ga-CPX-17: A novel PET probe for CXCR4-targeted tumor imaging

W. Hongyong, *Y. Liu, J. Wu, C. Lu, H. Wu;*
Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA.

EP-0153

Y. Guo, *J. Wang, X. Wang, M. Niu, F. Kang;*
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

EP-0154

Overcoming a Key Bottleneck in AMPA-PET: Practical and Robust Radiosynthesis of an ^{18}F-Labelled Tracer

T. Arisawa, *K. Kimura, Y. Takada, T. Takahashi;*
Yokohama City University, Yokohama, Kanagawa, JAPAN.

EP-0155

Radiosynthesis and preclinical evaluation of [^{18}F] HIFN as a PET tracer for TrkB imaging

V. Shalgunov[1,2], *E. Kolesnik*[1,2,3], *V. Richin*[1,3], *N. J. W. Straathof*[2], *C. A. Madsen*[1,2,3], *M. M. Herth*[2], *G. M. Knudsen*[3,4];
[1]*Department of Clinical Physiology, Nuclear Medicine & PET, Copenhagen University Hospital Rigshospitalet, Copenhagen, DENMARK,*
[2]*Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DENMARK,*
[3]*Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, DENMARK,*
[4]*Department of Clinical Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, DENMARK.*

EP-0156

Comparison of binding affinity of diaryl-substituted 123-triazoles for amyloid plaques: 2,4-Diaryl-123-triazoles are new scaffold for the imaging of Alzheimer disease

K. Kato[1], *R. Harada*[2], *T. Kumamoto*[3];
[1]*National Center of Neurology and Psychiatry, Kodaira, JAPAN,*
[2]*Tohoku Medical and Pharmaceutical Univercity, Sendai, JAPAN,*
[3]*Hiroshima Univercity, Hiroshima, JAPAN.*

EP-09

A: Preclinical and Translational Studies → A1 Medical Preclinical → A18 New Radiopharmaceuticals - Therapy

EP-0157

First-in-class Claudin 18.2 targeting radiopeptide, ^{64}Cu-PD-29875 and ^{225}Ac-PD-29875, exhibit promising theranostic potential in pancreatic and gastric cancer xenograft models

Y. Sato[1], *S. Tsuchida*[2], *Y. Mizukoshi*[2], *S. Kato*[2], *H. Inaba*[2], *R. Komura*[2], *M. Satake*[1], *N. Kanazawa*[1], *H. Yanagida*[2], *K. Suzuki*[1], *K. Matsuhara*[1], *S. Matsushima*[1], *P. C. Reid*[2], *M. Murakami*[1,2], *H. Kitamura*[2];
[1]*PDRadiopharma Inc., Tokyo, JAPAN,*
[2]*PeptiDream Inc., Kanagawa, JAPAN.*

EP-0158

Astatine-211 radiolabeling via aryliodonium ylides with data driven optimization

M. Ogawa[1], *A. Mukaimine*[1], *K. Nakajima*[1], *K. Matsuoka*[1], *T. Yoshino*[1,2], *S. Matsunaga*[1,2], *T. Kitano*[1], *Y. Mizuno*[1], *K. Tabata*[1], *T. Komatsuzaki*[1];
[1]*Hokkaido University, Sapporo, JAPAN,*
[2]*Kyoto University, Kyoto, JAPAN.*

EP-0159

Development of an anti-CD44v6 pretargeting-based approach for gastric cancer

S. Rinne[1], *S. Lundsten Salomonsson*[2,3], *I. Lodewijk*[1], *T. Xu*[1], *M. Nestor*[1];
[1]*Department of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala University, Uppsala, SWEDEN,*
[2]*Ridgeview Instruments AB, Uppsala, SWEDEN,*
[3]*Dept. of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN.*

EP-0160

Tandem [^{225}Ac]/[^{177}Lu]-PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: Real-World Efficacy and Safety Outcomes

P. Yesilkaya, *G. Beydağı, K. Akçay, T. Toklu, N. Alan;*
Yeditepe University, Istanbul, TÜRKIYE.

EP-0161

Feasibility of affibody-based pretargeted delivery of ^{225}Ac

V. Tolmachev[1], *E. Papalanis*[1], *K. Westerlund*[2], *I. Zelepukin*[1], *Y. Liu*[1], *A. Orlova*[3], *M. Din*[1], *A. Bitzios*[1], *A. Vorobyeva*[1], *S. Selivanova*[4], *A. Lebedev*[4], *J. Clinton*[2], *A. Eriksson Karlström*[2], *M. Oroujeni*[1];
[1]*Department of Immunology, Genetics and Pathology (IGP), Uppsala University, Uppsala, SWEDEN,*
[2]*Department of Protein Science, KTH Royal Institute of Technology, Stockholm, SWEDEN,*
[3]*Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN,*
[4]*Canadian Nuclear Laboratories, Chalk River, ON, CANADA.*

EP-0162

Development of ^{161}Tb-Labeled DTPA-Functionalized SPION@Mesoporous Silica Nanoparticles for Radiotheranostic Applications

A. Vukadinovic, *D. Stankovic, M. Mirkovic, D. Jankovic, P. Sitarica, M. Maric, S. Vranjes-Djuric, M. Radovic;*
Vinca Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Bel, Belgrade, SERBIA.

EP-0163

ATNM-400, a First-in-Class Actinium-225 Radioconjugate Improves Response to Standard-of-Care Therapeutics in Colorectal Cancer Models

A. Kamal[1], *R. Jiao*[2], *S. Kazerounian*[1], *S. Mukherjee*[1], *A. S. Chin*[1], *K. J. H. Allen*[2], *M. E. Malo*[2], *E. Dadachova*[2];
[1]*Actinium Pharmaceuticals, New York, NY, UNITED STATES OF AMERICA,*
[2]*University of Saskatchewan, Saskatoon, SK, CANADA.*

EP-0164

PreclinicalEvaluation of a Novel [^{177}Lu]Lu-Labeled PSMA/FAP Bispecific Radioligand for Prostate Cancer

R. Xue[1], *X. Wang*[2], *G. Wang*[3], *J. Cui*[1], *X. Wen*[1], *S. Geng*[1], *Y. Liu*[4], *B. Xu*[4];
[1]*Graduate School, Chinese PLA General Hospital, Beijing, CHINA,*
[2]*Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, CHINA,*
[3]*Beijing Friendship Hospital, Capital Medical University, Beijing, CHINA,*
[4]*The First Medical Centre, Chinese PLA General Hospital, Beijing, CHINA.*

EP-0165

[^{177}Lu]Lu-CBT-001-2334: A Novel CAIX-Targeted Peptide Radiotherapeutic for Clear Cell Renal Cell Carcinoma

J. Navarro Yepes[1], *B. Qi*[1], *M. Lin*[1], *A. Yamaguchi*[1], *J. Park*[2], *S. Lee*[3], *S. S. Krebs*[1], *H. C. Manning*[1];
[1]*UT MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA,*
[2]*C-BioMex., Co, Ltd, South Korea, KOREA, REPUBLIC OF,*
[3]*C-BioMex., Co., Ltd., South Korea, KOREA, REPUBLIC OF.*

EP-0166

[^{64}Cu]Cu-XT117/[^{177}Lu]Lu-XT117, a Novel Theranostic pair Targeting Fibroblast Activation Protein (+) Cancers

G. Zhang[1], *R. Liu*[1], *J. Zhu*[1], *L. Fu*[1], *Z. Li*[1], *R. Zhao*[1], *Y. Zhang*[2], *Y. Wang*[2], *P. Wang*[1], *X. Zhong*[1];
[1]*Beijing Sinotau Bio-pharmaceutical Technology Co., Ltd., Beijing, CHINA,*
[2]*Beijing Sinotau International Pharmaceutical Technology Co., Ltd., Beijing, CHINA.*

EP-0167

Preclinical Evaluation of SKL37321: a ^{177}Lu-Labeled CAIX-Targeted Radiopharmaceutical for the Treatment of Renal Cell Carcinoma

E. Jang, *M. Moon, S. Ki, J. Jung, B. Hong, C. Park, H. Jung, Y. Shin, K. Kim;*
SK Biopharmaceuticals Co., Ltd., Seongnam, KOREA, REPUBLIC OF.

EP-0168

XT381: A Next-Generation PSMA-Targeted Radioligand with Enhanced Tumor Retention and Efficacy

G. Zhang[1], *J. Zhu*[1], *Y. Zhou*[2], *L. Fu*[1], *Z. Zhao*[1], *Y. Shi*[1], *H. Ma*[1], *L. Qian*[2], *X. Zhong*[1];
[1]*Beijing Sinotau Bio-pharmaceutical Technology Co., Ltd., Beijing, CHINA,*
[2]*Shanghai Sinotau Biotechnology Co., Ltd., Shanghai, CHINA.*

EP-0169

Comparative Preclinical Evaluation of ^{161}Tb-Labeled Covalent, Internalizing, and Traditional FAPIs for Radionuclide Therapy

X. Wang, *J. Ye, F. Kang, J. Wang;*
The First Affiliated Hospital of Air Force Medical University, Xi'an, CHINA.

EP-0170

From [^{131}I]I-DualFAPi-5 to [^{211}At]At-DualFAPi-5: A Radiohalogenated FAPi-Dimer for Theranostic Application

M. Müller[1,2,3], *M. Martin*[1,2,3], *U. M. Battisti*[1,2], *J. Schichler*[1,2], *N. R. B. Pedersen*[2,1,3], *J. Bertram*[4,5], *P. Iakovidou*[1,2,3], *D. Beyer*[1,2,3], *S. Humpert*[5], *A. Miranda*[6], *V. Shalgunov*[1,3], *F. Elvas*[6,7], *B. Neumaier*[5,4], *A. I. Jensen*[1], *M. M. Herth*[1,3,2];
[1]*Tetrakit Technologies, Copenhagen, DENMARK,*
[2]*Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, DENMARK,*
[3]*Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DENMARK,*
[4]*Faculty of Medicine and University Hospital Cologne, Institute of Radiochemistry and Experimental Molecular Imaging, University of Cologne, Cologne, GERMANY,*
[5]*Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Forschungszentrum Jülich GmbH, Jülich, GERMANY,*
[6]*Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, BELGIUM,*
[7]*Department of Nuclear Medicine, Antwerp University Hospital, Antwerp, BELGIUM.*

EP-0171

Optimized Affibody Molecule targeting B7-H3 immune checkpoint: Improved Tumor Targeting Properties in a Syngeneic MC38 Model

E. Recasens Pérez-Vera[1], *M. Oroujeni*[1], *Y. Liu*[1,2], *A. Orlova*[3], *E. Gunneriusson*[2], *E. Ryer*[2], *V. Tolmachev*[1], *F. Y. Frejd*[1,2];
[1]*Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN,*
[2]*Affibody AB, Stockholm, SWEDEN,*
[3]*Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN.*

EP-0172

A Theranostic Study of ^{177}Lu-Labeled Anti-ADAM9 Antibody for the Treatment of Triple-Negative Breast Cancer

H. Zhang[1], *M. Tang*[2], *X. Hao*[3], *B. Lin*[4], *H. Du*[3], *H. Long*[5], *J. Hu*[5], *R. Luo*[6], *W. Wu*[7], *X. Du*[8];
[1]*College of Life Sciences and Agri-forestry, Southwest University of Science and Technology, Mianyang, CHINA,*
[2]*Clinical Medical School, North Sichuan Medical College, Nanchong, CHINA,*
[3]*Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, CHINA,*
[4]*NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, CHINA,*
[5]*Sichuan Kelun-Biotech Biopharmaceutical Co.,Ltd., Chengdu, CHINA,*
[6]*Department of Nuclear Medicine, Central hosital of Mianyang, Mianyang, CHINA,*
[7]*School of National Defense Science and Technology, Southwest University of Science and Technology, Mianyang, CHINA,*
[8]*Department of Oncology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, CHINA.*

EP-0173

A first-in-modality [^{225}Ac]Ac-SKL37171, a radiopharmaceutical therapy targeting ROR1, demonstrates potent antitumor activity in ROR1-positive solid Tumours

J. Yun[1], *D. Lee*[1], *H. Lee*[1], *H. Cho*[1], *J. Lee*[1], *D. Lee*[1], *G. Cho*[1], *W. Lee*[1], *C. Kang*[2], *S. Eom*[2], *K. Kim*[3], *S. Oh*[3], *J. Park*[3], *J. Seo*[3], *K. Lee*[2], *Y. Lee*[3], *Y. Shin*[1], *K. Kim*[1];
[1]*RPT Preclinical Center, RPT Division, SK Biopharmaceuticals Co., Ltd., Seoul, KOREA, REPUBLIC OF,*
[2]*Research Institute of Radiological & Medical Sciences, Korea Institute of Radiological & Medical Sciences (KIRAMS), Seoul, KOREA, REPUBLIC OF,*
[3]*Korea Radioisotope Center for Pharmaceuticals, Korea Institute of Radiological & Medical Sciences (KIRAMS), Seoul, KOREA, REPUBLIC OF.*

EP-0174

XT771, a bispecific molecule targeting CA9&CA12 for clear cell renal carcinoma and glioblastoma theranostics

G. Zhang[1], *J. Zhu*[1], *Y. Shi*[1], *H. Ma*[1], *R. Zhao*[1], *P. Wang*[1,2], *X. Zhong*[1,2];
[1]*Beijing Sinotau Bio-pharmaceutical Technology Co., Ltd., Beijing, CHINA,*
[2]*Beijing Sinotau International Pharmaceutical Technology Co., Ltd., Beijing, CHINA.*

EP-0175

Preclinical Evaluation of NYM158, a Novel177Lu-Labeled SSTR2 Antagonist Radiopharmaceutical for Aggressive Neuroendocrine Neoplasms and Small Cell Lung Cancer

P. Fang, *W. Lv, G. Cheng, S. Yang;*
Norroy bioscience Co., Ltd, Wuxi, CHINA.

EP-0176

ATNM-400, a First-in-Class Actinium-225 Radioconjugate Triggers Durable Antitumor Responses in Ovarian Cancer Models

A. Kamal, *S. Mukherjee, D. Lewis, K. Peregrina, V. Chavez, J. Li, A. S. Chin, M. Roy, J. Kim, S. Kazerounian;*
Actinium Pharmaceuticals, New York, NY, UNITED STATES OF AMERICA.

EP-0177

Preclinical Characterization of [^{225}Ac]Ac-AG1001, a Novel SSTR2 Antagonist Radiolabeled with Actinium-225

S. Xu, *X. Zhang, Z. Lu, X. Li, X. Huang, R. Shi, Q. Chen, X. Gu, X. Tang, G. Liu, M. Liao, T. Wu, D. Dai, X. Gan, X. Ye;*
AlphaGen Therapeutics, Shanghai, CHINA.

EP-0178

Preclinical Evaluation of ^{177}Lu-PSMA-XT for Targeted Treatment of Prostate Cancer with Moderate PSMA Expression

Y. Liu, *R. Xue, X. Zhang, B. Xu, H. Wang, R. Wang, J. Zhang;*
Chinese PLA General Hospital, Beijing, CHINA.

EP-0179

Thiol-directed antibody modification reduces hepatic uptake and enhances tumor accumulation for targeted radionuclide therapy

Z. Wang, *Q. Tan, Z. Yang, H. Zhu;*
Peking University Cancer Hospital & Institute, Beijing, CHINA.

EP-0180

Preclinical assessment of ^{177}Lu-labeled anti-B7-H3 antibody for targeted therapy in lung cancer PDX models

C. Zhao[1], *X. Wu*[2], *P. Bai*[3,4], *L. Li*[1];
[1]*Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA,*
[2]*Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA,*
[3]*Department of Pulmonary and Critical Care Medicine, West China Hospital. State Key Laboratory of Respiratory Health and Multimorbidity. Sichuan University, Chengdu, CHINA,*
[4]*Molecularly Targeted Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, CHINA.*

EP-0181

Computational, Chemical Caracterisation and Biological Assessment of [^{225}Ac]Ac-D-iFAP and [^{225}Ac]Ac-M-iFAP Radiopharmaceuticals for Targeted Alpha Therapy

D. García-Arce[1], *P. Cruz Nova*[1], *M. Luna Gutiérrez*[1], *A. Vidal Limón*[2], *E. Morales Ávila*[3], *L. Aranda Lara*[3], *N. Jiménez Mancilla*[1], *G. Ferro Flores*[1], *B. Ocampo García*[1];
[1]*Instituto Nacional de Investigaciones Nucleares (ININ), Ocoyoacac, MEXICO,*
[2]*Instituto de Ecología, Xalapa-Enríquez, MEXICO,*
[3]*Universidad Autónoma del Estado de México, Toluca, MEXICO.*

EP-10

A: Preclinical and Translational Studies → A1 Medical Preclinical → A19 New Biological Targets and Ligands

EP-0182

A Novel Nectin4-Targeting Peptide Radioligand with High Tumor Retention: Preclinical and Human IIT Study Evaluation

W. Xu, *S. Tung, Y. Li;*
PepLib, Zhuzhou, CHINA.

EP-0184

Development of Cyclic Peptide-based Radioligands Targeting B7-H3

C. Wang[1], *Z. Liu*[1,2,3];
[1]*Changping Laboratory, Beijing, CHINA,*
[2]*Peking University, Beijing, CHINA,*
[3]*Peking University Cancer Hospital & Institute, Beijing, CHINA.*

EP-0185

Evaluation of the pharmacological properties of trastuzumab bioconjugates generated using AbYlink™ regioselective conjugation technology in HER2-positive gastric cancer.

S. Belderbos[1], *C. Mothes*[1], *P. Provent*[1], *M. Ruch*[2], *M. Moreau*[2], *M. Claron*[2], *A. Helbling*[3], *V. Postupalenko*[4], *L. Marx*[4], *P. Garrouste*[4], *E. Koumarianou*[1];
[1]*Oncodesign Services, Dijon, FRANCE,*
[2]*Institut de Chimie Moléculaire de l'Université de Bourgogne, Dijon, FRANCE,*
[3]*Centre Georges François Leclerc, Dijon, FRANCE,*
[4]*Debiopharm Research & Manufacturing SA, Martigny, SWITZERLAND.*

EP-0186

FirstinClass Radiolabeled Affibody Molecule for SPECT Imaging of TumorAssociated ROR1 expression

A. Vorobyeva[1], *T. Xu*[1], *C. Westerberg*[2], *M. Ud Din*[1], *A. Orlova*[1], *S. Ståhl*[2], *J. Löfblom*[2], *V. Tolmachev*[1];
[1]*Uppsala University, Uppsala, SWEDEN,*
[2]*KTH Royal Institute of Technology, Stockholm, SWEDEN.*

EP-0187

Carbonic Anhydrase 12 in the Glioblastoma Infiltration Zone as a Target for Intracavitary Radioimmunotherapy

J. Schuler[1], *L. Waltermann*[1], *S. Baur*[1], *A. Wagner*[2], *B. Meyer*[2], *J. Kunert*[3], *H. Reulen*[4], *R. Zeidler*[5], *C. Mogler*[1], *C. Delbridge*[1];
[1]*Institute of Pathology, Technical University of Munich, Munich, GERMANY,*
[2]*Department of Neurosurgery, TUM Klinikum, TUM School of Medicine and Health, Technical University of Munich, Munich, GERMANY,*
[3]*ITM Medical Isotopes GmbH, Garching, GERMANY,*
[4]*Emeritus, Department of Neurosurgery, LMU University Hospital, Munich, GERMANY,*
[5]*Institute of Structural Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, GERMANY.*

EP-0188

Preclinical Evaluation of [^{177}Lu]Lu-DOTA-PN983: A Novel Neurokinin-1 Receptor Targeting Radioconjugate for Cancer Imaging and Therapy

S. Chopra[1], *T. Xu*[1], *M. Norling*[1], *U. Rosenström*[2], *U. Yngve*[2,3], *M. Nestor*[1];
[1]*Department of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala, SWEDEN,*
[2]*Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN,*
[3]*Science for Life Laboratory (SciLifeLab), Drug Discovery and Development platform, Uppsala, SWEDEN.*

EP-11

A: Preclinical and Translational Studies → A1 Medical Preclinical → A20 Radiopharmacokinetics and Drug Development

EP-0189

In vivo characteristics of radiolabeled APD indicators for atherosclerotic cardiovascular disease at early stage

M. Weng, *M. Chen, S. Chen, C. Chen, Y. Chang, X. Yao, C. Lo, C. Hsia;*
National Atomic Research Institute, Taoyuan City, TAIWAN, PROVINCE OF CHINA.

EP-0190

Kinetic Modeling of [^{89}Zr]Zr-DFO-adalimumab, a Novel Anti-TNF PET Tracer for Quantitative Imaging of Inflammation

A. Avendaño-Estrada[1,2], *J. Codesido*[3], *X. García-Otero*[3,4], *M. Kotrulev*[5], *C. Veloso-de-Simon*[5], *M. Muñoz-González*[3,4], *L. García-Varela*[3,4], *I. Gómez-Touriño*[5], *P. Aguiar*[3,4];
[1]*Unidad Radiofarmacia-Ciclotrón, División de Investigación, School de Medicina, Universidad Nacional Autónoma de México, Mexico, MEXICO,*
[2]*Centro de Investigación sobre el Envejecimiento, CINVESTAV Sede Sur, Mexico, MEXICO,*
[3]*Molecular Imaging and Pharmacokinetic Modeling Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Santiago de Compostela, SPAIN,*
[4]*Molecular Imaging Group and Nuclear Medicine, University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, SPAIN,*
[5]*Immunity and Small Molecules, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Santiago de Compostela, SPAIN.*

EP-0191

Development of a ^{68}Ga-labeled nanobody PET tracer for high-contrast CLDN18.2 imaging in vivo

Y. Deng[1], *X. Zhang*[1], *Z. Pan*[2], *J. Han*[3], *Q. Cui*[1], *Z. Wu*[1], *D. Zheng*[1], *R. An*[1], *Y. Zhang*[1], *D. jiang*[1], *J. Zhu*[4], *X. Lan*[1];
[1]*Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA,*
[2]*Asclevi Incorporated, Shanghai, CHINA,*
[3]*Department of bioengineering. University of Washington, Seattle, WA, UNITED STATES OF AMERICA,*
[4]*Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmaceutical Science, Shanghai Jiao Tong University, Shanghai, CHINA.*

EP-0192

Human tumor tissue microarray expression profiling and preclinical dosimetry support clinical translation of a neurotensin receptor 1-targeted theranostic pair

J. Na, *T. Lee, S. Jeon, H. Lee, S. Lee, Y. Shin, K. Kim;*
SK biopharmaceuticals, Seoul, KOREA, REPUBLIC OF.

EP-0193

Combination of PSMA Radiopharmaceuticals with Orthogonal Pharmacokinetics Improves Therapeutic Index in Castration-Resistant Prostate Cancer

J. Cabahug, *M. Idrissou, R. Hernandez;*
University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

EP-0194

A Dynamic PET-driven ^{89}Zr-labeled Nanotheranostic Enables Ultra-early Functional Diagnosis and Intervention of Acute Kidney Injury

P. Liu, *S. Hu;*
Central South University, Changsha, CHINA.

EP-0195

Click-Chemistry Enabled Radiolabeling of Tyr^3-Octreotate Derivatives for alpha therapy (^{211}At) and imaging: Synthesis and In Vivo Evaluation

P. Iakovidou[1,2], *D. Beyer*[2], *M. Martin*[1,2], *N. Hauser*[1,2], *L. Hvass*[3], *A. Kjaer*[3], *V. Shalgunov*[2,4], *U. M. Battisti*[1,2], *M. Herth*[1,2];
[1]*Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DENMARK,*
[2]*TetraKit Technologies ApS, Copenhagen, DENMARK,*
[3]*Cluster for Molecular Imaging, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, DENMARK,*
[4]*Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen, DENMARK.*

EP-0196

Effect of Metallic Impurities from the Generator on [^{68}Ga]Ga-NODAGA-Exendin-4 Labeling Efficiency

S. Migliari[1], *A. Guercio*[1], *A. Gagliardi*[1], *M. Scarlattei*[1], *G. Baldari*[1], *R. Aldigeri*[2], *V. Aldigeri*[2], *F. Fantuzzi*[2], *G. Cinquegrani*[2], *G. Talluto*[2], *V. Giannatiempo*[2], *R. Bonadonna*[2], *A. Dei Cas*[2], *L. Ruffini*[1];
[1]*Nuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Parma, ITALY,*
[2]*Laboratory of Endocrinology, Diabetes and Metabolic Disease, Department of Medicine and Surgery, Azienda Ospedaliero-Universitaria of Parma, Parma, ITALY.*

EP-0197

Ligand assembly does matter: albumin-binding moiety placement alters the pharmacokinetics of GRPR-targeting peptides

K. Obeid, *E. Håkansson, E. Bezverkhniaia, B. Skillinghaug, U. Rosenström, P. Kanellopoulos, L. R. Odell, A. Orlova;*
Uppsala University, Uppsala, SWEDEN.

EP-0198

Solid-phase synthesis and preclinical evaluation of a new bispecific radiopharmaceutical designed to target two different target receptors, PSMA and GRPR, overexpressed in prostate cancer.

S. Okarvi;
Cyclotron & Radiopharmaceutical;
King Faisal Specialist Hospital and Research Centre, Riyadh, SAUDI ARABIA.

EP-0199

Quantitative Systems Pharmacology Modeling of Targeted Radiotherapies to Predict Absorbed Dose, Inform NextGeneration Design, and Improve Therapeutic Index

S. Minucci, *B. Koirala, B. Lang, J. Nosbisch, A. Manon, D. Imbs, J. Grant;*
Certara, Radnor, PA, UNITED STATES OF AMERICA.

EP-0200

Niacin pre-administration enhanced retention of 6-[^{18}F]Fluoronicotinic acid in glioblastoma xenografts in mice

J. Kunnas[1,2], *E. Rajala*[3,2], *D. Ekwe*[2], *E. Bakay*[1,2], *L. Bai*[2], *X. Zhuang*[3,2], *P. Lövdahl*[1,2], *J. Rajander*[2,4], *J. M. Rosenholm*[1], *X. Li*[2,3,5];
[1]*Pharmaceutical Sciences Laboratory, Faculty of Sciences and Engineering, Åbo Akademi University, Turku, FINLAND,*
[2]*Turku PET centre, University of Turku, Turku, FINLAND,*
[3]*Department of Chemistry, University of Turku, Turku, FINLAND,*
[4]*Accelerator Laboratory, Åbo Akademi University, Turku, FINLAND,*
[5]*InFLAMES Research Flagship, University of Turku, Turku, FINLAND.*

EP-0201

Preclinical imaging assessment and pharmacokinetic modeling of ^{68}Ga-Phytate

A. Prignon[1], *A. Iwanoff*[1], *B. Elgrably*[1], *F. Ben Yahyaten*[2], *T. Rusu*[2];
[1]*Sorbonne Universite, UMS^{28}, LIMP laboratory, Paris, FRANCE,*
[2]*Radiopharmacie, Hôpital Tenon, AP-HP, Paris, FRANCE.*

EP-0202

Comparative Study on Biodistribution of161Tb-Labeled Radioimmunoconjugate and Radiochemical Forms of Terbium-161 potentially present in vivo

F. Trejtnar[1], *P. Barta*[1], *N. Mehdizadeh*[1], *M. Vlk*[2], *J. Kozempel*[2], *M. Skalova*[2], *T. Janska*[2];
[1]*Charles University, Faculty of Pharmacy in Hradec Kralove, Hradec Kralove, CZECH REPUBLIC,*
[2]*Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Prague, CZECH REPUBLIC.*

EP-0203

The impact of the molar activity on the biodistribution and kinetics of [^{18}F]DPA-714 in rats

R. Bergmann[1,2], *Á. Vizbel*[1,2], *L. Forgách*[1,2], *Z. Varga*[1], *M. Nacsa*[1,2], *N. Kovács*[1], *I. Horváth*[1], *P. Hajdrik*[1], *S. Nag*[3], *P. K. Datta*[3], *K. Szigeti*[1,2], *D. Máthé*[1,2], *C. Halldin*[1,3];
[1]*Semmelweis University Dept. Biophysics and Radiation Biology - HUN-REN TKI [1094] Budapest, Budapest, HUNGARY,*
[2]*Hungarian Centre of Excellence for Molecular Medicine In Vivo Imaging Advanced Core Facility Szeged Hungary, Budapest, HUNGARY,*
[3]*Karolinska Institutet, Stockholm, SWEDEN.*

EP-12

A: Preclinical and Translational Studies → A1 Medical Preclinical → A21 Other Preclinical and Translational

EP-0204

PET-based visualization of membrane-type 1 matrix metalloproteinase expression in solid Tumours: from bench to bedside

X. Ma, *T. Liu, H. Zhu, Z. Yang;*
Peking University Cancer Hospital, Beijing, CHINA.

EP-0205

Lateralized increase of synaptic dopamine after treatment with bicucullin partially overlaps with increases in BOLD signaling in limbic and auditory system

S. Nikolaus[1], *H. J. Wittsack*[1], *M. Beu*[1], *J. Henke*[1], *H. Hautzel*[2], *C. Antke*[1], *E. Mamlins*[1], *L. Abdel-Hafiz*[1], *B. Fazari*[1], *H. W. Müller*[1], *C. von Gall*[1], *G. Antoch*[1], *F. L. Giesel*[1];
[1]*University Hospital Düsseldorf, Düsseldorf, GERMANY,*
[2]*University Hospital Essen, Essen, GERMANY.*

EP-0206

[^{18}F]FAC-ImmunoPET enables in vivo visualization of dynamic immune cell activation in acute and chronic T cell-driven inflammation

C. Philippe[1], *B. Schörg*[2], *R. Mehling*[2], *J. Cotton*[2], *A. Würth*[2], *I. Gonzalez Menendez*[2], *L. Quintanilla-Martinez*[2], *J. Czernin*[3], *C. Radu*[3], *M. Hacker*[1], *B. Pichler*[2], *M. Kneilling*[2];
[1]*Medical University of Vienna, Vienna, AUSTRIA,*
[2]*Eberhard Karls University, Tuebingen, GERMANY,*
[3]*UCLA, Los Angeles, CA, UNITED STATES OF AMERICA.*

EP-0207

Preclinical validation of ^{18}F-NaF positron emission tomography for assessment of complex regional pain syndrome in a rat model

H. Yoon[1], *D. Kim*[2], *H. Kim*[2], *B. Kim*[1], *B. Moon*[1];
[1]*Department of Nuclear Medicine, Ewha Womans University School of Medicine, Seoul, KOREA, REPUBLIC OF,*
[2]*Department of Emergency Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF.*

EP-0208

Quantitative High-resolution radioHPLC analysis of ^{225}Ac-labelled compounds using a standard HPLC radioactivity detector

E. Jakobsson, *A. P. Belanger;*
Dana-Farber Cancer Institute, Boston, MA, UNITED STATES OF AMERICA.

EP-0209

How does BBB disruption influence the brain kinetic of PET radiotracers?

E. N'Diaye, *T. Ador, L. Sieu, S. Leterrier, S. Amargier-Barrial, M. Goislard, L. Jourdain, S. Goutal, A. Novell, N. Tournier;*
Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Orsay, FRANCE.

EP-0210

An immunoPET strategy to track Bordetella pertussis in a baboon model of whooping cough

F. Caillé[1], *S. Huvelle*[1], *T. Geara*[2], *A. Garnier*[2], *C. Chapon*[2], *C. Truillet*[1], *T. Naninck*[2];
[1]*CEA-Service Hospitalier Frédéric Joliot, Orsay, FRANCE,*
[2]*CEA-IDMIT, Fontenay-aux-Roses, FRANCE.*

EP-0211

Pre-clinical Physiologically Based Pharmacokinetic Modelling of PSMA Radioligands: Analysis of Unspecific Uptakes and Unspecific Uptake Reference Tissues

A. Alvers[1], *A. K. Mapanao*[2], *C. Müller*[2,3], *P. Bernhardt*[1,4];
[1]*Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN,*
[2]*Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, SWITZERLAND,*
[3]*Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, SWITZERLAND,*
[4]*Department of Medical Physics and Biomedical Engineering (MFT), Sahlgrenska University Hospital, Gothenburg, SWEDEN.*

EP-0212

Gastrointestinal biodistribution of oral ^{99}mTc-radiolabelled protein-basednanoparticles in healthy and experimental colitis mice: a microSPECT/CTImaging Study

F. Hendy Pérez-Aranda[1], *D. Lloves*[1], *A. Iglesias-Ochagavia*[1], *M. del Valle*[2], *A. Huidobro*[2], *M. Collantes*[3,4], *A. Fernández-Gonzalez*[1], *G. Quincoces*[1,3], *F. Pareja*[1], *J. Irache*[2], *I. Peñuelas*[1,4,3];
[1]*Radiopharmacy Unit. Nuclear Medicine Department. Clínica Universidad de Navarra, Pamplona, SPAIN,*
[2]*Department of Pharmaceutical Sciences, Universidad de Navarra, Pamplona, SPAIN,*
[3]*Navarra Institute for Health Research (IdISNA), Pamplona, SPAIN,*
[4]*Translational Molecular Imaging Unit (UNIMTRA). Nuclear Medicine Department. Clínica Universidad de Navarra, Pamplona, SPAIN.*

EP-0213

Phenoxy group as a convenient nucleofuge in photocatalyzed ^{18}F-fluorination of electron-rich and neutral arenes

C. Zheng, *K. Lu, W. Chen;*
West China Hospital, Sichuan University, Chengdu, Sichuan, CHINA.

EP-0214

A Kit to Prepare ^{111}In/^{225}Ac-DOTA-trastuzumab-F(ab')2 Injection Formulated under Good Manufacturing Practices (GMP) for Theranostic Imaging and α-Particle Radioimmunotherapy of HER2-Positive Cancers

C. Chan[1], *R. Wong*[2], *P. Veit-Haibach*[2], *S. Bratman*[2], *R. M. Reilly*[1,2];
[1]*Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, CANADA,*
[2]*Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CANADA.*

EP-0215

Preclinical evaluation and first-in-human study of [^{68}Ga]Ga/[^{177}Lu]Lu-JHE1, novel PSMA- & FAP-targeting radiopharmaceuticals

G. Wang[1], *J. Zang*[1], *J. Zhan*[2], *Y. Yu*[2], *R. Li*[2], *E. Wang*[2], *J. He*[2], *W. Miao*[1];
[1]*The First Affiliated Hospital, Fujian Medical University, Fuzhou, CHINA,*
[2]*Bivision Pharmaceuticals, Inc., Shanghai, CHINA.*

EP-0216

Nano Lights in Tumour Nights: Initial assessment of potent nanobodies targeting PD-L1

C. Donat[1], *H. Götzke*[2], *K. Kopka*[1,3], *S. Stadlbauer*[1,3];
[1]*Helmholtz Centre Dresden-Rossendorf, Dresden, GERMANY,*
[2]*NanoTag Biotechnologies GmbH, Göttingen, GERMANY,*
[3]*Technical University Dresden, Dresden, GERMANY.*

EP-0217

Dual-Tracer PET Imaging Combined with Flow Cytometry to Assess Early Immunotherapy Efficacy in Lung Cancer

R. Meng, *F. Kang;*
Military Medical University First Affiliated Hospital of No.4 Military Medical University, Shaanxi Xi'an, CHINA.

EP-0218

SSTR-targeted radiopharmaceutical therapy induces cellular senescence in neuroendocrine neoplasms: a translational study

N. Trautwein[1,2], *S. Mattern*[3], *O. Hihn*[2], *P. Krezer*[4], *E. Bag*[3], *M. Hinterleitner*[5], *G. Reischl*[2], *B. Weigelin*[2], *L. Zender*[5], *B. Pichler*[2], *C. la Fougère*[1], *S. Singer*[3], *J. Schwenck*[1,2];
[1]*Department of Nuclear Medicine and Clinical Molecular Imaging, Tübingen, GERMANY,*
[2]*Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Tübingen, GERMANY,*
[3]*Pathology Tübingen, Tübingen, GERMANY,*
[4]*Department of Diagnostic and Interventional Radiology, Tübingen, GERMANY,* [5]*, Department of Medical Oncology and Pneumology (Internal Medicine VIII), Tübingen, GERMANY.*

EP-0219

Alterations of functional connectivity after treatment with muscimol in the rat can be related to reductions of endogenous dopamine in neostriatum as well as limbic and auditory system

S. Nikolaus[1], *H. J. Wittsack*[1], *M. Beu*[1], *J. Henke*[1], *H. Hautzel*[2], *C. Antke*[1], *E. Mamlins*[1], *L. Abdel-Hafiz*[1], *B. Fazari*[1], *H. W. Müller*[1], *C. von Gall*[1], *G. Antoch*[1], *F. L. Giesel*[1];
[1]*University Hospital Düsseldorf, Düsseldorf, GERMANY,*
[2]*University Hospital Essen, Essen, GERMANY.*

EP-0220

Modulation of Tc-99m TRODAT Biodistribution by Moringa oleifera in Therapeutic and Preventive AIzheimer's DIsease mouse models

M. Othman[1], *W. Wan Kamal*[2], *N. Mokhtar*[3], *M. Hasan*[3], *Y. Yusof*[3], *S. Mohamad*[2], *A. Sued*[2], *S. Md Izah*[2], *Y. Ng*[2], *S. Muhamad*[2], *N. Mohd Kamil*[1], *G. Surindar Singh*[1], *M. Wan Chik*[1];
[1]*Universiti Teknologi MARA, Shah Alam, MALAYSIA,*
[2]*Malaysian Nuclear Agency, Bangi, MALAYSIA,*
[3]*Universiti Putra Malaysia, Serdang, MALAYSIA.*

EP-0221

Molecular imaging of microplastic and nanoplastic kinetics: evaluating systemic translocation and biological vulnerability through positron emission tomography

C. Ferreira[1,2];
[1]*Centre for Health and Life Sciences - Coventry University, Coventry, UNITED KINGDOM,*
[2]*NHS England, London, UNITED KINGDOM.*

EP-0222

Multiscale brain-wide mapping of α-synuclein-driven dopaminergic degeneration and white matter impairment in α-synucleinopathy mice

R. Ni[1], *S. Dong*[1], *B. Combes*[2], *L. Yang*[1], *K. Shi*[1], *A. Rominger*[1];
[1]*Inselspital, Bern, SWITZERLAND,*
[2]*University of Zurich, Zurich, SWITZERLAND.*

EP-0223

Targeting the Bone Microenvironment to Potentiate Bisphosphonate Radioligand Therapy in Lung Cancer Metastases

Z. Ruiyue[1], *Y. Deng*[1], *L. Zhu*[2], *H. F. Kung*[3], *X. Wang*[1];
[1]*The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CHINA,*
[2]*Beijing Normal University, Beijing, CHINA,*
[3]*University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.*

EP-13

B: Imaging Clinical Studies → B1 Oncological Imaging Clinical Study → B11 Central Nervous System

EP-0225

Evaluation of MRI-Independent Centiloid Quantification Methods: Comparison of syngo.PET and rPOP with the Standard MRI-Based Approach

P. Hu;
Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, CHINA.

EP-0226

Preoperative ^{68}Ga-DOTATOC PET/CT as a Potential Non-Invasive Predictor of DNA Methylation Classes in Intracranial Meningiomas - Preliminary Results of a Prospective Pilot Study

G. Schweighofer-Zwink[1], *M. Spendel*[2];
[1]*Universitätsklinik für Nuklearmedizin, Salzburg, AUSTRIA,*
[2]*Institut für Radioonkologie, Klagenfurt, AUSTRIA.*

EP-0227

Volumetric Analysis of Meningiomas on Ga-68 DOTA-TATE PET/CT: Segmentation Threshold Comparison with Contrast-Enhanced MRI and Agreement Analysis

E. Aslan[1], *N. Coşkun*[2], *T. Kaya*[3], *G. Ayberk*[4], *E. Özdemir*[2];
[1]*University of Health Sciences, Department of Nuclear Medicine, Ankara Bilkent City Hospital, Ankara, TÜRKIYE,*
[2]*Ankara Yildirim Beyazit University, Department of Nuclear Medicine, Ankara Bilkent City Hospital, Ankara, TÜRKIYE,*
[3]*Department of Radiology, Ankara Bilkent City Hospital, Ankara, TÜRKIYE,*
[4]*Ankara Yildirim Beyazit University Department of Neurosurgery, Ankara Bilkent City Hospital, Ankara, TÜRKIYE.*

EP-0228

Md

Z. Chen[1], *Z. Zeng*[2], *W. Miao*[1];
[1]*Department of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University, Fuzhou, CHINA,*
[2]*Department of Hematology, the First Affiliated Hospital, Fujian Medical University, Fuzhou, CHINA.*

EP-0229

Early-dominant TSR kinetics on dynamic ^{18}F-DOPA PET reveal a robust recurrence phenotype and enable simplified kinetic assessment

G. Sipka[1], *K. Apro*[1], *Z. Miko*[1], *B. Bardoczi*[1], *G. Kelemen*[2], *K. Hideghety*[2], *L. Pavics*[1], *A. Bakos*[1], *I. Farkas*[1], *Z. Besenyi*[1];
[1]*University of Szeged, Department of Nuclear Medicine and Theranostics, Szeged, HUNGARY,*
[2]*University of Szeged, Department of Oncotherapy, Szeged, HUNGARY.*

EP-0230

Preoperative SSTR PET Characteristics of Meningiomas: Association with Neuropathological Diagnosis & Molecular Profiles

T. Schabhüttl[1,2], *M. Mair*[1,2], *T. Greve*[3,4], *R. Stürzl*[1], *T. Eska*[5,6], *E. Barci*[1], *E. Istrefi*[1], *C. Schichor*[3], *A. Biczok*[7], *L. von Baumgarten*[3,8], *F. Ringel*[3], *R. Werner*[1], *M. Fabritius*[9], *F. Sahm*[10], *M. Preusser*[2], *P. Harter*[4,5,6], *N. Albert*[1,4,6];
[1]*Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY,*
[2]*Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, AUSTRIA,*
[3]*Department of Neurosurgery, LMU University Hospital, LMU Munich, Munich, GERMANY,*
[4]*Bavarian Cancer Research Center (BZKF), Munich, GERMANY,*
[5]*Center for Neuropathology and Prion Research, Institute of Neuropathology, Medical Faculty LMU University Hospital, LMU Munich, Munich, GERMANY,*
[6]*German Cancer Consortium (DKTK) partner site Munich, Germany and German Cancer Research Center (DKFZ), Heidelberg, GERMANY,*
[7]*Department of Neurosurgery, University Hospital Heidelberg, Heidelberg University, Heidelberg, GERMANY,*
[8]*Department of Neurology, LMU University Hospital, LMU Munich, Munich, GERMANY,*
[9]*Department of Radiology, LMU University Hospital, LMU Munich, Munich, GERMANY,*
[10]*Department of Neuropathology, University Hospital Heidelberg, Heidelberg, GERMANY.*

EP-0231

The Role of ^{18}F-DOPA PET/CT and SUVpeak in Differentiating Glioma Recurrence from Post-Treatment Changes

E. Valente, *G. Capriotti, A. Bozzao, A. Romano, T. Lanzolla, A. Festa, M. Pontico, L. Carideo, G. M. Granese, A. Ascolese, A. Signore;*
Sapienza University of Rome, Rome, ITALY.

EP-0232

Effects of Androgen Deprivation Therapy on Cerebral Glucose Metabolism in Prostate Cancer

X. Zhou;
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA.

EP-0233

Impact of Partial Volume Correction on Somatostatin Receptor PET Quantification in Meningioma: Method Comparison and Clinical Implications

J. Wang[1], *Y. Liu*[2], *Y. Kong*[3], *Y. Guan*[3], *K. Shi*[1], *G. S. P. Mok*[2], *Y. Ren*[4], *A. Rominger*[1], *R. Ni*[1,5];
[1]*Inselspital, University of Bern, Bern, SWITZERLAND,*
[2]*Biomedical Imaging Laboratory (BIG), Department of Electrical and Computer Engineering, Faculty of Science and Technology, University of Macau, Taipa, MACAO,*
[3]*PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA,*
[4]*Department of Radiology, Huashan Hospital, Fudan University, Shanghai, CHINA,*
[5]*Institute for Biomedical Engineering, ETH Zurich and University of Zurich, Zurich, SWITZERLAND.*

EP-0234

Dynamic ^{18}F-fluciclovine PET demonstrates tracer uptake in sub-cm brain metastases: a time-activity curve analysis

T. Buehner[1], *K. Rayasam*[2], *B. Stea*[3], *C. C. Hsu*[3], *H. Ozgur*[2], *J. Juganaru*[1], *B. Savir-Baruch*[1];
[1]*Division of Nuclear Medicine and Theranostics, Department of Radiology and Imaging Sciences, University of Arizona, Tucson, AZ, UNITED STATES OF AMERICA,*
[2]*Division of Neuroradiology, Department of Radiology & Imaging Sciences, University of Arizona, Tucson, AZ, UNITED STATES OF AMERICA,*
[3]*Department of Radiation Oncology, University of Arizona, Tucson, AZ, UNITED STATES OF AMERICA.*

EP-0235

Metabolic Semiotics with [^{18}F]F-FDG PET/TC in the Characterisation of Space-Occupying Lesions of the Brain

A. Bagán-Trejo[1], *M. Suárez-Piñera*[1], *J. Díaz-Moreno*[1], *M. Pudis*[1], *L. Rodríguez-Bel*[1], *C. Salomón*[1], *N. Vidal-Sarro*[2], *C. Martínez-Ramos*[1], *A. Rosselló-Gómez*[3], *A. Fernández-Coello*[3], *M. Zamorano-Rivas*[1], *C. García-Alcober*[4], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine-PET (IDI) Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN,*
[2]*Pathology Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN,*
[3]*Neurosurgery Department, Hospital Universitari de Bellvitge, Barcelona, SPAIN,*
[4]*Radiopharmacy Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN.*

EP-0236

First-in-Human Application of ^{99}mTc-CN7DG Quantitative SPECT/CT in Central nervous system Tumours: A prospective study

J. Wang[1], *C. Zhou*[1], *J. Ye*[1], *F. Kang*[1], *J. Zhang*[2], *G. Li*[1], *J. Wang*[1];
[1]*Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, CHINA,*
[2]*Key Laboratory of Radiopharmaceuticals of Ministry of Education;*
NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration);
College of Chemistry, Beijing Normal University, Beijing, CHINA.

EP-0237

CNS_MIND Study: Central Nervous System Tumour Metabolic Imaging using Novel Radiomics for Differentiation

S. Hebsur, *V. Rangarajan, I. Dev, A. Jha, N. Purandare, S. Shah, A. Puranik, A. Agrawal, S. Choudhury, S. Ghosh, M. Venkatachalam;*
Tata Memorial Centre, Mumbai, INDIA.

EP-0238

Impact of MR-Guided TOF-BSREM on Image Quality and Quantitative Parameters in [^{18}F]Fluciclovine PET/MRI for Glioblastoma

M. Nogami[1,2], *N. Sugiyama*[3], *J. I. Inukai*[3], *F. Zeng*[3], *M. G. Spangler-Bickell*[4], *T. Kurimoto*[5], *K. Kubo*[1], *K. Ishii*[3], *Y. Kiyono*[2], *T. Murakami*[3,1];
[1]*Department of Radiology, Kobe University Hospital, Kobe, JAPAN,*
[2]*Biomedical Imaging Research Center, University of Fukui, Fukui, JAPAN,*
[3]*Department of Radiology, Kobe University Graduate School of Medicine, Kobe, JAPAN,*
[4]*GE HealthCare, Waukesha, WI, UNITED STATES OF AMERICA,*
[5]*GE HealthCare, HIno, JAPAN.*

EP-0239

Machine learning-based ^{18}F-FET PET radiomics for differentiating glioma recurrence from treatment-related changes: a preliminary cross-validation study

W. Zhou, *J. Dai, Y. Guo, H. Ye;*
The Affiliated Cancer Hospital of Xiangya School of Medicine/Hunan Cancer Hospital, Central South Un, Changsha, CHINA.

EP-0240

Kinetic Analysis of Dynamic [^{18}F]FET LAFOV PET Differentiates Glioma Recurrence from Treatment-Related Changes

A. Lazar[1,2], *M. Amon*[2], *C. Mingels*[2], *J. Penner*[2], *K. Krieger*[2], *A. Chiti*[1,3], *P. Cumming*[2,4], *K. Shi*[2], *P. Radojewski*[5], *A. Rominger*[2], *T. Pyka*[2,6], *H. Sari*[2,7];
[1]*Vita-Salute San Raffaele University, Milan, ITALY,*
[2]*Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND,*
[3]*Department of Nuclear Medicine, IRCCS San Raffaele Hospital, Milan, ITALY,*
[4]*School of Psychology and Counselling, Queensland University of Technology, Brisbane, AUSTRALIA,*
[5]*University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND,*
[6]*TUM School of Medicine and Health, Munich, GERMANY,*
[7]*Siemens Healthineers International AG, Zurich, SWITZERLAND.*

EP-0241

MET-PET-defined metabolic habitats improve IDH mutation discrimination using quantitative synthetic MRI in diffuse gliomas

M. Kusunoki, *T. Isoda, K. Yamashita, K. Kikuchi, Y. Kitamura, D. Momosaka, M. Sando, S. Baba, K. Ishigami;*
Kyushu University, Fukuoka, JAPAN.

EP-0242

Volumetric Comparison of Contrast-Enhanced MRI, ^{11}C-Methionine PET, and ^{11}C-Methylleucine PET in Patients with Glioblastoma

Y. Manabe, *Y. Yamamoto, K. Mitamura, M. Tatano, N. Kudomi, M. Murao, T. Norikane, Y. Nishiyama;*
Kagawa university, Kita-gun, Kagawa, JAPAN.

EP-14

B: Imaging Clinical Studies → B1 Oncological Imaging Clinical Study → B12 Head and Neck

EP-0243

Accessory Parotid Salivary Glands on [^{68}Ga] Ga-PSMA-11 PET/CT: Prevalence and Clinical Imaging Characteristics

J. Stepien-Dziekan[1], *A. Iskandar*[1], *K. Rydsik*[2], *J. Kunikowska*[1];
[1]*Medical University of Warsaw, Warsaw, POLAND,*
[2]*UCK Medical University of Warsaw, Warsaw, POLAND.*

EP-0244

AI-Based PET/CT Analysis of Radiation-Associated Increase in Esophageal FDG Uptake Following Head and Neck Cancer Therapy

S. Mammen, *O. Fanta, A. Kim, D. Patel, A. Dejesusgarcia, J. Cruz, T. Werner, A. Alavi;*
Department of Radiology, Hospital of The University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.

EP-0245

Usefulness of [^{18}F]FDG PET/CT scan in laryngeal cancer (A Study of 80 Cases)

O. Zakaria, *G. Abdelamid, M. Ahmed, G. Amal;*
Department of Nuclear Medicine, CHU Ibn Rochd, Casablanca, MOROCCO.

EP-0246

Incremental Value of Post-Treatment FDG PET/CT Radiomic Features over Hopkins Score for Predicting Locoregional Recurrence in Head and Neck Cancer: A Prospective Study

S. C O, *S. H V, V. Pillai;*
Narayana Health, Bangalore, INDIA.

EP-0247

Role of PET-CT in the Staging of undifferentiated carcinoma of the nasopharynx (A Study of 70 Cases)

O. Zakaria, *G. Abdelamid, B. Halima, G. Amal;*
Department of Nuclear Medicine, CHU Ibn Rochd, Casablanca, MOROCCO.

EP-0248

Head-to-Head Comparison of ^{18}F-PSMA and ^{18}F-FDG PET/CT for Detecting Postoperative Residual Tumours in Head and Neck Adenoid Cystic Carcinoma

C. Ren;
Shanghai Proton and Heavy Ion Center, Shanghai, CHINA.

EP-0249

^{68}Ga-FAPI-04 PET/CT Predicts Pathological Response of Cervical Nodal Metastases to Neoadjuvant Chemoimmunotherapy in Locally Advanced Oral SCC

Y. Jiang, *H. Geng, Y. He;*
Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, CHINA.

EP-0250

Prognostic Value of ^{18}F-FDG-PET Metrics, Including Lean Body Mass-Normalized SUL, in Head and Neck Cancer

A. Doma[1], *T. Škerl*[1], *A. Studen*[2], *P. Strojan*[1];
[1]*Oncology institute, Ljubljana, SLOVENIA,*
[2]*Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana, SLOVENIA.*

EP-0251

AI Assessment of Common Carotid Artery ^{18}F-FDG Uptake Before and After Radiotherapy in Head and Neck Cancer Patients

O. Fanta[1], *S. Mammen*[1], *A. DeJesus Garcia*[1], *J. M. Cruz*[1], *A. Kim*[1,2], *D. Patel*[1,2], *W. Lee*[1,3], *T. Werner*[1], *A. Alavi*[1];
[1]*University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA,*
[2]*Thomas Jefferson University, Philadelphia, PA, UNITED STATES OF AMERICA,*
[3]*Drexel University, Philadelphia, PA, UNITED STATES OF AMERICA.*

EP-0252

Evaluation of Treatment Response in Oropharyngeal Squamous Cell Carcinoma with [^{18}F]-FDG PET/CT

A. Grozea[1], *D. Craciun*[1], *A. Atanase*[1], *C. Mazilu*[1], *R. Mititelu*[1,2];
[1]*Nuclear Medicine Department, Central Universitary Emergency Military Hospital, Bucharest, ROMANIA,*
[2]*University of Medicine and Pharmacy Dr Carol Davila, Bucharest, ROMANIA.*

EP-0253

Baseline ^{18}F-NaF PET/CT and SSTR2/FAP immunophenotype predict early post-radiotherapy response in nasopharyngeal carcinoma: a single-centre retrospective translational study

Q. Jie[1], *W. Fu*[2];
[1]*Guilin Medical University, GuiLin, Guangxi, CHINA,*
[2]*Department of Nuclear Medicine, Affiliated Hospital of Guilin Medical College, Guilin City, CHINA.*

EP-0254

Differential Diagnosis of Synchronous Lung Malignancies in Head and Neck Cancers Using FDG PET/CT Imaging

B. Bozca, *A. Erdem Karaoglu, D. Cayir, E. Tatci, O. Ozmen;*
Etlik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-0255

Comparison of Nodal Maximal and Peak SUV on FDG PET/CT in Predicting Recurrence in Patients with Oral Cancer.

D. Yu[1], *S. Hung*[1], *W. Hsu*[1], *I. Chang*[2];
[1]*Mennonite Christian Hospital, Hualien city, TAIWAN, PROVINCE OF CHINA,*
[2]*National Dong Hwa University, Hualien city, TAIWAN, PROVINCE OF CHINA.*

EP-0256

Correlation of metabolic parameters ^{18}F-FDG PET/CT & Tc-99m salivary scintigraphy with extent of xerostomia in head-neck cancer patients undergoing definitive radiotherapy.

S. Mali[1], *V. Rangarajan*[1], *I. Dev*[2], *A. Agrawa*[2], *S. Laskar*[1], *N. Purandare*[1], *S. Shah*[1], *A. Puranik*[1], *S. Choudhury*[2], *M. M. V.*[2], *S. Ghosh*[2];
[1]*TATA Memorial Hospital, Homi Bhabha National Institute, Mumbai, INDIA,*
[2]*Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Navi-Mumbai, INDIA.*

EP-0257

Concordance analysis between contrast-enhanced [^{18}F]F-FDG PET/CT and diagnostic CT, and its impact on staging and radiotherapy planning in head and neck cancer.

A. Suazo Montero, *L. Rubiano González, R. Zambrano Infantino, B. Jaramillo López, P. Negrete Montiel, N. Álvarez Mena, L. Gómez Heras, J. Gómez Hidalgo, R. Ruano Pérez;*
Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

EP-0258

Prognostic metabolic parameters from [^{18}F]F-FDG PET/CT in radiotherapy planning for head and neck cancer: relationship with clinical stage and therapeutic dose escalation.

A. Suazo Montero, *L. Rubiano González, P. Negrete Montiel, B. Jaramillo López, R. Zambrano Infantino, N. Álvarez Mena, L. Gómez Heras, F. Sebastián Palacid, R. Ruano Pérez;*
Hospital Universitario Valladolid, Valladolid, SPAIN.

EP-0259

Role of the SPECT/CT with ^{99}mTc-sestamibi in the localization of ectopic parathyroid tissue in persistent primary hyperparathyroidism: a case with inconclusive conventional imaging

G. dos Santos[1,2], *M. Díaz*[1], *E. Silvera*[1], *O. Alonso Nuñez*[1,2];
[1]*Hospital de Clinicas "Dr. Manuel Quintela", Montevideo, URUGUAY,*
[2]*CUDIM -Uruguayan Centre of Molecular Imaging, Montevideo, URUGUAY.*

EP-15

B: Imaging Clinical Studies → B1 Oncological Imaging Clinical Study → B13 Breast

EP-0260

Clinical Translation of a TROP2-Targeted Peptide PET Radiotracer [68Ga]Ga-DOTA-TTP for the Imaging of Primary Breast Cancers and Lymph Nodes Metastases

Y. Pei, *X. Guo, Z. Yang;*
Peking University Cancer Hospital & Institute, Department of Nuclear Medicine, Beijing, CHINA.

EP-0261

HER2-Ex PET trial:A multicentre, prospective, open-label study using [68Ga]Ga-ABY-025 PET-imaging to characterize HER2-expression and explore the therapy-predictive value for HER2antibody-drug conjugates in patients with metastatic breast cancer.

A. Kistner[1], *O. Wiklander*[1], *N. Susaeg Romdhani*[1], *D. Truong*[1], *M. Klintman*[2], *I. Skarping*[2], *H. Lindman*[3], *V. Sanchez Rodriguez*[3], *O. Frisell*[1], *P. Lindgren*[1], *K. Bratteby*[1], *E. Jussing*[1], *J. Feldwisch*[3], *F. Frejd*[3], *H. Silva Cascales*[1], *J. Siikanen*[1], *C. Hindorf*[1], *T. Tran*[1], *R. Altena*[1];
[1]*Karolinska Institutet, Stockholm, SWEDEN,*
[2]*Lund University, Lund, SWEDEN,*
[3]*Uppsala University, Uppsala, SWEDEN.*

EP-0262

Prognostic Role of Baseline FDG PET/CT Parameters and the Contribution of the Novel Parameter Dmax in Metastatic Breast Cancer

E. Çeliker[1], *M. Samsum*[2], *E. Tatcı*[1], *Ö. Korkmaz*[1], *H. Şahinli*[1], *Ö. Özmen*[1];
[1]*Etlik City Hospital, Ankara, TÜRKIYE,*
[2]*Etlik Şehir Hastanesi, Ankara, TÜRKIYE.*

EP-0263

Head-to-Head Comparison of [18F]FDG and [18F]FES PET/CT for Staging Newly Diagnosed ER-Positive Breast Cancer

Y. Zhang, *H. Ye, J. Yang, X. Peng;*
Hunan Cancer Hospital, Changsha, CHINA.

EP-0264

Complementary role and proposed appropriate use criteria of using 18F-FES PET CT and 18F-FDG PET CT in clinical management od estrogen receptor positive breast cancer

P. Choudhury, *S. Chowdhury, R. Kumar, M. Gupta;*
Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, INDIA.

EP-0265

The role of 18F-FDG PET/MRI texture features in predicting axillary metastasis in breast cancer staging

S. Küçükali, *S. Gülbahar Ateş, U. Aydos, N. İlgin Karabacak;*
Gazi University, Ankara, TÜRKIYE.

EP-0266

Imaging biomarkers and radiomic features associated with tumor aggressiveness using 18F-FDG PET/MR in breast cancer staging

L. Pinilla, *J. García, J. Urcia, A. Compte, N. Garrido, L. Mont-Castro, S. Tovar, D. Tovar, E. Valls, E. Riera;*
ASCIRES Cetir, Barcelona, SPAIN.

EP-0267

Impact of 68Ga-FAPI PET/CT on Staging and Management of Invasive Lobular Breast Cancer: A Prospective Comparative Study with 18F-FDG PET

K. Al Riyami, *S. Usmani, A. Al Busaidi, A. Jain, A. Ismailia, A. Trehan, A. Al Jarrah, K. Al Baimani, R. Al Sukaiti;*
Sultan Qaboos Comprehensive Cancer Care and Research Centre, University Medical City, Muscat, OMAN.

EP-0268

Characterization of Perfusion and Metabolic Profile of HER2-low Breast Cancer, Using Dynamic First-pass 18F-FDG PET/CT

L. Morin[1], *N. Payan*[1,2], *J. Vrigneaud*[1,2], *B. Presles*[3,2], *L. Arnould*[1], *S. Ladoire*[1], *A. Cochet*[1];
[1]*Centre Georges François Leclerc, Dijon, FRANCE,*
[2]*ICMUB CNRS 6302, Dijon, FRANCE,*
[3]*Université Bourgogne Europe, Dijon, FRANCE.*

EP-0269

Tumour asphericity on baseline 18F-FDG PET/CT adds incremental value for metastatic risk and outcome stratification in breast carcinoma

N. Gupta, *A. Rana;*
Dr Rajendra Prasad Government medical college Kangra Himachal Pradesh India, Kangra, INDIA.

EP-0270

Prognostic Value of Body Composition and Sarcopenic Obesity in Predicting Treatment Response in Metastatic Breast Cancer Patients Receiving CDK4/6 Inhibitors

U. Balaman, *G. Mütevelizade, F. Ekinci, N. Kolkıran, E. Bilgin;Celal Bayar Üniversitesi Hafsa Sultan Hastanesi, Manisa, TÜRKIYE.*

EP-0271

Prognostic Value of Compartment-Specific Baseline 18F-FDG PET/CT Parameters in De Novo Metastatic HR+/HER2− Breast Cancer

A. Agartioglu[1], *A. Aksu*[1], *Z. G. Güç*[2], *K. A. Küçüker*[1], *A. Özdal*[1], *A. Alacacıoğlu*[2], *B. Turgut*[1];
[1]*Izmir Katip Celebi University, Faculty of Medicine, Department of Nuclear Medicine, Izmir, TÜRKIYE,*
[2]*Izmir Katip Celebi University, Faculty of Medicine, Department of Medical Oncology, Izmir, TÜRKIYE.*

EP-0272

Intraoperative FDGPET/CT imaging for breast cancer with a high resolution mobile PET/CT-camera for surgical specimens

B. Lambert[1], ***V. Vergucht***[2], *T. Van Oostveldt*[2], *A. De Craene*[2], *H. De Mulder*[2], *C. Van Haverbeke*[2], *B. Van Den Bossche*[1], *J. Mertens*[1], *D. Berwouts*[1], *K. De Caestecker*[2];
[1]*Maria Middelares Hospital - Jan Palfijn Hospital, Gent, Gent, BELGIUM,*
[2]*Maria Middelares Hospital, Gent, BELGIUM.*

EP-0273

Predictive Value of [18F]AIF-HER2-BCH Molecular Imaging in Patients with Advanced HER2-Low Breast Cancer Treated with Trastuzumab Deruxtecan (T-DXd): A Phase II Clinical Trial

X. Guo, *X. Meng, G. Song, X. Liang, H. Zhu, Z. Yang;*
Beijing Institute For Cancer Research, Beijing, CHINA.

EP-0274

Imaging Findings of Tumor-Infiltrating Lymphocytes (TIL), Stroma, and Necrosis: The Relationship Between 18F-FDG PET/CT and Histopathology in Breast Cancer

D. Nak[1], *O. BÜLBÜL*[2], *Ç. ÖZTÜRK*[1], *O. Okçu*[1];
[1]*Recep Tayyip Erdogan University Training and Research Hospital, Rize, TÜRKIYE,*
[2]*Erciyes University Medical Faculty, Kayseri, TÜRKIYE.*

EP-0275

Baseline brain [18F]FDG metabolic activity predicts overall survival in breast cancer, with particular strength in the HER2-enriched subtype

B. Canitez, *M. T. Tatoglu;*
Göztepe Prof. Dr. Süleyman Yalçin City Hospital, Istanbul, TÜRKIYE.

EP-0276

The Value of Preoperative Staging F-18 FDG PET/CT Primary Tumor Metabolic Parameters in Predicting Axillary Lymph Node Metastasis and Pathologic Stage in Breast Cancer Patients

A. Bas, *S. Ceylan, S. Demirtaş, B. B. Demirel, G. Uçmak;*
Ankara Dr. Abdurrahman Yurtaslan Onkoloji Eğitim ve Araştırma Hastanesi, Ankara, TÜRKIYE.

EP-0277

Prospective paired imaging of poly(adenosine diphosphate-ribose) polymerase expression and tumour metabolism in triple-negative breast cancer

J. Kabunda[1,2], *H. Ndlovu*[1,2], *I. O. Lawal*[2,3], *R. R. Moholisa*[1,2], *C. Davis*[1,2], *L. Smith*[1,2], *Y. V. Mzizi*[1,2], *K. Singh*[4], *F. Holst*[5], *W. Mhlongo*[6], *J. van Tonder*[7], *S. Du Plessis*[8], *K. M. G. Mokoala*[1,2], *M. M. Sathekge*[1,2];
[1]*Nuclear Medicine Research Infrastructure (NuMeRI), Pretoria, SOUTH AFRICA,*
[2]*Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA,*
[3]*Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, UNITED STATES OF AMERICA,*
[4]*Department of Medical Oncology, Witwatersrand University & Chris Hani Baragwanath Hospital, Johannesburg, SOUTH AFRICA,*
[5]*Department of General Surgery, University of Pretoria & Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA,*
[6]*Department of Medical Oncology, Rob Ferreira Hospital, Mpumalanga, SOUTH AFRICA,*
[7]*PETLABS Pty Ltd, Pretoria, SOUTH AFRICA,*
[8]*NTP Radioisotopes SOC Ltd, Hartbeespoort, SOUTH AFRICA.*

EP-0278

Decoding Mixed Response: Partition-Based hTepe Scoring Identifies Persistent High-Burden Disease on FDG PET/CT in Skeletal-Predominant Metastatic Breast Cancer

G. Kaya[1], *Y. Eryılmaz*[2], *A. Aydın*[2], *S. Aksoy*[3], *P. Kıratlı*[2], *Ö. Uğur*[2];
[1]*Republic of Türkiye, Ministry of Health, Yozgat City Hospital and Hacettepe Faculty of Medicine Depts. of Nuclear Medicine, Ankara, TÜRKIYE,*
[2]*Hacettepe University Faculty of Medicine, Department of Nuclear Medicine, Ankara, TÜRKIYE,*
[3]*Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKIYE.*

EP-0279

68Ga-FAPI PET/CT Reveals Clinically Relevant Metastatic Disease Missed by18F-FDG PET/CT in Invasive Lobular Breast Carcinoma: A Histologically Confirmed Upstaging Case

A. Mukhay[1,2,3], *G. Alisherov*[1], *E. Igenbayev*[1], *A. Yerezhep*[1], *U. Elboga*[3], *Y. Dauytova*[2], *Z. Zholdybay*[2], *Z. Zhakenova*[2];
[1]*HiLife PET/CT Diagnostic Center, Almaty, KAZAKHSTAN,*
[2]*Asfendiyarov Kazakh National Medical University, Almaty, KAZAKHSTAN,*
[3]*Gaziantep University, Department of Nuclear Medicine, Gaziantep, TÜRKIYE.*

EP-0280

HER2-Targeted PET/CT Identifies HER2 Conversion and Influences Treatment Management in Breast Cancer

F. Novruzov[1], *E. Mehdi*[1], *N. Aliyeva*[1], *E. Mammadov*[2], *R. Hasanov*[3], *N. Orujova*[1], *E. Kazimov*[4], *G. Bolland*[5], *S. Rahimzade*[6], *J. Aliyev*[7];
[1]*Department of Nuclear Medicine, The National Centre of Oncology, Baku, AZERBAIJAN,*
[2]*Department of Medical Oncology, Liv Bonadea Hospital, Baku, AZERBAIJAN,*
[3]*Department of Medical Oncology, Hisar Intercontinental Hospital, Istanbul, TÜRKIYE,*
[4]*Department of Medical Oncology, The National Centre of Oncology, Baku, AZERBAIJAN,*
[5]*Abscint Precision Imaging, Liege, BELGIUM,*
[6]*Department of Women Health, The National Centre of Oncology, Baku, AZERBAIJAN,*
[7]*Department of General Surgery, The National Centre of Oncology, Baku, AZERBAIJAN.*

EP-0281

Image-Based Body Composition Analysis Reveals BMI-Muscle Discordance

M. Rusticali[1], *L. Förner*[2,1], *K. Tehlan*[2,1], *N. Ditsch*[2], *C. Lapa*[2], *T. Wendler*[2,1];
[1]*Technical University of Munich, Munich, GERMANY,*
[2]*Universitätsklinikum Augsburg, Augsburg, GERMANY.*

EP-0282

18F-FDG PET/CT In Male Breast Cancer: Metastatic Patterns And Clinical Impact

R. Bouchikhi, *Y. Lasry, A. Bakraoui, A. Adjal, Y. Moustapha, A. Benlemlih, A. Msoune, M. Ahmed, A. Gbadamassi, Z. Ouassafrar, A. Guensi;*
Ibn Roch University Hospital, Casablanca, MOROCCO.

EP-0283

Diagnostic performance of 3-min versus 10-min [18F]FES PET/MRI for axillary lymph node metastasis in ER-positive breast cancer

Y. Kitano[1,2], *K. Miyake*[3], *M. Watanabe*[1], *K. Itagaki*[4], *Y. Shimizu*[1], *M. Kawashima*[5], *S. Yasumura*[1], *M. Kataoka*[6], *Y. Takeuchi*[7], *N. Masuda*[5], *Y. Nakamoto*[1];
[1]*Department of Diagnostic Imaging and Nuclear*

Medicine, Kyoto University Hospital, Kyoto, JAPAN,
[2]Department of Diagnostic Radiology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, JAPAN,
[3]Department of Advanced Medical Imaging Research, Kyoto University Hospital, Kyoto, JAPAN,
[4]Department of Radiology, Kyoto University Hospital, Kyoto, JAPAN,
[5]Department of Breast Surgery, Kyoto University Hospital, Kyoto, JAPAN,
[6]Preemptive Medicine and Lifestyle-related Disease Research Center, Kyoto University Hospital, Kyoto, JAPAN,
[7]Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, JAPAN.

EP-0284

The clinical application of FDG PET/CT scan in female breast cancer patients institutional experience, Royal hospital

***S. Al hatmi**, Z. Al bimani, N. Al Balushi, H. Mohammed;*
Royal hospital, Muscat, OMAN.

EP-0285

Determining the Diagnostic Advantages of Hybrid SPECT/CT Compared to Bone Scintigraphy in Breast Cancer

***P. Korol**[1], O. Shcherbina[1], V. Ivchuk[1], M. Ivakh[1], M. Firsova[1], M. Kostylev[2];*
[1]Shupik National University Healthcare of Ukraine, Kyiv, UKRAINE,
[2]Shalimov National Scientific Center of Surgery and Transplantation, Kyiv, UKRAINE.

EP-0286

Comparative Evaluation of ^{68}Ga-FAPI PET/MR and ^{18}F-FDG PET/CT Across Breast Cancer Molecular Subtypes and Their Predictive Value for Neoadjuvant Therapy Response

***Y. Zhou**, Y. Hou, X. Xia;*
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Scien, Hubei, CHINA.

EP-0287

Prediction of Pathological Complete Response After Neoadjuvant Therapy in Breast Cancer Using ^{18}F-FDG PET/MR-Based Liver and Bone Marrow Organomics Analysis

***M. Bozyigit**, S. Gülbahar Ateş, U. Aydos, L. Ö. Atay;*
Gazi University Faculty of Medicine, Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-0288

An Open-Label, Single-Arm, Single-Dose, Prospective, Single Center Pilot Study to Assess the Clinical Utility of PSMA PET/CT for Invasive Lobular Breast Cancer

***Y. LU**, B. B. Briones, A. Lo;*
The University of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

EP-0289

Clinical Value of F-18 FDG PET/CT for Nodal Staging and Tumor Characterization According to Molecular Subtypes in Male Breast Cancer

***S. Kim**[1], W. Kang[2];*
[1]Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, KOREA, REPUBLIC OF,
[2]Severance Hospital, Seoul, KOREA, REPUBLIC OF.

EP-0290

Predictive and Prognostic Evaluation of Neutrophil-to-Lymphocyte Ratio and Metabolic PET Parameters in HER2-Positive Breast Cancer Undergoing Neoadjuvant Chemotherapy

***S. Damiani**[1], U. C. Riva[1], P. Guglielmo[2,3], G. Saltalamacchia[4], M. Rodari[5], G. Mansi[1], L. Evangelista[2,5];*
[1]Humanitas University, via Rita Levi Montalcini [4], 20072 Pieve Emanuele, Milan, ITALY,
[2]Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini [4], 20072 Pieve Emanuele, Milan, ITALY,
[3]Nuclear Medicine Unit, Humanitas Gavazzeni, via Mauro Gavazzeni 21, 24125, Bergamo, ITALY,
[4]Oncology Unit, IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, ITALY,
[5]Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, ITALY.

EP-0291

Dual-Tracer ^{18}F-FDG and ^{18}F-PSMA PET/CT in Triple-Negative Breast Cancer: A Prospective Pilot Study Exploring Uptake Patterns and Theranostic Implications

***M. Mehesen**[1], R. Shera[1], D. Deif[1], T. ElMaghraby[2];*
[1]National Cancer Institute, Cairo university, Cairo, EGYPT,
[2]Faculty of medicine, Cairo university, Cairo, EGYPT.

EP-0292

Impact of ^{18}F-Fluoroestradiol Positron Emission Tomography on clinical management of estrogen receptor positive breast cancer: A Preliminary Single-Center Retrospective Review of Clinical Outcomes

***H. Patel**, T. Khessib, J. Shah;*
Stanford University, Palo Alto, CA, UNITED STATES OF AMERICA.

EP-0293

Dual Time-Point [^{18}F]FDG PET/CT as a Predictor of Neoadjuvant Chemoimmunotherapy Response in Early TNBC

***R. Seban**[1], E. Bourichon[2], E. Lévêque[3], M. Leheurteur[2], N. Olympios-Gerotzortsoz[2], F. Clatot[2], N. Deleval[1], P. Cottu[4], L. Cabel[4], L. Djerroudi[5], V. Huchet[6], A. Edet-Sanson[7], C. Landoulsi[7], D. Tonnelet[7], C. Luo[1];*
[1]Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, Saint-Cloud, FRANCE,
[2]Department of Medical Oncology, Centre Henri Becquerel, Rouen, FRANCE,
[3]Unit of Clinical Research, Centre Henri Becquerel, Rouen, FRANCE,
[4]Department of Medical Oncology, Institut Curie, Paris, FRANCE,
[5]Department of Pathology, Institut Curie, Paris, FRANCE,
[6]Department of Nuclear Medicine, Institut Curie, Paris, FRANCE,
[7]Department of Nuclear Medicine, Centre Henri Becquerel, Rouen, FRANCE.

EP-0294

Preliminary results of a prospective pilot study (EXIGENCE), assessing imaging performance of [^{68}Ga]Ga-PentixaFor PET-CT in metastatic triple negative breast cancer patients

***C. Rousseau**[1], L. Ferrer[1], M. F. Heymann[2], M. Robert[3], C. Gourmelon[3], S. Miet[3], M. Taupin[4], M. Maajem[3], A. Morel[3], J. S. Frenel[1], M. Campone[1], N. Allam[3], L. Campion[1], F. Kraeber-Bodere[5];*
[1]ICO, F-44805 Saint-Herblain; Nantes University, Univ Angers, CNRS, Inserm, CRCI2NA, F-44000 NANTES, St Herblain, FRANCE,
[2]ICO, F-44805 Saint-Herblain; Nantes Université, CNRS, URM6286, US2B, F-44322, St Herblain, FRANCE,
[3]ICO, F-44805, St Herblain, FRANCE,
[4]ICO, Research pathology platform F-44805, St Herblain, FRANCE,
[5]Nantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, F-44000, NANTES, FRANCE.

EP-0295

Comparison of Diagnostic Performances of Dedicated Breast PET and Whole-Body PET-based Radiomics Analysis for Prediction of Pathological Complete Response After Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

***C.Rren**;*
Shanghai Proton and Heavy Ion Center, Shanghai, CHINA.

EP-0296

^{18}F-FDG PET/CT in Male Breast Cancer: Diagnostic and Prognostic Value of Volumetric Metabolic Parameters

***A. B. Özden**, G. Koca, K. Demirel, M. Korkmaz;*
Ankara, Ankara, TÜRKIYE.

EP-0297

^{18}F FDG PET-CT as an Early Prognosticator of Response to Treatment: Monitoring Hormone Receptor-Positive Breast Cancer Under CDK4/6 Inhibitor Treatment with Serial Imaging

***F. Alorfi**, Z. Haq, D. Priftakis, S. Voo, K. De Souza, Y. Mathur;*
UCLH, London, UNITED KINGDOM.

EP-0298

Long-term intraoperative detectability of I-125 seeds implanted in breast cancer patients prior to neoadjuvant chemotherapy.

***A. Minguillán Van Kapel**[1,2], J. Ribera-Perianes[2], J. Reyes-Lujan[1], X. Cases Moreno[3], M. Vega Álvarez[1], J. Cordón del Pozo[2], E. Agustí[2], M. Esteban[2], M. Macedo[2,4], X. Bargalló[2], S. Vidal-Sicart[2,5];*
[1]Hospital Gómez Ulla, Madrid, SPAIN,
[2]Hospital Clínic Barcelona, Barcelona, SPAIN,
[3]Hospital Clínic Barcelona, Madrid, SPAIN,
[4]Hospital Sant Pau, Barcelona, SPAIN, [54].Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SPAIN.

EP-0299

Molecular imaging with the innovative PET-tracer ^{68}Ga-ABS011 in HER2-low metastatic breast and gynaecological cancer

***L. Rossetti**[1], E. Sporer[1], C. Rangger[1], K. Merther[1], L. Wirth[1], C. Brunner[2], D. Egle[2], C. Marth[2], C. Decristoforo[1], I. Virgolini[1];*
[1]Department of Nuclear Medicine, Medical University of Innsbruck, AUSTRIA,
[2]Department of Gynaecology, Medical University of Innsbruck, AUSTRIA.

EP-0300

Somatostatin Receptor imaging in Breast Cancer: Comparative Analysis of [^{68}Ga]Ga-DOTATOC, [^{68}Ga]Ga-SSO120 and [^{18}F]FDG with Theranostic Implications

***A. Küper**[1], L. Shiyam Sundar[2], L. Djaileb[3], J. Roschlak[1], K. Pabst[1], I. Ciuciulkaite[1], S. C. Vaz[4], A. Welt[5], N. Hammersen[1], M. Nader[1], L. Umutlu[6], M. Schuler[5], K. Herrmann[1], W. P. Fendler[1], S. Kümmel[7], D. Kersting[1];*
[1]Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY,
[2]Department of Radiology, LMU University Hospital, München, GERMANY,
[3]LRB, Nuclear Medicine Department, CHU Grenoble Alpes, INSERM, Université Grenoble Alpes, Grenoble, FRANCE,
[4]Department of Nuclear Medicine and Radiopharmacology, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, PORTUGAL,
[5]Department of Oncology, University Hospital Essen, Essen, GERMANY,
[6]Department of Radiology, University Hospital Essen, Essen, GERMANY,
[7]Breast Unit Essen, Kliniken Essen-Mitte, Essen, GERMANY.

EP-0301

Association between ESR1 gene mutation and18F-FES PET uptake in ER-positive breast cancer

***Y. Hoda**[1,2], T. Yamane[1], M. Senda[1], M. Tokiwa[3], S. Takebe[3], N. Odan[3], Y. Oyama[3], E. Suzuki[3];*
[1]Department of Molecular Imaging Research, Kobe City Medical Center General Hospital, Kobe, JAPAN,
[2]Department of Diagnostic and Interventional Radiology, Nara Medical University, Kashihara, JAPAN,
[3]Department of Breast Surgery, Kobe City Medical Center General Hospital, Kobe, JAPAN.

EP-0302

Utility of metabolic parameters from initial ^{18}F-FDG PET/CT in breast cancer and their correlation with tumour histology

***S. Rama Alonso**, E. Casillas Sagrado, F. Gómez-Caminero López, F. Caltagirone Gutiérrez, B. Santos García, F. Ulloa Mejía, M. Fernández Arteaga, J. Valarezo Jimenez, J. Cañadas Salazar, L. Díaz González, J. Badell Martínez, P. García-Talavera San Miguel, A. Peñaherrera Cepeda, J. Villanueva Curto, E. Martín Gómez, P. Tamayo Alonso;*
Salamanca University Hospital, Salamanca, SPAIN.

EP-0303

Prognostic value of ^{18}F-FDG PET/CT metabolic parameters in patients with metastatic breast cancer treated with CDK4/6 inhibitors

***M. Estrella Caballero**, A. Prieto, M. Izquierdo Chamarro, M. Díez De Los Ríos Riobó, B. Cantos Sanchez de Ibargüen, C. Pradère, I. Garrido Solesio, K. Velasquez, X. Borja Logroño, M. Mitjavila Casanovas;*
Hospital Universitario Puerta de Hierro, Madrid, SPAIN.

EP-0304

FDG PET Accuracy in Preoperative Axillary Staging: Influence of Breast Cancer Molecular Subtype

C. Villaprado, *I. Blanco, k. Sanabria, A. Barrera, P. Carrera, P. Boya, M. Garcia, A. Rosero, L. Paruta, E. Goñi, M. Gimenez, C. Artieda;*
Hospital Universitario de Navarra, Pamplona, SPAIN.

EP-0305

Beyond Ductal Carcinoma: The Added Value of F-18 FDG PET/CT in a Rare Case of Breast Apocrine Porocarcinoma

F. Jibril;
Nuclear Medicine Research Infrastructure (NuMeRI);
Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital;
South Africa, Pretoria, SOUTH AFRICA.

EP-0306

Correlation Between ^{18}F-FDG PET/CT Metabolic Parameters and Ki-67 Expression Levels in Primary Breast Cancer

R. Milardovic[1], *A. Ahmovic*[2], *E. Bicakcic-Filipovic*[3], *N. Salkica*[1], *L. Dzananovic*[4];
[1]*Clinic of Nuclear Medicine, Clinical Center of Sarajevo University, Sarajevo, BOSNIA AND HERZEGOVINA,*
[2]*Clinic of Pathology, Cytology and Human Genetics, Clinical Center of Sarajevo University, Sarajevo, BOSNIA AND HERZEGOVINA,*
[3]*Clinic of Oncology, Clinical Center of Sarajevo University, Sarajevo, BOSNIA AND HERZEGOVINA,*
[4]*Independent Researcher (Epidemiology and Biostatistics), Kuala Lumpur, MALAYSIA.*

EP-0307

Subtype-specific metabolic patterns in breast cancer staging

A. Artesani[1], *S. Calzolai Lettieri*[1], *J. Jandric*[2], *L. Antunovic*[2], *M. Rodari*[2], *L. Evangelista*[1];
[1]*Humanitas University, Pieve Emanuele (Milano), ITALY,*
[2]*IRCCS Humanitas Research Hospital, Rozzano (Milano), ITALY.*

EP-16

B: Imaging Clinical Studies → B1 Oncological Imaging Clinical Study → B14 Lung (including Mesothelioma)

EP-0308

DLL3-Targeted PET Imaging of Small Cell Lung Cancer: A First-in-Human Study

H. Guo, *X. Ma;*
The Second Xiangya Hospital, Central South University, Changsha, Hunan, CHINA.

EP-0309

Evaluation of Regional Node Involvement in the Staging of Non-Small Cell Lung Cancer with ^{18}F-FDG PET/CT

M. Keskin, *H. Aslan;*
Mersin City Training and Research Hospital, Mersin, TÜRKIYE.

EP-0310

Integrating F-18 FDG PET/CT Radiomic Features with Genomics to Predict Outcomes of Anti-EGFR Therapy in Advanced NSCLC: A Prospective Observational Study

A. Rahman, *G. Parida, P. Mohapatra, S. Patra, S. Majumdar, K. Agrawal, B. Padhy, S. Mishra, P. Patro, T. Subudhi;*
All India Institue of Medical Sciences, Bhubaneswar, INDIA.

EP-0311

Restaging ^{18}F-FDG PET/CT Value in EGFR-mutated NSCLC under EGFR-TKI.

F. Lemus Ramírez, *R. Garibay Virués;*
Instituto Nacional De Enfermedades Respiratorias Ismael Cosío Villegas, México, MEXICO.

EP-0312

Preoperative Radioisotope Localization of Non-Palpable Pulmonary Nodules for Intraoperative Detection

A. Bakos[1], *R. Német*[1], *I. Farkas*[1], *G. Sipka*[1], *A. Kovács*[2], *J. Furák*[3], *L. Pávics*[1], *Z. Besenyi*[1];
[1]*Department of Nuclear Medicine and Theranostics, University of Szeged, Szeged, HUNGARY,*
[2]*Department of Radiology, University of Szeged, Szeged, HUNGARY,*
[3]*Department of Surgery, University of Szeged, Szeged, HUNGARY.*

EP-0313

Volumetric and metabolic parameters from ^{18}F-FDG PET/CT in non-small cell lung cancer: associations with histopathology and nodal metastasis

B. Bozdemir[1], *F. Aras*[2], *N. Aydin*[3];
[1]*Sivas Numune State Hospital, Sivas, TÜRKIYE,*
[2]*Manisa Celal Bayar Üniversitesi Tıp Fakültesi, Manisa, TÜRKIYE,*
[3]*Istanbul Prof. Dr. Cemil Taşcıoğlu Şehir Hastanesi, Istanbul, TÜRKIYE.*

EP-0314

^{18}F-FDG PET identifies an immune-activated phenotype associated with prognosis and neoadjuvant immunotherapy response in non-small cell lung cancer

Z. Jiang[1,2], *y. wang*[3], *J. Yu*[1], *H. Marcus*[1];
[1]*Medical University of Vienna, Vienna, AUSTRIA,*
[2]*The Affiliated Hospital of Guilin Medical University, Guilin, CHINA,*
[3]*Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen,People's Republic of China, China, CHINA.*

EP-0315

Predictive Value of 68Gagrazytracer PET/CT for Treatment Response and ProgressionFree Survival in Non-Small Cell Lung Cancer Patients Receiving Bronchial Arterial Infusion Chemotherapy Plus Immunotherapy

X. Shen, *Z. Wang, Z. Xia, X. Zhang, H. Pang;*
The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EP-0316

First-in-Human Evaluation of ^{68}Ga-XDLL3 PET/CT for Whole-Body Imaging of DLL3 Expression in Neuroendocrine Carcinomas

L. Zhao, *L. Yu, H. Fu, W. Guo, H. Chen;*
The First Affiliated Hospital of Xiamen University, Xiamen, CHINA.

EP-0317

[^{18}F]F-FAPI PET/CT is superior to [^{18}F]F-FDG PET/CT for lymph node staging in lung cancer:A Pathologically Validated Study

J. Jiang;
Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China, Shanghai, CHINA.

EP-0318

Integrative Transcriptomic and PET/CT Analysis Identifies CDH3 as a Metabolism-Associated Biomarker in Lung Adenocarcinoma

X. Liu, *X. Chen, N. Wang, Z. Cheng, Y. Xie, T. Jiang, Z. Pei;*
The Second Affiliated Hospital of Soochow University, Suzhou, CHINA.

EP-0319

PET/CT immune-related adverse events in non small cell lung cancer treated with immune checkpoint inhibitors: incidence and prognostic value

M. Masse, *J. Darcourt, J. Gal, S. Contu, V. Ferrari, O. Humbert;*
Centre Antoine Lacassagne, Nice, FRANCE.

EP-0320

Multimodal Deep Learning-Radiomics Model For Predicting Mediastinal-Hilar Lymph Node Metastasis in Non-Small Cell Lung Cancer

H. Habchi[1], *S. Mensi*[2,3], *N. Ben Ameur*[1], *K. Chatti*[2,4];
[1]*Department of Biophysics and Medical Imaging, Higher Institute of Medical Technologies of Tunis, Tunis, TUNISIA,*
[2]*Nuclear Medicine department, CHU Sahloul, Sousse, TUNISIA,*
[3]*Department of biophysics, School of medicine of Sousse, University of Sousse, Sousse, TUNISIA,*
[4]*School of Medicine of Monastir, University of Monastir, Monastir, TUNISIA.*

EP-0321

Personalised Lung Cancer Screening Integrating LDCT, [^{18}F]FDG-PET/CT, and AI-Based Risk Modelling: Preliminary Results of a Multicentre Prospective Study

F. Gelardi[1], *P. Muriana*[1], *D. Palumbo*[1], *M. Sollini*[1,2], *E. Busnardo*[1], *C. Pini*[1,2], *R. Petrelli*[1], *R. Di Donato*[1], *C. Catalano*[1], *P. Nonkina*[1], *E. Dieci*[1], *G. Bonfitto*[1], *M. De Salazar*[3], *A. Fatih*[4], *C. Caruso*[4], *F. De Cobelli*[1], *R. Cuocolo*[5,6], *P. Veltri*[3], *P. Soda*[4], *R. Ferrara*[1], *G. Veronesi*[1,2], *A. Chiti*[1,2];
[1]*IRCCS Ospedale San Raffaele, Milan, ITALY,*
[2]*Vita-Salute San Raffaele University, Milan, ITALY,*
[3]*DIMES, Università della Calabria, Rende (CS), ITALY,*
[4]*Università Campus Biomedico di Roma, Rome, ITALY,*
[5]*Ospedale San Giovanni di Dio e Ruggi d'Aragona, Salerno, ITALY,*
[6]*Università di Salerno, Baronissi (SA), ITALY.*

EP-0322

Brain [^{18}F]FDG Uptake is a Predictive Biomarker of Overall Survival in Patients with Advanced NSCLC Receiving First-Line Immunotherapy

J. Auriac[1], *N. Hovhannisyan-Baghdasarian*[1], *C. Nioche*[1], *N. Captier*[1], *P. Salamoun-Feghali*[2], *S. Lagha*[2], *R. Seban*[1,3], *N. Jehanno*[3], *J. Zhang-Yin*[4,5], *M. Luporsi*[1], *N. Girard*[2], *I. Buvat*[1], *F. Orlhac*[1];
[1]*Institut Curie, PSL, Université Versailles Saint-Quentin, Inserm, CNRS, Université Paris-Saclay, IRIS, Orsay, FRANCE,*
[2]*Institut Curie, Institut du Thorax Curie-Montsouris, Paris, FRANCE,*
[3]*Institut Curie, Department of Nuclear Medicine, Paris-St-Cloud, FRANCE,*
[4]*Service de médecine nucléaire, Clinique Sud Luxembourg, Vivalia, Arlon, BELGIUM,*
[5]*National PET Center, Centre Hospitalier de Luxembourg, Luxembourg, LUXEMBOURG.*

EP-0323

^{18}F-Fdg Pet/Ct In The Preoperative Diagnostic And Mediastinal Lymph Node Staging Of Lung Cancer

V. Lopez Prior, *M. Estors, C. Escoin, N. Perez, A. Blesa, L. Camacho, A. Tembl;*
La Ribera Hospital, Valencia, SPAIN.

EP-0325

SPECT-CT patterns of radiotracer distribution in pulmonary ROLL and their implications for intraoperative localization

S. Cifuentes, *V. Molina, A. Jiménez, A. Sanfiel, M. Santana, M. Isla;*
Hospital Universitario Materno-Infantil de Gran Canaria, Las palmas de gran canaria, SPAIN.

EP-0326

Preoperative risk stratification for mediastinal nodal involvement in resected non-small cell lung cancer: the emerging role of the SUVmean/SUVmax ratio

G. Jimenez Londoño[1], *M. I. Morales Lozano*[1], *J. Villena-Salinas*[2], *A. Leiva Montejo*[1], *C. Ruiz Corbalan*[1], *F. Perez Ángel*[1], *M. Gallego Peinado*[1];
[1]*Nuclear Medicine Department. Hospital Santa Lucia, Cartagena, SPAIN,*
[2]*Nuclear Medicine Department. University Hospital Costa del Sol, Marbella, SPAIN.*

EP-0327

Exploring The Link Between Circulating Tumor Dna And F-18 Fdg Pet/Ct-Based Metabolic Parameters In Non-Small Cell Lung Cancer

R. Tokac[1], *E. Bayram Tokac*[2], *U. Yararbas*[2], *A. Aykut*[2], *A. Durmaz*[2], *H. Akin*[2], *A. Argon*[2];
[1]*Izmir City Hospital, Izmir, TÜRKIYE,*
[2]*Ege University, Izmir, TÜRKIYE.*

EP-0328

Hotspot weighted uptake and spatial hotspot descriptors on baseline ^{18}F-FDG PET/CT for risk stratification in NSCLC treated with first line chemoimmunotherapy

N. Gupta, *A. Rana;*
Dr Rajendra Prasad Government medical college Kangra Himachal Pradesh India, Kangra, INDIA.

EP-0329

Beyond Single Biomarkers: Integration of FDG PET/CT Derived Metabolic Tumor Burden and Sarcopenia for Prognostic Stratification in Non Small Cell Lung Cancer

M. Keskin;
Mersin City Training and Research Hospital, Mersin, TÜRKIYE.

EP-0330

Kinetic Assessment of Pulmonary Nodules Using Dual-Time-Point FDG PET/CT

N. Kapsoritakis[1], *F. Tsitoura*[2], *O. Bourogianni*[1], *G. Barmparis*[2], *M. Stathaki*[3], *N. Tzanakis*[4], *S. Chatziioannou*[5], *G. Tsironis*[2], *S. Koukouraki*[1];
[1]*Nuclear Medicine Department, Medical School University of Crete, Heraklion, Crete, GREECE,*
[2]*Department of Physics, University of Crete, Heraklion, Crete, GREECE,*
[3]*Nuclear Medicine Department, University Hospital of Heraklion, Heraklion, Crete, GREECE,*
[4]*Department of Respiratory Medicine, Medical School University of Crete, Heraklion, Crete, GREECE,*
[5]*Nuclear Medicine Department, School of Medicine, National and Kapodistrian University of Athens, Athens, GREECE.*

EP-0331

The Influence of the Ga-68 Trivehexin PET-CT in staging of Lung Carcinoma Limited to the Torax

A. Gümüs[1], *Z. P. Koç*[1], *P. P. Özcan*[1], *K. Eser*[2], *E. Ayan*[3], *R. Bozdoğan Arpacı*[4];
[1]*Mersin University Department of Nuclear Medicine, Mersin, TÜRKIYE,*
[2]*Mersin University Department of Medical Oncology, Mersin, TÜRKIYE,*
[3]*Mersin University Department of Thoracic Surgery, Mersin, TÜRKIYE,*
[4]*Mersin University Department of Pathology, Mersin, TÜRKIYE.*

EP-0332

Tumor Spread Through Air Spaces in Non-Small Cell Lung Cancer: ^{18}F-FDG PET-Based Tumoral and Peritumoral Radiomics Analysis with Machine Learning

A. Dursun[1], *N. Dizdar*[1], *Ö. Korkmaz*[2], *K. Dizdar*[3], *E. TATCI*[1], *Ö. Özmen*[1];
[1]*Health Sciences University, Ankara Etlik City Hospital, Nuclear Medicine Clinic, Ankara, Türkiye, Ankara, TÜRKIYE,*
[2]*Health Sciences University, Ankara Etlik City Hospital, Pathology Clinic, Ankara, Türkiye, Ankara, TÜRKIYE,*
[3]*Mayo Clinic, Radyoloji Anabilim Dalı, Rochester, MN, ABD, Rochester, MN, UNITED STATES OF AMERICA.*

EP-0333

Machine Learning-Based Radiomics from ^{18}F-FDG PET/CT for Pulmonary Lesion Classification and Histopathological Subtyping

S. Asikovali, *S. Ozdemir, M. Dasar, G. Koca, K. Demirel, M. Korkmaz;*
Ankara Training and Research Hospital, Ankara, TÜRKIYE.

EP-0334

Changes in Splenic F18 FDG Uptake before and after ChemoImmunotherapy and Their Association with Treatment Response and Prognosis in Advanced NonSmall Cell Lung Cancer

S. Kim;
Pusan National University School of Medicine, Yangsan, KOREA, REPUBLIC OF.

EP-0335

Exploratory Evaluation of Immune Activation States via F-AraG PET/CT: Predicting Efficacy and Resistance in ICI-treated Lung Cancer

S. Yasumura[1], *T. W. Nobashi*[1], *Y. Shimizu*[1], *K. K. Miyake*[1], *R. Nakamoto*[1], *R. Sakamoto*[1], *K. Hosoya*[1], *H. Ajimizu*[1], *T. Nomizo*[1], *H. Yoshida*[1], *H. Ozasa*[1], *J. Levi*[2], *Y. Nakamoto*[1];
[1]*Kyoto University Hospital, Kyoto, JAPAN,*
[2]*Cellsight Technologies Inc., San Francisco, CA, UNITED STATES OF AMERICA.*

EP-0336

Development of a multi-omic prognostic model integrating FDG-PET/CT metrics, circulating tumour DNA methylation, and clinical data in advanced non-small cell lung cancer (aNSCLC) treated with immunotherapy: preliminary results.

C. Salesses[1], *S. Ahrari*[1], *M. Robert*[2,3], *S. Lemesle*[1], *T. Carlier*[1,3], *M. Denis*[2,3], *C. Sauzay*[2,3], *P. Hulo*[4], *J. Chen*[4], *E. Pons-Tostivint*[4,3], *C. Bodet-Milin*[1,3];
[1]*Nuclear Medicine Department, CHU Nantes, Nantes Université, Nantes, FRANCE,*
[2]*Department of Biochemistry, CHU Nantes, Nantes Université, Nantes, FRANCE,*
[3]*Nantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI²NA, Nantes, FRANCE,*
[4]*Oncology Department, CHU Nantes, Nantes Université, Nantes, FRANCE.*

EP-0337

Incidental Pneumothorax Detected on F-18 FDG PET/CT: Prevalence, Etiological Distribution, and Prognostic Impact on Overall Survival - A Multicenter Study

B. Demir[1], *D. Nak*[2], *R. H. Tokac*[3], *M. H. Baltacioglu*[4], *S. Ünal*[5], *M. Z. Yilmaztekin*[6];
[1]*Mehmet Akif Inan Education and Research Hospital Department of Nuclear Medicine, Sanliurfa, TÜRKIYE,*
[2]*Recep Tayyip Erdogan University Training and Research Hospital Department of Nuclear Medicine, Rize, TÜRKIYE,*
[3]*Izmir City Hospital Department of Nuclear Medicine, Izmir, TÜRKIYE,*
[4]*Trabzon University Medical School Department of Nuclear Medicine, Trabzon, TÜRKIYE,*
[5]*University of Health Sciences, Ankara Training and Research Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE,*
[6]*Harran University Medical School Department of Nuclear Medicine, Sanliurfa, TÜRKIYE.*

EP-0338

^{18}F-FDG PET Combined with Diffusion Kurtosis Imaging and Restriction Spectrum Imaging for Evaluating Pathological Subtypes of Invasive Lung Adenocarcinoma

y. LIU[1], *N. Meng*[2], *Q. q. Chen*[1], *J. y. Pan*[1], *X. y. Wang*[2], *Y. Yang*[3], *Z. Wang*[4], *F. f. Fu*[2], *M. y. Wang*[2];
[1]*The People's Hospital of Zhengzhou University, Zhengzhou, CHINA,*
[2]*Henan Provincial People's Hospital, Zhengzhou, CHINA,*
[3]*Beijing United Imaging Healthcare Co., Ltd., Beijing, CHINA,*
[4]*Central Research Institute, United Imaging Healthcare Group, Shanghai, CHINA.*

EP-0340

Whole-body metabolic phenotyping in non-small cell lung cancer: the interplay between tumour burden, brain hypometabolism, and lymphoid organ activation

A. Msoune, *A. Benlemlih, Y. Lasry, A. Bakraoui Samlali, R. Bouchikhi, Z. Ouassafrar, A. Guensi;*
CHU Ibn Rochd, Casablanca, MOROCCO.

EP-0341

Chest Ct And Pet-Ct Pleural Effusion Assessment Using A Pet-Ct Score

M. Simo Perdigo, *O. Persiva, A. Vazquez, L. Sanchez, I. Sansano, F. Ascanio, C. Aleman;*
Hospital Universitari Vall Hebron, Barcelona, SPAIN.

EP-0342

FDG PET Radiomics-Based Unsupervised Clustering Identifies Subtypes Associated With Recurrence and Glycolytic Signaling in Lung Adenocarcinoma: A Multicenter Study

Z. Jiang[1,2], *X. Mu*[3], *J. Yu*[1], *H. Marcus*[1];
[1]*Medical University of Vienna, Vienna, AUSTRIA,*
[2]*The Affiliated Hospital of Guilin Medical University, Guilin, CHINA,* [3] *The Affiliated Hospital of Guilin Medical University, Guilin, CHINA.*

EP-0343

Volumetric and Geometric Tumor Features Provide Greater Value than Texture Features in Interpretable PET Radiomics for Lung Cancer Classification

M. Salmanpour[1,2,3], *A. Fathi Jouzdani*[4,3], *A. Gorji*[1,4,3], *A. Rahmim*[1,2];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,*
[2]*University of British Columbia, Vancouver, BC, CANADA,*
[3]*Technological Virtual Collaboration Company (TECVICO CORP.), Vancouver, BC, CANADA,*
[4]*Hamadan University of Medical Sciences, Hamedan, IRAN, ISLAMIC REPUBLIC OF.*

EP-0344

Incremental Value of FDG PET/CT Over Clinical Risk Models for Characterization of Pulmonary Nodules: Emphasis on Visual Assessment and Quantitative Metrics

M. Araújo, *J. Villanueva-Meyer, E. T. Chandlee, P. Gongloor, U. Javaid, D. R. Cardoza-Ochoa;*
University of Texas Medical Branch, Galveston, TX, UNITED STATES OF AMERICA.

EP-0345

Preoperative Predictors of Residual Pulmonary Hypertension After Pulmonary Endarterectomy in CTEPH

P. Han, *R. Ma, W. Xie, H. Li, Z. Zhai, L. Fu;*
China Japan Friendship Hospital, Beijing, CHINA.

EP-0346

Machine learning model based on ultra-short echo time MRI for predicting histological subtypes of non-small cell lung cancer: A comparative study with CT

P. Feng;
Henan Provincial People's Hospital, Henan, CHINA.

EP-0347

Diagnostic value of ^{99}mTc-3PRGD2 SPECT/CT combined with enhanced CT for lymph node metastasis of lung malignancies

R. Wen[1], *H. Sun*[2], *X. Zhu*[1], *Q. Xie*[1], *X. Wang*[1,2];
[1]*The First Affiliated Hospital of University of Science and Technology of China., Hefei, CHINA,*
[2]*The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, CHINA.*

EP-0348

Integrating PET/CT Radiomics, Clinical and Pathological Features: A Parsimonious Machine Learning Signature for 1-Year Prognosis in Malignant Pleural Mesothelioma

A. Dursun[1], *Y. Çakir*[2], *Ü. N. Derya*[3], *A. Öztürk*[4], *E. Tatci*[1], *Ö. Özmen*[1];
[1]*Health Sciences University, Ankara Etlik City Hospital, Nuclear Medicine Clinic, Ankara, TÜRKIYE,*
[2]*University of Zurich, Institute of Molecular Cancer Research;*
University of Applied Sciences and Arts Northwestern Switzerland (FHNW), School of Life Sciences, Zurich, SWITZERLAND,
[3]*Atatürk Sanatorium Training and Research Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE,*
[4]*Atatürk Sanatorium Training and Research Hospital, Department of Chest Diseases, Ankara, TÜRKIYE.*

EP-0349

The Effectiveness of FDG PET/CT in Predicting Brain Metastases and 6-Month Prognosis in Small Cell Lung Cancer

B. Bozca[1], *E. Tatci*[1], *C. Engur Uyanik*[1], *M. Karakulak*[2], *O. Kaya Korkmaz*[2], *E. Konca Karabuga*[3], *N. Aydinbelge Dizdar*[1], *O. Ozmen*[1];
[1]*Etlik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE,*
[2]*Etlik City Hospital, Department of Pathology, Ankara, TÜRKIYE,*
[3]*Etlik City Hospital, Department of Medical Oncology, Ankara, TÜRKIYE.*

EP-0350

BAP-1 and FDG-PET in the diagnosis of malignant pleural mesothelioma

M. Simo Perdigo, *I. Sansano, O. Persiva, A. Vazquez, L. Sanchez, P. Montoya, C. Dinares, C. Aleman;*
Hospital Universitari Vall Hebron, Barcelona, SPAIN.

EP-0351

Utility of ^{68}Ga-DOTA-TOC PET/CT for the Diagnosis of Well-Differentiated Pulmonary Neuroendocrine Tumours in Indeterminate Solid Pulmonary Nodules on ^{18}F-FDG PET/CT

A. Segarra-Santatecla[1], *A. Cobo-Rodríguez*[1], *A. Farré-Melero*[1,2,3], *X. Setoain*[1,4,2], *E. García-Hernández*[1], *R. Caratini*[1,4], *J. Álvarez-Doral*[1], *Á. Muxí-Pradas*[1,5], *D.*

Fuster-Pelfort[1,4,5], M. Moragas-Solanes[1];
[1]Servicio de Medicina Nuclear, Hospital Clínic Barcelona, Barcelona, SPAIN,
[2]Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBERBBN), Instituto de Salud Carlos III, Madrid, SPAIN,
[3]Laboratorio de Biomarcadores de Imagen Molecular y Teragnosis, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS), Universidad de Santiago de Compostela, Santiago de Compostela, SPAIN,
[4]Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, SPAIN,
[5]Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SPAIN.

EP-17

B: Imaging Clinical Studies → B1 Oncological Imaging Clinical Study → B15 Gastro-Intestinal (including Liver and Non-Endocrine Pancreas)

EP-0352

^{99}mTc-mebrofenin HIDA SPECT/CT for preoperative assessment of the future liver remnant: initial experience and identification of volume-function mismatch

A. Dacosta Escobar[1], *J. Martín Marcuartu[1], L. Llado Garriga[2], M. Ruiz de la Cuesta López[2], M. Zamorano Rivas[1], A. Bagán Trejo[1], C. Tapias Mesa[1], J. Díaz Moreno[1], D. Tamayo Ossa[1], C. García Alcober[3], B. Hervás Sanz[1], M. Pudis[1], A. Rodríguez Gasen[1], V. Carrero Vásquez[1], L. Gràcia Sánchez[1], M. Cortés Romera[1];*
[1]Nuclear Medicine-PET department (ICS-IDI), Hospital Universitari de Bellvitge – IDIBELL, Barcelona, SPAIN,
[2]General and Digestive Surgery department, Hospital Universitari de Bellvitge – IDIBELL, Barcelona, SPAIN,
[3]Radiopharmacy department, Hospital Universitari de Bellvitge – IDIBELL, Barcelona, SPAIN.

EP-0353

Baseline [^{68}Ga] FAPI-04 PET/CT Parameters Enable Pretherapeutic Stratification of Conversion Surgery Eligibility in Gastric Cancer with Peritoneal Metastasis

P. Du[1], *Y. Fan[1], S. Lu[2], Z. Yang[2], B. Li[1], J. Hu[1];*
[1]Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA,
[2]Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, CHINA.

EP-0354

Synergistic Value of ^{18}F-FAPI and ^{18}F-FDG PET/CT with Multi-Phase CT in Predicting Chemotherapy Response in Gastric Cancer: A Multicenter Deep-Learning Framework

Z. Li, *Y. Cheng, X. Yu, W. Zheng, Y. Liu;*
Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, CHINA.

EP-0355

Diagnostic performance of ^{18}F-FAPI-74 PET/CT in gastric cancer and biological determinants of lymph node sensitivity: a prospective bi-center study with histopathological validation

L. Ma, *F. Kang, J. Wang;*
Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

EP-0356

An Investigator Initiated Trial to Assess the Clinical Utility of PSMA PET/CT for Detecting Pancreatic Adenocarcinoma

Y. Lu, *B. B. Briones, A. Lo;*
The University of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

EP-0357

Dynamic [^{68}Ga]PSMA-11 PET integrated with multiparametric MRI to phenotype the tumor microenvironment of hepatocellular carcinoma

P. Schindler, *E. Hoffmann, T. Krähling, F. Büther, B. Noto, W. Roll;*
University of Münster, Münster, GERMANY.

EP-0358

[^{68}Ga]NODAGA-SNA009: A Single-Domain Antibody Probe for Rapid PET Imaging of GPA33 in Colorectal Cancer

Z. Yang, *D. Dai;*
Tianjin Medical University Cancer Institute & Hospital, Tianjin, CHINA.

EP-0359

Survival Benefit of ^{68}Ga-FAPI PET/CT Staging for Prognostic Assessment in Gastric and Colorectal Cancer Compared with CE-CT and ^{18}F-FDG PET/CT: A Single-Center Retrospective Study

X. Wu, *J. Wang, F. Kang;*
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, CHINA.

EP-0360

Diagnostic Performance of ^{18}F-FAPI-42 PET/CT for Evaluating Tumor Viability after Locoregional Therapy in Hepatocellular Carcinoma: A Head-to-Head Comparison with Multiphasic CT/MRI

C. Chen, *W. Fu, X. Mu;*
Department of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, CHINA.

EP-0361

Predictive Value of Primary Tumor and Nodal ^{18}F-FDG PET/CT Parameters in Locally Advanced Rectal Cancer

T. Bilgücü, *G. Ucmak, B. Demirel;*
Ankara Abdurrahman Yurtaslan Educational and Research Onkology Hospital, Ankara, TÜRKIYE.

EP-0362

Tc-99m MAA Hepatic Arterial Perfusion Imaging in Detection of Extrahepatic Perfusion in Patients with Advanced Hepatocellular Carcinoma Receiving with Hepatic Arterial Infusion Chemotherapy.

D. Yu, *J. Juo;*
Mennonite Christian Hospital, Hualien, TAIWAN, PROVINCE OF CHINA.

EP-0363

Stromal-Targeted ^{18}F-FAPI-42 PET/CT for Preoperative Prediction of Tumor Budding in Colorectal Cancer: A Dual-Center Study

X. Mu, *J. Li, W. Fu, Z. Li;*
Department of Nuclear Medicine, Affiliated Hospital of Guilin Medical University, Guilin, CHINA.

EP-0364

Unspecific Bone Uptake (Ubu) On [^{18}F]F-Psma-1007 Pet/Ct In Patients With Hepatocellular Carcinoma: Frequency, Patterns And Clinical Implications

P. Guglielmo[1], *S. Damiani[2], M. Rodari[3], G. Torzilli[1], L. Rimassa[1], L. Evangelista[1];*
[1]Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ITALY,
[2]Humanitas University, Pieve Emanuele, Milan, ITALY,
[3]Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, Rozzano, ITALY.

EP-0365

Real-World Evidence in Gastric Cancer Diagnosis: FAPI PET/CT Proves Superior to FDG

M. Veenstra[1], *M. Jayanthi[2], L. Rietvelt[1], K. Harini[2], S. Batchu[2], D. de Jong[1], S. F. Memon[2], E. Vegt[1], A. Tyagi[2], S. Lakhtakia[2], M. Ramchandani[2], M. Bruno[1], N. D. Reddy[2], H. Rughwani[2], M. Thomeer[1];*
[1]Erasmus MC, Rotterdam, NETHERLANDS,
[2]AIG Hospitals, Hyderabad, INDIA.

EP-0366

Improved tumor contrast and recurrence detection in cholangiocarcinoma using LAFOV enabled ultra-late [^{18}F]FDG PET/CT imaging.

E. Calderón Ochoa[1], *B. Gückel[2], H. Dittmann[1], J. Schwenck[1,3,4], K. Nikolaou[2], C. la Fougère[1,3], C. P. Reinert[1];*
[1]Department of Nuclear Medicine and Molecular Imaging, University Hospital of Tübingen, Tübingen, GERMANY,
[2]Department of Diagnostic and Interventional Radiology, University Hospital of Tübingen, Tübingen, GERMANY,
[3]Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, GERMANY,
[4]Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tübingen, Tübingen, GERMANY.

EP-0367

Can Radiomics analysis of PET images support clinical decision making for Oesophageal Cancer?

N. Vennart[1], *G. Petrides[2], A. Phillips[2];*
[1]South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UNITED KINGDOM,
[2]Newcastle Upon Tyne Hospitals, Newcastle, UNITED KINGDOM.

EP-0368

^{68}Ga-FAPI PET/CT Imaging of Gastric Cancer

S. Sergieva[1], *B. Robev[2], B. Ilcheva[3], A. Fakirova[3], I. Takorov[4];*
[1]UH TOKUDA Acibadem Cityclinic, Sofia, BULGARIA,
[2]Department of Medical Oncology, UH "St Ivan Rilsky", Sofia, BULGARIA,
[3]Department of Pathohistology, Military Medical Academy, Sofia, BULGARIA,
[4]Department of Abdominal Surgery, Military Medical Academy, Sofia, BULGARIA.

EP-0369

Initial experiences mapping liver function using kinetic blood clearance values for ^{99}mTc-labelled galactosyl-human serum albumin (^{99}mTc-GSA)

B. Haddock[1], *R. De Nijs[1], J. Madsen[1], C. Denholt[1], N. Gillings[1], L. Enevoldsen[1], S. Schnabl[2], H. Pommergaard[3], P. Noergaard[4], C. Bardram[1];*
[1]Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen, DENMARK,
[2]Department of Digestive Diseases, Transplantation and General Surgery, Rigshospitalet, Copenhagen, DENMARK,
[3]Hepatic Malignancy Surgical Research Unit (HEPSURU), Rigshospitalet, Copenhagen, DENMARK,
[4]Department of Digestive Diseases, Transplantation and General Surgery, Rigshospitalet, Copenhagen, DENMARK.

EP-0370

Head-to-Head Comparison of ^{68}Ga-FAPI-04 PET/CT and ^{18}F-FDG PET/CT for Evaluating Post-Treatment Liver Tumours with Elevated Tumor Markers

Q. Shu, *L. Cai;*
The Department of Nuclear Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EP-0371

Assessing the performance of Ga-68-Fibroblast activating protein inhibitor (FAPI) in the diagnosis the cholangiocarcinoma.

D. Halanaik, *B. Pottakkat, V. Rajaraman;*
Jawaharlal Institute of postgraduate medical education and Research, Puducherry, INDIA.

EP-0372

Head to head comparison of [^{68}Ga]Ga-DOTA-FAPI-04 PET/CT with [^{18}F]FDG PET/CT in Upper-Abdominal Malignancies: Uruguayan experience

G. dos Santos[1,2], *M. Iraheta[1,2], M. Díaz[1,2], O. Alonso[1,2];*
[1]Hospital de Clinicas, Montevideo, URUGUAY,
[2]CUDIM - Uruguayan Centre of Molecular Imaging, Montevideo, URUGUAY.

EP-0373

Don't Ignore the Cold Spot: Malignant Evolution of FDG Non-Avid Hypodense Liver Lesions — A Follow-Up Study

V. Baghel;
Vedanta Medical Research Foundation, Balco Medical Centre Raipur, Raipur, INDIA.

EP-0374

The Role of ^{68}Ga-FAPI PET/CT Imaging in Gastric Cancer: A Single-Center Experience from Turkey

E. Harbi[1], *H. U. Bozbey[2], E. Perrone[3], R. Bilgin[4], D. Tastekin[2];*
[1]Bahcesehir University, Istanbul, TÜRKIYE,
[2]Istanbul University Institute of Oncology, Istanbul, TÜRKIYE,

[3]Nuclear Medicine Unit, Department of Diagnostic Imaging and Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY,
[4]Department of Nuclear Medicine, Istinye University Gaziosmanpasa Hospital, Istanbul, TÜRKIYE.

EP-0375

Correlation of ^{68}Ga FAPI-46 expression on PET/CT in Hepatobiliary and Pancreatic malignancies with FAP Immunohistochemistry

S. Shamim, *M. K. Taggar, N. Kumar, G. Arora, C. R, R. Yadav;*
All India Institute of Medical Sciences, New Delhi, Delhi, INDIA.

EP-0376

Baseline whole-body [^{18}F]FDG PET/CT-based neuro-visceral immunometabolic network phenotyping for predicting major pathologic response to neoadjuvant immunochemotherapy in resectable esophageal squamous cell carcinoma

T. Li;
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CHINA.

EP-0377

Preoperative Staging of Extrahepatic Cholangiocarcinoma: Diagnostic Performance of ^{18}F-FAPI-04 PET and Analysis of Potential Pitfalls and Causes of False Negatives Compared with MRI and CT

K. Zheng, *H. Ye;*
Hunan Cancer Hospital, Changsha, CHINA.

EP-0378

Predictive Value of a Second [^{18}F]FDG PET/CT in the Surgical Management of Oesophageal Cancer Following Neoadjuvant Therapy

D. Fraga, *P. Jorge, G. Fernandes, J. Pais, J. Aço, E. Sousa, L. Salgado;*
Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, PORTUGAL.

EP-0379

Differential Associations of Pancreatic FDG and NaF with Metabolic Risk Factors: Dual Tracer PET Study

S. Mammen[1], *O. Fanta*[1], *W. Lee*[1], *D. Patel*[1], *A. Tran*[1], *M. Ghonim*[1], *T. Werner*[1], *P. Heilund-Carlsen*[2], *A. Alavi*[1];
[1]*Department of Radiology, Hospital of The University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA,*
[2]*Department of Clinical Research, University of Southern Denmark, Odense, DENMARK.*

EP-0380

Diagnostic performance of ^{99}mTc-CTR-FAPI SPECT/CT versus ^{18}F-FDG PET/CT in colorectal cancer: a prospective head-to-head study

S. Li[1], *Z. Li*[2], *M. Xu*[3], *C. Van de Wiele*[1], *H. Xu*[4], *H. Yang*[2,5], *Z. Liu*[6], *Y. Wu*[5];
[1]*Gent University, Gent, BELGIUM,*
[2]*Peking University Cancer Hospital, Beijing, CHINA,*
[3]*Changping Laboratory, Beijing, CHINA,*
[4]*Peking University Cancer Hospital (Inner Mongolia Campus) & Affiliated Cancer Hospital of Inner Mongolia Medical University, hohhot, CHINA,*
[5]*Peking University Cancer Hospital (Inner Mongolia Campus) & Affiliated Cancer Hospital of Inner Mongolia Medical University, Hohhot, CHINA,*
[6]*Peking University, Beijing, CHINA.*

EP-0381

Incremental value of two-compartment irreversible model parametric images from ^{18}F-FDG total-body dynamic PET/CT in the detection of hepatic malignancies

R. Yang, *L. Zhang, X. Lu, H. Shi;*
Zhongshan Hospital, Shanghai, CHINA.

EP-0382

PostNeoadjuvant FAPI PET/CT in Pancreatic Cancer: Response Assessment and Perivascular Evaluation

P. Rasinski[1,2,3], *L. Loizou*[1,4], *M. F. M. Centelles*[5], *A. Tzortzakakis*[1,2,3], *A. Peillon*[6], *K. Søreide*[7,8,9], *E. Sparrelid*[1,10], *R. Axelsson*[11,2,3], *P. Ghorbani*[1,10];
[1]*Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, SWEDEN,*
[2]*Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Huddinge, Stockholm, SWEDEN,*
[3]*Theranostics Trial Center, Karolinska University Hospital, Huddinge, Stockholm, SWEDEN,*
[4]*Department of Radiology, Karolinska University Hospital, Huddinge, Stockholm, SWEDEN,*
[5]*Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Huddinge, Stockholm, SWEDEN,*
[6]*GE Healthcare Ltd., Buc, FRANCE,*
[7]*Department of Gastrointestinal Surgery, Stavanger University Hospital, Stavanger, NORWAY,*
[8]*Department of Clinical Medicine, University of Bergen, Bergen, NORWAY,*
[9]*Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN,*
[10]*Department of Upper Abdominal Diseases, Karolinska University Hospital, Huddinge, Stockholm, SWEDEN,*
[11]*Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, SWEDEN.*

EP-0383

Prognostic Value of Tc-99m MAA Hepatic Arterial Perfusion Imaging in Patients with Advanced Hepatocellular Carcinoma Receiving with Hepatic Arterial Infusion Chemotherapy.

D. Yu, *J. Juo;*
MCH, Hualien, TAIWAN, PROVINCE OF CHINA.

EP-0384

Novel Bifunctional PET Tracer [^{68}Ga]Ga-NI-FAPI PET/CT in Gastrointestinal Tumours: An Exploratory Comparative Study with [^{18}F]FDG

Y. Wang[1], *J. Xiang*[1], *W. Jin*[1], *K. Lin*[1], *X. Ma*[1], *J. Wang*[1], *L. Zhu*[2], *H. Kung*[3], *Z. Zhu*[1];
[1]*Peking Union Medical College Hospital, Beijing, CHINA,*
[2]*Beijing Normal University, Beijing, CHINA,*
[3]*University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.*

EP-0385

Clinical Significance of Incidental Colorectal ^{18}F-FDG Uptake on PET/CT: The Role of Metabolic Parameters and Dual-Time-Point Imaging in Guiding Colonoscopy Decisions

R. Yıldırım, *E. G. Işık, D. F. Arslan, M. I. Bayhan, Z. G. Özkan, Y. Şanlı, S. Kuyumcu;*
Istanbul University, Istanbul, TÜRKIYE.

EP-0386

FAPI PET Demonstrates Extended Tumor Coverage Beyond FDG Avidity: Potential Implications for CTV Delineation in Esophageal Cancer

J. Dai, *L. Yang, R. Tian;*
West China Hospital, Chengdu, CHINA.

EP-0387

Four empirical gastric emptying phenotypes on liquid-meal scintigraphy: clinical interpretation, extended imaging, and retention-curve clustering

I. Sisko Markos[1,2], *G. Buljan*[1], *I. Blazekovic*[1,2], *M. Romić*[1], *D. Filipan*[1], *M. Bosak Butković*[1];
[1]*UHC Sestre Milosrdnice, Zagreb, CROATIA,*
[2]*Croatian Catholic University, School of Medicine, Zagreb, CROATIA.*

EP-0388

Predictive clinical dosimetry of ^{177}Lu-PSMA based on ^{68}Ga-PSMA TEP imaging for upper gastrointestinal cancers, a prospective study

A. Chen[1,2,3], *J. Girard-Lauzière*[4], *É. Croteau*[2,3], *F. Lemay*[4,3], *Y. Collin*[5,3], *C. Wilhelmy*[2,3], *B. Guérin*[1,2,3], *É. Turcotte*[1,2,3], *G. Turgeon*[1,3], *E. Espinosa-Bentancourt*[2], *É. Lavallée*[2], *A. Têtu*[2,3], *M. Pavic*[5,3], *K. Tremblay*[3], *É. Rousseau*[1,2,3];
[1]*Département des sciences de l'imagerie médicale et des radiations, Université de Sherbrooke, Sherbrooke, QC, CANADA,*
[2]*Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, CANADA,*
[3]*Institut de recherche sur le cancer de l'Université de Sherbrooke (IRCUS), Sherbrooke, QC, CANADA,*
[4]*Département de médecine, Université de Sherbrooke, Sherbrooke, QC, CANADA,*
[5]*Département de chirugie, Université de Sherbrooke, Sherbrooke, QC, CANADA.*

EP-0389

Impact of Imaging Time on [^{68}Ga]FAPI PET/CT for Suspected Pancreatic Malignancy

M. Badarna[1,2], *C. Davis*[3,2], *L. Smith*[3,2], *Y. Mzizi*[3,2], *M. Sathekge*[4,3,2];
[1]*Department of Nuclear Medicine, Rambam Health care campus, Haifa, ISRAEL,*
[2]*Nuclear Medicine Research Infrastructure, Pretoria, SOUTH AFRICA,*
[3]*Department of Nuclear Medicine, Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA,*
[4]*Department of Nuclear Medicine, University of Pretoria, Pretoria, SOUTH AFRICA.*

EP-0390

Kinetic Modeling of PSMA Uptake in Hepatocellular Carcinoma Using LAFOV PET/CT: Insights into Histopathological Features

L. Vetrone[1], *E. Prosperi*[2], *E. Prosperi*[2], *D. Malvi*[3], *A. Degiovanni*[3], *F. Vasuri*[4], *I. Brusa*[1], *S. Emiliani*[1], *D. Dall'Olio*[4], *M. Ravaioli*[2], *M. Cescon*[2], *S. Fanti*[1,5], *A. Farolfi*[1];
[1]*Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[2]*Department of Hepatobiliary Surgery and LiverTransplant, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[3]*Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[4]*Department of Medical and Surgical Sciences (DIMEC), Bologna University, Bologna, ITALY,*
[5]*Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY.*

EP-0391

Salivary gland scintigraphy in Sjögren's syndrome: correlation between subjective symptoms, quantitative parameters, and serological markers of autoimmunity

E. Karol Vera, *A. Villena Garcia, A. Piñeiro Donis, L. Cagua Ruiz, E. Dominguez Polanco, R. Sanchez Sanchez;*
Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0392

^{18}F-FDG PET/CT Radiomics-Based Machine Learning Models for Pancreatic Lesion Characterisation: Comparison with Visual Assessment and Evaluation of Human-Radiomics Synergy

D. Arslan[1], *Z. Ozkan*[1], *A. Bayram*[2], *D. Denizmen Zorba*[1], *E. Isik*[1], *Y. Sanli*[1], *D. Has Simsek*[1], *S. Erturk*[3], *S. Kuyumcu*[1];
[1]*Istanbul University, Istanbul Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[2]*Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Neuroscience, Istanbul, TÜRKIYE,*
[3]*Istanbul University, Istanbul Faculty of Medicine, Department of Radiology, Istanbul, TÜRKIYE.*

EP-0393

Tc-99m Heat-Damaged Red Blood Cell Scintigraphy as a Problem-Solving Tool for Differentiating Intrapancreatic Accessory Spleen from Pancreatic Neuroendocrine Neoplasm

K. Šenica, *A. Socan, S. Rep, A. Tomazic, A. Smid, S. Stupar, L. Lezaic;*
University Medical Centre Ljubljana, Ljubljana, SLOVENIA.

EP-0394

CTR-FAPI PET/CT in Gastric Cancer: Head-to-Head Comparison with FDG and Correlation with Tumor Immune Microenvironment Markers

Y. Zhang, *J. Liu, X. Tian;*
Lanzhou University Second Clinical Medical School, Lanzhou, CHINA.

EP-0395

De-implementation of routine FDG-PET/CT use in staging locally advanced gastric cancer

S. W. J. M. Spruijt[1], *L. Triemstra*[2], *H. J. F. Brenkman*[2], *S. S. Gisbertz*[3], *R. van Hillegersberg*[2], *P. van Duijvendijk*[4], *B. P. L. Wijnhoven*[5], *B. P. L. Witteman*[6], *M. J. van Det*[7], *J. W. van Sandick*[8], *H. H. Hartgrink*[1], *A. Y. Thijssen*[9], *M. D. P. Luyer*[10], *M. I. van Berge Henegouwen*[3], *J. van den Berg*[2], *E. S. van der Zaag*[4], *S. M. Lagarde*[5], *E. A. Kouwenhoven*[7], *L. de Geus-Oei*[1], *J. S. E. Quik*[8], *W. O. de Steur*[1], *E. J. T. Belt*[9], *G. A. P. Nieuwenhuijzen*[10], *K. Keywani*[3], *P. C. van*

der Sluis[5], E. B. Wassenaar[4], S. J. M. van Hootegem[5], P. D. Siersema[5], T. B. Kool[11], N. Haj Mohammad[2], L. A. Brosens[2], M. P. van der Meulen[2], L. Timmermans[11], I. Somers[8], E. Vegt[5], J. P. Ruurda[2];
[1]Leids Universitair Medisch Centrum, Leiden, NETHERLANDS,
[2]University Medical Center Utrecht, Utrecht, NETHERLANDS,
[3]Amsterdam UMC Location University of Amsterdam, Amsterdam, NETHERLANDS,
[4]Gelre Hospital Apeldoorn, Apeldoorn, NETHERLANDS,
[5]Erasmus MC University Medical Center, Rotterdam, NETHERLANDS,
[6]Rijnstate Hospital, Arnhem, NETHERLANDS,
[7]ZGT Hospital Group, Almelo, NETHERLANDS,
[8]The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS,
[9]Albert Schweitzer Hospital, Dordrecht, NETHERLANDS,
[10]Catharina Hospital, Eindhoven, NETHERLANDS,
[11]Radboud University Medical Center, Nijmegen, NETHERLANDS.

EP-0396

Comparative Evaluation of AI-Derived Metabolic Tumor Volume on FDG versus FAPI PET/CT for Abdominal Malignant Neoplasms and Its Impact on patient management.

***P. Hj**[1], V. Varshney[2], P. Wadhwa[2], A. K R[1], R. Kumar C[1], A. B R[1], S. S P[1], S. Kommineni[1];*
[1]Aster Hospital, Bengaluru, INDIA,
[2]United Imaging Healthcare, Shanghai, CHINA.

EP-18

B: Imaging Clinical Studies → B1 Oncological Imaging Clinical Study → B16 Neuroendocrine (Pancreatic and Others)

EP-0397

[^{18}F]AIF-NOTA octreotide ([^{18}F]-OC) PET/CT imaging and pathological characteristics of pheochromocytoma/paraganglioma (PPGL) with different origins

***I. Huang**, J. Liu, Z. Cui, W. Ma, Y. Li;*
The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, CHINA.

EP-0398

Baseline ^{68}Ga-DOTA-SSA PET/CT Radiomics for Predicting Outcomes in GEP-NET Patients Treated with ^{177}Lu-Oxodotreotide: preliminary findings

***D. Maccora**[1], M. Longaroni[2], R. Gatta[3], S. Rea[1], M. De Summa[4], L. Boldrini[5], R. Sciuto[1], S. Annunziata[6];*
[1]Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, ITALY,
[2]Data Science Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,
[3]Department of Clinical and Experimental Sciences, University of Brescia, Brescia, ITALY,
[4]Medipass S.p.a. Integrative Service PET/CT - Radiofarmacy TracerGLab, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,
[5]Department of Diagnostic Imaging, Oncological Radiotherapy and Haematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,
[6]Nuclear Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY.

EP-0399

Preoperative Diagnostic Performance of AI18FNOTA-LM3 PET/CT in Suspected PPGL

***Y. Zhang**, M. Liu, C. Ren, Z. Huang, A. Tong, H. Jing, L. Huo;*
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, CHINA.

EP-0400

Tracer Uptake and Clinical Outcomes in FDG- and DOTATOC-PET: A Cohort Study of 222 Patients with Pulmonary Carcinoid Tumours

***A. Kistner**, O. Grundberg, D. Truong, S. Nyrén, D. Granberg, A. Sanchez Crespo;*
Karolinska Insitutet, Stockholm, SWEDEN.

EP-0401

Clinical Significance of Absent or Low SSTR Expression in Suspected Phaeochromocytoma/Paraganglioma: Correlation with Final Diagnosis

***S. Shamim**, P. Singh, N. A. Damle, S. Dixit, S. Agarwal, Y. Gupta;*
All India Institute of Medical Sciences, Delhi, INDIA.

EP-0402

Quantitative SPECT/CT Parameters in the Follow-up of Metastatic Neuroendocrine Tumours: Comparison with Visual Assessment

***D. Ionescu**[1,2], M. Păunescu[2], M. Mutuleanu[1,2], M. Gherghe[1,2];*
[1]University of Medicine and Pharmacy Carol Davila, Bucharest, ROMANIA,
[2]Institute of Oncology "Prof.Dr. Alexandru Trestioreanu", Bucharest, ROMANIA.

EP-0403

Limited association between [^{18}F]FET uptake and MRI characteristics in pituitary neuroendocrine tumours

***V. De Meulenaere**[1], B. Lapauw[2], F. Cordier[3], F. Dewaele[4], T. Van Zele[5], E. Genbrugge[1], D. Van Weehaeghe[1];*
[1]Department of Radiology and Nuclear Medicine, Ghent University Hospital, Ghent, BELGIUM,
[2]Department of Endocrinology, Ghent University Hospital, Ghent, BELGIUM,
[3]Department of Pathology, Ghent University Hospital, Ghent, BELGIUM,
[4]Department of Neurosurgery, Ghent University Hospital, Ghent, BELGIUM,
[5]Department Otorhinolaryngology, University Hospital Ghent, Ghent, BELGIUM.

EP-0404

Value of [^{68}Ga]Ga-DOTATOC PET/CT in the Detection of Cardiac Metastases in Neuroendocrine Tumours

***A. Bagán-Trejo**[1], J. Díaz-Moreno[1], L. Gràcia-Sánchez[1], R. Ramos-Polo[2], P. Notta-González[1], I. Sánchez-Rodríguez[1], B. Hervás-Sanz[1], J. Martín-Marcuartu[1], J. Vercher-Conejero[1], A. Dacosta-Escobar[1], D. Tamayo-Ossa[1], M. Cortés-Romera[1];*
[1]Nuclear Medicine-PET (IDI) Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN,
[2]Cardiology Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN.

EP-0405

Parasympathetic vs. Sympathetic Paragangliomas: Differences in Somatostatin Receptor Expression on Ga-68 DOTA-TATE PET/CT

***G. Deniz**, E. Isik, Z. Ozkan, S. Kuyumcu, Y. Sanli;*
Istanbul University, Istanbul Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

EP-0406

Preoperative [^{68}Ga]Ga-DOTATOC PET-derived biomarkers for early recurrence prediction after surgery in non-functioning pancreatic neuroendocrine tumours

***P. Mapelli**[1,2], C. Bezzi[2], S. Partelli[3,4], A. Battistella[3,4], S. Ghezzo[2], M. Schiavo Lena[5], D. Palumbo[1,6], F. De Cobelli[1,6], M. Falconi[3,4], A. Chiti[1,2], M. Picchio[1,2];*
[1]Vita-Salute San Raffaele University, Milan, ITALY,
[2]Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY,
[3]Pancreatic and Transplant Surgery Unit, Pancreas Translational and Clinical Research Center, Milan, ITALY,
[4]Pancreatic Surgery Unit, IRCCS San Raffaele Scientific Institute, Milan, ITALY,
[5]Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, ITALY,
[6]Radiology Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY.

EP-0407

Detection rate of cardiac uptake in small intestine neuroendocrine Tumours (NET) using 6-[^{18}F] fluoro-L-DOPA PET/CT and its clinical value

***A. Miqdadi**, M. Borsali, H. Noamen, C. Nappi, M. Longo, S. Moog, I. Pinigina, L. Lamartina, Y. Menu, B. Bonnet, E. Baudin, J. Hadoux, D. Deandreis;*
Gustave Roussy, Paris, FRANCE.

EP-0408

Beyond Staging: The Synergistic Role of 2-[^{18}F]FDG and [^{68}Ga]Ga-DOTA-NOC PET/CT in Predicting GEP-NETs Biological Behavior

***S. Paiva**, S. Barata, D. Carvalho, A. L. Alves, I. Casimiro, L. Lemos, G. Costa;*
ULS Coimbra, Coimbra, PORTUGAL.

EP-0409

Detection of residual or recurrent medullary thyroid carcinoma in patients with elevated calcitonin levels after surgery using Tc-99m-Tektrotyd SPECT and SPECT/CT imaging

***J. Petrovic**[1,2], M. Veljković[2,1], B. Radovic[1], J. Maličević[1], J. Živanović[1], M. Stojiljković[1,2], I. Grozdić Milojević[1,2], S. Odalović[1], D. Šobić Šaranović[1];*
[1]University Clinical Center of Serbia;
Center for Nuclear Medicine with PET, Belgrade, SERBIA,
[2]Faculty of Medicine University of Belgrade, Belgrade, SERBIA.

EP-0410

Validation of NET PET score in Grade II Gastroenteropancreatic Neuroendocrine Tumours

***S. Dewani**, A. Puranik, V. Rangarajan, S. Shah, N. Purandare;*
Tata Memorial Centre, Mumbai, INDIA.

EP-0411

^{177}Lu-DOTATATE Therapy in Patients with Metastatic Neuroendocrine Tumours: Toxicity, Survival, and Prognostic Factors

***E. Karol Vera**, A. Piñeiro Donis, L. Cagua Ruiz, E. Dominguez Polanco, T. Aroui Luquin, R. Sanchez Sanchez;*
Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0412

The Diagnostic and Prognostic Value of [^{68}Ga] Ga-DOTA-TATE PET in Gastroenteropancreatic Neuroendocrine Neoplasms

***X. Ren**[1,2,3], C. Qin[1,2,3], Z. Gao[1,2,3], X. Lan[1,2,3];*
[1]Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA,
[2]Hubei Province Key Laboratory of Molecular Imaging, Wuhan, CHINA,
[3]Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, CHINA.

EP-0413

[^{18}F]AIF-NOTA Octreotide PET/CT in Pheochromocytoma/Paraganglioma: Expanding the Role of Somatostatin Receptor Imaging Beyond Gastroenteropancreatic Neuroendocrine Tumours

***I. Huang**, J. Liu, Z. Cui, W. Ma, Y. Li;*
The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, CHINA.

EP-0414

Preoperative MIBG Uptake Predicts Perioperative Myocardial Injury in Patients Receiving Surgery for Pheochromocytoma and Paraganglioma

***J. Ma**, H. Ji, C. Wang, L. Huo;*
Peking union medical college hospital, Beijing, CHINA.

EP-0415

Diagnostic Value of [^{18}F]AIFNOTAOctreotide ([^{18}F] OC) PET/CT versus Adrenal ContrastEnhanced CT in the Etiological Diagnosis of TumorRelated Paroxysmal Hypertension

***I. Huang**, J. Liu, Z. Cui, W. Ma, Y. Li;*
The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, CHINA.

EP-0416

SSTR-PeRForm: Development of an ENETS Consensus Framework for Response Assessment Using SSTR PET in Neuroendocrine Tumours

***H. Leupe**[1], C. M. Deroose[1], R. J. Hicks[2], I. Virgolini[3], A. J. Braat[4], E. S. Mittra[5], N. L. Albert[6], D. Bailey[7], L. Bodei[8], D. Chan[7], J. Dekervel[1], T. Denecke[9], C. Dromain[10], M. Falconi[11], S. Grozinsky-Glasberg[12], J. Hofland[13], T. A. Hope[14], I. Karfis[15], B. Kos-Kudla[16], A. Koumarianou[17], A. Lamarca[18], M. Pavel[19], S. Stroobants[20], J. Strosberg[21], A. Sundin[22], C. Verslype[1], D. Wild[23], A. Kjaer[24], V.*

Ambrosini[25], V. Prasad[26];
[1]UZ Leuven, Leuven, BELGIUM,
[2]University of Melbourne, Melbourne, AUSTRALIA,
[3]Medical University Innsbruck, Innsbruck, AUSTRIA,
[4]University Medical Center Utrecht, Utrecht, NETHERLANDS,
[5]Oregon Health and Science University, Portland, OR, UNITED STATES OF AMERICA,
[6]LMU University Hospital, Munich, GERMANY,
[7]University of Sydney, Sydney, AUSTRALIA,
[8]Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA,
[9]University Medical Centre Leipzig, Leipzig, GERMANY,
[10]DCHUV Lausanne University Hospital, Lausanne, SWITZERLAND,
[11]IRCCS San Raffaele Scientific Institute, Milan, ITALY,
[12]Hadassah Mecial Organization and Faculty of Medicine, Jerusalem, ISRAEL,
[13]Erasmus MC Cancer Institute, Rotterdam, NETHERLANDS,
[14]University of California San Francisco, San Francisco, CA, UNITED STATES OF AMERICA,
[15]Institut Jules Bordet, Brussels, BELGIUM,
[16]Medical University of Silesia, Katowice, POLAND,
[17]Attikon University Hospital, Athens, GREECE,
[18]Universidad Autónoma de Madrid (UAM), Madrid, SPAIN,
[19]Friedrich-Alexander University Erlangen-Nürnberg, Erlangen-Nurnberg, GERMANY,
[20]Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, BELGIUM,
[21]Moffitt Cancer Center, Tampa, FL, UNITED STATES OF AMERICA,
[22]Uppsala University, Uppsala, SWEDEN,
[23]University Hospital Basel, Basel, SWITZERLAND,
[24]Copenhagen University Hospital, Copenhagen, DENMARK,
[25]University of Bologna, Bologna, ITALY,
[26]Washington University, Saint Louis, MO, UNITED STATES OF AMERICA.

EP-0417

Superior Overall Survival Prediction with RECIST 1.1 Compared to Choi and Volumetric Response Criteria in PRRT-Treated GEP-NET

***C. Dascalescu**, F. L. Herr, V. Fusch, C. Smith, R. Ebner, M. L. Schnitzer, J. Rübenthaler, M. Heimer, K. Klimek, R. A. Werner, C. C. Cyran;*
LMU Hospital, Munich, GERMANY.

EP-0418

Diagnostic Efficacy of [68Ga]Ga-Exendin-4 PET/CT in the Localisation of Insulinomas: A Comparative Single-Centre Study

***L. Schweiger**, G. Santo, L. Tross, L. Rossetti, S. Kaser, C. Decristoforo, G. di Santo, I. Virgolini;*
Medical University of Innsbruck, Innsbruck, AUSTRIA.

EP-0419

Risk-Adapted Prophylaxis for Carcinoid Crisis Prevention During PRRT: A 10-Year Single-Center Experience

***M. À. Hernández Fructuoso**, L. Rey Sánchez, C. G. Franco Monterroso, C. Jiménez Pena, J. Balala Rojo, E. Otero Ruíz, M. R. Marusso Fizzani, A. Casteràs Roman, T. Canela Coll, A. García Burillo;*
Hospital Universitario Vall d'Hebron, Barcelona, SPAIN.

EP-0420

SUVDOTATOC/FDG Ratio Shows Strongest Correlation with SSTR2A Expression in Neuroendocrine Neoplasms: A Dual-Tracer PET/CT Study

***W. Tseng**[1], C. Liu[1], Y. Chien[1], M. Hsieh[2], S. Peng[1], M. Cheng[1];*
[1]Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, TAIWAN, PROVINCE OF CHINA,
[2]Department of Pathology, National Taiwan University Cancer Center, Taipei, TAIWAN, PROVINCE OF CHINA.

EP-0421

Incidental Findings on 68Ga-DOTATOC PET/CT

***B. Santos García**, P. García-Talavera San Miguel, E. Campaña Díaz, A. Peñaherrera Cepeda, J. Badell Martínez, F. Gómez Caminero López, J. Villanueva Curto, M. Martín Gómez;*
Hospital Universitario de Salamanca, Salamanca, SPAIN.

EP-0422

Availability of 64Cu-DOTATATE PET/CT for Neuroendocrine Tumours: A New Opportunity for Staging and PRRT Selection

***M. Guiote Moreno**[1,2], A. De Agrela Serrao[1,2], I. Cejudo Liebana[1,2], J. Fernandez Fernandez[1,2], A. Rodriguez Llamas[1,2], J. Vallejo Casas[1,2];*
[1]Hospital Universitario Reina Sofía, Cordoba, SPAIN,
[2]IMIBIC, Cordoba, SPAIN.

EP-19

B: Imaging Clinical Studies → B1 Oncological Imaging Clinical Study → B17 Colorectal

EP-0423

Evaluation of the Relationship Between F-18 FDG PET/CT Parameters Derived from the Primary Tumor and Mismatch Repair Deficiency in Colorectal Cancer

***E. Tunca**[1], R. H. Tokac[2], F. Tamer[1], U. Yararbas[1];*
[1]Ege University Faculty of Medicine, Department of Nuclear Medicine, Izmir, TÜRKIYE,
[2]Izmir City Hospital, Department of Nuclear Medicine, Izmir, TÜRKIYE.

EP-0424

Evaluation of the Relationship Between Preoperative 18F-FDG PET/CT Parameters and Histopathological Features and Survival in Patients with Colon Cancer

***G. Aymandir**, G. Mütevelizade, F. Davarcı, E. Bilgin;*
Celal Bayara Üniversitesi Hafsasultan Hastanesi, Manisa, TÜRKIYE.

EP-0425

Clinical impact of 18F-FDG PET/CT in suspected colorectal cancer recurrence: Diagnostic and therapeutic outcomes

***M. K. Jalel**, O. Ben Hamida, M. Somai, I. Meddeb, A. Mhiri;*
Salah Azaiez Institute, Tunis, TUNISIA.

EP-20

B: Imaging Clinical Studies → B1 Oncological Imaging Clinical Study → B18a Prostate Staging

EP-0426

68Ga-PSMA PET/CT Findings In The Primary Staging of Prostate Cancer

***H. Eroglu Elden**[1], K. Demirel[2], M. Daşar[2], S. Özdemir[3], A. Akbulut[2], G. Koca[2], M. Korkmaz[2];*
[1]Kahramanmaraş Necip Fazıl City Hospital, Kahramanmaraş, TÜRKIYE,
[2]Ankara Training and Research Hospital, Ankara, TÜRKIYE,
[3]Hatay Training and Research Hospital, Hatay, TÜRKIYE.

EP-0427

Prognostic and Predictive Value of Baseline 68Ga-PSMA PET/CT-Derived Whole-Body Metabolic Tumor Parameters in Metastatic Prostate Cancer

***P. Akkus Gunduz**[1], F. Gunes[1], C. Soydal[1], E. Yekeduz[2], Y. Urun[2], O. Kucuk[1];*
[1]Ankara University Faculty of Medicine, Nuclear Medicine Department, Ankara, TÜRKIYE,
[2]Ankara University Faculty of Medicine, Medical Oncology Department, Ankara, TÜRKIYE.

EP-0428

Imaging More, Changing Nothing: Are There Predictors of PSMA PET Non-Impact on Patient Management After Conventional Imaging in Primary Staging of High-Risk Prostate Cancer?

***S. Urtaev**, A. Khalimon, M. Khodzhibekova, D. Khodakova, A. Nikiforuk, T. Lazutina, I. Pylova, G. Khamadeeva, A. Kalpinskiy, A. Leontev;*
P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

EP-0429

Role of PET/CT with [18F]F-PSMA-DCFPyL and [68Ga] Ga-PSMA-11 in the staging of high-risk prostate cancer. Agreement with conventional imaging techniques and impact on therapeutic management

***J. Robles**[1], J. J. Martín-Marcuartu[1], C. A. Tapias-Mesa[1], P. Perlaza-Jimenez[1], M. Zamorano-Rivas[1], A. Bagan-Trejo[1], B. Dacosta-Escobar[1], D. Tamayo-Ossa[1], D. Durany-Lara[2], J. F. Suarez-Novo[3], M. Cortés-Romera[1];*
[1]Servicio de Medicina Nuclear / PET (IDI). Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, SPAIN,
[2]Servicio de Radiología. Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, SPAIN,
[3]Servicio de Urología. Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, SPAIN.

EP-0430

Impact of PET/CT (predominantly PSMA) on TNM staging and NCCN risk categorization in unfavorable intermediate- and high-risk prostate cancer

***S. Abouzian**[1], I. Henríquez[2], B. Malavé[3,4], G. Benítez-Gabella[2], M. Canela[4], R. García-Pablo[4], J. Vargas[2], R. Benavides[2], J. Fuertes[1], D. Parada[5], F. Riu[5], M. Montero[6], R. Bultó[7], V. Monllau[7], M. Arenas[2];*
[1]Nuclear Medicine Department. Hospital Universitari Sant Joan de Reus, Reus, SPAIN,
[2]Radiotherapy oncology Department. Hospital Universitari Sant Joan de Reus, Reus, SPAIN,
[3]Radiotherapy oncology departament. Hospital Viamed Tarragona, Tarragona, SPAIN,
[4]Radiotherapy Oncology Research Group, Institute of Health Research Pere Virgili (IISPV), SPAIN,
[5]Pathology Department. Hospital Universitari Sant Joan de Reus, Reus, SPAIN,
[6]Radiology Department. Hospital Universitari Sant Joan de Reus, Reus, SPAIN,
[7]Urology Department. Hospital Universitari Sant Joan de Reus, Reus, SPAIN.

EP-0431

Incidence and Clinical Impact of Lower Extremity Metastases in 68Ga-PSMA PET/CT for Prostate Cancer: A Retrospective Analysis from a Single Center

***E. Ibrahim**, E. Alper;*
Department of Nuclear Medicine, Bursa Uludağ University Faculty of Medicine, Bursa, TÜRKIYE.

EP-0432

[18F] PSMA-3Q PET/CT Radiomics at 45% SUVmax Threshold: Predicting post-surgical ISUP Grade ≥4 and Extraprostatic Extension for Biopsy-Sparing Prostate Cancer Management

***C. Jianbo**[1,2], Y. Liu[1], R. Xue[1], B. Xu[1];*
[1]Chinese PLA General Hospital, Beijing, CHINA,
[2]Nuclear Medicine Department, The 983rd Hospital of the Joint Logistic Support Force, TianJin, CHINA.

EP-0433

Composite D'Amico high risk score: implications in diagnostic and therapeutic impact using [18F] DCFPyL PET/CT for primary staging of prostate cancer.

***J. Bonilla Plaza**[1], I. Garcia Megias[1], M. Amo Salas[2], M. Meneses Navas[1], M. Cruz Montijano[1], L. Garcia Zoghby[1], M. Casallas Cepeda[1], J. Montalva Pastor[1], A. Garcia Vicente[1];*
[1]Hospital Universitario de Toledo, Toledo, SPAIN,
[2]Universidad de Castilla la Mancha, Ciuidad Real, SPAIN.

EP-0434

Impact of PSMA PET/CT at initial staging of Prostate Cancer on biochemical recurrence and overall survival in a unicenter retrospective data base from 2013 to 2023

***S. Esmaeilzadeh Asl**, A. Sonnenfeld, T. Stange, H. Boehme, A. Rentsch, S. Hoberueck, T. Hoelscher, K. Boehm, C. Thomas, M. Miederer;*
University Hospital Dresden (Universitatsklinikum Carl Gustav Carus Dresden), Dresden, GERMANY.

EP-0435

Reshaping Prognosis: Visual PSMA-PET Morphology and Local Staging as Superior Independent Predictors of Recurrence in Localized Prostate Cancer

***Z. Isik**[1], G. Güner[2], M. Caglar[2], M. Karcaaltincaba[2], D. Akinci[2], M. Tuncel[2];*
[1]Düzce Atatürk State Hospital, Düzce, TÜRKIYE,
[2]Hacettepe University, Ankara, TÜRKIYE.

EP-0436

Impact of the PET/CT with ^{18}F-Piflufolastat on the initial staging of patients with intermediate-high risk prostate cancer. Comparison with conventional imaging techniques.

J. Badell[1], *M. T. Márquez Sanchez*[2], *A. C. Peñaherrera Cepeda*[1], *E. Casillas Sagrado*[1], *L. G. Díaz González*[1], *P. García-Talavera San Miguel*[1], *J. G. Villanueva Curto*[1], *J. C. Cañadas Salazar*[1], *J. M. Valarezo Jimenez*[1], *M. Fernandez Arteaga*[1], *F. Ulloa Mejia*[1], *P. Tamayo Alonso*[1];
[1]*Salamanca University Hospital, Salamanca, SPAIN,*
[2]*Salamanca Institute of Biomedical Research (IBSAL), Salamanca, SPAIN.*

EP-0437

Beyond SUVmax: Comparative Evaluation of Quantitative PSMA PET Parameters for predicting metastasis and tumour aggressiveness.

T. Subudhi, *P. Bambhroliya, G. K. Parida, P. Patro, K. Agrawal;*
AIIMS, Bhubaneswar, Bhubaneswar, INDIA.

EP-0438

Volumetric and semi-quantitative parameters of the primary prostate lesion on [^{18}F]-DCFPyL PSMA PET/CT and their correlation with clinical and pathological variables and predictive value for nodal and metastatic involvement in intermediate and high risk prostate cancer

X. Guarnizo Poma[1], *A. Gómez-Grande*[1], *P. Zaragoza-Ballester*[2], *E. López Llobet*[1], *S. Angiolillo Grau*[1], *M. Aviles Jurado*[1], *Á. Galiana Morón*[1], *E. Martínez Albero*[1], *R. Delgado García*[1], *D. Díaz Vega*[1], *D. Vega Pérez*[1], *P. Sarandeses Fernández*[1], *A. Saviatto Nardi*[1], *S. Ruiz Solis*[1];
[1]*Hospital Universitario 12 Octubre. Madrid, Madrid, SPAIN,*
[2]*Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.*

EP-0439

^{18}F-PSMA-1007 PET/CT Uptake Reflects PSA Levels and mpMRI Features of Local Tumor Extension in Gleason-Defined Low- to Intermediate-Risk Prostate Cancer

I. Sandler[1], *N. Zelinger*[1], *R. Murani*[2], *A. Zick*[3], *S. Srour*[3], *M. Safadi*[4], *I. Massalha*[5], *R. Katz*[6];
[1]*Department of Nuclear Medicine, Ziv Medical Center, Safed, ISRAEL,*
[2]*Department of Radiation Oncology, Ziv Medical Center, Israel, ISRAEL,*
[3]*Department of Radiology, Ziv Medical Center, Safed, ISRAEL,*
[4]*Department of Oncology, Ziv Medical Center, Safed, ISRAEL,*
[5]*Department of Radiation Oncology, Ziv Medical Center, Safed, ISRAEL,*
[6]*Department of Urology, Ziv Medical Center, Safed, ISRAEL.*

EP-0440

Quantitative [^{99m}Tc]Tc-PSMA SPECT/CT for detection of clinically significant prostate cancer: A proof-of-concept study.

T. Mefane[1], *K. Hlongwa*[1], *M. P. Rivombo*[1], *N. Jacobs*[1], *N. Govender*[1], *A. Al-Marrani*[1], *M. Makhele*[1], *D. Bhoojedhur*[1], *N. Wapi*[2], *S. More*[1];
[1]*University of Cape Town, Western Cape, SOUTH AFRICA,*
[2]*Groote Schuur Hospital, University of Cape Town, Western Cape, SOUTH AFRICA.*

EP-0441

Clinical dynamic whole-body PET/CT of a novel prostate cancer radioligand targeting the prostatic acid phosphatase 3 (ACP3): First pharmacokinetic modelling results

F. Büther[1], *J. Brosch-Lenz*[2], *K. E. Seifert*[1], *F. Schaeg*[1], *A. Schrader*[1], *M. Rust*[1], *M. Claesener*[1], *F. Landau*[1], *P. Schindler*[1], *D. Ventura*[1], *K. Rahbar*[1], *M. Schäfers*[1], *P. Backhaus*[1];
[1]*University Hospital Münster, Münster, GERMANY,*
[2]*University Hospital Augsburg, Augsburg, GERMANY.*

EP-0442

Comparison between PSMA PET/CT Staging and Pathology Results in Intermediate- and High-Risk Prostate Cancer Patients Treated with Radical Prostatectomy and Lymphadenectomy

M. Piñero, *Y. Santaella Guardiola, F. Cañete Sanchez, J. Rodriguez-Rubio Corona, A. Lara Hernandez;*
Hospital Puerta del Mar, Cadiz, SPAIN.

EP-0443

Shifting Paradigm in Initial Staging of Intermediate-Unfavorable and High-Risk Prostate Cancer: Is ^{18}F-Piflufolastat PET/CT Replacing Multiparametric Pelvic MRI? Our Experience and Clinical Implications

A. Peñaherrera Cepeda, *M. Márquez Sánchez, J. Badell Martínez, L. Diaz González, E. Casillas Sagrado, P. García Talavera, J. Villanueva Curto, B. Santos García, F. Ulloa Mejía, M. Lorenzo Gómez, P. Tamayo Alonso;*
Complejo asistencial universitario de Salamanca, Salamanca, SPAIN.

EP-0444

OptimizedSUVmax Threshold-Based [^{18}F]PSMA-^{3}Q PET/CT Radiomics with Ensemble Learning forPreoperative Identification of Aggressive Prostate Cancer

R. Xue[1,2], *J. Cui*[1], *G. Wang*[3], *Y. Liu*[2], *B. Xu*[2];
[1]*Graduate School, Chinese PLA General Hospital, Beijing, CHINA,*
[2]*The First Medical Centre, Chinese PLA General Hospital, Beijing, CHINA,*
[3]*Bejing Friendship Hospital, Affliated to CapitalMedical University, Beijing, CHINA.*

EP-0445

The Relationship of Skeletal Muscle Index and Its Changes with Survival and Clinical Outcomes in mCRPC Patients Receiving [^{177}Lu]Lu-PSMA Therapy

A. Kibar[1], *F. Aghazada*[2], *L. Uslu-Besli*[3], *O. Sahin*[3], *S. Asa*[3], *S. Sager*[3], *K. Sonmezoglu*[3], *H. Sayman*[3];
[1]*Trakya University Faculty of Medicine, Department of Nuclear Medicine, Edirne, TÜRKIYE,*
[2]*Basaksehir Cam and Sakura City Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[3]*Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE.*

EP-0446

PSMA SPECT/CT using99mTc-MIP-1404 in the primary staging of prostate cancer: detection rates and criteria for patient referral

M. Baehr[1], *T. M. Hoang*[2], *I. Dietrich*[3], *J. Borggrefe*[4], *K. Liepe*[3];
[1]*Ruhr University Bochum, Minden, GERMANY,* [2]*free statistician, Duesseldorf, GERMANY,*
[3]*General Hospital Frankfurt (Oder), Frankfurt (Oder), GERMANY,*
[4]*Ruhr University Bochum Johannes Wesling Hospital Minden, Minden, GERMANY.*

EP-0447

Prostate-to-Submandibular Gland SUVmax Ratio on [^{18}F]PSMA-1007 PET Predicts Aggressive Pathological Features and Biochemical Persistence After Radical Prostatectomy

C. Pini[1,2], *L. Quarta*[1,3], *P. Zaurito*[1,3], *R. Leni*[1,3], *A. Cosenza*[1,3], *A. Occhi*[1,3], *F. Barletta*[1,3], *S. Scuderi*[1,3], *V. Cucchiara*[1,3], *A. Stabile*[1,3], *A. M. Samanes Gajate*[2], *M. Picchio*[1,2], *A. Lazar*[1], *F. Gelardi*[2], *M. Sollini*[1,2], *F. Montorsi*[1,3], *G. Gandaglia*[1,3], *A. Briganti*[1,3], *A. Chiti*[1,2];
[1]*Vita-Salute San Raffaele University, Milan, ITALY,*
[2]*Department of Nuclear Medicine, IRCCS San Raffaele Hospital, Milan, ITALY,*
[3]*Department of Urology, IRCCS San Raffaele Hospital, Milan, ITALY.*

EP-0448

Can Whole-Body DWI-MRI Help Interpret Unspecific Bone Uptakes on Hybrid [^{18}F]PSMA-1007 PET/MRI? A Preliminary Analysis

A. Lazar[1], *C. Pini*[1], *T. Russo*[1,2], *C. Giancristofaro*[2], *G. Vito*[1], *F. Gelardi*[3], *R. Petrelli*[3], *V. Crippa*[3], *R. Menichini*[3], *R. Rigamonti*[3], *G. Orlandi*[3], *A. Roletto*[3], *R. Di Donato*[3], *A. Coliva*[3], *A. Stabile*[4], *G. Gandaglia*[1,4], *A. Briganti*[1,4], *F. Montorsi*[1,4], *G. Bonfitto*[3], *F. De Cobelli*[1,2], *M. Sollini*[1,3], *A. Chiti*[1,3];
[1]*Vita-Salute San Raffaele University, Milan, ITALY,*
[2]*Department of Radiology, IRCCS San Raffaele Hospital, Milan, ITALY,*
[3]*Department of Nuclear Medicine, IRCCS San Raffaele Hospital, Milan, ITALY,*
[4]*Department of Urology, IRCCS San Raffaele Hospital, Milan, ITALY.*

EP-0449

Privacy-Preserving LLM-Based Extraction of PROMISE V2-Aligned Structured Clinical Data for Prostate Cancer from Ga-68 PSMA PET/CT Reports: A Comparative Study

J. Chaudhary[1], *S. Kumar*[1], *P. D. Sharma*[2], *A. K. Pandey*[1], *R. Kumar*[1], *K. P. Haresh*[1], *S. Kaushal*[1], *C. J. Das*[1], *R. K. Sahoo*[1], *M. Kalaivani*[1];
[1]*All India Institute of Medical Sciences, AIIMS, New Delhi, New Delhi, INDIA,*
[2]*SGTB Khalsa College, University of Delhi, Delhi, INDIA.*

EP-0450

Real-World Impact of [^{18}F]rhPSMA-7.3 PET/CT on Initial Staging and Risk Classification in Treatment-Naïve Prostate Cancer

P. Chuang[1,2], *J. Huang*[3,2], *N. We*[3], *C. Chen*[3], *P. Kuo*[2], *J. Hong*[3,2], *C. Lu*[3,1,2];
[1]*National Taiwan University Cancer Center, Taipei, TAIWAN, PROVINCE OF CHINA,*
[2]*National Taiwan University School of Medicine, Taipei, TAIWAN, PROVINCE OF CHINA,*
[3]*National Taiwan University Hospital, Taipei, TAIWAN, PROVINCE OF CHINA.*

EP-0451

Evaluation of the Biodistribution of ^{99}mTc-PSMA-GCK01 SPECT/CT in a prospective, intraindividual comparison with ^{68}Ga-PSMA-11 PET/CT for Phenotyping in mCRPC prior to PSMA-targeted radioligand therapy

E. Novruzov[1], *E. Mamlins*[1], *J. Kabunda*[2], *C. Kratochwil*[3], *S. Martlbauer*[1], *J. Cardinale*[1], *M. Qebetu*[2], *A. Feisthauer*[1], *C. A. Kaoma*[2], *L. Smith*[2], *S. Sibiya*[2], *T. de Bruin*[2], *S. Mdanda*[2], *M. Shungube*[2], *C. Davis*[2], *Y. Mzizi*[2], *K. Mokoala*[2], *H. Ndlovu*[2], *K. Ramonaheng*[2], *F. Giesel*[1], *M. M. Sathekge*[2];
[1]*University Hospital Düsseldorf, Düsseldorf, GERMANY,*
[2]*University of Pretoria and Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA,*
[3]*University Hospital Heidelberg, Heidelberg, GERMANY.*

EP-0452

Multivariate Radiomic Signature in PET/CT with ^{18}F-PSMA-1007: Evaluation of Heterogeneity and Tumor Morphology as Predictors of Aggressiveness in Prostate Cancer: Beyond Visual Evaluation

M. Corza Ayala, *R. Hernández Ramírez, J. Vargas Ahumada, J. Chávez Tórres;*
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, MEXICO.

EP-0453

Is Early Imaging a Pitfall? Effect of[^{68}Ga]Ga-PSMA PET/CT Timing After Biopsy on SUVmax and Adverse Pathology Prediction in Low-to-Intermediate Risk Prostate Cancer

E. Kaya[1], ***M. C. Uluçay***[1], *B. Esen Akkaş*[1], *F. Aghazada*[1], *H. L. Canat*[2], *H. Özdemir*[2], *M. Kaya*[1];
[1]*Basaksehir Cam and Sakura City Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[2]*Basaksehir Cam and Sakura City Hospital, Department of Urology, Istanbul, TÜRKIYE.*

EP-0454

The role of [^{18}F]-Piflufolastat PET/CT in the initial staging of patients with unfavourable intermediate-risk prostate cancer. Correlation with the findings of prostate MRI.

J. Badell[1], *M. T. Márquez Sánchez*[2], *A. C. Peñaherrera Cepeda*[1], *L. G. Díaz González*[1], *E. Casillas Sagrado*[1], *E. Campaña Diaz*[1], *S. Rama Alonso*[1], *F. Caltagirone Gutiérrez*[1], *B. Santos García*[1], *M. F. Lorenzo Gómez*[1], *P. Tamayo Alonso*[1];
[1]*Salamanca University Hospital, Salamanca, SPAIN,*
[2]*Salamanca Institute of Biomedical Research (IBSAL), Salamanca, SPAIN.*

EP-0455

Whole-Prostate ^{18}F-PSMA-1007 PET/CT SUVmean Shows Stronger Association with PSA Than SUVmax in Gleason-Defined Low- to Intermediate-Risk Prostate Cancer at Primary Staging

I. Sandler[1], *N. Zelinger*[1], *F. Artoul*[1], *A. Zick*[2], *S. Srour*[2], *A. Hijab*[3], *M. Safadi*[4], *R. Katz*[5];
[1]*Department of Nuclear Medicine, Ziv Medical Center,*

Safed, ISRAEL,
[2]Department of Radiology, Ziv Medical Center, Safed, ISRAEL,
[3]Department of Radiation Oncology, Ziv Medical Center, Safed, ISRAEL,
[4]Department of Oncology, Ziv Medical Center, Safed, ISRAEL,
[5]Department of Urology, Ziv Medical Center, Safed, ISRAEL.

EP-0456

Staging of High-Risk Prostate Cancer with PET/PSMA 18FDCFyL: Correlation Between Standardized Standardized Uptake Value maximo Valor Pre-Radical Prostatectomy Indices and Histopathological Results

Y. Santaella Guardiola, *M. Piñero Fernandez-Reyes, J. Rodriguez-Rubio Corona, F. Cañete Sanchez, A. Lara Hernandez;*
Hospital Puerta del Mar, Cadiz, SPAIN.

EP-21

B: Imaging Clinical Studies → B1 Oncological Imaging Clinical Study → B18b Prostate BC Recurrence

EP-0457

Beyond the Phoenix Criterion: Early Detection of Prostate Cancer Recurrence After Definitive Radiotherapy in the Era of PSMA PET/CT

Y. Eryilmaz[1], *M. Yilmaz Aslan[2], P. Hurmuz[2], G. Ozyigit[2], M. Caglar[1], M. Tuncel[1];*
[1]Hacettepe University Medical School Department of Nuclear Medicine, Ankara, TÜRKIYE,
[2]Hacettepe University Medical School Department of Radiation Oncology, Ankara, TÜRKIYE.

EP-0458

REFINE: a prospective trial on the diagnostic value of (^{18}F)-Fluciclovine-PET/CT after negative or inconclusive PSMA-PET/CT in biochemical recurrence of prostate cancer patients

C. Moyses[1], *D. Sasse[1], S. Hein[1], C. Lapa[2], W. Weber[1], M. Eiber[1], T. Lorenzini[1];*
[1]Departement of Nuclear Medicine, School of Medicine and Health, Technical University of Munich, TUM University Hospital, Munich, GERMANY,
[2]Departement of Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY.

EP-0459

Free-to-Total PSA Ratio as an Independent Predictor of PSMA PET/CT Positivity in Biochemical Recurrence of Prostate Cancer: A Prospective Two-Centre Study

C. Rodríguez Vergara[1], *C. Cases Pellise[1], L. Cagua Ruiz[2], L. Brero Sanchez[1], E. Triviño Ibañez[2], A. Rodríguez Fernández[2], J. Freire Macias[1], J. Jiménez-Hoyuela García[1], R. Álvarez Pérez[1];*
[1]Hospital Universitario Virgen del Rocio, Sevilla, SPAIN,
[2]Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0460

Preliminary results from Phase 3 trial of [^{68}Ga] Ga-PSMA-11 PET for detection of biochemical recurrence of prostate cancer in Chinese men

J. Roetman[1], *X. Lan[2], S. Song[3], C. Qin[2], S. Hu[4], L. Li[5], Y. He[6], W. Tan[7], C. Yu[8], Y. Fan[9], Y. Hu[10], Z. Wang[10], K. Osipowicz[1], D. Cade[1];*
[1]Telix Pharmaceuticals, North Melbourne, AUSTRALIA,
[2]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA,
[3]Fudan University Shanghai Cancer Center, Shanghai, CHINA,
[4]Xiangya Hospital Central South University, Changsha City, CHINA,
[5]West China Hospital of Sichuan University, North Melbourne, AUSTRALIA,
[6]Zhongnan Hospital of Wuhan University, Wuhan, CHINA,
[7]Nanfang Hospital Southern Medical University, Guangzhou, CHINA,
[8]Affiliated Hospital of Jiangnan University, Wuxi, CHINA,
[9]Peking University First Hospital, Beijing, CHINA,
[10]Grand Pharmaceutical (China) Co Ltd, Wuhan, CHINA.

EP-0461

PSA-stratified ^{68}Ga PSMA-PET Positivity Prior to Salvage Radiotherapy in Patients with BCR Prostate Cancer: Insights from the PRIMORDIUM Study

P. Ost[1], C. De Nunzio[2], D. Tilki[3,4,5], N. Tunariu[6], M. Brezovsky[7], M. de Almeida Luz[8], A. Yildirim[9], Á. Juárez Soto[10], M. Dąbkowski[11], O. Ettala[12], R. M. D'Angelillo[13], M. Lukac[14], A. Grevendieck[14], L. Antoni[15], A. Jürgens[15], M. Efficace[15], K. Shafieian[15], K. Braga Lemos[15], P. De Koninck[16], B. A. Hadaschik[17], ***S. Fanti***[18];
[1]Radiation Oncology, Iridium Network, ZAS Hospitals, Antwerp, BELGIUM,
[2]Department of Urology, Sant'Andrea Hospital, Rome, ITALY,
[3]Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY,
[4]Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY,
[5]Department of Urology, Koç University Hospital, Istanbul, TÜRKIYE,
[6]The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM,
[7]Department of Urology, Faculty Hospital Nitra, Nitra, SLOVAKIA,
[8]Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA,
[9]Department of Urology, Istanbul Medeniyet University, Istanbul, TÜRKIYE,
[10]Hospital Universitario de Jerez de la Frontera, Cádiz, SPAIN,
[11]Department of Brachytherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, POLAND,
[12]Department of Urology, Turku University, Turku University Hospital, Turku, FINLAND,
[13]Radiation Oncology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, ITALY,
[14]Parexel International Czech Republic s.r.o, on behalf of Johnson & Johnson, Beerse, BELGIUM,
[15]Oncology, Johnson & Johnson, Beerse, BELGIUM,
[16]ICON PLC, Dublin, Ireland, on behalf of Johnson & Johnson, Beerse, BELGIUM,
[17]Department of Urology, University Hospital Essen, Essen, GERMANY,
[18]Nuclear Medicine, IRCCS AOU di Bologna, Bologna, ITALY.

EP-0462

Association of PSMA Expression with Progression-Free Survival in Low- to Intermediate-Grade Prostate Cancer After Radical Prostatectomy

G. Beydagi[1], *E. Hacihasanoglu[2], A. Dogan Ekici[3], F. Yencilek[4], L. Kabasakal[5], B. Caner Sayman[6], N. Alan[6];*
[1]Department of Nuclear Medicine, University of Health Sciences Turkey, Istanbul Training and Research Hospital, Istanbul, TÜRKIYE,
[2]Health Sciences University, Faculty of Medicine, Department of Medical Pathology, Istanbul, TÜRKIYE,
[3]Acıbadem Mehmet Ali Aydınlar University, Faculty of Medicine, Department of Medical Pathology, Istanbul, TÜRKIYE,
[4]Yeditepe University, Department of Urology, Istanbul, TÜRKIYE,
[5]Istanbul University-Cerrahpaşa, Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE,
[6]Yeditepe University, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

EP-0463

Diagnostic Value of PET/MR in Prostate Cancer Biochemical Recurrence (BCR) with Negative or Equivocal [^{18}F]-Piflufolastat PET/CT (PSMA PET/CT)

F. Serani[1], *M. Gardi[2], F. Zattoni[3,2], G. Novara[3,2], M. Iafrate[3,2], V. Bodanza[4], M. Sepulcri[5], C. Lacognata[6], A. Lauro[6], D. Cecchin[1], F. Dal Moro[3,2];*
[1]Nuclear Medicine Unit, Department of Medicine DIMED, University of Padova;
Nucleare Medicine Unit, DIDAS, University Hospital of Padova, Padova, ITALY,
[2]Urology Unit, University Hospital of Padova, Padova, ITALY,
[3]Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, ITALY,
[4]Nucleare Medicine Unit, DIDAS, University Hospital of Padova, Padova, ITALY,
[5]Radiation Oncology Unit, Veneto Institute of Oncology (IOV) - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padova, ITALY,
[6]Radiology Unit, DIDAS, University hospital of Padova, Padova, ITALY.

EP-0464

^{18}F-PSMA-1007 vs ^{18}F-DCFPyL PET-CT in occult biochemical recurrence of prostate. Detection ratio, locations, change in treatment and the UBU challenge.

P. Plaza López[1], *F. Amorelli[2], J. Blanco[1], A. Natali[3], E. Carrillo[1], A. Gene[1], R. Valhondo[1], P. Foro[1];*
[1]Hospital del Mar Barcelona, Barcelona, SPAIN,
[2]Institut Català d'Oncologia, Barcelona, SPAIN,
[3]Hospital Josep Trueta, Girona, SPAIN.

EP-0465

Impact of Urinary Radioactivity on Loco-regional Disease Detection Among Patients with Low Prostate-specific Antigen Recurrence of Prostate Cancer After Radical Prostatectomy: Results from an Intra-patient Head-to-head Study of ^{18}F-Piflufolastat and ^{18}F-Flotufolastat Positron Emission Tomography

E. Parent[1], *J. Sykes[2], R. Penny[2], S. Sonecha[2], BED-PSMA-411 Study Group;*
[1]Mayo Clinic Florida, Jacksonville, FL, UNITED STATES OF AMERICA,
[2]Blue Earth Diagnostics Ltd, Oxford, UNITED KINGDOM.

EP-0466

Positive Predictive Value of ^{18}F-Flotufolastat Positron Emission Tomography in Patients with Biochemical Recurrence of Prostate Cancer: Radio-Guided Salvage Surgery and Salvage Radiotherapy

D. Sasse[1], *M. Vogel[2], T. Horn[3], K. Schwamborn[4], S. Hein[1], T. Lorenzini[1], W. Weber[1], M. Eiber[1];*
[1]Department of Nuclear Medicine, TUM University Hospital, TUM School of Medicine and Health, Technical University of Munich, Munich, GERMANY,
[2]Department of Radiation Oncology, TUM University Hospital, TUM School of Medicine and Health, Technical University of Munich, Munich, GERMANY,
[3]Department of Urology, TUM University Hospital, TUM School of Medicine and Health, Technical University of Munich, Munich, GERMANY,
[4]Institute of General Pathology and Pathological Anatomy, Technical University of Munich, Munich, GERMANY.

EP-22

B: Imaging Clinical Studies → B1 Oncological Imaging Clinical Study → B18c Prostate Other

EP-0467

PSMA PET/CT for Post-HIFU Response Assessment: Uptake Patterns, Biochemical Correlates, and Grade-Specific Predictors of Persistent Disease

U. Riva[1], *S. Calzolai Lettieri[1], P. Guglielmo[1], S. Damiani[1], F. Debernardi[1], V. Fasulo[1], V. Mallia[2], A. Tallari[2], L. Cella[2], G. Lughezzani[1], L. Evangelista[1], A. Artesani[1];*
[1]Humanitas University, Pieve Emanuele, Milan, ITALY,
[2]IRCCS Humanitas Research Hospital, Rozzano, Milan, ITALY.

EP-0468

Optimization of Deep Learning-based ToF Enhancement for Shortened Acquisition Times in ^{68}Ga-PSMA-11 PET/CT Using a BGO-based Scanner

H. Kim[1], *R. Nakamoto[2], A. Katsuki[3], H. Kawakami[3], F. Kotasidis[4], K. Itagaki[2], K. Miyake[1], Y. Nakamoto[1];*
[1]Kyoto University Graduate School of Medicine, Kyoto, JAPAN,
[2]Kyoto University Hospital, Kyoto, JAPAN,
[3]GE Healthcare Japan, Tokyo, JAPAN,
[4]GE Healthcare, Zurich, SWITZERLAND.

EP-0469

Characterisation of responders to Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer using quantitative PSMA-PET-derived parameters

T. van Bergen[1], *S. van Wilpe[2], T. F. W. Soeterik[3], C. A. T. van den Berg[1], A. J. A. T. Braat[4], N. Mehra[2];*
[1]Computational Imaging Group for MR Diagnostics and Therapy, Center for Image Sciences, University Medical Center Utrecht, Utrecht, NETHERLANDS,

[2]Department of Medical Oncology, Radboud University Medical Center, Nijmegen, NETHERLANDS,
[3]Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, NETHERLANDS,
[4]Department of Nuclear Medicine and Radiology, Division of Imaging and Oncology, University Medical Center Utrecht, The Netherlands, Utrecht, NETHERLANDS.

EP-0470

[68Ga]Ga-PSMA-11 PET/CT Response Assessment and Survival Stratification During Systemic Therapy in Prostate Cancer

G. Beydagi[1], *M. Veronesi*[2], *F. Lancia*[3], *I. Sparagna*[3], *I. Badrane*[2], *S. Adamantiadis*[2], *L. Uccelli*[2], *C. Cittanti*[2], *M. Bartolomei*[2], *E. Arslan*[4,5], *L. Urso*[2];
[1]Department of Nuclear Medicine, University of Health Sciences Turkey, Istanbul Training and Research Hospital, Istanbul, TÜRKIYE,
[2]Translational Medicine Department, University of Ferrara, Ferrara, ITALY,
[3]Oncology Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferrara, ITALY,
[4]Department of Nuclear Medicine, University of Health Sciences, Istanbul, TÜRKIYE,
[5]Istanbul Training and Research Hospital, Istanbul, TÜRKIYE.

EP-0472

Prognostic Value of Baseline [68Ga]Ga-PSMA PET/CT Radiomics in mCRPC Patients Treated with [177Lu]Lu-PSMA Therapy

A. Kibar[1], *F. Aghazada*[2], *L. Uslu-Besli*[3], *O. Sahin*[3], *S. Asa*[3], *S. Sager*[3], *K. Sonmezoglu*[3], *H. Sayman*[3];
[1]Trakya University Faculty of Medicine, Department of Nuclear Medicine, Edirne, TÜRKIYE,
[2]Cam and Sakura City Hsopital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,
[3]Istanbul-University Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

EP-0473

Exploratory Multimodal Evaluation of PHI, MRI-Derived Parameters, and PSMA PET/MR for the Diagnosis of Prostate Cancer

L. Wang[1], *X. Su*[2], *Y. Yang*[2], *W. Wu*[1];
[1]Jilin Cancer Hospital, Changchun, CHINA,
[2]Beijing United Imaging Healthcare Technology Development Co., Ltd., Beijing, CHINA.

EP-0474

Uptake versus Tumor Burden in Predicting Early Biochemical Response: A SPARC-Aligned PSMA PET Study

F. Yousefirizi[1], *M. Pouromidi*[1], *N. Bayasi*[1], *R. Samimi*[2], *E. Hosseinzadeh*[2], *G. Divband*[3], *B. Nickkholgh*[4], *Z. Adinehpour*[5], *S. Shafiee Dastgerdi*[6], *J. Beauregard*[7], *A. Rahmim*[1];
[1]BC Cancer Research Institute, Vancouver, BC, CANADA,
[2]Department of Medical Radiation Engineering, Tehran, IRAN, ISLAMIC REPUBLIC OF,
[3]Nuclear Medicine Centre, Jam Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF,
[4]PET/CT Centre, Tehran, IRAN, ISLAMIC REPUBLIC OF,
[5]The Ottawa Hospital and University of Ottawa, Ottawa, ON, CANADA,
[6]University of Isfahan, Isfahan, IRAN, ISLAMIC REPUBLIC OF,
[7]Department of Radiology and Nuclear Medicine; and Cancer Research Centre, Université Laval, Quebec City, QC, CANADA.

EP-0475

The Adrenal-to-Liver SUVmax Ratio: A Pivotal Parameter for the Differential Diagnosis of Adrenal Lesions on 68Ga-PSMA PET/CT

H. Eroglu Elden[1], *A. Akbulut*[2], *S. Özdemir*[3], *M. Daşar*[2], *K. Demirel*[2], *G. Koca*[2], *M. Korkmaz*[2];
[1]Kahramanmaraş Necip Fazıl City Hospital, Kahramanmaraş, TÜRKIYE,
[2]Ankara Training and Research Hospital, Ankara, TÜRKIYE,
[3]Hatay Training and Research Hospital, Hatay, TÜRKIYE.

EP-0476

Multicenter analysis of distinct whole-body body composition and organ metabolic remodeling patterns after androgen deprivation therapy and [177Lu]Lu-PSMA therapy in advanced prostate cancer

Z. Wang[1], *S. Xue*[1], *Y. Jia*[1], *S. Wen*[1], *H. Zhang*[1], *H. Einspieler*[1], *D. Muin*[1], *A. A. Nikolic*[2], *J. Baessler*[2], *G. Kramer*[3], *S. F. Shariat*[3], *S. Dintner*[4], *R. A. Bundschuh*[5], *L. Li*[6], *J. Liu*[6], *X. Zhou*[6], *S. Rasul*[7], *C. Lapa*[8], *M. Hacker*[1], *X. Li*[1];
[1]Medical University of Vienna Department of Biomedical Imaging and Image-guided Therapy, Vienna, AUSTRIA,
[2]Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany, Augsburg, GERMANY,
[3]Department of Urology, Medical University of Vienna, Vienna, AUSTRIA,
[4]Pathology, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY,
[5]Department of Nuclear Medicine, University Hospital Carl Gustav Carus at the TU Dresden, Dresden, GERMANY,
[6]Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA,
[7]Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, AUSTRIA,
[8]Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY.

EP-0477

Reference Tissue Variability and Inter-Organ Correlations in PSMA PET/CT: A Retrospective Exploratory Analysis Across Three Radiopharmaceuticals

J. Burger, *M. Eiber, W. A. Weber;*
Technische Universität München, München, GERMANY.

EP-0478

Implementing radiation mapping during radioguided robotic surgery via artificial intelligence-assisted spatial correction of augmented reality projections

D. van Tuil[1,2], *V. A. Ottens*[1,2], *K. Pirkovets*[1,2], *B. A. Cakal*[1,3], *G. Pisano*[1,4], *M. J. V. Scheltema*[5], *D. D. D. Rietbergen*[1,6], *P. Dell'Oglio*[1,7], *E. Mazzone*[1,7], *P. J. van Leeuwen*[2], *H. G. van der Poel*[2,8], *M. N. van Oosterom*[1,2], *F. W. B. van Leeuwen*[1,2];
[1]Interventional Molecular Imaging laboratory, Leiden University Medical Center, Leiden, NETHERLANDS,
[2]Department of Urology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, NETHERLANDS,
[3]Crystal Photonics GmbH, Berlin, GERMANY,
[4]Nuclear Medicine Unit, Fondazione Poloclinico Universitario A. Gemelli IRCCS, Rome, ITALY,
[5]Department of Urology, St. Antonius Hospital, Nieuwegein, NETHERLANDS,
[6]Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS,
[7]Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY,
[8]Department of Urology, Amsterdam University Medical Centers, Amsterdam, NETHERLANDS.

EP-0479

A Head-to-Head Study to compare the biodistribution and dosimetry of 64Cu-TR2205 and 64Cu-PSMA-617 in Patients with metastatic Prostate Cancer

B. Zhang[1], *J. Liu*[2], *Y. Wu*[2];
[1]The First Affiliated Hospital of Soochow University, Suzhou, CHINA,
[2]C ray Therapeutics (Chengdu) Co., Ltd., Shanghai, CHINA.

EP-0480

PSMA PET-Derived Metrics in CHAARTED Low-Volume Metastatic Hormone-Sensitive Prostate Cancer Treated with First-Line Doublet Therapy

M. Olivieri[1], *A. Artesani*[2], *P. Zucali*[1,2], *N. Cordua*[1], *M. Perrino*[1], *A. Bertocchi*[1,2], *U. Riva*[1,2], *P. Guglielmo*[2], *A. Laghi*[1,2], *L. Evangelista*[1,2];
[1]IRCCS Humanitas Research Hospital, Rozzano, Milan, ITALY,
[2]Humanitas University, Pieve Emanuele, Milan, ITALY.

EP-0481

A Predictive Model for FDG-Positive/PSMA-Negative Mismatch in Metastatic Castration-Resistant Prostate Cancer

J. Passoni[1], *G. Rovera*[2,3,4], *L. Sofia*[1], *A. Giesen*[5], *C. Garcia*[4], *A. Di Giorgio*[6], *M. Donegani*[7], *V. Pau*[7], *S. Ratti*[7], *G. Sambuceti*[1,7], *A. Farolfi*[8], *S. Joniau*[5], *S. Morbelli*[2,3], *D. Deandreis*[4], *G. Marra*[3], *M. Bauckneht*[1,7];
[1]Department of Health Sciences (DISSAL), University of Genova, Genoa, ITALY,
[2]Nuclear Medicine Unit, AOU Città della Salute e della Scienza di Torino, Turin, ITALY,
[3]Department of Medical Sciences, University of Turin, Turin, ITALY,
[4]Nuclear Medicine Department, Institute Gustave Roussy, Villejuif, FRANCE,
[5]Department of Urology and Department of Development and Regeneration, KU Leuven, Leuven, BELGIUM,
[6]Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,
[7]IRCCS Azienda Ospedaliera Metropolitana, Genoa, ITALY,
[8]Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria Di Bologna, Bologna, ITALY.

EP-0482

Comparative Assessment of PSMA PET/CT-based Radiographic Progression-Free Survival Using RECIP and PCWG4 Criteria in a Retrospective APMR (mCRPC) 177Lu-PSMA-I&T Patient Cohort

S. Grigorascu, *T. Hekimsoy, K. Knorr, R. Tauber, M. Jahnen, I. Rauscher, D. Sasse, M. Eiber;*
TUM-Klinikum Rechts der Isar, Munich, GERMANY.

EP-0483

Parametric Voxel-wise Fusion of 18F-PSMA PET/MR Improves Preoperative Discrimination of High-Grade Prostate Cancer

H. Shao[1], *G. Huang*[1], *Z. Liu*[2], *J. Hao*[2], *C. Wang*[2], *J. Liu*[1];
[1]Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanhgai, CHINA,
[2]Shanghai United Imaging Healthcare Co., Ltd, Shanhgai, CHINA.

EP-0484

PSMA-PET tumour volume stratifies non-metastatic castration-resistant prostate cancer

C. Civan[1], *M. Karpinski*[1], *C. Darr*[2], *T. Selvamoorthy*[1], *L. M. Rennau*[1], *S. Hoberück*[3], *M. Miederer*[3], *T. Hölscher*[4], *M. Bögemann*[5], *M. Schäfers*[5], *I. Rauscher*[6], *O. Guven*[6], *J. Calais*[7], *K. Kimura*[7], *D. Ufton*[8], *M. Miszczyk*[9], *M. Hofman*[10], *T. Hope*[11], *C. Kesch*[2], *K. Herrmann*[1], *B. Hadaschik*[2], *M. Eiber*[6], *W. P. Fendler*[1], *K. Rahbar*[5];
[1]Department of Nuclear Medicine, University of Duisburg-Essen, Essen, GERMANY,
[2]Department of Urology, University of Duisburg-Essen, Essen, GERMANY,
[3]Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, GERMANY,
[4]Department of Radiation Oncology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, GERMANY,
[5]Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY,
[6]Department of Nuclear Medicine, School of Medicine and Health, TUM University Hospital, Munich, GERMANY,
[7]Ahmanson Translational Theranostics Division, David Geffen School of Medicine at UCLA, Los Angeles, CA, UNITED STATES OF AMERICA,
[8]Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, GERMANY,
[9]Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, AUSTRIA,
[10]Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, AUSTRALIA,
[11]Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, UNITED STATES OF AMERICA.

EP-0485

PSMA PET/CT Knowledge Gaps Among Uroradiologists: Insights from a Tertiary Uro-Oncology MDT

M. El-Sayed[1], *O. S. Ahmed*[2];
[1]*Queen Elizabeth Hospital Birmingham, Birmingham, UNITED KINGDOM,*
[2]*Northern Care Alliance NHS Foundation Trust, Manchester, UNITED KINGDOM.*

EP-0486

Prognostic value of baseline FDG PET-derived Dmax in metastatic castration-resistant prostate cancer patients undergoing [^{177}Lu]PSMA therapy

K. Amrane[1], *C. Massard*[1], *C. Pobel*[1], *L. Lazerges*[1], *K. Trabelsi*[1], *Y. Cras*[1], *A. Patrikidou*[1], *M. Rey-Cardenas*[1], *S. Barraud*[1], *J. Uliano*[1], *A. Megherbi*[1], *F. Orlhac*[2], *I. Buvat*[2], *M. Terlizzi*[1], *L. Albiges*[1], *P. Blanchard*[1], *N. Naoun*[1], *M. Dipalma*[1], *Y. Loriot*[1], *R. Flippot*[1], *A. Bernard-Tessier*[1], *D. Deandreis*[1], *C. Garcia*[1];
[1]*Institut Gustave Roussy, Villejuif, FRANCE,*
[2]*Institut Curie, Orsay, FRANCE.*

EP-0487

Differentiating Prostate Cancer from Normal Tissue using Radiomics from Ga-68 PSMA PET/CT:A Comparative Study of Twelve Machine Learning Classifiers

J. Chaudhary[1], *A. K. Pandey*[1], *P. D. Sharma*[2], *R. Kumar*[1], *S. Kumar*[1], *K. P. Haresh*[1], *S. Kaushal*[1], *C. J. Das*[1], *R. K. Sahoo*[1], *M. Kalaivani*[1];
[1]*All India Institute of Medical Sciences, AIIMS, New Delhi, New Delhi, INDIA,*
[2]*SGTB Khalsa College, University of Delhi, Delhi, INDIA.*

EP-0488

Balancing speed and diagnostic confidence in long axial field-of-view PSMA-PET/CT: identifying the shortest clinically reliable acquisition

L. Airo' Farulla, *M. Cuomo, G. Cabrini, S. Capitanio, A. Franchini, E. Gay, A. F. Scarale, A. Spataro, K. Shyli, C. Rossetti;*
ASST Grande Ospedale Metropolitano Niguarda, Milano, ITALY.

EP-0489

Peritoneal Metastases from Prostate Cancer on PSMA PET/CT: Imaging Spectrum — A Single Tertiary Centre Experience

M. Umar, *V. Goenka, A. Babu, S. Singh, V. R. Singh, R. Kumar;*
AIIMS, New Delhi, INDIA,

EP-0490

Additional prognostic value of automated PSMA-PET lesion tracking in mCRPC patients undergoing [^{177}Lu]Lu-PSMA therapy: the median single-lesion volume change

S. Hein, *T. Lorenzini, D. Sasse, R. Zaum, I. Rauscher, M. Eiber, W. Weber;*
Department of Nuclear Medicine, Technical University of Munich, Munich, GERMANY.

EP-0491

Pelvic PSMA PETMR for Predicting Distant Metastasis of Prostate Cancer: A Prospective, Single-Center Study

S. Liu[1], *L. Qi*[2], *Y. Yang*[3], *S. Song*[1], *H. Yi*[1];
[1]*Department of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hang Zhou, CHINA,*
[2]*United Imaging Healthcare, Shanghai, CHINA,*
[3]*Beijing United Imaging Healthcare Technology Development Co., Ltd, Beijing, CHINA.*

EP-0492

Interpretable MLP-Based Multi-Regional Radiomics for Highly Accurate Discrimination of GRPR-Positive Prostate Cancer from Benign Accumulation

Z. Wang, *Y. Li, Y. Tang, S. Hu;*
Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China, CHINA.

EP-0493

Added Value of Contrast-Enhanced CT Urography in the Interpretation of PSMA PET/CT

M. Azorin Belda, *C. Sandoval Moreno, M. Torres Tarraga, G. Figueroa Ardila, E. Marques Aparicio, P. Gonzalez Cabezas, A. Orozco Rodriguez;*
Hospital Universitario del Vinalopó, Elche, SPAIN.

EP-0494

PET PSMA Versus Multiparametric MRI In The Diagnosis Of Prostate Cancer.

A. Borges da Silva[1], *J. Brunca*[2], *J. Oliveira Doro*[1], *F. Sandoval do Carmo*[2], *F. Toledo Bueno Pereira*[1], *F. de Galiza Barbosa*[3], *A. Fernandes Moraes*[3], *F. Lewin*[2], *R. de Carvalho Fernandes*[1], *L. Morato de Toledo*[1];
[1]*Faculdade de Ciências Médicas da Santa Casa de Misericórdia de São Paulo, Sao Paulo, BRAZIL,*
[2]*Irmandade da Santa Casa de Misericórdia de São Paulo, Sao Paulo, BRAZIL,*
[3]*CEDIMEN, Sao Paulo, BRAZIL.*

EP-0495

Gleason Burden Associated with MRIorthogonal PSMA PET residuals

S. Adomeit[1], *K. Tehlan*[1,2], *L. Förner*[1,2], *K. Weisser*[1], *H. Scholtissek*[1], *D. Kaufmann*[1], *J. Steinestel*[1], *M. Heck*[1], *B. Märkl*[1], *C. Lapa*[1], *T. Kröncke*[1], *T. Wendler*[1,2], *SA and KT are first authors with equal contribution;*
[1]*University Hospital Augsburg, Augsburg, GERMANY,*
[2]*Technical University of Munich, Munich, GERMANY.*

EP-0496

Prognostic Value of [^{68}Ga]Ga-PSMA PET-Derived Imaging Parameters in Treatment-Naïve mHSPC Patients Undergoing PSMA-RLT

I. Langrate[1], *H. Einspieler*[1], *L. Nics*[1], *S. Shariat*[2], *G. Kramer*[2], *M. Hacker*[1], *S. Rasul*[1];
[1]*Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA,*
[2]*Department of Urology, Medical University of Vienna, Vienna, AUSTRIA.*

EP-0497

Prostate metastasis volume segmentation criteria assessment using the Lesion Scout tool

M. Savanovic[1], *A. Govindoorazoo*[2], *S. Masson*[3], *P. d'Abadie*[3], *K. Fard*[3];
[1]*Siemens Healthineers, Courbevoie, FRANCE,*
[2]*Institut Caribéen d'Imagerie Nucléaire, Centre Hospitalier Universitaire de Martinique, Fort-de-France, MARTINIQUE,*
[3]*Institut Caribéen d'Imagerie Nucléaire, Centre Hospitalier Universitaire de Martinique, Fort de France, MARTINIQUE.*

EP-0498

Optimizing 68GA-PSMA-11 PET/CT imaging: evaluating the impact of dose reduction on lesion detection and image quality.

V. Baghel;
Vedanta Medical Research Foundation, Balco Medical Centre Raipur, Raipur, INDIA.

EP-0499

Defining Tracer-Specific Predictive Biomarkers on [^{18}F]F-JK-PSMA-7 Prior to [^{177}Lu]Lu -PSMA-Treatment

J. Weindler, *K. Roth, H. Weis, F. Meyer, L. Schroeder, A. Drzezga, M. Schmidt;*
Department of Nuclear Medicine, University Hospital of Cologne, Cologne, GERMANY.

EP-0500

PRIMARY Score ≤3 Plus PSA Density ≤0.2 Safely Avoids Immediate Biopsy in Suspected Prostate Cancer: A Dual-Center Real-World Study

Y. Tang[1], *J. Yang*[1], *Y. Li*[1], *L. Xiao*[1], *K. Shi*[2], *S. Hu*[1];
[1]*Xiangya Hospital Central South University, Changsha, CHINA,*
[2]*Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.*

EP-0501

Comparison of SUV Normalization Strategies for Quantitative [^{68}Ga]Ga-PSMA-11 and [^{18}F]PSMA-1007 PET/CT

A. Nikiforuk[1], *A. Khalimon*[1], *A. Shakirova*[1], *M. Khodzhibekova*[1], *G. Khamadeeva*[1], *D. Khodakova*[1], *T. Lazutina*[1], *I. Pylova*[1], *A. Lokhova*[1], *V. Bobrov*[1], *I. Baltabaev*[1], *A. Leontev*[1], *V. Solomyaniy*[2];
[1]*P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION,*
[2]*N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.*

EP-0502

RET-Targeted Theranostic Peptides Enable PET Imaging and Radioligand Therapy of Neuroendocrine Prostate Cancer

Y. Tang[1], *Y. Li*[1], *M. Zhou*[1], *L. Xiao*[1], *J. Yang*[1], *K. Shi*[2], *S. Hu*[1];
[1]*Xiangya Hospital Central South University, Changsha, CHINA,*
[2]*Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.*

EP-0503

From RECIP to RECICH: adapting volumetric PET response criteria for Choline PET in metastatic prostate cancer

P. Guglielmo[1], *L. Filippi*[2], *L. Urso*[3], *L. Evangelista*[1];
[1]*Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ITALY,*
[2]*Department of Biomedicine and Prevention, University of Rome 'Tor Vergata', Rome, ITALY,*
[3]*Department of Translational Medicine, University of Ferrara, Ferrara, ITALY.*

EP-0504

Bi-centric radiomic based and machine learning [^{68}Ga]Ga-PSMA PET/CT models: prediction of biochemical recurrence in prostate cancer patients after radical prostatectomy.

I. Badrane[1], *L. Urso*[1], *G. Scribano*[2], *L. Manco*[2], *C. Battisti*[3], *C. Ferrari*[3], *V. Lavelli*[3], *E. Benacchio*[1], *L. Uccelli*[1], *M. Giganti*[4], *G. Rubini*[3], *M. Bartolomei*[1], *C. Cittanti*[1];
[1]*Department of Translational Medicine, University of Ferrara, Ferrara, ITALY,*
[2]*Medical Physics Unit, University Hospital of Ferrara, Italy, Ferrara, ITALY,*
[3]*Nuclear Medicine Unit, University Hospital of Bari, Italy, Bari, ITALY,*
[4]*Radiology Unit, University Hospital of Ferrara, Italy, Ferrara, ITALY.*

EP-0505

Baseline PSMA-PET/CT Volumetric Parameters as Independent Predictors of Early Systemic Therapy Failure in Metastatic Prostate Cancer: Preliminary Results from the PELICAN Study

A. Di Giorgio[1], *V. Liberini*[2], *G. Ricciardello*[3], *V. Pau*[4], *V. Mollica*[5], *P. Castellucci*[1], *S. Fanti*[1,6], *M. Bauckneht*[4], *R. Laudicella*[3], *A. Farolfi*[6];
[1]*Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,*
[2]*Department of Nuclear Medicine, Azienda Ospedaliera S Croce e Carle Cuneo, Cuneo, ITALY,*
[3]*Nuclear Medicine, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, ITALY,*
[4]*IRCCS Azienda Ospedaliera Metropolitana, Genova, ITALY,*
[5]*Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[6]*Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

EP-0506

Physiological Distribution of Ga-68 PSMA in Tubarial and Major Salivary Glands

C. Kapulu Akca;
Ankara City Hospital, Ankara, TÜRKIYE.

EP-0507

Determining the Added Value of CT and MR in the morphological characterization of bone uptake detected by ^{18}FPSMA1007 PET in patients with prostate cancer

J. Garcia, *S. Ruiz, A. Compte, L. Mont, L. Pinilla, D. Tovar, E. Riera;*
CETIR ASCIRES Grupo biomédico, Barcelona, SPAIN.

EP-23

B: Imaging Clinical Studies → B1 Oncological Imaging Clinical Study → B19 Thyroid

EP-0508

Experimental and clinical evaluation of thyroid uptake quantification with ^{99}mTc-pertechnetate: comparison between planar scintigraphy and quantitative ^{3}D SPECT/CT

G. Shumilov[1,2], *N. Balamoutoff*[3], *T. Beaumont*[4], *S. Baydi*[1], *R. Amblard*[1], *R. Villeneuve*[1], *N. Garnier*[1], *F. Hugonnet*[3], *L. Champion*[3], *V. Nataf*[3], *F. Mocquot*[3], *C. Montemagno*[5], *V. Picco*[5], *B. Paulmier*[3], *B. Serrano*[1];
[1]*Centre Hospitalier Princesse Grace, Division de Radiophysique et de Radioprotection, Monaco, MONACO,*
[2]*Université Cote d'Azur, Institut de Physique de Nice, UMR 7010 INPHYNI, Nice, FRANCE,*
[3]*Centre Hospitalier Princesse Grace, Service de Médecine Nucléaire, Monaco, MONACO,*
[4]*Laboratoire d'évaluation de la dose interne, Autorité de sûreté nucléaire et de radioprotection, Fontenay-aux Roses, FRANCE,*
[5]*Centre Scientifique de Monaco, Département de Biologie Médicale, Monaco, MONACO.*

EP-0509

Development and Bidirectional Temporal Validation of a Prediction Model for Disease Progression in Tg-Negative, WBS-Positive Differentiated Thyroid Carcinoma

D. Nan[1,2,3], *R. Wu*[1,2,3], *Y. Han*[1,2,3], *X. Ren*[1,2,3], *J. Yuan*[1,2,3], *Y. Zhang*[1,2,3], *Y. Zhang*[1,2,3], *R. An*[1,2,3], *Z. Gao*[1,2,3];
[1]*Huazhong University of Science and Technology, Union Hospital, Tongji Medical College, Department of Nuclear Medicine, Wuhan, CHINA,*
[2]*Hubei Key Laboratory of Molecular Imaging, Wuhan, CHINA,*
[3]*Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, CHINA.*

EP-0510

Sarcopenia Analysis using FDG PET/CT in Differentiated Thyroid Cancer: Associations with RAI Therapy, ATA Risk Stratification, and Tumor Size

C. Kilinç, *A. Kibar, U. Korkmaz Kara, F. Ustun, A. Sarikaya;*
Trakya University Faculty of Medicine, Department of Nuclear Medicine, Edirne, TÜRKIYE.

EP-0511

Clinical Impact of Preablation I-131 SPECT/CT in Low-Risk Thyroid Cancer and the Predictive Role of Stimulated Thyroglobulin

S. Medina-Ornelas;
Ángeles Lindavista, Mexico City, MEXICO.

EP-0512

Quantitative Post-Therapy SPECT/CT Predicts Ablation Outcome After First I-131 Therapy in Differentiated Thyroid Cancer

R. Dias Correia[1], *S. Medici*[2], *S. Gnesin*[2], *J. Prior*[2], *N. Schaefer*[2], *M. Jreige*[2], *M. Nicod Lalonde*[2];
[1]*HFR | Fribourg Hospital, Fribourg, SWITZERLAND,*
[2]*CHUV | Vaud University Hospital, Lausanne, SWITZERLAND.*

EP-0513

Sequential [^{68}Ga]Ga-PSMA-11 and [^{18}F]FDG PET/CT in Differentiated Thyroid Cancer: A Prospective Comparative Analysis

K. Zajkowska[1], *E. Bakuła-Zalewska*[2], *P. Cegla*[1], *M. Wojewódzka-Mirocha*[1], *P. Ochman*[1], *A. Sackiewicz*[1], *J. Januszkiewicz-Caulier*[1], *A. Żyłka*[1], *M. Dedecjus*[1];
[1]*Department of Endocrine Oncology and Nuclear Medicine, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, POLAND,*
[2]*Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, POLAND.*

EP-0514

The utility of the initial I-131 diagnostic scan in complementing pathological staging prior to initiation of radioactive iodine in patients with differentiated thyroid carcinoma

O. Mbakaza, *N. H. Wheeler, M. W. Vangu;*
University of the Witwatersrand, Johannesburg, SOUTH AFRICA.

EP-0515

Challenges in Detecting Distant Metastases and Interpreting Post-Therapy Scans in Patients with Differentiated Thyroid Cancer

A. Savchenko[1,2], *G. Grushka*[3,2];
[1]*V. N. Karazin Kharkiv National University, Kharkiv, UKRAINE,*
[2]*State Organization "Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine", Kharkiv, UKRAINE,*
[3]*Kharkiv National Medical University, Kharkiv, UKRAINE.*

EP-24

B: Imaging Clinical Studies → B1 Oncological Imaging Clinical Study → B20 Gynaecological

EP-0516

Hypoxia imaging with [^{18}F]FMISO of primary cervical carcinoma in women with locally advanced disease

J. Warwick[1], *C. Burger*[1], *H. Simonds*[1], *H. Burger*[1], *A. Doruyter*[1], *A. Ellmann*[1], *J. le Roux*[1], *J. Oliver*[1,2], *M. Mix*[2];
[1]*Stellenbosch University, Cape Town, SOUTH AFRICA,*
[2]*University of Freiburg, Freiburg, GERMANY.*

EP-0517

The diagnostic performance and uptake characteristics of [^{68}Ga]Ga-DOTA-FAPI-04 PET/CT for ovarian cancer metastases

J. Wang, *Z. Xia, L. Xu, H. Pang;*
The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EP-0518

Role of lymphatic mapping in targeted axillary dissection after neoadjuvant therapy: nodal concordance analysis.

L. Carreño Mancilla[1], *L. F. León Ramírez*[1], *C. G. Wakfie Corieh*[1], *C. González Roiz*[1], *M. Herrera de la Muela*[2], *J. M. Brenes Sánchez*[2], *M. Romero Porras*[1], *M. Zapardiel Martinez-Falero*[1], *M. Vaillant López*[1], *R. R. Arcondo Vargas*[1], *M. N. Cabrera-Martín*[1];
[1]*Nuclear Medicine Deparment, Hospital Clinico San Carlos, Madrid, SPAIN,*
[2]*Breast Pathology Unit, Institute of Women's Health, Hospital Clinico San Carlos, Madrid, SPAIN.*

EP-0519

Predictive Value of ^{18}F-FDG PET/MR Imaging Parameters for Molecular Biomarkers in GynecologicalMalignancies

L. Han[1], *Y. Xing*[1,2], *Q. Ji*[2], *Y. Hu*[2];
[1]*Shanghai General Hospital, Shanghai, CHINA,*
[2]*Shanghai United Imaging Healthcare Co., Ltd., Shanghai, CHINA.*

EP-0520

Dynamic Whole-Body FDG-PET for Differentiating Pathological from Physiological Uptake in Gynecological Cancer: Comparison with Dual-Time Imaging and Potential for Kinetic Analysis

S. Yamada[1], *T. Kotani*[1], *N. Tamaki*[2], *M. Kiba*[1], *S. Akiyama*[1], *T. Kanayama*[1], *Y. Tanada*[1];
[1]*Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, JAPAN,*
[2]*Kyoto University of Medical Science, Kyoto, JAPAN.*

EP-0521

Gross tumour volume delineation in uterine cervical cancer - comparison of mpMRI and ^{18}F-FDG PET/mpMRI

M. Zarei[1], *K. Sandgren*[1], *D. Lindquist*[2], *P. Cadavid*[2], *C. Öfverman*[2], *K. Söderkvist*[2], *T. Nyholm*[1], *E. Wallsten*[1], *S. Strandberg*[3];
[1]*Department of Diagnostics and Intervention, Radiation Physics, Umeå University, Umeå, SWEDEN,*
[2]*Department of Diagnostics and Intervention, Oncology, Umeå University, Umeå, SWEDEN,*
[3]*Department of Diagnostics and Intervention, Diagnostic Radiology, Umeå University, Umeå, SWEDEN.*

EP-0522

Evaluation of the diagnostic performance of pelvic ^{18}F-FDG PET/MRI in the initial staging of endometrial cancer at the University Hospital of Martinique

C. Bourgeois, *S. Masson, P. d'Abadie, L. Gieskes, Q. Hurlot, A. Lintis, K. Fard;*
Caribbean Institute of Nuclear Imaging, Martinique University Hospital, Fort de France Cedex, MARTINIQUE.

EP-25

B: Imaging Clinical Studies → B1 Oncological Imaging Clinical Study → B21 Lymphoma

EP-0523

Which tracer for which subtype? A prospective comparative study of ^{68}Ga-pentixafor and ^{18}F-FDG PET/CT across indolent non-Hodgkin lymphomas

J. Song;
Zhejiang Cancer Hospital, Hangzhou, CHINA.

EP-0524

Independent validation of the International Metabolic Prognostic Index in patients with aggressive diffuse large B-cell lymphoma treated with CAR-T

E. Romano Gargarella[1], *F. Portonera*[1], *A. Guarneri*[2], *E. Galli*[3], *F. Sorà*[4], *I. Pansini*[4], *L. Leccisotti*[1], *M. Calcagni*[1], *S. Hohaus*[4];
[1]*Section of Nuclear Medicine, Department of Radiological Sciences and Hematology, Sacred Heart Catholic University, Rome, ITALY,*
[2]*Unit of Nuclear Medicine, IRCCS A. Gemelli University Polyclinic Foundation, Rome, ITALY,*
[3]*Section of Hematology, Department of Laboratory and Hematological Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, ITALY,*
[4]*Hematology Section, Department of Radiological and Hematological Sciences, Catholic University of the Sacred Heart, Rome, ITALY.*

EP-0525

What can PET/CT tell us 60 days after CAR-T therapy?

P. Ziolkowska[1], *M. Wyrzykowski*[2], *K. Ślusarz*[2], *M. Ciesielski*[1], *M. Ruchała*[1], *E. Bembnista*[3], *L. Gil*[3], *R. Czepczyński*[1];
[1]*Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, POLAND,*
[2]*Department of Nuclear Medicine, Affidea Poznań, Poznan, POLAND,*
[3]*Department of Haematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, POLAND.*

EP-0526

PET-based outcome prediction in large B-Cell lymphoma patients undergoing CAR T-cell therapy with lisocabtagene maraleucel

C. Voltin[1,2], *S. Escribano-Serrat*[3,4], *B. Agridag Ucpinar*[1], *M. Gómez-Llobell*[3], *S. Einarsdottir*[3], *E. Luttwak*[5], *B. S. Imber*[6], *R. Shouval*[3,7], *H. Schöder*[1];
[1]*Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Centre, New York, NY, UNITED STATES OF AMERICA,*
[2]*Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, GERMANY,*
[3]*Adult Bone Marrow Transplant Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Centre, New York, NY, UNITED STATES OF AMERICA,*
[4]*Department of Medicine, Universitat Autònoma de*

Barcelona, Barcelona, SPAIN,
[5]Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Centre, New York, NY, UNITED STATES OF AMERICA,
[6]Department of Radiation Oncology, Memorial Sloan Kettering Cancer Centre, New York, NY, UNITED STATES OF AMERICA,
[7]Department of Medicine, Weill Cornell Medical College, New York, NY, UNITED STATES OF AMERICA.

EP-0527

Pathology-Correlated FDG-PET Radiomics to Differentiate FL Progression from Histologic Transformation at the Lesion Level

***J. Kuten**, E. Luttwak, C. White, A. Mauguen, P. Shobeiri, D. Lafontaine, A. Qiu, M. Okwali, G. Salles, H. Schoder;*
Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0528

CXCR4-Targeted PET/CT Identifies FDG-Negative Indolent Lymphoma: A Case Demonstrating the Potential of Receptor-Based Imaging

***R. Kakde**, A. Bhange, S. Bamborde;*
American Oncology Institute and Nangia Speciality Hospital, Nagpur, INDIA.

EP-0529

Baseline FDG PET-derived metabolic tumour burden identifies early progression in low-tumour burden follicular lymphoma managed with watchful waiting

***E. Abenavoli**[1], M. Ciceri[2], B. Puccini[2], L. Nassi[2], B. Sordi[2,3], A. Pasquini[4], A. M. Vannucchi[3], R. Sciagrà[5], V. Berti[5];*
[1]Nuclear Medicine Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY,
[2]Hematology Department, University of Florence and Azienda Ospedaliero Universitaria Careggi, Florence, ITALY,
[3]Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, ITALY,
[4]Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, ITALY,
[5]Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, ITALY.

EP-0530

Prognostic Value of Distance-Based Tumour Dissemination Metrics on Baseline ^{18}F-FDG PET/CT in Paediatric Hodgkin Lymphoma

***M. Dunaykin**, K. Chaurasiya, E. Kireeva, M. Yadgarov, Y. Likar;*
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, RUSSIAN FEDERATION.

EP-0531

Predictive Value of Left Ventricular FDG PET/CT Derived Parameters and Uptake Patterns for Chemotherapy-Induced Cardiotoxicity in Patients With Lymphoma

***S. Alex Hong**[1], M. Huy Thong[1], P. Jin Chun[2];*
[1]Military Hospital [108], Hanoi, VIET NAM,
[2]Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

EP-0532

Baseline Whole-Body Metabolic Tumour Volume as an Independent Predictor of Event-Free Survival in Diffuse Large B-Cell Lymphoma

***M. Yadav**, S. Shah, J. Goda, N. Purandare, A. Agrawal, A. Puranik, S. Choudhury, M. Sengar, L. Nayak, B. Bagal, H. Jain, V. Rangarajan;*
Tata Memorial Centre, Mumbai, INDIA.

EP-0533

The impact of EARL harmonization on inter-reconstruction variability of MTV and TLG in patients with primary aggressive lymphoma

***D. Khodakova**[1], A. Khalimon[1], V. Bobrov[1], G. Khamadeeva[1], M. Khodzhibekova[1], T. Lazutina[1], I. Pylova[1], A. Nikiforuk[1], A. Leontev[1], K. Dudukin[2], T. Dengina[2], O. Mukhortova[2], I. Aslanidi[2];*
[1]P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION,
[2]A. N. Bakulev National Medical Research Center for Cardiovascular Surgery of the Russian Ministry of Health, Moscow, RUSSIAN FEDERATION.

EP-0534

Head-to-head comparison of ^{18}F-FDG PET/CT and PET/MR for metabolic assessment in primary central nervous system lymphoma

***W. Zhou**, Y. Guo, J. Dai, H. Ye;*
The Affiliated Cancer Hospital of Xiangya School of Medicine/Hunan Cancer Hospital, Central South Un, Changsha, CHINA.

EP-0535

Investigating the Association between Diagnostic PET Parameters and Immune Features in Diffuse Large B-Cell Lymphoma

***J. Huang**[1], F. Mohammad[2], L. Hong[3], G. Shenoy[3], S. Shridar[3], I. Biju[3], C. Ong[3], P. Jaynes[3], M. Hoppe[3], L. Min[3,4], S. Fan[5], Y. Peng[3], X. Liu[6], R. Chua[6], J.[6], Y. Batumalai[6], S. De Mel[6,7], L. Poon[6,7], E. Chan[6,7], J. Lee[6,7], Y. Chee[6,7], S. Ng[3,5,7], S. Hue[5,7], A. Jeyasekharan[3,6,7,8], **P. Ngam**[1];*
[1]Department of Diagnostic Imaging, National University Hospital, Singapore, SINGAPORE,
[2]Clinical Imaging Research Centre, National University of Singapore, Singapore, SINGAPORE,
[3]Cancer Science Institute of Singapore, National University of Singapore, Singapore, SINGAPORE,
[4]Department of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing, CHINA,
[5]Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,
[6]Department of Haematology-Oncology, National University Cancer Institute, Singapore, SINGAPORE,
[7]NUS Centre for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,
[8]Institute of Molecular and Cell Biology, Agency of Science Technology and Research, Singapore, Singapore, SINGAPORE.

EP-0536

The Role of PET Radiomics Features Derived from Staging ^{18}F-FDG PET/MR in Predicting Interim PET Treatment Response and Progression-Free Survival in Diffuse Large B-Cell Lymphoma

***R. Kalkan**, S. Ateş, U. Aydos, L. Atay;*
Gazi University Faculty of Medicine, Ankara, TÜRKIYE.

EP-0537

Total-Body Dual Time-Point Interim [^{18}F]FDG PET/CT in Hodgkin and Non-Hodgkin Lymphoma: Prognostic Value of Deauville Score and Retention Index

***M. Di Franco**[1], G. Liu[1], Y. G. Abdelhafez[1], A. Di Giorgio[2], X. Wu[3], J. An[3], N. S. Esteghamat[3], S. Li[1], B. A. Spencer[1], L. Nardo[1];*
[1]Department of Radiology, University of California, Davis, Davis, CA, UNITED STATES OF AMERICA,
[2]Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,
[3]Department of Hematology and Oncology, University of California, Davis, Davis, CA, UNITED STATES OF AMERICA.

EP-0538

Volumetric tumor density index: a novel PET-based prognostic parameter for Hodgkin lymphoma — a single-center retrospective study

***E. Kaya**[1], B. Esen Akkaş[1], S. G. Yaran[1], S. Bayram[1], B. T. Tonyalı[2], I. Öztürk[1], A. B. Topçuoğlu[1], M. Ayer[2], M. Kaya[1];*
[1]Basaksehir Cam and Sakura City Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,
[2]Basaksehir Cam and Sakura City Hospital, Department of Hematology, Istanbul, TÜRKIYE.

EP-0539

Baseline ^{18}F-FDG PET/CT metabolic parameters and supplementary prognostic stratification in double-expressor diffuse large B-cell lymphoma

***J. Gui**, X. Long, X. Lan, W. Cao;*
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0540

Metabolic Tumor Volume Complements Metrics in RECIL and Lugano Criteria in Response Assessment in Multiple Relapsed Hodgkin Lymphoma

***J. Weindler**[1], P. Bröckelmann[2], C. Baues[3], J. Rosenbrock[4], K. Roth[1], C. Kobe[1];*
[1]Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany, Cologne, GERMANY,
[2]Department I of Internal Medicine, German Hodgkin Study Group (GHSG), Center of Integrated Oncology (CIO) Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany, Cologne, GERMANY,
[3]Department of Radiation Oncology, University Hospital of Ruhr-Universität Bochum, Marien Hospital Herne, Herne, Germany, Cologne, GERMANY,
[4]Department of Radiation Oncology, Cyberknife and Radiotherapy, University Hospital of Cologne, Cologne, Germany., Cologne, GERMANY.

EP-0541

Quantitative Interim PET Metrics Outperform Deauville Score in Predicting Progression-Free Survival in Follicular Lymphoma

***I. Nagy**[1], C. Csikos[1], P. Czina[1], I. Garai[1,2], Á. Illés[3], Á. Jóna[3];*
[1]Division of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY,
[2]Scanomed Ltd., Debrecen, HUNGARY,
[3]Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY.

EP-0542

Beyond Deauville: Quantitative PET Delta Parameters Outperform Categorical Interim Response in Predicting Progression-Free Survival in DLBCL

***M. Öztepe**, K. A. Küçüker, A. Aksu, A. Özdal, B. Turgut;*
Izmir Katip Celebi University, Faculty of Medicine, Department of Nuclear Medicine, Izmir, TÜRKIYE.

EP-0543

Baseline SUVmax on [^{18}F]FDG PET/CT Reflects Systemic Inflammation and Predicts Progression-Free Survival in MALT Lymphoma

***Y. Han**, X. Zhang, Z. Gao;*
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Scien, Wuhan, CHINA.

EP-0544

A Three-Tier Visual Grading Model of Bone Marrow FDG Uptake Improves Prognostic Stratification in Diffuse Large B-Cell Lymphoma

***B. Choi**[1], H. Song[2];*
[1]Department of Nuclear medicine, Daegu Catholic University School of Medicine, Daegu Catholic University Hospital, Daegu, KOREA, REPUBLIC OF,
[2]Department of Nuclear medicine, Chonnam National University School of Medicine, Chonnam National University Hospital, Gwangju, KOREA, REPUBLIC OF.

EP-0545

Multimodal deep learning-basedFDG PET/CTprognostic imaging biomarker for Hodgkin lymphoma patients: a multicenter study

***Y. Liu**, R. Tian, C. Jiang;*
Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, CHINA.

EP-0546

Investigation of the Contribution of ^{18}F-FDG PET/CT to Diagnosis and Treatment Management In Individuals Infected With HIV

***A. N. Beytur**[1], M. F. Beytur[2], B. Mete[1], Ö. F. Tabak[1], G. Aygün[1], N. Saltoğlu[1], I. I. Balkan[1], S. Yıldız Kaya[1], R. Karaali[1];*
[1]Istanbul University Cerrahpasa, Department of Infectious Diseases, Istanbul, TÜRKIYE,
[2]Istanbul Medeniyet University, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

EP-0547

Higher lesion conspicuity in lymphoma patients with delayed [18F]FDG Total-Body PET/CT

C. Mingels[1], *H. Nalbant*[2], *K. J. Chung*[2], *M. Pires*[3], *L. K. Sundar*[3], *S. Zoghi*[2], *F. Sen*[2], *N. S. Esteghamat*[4], *J. Tuscano*[4], *A. Rominger*[1], *Y. G. Abdelhafez*[2], *B. Spencer*[2], *L. Nardo*[2];
[1]*Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND,*
[2]*Department of Radiology, University of California Davis, Sacramento, CA, UNITED STATES OF AMERICA,*
[3]*Medical University of Vienna, Vienna, AUSTRIA,*
[4]*Division of Malignant Hematology, Cellular Therapy & Transplantation, Department of Internal Medicine, University of California Davis, Sacramento, CA, UNITED STATES OF AMERICA.*

EP-0548

Beyond Tumour Burden: Spleen-Referenced Spatial Dissemination on Baseline 18F-FDG PET/CT Predicts Interim Treatment Response in DLBCL

H. Althaf, *D. Datta, P. Pal, R. Kumar;*
All India Institute of Medical Sciences, Jodhpur, Jodhpur, Rajasthan, INDIA.

EP-0549

PET-Integrated Multimodal Nomograms: Predicting CAR T-cell Therapy Outcomes via Hematological and Clinical Resistance Markers in Large B-cell Lymphoma

S. Proto[1,2], *C. Malizia*[3], *B. Casadei*[4], *M. Gentilini*[5], *F. Bonifazi*[4], *R. Ussia*[6], *A. Paccagnella*[7], *P. L. Zinzani*[4,5], *C. Nanni*[8], *S. Fanti*[1,8], *A. Farolfi*[8];
[1]*Nuclear Medicine, Alma Mater Studiorum Bologna, Bologna, ITALY,*
[2]*Nuclear Medicine, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI) and University of Trieste, Trieste, ITALY,*
[3]*Medicina Nucleare, Azienda Ospedaliero-Universitaria di Modena, Modena, ITALY,*
[4]*IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, ITALY,*
[5]*Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, ITALY,*
[6]*Nuclear Medicine, Ospedale S.S. Annunziata, ASL2 Abruzzo, Chieti, ITALY,*
[7]*Nuclear Medicine, AUSL Romagna, Cesena, ITALY,*
[8]*Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

EP-0550

68Ga-Pentixafor PET/CT versus 18F-FDG PET/CT in Indolent B-Cell Lymphoma: A Prospective Head-to-Head Comparison

T. Han, *Z. Quan, M. Zhang, J. Wang, F. Kang;*
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

EP-0551

Virtual Non-Contrast CT for PET/CT Attenuation Correction: Influence on Deauville Score Assessment in Lymphoma

R. Gerdes[1], *P. Linder*[1], *E. Calderón*[1], *H. Dittmann*[1], *J. Sekler*[1], *C. la Fougère*[1], *N. Trautwein*[1], *A. Brendlin*[2];
[1]*University Hospital Tuebingen, Department of Nuclear Medicine and Clinical Molecular Imaging, Tuebingen, GERMANY,*
[2]*University Hospital Tuebingen, Department of Diagnostic and Interventional Radiology, Tuebingen, GERMANY.*

EP-0552

Impact of lesion selection and reconstruction methods on stability of PET-based radiomics predictions in DLBCL

E. Wallstén[1], *A. L. Bes*[2,3], *G. J. C. Zwezerijnen*[2], *M. C. Ferrandez-Ferrandez*[2], *S. E. Wiegers*[2], *J. M. Zijlstra*[3], *R. Boellaard*[2];
[1]*Department of Diagnostics and Intervention, Radiation Physics, Umeå University, Umeå, SWEDEN,*
[2]*Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, NETHERLANDS,*
[3]*Hematology, Amsterdam UMC, Amsterdam, NETHERLANDS.*

EP-0553

Baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography-derived cerebellum-to-liver index as an independent prognostic biomarker in diffuse large B-cell lymphoma

F. Montenegro Muñoz[1], *C. Siscar Gelo*[2], *L. Casas Calabuig*[1], *E. Donato Martín*[1], *M. Fernández Zarzoso*[1], *F. Cavagna Matti*[1], *G. Bonino*[1], *J. Fernández Bernal*[2], *M. Iborra Valls*[2], *P. Vólquez Díaz*[2], *N. Rudić Chipe*[2], *T. Mut Dólera*[3], *P. Abreu Sánchez*[1], *M. Á. Navas de la Cruz*[1], *A. Abella Tarazona*[1], *M. C. Plancha Mansanet*[1], *J. R. Infante de la Torre*[1], *D. Flores Couce*[2], *E. Caballero Calabuig*[1];
[1]*Hospital Universitari Dr. Peset, València, SPAIN,*
[2]*Consorci Hospitalari Provincial de Castelló, Castelló de la Plana, SPAIN,*
[3]*Hospital Clínic Universitari de València, València, SPAIN.*

EP-0554

[68Ga]Ga-PentixaFor imaging for the staging of patients with confirmed marginal zone lymphoma in comparison to [18F]FDG: final results of a prospective, multi-centre trial

S. Annunziata[1], *D. A. Pizzuto*[1], *L. Rossetti*[2], *D. Wolf*[3], *M. Celli*[4], *P. Rossi*[4], *A. Cottereau*[5], *M. Vignon*[5], *H. Reis*[6], *S. Pickel*[6], *A. Buck*[7];
[1]*Fondazione Policlinico A. Gemelli IRCCS, Roma, ITALY,*
[2]*Medical University of Innsbruck, Innsbruck, AUSTRIA,*
[3]*Universitätsklink Innsburck UKIM V, Innsbruck, AUSTRIA,*
[4]*Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS, Meldola, ITALY,*
[5]*Cochin Hospital, University Paris Cité, Paris, FRANCE,*
[6]*Pentixapharm AG, Berlin, GERMANY,*
[7]*University Hospital Würzburg, Würzburg, GERMANY.*

EP-0555

Longitudinal Evaluation of Metabolic Response Using PET/CT After CAR-T Therapy in Patients with Lymphoma

M. Avilés Jurado, *P. Sarandeses Fernandez, S. Angiolillo Grau, A. Saviatto Nardi, X. Guarnizo Poma, D. M. Diaz Vega;*
Hu 12 de Octubre, Madrid, SPAIN.

EP-0556

Radiogenomic Associations Between PET-Derived Tumor Burden, Dissemination Metrics, and Immune-Related Risk Profiles in Classical Hodgkin Lymphoma

R. Durmo, *B. Donati, T. Lazic, R. Valli, A. Gennaro, A. Arnone, F. Merli, A. Ciarrocchi, S. Luminari, A. Filice;*
AUSL-IRCCS of Reggio Emilia, Reggio Emilia, ITALY.

EP-0557

Siemens VB80 AI-based total metabolic tumour volume in lymphoma studies at baseline FDG-PET/CT - External validation

M. Sadik[1], *J. Lopez Urdaneta*[1], *M. Larsson*[2], *E. Trägårdh*[3], *L. Edenbrandt*[1];
[1]*Medicine, Gothenburg, SWEDEN,*
[2]*Eigenvision AB, Lund, SWEDEN,*
[3]*Clinical Physiology and Nuclear Medicine and Translational Medicine and Wallenberg Center for Molecular Medicine, Malmö, SWEDEN.*

EP-26

B: Imaging Clinical Studies → B1 Oncological Imaging Clinical Study → B22 Other Hemato-Oncology

EP-0558

Baseline 18FFDG PET/CT and WholeBody Diffusion MRI in Newly Diagnosed Multiple Myeloma: Preliminary Results of a Prospective Multimodality Imaging Study

M. Tormo Ratera[1], *M. Negre-Busó*[1], *E. Balliu Collgrós*[2], *E. de la Calle Vargas*[3], *J. García-Martínez*[1], *A. Afonso de Matos*[1], *S. Castanyer*[1], *X. Molina Arcas*[2], *R. Barquet Muro*[2], *I. Pelaez Hernández*[2], *A. Barceló Poch*[2], *M. Guillén Garcia*[2], *V. Pineda Sanchez*[2], *A. Garzo Moreno*[4], *Y. Gonzalez Montes*[4], *N. Ferran Sureda*[1], *A. Rubió Rodríguez*[1];
[1]*Nuclear medicine department, Hospital Universitari Doctor Josep Trueta, Girona, SPAIN,*
[2]*Radiology department, Hospital Universitari Doctor Josep Trueta, Girona, SPAIN,*
[3]*Department of Radiology, Hospital Universitari Doctor Josep Trueta, Girona, SPAIN,*
[4]*Hematology department, Hospital Universitari Doctor Josep Trueta, Girona, SPAIN.*

EP-0559

Identification of mature teratoma in post-chemotherapy residual masses of non-seminomatous germ cell tumour patients using αvβ3-integrin PET: the TERMATEP prospective pilot study

N. Aide[1], *F. Courbon*[2], *E. Mériaux*[1], *J. P. Lotz*[3], *J. M. Grellard*[1], *C. Chevraux*[2], *F. Joly*[1], *B. Clarisse*[1];
[1]*Centre Baclesse, Caen, FRANCE,*
[2]*Institut Universitaire du Cancer, Toulouse, FRANCE,*
[3]*CHU Tenon, Paris, FRANCE.*

EP-0560

Light-chain type and its potential influence on PET/CT findings in monoclonal gammopathies

M. Romero Porras, *L. Carreño Mancilla, C. Wakfie Corieh, R. Couto Caro, M. Zapardiel Martínez-Falero, M. Vaillant López, A. Berardinelli Isea, M. Cabrera-Martín;*
Nuclear Medicine Department, Hospital Clinico San Carlos, Madrid, SPAIN.

EP-0561

A multicenter phase II trial of [18F]mFBG PET/CT versus [123I]mIBG scintigraphy in neuroblastoma: the REDEFINE trial protocol

J. Rogasch[1,2], *T. Knieß*[3], *O. C. Kiß*[3], *S. Castelli*[2,4], *A. Szymansky*[2,4], *R. Roehle*[5], *A. S. Littooij*[6,7], *B. de Keizer*[6,7], *L. Borgwardt*[8], *J. F. Schäfer*[9,10], *M. Steffann*[11], *J. Fouque*[11], *H. Amthauer*[1], *W. Brenner*[1,2,10], *H. E. Deubzer*[2,4,10];
[1]*Department of Nuclear Medicine, Charité – Universitätsmedizin Berlin, Berlin, GERMANY,*
[2]*National Center for Tumor Diseases (NCT), NCT Berlin, a partnership between DKFZ, Charité – Universitätsmedizin Berlin, Berlin Institute of Health at Charité (BIH), Max Delbrück Center, Berlin, GERMANY,*
[3]*Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, GERMANY,*
[4]*Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, Berlin, GERMANY,*
[5]*Institute of Biometry and Clinical Epidemiology, Charité – Universitätsmedizin Berlin, Berlin, GERMANY,*
[6]*Department of Radiology and Nuclear Medicine, University Medical Centre Utrecht, Utrecht, NETHERLANDS,*
[7]*Princess Máxima Center for Pediatric Oncology, Utrecht, NETHERLANDS,*
[8]*Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, Copenhagen, DENMARK,*
[9]*Department of Diagnostic and Interventional Radiology, University Hospital Tübingen, Tübingen, GERMANY,*
[10]*German Cancer Consortium (DKTK), Partner Sites Berlin and Tübingen, and German Cancer Research Center (DKFZ), Heidelberg, GERMANY,*
[11]*Radiopharmacy, Institut Curie, Saint Cloud, Paris, FRANCE.*

EP-0562

Impact of Filgrastim Timing and Patient Age on Bone Marrow [18F]FDG Uptake: Validating Updated EANM Guidelines in Hemato-Oncology

W. Wong;
Queen Elizabeth Hospital, Hong Kong, HONG KONG.

EP-0563

18F-fluorocholine Versus 18F-fluorodeoxyglucose PET/CT For The Detection Of Bone Lesions In Patients With Multiple Myeloma

L. Bonniaud[1], *L. Jallet*[1], *P. Nunes*[1], *D. Caillot*[2], *A. Herbin*[3], *A. Payssot*[4], *J. Matuszak*[5], *A. Fouquier*[1], *A. Cochet*[1], *J. Fontan*[5], *C. Drouet*[1];
[1]*Centre Georges Francois Leclerc, Dijon, FRANCE,*
[2]*Institut de Cancérologie de Bourgogne, Dijon, FRANCE,*
[3]*CHU Dijon Bourgogne, Dijon, FRANCE,*
[4]*Clinique du Parc, Castelnau-Le-Lez, FRANCE,*
[5]*CHU Besançon Franche-Comté, Besançon, FRANCE.*

EP-0564

Automated Whole-Skeleton 11C-MET PET Quantification for Prognostic Stratification in Newly Diagnosed Multiple Myeloma

J. Lv;
Department of Nuclear Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, CHINA.

EP-0565

Blood-pool uptake on BCMA PET/CT enables in vivo imaging of circulating disease burden in multiple myeloma

T. Gu, *Z. Chen, Q. Yang, T. Wang, J. Zhang, L. Kang;*
Peking University First Hospital, Beijing, CHINA.

EP-0566

Metabolic characterization of multiple myeloma using ^{18}F-FDG PET/CT: added value of lesion-to-liver SUVmax ratio and uptake patterns

L. Carreño Mancilla, *M. Romero Porras, C. G. Wakfie Corieh, R. M. Couto Caro, M. Vaillant López, M. Zapardiel Martinez-Falero, R. R. Arcondo Vargas, M. Cornide Carallo, A. E. Berardinelli Isea, M. Cabrera-Martín;*
Nuclear medicine Deparment, Hospital Clinico San Carlos, Madrid, SPAIN.

EP-0567

Integrated FDG PET/MR Assessment at Staging and Post-Induction Therapy in Multiple Myeloma Patients Pre- Autologous Stem Cell Transplantation (ASCT), and preliminary results of the FDG PET/MR after ASCT: Prognostic Value of Deauville and MY-RADS Scores

F. Serani[1], *F. Crimì*[2], *L. Turk*[3], *E. Lacognata*[4], *M. Calcagni*[5], *R. Zambello*[6], *L. Pavan*[6], *D. Cecchin*[1];
[1]*Nuclear Medicine Unit, Department of Medicine DIMED, University of Padova;*
Nucleare Medicine Unit, DIDAS, University Hospital of Padova, Padova, ITALY,
[2]*Radiology Unit, Department of Medicine DIMED, University-Hospital of Padova;*
Radiology Unit, DIDAS, University hospital of Padova, Padova, ITALY,
[3]*Nuclear Medicine Unit, DIDAS, University-Hospital of Padova, Padova, ITALY,*
[4]*Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, ITALY,*
[5]*Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, ITALY,*
[6]*Hematology Unit, Department of Medicine DIMED, University of Padova, Padova, ITALY.*

EP-0568

Prognostic value of standardized quantitative PET-biomarkers in elderly newly diagnosed Multiple Myeloma

G. Krause, *S. E. Wiegers, B. G. J. B. Zwezerijnen, M. Heymans, S. Zweegman, J. M. Zijlstra - Baalbergen, R. Boellaard;*
Amsterdam UMC, Amsterdam, NETHERLANDS.

EP-0569

Predictive value of baseline quantitative PET parameters for early metabolic response following CAR-T therapy.

F. Caltagirone Gutierrez, *J. C. Cañadas Salazar, L. G. Diaz Gonzalez, E. Casillas Sagrado, S. Rama Alonso, A. C. Peñaherrera Cepeda, J. G. Villanueva Curto, J. A. Badell Martinez, F. Gomez Caminero Lopez, P. García-Talavera San Miguel, F. Ulloa Mejia, M. Fernandez Arteaga, J. M. Valarezo Jimenez, B. Santos García, E. Martin Gomez, M. P. Tamayo Alonso;*
Hospital Universitario de Salamanca, Salamanca, SPAIN.

EP-0570

Prognostic and Toxicity Predictive Value of Baseline [^{18}F]FDG PET/CT Metrics Combined with Clinical Biomarkers in Multiple Myeloma Patients Undergoing CAR-T Therapy

X. Feng, *W. Song, C. Qin, X. Lan;*
Union Hospital, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0571

Imaging patterns and biochemical markers in monoclonal gammopathies: a descriptive analysis of MGUS and multiple myeloma patients

M. Romero Porras, *L. Carreño Mancilla, C. Wakfie Corieh, R. Couto Caro, M. Vaillant López, M. Zapardiel Martínez-Falero, M. Cornide Carrallo, R. Arcondo Vargas, M. Cabrera-Martín;*
Nuclear Medicine Department, Hospital Clínico San Carlos, Madrid, SPAIN.

EP-27

B: Imaging Clinical Studies → B1 Oncological Imaging Clinical Study → B24 Melanoma

EP-0572

Role of ^{68}Ga- FAPI-46 in Melanoma patients: A comparative analysis with^{18}F-FDG PET/CT

S. Shamim, *Y. Dharmashaktu, M. K. Taggar, N. A. Damle, S. Rastogi, G. Arora;*
All India Institute of Medical Sciences, New Delhi, Delhi, INDIA.

EP-0573

Longitudinal FDG PET/CT metabolic changes at six months predict survival in melanoma patients treated with immunotherapy

B. M'Hamdi[1], *S. Latifyan*[1], *L. Borras-Ferris*[1,2], *M. Nicod-Lalonde*[1], *N. Schaefer*[1], *J. O. Prior*[1], *A. Depeursinge*[1,2], *M. Jreige*[1];
[1]*Centre hospitalier universitaire vaudois (CHUV), Lausanne, SWITZERLAND,*
[2]*HES-SO Valais, Sierre, SWITZERLAND.*

EP-0574

Precise monitoring of acquired drug resistance in melanoma: First-in-Humans PET Imaging of the key rate-limiting enzymes in the fatty acid synthesis pathway

J. Ye, *R. Yang, F. Kang, J. Wang;*
Xijing Hospital, Xi'an, CHINA.

EP-0575

Prognostic Value of ^{18}F-FDG PET/CT Imaging Parameters in Metastatic Melanoma Patients Undergoing Combined Immunotherapy

M. Breuer[1], *A. Chaban*[1], *O. Persa*[2], *W. Weber*[1];
[1]*Nuclear Medicine Department, Klinikum rechts der Isar, Munich, GERMANY,*
[2]*Department of Dermatology, Klinikum rechts der Isar, TUM, Munich, GERMANY.*

EP-0576

Head-to-head Comparison of [^{68}Ga]FAPI-46 and [^{18}F]FDG PET/CT in Patients with Malignant Melanoma

Y. Yang, *J. Guo, M. Zhou, J. Su, X. Chen, S. Hu;*
Xiangya Hospital, Central South University, Changsha, CHINA.

EP-0577

PET/CT versus RECIST 1.1 criteria in the evaluation of response to immunotherapy of advanced malignant melanoma

R. Czepczynski[1], *L. Galus*[1], *M. Wyrzykowski*[2], *J. Mackiewicz*[1], *M. Ruchała*[1];
[1]*Poznan University of Medical Sciences, Poznan, POLAND,*
[2]*Dept. of Nuclear Medicine, Affidea, Poznan, POLAND.*

EP-0578

Longitudinal Changes in Brain [^{18}F]FDG Uptake predicts Overall Survival in Metastatic Melanoma

J. Auriac[1], *C. Le Meur*[2], *R. Abgral*[3], *C. Nioche*[1], *C. Loisel*[1], *G. Fontaine*[4], *C. Massard*[5], *I. Buvat*[1], *F. Orlhac*[1], *K. Amrane*[5];
[1]*Institut Curie, PSL, Université Versailles Saint-Quentin, Inserm, CNRS, Université Paris-Saclay, IRIS, Orsay, FRANCE,*
[2]*Department of Radiotherapy, University Hospital of Brest, Brest, FRANCE,*
[3]*Department of Nuclear Medicine, University Hospital of Brest, Brest, FRANCE,*
[4]*Department of Nuclear Medicine Centre Hospitalier de Cornouaille, Centre Georges Charpak -Médecine Nucléaire, Quimper, FRANCE,*
[5]*Département d'Innovation Thérapeutique et des Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, FRANCE.*

EP-0579

First Use of a Lesion Classification System for Newly Appeared Lesions of Metastatic Malignant Melanoma in Patients Undergoing Immunotherapy

L. Kuehnle[1], *S. Hein*[1], *T. Lorenzini*[1], *D. Sasse*[1], *M. Naghavi-Behzad*[2], *W. Weber*[1];
[1]*University Hospital Rechts der Isar, Munich, GERMANY,*
[2]*University Hospital Odense, Odense, DENMARK.*

EP-0580

Beyond target lesions: prognostic value of longitudinal AI-derived whole-body [^{18}F]FDG PET/CT metrics in metastatic melanoma

C. Sachpekidis[1], *T. P. Vagenas*[2], *M. Müller*[1], *D. Strauss*[3], *A. Kopp-Schneider*[1], *L. Pan*[1], *J. C. Hassel*[4], *G. K. Matsopoulos*[2], *A. Dimitrakopoulou-Strauss*[1];
[1]*German Cancer Research Center (DKFZ), Heidelberg, GERMANY,*
[2]*School of Electrical and Computer Engineering, National Technical University of Athens, Athens, Greece, Athens, GREECE,*
[3]*Department of Diagnostic and Interventional Radiology, University Clinic Heidelberg, Heidelberg, Germany, Heidelberg, GERMANY,*
[4]*Heidelberg University, Medical Faculty Heidelberg, Department of Dermatology, Heidelberg, Germany, Heidelberg, GERMANY.*

EP-28

B: Imaging Clinical Studies → B1 Oncological Imaging Clinical Study → B25 Any Other Malignant (including Primary of Unknown Origin)

EP-0581

First-in-human pilot study of a CD147-targeted antagonistic peptide probe for tumor imaging

X. Ma, *T. Liu, H. Zhu, Z. Yang;*
Peking University Cancer Hospital, Beijing, CHINA.

EP-0582

Head-To-Head Comparison Of FDG PET/CT And PSMA PET/CT In Multiple Cancer Types For Potential Theranostics Applications

E. Etchebehere[1], *E. Nogueira-Lima*[1], *A. Portilho*[1], *C. S. P. Lima*[1], *P. Corbi*[1], *V. Deflon*[2], *J. B. Carvalheira*[1], *L. Malavolta*[3], *CancerThera Investigators, C. A. Souza*[1], *C. D. Ramos*[1];
[1]*University of Campinas, Campinas, BRAZIL,*
[2]*University of São Carlos, São Carlos, BRAZIL,*
[3]*Santa Casa de São Paulo, School of Medical Sciences., São Paulo, BRAZIL.*

EP-0584

Which Background Is Suitable as a Reference for Treatment Response Evaluation on ^{68}Ga-FAPI-04 PET After Neoadjuvant Chemotherapy in solid Tumours?

L. Yang, *P. Dong, Q. Shi, H. Zhou, L. Li, M. Su;*
Department of Nulcear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0585

^{68}Ga-NYM096 PET/CT in patients with metastatic or recurrent clear cell renal cell carcinoma: compared with contrast-enhanced CT

W. Zhu[1], *X. Yan*[1], *J. Wang*[1], *M. Liu*[1], *H. Zhuo*[1], *X. Li*[1], *C. Bai*[1], *G. Zheng*[1], *Y. Zhang*[1], *M. Ma*[2], *X. Gao*[2], *G. Zhang*[1], *O. Sartor*[3], *L. Huo*[1];
[1]*Peking Union Medical College Hospital, Beijing, CHINA,*
[2]*Peking University First Hospital, Beijing, CHINA,*
[3]*LCMC Health, Metairie, LA, UNITED STATES OF AMERICA.*

EP-0587

Iodine-131 MIBG scintigraphy for paediatric neuroblastoma: Bridging the gap where Iodine-123 is unavailable

M. K. Jalel, *W. El Ajmi, F. Ben Amar, I. Yeddes, M. El Iraqui, H. Hammami, A. Sellem;*
Nuclear Medicine Department, Military Hospital of Tunis, Tunis, TUNISIA.

EP-0592

^{18}F-FDG PET/CT Characteristics and Metabolic Heterogeneity ofSMARCA4-Deficient Malignancies: A Retrospective Analysis

Z. Xueqin, *F. Wei;*
The First Affiliated Hospital of Guilin Medical University, Department of Nuclear Medicine, Guilin, CHINA.

EP-0593

Secondopinion review of [18F]FDGPET/CT in invasive bladder cancer: limited incremental value in routine practice

R. Lijnen[1], *M. L. Vierling*[1,2], *J. B. Ringia*[1], *T. N. Boellaard*[1], *A. W. Postema*[2], *G. H. KleinJan*[2], *B. W. G. van Rhijn*[1,3,2], *A. J. A. T. Braat*[1,4], *L. S. Mertens*[1];
[1]*Netherlands Cancer Institute, Amsterdam, NETHERLANDS,*
[2]*LUMC, Leiden, NETHERLANDS,*
[3]*Caritas St Josef Medical Centre, University of Regensburg, Regensburg, GERMANY,*
[4]*UMC Utrecht, Utrecht, NETHERLANDS.*

EP-0594

[68Ga]Ga-FAPI-46 PET/CT vs [18F]F-FDG PET/CT and Contrast-Enhanced CT for TNM Staging in Bladder Cancer: Staging Accuracy and Clinically Relevant Stage Migration

E. Fortunati[1], *G. Cuzzani*[2], *P. Piazza*[3], *V. Mollica*[4], *I. Brusa*[1], *S. Emiliani*[1], *P. Castellucci*[1], *C. Nanni*[1], *R. Mei*[1], *F. Chessa*[3], *S. Fanti*[1,2], *A. Farolfi*[1];
[1]*Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[2]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,*
[3]*Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[4]*Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

EP-0595

89Zr-Girentuximab PET/CT in Von Hippel Lindau disease; initial real-world experience

A. Braat, *W. M. Brinkman, T. J. Snijders, T. Seute, W. P. G. Wolters, B. P. M. van Nesselrooij, K. E. Kleynen, A. V. S. Verrijn Stuart, R. S. van Leeuwaarde;*
University Medical Center Utrecht, Utrecht, NETHERLANDS.

EP-0596

18F-FDG PET/CT Radiomics Features in Renal Cell Carcinoma:Associations withNuclear Grade, Histological Subtype, and Pathological Invasion

N. Arslan, *M. Daşar, A. Özden, G. Koca, K. Demirel, M. Korkmaz;*
Ankara Research and Training Hospital, Ankara, TÜRKIYE.

EP-0597

Comparative Diagnostic Performance of 18F-FAPi-74 and 18F-FDG in Solid Tumours: Results from a Prospective Clinical Trial

E. Mena[1], *L. Lindenberg*[1], *B. Turkbey*[1], *Y. McKinney*[1], *D. Schrump*[1], *A. Rowland*[1], *F. Lin*[1], *I. Shamis*[1], *A. Chen*[1], *J. Ahmed*[1], *H. Alkaissi*[2], *A. B. Apolo*[1], *B. Kania*[1], *E. Turkbey*[3], *C. Millo*[3], *P. Herscovitch*[3], *P. L. Choyke*[1];
[1]*NCI. NIH, Bethesda, MD, UNITED STATES OF AMERICA,*
[2]*NIDDK. NIH, Bethesda, MD, UNITED STATES OF AMERICA,*
[3]*CC. NIH, Bethesda, MD, UNITED STATES OF AMERICA.*

EP-0598

Quantitative PSMA-PET/CT for differentiating viable brain metastases from cerebral radiation necrosis - preliminary results in malignant melanoma and non-small cell lung cancer cohorts

L. de Wit - van der Veen[1], *L. L. Kroon*[2], *K. C. Aalders*[1], *M. P. M. Stokkel*[1], *D. Brandsma*[2], *on behalf of the N18PET study team;*
[1]*Department of Nuclear Medicine, NKI-AVL, Amsterdam, NETHERLANDS,*
[2]*Department of Neuro-Oncology, NKI-AVL, Amsterdam, NETHERLANDS.*

EP-0599

[89Zr]Zr-girentuximab PET/CT in clear cell renal cell carcinoma: impact on staging and clinical management

C. Rodríguez Vergara, *R. Álvarez Pérez, J. Tirado Hospital, J. Jiménez-Hoyuela García;*
Hospital Universitario Virgen del Rocio, Sevilla, SPAIN.

EP-0600

Development and Preclinical Visualization of a Novel Cell Membrane-Anchored FAP-Targeted PET Imaging Probe

P. Xiang, *X. Yin, J. Ye, J. Wang, W. Yang;*
The First Affiliated Hospital of Air Force Medical University, Xi'an, CHINA.

EP-0601

Role of [64Cu]CuCl2 as a prognostic factor in patients with muscle-invasive bladder cancer

F. Fiz[1], *G. Bottoni*[1], *M. Massollo*[1], *D. Cecchin*[2], *S. Panareo*[3], *G. Treglia*[4], *A. Piccardo*[1];
[1]*Ospedale Galliera, Genova, ITALY,*
[2]*University of Padua, Padua, ITALY,*
[3]*University of Modena, Modena, ITALY,*
[4]*Università della Svizzera Italiana, Lugano, SWITZERLAND.*

EP-0602

Clinical Consequences of Incidental Findings on [18F]FDG PET-CT in Staging Suspected Advanced Urothelial Carcinoma

R. Fridriksdóttir[1,2], *J. Bobjer*[1,3], *A. Gerdtsson*[1,3], *I. Patras*[1,3], *F. Liedberg*[1,3], *E. Trägårdh*[1,2];
[1]*Department of Translational Medicine, Lund University, Malmö, SWEDEN,*
[2]*Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund/Malmö, SWEDEN,*
[3]*Department of Urology, Skåne University Hospital, Malmö, SWEDEN.*

EP-0603

Differentiation of morphologically inconclusive lymph nodes in germ cell Tumours by68Ga-FAPI-PET/CT

A. Spektor[1], *N. Rölz*[2], *L. Frey*[2], *M. Schreckenberger*[1], *M. Röhrich*[1], *M. P. Brandt*[2];
[1]*Department of Nuclear Medicine, University Center Mainz, Mainz, GERMANY,*
[2]*Department of Urology and Pediatric Urology, University Center Mainz, Mainz, GERMANY.*

EP-0604

[89Zr]Trastuzumab PET/CT - a Non-Invasive Guide for HER2-Targeted Tumour Therapy Assessment

A. Valitova[1], *F. Hofheinz*[2], *S. Loges*[3,4,5], *N. Berenbrock*[3,4], *S. Zschäbitz*[6], *A. Mavratzas*[7], *F. Marmé*[7], *R. Hofheinz*[8], *C. Cotarelo*[9], *L. Bunse*[10], *A. Kocharyan*[10], *B. Wängler*[11], *P. Cieslik*[11], *H. Rudolf*[11], *F. Grawe*[1,12];
[1]*DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Heidelberg, GERMANY,*
[2]*Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY,*
[3]*Department of Personalized Oncology, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, GERMANY,*
[4]*Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, GERMANY,*
[5]*DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, GERMANY,*
[6]*Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, GERMANY,*
[7]*Faculty of Medicine Mannheim, Department of Obstetrics and Gynecology, University of Heidelberg, Mannheim, GERMANY,*
[8]*Third Department of Medicine (Oncology), Day Treatment Center (TTZ), Interdisciplinary Tumor Center Mannheim (ITM), Medical Faculty Mannheim, University of Heidelberg, Mannheim, GERMANY,*
[9]*Institute of Pathology, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY,*
[10]*Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience (MCTN), Heidelberg University, Mannheim, GERMANY,*
[11]*Molecular Imaging and Radiochemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Mannheim, GERMANY,*
[12]*Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim, University Medical Center Mannheim, Heidelberg University, Mannheim, GERMANY.*

EP-0605

68Ga-FAPI-46 PET/CT shows high detection rate in solid Tumours at restaging: a prospective single-centre experience

F. Matteucci[1], *M. Celli*[1], *I. Marini*[1], *V. Di Iorio*[1], *V. Rossetti*[1], *M. Sansovini*[1], *D. Bezzi*[2], *S. Nicolini*[1], *L. Fantini*[1], *E. Brugugnoli*[1], *V. Fausti*[1], *N. Ranallo*[1], *I. Rapposelli*[1], *A. Sarnelli*[1], *P. Caroli*[1];
[1]*IRCCS IRST, Meldola, ITALY,*
[2]*AUSL Romagna, Cesena, ITALY.*

EP-0606

Impact of girentuximab-based radionuclide imaging in patients with renalcell carcinoma on virtual tumor board decision-making

T. van der Werff[1], *J. J. Futterer*[2], *S. F. Mulder*[3], *J. F. Langenhuijsen*[1], *O. Wegelin*[1], *D. E. Oprea-Lager*[1], *P. F. A. Mulders*[1], *C. H. J. Muselaers*[1];
[1]*Radboud University Medical Center, Dpt. Urology, Nijmegen, NETHERLANDS,*
[2]*Radboud University Medical Center, Dpt. Medical Imaging, Nijmegen, NETHERLANDS,*
[3]*Radboud University Medical Center, Dpt. Medical Oncology, Nijmegen, NETHERLANDS.*

EP-0607

A Preliminary Analysis of [18F]FAPI-74 PET/CT for Response Prediction of Enfortumab Vedotin plus Pembrolizumab vs. Platinum-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma

K. Assadi[1], *L. Unterrainer*[1], *S. C. Siegmund*[1], *C. Aydogdu*[2], *B. Enzinger*[2], *I. Brinkmann*[2], *M. Götz*[2], *M. Semmler*[2], *E. Berg*[2], *C. Stief*[2], *R. Werner*[1], *J. Casuscelli*[2], *A. Holzgreve*[1];
[1]*Department of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Munich, GERMANY,*
[2]*Department of Urology, LMU Munich University Hospital, Munich, GERMANY.*

EP-0608

[18F]FDG-PET/CT Refines Staging and Treatment Selection in High-Risk Upper Tract Urothelial Carcinoma

R. Lijnen[1], *J. B. Ringia*[1], *K. Hendricksen*[1], *W. V. Vogel*[1], *T. N. Boellaard*[1], *A. J. Braat*[1,2], *B. W. G. van Rhijn*[1,3,4], *L. S. Mertens*[1];
[1]*Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS,*
[2]*UMC Utrecht, Utrecht, NETHERLANDS,*
[3]*LUMC, Leiden, NETHERLANDS,*
[4]*Caritas St Josef Medical Centre, University of Regensburg, Regensburg, NETHERLANDS.*

EP-0609

Four Different Patterns of Intralesional Uptake Mismatch Between FDG and PSMA PET/CT in Neoplastic Lesions

A. Portilho, *M. Seren Takahashi, S. Kuba, N. T. T. P. da Silva, M. O. Cerci, C. A. de Souza, C. D. Ramos;*
University of Campinas (UNICAMP), Campinas, BRAZIL.

EP-0610

Serum Vascular Endothelial Growth Factor Fails to Differentiate Clear Cell Renal Cell Carcinoma Patients: Comparative Suitability of PSMA- Versus CD70-Targeted PET Imaging

M. Zhang;
Xijing Hospital, the Fourth Military Medical University, Xi'an, CHINA.

EP-0611

Tc-99m MIBI SPECT/CT Scintigraphy in the Differential Diagnosis of Oncocytoma and Clear Cell Renal Cell Carcinoma: Initial Experience

E. Inal[1], *T. Aydinoglu*[2], *S. Erdem*[3], *O. Sanli*[3], *E. Arslan*[4], *T. Esen*[5], *S. Kuyumcu*[1], *Y. Sanli*[1];
[1]*Istanbul University, Istanbul Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[2]*Istanbul University, Istanbul Faculty of Medicine, Department of Urology, Istanbul, TÜRKIYE,*
[3]*Istanbul University, Istanbul Faculty of Medicine, Department of Urology, Division of Urologic Oncology, Istanbul, TÜRKIYE,*
[4]*Istanbul Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[5]*Koc University, School of Medicine, Department of Urology, Istanbul, TÜRKIYE.*

EP-0612

Clinical Utility of ^{68}Ga-PSMA PET/CT in Non-Prostatic Malignancies: A Preliminary Experience from a Tertiary Care Center in Pakistan

H. Dilawar[1], *S. Habib*[1], *F. Rizvi*[2], *S. Mardan*[3], *J. Iqbal*[1], *I. Hadi*[1], *T. Abdul Rehman*[1];
[1] *Kiran Hospital, Karachi, PAKISTAN,*
[2]*Norin Hospital, Nawabshah, PAKISTAN,*
[4]*Pakistan Institute of Engineering and Applied Sciences, Islamabad, PAKISTAN.*

EP-0613

Prognostic Value of FDG PET/CT Imaging in the Postoperative Follow-up of Patients with Gastrointestinal Stromal Tumours

V. Artiko[1,2], *M. Kotur*[3,2], *I. Grozdić Milojević*[1,2], *S. Odalović*[1,2], *D. Šobić Šaranović*[1,2];
[1]*University Clinical Center of Serbia;*
Center for Nuclear Medicine with PET, Belgrade, SERBIA,
[2]*Faculty of Medicine University of Belgrade, Belgrade, SERBIA,*
[3]*University Clinical Center of Serbia;*
Center for Nuclear Medicine with PET, Belgrade, SERBIA.

EP-29

B: Imaging Clinical Studies → B10 Dosimetry in Diagnostic Applications → B101 Dosimetry in Diagnostic Applications

EP-0614

Scanner-specific optimization of a fluorodeoxyglucose administered activity regimen for whole-body positron emission tomography/computed tomography using liver signal-to-noise analysis

I. Androulakis, *J. M. Mostert, Q. G. de Lussanet, T. A. Mulders, F. A. Verburg, M. Segbers;*
Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands, Rotterdam, NETHERLANDS.

EP-0615

Biodistribution and dosimetry of [^{64}Cu]Cu-NECT-224 in patients with urothelial carcinoma using PET/MRI

M. Hesse[1], *R. Apolle*[1], *I. Platzek*[2], *M. Pretze*[3], *F. Brandt*[3], *R. Wodtke*[4], *K. Kopka*[4], *S. G. J. Banek*[5], *C. Thomas*[5], *R. A. Bundschuh*[3], *M. Miederer*[1];
[1]*National Center for Tumor Diseases (NCT), Dresden, GERMANY,*
[2]*University Hospital Carl Gustav Carus, Department of Radiology, Dresden, GERMANY,*
[3]*University Hospital Carl Gustav Carus, Department of Nuclear Medicine, Dresden, GERMANY,*
[4]*Helmholtz-Zentrum Dresden-Rossendorf (HZDR) e.V., Institute of Radiopharmaceutical Cancer Research, Dresden, GERMANY,*
[5]*University Hospital Carl Gustav Carus, Department of Urology, Dresden, GERMANY.*

EP-0616

Preliminary dosimetry of [^{18}F]F-D-Deprenyl-PET/CT in patients with neuroinflammation

L. Tagnin[1], *A. Noto*[1], *J. S. Dorneich*[1], *M. Zeinaki*[1], *J. S. Gnörich*[1,2], *E. Joseph*[1], *R. A. Werner*[1,3], *M. Brendel*[1,2,4], *A. Delker*[1];
[1]*Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, GERMANY,*
[2]*German Center for Neurodegenerative Diseases (DZNE), Munich, GERMANY,*
[3]*Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA,*
[4]*Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY.*

EP-0617

Biodistribution and dosimetry for PET imaging of HER2-receptor expression using [^{18}F]-HER2 in metastatic breast cancer

U. Estenberg[1], *M. Battle*[2], *M. Mahdi Moein*[1], *M. Holstensson*[1], *K. Bratteby*[1], *H. Alfredéen*[1], *A. Matikas*[1], *R. Axelsson*[1], *T. Tran*[1], *A. Tzortzakakis*[1], *C. Hindorf*[1];
[1]*Karolinska University Hospital, Stockholm, SWEDEN,*
[2]*GE HealthCare, Amersham, UNITED KINGDOM.*

EP-0618

Safety and Diagnostic efficacy of [^{68}Ga]Ga-XT771 PET/CT to identify clear cell renal cell carcinoma

R. Wang[1], *L. Du*[1], *S. Geng*[1], *L. Yuan*[2];
[1]*The First Medical Center, Chinese PLA General Hospital, Beijing, CHINA,*
[2]*Medical Department, Sinotau Pharmaceutical Group, Beijing, CHINA.*

EP-30

B: Imaging Clinical Studies → B3 Other Oncological Clinical Study → B31 Molecular image-guided interventions

EP-0619

^{125}I radioactive seed localization (RSL) technique in surgery for suspected lung lesions: our center´s experience

A. Torres Consiglieri, *O. Ajuria Illarramendi, A. Martínez Lorca, M. Ottino, L. Santucci, P. Azpeitia Hernández, T. Navarro Martínez, M. Orduña Díez;*
Hospital Universitario Ramon y Cajal, Madrid, SPAIN.

EP-0620

F-18 FDG PET/CT-guided biopsy in metabolically active lesions of uncertain etiology

M. Tripathi, *B. Nayak, A. Murugan, G. Arora, A. Tyagi, M. Umar, V. Jain, N. Damle, A. Kakkar;*
All India Institute Of Medical Sciences, New Delhi, INDIA.

EP-0621

Efficacy of PSMA PET-Ultrasound Fusion-Guided Targeted Biopsy for Prostate Cancer Based on PRIMARY Score

S. Chen, *S. Cheung, K. Li, K. Wu, Y. Wong, Y. Yip, K. Cheng, C. Ho;*
Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.

EP-31

B: Imaging Clinical Studies → B3 Other Oncological Clinical Study → B32 Sentinel Node

EP-0622

Following the Flow: Postoperative Lymphoscintigraphy after Lymphovenous Bypass

C. Lambie, *A. Rebecca, D. Rhee, S. Huang, J. Flug, M. Yang;*
Mayo Clinic, Phoenix, AZ, UNITED STATES OF AMERICA.

EP-0623

Clinical and Quality Efficiency of Fractionated Nano colloid Kits in Pre-Operative Visualization of Sentinel Lymph Nodes: A Cost-Effective Strategy for Public Sector Hospitals

N. Fatima[1,2], *M. Zaman*[2];
[1]*Dow University Health Sciences, Karachi, PAKISTAN,*
[2]*Aga Khan University Hospital, Karachi, PAKISTAN.*

EP-0624

Mapping the "Unpredictable": Anatomical Distribution and Predictors of Interval Lymph Nodes in a Large Truncal Melanoma Cohort

F. Iuele[1], *C. Battisti*[1], *N. C. Merenda*[1], *C. Altini*[1], *D. Candido*[1], *A. R. Pisani*[2], *G. Rubini*[2];
[1]*Nuclear Medicine Unit, Interdisciplinary Department of Medicine, University "Aldo Moro" of Bari, Bari, ITALY,*
[2]*University "Aldo Moro" of Bari, Bari, ITALY.*

EP-0625

SPECT-CT with ^{3}D Volumetric Reconstruction Reduces Intraoperative Time in Sentinel Lymph Node Biopsy: A Comparative Study in Breast Cancer

J. Orozco Cortes[1], *G. Bonino*[1], *F. Cavagna Matti*[1], *R. Martinez García*[2], *C. Cifre Martinez*[2], *P. Abreu Sánchez*[1], *J. Infante de la Torre*[1], *E. Martinez Lopez*[2], *M. Escudero*[1], *F. Montenegro Muñoz*[1], *G. Garrigoz*[2], *E. caballero Calabuig*[1];
[1]*Hospital Universitario Dr. Peset, Nuclear Medicine, Valencia, SPAIN,*
[2]*Hospital Universitario Dr. Peset, Breast Surgery, Valencia, SPAIN.*

EP-0626

Does Wire Localization Affect Sentinel Node Mapping? A Retrospective Analysis

O. Turko, *H. Bernstine;*
Belinson, Petah Tikva, ISRAEL.

EP-0627

Repeat sentinel lymph node biopsy (re-SLNB) in breast cancer recurrence after a previous negative SLNB: aberrant lymphatic drainage and its implications for surgical management and disease staging

D. J. Tamayo-Ossa[1], *D. S. Ramirez-Muñoz*[1], *A. B. Dacosta-Escobar*[1], *A. M. Benitez-Segura*[1], *M. T. Bajen-Lazaro*[1], *J. G. Reyes-Junca*[1], *A. Bagán-Trejo*[1], *M. Zamorano-Rivas*[1], *J. L. Díaz-Moreno*[1], *M. Argeles-Colet*[1], *E. Ricard-Paredes*[2], *C. Garcia-Alcober*[2], *S. Orts-Exposito*[2], *L. Benaches Magraner*[3], *F. M. Camba-Capitan*[3], *M. A. Garcia-Tejedor*[4], *A. Gumà-Martinez*[5], *J. Azcarate-Rodriguez*[6], *M. Silva-Bueno*[7], *C. Falo-Zamora*[8], *E. Martinez-Perez*[9], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine-PET (IDI) Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN,*
[2]*Radiopharmacy Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN,*
[3]*Radiophysics Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN,*
[4]*Gynaecology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, SPAIN,*
[5]*Radiodiagnosis Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, SPAIN,*
[6]*Anatomical Pathology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, SPAIN,*
[7]*Plastic and Reconstructive Surgery Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, SPAIN,*
[8]*Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, SPAIN,*
[9]*Radiation Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, SPAIN.*

EP-0628

Health technology assessment of the hybrid sentinel node tracer Indocyanine green-^{99}mTc-nanocolloid

T. Buckle, *F. W. B. van Leeuwen;*
Leiden University Medical Center, Leiden, NETHERLANDS.

EP-0629

Sentinel Lymph Node Biopsy in Head and Neck Cancer: Detection Rates and Factors Influencing Lymphoscintigraphic Visualization in Squamous Cell Carcinoma and Melanoma

S. Nieves Maldonado, *S. Seijas Marcos, F. Zelaya Reinquet, S. Rodriguez Martinez de LLano, P. Pais Silva;*
Centro Oncologico de Galicia, A Coruña, SPAIN.

EP-0630

Beyond the Gamma Camera: AI-Powered Augmented Reality with Portable SPECT for Real-Time Sentinel Node Localization in Breast Cancer

J. Orozco Cortes[1], *F. Cavagna Matti*[1], *A. Esteban Hurtado*[2], *G. Bonino*[1], *P. Abreu Sánchez*[1], *J. Infante de la Torre*[1], *F. Montenegro Muñoz*[1], *L. Casas Calabuig*[1], *M. Reyes Ojeda*[1], *E. Caballero Calabuig*[1];
[1]*Hospital Universitario Dr. Peset, Nuclear Medicine, Valencia, SPAIN,*
[2]*Centre Medic Alomar, Nuclear Medicine, Barcelona, SPAIN.*

EP-0631

^{68}Ga-DOTA-DX as a radioligand agent for PET/CT imaging of the lymphatic system: A translational study in medical imaging involving animals and humans

Y. Wang, *Y. Chen;*
The Affiliated Hospital of Southwest Medical University, Luzhou, CHINA.

EP-0632

From Checklist to Quality Cycle: A Comprehensive Worksheet Tool for Monitoring and Optimizing Sentinel Lymph Node Biopsy in Breast Cancer

J. Orozco Cortes[1], *G. Bonino*[1], *R. Jover Diaz*[2], *M. Reyes*

Ojeda[1], F. Cavagna Matti[1], J. Infante de la Torre[1], P. Abreu Sánchez[1], L. Casas Calabuig[1], F. Montenegro Muñoz[1], E. Caballero Calabuig[1];
[1]Hospital Universitario Dr. Peset, Nuclear Medicine, Valencia, SPAIN,
[2]Hospital de la Princesa, Nuclear Medicine, Madrid, SPAIN.

EP-0633

From spect/ct to the operating room: anatomical correlation in sentinel lymph node biopsy for oral cavity cancer

***A. Torres Consiglieri**, A. Martínez Lorca, O. Ajuria Illarramendi, M. Ottino, L. Santucci, P. Azpeitia Hernández, U. Vera Schmülling, I. Hernandez Perez, M. Orduña Díez;*
Hospital Universitario Ramon y Cajal, Madrid, SPAIN.

EP-32

B: Imaging Clinical Studies → B4 Cardiovascular Imaging Clinical Study → B41 Perfusion

EP-0634

Adenosine FDG PET/CT Reveals Potentially Viable Myocardium in Ischemic Cardiomyopathy

***M. Keskin**;*
Mersin City Training and Research Hospital, Mersin, TÜRKIYE.

EP-0635

Assessment of Left Ventricular Diastolic Filling Parameters by Gated SPECT in Patients with Left Bundle Branch Block and Preserved Ejection Fraction

***J. Nekic**[1,2], J. Anicic[3,4], T. Klarica Gembic[1];*
[1]Clinical Hospital Center Rijeka, Department of Nuclear Medicine, Rijeka, CROATIA,
[2]Univesity of Rijeka, Faculty of Medicine, Department of Nuclear Medicine, Rijeka, CROATIA,
[3]Clinical Hospital Center Rijeka, Department of Cardiology, Rijeka, CROATIA,
[4]Univesity of Rijeka, Faculty of Medicine, Department of Internal Medicine, Rijeka, CROATIA.

EP-0636

Clinical risk phenotype and segmental defect burden on stress-rest myocardial perfusion SPECT/CT in coronary artery disease

***I. Ilinoiu**[1], R. Mititelu[1,2];*
[1]Clinic of Nuclear Medicine, "Dr. Carol Davila" Central Military Emergency University Hospital, Bucharest, ROMANIA,
[2]Department of Nuclear Medicine, "Carol Davila" University of Medicine and Pharmacy, Bucharest, ROMANIA.

EP-0637

Comparative Efficacy of Composite Inflammatory Indices and Cardiovascular Risk Scores in Predicting Myocardial Ischemia on Myocardial Perfusion Scintigraphy

***I. Evirgen**[1], M. Daşar[1], H. Eroğlu Elden[2], G. Koca[1], K. Demirel[1], M. Korkmaz[1];*
[1]Ankara Training and Research Hospital, Ankara, TÜRKIYE,
[2]Kahramanmaraş City Hospital, Kahramanmaraş, TÜRKIYE.

EP-0638

The Gustave Roussy Immune Score is a Superior 'Gatekeeper' in Predicting Myocardial Perfusion Defects on SPECT: A Comparative Study with Naples Score and Inflammatory Indices

***M. Genc**;*
Sivas Numune Hospital Department of Nuclear Medicine, Sivas, TÜRKIYE.

EP-0639

Development and Validation of a D-SPECT Standardized Database (NOR-DSPECT) for the Chinese Population: A Single-Center Pilot Study

***H. Zhang**[1], f. Caobelli[2], F. Yu[1];*
[1]Tongji university School of Medicine,shanghai Tenth people's hospital, Shanghai, CHINA,
[2]Department of Nuclear Medicine, Bern University Hospital, Inselspital, University of Bern, Bern, SWITZERLAND.

EP-0640

Myocardial Perfusion PET and Epicardial Adipose Tissue Differences in Type 2 Diabetes Phenotypes: Preliminary Results from a Randomized Trial

***A. Guarneri**[1], V. Scolozzi[1], A. Splendore[2], S. Gugliandolo[2], C. Morciano[3], F. Cinti[2], L. Cappannoli[4], F. Burzotta[5], A. Giaccari[6], M. Calcagni[7], L. Leccisotti[7];*
[1]Unit of Nuclear Medicine, Fondazione Policlinico Universitario Agostino Gemelli, Rome, ITALY,
[2]Endocrine and Metabolic Diseases Center, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, ITALY,
[3]Endocrine and Metabolic Diseases Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,
[4]Unit of Cardiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY,
[5]Unit of Cardiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, ITALY,
[6]Endocrine and Metabolic Diseases Center, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, ITALY,
[7]Unit of Nuclear Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, ITALY.

EP-0641

pNorm, a phantom simulation based MPI SPECT normal database builder

***A. Szucs**[1], B. Kari[2], O. Partos[2];*
[1]Tenucor Ltd., Budapest, HUNGARY,
[2]Semmelweis University, Budapest, HUNGARY.

EP-0642

Can Peripheral Hemodynamic Changes Predict Dipyridamole Response? Insights from Myocardial Flow Reserve Using Rubidium-82 PET

***H. Bachir Melhem**, V. Ngo, C. Régis, F. Harel, V. Finnerty, M. Pelletier-Galarneau;*
Institut de cardiologie de Montréal, Montréal, QC, CANADA.

EP-0643

Myocardial blood flow and myocardial flow reserve assessed by dynamic SPECT and quality of life in non-obstructive coronary artery disease

***A. Maltseva**, A. Mochula, K. Kopeva, A. Tsygikalo, E. Grakova, K. Zavadovsky;*
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

EP-0644

Impact of Reconstruction and Attenuation Correction on Retention and Kinetic Modeling using Multi-pinhole Collimator on Triple-NaI-Detector SPECT/CT

***A. Ogum**[1], P. Czina[2], S. Barna[2,3], K. Kukuts[4], Z. Szoboszlai[3], J. Varga[2], J. Renaud[5], T. Mitchell[5], A. Krizsan[4], I. Garai[3,2];*
[1]Gyula Petranyi Doctoral School of Allergy and Clinical Immunology, University of Debrecen, Debrecen, HUNGARY,
[2]University of Debrecen, Faculty of Medicine, Medical Imaging Department, Division of Nuclear Medicine, Debrecen, HUNGARY,
[3]Scanomed Ltd, Debrecen, HUNGARY,
[4]Mediso Ltd., Budapest, HUNGARY,
[5]INVIA Medical Imaging Solutions, Ann Arbor, MI, UNITED STATES OF AMERICA.

EP-0645

The Role of Myocardial Perfusion Scintigraphy in the Diagnosis of Coronary Artery Disease: A Vessel-Based Comparative Analysis

***M. Ebrahimpoortajdar**, G. Mütevelizade, B. Düşova, F. Gümüşer, Y. Parlak, E. Bilgin;*
Celal Bayar Üniversitesi Hafsa Sultan Hastanesi, Manisa, TÜRKIYE.

EP-0646

Investigation of Parameters Predicting Revascularization Decisions in Patients with Severe Ischemia on Myocardial Perfusion Scintigraphy

***S. Demirkan Cortoglu**[1], S. A. Yilmaz[1], U. Kutlusoy[1], E. M. Kaya[1], M. B. Cortoglu[2], B. Esen Akkaş[1], M. Kaya[1];*
[1]Cam and Sakura City Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,
[2]Cam and Sakura City Hospital, Department of Cardiology, Istanbul, TÜRKIYE.

EP-33

B: Imaging Clinical Studies → B4 Cardiovascular Imaging Clinical Study → B42 Metabolism and Innervation

EP-0647

Preserved ^{18}F-FDG Uptake Predicts Functional Recovery in LGE-Defined Nonviable Myocardium Early After STEMI

***E. Kong**;*
Yeungnam University Hospital, Daegu, KOREA, REPUBLIC OF.

EP-0648

The Relationship Between Metabolic Tumor Burden and Myocardial FDG Uptake in Patients with Lymphoma

***B. Aydur**, S. Zorlu, B. Özdemir Günay;*
Giresun Training and Research Hospital, Giresun, TÜRKIYE.

EP-0649

Cardiac involvement in Fabry disease: a case report

***A. Segarra-Santatecla**[1], B. Hervás-Sanz[2], G. Burcet-Rodríguez[3], C. Díez-López[4], M. Cortés-Romera[2], M. Zamorano-Rivas[2], A. Bagán-Trejo[2], P. Notta-González[2];*
[1]Department of Nuclear Medicine, Hospital Clínic de Barcelona, Barcelona, SPAIN,
[2]Department of Nuclear Medicine, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, SPAIN,
[3]Department of Radiology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, SPAIN,
[4]Department of Cardiology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, SPAIN.

EP-0650

Image quality and Lesion detectability in simulated [^{124}I]MIBG cardiac imaging across 3-generation PET/CT scanners using a phantom model. Implications for activity and acquisition time reduction in clinical practice

***F. Aghapour Zangeneh**[1], K. Zeimpekis[1], S. Gnesin[2], L. Knappe[3], V. Garibotto[3], C. Kamani[4], J. Prior[4], A. Rominger[1], F. Caobelli[1];*
[1]Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND,
[2]Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND,
[3]Division of Nuclear Medicine and Molecular Imaging, University Hospitals of Geneva, Geneva, SWITZERLAND,
[4]Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, SWITZERLAND.

EP-0651

Whole-body Organ Metabolic Connectivity in Extranodal NK/T-cell Lymphoma: A ^{18}F-FDG PET/CT-based Metabolic Network Analysis

***X. Liu**, C. Qin, Y. Lv, W. Ruan, S. Wei, X. Lan;*
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-34

B: Imaging Clinical Studies → B4 Cardiovascular Imaging Clinical Study → B43 Heart Failure (including Sarcoidosis and Amyloidosis)

EP-0652

Structural-Metabolic Brain Coupling in Heart Failure: A Simultaneous ^{18}F-FDG PET/MR Study

***R. Qin**[1], C. Zheng[1], X. Su[2], Y. Yang[2], J. Lu[1];*
[1]Xuanwu Hospital, Capital Medical University, Beijing, CHINA,

[2]Beijing United Imaging Healthcare Technology Development Co., Ltd., Beijing, CHINA.

EP-0653

Comparison of quantitative parameters from planar and gated SPECT radionuclide blood pool studies between conventional NaI versus ZnCd SPECT/CT machines and transthoracic echocardiography

T. Thientunyakit, *Y. Jirawattanapalin, S. Chirakarnjanakorn, K. Korphaisarn, T. Thongpraparn, P. Mali, C. Sethanandha, D. Polyeum;*
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, THAILAND.

EP-0654

Evaluating [18F]-FDG PET/CT for Detecting Myocardial and Systemic Inflammation in HFpEF

B. Dinh[1], *A. Strassburg*[1], *D. Hazard*[2], *L. Heger*[1], *C. Olivier*[1], *D. Westermann*[1], *P. Meyer*[3], *L. Bacmeister*[1], *A. Maier*[1], *C. Goetz*[3];
[1]*Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY,*
[2]*Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, GERMANY,*
[3]*Department of Nuclear Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY.*

EP-0655

Clinical impact of additional SPECT/CT on diagnostic reclassification in patients with Grade 1 myocardial uptake on planar whole-body scintigraphy

A. Gudauskaite[1], *K. Lusaite*[2], *D. Vajauskas*[2];
[1]*Lithuanian University of Health Sciences, Kaunas, LITHUANIA,*
[2]*Hospital of Lithuanian University of Health Sciences, Kaunas, LITHUANIA.*

EP-0656

Multi-Tracer PET and Scintigraphy Biomarkers Reflect Structural Rather Than Functional Disease Burden in Cardiac Amyloidosis

T. Norikane, *Y. Yamamoto, Y. Takami, Y. Nishiyama;*
Kagawa University, Kita, JAPAN.

EP-0657

Comparison and cut-off values of quantitative parameters obtained by SPECT/CT with[99mTc] Tc-DPD in patients with cardiac amyloidosis

S. Bondia Bescós[1], *A. Palomar-Muñoz*[1], *M. Díez-Castro*[1], *Ó. Hernández-Cristancho*[1], *A. Cardozo-Saavedra*[1], *M. Pizzi*[2], *A. Roque-Pérez*[3], *D. Sanchez-Artuñedo*[4], *C. Gámez-Cenzano*[1];
[1]*Nuclear Medicine Department, Vall d'Hebrón University Hospital, Barcelona, SPAIN,*
[2]*Cardiology Department, Vall d'Hebrón University Hospital, Barcelona, SPAIN,*
[3]*Radiology Department, Vall d'Hebrón University Hospital, Barcelona, SPAIN,*
[4]*Medical Physics and Radiation Protection Department, Vall d'Hebrón University Hospital, Barcelona, SPAIN.*

EP-0658

Extracardiac Findings and Multifocal Uptake on 99mTc-DPD Scintigraphy in Patients with Transthyretin Amyloid Cardiomyopathy: A 2023-2025 Single-Center Experience

F. Caltagirone Gutierrez, *J. C. Cañadas Salazar, L. G. Diaz Gonzalez, E. Casillas Sagrado, S. Rama Alonso, J. A. Badell Martinez, F. Gomez Caminero Lopez, A. C. Peñaherrera Cepeda, J. G. Villanueva Curto, P. García-Talavera San Miguel, E. Martin Gomez, F. Ulloa Mejia, M. Fernandez Arteaga, J. M. Valarezo Jimenez, B. Santos García, M. P. Tamayo Alonso;*
Hospital Universitario de Salamanca, Salamanca, SPAIN.

EP-0659

Segmental 99mTc-DPD SPECT/CT Quantification of the Left Ventricle in Transthyretin Cardiac Amyloidosis: Clinical and Echocardiographic Correlations and Prognostic Implications.

M. Zapardiel, *C. Wakfie Corieh, M. Vaillant López, A. Espinoza Roca, M. Restrepo Córdoba, J. Goirigolzarri, M. Romero Porras, A. Berardinelli Isea, M. Cornide Carrallo, L. Carreño Mancilla, M. Cabrera Martin;*
H. U. Clínico San Carlos, Madrid, SPAIN.

EP-0660

Perugini Grade 1 in 99mTc-DPD Scintigraphy for Suspected Cardiac Amyloidosis: Diagnostic Challenges in Real-World Practice

M. Zapardiel, *C. Wakfie Corieh, M. Vaillant López, C. Rodríguez Rey, G. Cuesta, A. Berardinelli Isea, M. Romero Porras, L. Carreño Mancilla, R. Arcondo, M. Cabrera Martin;*
H. U. Clínico San Carlos, Madrid, SPAIN.

EP-0661

Myocardial amyloid burden by SPECT/CT [99mTc] Tc-DPD and clinical outcomes in patients with transthyretin cardiac amyloidosis undergoing Tafamidis therapy. Preliminary experience at our centre

S. Bondia Bescós[1], *M. Díez-Castro*[1], *A. Palomar-Muñoz*[1], *Ó. Hernández-Cristancho*[1], *A. Cardozo-Saavedra*[1], *M. Pizzi*[2], *A. Roque-Pérez*[3], *D. Sanchez-Artuñedo*[4], *J. Limeres-Freire*[2], *C. Gámez-Cenzano*[1];
[1]*Nuclear Medicine Department, Vall d'Hebrón University Hospital, Barcelona, SPAIN,*
[2]*Cardiology Department, Vall d'Hebrón University Hospital, Barcelona, SPAIN,*
[3]*Radiology Department, Vall d'Hebrón University Hospital, Barcelona, SPAIN,*
[4]*Medical Physics and Radiation Protection Department, Vall d'Hebrón University Hospital, Barcelona, SPAIN.*

EP-0662

Heart failure as a risk factor for Alzheimer's disease and the role of 18FFDG brain PET in its early detection.

R. Jover Diaz, *D. Tamayo-Carabaño, I. López-Villar, P. Díez-Villanueva, J. Vázquez-López-Ibor, T. Carreras-Rodriguez, A. Viera-Campos, R. Aguilar-Torres;*
Hospital Universitario La Princesa, Madrid, SPAIN.

EP-0663

Heart-to-lung ratio in bone scintigraphy: evaluating its role as a functional and prognostic marker in ATTR cardiac amyloidosis

A. Stacey Solis, *N. Colombo Vina, L. Blanco Verdejo, C. Rillo Mena, T. Mut Dolera, P. Oliván Sasot, H. Rodríguez Parra, A. Crespo Jara, M. Redal Peña, J. Sabater Sancho, M. Cozar Santiago;*
Hospital Clínico Universitario de Valencia, Valencia, SPAIN.

EP-0664

Distinct [99mTc]Tc-DPD-Positive Phenotypes in Transthyretin Spectrum Cardiac Amyloidosis: Clinical Profile and Prognostic Implications

R. Sá e Silva[1], *R. Vieira*[2], *J. Escaleira*[1], *L. Costa*[1], *P. Rodrigues*[1];
[1]*Centro Hospitalar Universitário do Porto, Porto, PORTUGAL,*
[2]*Instituto de Ciências Biomédicas Abel Salazar, Porto, PORTUGAL.*

EP-0665

Value of Qualitative and Quantitative 99mTcDPD SPECT/CT Parameters for Diagnosis and Prognostic Stratification in Cardiac Amyloidosis

J. Garcia, *M. Negre, N. Ferran, A. Afonso, M. Tormo, E. Torrent, I. Trias, M. Martinez, A. Ruiz, M. Sanchez, B. Ramiro, S. Castanyer, S. Bereau, P. Simón, M. Ayats, E. Vila, N. Caballero, J. Marti, A. Armengou, A. Rubio, E. de la Calle Vargas;*
Hospital Universitari Dr Josep Trueta, Girona, SPAIN.

EP-0666

Quantitative 99mTc-PYP SPECT/CT for ATTR-CA Diagnosis: Comparison of SUVmax, Myocardium-to-Blood and Myocardium-to-Bone Metrics.

R. Ferrando[1,2], *L. Santos*[2], *A. Pérez*[1,2], *K. Bayardo*[2,1], *C. Ramírez*[3], *R. Cardenas*[3], *M. Lázaro*[4], *S. Alarcón*[4], *P. Roman*[2], *F. Ferrando*[2,5];
[1]*Nuclear Medicine and Molecular Imaging Center, Clinics Hospital, Universidad de la República, Montevideo, URUGUAY,*
[2]*Ferrari Ferrando Páez Nuclear Medicine Clinic, Montevideo, URUGUAY,*
[3]*Clínica de Occidente, Cali, COLOMBIA,*
[4]*Clínica Ricardo Palma, Lima, PERU,*
[5]*University Cardiovascular Center, Clinics Hospital, Montevideo, URUGUAY.*

EP-0667

Patterns of Extra-Cardiac Organ Involvement in FDG PET/CT-Detected Cardiac Sarcoidosis: A Whole-Body Imaging Study

S. Sharma, *M. Rai, M. Ora, H. NG;*
Sanjay Gandhi Post Graduate Institute of Medical sciences, Lucknow, INDIA.

EP-0668

Inter-Observer and Intra-Observer Agreement in Visual Perugini Grading of Tc-99m PYP Scintigraphy for Transthyretin Cardiac Amyloidosis: Focus on Grade 1 versus Grade 2 Differentiation.

H. Cayvarli, *B. Kirtiloglu, S. Sungur, D. Kocabicak, B. Atmaca Saglik;*
City Hospital, Samsun, TÜRKIYE.

EP-0669

Repeatability of Visual and Quantitative Analysis of SPECT pyrophosphate imaging for Transthyretin Cardiac Amyloidosis

G. Wells[1], *M. O. Omaygenc*[1], *D. O. Omaygenc*[1], *J. Alharbi*[1], *V. Anderson*[1], *G. Small*[1], *W. McDougald*[2,3], *F. Massanes*[2], *H. Vija*[2], *T. D. Ruddy*[1];
[1]*Univ Ottawa Heart Institute, Ottawa, ON, CANADA,*
[2]*Siemens Healthineers, Chicago, IL, UNITED STATES OF AMERICA,*
[3]*University of Edinburgh, Edinburgh, UNITED KINGDOM.*

EP-0670

Tracheal Wall Thickening as a Marker of Tracheal Involvement in Patients with Suspected Amyloid Transthyretin-Related Cardiomyopathy: A Retrospective SPECT/CT-Based Analysis.

F. Aghapour Zangeneh[1], *A. Rominger*[1], *C. Gräni*[2], *F. Caobelli*[1];
[1]*Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND,*
[2]*Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.*

EP-0671

Impact of disease-modifying therapy approval on ATTR-CM scintigraphy referral patterns and phenotypic profile of scan-positive patients.

J. Gatón Ramírez, *G. Molina Mendoza, F. Pena Pardo, J. Rodríguez Gómez, C. Ortiz Muñoz, D. Martínez Osorio, F. López-Bermejo García, N. Almeida Romera, P. Bravo Torrivilla, L. Fermín Ledesma, M. Talavera Rubio, V. Poblete García;*
Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN.

EP-0672

Fast cardiac bone 360° SPECT-CZT accurately reproduces planar Perugini ≥ 2 classification with high reproducibility in transthyretin cardiac amyloidosis

S. Heyer[1], *L. Imbert*[2], *T. Zaragori*[3], *D. Legallois*[4], *M. Claudin*[5], *M. Perrin*[5], *A. Bahloul*[1], *D. Agostini*[6], *A. Manrique*[7], *P. Marie*[1], *N. Broutin*[5];
[1]*Department of Nuclear Medicine, CHRU Nancy, Nancyclotep Imaging Platform, IADI, INSERM, U1254, Université de Lorraine, Nancy, FRANCE,*
[2]*Department of Nuclear Medicine, CHRU Nancy, Nancyclotep Imaging Platform, IADI, Inserm, U1254, Université de Lorraine, Nancy, FRANCE,*
[3]*CIC 1433, Inserm, CHRU of Nancy, IADI, U1254, Inserm, Université de Lorraine, Nancy, FRANCE,*
[4]*Department of Cardiology, Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE, Caen Normandie University Hospital, Caen, FRANCE,*
[5]*Department of Nuclear Medicine, CHRU Nancy, Nancyclotep Imaging Platform, Nancy, FRANCE,*
[6]*Department of Nuclear Medicine, University Hospital of Caen and Normandie Université, Caen, 4650, EA, Caen, FRANCE,*
[7]*Nuclear Medicine Department, Caen University Hospital, Cyceron UR4650 PSIR, Université Caen Normandie, GIP Cyceron, Caen, FRANCE.*

EP-35

B: Imaging Clinical Studies → B4 Cardiovascular Imaging Clinical Study → B44 Other Cardiovascular Imaging (including Plaque)

EP-0673

Dynamic F-18 FDG PET/CT with Two-Compartment Kinetic Modeling for Myocardial Viability Assessment: Feasibility and Determinants of Analysis Quality in a Real-World Cohort

B. Canitez[1,2], *H. USLU*[1];
[1]*Göztepe egitim arastirma hastanesi, Istanbul, TÜRKIYE,*
[2]*Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Istanbul, TÜRKIYE.*

EP-0674

Somatostatin expression derived from [18F]F-SiTATE PET is not consistently linked to aortic diameter

S. Berthold[1], *M. G. Fischer*[2], *F. J. Gildehaus*[1], *M. Brendel*[1,3], *C. Kreuer*[1], *K. Stark*[2,3,4], *T. Higuchi*[5], *R. A. Werner*[1,3,6], *S. C. Siegmund*[1];
[1]*Department of Nuclear Medicine, LMU University Hospital, Ludwig-Maximilians-Universität München, Munich, GERMANY,*
[2]*Medical Clinic I, Department of Cardiology, LMU University Hospital, Ludwig-Maximilians-Universität München, Munich, GERMANY,*
[3]*Interfaculty Center for Endocrine and Cardiovascular Disease Network Modelling and Clinical Transfer (ICONLMU), Ludwig-Maximilians-Universität München, Munich, GERMANY,*
[4]*German Center for Cardiovascular Research (DZHK), Munich Heart Alliance (MHA), Partner Site Munich, Munich, GERMANY,*
[5]*Department of Nuclear Medicine and Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, GERMANY,*
[6]*Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM, ENETS Certified Center of Excellence), LMU University Hospital, Ludwig-Maximilians-Universität München, Munich, GERMANY.*

EP-0675

Development of Metabolic Activity of the Fetal Myocardium Measured with [18F]FDG LAFOV PET/ldCT imaging

K. Madsen[1], *F. Hoei-Hansen*[1], *M. M. K. Stolberg*[1], *F. L. Andersen*[1,2], *K. Korsholm*[1], *P. Hasbak*[1];
[1]*Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital Rigshosp, Copenhagen, DENMARK,*
[2]*Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen, DENMARK.*

EP-0676

Beyond Fibrosis: Metabolic and Tissue Assessment of the Myocardium in Fabry Disease Using PET/MRI

B. Hervás-Sanz[1], *P. C. Notta*[1], *E. Claver-Garrido*[2], *C. Díez-López*[3], *S. A. Bolívar-Cuevas*[4], *L. M. Gràcia-Sánchez*[1], *I. E. Sánchez-Rodríguez*[1], *G. Burcet-Rodríguez*[4], *A. Aubanell-Creus*[4], *J. L. Díaz-Moreno*[1], *A. Bagán-Trejo*[1], *M. Zamorano-Rivas*[1], *C. García-Alcober*[5], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,*
[2]*Cardiology Department Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,*
[3]*Cardiology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,*
[4]*Radiology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,*
[5]*Radiopharmacy Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN.*

EP-0677

Required Perfusion-to-Ventilation Count Ratio for Automated Evaluation of V/Q SPECT/CT in the Work-up of CTEPH.

H. Weis[1], *M. Kural*[2], *J. Hertel*[1], *J. Weindler*[1], *T. Kramer*[2], *M. Hellmich*[3], *A. Drzezga*[1], *S. Rosenkranz*[2], *M. Schmidt*[1];
[1]*Department of Nuclear Medicine, Faculty of Medicine and University Hospital of Cologne, Cologne, GERMANY,*
[2]*Department of Internal Medicine III, Heart Center, Faculty of Medicine and University Hospital Cologne, Cologne, GERMANY,*
[3]*Department of Medical Statistics, University Medical Center Göttingen, Göttingen, GERMANY.*

EP-0678

Preliminary Study on Correlation Between 18F-NaF Uptake and Aortic Calcification, Aneurysm Sac Expansion and Endoleak After Abdominal Aortic Aneurysm Endovascular Repair

X. Bi[1], *L. Cao*[2], *J. Liu*[1], *S. Wu*[1], *X. Zhang*[1], *Z. Guan*[1], *W. Guo*[2], *B. Xu*[1], *R. Wang*[1];
[1]*Department of Nuclear Medicine, The First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, CHINA,*
[2]*Department of Vascular Surgery, The First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, CHINA.*

EP-0679

Interobserver Reproducibility and Agreement of Left Ventricular Ejection Fraction Measurements by Planar MUGA, Gated Blood-Pool SPECT, and Gated Myocardial Perfusion SPECT with Echocardiography

N. Talay, *E. Sahin Kutuk, O. Bayrakci, H. San;*
Ankara Bilkent Sehir Hastanesi, Ankara, TÜRKIYE.

EP-0680

Assessment of Left Ventricular Systolic Function by Planar MUGA, Gated Blood Pool SPECT, and CT Attenuation-Corrected Gated Blood Pool SPECT: Interobserver Reproducibility and Agreement with Echocardiography

E. Sahin Kutuk, *N. Talay, O. Bayrakci, H. San;*
Ankara City Hospital, Ankara, TÜRKIYE.

EP-0681

Optimization of FDG Injection Protocol for First-Pass PET Angiography: Impact on Peripheral Arterial Signal and Uniformity

M. Murao, *T. Norikane, Y. Yamamoto, M. Imajo, Y. Nishiyama;*
Kagawa University, Miki, JAPAN.

EP-0682

Integrated diagnostic evaluation combining myocardial scintigraphy (SPECT) and coronary calcium score: comparative analysis and combinatory strategies, a retrospective study

S. Schiavariello[1], *G. Bianco*[1], *R. Armeno*[1], *L. Becce*[2], *C. Loiodice*[3], *A. Vitullo*[3], *A. Ciccarone*[3], *C. Morea*[3], *G. Tarsia*[3], *F. Salomone*[1], *L. Contini*[1], *D. Palone*[1], *S. Scalera*[1], *V. Germano*[1], *V. Sugamiele*[1];
[1]*ASM Matera - Nuclear Medicine, Matera, ITALY,*
[2]*University of Potenza, Potenza, ITALY,*
[3]*ASM Matera - U.O.C Cardiology, Matera, ITALY.*

EP-36

B: Imaging Clinical Studies → B5 Neurological Imaging Clinical Study → B51 Neurodegeneration

EP-0683

L. Li[1], *M. Wang*[2];
[1]*Department of Nuclear medicine, Zhongnan Hospital, Wuhan University, Wuhan, CHINA,*
[2]*School of Life Sciences, Shanghai University, Shanghai, CHINA.*

EP-0684

PET Evaluation of Amyloid Clearance Following Anti-Aβ Monoclonal Antibody Therapy: Preliminary Findings in 25 Patients

A. Samanes Gajate[1], *A. Ghirelli*[2,3], *G. Pepe*[1], *A. Panzacchi*[1], *S. Vadala'*[1,4], *G. Cecchetti*[2], *E. G. Spinelli*[2,3], *G. Rugarli*[2,3], *S. Pisano*[2], *F. Agosta*[2,3], *M. Filippi*[2,3], *A. Chiti*[1,3];
[1]*Department of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, ITALY,*
[2]*Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, ITALY,*
[3]*Vita-Salute San Raffaele University, Milan, ITALY,*
[4]*Milano-Bicocca University, Milan, ITALY.*

EP-0685

Reduced acquisition time in Amyloid PET: Impact on clinical interpretation and centiloid quantification

A. Spataro, *S. Capitanio, A. Scarale, A. Franchini, L. Airò Farulla, M. Cuomo, G. Cabrini, E. Gay, G. Muti, C. Romanò, K. Shyli, C. Rossetti;*
Nuclear Medicine Unit, Dipartimento Ematologia, Oncologia e Medicina Molecolare, ASST Niguarda, Milan, ITALY.

EP-0686

Biological Staging of Alzheimer's Disease via Tau PET: Associations with Amyloid-β, Entorhinal Vulnerability, and Cognitive Decline

X. Liu, *R. Wang;*
Department of Nuclear Medicine, The First Medical Center of Chinese PLA General Hospital, Beijing, CHINA.

EP-0687

Spatial Consistency of Tau-Mediated Regions Multimodal PET Imaging Reveals How Tau Links Aβ Pathology and Neuronal Hypometabolism Across Diverse Cohorts

Z. Zhu[1], *K. Shen*[2], *C. Du*[2], *B. Pan*[1], *S. Wang*[1], *J. Shi*[2];
[1]*Department of Nuclear Medicine, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, CHINA,*
[2]*Department of Neurology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, CHINA.*

EP-0688

Concordance And Discordance Across FDG PET, Amyloid PET, And Fluid Biomarkers In Patients With Suspected Alzheimer's Disease

E. Akgun[1], *Y. Anzai*[2], *S. Minoshima*[2];
[1]*University of Health Science Turkey, Istanbul Training and Research Hospital, Istanbul, TÜRKIYE,*
[2]*University of Utah, Salt Lake City, UT, UNITED STATES OF AMERICA.*

EP-0689

Investigating the Disrupted Synchronicity of Monoamine Oxidase B Expression in the Alzheimer's Disease Brain using [18F]F-DED PET

G. Müller[1], *A. Zatcepin*[2,1], *M. Zeinaki*[1], *B. Rauchmann*[3,4,5], *J. S. Dornreich*[1], *L. Tagnin*[1], *L. Vogler*[1], *J. S. Gnörich*[1], *A. Gesenhues*[1], *D. Dhoqina*[1], *G. Höglinger*[5,6,7], *R. A. Werner*[1,8], *L. Frontzkowski*[1,9], *G. Salvadó*[10,11,12], *D. Vállez-Garcia*[10], *F. Hirsch*[9], *D. Janowitz*[9], *K. Bürger*[5,9], *J. Vöglein*[5,6,7], *S. Stöcklein*[13], *S. Lindner*[1], *J. Levin*[5,6,7], *G. N. Bischof*[14,15], *N. Franzmeier*[6,9], *R. Perneczky*[4,5], *S. Ziegler*[1,2], *M. Brendel*[1,5,6];
[1]*Department of Nuclear Medicine, LMU University Hospital, LMU Munich, München, GERMANY,*
[2]*Department of Nuclear Medicine, Hannover Medical School (MHH), Hannover, GERMANY,*
[3]*Institute of Neuroradiology, LMU University Hospital, LMU Munich, München, GERMANY,*
[4]*Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, München, GERMANY,*
[5]*German Center for Neurodegenerative Diseases (DZNE), München, GERMANY,*
[6]*Munich Cluster for Systems Neurology (SyNergy), München, GERMANY,*
[7]*Department of Neurology, LMU University Hospital, LMU Munich, München, GERMANY,*
[8]*Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Balitmore, MD, UNITED STATES OF AMERICA,*
[9]*Institute for Stroke and Dementia Research (ISD), LMU University Hospital, LMU Munich, München, GERMANY,*
[10]*Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, SPAIN,*
[11]*Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, SWEDEN,*
[12]*Hospital del Mar Research Institute, Barcelona, SPAIN,*
[13]*Department of Radiology, LMU University Hospital, LMU Munich, München, GERMANY,*
[14]*Department of Nuclear Medicine, University Hospital of Cologne, Cologne, GERMANY,*
[15]*Life Molecular Imaging (LMI), Berlin, GERMANY.*

EP-0690

Differential Diagnostic Utility of [18F]PI-2620 Tau PET: Quantitative SUVR in the Basal Ganglia across Neurodegenerative Disorders (AD, PD, PSP,MSA)

S. Gao[1], *M. Xin*[1], *Y. Zhang*[1], *G. Huang*[1], *J. Hao*[2], *L. Qi*[2], *J. Liu*[1], *C. Zhang*[1];
[1]*Department of Nuclear Medicine, Renji*

Hospital,Shanghai Jiaotong University School of Medicine, Shanghai, CHINA,
[2]United Imaging Healthcare, Shanghai, CHINA.

EP-0691

Increased TSPO-PET measurable glial activation associates with later brain atrophy in multiple sclerosis

A. Yenikekaluva[1,2,3], *T. Sjöros*[1,2,3], *M. Matilainen*[1,2,4], *M. Saraste*[1,2,4], *L. Airas*[2,3,4];
[1]*Turku PET Centre, University of Turku, Turku University Hospital, and Åbo Akademi University, Turku, FINLAND,*
[2]*Clinical Neurosciences, University of Turku, Turku, FINLAND,*
[3]*InFLAMES Research Flagship, University of Turku, Turku, FINLAND,*
[4]*Neurocenter, Turku University Hospital, Turku, FINLAND.*

EP-0692

Interchangeable or Not? [^{18}F]Florbetaben PET on PET/MR versus LAFOV PET/CT

M. Rullmann, *M. Kullmann, K. Messerschmidt, P. M. Meyer, O. Sabri, S. Tiepolt;*
Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY.

EP-0693

Head-to-head quantitative comparison of β-amyloid PET between dedicated brain PET and conventional PET/CT

D. Dhoqina[1], *J. Gnörich*[1], *L. Tagnin*[1], *G. Böning*[1], *C. Zach*[1], *A. Delker*[1], *J. Levin*[2], *G. Höglinger*[2], *S. Schönecker*[2], *N. Franzmeier*[3], *L. Frontzkowski*[3], *S. N. Roemer*[2], *R. Perneczky*[4], *C. Kurz*[4], *C. A. M. Koriath*[4], *R. A. Werner*[1], *M. Brendel*[1], *M. Scheifele*[1];
[1]*Department of Nuclear Medicine, LMU University Hospital, Munich, GERMANY,*
[2]*Department of Neurology, LMU University Hospital, Munich, GERMANY,*
[3]*Institute for Stroke and Dementia Research, LMU University Hospital, Munich, GERMANY,*
[4]*Department of Psychiatry and Psychotherapy, LMU University Hospital, Munich, GERMANY.*

EP-0694

Baseline Amyloid PET Burden, but Not Longitudinal Change Predicts ARIA-H Risk in the A4 Study

C. Hill, *H. Morgan, S. Michopoulou;*
University of Southampton, Southampton, UNITED KINGDOM.

EP-0695

^{18}F-FD4 PET Visualizes α-Synuclein Aggregates Independent of Iron Deposition in Synucleinopathies

Q. Jiang[1], *R. Ni*[2], *A. Rominger*[2], *K. Shi*[2], *M. Wadsak*[2], *K. Pandya*[2], *J. Ge*[1], *F. Liu*[3], *J. Lu*[1], *J. Wang*[3], *C. Liu*[4], *C. Zuo*[1];
[1]*Department of Nuclear Medicine/PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA,*
[2]*Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, SWITZERLAND,*
[3]*Department of Neurology, National Clinical Research Center for Aging and Medicine, & National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, CHINA,*
[4]*Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, CHINA.*

EP-0696

Quantifying the Independent Contributions of APOE4 Dosage and Sex to Alzheimer's Disease Progression Velocity: A Multimodal Analysis

T. Zhang, *B. Nie, B. Shan;*
Institute of High Energy Physics, CAS, Beijing, CHINA.

EP-0697

Multimodal PET/MRI in AD Spectrum: CSVD/DTI Differentiate Clinical Decline, while PET Captures Advanced Braak Stages

Y. Zhang[1], *G. Huang*[1], *S. Gao*[1], *H. Shao*[1], *M. Xin*[1], *J. Hao*[2], *L. Qi*[2], *J. Liu*[1], *C. Zhang*[1];
[1]*Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Ren Ji Hospital, Shanghai Ji, Shanghai, CHINA,*
[2]*United Imaging Healthcare, Shanghai, China, Shanghai, CHINA.*

EP-0698

Plasma amyloid ratio and phosphorylated tau biomarkers map onto [F]FDG PET hypometabolism: a voxel-wise study in a clinical cohort of 100 patients with CSF-confirmed AD sensitivity analysis.

A. Chiaravalloti[1], *C. Motta*[2], *C. Bonomi*[2], *M. Poli*[2], *C. Di Russo*[3], *O. Schillaci*[1], *A. Martorana*[4];
[1]*Department of Biomedicine and Prevention, University of Rome Tor Vergata,Rome, taly, Rome, ITALY,*
[2]*Memory Clinic and Neurodegenerative Dementia Research Unit, Policlinico Tor Vergata, University of Rome "Tor Vergata", Rome, Italy, Rome, ITALY,*
[3]*Nuclear Medicine Unit, Policlinico Tor Vergata, Rome, IT, Rome, ITALY,*
[4]*Memory Clinic and Neurodegenerative Dementia Research Unit, Policlinico Tor Vergata, University of Rome "Tor Vergata", Rome, Italy, Rome, Italy, Rome, ITALY.*

EP-0699

Impact of Ultra-High-Resolution PET on Quantification of Amyloid Burden

H. Goesseye[1], *M. Van Looy*[2], *C. Carron*[1,3], *G. Vanderlinden*[1], *K. Van Laere*[1,3];
[1]*Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology - Leuven Brain Institute, KU Leuven, Leuven, BELGIUM,*
[2]*Faculty of Medicine, KU Leuven, Leuven, BELGIUM,*
[3]*Division of Nuclear Medicine, University Hospitals Leuven, Leuven, BELGIUM.*

EP-0700

Prevalence of the Cingulate Island Sign on [^{18}F]FDG PET in Dementia with Lewy Bodies and the Impact of Alzheimer's Disease Co-pathology.

Y. Delisau[1], *P. Zaragoza-Ballester*[1], *G. Arís-Cuadras*[1], *M. Calls-Calahorro*[1], *M. Rodriguez-Fontán*[1], *S. Asadurova*[1], *A. Fernández-León*[1], *M. Velasco-Nuño*[1], *G. Guzmán Prudencio*[1], *S. Castejón*[1], *C. Abdelnour*[2], *J. Duch*[1], *D. Alcolea*[2], *A. Flotats*[1], *V. Camacho*[1];
[1]*Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN,*
[2]*Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.*

EP-0701

Quantitative analysis with ^{11}C-PiB PET in logopenic variant Primary Progressive Aphasia

S. Iaria[1], *F. Vocaturo*[1], *F. Cocciolillo*[2], *V. Scolozzi*[2], *A. Capotosti*[3], *A. Scalese*[4,5], *D. Quaranta*[4,5,6], *R. Moretti*[3], *I. Moretti*[7], *M. Calcagni*[1,2];
[1]*Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, 00168, Rome, ITALY,*
[2]*Nuclear medicine Unit, Department of Diagnostic Imaging and Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168, Rome, ITALY,*
[3]*Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY,*
[4]*Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168, Rome, ITALY,*
[5]*Department of Neuroscience, Catholic University of the Sacred Heart, 00168, Rome, ITALY,*
[6]*Department of Psychology, Catholic University of the Sacred Heart, 20123, Milan, ITALY,*
[7]*Azienda USL Toscana sud est, Arezzo, ITALY.*

EP-0702

Distinct Patterns of Hypometabolism, Atrophy, and Metabolic-Structural Mismatch in Alzheimer's Disease and Frontotemporal Lobar Degeneration

Y. Gu[1], *X. Li*[1], *J. Hao*[2], *M. Shang*[1], *N. Chen*[3], *Y. Zhang*[3], *F. Wang*[1];
[1]*Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, CHINA,*
[2]*United Imaging Healthcare, Shanghai, CHINA,*
[3]*Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, CHINA.*

EP-0703

Effects of Lifestyle and Serotonin on Motor Function in Prodromal and Clinical Parkinson's Disease: Signatures of Resilience

E. Guerra[1], *S. Kalytta*[1], *A. Asendorf*[1], *M. Banwinkler*[1], *V. Dzialas*[1,2], *H. Theis*[1,3], *P. C. Prokopiou*[4], *M. C. Hönig*[1,5], *T. van Eimeren*[1,3];
[1]*Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, GERMANY,*
[2]*Faculty of Mathematics and Natural Sciences, University of Cologne, Cologne, GERMANY,*
[3]*Department of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, GERMANY,*
[4]*Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA,*
[5]*Institute for Neuroscience and Medicine II, Molecular Organization of the Brain, Research Center Juelich, Juelich, GERMANY.*

EP-0704

The Dorsality Index Captures Convergent and Divergent Spatial Patterns of Hypometabolism and Atrophy in Alzheimer's Disease and Frontotemporal Lobar Degeneration

Y. Gu[1], *X. Li*[1], *J. Hao*[2], *M. Shang*[1], *N. Chen*[3], *Y. Zhang*[3], *F. Wang*[1];
[1]*Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, CHINA,*
[2]*United Imaging Healthcare, Shanghai, CHINA,*
[3]*Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, CHINA.*

EP-0705

Cross-vendor harmonization of multi-tracer PET quantification in neurodegenerative disease: a multi-platform benchmark validation of a unified deep-learning framework

J. Wang[1], *A. Zhong*[2], *Y. Zhu*[1], *M. Tian*[1], *Q. Wang*[2], *C. Zuo*[1];
[1]*Department of Nuclear Medicine/PET center, Huashan Hospital, Fudan University, Shanghai, CHINA,*
[2]*School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai, CHINA.*

EP-0706

Detecting Coexisting Lewy Body Disease in Alzheimer's Disease Using Amyloid PET, Aided by SWI

A. Tang[1], *M. Wan*[1], *C. Tang*[1], *Z. Liang*[2], *Y. Gai*[1], *X. Lan*[1], *X. Sun*[1];
[1]*Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA,*
[2]*Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.*

EP-0707

Brain-Organ Hypersynchrony and Cognitive Decline in Alzheimer's Disease: Potential Links with Tauopathy and Glymphatic Dysfunction

L. Wang[1], *L. Li*[2], *Y. Tao*[1], *Y. Jia*[1], *J. Yue*[1], *Y. Zhang*[1], *Y. Wang*[1], *Y. Zhang*[2], *M. Xin*[2], *J. Liu*[2], *F. Shi*[3], ***C. Zhang***[2], *H. Zhang*[1];
[1]*ShanghaiTech University, Shanghai, CHINA,*
[2]*Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA,*
[3]*United Imaging Intelligence, Shanghai, CHINA.*

EP-0708

Optimizing Amyloid PET Reference Regions for Therapy Monitoring: A Comparative Study of Intracerebral and Extracerebral SUVR in Staging and Assessing Aβ Immunotherapies

C. Zhang[1], *T. Sun*[2], *G. Huang*[1], *Y. Zhang*[1], *S. Gao*[1], *M. Xin*[1], *F. Shi*[2], *J. Liu*[1];
[1]*Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, CHINA,*
[2]*Department of Research and Development, United Imaging Intelligence, Shanghai, CHINA.*

EP-0709

Visual Interpretation Versus Centiloid Scale in ^{18}F-Florbetaben Amyloid PET: Maximising Diagnostic Precision in Alzheimer's Disease

N. Canchumanya Huatuco[1], *V. Vallejos Arroyo*[1], *A. Menendez Albarracin*[1], *X. Valverde Guillén*[1], *R. Ferrándiz Hervella*[1], *J. Mora Sospedra*[1], *A. Caresia Aroztegui*[1], *G. Martínez Arias*[2], *P. Hinojosa Salas*[1], *M. Boronat de Ferrater*[1], *M. Salcedo Pujantell*[1], *M. Solà Suárez*[1], *S. Lafuente Carrasco*[1], *J. Deportós Moreno*[1], *G. Moragas Freixa*[1], *S. Ruiz Llama*[1], *M. Diaz López*[1], *M. López Gómez*[1], *N. Torres Nuncio*[1], *R. Benito Paredes*[1], *A. Olmo Crespo*[1], *J. Salamero García*[1];
[1]*Hospital Universitari Germans Trias I Pujol, Badalona,*

SPAIN,
[2]Hospital Clinico Universitario Lozano Blesa, Zaragoza, SPAIN.

EP-0710

Frontal Lobe Predominance in Amyloid Reduction After Anti-Amyloid Therapy: A Longitudinal Comparative ^{18}F-AV45 PET Study

Y. Zhang[1], *G. Huang*[1], *S. Gao*[1], *H. Shao*[1], *M. Xin*[1], *J. Hao*[2], *L. Qi*[2], *J. Liu*[1], *C. Zhang*[1];
[1]Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Ren Ji Hospital, Shanghai Ji, Shanghai, CHINA,
[2]United Imaging Healthcare, Shanghai, China, Shanghai, CHINA.

EP-37

B: Imaging Clinical Studies → B5 Neurological Imaging Clinical Study → B52 Cognitive Impairment

EP-0711

Interactive effects of nucleus basalis of Meynert atrophy and perivascular imaging abnormalities on medial temporal tau burden and cognitive impairment in mild cognitive impairment and Alzheimer's disease

X. Liu, *R. Wang;*
Department of Nuclear Medicine, The First Medical Center of Chinese PLA General Hospital, Beijing, CHINA.

EP-0712

Optimizing Amyloid PET Workflows for Anti-Amyloid Therapy: simulated shortened scan durations and impact of denoising

E. Greco[1], *C. Poggio*[2], *A. Chincarini*[3], *S. DeKeyser*[4], *M. Zotta*[2], *V. De Ridder*[4], *E. Rubino*[5], *F. Roveta*[5], *M. Pardini*[6], *L. Sofia*[7], *S. Raffa*[7], *M. Bauckneht*[7], *F. Massa*[6], *D. Arnaldi*[6], *B. Orso*[6], *I. Rainero*[5], *S. Morbelli*[2], *G. Rovera*[2];
[1]Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,
[2]Nuclear Medicine, University of Turin, Turin, ITALY,
[3]INFN, Genoa, Genoa, ITALY,
[4]Nuclivision, Ghent, BELGIUM,
[5]Department of Neuroscience "Rita Levi-Montalcini", University of Turin, Turin, ITALY,
[6]DINOGMI, University of Genoa, Genoa, ITALY,
[7]Nuclear Medicine, University of Genoa, Genoa, ITALY.

EP-0713

Divergent Trends in the Association Between Depressive Symptoms and^{18}F-FDG PET Metabolism Across Cognitive Impairment Stages

H. Yi, *K. Song, H. Ko, M. Cheon;*
VHS medical center, Seoul, KOREA, REPUBLIC OF.

EP-0714

Lecanemab reduces neuropsychiatric symptoms and related regional brain amyloid load in early Alzheimer's disease: a preliminary prospective study

Y. Chang, *R. Wang;*
Chinese PLA General Hospital, Beijing, CHINA.

EP-0715

Comparison of Two Semiquantitative Amyloid PET Softwares in Clinical Practice: A Real-World Study

X. Zhou[1], *C. Zhou*[1], *J. Zhong*[1], *J. Li*[1], *H. Fang*[1], *Y. Cao*[1], *T. Song*[2], *J. Lee*[3], *M. Zhao*[1];
[1]Department of Nuclear Medicine, The Third Xiangya Hospital, Central South University, Changsha, CHINA,
[2]Department of Neurology, Xiangya Hospital, Central South University, Changsha, CHINA,
[3]Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0716

Brain Hemodynamics Are Linked to Body Fat Composition: Evidence from Total-Body Dynamic ^{18}F-FDG PET/CT

T. Sun[1], *Y. Shen*[1], *Y. Wu*[2], *M. Wang*[2];
[1]Paul C. Lauterbur Research Center for Biomedical Imaging, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, CHINA,
[2]Department of Medical Imaging, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, Zhengzhou, CHINA.

EP-0717

Brain-Dedicated PET Outperforms Standard PET/CT in the Diagnosis of Frontotemporal Dementia

P. Nespral, *G. Cuesta Domingo, M. Vaillant López, A. Delgado-Cano, J. Matías-Guiu, J. Carreras-Delgado, P. Bascuñana Almarcha, M. Cabrera-Martín;*
Hospital Clínico San Carlos, Madrid, SPAIN.

EP-0718

Diagnostic performance of the CSF p-tau/Aβ42 ratio for predicting amyloid PET positivity in patients with suspected Alzheimer´s disease and discordant CSF biomarkers

J. Lojo Ramírez, *P. Fernández Rodríguez, M. Marín Cabañas, E. Franco Macías, J. Jiménez-Hoyuela García; H.U. Virgen Del Rocío, Seville, SPAIN.*

EP-0719

Clinical Value and Predictive Performance of [^{18}F] Florbetaben PET/CT in Patients with Cognitive Impairment

N. Colombo Vina, *L. Blanco-Verdejo, A. Stacey Solis, C. Rillo Mena, A. Crespo de la Jara, T. Mut Dólera, P. Olivan Sasot, M. Redal Peña, M. Cozar Santiago;*
Hospital Clinico Universitario de Valencia, Valencia, SPAIN.

EP-0720

Amyloid pathology drives cognitive decline in Alzheimer's disease through impairing dynamic structure-function coupling: An [^{18}F]-Florbetapir PET/MRI Study

X. Hao[1,2], *S. Wang*[3], *X. Su*[4], *Y. Yang*[4], *X. Wang*[1,2], *Y. Li*[1,2], *C. Dong*[5], *J. Liu*[1,2];
[1]Stem Cell Clinical Research Center, The First Affiliated Hospital of Dalian Medical University, No. [193] Lianhe Road, Dalian, CHINA,
[2]Dalian Innovation Institute of Stem Cell and Precision Medicine, No. [57] Xinda Road, Dalian, CHINA,
[3]Department of Urology, The First Affiliated Hospital of Dalian Medical University, No. [193] Lianhe Road, Dalian, CHINA,
[4]Beijing United Imaging Healthcare Technology Development Co., Ltd., Room [101], [1]st Floor, Building [3], Courtyard [9], Yongteng North Road, Haidian District, Beijing, CHINA,
[5]Department of Neurology, The First Affiliated Hospital of Dalian Medical University, No. [222] Zhongshan Road, Dalian, CHINA.

EP-0721

Glymphatic dysfunction is associated with cerebral glucose metabolism and cognition after myocardial infarction: an integrated ^{18}F-FDG PET/MR study

C. Zheng[1], *Y. Cui*[1], *R. Qin*[1], *N. Li*[2], *Y. Hu*[2], *J. Lu*[1];
[1]Xuanwu Hospital, Capital Medical University, Beijing, CHINA,
[2]Beijing United Imaging Research Institute of Intelligent Imaging, Shanghai, CHINA.

EP-0722

Brain-body Axis Revealed by Metabolic Coupling in Alzheimer's Disease: A Preliminary Research Based on LAFOV PET/CT

F. Jiao[1], *X. Zhu*[2], *W. Li*[1], *H. Pang*[1];
[1]The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA,
[2]Shanghai University, Shanghai, CHINA.

EP-0723

Stage-Dependent Biomarker Trajectories and Multimodal Diagnosis in Alzheimer's Disease

T. Zhiqiang, *Z. Ruiyue, W. Xinlu;*
Department of Nuclear Medicine, the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, CHINA.

EP-0724

Correlation of Regional Amyloid-β Accumulation with Transcriptomic Signatures and Genetic Variants in Alzheimer's Disease

Y. Yang, *L. Xiao, Y. Tang, S. Hu;*
Xiangya Hospital, Central South University, Changsha, CHINA.

EP-0725

Distribution and clinical relevance of visually detected amyloid subtypes using [^{18}F]Flutemetamol amyloid PET

C. Steenhout[1,2], *C. Boccalini*[2], *G. Mathoux*[3], *D. E. Peretti*[2], *M. Scheffler*[4], *G. B. Frisoni*[5,6], *V. Garibotto*[2,3,7];
[1]Division of Nuclear Medicine and Oncological Imaging, Department of Medical Physics, University Hospital of Liège, Liège, BELGIUM,
[2]Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, SWITZERLAND,
[3]Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, SWITZERLAND,
[4]Division of Radiology, Geneva University Hospitals, Geneva, SWITZERLAND,
[5]Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, SWITZERLAND,
[6]Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, SWITZERLAND,
[7]CIBM, Center for Biomedical Imaging, University of Geneva, Geneva, SWITZERLAND.

EP-0726

Assessment of Regional Cerebral Blood Flow by ^{99m}Tc-ECD Brain SPECT with eZIS Quantification in Children with Autism Spectrum Disorder

S. Adnan[1], *N. Sultana*[2];
[1]Department of Nuclear Medicine and Radiology, Combined Military Hospital, Dhaka, BANGLADESH,
[2]National Institute of Nuclear Medicine and Allied sciences, Dhaka, BANGLADESH.

EP-0727

White matter-weighted temporal shift between 60- and 90-min [^{18}F]flutemetamol PET: a voxel-wise explanation for borderline interpretive instability

K. Sohara[1], *H. Matsuda*[2], *S. Mizumura*[1,3], *Y. Nakaoka*[1], *S. Imai*[1,2], *M. Suda*[1], *T. Sekine*[1], *T. Ando*[1], *H. Hayashi*[1], *S. Kumita*[1];
[1]Department of Radiology, Nippon Medical School, Tokyo, JAPAN,
[2]Clinical Imaging Center for Healthcare, Nippon Medical School, Tokyo, JAPAN,
[3]Department of Radiology, Toho University Omori Medical Center, Tokyo, JAPAN.

EP-0728

Clinical value of florzolotau (^{18}F) PET in the differential diagnosis of patients with cognitive impairment

J. Brumberg, *L. Frings, S. Hellwig, C. Volz, H. Wiendl, J. Hosp, P. T. Meyer;*
Medical Center - University of Freiburg, Freiburg, GERMANY.

EP-0729

Correlation between [^{18}F]Florzolotau retention and neuropsychological performance in frontotemporal lobar degeneration spectrum disorders

A. Shimizu[1], *Y. Iwabuchi*[1], *S. Bun*[2], *M. Watanabe*[1], *M. Kubota*[3], *S. Shimohama*[3], *T. Tezuka*[3], *K. Takahata*[2], *H. Tabuchi*[2], *M. Seki*[3], *Y. Momota*[2], *Y. Yamamoto*[2], *R. Shikimoto*[2], *Y. Mimura*[2], *S. Kurose*[2], *R. Sakurai*[1], *T. Takayama*[4], *Y. Hoshino*[2], *T. Hoshino*[2], *N. Suzuki*[2], *A. Morimoto*[2], *A. Osumi*[2], *M. Mimura*[2], *M. Jinzaki*[1], *D. Ito*[3];
[1]Department of Radiology, Keio University School of Medicine, Tokyo, JAPAN,
[2]Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, JAPAN,
[3]Department of Neurology, Keio University School of Medicine, Tokyo, JAPAN,
[4]Department of Psychiatry and Behavioral Science, Graduate School of Medicine, Juntendo University, Tokyo, JAPAN.

EP-0730

Differences in brain metabolism and brain network topological properties in Alzheimer's disease patients with depression

H. Zhang, *J. Liu, H. Zhang;*
the second hospital of lanzhou university, Lanzhou City, Gansu Province, CHINA.

EP-0731

Metabolic subtyping in Amyloid-β-Positive Alzheimer's Disease Using Simultaneous PET/MRI

F. Hao[1,2], *M. Liang*[1,2], *X. Zhang*[1,2], *Q. Ji*[3], *J. Cao*[1,2], *Z. Wu*[1,2], *S. Li*[1,2];
[1]Shanxi Medical University, Taiyuan, CHINA,
[2]Shanxi Medical University First Hospital, Taiyuan,

CHINA,
[3]Shanghai United Imaging Healthcare Co., Ltd., Shanghai, CHINA.

EP-0732

Network Decoupling Effects in the Competing Cognitive Impairment Mechanisms of Tau Pathology and Cerebral Small Vessel Disease During Alzheimer's Disease Progression

***H. Fang**, J. Chen, C. Tang, X. Sun, X. Lan;*
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0733

The Correlation Between Individualized Brain Metabolic Networks Based on ^{18}F-FDG PET/CT and Cognitive Function Changes in DLBCL Patients Before and After Chemotherapy

***Y. Gu**;*
The Second Hospital of Lanzhou University, Lanzhou, CHINA.

EP-0734

Regional cerebral hypometabolism on ^{18}F-FDG brain PET/CT and long-term neurological outcomes after traumatic brain injury

***T. Moncada-Marzan**[1,2], J. A. Lojo-Ramirez[1,2], P. Fernandez-Rodriguez[1,2], B. Hernandez-Carreras[1,2], M. O. Gonzalez-Oria[3,2], J. M. Jimenez-Hoyuela[1,2];*
[1]Department of Nuclear Medicine, Virgen del Rocío University Hospital, Seville, SPAIN,
[2]Seville Institute of Biomedicine (IBIS)/Virgen del Rocío University Hospital/CSIC/University of Seville, Seville, SPAIN,
[3]Department of Neurological Rehabilitation, Virgen del Rocío University Hospital, Seville, SPAIN.

EP-0735

Dynamic ^{18}F-FDG PET Improves Detection of Alzheimer's Disease Patterns in Cognitive Impairment: A Comparative Study with Static Imaging

***M. Vaillant**[1], G. Cuesta[1], P. Nespral[1], B. Garcia-Raldua[1], G. Muñoz[1], C. Wakfie[1], J. Matías-Guiu[2], M. Cabrera[1], P. Bascuñana[3];*
[1]Nuclear Medicine Department, Hospital Clínico San Carlos, Madrid, SPAIN,
[2]Neurology Department, Hospital Clínico San Carlos, Madrid, SPAIN,
[3]Cartografía Cerebral, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, SPAIN.

EP-38

B: Imaging Clinical Studies → B5 Neurological Imaging Clinical Study → B53 Movement Disorders

EP-0736

Regional Alterations in Cerebral Metabolism, Perfusion, and Magnetic Susceptibility in Parkinson's Disease with Depression

***M. Zhao**[1], B. Chen[1], L. Li[1], J. Wang[1], X. Su[2];*
[1]Department of Nuclear Medicine, China-Japan Union Hospital, Jilin University, Changchun, CHINA,
[2]Beijing United Imaging Healthcare Technology Development Co., Ltd., Beijing, CHINA.

EP-0737

Comparative Evaluation of Global Tau Propagation and Accumulation Using ^{18}F-Florzolotau PET in Progressive Supranuclear Palsy

***X. Chen**[1], J. Lu[2], C. Zuo[2], J. Jiang[1], M. Wang[1];*
[1]Institute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, CHINA,
[2]Department of Nuclear Medicine/PET center, Huashan Hospital, Fudan University, Shanghai, CHINA.

EP-0738

Longitudinal evaluation of brain and cardiac mitochondrial complex 1 expression in patients with Friederich's Ataxia

***E. A. Rabiner**[1], S. Golla[1], F. van den Berg[1], A. Whittington[1,2], L. Fonville[1], Y. Lewis[1], J. Labao[3], P. Giunti[2], C. Salinas[4], R. Festenstein[3];*
[1]Perceptive Discovery, London, UNITED KINGDOM,
[2]University College, London, UNITED KINGDOM,
[3]Imperial College, London, UNITED KINGDOM,
[4]Takeda Pharmaceuticals, Boston, MA, UNITED STATES OF AMERICA.

EP-0740

Specific Damage to the Mesocortical Dopaminergic Pathway in Early-Onset Parkinson's Disease with Genetic Mutation: Evidence from ^{11}C-β-CFT and ^{18}F-FDG Positron Emission Tomography

***Y. Chang**, R. Wang;*
Chinese PLA General Hospital, Beijing, CHINA.

EP-0741

Integrating WMH, CPV, and DTI with ^{11}C-CFT PET/MR to assess glymphatic dysfunction, distinguishing motor and cognitive decline across subtypes in Parkinson's Disease

***M. Xin**[1], Y. Zhang[1], J. Hao[2], S. Gao[1], G. Huang[1], L. Qi[2], T. Sun[3], C. Zhang[1];*
[1]Renji hospital, Shanghai Jiao Tong university School of Medicine, Shanghai, CHINA,
[2]United Imaging Healthcare Co, Ltd, Shanghai, CHINA,
[3]Department of Research and Development, United Imaging Intelligence, Shanghai, CHINA.

EP-0742

Beyond the Striatum: FDG-PET Signatures of Brainstem and Cerebellar Degeneration in Parkinsonian Syndromes

***M. Nerattini**[1,2], S. Arena[1], L. Maccioni[1], A. Buoncompagni[1], V. Matteoni[1], V. Callotti[1], F. Montanini[2], E. Abenavoli[2], V. Berti[1];*
[1]University of Florence, Florence, ITALY,
[2]Nuclear Medicine Unit, Careggi University Hospital, Florence, ITALY.

EP-0743

Basal ganglia perfusion assessed by R1 from dynamic ^{18}F-PR04.MZ PET/CT in Parkinson's disease and atypical parkinsonisms

***A. Damian**[1], I. Amorín[2], V. Kramer[3], L. Gutierrez[1], G. Falasco[1], L. Urrutia[1], A. Haeger[4], I. Cordero[1], E. Savio[1], J. Higgie[2], A. Lescano[2], T. Arias[5], O. Alonso[1], R. Ferrando[1];*
[1]Uruguayan Centre of Molecular Imaging (CUDIM), Montevideo, URUGUAY,
[2]Instituto de Neurología, Hospital de Clínicas, Montevideo, URUGUAY,
[3]Positronpharma, Santiago, CHILE,
[4]Positronmed, Santiago, CHILE,
[5]Unidad Académica de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Montevideo, URUGUAY.

EP-0744

Nucleus Accumbens Dopaminergic Dysfunction is Directly Associated with Mild Cognitive Impairment in Parkinson's Disease: Evidence from Dopamine Transporter and Glucose Metabolism PET Imaging

***Y. Chang**, R. Wang;*
Chinese PLA General Hospital, Beijing, CHINA.

EP-0745

Diagnosis of Multiple System Atrophy and Subtypes Using ^{18}F-FDG PET-Based Machine Learning

***M. Liang**[1], Y. Wang[2], C. Jia[1], h. Wang[3], R. Cui[1];*
[1]Department of Nuclear Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sci, Beijing, CHINA,
[2]Department of Neurology, Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA,
[3]Department of Neurology, Peking Union Medical College Hospital Chinese Academy of Medical Sci, Beijing, CHINA.

EP-0746

Topological characteristics of multiplex network functional segregation in Parkinson's disease: a simultaneous PET/MR study

***M. Wang**[1], Y. Jiao[1], Y. Hu[2], Y. Yang[3], P. Fu[1], C. ZHao[1];*
[1]Department of Nuclear Medicine, [1]st Hospital of Harbin Medical University, Harbin, CHINA,
[2]Central Research Institute, United Imaging Healthcare Group Co., Ltd, Shanghai, CHINA,
[3]Beijing United Imaging Healthcare Co., Ltd, Beijing, CHINA.

EP-0747

Diagnostic Accuracy of [^{99m}Tc]Tc-TRODAT-1 Dopamine Transporter SPECT for Parkinsonian Syndromes: A Systematic Review and Meta-Analysis

***B. Alencar**[1], S. C. Campos[2];*
[1]Unicamp, Campinas, São Paulo, BRAZIL,
[2]UFPI, Federal University Of Piaui, Piaiui, BRAZIL.

EP-0748

Analysis of brain FDG PET/CT findings in Parkinson's disease (PD): comparison between GBA-PD and non-mutated PD

***A. Arnone**[1], F. Cavallieri[2], A. Fraternali[1], G. Argenziano[2], R. Langridge[3], J. Ko[3], G. Battisti[1], R. Durmo[1], M. Roncali[1], N. Bonazzi[1], S. Montepietra[2], E. Valente[4], A. Di Fonzo[5], G. Di Rauso[2], V. Fioravanti[2], S. Caminiti[6], G. Toschi[2], M. Avenali[6], O. Iotti[2], E. Monfrini[5], G. Portaro[2], A. Gessani[7], G. Salomone[2], R. Sabadini[2], L. Caprari[2], J. Paul[8], P. Bauer[8], F. Valzania[9], A. Strafella[10], A. Filice[1];*
[1]Nuclear Medicine Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ITALY,
[2]Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ITALY,
[3]Department of Human Anatomy and Cell Science, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, CANADA,
[4]Department of Molecular Medicine, University of Pavia, Pavia, ITALY,
[5]Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit, Milan, ITALY,
[6]Department of Brain and Behavioral Sciences, University of Pavia, Pavia, ITALY,
[7]Colibri LAB, Maranello, ITALY,
[8]Centogene GmbH, Rostock, GERMANY,
[9]Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ITALY,
[10]Krembil Brain Institute, University Health Network, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, CANADA.

EP-0749

Beyond Z-Scores: The Diagnostic Role of Anterior Putamen Uptake in Indeterminate DATSCAN Imaging

***M. Vaillant**[1], P. Bascuñana[2], L. León[1], C. González Roiz[1], M. Romero[1], L. Carreño Mancilla[1], G. Cuesta[1], P. Nespral[1], C. Wakfie[1], M. Cabrera[1];*
[1]Nuclear Medicine Department, Hospital Clínico San Carlos, Madrid, SPAIN,
[2]Cartografía Cerebral, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, SPAIN.

EP-39

B: Imaging Clinical Studies → B5 Neurological Imaging Clinical Study → B54 Neurotransmission and Receptors

EP-0750

^{18}F-DOPA PET/CT as an Indicator of Functional Recovery after Gene Therapy in Adult AADC Deficiency: a Case Report

***E. Valente**, T. Lanzolla, M. Pontico, G. M. Granese, A. Signore, G. Capriotti;*
Sapienza University of Rome, Rome, ITALY.

EP-0751

Can PDE4D Be Effectively Imaged in Ischemic Stroke? Mechanistic Basis, PET Radioligand Design and Unresolved Challenges

***Y. Lu**;*
Affiliated hospital of Guilin medical University, Guilin, CHINA.

EP-0752

Software semiquantitative FBP and OSEM applications in scintigraphic investigation of presynaptic dopaminergic nigrostriatal integrity with 123I-Ioflupane SPET: a higher z-score threshold augments sensitivity

***E. Karathanos**[1,2], T. Toka[3], A. Terzoudi[1], A. Arvaniti[1], E. Mavraki[1], M. Katsikidou[1], K. Vadikolias[1], G. Trypsianis[1], C. Sachpekidis[1], P. Valsamaki[1];*
[1]School Of Medicine, Democritus University of Thrace,

Alexandroupolis, GREECE, [2]"Sotiria" Hospital, Athens, GREECE,
[3]School of Molecular Biology & Genetics, Democritus University of Thrace, Alexandroupolis, GREECE.

EP-0753

Characterization of sex-specific brain aging trajectories of synaptic AMPA receptor density in healthy individuals using [11C]K-2 PET

M. Hatano[1], *W. Nakajima*[1], *S. Tsuchimoto*[2], *T. Arisawa*[1], *S. Ichijo*[1], *H. Abe*[1], *Y. Kimura*[3], *T. Takahashi*[1];
[1]*Department of Physiology, Yokohama City University Graduate School of Medicine, Yokohama, JAPAN,*
[2]*Division of Neural Dynamics, Department of System Neuroscience, National Institute for Physiological Sciences, Okazaki, JAPAN,*
[3]*Faculty of Informatics, Cyber Informatics Research Institute, Kindai University, Higashi-Osaka, JAPAN.*

EP-40

B: Imaging Clinical Studies → B5 Neurological Imaging Clinical Study → B55 Other Neurological Imaging

EP-0754

Contrasting Effective Connectivity of Frontal-Limbic-Cerebellar Circuits in Adolescent Bipolar Disorder and Major Depressive Disorder

T. Yu[1], *J. Hui*[2], *L. Liu*[3], *Y. Cheng*[4], *E. Cong*[1,5], *C. Ma*[4];
[1]*Department of Psychiatry, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, CHINA,*
[2]*Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine and School of Psychology, Shanghai, CHINA,*
[3]*Shanghai United Imaging Healthcare Co., Ltd., Shanghai, CHINA,*
[4]*Department of Nuclear Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, CHINA,*
[5]*Shanghai Mental Health Centre, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.*

EP-0755

Dynamic 68Ga-PSMA-11 PET Identifies Blood-Brain Barrier Permeability As the Main Driver of Tracer Uptake in Glioma

R. Yang, *K. Guo, G. Li, J. Ye, K. Yu, Y. Guo, T. Ma, J. Wang, F. Kang, J. Wang;*
Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

EP-0756

Integrated PET/MR Imaging Reveals Perfusion and Metabolic changes of Crossed Cerebellar Diaschisis in Ischaemic Cerebrovascular Disease

X. Wei[1], *B. Cui*[2], *R. Ling*[3], *M. Wang*[1], *J. Jiang*[1], *J. Lu*[2];
[1]*Institute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, CHINA,*
[2]*Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China, Beijing, CHINA,*
[3]*Shanghai University of Medicine and Health Science (SUMHS), Shanghai, CHINA.*

EP-0757

PET metabolic brain network characteristics in temporal lobe epilepsy patients with different drug sensitivities

H. Zhang, *J. Liu;*
The second hospital&clinical medical school. Lanzhou University, Lanzhou, CHINA.

EP-0758

Subregion-Specific Connectivity Patterns and Directional Effective Connectivity among the Hippocampus, Amygdala, and Cerebellum in Adolescents with Bipolar Disorder versus Major Depressive Disorder

T. Yu[1], *Y. Cheng*[2], *L. Liu*[3], *J. Hui*[4], *X. Luo*[1], *C. Ma*[2], *E. Cong*[1,5];
[1]*Department of Psychiatry, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, CHINA,*
[2]*Department of Nuclear Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, CHINA,*
[3]*Shanghai United Imaging Healthcare Co., Ltd., Shanghai, CHINA,*
[4]*Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine and School of Psychology, Shanghai, China, Shanghai, CHINA,*
[5]*Shanghai Mental Health Centre, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.*

EP-0759

Contribution of Functional Neuroimaging to the Presurgical Evaluation of Drug-Resistant Focal Epilepsy and its clinical impact

M. Zamorano Rivas[1], *L. Rodríguez Bel*[1], *M. Pudis*[1], *M. Suárez Piñera*[1], *A. Jareño Badenas*[2], *A. Camins Simón*[2], *J. Sala i Padró*[3], *A. Roselló Gómez*[4], *A. Fernández Coello*[4], *A. Bagán Trejo*[1], *J. Díaz Moreno*[1], *M. Cortés Romera*[1];
[1]*Nuclear Medicine- PET Department (ICS-IDI). Hospital Universitari de Bellvitge - IDIBELL, Barcelona, SPAIN,*
[2]*Radiology Department. Neuroradiology Section. Hospital Universitari de Bellvitge - IDIBELL, Barcelona, SPAIN,*
[3]*Neurology Department. Hospital Universitari de Bellvitge, Barcelona, SPAIN,*
[4]*Neurosurgery Department. Hospital Universitari de Bellvitge, Barcelona, SPAIN.*

EP-0760

Evaluation of Chemotherapy-Induced Alterations in Brain Glucose Metabolism with [18F]FDG PET/CT in Breast Cancer Patients Receiving Adjuvant and Neoadjuvant Treatment

B. Demir[1], *M. Atalay*[1], *H. K. Yurtcu*[2], *F. Ertek*[1], *A. Aytac*[3], *H. I. Ellez*[3], *Y. Aydinalp Camadan*[3];
[1]*Mehmet Akif Inan Education and Research Hospital Department of Nuclear Medicine, Sanliurfa, TÜRKIYE,*
[2]*Harran University Medical School Department of Nuclear Medicine, Sanliurfa, TÜRKIYE,*
[3]*Mehmet Akif Inan Education and Research Hospital Department of Medical Oncology, Sanliurfa, TÜRKIYE.*

EP-0761

Voxel-Based Analysis of Brain Glucose Metabolism on 18F-FDG PET/CT: From Subjective Scores to Objective Biomarkers of Cancer-Related Distress

N. Fatima[1,2], *M. Zaman*[2], *A. Muhammad*[1], *N. Panhwar*[1], *Z. Khan*[3], *S. Zaman*[4], *K. Khan*[1], *N. Haider*[1];
[1]*Dow University Health Sciences, Karachi, PAKISTAN,*
[2]*Aga Khan University Hospital, Karachi, PAKISTAN,*
[3]*Karachi Metropolitan University Pakistan, Karachi, PAKISTAN,*
[4]*Ziauddin University Karachi Pakistan, Karachi, PAKISTAN.*

EP-0762

[18F]FDG PET Metabolic Evaluation of Thalamic Nuclei in Temporal Lobe Epilepsy

N. Martinage[1], *C. Bordier*[1], *M. Dhoisne*[1], *M. Gérard*[1], *P. Derambure*[1,2], *F. Semah*[1,2], *R. Lopes*[1,2];
[1]*Centre Hospitalier Universitaire de Lille, Lille, FRANCE,*
[2]*Faculté de Médecine - Université de Lille, Lille, FRANCE.*

EP-0763

FDG PET/CT in Paraneoplastic Cerebellar Degeneration: Diagnostic and Follow-Up Findings

R. Ferrando[1,2], *C. Bentancourt*[2], *K. Mosci*[3], *A. Damian*[1,2];
[1]*Nuclear Medicine and Molecular Imaging Center, Clinics Hospital, Universidad de la República, Montevideo, URUGUAY,*
[2]*Uruguayan Centre for Molecular Imaging (CUDIM), Montevideo, URUGUAY,*
[3]*Hospital das Forças Armadas (HFA), Brasilia, BRAZIL.*

EP-0764

18F-DPA-714 PET/MR Outperforms 18F-FDG PET/MR for Presurgical Localization of Bottom-of-Sulcus Focal Cortical Dysplasia in Drug-Resistant Epilepsy

Y. Zhang, *X. Zhang;*
The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, CHINA.

EP-0765

Impact of Extended Axial Field-of-View on Low Dose Brain PET/CT Protocols

Y. Sun[1], *H. Yi*[2], *W. Liu*[1], *Y. Zhao*[2], *Y. Zhu*[3], *X. Chen*[1];
[1]*Institute of Biomedical Manufacturing and Life Quality Engineering, State Key Laboratory of Mechanical System and Vibration, School of Mechanical Engineering, Shanghai Jiao Tong University, Shanghai, CHINA,*
[2]*Clinical Application Engineering, United Imaging Healthcare, Shanghai, CHINA,*
[3]*Kunshan Hospital of Jiangsu University, Kunshan, CHINA.*

EP-0766

Radiotracer and Pathway-Specific PET Imaging in Neuroimmunological CNS Disorders: A Scoping-Informed Systematic Review in Progress

B. Collins, *C. Ong, V. Santhara, J. Hwang, R. Yang,* ***T. Erfani****;*
University of Newcastle, Newcastle, AUSTRALIA.

EP-0767

Diagnostic Value and the Role in Clinical Decision-Making of Brain Perfusion Scintigraphy in Brain Death: Single Center Experience

A. Erdem Karaoglu, *E. Tatcı, D. Çayır, N. Altun Yoloğlu, Ö. Özmen;*
Ankara Etlik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-0768

Added value of [18F]-FDG PET/MRI in PET-positive patients with drug-resistant focal epilepsy: focus localization and guidance of invasive evaluation

A. Dacosta Escobar[1], *L. Rodíguez Bel*[1], *M. Pudis*[1], *B. Hervás Sanz*[1], *M. Zamorano Rivas*[1], *M. Suárez Piñera*[1], *A. Jareño Badenas*[2], *A. Camins Simón*[2], *J. Díaz Moreno*[1], *G. Hernández Pérez*[3], *A. Fernández Coello*[4], *M. Cortés Romera*[1];
[1]*Nuclear Medicine-PET department (ICS-IDI), Hospital Universitari de Bellvitge – IDIBELL, Barcelona, SPAIN,*
[2]*Radiology department - Neuroradiology subsection, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, SPAIN,*
[3]*Neurology department, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, SPAIN,*
[4]*Neurosurgery department, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, SPAIN.*

EP-0769

ErbB2 links oxidative stress to glucose hypometabolism in drug-resistant temporal lobe epilepsy

L. Xiao, *J. Wang, Y. Tang, S. Hu;*
Xiangya Hospital Central South University, Changsha, CHINA.

EP-0770

The Role of CortexID Quantitative FDG-PET Analysis in Localizing the Epileptogenic Focus in Temporal Lobe Epilepsy

A. Dursun[1], *S. Kubat*[1], *C. Ö. Engür Uyanik*[1], *E. A. Tan Kaynar*[2], *N. A. Dizdar*[1], *A. E. Çilliler*[3], *E. Tatci*[1], *Ö. Özmen*[1];
[1]*Health Sciences University, Ankara Etlik City Hospital, Nuclear Medicine Clinic, Ankara, TÜRKIYE,*
[2]*Ankara Atatürk Sanatorium Training and Research Hospital, Radiology Clinic, Ankara, TÜRKIYE,*
[3]*Health Sciences University, Ankara Etlik City Hospital, Neurology Clinic, Ankara, TÜRKIYE.*

EP-41

B: Imaging Clinical Studies → B6 Endocrinological Imaging Clinical Study → B61 Endocrinology (including Thyroid Benign)

EP-0771

18F-Fluorocholine PET/CT outperforms sestamibi-based imaging in a real-world stepwise pathway for primary hyperparathyroidism and impacts surgical management

F. Matteucci[1], *P. Caroli*[1], *A. Paccagnella*[2], *D. Bezzi*[2], *S. Mattoni*[2], *M. Casi*[2], *G. Pontone*[3], *F. Di Mauro*[3], *A. Ambrosetti*[2], *V. Mattone*[2], *R. Galassi*[3], *A. Moretti*[3];
[1]*IRCCS IRST, Meldola, ITALY,*
[2]*AUSL Romagna, Cesena, ITALY,*
[3]*AUSL Romagna, Forlì, ITALY.*

EP-0772

Shear wave elastography differentiates healthy individuals from patients with euthyroid Hashimoto's thyroiditis

K. Zaletel[1,2], *A. Jarc*[2], *T. Krokter Kogoj*[1], *S. Gaberscek*[1,2];
[1]*Division of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA,*
[2]*Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.*

EP-0773

Evaluation of the Relationship Between F18-FDG PET/CT Parameters and Pituitary MRI Findings in Pituitary Lesions

N. Talay, *E. Sahin Kutuk, O. Bayrakci, H. San;*
Ankara Bilkent Sehir Hastanesi, Ankara, TÜRKIYE.

EP-0774

^{3}D Semi-Quantitative SPECT/CT Assessment of Sestamibi Bone Uptake in Primary Hyperparathyroidism: Correlation with Biochemical Severity

J. Mendes, *P. Ferreira, P. Soeiro;*
Hospital de São João, Porto, PORTUGAL.

EP-0775

Bone Mineral Density in Hyperthyroidism: Impact ofNa[^{99m}Tc]TcO4ScintigraphyPatterns and Age

A. Lima Alves[1], *A. Isabel*[2], *D. Carvalho*[1], *S. Barata*[1], *S. Paiva*[1], *I. Casimiro*[1], *G. Costa*[1], *A. Moreira*[1];
[1]*ULS Coimbra, Coimbra, PORTUGAL,*
[2]*ULS de Coimbra - Serviço de Física Médica e Proteção Radiológica, Hospitais da Universidade de Coimbra, 3004-561 Coimbra, Portugal;*
LIBPhys-UC, LA-REAL, Department of Physics, University of Coimbra, Portugal, Coimbra, PORTUGAL.

EP-0776

Dual-phase vs one-phase choline PET/CT for the diagnosis of parathyroid adenoma

K. Sanabria Ramírez, *I. Blanco Saenz, P. Boya, S. Blanco, C. Villaprado, A. Barrera, P. Carrera, P. Salvador, E. Goñi;*
Hospital Universitario De Navarra, Pamplona, SPAIN.

EP-0777

Optimizing Parathyroid Imaging: The Role of Acquisition Timing in F-18-Fluorocholine PET/CT Performance

J. Petrovic[1,2], *B. Radovic*[1], *L. Grujičić*[1], *N. Pantić*[1], *M. Veljković*[1,2], *M. Stojiljković*[1,2], *S. Odalović*[1,2], *I. Grozdić Milojević*[1,2], *D. Šobić Šaranović*[1,2];
[1]*University Clinical Center of Serbia;*
Center for Nuclear Medicine with PET, Belgrade, SERBIA,
[2]*Faculty of Medicine University of Belgrade, Belgrade, SERBIA.*

EP-0778

^{18}F-Fluorocholine PET-CT for Localization of Hyperplastic Parathyroid Glands in End Stage Renal Disease Secondary Hyperparathyroidism

Z. LI, *w. Fu;*
Department of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, CHINA.

EP-0779

Clinical Validation of ^{18}F-Fluorocholine PET/CT in a Large Academic Center for Lesion Localization and Surgical Outcomes in Hyperparathyroidism

A. Giarratana, *C. Jinadasa, N. Menon, S. Perlman;*
University of Wisconsin - Madison, Madison, WI, UNITED STATES OF AMERICA.

EP-0780

Ga-68 Pentixafor PET/CT accurately lateralises aldosterone-producing adenomas in primary aldosteronism: a retrospective study

M. Rai, *R. Maurya, P. k. Pradhan;*
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, INDIA.

EP-0781

Characterization of Extra-Adrenal Lesions Using [^{99m}Tc]Nanocolloid SPECT/CT: A Case Series Study.

L. Henrich Malizia, *J. Cruz Vasquez, A. Gomez Lopez, I. Cillero Etxebeste, B. Aguiar Lozada, C. Castro, N. Etxabeguren Gallo, A. Garin Rodriguez, F. Arraut Serrano, D. Rodriguez Oviedo, A. Roteta Unceta Barrenechea;*
Hospital Universitario Donostia - Onkologikoa, Donostia - San Sebastian, SPAIN.

EP-0782

DXA in Body Composition Analysis: A Novel Tool in the Diagnosis of Familial Partial Lipodystrophy

F. Avci[1], *T. Mermer*[2], *R. Meral*[3], *S. İbrahim*[4], *B. Akıncı*[5], *S. Eyigör*[4], *I. Y. Şimşir*[6], *A. M. Argon*[1];
[1]*Ege University, School of Medicine, Nuclear Medicine Department, Izmir, TÜRKIYE,*
[2]*Siirt Training and Research Hospital, Department of Internal Medicine, Siirt, TÜRKIYE,*
[3]*Istanbul University, Institute of Health Sciences, Medical Biology, Istanbul, TÜRKIYE,*
[4]*Ege University, Department of Physical Therapy and Rehabilitation, Izmir, TÜRKIYE,*
[5]*Dokuz Eylül University, Department of Internal Medicine, Izmir, TÜRKIYE,*
[6]*Ege University, Department of Internal Medicine, Endocrinology, Izmir, TÜRKIYE.*

EP-0783

^{18}F-Choline PET/CT as a Second-Line Imaging Modality in Primary Hyperparathyroidism: Impact on Localization and Surgical Management

S. Seijas Marcos, *S. Nieves Maldonado, F. Zelaya Reinquet, S. Rodríguez Martínez De Llanos, Y. García López, M. González Vazquez, P. Pais Silva;*
Centro Oncológico de Galicia, A Coruña, SPAIN.

EP-0784

Diagnostic Performance of [^{18}F]F-Choline PET/CT in Patients with Primary Hyperparathyroidism and Inconclusive [^{99m}Tc]Tc-MIBI SPECT/CT, Biochemical and Histological Correlation

C. Fercalo, *E. Martínez Montalbán, R. Maestre Cutillas, M. García Arévalo, J. Nieto Margareto, B. Martínez de Miguel;*
La Paz University Hospital, Madrid, SPAIN.

EP-0785

[^{18}F] flurocholine PET-CT for localisation of parathyroid adenomas: a match made in heaven?

S. Sa, *M. Kale, B. Sanghera, T. Hussain, M. Waterhouse, E. Ng, M. Krishnamurthy;*
Barts Health NHS Trust, London, UNITED KINGDOM.

EP-0786

Diagnostic utility of ^{4}D Computed Tomography in Patients with Suspected Primary Hyperparathyroidism and Negative ^{99}mTc-Sestamibi SPECT/CT

L. Lucas Benitez[1], *E. Cortés Mancera*[1], *C. Carreras Velázquez*[1], *J. Ponce de Leon*[2];
[1]*Hospital Angeles Lomas, Estado de Mexico, MEXICO,*
[2]*Hospital Angeles Pedregal, Ciudad de México, MEXICO.*

EP-0787

Age-Dependent Spatial Remodelling of Brown Adipose Tissue on FDG-PET/CT: A Systematic Review and Qualitative Synthesis

T. Kotani[1], *N. Tamaki*[2], *S. Yamada*[1], *M. Kiba*[1], *S. Akiyama*[1], *T. Kanayama*[1];
[1]*Kyoto Prefectural University of Medicine, Kyoto, JAPAN,*
[2]*Kyoto University of Advanced Science, Kyoto, JAPAN.*

EP-0788

Ga-68 Trivehexin PET/CT outperforms conventional imaging for preoperative localisation in primary hyperparathyroidism: A Prospective Comparative Study

M. Dutta, *M. Roop Jayanthi, S. Batchu, K. D. J. Prakash, B. Naren, K. K. Pasam;*
Asian Institute of Gastroenterology, Hyderabad, INDIA.

EP-0789

Parathyroid Carcinoma: A single-centre experience with a sequential dual-tracer PET/CT strategy

M. Zamorano Rivas[1], *V. Carrero Vásquez*[1], *R. Sánchez Barrera*[2], *J. Puig de Bellacasa Suils*[2], *E. Dorca Duch*[3], *M. Argeles Colet*[1], *S. Ramírez Muñoz*[1], *M. Cortés Romera*[1], *I. Sánchez Rodríguez*[1];
[1]*Nuclear Medicine- PET Department (ICS-IDI). Hospital Universitari de Bellvitge - IDIBELL, Barcelona, SPAIN,*
[2]*Endocrinology Department. Hospital Universitari de Bellvitge, Barcelona, SPAIN,*
[3]*Pathology Department. Hospital Universitari de Bellvitge, Barcelona, SPAIN.*

EP-0790

Quantification of Functional Heterogeneity in Thyroid Autonomy Using a Structural Target Index Derived from Tc-99m Scintigraphy

M. Gammel, *K. Hansen, T. Spenger, M. Eiber;*
TUM Klinikum, Rechts der Isar, Department of Nuclear Medicine TUM School of Medicine and Health, Munich, GERMANY.

EP-0791

Assessment of [^{18}F]-fluorocholine PET/CT in the Preoperative Detection of Parathyroid Adenomas: A Retrospective Analysis

R. Salvador-Arthur, *P. Paez Vargas, A. M. Paguay-Moina, M. Parra-Rina, G. Martinez-Arias, A. L. Tardin-Cardoso, D. Nogueira-Souto, P. Razola-Alba, L. Cancer-Garza, T. Escalera-Temprado, M. Delgado-Castro, A. Andres-Gracia;*
Hospital Clinico Universitario Lozano Blesa, Zaragoza, SPAIN.

EP-0792

Non-parathyroidal ^{99}mTc-MIBI Uptake Mimicking Ectopic Parathyroid Lesions on Planar Imaging: Added Value of SPECT/CT in a Retrospective Cohort

M. Ciorbea[1], *E. Apostu*[1], *I. Grierosu*[1,2], *A. Oarza*[1], *W. Jalloul*[1,2], *C. Stolniceanu*[1,2], *A. Statescu*[1], *V. Ghizdovat*[1,2], *C. Stefanescu*[1,2];
[1]*Nuclear Medicine Laboratory, County Emergency Hospital „Sf. Spiridon", Iasi, ROMANIA,*
[2]*University of Medicine and Pharmacy „Grigore T. Popa", Iasi, ROMANIA.*

EP-0793

Diagnostic Accuracy of Imaging Techniques in MEN1-Associated Primary Hyperparathyroidism: A Systematic Review and Meta-analysis

M. Bankowski, *D. Tomkiel, A. Skowrońska-Szcześniak;*
Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, POLAND.

EP-0794

Exploring the Role of Body Mass Index in Clinical Presentation and Response to I-131 Therapy in Differentiated Thyroid Cancer: A Retrospective Study

K. Guichay Duran, *B. Tagliatori Nogueira, C. Galindo Fernández, A. Sicilia Tafalla, L. Castillejos Rodríguez, C. Paniagua Correa, A. Herrero Muñoz, S. Perez Quiros, A. Ortega Valle, M. Álvarez Moreno, P. García Alonso, M. De la Rubia Marcos;*
Departamento de Medicina Nuclear, Hospital Universitario de Getafe, Madrid., SPAIN.

EP-0795

[^{18}F] fluorocholine PET-CT: A disruptor here to stay? A comparative outcome analysis with computed tomography, ultrasound, and [^{99m}Tc] sestamibi imaging

S. Sa, *M. Kale, B. Sanghera, I. Badreddine, E. Nowosinska, N. Nagabhushan, A. Parsai, T. Hussain, E. Ng, M. Waterhouse, M. Krishnamurthy;*
Barts Health NHS Trust, London, UNITED KINGDOM.

EP-0796

Diagnostic Performance of [^{18}F]Fluorocholine PET/CT in Parathyroid Lesion Localization: Correlation with Lesion Characteristics and Comparison with Ultrasound and MIBI Scintigraphy

V. Artiko[1,2], *B. Radovic*[2], *L. Grujičić*[2], *N. Pantić*[2], *M.*

Veljković[3], M. Kovačević[2], A. Novković[2], A. Afgan[2], J. Petrović[1];
[1]Faculty of Medicine University of Belgrade, Belgrade, SERBIA,
[2]University Clinical Center of Serbia;
Center for Nuclear Medicine with PET, Belgrade, SERBIA,
[3]Faculty of Medicine University of Belgrade, Belgrade, SERBIA.

EP-0797

Tc-^{99}M Mibi Scintigraphy In Primary Hyperparathyroidism: Diagnostic Value Of Retention And Washout Indices

***N. Arslan**, M. Daşar, G. Koca, K. Demirel, M. Korkmaz;*
Ankara Research and Training Hospital, Ankara, TÜRKIYE.

EP-0798

Cost-effectiveness of preoperative parathyroid imaging in primary hyperparathyroidism

***P. Petranovic Ovcaricek**[1], M. Romić[1], V. Gladić Nenadić[1], M. W. Huellner[2];*
[1]Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, CROATIA,
[2]Department of Nuclear Medicine, University Hospital Zurich, Zurich, SWITZERLAND.

EP-0798a

Diagnostic Performance of Imaging Modalities for Preoperative Localisation of Hyperfunctioning Parathyroid Glands in Hyperparathyroidism: A Synthesis of Meta-Analyses from the Past Decade

***P. Petranovic Ovcaricek**[1], M. Romić[1], V. Gladić Nenadić[1], M. W. Huellner[2];*
[1]Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, CROATIA,
[2]Department of Nuclear Medicine, University Hospital Zurich, Zurich, SWITZERLAND.

EP-42

B: Imaging Clinical Studies → B7 Musculoskeletal, Infection and Inflammation Imaging Study → B72 Vasculitis and Endocarditis

EP-0799

CD8 T cell imaging with PET ^{89}Zr-Df-crefmirlimab in giant cell arteritis: a preliminary study

***E. Hendrikse**, K. S. M. van der Geest, M. Sandovici, R. H. J. A. Slart, E. Brouwer;*
University Medical Center Groningen, Groningen, NETHERLANDS.

EP-0800

Fibroblast Activation Protein Imaging with [^{68}Ga]Ga-FAPI PET/CT Reveals Subclinical Fibroinflammatory Vascular Activity in Takayasu Arteritis: A Prospective Pilot Study

***R. Maurya**, M. Rai, M. Ora;*
Sanjay Gandhi post graduate institute of medical sciences, Lucknow, INDIA.

EP-0801

Relationships of Vascular Activity, Total Vascular and Visual Scores Derived from Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography with Inflammatory Markers and Quantitative Imaging Parameters in Large-Vessel Vasculitis

***H. San**[1], Ö. Bayrakcı[2], M. Baydar[2], M. Serdengeçti[1], A. Uran Şan[3];*
[1]University of Health Sciences, Bilkent City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE,
[2]Bilkent City Hospital, Ankara, TÜRKIYE,
[3]University of Health Sciences, Gaziler Physical Medicine and Rehabilitation Hospital, Ankara, TÜRKIYE.

EP-0802

Cardiac and systemic [^{18}F]FDG PET/CT phenotypes in blood culture-negative infective endocarditis

***F. Garrou**[1], E. Bressan[2], I. Gotuzzo[1], F. Lattuada[1], F. Del Gaudio[1], E. Gavinelli[1], P. A. Erba[2];*
[1]ASST Papa Giovanni XXIII, Bergamo, ITALY,
[2]University of Milano Bicocca, Milano, ITALY.

EP-0803

Robustness of Liver SUVmax as a Quantitative Reference Standard in [^{18}F]FDG PET/CT for Giant Cell Arteritis: Impact of Corticosteroids and Other Clinical Factors

***M. Calls-Calahorro**[1], M. Velasco-Nuño[1], A. Fernández-León[1], Y. Delisau[1], G. Arís Cuadras[1], M. Rodríguez-Fontán[1], P. Zaragoza-Ballester[1], S. Asadurova[1], V. Camacho[1], G. Guzmán Prudencio[1], J. Duch[1], S. Castejón[1], A. Barros-Membrilla[2], P. Moya Alvarado[3], H. Codes Mendez[3], A. Flotats[1];*
[1]Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN,
[2]Cardiology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN,
[3]Rheumatology and Systemic Autoimmune Diseases Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.

EP-0805

Comparative evaluation of [^{68}Ga]Ga-FAPI-46 PET/CT and [^{18}F]FDG PET/CT in patients with recent-onset or relapsing polymyalgia rheumatica and/or giant cell arteritis

***P. Le Roux**, S. Querellou, C. Quéré, B. Quéré, F. Blanc-Béguin, K. Postec, S. Hennebicq, B. Chevet, J. Dolou, R. Abgral, E. Courtois-Communier, D. Cornec, P. Salaun, V. Devauchelle-Pensec, D. Guellec;*
Brest University Hospital, Brest, FRANCE.

EP-0806

Prognostic Value of ^{18}F-FDG PET/CT for early response assessment in Giant Cell Arteritis

***R. Bardy**[1], S. Ahrari[1], T. Carlier[1], E. Detournay[2], F. L. Besson[2], A. F. Guedon[3], A. Mekinian[4], F. Kraeber-Bodéré[5], B. Jamet[1], O. Espitia[6];*
[1]Department of Nuclear Medicine, University Hospital of Nantes, Nantes Université, Nantes, FRANCE,
[2]Department of Nuclear Medicine - Molecular Imaging, Hôpitaux Universitaires Paris-Saclay AP-HP, DMU SMART IMAGING, Hôpital Bicêtre, School of Medicine, Université Paris-Saclay ;
CEA/Inserm/CNRS/Université Paris-Saclay, BioMaps, Le Kremlin-Bicêtre ;
Orsay, FRANCE,
[3]Sorbonne University, National Institute of Health and Medical Research, Pierre Louis Institute of Epidemiology and Public Health, Paris, FRANCE,
[4]Sorbonne Université, AP-HP, Hôpital Saint Antoine, service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU i[3]) ; French Armenian Research Center, Paris, FRANCE,
[5]Department of Nuclear Medicine, University Hospital of Nantes, Nantes Université, Department of Nuclear Oncology, ICAGEN, reMoVE-B, INSERM, National Centre for Scientific Research, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, Nantes, FRANCE,
[6]Department of Internal and Vascular Medicine, University Hospital of Nantes, Nantes Université, l'institut du thorax Team III Vascular and Pulmonary Diseases, Nantes, FRANCE.

EP-0807

AI-Assisted Automated Circumferential Analysis of Aortic FDG Uptake in PET/CT for Large Vessel Vasculitis: A Rule-Based Grading System with Quantitative Volume, Angle, and Anatomical Localization Assessment

***S. Asa**[1], M. Isenkul[2], M. Cagan[1], S. Biyikoglu[1], B. Ocal[1], S. Sager[1];*
[1]Istanbul University Cerrahpasa Medical Faculty Department of Nuclear Medicine, Istanbul, TÜRKIYE,
[2]Istanbul University Cerrahpasa Faculty of Engineering Department of Computer Engineering, Istanbul, TÜRKIYE.

EP-0808

The Impact of Cardiac Gating in [^{18}F]FDG PET/CT for Infective Endocarditis: Preliminary Data

***A. Roy**[1], A. Naeimi[1], Y. Heniche[1], E. McNabb[1], S. Karls[1], M. Hickeson[1], F. Abbaspour-Raddakheli[1,2];*
[1]McGill University Health Centre, Montréal, QC, CANADA,
[2]The Ottawa Hospital, Ottawa, ON, CANADA.

EP-0809

Predicting cardiac suppression in PET/CT before FDG injection using fingertip ketone measurement and the relationship between ketone levels and FDG biodistribution

***A. Inanir**, Ö. Özmen;*
Etlik City Hospital, Ankara, TÜRKIYE.

EP-43

B: Imaging Clinical Studies → B7 Musculoskeletal, Infection and Inflammation Imaging Study → B73 Other Infections and Inflammatory Diseases

EP-0810

[^{18}F]-FDG PET/CT findings in patients with recent Chikungunya infection: a retrospective cohort study

***C. Chmielowski**, F. Anjary, B. Enilorac, A. Grulière, A. Lebasnier, A. Revel, C. Revel, P. Guerard, E. Paquet;*
CHU de La Réunion, Hôpital Félix Guyon, Saint-Denis, FRANCE.

EP-0811

FAPI PET in preclinical rheumatoid arthritis

***A. Atzinger**[1], K. Tascilar[1], T. Kuwert[1], M. Beck[1], F. Fagni[1], G. Corte[1], A. Ramming[1], G. Schett[1], A. Hueber[2], C. Schmidkonz[3], A. Kleyer[4], S. Bayat[1];*
[1]University Hospital, Erlangen, GERMANY,
[2]Klinikum Nürnberg, Nürnberg, GERMANY,
[3]OTH Amberg-Weiden, Weiden, GERMANY,
[4]Charité Berlin, Berlin, GERMANY.

EP-0812

diagnostic accuracy of 18f-fdg pet-ct scores in distinguishing polymyalgia rheumatica from other inflammatory rheumatologic disease: a multicentre retrospective study (rhumatep)

***S. Querellou**[1], C. Quéré[1], P. Thuillier[1], F. Besson[2], A. Le Madec[1], R. Seror[2], M. Pean de Ponfilly[3], D. Wendling[4], H. Boulahdour[4], T. Pascart[5], A. Pacaud[5], A. Bailliez[5], T. Eugène[6], S. Ottaviani[3], P. Dieude[3], K. Ben Ali[3], F. Paycha[7], A. Latourte[7], L. Carré[7], B. Fautrel[8], P. Cacoub[8], S. Desarnaud[8], P. Salaun[1], R. Abgral[1], V. Devauchelle-Pensec[1];*
[1]Brest University Hospital, Brest, FRANCE,
[2]APHP Bicêtre, Kremlin-Bicêtre, FRANCE,
[3]APHP Bichat, Paris, FRANCE,
[4]Besançon university hospital, Besançon, FRANCE,
[5]Saint Philibert hospital, Lille, FRANCE,
[6]Nantes University Hospital, Nantes, FRANCE,
[7]APHP Lariboisière, Paris, FRANCE,
[8]APHP Pitié Salpétrière, Paris, FRANCE.

EP-0813

Diagnostic Value of Leukocyte Scintigraphy in Vascular Prosthesis Infection According to MAGIC Criteria

***P. Negrete Montiel**[1], B. M. Jaramillo López[1], Á. R. Suazo Montero[1], R. D. C. Zambrano Infantino[1], N. Álvarez Mena[1], F. Sebastián Palacid[1], M. D. J. González Soto[1], R. Ruano Pérez[1], G. M. Melo[2];*
[1]Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN,
[2]NOVA Medical School, Lisboa, PORTUGAL.

EP-0814

FAPI PET/CT as biomarker of progression in fibrosing interstitial lung diseases: final results of a prospective single-center multi-cohort study

***A. Deleu**[1,2], B. Lesire[2], Z. Wimana[1,2], S. Vercauteren[1], C. Marin[1], B. Vanderlinden[1], A. Arçay Öztürk[1,2], L. Taraji[1], P. Lavis[1], S. De Bontridder[1], J. Pingitore[1], C. Artigas[1,2], P. Flamen[1,2], B. Bondue[1,2];*
[1]Hôpital Universitaire de Bruxelles (H.U.B.), Brussels, BELGIUM,
[2]Université Libre de Bruxelles, Brussels, BELGIUM.

EP-0815

Extrahepatic Skeletal Muscle ^{18}F-FAPI Signal in MASLD: A Total-Body PET Study Across Fibrosis Stages

***S. Malige**, Y. G. Abdelhafez, B. A. Spencer, L. Nardo, G. Wang, V. Lyo, V. Medici, R. D. Badawi;*
University of California at Davis, Sacramento, CA, UNITED STATES OF AMERICA.

EP-0816

[^{68}Ga]Ga-FAPI PET/CT for Noninvasive Assessment of Disease Severity and Antifibrotic Treatment Response in Idiopathic Pulmonary Fibrosis: Preliminary Results

H. Önner[1], *B. Demir*[2], *A. Kılınçer*[3], *F. Balcı*[4], *S. Erol*[3], *G. Kara Gedik*[5], *F. Kanat*[4];
[1]*Selçuk University, Medical Faculty, Department of Nuclear Medicine, Konya, TÜRKIYE,* [2]*Şanlıurfa Mehmet Akif İnan Education and Research Hospital, Department of Nuclear Medicine, Şanlıurfa, TÜRKIYE,*
[3]*Selçuk University, Medical Faculty, Department of Radiology, Konya, TÜRKIYE,*
[4]*Selçuk University, Medical Faculty, Department of Pulmonary Medicine, Konya, TÜRKIYE,*
[5]*Akdeniz University, Medical Faculty, Department of Nuclear Medicine, Antalya, TÜRKIYE.*

EP-44

B: Imaging Clinical Studies → B7 Musculoskeletal, Infection and Inflammation Imaging Study → B74 Orthopedics, benign, no infection

EP-0817

High Prevalence of Low Bone Mineral Density in Sickle Cell Disease: A Prospective Cohort Study from Saudi Arabia

M. Algarni;
KFMMC, Dhahran, SAUDI ARABIA.

EP-0818

Na[^{18}F]F targeted PET/CT imaging for quantifying disease progression and treatment response in fibrous dysplasia.

L. van Schaik, *L. de Geus-Oei, N. M. Appelman-Dijkstra, F. Smit, P. Dibbets-Schneider, O. O. Bulaicon-Danila, S. A. Huisman;*
LUMC, Leiden, NETHERLANDS.

EP-0819

^{99}mTc-NTP-15-5, tracer of proteoglycans: from phase I to phases II

M. Chanchou[1,2], *P. Auzeloux*[2], *N. Sas*[3,2], *T. Billoux*[3,2], *S. Levesque*[4,2], *E. Thivat*[5,2], *E. Jouberton*[2,1], *E. Miot-Noirault*[2], *M. Couderc*[6], *S. Mathieu*[6], *X. Durando*[7,2], *F. Cachin*[1,2];
[1]*Centre Jean Perrin, Médecine Nucléaire, Clermont-Ferrand, FRANCE,*
[2]*INSERM UMR 1240 IMoST/UCA, Clermont-Ferrand, FRANCE,*
[3]*Centre Jean Perrin, Physique Médicale, Clermont-Ferrand, FRANCE,*
[4]*Centre Jean Perrin, Radiopharmacie, Clermont-Ferrand, FRANCE,*
[5]*Centre Jean Perrin, Recherche Clinique, Clermont-Ferrand, FRANCE,*
[6]*CHU Clermont-Ferrand, Rhumatologie, Clermont-Ferrand, FRANCE,*
[7]*Centre Jean Perrin, Oncologie Médicale, Clermont-Ferrand, FRANCE.*

EP-0820

18Fluor-FDG shows displays joint-related pain better than 68Gallium-FAPI - analysis of 68Gallium-FAPI- and 18Fluor-FDG-uptake of joints and periarticular tissue with structured pain anamnesis in 192 patients

L. Brückner[1], *A. Spektor*[2], *P. Mildenberger*[3], *H. Lorenz*[4], *U. Haberkorn*[1,5,6], *W. Merkt*[4,7], *M. Schreckenberger*[2], *M. Röhrich*[2,1];
[1]*Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY,*
[2]*Department of Nuclear Medicine, University Hospital Mainz, Mainz, GERMANY,*
[3]*Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University, Mainz, GERMANY,*
[4]*Department of Internal Medicine V Hematology Oncology Rheumatology, University Hospital Heidelberg, Heidelberg, GERMANY,*
[5]*Translational Lung Research Center Heidelberg (TLRC), Member of the German Center for Lung Research DZL, Heidelberg, GERMANY,*
[6]*Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, GERMANY,*
[7]*Department of Rheumatology, University Hospital Düsseldorf, Düsseldorf, GERMANY.*

EP-45

B: Imaging Clinical Studies → B8 Nephro-Urological Imaging Study → B81 Nephro-Urology

EP-0821

Age-Related Decline in Testicular Metabolism Beyond Organ Size Using FDG PET/CT

M. Keskin;
Mersin City Training and Research Hospital, Mersin, TÜRKIYE.

EP-0822

Longitudinal Analysis of NORA 2-3′ in Nephro-Urological Follow-up: A More Sensitive Marker than Differential Renal Function?

J. Mendes, *T. Faria;*
Hospital de São João, Porto, PORTUGAL.

EP-0823

Characterisation of Renal and Adrenal Lesions: How Reliable Is the CT Component of PET and SPECT?

M. El-Sayed[1], *O. S. Ahmed*[2];
[1]*Queen Elizabeth Hospital Birmingham, Birmingham, UNITED KINGDOM,*
[2]*Northern Care Alliance NHS Foundation Trust, Manchester, UNITED KINGDOM.*

EP-46

B: Imaging Clinical Studies → B9 Paediatric Imaging Study → B91 Paediatric Study

EP-0824

Clinical utility of [^{99m}Tc]Tc-Human serum albumin scintigraphy for the diagnosis of protein-losing enteropathy in a pediatric patient

C. G. Franco Monterroso, *L. Rey Sánchez, J. Balala Rojo, M. À. Hernández Fructuoso, E. Otero Ruiz, C. Jiménez Pena, M. Rubio Alvarez;*
Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.

EP-47

B11 Other Imaging Clinical Studies → B111 Other Clinical Studies

EP-0825

One-Stop-Shop Imaging for Cancer Diagnosis in the Caribbean: An Integrated PET-CT and PET-MRI Approach

K. Fard, *S. Masson, P. d'Abadie, G. Crespel, A. d'Abadie;*
Caribbean Institute of Nuclear Imaging, Martinique University Hospital, Fort de France, MARTINIQUE.

EP-0826

Health Economic Analysis of [^{18}F]FDG PET/CT for Rare and Less-common Cancers: A Policy Model with Evidence-Based Validation

A. Scott[1], *N. Ayati*[2], *F. Khafagi*[3], *R. Moorin*[4], *S. Norris*[5], *S. Simons*[6], *S. Ramsey*[7], *D. Stringer*[8], *W. MacDonald*[9], *J. Li*[2];
[1]*Austin Health and ONJCRI, Melbourne, AUSTRALIA,*
[2]*Centre for Health Economics, Monash Business School, Monash University, Melbourne, AUSTRALIA,*
[3]*The Prince Charles Hospital, Brisbane, AUSTRALIA,*
[4]*University of Western Australia, Perth, AUSTRALIA,*
[5]*Leeder Centre for Health Policy, Economics and Data, University of Sydney, Sydney, AUSTRALIA,*
[6]*Department of Health and Ageing, Canberra, AUSTRALIA,*
[7]*Royal Brisbane and Womens Hospital, Brisbane, AUSTRALIA,*
[8]*ASERNIP-S, Adelaide, AUSTRALIA,*
[9]*Fiona Stanley Hospital, Perth, AUSTRALIA.*

EP-0827

Role of[^{18}F]FDG PET in Pancreas Transplantation: A Single-Centre Retrospective Study

P. Mapelli[1,2], *S. Partelli*[3,4], *A. Battistella*[3,4], *G. Pepe*[2], *C. Festorazzi*[5], *R. Caldara*[5], *C. Bezzi*[2], *S. Ghezzo*[2], *D. Catarinella*[5], *L. Piemonti*[5], *P. Rigotti*[3], *V. Tomajer*[3], *M. Falconi*[3,4], *A. Chiti*[1,2], *M. Picchio*[1,2];
[1]*Vita-Salute San Raffaele University, Milan, ITALY,*
[2]*Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY,*
[3]*Pancreatic and Transplant Surgery Unit, Pancreas Translational and Clinical Research Center, Milan, ITALY,*
[4]*Pancreatic Surgery Unit, IRCCS San Raffaele Scientific Institute, Milan, ITALY,*
[5]*Unit of Transplantation and Regenerative Medicine, IRCCS San Raffaele Scientific Institute, Milan, ITALY.*

EP-0828

A Novel Framework for Response Evaluation Criteria in Bone Metastases: Initial Assessment and Comparative Performance with MDA, PERCIST, and EORTC Criteria

T. Xu[1], *X. Yu*[1], *X. Li*[2], *Y. Chen*[1];
[1]*Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, China, CHINA,*
[2]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, AUSTRIA.*

EP-0829

Repurposing the MAPH Score for Predicting Acute Pulmonary Embolism and Thrombotic Burden on Perfusion SPECT/CT

N. Álvarez Mena, *Á. R. Suazo Montero, F. Sebastián Palacid, B. M. Jaramillo López, P. A. Negrete Montiel, R. Ruano Pérez;*
Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

EP-0830

Evaluating the Utility & Diagnostic Accuracy of Bone SPECT-CT vs. MRI in Identifying Spinal Pain Generators

M. Fotuhi, *E. Nowosinska, K. Ordidge, A. Syed, A. Parsai, N. Nagabhushan, T. Hussain, H. Mohan;*
Barts Health NHS Trust, London, UNITED KINGDOM.

EP-0831

Determining Body Surface Area Using Total-Body Long-Axial Field-of-View PET: A Novel Method Without Additional Radiation Exposure

J. Xu[1], *W. Huang*[1], *J. Yu*[1], *N. Xie*[1], *C. Han*[2];
[1]*Zhuhai People's Hospital, The Affiliated Hospital of Beijing Institute of Technology, Zhuhai, CHINA,*
[2]*Turku PET Centre and Turku University Hospital, Turku, FINLAND.*

EP-0832

PET/CT-Derived Muscle Quality and Its Association With Physical and Cognitive Domains in Geriatric Oncology

H. Chung, *S. Han, J. Kim, J. S. Oh, M. Oh, J. Kim, J. Ryu, D. Lee;*
Asan medical center, Seoul, KOREA, REPUBLIC OF.

EP-0833

Multi-Organ Metabolic Trajectories of Ageing Using Whole-Body Longitudinal [^{18}F]FDG PET/CT Imaging

X. Yang[1,2], *C. Vu*[1,3], *N. Akatani*[1], *J. Taki*[4], *S. Takeda*[4], *T. Yamase*[5], *K. Yokoyama*[5], *M. Pires*[6], *S. Gutschmayer*[6], *D. Ferrara*[6], *T. Beyer*[6], *H. Wakabayashi*[1];
[1]*Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, JAPAN,*
[2]*Department of Nuclear Medicine, Graduate School of Medical Sciences, Kanazawa, Ishikawa, JAPAN,*
[3]*Division of Advanced Preventive Medical Science, Graduate School of Advanced Preventive Medical Sciences, Kanazawa, Ishikawa, JAPAN,*
[4]*PET Center, Kanazawa Advanced Medical Center, Kanazawa, Ishikawa, JAPAN,*
[5]*Public Central Hospital of Matto Ishikawa, Kanazawa, Ishikawa, JAPAN,*
[6]*Quantitative Imaging Medical Physics (QIMP) Team, Medical University of Vienna, Vienna, AUSTRIA.*

EP-0834

Regional load mapping in response to mechanical stress in the spine: A LAFOV [18F]NaF PET/CT study

R. Pedersen[1], *M. Thomsen*[2], *L. Jensen*[3], *A. Loft*[4], *L. Gasbjerg*[2], *D. Fuglø*[3], *R. Tønnesen*[1], *B. Haddock*[1];
[1]*Copenhagen University Hospital - Dept. of Clinical Physiology, Nuclear Medicine and PET, Glostrup, Denmark, Glostrup, DENMARK,*
[2]*Department of Biomedical Sciences, Copenhagen, DENMARK,*
[3]*Department of Nuclear Medicine, Copenhagen University Hospital, Herlev, Copenhagen, Denmark, Herlev, DENMARK,*
[4]*Copenhagen University Hospital - Dept. of Clinical Physiology, Nuclear Medicine and PET, Denmark, Copenhagen, DENMARK.*

EP-0835

Longitudinal Changes in FDG, Aβ, and Tau PET Imaging in an Alzheimer's Disease Patient Following Lymphaticovenous Anastomosis

G. Huang[1], *Y. Zhang*[1], *H. Shao*[1], *S. Gao*[1], *M. Xin*[1], *J. Hao*[2], *L. Qi*[2], *J. Liu*[1], *C. Zhang*[1];
[1]*Department of Nuclear Medicine, Renji Hospital,Shanghai Jiaotong University School of Medicine, Shanghai, CHINA,*
[2]*United Imaging Healthcare, Shanghai, CHINA.*

EP-0836

Volume-to-Perfusion Ratio Derived from AI-Based Lobar Segmentation on Lung Perfusion SPECT/CT for Target Lobe Selection Prior to Lung Volume Reduction Surgery in Severe Emphysema

N. Álvarez Mena, *Á. R. Suazo Montero, F. Sebastián Palacid, B. M. Jaramillo López, P. A. Negrete Montiel, R. Ruano Pérez;*
Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

EP-0837

Impact of CT-Based Attenuation Correction on the Homogeneity of Ventilation and Perfusion SPECT Data on the Symbia Pro.specta

W. Schaefer, *D. Knollmann;*
Nuklearmedizin, Moenchengladbach, GERMANY.

EP-0838

Evaluation of Subcutaneous Calcinosis in Systemic Sclerosis Using [18F]NaF PET/CT: A Pilot Study

K. Apró[1], *G. Bodor*[2], *T. Czékus*[1], *E. Makai*[3], *D. Jász*[4], *D. Tari*[4], *G. Kumánovics*[4], *L. Czirják*[4], *G. Szűcs*[5], *Z. Szekanecz*[5], *L. Kovács*[2], *M. Szolikova*[6], *A. Kubovje*[6], *I. Polyák*[3], *Z. Besenyi*[1];
[1]*Department of Nuclear Medicine and Theranostics, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, HUNGARY,*
[2]*Department of Rheumatology and Immunology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, HUNGARY,*
[3]*Department of Radiology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, HUNGARY,*
[4]*Department of Rheumatology and Immunology, Medical School, University of Pécs, Pécs, HUNGARY,*
[5]*Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY,*
[6]*Mediso Medical Imaging Systems Ltd, Budapest, HUNGARY.*

EP-0839

Whole gastrointestinal transit scintigraphy for quantitative assessment of gastrointestinal dysmotility in VEDOSS and systemic sclerosis

F. Montenegro Muñoz[1], *L. Casas Calabuig*[1], *C. Valera Ribera*[1], *C. Siscar Gelo*[2], *F. J. Cavagna Matti*[1], *G. Bonino*[1], *J. J. Alegre Sancho*[1], *N. Carrasco Vela*[1], *M. Á. Navas de la Cruz*[1], *P. Abreu Sánchez*[1], *A. Abella Tarazona*[1], *M. C. Plancha Mansanet*[1], *J. Orozco Cortés*[1], *D. Balaguer Muñoz*[1], *J. R. Infante de la Torre*[1], *E. Caballero Calabuig*[1];
[1]*Hospital Universitari Dr. Peset, València, SPAIN,*
[2]*Consorci Hospitalari Provincial de Castelló, Castelló de la Plana, SPAIN.*

EP-0840

Complementary Clinical Value of [68Ga]Ga-FAPI-74 PET/CTin Real-World Clinical Settings for Inconclusive [18F]FDG PET/CT Findings: A Large Head-to-Head Clinicopathological Cohort Study

M. Xie, *W. Tao, J. Wei, J. Fan;*
Department of Nuclear Medicine, The Affiliated Huaian No. [1] People's Hospital of Nanjing Medical University, Huai'a, CHINA.

EP-0841

Clinical Utility of18F-FDG PET/CT in Fever of Unknown Origin: Diagnostic Yield and Impact on Patient Management in a Large Academic Center

A. Giarratana, *T. A. Romero Garcia;*
University of Wisconsin - Madison, Madison, WI, UNITED STATES OF AMERICA.

EP-0842

Towards high throughput and efficient long-axial PET with oral [18F]FDG- A prospective head to head study

I. Alberts, *N. Colpo, C. Williams, A. Weppler, P. Ravi, C. Uribe, F. Benard;*
BC Cancer Agency, Vancouver, BC, CANADA.

EP-0843

Correlation Between Tissue Density and Ventilation in Lung Parenchyma with Perfusion Defects

C. Aydın, *Ü. Korkmaz Kara, Ö. Kısa;*
Trakya University Department of Nuclear Medicine, Edirne, TÜRKIYE.

EP-0844

The Value of Distal Forearm Bone Mineral Density in Assessing Major Osteoporotic Fracture Risk in Postmenopausal Women

A. Aguilar Pinto, *A. Montes, M. Romera, F. Minguez, A. Basanta, S. Peralta, J. J. Rosales, M. Rodriguez;*
Clínica Universidad de Navarra, Pamplona, SPAIN.

EP-0845

Sub-millisievert Ultra-low Dose Impact on Image Quality of LAFOV PET/CT: A Protocol Optimization Study

H. Yi[1], *J. Shen*[2], *J. Wang*[2], *Q. Tang*[2], *J. Bai*[1], *Y. Sun*[3], *W. Liu*[3], *S. Zhu*[2], *Y. Zhao*[1], *Y. Zhu*[2];
[1]*Clinical Application Engineering, United Imaging Healthcare, Shanghai, CHINA,*
[2]*Department of Nuclear Medicine, Kunshan Hospital of Jiangsu University, Kunshan, CHINA, [3], Shanghai Jiao Tong University, Shanghai, CHINA.*

EP-0846

Impact of Count Reduction on [68Ga]-PET Image Quality and Lesion Detection in LAFOV PET/CT

M. Steemers - de Boer[1], *B. J. de Wit - van der Veen*[1], *S. M. Jansen*[1], *A. J. A. T. Braat*[1,2];
[1]*Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, NETHERLANDS,*
[2]*University Medical Center Utrecht, Utrecht, NETHERLANDS.*

EP-0847

RADIANZ: Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89 Study of 89Zr-Labeled Antibody Radioconjugate to Evaluate Biodistribution and Tumor Uptake in Patients with Solid Tumours

M. Vangu[1], *R. Mosley*[1], *J. Gibson*[2], *M. Roy*[2], *A. Kamal*[2], *J. Kim*[2];
[1]*University of the Witwatersrand, Johannesburg, SOUTH AFRICA,*
[2]*Actinium Pharmaceutical, Inc., New York, NY, UNITED STATES OF AMERICA.*

EP-0848

Facilitating PERCIST 1.0 Response Assessment through SUV Harmonization across Different PET Scanners

Z. Zhang, *X. Lu, H. Pang;*
The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EP-0849

Splanchnic Perfusion Measurement Has No Value in the Diagnosis of Median Arcuate Ligament Syndrome

J. Yde[1], *V. Stefanov*[2], *C. Høyer*[1];
[1]*Department of Physiology, Viborg Regional Hospital, Viborg, DENMARK,*
[2]*Department of Radiology, Viborg Regional Hospital, Viborg, DENMARK.*

EP-0850

Peritoneal scintigraphy in the diagnosis of pleuro-peritoneal fistula in patients on peritoneal dialysis

C. Moriana Simón, *G. Martínez Gómez, A. Sagastegui Alca, T. Moreno Monsalve, T. Rodríguez Locarno, N. Sánchez Izquierdo, M. Castellón Sánchez, A. Hernandez Martínez, M. Ibañez Ibañez, L. Mohamed Salem, J. Navarro Fernández, L. Frutos Esteban, J. Contreras Gutiérrez;*
Hospital Virgen de la Arrixaca, Murcia, SPAIN.

EP-0851

Recommended acquisition duration and dose strategy across uMI Panvivo Family

H. Yi[1], *E. Gabiache*[2], *J. Shen*[3], *Q. Tang*[3], *J. Wang*[3], *J. Li*[1], *Y. Wang*[1], *Y. Sun*[4], *M. Wang*[3], *Y. Zhu*[3], *Y. Zhao*[1];
[1]*United Imaging Healthcare, Shanghai, CHINA,*
[2]*Lutecia Care CMNM centres de médecine nucléaire du Morbihan, Vannes, FRANCE,*
[3]*Kunshan Hospital of Jiangsu University, Kunshan, CHINA,*
[4]*Institute of Biomedical Manufacturing and Life Quality Engineering, State Key Laboratory of Mechanical System and Vibration, School of Mechanical Engineering, Shanghai Jiao Tong University, Shanghai, CHINA.*

EP-0852

uExcel DPR Enables Accurate Quantitation: Phantom and Patient Study

F. Besson[1], *H. Yi*[2], *W. Zhou*[3], *H. Dai*[4], *N. Li*[4], *S. Young*[5], *Y. Zhao*[2], *Y. Zhu*[3];
[1]*Service de Médecine Nucléaire - Imagerie Moléculaire, Hôpitaux Universitaires Paris-Saclay AP-HP, site Bicêtre, Paris, FRANCE,*
[2]*Clinical Application Engineering, United Imaging Healthcare, CHINA, Shanghai, CHINA,*
[3]*Department of Nuclear Medicine, Kunshan Hospital of Jiangsu University, Kunshan, CHINA,*
[4]*Algorithm & Application, United Imaging Healthcare, CHINA., Shanghai, CHINA,*
[5]*United Imaging Healthcare Europe, Rotterdam, NETHERLANDS.*

EP-0853

Association Between Muscle Gallium-68 FAPI PET Uptake and Sarcopenia in Oncologic Patients

C. Soydal, *M. Çidemal, M. Araz, N. Ö. Küçük;*
Ankara University Medical Faculty, Ankara, TÜRKIYE.

EP-0854

The Role of Salivary Gland Scintigraphy in Clinical Practice Ten Years After ACR/EULAR 2016

H. Calqueiro, *R. T. Ferreira, O. Silva, I. C. Ferreira, T. S. Novais, J. A. Sequeira, S. Carmona, A. I. Santos;*
ULS Almada-Seixal - Hospital Garcia de Orta, Almada, PORTUGAL.

EP-0855

Incidence Of Lymphedema Observed on Lymphoscintigraphy After Cosmetic and Weight Loss Surgeries

Z. Khurshid, *S. Sabri;*
Al-Jahra Hospital Kuwait, Jahra, KUWAIT.

EP-0856

Diagnostic concordance between V/Q SPECT-CT and dual-energy CT angiography in suspected chronic pulmonary embolism

G. Aris[1], *G. Guzmán Prudencio*[1], *M. Calls-Calahorro*[1], *Y. Delisau*[1], *M. Rodríguez-Fontán*[1], *P. Zaragoza-Ballester*[1], *S. Asadurova*[1], *A. Fernández-León*[1], *M. Velasco-Nuño*[1], *V. Camacho*[1,2], *J. Brenes Castro*[2], *D. Selva Talón*[2], *J. Duch*[1], *S. Castejón*[1], *A. Flotats*[1];
[1]*Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN,*
[2]*Radiology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.*

EP-0857

Clinical Outcomes Following SPECT-CT Guided Interventions in Chronic Spinal Pain

M. Fotuhi, *E. Nowosinska, K. Ordidge, A. Syed, A. Parsai, N. Nagabhushan, T. Hussain, H. Mohan;*
Barts Health NHS Trust, London, UNITED KINGDOM.

EP-0858

Gastric Shape as a Novel Morphological Biomarker in Gastric Emptying Scintigraphy

I. Iskra[1], *M. Ilić Tomaš*[2,1], *T. Bogović Crnčić*[2,1], *L. Fischer*[1];
[1]*Clinical Hospital Center Rijeka, Rijeka, CROATIA,*
[2]*Faculty of Medicine, University of Rijeka, Rijeka, CROATIA.*

EP-0859

Esophageal transit scintigraphy: usefulness of acquisition in both upright and supine positions

F. Montenegro Muñoz[1], *L. Casas Calabuig[1], C. Sicar Gelo[2], F. J. Cavagna Matti[1], G. Bonino[1], N. Carrasco Vela[1], M. Á. Navas de la Cruz[1], P. Abreu Sánchez[1], A. Abella Tarazona[1], M. C. Plancha Mansanet[1], J. Orozco Cortés[1], D. Balaguer Muñoz[1], J. R. Infante de la Torre[1], E. Caballero Calabuig[1];*
[1]Hospital Universitari Dr. Peset, València, SPAIN,
[2]Consorci Hospitalari Provincial de Castelló, Castelló de la Plana, SPAIN.

EP-0860

Diagnostic utility of planar ventilation-perfusion scintigraphy and the added value of V/Q SPECT/CT in the screening of suspected chronic thromboembolic pulmonary hypertension

M. Romero, *C. González Roiz, L. León Ramírez, L. Carreño Mancilla, M. Zapardiel Martínez-Falero, M. Vaillant López, M. Cornide Carrallo, V. Sendín Martín, M. Cabrera-Martín;*
HCSC, Madrid, SPAIN.

EP-48

C: Therapy Clinical Study → C1
Oncological Therapy Clinical Study → C11
Neuroendocrine Therapy

EP-0861

The effect of somatostatin analogues on PRRT in metastatic neuro-endocrine tumours: interim results of a prospective phase III randomized clinical trial

C. Veerman, *M. Dotinga, M. E. T. Tesselaar, M. P. M. Stokkel, E. A. Aalbersberg;*
Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

EP-0862

Longitudinal integrated biomarkers for OS prediction in GEP-NET under PRRT

F. Herr, *C. Dascalescu, R. Ebner, M. Schnitzer, A. Holzgreve, R. Werner, C. Cyran;*
LMU University Hospital Munich, Munich, GERMANY.

EP-0863

Radiation Dose Kinetics and Tumor Burden Dynamics as Predictors of Outcome After PRRT

A. Chicheportiche, *Y. Shachor, L. Hamzah, M. Zidan, J. Godefroy, V. Denisov, A. Bel-Ange, E. Solomonov, O. Maimon, S. Grozinsky-Glasberg, S. Ben-Haim;*
Hadassah Ein Kerem Hospital, Jerusalem, ISRAEL.

EP-0864

Efficacy and safety of dosimetry-based, personalized^{177}Lu-DOTATATE PRRT of neuroendocrine tumours: results of P-PRRT trial

S. Kurkowska[1], *M. Morin[2,3], C. Uribe[1], A. Beaulieu[2,3], F. Arsenault[2,3], G. April[2,3], F. Buteau[2,3], J. M. Beauregard[2,3];*
[1]BC Cancer Research Institute, Vancouver, BC, CANADA,
[2]Department of Radiology and Nuclear Medicine, Université Laval, Quebec City, QC, CANADA,
[3]Division of Nuclear Medicine, Department of Medical Imaging, CHU de Québec - Université Laval, Québec City, QC, CANADA.

EP-0865

Safety and Efficacy of [^{177}Lu]Lu-Oxodotreotide (XTR008) in Advanced SSTR-Positive Neuroendocrine Neoplasms Excluding G1/G2 GEP-NET: A Single-Arm Phase II Study

Y. Liang, *J. Xu, F. Liu, J. Chen, S. Song;*
Fudan university Shanghai Cancer Center, Shanghai, CHINA.

EP-0866

Salvage Radiopharmaceutical Therapy (RPT) in Neuroendocrine Carcinoma (NEC) after standard treatment failure: Clinical experience with α-emitters and combinations of FAP-directed and antagonist SSTR-directed approaches

E. Perrone[1,2], *K. Ghai[2], T. Parkar[2], A. Eismant[2], S. Stephan[2], L. Greifenstein[2], M. Pavel[3], R. P. Baum[2];*
[1]Nuclear Medicine Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ITALY,
[2]CURANOSTICUM Wiesbaden-Frankfurt, ICPO Center of Excellence for Advanced Radiomolecular Precision Oncology, Wiesbaden, GERMANY,
[3]Department of Medicine [1], Uniklinikum Erlangen, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, GERMANY.

EP-0867

Final results of body surface area-adapted [^{177}Lu] Lu-DOTA-JR11 peptide receptor radionuclide therapy in somatostatin receptor-positive tumours, with progression-free survival assessed in gastroenteropancreatic neuroendocrineTumours

F. Schmidt[1], *T. Racunica[1], A. Bauman[1], M. Fani[1], D. Wild[1,2];*
[1]Division of Nuclear Medicine, University Hospital Basel, Basel, SWITZERLAND,
[2]ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, SWITZERLAND.

EP-0868

Long-Term Response to ^{177}Lu-DOTATATE in Localised Head and Neck Paraganglioma: A Retrospective Single-Centre Study

G. Ferreira[1,2], *J. Ferro[2], A. Santos[2], I. Azevedo[2], C. Sanches[2], L. Giesteira[2], P. Antunes[2], E. Monteiro[2], I. L. Sampaio[2];*
[1]Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, UNITED ARAB EMIRATES,
[2]Instituto Português de Oncologia Francisco Gentil, Porto, PORTUGAL.

EP-0869

Radioligand therapy access gap in neuroendocrine tumours: First national multicentric study from Uruguay

F. Savio[1], *I. Lyra[2], D. Amarillo[2], F. Gentini[3], D. Ferreira[4], M. Jeldrés[5], N. Niell[6], J. P. Gambini[6], M. Fazzino[6], E. Savio[1], C. Castillo[7], G. Krygier[7];*
[1]Unidad Académica de Medicina Nuclear e Imagenología Molecular Hospital de Clínicas "Dr. Manuel Quintela" Facultad de Medicina Universidad de la República, Montevideo, URUGUAY,
[2]Unidad Académica de Oncología Clínica Hospital de Clínicas "Dr. Manuel Quintela" Facultad de Medicina Universidad de la República, Montevideo, URUGUAY,
[3]Servicio de Oncología Clínica Médica Uruguaya, Montevideo Uruguay, Montevideo, URUGUAY, [44].Servicio de Oncología Clínica, Asistencial Médica Maldonado, Montevideo, URUGUAY,
[5]Servicio de Oncología Clínica Hospital Británico, Montevideo Uruguay, Montevideo, URUGUAY,
[6]Centro Uruguayo de Imagenología Molecular, Montevideo, URUGUAY,
[7]Unidad Académica de Oncologia Clinica Hospital de Clínicas "Dr. Manuel Quintela" Facultad de Medicina Universidad de la República, Montevideo, URUGUAY.

EP-0870

Risk Factors Associated with Early Progression After ^{177}Lu-DOTATATE in Patients with Advanced/Metastatic Neuroendocrine Tumours

D. Maccora[1], *S. Rea[1], A. Annovazzi[1], G. Iaccarino[2], A. Soriani[2], R. Sciuto[1];*
[1]Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, ITALY,
[2]Laboratory of Medical Physics, IRCCS Regina Elena National Cancer Institute, Rome, ITALY.

EP-0871

LuNET-3: Somatostatin receptor-targeted radioligand therapy (RLT) in patients with pancreatic neuroendocrine Tumours in Germany

M. Schmidt[1], *N. Trautwein[2], C. LaFougere[2], B. Kreppel[3], M. Essler[3], C. Däubler[4], A. Weich[5], S. Ezziddin[6], F. Eilsberger[7], M. Beck[8], A. Küper[9], K. Pabst[9], W. Fendler[9], H. Lahner[10], K. Herrmann[9], D. Waldschmidt[11], M. Pavel[12];*
[1]Department of Nuclear Medicine, Cologne, GERMANY,
[2]Department of Nuclear Medicine, Tübingen, GERMANY,
[3]Department of Nuclear Medicine, Bonn, GERMANY,
[4]Department of Gastroenterology, Würzburg, GERMANY,
[5]Department of Nuclear Medicine, Würzburg, GERMANY,
[6]Department of Nuclear Medicine, Homburg, Saarland, GERMANY,
[7]Department of Nuclear Medicine, Marburg, GERMANY,
[8]Department of Nuclear Medicine, Erlangen, GERMANY,
[9]Department of Nuclear Medicine, Essen, GERMANY,
[10]Department of Endocrinology, Diabetes, and Metabolism, Essen, GERMANY,
[11]Department of Gastroenterology and Hepatology, Cologne, GERMANY,
[12]Department of Endocrinology and Diabetes, Erlangen, GERMANY.

EP-0872

Renal safety after PRRT with [^{177}Lu]Lu-oxodotreotide: short-term follow-up

C. G. Franco Monterroso, *L. Rey Sánchez, M. À. Hernández Fructuoso, E. Otero Ruiz, J. Balala Rojo, C. Jiménez Pena, A. García Burillo;*
Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.

EP-0873

Post PRRT quantitative PET/CT response assessment in neuroendocrine Tumours: SUVmax reduction as a site independent marker of treatment response

N. Bhulania[1], *P. S. Choudhury[1], M. Gupta[2], A. Pathak[2];*
[1]Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, INDIA,
[2]Rajiv Gandhi Cancer Institute and Research Centre, Delhi, INDIA.

EP-0874

Therapy Response vs. Ki-67 Index, Absorbed Dose and Tumor Size Variability after ^{177}Lu-DOTA-TOC Intra-arterial Infusions

G. Limouris[1,2], *M. Paphiti[1], V. McCready[3], A. Zafeirakis[2];*
[1]Nuclear Medicine, Medical School, National and Kapodistrian University, Athens, GREECE,
[2]Nuclear Medicine Dept, Army Share Fund Hospital, Athens, GREECE,
[3]Institute Cancer Research, Sutton Surrey and Royal Sussex County Hospital, Brighton, UNITED KINGDOM.

EP-0875

Comparison of the safety profile of [^{177}Lu] Lu-DOTATATE between the NETTER-1 and NETTER-2 trials and pharmacovigilance data from EudraVigilance and FAERS

A. Blesa Jimenez[1], *L. Camacho Berné[1], M. Bravo-Ferrer Moreno[2], N. Pérez Castro[1], V. Lopez Prior[1], A. Tembl Ferrairo[1];*
[1]Hospital Universitario de la Ribera, Alzira, SPAIN,
[2]Centro Andaluz de Farmacovigilancia, Sevilla, SPAIN.

EP-0876

Progression-free survival (PFS) and objective response rate (ORR) in patients with liver-dominant neuroendocrine neoplasms (NENs) after ^{177}Lu-DOTA-TATE / TOC Intra-arterial Infusions

G. Limouris[1,2], *M. Paphiti[1], M. B. Dolgushin[3], V. Krylov[4], A. Zafeirakis[2];*
[1]Nuclear Medicine, Medical School, National and Kapodistrian University, Athens, GREECE,
[2]Nuclear Medicine Dept, Army Share Fund Hospital, Athens, GREECE,
[3]Radiology Dept, FTsMN Federal State Institute, Federal Med Biol Agency, Moscow, RUSSIAN FEDERATION,
[4]Nuclear Medicine Dept "Anatoly Tsyb" Research Center, Obninsk, RUSSIAN FEDERATION.

EP-0877

Bowel Obstruction in Patients with Neuroendocrine Tumor (NET) Treated With ^{177}LuDOTATATE: A Comparative Cohort and Time-to-Event Analysis

A. Ordonez, *A. Pepin, N. K. Taunk, J. R. Eads, P. G. Mulugeta;*
Hospital of the University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.

EP-0878

Nuclear Medicine Modalities Utilization in Management of NETs - Global and European Trends

S. Dureja[1], *T. Kolarova[2], M. Cummins[3], C. Rodien-Louw[4], D. Van Genechten[5], M. McDonnell[6], I. Zervino[7], E. Gellerman[8], J. Chen[9], S. Singh[10], N. Fazio[11];*
[1]Theranostics India Centre, New Delhi, INDIA,
[2]International Neuroendocrine Cancer Alliance, Newton, Boston, MA, UNITED STATES OF AMERICA,
[3]NeuroEndocrine Cancer Australia, Sydney, AUSTRALIA,
[4]APTED, Paris, FRANCE, [5]vzw NET & MEN Kanker Belgium, Kortrijk, BELGIUM,
[6]NET Patient Network, Dublin, IRELAND,
[7]ACIAPO, Buenos Aires, ARGENTINA,
[8]NET Research Foundation, Boston, MA, UNITED STATES OF AMERICA,
[9]Centre for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, CHINA,
[10]Odette Cancer Center, Sunnybrook Health Sciences

Center, Toronto, ON, CANADA,
[11]Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO), IRCCS, Milan, ITALY.

EP-0879

Targeting the tumour microenvironment in advanced neuroendocrine neoplasms (NEN) with Fibroblast Activation Protein (FAP)-directed Radiopharmaceutical Therapy: A real-world safety and outcome analysis

E. Perrone[1,2], *K. Ghai[2], A. Eismant[2], C. Landvogt[2], C. Mueller[2], L. Greifenstein[2], M. Pavel[3], R. P. Baum[2];*
[1]Nuclear Medicine Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ITALY,
[2]CURANOSTICUM Wiesbaden-Frankfurt, ICPO Center of Excellence for Advanced Radiomolecular Precision Oncology, Wiesbaden, GERMANY,
[3]Department of Medicine [1], Uniklinikum Erlangen, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, GERMANY.

EP-0880

Bellmunt Risk Score for Survival Prediction in Gastroenteropancreatic Neuroendocrine Tumours with [177Lu]Lu-DOTA-TATE Therapy

E. Dema[1], *S. C. Siegmund[1], F. J. Gildehaus[1], C. Spitzweg[2], C. J. Auernhammer[2], R. A. Werner[1];*
[1]Department of Nuclear Medicine, LMU University Hospital, Munich, GERMANY,
[2]Department of Internal Medicine IV and Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM), LMU University Hospital, Munich, GERMANY.

EP-0881

Beyond Recist: Application of Modified Tumor Growth Rate to Predict Early Radiological Progression in NET after RLT

F. Scalorbi[1], *E. Garanzini[1], C. Marzi[2], G. Calareso[1], G. Argiroffi[1], M. Baccini[2], S. Pusceddu[1], A. Marchiano[1], M. Maccauro[1];*
[1]Istituto Nazionale Tumori Milano, Milan, ITALY,
[2]Department of Statistics, Computer Science, Applications "G. Parenti", University of Florence, Viale Morgagni [59], [50134] Florence, ITALY.

EP-0882

A Novel Pathophysiological Scoring System to Estimate the Risk of Severe Hematological Toxicity in rePRRT: The Marrow Exposure Score

Ó. Hernández Cristancho, *A. García-Burillo, J. Hernando, J. Suils-Ramón, M. Simó Perdigó, D. Sanchez-Artuñedo, A. Casteràs Roman, L. Blanco, A. García-Álvarez, C. Gámez Cenzano, J. Capdevila;*
Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.

EP-0883

The Polish RLT Registry: A Comprehensive Real-World Portrait of NET Patients Undergoing [177Lu] Lu-DOTA-TATE Therapy

M. Kolodziej[1], *V. Rosiek[2], J. Musiałkiewicz[3], A. Ledwon[4], A. Lewczuk-Myślicka[5], K. P. Sagan[6], K. Jozwik-Plebanek[1], B. Kos-Kudła[2], M. Ruchała[3], D. Handkiewicz-Junak[4], R. Swiatkowska-Stodulska[5], A. Syrenicz[6], G. Kamiński[1];*
[1]Military Institute of Medicine - National Research Institute, Warsaw, POLAND,
[2]Medical University of Silesia, Katowice, POLAND,
[3]University of Medical Science, Poznań, POLAND,
[4]National Institute of Oncology - National Research Institute, Gliwice, POLAND,
[5]Medical University of Gdansk, Gdansk, POLAND,
[6]Pomeranian Medical University, Szczecin, POLAND.

EP-0884

Lesion and Organ Dosimetry To Guide Efficacy and Safety in Rechallenge PRRT for Progressive Neuroendocrine Neoplasms

M. Mattke[1], *H. Dittmann[1], P. M. Linder[1], S. von Beschwitz[1], M. Hinterleitner[2,3,4], J. Schwenck[1,5,3], C. la Fougère[1,3,4], N. F. Trautwein[1,3,4];*
[1]Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Tuebingen, GERMANY,
[2]Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, GERMANY,
[3]Cluster of Excellence iFIT (EXC [2180]) "Image-Guided and Functionally Instructed Tumor Therapies", Eberhard Karls University Tuebingen, Tuebingen, GERMANY,
[4]ENETS Center of Excellence, University Hospital Tuebingen, Tuebingen, GERMANY,
[5]Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tuebingen, GERMANY.

EP-0885

Patient survival and its relation to tumor absorbed dose in [177Lu]Lu-DOTA-TATE therapy of neuroendocrine Tumours

C. Warfvinge, *S. Curkic Kapidzic, J. Gustafsson, L. Jessen, J. Svensson, A. Sundlöv, K. Sjögreen Gleisner;*
Lund University, Lund, SWEDEN.

EP-49

C: Therapy Clinical Study → C1 Oncological Therapy Clinical Study → C12 Prostate Cancer Therapy

EP-0886

P Prognostic role of PSMA PET IMaging and predictive value for toxicity of personalized DOSimetry in patients with hormone-sensitive de novo metastatic prostate cancer treated in phase III PEACE 6 Poor responders trial : Preliminary results of IM-DOSE PEACE 6 PR study

D. Deandreis[1], *C. Garcia[1], A. Bernard-Tessier[1], A. Tauty[2], N. Charrier[2], C. Guery[3], L. Crouzet[3], A. Devillers[3], P. BONNEFOY[4], P. Cornillon[4], O. Huillard[5], M. Wartski[5], A. Giraudet[6], A. Flechon[6], K. Weyts[7], F. Joly[7], N. Simon-Tillaux[1], C. Leger[8], F. Tantot[8], S. Foulon[9], G. Gravis[2], K. Fizazi[10];*
[1]Gustave Roussy, Villejuif, FRANCE,
[2]Institut Paoli-Calmettes, Marseille, FRANCE,
[3]Centre Eugène Marquis, Rennes, FRANCE,
[4]CHU St Etienne, Saint Etienne, FRANCE,
[5]Hopital Cochin, Paris, FRANCE,
[6]Centre Léon Bérard, Lyon, FRANCE,
[7]Centre Francois Baclesse, Caen, FRANCE,
[8]Unicancer, Villejuif, FRANCE,
[9]Gustave Roussy, Villejuif, FRANCE,
[10]Centre Oscar Lambret, Lille, FRANCE.

EP-0887

Predictive Value of Interim Post-Therapy SPECT/CTin Patients with Metastatic Castration-ResistantProstate Cancer Treated with [177Lu] Lu-PSMA-617

L. Albe[1], *P. Decazes[2], A. Dieudonne[2], F. Di Fiore[3], L. Augusto[3], S. Perret-Neveux[2], P. Bohn[1], P. Vera[1], D. Tonnelet[1], A. Edet-Sanson[1];*
[1]Centre Henri Becquerel, Rouen, FRANCE,
[2]Equipe QuantIF, Centre Henri Becquerel, Rouen, FRANCE,
[3]Centre Hospitalier Universitaire de Rouen, Rouen, FRANCE.

EP-0888

Factors Associated with Completion of Radium-223 Treatment

C. González Navarro, *O. Rosas Lozano, M. Catalá Espí, J. Clavel Claver, A. Palazón Vives, Á. García Aliaga, M. Martínez Ramírez;*
San Juan de Alicante University Hospital, Alicante, SPAIN.

EP-0889

Safety and tolerability of Copper-64 chloride in metastatic prostate cancer: preliminary clinical experience

S. Valentini[1], *D. Milakovic[2], J. Mijatovic[2], I. Rakita[2], G. Vuleta[2], M. Basile[1], G. Valentini[1], D. Stanimirovic[2];*
[1]A.C.O.M. S.R.L., Montecosaro (MC), ITALY,
[2]University Clinical Center of the Republic of Srpska, Banja Luka, BOSNIA AND HERZEGOVINA.

EP-0890

Synergistic Effect and Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Prior Radiotherapy for Metastatic Castration-Resistant Prostate Cancer

W. Chen, *Z. Liu;*
Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, CHINA.

EP-0891

Visual RECIP 1.0 on [177Lu]Lu-PSMA SPECT/CT: Impact of Imaging Time Point on Reliability, Temporal Stability and Prognostic Performance

F. Shenas, *W. Lehnert, M. Dependehner, A. Kisters, J. H. Lund, I. Apostolova, S. Klutmann, R. Braren, A. Karimzadeh;*
Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY.

EP-0892

177Lu-PSMA Radioligand Therapy in Chemo-Naïve mCRPC Patients: Is There Added Benefit from ARPI Combination?

G. Santo, *F. Goetting, L. Schweiger, L. Wirth, E. von Guggenberg, A. Kronthaler, C. Decristoforo, G. di Santo, I. Heidegger-Pircher, I. Virgolini;*
Medical University of Innsbruck, Innsbruck, AUSTRIA.

EP-0893

Real-world outcomes of radium-223 in metastatic castration-resistant prostate cancer: a 10-year single-centre experience

C. Rodríguez Vergara, *R. Álvarez Pérez, M. Guerra Gómez, L. Brero Sánchez, J. Jiménez-Hoyuela García;*
Hospital Universitario Virgen del Rocio, Sevilla, SPAIN.

EP-0894

Comparison of PSA Levels and miPSMA Expression Between Baseline Imaging and Post-Therapy SPECT/CT After Two Cycles of [177 Lu] Lu-PSMA Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC).

A. Al-Marrani, *K. Hlongwa, M. Rivombo, N. Jacobs, N. Govender, T. Mefane, M. Makhele, D. Bhoojedhur -Jugroo, S. More;*
University of Cape Town, Cape Town, SOUTH AFRICA.

EP-0895

Importance of Body Composition Changes and a Novel Prognostic Marker in mCRPC Patients Receiving Lu-177 PSMA Therapy: The SAT/SMI Ratio

F. Davarci, *G. Mütevelizade, E. Bilgin;*
Manisa Celal Bayar University, Faculty of Medicine, Department of Nuclear Medicine, Yunusemre, TÜRKIYE.

EP-0896

HIPS Don't Lie: A Novel Prognostic Score for Predicting Overall Survival After Lu-177 PSMA Therapy

H. Pekedis, *B. Guner, A. Dere, E. Kaya, B. Akkaş, M. Kaya;*
Basaksehir Çam ve Sakura City Hospital Nuclear Medicine Department, Istanbul, TÜRKIYE.

EP-0897

Safety and Toxicity Profile of[177Lu]-PSMA Radioligand Therapy in Geriatric Patients (≥75Years) with Metastatic Castration-Resistant Prostate Cancer

M. Borsali, *H. Noamen, A. Daverio, Y. Cras, C. Garcia, D. Deandreis, K. Trabelsi;*
Gustave Roussy, Villejuif, FRANCE.

EP-0898

Pre-therapeutic PSMA PET Imaging Biomarkers Demonstrate Prognostic Value in Patients Undergoing [177Lu]Lu-PSMA Therapy: a Systematic Review and Meta-analysis

K. Molin[1,2], *S. Li[1,2,3], N. Barry[1,2,3], J. S. L. Ong[4], A. Iravani[5,6], M. S. Hofman[7,8], G. M. Hassan[1], M. A. Ebert[1,2,3], J. Kendrick[1,2];*
[1]School of Physics, Mathematics and Computing, University of Western Australia, Crawley, AUSTRALIA,
[2]Centre for Advanced Technologies in Cancer Research (CATCR), Perth, AUSTRALIA,
[3]Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, AUSTRALIA,
[4]Department of Nuclear Medicine, Fiona Stanley Hospital, Murdoch, AUSTRALIA,
[5]Department of Radiology, University of Washington School of Medicine, Seattle, WA, UNITED STATES OF AMERICA,
[6]Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA, UNITED STATES OF AMERICA,
[7]Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA,
[8]Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, AUSTRALIA.

EP-0899

A pretherapeutic radiation-prediction score to identify Lu-177-PSMA-617 patients at increased radiation risk for nursing staff

K. Hansen[1], *A. Haslauer*[1], *S. Boyaci*[1], *M. Eiber*[1,2], *M. C. M. Gammel*[1];
[1]*Department of Nuclear Medicine, TUM Klinikum Rechts der Isar, Munich, GERMANY,*
[2]*Bavarian Cancer Research Center (BZKF), Erlangen, GERMANY.*

EP-0900

Clonal hematopoiesis of indeterminate potential in mCRPC patients treated with ^{177}Lu-PSMA-617

L. Vija, *L. Keller, S. Figarol, M. Bros, N. Hasan, S. Zerdoud, F. Rezungles, T. Cassou Mounat, L. Mourey, F. Courbon, B. Cabarrou;*
Institut Claudius Regaud-Oncopole, Toulouse Cedex [9]*, FRANCE.*

EP-0901

Machine Learning for PredictingRadiotherapy Response in Oligometastatic Prostate Cancer: A Pilot PSMA PET/Clinical Integration Study

M. Karacan[1], *B. Okudan*[1], *K. Ceviz*[2], *C. Ceylan*[2], *H. Sayan*[3], *T. A. Serel*[4], *S. Yahşi*[2];
[1]*Bilkent City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE,*
[2]*Bilkent City Hospital, Department of Urology, Ankara, TÜRKIYE,*
[3]*Bilkent City Hospital, Department of Radiation Oncology, Ankara, TÜRKIYE,*
[4]*Suleyman Demirel University Hospital, Department of Urology, Isparta, TÜRKIYE.*

EP-0902

Risk of Bowel Obstruction in Patients with Androgen Pathway Modulation-Resistant Prostate Cancer and Peritoneal Disease Receiving Lutetium-177 PSMA-targeted Radionuclide Therapy

J. Walsh, *A. Pepin, N. Taunk, P. Mulugeta;*
University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.

EP-0903

Efficacy and tolerability of177Lu prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer. Hospital experience of a Theranostic Center in Athens, Greece

A. Fothiadaki, *T. Tegos, S. Gavriilidis, M. Papachristou, N. Bertsekas, G. Chitiroglou, S. Kalentziou, F. Rontogianni, E. Vlontzou;*
General Hospital Evagelismos, Athens, GREECE.

EP-0904

Assessing Eligibility for ^{177}Lu-PSMA Radioligand Therapy with ^{68}Ga-PSMA-11 and ^{18}F-Flotufolastat Positron Emission Tomography: A Matched Cohort Comparison

D. Sasse, *L. Eibensteiner, S. Grigorascu, M. Gammel, I. Rauscher, W. Weber, M. Eiber;*
Department of Nuclear Medicine, TUM University Hospital, TUM School of Medicine and Health, Technical University of Munich, Munich, GERMANY.

EP-0905

Triple-Photopeak Acquisition Improves Image Quality in Serial Post-Therapy [^{177}Lu]Lu-PSMA SPECT/CT

F. Farhadi[1], *F. Massanes Basi*[2], *A. Ramirez*[1], *M. Morris*[1], *M. Ghesani*[1], *E. Siegel*[1], *H. Vija*[2], *B. Saboury*[1];
[1]*Institute of Nuclear Medicine, Bethesda, MD, UNITED STATES OF AMERICA,*
[2]*Siemens Healthineers, Hoffman Estates, IL, UNITED STATES OF AMERICA.*

EP-0906

Lu-177 Therapy in mCRPC: Relationships Between Hematological and Muscular Reserves and the "Uremic" Dissociation During Treatment

F. Davarci, *G. Mütevelizade, G. Aymandir, E. Bilgin;*
Manisa Celal Bayar University, Faculty of Medicine, Department of Nuclear Medicine, Yunusemre, TÜRKIYE.

EP-0907

Dual-Tracer ^{4}D PET Lesion Tracking for Dynamic Risk Stratification During Lu-177 PSMA Radioligand Therapy in mCRPC

S. Wen[1], *Y. Jia*[1], *A. A. Nikolic*[2], *S. Dintner*[3], *R. A. Bundschuh*[4], *M. Hacker*[1], *S. Xue*[1], *X. Li*[1], *C. Lapa*[2];
[1]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna, AUSTRIA,*
[2]*Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY,*
[3]*Pathology, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY,*
[4]*Department of Nuclear Medicine, University Hospital Carl Gustav Carus at the TU Dresden, Dresden, GERMANY.*

EP-0908

The predictive role of [^{177}Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters from the 1st RLT cycle in advanced mCRPC: a preliminary lesion-based analysis

R. Laudicella[1], *G. Celesti*[1], *G. Ricciardello*[1], *A. Micali*[2], *F. Midili*[2], *A. Bucca*[3], *V. M. Ferro*[3], *M. Piergentili*[4], *M. Arco*[1], *D. Stanà*[1], *S. Russo*[1], *A. Brogna*[2], *B. Pagano*[1], *S. Baldari*[1], *I. A. Burger*[5,6], *M. Bauckneht*[4,7], *F. Minutoli*[1];
[1]*Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, ITALY,*
[2]*Health Physics Unit, Messina University Hospital G. Martino, Messina, ITALY,*
[3]*Health Physics School of Specialization, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, ITALY,*
[4]*IRCCS Azienda Ospedaliera Metropolitana, Genova, ITALY,*
[5]*Department of Nuclear Medicine, Kantonsspital Baden, affiliated Hospital for Research and Teaching of the Faculty of Medicine of the University of Zurich, Baden, SWITZERLAND,*
[6]*Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND,*
[7]*Department of Health Sciences (DISSAL), University of Genova, Genova, ITALY.*

EP-0909

Towards clinical routine: Preliminary results of225Ac-PSMA quantification for clinical routine Whole-Body imaging with an extreme sensitivity Triple-NaI-Detector SPECT/CT system

Á. Krizsán[1], *G. Komuves*[1], *A. Delker*[2], *D. Legrady*[1], *Z. Szoboszlai*[3], *K. Annus*[1], *B. Szabo*[1], *W. Al-Muhanna*[1], *A. Gonye*[1], *A. Zounek*[2], *J. Kiss*[4], *A. Forgacs*[4], *C. Kratochwil*[5];
[1]*Mediso Ltd., Budapest, HUNGARY,*
[2]*Ludwig-Maximilians University, Munich, GERMANY,*
[3]*Scanomed Nuclear Medicine Centers, Debrecen, HUNGARY,*
[4]*University of Debrecen, Debrecen, HUNGARY,*
[5]*Heidelberg University Hospital, Heidelberg, GERMANY.*

EP-0910

Significant Acquisition Time Reduction of Lu-177 PSMA Studies on a Full-Ring CZT SPECT/CT System

K. Knesaurek, *A. Abdelrahman;*
Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.

EP-0911

Safety and Efficacy of Dose-Escalated ^{177}Lutetium PSMA Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Dose Escalation Study.

D. Malik, *I. Sen, P. Thakral, A. Uppal, J. Gupta;*
Fortis Memorial research institute (FMRI), Gurugram, INDIA.

EP-0912

Safety and Efficacy of Multi-Cycle ^{177}Lu-DOTA-IBA Therapy for Bone Metastases in Prostate Cancer

C. Tian, *W. Wang, Y. Chen, Z. Liu;*
Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, CHINA.

EP-0913

[^{177}Lu]Lu-PSMA-617 for mCRPC: Real-World Outcomes With and Without Concurrent ARPI

M. Rust[1], *D. Ventura*[1], *C. Backhaus*[1], *O. Platte*[1], *B. Matheja*[1], *M. Schäfers*[1], *M. Bögemann*[2], *L. Stegger*[1], *W. Roll*[1], *K. Rahbar*[1];
[1]*Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY,*
[2]*Department of Urology, University Hospital Münster, Münster, GERMANY.*

EP-0914

A universal rule of theranostics? FDG-receptor mismatch consistently predicts failure of radioligand therapy across malignancies

E. Gromova, *N. Kataev, N. Grigorev, D. Susin, M. Cherkashin, N. Berezina;*
LDC MIBS, Saint-Petersburg, RUSSIAN FEDERATION.

EP-0915

Beyond Batson's Plexus: Osteopontin-Rich Bone Microenvironment as a Potential Biological Driver of Osteoblastic Skeletal Burden in Prostate Cancer

A. Al Nabulsi;
Jouf University, Aljouf, SAUDI ARABIA.

EP-0916

Inhibition of LDHA Upregulates PSMA Protein Expression and Sensitizes PSMA-RLT in Prostate Cancer

X. Zhou;
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA.

EP-0917

Imaging screening with [^{68}Ga]Ga PSMA 11, [^{18}F] FDG, and [^{18}F]FCholine PET/CT for [^{177}Lu]Lu PSMA radioligand therapy in metastatic castration resistant prostate cancer: Part 2 - prognostic impact of PET profiles on patient outcome.

L. Djaileb[1], *P. Ferrier*[1], *M. Haeck*[1], *E. Jacquet*[1], *A. Mercier*[1], *E. Paquet*[2], *C. Margail*[3], *C. Drouet*[4], *S. Le Bon*[1], *M. Faure*[1], *V. Ruggeri*[1], *P. Castelluci*[5], *F. Barbato*[6], *E. Mairal*[3], *M. Laramas*[1], *W. Fendler*[7], *K. Herrmann*[6], *A. Gafita*[8], *A. Giraudet*[9], *C. Merlin*[3], *F. Andrea*[5];
[1]*University Grenoble Alpes, Grenoble, FRANCE,*
[2]*Centre Leon Berard, Lyon, FRANCE,*
[3]*Centre Jean Perrin, Clermont Ferrand, FRANCE,*
[4]*Centre Georges François Leclerc, Dijon, FRANCE,*
[5]*IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[6]*Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY,*
[7]*Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, FRANCE,*
[8]*John Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA,*
[9]*Centre Léon Berrard, Lyon, FRANCE.*

EP-0918

Hematological Safety Profile of Lu-PSMA-617 therapy: Identifying Patients at Risk for Cytopenia

A. Nazar, *M. Ora, P. Pradhan, A. Gupta;*
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, INDIA.

EP-0919

Toxicity-Driven Dose Adaptation of ^{177}Lu-PSMA-617 Radioligand Therapy in Clinical Practice: A Single-Center Experience

I. Marini[1], *M. Sansovini*[1], *S. Nicolini*[1], *M. Celli*[1], *E. F. Giunta*[2], *G. Schepisi*[2], *F. Foca*[3], *A. Sarnelli*[4], *V. Di Iorio*[5], *L. Vizza*[3], *E. Giani*[3], *M. Monti*[3], *P. Caroli*[1], *F. Matteucci*[1], *I. Grassi*[1];
[1]*Nuclear Medicine Department, I.R.C.C.S Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola (FC), ITALY,*
[2]*Oncology Department, I.R.C.C.S Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola (FC), ITALY,*
[3]*Unit of Biostatistics and clinical trials, I.R.C.C.S Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola (FC), ITALY,*
[4]*Medical Physics Department, I.R.C.C.S Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola (FC), ITALY,*
[5]*Oncological Pharmacy Unit, I.R.C.C.S Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola (FC), ITALY.*

EP-0920

Comparative effectiveness of ^{177}Lu-PSMA-617 versus ^{177}Lu-PSMA-I&T for metastatic castration-resistant prostate cancer

R. Fakkert, *K. J. Nijenhuis, T. F. F. T. Ververs, C. P. Bruijnen, A. J. A. T. Braat, B. de Keizer, M. G. E. H. Lam; UMC Utrecht, Utrecht, NETHERLANDS.*

EP-0921

Assessment of PSMA Occupancy and Recovery During Lu-177-PSMA-617 Therapy Using Ga-68-PSMA-11 Dynamic PET/CT

Z. Lu, *A. Hillmer, M. Roseland, K. Suresh, D. Raffel, B. Viglianti, P. Scott, K. Wong, K. Frey, Y. Dewaraja; University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA.*

EP-0922

Association of PSMA-PET-derived tumour volume with organ and tumour absorbed dose in [^{177}Lu] Lu-PSMA-617 therapy

J. Wang[1], *W. Jutidamrongphan[1], L. Serrano Lopes[1], A. Lazar[2], M. Amon[1], Y. Chen[1], K. Pandya[1], K. Zeimpekis[1], T. Läppchen[1], D. Akhoundova Sanoyan[3], M. Shelan[4], A. Afshar-Oromieh[1], C. Sachpekidis[1], A. Chiti[5], A. Rominger[1], K. Shi[1], R. Seifert[1];*
[1]Department of Nuclear Medicine, Inselspital, Bern, SWITZERLAND,
[2]Vita-Salute San Raffaele University, Milan, ITALY,
[3]Department of Medical Oncology, Inselspital, Bern, SWITZERLAND,
[4]Department of Radiation Oncology, Inselspital, Bern, SWITZERLAND,
[5]Department of Nuclear Medicine, IRCCS San Raffaele Hospital,Vita-Salute San Raffaele University, Milan, ITALY.

EP-0923

Evaluation of the Effect of Lu-177 PSMA Radioligand Therapy on Renal Functions Using Ga-68 PSMA PET/CT, Renal Scintigraphy, and Biochemical Parameters

M. Kaya[1], *F. Demir[1], S. Karacavus[1], M. Demir[2], N. Koyluce[1];*
[1]University of Health Sciences, Kayseri Faculty of Medicine, Department of Nuclear Medicine, Kayseri, TÜRKIYE,
[2]University of Health Sciences, Kayseri Faculty of Medicine, Department of Nephrology, Kayseri, TÜRKIYE.

EP-0924

The clinical use of ^{177}Lu[Lu]-PSMA treatment for prostate cancer patients who are not eligible to receive chemotherapy

O. Ekmekcioglu[1], *E. Demirci[1], O. Sahin[2], N. Alan[1], L. Kabasakal[2];*
[1]Nuclear Medicine Department, Yeditepe University Medical Faculty, Istanbul, TÜRKIYE,
[2]Nuclear Medicine Department, Cerrahpasa Medical Faculty, Istanbul, TÜRKIYE.

EP-0925

Feasibility of AI-Assisted Organ-Resolved Tumor Burden Quantification in Serial18F-Flotufolastat PSMA PET During ^{177}Lu-PSMA-I&T Therapy

L. Eibensteiner[1], *M. Gammel[1], M. Eiber[2], I. Rauscher[1];*
[1]Department of Nuclear Medicine, TUM Klinikum, Rechts der Isar, Technical University of Munich (TUM), School of Medicine and Health, Munich, GERMANY, [21] Department of Nuclear Medicine, TUM Klinikum, Rechts der Isar, Technical University of Munich (TUM), School of Medicine and Health [2] Bavarian Cancer Research Center (BZKF), Erlangen, Germany, [1] Munich, [2] Erlangen, GERMANY.

EP-0926

Assessment of [^{177}Lu]Lu-PSMA-617 scintigraphic imaging-based lesion quantification reliability across multiple acquisition time points

M. Machado, *H. Delgado, F. P. M. Oliveira, A. Silva, L. C. Silva, D. C. Costa;*
Champalimaud Foundation, Lisbon, PORTUGAL.

EP-0927

Dual-tracer Lesion Tracking for Quantitative Assessment of Lesion-level Response and Phenotypic Divergence in Prostate Cancer During Androgen Deprivation Therapy

Y. Jia[1], *H. Zhang[1], M. Hacker[1], X. Li[1], J. Liu[2], X. Zhou[3], S. Xue[1];*
[1]Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, vienna, AUSTRIA,
[2]Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA,
[3]Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.

EP-0928

Early Prostate-Specific Antigen Rise During Lutetium-177 Prostate-Specific Membrane Antigen Radioligand Therapy: A Cycle 3 Landmark Analysis in Metastatic Castration-Resistant Prostate Cancer

K. Klimek[1,2], *A. Husseini[2], C. Happel[2], N. Mader[3], M. Wenzel[4], F. Chun[4], F. Grünwald[2], A. Sabet[3], D. Groener[2];*
[1]Department of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, München, GERMANY,
[2]Department of Nuclear Medicine, Clinic for Radiology and Nuclear Medicine, University Hospital, Goethe University Frankfurt, Frankfurt, Germany, Frankfurt, GERMANY,
[3]Department for Nuclear Medicine and Theranostics, Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Deutschland, Ludwigshafen, GERMANY,
[4]Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany, Frankfurt, GERMANY.

EP-0929

Prognostic Value of a Composite Score Including Baseline [^{18}F]FDG PET/CT and [^{68}Ga]Ga-PSMA PET/CT in Patients Screened for [^{177}Lu]Lu-PSMA Treatment Eligibility (the PROFILE Study)

A. Jougla[1], *A. Giraudet[2], A. Olivier[3], P. Nunes[4], J. Blanc[4], A. Cochet[1], S. Ladoire[5], J. Vrigneaud[1], L. Vija[6], C. Drouet[1];*
[1]Department of Nuclear Medicine, Centre Georges-François Leclerc, Dijon, FRANCE,
[2]Department of Nuclear Medicine, Centre Léon Bérard, Lyon, FRANCE,
[3]Department of Nuclear Medicine, Centre Oscar Lambret, Lille, FRANCE,
[4]Department of Statistics, Centre Georges-François Leclerc, Dijon, FRANCE,
[5]Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, FRANCE,
[6]Department of Nuclear Medicine, Oncopole Claudius Regaud, Toulouse, FRANCE.

EP-0930

Real-World Biochemical Response and Safety of [^{177}Lu]Lu-PSMA Therapy in Heavily Pretreated mCRPC: The Mexican Multicenter Experience

E. Hernández Suazo[1], *F. García Pérez[2], I. Soldevilla Gallardo[2], Q. Pitalua Cortes[2], S. Gonzalez Rueda[2], R. Pedrero Piedras[2];*
[1]Instituto Nacional de Cancerología, Mexico City, MEXICO,
[2]Instituto Nacional de Cancerologia, Ciudad de México, MEXICO.

EP-0931

Safety and Efficacy of ^{177}Lu-PSMA I&T Radioligand Therapy in Prostate Cancer: Results from the LUBASKET Trial

I. Grassi[1], *S. Nicolini[1], N. Brighi[2], A. Sarnelli[3], I. Marini[1], M. Casi[4], M. Celli[1], G. Schepisi[2], F. Matteucci[5], A. Prochowski Iamurri[6], E. Giani[7], I. Azzali[7], E. Eleuteri[7], V. Di Iorio[8], M. Monti[7], P. Caroli[1], M. Sansovini[1];*
[1]Nuclear Medicine Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola Fc, ITALY,
[2]Oncology Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola Fc, ITALY,
[3]Medical physics Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola Fc, ITALY,
[4]Nuclear Medicine Department, Romagna local health authority, Cesena, ITALY,
[5]Nuclear Medicine Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Nuclear Medicine Department Romagna local health authority, Meldola Fc, Cesena, ITALY,
[6]Radiology Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola Fc, ITALY,
[7]Unit of Biostatistics and clinical trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola Fc, ITALY,
[8]Oncological Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola Fc, ITALY.

EP-0932

Renal Safety of [^{177}Lu]Lu-PSMA Radioligand Therapy: First Prospective Study Using Measured GFR Reveals Systematic Underestimation of Nephrotoxicity by Estimated GFR

R. Mehra, *S. Srivastava, A. H. Nazar, P. K. Pradhan; Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, INDIA.*

EP-0933

Evaluating ^{18}F-PSMA PET CT as a Predictive Criterion for ^{223}Ra Therapy Efficacy in Castration-Resistant Prostate Cancer with Bone Metastases

N. Kataev, *E. Gromova, N. Grigorev, N. Berezina, K. Suprun;*
MIBS, Saint Petersburg, RUSSIAN FEDERATION.

EP-0934

Comparison of Pretherapeutic ^{18}F-PSMA-1007 PET/CT with posttherapeutic ^{177}Lu-PSMA SPECT/CT and 3-day dosimetry

J. Hornfeck[1], *L. Widjaja[1,2], S. Siegmund[1], F. Gildehaus[1], K. Klimek[1], A. Holzgreve[1], A. Delker[1], R. A. Werner[1,2,3];*
[1]Department of Nuclear Medicine, LMU Hospital, Munich, GERMANY,
[2]Bavarian Cancer Research Center (BZKF), partner site Munich, Munich, GERMANY,
[3]German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and LMU University Hospital Munich, Munich, GERMANY.

EP-0935

Interim Safety Analysis of the Prospective Phase 2 Trial "Retreatment with [^{177}Lu]Lu-PSMA-617" (Re-LuPSMA: NCT06288113)

K. Kimura[1], *J. Enke[1], L. Theus[1], A. Nguyen[1], J. Nikitas[2], A. Holzgreve[1,3], J. Juarez[4], E. Kimura[1], Y. A. Gonzalez[1], C. Odum[1], M. Contreras[1], H. Alam[1], R. M. Nabong[1], S. Lira[1], S. Bahri[1], P. K. Gupta[1], A. Quon[1], A. Salavati[1], D. H. Silverman[1], M. Allen-Auerbach[1], J. Czernin[1], J. Calais[1];*
[1]Department of Nuclear Medicine and Theranostics, David Geffen School of Medicine at UCLA, Los Angeles, CA, UNITED STATES OF AMERICA,
[2]Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA,
[3]Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, GERMANY,
[4]Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, UNITED STATES OF AMERICA.

EP-0936

Global Estimates for [^{177}Lu]Lu-PSMA and [^{177}Lu] Lu-DOTATATE Patient Eligibility: Implications for Planning Equitable Access to Theranostics

A. Scott[1], *N. Ayati[2], M. S. Hofman[3], G. Kong[4], A. A. Azad[3], M. J. Morris[5], M. Michael[4], D. Paez[6], F. Giammarile[6], J. Li[2];*
[1]Austin Health and ONJCRI, Melbourne, AUSTRALIA,
[2]Centre for Health Economics, Monash Business School, Monash University, Melbourne, AUSTRALIA,
[3]Pater MacCallum Cancer Centre, Melbourne, AUSTRALIA,
[4]Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA,
[5]Memorial Sloan-Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA,
[6]Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, AUSTRIA.

EP-0937

Tumor Sink Effect in ^{177}Lu-PSMA-617.Results from Pan-Canadian PR21 trial(NCT04663997)

S. Kurkowska[1], *P. L. Esquinas[2], X. Hou[2], N. Colpo[1], C. Williams[1], S. Harsini[3], C. Dellar[4], W. Parulekar[4], F. Saad[5], K. Zukotynski[6], K. Chi[2], J. M. Beauregard[7,8], F. Benard[1], C. Uribe[1];*
[1]BC Cancer Research Institute, Vancouver, BC, CANADA,
[2]BC Cancer Agency, Vancouver, BC, CANADA,
[3]University of Toronto, Toronto, ON, CANADA,
[4]Canadian Cancer Trials Group, Kingston, ON, CANADA,
[5]University of Montreal Hospital Center, Montreal, QC, CANADA,

[6]McMaster University, Hamilton, ON, CANADA,
[7]Department of Radiology and Nuclear Medicine, Université Laval, Quebec City, QC, CANADA,
[8]Division of Nuclear Medicine, Department of Medical Imaging, CHU de Québec - Université Laval, Québec City, QC, CANADA.

EP-0938

Real-world safety and feasibility of ^{177}Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer: a retrospective tolerability analysis

S. Shamim, *M. Umar, N. Damle, A. Batra;*
AIIMS, Delhi, INDIA.

EP-50

C: Therapy Clinical Study → C1 Oncological Therapy Clinical Study → C13 Local Radionuclide Therapy (including Spheres)

EP-0939

Des-γ-carboxy Prothrombin as a Biomarker for Treatment Assessment After Yttrium-90 Radioembolization in Hepatocellular Carcinoma

X. Zheng, *A. C. Muller Kobold, R. J. de Haas, M. G. Kater, K. P. de Jong, M. W. Nijkamp, M. Chvatal-Medina, F. G. I. van Vilsteren, W. Noordzij, S. J. S. Ruiter;*
University Medical Center Groningen, Groningen, NETHERLANDS.

EP-0940

Long term efficacy, safety and dose response relationship with188Re-N-DEDC lipiodol Transarterial Radionuclide Therapy (TART) in Inoperable Hepatocellular Carcinoma: A pilot study

N. Kumar, *S. Shamim, P. Gupta, S. Gamanagatti, Shalimar;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0941

Combined functional and vascular assessment using CT perfusion with temporal summation for Y90 radioembolization planning

E. Roncali[1], *Y. Gao*[2], *B. Spencer*[1], *K. Chung*[3], *R. E. Goldman*[1], *A. Chandler*[2], *B. Mehadji*[1];
[1]*University of California Davis, Davis, CA, UNITED STATES OF AMERICA,*
[2]*United Imaging Healthcare North America, Inc., Houston, TX, UNITED STATES OF AMERICA,*
[3]*Athinoula A. Martinos Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA.*

EP-0942

Synergistic Efficacy of Sequential ^{90}Y Radioembolization and Stereotactic Body Radiotherapy in Advanced Hepatic Malignancies: A ^{18}F-FDG PET/CT Documented Complete Local Response

N. Zumbul[1], *A. Apti*[2], *M. Adli*[2], *T. Ones*[1];
[1]*Department of Nuclear Medicine, Marmara University School of Medicine, Marmara University Pendik Training and Research Hospital, Istanbul, TÜRKIYE,*
[2]*Department of Radiation Oncology, Marmara University School of Medicine, Marmara University Pendik Training and Research Hospital, Istanbul, TÜRKIYE.*

EP-0943

Targeted Pancreatic Intratumoural Implantation of ^{32}P-Microparticles Under Endoscopic Ultrasound Guidance (EUG). A Local Radionuclide Therapy Used in Interventional Oncology

C. Fragkaki[1], *A. Kontos*[2], *K. Kasviki*[3], *D. Kypraios*[2], *I. Tsaousidis*[1];
[1]*Nuclear Medicine Department of General Anticancer Oncological Hospital of Athens "Agios Savvas", Athens, GREECE,*
[2]*Gastroenterology Department of General Anticancer Oncological Hospital of Athens "Agios Savvas", Athens, GREECE,*
[3]*Medical Physics/Radiation Protection Department of General Anticancer Oncological Hospital of Athens "Agios Savvas", Athens, GREECE.*

EP-0944

Predicting Voxel-Based ^{90}Y Microsphere Distribution in Hepatocellular Carcinoma with Dual-Tracer ^{18}F-Fluorocholine and ^{18}F-FDG PET/CT — A Pilot Study

C. Turkan[1], *F. Çay*[2], *F. G. Eldem*[2], *B. Volkan Salancı*[1], *M. F. Bozkurt*[1];
[1]*Hacettepe University, Department of Nuclear Medicine, Ankara, TÜRKIYE,*
[2]*Hacettepe University, Department of Radiology, Ankara, TÜRKIYE.*

EP-0945

Characterization of HCC tumor response using prospective voxel dosimetry in ^{90}Y-radioembolization clinical trial RAPY90D

S. Kappadath, *A. Mahvash;*
University of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

EP-0946

Optimizing Y-90 Radioembolization in Hepatocellular Carcinoma: Towards Routine Implementation of Voxel-Based Dosimetry

S. Naranjo Sancho[1], *J. Otero Figar*[1], *N. González Hompanera*[1], *A. Álvarez Amigo*[1], *J. Guzmán de la Cerda*[1], *A. Rugeles Niño*[1], *R. Franchini Tirone*[1], *V. Chiminazzo*[2], *S. Sanmartino González*[1], *A. Castaño García*[1], *A. Mesa Álvarez*[1], *A. de Menezes-Falcao Gomes-Marques*[1], *A. Piedra Cerezal*[1], *M. Varela*[1,3,4], *M. Domínguez Grande*[1], *C. Vigil Díaz*[1,3];
[1]*Central University Hospital of Asturias, Oviedo, SPAIN,*
[2]*Plataforma de Bioestadística y Epidemiología. Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, SPAIN,*
[3]*University of Oviedo, Oviedo, SPAIN,*
[4]*Instituto de Investigación Sanitaria del Principado de Asturias. Fundación para la Investigación y la Innovación Biosanitaria del Principado de Asturias. Instituto Universitario de Oncología del Principado de Asturias. (ISPA-FINBA-IUOPA), Oviedo, SPAIN.*

EP-0947

Assessment of Radiation-Induced Hepatic Fibrosis After Transarterial Radioembolization Using ^{68}Ga-FAPI PET

K. Saglam[1], *O. E. Şahin*[1], *S. Asa*[1], *S. Andaç*[2], *L. Kabasakal*[1];
[1]*Istanbul University-Cerrahpasa, Istanbul, TÜRKIYE,*
[2]*Section for Clinical and Experimental Sensory Physiology, Ophthalmology Department, Otto-von-Guericke University Magdeburg, Magdeburg, GERMANY.*

EP-0948

Transarterial Radioembolization (TARE) in Colorectal Cancer: The Relationship Between Post-Treatment Absorbed Dose Values and Changes in ALBI Score in Conjunction with Quantitative PET/CT Parameters

S. Çetin[1], *Ö. Erez*[1], *S. Kesim*[2], *E. Soydemir*[3], *E. Arık*[3], *Z. Balaban Genç*[4], *N. Zümbül*[1], *A. Eroğlu*[1], *T. Öneş*[1];
[1]*Marmara University Pendik Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[2]*Kartal Dr. Lütfi Kırdar City Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[3]*Marmara University Pendik Training and Research Hospital, Department of Radiology, Istanbul, TÜRKIYE,*
[4]*Ümraniye Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE.*

EP-0949

Dosimetry-Driven Holmium-166 Radioembolization in Liver Malignancies: Real-World Survival and Tumor-Type Stratification from a 7-Year Experience

J. Deportos, *S. Lafuente-Carrasco, J. Riba Jofré, J. Mora-Sospedra, F. Pardo-Aranda, M. Cremades-Perez, L. Castro-Frias, M. Sanchez-Torres, L. Prats-Cabaces, G. Moragas-Freixa;*
Hospital Universitari Germans Trias i Pujol, Badalona, SPAIN.

EP-0950

High Local Tumour Control Following Y90 "Radiation Tumourectomy" Using Partition Dosimetry

B. Corcoran, *A. Elsaadany, M. Vadrucci;*
Barts Health NHS Trust, London, UNITED KINGDOM.

EP-0951

Overall Survival After Radioembolization in Intrahepatic Cholangiocarcinoma: A Single-Center Real-World Experience

J. Deportos, *S. Lafuente-Carrasco, M. Salcedo-Pujantell, N. Canchumanya-Huatuco, P. Hinojosa-Salas, M. Boronat-De Ferrater, A. Caresia-Aroztegui, V. Vallejos-Arroyo, M. Solà-Suarez, X. Valverde-Guillen, R. Ferrandiz-Hervella, N. Torres-Nuncio, L. Layos-Romero, S. Ruiz-Llama, G. Moragas-Freixa;*
Hospital Universitari Germans Trias i Pujol, Badalona, SPAIN.

EP-0952

Initial Experience with Intratumoral Phosphorus-32 Microparticle Injection in Pancreatic Adenocarcinoma

N. Coskun, *M. Akdogan, R. Okten, M. Sendur, E. Bostanci, E. Ozdemir;*
Bilkent City Hospital, Ankara, TÜRKIYE.

EP-0953

Evaluation of Treatment Efficacy Using Quantitative ^{18}F-FDG PET/CT Parameters Based on Predosimetric Perfused Area Dose in Intrahepatic Cholangiocarcinoma Patients Treated with ^{90}Y Glass Microspheres

N. Zümbül[1], *A. Eroglu*[1], *S. Cetin*[1], *O. Erez*[1], *Z. C. Balaban Genc*[2], *B. Mirzamli*[1], *S. N. Sari*[1], *A. Erdal Karaduran*[1], *S. Aktas*[1], *F. C. Saka*[1], *E. Arik*[3], *E. Soydemir*[3], *T. Ones*[1];
[1]*Marmara University Pendik Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[2]*Umraniye Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[3]*Marmara University Pendik Training and Research Hospital, Department of Radiology, Istanbul, TÜRKIYE.*

EP-0954

Impact of the Density of Microspheres on the Heterogeneity of ^{90}Y Dose Distribution at Biopsy Specimen Level in Transarterial Radioembolization with Glass Microspheres

A. Kirov, *L. Carter, O. Talarico, A. Teplov, K. Schieck, Z. Zhang, S. Lee, D. Xenos, H. Kunin, E. Petre, Y. Yagi, V. Sotirchos, A. Kesner, J. L. Humm, C. Sofocleous;*
Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0955

Clinical impact of transarterial radioembolization in hepatic malignancies: retrospective realworld cohort evaluation in elderly patients.

A. Minguillán Van Kapel[1], *R. de Teresa Herrera*[1], *S. de la Torre Fernández*[1], *A. Seva Delgado*[1], *B. Aradas Cabado*[1], *M. Tello Galán*[1], *A. de Jesús Fernandez*[2], *G. Rubio Fernández.*[2], *C. de García González*[2], *C. Hernández Heredia*[1];
[1]*Hospital Gómez Ulla, Sº Medicina Nuclear, Madrid, SPAIN,*
[2]*Hospital Gómez Ulla, Sº Radiofarmacia, Madrid, SPAIN.*

EP-0956

Integrating ^{90}Y-TARE into the iCCA Treatment Landscape: Planning Keys and Clinical Evolution

I. Garrido-Solesio, *M. Grajeda Gallardo, C. Pradère, M. Estrella Caballero, O. Borja Logroño, R. Gonzalez Costero, J. Gomez Patiño, M. Lopez Gomez, A. Prieto Soriano, L. Gutierrez Sanz, M. Mitjavila Casanovas;*
Hospital Universitario Puerta de Hierro Majadahonda, Madrid, SPAIN.

EP-0957

Bridging Macro- and Micro-Dosimetry After Yttrium-90 Radioembolisation Using an Oncopig Liver Tumour Model

C. Huesa-Berral[1], *E. Wehrenberg-Klee*[2], *F. Moloudi*[2], *C. Ferguson*[2], *K. Joseph*[1], *J. Lopez-Valverde*[1], *A. Bertolet*[1];
[1]*Massachusetts General Hospital, Department of Radiology, Division of Nuclear Medicine, Boston, MA, UNITED STATES OF AMERICA,*
[2]*Massachusetts General Hospital, Department of Radiology, Division of Interventional Radiology, Boston, MA, UNITED STATES OF AMERICA.*

EP-0958

Dosimetry and safety profile of Transarterial Radioembolization with90Y-microspheres/^{188}Re-lipiodol in Metastatic Lung lesions

N. Kumar, *B. Jain, S. Shamim, P. Naranje;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0959

Pathological Response and Dosage Correlation in Hepatocellular Carcinoma Following Radioembolization with Holmium-166: A Surgical Series Analysis

S. Lafuente, *J. Deportos, M. Salcedo, S. Ruiz, G. Tovar, J. Cordero, J. Sampere, G. Moragas;*
Hospital German Trias i Pujol, Barcelona, Badalona, SPAIN.

EP-0960

Dosimetric performance and Clinical Outcomes in Hepatic Transarterial Radioembolization (TARE) with ^{90}Y-Microspheres: A Comparative Analysis of Single-Session and Multi-Session Treatment Strategies

B. Jaramillo Lopez, *A. R. Suazo Montero, P. A. Negrete Montiel, S. Pena Vaquero, N. Álvarez Mena, F. Sebastián Palacid, C. Gamazo Laherrán, J. Gómez Hidalgo, R. Ruano Pérez;*
Hospital Clínico Universitario Valladolid, Valladolid, SPAIN.

EP-0961

Impact of Tumor Absorbed Dose on Overall Survival in HCC Patients Treated with Y-90 Microspheres

K. Knesaurek[1], *A. Alam*[1], *A. Abdelrahman*[1], *I. Hume Braun*[2];
[1]*Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA,*
[2]*Hospital Italiano de Buenos Aires, Buenos Aires, ARGENTINA.*

EP-0962

Efficiacy and Safety of Single-session Resin-based Yttrium-90 Transarterial Radioembolization Segmentectomy for Small Hepatocellular Carcinoma: Short-Term Results From The One & Done Trial

N. Kokabi, *S. Gad, M. Mohnasky, A. Villalobos, A. Moon, H. Sanoff, J. Jia, S. Barritt, N. Shah, D. Mauro, P. Mody, M. Xing, H. Yu;*
University of North Carolina, Chapel Hill, NC, UNITED STATES OF AMERICA.

EP-0963

Comparison of Personalized Dosimetric Parameters Calculated Using Simplicit90Y and MIM 64-bit Software in Patients Treated with Resin Y-90 Microspheres for Transarterial Radioembolization

F. Saka[1], *S. Aktas*[1], *O. Erez*[1], *S. Cetin*[1], *A. Eroglu*[1], *N. Zumbul*[1], *E. Soydemir*[2], *E. Arik*[2], *T. Ones*[1];
[1]*Marmara University Pendik Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[2]*Marmara University Pendik Training and Research Hospital, Department of Radiology, Istanbul, TÜRKIYE.*

EP-0964

Durable Pathological Complete Response After FAP-Targeted Intravesical Lu-177-3BP-3940 Radioligand Therapy in Two Patients with Treatment-Refractory Muscle-Invasive Bladder Cancer

A. Eismant[1], *R. M. Wirtz*[2], *E. Veltrup*[2], *M. Freifrau von Brandenstein*[3], *E. Storz*[3], *A. Heidenreich*[3], *R. P. Baum*[1];
[1]*Curanosticum, Wiesbaden, GERMANY,*
[2]*STRATIFYER Molecular Pathology GmbH, Köln, GERMANY,*
[3]*Uniklinik Köln, Klinik für Urologie, Köln, GERMANY.*

EP-0965

High early objective response after Yttrium-90 transarterial radioembolization in primary and secondary liver malignancies: a single-centre real-world series

F. Matteucci[1], *A. Vizzuso*[2], *R. Galassi*[2], *G. Musacchia*[2], *D. Tirotta*[2], *E. Liverani*[2], *C. Fabbri*[2], *G. Giorgetti*[2], *V. D'Errico*[2], *M. Renzulli*[2], *E. Giampalma*[2], *A. Moretti*[2];
[1]*IRCCS IRST, Meldola, ITALY,*
[2]*AUSL Romagna, Forlì, ITALY.*

EP-0966

Single institution experience of liver transplantation and downstaging for HCC post trans-arterial radioembolization

A. Alsugair, *B. Aljudaibi, D. Broering, A. AlEhaideb, S. Abulaganam, I. Ahmad, A. Albenmousa;*
King Fasial Specilaist Hospital And Research Center, Riyadh, SAUDI ARABIA.

EP-0967

ALBI score for prediction of hepatic toxicity and treatment response after ^{90}Y transarterial radioembolization: correlation with dosimetric parameters

P. Merlo Benitez, *J. Salamanca Varela, S. Romero García, P. Bello Arques, V. Vera Pinto, S. Pisoni, R. Díaz Expósito, D. Pérez Enguix, I. Torres Espallardo;*
Hospital Universitari i Politecnic La Fe, Valencia, SPAIN.

EP-0968

Adverse events after ^{90}Y selective internal radiation therapy: a retrospective single-centre analysis

C. García-Alcober[1], *J. J. Martín-Marcuartu*[2], *A. Bagán-Trejo*[2], *C. A. Tapias-Mesa*[2], *S. Maymó-Garrido*[1], *D. Rodríguez-Puig*[1], *E. Ricart-Paredes*[1], *S. Orts-Expósito*[1], *M. Zamorano-Rivas*[2], *M. Cortés-Romera*[2];
[1]*Radiopharmacy Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, SPAIN,*
[2]*Nuclear Medicine-PET (IDI) Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, SPAIN.*

EP-0969

Impact of Administered Tumour Dose on Survival in Patients Undergoing Multi-Session ^{90}Y-Microsphere Hepatic Radioembolization (TARE)

B. Jaramillo Lopez, *A. R. Suazo Montero, P. A. Negrete Montiel, S. Pena Vaquero, F. Sebastián Palacid, N. Álvarez Mena, C. Gamazo Laherrán, J. Gómez Hidalgo, R. Ruano Pérez;*
Hospital Clínico Universitario Valladolid, Valladolid, SPAIN.

EP-0970

Radioembolization with Yttrium-90 in patients with primary and secondary liver Tumours: A single-center experience

A. Velidaki, *S. Episkopopoulou, I. Sevaslidou, G. Bramis, M. Adamantou, P. Pappas, A. Kolindou;*
Laiko General Hospital of Athens, Athens, GREECE.

EP-51

C: Therapy Clinical Study → C1
Oncological Therapy Clinical Study → C14
Thyroid Therapy

EP-0971

No Adverse Effects of ^{131}I-Dx-WBS: A Comparative Study of Different Doses in Intermediate- to High-Risk Differentiated Thyroid Cancer Patients

T. Ming, *W. Yang, F. Kang, J. Wang, W. Ma;*
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

EP-0972

Radiodine therapy in differentiated thyroid cancer: a three year restrospective analysis of clinical outcomes, safety and risk stratification.

O. Rosas Lozano, *A. Palazón Vives, C. González Navarro, M. Catala Espí, T. Díaz Capilla, J. Clavel Claver, A. Martínez Esteve, A. Martínez Caballero, M. Anton Leal, J. Verdú Rico;*
Hospital Univeristario San Juan de Alicante, Alicante, SPAIN.

EP-0973

Extent of Lymphadenectomy and Prognosis in N1b PTC: A Multicenter Retrospective Cohort Study

C. Liu, *B. Liu;*
West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0974

Age-Dependent Heterogeneity of Radioactive Iodine Therapy in Papillary Thyroid Cancer:A SEER-based analysis via Causal Survival Forests

Y. Jin, *F. Yu;*
Shanghai Tenth People's Hospital and Institute of Nuclear Medicine, School of Medicine, Tongji University, Shanghai, CHINA.

EP-0975

First Radioiodine Therapy in Papillary Thyroid Carcinoma: Predictive Value of Pre-Ablation Thyroglobulin

G. Mani, *F. Ben Amar, I. Yeddes, W. Ajmi, H. Hammemi, A. Sellem;*
Military Hospital of Tunis, Tunis, TUNISIA.

EP-0976

Biochemical and Metabolic Response to Radioactive Iodine Therapy in Differentiated Thyroid Carcinoma with Lung Metastases: An Expanded Retrospective Analysis

A. Akil, *M. S. Sağer, O. E. Şahin, S. Asa, R. Uslu-Beşli, K. Sönmezoğlu;*
Istanbul University – Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

EP-0977

Latent Class Analysis-Based Heterogeneity in Symptoms, Quality of Life, and Social Support among Thyroid Cancer Patients Receiving Iodine-131 Therapy

L. Cao;
Mianyang Central Hospital, Mianyang, CHINA.

EP-0978

Re-evaluating Routine Electrolyte Monitoring Before Radioactive Iodine Therapy: Limited Utility for Sodium and Potassium, Essential for Calcium

R. Wijaya, *T. As'ad, A. Gozian, N. Indiarti, A. Latuheru, P. Pratamadinata, H. Budiawan, A. Achmad, A. Kartamihardja;*
Faculty of Medicine, Universitas Padjadjaran, Bandung, INDONESIA.

EP-52

C: Therapy Clinical Study → C1
Oncological Therapy Clinical Study → C15
Brain Tumour Therapy

EP-0979

A Multicenter, Randomized, Open-Label, Seamless Adaptive Phase II/III Study Design of [^{177}Lu]Lu-Oxodotreotide Alone or Combined with Bevacizumab versus Bevacizumab Monotherapy in SSTR-Positive Recurrent/Refractory Meningioma

D. Li[1], *L. Wang*[1], *Z. Zhu*[2], *L. Zhou*[3], *X. Li*[4], *Z. Chen*[3];
[1]*Beijing Tiantan Hospital, Beijing Neurosurgical Institute, Capital Medical University, Beijing, CHINA,*
[2]*Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, CHINA,*
[3]*NHC Key Laboratory of Nuclear Technology Medical Transformation (Mianyang Central Hospital), Mianyang, CHINA,*
[4]*Beijing Tiantan Hospital, Capital Medical University, Beijing, CHINA.*

EP-53

C: Therapy Clinical Study → C1
Oncological Therapy Clinical Study → C16
Other Oncological Treatments

EP-0980

Safety, Dosimetry, and Preliminary Efficacy of [^{68}Ga]Ga/[^{177}Lu]Lu-CTR-FAPI Theranostics in Patients with Metastatic Solid Tumours: A First-in-Human Study

X. Tian, *Y. Zhang, Y. Teng, Z. Cui, J. Liu;*
Department of Nuclear Medicine, The Second Hospital & Clinical Medical School, Lanzhou University, lanzhou, CHINA.

EP-0981

A First-in-Human Phase 1 Trial Safety and Biodistribution of [^{177}Lu]Lu-ABY-271 in Subjects with HER2-Positive Metastatic Breast Cancer (NCT07081555)

J. Feldwisch[1], *O. P. B. Wiklander*[2,3], *L. Klint*[4], *K. Grünbaum*[1], *L. Osterling Koskinen*[1], *G. Wuerth*[1], *C. Ahlin*[1], *F. Y. Frejd*[1,5], *P. Bernhardt*[6,7], *H. Lindman*[8];
[1]*Affibody AB, Solna, SWEDEN,*
[2]*Breast Center, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Stockholm, SWEDEN,*
[3]*Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, SWEDEN,*
[4]*Department of Oncology, Sahlgrenska University Hospital, Gothenburg, SWEDEN,*
[5]*Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN,*
[6]*Department of Medical Radiation Sciences, Institution of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN,*
[7]*Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, SWEDEN,*
[8]*Department of Oncology, Uppsala University Hospital, Uppsala, SWEDEN.*

EP-0982

Clinical efficacy and safety of integrin αvβ3 targeted radionuclide therapy with lutetium-177 labeled AB-3PRGD2 in advanced metastatic solid Tumours: a prospective, single-arm, single center, investigator-initiated study

H. Fu, *J. Huang, G. Yue, L. Zhao, H. Wu, W. Guo, H. Chen;*
The First Affiliated Hospital of Xiamen University, Xiamen, CHINA.

EP-0983

Expanding therapeutic options in metastatic pancreatic ductal adenocarcinoma (PDAC): Fibroblast activation protein (FAP)-directed Radiopharmaceutical Alpha Therapy

E. Perrone[1,2], *K. Ghai*[2], *A. Eismant*[2], *F. Vocaturo*[3], *L. Greifenstein*[2], *J. Zhang*[4], *R. P. Baum*[2];
[1]*Nuclear Medicine Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ITALY,*
[2]*CURANOSTICUM Wiesbaden-Frankfurt, ICPO Center of Excellence for Advanced Radiomolecular Precision Oncology, Wiesbaden, GERMANY,*
[3]*Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, ITALY,*
[4]*Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, MALAYSIA.*

EP-0984

[Lu-177]RTX-2358 Combined with Immune Checkpoint Inhibition in Patients with FAP-Positive Metastatic Non-Small Cell Lung Cancer

X. Zhang[1], *V. Jardine*[2], *D. Zhang*[3], *M. Li*[1], *F. Feng*[1], *Y. Gai*[1], *R. Meng*[3], *X. Lan*[1];
[1]*Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA,*
[2]*Ratio Therapeutics Inc., Boston, MA, UNITED STATES OF AMERICA,*
[3]*Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.*

EP-0985

Clinical feasibility, efficacy and safety profile of177Lu-FAPi 2286 radioligand therapy in metastatic Breast Cancer (mBC) patients, refractory to other conventional treatments

N. Kumar, *S. Shamim, A. Batra;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0986

Synergistic Therapeutic Outcomes of FAP-Targeted Radiopharmaceutical Therapy with ^{177}Lu-, ^{90}Y-, and ^{225}Ac-Labeled 3BP-3940 in Combination with Immunothery, Chemotherapy and other Targeted Therapies for Sarcoma Patients

J. Li[1,2], *J. Zhang*[1,2,3], *Y. Tan*[1,2], *E. Perrone*[4], *L. Greifenstein*[5], *R. P. Baum*[5];
[1]*Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,*
[2]*Theranostics Center of Excellence, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,*
[3]*Clinical Imaging Research Centre, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,*
[4]*Nuclear Medicine Unit, Diagnostic Imaging and Radiation Oncology Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY,*
[5]*Curanosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Department of Nuclear Medicine, DKD HELIOS Klinik, Wiesbaden, GERMANY.*

EP-0987

Covalent FAPTargeted Radioligand Therapy with Lu177CTR01 in Advanced Solid Tumours: Early Clinical Experience

A. Eismant[1], *L. Greifenstein*[1], *A. Zounek*[2], *R. P. Baum*[1];
[1]*Curanosticum, Wiesbaden, GERMANY,*
[2]*Private Investigator, Wiesbaden, GERMANY.*

EP-0988

Safety and Efficacy Study of ^{225}Ac-DOTA-IBA in the Treatment of Bone Metastases

H. Liu, *X. Shang, K. Cheng, X. Guo, Y. Zhao, Y. Liu, L. Lei, L. Wang, C. Qi, L. Qiu, N. Xing, C. Zhang, Z. Huang, W. Wang, Y. Chen;*
the Affiliated Hospital of Southwest Medical University, Luzhou, CHINA.

EP-0990

Rhenium-188 Resin Therapy for Non-Melanoma Skin Cancer: Prospective Assessment of Clinical outcomes, Acute Toxicity, and Cosmetic Outcomes

D. Vega Perez, *E. Martínez Albero, A. Saviatto Nardi, B. García Bracamonte, P. Ortiz Romero, S. Ruíz Solís, C. García Donoso;*
Hospital 12 de Octubre, Madrid, SPAIN.

EP-0991

Combination with seribantumab increases the effect of affibody-based radionuclide therapy of CEACAM5/HER3-expressing pancreatic tumour xenografts

E. Papalanis[1], *M. Oroujeni*[1], *A. Orlova*[1], *R. Li*[2], *T. Gräslund*[2], *V. Tolmachev*[1];
[1]*Uppsala university, Uppsala, SWEDEN,*
[2]*KTH, Stockholm, SWEDEN.*

EP-0992

Dual-tracer FDG/FAPI PET biomarkers predict survival after radiotherapy in nasopharyngeal carcinoma

Y. Jia[1], *D. Ruan*[2], *M. Pan*[3], *M. Hacker*[1], *S. Xue*[1], *H. Chen*[2], *X. Li*[1];
[1]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, vienna, AUSTRIA,*
[2]*Department of Nuclear Medicine and Minnan PET Center, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, CHINA,*
[3]*Department of Otorhinolaryngology, General Hospital and Medical University of Vienna, Vienna, AUSTRIA.*

EP-0993

The ATLAS Study: A First-in-Human Phase 1/2 Trial of [Ac-225]RTX-2358 in Patients with Relapsed or Refractory Soft Tissue Sarcoma (STS)

C. Hayward[1], *G. Johnson*[2], *H. Schöder*[3], *Q. Li*[4], *N. Nguyen*[5], *G. Ravizzini*[5], *J. Calais*[6], *M. Allen-Auerbach*[6], *P. Veit-Haibach*[7], *V. Jardine*[1], *J. Babich*[1], *J. Hesterman*[1];
[1]*Ratio Therapeutics, Boston, MA, UNITED STATES OF AMERICA,*
[2]*Mayo Clinic, Rochester, NY, UNITED STATES OF AMERICA,*
[3]*Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA,*
[4]*Case Western Reserve University School of Medicine, Cleveland, OH, UNITED STATES OF AMERICA,*
[5]*MD Anderson, Houston, TX, UNITED STATES OF AMERICA,*
[6]*UCLA, Los Angeles, CA, UNITED STATES OF AMERICA,*
[7]*Princess Margaret Hospital, Toronto, ON, CANADA.*

EP-0994

LuFOSTAR Trial-in-Progress: A Phase 1 First-in-Human Dose-Escalation Trial of [^{177}Lu]-FO-004, a FAP-Targeted Radiopharmaceutical, in Advanced Solid Tumours

A. Scott[1,2], *J. Cardaci*[3], *M. P. Brown*[4], *C. L. Gan*[5], *M. S. Hofman*[6], *G. Ninatti*[1], *T. Chan*[1], *S. McClusky*[1], *J. Kaufmann*[7], *A. Enke*[7], *J. von-Hacht*[7], *V. Wills*[7], *A. Gurgen*[7], *L. Rolfe*[7], *S. Luen*[6];
[1]*Austin Health, Melbourne, AUSTRALIA,*
[2]*Olivia Newton-John Cancer Research Institute, Melbourne, AUSTRALIA,*
[3]*Genesis Care, Perth, AUSTRALIA,*
[4]*Royal Adelaide Hospital, Adelaide, AUSTRALIA,*
[5]*Royal Brisbane and Women's Hospital, Brisbane, AUSTRALIA,*
[6]*Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA,*
[7]*3B Pharmaceuticals GmbH, Berlin, GERMANY.*

EP-0995

Localization-Dependent Therapy Response to FAP-Targeted Radioligand Therapy in Pancreatic Ductal Adenocarcinoma - a Lesion-Wise Analysis of Primary Tumours, Hepatic, Lymph Node, Bone and Pulmonary Metastases

A. Skrinjar[1], *C. Eckert*[2], *A. Spektor*[1], *L. Greifenstein*[3], *M. Gaida*[2], *M. Schreckenberger*[1], *R. P. Baum*[3], *M. Röhrich*[1];
[1]*Klinik für Nuklearmedizin, Universitätsmedizin Mainz, Mainz, GERMANY,*
[2]*Institut für Pathologie, Universitätsmedizin Mainz, TRON - Translational Oncology Mainz gGmbH, Mainz, GERMANY,*
[3]*Curanosticum, Wiesbaden, GERMANY.*

EP-0996

Efficacy and Safety of177Lu-FAP-2286 Targeted Radionuclide Therapy in Patients with Locoregionally Advanced or Metastatic Pancreatic Cancer

T. Xu, *C. Tian, H. Yang, Y. Chen;*
Affiliated Hospital of Southwest Medical University, Luzhou, CHINA.

EP-0997

Molecularly Guided Combined Lutetium-177 FAP-2286 and DOTA-Ibandronic Therapy for Bone Metastases: A Dual-Tracer PET/CT Study

M. Fan, *Y. Chen;*
Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, CHINA.

EP-0998

Long-term Safety and Cumulative Efficacy of Multi-cycle177Lu-DOTA-IBA Therapy in Bone Metastases: A Retrospective Cohort Study

T. Xu, *K. Cheng, P. Wang, W. Wang, Y. Chen;*
Affiliated Hospital of Southwest Medical University, Luzhou, CHINA.

EP-0999

A Semi-mechanistic Population Biodistribution Model of ^{89}Zr-TLX250-Px for the Diagnosis of Clear Cell Renal Cell Carcinoma

H. Stephens[1], ***A. Adam***[2], *M. Ferris*[2], *A. Kakade*[2,1], *M. Trame*[1], *D. Cade*[2];
[1]*Certara Drug Development Solutions, Concord, MA, UNITED STATES OF AMERICA,*
[2]*Telix Pharmaceuticals, Herstal, BELGIUM.*

EP-1000

Posttreatment Gallium-68 FAP-2286 Positron Emission Tomography/Computed Tomography Parameters for Response and Survival Assessment After Lutetium-177 FAP-2286 Radioligand Therapy in Advanced Solid Tumours

M. Fan, *Y. Chen;*
Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, CHINA.

EP-1001

Safety and Efficacy Analysis of Multi-Cycle ^{177}Lu-DOTA-IBA Therapy for Bone Metastases

H. Liu, *Y. Liu, T. Du, D. Fan, L. Mou, N. Xing, L. Qiu, W. Wang, J. Zhang, Y. Chen;*
the Affiliated Hospital of Southwest Medical University, Luzhou, CHINA.

EP-1002

FAP-directed Actinium-225 Radiopharmaceutical Therapy (FRT) in metastatic breast cancer: retrospective assessment of safety, efficacy and survival

E. Perrone[1,2], *F. Vocaturo*[3], *K. Ghai*[2], *A. Eismant*[2], *A. Klega*[2], *L. Greifenstein*[2], *R. M. Wirtz*[4], *R. P. Baum*[2];
[1]*Nuclear Medicine Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ITALY,*
[2]*CURANOSTICUM Wiesbaden-Frankfurt, ICPO Center of Excellence for Advanced Radiomolecular Precision Oncology, Wiesbaden, GERMANY,*
[3]*Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, ITALY,*
[4]*STRATIFYER Molecular Pathology GmbH, Cologne, GERMANY.*

EP-1003

Imaging Discordance Drives Treatment Change Despite Limited Association with Progression After Lutetium-Based Radioligand Therapy

N. Kataev, *E. Gromova, N. Grigorev, N. Berezina, K. Suprun;*
MIBS, Saint Petersburg, RUSSIAN FEDERATION.

EP-54

C: Therapy Clinical Study → C2 Non-Oncological Treatments → C21 Non-Oncological Treatments (including Thyroid Benign)

EP-1004

Amiodarone-induced hyperthyroidism - the efficacy of different types of management

K. Bajuk Studen[1,2], *L. Nemeš*[2], *E. Igličar*[2], *K. Zaletel*[1,2], *S. Gaberščček*[1,2];
[1]*University Medical Centre Ljubljana, Ljubljana, SLOVENIA,*
[2]*University of Ljubljana, Ljubljana, SLOVENIA.*

EP-1005

Ultrasound-Guided Radiosynoviorthesis: Effectiveness and Predictors of Response in an Expanded Cohort

M. Marusso Fizzani, *A. García-Burillo, S. Asadurova, M. de Bonilla-Candau, S. Martinez Rosales, O. Hernandez, N. Calviño, M. de Albert, C. Gamez-Cenzano;*
Hospital Universitario Vall d'Hebron, Barcelona, SPAIN.

EP-55

C: Therapy Clinical Study → C3 Dosimetry in Therapeutic Applications → C31 Dosimetry in Therapeutic Applications

EP-1006

Dosimetry and Uptake Patterns on ^{177}Lu-PSMA Scintigraphy Correlation with Gastro-Intestinal Adverse Events in mCRPC Treated Patients

Z. Ells[1], *I. C. Azour*[1], *V. B. Ludwig*[1], *C. A. Meyer*[1], *L. M. Unterrainer*[1,2], *P. G. Maliha*[1], *T. Grogan*[1], *J. Czernin*[1], *M. Dahlbom*[1], *J. Calais*[1];
[1]*University of California - Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA,*
[2]*Technical University of Munich, Munich, GERMANY.*

EP-1007

Is less more? The influence of the number of sequential SPECT acquisitions on the intra-therapeutic intra-renal effective half-life of ^{177}Lu-PSMA-617 in Radioligand Therapy

E. Schmuck, *B. Bockisch, B. Leonhäuser, M. J. Kappenstein, S. Husseini, A. Nörthen, D. Groener, C. Happel;*
Universitätsmedizin Frankfurt am Main, Frankfurt am Main, GERMANY.

EP-1008

Inter-patients and intra-patient variability of critical organs absorbed doses and haematological changes during ^{177}Lu-DOTATATE therapy in patients with neuroendocrine tumours.

M. Poniatowska[1,2,3], *H. Piwowarska-Bilska*[2,1], *A. Marciniak*[1], *J. Stenka*[1], *B. Birkenfeld*[2,1];
[1]*University Clinical Hospital No. [1] of the Pomeranian Medical University in Szczecin, Szczecin, POLAND,*
[2]*Pomeranian Medical University, Szczecin, POLAND,*
[3]*Department of Nuclear Medicine, University Medicine Greifswald, Greifswald, GERMANY.*

EP-1009

Avidination for Radionuclide Therapy in Nonpalpable Breast Cancer (ARTHE): patient-based Monte Carlo dosimetry of ^{90}Y-DOTA-biotin locoregional therapy

C. Macis[1], *A. Arzenton*[2], *A. Andrighetto*[3], *G. S. Valli*[4], *E. Mariotti*[5], *P. Caroli*[6], *C. Cuni*[6], *M. Sansovini*[7], *A. Sarnelli*[1];
[1]*Medical Physics Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola, ITALY,*
[2]*Department of Physics and Astronomy, University of Padua, Padua, ITALY,*
[3]*INFN - Legnaro National Laboratories, Legnaro, ITALY,*
[4]*Department of Physical Sciences, Earth and Environment, University of Siena, Siena, ITALY,*
[5]*INFN Pisa, Pisa, ITALY,*
[6]*Diagnostic Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, ITALY,*
[7]*Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, ITALY.*

EP-1010

Individualised Radioiodine Dosimetry in Benign Thyroid Disease Using Population-Based NLME Pharmacokinetic Modelling

E. Yousefzadeh-Nowshahr[1,2], *B. Endres*[1], *M. Emmanuel*[1], *T. Kull*[2], *N. Eberhardt*[2], *A. J. Beer*[2], *G. Glatting*[1,2];
[1]*Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, GERMANY,*
[2]*Department of Nuclear Medicine, Ulm Hospital University, Ulm, GERMANY.*

EP-1011

Cycle-dependent shift in optimal acquisition window for single-time-point tumor dosimetry in [^{177}Lu]Lu-PSMA therapy

N. Cavedini[1,2], *V. Zolkina*[2], *A. Riznychenko*[2], *U. Nemer*[3], *W. Noordzij*[2], *A. Marques da Silva*[4], *C. Moriguichi Jeckel*[1], *M. Mix*[3], *O. Ivashchenko*[2];
[1]*Graduate Program of Biomedical Gerontology, School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, BRAZIL,*
[2]*Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, NETHERLANDS,*
[3]*Department of Nuclear Medicine, Faculty of Medicine, University of Freiburg Medical Center, University of Freiburg, Freiburg, GERMANY,*
[4]*Hospital das Clínicas, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, BRAZIL.*

EP-1012

A Rigorous Monte Carlo Simulation Framework for Actinium-225-PSMA-617 Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer

A. Alshehri;
Radiological sciences department | Collage of applied medical science | Najran University, Najran, SAUDI ARABIA.

EP-1013

Validation of single-time-point dosimetry for [^{177}Lu]Lu-PSMA-617 therapy using population-based Time Dose Factors

A. Terro[1], *T. Zaragori*[2,3], *C. Boursier*[4], *P. Vera*[1,5], *P. Decazes*[1,5], *L. Imbert*[3,4], *A. Dieudonné*[1,5];
[1]*QuantIF-AIMS, Rouen University, Rouen, FRANCE,*
[2]*CIC [1433], Inserm, University of Lorraine, CHRU Nancy, Nancy, FRANCE,*
[3]*IADI, U[1254], Inserm, University of Lorraine, Nancy, FRANCE,*
[4]*Department of Nuclear Medicine, Nancyclotep Imaging Platform, University of Lorraine, CHRU Nancy, Nancy, FRANCE,*
[5]*Department of Nuclear Medicine, Henri Becquerel Center, Rouen, FRANCE.*

EP-1014

Lesion Selection for Tumour Absorbed Dose-Response Relationships for PRRT; Implementation in a Real-World Dataset

M. Kvassheim[1,2], *C. M. B. Martinsen*[1], *A. K. Martinsen*[1], *A. Schypulski*[3], *H. Ramsvik*[1], *T. Husevåg*[1], *J. Blakkisrud*[1], *C. Stokke*[1,4];
[1]*Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo, NORWAY,*
[2]*Institute of Clinical Medicine, University of Oslo, Oslo, NORWAY,*
[3]*Department of Nuclear Medicine, Division of Radiology and Nuclear Medicine, Oslo, NORWAY,*
[4]*Department of Physics, University of Oslo, Oslo, NORWAY.*

EP-1015

Bone marrow dosimetry in ^{177}Lu-PSMA therapy: a comparison of blood-based and SPECT CT-based methods

F. Fioroni[1], *E. Grassi*[1], *C. Marella*[2], *N. Bonazzi*[3], *A. Arnone*[3], *R. Durmo*[3], *M. Roncali*[3], *M. Iori*[1], *A. Filice*[3];
[1]*Madical Physics Unit, AUSL-IRCSS di Reggio Emilia, Reggio Emilia, ITALY,*
[2]*Department of Physics and Astronomy, University of Bologna, Bologna, ITALY,*
[3]*Nuclear Medicine Unit, AUSL-IRCSS di Reggio Emilia, Reggio Emilia, ITALY.*

EP-1016

Pre-Therapy Prediction of Absorbed Dose in [^{177}Lu]Lu-PSMA-617 Therapy Using Radiomic Features from [^{68}Ga]Ga-PSMA-11 PET/CT

P. Geramifar[1], *E. Yazdani*[1,2], *I. Klyuzhin*[1,3], *A. Dhalla*[1], *P. Esquinas*[1,4,5], *F. Farhadi*[3], *B. Saboury*[3,4], *C. Uribe*[1,4,5], *A. Rahmim*[1,4,5];
[1]*Ascinta Technologies Inc., Vancouver, BC, CANADA,*
[2]*Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,*
[3]*Institute of Nuclear Medicine, Bethesda, MD, UNITED STATES OF AMERICA,*
[4]*BC Cancer, Vancouver, BC, CANADA,*
[5]*University of British Columbia, Vancouver, BC, CANADA.*

EP-1017

Impact of Spatial Resolution on ^{177}Lu Dosimetry: A Pharmacokinetic Digital Phantom Study Demonstrating that Resolution-Induced TIA Errors Dictate Absorbed Dose

T. Ogino, *S. Ito, K. Onuma, T. Kita, F. Sasaki, H. Sagara, M. Sato, H. Daisaki;*
Gunma Prefectural College of Health Sciences, Maebashi, JAPAN.

EP-1018

Towards Personalised Dosimetry Prediction for ^{177}Lu-PSMA Therapy Using Pre-therapy ^{18}F-PSMA PET/CT, Radiomics and Machine Learning

A. Nautiyal[1], *Y. Dewaraja*[2], *J. Dickson*[3], *S. Crabb*[4], *F. Sundram*[5], *Z. Saad*[5], *S. Michopoulou*[1];
[1]*University Hospital Southampton and University of Southampton, Southampton, UNITED KINGDOM,*
[2]*University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA,*
[3]*University College London Hospital, London, UNITED KINGDOM,*
[4]*University of Southampton, Southampton, UNITED KINGDOM,*
[5]*University Hospital Southampton, Southampton, UNITED KINGDOM.*

EP-1019

Patient-Specific ^{131}I Therapy in End-Stage Renal Disease: Integrated Dosimetry, Segmented Kinetics, Hemodialysis Clearance, and Radiation Safety

H. Al Saidi, *N. Al Makhmari, N. AL Maymani, S. Kheruka, A. Al Balushi, S. AL Rashdi, T. AL Raii, K. AL Riyami, R. AlSukaiti;*
Sultan Qaboos Comprehensive Cancer Care & Research Centre, Muscat, OMAN.

EP-1020

Towards DVH-based Renal Dosimetry in Patients Treated with ^{177}Lu PSMA-RLT: Impact of Activity and Quantitative SPECT Reconstruction on Voxel-level Absorbed Dose and DVH Metrics

M. Obaid[1,2], *M. Aanounou*[3,4], *L. Archambault*[1,5], *J. M. Beauregard*[3,4];
[1]*Département de physique, de génie physique et*

d'optique, Université Laval, Québec City, QC, CANADA,
[2]Département de Radio-Oncologie et Axe Oncologie du CRCHU de Québec, CHU de Québec, Québec City, QC, CANADA,
[3]Cancer Research Centre and Department of Radiology and Nuclear Medicine, Université Laval, Québec City, QC, CANADA,
[4]Division of Nuclear Medicine, Department of Medical Imaging, CHU de Québec – Université Laval, Québec City, QC, CANADA,
[5]Service de physique médicale et de radioprotection, Centre intégré de cancérologie, CHU de Québec-Université Laval, Québec City, QC, CANADA.

EP-1021

Time allocation across three imaging time points: a systematic dosimetric optimisation for Lutetium-177 Prostate-Specific Membrane Antigen Therapy

E. Balduzzi*[1], E. Pesenti[2], C. Bianchi[1], S. Chinzorig[3], I. Gotuzzo[1], F. Lattuada[1], F. Garrou[1], P. Erba[1,4], G. Poli[1];*
[1]ASST Papa Giovanni XIII, Bergamo, ITALY,
[2]Università degli Studi di Bergamo, Bergamo, ITALY,
[3]ICTP, Trieste, ITALY,
[4]Università degli Studi di Milano-Bicocca, Milan, ITALY.

EP-1022

Optimizing acquisition time in 360°ring-shaped CZT SPECT/CT for ^{177}Lu dosimetry: balancing quantitative accuracy and image quality

K. Khamwan*[1,2], W. Handayani[3,2], D. Hardiansyah[4], M. Chantadisai[5], S. Chokyakorn[1], G. Sgouros[6];*
[1]Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, THAILAND,
[2]Chulalongkorn University Biomedical Imaging Group, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, THAILAND,
[3]Medical Physics Program, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, THAILAND,
[4]Medical Physics and Biophysics, Physics Department, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, INDONESIA,
[5]Division of Nuclear Medicine, Department of Radiology, King Chulalongkorn Memorial Hospital, Bangkok, THAILAND,
[6]Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA.

EP-1023

Predictive Dosimetry for ^{177}Lu-PRRT: A Foundation Model Approach Using Pre-Therapeutic ^{68}Ga-DOTATATE PET/CT

Y. Shachor*[1], T. Yeshua[2], D. Amram[1], J. Godefroy[1], E. Solomonov[1], M. Zidan[1], A. Bel-Ange[3], S. Grozinsky-Glasberg[3], S. Ben-Haim[1,4], A. Chicheportiche[1];*
[1]Department of Nuclear Medicine & Biophysics, Hadassah-Hebrew University Medical Center, Jerusalem, ISRAEL,
[2]Department of Physics, Jerusalem College of Technology, Jerusalem, ISRAEL,
[3]Neuroendocrine Tumor Unit, Division of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, ISRAEL,
[4]Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, ISRAEL.

EP-1024

Radiological safety profile evaluation via internal dosimetry: A multicentric comparative study between two ^{177}Lu-PSMA ligands in metastatic castration-resistant prostate cancer

A. Arriaga Contreras*[1], R. Hernández Ramírez[1], M. Corza Ayala[1], J. Chávez Torres[1], A. Cruz Cortes[2], Q. Pitalua Cortes[2];*
[1]Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MEXICO,
[2]Médica Sur, Mexico City, MEXICO.

EP-1025

Open-Source and Spreadsheet-Based Dosimetry as Alternatives to Commercial Software in Lutetium177 Radioligand Therapy

L. Lampertico*[1,2], G. Muti[2], C. Carbonini[2], C. Romanò[2], A. Scarale[3], P. Colombo[2], C. Rossetti[3];*
[1]Università degli Studi di Milano, Milano, ITALY,
[2]S.C. Fisica Sanitaria, ASST GOM Niguarda, Milano, ITALY,
[3]S.C. Medicina Nucleare, ASST GOM Niguarda, Milano, ITALY.

EP-1026

Retrospective comparison of voxel-wise dosimetry from ^{99}mTc-MAA SPECT/CT and post-treatment ^{90}Y PET/CT in tumor and perfused liver VOIs

C. Lv*[1], Z. Liang[2], Z. Hang[3], H. Liu[4], Z. He[2,3];*
[1]School of Biomedical Engineering, Tsinghua University, Haidian District, Beijing, CHINA,
[2]Department of Nuclear Medicine, Tsinghua ChangGung Hospital, Haidian District, Beijing, CHINA,
[3]School of Clinical Medicine, Tsinghua University, Haidian District, Beijing, CHINA,
[4]Molecular Imaging Business Unit, United Imaging Healthcare, Jiading District, Shanghai, CHINA.

EP-1028

Comparison of [^{203}Pb]Pb-PSV359 and [^{64}Cu]Cu-PSV377 for Predictive Dosimetry in Targeted Alpha Therapy with ^{212}Pb

J. Mueller*[1], D. Kaestner[1], E. Michler[1], S. Hoberueck[1], C. Brogsitter[1], F. Brandt[1], M. Pretze[1], R. Freudenberg[1], M. K. Schultz[2], R. A. Bundschuh[1];*
[1]Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, GERMANY,
[2]Perspective Therapeutics Inc., Coralville, IA, UNITED STATES OF AMERICA.

EP-1029

Serial ^{212}Pb-SPECT Single-Time-Point Dosimetry Supports Prediction of Cumulative Kidney Absorbed Dose from Cycle 1 Dose Estimates in Patients Receiving ^{212}Pb-ADVC001

D. Pattison*[1], A. S. Ravi Kumar[2], D. Wyld[1], M. Griffiths[1], E. O'Mahoney[2], L. Katchel[2], J. Duong[2], H. Biggs[2], S. Baker[2], I. Holmes[2], L. Campbell[1], M. C. Baronet[3], P. Santoro[3], A. Aalami[3], R. Grace[3], P. Shama[3], J. Brilhante[3], S. Rose[3], M. Crumbaker[3], A. Karmann[3], A. R. Hansen[2], S. Ngai[2];*
[1]Royal Brisbane and Women's Hospital, Brisbane, AUSTRALIA,
[2]Princess Alexandra Hospital, Brisbane, AUSTRALIA,
[3]AdvanCell Pty Ltd, Boston, MA, UNITED STATES OF AMERICA.

EP-1030

Quantitative Imaging in ^{3}D Voxel Dosimetry for ^{177}Lu and ^{131}I Radionuclide Therapies

E. Richetta*, E. Lombardo, C. Bracco, B. Elia, M. Stasi; Ordine Mauriziano Hospital, Torino, ITALY.*

EP-1031

Automated Organ Segmentation using TotalSegmentator for ^{177}Lu-DOTATATE Dosimetry: Validation of Efficiency and Accuracy against Manual Contouring

S. Ito*[1], T. Ogino[1], K. Onuma[1], T. Kita[2], F. Sasaki[2], M. Shiga[2], H. Sagara[1], M. Sato[1], H. Daisaki[1];*
[1]Gunma Prefectural College of Health Sciences, Maebashi, JAPAN,
[2]Graduate School of Radiological Technology, Gunma Prefectural College of Health Sciences, Maebashi, JAPAN.

EP-1032

Optimal Lesion Selection: Time-point dependent correlations of SPECT/CT Uptake with Absorbed Dose to Tumours

B. Fongenie*, N. Scott, F. Friend;*
Blue Earth Therapeutics, Oxford, UNITED KINGDOM.

EP-1033

Renal dosimetry in ^{177}Lu-PSMA-617: What predicts kidney dose?

N. Zindler*, S. Schumann, P. E. Hartrampf, N. Hasenauer, I. Strobel, M. Lassmann, U. Eberlein;*
University Hospital Würzburg, Würzburg, GERMANY.

EP-1034

Dosimetry and Radiation Safety of [^{177}Lu]Lu-PSMA-617 in End-Stage Renal Disease on Hemodialysis: A Three-Cycle Case

A. Al-Balushi*, K. Al-Riyami, N. Al-Maymani, H. Al-Saidi, T. Al-Raii, S. Kheruka, A. Al-Busaidi, A. Jain, N. Al-Makhmari, S. Al-Rashdi, S. Usmani;*
Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City, Muscat, OMAN.

EP-1035

Organs-at-risk (OaR) Dosimetry over the course of Radioligand therapy with ^{177}Lu-PSMA-617 in patients with mCRPC: a single-centre experience

G. Follacchio*[1], G. Rossi[2], F. Chiumiento[1], B. Criscuoli[1], C. Manni[1], S. Fattori[2], M. Santoni[3], L. Servi[4], F. Capoccetti[1];*
[1]Nuclear Medicine Unit, Macerata Hospital, Macerata, ITALY,
[2]Medical Physics Unit, Macerata Hospital, Macerata, ITALY,
[3]Oncology Unit, Macerata Hospital, Macerata, ITALY,
[4]Urology Unit, Macerata Hospital, Macerata, ITALY.

EP-1036

^{177}Lu-DOTATATE Therapy in Metastatic Adrenocortical Carcinoma: Lesion Dosimetry and Clinical Outcome

D. Denizmen Zorba*[1], E. Inal[2], D. F. Arslan[2], B. Kovan[2], Y. Sanli[2];*
[1]Adiyaman Research and Training Hospital Department of Nuclear Medicine, Adiyaman, TÜRKIYE,
[2]Istanbul University Department of Nuclear Medicine, Istanbul, TÜRKIYE.

EP-1037

Predictive value of diagnostic PET with ^{68}Ga DOTATATE/TOC in treatment response to peptide receptor radionuclide therapy (PRRT) with ^{177}Lu-DOTATATE/TOC: a systematic review and meta-analysis.

A. Blesa Jimenez*, Á. Luján Expósito, L. Camacho Berné, V. López Prior, N. Pérez Castro, A. Tembl Ferrairo; Hospital Universitario de la Ribera, Alzira, SPAIN.*

EP-1038

BED-based cross-radionuclide estimation of alpha-PSMA dosing from ^{177}Lu-PSMA dosimetry

H. Liu*[1], C. Lv[2];*
[1]United Imaging Healthcare, Jiading District, Shanghai, CHINA,
[2]School of Biomedical Engineering, Tsinghua University, Haidian District, Beijing, CHINA.

EP-56

D: Technical Studies → D1 Instrumentation → D11 SPECT and SPECT/CT

EP-1039

Scan time and effective dose reduction with a novel tomographic ultra-fast molecular breast imaging system

A. Cherlin*[1], M. Exley[1], N. Atkins[1], K. Erlandsson[2], I. Baistow[1], B. Hutton[2], M. O'Connor[3], C. Hruska[3], K. Thielemans[2];*
[1]Kromek Ltd, Sedgefield, UNITED KINGDOM,
[2]Institute of Nuclear Medicine, University College London, London, UNITED KINGDOM,
[3]Department of Radiology, Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA.

EP-1040

Wide-Energy Sensitivity Enhancement for Small-pixel CZT Camera via Novel Event Split Correction

R. Zananiri*, I. Baum, Y. Hazan;*
GE HeathCare, Haifa, ISRAEL.

EP-1041

^{3}D-ring CZT SPECT/CT quantitative imaging of Lu-177: improving the 113 keV photopeak accuracy with adapted scatter correction method

T. Assoignon*[1], F. Dupont[2], R. Danieli[3], M. Hesse[2];*
[1]UCLouvain, Woluwe-Saint-Lambert, BELGIUM,
[2]Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, BELGIUM,
[3]Hopital Universitaire de Bruxelles, Bruxelles, BELGIUM.

EP-57

D: Technical Studies → D1 Instrumentation → D12 PET/CT

EP-1042

The Effect of Different PET Reconstruction Algorithms Used in New-Generation Digital PET/CT Systems on Semiquantitative Parameters and Their Relationship with Lesion Peripherality

H. Sezgin, *U. Aydos, S. Gülbahar Ateş, E. Balcı, Ü. Ö. Akdemir, L. Ö. Atay;*
Gazi University Faculty of Medicine, Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-1043

Can Scan Time Be Further Reduced in Digital PET/CT ? A Qualitative and Quantitative Evaluation of Clinical Feasibility

B. Yilmaztekin, *G. Uçmak, G. Yilmaztekin, B. B. Demirel; Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, TÜRKIYE.*

EP-1044

The Limited Impact of Precise Cortical Bone Modeling in CT-Derived Attenuation Correction on Brain PET Quantification

J. Ni, *A. Chaban, S. Nekolla;*
Nuclear Medicine Department, TUM Universitäts Klinikum, Munich, GERMANY.

EP-1045

CXCR4-targeted PET/CT with [18F]AlF-NOTA-QHY-04 in Primary Central Nervous System Lymphoma: A Prospective Comparison with MRI and [18F]FDG PET/CT

Y. Pang[1], *P. Liu*[1], *J. Yu*[1], *H. Chen*[2], *J. Liu*[1];
[1]*Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CHINA,* [2]*the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, CHINA.*

EP-1046

First clinical experience and activity reduction with a novel digital BGO detector long axial field-of-view PET-CT system

J. Mostert, *F. Voorhorst, A. van de Burgt, A. A. Harteveld, T. A. Mulders, M. Segbers, F. A. Verburg; Erasmus Medical Center, Rotterdam, NETHERLANDS.*

EP-1047

Optimising Ga-68 PET/CT Quantification: Impact of Acquisition Parameters and Reconstruction Methods on SUV Accuracy in a Phantom Model

M. Al-Qabandi[1], *L. Ghadhanfar*[2], *E. Alawadhi*[2], *T. Taibah Alahmad*[2], *F. Marafi*[3];
[1]*College of Medicine, Kuwait University, Kuwait, KUWAIT,* [2]*College of Allied Health, Kuwait University, Kuwait, KUWAIT,*
[3]*Jaber Al-Ahmad Centre for Nuclear Medicine and Molecular Imaging, Kuwait, KUWAIT.*

EP-1048

Random generation in the axial FOV of a LAFOV scanner and associated consequences for reconstruction protocols

V. Nadig[1,2], *P. Mohr*[1,2], *S. Meaney*[2], *D. Darian*[1], *J. Mackewn*[2], *L. C. Davies*[2], *S. Gould*[2], *G. Krokos*[2], *J. Cabello*[3], *P. Schleyer*[3], *A. Hammers*[2,4,5], *G. J. R. Cook*[2], *P. K. Marsden*[2,6];
[1]*Siemens Healthcare Limited, Camberley, UNITED KINGDOM,*
[2]*King's College London and Guy's & St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UNITED KINGDOM,*
[3]*Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA,*
[4]*Department of Biomedical Computing, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UNITED KINGDOM,*
[5]*Department of Early Life Imaging, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UNITED KINGDOM,*
[6]*Department of Imaging Physics and Engineering, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UNITED KINGDOM.*

EP-1049

SUV Normalisation Bias in PET-CT: A Comparison Between Mobile and Static Units

N. Musa, ***B. Sanghera****, T. Hussain, M. Krishnamurthy; Barts Health NHS Trust, London, UNITED KINGDOM.*

EP-1050

Quantitation of Y90 using Siemens Vision 600 PET/CT

J. Boucek*;*
Royal Perth Hospital, Perth, AUSTRALIA.

EP-1051

AI-Based Metabolic Imaging Biomarkers from F-18 FDG PET/CT for Predicting Pathologic Tumor Regression and Survival after Neoadjuvant Immunochemotherapy in Esophageal Cancer

S. Kim*;*
Pusan National University School of Medicine, Yangsan, KOREA, REPUBLIC OF.

EP-1052

18F-NOTA-FAPI-04 PET/CT in Occult Metastasis Detection and Treatment Planning for Platinum-Sensitive Recurrent Ovarian Cancer: Comparison with Contrast-Enhanced CT

J. Dai, *H. He, C. Jiang, W. Zhou, Y. Zhang, K. Zheng, H. Ye;*
The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University / Hunan Cancer Hospital, Changsha, CHINA.

EP-1053

EARL performance standardisation of a 128 cm long axial FOV digital BGO-based PET/CT system

J. Mostert[1], *D. Kersting*[2], *A. van de Burgt*[1], *E. Zoubenko*[3], *A. Nemirovsky*[3], *F. Kotasidis*[4], *Z. Chalampalakis*[5], *M. Segbers*[1];
[1]*Erasmus Medical Center, Rotterdam, NETHERLANDS,*
[2]*Essen University Hospital, Essen, GERMANY,*
[3]*GE Healthcare, Haifa, ISRAEL,*
[4]*GE Healthcare, Zurich, SWITZERLAND,*
[5]*GE Healthcare, Buc, FRANCE.*

EP-1054

Trop2-targeted PET/CT imaging with 68Ga-MY6349 influences treatment decisions and predicts early response to ADC therapy

H. Chen, *L. Zhao, W. Guo, H. Fu, D. Ruan, H. Wu;*
The First Affiliated Hospital of Xiamen University, Xiamen, CHINA.

EP-1055

Potential for Monitoring Left Ventricular Ejection Fraction Longitudinally Without Attenuation Correction with 82Rb PET

M. Edelbo, *C. Klarskov, M. Nielsen, J. Larsson, B. Zerahn;*
Herlev Hospital, Herlev, DENMARK.

EP-1056

Title: Clinical evaluation of immersive virtual reality for patient support in pet/ct imaging

J. Camara, *Y. Cras, A. Ndoumbe, D. Deandreis; Gustave Roussy, Villejuif, FRANCE.*

EP-58

D: Technical Studies → D1 Instrumentation → D13 PET/MR

EP-1057

Performance evaluation of Deep Progressive Reconstruction versus OSEM algorithms on 18FFDG PET in half-dose PET/MR

H. Ju[1], *Y. Bai*[1], *Y. Zhang*[1], *Y. Wei*[2], *Z. Lin*[2], *Y. Yang*[3], *B. Li*[1];
[1]*Department of Nuclear Medicine, Ruijin Hospital: Shanghai Jiao Tong University Medical School Affili, Shanghai, CHINA,*
[2]*Shanghai United Imaging Healthcare Co., Ltd, Shanghai, CHINA,*
[3]*Beijing United Imaging Healthcare Co., Ltd., Beijing, CHINA.*

EP-1058

Integrated18F-NOTA-FAPI-04 PET/MRI for Complementary Assessment of Disease Activity in Thyroid-Associated Ophthalmopathy

X. Yang[1], *X. Shi*[1], *L. Gan*[1], *M. Wu*[1], *H. Xing*[1], *E. Li*[2], *Z. Hao*[1], *Y. Zhang*[1], *L. Huo*[1];
[1]*Peking Union Medical Collage Hospital, Beijing, CHINA,*
[2]*Shanghai United Imaging Healthcare Co., Ltd., Shanghai, CHINA.*

EP-1059

Integrating Multi-Organ and Peri-Organ Adipose Tissue Features for Lung Cancer : A Study Based on Simultaneous PET/MR

N. Meng[1], *J. Kong*[1], *X. Yu*[1], *F. Fu*[1], *Z. Wang*[2], *Y. Yang*[3], *Q. Ji*[2], *M. Wang*[1];
[1]*Henan Provincial People's Hospital, Zhengzhou, CHINA,*
[2]*Central Research Institute, United Imaging Healthcare Group, Shanghai, Shanghai, CHINA,*
[3]*Beijing United Imaging Healthcare Co., Ltd, Beijing, CHINA.*

EP-1060

Multi-Organ PET/MR Information for Characterizing Lung Cancer Pathology on Simultaneous PET/MR

N. Meng[1], *J. Jing*[1], *Z. Wang*[2], *Q. Ji*[2], *X. Yu*[3], *Y. Yang*[4], *M. Wang*[1];
[1]*Henan Provincial People's Hospital, Zhengzhou, CHINA,*
[2]*Central Research Institute, United Imaging Healthcare Group, Shanghai, Shanghai, CHINA,*
[3]*Henan Provincial People's Hospital, Zhengzhou, CHINA,*
[4]*Beijing United Imaging Healthcare Co., Ltd, Beijing, CHINA.*

EP-1061

Enhanced Reader Confidence and Reliability of Binary Visual Interpretation with MR-Guided TOF-BSREM Reconstruction in [18F]Flutemetamol PET/MR: A Retrospective Two-Center Study

J. Inoue Inukai[1], *M. Nogami*[2,3], *N. Sugiyama*[1], *F. Zeng*[2], *K. Kubo*[2], *T. Kurimoto*[4], *F. Kotasidis*[5], *M. Spangler-Bickell*[5], *M. W. Huellner*[6], *T. Murakami*[1,2];
[1]*Department of Radiology, Kobe University Graduate School of Medicine, Kobe, JAPAN,*
[2]*Department of Radiology, Kobe University Hospital, Kobe, JAPAN,*
[3]*Division of Medical Imaging, Biomedical Imaging Research Center, University of Fukui, Fukui, JAPAN,*
[4]*GE Healthcare, Hino, JAPAN,*
[5]*GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA,*
[6]*Department of Nuclear Medicine, University Hospital Zurich and University of Zurich, Zurich, SWITZERLAND.*

EP-1062

The Value of Multiparametric Imaging Data in Predicting High-Grade Prostate Cancer: An integrated PSMA PET/MR study

S. Liu[1], *Y. Yang*[2], *L. Qi*[3], *S. Song*[1], *H. Yi*[1];
[1]*Department of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hang Zhou, CHINA,*
[2]*Beijing United Imaging Healthcare Technology Development Co., Ltd., Beijing, CHINA,*
[3]*United Imaging Healthcare, Shanghai, CHINA.*

EP-1063

Standard versus extended PET Acquisition in [18F] Fluorocholine PET/MR for Parathyroid Imaging

S. Isenschmid*;*
University Hospital Zurich, Zurich, SWITZERLAND.

EP-1064

Dynamic Association Between Microenvironment and Pathological Protein Deposition in Alzheimer's Disease: A Preliminary Study Using Integrated PET/MR

X. Zhang[1], *S. Zhang*[1], *X. Su*[2], *Y. Yang*[2], *X. Du*[1], *H. Feng*[1], *C. Yang*[1];
[1]*First Affiliated Hospital of Dalian Medical University, Dalian, CHINA,*
[2]*Beijing United Imaging Healthcare Technology Development, Beijing, CHINA.*

EP-1065

Added Value of Delayed Diuretic PET/MRI over Delayed Diuretic PET/CT inthe Evaluation of Carcinoma Urinary Bladder: A Prospective ComparativeStudy

P. Shinkar[1], *M. Vamsy*[1], *D. Kumar*[2], *P. Wadhwa*[2], *L. Somepalli*[1], *V. R. Parapati*[3];
[1]*Omega Hospital, Hyderabad, INDIA,*
[2]*United Imaging Healthcare, Delhi, INDIA,*
[3]*Omega Hospital, Hyderabad, INDIA.*

EP-1066

Work Demands, Resources, Workload and Fatigue Among Healthcare Professionals During Peri-Procedural Positron Emission Tomography/ Magnetic Resonance Imaging: A Qualitative Study

L. Xia, *X. Wu, M. Li;*
Department of Radiology Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, CHINA.

EP-59

D: Technical Studies → D1 Instrumentation → D14 Imaging Guided Surgery and Other Instruments

EP-1067

Characterization of an Intravital Theranostic Imaging Camera

N. Rathod[1], *K. Shi*[1], *A. Rominger*[1], *K. Pandya*[1], *J. Hu*[1], *R. Seifert*[1], *R. Ni*[1], *M. kruithof-de julio*[1], *J. Wang*[1], *C. Clement*[1], *J. Moore*[2], *B. Miller*[2], *B. Hunkeler*[3], *C. Mueller*[3], *A. Benechet*[4], *D. Viertl*[5];
[1]*University of Bern (Department of Nuclear Medicines) / Inselpsital Bern Switzerland, 3012, SWITZERLAND,*
[2]*QScint Imaging Solutions, Tucson, AZ, 85704, AZ, UNITED STATES OF AMERICA,*
[3]*Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland, 5232, SWITZERLAND,*
[4]*In Vivo Imaging Facility (IVIF), Department of Research and Training, Lausanne University Hospital and University of Lausanne, Lausanne, 1011, SWITZERLAND,*
[5]*Translational Radiopharmaceutical Sciences, Department of Nuclear Medicine, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, SWITZERLAND.*

EP-1068

Optimizing Radiation Protection for Intraoperative Micro-PET/CT in Head and Neck Cancer Surgery

S. Hapdey[1], *A. Berghian*[2], *D. Richard*[3], *E. Lévêque*[3], *R. Elaldi*[2], *F. Clatot*[4], *L. Roussel*[4];
[1]*Henri Becquerel Cancer Center, Imaging department & QuantIF-LITIS, Rouen, FRANCE,*
[2]*Henri Becquerel Cancer Center, Rouen, FRANCE,*
[3]*Henri Becquerel Cancer Center, Clinical Research Unit, Rouen, FRANCE,*
[4]*Henri Becquerel Cancer Center & Inserm U1245, Rouen, FRANCE.*

EP-1069

Beta Radio-Guided surgery in patients with pulmonary NET eligible for radical surgery

E. d'Ippolito[1], *P. Paravani*[2], *V. Bentivoglio*[1], *F. Collamati*[3], *R. Mirabelli*[4], *R. Faccini*[5], *F. Nicolanti*[5], *M. Tiracorrendo*[6], *M. Ibrahim*[6], *C. Lauri*[1], *V. Brainovich*[7], *A. Faggiano*[2], *M. Mancini*[8], *A. Signore*[1], *C. Bolzan*[7], *C. Mancini*[2], *D. Prosperi*[1];
[1]*Nuclear Medicine Unit, Sant'Andrea University Hospital of Rome, Department of Medical-Surgical Sciences and Translational Medicine of "Sapienza" University of Rome, Rome, ITALY,*
[2]*Endocrinology Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant'Andrea Hospital, ENETS Center of Excellence, Rome, ITALY,*
[3]*Italian Institute For Nuclear Physics, INFN, Section of Rome, Rome, ITALY,*
[4]*ENEA-INMRI, National Institute of Ionizing Radiation Metrology, Rome, ITALY,*
[5]*Department of Physics, University of Rome La Sapienza, Rome, ITALY,*
[6]*Department of Thoracic Surgery, Sant'Andrea Hospital, Sapienza University, Rome, ITALY,*
[7]*Medical Physics Dept., Sant'Andrea Hospital Rome, Rome, ITALY,*
[8]*Morphologic and Molecular Pathology Unit, Sant'Andrea Hospital, Rome, ITALY.*

EP-1070

Potential for Radioguided Surgery Based on Internal Conversion Electron Detection Using a Compact CMOS Detector

J. Moo[1], *J. Bordes*[2], *S. Yau*[3], *P. A. Marsden*[4], *E. Marimón Muñoz*[4], *R. R. Thomson*[3], *A. J. Reader*[5], *P. K. Marsden*[5], *D. G. Jenkins*[2], *K. Vyas*[1];
[1]*Telix Pharmaceuticals UK, London, UNITED KINGDOM,*
[2]*School of Physics, Engineering and Technology, University of York, York, UNITED KINGDOM,*
[3]*School of Engineering and Physical Sciences, Herriot-Watt University, Edinburgh, UNITED KINGDOM,*
[4]*Unitive Design & Analysis Ltd, London, UNITED KINGDOM,*
[5]*School of Biomedical Engineering and Imaging Sciences, King's College London, London, UNITED KINGDOM.*

EP-1071

Clinical application of a novel SFOV hybrid optical-gamma camera in the nuclear medicine clinic

A. Ng[1], *M. Sofian*[1], *I. Md Musidek*[1], *M. Md Shah*[1], *C. Yeong*[2], *A. Perkins*[3];
[1]*Universiti Malaya, Kuala Lumpur, MALAYSIA,*
[2]*Taylor's University, Subang Jaya, MALAYSIA,*
[3]*Universiti of Nottingham, Nottingham, UNITED KINGDOM.*

EP-60

D: Technical Studies → D1 Instrumentation → D15 Quality Control, Performance and Standardization

EP-1072

A Reproducible and Quantitatively Accurate Digital Phosphor Imaging Workflow for Pre-Clinical Radiopharmaceutical Autoradiography

E. D'ercole[1], *A. Florit*[2,3], *D. Nardi*[4], *M. R. Ruggiero*[5], *L. Alic*[6], *F. H. P. Van Velden*[7], *L. De Geus-Oei*[3,8,9], *L. Indovina*[10,11], *M. De Spirito*[10,11], *A. Collarino*[2], *R. Moretti*[11], *A. Capotosti*[11];
[1]*University of Twente, Enschede, NETHERLANDS,*
[2]*Nuclear Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,*
[3]*Biomedical Photonic Imaging Group, University of Twente, Enschede, NETHERLANDS,*
[4]*PET/CT Centre, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,*
[5]*PET/CT Centre, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, ITALY,*
[6]*Magnetic Detection & Imaging Group, Technical Medical Centre, University of Twente, Enschede, NETHERLANDS,*
[7]*Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Centre, Leiden, NETHERLANDS,*
[8]*Section of Nuclear Medicine, Leiden University Medical Center, Leiden, NETHERLANDS,*
[9]*Department of Radiation Science and Technology, Delft University of Technology, Delft, NETHERLANDS,*
[10]*Università Cattolica del Sacro Cuore, Rome, ITALY,*
[11]*Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY.*

EP-1073

Image quality and quantitative accuracy of a rotating dual-head benchtop PET: a comparative study to standard preclinical PET/CT and PET/MRI systems

T. Balber[1,2], *I. Rausch*[3], *T. Wanek*[4], *T. H. Helbich*[5], *M. Hacker*[1], *J. Friske*[4], *C. Kuntner*[4];
[1]*Divison of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA,*
[2]*Joint Applied Medicinal Radiochemistry Facility, Vienna, AUSTRIA,*
[3]*QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA,*
[4]*Preclinical Imaging Lab (PIL), Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA,*
[5]*Division of General and Paediatric Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.*

EP-1074

Improving patient safety through structured internal audit in 18FFDG PET/CT imaging

S. Patel;
The Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM.

EP-1075

Conversational Large Language Model-Assisted Workflow for Multi-Tracer PET/CT Report Standardisation in the Absence of Dedicated Deep Learning Software: A Quality Improvement Experience Including Hallucination Identification and Multilingual Application.

E. Ibrahim, *E. Alper;*
Department of Nuclear Medicine, Bursa Uludağ University Faculty of Medicine, Bursa, TÜRKIYE.

EP-1076

^{3}D-Printed Refillable Phantom with Replaceable Spheres: A Flexible Alternative to NEMA IEC Phantoms

A. Bartrés Salido, *N. Garcia Apellaniz, P. Liñan Rodriguez, C. Fernandez Leira, M. Sanchez Casi, S. Panzuela Perez, M. Lamaison Vidarte, V. Alba Esocrihuela, V. Pastor i Sanchis, M. Erzilbengoa Izaguirre, M. Alonso Etxarri;*
Hospital Universitario Donostia, San Sebastián, SPAIN.

EP-1077

UKPET-CT Service Quality: A Review of the Effect of Increased Activity and Reporter Numbers over 10 years

P. Strouhal[1,2], *M. Ferreira*[1], *I. Lyburn*[3,4,5], *K. Bradley*[6], *F. Gleeson*[7];
[1]*Alliance Medical Ltd, Warwick, UNITED KINGDOM,*
[2]*Russells Hall NHS Trust, Dudley, UNITED KINGDOM,*
[3]*Glouscester Hospitals NHS Trust, Cheltenham, UNITED KINGDOM,*
[4]*Cobalt Medical Charity, Cheltenham, UNITED KINGDOM,*
[5]*Cranfield University, Cranfield, UNITED KINGDOM,*
[6]*University Hospital Wales, Cardiff, UNITED KINGDOM,*
[7]*Oxford University Hospitals, Oxford, UNITED KINGDOM.*

EP-1078

Carrier-Solution Dependent Adsorption of [^{177}Lu] Lu-DOTA-TOC in Phantom Materials

A. Theisen[1], *L. Jessen*[2], *E. Larsson*[2], *P. Otto*[3], *U. Gbureck*[3], *J. Gustafsson*[2], *J. Stenhammar*[4], *J. Tran-Gia*[1], *K. Sjögreen-Gleisner*[2];
[1]*Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,*
[2]*Medical Radiation Physics Lund, Lund University, Lund, SWEDEN,*
[3]*Department for Functional Materials in Medicine and Dentistry, University Hospital Würzburg, Würzburg, GERMANY,*
[4]*Division of Physical Chemistry, Lund University, Lund, SWEDEN.*

EP-1079

Adsorption of [^{18}F]-Florbetaben on Medical Devices: Influence of Material and Injection Configuration

M. Aouaouche, *J. Fouillet, L. Barthelemi, D. Alize;*
Radiopharmacy unit, Pharmacy, Nîmes University Hospital, Nimes, FRANCE.

EP-1080

A Real-Time Count Rate Threshold for Lung Perfusion SPECT/CT Quality: Multi-Reader Cohort Insights into Tc-99m-MAA Batch Stability and Patient-Level Determinants

C. Turkan, *A. Aydın, Y. Eryılmaz, M. F. Bozkurt, P. Özgen Kıratlı, M. Tuncel;*
Hacettepe University, Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-1081

Reconstruction optimization of bone SPECT/CT image in a full-ring CZT-based system: a phantom study.

M. Yáñez Barro[1], *R. Cuevas Jurado*[1], *E. Prieto*[1], *R. Alarcón Ros*[2], *J. Martí-Climent*[1];
[1]*Clínica Universidad de Navarra, Pamplona/Iruña, SPAIN,*
[2]*Hospital Universitario Son Espases, Palma, SPAIN.*

EP-1082

Energy-based Discrimination of ^{89}Zr and ^{18}F Activity in Blood Samples using a Gamma Counter

A. Elkayee Dehno[1], *L. Pot-de Jong*[2], *D. R. Overbeek*[1], *R. Zijlma*[1], *M. L. Achterkamp*[1], *J. van Sluis*[1], *A. A. Lammertsma*[1], *A. H. Brouwers*[1], *C. Tsoumpas*[1];
[1]*University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Groningen, NETHERLANDS,*
[2]*University of Groningen, University Medical Center Groningen, Department of Medical Oncology, Groningen, NETHERLANDS.*

EP-1083

The influence of ^{177}Lu-DOTA-TATE radioligand therapy peak selection on image quality and clinical diagnosis

S. Sun, *D. Zhao, Y. Dong, Y. Wang, J. Liu, R. Wang;*
Chinese PLA General Hospital, Beijing, CHINA.

EP-1084

Quantitative performance of P-32 SPECT/CT in microparticle brachytherapy: comparison of clinical and high-statistics phantom imaging

A. Capotosti[1], *R. Moretti*[1], *B. Cassano*[2], *G. Santi Amantini*[3], *T. Scotognella*[1], *M. Felicetti*[1], *D. Fortini*[1], *M. Calcagni*[4,1], *M. De Spirito*[4,1], *L. Indovina*[4,1];
[1]*Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY,*
[2]*IRCCS Regina Elena National Cancer Institute, Rome, ITALY,*
[3]*Post Graduation School of Medical Physics, Tor Vergata, Rome, ITALY,*
[4]*Università Cattolica del Sacro Cuore, Rome, ITALY.*

EP-1085

Radionuclide Roulette: Investigating the Accuracy of Lutetium-177 Measurements

I. Taschwer, *M. Mitterhauser, L. Nics;*
Medical University of Vienna, Vienna, AUSTRIA.

EP-1086

Injection-Site Extravasation in ^{18}F-FDG PET/CT: Quantification and Impact on SUV

L. Sobral Torres, *R. Albergueiro, R. Nunes, J. Veloso Trevisan, H. Martins;*
ULS S.João, Porto, PORTUGAL.

EP-1087

Estimation of Effective Image Resolution on a PET/CT Scanner Using a Jaszczak Phantom in Comparison with Hoffman Phantom Evaluation

K. Hirschmüller, *E. Prieto;*
Clínica Universidad de Navarra, Pamplona, SPAIN.

EP-1088

Quantitative Characterization of the MEDISO AnyScan TRIO Theramax for ^{177}Lu SPECT/CT: ListModeBased AcquisitionTime Optimization of Noise Behavior and Recovery Coefficients

D. Schmidt, *S. Krottenthaler, J. Degenhart, D. Hellwig;*
Universitätsklinikum Regensburg, Regensburg, GERMANY.

EP-1089

Analysis of the elution performance of three TiO_2-based ^{68}Ge/^{68}Ga generators following reversals of the inlet and outlet HCl 0.1% ports

M. Aouaouche, *Y. Elaroui, O. Perrin, J. Sekkar, J. Fouillet, L. Barthelemi, D. Alize;*
Radiopharmacy unit, Pharmacy, Nîmes University Hospital, Nimes, FRANCE.

EP-1090

Evaluation of the depth-response curve in the quality control of gamma probes for radioguided surgery: assessment of a brand-new setup

A. Pisani[1], *M. L. Modugno*[2], *A. Terlizzi*[2], *M. Leo*[2], *F. Iuele*[2], *C. Altini*[2], *S. Sisto*[2], *V. De Nittis*[2], *G. Rubini*[1];
[1]*University of Bari, Bari, ITALY,*
[2]*Policlinico of Bari, Bari, ITALY.*

EP-1091

Introduction of Ge-68 Line Source as an Alternative for Constancy Testing of Dose Calibrators in Nuclear Medicine

S. Alanazi[1], *O. Noor*[1], *B. Alhuzaimy*[2], ***A. Alosaimi***[1], *R. Aldamuk*[1], *A. Almujally*[1], *A. Sulieman*[1], *K. Theodorou*[1];
[1]*King Faisal Specialist Hospital and Research Centre, Department of Biomedical Physics, Riyadh, SAUDI ARABIA,*
[2]*King Faisal Specialist Hospital and Research Centre, Department of Radiation Therapy, Riyadh, SAUDI ARABIA.*

EP-1092

Hospital-based three-dimensional printing in Nuclear Medicine and Radiopharmacy: three operational applications

M. Rosado Hidalgo, *E. Martel Gimeno, V. Pascual Pascual, M. S. Batista Herrera, M. Azkonobieta Carballo, C. Garrido Bretón, L. M. Ramos Rodríguez, S. Romero Acevedo, J. F. Vela León, M. F. Lara Martínez, M. A. González Díaz, C. Sabin San Julián, F. Medina Romero;*
Hospital Universitario de Canarias HUC, Tenerife, SPAIN.

EP-1093

Optimization of ^{68}Ga-PSMA PET/CT Acquisitions Using Quantitative and Qualitative Metrics: A Clinical and Phantom Study

I. Macdonald, *L. Sept, E. Henry, S. Burrell;*
Dalhousie University, Halifax, NS, CANADA.

EP-1094

Comprehensive Validation of Quantitative Reconstruction for ^{177}Lu SPECT/CT Imaging Using Phantom-Based Accuracy Assessment

L. Lampertico[1,2], *G. Muti*[2], *C. Carbonini*[2], *C. Romanò*[2], *A. Scarale*[3], *P. Colombo*[2], *C. Rossetti*[3];
[1]*Università degli Studi di Milano, Milano, ITALY,*
[2]*S.C. Fisica Sanitaria, ASST GOM Niguarda, Milano, ITALY,*
[3]*S.C. Medicina Nucleare, ASST GOM Niguarda, Milano, ITALY.*

EP-1095

Breathing Life into Phantoms: Galligas for PET-CT Lung Imaging

J. Gladstone, *E. Aveyard, D. Dixon, L. Rowley;*
University Hospitals Coventry & Warwickshire, Coventry, UNITED KINGDOM.

EP-1096

Pre-imaging assessment of ^{18}F-based tracer injection failure

I. Baltabaev, *A. Khalimon, A. Nikiforuk, M. Khodzhibekova, I. Pylova, T. Lazutina, D. Khodakova, A. Leontev;*
P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

EP-1097

Comparative Study between QC1-Automated System and Standard Procedures for Radiopharmaceuticals: A Focus on [^{18}F]DPA-714

L. Pineda[1], *C. Coulon*[1], *Y. Zandona*[2], *B. Kuhnast*[1];
[1]*BioMaps, CEA, Université Paris Saclay, Orsay, FRANCE,*
[2]*Trasis, Liège, BELGIUM.*

EP-1098

Performance Characterization of a 64 cm Extended Axial Field-of-View digital BGO-Based PET/CT Scanner Based on NEMA NU-2024 standard

V. Treyer[1], *A. Nemirovsky*[2], *Y. Barak*[2], *I. Baum*[2], *F. Kotasidis*[3], *P. A. Kaufmann*[1], *M. W. Huellner*[1];
[1]*Department of Nuclear Medicine, University Hospital Zurich, Zürich, SWITZERLAND,*
[2]*GE Healthcare, Haifa, ISRAEL,*
[3]*GE Healthcare, Zürich, SWITZERLAND.*

EP-1099

Impact of Extending Axial FOV on PET Quantification: Validation of EARL 2.0 Harmonization Across a Shared Hardware Platform

Y. Zhao, *Y. Wu, J. Li, N. Li, H. Yi, Q. Ge, L. He, Y. Dong;*
Shanghai United Imaging Healthcare Co., Ltd., Shanghai, CHINA.

EP-1100

Efficiency Gains in Hybrid Human-AI FDG PET/CT Reporting for Breast Cancer: A Blinded Multireader Study Using Imange-Based Large Language Model Prompting

M. Heide, *S. L. Dreier, A. Rominger, A. Afshar-Oromieh, R. Seifert, K. Shi, W. A. Bosbach;*
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.

EP-1101

Dynamic renal imaging with a ^{3}D-ring SPECT using a novel dynamic renal phantom: comparison with a ^{2}D CZT system

H. Suoraniemi[1], *S. Arvola*[1], *M. Seppänen*[2], *T. Noponen*[1];
[1]*Department of Clinical Physiology, Nuclear Medicine, Turku PET Centre and Medical Physics, Turku University Hospital and Wellbeing Services county of Southwest Finland, Turku, FINLAND,*
[2]*Department of Clinical Physiology, Nuclear Medicine and Turku PET Centre, Turku University Hospital and Wellbeing Services county of Southwest Finland, Turku, FINLAND.*

EP-1102

EARL Compliance Assessment of a 64 cm digital BGO-based Long Axial Field of View PET/CT System: A Comprehensive Phantom Based Evaluation

V. Treyer[1], *E. Zoubenko*[2], *A. Nemirovsky*[2], *F. Kotasidis*[3], *V. Ferri*[4], *P. A. Kaufmann*[1], *M. W. Huellner*[1];
[1]*Department of Nuclear Medicine, University Hospital Zurich, Zürich, SWITZERLAND,*
[2]*GE Healthcare, Haifa, ISRAEL,*
[3]*GE Healthcare, Zürich, SWITZERLAND,*
[4]*GE Healthcare, Milan, ITALY.*

EP-1103

Optimization and preliminary validation of a time-reduced [^{99m}Tc]Tc-HMDP bone SPECT/CT protocol on CZT cameras in mCRPC

Y. Cras, *C. Besnier, H. Noamen, S. Bouaziz, P. Lacassagne, L. Ferreol, C. Garcia, D. Deandreis; Gustave Roussy, Villejuif, FRANCE.*

EP-1104

Optimization and Validation of Quantitative ^{177}Lu-DOTATATE SPECT Imaging for Translational Dosimetry

A. Littau, *L. Hvass, J. Mortensen, E. Christensen, A. Clemmensen, A. Kjaer;*
Department of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, DENMARK.

EP-1105

Optimization of Plastic Scintillator Dimensions for High-Energy Gamma Photon Detection: A Geant4 Monte Carlo Simulation Study for TLC Scanner Development

A. Jha[1,2], *L. Nawale*[1,2], *S. R. Ghag*[1,2], *A. Jain*[3], *N. Purandare*[1,2], *P. K. Mohanty*[3], *V. Rangarajan*[1,2];
[1]*Tata Memorial Hospital, Tata Memorial Centre, Mumbai, INDIA,*
[2]*Homi Bhabha National Institute, Mumbai, INDIA,*
[3]*Tata Institute of Fundamental Research, Mumbai, INDIA.*

EP-1106

Cross-calibration of dose calibrators with a gamma counter for ^{68}Ga measurements

T. Assoignon[1], *F. Dupont*[2], *M. Hesse*[2];
[1]*UCLouvain, Woluwe-Saint-Lambert, BELGIUM,*
[2]*Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, BELGIUM.*

EP-1107

Local harmonisation of multiple radionuclide calibrators in a PET department: ensuring device interchangeability and reproducible PET quantification

I. Baltabaev, *A. Khalimon, A. Nikiforuk, M. Khodzhibekova, I. Pylova, T. Lazutina, D. Khodakova, A. Leontev;*
P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

EP-1108

Evolution of Routine Quality Control Data for Assessing Long-Term Performance Stability in a SPECT/CT System

M. Alezzi, *H. Yamani, F. Alshareef, A. Bantan;*
King Abdullah Medical City, Makkah, SAUDI ARABIA.

EP-61

D: Technical Studies → D2 Data Analysis and Artificial Intelligence → D21 Image Reconstruction / Denoising / Filtering

EP-1109

Clinical Evaluation of a Trimodal Wavelet Diffusion Model for Synthetic CT Generation from Uncorrected [^{68}Ga]Ga-PSMA11 PET.

J. Mitura[1], *J. Wybranska*[1], *B. Klein*[1], *M. Schaefer*[2], *M. C. Kreissl*[1];
[1]*Division of Nuclear Medicine, Department of Radiology & Nuclear Medicine, Faculty of Medicine, Otto von Guericke University Magdeburg, Magdeburg, GERMANY,*
[2]*Otto von Guericke University Magdeburg, Magdeburg, GERMANY.*

EP-1110

Physics-Informed ^{3}D Diffusion Reconstruction for Ultra-Low-Count SPECT in Alpha Therapy Dosimetry using Patient-Specific Learning

A. Lopez Montes[1,2], *A. Delker*[3], *D. Groschupf*[3], *K. Ramonaheng*[4,5,5], *R. Seifert*[1], *S. Resch*[3], *A. Rominger*[1], *M. Sathekge*[4], *G. Boening*[3], *A. Afshar-Oromieh*[1], *K. Shi*[1,2];
[1]*Department of Nuclear Medicine, University Hospital Bern, University of Bern, Bern, SWITZERLAND,*
[2]*Department of Digital Medicine, University of Bern, Bern, SWITZERLAND,*
[3]*Department of Nuclear Medicine, LMU Hospital, Munich, GERMANY,*
[4]*Nuclear Medicine Research Infrastructure (NuMeRI), Pretoria, SOUTH AFRICA,*
[5]*Department of Nuclear Medicine, University of Pretoria, Pretoria, SOUTH AFRICA.*

EP-1111

Impact of Deep Learning Denoising on Time Activity Curves and Dosimetric Accuracy in Preclinical Theranostic SPECT

E. Taragola[1], *A. Meskens*[1], *F. M. Muller*[1,2], *S. Neyt*[1], *M. Abi Akl*[1], *F. De Vos*[1], *S. Vandenberghe*[1], *C. Vanhove*[1];
[1]*Ghent University, Ghent, BELGIUM,*
[2]*University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.*

EP-1112

Clinical Impact of Reduced Acquisition Time in Bone Scintigraphies Using a Deep Learning Noise Reduction Algorithm and a 360° CZT SPECT/CT Camera System

A. Sher[1,2], *M. Léger*[1,2], *A. Desy*[1,2], *D. Juneau*[1,2];
[1]*Centre Hospitalier de l'Université de Montréal, Montréal, QC, CANADA,*
[2]*Centre de recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC, CANADA.*

EP-1113

Variability and consistency of respiratory motion correction strategies in long axial field-of-view PET/CT: an intra-patient analysis

A. Spataro, *S. Capitanio, A. Scarale, A. Franchini, L. Airò Farulla, M. Cuomo, G. Cabrini, E. Gay, K. Shyli, C. Rossetti;*
Nuclear Medicine Unit, Dipartimento Ematologia, Oncologia e Medicina Molecolare, ASST Niguarda, Milano, ITALY.

EP-1114

Improving Image Quality and Lesion Conspicuityin Breast Cancer Using a Probabilistic Post-Reconstruction Algorithm for [^{18}F]FDG PET/CT

N. Christensen[1], *A. H. Dias*[1,2], *H. D. Zacho*[3,4], *M. H. Vendelbo*[1,2], *T. M. Hansen*[2];
[1]*Aarhus University Hospital, Aarhus N, DENMARK,*
[2]*Aarhus University, Aarhus C, DENMARK,*
[3]*Aalborg University Hospital, Aalborg, DENMARK,*
[4]*Aalborg University, Aalborg, DENMARK.*

EP-1115

List-Mode Versus Sinogram-based Reconstruction for Count Reduced Brain PET Quantification

A. Sanaat[1], *Y. Salimi*[1], *H. Sari*[2], *D. Bharkhada*[3], *V. Garibotto*[1], *H. Zaidi*[1];
[1]*University of Geneva, Geneva, SWITZERLAND,*
[2]*Siemens Healthineers International, Zurich, SWITZERLAND,*
[3]*Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA.*

EP-1116

Comparative Study of Spatial Feature Transformation Network (SFT) in Ultra-High-Resolution Reconstruction of ^{18}F-AV45 PET Images

W. Bin[1], *Y. Shaozhen*[1], *G. Cui*[2], *P. Boyang*[3], *G. Nanjie*[2], *L. Jie*[1];
[1]*Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, CHINA,*
[2]*Shanghai Key Laboratory of Magnetic Resonance, School of Physics, East China Normal University, Shanghai, CHINA,*
[3]*Shanghai Yingdong Medical Technology Co., Ltd., Shanghai, CHINA.*

EP-1117

DL-SC: A Deep Learning-Based Scatter Correction Method for Quantitative ^{177}Lu SPECT/CT Imaging

J. Leube[1], *A. Theisen*[1], *A. Gehring*[1], *J. Gustafsson*[2], *M. Salas-Ramirez*[1], *J. Tran-Gia*[1];
[1]*Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,*
[2]*Medical Radiation Physics Lund, Lund University, Lund, SWEDEN.*

EP-1118

Impact of Count Statistics on ^{225}Ac-SPECT/CT Reconstructions

W. Claeys, *M. Koole;*
KULeuven, Leuven, BELGIUM.

EP-1119

AI-based CT-less attenuation correction for brain amyloid PET: impact on Centiloid quantification

L. Partin[1], *R. Fahmi*[1], *M. Georgiou*[2], *B. Spottiswoode*[1];
[1]*Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA,*
[2]*University of Miami Miller School of Medicine, Department of Radiology / Nuclear Medicine, Miami, FL, UNITED STATES OF AMERICA.*

EP-1120

Quantitative and Operational Benefits of Artificial Intelligence (AI) -Integrated Positron Emission Tomography/Computed Tomography (PET/CT): A Comparative Pre- and Post-Implementation Study

E. Skoura, *G. Thiveos, I. Aroni, I. Papantoniou, A. Kokkini-Paschou, G. Georgoulas, J. Koutsikos, I. Datseris;*
Theranostics Nuclear Medicine Center, Henry Dunant Hospital Center, Athens, GREECE.

EP-1121

When Is Synthetic PET Truly Recoverable? A Physics-Grounded Roadmap for PET Image Translation

M. Salmanpour[1,2,3], *C. Uribe*[1,2], *A. Rahmim*[1,2];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,*
[2]*University of British Columbia, Vancouver, BC, CANADA,*
[3]*Technological Virtual Collaboration Company (TECVICO CORP.), Vancouver, BC, CANADA.*

EP-1122

Deep Learning reconstruction supports reduced acquisition time for Bone SPECT

I. Handford[1], *M. Khonsari*[1], *A. Vasiljevic*[2], *E. Comber*[2], *L. Rowley*[2], *D. R. McGowan*[1,3];
[1]*Oxford University Hospitals, Oxford, UNITED KINGDOM,*
[2]*University Hospitals Coventry and Warwickshire, Coventry, UNITED KINGDOM,*
[3]*Department of Oncology, University of Oxford, Oxford, UNITED KINGDOM.*

EP-1123

Preliminary evaluation of an automated patient-specific delay for reconstruction of static relative perfusion images in cardiac PET

I. Armstrong[1], *C. Hayden*[2], *P. Arumugam*[1];
[1]*Manchester University NHS Foundation Trust, Manchester, UNITED KINGDOM,*
[2]*Siemens Healthineers, Knoxville, TN, UNITED STATES OF AMERICA.*

EP-1124

PET listmode-only global motion detection,characterizationand correction for single and multibed totalbody PET

A. Hanuka[1], *M. Qvarfort*[2], *B. Yuzefovich*[1], *A. Lulinksy*[1], *G. Kovalski*[1];
[1]*GE Healthcare, Haifa, ISRAEL,*
[2]*GE Healthcare, Ekerö, SWEDEN.*

EP-1125

Comparison of OSEM-Based Reconstruction Strategies and HYPER Iterative Reconstruction for ^{18}F-FAPI PET/MR Myocardial Imaging in Myocardial Infarction

P. Guo[1], *X. Su*[2], *Y. Yang*[2], *S. Zhang*[1];
[1]*First Affiliated Hospital of Dalian Medical University, Dalian, CHINA,*
[2]*Beijing United Imaging Healthcare Technology Development Co., Ltd., Beijing, CHINA.*

EP-1126

Simultaneous SPECT Reconstruction of Ac-225 Daughter Distributions for Bi-213 Translocation Assessment Using Monte Carlo-Based Radiation Transport in Torch® Recon

L. Polson[1], *F. J. Wilson*[1], *S. Graves*[2];
[1]*Voximetry, Madison, WI, UNITED STATES OF AMERICA,*
[2]*University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA.*

EP-1127

Deep Learning-Based Denoising and Deblurring of Short-Duration PET Images Using Monte Carlo Simulations

P. Iosifidis[1], *B. Presles*[1], *A. Merlet*[2], *N. Payan*[1], *L. Morin*[1], *A. Cochet*[1], *J. Vrigneaud*[1];
[1]*Université Bourgogne Europe, Dijon, FRANCE,*
[2]*CMKL University, Bangkok, THAILAND.*

EP-1128

Performance Evaluation of the BSREM Algorithm for Quantitative ^{99}mTc-imaging on a ring-configured CZT system

I. Ceric Andelius[1,2], *P. Kalaitzidis*[1,3], *E. Nilsson*[1], *J. Oddstig*[1,2], *J. Gustafsson*[3];
[1]*Radiation Physics, Department of Haematology, Oncology, and Radiation Physics, Skåne University Hosp, Lund, SWEDEN,*
[2]*Department of Translational Medicine and Wallenberg Centre of Molecular Medicine, Lund, SWEDEN,*
[3]*Medical Radiation Physics, Lund, Lund University, Lund, SWEDEN.*

EP-1129

Quantitative Impact of AI-Based Motion-Corrected Reconstruction on Lesion-Level [^{18}F]FDG PET/CT Metrics: A Retrospective Paired Analysis

B. Canitez, *H. USLU;*
Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Istanbul, TÜRKIYE.

EP-1130

Relaxing the Uniformity Assumption Stabilises Region-Based Partial-Volume Correction

J. Gustafsson[1], *E. Larsson*[2], *K. Sjögreen Gleisner*[1];
[1]*Lund University, Lund, SWEDEN,*
[2]*Skåne University Hospital, Lund, SWEDEN.*

EP-1131

The added value of Deep Learning based TOF to Data Driven Respiratory Motion Correction versus Prolonged Acquistion Time in PET/CT: Impact on Noise Level, Lesion Size and SUVmean in Lung Cancer

A. Nasr[1], *R. Fendi*[1], *U. Bitzén*[1], *A. Stenvall*[2], *S. Kvernby*[2,3];
[1]*Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund University, Lund, SWEDEN,*
[2]*Radiation Physics, Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, SWEDEN,*
[3]*Department of Translational Medicine and Wallenberg Centre of Molecular Medicine, Lund University, Malmö, SWEDEN.*

EP-1132

Mitigating Motion in Dopamine Transporter SPECT: Feasibility of a Multi-Frame Acquisition Strategy

P. Young[1,2], *L. Collett*[1], *A. Nawwar*[1,2,3];
[1]*University Hospitals Bristol NHS Foundation Trust, Bristol, UNITED KINGDOM,*
[2]*Cobalt Medical Charity, Cheltenham, UNITED KINGDOM,*
[3]*University of Cairo, Cairo, EGYPT.*

EP-1133

Impact of patient size on quantitative ^{177}Lu SPECT/CT imaging

S. Ivanov, *E. Zoetelief, A. Harteveld, M. Konijnenberg, J. Hofland, T. Brabander, M. Segbers;*
Erasmus MC, Rotterdam, NETHERLANDS.

EP-1134

Volumetric Restoration of Short-Time Amyloid PET Image Using a ^{3}D Implicit Representation

Y. Jeong[1], *K. Jeon*[2], *H. Park*[2];
[1]*Dong-A University Hospital, Busan, KOREA, REPUBLIC OF,*
[2]*National Institute for Mathematical Sciences, Daejeon, KOREA, REPUBLIC OF.*

EP-1135

Physics-aware Neural Network Integrating Geometric Priors and Structure-preserving Constraints for Y-90 Bremsstrahlung SPECT/CT Scatter Correction

Z. Li, *Y. Huang, T. Xiong, C. Liu, J. Cai;*
The Hong Kong Polytechnic University, Kowloon, Hong Kong, HONG KONG.

EP-62

D: Technical Studies → D2 Data Analysis and Artificial Intelligence → D22 Image Classification / Segmentation / Anomaly Detection

EP-1136

Deep Learning Segmentation for ^{18}F-Flotufolastatand ^{18}F-PSMA-1007 PET/CT: Combined versus Tracer-Specific Models

A. Soliman[1], *N. Capobianco*[2], *R. Seifert*[3], *V. Shah*[1], *S. Daniel*[1], *G. Platsch*[2], *B. Spottiswoode*[1];
[1]*Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA,*
[2]*Siemens Healthineers AG, Erlangen, GERMANY,*
[3]*Universitätsspital Bern, Bern, SWITZERLAND.*

EP-1137

Tissue-Specific Geometric complementarity of FET-PET and MRI in Brain Metastases

L. Förner[1,2], *K. Tehlan*[1,2], *J. Bäßler*[1], *N. Dreher*[1], *C. Lapa*[1], *T. Wendler*[1,2], *LF and KT are authors with equal contribution;*
[1]*University Hospital Augsburg, Augsburg, GERMANY,*
[2]*Technical University of Munich, Munich, GERMANY.*

EP-1138

Deep Learning-Based Automated Tumour Delineation on [^{18}F]FDG PET/CT for Complementary Detection of Cervical Nodal Metastases in Head and Neck Cancer

S. Chan[1], *M. Liu*[1], *S. Ng*[2];
[1]*Hualien Tzu Chi Hospital, Hualien, TAIWAN, PROVINCE OF CHINA,*
[2]*Linkou Chang Gung Memorial Hospital, Taoyuan, TAIWAN, PROVINCE OF CHINA.*

EP-1139

Multimodal Deep Learning Based on Perfusion Scintigraphy and Chest Radiography for the Diagnosis of Pulmonary Embolism: An Ensemble Approach

H. Eroglu Elden[1], *S. Özdemir*[2], *M. Daşar*[3], *K. Demirel*[3], *A. Akbulut*[3], *G. Koca*[3], *M. Korkmaz*[3];
[1]*Kahramanmaraş Necip Fazıl City Hospital, Kahramanmaraş, TÜRKIYE,*
[2]*Hatay Training and Research Hospital, Hatay, TÜRKIYE,*
[3]*Ankara Training and Research Hospital, Ankara, TÜRKIYE.*

EP-1140

Total Tau Burden Decomposed into Intensity and Spatial Extent: Focal Uptake Correlates More Closely with Cognition than Volume Across Most Cognitive Measures

G. Huang[1], *T. Sun*[2], *Y. Zhang*[1], *S. Gao*[1], *H. Shao*[1], *M. Xin*[1], *J. Liu*[1], *F. Shi*[2], *C. Zhang*[1];
[1]*Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA,*
[2]*Department of Research and Development, United Imaging Intelligence, Shanghai, CHINA.*

EP-1141

A comparison of the use of different deep convolutional neural networks for cardiac amyloidosis classification from99mTc-DPD Images of heart, kidney and heart, and kidney

E. Sousa[1,2], *G. Avery*[3], *A. Turner*[4], *S. J. Archibald*[5];
[1]*Centre of Excellence for Data Science, Artificial Intelligence and Modelling, University of Hull, Hull, UNITED KINGDOM,*
[2]*Biomedical Institute for Multimorbidity, Centre for Biomedicine, Hull York Medical School, University of Hull, Hull, UNITED KINGDOM,*
[3]*Castle Hill Hospital, Hull, UNITED KINGDOM,*
[4]*University of Nottingham, Nottingham, UNITED KINGDOM,*
[5]*School of Biomedical Engineering and Imaging Sciences, King's College London, London, UNITED KINGDOM.*

EP-1142

Automated longitudinal PSMA-PET quantification pipeline for ^{177}Lu-PSMA therapy response assessment in mCRPC: a pilot cohort

S. Asa[1], *M. Isenkul*[2], *M. Cagan*[1], *B. Ocal*[1], *S. Biyikoglu*[1], *S. Sager*[1];
[1]*Istanbul University Cerrahpasa Medical Faculty Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[2]*Istanbul University Cerrahpasa Faculty of Engineering Department of Computer Engineering, Istanbul, TÜRKIYE.*

EP-1143

Analysis of Lower Extremity Lymphoscintigraphy Findings and Comparison with Deep Learning Model Results

U. Turan, *B. Bedi Alpay, H. Peker;*
Gulhane Training and Research Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-1144

Incremental Value of AI-Derived PET Radiomics Combined with Clinical Factors and Functional MRI from Integrated PET/MRI for Survival Prediction in Oropharyngeal and Hypopharyngeal Cancer

S. Chan[1], *S. Ng*[2];
[1]*Hualien Tzu Chi Hospital, Hualien, TAIWAN, PROVINCE OF CHINA,*
[2]*Linkou Chang Gung Memorial Hospital, Taoyuan, TAIWAN, PROVINCE OF CHINA.*

EP-1145

Non-invasive Diagnosis Strategy integrating PSMA PET/CT and mpMRI for Patients with Suspected Prostate Cancer: a multi-center study

Y. Tang[1], *J. Yang*[1], *L. Xiao*[1], *Y. Li*[1], *K. Shi*[2], *S. Hu*[1];
[1]*Xiangya Hospital Central South University, Changsha, CHINA,*
[2]*Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.*

EP-1146

Impact of Harmonization-Related Differences on PET-based Volumetric Parameters in Neuroendocrine Neoplasms: A Comparative Analysis of [^{18}F]FDG and [^{68}Ga]Ga-DOTATOC

T. Jedamzik[1], *M. Heinrich*[1], *P. Kohnle*[1], *A. K. Buck*[1], *J. Tran-Gia*[1], *A. Weich*[2], *K. Michalski*[1];
[1]*Department of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, GERMANY,*
[2]*NET-Zentrum Wuerzburg, European Neuroendocrine Tumor Society Center of Excellence (ENETS CoE), University Hospital Wuerzburg, Wuerzburg, GERMANY.*

EP-1147

Transfer Learning-Enhanced nnU-Net for Automated Lesion and Organ Segmentation in FAPI-PET Imaging

Y. Salimi[1], *Z. Mansouri*[1], *E. Jafari*[2], *E. Yazdani*[3], *S. Hasanabadi*[4], *M. Cheraghi*[5], *M. Asadi*[2], *H. Zaidi*[1];
[1]*Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, SWITZERLAND,*
[2]*Department of Nuclear Medicine, Molecular Imaging and Theranostics, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF,*
[3]*Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,*
[4]*Department of Medical Radiation Engineering, Shahid Beheshti University, Tehran, IRAN, ISLAMIC REPUBLIC OF,*
[5]*PET-CT Unit, Nuclear Medicine Department, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EP-1148

An integrated phantomless PET/CT workstation with a semi-automated ROI workflow for opportunistic bone mineral density assessment: comparison with DXA and pilot clinical validation

N. Gupta;
Dr Rajendra Prasad Government medical college Kangra Himachal Pradesh India, Kangra, INDIA.

EP-1149

Revealing Pituitary Neuroendocrine Tumours Occult on Static [^{18}F]FET PET-MRI using Dynamic Imaging and Temporal Subtraction

M. Allaoui[1,2], *I. Pruis*[1,2], *M. Segbers*[1], *A. Harteveld*[1], *R. Valkema*[1], *S. Veldhuijzen van Zanten*[1,2,3];
[1]*Dept. of Radiology & Nuclear Medicine, Erasmus MC – University Medical Centre, Rotterdam, NETHERLANDS,*
[2]*Brain Tumour Centre, Erasmus MC Cancer Institute, Rotterdam, NETHERLANDS,*
[3]*Medical Delta, Delft, NETHERLANDS.*

EP-1150

AI-Assisted Detection of Deep Vein Thrombosis on Radionuclide Venography Using a Clinically Aligned Evaluation Framework

H. Chen[1,2], *C. Wang*[3], *T. Yu*[1], *Y. Huang*[2], *S. Hsu*[1];
[1]*Department of Information Engineering, I-Shou University, Kaohsiung, TAIWAN, PROVINCE OF CHINA,*
[2]*Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TAIWAN, PROVINCE OF CHINA,*
[3]*Department of Medical Imaging and Radiological Sciences, I-Shou University, Kaohsiung, TAIWAN, PROVINCE OF CHINA.*

EP-1151

Sex-related differences in the impact of attenuation correction on diagnostic performance of SPECT/CT myocardial perfusion imaging

S. Mammeri;
University Military Hospital of Ouargla Algeria, Constantine, ALGERIA.

EP-1152

Multimodal machine learning for the differential diagnosis of dementia with Lewy bodies using simultaneous [^{99m}Tc]Tc-HMPAO and [^{123}I]FP-CIT acquisition on a CZT SPECT/CT

A. El Barkaoui[1], *G. Prisacariu*[1], *C. Scheiber*[1], *M. Janier*[1], *S. Thobois*[1], *S. Dautricourt*[1], *V. Desestrert*[1], *A. Garnier-Crussard*[1], *T. Grenier*[2], *A. Flaus*[1];
[1]*Hospices Civils de Lyon, Lyon, FRANCE,*
[2]*INSA Lyon, Lyon, FRANCE.*

EP-1153

Automated SPECT quantification of periprosthetic ^{99}mTc DPD uptake in aseptic loosening of total hip arthroplasty

M. Kretzschmar[1], *B. C. Jones*[2], *L. McDougall*[1], *H. A. Vija*[2], *D. Wild*[1];
[1]*University Hospital, Basel, SWITZERLAND,*
[2]*Siemens Medical Solutions USA Inc., Hoffman Estates, IL, UNITED STATES OF AMERICA.*

EP-1154

Routine PET/CT enables accurate whole-body composition using multi-level CT features: superiority over L3 approaches

P. Decazes;
Henri Becquerel Cancer Center, Rouen Cedex[1], *FRANCE.*

EP-1155

Predictive value of baseline PET/CT metabolic parameters in risk stratification for classical Hodgkin lymphoma (cHL)

L. Cagua Ruiz[1], *E. Dominguez-Polanco*[1], *A. Piñero Donis*[1], *E. Karol Vega*[1], *A. Martínez Conejo*[2], *F. Hernandez Mohedo*[3], *C. Ramos Font*[1];
[1]*Servicio Medicina Nuclear Hospital universitario Virgen de las Nieves, Granada, SPAIN,*
[2]*Servicio Hematología, Hospital universitario Virgen de las Nieves, Granada, SPAIN,*
[3]*Servicio Hematologia, Hospital universitario Virgen de las Nieves, Granada, SPAIN.*

EP-1156

Are Liver Metastases from Uveal melanoma a Clinical Indication for Dynamic PET? A Comparison of Patlak Parametric Imaging with Standard and Delayed Static SUV Imaging Using Long Axial Field-of-View PET/CT

L. Pan[1], *C. Sachpekidis,*[1], *D. S. Strauss*[2], *J. C. Hassel*[3], *A. Dimitrakopoulou-Strauss*[1];
[1]*German Cancer Research Center, Heidelberg, GERMANY,*
[2]*University Hospital Heidelberg, Heidelberg, GERMANY,*
[3]*National Center for Tumor Diseases, Heidelberg, GERMANY.*

EP-1157

Brain [^{18}F]FDG PET versus T1W MRI for the Differential Diagnosis of Neurodegenerative Dementias Using Machine Learning on an Extensive Validation Cohort

L. Castelbranco Silva, *F. P. M. Oliveira, D. C. Costa;*
Champalimaud Foundation, Lisbon, PORTUGAL.

EP-1158

Agentic Artificial Intelligence for Longitudinal Lesion Tracking in Quantitative SPECT/CT: A Human-in-the-Loop Framework

F. Yousefirizi[1], *R. Hamidpour*[1], *S. Kurkowska*[1], *N. Colpo*[2], *C. Williams*[2], *C. Dellar*[3], *W. Parulekar*[3], *D. Juneau*[4], *F. Saad*[4], *K. Chi*[2], *K. Zukotynski*[1], *J. Beauregard*[5], *M. Soleimani*[2], *D. Wilson*[2], *A. Rahmim*[1], *P. L. Esquinas*[2], *F. Benard*[2], *C. Uribe*[2];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,*
[2]*BC Cancer, Vancouver, BC, CANADA,*
[3]*Canadian Cancer Trials Group, Kingston, ON, CANADA,*
[4]*University of Montreal Hospital Center, Montreal, QC, CANADA,*
[5]*Université Laval, Quebec City, QC, CANADA.*

EP-1159

Automated Whole-Body Lymph Node Station Assignment: A Novel Explainable Computational Framework for Segmentation Tasks.

J. Mitura[1], *D. Maicher*[1], *M. Schaefer*[2], *M. C. Kreissl*[1], *J. Wybranska*[1];
[1]*Division of Nuclear Medicine, Department of Radiology & Nuclear Medicine, Faculty of Medicine, Otto von Guericke University Magdeburg, Magdeburg, GERMANY,*
[2]*Otto von Guericke University Magdeburg, Magdeburg, GERMANY.*

EP-1160

Automated PERCIST-Based FDG PET Quantification in mCRPC: Validation Against Expert Ground Truth in 127 Baseline Studies from the LuPSMADose Registry

P. Jehanno[1], *Y. Cras*[2], *J. Tomas Donoso*[2,3], *H. Noamen*[2], *A. Daverio*[2], *P. Blanc Durand*[1,4], *M. Borsali*[2], *K. Trabelsi*[2], *L. Agriroroaie*[2], *D. Deandreis*[2], *C. Garcia*[2];
[1]*PAIRE, Paris, FRANCE,*
[2]*Nuclear Medicine Dpt. Gustave Roussy, Villejuif, FRANCE,*
[3]*Nuclear Medicine Section, Hospital Clinico, Universidad de Chile, Santiago, CHILE,*
[4]*Nuclear Medicine Dpt. Henri-Mondor, APHP, Paris, FRANCE.*

EP-1162

Reliability of Automated Quantitative Perfusion SPECT/CT Segmentation in Acute Pulmonary Embolism: Intra- and Interobserver Agreement for Diagnosis and Follow-up

N. Álvarez Mena, *Á. R. Suazo Montero, F. Sebastián Palacid, A. E. Hurtado Romero, S. Pena Vaquero, R. Ruano Pérez;*
Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

EP-1163

Fully Automated Semi-Quantitative Assessment of Multi-Organ Involvement in Immunoglobulin Light Chain Amyloidosis: A Validation Study

Y. Hu, *H. L. A. Nienhuis, O. V. Ivashchenko, R. H. J. A. Slart;*
University Medical Center Groningen, Groningen, NETHERLANDS.

EP-1164

Left Ventricular Segmentation in Myocardial Perfusion Scintigraphy: Comparison of UNet and SwinUNETR-v2 Architectures

S. Ünal[1,2], *B. Demir*[3], *E. Karataş*[2], *M. Korkmaz*[1];
[1]*University of Health Sciences, Ankara Training and Research Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE,*
[2]*Ankara University, Natural and Applied Sciences Institute, Informatics Department, Ankara, TÜRKIYE,*
[3]*Şanlıurfa Mehmet Akif Inan Training and Research Hospital, Nuclear Medicine Department, Ankara, TÜRKIYE.*

EP-63

D: Technical Studies → D2 Data Analysis and Artificial Intelligence → D24 Outcome Prediction

EP-1165

Predicting Tumour Response to ^{90}Y-SIRT in Hepatocellular Carcinoma Using Post-Treatment Imaging: A Comparative Evaluation of AI Methods

P. Bugnon[1], *R. Popoff*[2], *J. Vrigneaud*[2], *N. Payan*[2], *O. Chevalier*[3], *B. Presles*[1], *J. Alberini*[2];
[1]*Université Bourgogne Europe, CNRS, ICMUB UMR 6302, Dijon, FRANCE,*
[2]*Université Bourgogne Europe, Centre de Lutte Contre le Cancer G.-F. Leclerc, Service de médecine nucléaire, CNRS, ICMUB UMR 6302, Dijon, FRANCE,*
[3]*Université Bourgogne Europe, CHU Dijon Bourgogne, Département de Radiologie et Imagerie Médicale, CNRS, ICMUB UMR 6302, 21000 Dijon, France, Dijon, FRANCE.*

EP-1166

[^{68}Ga]Ga-PSMA-11 PET Radiomics for Prediction of Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer: a Multicentre Study

S. Ghezzo[1], *R. Laudicella*[2], *F. Moradi*[3], *A. Stefano*[4], *C. Bezzi*[1], *P. Mapelli*[1], *T. Russo*[5], *S. Scuderi*[6], *G. Gandaglia*[6], *G. Brembilla*[5], *A. Briganti*[6], *P. Scifo*[1], *A. Samanes Gajate*[1], *F. De Cobelli*[5], *A. Iagaru*[3], *A. Chiti*[1], *I. A. Burger*[7], *M. Picchio*[1];
[1]*Nuclear Medicine Department, IRCCS San Raffaele, Milan, ITALY,*
[2]*Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and MorphoFunctional Imaging, University of Messina, Messina, ITALY,*
[3]*Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, CA, UNITED STATES OF AMERICA,*
[4]*Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Cefalù, ITALY,*
[5]*Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, ITALY,*
[6]*Division of Experimental Oncology, Department of Urology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, ITALY,*
[7]*Department of Nuclear Medicine, University Hospital Zürich, University of Zurich, Zurich, SWITZERLAND.*

EP-1167

Beyond Conventional PET Metrics: Radiomics-Based Machine Learning for Prediction of Lymph Node Metastasis in Endometrial Cancer

S. Yagci[1], *S. S. Sengul*[2], *E. Erdemoglu*[2], *M. Erdogan*[2];
[1]*Isparta City Hospital, Isparta, TÜRKIYE,*
[2]*Suleyman Demirel University, Isparta, TÜRKIYE.*

EP-1168

Regional Brain Perfusion Predicts the Trajectory of Cognitive Decline Using Machine Learning

H. Morgan[1], *C. Hill*[1], *D. Evenden*[1], *A. Prosser*[1], *C. Kipps*[2], *M. Niranjan*[1], *S. Michopoulou*[2];
[1]*University of Southampton, Southampton, UNITED KINGDOM,*
[2]*University Hospital Southampton NHS Foundation Trust, Southampton, UNITED KINGDOM.*

EP-1169

Automated Deauville Scores from Baseline [^{18}F]FDG PET/CT Predict Overall Survival in Newly Diagnosed Multiple Myeloma: the autoDS-PET Pipeline

S. Peluso[1,2], *L. Pagnini*[1,3], *S. Polizzi*[4], *E. Rocchi*[1,2], *M. Tarozzi*[1,2], *V. Dragonetti*[5], *V. Solli*[1,6], *D. Dall'Olio*[1], *M. Talarico*[1], *C. Terragna*[6], *C. Sala*[1,2], *E. Zamagni*[1,6], *S. Fanti*[1,3], *C. Nanni*[3], *G. Castellani*[1,2];
[1]*Department of Medical and Surgical Sciences, University of Bologna, Bologna, ITALY,*
[2]*IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, ITALY,*
[3]*Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,*
[4]*IRCCS Istituto delle Scienze Neurologiche di Bologna, Data Science and Bioinformatics Laboratory, Bologna, ITALY,*
[5]*Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS, Milano, ITALY,*
[6]*IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, ITALY.*

EP-1170

Baseline Ga-68-PSMA-11 PET/CT-Derived Biomarkers from AI-Assisted and Rule-Based Segmentation Predict Survival After Lu-177-PSMA-617 Radioligand Therapy

A. Szabo, *J. Mikolajczak, D. Waldmannstetter, D. Schmidt, J. Moosbauer, D. Weidt, D. Hellwig;*
Department of Nuclear Medicine, Regensburg, GERMANY.

EP-1171

Fully Automated AI-based Quantification of Tumour Volume on PSMA PET-CT Images is Significantly Associated With Overall Survival in Patients With Prostate Cancer

J. Wittgren[1,2], *J. Ingvar*[1,2], *O. Enqvist*[3,4], *M. Larsson*[3], *D. Minarik*[1,2], *L. Edenbrandt*[5], *A. Bjartell*[1,2], *E. Trägårdh*[1,2];
[1]*Lund University, Lund, SWEDEN,*
[2]*Skåne University Hospital, Malmö, SWEDEN,*
[3]*Eigenvision AB, Lund, SWEDEN,*

[4]Chalmers University of Technology, Gothenburg, SWEDEN,
[5]Gothenburg University, Gothenburg, SWEDEN.

EP-1172

Skeletal Metabolic Network Derived from Baseline Whole-Body ^{18}F-FDG PET/CT Predicts Survival in NSCLC

T. Sun[1], *J. Qin*[1], *Z. He*[2], *Y. Chen*[2];
[1]Paul C. Lauterbur Research Center for Biomedical Imaging, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, CHINA,
[2]Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA.

EP-1173

Integrating Molecular Imaging and Human Cell Atlas Single-Cell Transcriptomics Data for Next-Generation Drug Discovery Tools in Radiotheranostics

E. von Moeller[1,2], *I. Castarède*[3], *K. Gariani*[4,5], *E. Dobra Neacsu*[6], *L. Cebollada Cameo*[6], *C. Piedelobo Vaquero*[6], *L. Sanz Vázquez*[6], *J. Pérez Iruela*[6], *Y. Salimi*[3], *Y. You*[1], *L. Fei*[1], *P. Jané Soler*[1,3], *S. A. Teichmann*[1];
[1]Cambridge Stem Cell Institute and Department of Medicine, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UNITED KINGDOM,
[2]Vrije Universiteit, Amsterdam Institute of Molecular and Life Sciences (AIMMS), Amsterdam, NETHERLANDS,
[3]Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, SWITZERLAND,
[4]Division of Endocrinology, Geneva University Hospitals, Geneva, SWITZERLAND,
[5]Faculty of Medicine, University of Geneva, Geneva, SWITZERLAND,
[6]Hospital Universitario Ramón y Cajal, Madrid, SPAIN.

EP-1174

A Reproducible, Literature-Informed and Stability-Aware PET/CT Radiomics Framework for Lung Cancer Survival Prediction

M. Salmanpour[1,2,3], *A. Shahsavan*[4], *H. Abedini*[5], *S. Mehrnia*[6], *M. Luo*[1,2], *C. Uribe*[1,2], *A. Rahmim*[1,2];
[1]BC Cancer Research Institute, Vancouver, BC, CANADA,
[2]University of British Columbia, Vancouver, BC, CANADA,
[3]Technological Virtual Collaboration Company (TECVICO CORP.), Vancouver, BC, CANADA,
[4]Kerman University of Medical Sciences, Kerman, IRAN, ISLAMIC REPUBLIC OF,
[5]Islamic Azad University, Tehran, IRAN, ISLAMIC REPUBLIC OF,
[6]Motamed Cancer Institute, Terhan, IRAN, ISLAMIC REPUBLIC OF.

EP-1175

Baseline PET/CT prognostics factors to predict POD24 in First Line Follicular patients: a Bidifly-Lysa Study

S. Malmon[1], *Y. Al Tabaa*[2], *G. Henique*[3], *T. Reichert*[4], *R. Metz*[5], *P. Viau*[6], *L. Vercellino*[7], *N. Deleval*[8], *D. Bessac*[9], *A. Cottereau*[10], *C. Antoine*[11], *I. Buvat*[3], *G. Cartron*[12], *C. Sarkozy*[13], *S. Kanoun*[1];
[1]Pixilib, Toulouse, FRANCE,
[2]Scintidoc - Nuclear Medicine Center, Montpellier, FRANCE,
[3]Institut Curie - LITO, Paris, FRANCE,
[4]Nuclear Medicine Center - Institut Paoli-Calmettes, Marseille, FRANCE,
[5]Nuclear Medicine Center - CHU Nantes, Nantes, FRANCE,
[6]Nuclear Medicine Center - CHU Nice, Nice, FRANCE,
[7]Nuclear Medicine Center - CHU Saint-Louis, Paris, FRANCE,
[8]Nuclear Medicine Center - Institut Curie, Paris, FRANCE,
[9]Nuclear Medicine Center - CHU Strasbourg, Strasbourg, FRANCE,
[10]Nuclear Medicine Center - CHU Cochin, Paris, FRANCE,
[11]Lysarc, Créteil, FRANCE,
[12]Hematology Department - CHU Montpellier, Montpellier, FRANCE,
[13]Hematology Department - Institut Curie, Paris, FRANCE.

EP-1176

Automated Prediction of PROMISE v2 miTNM Staging in Prostate Cancer Using ^{18}F and ^{68}Ga PSMA PET Deep Learning

A. Ghujeh[1], *A. Abd Al Rahim*[1], *M. Kharita*[1], *H. Fayad*[1,2];
[1]Hamad Medical Corporation, Doha, QATAR,
[2]Weill Cornell Medicine, Doha, QATAR.

EP-1177

FDG2TAU: A Cross-modal Neuropathological Synthesis Framework for Alzheimer's Disease Diagnosis

Y. Tao[1], *L. Wang*[1], *G. Huang*[2], *L. Li*[2], *Y. Zhang*[1], *Y. Zhang*[2], *M. Xin*[2], *J. Liu*[2], *C. Zhang*[2], *H. Zhang*[1,3,4];
[1]School of Biomedical Engineering, ShanghaiTech University, Shanghai, CHINA,
[2]Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA,
[3]Shanghai Clinical Research and Trial Center, Shanghai, CHINA,
[4]State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai, CHINA.

EP-1178

Multimodal Radiomic Analysis of Radioiodine-Avid Cervical Lymph Nodes on Post- therapeutic ^{131}I SPECT/CT Predicts Treatment Response in Papillary Thyroid Carcinoma

W. Weng[1], *X. Huang*[2], *Y. Tian*[3], *X. Chen*[1], *S. Zhang*[1], *Y. Ning*[2], *X. Su*[1];
[1]The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA,
[2]Sir Run Run Shaw Hospital,Zhejiang University School of Medicine, Hangzhou, CHINA,
[3]College of Biomedical Engineering & Instrument Science , Zhejiang University, Hangzhou, CHINA.

EP-1179

Weakly Supervised PET-Based Learning for Early Risk Stratification of Radioiodine-Refractory Differentiated Thyroid Cancer

Z. LI[1], *H. Endo*[2], *S. Watanabe*[1,3,4], *K. Hirata*[1,3,4], *J. Takenaka*[1,3,4], *N. Wakabayashi*[1,3,4], *K. Kudo*[1,3,4];
[1]Department of Diagnostic Imaging, Faculty of Medicine, Hokkaido University, Sapporo, JAPAN,
[2]Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, JAPAN,
[3]Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, JAPAN,
[4]Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, JAPAN.

EP-1180

From Small Cohorts to Large Datasets: Comparing Handcrafted Radiomics, Deep Features, Fusion Models, and Deep Learning for PET and SPECT Disease Outcome Prediction

M. Salmanpour[1,2,3], *S. Mehrnia*[4], *S. Jabarzadeh Ghandilu*[3], *S. Falahati*[5,3], *S. Taeb*[6], *G. Mousavi*[7], *A. Rahmim*[1,2];
[1]BC Cancer Research Institute, Vancouver, BC, CANADA,
[2]University of British Columbia, Vancouver, BC, CANADA,
[3]Technological Virtual Collaboration Company (TECVICO CORP.), Vancouver, BC, CANADA,
[4]Motamed Cancer Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF,
[5]Nooshirvani University of Technology, Babol, IRAN, ISLAMIC REPUBLIC OF,
[6]Guilan University of Medical Sciences, Rasht, IRAN, ISLAMIC REPUBLIC OF,
[7]University of Tehran, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-1181

Prognostic value of theranostic imaging in mCRPC PSMA using a fully automatic AI pipeline

L. Baptista Da Silva[1], *J. O. Prior*[1], *N. Schaefer*[1], ***A. Depeursinge***[1,2], *V. Andrearczyk*[1,2], *M. Jreige*[1];
[1]Department of Nuclear Medicine and Molecular Imaging, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SWITZERLAND,
[2]Institute of Informatics, HES-SO Valais-Wallis, Sierre, SWITZERLAND.

EP-64

D: Technical Studies → D2 Data Analysis and Artificial Intelligence → D25 Tracer Kinetic Analysis

EP-1182

Improved Lesion Characterisation with Dynamic [^{18}F]FDG LAFOV PET: Added Value of Delivery-Metabolism Mismatch

A. Lazar[1,2], *C. Mingels*[2], *I. Alberts*[3], *A. Chiti*[1,4], *A. Rominger*[2], *H. Sari*[2,5];
[1]Vita-Salute San Raffaele University, Milan, ITALY,
[2]Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND,
[3]Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, BC, CANADA,
[4]Department of Nuclear Medicine, IRCCS San Raffaele Hospital, Milan, ITALY,
[5]Siemens Healthineers International AG, Zurich, SWITZERLAND.

EP-1183

Tracer-Agnostic Estimation of Blood Flow and Kinetics from a Single Dynamic PET Scan Using the Flow-Scaled 2-Tissue Compartment Model

D. De Sarno[1], *J. Bhangu*[2], *M. Borrie*[2], *M. Qu*[3], *G. Bauman*[3], *T. Lee*[4,1,5];
[1]Department of Medical Biophysics, Western University, London, ON, CANADA,
[2]Parkwood Institute, St. Joseph's Health Care London, London, ON, CANADA,
[3]Verspeeten Family Cancer Centre, London Health Sciences Centre, London, ON, CANADA,
[4]Lawson Research Institute, St. Joseph's Health Care London, London, ON, CANADA,
[5]Department of Medical Imaging, Western University, London, ON, CANADA.

EP-1184

Feasibility of shortened whole-body dynamic Patlak reconstruction using population-based input function on a LAFOV PET system in advanced-stage non-small cell lung cancer

M. Pavoine[1], *M. Geier*[2], *H. Morel*[3], *R. Floch*[1], *K. Kerleguer*[1], *N. Karakatsanis*[4], *C. Robert Le Guen*[1], *S. Hennebicq*[5], *P. Le Roux*[5], *P. Salaun*[5], *R. Abgral*[5], *D. Bourhis*[5];
[1]CHU Brest, médecine nucléaire, Brest, FRANCE,
[2]CHU Brest, oncologie, UMR INSERM [1304] GETBO, Brest, FRANCE,
[3]CH Morlaix, pneumologie, Morlaix, FRANCE,
[4]Weill Cornell Medical College of Cornell University, New York, NY, UNITED STATES OF AMERICA,
[5]CHU Brest, médecine nucléaire, UMR INSERM [1304] GETBO, Brest, FRANCE.

EP-1185

Optimizing acquisition timing of Ga-FAPI PET in polymyalgia rheumatica using dynamic whole-body LAFOV imaging

M. Pavoine[1], *P. Le Roux*[2], *S. Querellou*[2], *D. Guellec*[3], *F. Blanc Béguin*[2], *S. Hennebicq*[2], *B. Quéré*[3], *D. Bourhis*[2], *R. Abgral*[2];
[1]CHU Brest, médecine nucléaire, Brest, FRANCE,
[2]CHU Brest, médecine nucléaire, UMR INSERM [1304] GETBO, Brest, FRANCE,
[3]Univ Brest, CHU Brest, Rhumatologie, LBAI, UMR[1227], CIC INSERM [1412], Brest, FRANCE.

EP-1186

Dynamic Total-Body ^{18}F-FCH PET/CT Reveals Kinetic Characteristics and Improves Lesion Visualization with parameter Imaging in Hyperparathyroidism

L. Guan, *H. Pang*, *Y. Li*;
The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EP-1187

Dual-Isotope NEMA Phantom Assessment of Apparent Logan and Patlak Parameters on Total-Body Dynamic PET

L. Strigari[1], *F. Zagni*[1], *F. Lodi*[1], *S. Fanti*[2,3], *M. Santoro*[1];
[1]IRCCS Azienda Ospedaliero Universitario di Bologna, Bologna, ITALY,
[2]IRCCS AOUBO, Bologna, ITALY,
[3]University of Bologna, Bologna, ITALY.

EP-1188

Translating quantitative paired-agent molecular imaging principles from optical systems to PET/CT for PSMA-targeted prostate cancer imaging

K. Tichauer[1,2], *E. Puley*[2], *D. De Sarno*[2], *T. Lee*[1,2];
[1]*Lawson Research Institute, London, ON, CANADA,*
[2]*Western University, London, ON, CANADA.*

EP-1190

What is the optimal PET scan time for quantification of brain perfusion from ^{15}O[H2O] PET?

M. Stavrinou[1], *L. Mikalsen*[2], *J. Connelly*[2,3], *A. Sherwani*[2], *L. Gridset*[2], *O. Geier*[2], *A. Aamodt*[4,5,6], *C. Stokke*[2,7];
[1]*Oslo University Hospital, Oslo, NORWAY,*
[2]*Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY,*
[3]*University of Oslo, Oslo, NORWAY,*
[4]*Department of Neurology, Oslo University Hospital, Oslo, NORWAY,*
[5]*NorHead, Department of Neuroscience and Movement Science, The Norwegian University of Science and Technology, Trondheim, NORWAY,*
[6]*Institute of Population Health, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UNITED KINGDOM,*
[7]*Department of Physics, University of Oslo, Oslo, NORWAY.*

EP-1191

Abbreviated and Dual-Time-Point Protocols for Quantitative [^{18}F]FET Kinetics on Long Axial Field-of-View PET

F. Stefani[1,2], *A. Lazar*[3,2], *M. Amon*[2], *P. Radojewski*[4], *M. Veronese*[1], *T. Pyka*[2,5], *A. Rominger*[2], *C. Mingels*[2], *H. Sari*[2,6];
[1]*Department of Information Engineering, University of Padova, Padua, ITALY,*
[2]*Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND,*
[3]*Vita-Salute San Raffaele University, Milan, ITALY,*
[4]*University Institute of Diagnostic and Interventional Neuroradiology, Inselspital Bern University Hospital and University of Bern, Bern, SWITZERLAND,*
[5]*TUM School of Medicine and Health, Munich, GERMANY,*
[6]*Siemens Healthineers International AG, Zurich, SWITZERLAND.*

EP-1192

Differentiation of Renal Cortical and Medullary Metabolism based on AI-estimated Parametric Maps

K. Tehlan[1,2], *K. Shi*[3], *A. Rominger*[3], *C. Lapa*[1], *T. Wendler*[1,2];
[1]*University Hospital Augsburg, Augsburg, GERMANY,*
[2]*Technical University of Munich, Munich, GERMANY,*
[3]*Inselspital, Bern University Hospital, Bern, SWITZERLAND.*

EP-1193

Optimal Acquisition Timing for Perfusion Imaging in Dual-Phase Amyloid Positron Emission Tomography: A Within-Patient List-Mode Comparison of 5-Minute versus 10-Minute Protocols

A. M. Maffione[1], *A. Ferretti*[2], *L. Pavan*[1], *A. Massaro*[1], *P. Bartoletti*[1], *S. Chondrogiannis*[1], *A. Osele*[1], *F. Padovano*[1], *I. Zamberlan*[1], *M. Gava*[2], *M. Marzola*[1];
[1]*Nuclear Medicine Unit, Imaging Department, S.M. della Misericordia Hospital, Rovigo, ITALY,*
[2]*Medical Phisics Unit Imaging Department S.M. della Misericordia Hospital, Rovigo, ITALY.*

EP-1194

A Minimal Physiologically Based Pharmacokinetic Model for PSMA Radiopharmaceuticals

J. Fowler[1,2], *T. J. McColl*[1,2], *M. Sabouri*[1,2], *D. Hardiansyah*[3], *A. Rahmim*[1,2,4], *C. Uribe*[1,2,4];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,*
[2]*University of British Columbia, Vancouver, BC, CANADA,*
[3]*Universitas Indonesia, Depok, INDONESIA,*
[4]*BC Cancer, Vancouver, BC, CANADA.*

EP-1195

Quantitative Assessment of Blood-Brain Barrier Permeability to Antibody-Based Radiopharmaceuticals in a Human Glioblastoma Mouse Model Using Kinetic Modeling

M. Muñoz-González, *E. Ramos-Docampo, S. Groba, J. Codesido, N. Gómez-Lado, P. Aguiar, L. Gracía-Varela;*
Molecular Imaging Biomarkers and Theragnosis Lab, University of Santiago de Compsotela, Santiago de Compostela, SPAIN.

EP-1196

Bayesian Inference and Uncertainty Estimation for Robust Kinetic Modelling in LAFOV PET

M. Mureddu[1,2], *I. Alberts*[3,4], *K. Shi*[5], *H. Sari*[5,6], *P. Cumming*[7], *R. Hamidpour*[2,8,9], *C. F. Uribe*[2,3,4], *A. Rahmim*[2,3,4], *P. L. Esquinas*[3,4];
[1]*Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), University of Genoa, Genoa, ITALY,*
[2]*Department of Basic and translational Research, BC Cancer Research Institute, Vancouver, BC, CANADA,*
[3]*Molecular Imaging and Therapy, BC Cancer, Vancouver, BC, CANADA,*
[4]*Department of Radiology, University of British Columbia, Vancouver, BC, CANADA,*
[5]*Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND,*
[6]*Siemens Healthineers International AG, Zurich, SWITZERLAND,*
[7]*School of Psychology and Counselling, Queensland University of Technology, Brisbane, AUSTRALIA,*
[8]*School of Biomedical Engineering, University of British Columbia, Vancouver, BC, CANADA,*
[9]*BC Cancer Medical Imaging Core Lab, BC Cancer Research Institute, Vancouver, BC, CANADA.*

EP-1197

Evaluation of Dynamic [^{18}F]FET PET Scan Duration on Kinetic Model Selection and Stability

S. Bogoi[1], *T. Traub-Weidinger*[2], *I. Rausch*[1];
[1]*QIMP team, Center for medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA,*
[2]*Department of Diagnostic and Therapeutic Nuclear Medicine, Clinic Donaustadt, Vienna, AUSTRIA.*

EP-1198

Organ-Specific Dose Bias from Daughter Redistribution in [^{225}Ac]Ac-PSMA-617 Targeted Alpha Therapy: A Simulation Study with Physiologically Based Pharmacokinetic Model

Y. Chen, *K. Zeimpekis, J. Hu, A. López Montes, R. Seifert, A. Rominger, A. Afshar-Oromieh, K. Shi;*
Department of Nuclear Medicine, Inselspital, University of Bern, Bern, SWITZERLAND.

EP-1199

Dynamic [^{18}F]FET PETMRI for Localization of Radiographically Occult Pituitary Neuroendocrine Tumours: Uptake Kinetics and Perfusion Effects

I. Pruis, *M. Allaoui, M. Segbers, A. A. Harteveld, S. E. M. Veldhuijzen van Zanten;*
Erasmus MC, Rotterdam, NETHERLANDS.

EP-1200

Prognostic value of [^{18}F]FET PET time-activity curve shape derived from non-linear modelling in patients with glioblastoma

I. Syaridatul Muminah[1,2], *K. G. Ciantar*[1,3], *C. Fills*[1,4,5], *P. Lohmann*[1,4], *J. Werner*[6], *N. Galldiks*[7,8], *J. Dammers*[1,9], *N. Shah*[1,10,11], *C. Lerche*[1];
[1]*Medical Imaging Physics (INM-4), Institute of Neuroscience and Medicine (INM), Forschungszentrum Jülich, Jülich, GERMANY,*
[2]*Faculty of Medicine, RWTH Aachen University, Aachen, GERMANY,*
[3]*Chair of Imaging and Computer Vision, RWTH Aachen University, Aachen, GERMANY,*
[4]*Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, GERMANY,*
[5]*Center of Integrated Oncology (CIO), University of Aachen, Bonn, Cologne and Düsseldorf, Germany, Aachen, GERMANY,*
[6]*Department of Neurology, Faculty of Medicine and University Hospital, Cologne, GERMANY,*
[7]*Institute of Neuroscience and Medicine (INM-3), Forschungszentrum Jülich, Jülich, GERMANY,*
[8]*Department of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, GERMANY,*
[9]*Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, GERMANY,*
[10]*JARA - BRAIN - Translational Medicine, RWTH Aachen University, Aachen, GERMANY,*
[11]*Department of Neurology, RWTH Aachen University Hospital, Aachen, GERMANY.*

EP-1201

Patlak Ki May Provide Better Lesion Contrast than SUV in Chest and Abdominal Lesions on Whole-Body Dynamic FDG PET

T. Kotani[1], *Y. Nakai*[2], *N. Tamaki*[3], *S. Yamada*[1], *M. Kiba*[1], *S. Akiyama*[1], *T. Kanayama*[1];
[1]*Kyoto Prefectural University of Medicine, Kyoto, JAPAN,*
[2]*National Center for Child Health and Development, Tokyo, JAPAN,*
[3]*Kyoto University of Advanced Science, Kyoto, JAPAN.*

EP-1202

Dynamic PET biodistribution of free $^{68}Ga^{3+}$

I. Matias[1], *P. Soeiro*[1], *R. Albergueiro*[1], *S. Lemos*[1], *J. Silva*[1], *T. Faria*[1], *E. Martins*[2], *J. Santos*[2], *I. Fortuna*[2];
[1]*ULS São João, Porto, PORTUGAL,*
[2]*Faculty of Medicine, University of Porto, Porto, PORTUGAL.*

EP-1203

MC-TAC: An Open-Source Tool for Harmonized Extraction, Pooling, and Interactive Analysis of PET Time-Activity Curves

C. Hinge[1], *S. Gutschmayer*[2], *M. Pires*[2], *M. K. Eldevik*[3,4], *C. Loisel*[5], *I. Buvat*[5], *O. L. Munk*[3,4], *T. Beyer*[2], *F. L. Andersen*[1,6];
[1]*Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, DENMARK,*
[2]*QIMP Team, Medical University of Vienna, Vienna, AUSTRIA,*
[3]*Department of Nuclear Medicine, Aarhus University Hospital, Aarhus, DENMARK,*
[4]*Department of Clinical Medicine, Aarhus University, Aarhus, DENMARK,*
[5]*IRIS Inserm, CNRS, Institut Curie, PSL University, Versailles Saint-Quentin University, Orsay, FRANCE,*
[6]*Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DENMARK.*

EP-1204

A short and early dynamic acquisition protocol provides a diagnostic accuracy comparable to late static68Ga-FAPI-PET/CT

A. Spektor, *A. Pashazadeh, H. Buchholz, L. Fritzsche, M. Schreckenberger, M. Röhrich;*
Department of Nuclear Medicine, University Center Mainz, Mainz, GERMANY.

EP-65

D: Technical Studies → D2 Data Analysis and Artificial Intelligence → D26 Other Data Analysis

EP-1205

Pharmacometrics applied to peptide receptor radionuclide therapy: a proof-of-concept population pharmacodynamic model of [^{177}Lu] Lu-DOTATATE-induced thrombocytopenia in metastatic neuroendocrine tumours

A. Moussali[1], *J. Cocquebert*[1], *D. Ouk*[1], *S. Oziel-Taieb*[1], *N. Charrier*[1], *S. Benzekry*[2], *F. Gattacceca*[2], *R. Ferrara*[1,2];
[1]*Institut Paoli Calmettes, Marseille, FRANCE,*
[2]*COMputational Pharmacology and clinical Oncology (COMPO), INRIA-INSERM, Marseille, FRANCE.*

EP-1206

Comparative Evaluation of Large Language Models (LLMs) for Automated TNM staging from PET/CT Reports in Breast Cancer: A preliminary study

P. Chauhan, *T. Deepa, A. Tom, S. Deswal;*
Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, INDIA.

EP-1207

Large Language Models in Nuclear Medicine: A Bibliometric Analysis of Applications, Trends and Gaps in an Emerging Field (2022-2025)

T. Gupta;
PayloadAlphaHQ, Hyderabad, INDIA.

EP-1208

Impact of height and body surface on the determination of Dmax and other dispersion measurements in stage III-IV melanoma evaluated by [^{18}F]FDG PET/CT: an initial analysis

A. Flores, *J. L. Muñoz-Morales, C. Contreras-Rivera, M. A. Olarte-Casas;*
National Autonomous University of Mexico, Mexico City, MEXICO.

EP-1209

From Structured Capture to Computable Clinical Knowledge: A Workflow-Derived Clinical-Semantic Framework for ^{177}Lu PSMA Theranostic Research

A. Gamboa[1], *M. Pabón*[2];
[1]*Universidad Autónoma de Bucaramanga (UNAB), Bucaramanga, COLOMBIA,*
[2]*Fundación Valle del Lilli, Cali, COLOMBIA.*

EP-1210

Simulation-Based Mapping of ^{18}FDG PET/CT Radiomic Risk Scores to Biologically Interpretable Tumour Parameters in Sarcoma

L. Bonney[1,2], *K. M. Bradley*[3], *A. B. Hassan*[2], *D. R. McGowan*[1,4];
[1]*Department of Medical Physics and Clinical Engineering, Oxford University Hospitals NHS Foundation T, Oxford, UNITED KINGDOM,*
[2]*Sir William Dunn School of Pathology, University of Oxford, Oxford, UNITED KINGDOM,*
[3]*Wales Research and Diagnostic Positron Emission Tomography Centre (PETIC), Cardiff University, Cardiff, UNITED KINGDOM,*
[4]*Department of Oncology, University of Oxford, Oxford, UNITED KINGDOM.*

EP-1211

Metabolic upregulation in ageing skeletal muscle revealed by [^{18}F]FDG-PET/CT

S. Gutschmayer[1], *L. K. S. Sundar*[2], *M. Pires*[1], *C. H. M. Vu*[3,4], *X. Yang*[3,5], *N. Akatani*[3], *J. Taki*[6], *S. Takeda*[6], *T. Beyer*[1], *H. Wakabayashi*[3];
[1]*QIMP Team, Medical University of Vienna, Vienna, AUSTRIA,*
[2]*DIGIT-X Lab, Department of Radiology, LMU Munich, Munich, GERMANY,*
[3]*Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN,*
[4]*Division of Advanced Preventive Medical Science, Graduate School of Advanced Preventive Medical Sciences, Kanazawa University, Kanazawa, JAPAN,*
[5]*Department of Nuclear Medicine, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, JAPAN,*
[6]*PET Center, Kanazawa Advanced Medical Center, Kanazawa, JAPAN.*

EP-1212

Multimodal integration of whole-body [^{18}F]-FDG PET/CT, wearable and biomarker data to characterise physiological variability

L. Mathis[1,2], *S. Gutschmayer*[1], *M. Pires*[1], *T. Beyer*[1];
[1]*QIMP Team, Medical University of Vienna, Vienna, AUSTRIA,*
[2]*Department of Information Technology and Electrical Engineering, ETH Zurich, Zurich, SWITZERLAND.*

EP-1214

A Cloud-Based Framework for AI Model Sharing and Clinical Evaluation in Nuclear Medicine and Theranostics

C. Barker[1], *B. Sue*[1], *P. Esquinas*[1,2,3], *F. Farhadi*[4], *B. Saboury*[3,4], *N. A. Karakatsanis*[5], *A. Rahmim*[1,2,4], *C. Uribe*[1,2,3], ***I. S. Klyuzhin***[1,4];
[1]*Ascinta Technologies, Vancouver, BC, CANADA,*
[2]*University of British Columbia, Vancouver, BC, CANADA,*
[3]*BC Cancer Research Institute, Vancouver, BC, CANADA,*
[4]*Institute of Nuclear Medicine, Bethesda, MD, UNITED STATES OF AMERICA,*
[5]*Department of Radiology, Weill Cornell Medical College, New York, NY, UNITED STATES OF AMERICA.*

EP-1215

Two-Stage Visual Instruction Tuning Improves Vision-Language Grounding in Automated Bone Scan Reporting

K. Park, *D. Park, J. Kim, S. Cho, B. Choi, H. Song;*
Chonnam National University Medical School and Hospital, Gwangju, KOREA, REPUBLIC OF.

EP-1216

^{18}F-FDG PET/CT-Based Multimodal Fusion Model for Bone Marrow Involvement Predictionand Prognostic Stratification in Lymphoma Patients

C. Yiqiu, *M. XingYu, F. Wei;*
Department of Nuclear Medicine, Affiliated Hospital of Guilin Medical University, Guilin,Guangxi Zhuang Autonomous Region, CHINA.

EP-1217

Knowledge-Graph-Enhanced RAG Improves Guideline-Based Clinical MCQ Answeringwith LLMs in thyroid cancer.

J. Wybranska, *A. Heidari, M. Kreissl, J. Mitura;*
Medical Faculty of the Otto-von-Guericke-University (OvGU) Magdeburg, Magdeburg, GERMANY.

EP-1218

AI-Driven Volumetric 17-Segment Myocardial Blood Flow Characterisation Using ^{82}Rb PET/CT

A. Chevalley[1,2], *M. Martin Asiain*[2], *E. Moulton*[3,4,5], *R. Klein*[6], *R. A. DeKemp*[3], *J. O. Prior*[1], *C. H. Kamani*[1,7], *M. Jreige*[1], *A. Depeursinge*[1,2];
[1]*Department of Nuclear Medicine and Molecular Imaging, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SWITZERLAND,*
[2]*Institute of Informatics, HES-SO Valais-Wallis, Sierre, SWITZERLAND,*
[3]*Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, CANADA,*
[4]*University of Ottawa, Ottawa, ON, CANADA,*
[5]*Jubilant DraxImage Inc., Kirkland, QC, CANADA,*
[6]*Division of Nuclear Medicine and Molecular Imaging, University of Ottawa, Ottawa, ON, CANADA,*
[7]*Department of Cardiology, CHUV, Lausanne, SWITZERLAND.*

EP-1219

Structured Empathy Enhances Communication Quality in Clinical AI: A Pilot Evaluation in PSMA Radioligand Therapy

P. Koller[1], *J. Penner*[1], *C. Clement*[1], *W. Bosbach*[1], *B. Becker*[2], *R. Seifert*[1], *K. Shi*[1,3,4];
[1]*Department of Nuclear Medicine, Bern University Hospital, University of Bern, Bern, SWITZERLAND,*
[2]*Department of Psychology, University of Hong Kong, Hong Kong, HONG KONG,*
[3]*Department of Nuclear Medicine, Technical University Munich, Munich, GERMANY,*
[4]*Chair for Computer-aided Medical Procedure, School of Computation, Information & Technology, Technical University Munich, Munich, GERMANY.*

EP-1220

Automated Structured Data Extraction from ^{18}F-FDG PET/CT Reports of Lymphoma patients Using a Locally Deployed Large Language Model

H. Prasad[1], *A. K. Pandey*[1], *J. Chaudhary*[1], *S. Rayamajhi*[1], *P. D. Sharma*[2], *C. D. Patel*[1], *R. Kumar*[1];
[1]*all India Institute Of Medical Sciences, New Delhi, INDIA,*
[2]*SGTB Khalsa College, University of Delhi, Delhi, INDIA.*

EP-1221

GenAI-Driven Quality Management in Nuclear Medicine: An Expert-Validated Framework for Automated Auditing, SOP Generation, and Regulatory Compliance

O. Obolenski[1], *S. Koenig*[2], *K. Shi*[3], *R. A. Bundschuh*[4], *M. Holstensson*[5], *M. Shekari*[6], *V. Goh*[7], *A. F. S. Mikkelsen*[8], *I. Hristova*[9], *B. Kreppel*[1], *R. Boellaard*[10], *P. Chareonthaitawee*[11], *M. Essler*[1], *C. Stokke*[12], *B. J. Erickson*[13], *R. H. J. A. Slart*[14], *M. Marinova*[1];
[1]*Department of Nuclear Medicine, University Hospital Bonn, University of Bonn, Germany, Bonn, GERMANY,*
[2]*Department of Mechanical Engineering, University College London, London, UNITED KINGDOM,*
[3]*Department of Nuclear Medicine, Bern University Hospital, University Hospital Bern, Bern, SWITZERLAND,*
[4]*Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, GERMANY,*
[5]*Department of Nuclear Medicine, Karolinska University Hospital, Stockholm, SWEDEN,*
[6]*Barcelonabeta Brain Research Center, Barcelona, Catalonia, SPAIN,*
[7]*Department of Cancer Imaging, School of Biomedical Engineering & Imaging Sciences, King's College London, London, UNITED KINGDOM,*
[8]*Department of Nuclear Medicine, Aarhus University Hospital, Aarhus, DENMARK,*
[9]*EANM Forschungs GmbH (EARL), Vienna, AUSTRIA,*
[10]*Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, NETHERLANDS,*
[11]*Department of Cardiovascular Medicine, Mayo Clinic, Rochster, MN, UNITED STATES OF AMERICA,*
[12]*Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY,*
[13]*Department of Radiology, Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA,*
[14]*Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, Groningen, NETHERLANDS.*

EP-1222

Validating the Gluteus-C6 Surrogate for Automated PET/CT Body Composition and SUL Normalisation

J. Böhringer[1], *S. Adomeit*[1], *L. Förner*[1,2], *H. Scholtissek*[1], *J. Steinestel*[1], *T. Kröncke*[1], *C. Lapa*[1], *D. Kaufmann*[1], *T. Wendler*[1,2], *SA and JB are first authors with equal contribution;*
[1]*University Hospital Augsburg, Augsburg, GERMANY,*
[2]*Technical University of Munich, Munich, GERMANY.*

EP-1223

From chewing gum during to airport security after scan: Real-world use of Large Language Model for patient's administrative and medical question for Nuclear Medicine scans

A. Latifoltojar[1], *A. Orunmuyi*[1], *M. Wang*[1], *S. A. Voo*[1], *I. Kayani*[1], *R. Oyibo*[1], *K. Gurung*[1], *J. Williams*[1], *M. Rashid*[2], *A. Lopes*[2], *A. Groves*[1], *J. Bomanji*[1];
[1]*University College London Hospital and University College London, London, UNITED KINGDOM,*
[2]*University College London, London, UNITED KINGDOM.*

EP-1225

Altered tumor uptake and cycledependent effects of [^{177}Lu]LuPSMA617 combined with EBRT and ADT in treatmentnaïve patients: a population pharmacokinetic analysis

D. van Asten[1,2], *B. J. de Wit-van der Veen*[2], *W. V. Vogel*[2], *A. Huitema*[1,3,4], *H. Huisman-Siebinga*[1,2];
[1]*Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, NETHERLANDS,*
[2]*Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, NETHERLANDS,*
[3]*Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, NETHERLANDS,*
[4]*Princess Máxima Center for Pediatric Oncology, Utrecht, NETHERLANDS.*

EP-66

D: Technical Studies → D3 Radiation Protection → D31 Radiation Exposure and Protection

EP-1226

Establishment of Diagnostic Reference Levels in PET/CT in Morocco

A. Gbadamassi[1,2], *H. Harrass*[2,3], *Y. Khoulaki*[2], *B. Ibdelkas*[1], *A. Guensi*[1], *D. Benchekroun*[2];
[1]*Department of Nuclear Medicine, CHU Ibn Rochd, Casablanca, MOROCCO,*
[2]*Laboratory of Mechanics and High Energy Physics, Faculty of Sciences Ain Chok, Hassan Second University of Casablanca, Casablanca, MOROCCO,*

[3]Biophysics Laboratory, Faculty of Medicine and Pharmacy, Hassan Second University of Casablanca, Casablanca, MOROCCO.

EP-1227

FLUKA Monte Carlo model for SPECT radiation shielding assessment in a clinical SPECT/CT installation

S. Grima, *S. Agius, G. Valentino, C. J. Caruana;*
University of Malta, Msida, MALTA.

EP-1228

Comparative External Radiation Exposure from ^{18}F-FDG, ^{18}F-NaF, and ^{18}F-PSMA in PET/CT: Implications for Occupational Radiation Safety

L. Ghadhanfer[1], *M. Alqabandi*[2], *E. Alawadhi*[1], *F. Marafi*[3];
[1]*Faculty of Allied Health Sciences, Kuwait University, KUWAIT,*
[2]*Faculty of Medicine, Kuwait University, KUWAIT,*
[3]*Jaber Al-Ahmad Centre for Nuclear Medicine and Molecular Imaging, Ministry of Health, KUWAIT.*

EP-1229

Radiation exposure of patients receiving outpatient lutetium therapy

J. Hudzietzova[1], *M. Fülöp*[2], *A. Vondrák*[3], *P. Ragan*[4], *J. Sabol*[5], *P. Nemček*[3];
[1]*Czech Technical University in Prague, Kladno, CZECH REPUBLIC,*
[2]*ABRS, Ltd., Samorin, SLOVAKIA,*
[3]*Izotopcentrum, Ltd., Nitra, SLOVAKIA,*
[4]*Slovak Medical University, Bratislava, SLOVAKIA,*
[5]*Police Academy of the Czech Republic in Prague, Prague, CZECH REPUBLIC.*

EP-1230

Assessment of dose constraints for pregnant carers in paediatric nuclear medicine

A. Carvalho, *R. Albergueiro, M. Freitas, T. Reis, A. Figueira;*
ULS São João, Porto, PORTUGAL.

EP-1231

Development and evaluation of a system for risk analysis of radioligand therapy with ^{177}Lu-PSMA

C. Happel[1], *C. Stark*[1,2], *W. T. Kranert*[1], *K. Klimek*[1], *B. Sobahi*[1], *B. Bockisch*[1], *M. Fiebich*[2], *D. Groener*[1];
[1]*University Medical Center Frankfurt;*
Clinic for Radiology and Nuclear Medicine, Frankfurt, GERMANY,
[2]*Technische Hochschule Mittelhessen, FB Life Science Engineering, Gießen, GERMANY.*

EP-67

D: Technical Studies → D4 Dosimetry and Radiobiology → D41 Dosimetry Methodology

EP-1232

Probabilistic single-time-point dosimetry for ^{177}Lu-PSMA-617 and ^{177}Lu-DOTATATE: a Bayesian framework using VISION and NETTER-1 priors

A. Bertolet;
Massachusetts General Hospital, Boston, MA, UNITED STATES OF AMERICA.

EP-1233

Estimation of Fetal Radiation Dose from Iodine-131 Following Thyroid Remnant Ablation Performed on Female Patients

V. Spielmann[1], *A. Kamp*[1], *D. Broggio*[2];
[1]*Federal Office for Radiation Protection, Oberschleißheim, GERMANY,*
[2]*Autorité de Sûreté Nucléaire et de Radioprotection (ASNR), Fontenay-aux-Roses, FRANCE.*

EP-1234

Feasibility of Quantitative P-32 Bremsstrahlung SPECT via Monte Carlo Reconstruction: Toward Accurate Activity Recovery

A. Capotosti[1], *L. Polson*[2], *F. Wilson*[2], *R. Moretti*[1], *B. Cassano*[3], *G. Santi Amantini*[4], *M. Felicetti*[1], *D. Fortini*[1], *M. Calcagni*[5,1], *M. De Spirito*[5,1], *L. Indovina*[5,1];
[1]*Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY,*
[2]*VOXIMETRY, Inc, Madison, WI, UNITED STATES OF AMERICA,*
[3]*IRCCS Regina Elena National Cancer Institute, Rome, ITALY,*
[4]*Post Graduation School of Medical Physics, Tor Vergata, Rome, ITALY,*
[5]*Università Cattolica del Sacro Cuore, Rome, ITALY.*

EP-1235

Comparison of ^{177}Lu-PSMA Activity Concentration Recovery between a Digital ^{3}D CZT Ring-Design and a Conventional SPECT/CT System across a Clinically Relevant Activity Concentration Range

T. Noponen, *L. Kääriä, S. Arvola;*
Department of Clinical Physiology, Nuclear Medicine, Turku PET Centre and Medical Physics, Turku University Hospital and Wellbeing services county of Southwest Finland and University of Turku, Turku, FINLAND.

Single-time-point dosimetry in [^{177}Lu]Lutetium-vipivotide tetraxetan therapy: systematic evaluation of day-1 imaging as a surrogate of multi-time-point dosimetry across organs, systems and treatment cycles

J. Donoso[1,2], *Y. Cras*[3], *K. Trabelsi*[1], *H. Noamen*[1], *A. L. Daverio*[1], *M. Borsali*[1], *L. Agrigoroaie*[1], *D. Deandreis*[1], *C. Garcia*[1];
[1]*Nuclear Medicine Dpt. Gustave Roussy, Villejuif, FRANCE,*
[2]*Nuclear Medicine Section. Hospital Clinico. Universidad de Chile, Santiago de Chile, CHILE,*
[3]*Radiophysics Dpt. Gustave Roussy, Villejuif, FRANCE.*

EP-1237

Comparative Analysis of LDM and VSV Voxel-Based Dosimetry Using Post-Therapy ^{90}Y-microsphere PET/CT in transarterial radioembolisation (TARE)

A. Jha[1,2], *A. P M*[1,2], *S. R. Ghag*[1,2], *A. D. Puranik*[1,2], *S. Shah*[1,2], *N. C. Purandare*[1,2], *S. Kulkarni*[1,2], *V. Rangarajan*[1,2];
[1]*Tata Memorial Hospital, Tata Memrial Centre, Mumbai, INDIA,*
[2]*Homi Bhabha National Institute, Mumbai, INDIA.*

EP-1238

Personalised [^{177}Lu]Lu-PSMA Treatment Planning from [^{68}Ga]Ga-PSMA PET/CT Radiomics: A Machine Learning Approach

R. Simões[1,2], *P. Ferreira*[1], *F. Oliveira*[1], *D. Rombo*[1], *Â. Silva*[1], *L. C. Silva*[1], *R. Parafita*[1], *M. Costa*[1], *M. L. Dias*[1], *J. Machado*[2], *D. C. Costa*[1];
[1]*Nuclear Medicine-Radiopharmacology, Champalimaud Foundation, Lisbon, PORTUGAL,*
[2]*NOVA School of Science and Technology, NOVA University Lisbon, Caparica, PORTUGAL.*

EP-1239

A dosimetric study of bladder endocavitary therapy using astatine-211

N. Varmenot[1,2,3], *M. Geffroy*[1], *M. Heymann*[1,4], *J. Chatal*[5], *Z. Lu*[6], *Y. Dewaraja*[6], *J. Barbet*[5], *C. Rousseau*[1,2], *L. Ferrer*[1,2];
[1]*Institut de Cancérologie de l'Ouest - GIP ARRONAX, Saint-Herblain, FRANCE,*
[2]*CRCI²NA, UMR 1307 Inserm-UMR 6075 CNRS, Nantes University, Nantes, FRANCE,*
[3]*GIP ARRONAX, Saint-Herblain, FRANCE,*
[4]*Nantes Université, CNRS, UMR6286, US²B, Nantes, FRANCE,*
[5]*Atonco, Saint-Herblain, FRANCE,*
[6]*Department of Radiology, University of Michigan Medical Center, Ann Arbor, MI, UNITED STATES OF AMERICA.*

EP-1240

Quantitative SPECT/CT dosimetry in [^{177}Lu]Lutetium-vipivotide tetraxetan therapy is system-dependent despite phantom calibration: implications for multicenter studies

Y. Cras[1], *J. T. Donoso Jaurès*[2,1], *H. Noamen*[1], *A. Daverio*[1], *M. Borsali*[1], *K. Trabelsi*[1], *L. Agrigoroaie*[1], *D. Deandreis*[1], *C. Garcia*[1];
[1]*Gustave Roussy, Villejuif, FRANCE,*
[2]*Hospital Clinico Universidad de Chile, Santiago, CHILE.*

EP-1241

Virtual theranostic trial for tracer-specific PSMA PET imaging protocol optimization: towards reliable digital-twin-based predictive dosimetry

M. Sabouri[1,2], *J. Fowler*[1,2], *T. J. McColl*[1,2], *C. F. Uribe*[1,2], *A. Rahmim*[1,2];
[1]*University of British Columbia, Vancouver, BC, CANADA,*
[2]*BC Cancer Research Centre, Vancouver, BC, CANADA.*

EP-1242

A Population-Based Pharmacokinetic Model of [^{177}Lu]Lu-PSMA-617 for Predicting Organ and Tumor Biodistribution in Prostate Cancer Patients

V. Spielmann[1], *D. Kupitz*[2], *W. Li*[1], *M. Kreißl*[2,3];
[1]*Federal Office for Radiation Protection, Oberschleißheim, GERMANY,*
[2]*University Hospital Magdeburg and Medical Faculty of Otto-von-Guericke University, Magdeburg, GERMANY,*
[3]*Research Campus STIMULATE, Otto-von-Guericke University, Magdeburg, GERMANY.*

EP-1243

The Impact of Volume-Integrated Scatter on LEHR Collimator Performance in Large-Volume Lu-177 Dosimetry

N. Kodaloglu[1], *G. Ucmak*[2];
[1]*Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, TÜRKIYE,*
[2]*Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, TÜRKIYE.*

EP-1244

^{225}Ac-DOTATATE Single-Time-Point Absorbed Dose Estimation Using ^{177}Lu-DOTATATE Effective Half-Life

M. Al-Maslamani[1], *J. Yang*[2], *I. Lee*[2], *I. Lim*[2], *S. Woo*[2];
[1]*Korea Institute of Radiological & Medical Sciences (KIRAMS), Seoul, KOREA, REPUBLIC OF,*
[2]*Korea Institute of Radiological & Medical Sciences (KIRAMS), Seoul, KOREA, REPUBLIC OF.*

EP-1245

Monte Carlo simulation of dose distribution in the irradiation of spheroids with Hg-197(m)

A. Hulsch[1], *R. Freudenberg*[2], *F. Brandt*[2], *R. Bundschuh*[2];
[1]*Universitätsklinikum TU Dresden, Dresden, GERMANY,*
[2]*UKDD, Dresden, GERMANY.*

EP-1246

Optimal Acquisition Time for a Population-based Single-Time-Point Dosimetric Method in Lu-177-PSMA Therapy

Y. Liu[1], *A. Afshar-Oromieh*[2], *A. Rominger*[2], *K. Shi*[2], *G. Mok*[1];
[1]*Biomedical Imaging Laboratory (BIG), Department of Electrical and Computer Engineering, Faculty of Science and Technology, Macao, MACAO,*
[2]*Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.*

EP-1247

Personalised Dosimetry in [^{177}Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy: A Machine Learning Approach Using Pre-therapeutic [^{68}Ga] Ga-DOTATATE Radiomics

J. Teles[1,2], *P. Ferreira*[1], *F. Oliveira*[1], *D. Rombo*[1], *Â. Silva*[1], *L. Silva*[1], *R. Parafita*[1], *M. Costa*[1], *M. Dias*[1], *D. C. Costa*[1];
[1]*Champalimaud Foundation, Lisbon, PORTUGAL,*
[2]*NOVA School of Science and Technology, Lisbon, PORTUGAL.*

EP-1248

Validation of Single-Time-Point Dosimetry in Benign Thyroid Disease Using Bateman-Based Nonlinear Mixed-Effects Modelling: Impact of Sampling Time and Disease Kinetics

M. Abuqbeitah[1], *N. Yeyin*[2], *S. Sager*[2], *M. Demir*[2];
[1]*Palestine Polytechnic University, Hebron, PALESTINIAN TERRITORY,*
[2]*Istanbul-University-Cerrahpsa, Istanbul, TÜRKIYE.*

EP-1249

PyTheraTwin: An Open-Source Virtual Theranostic Trial Framework for Ground-Truth Dosimetry in Radiopharmaceutical Therapies

P. Yazdi[1], *J. Fowler*[1,2], *F. Yousefirizi*[1,2], *A. Rahmim*[1,2], *C. Uribe*[1,2], *P. L. Esquinas*[1,2];
[1]*BCCRI, Vancouver, BC, CANADA,*
[2]*UBC, Vancouver, BC, CANADA.*

EP-1250

Uncertainty due to Quantum Noise in Dual Radionuclide SPECT Volume-of-Interest Activities: An Analytical Approach

E. Pearson[1], *T. Stork*[1], *P. Fragoso Costa*[2], *C. Lois*[2], *W. Zhao*[3], *X. Luo*[3], *Y. Du*[3], *E. Frey*[1];
[1]*Radiopharmaceutical Imaging and Dosimetry, LLC,*

Baltimore, MD, UNITED STATES OF AMERICA,
[2]Novartis Pharma AG, Basel, SWITZERLAND,
[3]Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

EP-1251

A Framework for simulating Reactive Oxygen Species generation from Beta- Emitting Radionuclides using Geant4-DNA

D. Thompson[1], *E. Bertelsen*[1], *B. Bednarz*[2], *E. Sajo*[1];
[1]University of Massachusetts- Lowell, Lowell, MA, UNITED STATES OF AMERICA,
[2]University of Wisconsin- Madison, Madison, WI, UNITED STATES OF AMERICA.

EP-1252

Uncertainty Estimation and Propagation in ^{177}Lu Dosimetry: A Phantom Study Using EANM Guidelines

A. Jha[1,2], *P. More*[1,2], *S. R. Ghag*[1,2], *N. Purnadare*[1,2], *V. Rangarajan*[1,2];
[1]Tata Memorial Hospital, Tata Memorial Centre, Mumbai, INDIA,
[2]Homi Bhabha National Institute, Mumbai, INDIA.

EP-1253

Feasibility of Single-Time-Point Dosimetry in [^{225}Ac] Ac-PSMA Radioligand Therapy

M. Dias, *P. Ferreira, F. Oliveira, R. Parafita, M. Costa, L. C. Silva, Â. Silva, D. Rombo, D. C. Costa;*
Champalimaud Foundation, Lisboa, PORTUGAL.

EP-1254

Impact of cross-talk on red marrow absorbed dose estimates and hematological dose-response in [^{177}Lu]Lu-DOTATATE therapy

K. Smits[1], *J. Hemmingsson*[1], *E. Brynjarsdóttir*[1,2], *A. Alvers*[1], *A. Theisen*[3], *A. Gehring*[4], *A. Hallqvist*[1,2], *T. Rydén*[5], *J. Tran-Gia*[3], *P. Bernhardt*[1,5];
[1]Institute of Clinical Sciences, Gothenburg, SWEDEN,
[2]Department of Oncology, Sahlgrenska University Hospital, Gothenburg, SWEDEN,
[3]Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,
[4]Department of Nuclear Medicine, University Hospital Würzburg Würzburg, Würzburg, GERMANY,
[5]Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, SWEDEN.

EP-1255

Pre-therapeutic ^{124}I dosimetry for determining the maximum tolerable activity in (re)differentiated thyroid cancer: evaluating PET-based and reduced-sampling strategies

M. Dotinga[1,2], *L. F. de Geus-Oei*[1,3,4], *F. H. P. van Velden*[1], *P. Dibbets-Schneider*[1], *E. Kapiteijn*[1], *M. Pool*[1], *L. Heijmen*[1], *M. K. Stam*[1], *D. Vriens*[5];
[1]Leiden University Medical Center, Leiden, NETHERLANDS,
[2]Netherlands Cancer Institute, Amsterdam, NETHERLANDS,
[3]University of Twente, Enschede, NETHERLANDS,
[4]Delft University of Technology, Delft, NETHERLANDS,
[5]Radboud University Medical Center, Nijmegen, NETHERLANDS.

EP-1256

Validation of Monte Carlo-Based Voxel-Wise Dosimetry in the Updated MIM SurePlan™ MRT: Application to ^{177}Lu Radionuclide Therapy

K. Miwa[1], *K. Wachi*[1], *A. Komatsu*[1], *N. Miyaji*[1], *T. Yamao*[1], *N. Akiya*[1], *T. Horikawa*[1], *Y. Ogane*[1], *D. Mirando*[2], *M. Morimoto*[3], *A. Oishi*[3], *Y. Yamamoto*[4], *Y. Nishiyama*[4];
[1]Fukushima Medical University, Fukushima, JAPAN,
[2]GE HealthCare, Chicago, IL, UNITED STATES OF AMERICA,
[3]Kagawea University Hospital, Kagawa, JAPAN,
[4]Kagawa University, Kagawa, JAPAN.

EP-1257

Effect of a personalised S value on active bone marrow absorbed doses in patients treated with ^{90}Y Anti-CD66 radioimmunotherapy for haematological malignancies

E. Morris[1,2], *S. Michopoulou*[2,3], *K. Orchard*[2,3], *P. Schneider*[2], *A. Dickinson*[2];
[1]Barts Health NHS Trust, London, UNITED KINGDOM,
[2]University of Southampton, Southampton, UNITED KINGDOM,
[3]University Hospital Southampton, Southampton, UNITED KINGDOM.

EP-1258

Feasibility of Cumulative Dosimetry after External Beam Radiotherapy and Targeted Radionuclide Therapy with ^{177}Lu-DOTATATE in Refractory Meningiomas

J. Badel[1], *D. Toalombo-Montero*[1], *M. P. Sunyach*[1], *D. Kryza*[1], *L. Vergnaud*[2], *D. Sarrut*[2], *T. Mognetti*[1], *A. Sanchez-Lajusticia*[1], *A. L. Giraudet*[1];
[1]Centre Leon-Berard, Université de Lyon, Lyon Cedex 08, FRANCE,
[2]CREATIS, Villeurbanne, FRANCE.

EP-1259

A new framework to evaluate the absorbed dose distribution in a tumour microenvironment with heterogeneous target expression

A. Larouze[1], *R. J. Giedt*[2], *U. Olgac*[1], *A. Kristian*[1], *G. Tamborino*[2], *S. Gaudet*[2], *G. Birindelli*[1];
[1]Novartis, Basel, SWITZERLAND,
[2]Novartis, Cambridge, MA, UNITED STATES OF AMERICA.

EP-1260

Dosimetry of the Peritoneum from Radium-224 Calcium Carbonate Microparticles Estimated Using Monte Carlo Simulations

S. Grønningsæter[1,2], *S. Westrøm*[3], *A. Aksnes*[3], *K. Myren*[3], *M. Revheim*[4,5], *C. Stokke*[1,6];
[1]Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY,
[2]Department of Physics, University of Oslo, Oslo, NORWAY,
[3]Oncoinvent Solutions AS, Oslo, NORWAY,
[4]The Intervention Centre, Division of Technology and Innovation, Oslo University Hospital, Oslo, NORWAY,
[5]Faculty of Medicine, University of Oslo, Oslo, NORWAY,
[6]Department of Physics, Oslo University Hospital, Oslo, NORWAY.

EP-1261

Towards traceable and PET-based verification of administered ^{90}Y activity in SIRT

M. Sevenois[1], *W. Deckers*[1], *C. Terwinghe*[1], *G. Schramm*[2], *M. Koole*[2], *C. M. Deroose*[1], *K. Baete*[1];
[1]UZ Leuven, Leuven, BELGIUM,
[2]KU Leuven, Leuven, BELGIUM.

EP-1262

Single-Time-Point Time-Integrated Activity Estimation in ^{177}Lu-PSMA Therapy: Evaluation of Analytical and Hybrid Machine Learning Methods

Z. Mansouri[1], *K. Fitzpatrick*[2], *M. Fredericks*[2], *K. Suresh*[3], *M. Roseland*[2], *K. Wong*[2], *H. Zaidi*[1], *Y. K. Dewaraja*[2];
[1]Geneva University Hospital, Geneva, SWITZERLAND,
[2]Department of Radiology, University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA,
[3]Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA.

EP-1263

Application of new uncertainty methodologies to SPECT activity quantification

A. Robinson[1,2], *D. Deidda*[1], *A. M. Denis-Bacelar*[1], *K. M. Ferreia*[1], *A. J. Fenwick*[1], *W. Heetun*[1,3], *B. F. Hutton*[4], *J. Scuffham*[1,2], *K. Thielemans*[4];
[1]National Physical Laboratory, Teddington, UNITED KINGDOM,
[2]Royal Surrey NHS Foundation Trust, Guildford, UNITED KINGDOM,
[3]St George's Hospital, London, UNITED KINGDOM,
[4]University College of London, London, UNITED KINGDOM.

EP-1264

A Parametric Approach to Background-Corrected Partial Volume Correction in Lu-177 SPECT/CT Using the SNMMI Torso Phantom

J. Anton-Rodriguez[1], *S. Qasim*[1], *F. Eddy*[1], *A. P. Robinson*[2], *P. Julyan*[1], *H. A. Williams*[1], *G. James*[1];
[1]The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM,
[2]National Physical Laboratory, Teddington, UNITED KINGDOM.

EP-1265

Algorithmic Biases in dose summation between External Beam Radiotherapy and Molecular Radiotherapy: Effects of registration and dose map resampling across two dosimetric approaches.

J. Badel[1], *G. Bourdon*[1], *D. Toalombo-Montero*[1], *D. Sarrut*[2], *A. Sanchez-Lajusticia*[1], *A. L. Giraudet*[1], *T. Mognetti*[1];
[1]Centre Leon-Berard, Université de Lyon, Lyon Cedex 08, FRANCE,
[2]CREATIS, Villeurbanne, FRANCE.

EP-1266

Does Bed Overlap Affect the Accuracy of Y-90 Treatment Planning?

L. Gilys, *M. Merkis, I. Jogaitė;*
Hospital of Lithuanian University of Health Sciences Kauno klinikos, Kaunas, LITHUANIA.

EP-1267

DEQCT-Based Quantification of Bone and Marrow-Equivalent Materials in Calibrated Electron-Density Phantom Inserts

M. Salas Ramirez[1], *H. Huflage*[2], *J. Hemmingsson*[3], *A. Theisen*[1], *E. Pettersson*[4], *C. Choi*[5], *R. J. Dawson*[6], *B. Shin*[5], *P. Bernhardt*[3], *M. Lassmann*[1], *W. E. Bolch*[5], *J. Tran-Gia*[1];
[1]Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,
[2]Department of Diagnostic and Interventional Radiology, University Hospital Würzburg, Würzburg, GERMANY,
[3]Department of Medical radiation Sciences, University of Gothenburg, Gothenburg, SWEDEN, [4]•Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN,
[5]J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, UNITED STATES OF AMERICA,
[6]Medical Physics Program College of Medicine, University of Florida University of Florida, Gainesville, FL, UNITED STATES OF AMERICA.

EP-68

D: Technical Studies → D4 Dosimetry and Radiobiology → D42 Clinical Radiobiology

EP-1268

Using radiobiology to infer biomarkers: an adaptive Bayesian trial design for ^{177}Lu-PSMA from the LUNAR trial

A. Bertolet, *C. Huesa-Berral;*
Massachusetts General Hospital, Boston, MA, UNITED STATES OF AMERICA.

EP-1269

Preclinical Evaluation of Carbon Ion Irradiation Combined with ^{177}Lu-CTR-FAPI for Metastatic Pancreatic Cancer

L. Jicheng, *J. Liu;*
lanzhou university, lanzhou, CHINA.

EP-1270

Actinium-225 (Ac-225) SPECT and Radiation Dosimetry from CONVERGE-01 Phase 2: Ac-225 Rosopatamab Tetraxetan (CONV01-α) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

H. A. Jacene[1], *P. Ravi*[1], *S. Gavane*[2], *A. Hamid*[2], *L. Nordquist*[3], *K. P. Friedmann*[4], *J. R. Osborne*[5], *C. N. Sternberg*[5], *E. Zan*[6], *S. Gupta*[6], *J. Dormer*[7], *B. He*[7], *S. Chandrasekhar*[8], *N. A. Schreiber*[8], *R. A. Messmann*[8], *P. W. Kantoff*[8], *N. H. Bander*[8], *J. Nauseef*[8], *S. Vallabhajosula*[8], *D. R. Wise*[4];
[1]Dana-Farber Cancer Institute, Boston, MA, UNITED STATES OF AMERICA,
[2]Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA,
[3]XCancer, Omaha, NE, UNITED STATES OF AMERICA,
[4]Perlmutter Cancer Center, NYU Langone, New York, NY, UNITED STATES OF AMERICA,
[5]Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA,

[6]Cleveland Clinic - Taussig Cancer Institute, Cleveland, OH, UNITED STATES OF AMERICA,
[7]Radiopharmaceutical Imaging and Dosimetry, LLC (Rapid), Baltimore, MD, UNITED STATES OF AMERICA,
[8]Convergent Therapeutics, Inc., Cambridge, MA, UNITED STATES OF AMERICA.

EP-69

D: Technical Studies → D5 Radiopharmacy/Radiochemistry → D51 Radionuclide Production

EP-1271

A Study on the Integrated Regulatory Approach to Licensing Medical Radioisotope Processing Facilities

S. Jung, *J. Kim;*
Korea Hydro & Nuclear Power Co., Ltd, Seoul, KOREA, REPUBLIC OF.

EP-70

D: Technical Studies → D5 Radiopharmacy/Radiochemistry → D52 Radiopharmaceutical Preparation and Quality Control

EP-1272

Quality Performance and Process Capability of [18F]F-PSMA-1007 Productionandcorrectiveactionsmade: A Two-Year Retrospective Analysis

E. Otero Ruiz[1], *L. Pérez Sánchez*[2], *E. Segura Bru*[2], *I. Gana Watkins*[2], *G. Pla González*[2];
[1]*Hospital Universitario Vall d'Hebron, Barcelona, SPAIN,*
[2]*Institut de Radiofarmàcia Aplicada de Barcelona (IRAB), Barcelona, SPAIN.*

EP-1273

Development and Preliminary Evaluation of a Sterilizable Ga-68-APD Kit for CXCR4-Targeted PET Imaging of Atherosclerosis

S. Chen, *C. Chen, C. Hsia;*
National Atomic Research Institute, Taoyuan, TAIWAN, PROVINCE OF CHINA.

EP-1274

Metrological control of clinical dose calibrators: results from a calibration campaign using a secondary standard laboratory

C. Hoog, *S. Douillard, M. Messéant, J. Gratiaux, L. Paty, P. Paris, D. Papathanassiou, D. Morland;*
Godinot institute, Reims, FRANCE.

EP-1275

Radiosynthesis of the novel 18F-fluoroethyl derivative of LBQ657 for neprilysin PET Imaging

E. Ourhzif[1,2,3], *V. Teyssier*[1,2,3], *J. DaSilva*[1,2,3];
[1]*Centre de recherche du centre hospitalier de l'Université de Montréal, Montreal, QC, CANADA,*
[2]*Département de pharmacologie et physiologie, Université de Montréal, Montreal, QC, CANADA,*
[3]*Institut de Génie Biomédical, Faculté de Médecine, Université de Montréal, Montreal, QC, CANADA.*

EP-1276

The Specialty of Radiopharmacy is Strengthened by the Strategy in Theragnostics.

C. Piedelobo Vaquero[1], *P. Pastor Fructuoso*[2], *L. Cebollada Cameo*[1], *L. Sanz Vazquez*[1], *E. Dobra Neacsu*[1], *J. Pérez Iruela*[1];
[1]*Servicio de Radiofarmacia. Hospital Universitario Ramón y Cajal., Madrid, SPAIN,*
[2]*Unidad de Calidad. Hospital Universitario Ramón y Cajal., Madrid, SPAIN.*

EP-1277

Radiopharmaceutical Prescription Validation: The Impact of Systematization

E. Dobra Neacsu, *P. Pastor Fructuoso, L. Cebollada Cameo, C. Piedelobo Vaquero, L. Sanz Vázquez, J. Pérez Iruela;*
Hospital Universitario Ramón y Cajal, Madrid, SPAIN.

EP-1278

Radiosynthesis and In Vitro Stability Assessment of SO2F-Functionalised Curcumin Derivatives for PET Radiotracer Development

J. Chun[1], *J. Son*[2], *S. Kim*[1], *S. Kim*[1], *J. Jeong*[2];
[1]*Nuclear Medicine, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF,*
[2]*Nuclear Medicine, Severance Hospital, Yonsei University Health System, Seoul, KOREA, REPUBLIC OF.*

EP-1279

A Novel Approach to Radiometabolite Analysis of High Molecular Weight Molecules: Radiometabolite Profiling from Blood Samples Using SPE-HPLC Technique for [18F]-HER2

M. Moein[1,2], *K. Bratteby*[1], *A. Nisiewicz*[3], *R. Afram*[3], *H. Bozkurt*[3], *H. Marefat Yusofi*[3], *C. Hindorf*[1], *T. Tran*[1,2], *A. Tzortzakakis*[3,4], *M. Holstensson*[3,4];
[1]*Theranostics Trial Center, Karolinska University Hospital, Stockholm, Sweden, Stockholm, SWEDEN,*
[2]*Dept of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden., Stockholm, SWEDEN,*
[3]*Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Huddinge, Sweden., Stockholm, SWEDEN,*
[4]*Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden, Stockholm, SWEDEN.*

EP-1280

Pitfalls of Automated Elution Systems: Practical Errors

A. Mihelcic, *B. Hudomalj;*
Institute of Oncology Ljubljana, Ljubljana, SLOVENIA.

EP-1281

Comparison of two sedimentation agents in the labelling of leucocytes with [99mTc]Tc-HMPAO: Hydroxyethyl starch vs succinylated gelatin

A. Puig Colom[1], *M. Villar Pulido*[1], *M. Vivar Pérez*[1], *M. Ruíz Santaella*[1], *S. Chamizo Ruiz*[1], *A. Guerra*[2], *E. Durand Gomez*[2], *A. Luján Colás*[2], *F. Vega Martinez*[1];
[1]*Radiopharmacy Unit, Hospital Universitario Son Espases, Palma, SPAIN,*
[2]*Nuclear Medicine Department, Hospital Universitario Son Espases, Palma, SPAIN.*

EP-1282

Determination of plasma volumen by radioisotopic method as the gold standard for the differential diagnosis between the syndrome of inappropriate antidiuretic hormone secretion and cerebral salt-wasting syndrome.

L. Cebollada-Cameo[1], *M. Domínguez-Tejedor*[2], *E. Dobra-Neacsu*[1], *C. Piedelobo-Vaquero*[1], *L. Sanz-Vázquez*[1], *J. Pérez-Iruela*[1];
[1]*Servicio de Radiofarmacia. Hospital Universitario Ramón y Cajal, Madrid, SPAIN,*
[2]*Servicio de Nefrología, Hospital Universitario Ramón y Cajal, Madrid, SPAIN.*

EP-1283

Dual Fractionated Elution of Paired 68Ge/68Ga Generators for [68Ga]Ga-PSMA-11: Enhanced Yield, Extended Generator Lifetime and Reduced Radioactive Waste

S. Kijprayoon, *P. Ruangma;*
Bangkok Hospital, Bangkok, THAILAND.

EP-1284

Analytical Performance of TLC scanner, Gamma Camera, and Contamination monitor in Determining Technetium-99m Radiochemical Purity

M. Znati Jouini[1,2], *W. Saidi*[1,2], *M. Romdhani*[1], *C. Habechi*[1], *A. Toumi*[1,2], *N. Ayachi*[1,2], *K. Chatti*[1,3];
[1]*Nuclear Medicine Department of Sahloul University Hospital, Sousse, TUNISIA,*
[2]*Faculty of pharmacy of Monastir, Monastir, TUNISIA,*
[3]*Faculty of medicine of Monastir, Monastir, TUNISIA.*

EP-1285

Harnessing Terbium-161 for FAP-Targeted Theranostics: Radiolabeling and In Vitro Characterization of [161Tb]Tb-FAPI-46 and [161Tb]Tb-FAP-2286

C. Sezgin[1], *E. Uygur*[2], *D. Baran*[3], *R. Çelik*[3], *B. Özel*[2], *Y. Parlak*[2], *F. Gümüşer*[4], *F. Biber Müftüler*[3];
[1]*Manisa City Hospital, Manisa, TÜRKIYE,*
[2]*Manisa Celal Bayar University, Manisa, TÜRKIYE,*
[3]*Ege University, İzmir, TÜRKIYE,*
[4]*Manisa Cielal Bayar University, Manisa, TÜRKIYE.*

EP-1286

Improved Synthesis of DFO*SP and oxoDFO* for Zirconium-89 Radiopharmaceutical Development

K. Lumyong[1,2,3], *R. A. J. Maradan*[1,2,3], *D. Svatunek*[4], *C. Decristoforo*[5], *T. L. Mindt*[1,3];
[1]*Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, AUSTRIA,*
[2]*Vienna Doctoral School in Chemistry, University of Vienna, Vienna, AUSTRIA,*
[3]*Joint Applied Medicinal Radiochemistry Facility, University of Vienna and Medical University of Vienna, Vienna, AUSTRIA,*
[4]*Institute of Applied Synthetic Chemistry, TU Wien, Vienna, AUSTRIA,*
[5]*Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA.*

EP-1287

The role of Radiolabelling during the RESTORE Clinical Trial

R. Tegala, *S. Edmonds;*
Guy's & St, Thomas NHS Trust, London, UNITED KINGDOM.

EP-1288

Clinical and Biological Determinants of Ictal SPECT success using Stabilised [99mTc]Tc-HMPAO: Implications for Radiopharmaceutical Planning

M. Ruiz Santaella[1], *M. Villar Pulido*[1], *A. Puig Colom*[1], *M. Vivar Perez*[1], *S. Chamizo Ruiz*[1], *F. Vega Martinez*[1], *A. Guerra*[2], *E. Durand Galindez*[2], *A. Luján Colás*[2];
[1]*Radiopharmacy Unit, Hospital Universitario Son Espases, Palma de Mallorca, SPAIN,*
[2]*Nuclear Medicine Department, Hospital Universitario Son Espases, Palma de Mallorca, SPAIN.*

EP-1289

From Procurement to R&D Partnership: A Physician-Led Management Model for Outsourced Radiopharmaceutical Integration in Nuclear Medicine

A. Pisani[1], *F. Iuele*[2], *C. Altini*[2], *V. Lavelli*[2], *G. Rubini*[2];
[1]*Univerisity of Bari, Bari, ITALY,*
[2]*Nuclear Medicine Unit, DIM, University of Bari "Aldo Moro", Policlinic of Bari, Bari, ITALY.*

EP-1290

Apheresis-derived [111In]In-Oxine platelet kinetics and sequestration patterns: A predictive tool for clinical management and the avoidance of futile splenectomy in refractory immune thrombocytopenia (ITP).

L. Sanz Vázquez, *A. Martínez Lorca, G. Moreno Jiménez, L. Cebollada Cameo, C. Piedelobo Vaquero, E. Dobra Neacsu, J. Pérez Iruela;*
Hospital Universitario Ramón y Cajal, Madrid, SPAIN.

EP-1291

Validation Of A New Method for assesing the radiochemical purity of [99mTc]Tc-Tetrofosmin Using Radio-TLC

A. Barca Gil, *M. Martín Cerecedo, R. Sánchez Sánchez;*
Hospital Universitario de Badajoz, Badajoz, SPAIN.

EP-1292

Automatization of the convesion proccess of [67Ga]Ga-citrate to [67Ga]Ga-chloride

M. De Arcocha Torres[1], *V. Mendi-Barcina*[1], *L. García-Lama*[1], *I. Martínez-Rodríguez*[2], *F. Gómez-De la Fuente*[2], *N. Martínez-Amador*[2], *A. Sánchez-Salmón*[2], *J. Jiménez-Bonilla*[2], *B. Lucas-Velázquez*[2], *N. Carvalho-Duarte*[2], *F. Rodríguez-Rodríguez*[2], *M. Botanch-Domingo*[2], *L. Cabrera-Portillo*[2], *P. Andrade-Mejía*[2], *A. Clavijo-Umbarila*[2], *S. Cabrera-Zuñiga*[2], *D. Hernández-Serrano*[2], *R. Quirce*[2];
[1]*Radiopharmacy Unit. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN, Santander, SPAIN,*
[2]*Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN, Santander, SPAIN.*

EP-1293

Evaluation of In Vitro and In Vivo Stability of ^{188}Re-Liposome Prepared at Increased Labelling Activities

S. Chen[1], *Y. Chang*[1], *Y. Lai*[2];
[1]*National Atomic Research Institute, Taoyuan, TAIWAN, PROVINCE OF CHINA,*
[2]*University of North Carolina at Chapel Hill, Chapel Hill, NC, UNITED STATES OF AMERICA.*

EP-1294

Development of radioiodinated nucleosides for conjugation to the neural stem cells-grafted nanogel as drug carriers for potential application in targeted therapy of glioblastoma

M. Sadeghzadeh[1], *R. Ajana*[1,2], *A. T. J. Vogg*[1], *B. Altunay*[1], *A. Morgenroth*[1], *F. M. Mottaghy*[1,3];
[1]*Department of Nuclear Medicine, Faculty of Medicine, Uniklinik RWTH Aachen, Aachen, GERMANY,*
[2]*Department of Chemistry and Biotechnology, Aachen University of Applied Sciences, Jülich, GERMANY,*
[3]*Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, NETHERLANDS.*

Aim/Introduction: Neural stem cells (NSCs) have been investigated as biological drug carriers for targeted therapy in glioblastoma using their ability to cross the blood brain barrier and migrating to the tumor side [1]. We previously developed novel conjugates [^{125}I]ITdU-MMP2-nanogel (a highly cytotoxic Auger electron emitting agent) and NSC-grafted EdC-DTBP-nanogel as nucleoside carriers, which showed promising biological performance and pharmacokinetics [2a-b]. However, the DTBP linker was not stable enough in vitro, therefore we aimed to develop a stable aliphatic disulfide-linker to conjugate ^{125}I-labelled 2-deoxycytidine (DCT) analogues with NSC-grafted nanogels. Here we report the organic synthesis of the linker and the radiolabelling of two nucleoside analogues to evaluate their suitability for conjugation to nanogels. ***Materials and Methods:*** A six-carbon aliphatic disulfide-linker was coupled with DCT and EdC via a five-step synthetic approach. Intermediates and final products were characterized by TLC, NMR, MS and HPLC. Radioiodination of nucleoside derivatives with ^{125}I was carried out via direct electrophilic substitution using in situ-prepared [^{125}I]NIS, with or without $Ag(NTFA)_2$ catalyst, depending on site-selective substitution of hydrogen by ^{125}I at heterocyclic alkenic position of DCT or alkyne substituent at the 5-position of EdC. Quality control of the radioiodinated compounds was performed by Radio-TLC and -HPLC. ***Results:*** The first approach coupling DCT derivatives with the disulfide-linker bearing an activated either chloroformate or carbonate intermediate was not successful. This was due to the limited nucleophilicity of the amino group of the EdC caused by tautomerisation, steric hindrance effects and low stability of the chloroformate group which finally hindered the formation of the coupled product. Redesigning the conjugate by introducing an amide instead of a carbamate group and removing the alkyne substitution of the EdC gave the coupled product in 35% yield, confirmed by the NMR and LC-MS. Direct radioiodination of both DCT and EdC using [^{125}I]NIS afforded the corresponding ^{125}I-labelled nucleosides with >50% radiochemical conversion and >95% radiochemical purity. ***Conclusion:*** The developed disulfide-linker facilitated the selective and stable conjugation of the ^{125}I-labelled nucleosides to the NSC-grafted nanogels. Robust synthetic and radioiodination protocols were established to achieve the ^{125}I-labelled nucleosides in high labelling yield. Radioiodination of the DCT coupled with the disulfide-linker and further in vitro stability studies are ongoing to pave the way for the preclinical evaluation of the NSC-grafted nanogels. ***References:*** [1] Qu D, et al. Anal Biochem. 2011, 417:112; [2] a)Singh et al. Adv. Healthcare Mater. 2021, 2100812; b)Morgenroth A, et al. Appl. Mater. Interfaces 2023, 15:21792.

EP-1295

Rapid Sterility Testing for ^{18}F-labelled radiopharmaceuticals: Comparability of a Solid-Phase Cytometry Method with the Compendial Test

J. Gitz Holler, *S. Westly, V. Gjervan, V. Wist Holthe, L. Sørum Tarbotton;*
PET center, St. Olavs Hospital, Trondheim, NORWAY.

EP-1296

Optimized Tc99m-HMPAO Radiolabelling of DonorDerived Platelets for Clinical Platelet Kinetics Imaging

A. Socan[1], *M. Leskovec*[1], *M. Fink*[1], *K. Dvoršak*[1], *T. Furlan*[1], *N. Vrhovec Damijanovič*[2];
[1]*University Medical Centre Ljubljana, Ljubljana, SLOVENIA,*
[2]*Faculty of Medicine, University of Ljubljana, Institute of Microbiology and Immunology, Ljubljana, SLOVENIA.*

EP-1297

Optimization of the stability of 177LuPSMAI&T productions

L. Zucaro[1,2], *K. Casagrande*[1,2], *J. Costes*[1,2], *A. Pierrot*[1,2], *J. Masset*[3], *F. Sadeghipour*[1,2], *J. Delage*[1,2];
[1]*Radiopharmacy Unit, Department of Pharmacy, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, SWITZERLAND,*
[2]*Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva and University of Lausanne, Lausanne, SWITZERLAND,*
[3]*Department of Research and Development, Trasis Radiopharmacy Instruments, Ans, BELGIUM.*

EP-1298

Qualification of a Laminar Airflow Cabinet in a Radiopharmacy Unit

E. Ricart-Paredes, *S. Orts Expósito, C. García Alcober, D. Rodríguez Puig, S. Maymó Garrido, D. Tamayo Ossa, M. Zamorano Rivas, J. Díaz Moreno, M. Argelés Clotet, M. Cortés Romera;*
Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, SPAIN.

EP-1299

Molar activity with carbon-11: analysis of influencing factors and comparison of gas and wet production methods

N. Malié[1,2], *A. Bruno*[2], *L. Lopez*[2], *A. Bruyère*[1,2], *L. Kazek*[1,2], *C. Tourvieille*[2], *S. Lancelot*[1,2,3], *P. Courault*[1,2,3];
[1]*Hospices Civils de Lyon, Lyon, FRANCE,*
[2]*CERMEP, Bron, FRANCE,*
[3]*Université Claude Bernard Lyon [1], CNRS, INSERM, Lyon Neuroscience Research Center, Lyon, FRANCE.*

EP-1300

Does Radiolabeling Complexity Predict Radiochemical Purity Variability in Routine ^{99m}Tc Preparations?

M. Znati Jouini[1,2], *A. Toumi*[1,2], *W. Saidi*[1,2], *C. Habechi*[1], *N. Ayachi*[1,2], *K. Chatti*[1,3];
[1]*Nuclear Medicine Department of Sahloul University Hospital, Sousse, TUNISIA,*
[2]*Faculty of pharmacy of Monastir, Monastir, TUNISIA,*
[3]*Faculty of medicine of Monastir, Monastir, TUNISIA.*

EP-1301

Inter-operator variability of radiochemical purity in ^{99m}Tc-MIBI radiolabelling under routine radiopharmacy conditions

M. Znati Jouini[1,2], *M. Romdhani*[1], *W. Saidi*[1,2], *C. Habechi*[1], *A. Toumi*[1,2], *N. Ayachi*[1,2], *K. Chatti*[1,3];
[1]*Nuclear Medicine Department of Sahloul University Hospital, Sousse, TUNISIA,*
[2]*Faculty of pharmacy of Monastir, Monastir, TUNISIA,*
[3]*Faculty of medicine of Monastir, Monastir, TUNISIA.*

EP-1302

Validation of 40 mg/mL Succinylated Gelatineas a Settling Agent in Leukocyte Labelling with [^{99m}Tc] Tc-HMPAO

C. Piedelobo Vaquero[1], *L. Cebollada Cameo*[1], *L. Sanz Vazquez*[1], *E. Dobra Neacsu*[1], *S. Horcas Villaverde*[2], *J. Pérez Iruela*[1];
[1]*Servicio de Radiofarmacia. Hospital Universitario Ramón y Cajal., Madrid, SPAIN,*
[2]*Medicina Nuclear. Hospital Universitario Ramón y Cajal., Madrid, SPAIN.*

EP-71

E: Other Studies → E1 Case Reports

EP-1303

[^{68}Ga]Ga-PSMA-11 PET/CTin Suspected Intracranial Metastatic Seeding of Clear Cell Renal Cell Carcinoma Within a Known Meningioma: A Case Report

G. Beydagi[1], *L. Urso*[2], *F. Lancia*[3], *A. Iudicello*[4], *L. Uccelli*[2], *C. Cittanti*[2], *E. Arslan*[5], *M. Bartolomei*[4];
[1]*Department of Nuclear Medicine, University of Health Sciences Turkey, Istanbul Training and Research Hospital, Istanbul, TÜRKIYE,*
[2]*Translational Medicine Department, University of Ferrara, Ferrara, ITALY,*
[3]*Oncology Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferrara, ITALY,*
[4]*Nuclear Medicine Unit, Onco-Hematological Department, University Hospital of Ferrara, Ferrara, ITALY,*
[5]*Department of Nuclear Medicine, University of Health Sciences Turkey, Istanbul Training and Research Hospital, Istanbul, Türkiye, Istanbul, TÜRKIYE.*

EP-1304

Sequential Organ-Specific Relapse in Paucibacillary Extrapulmonary TB: Longitudinal ^{18}F-FDG PET/CT Documentation with IGRA Seroconversion

S. C O, *S. H V, K. G A;*
Narayana Health, Bangalore, INDIA.

EP-1305

Application of Gastric Emptying Scintigraphy in Middleton Syndrome - Initial Diagnosis and Assessment of Efficacy of Novel Treatment with a Calcium Channel Blocker - a Case Report

P. Cichocki, *P. Gadzicki, Z. Adamczewski;*
Department of Nuclear Medicine, Medical University of Lodz, Lodz, POLAND.

EP-1306

Severe salivary gland involvement on salivary gland scintigraphy in seronegative Sjögren's syndrome associated with primary biliary cholangitis

A. Sagastegui Alca, *G. Martínez Gómez, C. Moriana Simón, T. Moreno Monsalve, T. Rodríguez Locarno, N. Sánchez Izquierdo, M. Castellón Sánchez, M. Ibañez Ibañez, L. Mohamed Salem, J. Navarro Fernández, L. Frutos Esteban, J. Contreras Gutiérrez;*
Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-1307

Markedly Asymmetric FDG PET Pattern in Genetically Confirmed C9orf72-Related Frontotemporal Dementia-ALS Spectrum: A Case Report

M. Sanchez Torrente, *S. Martin Aguilar, E. Moratalla Aranda, M. Ureña Lara;*
Hospital Universitario de Jaén, Jaén, SPAIN.

EP-1308

^{177}Lu-PSMA as a therapeutic opportunity in advanced chondrosarcoma with limited treatment options: Insights from dual-tracer PET/CT

C. Torricelli, *E. Nogueira-Lima, M. Silva, N. Tobar, A. Santos, M. Lima, J. B. C. Carvalheira, M. Etchebehere, E. Etchebehere;*
University of Campinas (UNICAMP), Campinas, BRAZIL.

EP-1309

The "Hot Quadrate Lobe" Sign: A Diagnostic Pitfall of ^{18}F-FDG PET/CT in Primary Mediastinal Large B-Cell Lymphoma with SVC Obstruction

W. Wong;
Nuclear Medicine Unit, Queen Elizabeth Hospital, Hong Kong, HONG KONG.

EP-1310

From non-specific pleural uptake to advanced mesothelioma: the evolving role of serial ^{18}F-FDG PET/CT in an atypical post-pleurodesis presentation.

D. J. Tamayo-Ossa[1], *A. Bagán-Trejo*[1], *M. Suarez-Piñera*[1], *C. A. Tapias-Mesa*[1], *A. B. Dacosta-Escobar*[1], *H. I. Jofre-Grimaldo*[2], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine-PET (IDI) Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN,*
[2]*Radiodiagnosis Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, SPAIN.*

EP-1311

^{18}F-FDG PET/CT for Staging Mycosis Fungoides

Z. Kikich, *A. Mouaden, A. Taalabi, D. Alami, H. Guerrouj;*
Mohammed V University, Rabat, MOROCCO.

EP-1312

Functioning pulmonary metastases as the cause of euthyroidism after total thyroidectomy in pediatric differentiated thyroid carcinoma: a case report

L. Castillejos, *C. Paniagua, S. Pérez Quirós, A. Ortega Valle, M. Tagliatori, A. Herrero, M. de la Rubia, C. Galindo, K. Guichay, A. Sicilia, M. García Alonso;*
Hospital Universitario de Getafe, Madrid, SPAIN.

EP-1313

When Tumor and Toxicity Overlap: [^{18}F]FDG PET/CT Assessment of Divergent Response and Bleomycin-Induced Pneumonitis in Metastatic Embryonal Carcinoma

T. Stoeva, *M. Dyankova, S. Chausheva, T. Yordanova, B. Chaushev, A. Klisarova;*
UMHAT "Sveta Marina", Varna, BULGARIA.

EP-1314

Isolated Tibial Metastasis from Endometrial Carcinoma Detected by Whole-Body PET/CT: A Case Report

S. Fares Bratic[1,2], *V. Jozanovic*[1,3], *A. Tabain*[1];
[1]*Department of Radiology and Nuclear Medicine, PET/CT Centre, Medikol Polyclinic, Zagreb, CROATIA,*
[2]*Department of Nuclear Medicine, General Hospital Varazdin, Varazdin, CROATIA,*
[3]*Department of Nuclear Medicine, Clinical Hospital Dubrava, Zagreb, CROATIA.*

EP-1315

Heterogeneous Bone Marrow FDG Uptake Mimicking Skeletal Metastases in a Patient with Prior Fallopian Tube Carcinoma: Diagnosis of Secondary Myeloproliferative Disorder

O. Bourogianni, *N. Kapsoritakis, E. Papadaki, M. Stathaki, S. Koukouraki;*
Nuclear Medicine Department, University Hospital of Crete, Heraklion, GREECE.

EP-1316

Dual Diagnostic Role of ^{18}F-FDG PET/CT in a Rare Case of Atezolizumab-Induced Thoracic Aortitis and Incidental Gastrointestinal Stromal Tumour: A Case Report

M. Kotur[1], *S. Odalovic*[1,2], *I. Grozdic Milojevic*[1,2], *L. Grujicic*[1], *N. Pantic*[1], *M. Mihajlovic*[1], *D. Sobic Saranovic*[1,2], *V. Artiko*[1,2];
[1]*Center for Nuclear Medicine with PET, University Clinical Center of Serbia, Belgrade, SERBIA,*
[2]*Faculty of Medicine, University of Belgrade, Belgrade, SERBIA.*

EP-1317

Searching for the culprit: ^{18}F-FDG PET/CT in persistent candidemia

A. De Agrela Serrao, *M. V. Guiote Moreno, A. Baumela Puertas, I. Cejudo Liebana, J. Fernandez Fernandez, J. Vallejo Casas;*
Hospital Universitario Reina Sofía, Córdoba, SPAIN.

EP-1318

Redifferentiation of BRAF V600E-Mutant Radioiodine-Refractory Papillary Thyroid Carcinoma with Dabrafenib and Trametinib, Enabling a Third Radioiodine Therapy: A Case Report

B. Revesz, *G. Sipka, K. Apro, L. Pavics, Z. Besenyi;*
University of Szeged, Department of Nuclear Medicine and Theranostics, Szeged, HUNGARY.

EP-1319

Peritoneal Superscan on ^{18}F-FDG PET/CT Identifying Newly Diagnosed Lymphoma

S. Asikovali, *M. Dasar, G. Koca, K. Demirel, M. Korkmaz;*
Ankara Training and Research Hospital, Ankara, TÜRKIYE.

EP-1320

False-Positive Vascular FDG Uptake: A Pattern-Based Approach to Avoiding Misdiagnosis of Vasculitis

K. Hartmann, *P. Bravo;*
University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.

EP-1321

FDG PET/CT Findings of Interferonopathy-Associated Polymorphic Lymphoproliferative Disease in Singleton-Merten Syndrome

R. Tokac[1], *E. Bayram Tokac*[2], *M. Bereketoglu*[3], *H. Akin*[2], *A. Argon*[2];
[1]*Izmir City Hospital, Izmir, TÜRKIYE,*
[2]*Ege University, Izmir, TÜRKIYE,*
[3]*Cukurova University, Adana, TÜRKIYE.*

EP-1322

Planned Cycle Reservation in Repeated ^{177}Lu-PSMA Treatment in Relapsing mCRPC: Lessons from the first Rechallenge in Greece

J. Koutsikos[1,2], *S. Bacalis*[2], *A. Kokkini - Paschou*[2], *G. Papadopoulos*[1];
[1]*Henry Dunant Hospital Center, Athens, GREECE,*
[2]*401 General Military Hospital of Athens, Athens, GREECE.*

EP-1323

A pharmacodynamically guided insulin bridging strategy to optimize myocardial FDG suppression: proof of concept in an insulin-treated diabetic patient

M. Bettaieb[1], *W. Saidi*[1], *M. Garma*[2], *C. Habechi*[1], *R. Sfar*[1], *M. Nouira*[1], *K. Chatti*[1];
[1]*Médecine nucléaire - Centre hospitalo-universitaire Sahloul, Sousse, TUNISIA,*
[2]*Service de maladies infectieuses - CHU Farhat Hached, Sousse, TUNISIA.*

EP-1324

Potential Role of ^{68}Ga-FAPI PET/CT Imaging in the Diagnosis of Endometriosis

H. Kösem, *H. Uslu, M. Hocaoglu, B. Canitez, D. Sahin;*
Goztepe Prof Dr Suleyman Yalcin City Hospital: TC Saglik Bakanligi Goztepe Prof Dr Suleyman Yalcin, Istanbul, TÜRKIYE.

EP-1325

From childhood misdiagnosis to adolescent systemic involvement: FDG PET/CT revealing atypical langerhans cell histiocytosis

R. Mehri, *F. Hamza, O. Abdelhedi, I. Mhiri, M. Maaloul, K. Ben Ahmed, I. Jardak, S. Charfeddine;*
Habib Bourguiba Hospital, Sfax, TUNISIA.

EP-1326

^{18}F FDG PET-CT as a Diagnostic Tool in Systemic Onset Juvenile Idiopathic Arthritis: A Paediatric Case Report.

C. Puranicmath, *M. L. Narayan, P. K. Panda, S. Sopanam, A. S. K, R. Shah;*
All India Institute Of Medical Sciences Rishikesh, Rishikesh, INDIA.

EP-1327

multifocal skeletal melanoma of unknown primary presenting as a paravertebral mass: a case report

G. Rakia, *H. Boudriga, M. Allague, F. Skarfi, S. Mensi, A. Ezzine, K. Chatti;*
CHU Sahloul, Sousse, TUNISIA.

EP-1328

Combined R.O.L.L. Technique and Microcoil Placement for CT-Guided Localization of a Non-Metabolic Pulmonary Micronodule: A Case Report

M. Fornito[1], *S. Strano*[2], *G. Giordano*[3];
[1]*ARNAS Garibaldi Catania Nuclear Medicine - PET/TC center dep., Catania, ITALY,*
[2]*ARNAS Garibaldi Catania Thoracic Surgery ep., Catania, ITALY,*
[3]*ARNAS Garibaldi Catania Interventional Radiology, Catania, ITALY.*

EP-1329

Bing-Neel Syndrome, a Rare Manifestation of Waldenström Macroglobulinemia Evaluated by ^{18}F-FDG PET/CT: Diagnostic Impact in a Challenging Case

S. Marian[1], *A. Jougla*[1], *A. Cochet*[1,2];
[1]*Centre Georges-François Leclerc, Dijon, FRANCE,*
[2]*Université Bourgogne Europe, ICMUB UMR CNRS 6302, Dijon, FRANCE.*

EP-1330

Detection of Cerebrospinal Fluid Leak Using SPECT/CT: A Case Report

N. Friedrich[1], *R. Nemet*[1], *G. Sipka*[1], *A. Bakos*[1], *I. Farkas*[1], *Z. Besenyi*[1];
[1]*University of Szeged, Department of Nuclear Medicine and Theranostics, Szeged, HUNGARY.*

EP-1331

When PSMA Avidity is Not Enough: Cerebral Metastasis Mimic in Prostate Cancer Restaging

G. Prisacariu[1], *S. Isal*[2], *G. Nottet*[1], *A. Flaus*[1], *M. Janier*[1,3];
[1]*Service de Médecine Nucléaire des Hospices Civils de Lyon (GHE - Hôpital Cardiologique), Lyon, FRANCE,*
[2]*Service de Médecine Nucléaire des Hospices Civils de Lyon (GHS), Lyon, FRANCE,*
[3]*Faculté de Médecine Lyon-Est – Laboratoire LAGEPP – Université Claude Bernard, Lyon, FRANCE.*

EP-1332

Orbital Metastases from Well-Differentiated Neuroendocrine Tumours: A Case Series and Pictorial Review

M. El-Sayed[1], *O. S. Ahmed*[2];
[1]*Queen Elizabeth Hospital Birmingham, Birmingham, UNITED KINGDOM,*
[2]*Northern Care Alliance NHS Foundation Trust, Manchester, UNITED KINGDOM.*

EP-1333

Unexpected Intense FDG Uptake in Collecting Duct (Bellini Duct) Carcinoma: Diagnostic Value of ^{18}F-FDG PET/CT in Cancer of Unknown Primary

K. Petrovic[1], *I. Grozdic-Milojevic*[1,2];
[1]*Center for Nuclear Medicine, University Clinical Center of Serbia, Belgrade, SERBIA,*
[2]*Faculty of Medicine, University of Belgrade, Belgrade, SERBIA.*

EP-1334

^{68}Ga-PSMA PET/CT in Intracranial Teratoma with Somatic-Type Malignant Transformation: A Case and Literature Review

Z. Chen, *Y. Han, W. Ma, Z. Cui, J. Liu, Y. Luo(corresponding author);*
Lanzhou University Second Hospital (Second Clinical Medical College), LanZhou, CHINA.

EP-1335

Axial Skeletal Involvement in Systemic Sarcoidosis: Contribution of Bone Scintigraphy

Z. Kikich, *M. Bel Lakhdar, A. Taalabi, N. Mahersi, S. Jaouhari, Z. Laadissi, D. Alami, A. Tabich, D. Mossi, A. Mouaden, I. Ghfir, H. Guerrouj;*
Mohammed V University, Rabat, MOROCCO.

EP-1336

Strengths and Pitfalls of [^{18}F]FDG PET/CT in LVAD management: Infection, Staging and a False Alarm

I. Casimiro[1], *L. G. Rocha*[1], *T. Saraiva*[1], *S. Costa*[1], *M. J. V. Ferreira*[1,2,3], *G. Costa*[1,3,2];
[1]*Unidade Local de Saúde de Coimbra, Coimbra, PORTUGAL,*
[2]*Institute of Nuclear Sciences Applied to Health, Coimbra, PORTUGAL,*
[3]*University of Coimbra, Coimbra, PORTUGAL.*

EP-1337

Choroidal metastasis accidentally detected on FDG-PET in a patient with lung cancer: a case report.

A. Branca, *A. Cimino, A. Mita;*
Ospedale Vito Fazzi, Lecce, ITALY.

EP-1338

[^{18}F]Fluorocholine PET/CT Functional Unmasking of a Mammographically and Ultrasonographically Occult Lobular Breast Cancer in a Patient with Primary Hyperparathyroidism

E. Mesiani, *C. Colombo, M. Castellani;*
Nuclear Medicine Unit, Fondazione IRCCS Ca' Granda, Milan, ITALY.

EP-1339

Beyond Anatomy: The Crucial Role of ^{18}F-FDG PET/CT in Mapping Metabolic Heterogeneity in Aggressive Mesenchymal ChondrosarcomaMiriam Abas[1], Nicolas Ignătescu[1], Mario Mutuleanu[1,2], Mirela Gherghe[1,21] Nuclear Medicine Department, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania2Nuclear Medicine Department, Institute of Oncology "Prof. Dr. Alexandru Trestioreanu", Bucharest, Romania[2]

M. Abas;
Bucharest Oncology Institute "Prof. Dr. Alexandru Trestioreanu", Bucharest, ROMANIA.

EP-1340

False-Positive ^{18}F-FDG Uptake Mimicking Disease Progression in EBV-Associated Lymphoproliferative Disorder: Appendiceal Abscess Presenting as Metabolic Progression on Interim PET/CT

O. Bourogianni[1], *N. Kapsoritakis*[1], *M. Psyllaki*[2], *M. Stathaki*[1], *S. Koukouraki*[1];
[1]*Nuclear Medicine Department, University Hospital of Crete, Heraklion, GREECE,*
[2]*Department of Hematology, University of Crete School of Medicine, University Hospital of Heraklion, Heraklion, Greece., Heraklion, GREECE.*

EP-1341

Deceptive Leg PTCL (peripheral T cell lymphoma) Skin Lesions Masquerading as FDG Urinary Contamination

M. K. Taggar[1], *S. A. Shamim*[1], *M. Verma*[2];
[1]*All India Institute Of Medical Sciences, New Delhi, INDIA,*
[2]*Maulana Azad Medical College, New Delhi, INDIA.*

EP-1342

SSTR Agonist-Antagonist Paradox: Incidental DOTANOC-Avid Fibroadenoma Invisible on NJR11 PET/CT

M. K. Taggar, *S. A. Shamim, G. Arora;*
All India Institute Of Medical Sciences, New Delhi, INDIA.

EP-1343

From Theory to Clinical Practice: the Value of ^{18}F-FDG PET/CT in the Diagnosis and Monitoring of NMDA Encephalitis

A. Bagán-Trejo[1], *L. Rodríguez-Bel*[1], *M. Suárez-Piñera*[1], *M. Pudis*[1], *C. Martínez-Ramos*[1], *A. Jareño-Badenas*[2], *J. Díaz-Moreno*[1], *D. Tamayo-Ossa*[1], *D. Ramírez-Muñoz*[1], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine-PET (IDI) Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN,*
[2]*Radiology Department, Hospital Universitari de Bellvitge, Barcelona, SPAIN.*

EP-1344

It's Not Malignant, It Just Acts Like It: Fibrous Dysplasia on FDG PET/CT

M. Pešorda, *I. Rogić, E. Pasini Nemir, D. Huić;*
University Hospital Centre Zagreb, Zagreb, CROATIA.

EP-1345

Subacute disseminated intravascular coagulation following Lu-177 dotatate therapy in a patient with rectal neuroendocrine tumor: A case report

P. Lee, *H. Cheng, W. Lin, B. Hung, Y. Huang;*
Koo Foundation Sun-Yat Sen Cancer Center, Taipei, TAIWAN, PROVINCE OF CHINA.

EP-1346

Atypical Initial Presentation of Hepatocellular Carcinoma with Skull Metastasis on [^{18}F]FDG PET/CT

D. Denizmen Zorba[1], *I. Sezgin*[1], *G. Yavan*[1], *M. Corapli*[2], *M. R. Ozercan*[3];
[1]*Adiyaman Research and Training Hospital Department of Nuclear Medicine, Adiyaman, TÜRKIYE,*
[2]*Adiyaman Research and Training Hospital Department of Radiology, Adiyaman, TÜRKIYE,*
[3]*Adiyaman Research and Training Hospital Department of Pathology, Adiyaman, TÜRKIYE.*

EP-1347

[^{18}F]DOPA PET/CT in the Diagnosis of Occult Pheochromocytoma Following Adrenal Hemorrhage in Pregnancy: A Case Report.

L. Henrich Malizia, *A. Gomez Lopez, A. Roteta Unceta Barrenechea, A. Garin Rodriguez, N. Etxabeguren Gallo, J. Cruz Vasquez, D. Rodriguez Oviedo, F. Arraut Serrano, I. Cillero Etxebeste;*
Hospital Universitario Donostia - Onkologikoa, Donostia - San Sebastian, SPAIN.

EP-1348

Neurological behavior of aggressive glioblastoma faithfully delineated by ^{18}F-FET PET

I. Pavaluta, *L. Agrigoroaie, D. Deandreis, J. Grill, S. Bockel, F. Chehade;*
Gustave Roussy, Villejuif, FRANCE.

EP-1349

Thymic Squamous Cell Carcinoma : FDG PET/CT as the Key to Accurate Staging

D. Alami[1], *A. Mouaden*[1], *M. Bel Lakhdar*[2], *A. Taalabi*[1], *Z. Kikich*[1], *S. Jaouhari*[1], *Z. Laadissi*[1], *H. Guerrouj*[1];
[1]*Ibn Sina Teaching Hospital, Rabat, MOROCCO,*
[2]*Mohammed VI Teaching Hospital, Agadir, MOROCCO.*

EP-1350

^{18}F-FDG PET/CT in High-Grade Embryonal Carcinoma with Rare Left Atrial Extension: Documentation of Complete Metabolic Response Following BEP Chemotherapy

S. C O, *S. H V, B. Sadeed;*
Narayana Health, Bangalore, INDIA.

EP-1351

Discordant FDG and PSMA Imaging in Synchronous Breast Cancer and Hepatocellular Carcinoma: A Case Report

A. Bakos[1], *L. Libor*[2], *I. Farkas*[1], *S. Nagy*[1], *L. Pávics*[1], *Z. Besenyi*[1];
[1]*Department of Nuclear Medicine and Theranostics, University of Szeged, Szeged, HUNGARY,*
[2]*Department of Surgery, University of Szeged, Szeged, HUNGARY.*

EP-1352

Heterogeneous Osteoblastic Bone Uptake in a Lung Cancer Patient: Not Always Metastasis

E. Isleyen Çolak, *S. Bilgiç, E. Alper;*
Bursa Uludag University, Bursa, TÜRKIYE.

EP-1353

Diagnostic Challenges in Persistent ACTH-Dependent Cushing's Syndrome: Why Negative [^{68}Ga]- DOTATATE PET/CT] Does Not Exclude Occult Ectopic ACTH-secreting Tumours?

S. Chausheva, *M. Dyankova, T. Stoeva, T. Yordanova, D. Bacheva- Chausheva, A. Klisarova;*
University Hospital St Marina Varna, Varna, BULGARIA.

EP-1354

Dacryoscintigraphic patterns in lacrimal duct obstruction: A visual and semi quantitative comparison series of symptomatic versus incidental cases

P. Nemutaduni[1,2], *M. Nonyane*[1], *G. Tesema*[1], *T. Kubheka*[1], *N. Masango*[1], *R. Tshivhase*[1], *X. Msingapantsi*[1], *A. More*[1];
[1]*Sefako Makgatho University/NumedGroup/PNOAT, Pretoria, SOUTH AFRICA,*
[2]*Sefako Makgatho University, Pretoria, SOUTH AFRICA.*

EP-1355

Primary Vaginal choriocarcinoma- A rare gestational trophoblastic neoplasm with serial FDG PET/CT monitoring

D. Thulasi Sunitha, *P. Chauhan, A. Tom, S. Deswal;*
Dr. Ram Manohar Lohia Institute of Medical sciences, Lucknow, INDIA.

EP-1356

Unusual ^{99}mTc-Diphosphonate Uptake in an Oncological Patient: the Importance of Clinical History Correlation

A. Bagán-Trejo[1], *A. Benítez-Segura*[1], *M. Bajén-Lázaro*[1], *J. Reyes-Junca*[1], *M. Pudis*[1], *L. Rodríguez-Bel*[1], *M. Suárez-Piñera*[1], *M. Zamorano-Rivas*[1], *E. Ricart-Paredes*[2], *M. Argelés-Colet*[1], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine-PET (IDI) Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN,*
[2]*Radiopharmacy Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, SPAIN.*

EP-1357

Incidental breast sarcoidosis on staging FDG PET/CT in uterine sarcoma: a granulomatous mimic of metastatic disease

C. Habachi[1,2], *A. Ezzine*[1,3], *R. Mehri*[1,3], *R. Ghannem*[1,2], *M. Ben Fredj*[1,3], *S. Mensi*[1,3], *K. Chatti*[1,2];
[1]*University hospital Sahloul of Sousse, Nuclear medicine department, Sousse, TUNISIA,*
[2]*University of Monastir, Monastir, TUNISIA,*
[3]*University of Sousse, Sousse, TUNISIA.*

EP-1358

Diagnostic Value of ^{18}F-FDG PET/CT in Intravascular Large B-Cell Lymphoma Presenting with Endocrine and Haematological Abnormalities

D. Denizmen Zorba[1], *D. Has Simsek*[2], *Y. Sanli*[2];
[1]*Adiyaman University Research and Training Hospital, Department of Nuclear Medicine, Adiyaman, TÜRKIYE,*
[2]*Istanbul University, Department of Nuclear Medicine, Istanbul, TÜRKIYE.*

EP-1359

Comparative Imaging of Relapsed Primary Central Nervous System Diffuse Large B-Cell Lymphoma with Intraventricular Dissemination Using ^{68}Ga-Pentixafor and ^{18}F-FDG PET/CT: A Case Report

Z. Ju[1], *J. Wang*[1], *C. Zuo*[1], *M. Zhang*[2];
[1]*Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA,*
[2]*Department of Hematology, Huashan Hospital, Fudan University, Shanghai, CHINA.*

EP-1360

Incidental Detection of a Gastrointestinal Stromal Tumour (GIST) during Tc-99m-labelled Red Blood Cell Scintigraphy: The Clinical Value of Hybrid SPECT-CT

L. Estenar, *R. A. Curiba, N. P. Hui;*
The Medical City, Ortigas, Pasig City, PHILIPPINES.

EP-1361

[^{18}F]FDG PET/CT in fever of unknown origin revealing extensive large-vessel vasculitis in a patient with Crohn's disease

C. Moriana Simón[1], *G. Martínez Gómez*[1], *A. Sagastegui Alca*[1], *C. Ruiz Corbalan*[2], *T. Moreno Monsalve*[1], *T. Rodríguez Locarno*[1], *N. Sánchez Izquierdo*[1], *M. Castellón Sánchez*[1], *A. Hernandez Martínez*[1], *M. Ibañez Ibañez*[1], *L. Mohamed Salem*[1], *J. Navarro Fernández*[1], *L. Frutos Esteban*[1], *J. Contreras Gutiérrez*[1];
[1]*Hospital Virgen de la Arrixaca, Murcia, SPAIN,*
[2]*Hospital Universitario Santa Lucía, Cartagena, SPAIN.*

EP-1362

Beyond Typical Spread: ^{18}F-FDG PET/CT Reveals Rare Cardiac and Skeletal Muscle Metastases in Renal Urothelial Carcinoma

P. Spiridon[1,2];
[1]*Carol Davila University of Medicine and Pharmacy, Bucharest, ROMANIA,*
[2]*Affidea, Bucharest, ROMANIA.*

EP-1363

Role of ^{18}F-FDG PET/CT in the Initial Staging of a Rare Gallbladder Small Cell Neuroendocrine Carcinoma

A. Taalabi, *A. Mouaden, D. Alami, H. Guerrouj;*
Ibn Sina Teaching Hospital, Rabat, MOROCCO.

EP-1364

Dramatic complete metabolic response on ^{18}F-FDG positron emission tomography/computed tomography after bispecific antibody therapy in CAR-T refractory diffuse large B-cell lymphoma

E. Moratalla-Aranda, *S. Martin Aguilar, M. Sanchez Torrente, L. Mena Bares, M. Ureña Lara;*
Hospital Universitario de Jaen, Jaen, SPAIN.

EP-1365

Merkel cell carcinoma incidentally detected by [^{99m}Tc]Tc-MIBI parathyroid scintigraphy

P. Petranovic Ovcaricek, *V. Gladić Nenadić, M. Romić;*
Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, CROATIA.

EP-1366

Role of ^{18}F-FDG-PET/CT in a case of suspected Rasmussen encephalitis

S. Georga[1], *A. Morfesi*[1], *I. Gourgiotis*[2], *D. Katsampoukas*[1], *N. Vavlas*[1], *G. Charisi*[2], *G. Arsos*[1];
[1]3rd *Department of Nuclear Medicine, Aristotle University Medical School, Papageorgiou General Hospital, Thessaloniki, GREECE,*
[2]*Department of Neurology, Agios Paulos General Hospital, Thessaloniki, GREECE.*

EP-1367

False-Positive PSMA PET/CT Pulmonary Uptake Mimicking Metastatic Prostate Cancer Recurrence: A Case of Solitary Fibrous Tumor of the Lung

O. Bourogianni, *N. Kapsoritakis, M. Stathaki, S. Koukouraki;*
Nuclear Medicine Department, University Hospital of Crete, Heraklion, GREECE.

EP-1368

An Incidental Splenic Hemangioma Causing a False-Positive Finding on Ga-68 PSMA PET/CT: A Case Report

G. Aymandir, *G. Mütevelizade, U. Balaman, E. Bilgin;*
Celal Bayara Üniversitesi Hafsasultan Hastanesi, Manisa, TÜRKIYE.

EP-1369

Diagnosis and Staging of Avascular Necrosis in Bilateral Slipped Capital Femoral Epiphysis: Added Value of SPECT/CT

Z. Kikich, *Z. Laadissi, M. Bel Lakhdar, S. Jaouhari, A. Taalabi, D. Alami, N. Mahersi, A. Tabich, D. Mossi, A. Mouaden, I. Ghfir, H. Guerrouj;*
Mohammed V University, Rabat, MOROCCO.

EP-1370

Tau-PET/CT Hints for Intracerebral Hemorrhage Staging

X. Xiang[1], *Z. Xu*[2];
[1]*Department of Nuclear medicine, The Second Afffliated Hospital of Chongqing Medical University, Chongqing, CHINA,*
[2]*Department of Nuclear Medicine, Chongqing Jiulongpo People's Hospital, Chongqing, CHINA.*

EP-1371

Asymptomatic Spinal Meningioma Exhibiting Calcification and Increased Nuclear Uptake

S. Mammen, *D. Weinstein, B. Kamat;*
Lewis Katz School of Medicine, Philadelphia, PA, UNITED STATES OF AMERICA.

EP-1372

^{18}F-FDG PET/CT Unmasking a Hidden Oesophageal Carcinoma Presenting as Paraneoplastic Sensory Ataxia in a Patient with Prior Renal Cell Carcinoma: A Case Report

M. Kotur[1], *M. Stojiljkovic*[1,2], *S. Odalovic*[1,2], *M. Mihajlovic*[1], *O. Radivojevic*[1], *J. Petrovic*[1,2], *J. Pantovic*[1], *I. Grozdic Milojevic*[1,2], *D. Sobic Saranovic*[1,2], *V. Artiko*[1,2];
[1]*Center for Nuclear Medicine with PET, University Clinical Center of Serbia, Belgrade, SERBIA,*
[2]*Faculty of Medicine, University of Belgrade, Belgrade, SERBIA.*

EP-1373

Preoperative localisation of intrathyroidal parathyroid gland in pediatric primary hyperparathyroidism: integrating ^{99}mTc-MIBI SPECT with FNA cytology and PTH washout

I. Sisko Markos[1,2], *V. Gladic Nenadic*[1], *A. Deak*[1], *L. Lučev*[1], *M. Požgaj Šepec*[1], *L. Beljan*[1], *G. Šutić*[3];
[1]*UHC Sestre Milosrdnice, Zagreb, CROATIA,*
[2]*Croatian Catholic University, School of Medicine, Zagreb, CROATIA,*
[3]*Croatian Catholic University, Zagreb, CROATIA.*

EP-1374

Diagnostic Pitfall of PSMA PET: Intrahepatic Lymphoid Hyperplasia Mimicking Liver Malignancy

P. Chuang[1,2], *Y. Chang*[1,2], *C. Wang*[3,2], *J. S. Chueh*[3,2], *C. Lu*[3,2];
[1]*National Taiwan University Cancer Center, Taipei, TAIWAN, PROVINCE OF CHINA,*
[2]*National Taiwan University School of Medicine, Taipei, TAIWAN, PROVINCE OF CHINA,*
[3]*National Taiwan University Hospital, Taipei, TAIWAN, PROVINCE OF CHINA.*

EP-1375

Bone scintigraphy in the differential diagnosis between calciphylaxis vs paraneoplastic panniculitis in a hemodialysis patient with soft tissue infection, acute exacerbation of chronic kidney disease and pancreatic tumor

S. Martin Aguilar, *M. Sanchez Torrente, E. Moratalla Aranda, L. M. Mena Bares, M. J. Ureña Lara;*
Complejo Hospitalario de Jaén, Jaén, SPAIN.

EP-1376

Evaluation of atypical Tc-99m uptake in suspected Meckel's diverticulum: two cases with asynchronous Tc-99m increased uptake

M. Agolti[1], *L. Solari*[1], *E. Formenti*[1], *M. Gutierrez*[1], *A. Pais*[2];
[1]*Centro de Medicina Nuclear Clínica Modelo, Paraná, ARGENTINA,*
[2]*Sanatorio del Niño, Paraná, ARGENTINA.*

EP-1377

Occult skeletal muscle metastasis detected only by ^{18}F-FDG positron emission tomography/computed tomography in oesophageal adenocarcinoma: histological confirmation and decisive impact on staging and management

E. Moratalla-Aranda, *M. Sanchez Torrente, L. Mena Bares, S. Martin Aguilar, M. Ureña Lara;*
Hospital Universitario de Jaen, Jaen, SPAIN.

EP-1378

The role of ^{18}F-FDG PET/CT in staging and therapy response assessment in Kaposi's sarcoma: two clinical cases

T. Nachova;
Acibadem City Clinic Tokuda Hospital, Sofia, BULGARIA.

EP-1379

SPECT/CT localisation of lymphatic leakage in chylous ascites with inconclusive conventional imaging: a decisive diagnostic tool

E. Moratalla-Aranda, *S. Martin Aguilar, M. Sanchez Torrente, L. Mena Bares, M. Ureña Lara;*
Hospital Universitario de Jaen, Jaen, SPAIN.

EP-1380

Gastrointestinal lymphoma and Crohn's disease: When cognitive bias obscures the inflammatory reality on FDG PET/CT

C. Habachi[1,2], *M. Nouira*[1,3], *R. Ghannem*[1,2], *H. Boudriga*[1,3], *R. Sfar*[1,2], *K. Chatti*[1,2];
[1]*University hospital Sahloul of Sousse, Nuclear medicine department, Sousse, TUNISIA,*
[2]*University of Monastir, Monastir, TUNISIA,*
[3]*University of Sousse, Sousse, TUNISIA.*

EP-1381

^{18}F-PSMA PET/CT Detection of Suspected Penile Metastases in Biochemical Recurrence of High-Risk Prostate Cancer

L. Grujicic[1], *M. Kotur*[1], *N. Pantic*[1], *M. Stojiljkovic*[1,2], *J. Petrovic*[1,2], *V. Artiko*[1,2], *D. Sobic Saranovic*[1,2], *S. Odalovic*[1,2];
[1]*University Clinical Center of Serbia, Center for nuclear medicine with PET, Belgrade, SERBIA,*
[2]*University of Belgrade, Medical faculty, Belgrade, SERBIA.*

EP-1382

Value of Whole-Body Bone Scintigraphy with SPECT/CT in Multifocal Pediatric Osteomyelitis: A Case Report of an Uncommon Clavicular Involvement

M. Romdhani, *A. Ezzine, C. Habechi, M. Allegue, T. Dardouri, M. Benfredj, K. Chatti;*
Department of Nuclear Medicine, Sahloul University Hospital, Sousse, TUNISIA.

EP-1383

Incidental Detection of Clear Cell Renal Cell Carcinoma on ^{18}F-PSMA PET/CT During Staging of High-Risk Prostate Cancer

O. Bourogianni, *N. Kapsoritakis, M. Stathaki, E. Papadaki, S. Koukouraki;*
Nuclear Medicine Department, University Hospital of Crete, Heraklion, GREECE.

EP-1384

Incidental Late-Onset Zinner Syndrome Detected During Lung Nodule Characterization via PET/CT: A Case Report

F. Ates Kahya;
Aydın Training And Research Hospital, Aydın, TÜRKIYE.

EP-1385

The Tiger Within: 2-[^{18}F]FDG PET/CT Unmasking Sarcoid Myopathy

S. Ramos Barata[1], *S. Paiva*[1], *D. Carvalho*[1], *I. Casimiro*[1], *A. Alves*[1], *A. Albuquerque*[1], *T. Saraiva*[1], *G. Costa*[1,2];
[1]*Hospitais da Universidade de Coimbra - ULS Coimbra, Coimbra, PORTUGAL,*
[2]*Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.*

EP-1386

A Rare Case of a Neuroendocrine Tumor With Intracardiac Metastasis: Diagnostic Challenges and Multimodal Imaging

R. Lita[1], *B. Manea*[1], *S. El Moataz Billah*[1], *A. Barabas*[1], *M. Gherghe*[2,1];
[1]*Insitute of Oncology Professor Doctor Alexandru Trestioreanu, Bucharest, ROMANIA,*
[2]*University of Medicine and Pharmacy "Carol Davila", Bucharest, ROMANIA.*

EP-1387

False-Positive Iodine-131 Diffuse Uptake in Bilateral Lungs Due to Bronchitis in a Patient Receiving Adjuvant Therapy

K. Oguri[1], *J. Takenaka*[1], *S. Watanabe*[1], *N. Wakabayashi*[1], *K. Hirata*[1], *M. Eguchi*[2], *D. Nakazawa*[2], *K. Kudo*[1];
[1]*Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, JAPAN,*
[2]*Department of Rheumatology, Endocrinology, and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, JAPAN.*

EP-1388

^{18}F-FDG PET/CT-Positive Lymph Nodes Unmasking Signet Ring Gastric Cancer: A Case Report

P. Ilieva-Gabarska[1,2,3], *L. Petrakiev*[1,2], *B. Mukova*[1,2], *T. Dragnev*[1], *Z. Gorcheva*[4,2], *N. Stefanova*[2];
[1]*Medical center "St. Marina - diagnostics and therapy" Ltd. Pleven, Nuclear medicine laboratory, Pleven, BULGARIA,*
[2]*Medical university Pleven, Department of Medical Oncology, Pleven, BULGARIA,*
[3]*Medical university "Prof. Dr Paraskev Stoyanov", Department of Nuclear Medicine, Metabolic Therapy and Radiotherapy, Varna, BULGARIA,*
[4]*University hospital "St. Marina" - Pleven, Medical oncology, Pleven, BULGARIA.*

EP-1389

Metabolic Characterization of Rapidly Progressing Metastatic Malignant Phyllodes Tumor: A Case Report

F. Aras;
Manisa Celal Bayar University Medical Faculty, Manisa, TÜRKIYE.

EP-1390

Incidental Detection of Bone Hemangiomas on Ga68-DOTATATE PET/CT Mimicking Metastases

A. B. Özden, *A. Akbulut, G. Koca, K. Demirel, M. Korkmaz;*
Ankara, Ankara, TÜRKIYE.

EP-1391

From "Cherry on Top" to Definitive Diagnosis: Multimodal Imaging in Transthyretin Cardiac Amyloidosis—The Role of ^{99}mTc-PYP SPECT/CT in an 87-Year-Old Patient

M. Dyankova[1,2], *T. Stoeva*[1], *S. Chausheva*[1], *T. Yordanova*[1], *P. Ilieva-Gabarska*[2], *D. Bacheva-Chausheva*[1], *A. Klisarova*[1];
[1]*St. Marina University Hospital, Varna, BULGARIA,*
[2]*Medical University Varna "Prof. Dr. Paraskev Stoyanov", Department of Nuclear Medicine, Metabolic Therapy and Radiotherapy, Varna, BULGARIA.*

EP-1392

Ga-68 DOTATATE PET/CT Imaging and Incidental Meningioma in a Patient with Type 2 Diabetes Diagnosed with Insulinoma: A Rare Case

A. Erdem Karaoglu, *D. Çayır, E. Tatcı, Ö. Özmen;*
Ankara Etlik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-1393

Image of tracheitis on a follow-up FDG PET-CT scan in lymphoma

S. Martin Aguilar, *E. Moratalla-Aranda, M. Sanchez Torrente, L. M. Mena Bares, M. J. Ureña Lara;*
Complejo Hospitalario de Jaén, Jaén, SPAIN.

EP-1394

An incidental finding of gastrointestinal stromal tumor in bone scintigraphy

A. Aulich, *P. Cichocki, Z. Adamczewski;*
Nuclear Medicine Department, Medical University of Lodz, Lodz, POLAND.

EP-1395

Coexisting primary lung adenocarcinoma and microscopic pulmonary metastases from papillary thyroid carcinoma: a two-case report

J. Gui, *X. Long, D. Zheng, X. Lan, W. Cao;*
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-1396

Hybrid Imaging in Erdheim-Chester Disease: A Case Report of a Characteristic Skeletal Pattern

F. Timar Pasztor[1], *A. Bakos*[1], *T. Czekus*[1], *I. Farkas*[1], *R. Hemelein*[2], *L. Kovacs*[2], *Z. Miko*[1], *S. Nagy*[1], *R. Nemet*[1], *L. Pavics*[1], *G. Sipka*[1], *Z. Besenyi*[1];
[1]*University of Szeged, Albert Szent-Gyorgyi Health Centre, Department of Nuclear Medicine, Szeged, HUNGARY,*
[2]*University of Szeged, Albert Szent-Gyorgyi Health Centre, Department of Rheumatology and Immunology, Szeged, HUNGARY.*

EP-1397

The Diagnostic and Therapeutic Role of I-131 in Isolated Iliac Bone Metastasis from Follicular Thyroid Carcinoma with an Occult Primary

L. Estenar, *J. Ahorro-Villaseran, E. Paz-Pacheco;*
The Medical City, Ortigas, Pasig City, PHILIPPINES.

EP-1398

A Misleading Presentation of Paediatric Ischiopubic Osteomyelitis: The Added Value of Bone Scintigraphy

G. Mani, *O. Ben Hamida, M. Somai, I. Slim, I. Meddeb, A. Mhiri;*
Salah Azaeiz Institute, Tunis, TUNISIA.

EP-1399

The Silent Thyroid: Parathyroid Adenoma Localisation Without Thyroidal Tracer Uptake

A. B. Özden[1], *G. Koca*[1], *A. Akbulut*[2], *K. Demirel*[1], *M. Korkmaz*[1];
[1]*Ankara, Ankara, TÜRKIYE,*
[2]*Ankara, Ankara, TÜRKIYE.*

EP-1400

Parotid gland and ureteral metastases from breast cancer detected by ^{18}F-FDG PET/CT study: a case report.

S. Pacella[1], *M. Gaffuri*[2], *L. Airò Farulla*[3], *V. Longari*[1], *L. Pignataro*[2], *P. Capaccio*[4], *M. Castellani*[1];
[1]*IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milan, ITALY,*
[2]*IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, ITALY,*
[3]*ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY,*
[4]*ASST Fatebenefratelli Sacco, Università degli Studi di Milano, Milan, Milan, ITALY.*

EP-1401

Radioguided Parathyroidectomy Using [^{99m}Tc] Tc-MIBI and [^{18}F]Fluorocholine: A Single-Centre Experience.

A. Rodríguez Llamas, *A. De Agrela Serrao, I. Cejudo Liébana, S. Tejerina Tejerina, M. Guiote Moreno, J. Vallejo Casas;*
Hospital Universitario Reina Sofía, Córdoba, SPAIN.

EP-1402

^{18}F-FDG PET/CT in a Breast Cancer Survivor Revealing Disseminated Cutaneous and Soft Tissue B-Cell Non-Hodgkin Lymphoma Mimicking Metastatic Disease

O. Bourogianni, *M. Stathaki, N. Kapsoritakis, S. Koukouraki;*
Nuclear Medicine Department, University Hospital of Crete, Heraklion, GREECE.

EP-1403

Multifocal Bone and Lymph Node Tuberculosis Mimicking Pulmonary Malignancy: The Role and Limitations of [^{18}F]FDG PET/CT

F. Silva-Ribeiro, *B. Martins, C. V. Pinto, N. Caires, V. C. Sousa;*
Unidade Local de Saúde de Loures / Odivelas, Lisboa, PORTUGAL.

EP-1404

Rare but Not Forgotten: Whole-Body ^{99}mTc-Sestamibi SPECT/CT Mapping of Multifocal Brown Tumours in Tertiary Hyperparathyroidism

F. Sekrafi, *M. Alleugue, A. Ezzine, C. Habachi, M. Ben Fredj, S. Mensi, K. Chatti;*
Department of Nuclear Medicine, Sahloul University Hospital, Sousse, TUNISIA.

EP-1405

When rare becomes the protagonist: Penile metastasis in Prostate Cancer

I. Casimiro[1], *J. R. Duarte*[2], *R. Silva*[1], *T. Saraiva*[1], *G. Costa*[1];
[1]*Unidade Local de Saúde de Coimbra, Coimbra, PORTUGAL,*
[2]*Unidade Local de Saúde de Lisboa Ocidental. E.P.E, Lisboa, PORTUGAL.*

EP-1406

Visualizing Thalamic Response after rTMS: ^{99}mTc-HMPAO SPECT/CT as a Therapy Marker

D. Filipan[1], *V. Peitl*[2,3], *M. Raguž*[3,4], *D. Karlović*[2,3], *I. Šiško Marković*[1,3];
[1]*Department of Oncology and Nuclear Medicine, University Hospital Centre "Sestre milosrdnice", Zagreb, CROATIA,*
[2]*Department of Psychiatry, University Hospital Centre "Sestre milosrdnice", Zagreb, CROATIA,*
[3]*School of Medicine, Catholic University of Croatia, Zagreb, CROATIA,*
[4]*Department of Neurosurgery, Clinical Hospital Dubrava, Zagreb, CROATIA.*

EP-1407

Incidental Finding of Gastric Gastrointestinal Stromal Tumor (GIST) on Bone Scintigraphy: A Case Report of Unusual Extraosseous Tracer Uptake

W. Wong;
Queen Elizabeth Hospital, Hong Kong, HONG KONG.

EP-1408

Multiple muscular septic localizations ina ^{18}F-FDG PET/CT study in a patient withspondylodiscitis

S. Pacella[1], *L. Airò Farulla*[2], *V. Longari*[1], *B. Parducci*[3], *A. Bandera*[4], *M. Castellani*[1];
[1]*IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milan, ITALY,*
[2]*ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY,*
[3]*Università degli Studi di Milano, Milan, ITALY,*
[4]*IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, ITALY.*

EP-1409

To Treat Or Not To Treat: ^{18}F-FDG PET/CT Monitoring Of Atypical Erdheim-Chester Disease Under Watchful Waiting

P. Spiridon[1,2];
[1]*Carol Davila University of Medicine and Pharmacy, Bucharest, ROMANIA,*
[2]*Affidea, Bucharest, ROMANIA.*

EP-1410

Beyond Adenocarcinoma: [^{18}F]FDG PET/CT in the Multimodal Evaluation of a Rare Prostatic Leiomyosarcoma

A. Barabas[1], *S. Ilieș*[1], *M. Gherghe*[2,1];
[1]*The Oncology Institute "Prof. Dr. Alexandru Trestioreanu Bucharest, Bucharest, ROMANIA,*
[2]*University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania, Bucharest, ROMANIA.*

EP-1411

Beyond the Tear Duct: A Rare Presentation of Bilateral Lacrimal duct Fistula revealed on Dacryoscintigraphy

D. Datta, *D. Palivela, S. Kumbhar, R. Kumar;*
All India Institute of Medical Sciences, Jodhpur, Rajasthan, INDIA.

EP-1412

Synchronous Lacrimal Gland and Gastric MALT Lymphomas on ^{18}F-FDG PET/CT: An Exceptionally Rare Presentation

Y. Eryilmaz[1], *E. Gezmis*[2], *A. Uner*[2], *S. Akin*[3], *M. Bozkurt*[1];
[1]*Hacettepe University Medical School Department of Nuclear Medicine, Ankara, TÜRKIYE,*
[2]*Hacettepe University Medical School Department of Pathology, Ankara, TÜRKIYE,*
[3]*Hacettepe University Medical School Department of Medical Oncology, Ankara, TÜRKIYE.*

EP-1413

Postpolypectomy Syndrome:A Very Rare Mimicker for Malignancy on FDG PET/CT Imaging

M. Bozkurt, *E. Iman;*
Hacettepe University Faculty of Medicine Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-1414

Beyond the Heart: Atypical Gastrointestinal Manifestation of Hereditary Transthyretin Amyloidosis — A Diagnostic Challenge

M. Dyankova[1,2], *T. Stoeva*[1], *S. Chausheva*[1], *T. Yordanova*[1], *D. Bacheva-Chausheva*[1], *A. Klisarova*[1];
[1]*St. Marina University Hospital, Varna, BULGARIA,*
[2]*Medical University Varna "Prof. Dr. Paraskev Stoyanov", Department of Nuclear Medicine, Metabolic Therapy and Radiotherapy, Varna, BULGARIA.*

EP-1415

Clinical impact of FDG-PET/CT in the management of ophtalmic and orbital Malignancies : a case series

R. Mehri, *F. Hamza, I. Mhiri, O. Abdelhedi, M. Maaloul, K. Ben Ahmed, I. Jardak, S. Charfeddine;*
Habib Bourguiba Hospital, Sfax, TUNISIA.

EP-1416

Primary Myeloid Sarcoma Presenting Without Bone Marrow Involvement: A Case Report

S. Kubat, *A. Dursun, C. Engür Uyanık, E. Tatcı, Ö. Özmen;*
Health Sciences University, Ankara Etlik City Hospital, Nuclear Medicine Department, Ankara, TÜRKIYE.

EP-1417

FDG PET/CT spectrum of disseminated tuberculosis: emphasis on unusual extrapulmonary localizations

C. Habachi[1,2], *H. Charfi*[1,2], *T. Dardouri*[1,3], *Z. Jemni*[1,2], *M. Romdhani*[1,4], *A. Toumi*[1,2], *K. Chatti*[1,2];
[11]*.University hospital Sahloul of Sousse, Nuclear medicine department, Sousse, TUNISIA,*
[2]*University of Monastir, Monastir, TUNISIA,*
[3]*University of Sousse, Sousse, TUNISIA,*
[4]*University of Tunis El Manar, Tunis, TUNISIA.*

EP-1418

Complete absence of tracer uptake on [^{99m}Tc] Tc-MAG3 renography: a critical indicator of renal allograft vascular thrombosis and graft loss

A. Sagastegui Alca, *G. Martínez Gómez, C. Moriana Simón, T. Moreno Monsalve, T. Rodríguez Locarno, N. Sánchez Izquierdo, M. Castellón Sánchez, A. Hernandez Martínez, M. Ibañez Ibañez, L. Mohamed Salem, J. Navarro Fernández, L. Frutos Esteban, J. Contreras Gutiérrez;*
Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-1419

Metachronous Ectopic CRH-Secreting Tumours Precisely Localized by68Ga-Pentixafor PET/CT

Y. Yang, *C. Hu, T. Long, S. Hu;*
Xiangya Hospital, Central South University, Changsha, CHINA.

EP-1420

[^{18}F]FDG PET/CT in Rare Male Müllerian-Type Adenocarcinoma: A Diagnostic Edge

D. Negau, *A. Dragut, I. Sandu, M. Matei, C. Mazilu, R. Mititelu;*
Central University Emergency Military Hospital "Dr. Carol Davila", Bucharest, ROMANIA.

EP-1421

Late intrathyroid metastasis from renal cell carcinoma 19 years after nephrectomy mimicking benign nodular goitre

G. Buljan[1,2], *B. Ivkic*[3], *M. Punda*[1,2];
[1]*Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Vinogradska 29, Zagreb, CROATIA,*
[2]*University of Applied Health Sciences, Zagreb, CROATIA,*
[3]*Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Center Sestre Milosrdnice, Zagreb, CROATIA.*

EP-1422

Vigilance Beyond Remission: Late-Onset Leiomyosarcoma Following Post-Mastectomy Radiotherapy. A Case Report.

B. Constantinescu[1], *C. Mazilu*[1], *L. Mititelu*[2], *R. Mititelu*[1,3];
[1]*Clinic of Nuclear Medicine, Central Universitary Emergency Military Hospital, Bucharest, ROMANIA,*
[2]*Institute of Military Medicine, Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", Bucharest, ROMANIA,*
[3]*Department of Nuclear Medicine, University of Medicine and Pharmacy "Carol Davila", Bucharest, ROMANIA.*

EP-1423

Ectopic ACTH-secreting paraganglioma of the ethmoidal sinus presenting with severe hypercortisolism and transient panhypopituitarism: a case report

G. Barbosa[1], *A. Santos*[1], *V. de Sá Cardassi*[1], *B. Casola Olivetti*[1,2], *N. Tobar*[1], *E. Etchebehere*[1], *D. Minutti de Oliveira*[1];
[1]*Unicamp, Campinas, BRAZIL,*
[2]*Clinics Hospital, University of São Paulo Medical School (HCFMUSP), Sao Paulo, BRAZIL.*

EP-1424

Extravasation of 7.4 GBq ^{177}Lu-DOTATATE - A Case Report

S. Jacobsson Svärd[1,2], *L. Danner*[3], *A. Moreno*[1,2], *C. Sigfridsson Held*[1], *T. Sjöholm*[1,2], *P. Witt Nyström*[3,2], *M. Sandström*[1,2];
[1]*Section of Medical Physics, Department of Medical Technology and Physics, Uppsala University Hospital, Uppsala, SWEDEN,*
[2]*Section of Molecular Imaging and Medical Physics, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN,*
[3]*Section of Nuclear Medicine, Department of Imaging and Functional Medicine, Uppsala University Hospital, Uppsala, SWEDEN.*

EP-1425

Beyond Conventional Limits: ^{18}F-FDG PET/CT in the Staging of Aggressive Collecting Duct Carcinoma with Peritoneal Dissemination

I. Tircomnicu[1], *A. Parvu*[1], *M. Mutuleanu*[1,2], *M. Gherghe*[1,2];
[1]*Institute of Oncology "Prof. Dr. Alexandru Trestioreanu", Bucharest, ROMANIA,*
[2]*University of Medicine and Pharmacy "Carol Davila", Bucharest, ROMANIA.*

EP-1426

^{68}Ga-PSMA PET/CT Restaging in Prostate Cancer Revealing Metachronous Small-Cell Lung Carcinoma: A Case Report

M. Dyankova[1,2], *T. Stoeva*[1], *S. Chausheva*[1], *T. Yordanova*[1], *D. Bacheva-Chausheva*[1], *A. Klisarova*[1];
[1]*St. Marina University Hospital, Varna, BULGARIA,*
[2]*Medical University Varna "Prof. Dr. Paraskev Stoyanov", Department of Nuclear Medicine, Metabolic Therapy and Radiotherapy, Varna, BULGARIA.*

EP-1427

Advanced Adenoid Cystic Carcinoma: Assessing Eligibility for PSMA-Targeted Theranostics

C. Pereira, *P. Soeiro;*
Unidade de Saúde Local de São João, Porto, PORTUGAL.

EP-1428

Pulmonary nocardiosis mimicking malignancy on ^{18}F-FDG-PET/CT in a patient with a history of melanoma

A. Morfesi[1], *S. Ouzouni*[2], *D. Katsampoukas*[1], *A. Triantafyllou*[2], *N. Vavlas*[1], *C. Savvopoulos*[2], *S. Georga*[1];
[1]*3rd Department of Nuclear Medicine, Aristotle University Medical School, Papageorgiou General Hospital, Thessaloniki, GREECE,* [2]*1st Propaedeutic Internal Medicine Department, Aristotle University Medical School, AHEPA General Hospital, Thessaloniki, GREECE.*

EP-1429

Horner's syndrome in conjunction with a toxic thyroid adenoma: case report

A. Vendramin[1], *K. Zaletel*[1,2], *S. Gaberšček*[1,3];
[1]*University Medical Centre Ljubljana, Ljubljana, SLOVENIA,*
[2]*Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA,*
[3]*Faculty of Medicine, University of Ljubljana, Ljubjana, SLOVENIA.*

EP-1430

Timing Matters: Corticosteroids as a Key Strategy to Mitigate Spinal Cord Compression After Radioiodine Therapy in Metastatic Follicular Thyroid Carcinoma

A. Lima Alves[1], *D. Carvalho*[1], *S. Barata*[1], *S. Paiva*[1], *I. Casimiro*[1], *L. A. Silva*[2], *A. F. B. Isabel*[1,3], *A. Moreira*[1], *G. Costa*[1,4];
[1]*ULS Coimbra, Coimbra, Portugal, PORTUGAL,*
[2]*Endocrinology, IPO Coimbra, Coimbra, PORTUGAL,*
[3]*LIBPhysics-UC, LA-REAL, Department of Physics, University of Coimbra, Coimbra, PORTUGAL,*
[4]*Faculty of Medicine - University of Coimbra, Coimbra, PORTUGAL.*

EP-1431

Incidental Meningioma Detected on PSMA PET/CT in a Patient with Prostate Cancer

M. Dyankova[1,2], *T. Stoeva*[1], *S. Chausheva*[1], *T. Yordanova*[1], *D. Bacheva-Chausheva*[1], *A. Klisarova*[1];
[1]*St. Marina University Hospital, Varna, BULGARIA,*
[2]*Medical University Varna "Prof. Dr. Paraskev Stoyanov", Department of Nuclear Medicine, Metabolic Therapy and Radiotherapy, Varna, BULGARIA.*

EP-1432

Beyond the limits of conventional imaging: FDG PET/CT reveals the mystery in a challenging case of fever of unknown origin

R. Mehri, *O. Abdelhedi, I. Jardak, I. Mhiri, S. Charfeddine;*
Habib Bourguiba Hospital, Sfax, TUNISIA.

EP-1433

Intracranial PSMA Uptake Mimicking Metastasis: Arachnoid (Pacchionian) Granulation as a Potential Pitfall

M. Sanchez Torrente, *E. Moratalla Aranda, S. Martin Aguilar, M. Ureña Lara;*
Hospital Universitario de Jaén, Jaén, SPAIN.

EP-1434

Rare congenital medical condition Klippel-Trénaunay syndrome explain unusual image in bone scintigraphy with SPECT/CT

P. Gadzicki[1], *Z. Seweryn*[2], *Z. Adamczewski*[1];
[1]*Medical University of Lodz, Nuclear Medicine Departament, Lodz, POLAND,*
[2]*Medical University of Lodz, Lodz, POLAND.*

EP-1435

Negative ^{99}mTc-Ubiquicidin SPECT/CT in the Evaluation of Suspected Osteoradionecrosis of the Mandible in a Patient with Recurrent Tongue Carcinoma

B. Alencar, *M. Osmak, T. Agnello, R. Marques, A. Fochi, I. Costa, E. Camargo, C. Ramos, B. Amorim, A. Oliveira Santos, M. Lima;*
Unicamp, Campinas, São Paulo, BRAZIL.

EP-1436

Odontogenic Malignancies: A Case of Ameloblastic Carcinoma

A. Erdem Karaoglu, *D. Çayır, Ö. Özmen;*
Ankara Etlik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-1437

Preoperative ^{99}mTc-Sestamibi SPECT/CT Characterization of a Histopathologically Confirmed Very SmallRenal Oncocytoma: A Case Report

G. Beydagi[1], *L. Urso*[2], *C. Cittanti*[2], *G. Giannarini*[3], *A. Cimadamore*[4], *L. Uccelli*[2], *M. Giganti*[2], *E. Arslan*[5], *M. Bartolomei*[6];
[1]*Department of Nuclear Medicine, University of Health Sciences Turkey, Istanbul Training and Research Hospital, Istanbul, TÜRKIYE,*
[2]*Translational Medicine Department, University of Ferrara, Ferrara, ITALY,*
[3]*Urology Unit, Santa Maria della Misericordia University Hospital, Udine, ITALY,*
[4]*Institute of Pathological Anatomy, Department of Medicine, University of Udine, Udine, ITALY,*
[5]*Health Sciences University, Faculty of Medicine, Department of Medical Pathology, Istanbul, TÜRKIYE,*
[6]*Nuclear Medicine Unit, Onco-Hematological Department, University Hospital of Ferrara, Ferrara, ITALY.*

EP-1438

A Rare Triad of Extranodal DLBCL: Concurrent Renal, Muscular, and Subcutaneous Involvement Demonstrated by FDG PET/CT

R. Ancuceanu[1], *D. Ionescu*[2,1], *M. Mutuleanu*[2,1], *M. Gherghe*[2,1];
[1]*Nuclear Medicine Department, Institute of Oncology "Prof. Dr. Alexandru Trestioreanu", Bucharest, Romania, Bucharest, ROMANIA,*
[2]*Nuclear Medicine Department, University of Medicine and Pharmacy "Carol Davila" Bucharest, Romania, Bucharest, ROMANIA.*

EP-1439

Complementary Role of Cardiac [123I]meta-iodobenzylguanidine Scintigraphy and [123I] ioflupane SPECT in Pure Autonomic Failure: A Case Report

A. Sagastegui Alca, *G. Martínez Gómez, C. Moriana Simón, T. Moreno Monsalve, T. Rodríguez Locarno, N. Sánchez Izquierdo, M. Castellón Sánchez, A. Hernandez Martínez, M. Ibañez Ibañez, L. Mohamed Salem, J. Navarro Fernández, L. Frutos Esteban, J. Contreras Gutiérrez;*
Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-1440

No Single Radiotracer Tells the Whole Story: A Multitracer PET/CT Case in Medullary Thyroid Carcinoma

O. Kodaz, *M. Tuncel;*
Hacettepe University Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-1441

Fever of Unkown Origin in a Child With Complex Congenital Heart Disease: 18FDG-PET/CT Uncovers Silent Infective Pulmonary Artery Banding-Related Endarteritis

L. Zaabar[1,2], *G. Mani*[1], *Y. Kasbi*[1], *H. Cherif*[3], *I. Meddeb*[1,2], *A. Mhiri*[1,2];
[1]*Salah Azaeiz Institute, Tunis, TUNISIA,*
[2]*Faculty of Medicine, Tunis, TUNISIA,*
[3]*Peadiatric Departement, Regional Hospital of Ben Arous, Ben Arous, TUNISIA.*

EP-1442

Differentiating Residual Tumour and Radiation-Induced Inflammatory Changes in Post-Chemoradiotherapy Lung Cancer Using ^{68}Ga-FAPI PET/CT: A Case Report

Z. Chen, *A. Shi, W. Ma, Y. Luo(corresponding author);*
Lanzhou University Second Hospital(Second Clinical Medical College), LanZhou, CHINA.

EP-1443

Aggressive Parathyroid Adenoma in a Pediatric Patient with Multi-System Complications: A Molecular Imaging Perspective

M. Paunescu[1], *A. Tomescu*[1], *D. Ionescu*[1,2], *M. Gherghe*[1,2];
[1]*Institute of Oncology "Prof. Dr. Alexandru Trestioreanu", Bucharest, ROMANIA,*
[2]*University of Medicine and Pharmacy "Carol Davila", Bucharest, ROMANIA.*

EP-1444

When the Brain Leads the Way: ^{18}F-FDG PET/CT Uncovers Occult Breast Cancer in Paraneoplastic Cerebellar Degeneration

A. Leiva Montejo, *G. Jimenez Londoño, C. Ruiz Corbalán, M. Morales Lozano, F. Perez Angel, J. Cegarra Macia, I. Saura Lopez, V. Roca Hernandez, M. Gallego Peinado;*
Hospital General Universitario Santa Lucia, Murcia, SPAIN.

EP-1445

Comparative Evaluation of ^{18}F-FDG and ^{68}Ga-PSMA PET/CT in Metastatic Clear-Cell Renal Cell Carcinoma: A Case Report

M. Dasar[1], *S. Özdemir*[2], *A. B. Özden*[1], *K. Demirel*[1], *G. Koca*[1], *M. Korkmaz*[1];
[1]*University of Health Sciences, Ankara Training and Research Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE,*
[2]*Hatay Training and Research Hospital, Department of Nuclear Medicine, Hatay, TÜRKIYE.*

EP-1446

[^{18}F]FDG PET/CT in the differential diagnosis between disseminated tuberculosis and lymphoma: role in biopsy guidance in a case of uncertain diagnosis

A. Sagastegui Alca, *G. Martínez Gómez, C. Moriana Simón, T. Moreno Monsalve, T. Rodríguez Locarno, N. Sánchez Izquierdo, M. Castellón Sánchez, A. Hernandez Martínez, M. Ibañez Ibañez, L. Mohamed Salem, J. Navarro Fernández, L. Frutos Esteban, J. Contreras Gutiérrez;*
Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-1447

When Particle Disease Mimics Periprosthetic Infection: The Decisive Value of Combined WBC and Bone Marrow SPECT/CT

S. Paiva, *S. Barata, D. Carvalho, I. Casimiro, A. L. Alves, L. Lemos, G. Costa;*
ULS Coimbra, Coimbra, PORTUGAL.

EP-1448

Rare Case of Esophageal Hodgkin Lymphoma with Rotter's Node Involvement

D. Alami[1], *A. Mouaden*[1], *M. Bel Lakhdar*[2], *A. Taalabi*[1], *N. Mahersi*[1], *A. Tabich*[1], *H. Guerrouj*[1];
[1]*Ibn Sina Teaching Hospital, Rabat, MOROCCO,*
[2]*Mohammed VI Teaching Hospital, Agadir, MOROCCO.*

EP-1449

Beyond Conventional Imaging: ^{18}F-FDG PET/CT in the Detection of a Mycotic Arch Aneurysm.

A. Leiva Montejo, *C. Ruiz Corbalán, G. Jimenez Londoño, M. Morales Lozano, F. Perez Angel, I. Saura Lopez, J. Cegarra Macia, V. Roca Hernandez, M. Gallego Peinado;*
Hospital General Universitario Santa Lucia, Murcia, SPAIN.

EP-1450

Acetazolamide-Challenge Cerebral Perfusion SPECT-CT in the Management of Moyamoya Disease.

G. Martínez Gómez, *C. Moriana Simón, A. Sagastegui Alca, L. Mohammed Salem, T. Moreno Monsalve, N. Sánchez Izquierdo, T. Rodríguez Locarno, M. Ibáñez Ibáñez, M. Castellón Sánchez, A. Hernández Martínez, L. Frutos Esteban, J. Navarro Fernández, J. Contreras Gutiérrez;*
Hospital Universitario Virgen De La Arrixaca, Murcia, SPAIN.

EP-1451

Incidental detection of Papillary thyroid carcinoma and Cystic Struma Ovarii on FDG PET/CT scan: A Rare Dual Pathology case

P. Kumar;
All India Institute Of Medical Sciences Patna India, Patna, INDIA.

EP-1452

PET/CT-guided Biopsy in a large Myxoid Liposarcoma

G. Barbosa, *N. Tobar, E. Nogueira-Lima, M. Branco, R. Contriciani, T. Souza, J. Barreto, M. Etchebehere, E. Etchebehere, A. Santos;*
Unicamp, Campinas, BRAZIL.

EP-1453

From detection to intervention: radioguided robotic (da Vinci) surgery for precise excision of ectopic parathyroid adenoma

G. Mera, *D. Zamudio, J. Ardila, S. Salcedo, S. Álvarez, Y. Ascanio, I. Gómez, J. Ardila, L. Reguera, V. Castillo, J. Orcajo, J. Guzmán, A. Mari, J. Alonso;*
Hospital General Universitario Gregorio Marañon, Madrid, SPAIN.

EP-1454

Extensive extranodal involvement with skeletal muscle uptake in pediatric ALK-negative anaplastic large cell lymphoma: diagnostic role of FDG PET/CT

S. Srivastava, *R. Mehra, M. Ora;*
Sanjay Gandhi Post graduate institute of medical sciences, Lucknow, INDIA.

EP-1455

^{18}F-FDG PET/CT Revealing Occult Cardiac and Multisystemic Extranodal Involvement in DLBCL After Equivocal Echocardiographic Findings: A Case Report

M. Romdhani[1], *M. Bettaieb*[1], *M. Znati Jouini*[1], *C. Habechi*[1], *I. Bizid*[2], *A. Slama*[2], *N. Bouchahda*[3], *R. Sfar*[1], *K. Chatti*[1];
[1]*Department of Nuclear Medicine, Sahloul University Hospital, Sousse, TUNISIA,*
[2]*Hematology Department, University Hospital of Monastir, Monastir, TUNISIA,*
[3]*Department of Cardiology, Monastir University Hospital, Monastir, TUNISIA.*

EP-1456

Spondylodiscitis On [^{18}F]F-Psma-1007 Pet/Ct: A Pitfall Or An Alternative Imaging Tool?

P. Guglielmo[1], *C. Vallone*[2], *M. Bartoletti*[1], *U. Riva*[3], *S. Calzolai Lettieri*[4], *S. Damiani*[4], *G. Mansi*[4], *L. Evangelista*[1];
[1]*Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ITALY,*
[2]*Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY,*
[3]*Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, ITALY,*
[4]*Humanitas University, Pieve Emanuele, Milan, ITALY.*

EP-1457

Scattered Remnants: ^{99}mTc-Sulphur Colloid SPECT/CT in the Definitive Diagnosis of Abdominal Splenosis After Post-traumatic Splenectomy

A. S Babu, *M. Umar, A. Mahalik, K. Vengadesan, R. Kumar;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-1458

Real-world Detection of Prostate Cancer Recurrence With ^{64}Cu-SAR-bisPSMA Imaging Following Negative Standard-Of-Care PSMA PET: A Three-Patient Case Report

L. Lam, *E. Lengyelova, O. Gervasio, K. Chia;*
Clarity Pharmaceuticals, Sydney, AUSTRALIA.

EP-1459

[^{18}F]Fluorocholine-Guided Robotic Surgery for Ectopic Parathyroid Adenoma with Rapid MIBI Washout.

A. Rodríguez Llamas, *M. Guiote Moreno, A. De Agrela Serrao, S. Tejerina Tejerina, I. Cejudo Liébana, J. Vallejo Casas;*
Hospital Universitario Reina Sofía, Córdoba, SPAIN.

EP-1460

PSMA-avid metastatic brain lesion in prostatic cancer patient

M. Mehesen, *R. Shera;*
National Cancer Institute, Cairo University, Cairo, EGYPT.

EP-1461

Not All New Lesions Mean Progression: Adrenal Tuberculosis MasqueradingasMetastasison^{18}F-FDG PET/CT During Neoadjuvant Chemotherapy Response AssessmentinBreast Cancer

A. S Babu, *M. Umar, R. Kumar;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-1462

Dual Tracer Dilemma in an Ultra Rare SDH Deficient Carney's Triad: Multifocal Gastric GISTs with Opposing ^{68}Ga DOTANOC and ^{18}F FDG Signatures

M. K. Taggar, *S. A. Shamim, S. Rastogi;*
All India Institute Of Medical Sciences, New Delhi, INDIA.

EP-1463

Evaluation of Suspected Periprosthetic Infection and Systemic Inflammatory Activity in a Patient with Rheumatoid Arthritis Using ^{99}mTc-Ubiquicidin SPECT/CT

B. Alencar, *M. Osmak, T. Agnello, R. Marques, I. Costa, A. Fochi, A. Santos, B. Amorim, M. Lima;*
Unicamp, Campinas, São Paulo, Brazil, BRAZIL.

EP-1464

Scintigraphic-histopathological Correlation in a Giant Cystic Atpypical Parathyroid Tumour with Mediastinal Extension: A nuclear Medicine Perspective

I. Sisko Markos[1,2], *N. Dabelić*[1], *G. Šutić*[3];
[1]*UHC Sestre Milosrdnice, ZAGREB, Zagreb, CROATIA,*
[2]*Croatian Catholic University, School of Medicine, Zagreb, CROATIA,*
[3]*Catholic University of Croatia, Zagreb, CROATIA.*

EP-1465

Cholangitis on [^{18}F]FDG PET/CT During Pembrolizumab Treatment: A Case Report

O. Silva, *H. Calqueiro, J. A. Sequeira, S. Carmona, A. I. Santos;*
Centro de Responsabilidade Integrada de Medicina Nuclear, Unidade Local de Saúde de Almada-Seixal, E.P.E., Almada, PORTUGAL.

EP-1466

Hepatic fibrosis mimicking metabolic progression on FDG PET/CT in Hodgkin lymphoma: a clinically significant pitfall in treatment response assessment

C. Habachi[1,2], *T. Dardouri*[1,3], *M. Allegue*[1,2], *S. Mensi*[1,3], *M. Guermazi*[4,3], *M. Ben Fredj*[1,3], *K. Chatti*[1,2];
[1]*University hospital Sahloul of Sousse, Nuclear medicine department, Sousse, TUNISIA,*
[2]*University of Monastir, Monastir, TUNISIA,*
[3]*University of Sousse, Sousse, TUNISIA,*
[4]*University hospital Farhat Hached of Sousse, haematology department, Sousse, TUNISIA.*

EP-1467

When Scans Tell Different Stories: Tumour Heterogeneity in Thyroid Carcinoma

R. Marão, *D. Silva, N. Vasconcelos, R. Lopes, I. Lopo, J. Ferro, I. Lucena e Sampaio;*
Instituto Português Oncologia do Porto Francisco Gentil, Porto, PORTUGAL.

EP-1468

Unusual Metastatic Pattern in Pulmonary Sarcomatoid Carcinoma: The Added Value of [^{18}F] FDG PET/CT

J. Monibi[1], *A. Stanciu*[1], *M. Matei*[1], *C. Mazilu*[1], *R. Mititelu*[1,2];
[1]*Central Universitary Emergency Military Hospital "Dr. Carol Davila", Bucharest, ROMANIA,*
[2]*University of Medicine and Pharmacy Dr. Carol Davila, Bucharest, ROMANIA.*

EP-1469

FDG-Avid Maxillary Sinus Oncocytoma in a Patient with Cutaneous T-Cell Lymphoma: A PET/CT Pitfall

K. Petrovic, *J. Pantovic;*
Center for Nuclear Medicine, University Clinical Center of Serbia, Belgrade, SERBIA.

EP-1470

Venous thrombosis in large B-cell lymphoma; the risk it poses to the patient's prognosis and the ability of PET-CT to detect it and assess response to treatment

S. Martin Aguilar, *M. Sanchez Torrente, E. Moratalla-Aranda, M. J. Ureña Lara;*
Complejo Hospitalario de Jaén, Jaén, SPAIN.

EP-1471

Seeing Is Not Treating: A Case of IodineAvid but Progressive Metastatic Thyroid Carcinoma

D. Silva, *N. Vasconcelos, R. Marão, R. Lopes, I. Lopo, J. Ferro, H. Duarte, I. L. Sampaio;*
Instituto Português de Oncologia do Porto Francisco Gentil, Porto, PORTUGAL.

EP-1472

Beyond Anatomy: [^{18}F]FDG-PET/TC unveils Large Vessel Vasculitis

S. Alvarez, *V. Castillo, S. Salcedo, G. Mera, Y. P. Ascanio, J. Ardila, D. Zamudio, I. Gomez, J. Ardila, L. Reguera, A. Mari, J. Orcajo, J. Guzman, J. C. Alonso;*
Hospital General Universitario Gregorio Marañón, Madrid, SPAIN.

EP-1473

Dynamic total body PET/CT after oral administration of [^{18}F]FDG: a case report

M. Baas, *J. Mostert, Q. de Lussanet de la Sabloniere, M. Segbers, F. Verburg;*
Erasmus MC, Rotterdam, NETHERLANDS.

EP-1474

Evaluation of newly appearing hypermetabolic liver lesions on end-of-treatment FDG PET-CT in a patient with classical Hodgkin lymphoma; differential diagnosis between malignancy vs inflammatory/reactive processes

S. Martin Aguilar, *E. Moratalla-Aranda, M. Sanchez Torrente, M. J. Ureña Lara;*
Complejo Hospitalario de Jaén, Jaén, SPAIN.

EP-1475

Perfusion Insight: Crossed Cerebellar Diaschisis in Cerebellar Hypoplasia

D. Filipan[1], *D. Karlović*[2,3], *I. Šiško Markoš*[1,3];
[1]*Department of Oncology and Nuclear Medicine, University Hospital Centre "Sestre milosrdnice", Zagreb, CROATIA,*
[2]*Department of Psychiatry, University Hospital Centre "Sestre milosrdnice", Zagreb, CROATIA,*
[3]*School of Medicine, Catholic University of Croatia, Zagreb, CROATIA.*

EP-1476

F ^{18}FDG PET-CT Statging in GNAQ-Mutant Uveal Melanoma with Melanoma with Multisite Systemic Metastasis: A Case Report

A. B. Özden[1], *N. Arslan*[2], *G. Koca*[1], *K. Demirel*[1], *M. Korkmaz*[1];
[1]*Ankara, Ankara, TÜRKIYE,*
[2]*Ankara, Ankara, TÜRKIYE.*

EP-1477

^{67}Cu-SAR-bisPSMA leads to Undetectable Disease in Metastatic Castration-Resistant Prostate Cancer Patients: Two Case Reports From The Phase I/IIa SECuRE Trial

O. Gervasio[1], *E. Lengyelova*[1], *V. Prasad*[2], *G. B. Johnson*[3], *on behalf of the SECuRE Trial Investigators;*
[1]*Clarity Pharmaceuticals, Sydney, AUSTRALIA,*
[2]*Mallinckrodt Institute of Radiology, Washington University, St. Louis, MO, UNITED STATES OF AMERICA,*
[3]*Department of Radiology, Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA.*

EP-1478

Imaging Spectrum of Malignancy Related Superior Vena Cava Syndrome on PET/CT: A Case Series

S. I. Ünal, *M. Daşar, S. Aşıkovalı, K. Demirel, G. Koca, M. Korkmaz;*
University of Health Sciences, Ankara Training and Research Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-1479

Role of ^{18}F-FDG PET/CT in Initial Staging of Langerhans Cell Histiocytosis: A Pediatric Case

Y. Igenbayev, *G. Alisherov, A. Mukhay, A. Yerezhep;*
HiLife, Almaty, KAZAKHSTAN.

EP-1480

Role of ^{18}F-FDG PET/CT in the Evaluation and Diagnosis of Relapsing Polychondritis: A Case Report

A. Orozco Rodríguez, *C. Sandoval Moreno, G. Figueroa Ardila, M. Torres Tarraga, E. Marques Aparicio, P. Gonzalez Cabezas, M. Azorin Belda;*
Hospital Universitario del Vinalopó, Elche, SPAIN.

EP-1481

A rare presentation of IgG4 - related disease in a patient with obstruction of the pulmonary trunk

M. Dobrenic, *A. Sporcic Rak, S. Dotlic, M. Andrassy;*
Clinical Hospital Centre Zagreb, Zagreb, CROATIA.

EP-1482

When Perfusion Lies: Systemic [^{99m}Tc]Tc-MAA Uptake Leading to V/Q Mismatch in the Setting of Venous Collateral Shunting

D. Carvalho, *S. Paiva, S. Barata, A. Lima Alves, I. Casimiro, G. Costa, P. Lapa;*
ULS Coimbra - HUC, Coimbra, PORTUGAL.

EP-1483

^{18}F-FDG PET/CT In Suspected Paraneoplastic Pulmonary Thromboembolism: Ruling Out Hilar Malignancy and Identifying the Metabolic Signature of Pulmonary Infarction in a Patient with Systemic Sarcoidosis

S. Chausheva, *T. Stoeva, M. Dyankova, T. Yordanova, D. Bacheva- Chausheva, A. Klisarova;*
University Hospital St Marina Varna, Varna, BULGARIA.

EP-1484

Beyond Deauville: interpreting unexpected findings and residual uptake after therapy

A. Dacosta Escobar[1], *C. Martínez Ramos*[1], *J. Martín Marcuartu*[1], *B. Hervás Sanz*[1], *D. Tamayo Ossa*[1], *D. Ramírez Muñoz*[1], *M. Argelés Colet*[1], *S. Orts Expósito*[2], *M. Cortés Romera*[1];
[1]*Nuclear Medicine-PET department (ICS-IDI), Hospital Universitari de Bellvitge – IDIBELL, Barcelona, Barcelona, SPAIN,*
[2]*Radiopharmacy department, Hospital Universitari de Bellvitge – IDIBELL, Barcelona, SPAIN.*

EP-1485

Personalized ^{90}Y Radioembolization for Multifocal Hepatocarcinoma Recurrence in a Transplanted Liver: A Case Report

A. Constantin[1], *I. S. Cantea*[1], *D. M. Ionescu*[2,1], *M. D. Mutuleanu*[2,1], *M. Gherghe*[2,1];
[1]*Institute of Oncology "Prof. Dr. Alexandru Trestioreanu", Bucharest, ROMANIA,*
[2]*University of Medicine and Pharmacy "Carol Davila", Bucharest, ROMANIA.*

EP-1486

Early Diagnosis Of Diffuse Congenital Hyperinsulinsm: A F18-Dopa Pet-Mri Case Of Pancreatic Diffuse Uptake In A Newborn With Persistent Hypoglicemia.

M. Palumbi[1], *V. Tiberi*[2], *C. Fatjon*[3], *V. Cherubini*[2], *F. Fringuelli*[1], *M. Carotti*[4];
[1]*Azienda Ospedaliero Universitaria delle Marche-SOD Medicina Nucleare, Ancona, ITALY,*
[2]*Azienda Ospedaliero Universitaria delle Marche-SOD Diabetologia Pediatrica, Ancona, ITALY,*
[3]*Azienda Ospedaliero Universitaria delle Marche-SOD Radiologia Materno Infantile, Senologica, Cardiologica ed Ecografica Ambulatoriale, Ancona, ITALY,*
[4]*Azienda Ospedaliero Universitaria delle Marche-SOD Clinica di Radiologia, Ancona, ITALY.*

EP-1488

The Role of ^{18}F-FDG PET/CT in Facilitating the Diagnosis of Metastatic Anaplastic Thyroid Carcinoma: A Case Study

D. Todorova-Stefanovski[1], *S. Tasevski*[1], *S. Beshliev*[1], *B. Janevski*[2], *N. Manevska*[1], *S. Stojanoski*[2];
[1]*University Institute of Positron Emission Tomography, Skopje, NORTH MACEDONIA,*
[2]*Institute of pathophysiology and nuclear medicine- Medical Faculty, Ss Cyril and Methodius University, Skopje, North Macedonia, The Republic of, Skopje, NORTH MACEDONIA.*

EP-1489

Nitrat Enhanced Tc99m Perfusion Scintigraphy Demonstrating Reversible Resting Hypoperfusion in Takayasu Arteritis

Z. Isik, *M. Çiçek, M. Nalbant;*
Düzce Atatürk State Hospital, Düzce, TÜRKIYE.

EP-1490

Diagnostic Pitfalls in Oncological Metabolic Imaging: A Rare Case Series

E. Alan, *M. Daşar, A. Köroğlu, G. Koca, K. Demirel, M. Korkmaz;*
Ankara Training and Research Hospital, Ankara, TÜRKIYE.

EP-1491

[^{18}F]FDG PET/CT as a Potential Imaging Biomarker in Pediatric NUT Carcinoma

C. Battisti[1], *N. C. Merenda*[1], *D. Rubini*[2], *C. Ferrari*[1], *G. Rubini*[1];
[1]*Nuclear Medicine Unit, DIM, University-Policlinico, Bari, ITALY,*
[2]*Radiology Unit, DIM, University-Policlinico, Bari, ITALY.*

EP-1492

The Clinical Utility of ^{18}F-FDG PET/CT in Detecting Late-Onset Solitary Pulmonary Metastasis from Myoepithelial Carcinoma ex Pleomorphic Adenoma

W. Wong;
Queen Elizabeth Hospital, Hong Kong, HONG KONG.

EP-1493

Skin Nodules Unveiling a Silent Threat: A Case of Rapidly Progressing Lung Adenocarcinoma

A. Militaru[1], *G. Ilinoiu*[1], *H. Negau*[1], *R. Mititelu*[1,2];
[1]*Clinic of Nuclear Medicine- Central Universitary Emergency Military Hospital, Bucharest, Bucuresti, ROMANIA,*
[2]*Nuclear Medicine Department- University of Medicine and Pharmacy "Carol Davila" Bucharest, Bucuresti, ROMANIA.*

EP-1494

Role of ^{18}F-FDG PET/CT in the Diagnostic Evaluation of a Hypermetabolic Pulmonary Artery lesion: A Case Report of IgG4-Related Disease Mimicking Malignancy

K. Guichay Duran, *B. Tagliatori Nogueira, C. Paniagua Correa, C. Galindo Fernández, A. Sicilia Tafalla, L. Castillejos Rodríguez, A. Herrero Muñoz, S. Perez Quiros, A. Ortega Valle, M. Alvares Moreno, M. De la Rubia Marcos, P. García Alonso, P. Nespral Torres;*
Department of Nuclear Medicine, Getafe University Hospital, Madrid, SPAIN.

EP-1495

Mazabraud syndrome on FDG PET/CT scan - a case report

N. Manevska[1,2], *D. Todorova Stefanovski*[1], *S. Tasevski*[1], *B. Stoilovska Rizova*[2], *A. Jankulovska*[2], *N. Kolovcevska Bozinovska*[2], *T. Makazlieva*[2], *S. Stojanoski*[2];
[1]*Institute of positron emission tomography, Skopje, NORTH MACEDONIA,*
[2]*Institute of pathophysiology and nuclear medicine, Faculty of medicine, University of Ss Cyril and Methodius, Skopje, NORTH MACEDONIA.*

EP-1496

Diffuse Cutaneous PSMA Uptake Mimicking Metastatic Disease: Neurofibromatosis Type 1 as a Diagnostic Pitfall in PSMA PET-CT

M. Sanchez Torrente, *L. Mena Bares, E. Moratalla-Aranda, S. Martin Aguilar, M. Ureña Lara;*
Hospital Universitario de Jaén, Jaén, SPAIN.

EP-1497

Xanthoma Disseminatum : A Case Report

Y. Ma, *B. Du, Y. Cui, Q. Wang, Y. Liu;*
The First Affiliated Hospital of Zhengzhou University, Zhengzhou City, CHINA.

EP-1498

When Atrophy Does Not Match Metabolism: FDG PET Findings Suggesting Myotonic Dystrophy Over Frontotemporal Dementia

M. Sanchez Torrente, *E. Moratalla Aranda, S. Martin Aguilar, M. Ureña Lara;*
Hospital Universitario de Jaén, Jaén, SPAIN.

EP-1499

Diagnostic Value of [^{18}F]FDG PET/CT in Immunotherapy-Related Meningoencephalitis: A Paediatric Case Report

D. Silva, *N. Vasconcelos, R. Marão, R. Lopes, I. Lopo, I. Próspero, J. P. Teixeira, H. Duarte, I. L. Sampaio;*
Instituto Português de Oncologia do Porto Francisco Gentil, Porto, PORTUGAL.

EP-1500

Multimodality Imaging of a Calcified Cardiac Mass: A Mimic of Metastatic Disease in a Breast Cancer Patient

W. Wong;
Queen Elizabeth Hospital, Hong Kong, HONG KONG.

EP-1501

Rapid Systemic Recurrence of Thoracic SMARCA4-Deficient Undifferentiated Tumour Visualised on ^{18}F-FDG PET/CT

W. Wong;
Queen Elizabeth Hospital, Hong Kong, HONG KONG.

EP-1502

Solitary Sternal Nonbacterial Osteomyelitis Mimicking Bone Metastasis: A Diagnostic Pitfall in Oncological Surveillance

M. Dasar[1], *A. Akbulut*[2], *K. Demirel*[1], *G. Koca*[1], *M. Korkmaz*[1];
[1]*University of Health Sciences, Ankara Training and Research Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE,*
[2]*Sultan [2]. Abdülhamid Han Training and Research Hospital, Istanbul, TÜRKIYE.*

EP-1503

Axial Skeletal Chronic Recurrent Osteomyelitis Mimicking Metastatic Prostate Cancer

A. Baqer, *T. Ingle, M. Christy, D. Mukherjee, R. Balachandar, D. Priftakis, A. Latifoltojar;*
Institute of Nuclear Medicine, University College London Hospitals, London, UNITED KINGDOM.

EP-1504

Positive [18F]AlF-NOTA-octreotide PET/CT in Ectopic Adrenocortical Adenoma with SSTR2-Negative Expression and ACTH Elevation: A Case Report

L. Yuan, *L. Huang, Z. Cui, J. Liu;*
Lanzhou University Second Hospital, Lanzhou, CHINA.

EP-1505

Extramedullary Multiple Myeloma Involving the Thyroid Cartilage: An Exceptionally Rare Clinical Presentation

J. Duarte[1], *I. Casimiro*[2], *R. Silva*[2], *A. Marques*[1,3], *G. Costa*[2], *S. Pintão*[1];
[1]*Unidade Local de Saúde de Lisboa Ocidental, Lisbon, PORTUGAL,*
[2]*Unidade Local de Saúde de Coimbra, Coimbra, PORTUGAL,*
[3]*Instituto de Medicina Nuclear da Faculdade de Medicina de Lisboa, Lisbon, PORTUGAL.*

EP-1506

The Dark Knight of Bone Scintigraphy: the Mask Sign in Identifying Fibrous Dysplasia

J. Duarte[1], *A. Marques*[1,2], *J. P. Carvalho*[1], *F. Abreu*[1,2], *S. Pintão*[1];
[1]*Unidade Local de Saúde de Lisboa Ocidental, Lisbon, PORTUGAL,*
[2]*Instituto de Medicina Nuclear da Faculdade de Medicina de Lisboa, Lisbon, PORTUGAL.*

EP-1507

Somatostatin receptor uptake in papillary renal cell carcinoma as a diagnostic false positive.

M. Zambrana-Delgadillo, *M. Cardoso-Rodríguez, F. Partida-Palma, M. Piñero Fernandez-Reyes, M. Jerez-Jaimes, M. Pajares-Vinardell;*
Hospital Universitario Puerta Del Mar, Cadiz, SPAIN.

EP-72

E: Other Studies → E2 Other Study (including Training, Projects)

EP-1508

What PET research is interested by clinical oncologists? A bibliometric analysis of ASCO 2024 Annual Meeting Abstracts

L. Yang[1], *F. Cui*[1], *Y. Jing*[2], *Y. Liu*[3], *L. Li*[1], *M. Su*[1], *Q. Li*[1];
[1]*Department of Nulcear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA,*
[2]*West China School of Medicine, Sichuan University, Chengdu, CHINA,*
[3]*The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CHINA.*

EP-1509

Strategic Planning for Technology Development within Nuclear Medicine Departments-Initial Case Studies Based on selected Nuclear Medicine Centres of Excellence in Europe

S. Agius, *C. Caruana, M. Marengo;*
University of Malta, Imsida, MALTA.

EP-1510

Image Manipulation Takes Nearly Four Times Longer to Retract Than Other Misconduct: An International Cohort Study with Implications for Nuclear Medicine Research Integrity

S. Nurmsoo;
Brigham and Women's Hospital / Dana-Farber Cancer Institute / Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA.

EP-1511

The State of the Union - Results of a survey on Traceability in Europe (By the ETrain Project)

A. Fenwick[1], *J. de Pooter*[2], *P. Toroi*[3], *J. Rusnak*[4], *K. Sjogreen Gleisner*[5], *The ETrain Consortium ([24]RPT[01]);*
[1]*National Physical Laboratory, Teddington, UNITED KINGDOM,*
[2]*VSL, Delft, NETHERLANDS,*
[3]*STUK, Helsinki, FINLAND,*
[4]*CMI, Prague, CZECH REPUBLIC,*
[5]*Lund University, Lund, SWEDEN.*

EP-1512

Training Tomorrow'S Eyes: A National Student Contest On Rare Tumours And Hybrid Molecular Imaging

P. Guglielmo[1], *C. Alaadik*[2], *V. Asta*[3], *A. Cairo*[4], *M. Costantini*[5], *S. Damiani*[6], *V. Esposito*[7], *G. Hoxha*[4], *A. Jesuraj*[6], *A. Li Gregni*[8], *V. Lombardi*[2], *D. Musabelliu*[4], *J. Passoni*[9], *C. Pisati*[9], *A. Spolidoro*[3], *F. Testani*[3], *G. Toriggia*[10], *F. Zambetta*[2], *L. Evangelista*[1], *L. Filippi*[3];
[1]*Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ITALY,*
[2]*Catholic University of the Sacred Heart, Rome, ITALY,*
[3]*Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, ITALY,*
[4]*Department of Biomedical Sciences, Catholic University "Our Lady of Good Counsel", Tirana, ALBANIA,*
[5]*Modena and Reggio Emilia University, Modena, ITALY,*
[6]*Humanitas University, Pieve Emanuele, Milan, ITALY,*
[7]*University of Naples Federico II – Unina, Naples, ITALY,*
[8]*Sapienza University of Rome, Rome, ITALY,*
[9]*University of Genoa, Genoa, ITALY,*
[10]*University of Eastern Piedmont, Vercelli, ITALY.*

EP-1513

Drug interactions involving therapeutic radiopharmaceuticals: towards a practical screening tool to ensure safe patient management

R. Gacon[1], *R. Chapuis*[1], *L. Fabris-Davet*[1], *M. Gallet*[2], *S. Goutelle*[1], *L. Bourguignon*[1], *A. Flaus*[1], *C. Bolot*[1], *E. Levigoureux*[1], *N. Ranjit*[2], *S. Chaïb*[1];
[1]*Hospices Civils de Lyon, Lyon, FRANCE,*
[2]*Centre Georges-François Leclerc, Dijon, FRANCE.*

EP-1514

Radionuclide-based functional stratification for kidney selection in living donors: a prospective study

A. Khikmatov[1], *B. Umarov*[1], *F. Khamidov*[1], *G. Arifkhodjaev*[2];
[1]*National Children's Medical Center, Tashkent, UZBEKISTAN,*
[2]*V. Vakhidov Republican Specialized Scientific and Practical Medical Center of Surgery, Tashkent, UZBEKISTAN.*

EP-1515

Clinical audit implementation in nuclear medicine and radiology across Europe: a multi-country survey from the CLAUD-IT project

G. Pisano[1,2], *I. Kralik*[3], *B. Brkljacic*[4], *D. Faj*[5], *A. Skwara-Eggenbauer*[6], *N. Peld*[6], *N. Bargalló*[7], *T. Sulkowski*[8], *R. Kloeckner*[8], *S. Annunziata*[1], *L. Evangelista*[9,10];
[1]*Nuclear Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, ITALY,*
[2]*Interventional Molecular Imaging Laboratory, Leiden University Medical Center, Leiden, NETHERLANDS,*
[3]*Dubrava University Hospital, Zagreb, CROATIA,*
[4]*University of Zagreb School of Medicine, Dubrava University Hospital, Zagreb, CROATIA,*
[5]*Faculty of Medicine Josip Juraj Strossmayer University of Osijek, Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek, Osijek, CROATIA,*
[6]*European Institute for Biomedical Imaging Research, Vienna, AUSTRIA,*
[7]*Centro de Diagnóstico por Imagen, Hospital Clínic de Barcelona, Barcelona, SPAIN,*
[8]*Institute of Interventional Radiology, University Hospital Schleswig-Holstein, Lübeck, GERMANY,*
[9]*Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ITALY,*
[10]*Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, Rozzano, ITALY.*

EP-1516

A Lightweight Monte Carlo Framework for Quantifying Count Rate and Energy Peaking Effects on Gamma Camera Uniformity

A. Pandey[1], *H. Yadav*[1], *J. Chaudhary*[1], *H. Prasad*[1], *S. Rayamajhi*[1], *P. D. Sharma*[2], *R. Kumar*[1];
[1]*All India Institute of Medical Sciences, New Delhi, INDIA,*
[2]*SGTB Khalsa College, University of Delhi, Delhi, INDIA.*

EP-1517

Bridging the gap? AI adoption in Austrian Nuclear Medicine in the face of rising PET/CT demand yet workforce stagnation

G. Schweighofer-Zwink, *G. Rendl, C. Pirich;*
Nuklearmedizin, Salzburg, AUSTRIA.

EP-1518

Implementation of pharmaceutical consultations within the framework of the ^{177}Lu-PSMA treatment

J. Costes[1], *L. Lansard*[2,3,4], *K. Casagrande*[1], *A. Pierrot*[1], *The Oncidium Foundation, N. Schaefer*[5], *M. Tissier*[5], *J. Prior*[5], *F. Sadeghipour*[1,2,3], *J. Delage*[1];
[1]*Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND,*
[2]*Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Lausanne, SWITZERLAND,*
[3]*Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND,*
[4]*School of Pharmaceutical Sciences, University of Geneva, Geneva, SWITZERLAND,*
[5]*Nuclear Medicine and Molecular Imaging Department, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND.*

EP-1519

Pediatric Sedated Cerebral Pet Imaging: A Standardized Nursing Protocol for Safety and Confort

V. Pirami, *P. Coretti, M. Marchetti, M. Monteleone;*
ASST Grande Ospedale Metropolitano Niguarda, Milano, ITALY.

EP-1520

Radiopharmaceutical Therapy for the Management of Metastatic Castration-Resistant Prostate Cancer: A Longitudinal Analysis of the Impact of Continuous Medical Education

Z. Fiske[1], *U. Patel*[1], *A. Carothers*[1], *S. Dunn*[1], *S. Koekkoek*[1], *K. Peters*[1], *E. Castro*[2], *B. Tombal*[3];
[1]*Medscape, Newark, NJ, UNITED STATES OF AMERICA,*
[2]*Hospital Universitario 12 de Octubre, Madrid, SPAIN,*
[3]*Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, BELGIUM.*

EP-1521

Interactive software development process for creation of improved data presentation in an interdisciplinary tumour board

M. Miederer[1], *T. Geißler*[2], *R. Mollitor*[2], *S. Bulka*[2], *A. Sonnenfeld*[1], *R. Herout*[1], *K. Boehm*[1], *S. Banek*[1], *C. Thomas*[1], *R. A. Bundschuh*[1], *S. Mehralivand*[1];
[1]*University Hospital Dresden, Dresden, GERMANY,*
[2]*Qualitype, Dresden, GERMANY.*

EP-1522

From Processes to Value: Measurable Impact of an ISO 9001-Based Quality Management System in Nuclear Medicine

I. Lopez Villar[1], *M. Vinuesa Sebastian*[2], *R. Jover Díaz*[1], *D. Tamayo Carabaño*[1], *J. Alonso Farto*[3], *A. Friera Reyes*[4], *C. Prieto Martín*[5], *P. García Castañón*[5], *M. Ballesteros Escolar*[1], *P. Nuñez Herrero*[1], *Á. Soria Coiradas*[1], *P. Arranz Granero*[1], *F. García Pérez*[1], *C. Martín Fuertes*[1], *S. Miranda Martínez*[1], *A. Puerto Cabreras*[1], *M. Sánchez Morales*[1], *M. Rodríguez Díaz*[1], *M. Roig Sánchez*[1], *M. Hernández Pereña*[6], *S. García de San Jose*[7], *J. Díaz Melguizo*[6];
[1]*Department of Nuclear Medicine, La Princesa University Hospital, Madrid, SPAIN,*
[2]*Quality Coordinator, La Princesa University Hospital, Madrid, SPAIN,*
[3]*Department of Nuclear Medicine, Gregorio Marañón University Hospital, Madrid, SPAIN,*
[4]*Department of Radiology, La Princesa University Hospital, Madrid, SPAIN,*
[5]*Department of Physics and Radiation Protection, La Princesa University Hospital, Madrid, SPAIN,*
[6]*General Management, La Princesa University Hospital, Madrid, SPAIN,*
[7]*General Management, Gregorio Marañón University Hospital, Madrid, SPAIN.*

EP-1523

From Vision to Implementation: Establishing a Theranostics Program at a Large Academic Health Network in Canada

L. Brzozowski;
University Health Network, Toronto, ON, CANADA.

EP-1524

Monte Carlo Simulation of Photopeak Misalignment Effects on Gamma Camera Uniformity: Validation Against Experimental QC Data and Teaching Application

H. Prasad[1], *A. K. Pandey*[1], *P. D. Sharma*[2], *R. Kumar*[1];
[1]*All India Institute Of Medical Sciences, New Delhi, India,*
[2]*Sgtb Khalsa College, University Of Delhi, New Delhi, INDIA.*

EP-1525

A Lightweight Monte Carlo Simulation Framework for Teaching Dose Calibrator Physics in Nuclear Medicine.

S. Rayamajhi, *A. K. Pandey, H. Prasad, J. Chaudhary, P. D. Sharma;*
All India Institute Of Medical Sciences, New Delhi, INDIA.

EP-1526

Burnout in Nuclear Medicine in Germany: A Specialty with Comparatively Low Prevalence and High Professional Satisfaction

M. Bastian[1], *L. Freudenberg*[2,3], *F. Rosar*[1], *A. Blickle*[1], *C. Burgard*[1], *T. Speicher*[1], *S. Ezziddin*[1];
[1]*Department of Nuclear Medicine, Saarland University, Homburg, GERMANY,*
[2]*ZRN Rheinland und ZRN MVZ GmbH, Korschenbroich, GERMANY,*
[3]*Department of Nuclear Medicine, Essen University Hospital, Essen, GERMANY.*

EP-1527

Enabling Surgical Navigation of Tethered Drop-In Probes: A Systematic Review of Tracking Technologies

G. Pisano[1,2], *D. van Tuil*[1,3], *K. Pirkovets*[1,3], *M. N. van Oosterom*[1,3], *F. W. B. van Leeuwen*[1,3];
[1]*Interventional Molecular Imaging Laboratory, Leiden University Medical Centre, Leiden, NETHERLANDS,*
[2]*Nuclear Medicine Unit, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,*
[3]*Department of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.*

EP-1528

Rethinking the Attenuation Map: A CT-Dominant Safety Checklist for the Low-Dose CT Component of Hybrid PET/CT

G. Kaya[1], *M. Tuncel*[2], *V. Beylergil*[3], *U. Balyemez*[4], *S. Ilgan*[5], *A. Yıldız*[6], *N. Arslan*[7], *Ö. Uğur*[2];
[1]*Republic of Türkiye, Ministry of Health, Yozgat City Hospital and Hacettepe Faculty of Medicine Depts. of Nuclear Medicine, Ankara, TÜRKIYE, Ankara, TÜRKIYE,*
[2]*Hacettepe University Faculty of Medicine, Dept. of Nuclear Medicine, Ankara, TÜRKIYE,*
[3]*Memorial Sloan Kettering Cancer Center Department of Radiology, Body Imaging Service, New York City, NY, UNITED STATES OF AMERICA,*
[4]*Near East University Faculty of Medicine, Dept. of Radiology, Lefkoşa, CYPRUS,*
[5]*Maltepe University Faculty of Medicine, Dept. of Nuclear Medicine, Istanbul, TÜRKIYE,*
[6]*Memorial Bahcelievler Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,*
[7]*Near East University Faculty of Medicine, Dept. of Nuclear Medicine, Lefkoşa, CYPRUS.*

EP-1529

Expanding global access to radioligand therapy: real-world experience from the Oncidium RLT-Connect platform

L. Ravasi[1,2], *M. Bastianello*[3], *S. Dash*[4], *I. Hume*[5], *A. Rufai*[6], *R. Lim*[7], *Y. Omar*[8], *T. Tebeila*[9], *E. da Rocha*[10], *B. Hadebe*[11], *F. Faccio*[12], *R. Felix*[13], *A. Armesto*[14], *N. İlkmen*[15], *F. Daza Sifontes*[16], *E. Cannarozzo*[2], *A. Viana*[2];
[1]*KAX Consulting Sàrl, Le Grand Saconnex, SWITZERLAND,*
[2]*Oncidium foundation, Mont-Saint-Guibert, BELGIUM,*
[3]*Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno" (CEMIC), Buenos aires, ARGENTINA,*
[4]*Sarvodaya Hospital, Faridabad, INDIA,*
[5]*Hospital Italiano de Buenos Aires, Buenos Aires, ARGENTINA,*
[6]*National Hospital, Abuja, NIGERIA,*
[7]*Allevia Radiology, Auckland, NEW ZEALAND,*
[8]*Misr Radiology Center, Cairo, EGYPT,*
[9]*Universitas Academic Hospital, Bloemfontein, SOUTH AFRICA,*
[10]*Hospital de Amor de Barretos, Barretos, BRAZIL,*
[11]*Inkosi Albert Luthuli Central Hospital, Durban, SOUTH AFRICA,*
[12]*Sanatorio San Geronimo, Santa Fe, ARGENTINA,*
[13]*Instituto Nacional de Câncer, Rio de Janiero, BRAZIL,*
[14]*Instituto Roffo, Buenos Aires, ARGENTINA,*
[15]*Liv Hospitals- Ulus, Istanbul, TÜRKIYE,*
[16]*Centro de medicina nuclear y diagnostico nor oriental, Barcelona, VENEZUELA, BOLIVARIAN REPUBLIC OF.*

EP-1530

Implementation of an Early Discharge Protocol in Patients with Differentiated Thyroid Cancer Treated with I-131: Safety, Humanization, and Resource Optimization

M. De La Rubia Marcos, *G. Guijarro de Armas, B. Tagliatori Nogueira, A. Herrero Muñoz, C. Galindo Fernandez, M. Álvarez Moreno, K. Guichay Durán, A. Sicilia Tafalla, L. Castillejos Rodriguez, C. Paniagua Correa, S. Pérez Quirós, P. García Alonso;*
H.U. Getafe, Madrid, SPAIN.

EP-1531

Perspectives, activities, and current needs of the new generation in nuclear medicine: Results from two surveys conducted by the EANM Young Professionals Council

C. Voltin[1,2], *A. Eder*[2,3,4], *G. Gnanasegaran*[2,5], *M. Schottelius*[2,6,7], *S. E. M. Veldhuijzen van Zanten*[2,8,9], *A. Holzgreve*[10,11], *T. Van den Wyngaert*[2,12,13];
[1]*Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, GERMANY,*
[2]*Young Professionals Council (YPC), European Association of Nuclear Medicine (EANM), Vienna, AUSTRIA,*
[3]*Department of Nuclear Medicine, University Medical Centre Freiburg, University of Freiburg, Freiburg, GERMANY,*
[4]*Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK) Partner Site Freiburg, Freiburg, GERMANY,*
[5]*Department of Nuclear Medicine, Royal Free Hospital National Health Service (NHS) Foundation Trust, London, UNITED KINGDOM,*
[6]*Laboratory for Translational Radiopharmaceutical Sciences, Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, University of Lausanne, Lausanne, SWITZERLAND,*
[7]*Agora Cancer Research Centre, Lausanne, SWITZERLAND,*
[8]*Department of Radiology and Nuclear Medicine, Erasmus Medical Centre, Rotterdam, NETHERLANDS,*
[9]*Medical Delta, Delft, NETHERLANDS,*
[10]*Department of Nuclear Medicine, University Hospital Munich, Ludwig Maximilian University Munich, Munich, GERMANY,*
[11]*Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA,*
[12]*Department of Nuclear Medicine, Antwerp University Hospital, University of Antwerp, Edegem, BELGIUM,*
[13]*Molecular Imaging Centre Antwerp (MICA), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, BELGIUM.*

EP-1532

Preliminary Results of a European Delphi Consensus on Sentinel Node Biopsy in Oncology

G. Pisano[1,2], *D. D. D. Rietbergen*[1,3], *T. Wendler*[4,5,6], *K. Goffin*[7,8], *S. C. Vaz*[9,10], *M. Schmidt*[11], *G. Gnanasegaran*[12], *J. K. Jakobsen*[13,14], *G. Garganese*[15,16], *F. Giammarile*[17], *R. A. Valdés Olmos*[1,3], *S. Vidal-Sicart*[18,19], *A. Collarino*[2], *T. Buckle*[1], *F. W. B. van Leeuwen*[1];
[1]*Interventional Molecular Imaging Laboratory, Leiden University Medical Center, Leiden, NETHERLANDS,*
[2]*Nuclear Medicine Unit, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,*
[3]*Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, NETHERLANDS,*
[4]*Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Augsburg, Augsburg, GERMANY,*
[5]*Digital Medicine, University Hospital Augsburg, Neusaess, GERMANY,*
[6]*School of Computation, Information and Technology, Technical University of Munich, Garching bei München, GERMANY,*
[7]*Nuclear Medicine, University Hospitals Leuven, Leuven, BELGIUM,*
[8]*Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM,*
[9]*Department of Nuclear Medicine and Radiopharmacology, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, PORTUGAL,*
[10]*Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS,*
[11]*Department of Nuclear Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, GERMANY,*
[12]*Department of Nuclear Medicine, Royal Free London NHS, London, UNITED KINGDOM,*
[13]*Department of Urology, Aarhus University Hospital, Aarhus, DENMARK,*
[14]*Department of Clinical Medicine, Aarhus University, Aarhus, DENMARK,*
[15]*Unità Operativa di Chirurgia degli Organi Genitali Esterni Femminili, Divisione di Ginecologia Oncologica, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,*
[16]*Gemelli Women's Health Center for Digital and*

Personalized Medicine, Dipartimento Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, ITALY,
[17]Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), Vienna, AUSTRIA,
[18]Department of Nuclear Medicine, Hospital Clinic Barcelona, Barcelona, Barcelona, SPAIN,
[19]Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SPAIN.

EP-1533

Overcoming access barriers to theranostics in Latin America through integrated microregional radiopharmacy hubs

N. Ramos, *M. I. C. C. Guimarães, H. S. Videira;*
University of São Paulo, São Paulo, BRAZIL.

EP-1534

Development of a Structured Residency Training Program for Nuclear Medicine Physicists

C. Meyer, *D. Sennung, M. Dahlbom;*
Department of Nuclear Medicine and Theranostics, UCLA, Los Angeles, CA, UNITED STATES OF AMERICA.

EP-1535

The trend over time (10 years) of nuclear medicine exams per year. An example in a Nuclear Medicine center for a territory of half a million of people.

D. Donner[1], *L. Picori*[1], *G. Carbone*[1], *M. Erini*[1], *E. Bagatin*[1], *F. Magnani*[1], *A. Palermo*[1], *V. Vultaggio*[2], *D. Cimino*[3], *S. Agostini*[1], *D. Berti*[4];
[1]Nuclear Medicine Unit, DAI Scienze radiologiche e imaging medico, ASUIT, Trento, ITALY,
[2]Nuclear Medicine Unit, ARNAS civico Palermo, Trento, ITALY,
[3]Nuclear Medicine Unit, DAI Scienze radiologiche e imaging medico, ASUIT, ITALY,
[4]ASUIT, Direzione Medica, Ospedale S. Chiara Trento, Trento, ITALY.

EP-73

Technologists e-Poster

EP-1536

Can SmartZoom Replace Pinhole for Thyroid Imaging? A Phantom-Based Evaluation of Lesion Detectability.

E. Alawadhi[1], *H. Mahmood*[2], *B. Bashayer Alajmi*[1], *H. Alqhatani*[1], *A. Almutairi*[1], *N. Aldaihani*[1], *L. Ghadanfer*[1];
[1]Faculty of Allied Health Sciences, Kuwait University, KUWAIT, Kuwait City, KUWAIT,
[2]Nuclear Medicine Department, AlAdan Hospital, Kuwait City, KUWAIT.

EP-1537

Phantom-Dependent TBS Offset and Repeat-Scan Effects in Daily Triplicate DXA Quality Control: An Ongoing Cross-Vendor Lumbar Spine Phantom Study

C. Lo[1,2], *C. Huang*[1,3], *H. Chen*[4];
[1]Department of nuclea medicine, Chung Shan Medical University Hospital, Taichung, TAIWAN, PROVINCE OF CHINA,
[2]Department of Medical Imaging Radiological Sciences, Chung Shan Medical University, Taichung, TAIWAN, PROVINCE OF CHINA,
[3]The School of Medicine, Chung Shan Medical University, Taichung, Taiwan, Taichung, TAIWAN, PROVINCE OF CHINA,
[4]Department of Medical Imaging, Chung Shan Medical University Hospital, Taichung, Taiwan, Taichung, TAIWAN, PROVINCE OF CHINA.

EP-1538

Optimization of Low-Dose Abdominal ^{18}F-FDG PET/MR Imaging Using Deep Progressive Reconstruction: A Comparative Study in the Liver and Pancreas

Y. Wang[1], *X. Yang*[1], *Z. Hao*[1], *X. Su*[2], *E. Li*[2], *L. Huo*[1], *H. Xing*[1];
[1]Peking Union Medical College Hospital, Beijing, CHINA,
[2]Beijing United Imaging Healthcare Technology Development Co., Ltd., Beijing, China, Beijing, CHINA.

EP-1539

Comparative Radiobiological Effects and Dosimetric Precision of Proton and Photon Irradiation in a Zebrafish Model: Implications for Nuclear Medicine Applications

K. Chang[1], *T. Lin*[2];
[1]Taipei Medical University, Taipei, TAIWAN, PROVINCE OF CHINA,
[2]National Atomic Research Institute, Taoyuan, TAIWAN, PROVINCE OF CHINA.

EP-1540

Enhanced diagnostic performance for coronary artery disease using artificial-intelligence-based software in a cadmium-zinc-telluride camera: Synergistic effect of myocardial flow reserve and phase analysis

T. Niimi[1], *K. Hirayama*[2], *S. Ohshima*[3], *S. Morita*[4], *M. Nanasato*[5];
[1]Kaikoukai Nagoya Jyosai Hospital, Nagoya, JAPAN,
[2]Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, JAPAN,
[3]Kaikoukai Nagoya Kyoritsu Hospital, Nagoya, JAPAN,
[4]Daido Hospital, Nagoya, JAPAN,
[5]Sakakibara Heart Institute, Fuchu, JAPAN.

EP-1541

Dynamic and Cardiac-Gated ^{18}F-FDG PET/CT in Suspected Cardiac suspected inflammatory or infectious cardiac diseases: Description of a Clinical Protocol

K. Shyli, *A. Sotgiu, F. Firinu, S. Fraschina, F. Casaburo, C. Serra, A. Lomartire, M. Mantovani, F. S. Oliverio;*
ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY.

EP-1542

Precise Chemogenetic Activation of the Somatosensory Cortex Induces Chronic Pain and Depression Comorbidity: Molecular Imaging Evidence and Therapeutic Effects of Electroacupuncture via TRPV1 Modulation

K. Chang[1], *T. Chen*[2], *Y. Lin*[3];
[1]Taipei Medical University, Taipei, TAIWAN, PROVINCE OF CHINA,
[2]I-Shou University, Kaohsiung, TAIWAN, PROVINCE OF CHINA,
[3]China Medical University, Taichung, TAIWAN, PROVINCE OF CHINA.

EP-1543

Clinical Flexible Coil Optimizes PET/MR Imaging in Macaques: Enhancing Image Quality and Reducing Neuroscience Research Costs

N. Chai, *M. Liu, K. Guo, T. Ma, J. Wang, G. Li, Y. Wang, Z. Quan, F. Kang, J. Wang;*
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

EP-1544

Longitudinal PET Imaging of Brain-Heart Inflammatory Dynamics with ^{18}F-D2-LW223 in a Rat Stroke Model

K. Liao, *H. Pang;*
Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, CHINA.

EP-1545

Implementing CXCR4 theranostics in clinical routine: Challenges from PET/CT acquisition to radioligand therapy

S. Seifert, *A. K. Buck, P. Hartrampf;*
University Hospital Würzburg, Clinic for Nuclear Medicine, Würzburg, GERMANY.

EP-1546

Added Value of ^{18}F-Choline PET/CT in Patients With Negative or Equivocal ^{99}mTc-MIBI SPECT/CT for Parathyroid Imaging

A. Landolfi;
AUSL Reggio Emilia Santa Maria Nuova Hospital, Reggio Emilia, ITALY.

EP-1547

Variation in Tracer Kinetics Between Standard and Low-Dose [^{18}F]FDG and [^{18}F]DCFPyL Using Long Axial Field of View PET

S. Karaer[1], *L. M. M. W. Straaijer*[1], *B. J. de Wit-van der Veen*[1], *A. J. A. T. Braat*[1,2], *M. M. Steemers-de Boer*[1];
[1]Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, NETHERLANDS,
[2]University Medical Center Utrecht, Utrecht, NETHERLANDS.

EP-1548

Subjective Assessment of ^{18}F-FDG PET/CT Image Quality Using Different Reconstruction Protocols in Normal-Weight and Obese Patients

S. Hadzimusic, *A. Begić, A. Beganović, Š. Cerić, S. Agić-Bilalagić, N. Salkica, A. Skopljak-Beganović, A. Arnautović-Halimić, B. Tukić;*
Clinical Center of the Sarajevo University, Sarajevo, BOSNIA AND HERZEGOVINA.

EP-1549

Impact of Respiratory Motion Correction on Physiological Adrenal [^{18}F]FDG Uptake, Quantification and Image Quality in PET/CT

I. Rodrigues[1,2], *A. Martins*[1,2], *V. Bicho*[1], *M. Santos*[1], *S. Carmona*[1], *L. Oliveira*[1];
[1]Nuclear Medicine Department, Joaquim Chaves Saúde, Lisbon, PORTUGAL,
[2]CrossI&D Lisbon Research Center, Escola Superior de Saúde da Cruz Vermelha Portuguesa - Lisboa, Lisbon, PORTUGAL.

EP-1550

Focus Versus Non-Focus Acquisition in Parathyroid Scintigraphy Using a 360° CZT SPECT/CT

W. Chang[1], *K. Ko*[1], *M. Cheng*[2], *C. Chen*[2];
[1]National Taiwan University Cancer Center, TAIPEI, TAIWAN, PROVINCE OF CHINA,
[2]National Taiwan University Hospital, TAIPEI, TAIWAN, PROVINCE OF CHINA.

EP-1551

A comparison of the use of different deep convolutional neural networks for cardiac amyloidosis classification from99mTc-DPD whole-body imagesand regional scintigraphy highly curated databases

E. Sousa[1,2], *G. Avery*[3], *A. Turner*[4], *S. J. Archibald*[5];
[1]Centre of Excellence for Data Science, Artificial Intelligence and Modelling, University of Hull, Hull, UNITED KINGDOM,
[2]Biomedical Institute for Multimorbidity, Centre for Biomedicine, Hull York Medical School, University of Hull, Hull, UNITED KINGDOM,
[3]Castle Hill Hospital, Hull, UNITED KINGDOM,
[4]University of Nottingham, Nottingham, UNITED KINGDOM,
[5]School of Biomedical Engineering and Imaging Sciences, King's College London, London, UNITED KINGDOM.

EP-1552

Development of a Voice-Driven Question-Answering System Using Locally Operated Open-Source Large Language Models for Nuclear Medicine Patient Enquiries: A Feasibility Study

A. Yamagami, *M. Sato, Y. Iyoku, K. Okubo, K. Onuma, S. Ito, T. Ogino, M. Shiga, H. Sagara, H. Daisaki;*
Gunma Prefectural College of Health Sciences, Maebashi, JAPAN.

EP-1553

Simulation-Based Radiation Safety Validation for Supra-Dose I-131 mIBG Therapy: A First Indian Experience

P. Dwivedi[1,2], *A. Agrawal*[1,2];
[1]Advanced Centre for Treatment Research and Education In Cancer, Tata Memorial Centre, Mumbai, INDIA,
[2]Homi Bhabha National Institute, Mumbai, INDIA.

EP-1554

Four-Year Occupational Dosimetry and Implementation of Evidence-Based Dose Constraints in Nuclear Medicine Staff: Impact of an FDG Autoinjector on Extremity Exposure (2022-2025).

H. Al Saidi, *N. AL Maymani, S. Kheruka, S. AL Rashdi, A. AL Balushi, N. AL Shukairi;*
Sultan Qaboos Comprehensive Cancer Care and Research Center, Muscat, OMAN.

EP-1555

Efficient synthesis of 4-[18F]fluorobenzenesulfonyl chloride for PET tracer preparation and development

W. Chen, *K. Lu, C. Zheng;*
West China Hospital, Sichuan University, Chengdu, CHINA.

EP-1556

A Study on the Verification of the Limit of Quantitation for a Serum Thyroglobulin Radioimmunoassay According to CLSI Guidelines

J. An, *J. Kim, Y. Kim;*
National Cancer Center, Gyeonggi-do, KOREA, REPUBLIC OF.

EP-1557

Developing a Pilot Programme for Specialist Modalities Training in Positron Emission Tomography, Nuclear Medicine and Magnetic Resonance Imaging.

G. Testanera[1], *I. Vaitkute[1], A. Jacob[1], T. Yamamoto[2], M. Fukami[2], F. Bosio[3], M. Azmat[4], D. Bailey[4];*
[1]King College London, London, UNITED KINGDOM,
[2]Department of Medical Radiological Technology, Kyorin University, Tokyo, JAPAN,
[3]King's College, London, UNITED KINGDOM,
[4]Guy's and St Thomas' NHS Foundation Trust, London, UNITED KINGDOM.

EP-1559

Impact of peripheral cannula needle versus butterfly needle on White Blood Cell radiolabelling efficiency

M. Ciaccio[1], *A. Madravio[1], R. Carmassi[1], F. Elisei[1], L. Guerra[2];*
[1]IRCCS Fondazione San Gerardo dei Tintori, Monza, ITALY,
[2]Università degli studi di Milano-Bicocca, Monza, ITALY.

EP-1560

Clinical impact of whole-body SPECT/CT as an adjunct to planar bone scintigraphy in oncology: a retrospective analysis of radiation exposure, efficiency, and diagnostic yield

T. Schnalzer[1], *S. Stanzel[2], P. Mildner Munda[2];*
[1]LKH Graz, Graz, AUSTRIA,
[2]Division of Nuclear Medicine, Department of Radiology, Medical University of Graz, Graz, AUSTRIA.

EP-1561

Clinical Utility of SUV-Based Quantification in 99mTc Myocardial Perfusion SPECT Using a Standalone System

Y. Ichikawa[1,2], *H. Daisaki[2];*
[1]Sumitomo Besshi Hospital, Ehime, JAPAN,
[2]Graduate School of Radiological Technology, Gunma Prefectural College of Health Sciences, Gunma, JAPAN.

EP-1562

SPECT/CT Radiomics in Cardiac Amyloidosis: Beyond Perugini Scoring

F. Montanini[1,2], *E. Abenavoli[1], M. Nerattini[1,3], V. Briganti[1], F. Cappelli[4,5], F. Perfetto[4,5], N. Iosca[2], A. Lastrucci[2], C. Galeotti[1,2], R. Ricci[2], R. Sciagrà[1,3], V. Berti[1,3];*
[1]Nuclear Medicine Unit, Careggi University Hospital, Florence, ITALY,
[2]Department of Allied Health Professions, Careggi University Hospital, Florence, ITALY,
[3]Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, ITALY,
[4]Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, ITALY,
[5]Department of Experimental and Clinical Medicine, University of Florence, Florence, ITALY.

EP-1563

Optimising PET-CT Workflow Through Radiopharmaceutical-Aware Administrative Training

C. Ferreira[1,2];
[1]Centre for Health and Life Sciences - Coventry University, Coventry, UNITED KINGDOM,
[2]NHS England, London, UNITED KINGDOM.

EP-1564

Artificial intelligence in nuclear medicine: a review of current applications and prospective directions

C. Ferreira;
NHS England and Coventry University, Coventry, UNITED KINGDOM.

EP-1565

Comparative Performance of Three Open-Source Large Language Models with and without Retrieval-Augmented Generation for Nuclear Medicine Pre-Examination Preparation Enquiries

Y. Iyoku, *M. Sato, N. Imaizumi, A. Yamagami, K. Okubo, H. Daisaki;*
Gunma Prefectural College of Health Sciences, Maebashi, JAPAN.

EP-1566

Development of a Voice-Driven Natural User Interface for SPECT/CT and PET/CT Console Operation Using a Locally Operated Open-Source Large Language Model: A Feasibility Study

M. Sato, *A. Yamagami, Y. Iyoku, K. Okubo, K. Onuma, S. Ito, T. Ogino, M. Shiga, H. Sagara, H. Daisaki;*
Gunma Prefectural College of Health Sciences, Maebashi, JAPAN.

EP-1567

Is the residue activity in the administration set of Y-90 Radioembolization negligable?

A. Yilmaz[1], *E. Polat[1], B. Ç. Karagedik[1], S. Beykan Schürrle[2], &. B. Güney[1];*
[1]Cukurova University, Adana, TÜRKIYE,
[2]Oncosia Scientific GmbH, Dürrwangen, GERMANY.

EP-1568

Determination of optimal peptide load for <;177Lu>;Lu-DOTATATE radio labelling based on radiochemical purity assessment.

V. Vajarkar, *S. Paunikar, D. Prakash, M. Chauhan, A. Agrawal;*
Advance Centre for Treatment, Research and Education in Cancer, New Mumbai, INDIA.

EP-1569

Impact of technologist-led patient release after PET/CT on workflow efficiency, safety, and patient experience: a real-world implementation study

P. Genoud, *C. Pozza, M. Nicod-Lalonde, N. Schaefer, J. Prior, P. M. Leite Ferreira, M. Jreige;*
CHUV, Lausanne, SWITZERLAND.

EP-1570

NucMed Access: A Mobile Application to Improve Patient Preparation and Adherence in Nuclear Medicine Procedures

S. Bertola[1,2], *N. L. Mella[1,3];*
[1]Hospital de Clínicas "José de San Martín", Ciudad Autónoma de Buenos Aires, ARGENTINA,
[2]Comisión Nacional de Energía Atómica, Ciudad de Buenos Aires, ARGENTINA,
[3]Universidad de Buenos Aires, Ciudad de Buenos Aires, ARGENTINA.

EP-1571

Roles of Respiratory Motion Correction and Deep-Learning Reconstruction in 90Y-SIRT Dosimetry on LAFOV PET/CT

H. Zhang, *L. Huo;*
Peking Union Medical College Hospital, Beijing, CHINA.

EP-1572

Towards Standardized and Time-Efficient Quantitative MRONJ Imaging: Phantom Evaluation of a Full-Ring CZT SPECT/CT System

Y. Owaki, *R. Kawamura, Y. Iwabuchi, R. Sakurai, A. Shimizu, T. Kogo, K. Tonda, A. Tomiyama, K. Minamishima;*
Keio University Hospital, Shinjuku-ku, Tokyo, JAPAN.

EP-1573

Current State of Oncologic 18F-FDG PET/CT in Saudi Arabia: A Systematic Review

M. Alqahtani;
Najran University, Najran, SAUDI ARABIA.

EP-1574

Comparison of "Hot Air Spot" Artifacts between 68Ga-PSMA and 18F-PSMA PET/MR Based on GATE Simulation and Clinical Validation and the Value of TOF Technique for Artifact Correction

M. Liu, *J. Wang, G. Li, Z. Quan, Y. Wang, F. kang, J. Wang;*
The First Affiliated Hospital of Fourth Military Medical University, Xian, CHINA.

EP-1575

Feasibility of Simultaneous Dual-Tracer Imaging with Fluorine-18 and Technetium-99m Using a Newly Developed Electron-Tracking Compton Camera: Basic Evaluation of Tracer Separation and Quantitative Performance

K. Itagaki[1], *H. Kitano[2], T. Mizumoto[3], Y. Takemura[3], K. Ota[3], T. Amano[3], S. Sasaki[3], K. Mitsumoto[1], K. K. Miyake[4], M. Kajisako[1], Y. Shimizu[5], A. Takada[6], Y. Nakamoto[5];*
[1]Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, JAPAN,
[2]Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, JAPAN,
[3]Dai Nippon Printing Co., Ltd., Chiba, JAPAN,
[4]Department of Advanced Medical Imaging Research, Graduate School of Medicine Kyoto University, Kyoto, JAPAN,
[5]Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine Kyoto University, Kyoto, JAPAN,
[6]Graduate School of Science, Kyoto University, Kyoto, JAPAN.

EP-1576

Lymph Node Metastasis Detectability Study of Deep Learning-Based Time-of-Flight-Enhanced BGO PET/CT Scans

K. Itagaki[1], *K. K. Miyake[2], R. Nakamoto[3], H. Kim[4], Y. Kitano[4], A. Katsuki[5], H. Kawakami[5], F. Kotasidis[6], Y. Nakamoto[4];*
[1]Division of Clinical Radiology Service, Kyoto University Hospital, Kyoto, JAPAN,
[2]Department of Advanced Medical Imaging Research, Graduate School of Medicine Kyoto University, Kyoto, JAPAN,
[3]Preemptive Medicine and Lifestyle Related Disease Research Center, Kyoto University Hospital, Kyoto, JAPAN,
[4]Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine Kyoto University, Kyoto, JAPAN,
[5]GE HealthCare, Japan, Tokyo, JAPAN,
[6]GE HealthCare, Zurich, SWITZERLAND.

EP-1577

Protocol Optimization for 18F-FDG Brain PET Imaging Using a Novel Anthropomorphic STEP-BRAIN Phantom.

G. Bruni[1], *L. Fedeli[2], P. Galardini[1], S. Montalbano[1], E. Longo[1], B. Maraviglia[1], C. Costanza[1], A. Gonfiantini[1], T. Tognerelli[1], S. Gamannossi Degl'innocenti[1], C. Mazzeo[1];*
[1]SOC Medicina Nucleare, Ospedale Santo Stefano - Azienda USL Toscana Centro, Prato, ITALY,
[2]SOC Fisica Sanitaria, Ospedale Santo Stefano - Azienda USL Toscana Centro, Prato, ITALY.

EP-1578

Optimising Dose and Image Quality Using Deep Learning Image Reconstruction on a GE Discovery MI-5 PET/CT System

J. Madsen, *N. Elgaard Toft, A. Frodo Stegmann Mikkelsen;*
Aarhus University Hospital Department of Nuclear Medicine, Aarhus, DENMARK.

EP-1579

A comparison of the use of different deep convolutional neural networks for cardiac amyloidosis classification from99mTc-DPD whole-body images

E. Sousa[1,2], *G. Avery[3], A. Turner[4], S. J. Archibald[5];*
[1]Centre of Excellence for Data Science, Artificial Intelligence and Modelling, University of Hull, Hull, UNITED KINGDOM,
[2]Biomedical Institute for Multimorbidity, Centre for Biomedicine, Hull York Medical School, University of Hull, Hull, UNITED KINGDOM,
[3]Castle Hill Hospital, Hull, UNITED KINGDOM,
[4]University of Nottingham, Nottingham, UNITED KINGDOM,
[5]School of Biomedical Engineering and Imaging Sciences, King's College London, London, UNITED KINGDOM.

EP-1580

Chief Technician
W. Li, *I. Ju, h. Pang;*
Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chong qing, CHINA.

EP-1581

Repeat PET/CT Imaging in Clinical Practice: A One-Year Retrospective Analysis of Contributing Factors
M. Gegovski, *G. Anchevski, B. Jovanovska Ivkovska, S. Jovanovska, D. Todorova Stefanovski, N. Manevska;*
Public Health Institution University Institute For Positron-Emission Tomography Republic of North Macedonia, Skopje, NORTH MACEDONIA.

EP-1582

Evaluation of Patient-Induced Radiation for Shielding Verification in a PET Imaging Facility Using Monte Carlo Software RayXpert
J. Hemptinne, *A. Ghilardi, C. Dossat;*
TRAD Tests & Radiations, Labège, FRANCE.

EP-1583

Comparative study of two injection systems used in ^{177}Lu therapy
C. Sobral, *L. Machado Pacheco, S. Medici, P. Ferreira Leite, M. Tissier, J. Prior;*
Centre hospitalier universitaire vaudois (CHUV), Lausanne, SWITZERLAND.

EP-1584

ProcedureSpecific External Dose Rates in Nuclear Medicine: Identifying HighExposure Studies to Support ALARA Optimization
S. Korkalainen[1], *M. Elfving*[1], *M. Hurskainen*[2], *M. Hakulinen*[1], *H. Gröhn*[1];
[1]*Kuopio University Hospital, Kuopio, FINLAND,*
[2]*North Karelia Central Hospital, Joensuu, FINLAND.*

EP-1585

Effect of reduced CT acquisition parameters on quantitative accuracy in ^{99}mTc SPECT/CT: A NEMA phantom study
S. Rep, *S. Sustar, I. Slodnjak, B. Simonic, L. Lezaic;*
University Medical Centre Ljubljana, Ljubljana, SLOVENIA.

EP-1586

Radiation Exposure from PET Patients to Healthcare Staff: Impact of Distance, BMI and Clinical Workflow
M. Elfving[1], *S. Korkalainen*[1], *M. Hurskainen*[2], *H. Gröhn*[1], *M. Hakulinen*[1];
[1]*Kuopio University Hospital, Kuopio, FINLAND,*
[2]*North Karelia Central Hospital, Joensuu, FINLAND.*

EP-1587

Comparison of Voxel-Based Dosimetry Using SPECT/CT and PET/CT After Y-90 Radioembolization
A. Yilmaz[1], *E. Polat*[1], *B. Ç. Karagedik*[1], *S. Beykan Schürrle*[2], *&. B. Güney*[1];
[1]*Cukurova University, Adana, TÜRKIYE,*
[2]*Oncosia Scientific GmbH, Dürrwangen, GERMANY.*

EP-1588

In-house Synthesis of ^{177}Lu-CHX-A″-DTPA-Trastuzumab: Preparation of Diagnostic and Therapeutic Doses, Optimization of Labelling Parameters, and Performance evaluation of Immunoconjugate over the Period
B. Shetye, *S. Shah, S. Mithun, M. Kameswaran, S. Gupta, V. Rangarajan;*
Tata Memorial Hospital, Mumbai, INDIA.

EP-1589

Development of ^{68}Ga-HER2 Single-Domain Antibody Radiosynthesis with Cyclotron-Produced ^{68}Ga via NIRTA® Liquid Target Technology
F. Novruzov[1], *M. Valiyev*[1], *Z. Dadashov*[1], *M. Balashov*[1], *J. Isayev*[1], *G. Bolland*[2], *R. Shukurov*[1];
[1]*Department of Nuclear Medicine, The National Centre of Oncology, Baku, AZERBAIJAN,*
[2]*Abscint Precision Imaging, Liège, BELGIUM.*

EP-1590

A Methodological Comparison of HPLC and TLC in the Quality Control of ^{68}Ga-PSMA-11
J. An, *J. Kim, Y. Kim;*
National Cancer Center, Gyeonggi-do, KOREA, REPUBLIC OF.

EP-1591

Innovating And Simplifying Automation In Modern Radiopharmacy
L. Metello[1], *L. Cunha*[1], *M. Capoulas*[1], *V. Hugenberg*[2], *A. Uhlending*[2], *V. Gupta*[3], *D. Jolly*[1];
[1]*IsoPor Group, Angra do Heroismo - Terceira Island - Azores, PORTUGAL,*
[2]*Herz und Diabeteszentrum NRW - HDZ, Univ der Ruhr - Univ. Bochum, Bad Oeynhausen, GERMANY,*
[3]*German Cancer Research Center (DKFZ), Heidelberg, GERMANY.*

EP-1592

Injection-related pitfalls in ^{18}F-FDG PET/CT: A case-based review of improper radiopharmaceutical administration
D. Sercic, *J. Peric, I. Zagar;*
Institute of Oncology Ljubljana, Ljubljana, SLOVENIA.

EP-1593

Correlation between number of punctures and radiochemical purity in a radiopharmaceutical vial
F. Coppe, *A. Peréz, A. Damian, O. Alonso;*
Clinical Hospital, Montevideo, URUGUAY.

EP-1594

Implementing Complex Human PET Studies: The Central Role of the Research Technologist
D. Jespersen;
Aarhus University Hospital Department of Nuclear Medicine, Aarhus, DENMARK.

EP-1595

Procedural Pain in Nuclear Medicine: A Prospective VAS-Based Study Highlighting an Underestimated Clinical Burden
B. Chariot, *S. Erismann, G. Schindler, M. Morais Romeu, C. Pozza, J. Prior, P. Leite Ferreira, M. Jreige;*
CHUV, Lausanne, SWITZERLAND.

EP-1596

Barriers to Infection Prevention and Control Adherence in Nuclear Medicine: A Qualitative Study
P. Kench, *D. Abu Awwad, S. Hill, Y. Jimenez;*
The University of Sydney, Sydney, AUSTRALIA.

EP-1597

Repurposing a Gooseneck Microphone Stand as a Hands-Free Vial Shield Holder: A Split-Rotation Crossover Observational Study in Bone Scan Dispensing
G. Kim;
Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Seoul, KOREA, REPUBLIC OF.

EP-1598

The Cost of Distance: Quantifying the "Financial Toxicity" of Centralized PET/CT Access in Kenya
T. Wainaina;
JKUAT, Nairobi, KENYA.

ADlearn

AN INITIATIVE BY ESMIT | SUPPORTED BY AN UNRESTRICTED EDUCATION GRANT FROM ELI LILLY

Join

the free course on Alzheimer's Disease!

- *Online modules available!*
- *Register now for the recording of the final course!*

More *here*

adlearn.eanm.org



ESMIT

European School of Multimodality Imaging and Therapy

The 2027 programme is out now, so register today and visit us at the ESMIT booth in the EANM Village.

esmit.eanm.org/programme-2027

RLT Academy

ESMIT

Radioligand Therapy Academy

Course Overview

Basic Course

Radioprotection
Radiopharmacy
Radiobiology
Organisation

Advanced Course

Dosimetry
Thyroid
NET
Bone
Prostate & Urinary Cancers
Special topics

Sign up for the course here

Check out our newest topics:

Radioembolization
Women's Health
Alpha Therapies

Discover more about the RLT Academy

SATELLITE SYMPOSIA

Sunday, October 18, 2026 (livestream available) — **13:15 – 14:45, Hall E2**

Symposium by PharmaLogic

Scaling Radiopharmaceutical Therapeutics for Commercial manufacturing

Framework: Introduction: 5 min, 3 × 15 min for each presentation, plus final 25 min Q&A discussion

Objectives:

• GMP regulatory framework for large-scale RLT manufacturing: Examine the GMP requirements applicable to the commercial-scale manufacture of radioligand therapies (RLTs) across major global markets. Assess how EU GMP requirements, including Annex 1, and U.S. cGMP requirements under 21 CFR Part 211 apply to therapeutic radiopharmaceutical manufacturing, with particular focus on contamination control strategy (CCS), aseptic processing, facility and operational controls, and pharmaceutical quality systems. Extend the assessment to other key jurisdictions, including Japan and China, identifying areas of regulatory convergence and divergence and the implications for sponsors seeking to establish a globally aligned manufacturing and supply strategy.

Speaker: *Nina Aalén Dørre | Bayer | VP, CMC Radiopharm Lead*

• Building the right capabilities to successfully scale RLT manufacturing: Examine the practical requirements for building, expanding, or adapting manufacturing capacity for radioligand therapies (RLTs), from facility and process design through operational readiness. Address key considerations including hot cell and shielding design, equipment and automation strategy, radiation safety and material flows, facility and equipment qualification, process and analytical validation, and quality system implementation. Highlight the unique challenges associated with short half-life products, including compressed manufacturing and release timelines, decentralized versus centralized manufacturing models, supply chain coordination, and the need to integrate production, quality control, release, and distribution within tightly controlled time windows.

Speaker: *Silje Sivesind | Agilera | Production Director*

• Manufacturing technology – what will RLT manufacturers need tomorrow? Explore the next generation of manufacturing technologies required to support the continued growth and industrialization of radioligand therapies (RLTs). Examine the evolving needs of large pharmaceutical and biotechnology companies, including greater automation, throughput, flexibility, closed processing, digital integration, real-time monitoring, and reduced operator intervention and radiation exposure. Consider how RLT manufacturers and equipment suppliers can collaborate earlier and more strategically to develop scalable, standardized, and GMP-ready manufacturing platforms. Address how responsibilities should be defined and shared between manufacturers and equipment suppliers for GMP compliance, qualification and validation, data integrity, contamination control, and radiation protection, and how equipment design can better integrate pharmaceutical quality and safety requirements from the outset.

Speaker: *Matteo Camaggi | TEMA Sinergie | Key Account Manager & Sales Engineer – Radiopharma & Nuclear Medicine*

Sunday, October 18, 2026 (livestream available) — **13:15 – 14:45, Hall F1**

Symposium by Medscape Education Global

Sunday, October 18, 2026 (livestream available) — **13:15 – 14:45, Hall F2**

Symposium by Telix Pharmaceuticals

The Future Doesn't Wait:
The Next Era of Theranostics in Urologic Oncology

Moderator : Prof. Jeremie Calais

The Evolving Role of PSMA-PET in Prostate Cancer Where Are We Going?
Optimizing Clinical Practice
Prof. Ken Herrmann & Prof. Munir Ghesani

Next-Generation PSMA Therapeutics: Overcoming Today's Challenges
Overcoming current challenges in PCa RNT
The OPTIMAL experience
Prof. Daniela Oprea-Lager & Prof. Louise Emmett

Panel discussion
All Speakers

How Extending PCa theranostic Success to broader GU diseases ?
Prof. Jeremie Calais

Moderator & Speaker :
Prof. Dr. Jeremie Calais : Professors of nuclear medicine at Gustave Roussy, IGR and Université Paris-Saclay, Paris, France

Speakers:
Prof. Dr. Ken Herrmann : Professor of nuclear medicine at the University Hospital Essen, Germany
Prof. Dr. Munir Ghesani : Professor of nuclear medicine and Chief Medical Officer at United Theranostics, USA
Prof. Dr. Daniela Oprea-Lager : Professor of nuclear medicine at the Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands
Prof. Dr. Louise Emmett : Director of Theranostics and Nuclear Medicine St Vincent's Hospital, Sydney, Australia

Sunday, October 18, 2026 **13:15 – 14:45, Hall G2**

Symposium by ABX advanced biochemical compounds

Seeing more, treating better: the evolving role of psma theranostics

Welcome and Introduction
Prof. M. Eiber, Prof. F.Giesel
5 minutes

Beyond Detection: Phenotyping Prostate Cancer with PSMA PET
Prof. Rudolf Werner
Department of Nuclear Medicine, LMU University Hospital Munich
20 minutes

From Images to Insights: Artificial Intelligence in PSMA Theranostics
Prof. Mijin Yun
Department of Nuclear Medicine, Yonsei University Hospital Seoul, Soth Korea
20 minutes

PSMA-Theranostics in Japan – Implementation into clinical practice
Prof. Tadashi Watabe
Department of Nuclear Medicine, University of Osaka, Japan
20 minutes

PSMA PET/CT in Clinical Practice: From New Guidelines to Prognostic Biomarkers for Treatment Response and Progression-Free Survival
Dr. Karen Buch-Ohlsen
Department of Nuclear Medicine, University Hospital Lillebaelt Vejle, Denmark
20 minutes

Closing remarks
Prof. M. Eiber, Prof. F.Giesel
5 minutes

Sunday, October 18, 2026 (livestream available) **13:15 – 14:45, Hall K**

Symposium by Siemens Healthineers

Evolution in action: Advancing our molecular imaging portfolio

Discover how continuous innovation is shaping the future of molecular imaging at this lunch symposium, which highlights evolving developments across PET/CT, PET/MR and AI tools. Learn about improved time-of-flight performance on the Biograph Quadra PET/CT, AI-assisted reading and reporting with syngo.via, and more.

Speakers:
1 Prof. Dr. Michael Schäfers MD – Universität Münster, GER
2 Prof. Dr. Alexander Hammers – Kings College London, UK
3 Prof. Dr. Mohsen Beheshti MD, FEBNM, FASNC – Paracelsus Medical University, Salzburg, AT

Sunday, October 18, 2026 (livestream available) **13:15 – 14:45, Hall G1**

Symposium by GE Healthcare (PDx)

Molecular Imaging in Dementia and Co-Pathologies with Alzheimer Disease

Moderator: Pr Antoine Verger, Nuclear Physician (CHRU Nancy, France)

Agenda:

» *Pr Federica Agosta, Neurologist (UniSR, Milan, Italy)*
When Dementia Overlaps: The Clinical Impact of Co-Pathologies with Alzheimer's Disease

» *Pr Matthias Brendel, Nuclear Physician (University of Munich, Germany)*
Molecular Imaging at the DLB–AD Intersection: Differential Diagnosis and Co-Pathology in Practice

» *Dr Javier Arbizu, Nuclear Physician (University of Navarra, Spain)*
Relevance of amyloid PET Ima ging in AD diagnosis

Summary

This symposium explores the growing role of molecular imaging in improving the diagnosis and management of dementia, starting from the complex overlap between Alzheimer's disease (AD) and other neurodegenerative disorders. Through a multidisciplinary perspective combining neurology and nuclear medicine, the faculty will discuss how co-pathologies can influence clinical presentation, diagnostic pathways, and patient management. Topics include the clinical impact of overlapping dementia pathologies, the value of molecular imaging in differentiating Dementia with Lewy Bodies (DLB) from Alzheimer's disease, and the role of amyloid PET imaging in supporting accurate and timely AD diagnosis. Together, these sessions highlight how advanced imaging techniques can help clinicians navigate diagnostic complexity and enable more personalized patient care.

Monday, October 19, 2026 **13:15 – 14:45, Hall B**

Symposium by GE Healthcare

Real-World Evidence and Innovation in Molecular Imaging and Theranostics

Monday, October 19, 2026 (livestream available) **13:15 – 14:45, Hall F1**

Symposium by Curium

Expanding the Horizons of PSMA Theranostics and beyond

The diagnostic landscape of PSMA targeting – the role of 18F-DCFPYL

Prof. Dr. Irene Andrea Burger
Nuclear Medicine Physician and Radiologist
Kantonsspital Baden, Baden, Switzerland

Standardized reporting – What is new and what do we need?

Prof. Dr. Matthias Eiber
Nuclear Medicine Physician and Radiologist
Technical University of Munich (TUM), University Hospital rechts der Isar, Munich, Germany

Where is PSMA therapy going – a future perspective on opportunities and limitations

Prof. Dr. Jeremie Calais
Nuclear Medicine Physician
Gustave Roussy, Villejuif, France
University of California, Los Angeles (UCLA), Los Angeles, CA, USA

Panel Discussion Moderator

Prof. Dr. Bertrand Tombal
Urologist, Surgeon
University Hospitals Saint-Luc, Brussels
Catholic University, Louvain, Belgium

Monday, October 19, 2026 (livestream available) **13:15 – 14:45, Hall F2**

Symposium by Novartis Pharma

Shaping the Future of Radioligand Therapy: From Drug Development to Clinical Application

This expert-led symposium brings together a multidisciplinary faculty to explore the evolving landscape of radioligand therapy (RLT) development—from foundational principles and approved therapies to novel targets, radionuclides, and indications. The panel will discuss key challenges and opportunities in early clinical development, including the role of dosimetry, safety reference thresholds, and other available evidence to inform development decisions. The symposium will conclude by looking ahead to what is needed to successfully integrate novel RLTs into routine clinical practice.

Faculty:

- ***Chair:*** *Ken Herrmann, University Hospital Essen, Essen, Germany*
- *Christophe Deroose, University Hospitals Leuven, Leuven, Belgium*
- *Oliver Sartor, East Jefferson General Hospital Cancer Center, New Orleans, LA, USA*
- *Caroline Stokke, Oslo University Hospital Oslo, Norway*

Agenda:

13:15–13:20
Welcome, introduction, and educational objectives
Ken Herrmann (Chair & Moderator)

13:20–13:25
History and evolution of radioligand therapies
Ken Herrmann

13:25–13:45
The evolving radioligand therapy landscape: Building on an established platform to unlock novel opportunities
All faculty

13:45–14:30
Navigating early clinical development of radioligand therapies: Challenges and opportunities
All faculty

14:30–14:40
Novel radioligand therapies in clinical practice: Meeting today's needs, shaping tomorrow's standards
All faculty

14:40–14:45
Conclusion and key takeaways
Ken Herrmann

FINAL PROGRAMME | INDUSTRY EXHIBITION

Monday, October 19, 2026 (livestream available) **13:15 – 14:45, Hall K**

Symposium by United Imaging Healthcare

Living Body, Living Image: Dynamic and Quantitative PET/CT

Molecular imaging is moving from static images to quantitative imaging of biological changes over time. Join an international panel to explore what next-generation PET systems can now measure, and what that means in daily practice.

The discussion will cover dynamic acquisition and quantification across whole-body and brain imaging, and in systemic diseases such as myeloma and leukemia, as well as how reconstruction methods influence image quality, radiation dose, and scan time.

As the speakers work with diverse PET/CT scanners and axial field-of-view, the session will focus on a shared practical question: how do these differences change the way we scan, quantify, and report?

Join us to discover how these technologies translate into actionable clinical care.

We are delighted to welcome our keynote speakers:

Prof. Dr. Sibylle Ziegler, Ph.D.
Head of PET/CT Research, Department of Nuclear Medicine, Hannover, Germany
Using all Four Dimensions in TB-PET Data Analysis to Image Biology
Dr. Cristina Nanni, Ph.D.
Nuclear Medicine Physician, Adjunct Professor, Bologna, Italy
Contribution of Total Body PET in Multiple Myeloma and Acute Leukemia.
Prof. Dr. Florent Besson, M.D., Ph.D.
Professor of Nuclear Medicine, AP-HP, CHU Bicêtre; Université Paris-Saclay; CEA/CNRS/Inserm/BioMaps, Le Kremlin-Bicêtre, France
Deep Progressive Reconstruction in PET: Changing the Way We Practice?
Dr. Greet Vanderlinden, Ph.D.
Postdoctoral Researcher / Special Research Associate, Leuven, Belgium

Ultra-High-Resolution Brain PET Quantification: Towards Non-invasiveness?

You Really should Get to Know Us.

Explore our website at https://global.united-imaging.com/en/

Monday, October 19, 2026 (livestream available) **13:15 – 14:45, Hall G1**

Symposium by BlueEarth Diagnostics

This is a non-promotional symposium sponsored and organised by Blue Earth Diagnostics

The PET Effect: Transforming Prostate Cancer Care Yesterday, Today & Tomorrow

Faculty:

- Prof. Stefano Fanti, University of Bologna, Italy
- Prof. Daniela Oprea-Lager, Radboud University, Nijmegen, The Netherlands
- Prof. Wolfgang Fendler, University Hospital Essen, Germany

First-generation PET tracers

Begin the journey by revisiting the lessons learned from first-generation PET tracers and how they helped lay the foundations for modern prostate cancer imaging.

Transforming Clinical Practice Through Molecular Imaging

Explore how PSMA PET is shaping today's clinical practice, from recurrence assessment to interpretation challenges and the complexities of PSMA-negative disease.

Imaging and Imagining the Future of Prostate Cancer

Look ahead to a rapidly expanding PET landscape and explore how new risk tools, response frameworks and emerging targets could broaden the future of prostate cancer care.

Q&A

Monday, October 19, 2026 (livestream available) **13:15 – 14:45, Hall E2**

Symposium by Spectrum Dynamics Medical

EANM Spectrum Dynamics Symposium – "Driving Precision Nuclear Medicine with 360° CZT SPECT/CT: Quantitation, AI, and Clinical Impact"

Pr. Denis Agostini MD PhD
Host, Moderator, Introductions

Laetitia Imbert, PhD
360 CZT SPECT/CT Quantitation and validation of high energy and AI applications

Désirée DEANDREIS, MD PhD
From Discovery to Daily Practice: Clinical and Research Applications of VERITON-CT CZT SPECT/CT in Oncology and Theranostics

Daniel Juneau, MD
Optimizing clinical and research workflows in a large tertiary center using a 360 CZT SPECT/CT

Monday, October 19, 2026 (livestream available) **13:15 – 14:45, Hall G2**

Symposium by Boston Scientific

Y-90 radioembolisation: Translating Real-World evidence into practice – Advancing personalised dosimetry and treatment optimisation in HCC

This 60-minute symposium reviews how personalised dosimetry and microsphere characteristics shape outcomes in radioembolisation with TheraSphere Y-90 Therapy for HCC. Faculty will interpret the clinical evidence supporting personalised dosimetry, explain how high radiation per microsphere influences CPN and clinical outcomes, and show how dosimetry principles and recent real-world evidence can be applied to optimise treatment planning. Lectures are followed by an interactive case discussion applying these principles to complex HCC cases.

Program:

1:15 – 1:20pm
Prof M. Lam

Welcome and faculty presentation

1:20 – 1:35pm
Prof M.Lam

TheraSphereTM High Specific Activity: Why Radiation per Microsphere Matters

1:35-1:50pm
Prof E.Garin

Personalised Dosimetry in Clinical Practice: Redefining HCC Treatment Strategies

1:50-2:05pm
Prof La Fougere

Can We Reliably Predict Absorbed Dose? From MAA-Based Planning to Personalised Dosimetry

2:05-2:20pm
Prof M.Lam
(discussant All)

Interactive Case Discussion: Applying Personalised Dosimetry in Complex HCC

Faculty:
Prof. Marnix Lam
Moderator & Speaker
M.Lam@umcutrecht.nl
University Medical Center Utrecht, Utrecht, The Netherlands
Prof. Etienne Garin

Speaker
e.garin@rennes.unicancer.fr
University of Rennes, Rennes, France
Prof. Christian La Fougère

Speaker
christian.lafougere@med.uni-tuebingen.de
University Hospital Tübingen, Tübingen, Germany

Tuesday, October 20, 2026 **13:15 – 14:45, Hall G1**

Symposium by OmniAb

OmniUltra™: An In Vivo Discovery Platform for Structured Peptides to Enable Radioligand Therapy

Speaker: Christel Iffland, PhD, Sr. Vice President, R&D Portfolio Management and Technology Operations, OmniAb

OmniUltra is an in vivo discovery platform designed to identify compact, target-selective peptide ligands with potential advantages for radioligand therapy and other applications. Peptides are generated and optimized in vivo, using natural selection mechanisms to enrich for high-affinity target engagement, specificity, favorable size, and tunable pharmacokinetic clearance. OmniUltra harnesses immune-system biology which may enable identification of drug-like binders earlier in discovery compared to traditional approaches.



Sign up today!

European Association Nuclear Medicine

eanm.org/get-involved

Get Involved! Join EANM's volunteer community

LIST OF EXHIBITORS

(A – Z)

	Booth Nr.	Exhibiting Company
	280	3CON Pharma Medical GmbH
	523	A.C.O.M. Advanced Center Oncology Macerata S.R.L.
CM	419	ABX advanced biochemical compounds
	244	ABX-CRO advanced pharmaceutical services Forschungsgesellschaft mbH
	233	Advanced Cyclotron Systems Inc.
	281	AI4R
CM	401	Alliance Medical
	228	Almac Group
	406	Amber Bridge Isotopes
	271	ARALE Laboratory
	203	Argonsoft LTD.
	258	AtomVie Global Radiopharma Inc.
	511	Avelion (PMB – ALCEN)
CM	420	AWEX – Wallonia Export & Investment Agency
CM	524	Bayer AG
	241	Becquerel & Sievert Co., Ltd
	206	Berthold Technologies GmbH
	312	Best Cyclotron Systems
	517	Bianco Healthcare
	209	Bioemtech
	420	BioVendor
CM	324	Blue Earth Diagnostics Ltd.
	306	Borchardt Logistics GmbH
	277	Boston Scientific International SA
	324	Bracco Imaging SpA
	329	Brightonix Imaging
CM	301	Bruker BioSpin GmbH & Co. KG
	416	BV Cyclotron VU
CM	411	C Ray Therapeutics (Chengdu) Co. Ltd.
	313	Casram
	332	Cedars Sinai Cadriac Suite
	231	Cencora – World Courier
	317	CGN Isotope (Mianyang) Co., Ltd
	222	Champions Oncology

	201	Chelatec
	243	Chematech
	309	Chengdu Novel Medical Equipment Co., Ltd.
CM	**403**	CMR Corporation GmbH
	207	CMR Molecular Imaging
	501	Colibri Isotopes Corporation
CM	**319**	Comecer
	239	Corning
	234	CRL – Central Research Laboratories
	208	Croft Associates Ltd
	215	Crystal Photonics GmbH
	414 e	CUP Laboratorien Dr. Freitag GmbH
CM	**507**	Curium International Managment SAS
CM	**418**	Cyclomedica Ltd
	279	DC Pharma
	330	DEC Group
	513	DOSIsoft
	326	DSD Pharma GmbH
CM	**257**	Eckert & Ziegler
	335	EDL Software Deutschland GmbH
	245	Eichrom Technologies
	223	EITA
CM	**408**	ELSE Solutions S.r.l.
	420	ELYSIA RAYTEST
	416	Epsilon Elektronik Sanayi ve Ticaret A.Ş.
	414 b	Epsilon Radioactive Sources – ERS
	416	EuroMedical Instruments
	284	FemtoIsotope GmbH
	278	Gamma Medical Technology
CM	**525 515**	GE Healthcare
	270	Glotope (Chengdu) Advanced Pharmaceutical Technology Ltd
	275	Guangzhou Diqi Trading Co.,Ltd
	237	Harvest Integrated Research Organization (HiRO)
CM	**505**	Hermes Medical Solutions AB
	416	Hidex
	416	HOY Scandinavian ApS
	268	HTA Co., Ltd.
	516	Hyperion Hybrid Systems GmbH
	261	I.M.A. Industria Macchine Automatiche S.p.A.
CM	**413**	IBA SA

	236	IBC Advanced Technologies, Inc.
	310	ICPO Foundation
	522	Imaging Endpoints
	322	Institute of Isotopes Co. Ltd
	217	Inter Medical Medizintechnik GmbH
	303	INVIA Medical Imaging Solutions
	250	Inviscan
	307	Ionetix Corporation
	252	IPHASE technologies
	420	IRE ELIT
	510	Isotopia Molecular Imaging
	318	ITEL Telecomunicazione SRL
CM	**415**	ITM Isotope Technologies Munich SE
CM	**503**	Jiangsu Huayi Radiopharmaceuticals Co., Ltd.
	213	Jiangsu Sinogram Medical Technology Co., Ltd.
CM	**402**	Jubilant Radioharma
	256	Kev Medical Imaging
	328	La Calhene
	262	Lablogic Systems Limited
CM	**320**	Lantheus
CM	**508**	Lemer Pax
CM	**520**	Life Couriers
	416	LYLA B.V.
	225	Lynax s.r.o.
	255	Macrocyclics, Inc.
	266	Marken, UPS Healthcare Precision Logistics
	211	Medhub Arge Sağlık Hizmetleri Sanayive Ticaret AŞ
CM	**321**	Medi-Radiopharma Ltd.
	235	Medicines Discovery Catapult
CM	**323**	Mediso Ltd.
	285	MedTrace Pharma A/S
	212	Mias Pharma Ltd
	414 g	MIE medical imaging electronics GmbH
	286	MILabs
	525	MIM Software
	247	Mindview
	521	Minerva Imaging ApS
CM	**410**	Mirion Medical
	414 a	MNT Saglik Hizmetleri Ve Ticaret A.S.
	301	MOLECUBES, a Bruker Company

CM	504	MOLTEK SAĞLIK HİZMETLERİ ÜRETİM VE PAZ. A.Ş.
	216	Nancyclotep
	238	Neusoft Medical Systems Co., Ltd.
	331	Niowave, Inc.
	229	Nippon Sanso Corporation
	267	Norroy Bioscience Co., Ltd.
	414 f	NorthStar Medical Radioisotopes
CM	230	Novartis Pharma
CM	417	NRG Pallas BV
	416	NucAdvisor / MEDraysintell
	514	Nuclear Medicine Europe
	224	Nuclear Shields B.V.
	519	Nuclivision NV
	416	Nuvia
	273	OmniAb Inc.
	218	OncoBeta GmbH
	242	Oncodesign Services
CM	304	P.B.L. SpA
	219	Paire SAS
	512	Perceptive
	420	PHSE
	416	PI Medical Equipment B.V.
	326	piCHEM Forschungs- und Entwicklungs GmbH
	305	Picorad Medikal San. Ve Tic. Ltd şti
	301	PMOD
CM	530	Polatom
	259	Positrigo
	254	PSI CRO AG
	265	R2Pharma
	205	Radiaprot
	518	Radioprotech
	264	Radnostix
	334	Redberry
	248	Rotem GmbH
CM	414 c	ROTOP Pharmaka GmbH
	202	RoweMed AG – Medical 4 Life
	253	RPT Labworks
CM	249	RQS Alexander Ruffani
	240	Santenov Dijon Bourgogne
	283	Scintomics Molecular, ATT GmbH

CM	404	SCK CEN
	314	SDS Life Sciences
	274	SEDECAL MOLECULAR IMAGING S.L.U. (SMI)
	315	Shandong Zhengyue International Trade Co., Ltd
	282	Shanghai Leading Technology Co., Ltd
CM	409	SHINE Technologies
	316	Sichuan Longevous Beamtech Co., Ltd
	227	Sidam S.R.L.
CM	526 531 529	Siemens Healthineers AG
	269	Sirtex Medical Europe GmbH
	210	Skistad Elektroautomasjion AS
	416	Special Cargo Services BV
	407	SpectronRx
CM	520	Spectrum Dynamics Medical SA
	327	Sumitomo Heavy Industries, Ltd.
	414 d	Sykam Chromatographie Vertriebs GmbH
	311	Syntermed Inc.
	302	Synthra GmbH
CM	527	Telix Pharmaceuticals
CM	325	Tema Sinergie S.p.A.
CM	321	TerThera b.v.
	420	THE ONCIDIUM FOUNDATION
	405	Tianjin Nuclear Saftey Technology Co., Ltd.
	260	time:matters GmbH
	272	TMC Group Manufacturing Company Inc.
	204	TRAD
CM	528	Trasis SA
CM	214	Triskem International
	226	Truking Technology Limited
	308	U.S. National Isotope Development Center
CM	506	United Imaging Healthcare Europe B.V.
CM	502	Urenco Isotopes
	416	Van Der Wilt Techniques
CM	412	Von Gahlen Nederland B.V.
	220	VS Medical Mühendislik Danışmanlık İthalat İhracat A.Ş.
	251	Wälischmiller Engineering GmbH
	333	WuXi AppTec
	246	Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd
	246	Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd
	221	XEOS

RESEARCH4LIFE©

EARL welcomes you to Special Session 2

Sunday, 18 October 2026 | 09:45–11:45 | Hall D Arena

Clinical Implications of EARL PET/CT Accreditation Standards 3, ^{177}Lu SPECT/CT Accreditation for NaI and CZT: Results, Specifications, and Future Directions

ACCREDITED CENTRE OF EXCELLENCE ·2026· RESEARCH4LIFE© an EANM initiative European Association Nuclear Medicine ·^{177}LU SPECT/CT·

ACCREDITED CENTRE OF EXCELLENCE ·2026· RESEARCH4LIFE© an EANM initiative European Association Nuclear Medicine PET/CT · PET/MR

RESEARCH4LIFE©

EARL invites you to Special Session 3

Monday, 19 October 2026 | 09:45–11:45 | Hall G1

Unlock precision in imaging. Discover the clinical benefits of the EARL PET accreditations.



ACCREDITED CENTRE OF EXCELLENCE ·2026· RESEARCH4LIFE© an EANM initiative European Association Nuclear Medicine PET/CT · PET/MR

LIST OF EXHIBITORS

(SORTED BY BOOTH NO.)

	Booth Nr.	Exhibiting Company
	201	Chelatec
	202	RoweMed AG – Medical 4 Life
	203	Argonsoft LTD.
	204	TRAD
	205	Radiaprot
	206	Berthold Technologies GmbH
	207	CMR Molecular Imaging
	208	Croft Associates Ltd
	209	Bioemtech
	210	Skistad Elektroautomasjion AS
	211	Medhub Arge Sağlık Hizmetleri Sanayive Ticaret AŞ
	212	Mias Pharma Ltd
	213	Jiangsu Sinogram Medical Technology Co., Ltd.
CM	214	Triskem International
	215	Crystal Photonics GmbH
	216	Nancyclotep
	217	Inter Medical Medizintechnik GmbH
	218	OncoBeta GmbH
	219	Paire SAS
	220	VS Medical Mühendislik Danışmanlık İthalat İhracat A.Ş.
	221	XEOS
	222	Champions Oncology
	223	EITA
	224	Nuclear Shields B.V.
	225	Lynax s.r.o.
	226	Truking Technology Limited
	227	Sidam S.R.L.
	228	Almac Group
	229	Nippon Sanso Corporation
CM	230	Novartis Pharma
	231	Cencora – World Courier
	233	Advanced Cyclotron Systems Inc.
	234	CRL – Central Research Laboratories
	235	Medicines Discovery Catapult
	236	IBC Advanced Technologies, Inc.
	237	Harvest Integrated Research Organization (HiRO)
	238	Neusoft Medical Systems Co., Ltd.
	239	Corning
	240	Scintomics Molecular, ATT GmbH
	241	Becquerel & Sievert Co., Ltd
	242	Oncodesign Services
	243	Chematech
	244	ABX-CRO advanced pharmaceutical services Forschungsgesellschaft mbH
	245	Eichrom Technologies
	246	Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd
	246	Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd
	247	Mindview
	248	Rotem GmbH
CM	249	RQS Alexander Ruffani
	250	Inviscan
	251	Wälischmiller Engineering GmbH
	252	IPHASE technologies
	253	RPT Labworks
	254	PSI CRO AG
	255	Macrocyclics, Inc.
	256	Kev Medical Imaging
CM	257	Eckert & Ziegler
	258	AtomVie Global Radiopharma Inc.
	259	Positrigo
	260	time:matters GmbH
	261	I.M.A. Industria Macchine Automatiche S.p.A.
	262	Lablogic Systems Limited
	264	Radnostix
	265	R2Pharma
	266	Marken, UPS Healthcare Precision Logistics
	267	Norroy Bioscience Co., Ltd.
	268	HTA Co., Ltd.
	269	Sirtex Medical Europe GmbH
	270	Glotope (Chengdu) Advanced Pharmaceutical Technology Ltd
	271	ARALE Laboratory
	272	TMC Group Manufacturing Company Inc.
	273	OmniAb Inc.
	274	SEDECAL MOLECULAR IMAGING S.L.U. (SMI)
	275	Guangzhou Diqi Trading Co.,Ltd
	277	Boston Scientific International SA

	278	Gamma Medical Technology
	279	DC Pharma
	280	3CON Pharma Medical GmbH
	281	AI4R
	282	Shanghai Leading Technology Co., Ltd
	283	Santenov Dijon Bourgogne
	284	FemtoIsotope GmbH
	285	MedTrace Pharma A/S
	286	MILabs
CM	301	Bruker BioSpin GmbH & Co. KG
	301	MOLECUBES, a Bruker Company
	301	PMOD
	302	Synthra GmbH
	303	INVIA Medical Imaging Solutions
CM	304	P.B.L. SpA
	305	Picorad Medikal San. Ve Tic. Ltd şti
	306	Borchardt Logistics GmbH
	307	Ionetix Corporation
	308	U.S. National Isotope Development Center
	309	Chengdu Novel Medical Equipment Co., Ltd.
	310	ICPO Foundation
	311	Syntermed Inc.
	312	Best Cyclotron Systems
	313	Casram
	314	SDS Life Sciences
	315	Shandong Zhengyue International Trade Co., Ltd
	316	Sichuan Longevous Beamtech Co., Ltd
	317	CGN Isotope (Mianyang) Co., Ltd
	318	ITEL Telecomunicazione SRL
CM	319	Comecer
CM	320	Lantheus
CM	321	Medi-Radiopharma Ltd.
CM	321	TerThera b.v.
	322	Institute of Isotopes Co. Ltd
CM	323	Mediso Ltd.
CM	324	Blue Earth Diagnostics Ltd.
	324	Bracco Imaging SpA
CM	325	Tema Sinergie S.p.A.
	326	DSD Pharma GmbH
	326	piCHEM Forschungs- und Entwicklungs GmbH
	327	Sumitomo Heavy Industries, Ltd.

	328	La Calhene
	329	Brightonix Imaging
	330	DEC Group
	331	Niowave, Inc.
	332	Cedars Sinai Cadriac Suite
	333	WuXi AppTec
	334	Redberry
	335	EDL Software Deutschland GmbH
CM	401	Alliance Medical
CM	402	Jubilant Radioharma
CM	403	CMR Corporation GmbH
CM	404	SCK CEN
	405	Tianjin Nuclear Saftey Technology Co., Ltd.
	406	Amber Bridge Isotopes
	407	SpectronRx
CM	408	ELSE Solutions S.r.l.
CM	409	SHINE Technologies
CM	410	Mirion Medical
CM	411	C Ray Therapeutics (Chengdu) Co. Ltd.
CM	412	Von Gahlen Nederland B.V.
CM	413	IBA SA
CM	415	ITM Isotope Technologies Munich SE
	416	BV Cyclotron VU
	416	Epsilon Elektronik Sanayi ve Ticaret A.Ş.
	416	EuroMedical Instruments
	416	Hidex
	416	HOY Scandinavian ApS
	416	LYLA B.V.
	416	NucAdvisor / MEDraysintell
	416	Nuvia
	416	PI Medical Equipment B.V.
	416	Special Cargo Services BV
	416	Van Der Wilt Techniques
CM	417	NRG Pallas BV
CM	418	Cyclomedica Ltd
CM	419	ABX advanced biochemical compounds
CM	420	AWEX – Wallonia Export & Investment Agency
	420	BioVendor
	420	ELYSIA RAYTEST
	420	IRE ELIT
	420	PHSE

	420	THE ONCIDIUM FOUNDATION
	501	Colibri Isotopes Corporation
CM	**502**	Urenco Isotopes
CM	**503**	Jiangsu Huayi Radiopharmaceuticals Co., Ltd.
CM	**504**	MOLTEK SAĞLIK HİZMETLERİ ÜRETİM VE PAZ. A.Ş.
CM	**505**	Hermes Medical Solutions AB
CM	**506**	United Imaging Healthcare Europe B.V.
CM	**507**	Curium International Managment SAS
CM	**508**	Lemer Pax
	510	Isotopia Molecular Imaging
	511	Avelion (PMB – ALCEN)
	512	Perceptive
	513	DOSIsoft
	514	Nuclear Medicine Europe
	516	Hyperion Hybrid Systems GmbH
	517	Bianco Healthcare
	518	Radioprotech
	519	Nuclivision NV
CM	**520**	Life Couriers
CM	**520**	Spectrum Dynamics Medical SA
	521	Minerva Imaging ApS
	522	Imaging Endpoints
	523	A.C.O.M. Advanced Center Oncology Macerata S.R.L.
CM	**524**	Bayer AG
	525	MIM Software
CM	**527**	Telix Pharmaceuticals
CM	**528**	Trasis SA
CM	**530**	Polatom
	414 a	MNT Saglik Hizmetleri Ve Ticaret A.S.
	414 b	Epsilon Radioactive Sources – ERS
CM	**414 c**	ROTOP Pharmaka GmbH
	414 d	Sykam Chromatographie Vertriebs GmbH
	414 e	CUP Laboratorien Dr. Freitag GmbH
	414 f	NorthStar Medical Radioisotopes
	414 g	MIE medical imaging electronics GmbH
CM	**525 515**	GE Healthcare
CM	**526 531 529**	Siemens Healthineers AG

EANM Podcast
Uptake: The podcast of the European Association of Nuclear Medicine


Tune in to EANM's very first podcast: Uptake!

Available on Amazon Music, Apple Music, Spotify and YouTube Music!

eanm.org/podcast

EXHIBITION HALLS

HALL X2
LEVEL -2



201	Chelatec	
202	RoweMed AG – Medical 4 Life	
203	Argonsoft LTD.	
204	TRAD	
205	Radiaprot	
206	Berthold Technologies GmbH	
207	CMR Molecular Imaging	
208	Croft Associates Ltd	
209	Bioemtech	
210	Skistad Elektroautomasjion AS	
211	Medhub Arge Sağlık Hizmetleri Sanayive Ticaret AŞ	
212	Mias Pharma Ltd	
213	Jiangsu Sinogram Medical Technology Co., Ltd.	
CM	214	Triskem International
215	Crystal Photonics GmbH	
216	Nancyclotep	
217	Inter Medical Medizintechnik GmbH	
218	OncoBeta GmbH	
219	Paire SAS	
220	VS Medical Mühendislik Danışmanlık İthalat İhracat A.Ş.	
221	XEOS	
222	Champions Oncology	
223	EITA	
224	Nuclear Shields B.V.	
225	Lynax s.r.o.	
226	Truking Technology Limited	
227	Sidam S.R.L.	
228	Almac Group	
229	Nippon Sanso Corporation	
CM	230	Novartis Pharma
231	Cencora – World Courier	
233	Advanced Cyclotron Systems Inc.	
234	CRL – Central Research Laboratories	
235	Medicines Discovery Catapult	
236	IBC Advanced Technologies, Inc.	
237	Harvest Integrated Research Organization (HiRO)	
238	Neusoft Medical Systems Co., Ltd.	
239	Corning	
240	Scintomics Molecular, ATT GmbH	
241	Becquerel & Sievert Co., Ltd	
242	Oncodesign Services	
243	Chematech	
244	ABX-CRO advanced pharmaceutical services Forschungsgesellschaft mbH	
245	Eichrom Technologies	
246	Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd	
246	Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd	
247	Mindview	
248	Rotem GmbH	
CM	249	RQS Alexander Ruffani
250	Inviscan	
251	Wälischmiller Engineering GmbH	
252	IPHASE technologies	
253	RPT Labworks	
254	PSI CRO AG	
255	Macrocyclics, Inc.	
256	Kev Medical Imaging	
CM	257	Eckert & Ziegler
258	AtomVie Global Radiopharma Inc.	
259	Positrigo	
260	time:matters GmbH	
261	I.M.A. Industria Macchine Automatiche S.p.A.	
262	Lablogic Systems Limited	
264	Radnostix	
265	R2Pharma	
266	Marken, UPS Healthcare Precision Logistics	
267	Norroy Bioscience Co., Ltd.	
268	HTA Co., Ltd.	
269	Sirtex Medical Europe GmbH	
270	Glotope (Chengdu) Advanced Pharmaceutical Technology Ltd	
271	ARALE Laboratory	
272	TMC Group Manufacturing Company Inc.	
273	OmniAb Inc.	
274	SEDECAL MOLECULAR IMAGING S.L.U. (SMI)	
275	Guangzhou Diqi Trading Co.,Ltd	
276	INSPIRE by EANM	
277	Boston Scientific International SA	
278	Gamma Medical Technology	
279	DC Pharma	
280	3CON Pharma Medical GmbH	
281	AI4R	
282	Shanghai Leading Technology Co., Ltd	
283	Santenov Dijon Bourgogne	
284	Femtolsotope GmbH	
285	MedTrace Pharma A/S	
286	MILabs	


FINAL PROGRAMME | INDUSTRY EXHIBITION

WORLD LEADING MEETING — EANM'26
OCTOBER 17–21, 2026

EXHIBITION HALLS

HALL X3
LEVEL -2

CM	301	Bruker BioSpin GmbH & Co. KG
	301	MOLECUBES, a Bruker Company
	301	PMOD
	302	Synthra GmbH
	303	INVIA Medical Imaging Solutions
	302	Synthra GmbH
	303	INVIA Medical Imaging Solutions
CM	304	P.B.L. SpA
	305	Picorad Medikal San. Ve Tic. Ltd şti
	306	Borchardt Logistics GmbH
	307	Ionetix Corporation
	308	U.S. National Isotope Development Center
	309	Chengdu Novel Medical Equipment Co., Ltd.
	310	ICPO Foundation
	311	Syntermed Inc.
	312	Best Cyclotron Systems
	313	Casram
	314	SDS Life Sciences
	315	Shandong Zhengyue International Trade Co., Ltd
	316	Sichuan Longevous Beamtech Co., Ltd
	317	CGN Isotope (Mianyang) Co., Ltd
	318	ITEL Telecomunicazione SRL
CM	319	Comecer
CM	320	Lantheus
CM	321	Medi-Radiopharma Ltd.
CM	321	TerThera b.v.
	322	Institute of Isotopes Co. Ltd
CM	323	Mediso Ltd.
CM	324	Blue Earth Diagnostics Ltd.
	324	Bracco Imaging SpA
CM	325	Tema Sinergie S.p.A.
	326	DSD Pharma GmbH
	326	piCHEM Forschungs- und Entwicklungs GmbH
	327	Sumitomo Heavy Industries, Ltd.
	328	La Calhene
	329	Brightonix Imaging
	330	DEC Group
	331	Niowave, Inc.
	332	Cedars Sinai Cadriac Suite
	333	WuXi AppTec
	334	Redberry
	335	EDL Software Deutschland GmbH




FINAL PROGRAMME | INDUSTRY EXHIBITION

WORLD LEADING MEETING — EANM'26
OCTOBER 17–21, 2026

EXHIBITION HALLS

HALL X4
LEVEL 0

CM	401	Alliance Medical
CM	402	Jubilant Radioharma
CM	403	CMR Corporation GmbH
CM	404	SCK CEN
	405	Tianjin Nuclear Saftey Technology Co., Ltd.
	406	Amber Bridge Isotopes
	407	SpectronRx
CM	408	ELSE Solutions S.r.l.
CM	409	SHINE Technologies
CM	410	Capintec, a Mirion Medical Company
CM	411	C Ray Therapeutics (Chengdu) Co. Ltd.
CM	412	Von Gahlen Nederland B.V.
CM	413	IBA SA
	414 a	MNT Saglik Hizmetleri Ve Ticaret A.S.
	414 b	Epsilon Radioactive Sources – ERS
CM	414 c	ROTOP Pharmaka GmbH
	414 d	Sykam Chromatographie Vertriebs GmbH
	414 e	CUP Laboratorien Dr. Freitag GmbH
	414 f	NorthStar Medical Radioisotopes
	414 g	MIE medical imaging electronics GmbH
CM	415	ITM Isotope Technologies Munich SE
	416	BV Cyclotron VU
	416	Epsilon Elektronik Sanayi ve Ticaret A.Ş.
	416	EuroMedical Instruments
	416	Hidex
	416	HOY Scandinavian ApS
	416	LYLA B.V.
	416	NucAdvisor / MEDraysintell
	416	Nuvia
	416	PI Medical Equipment B.V.
	416	Special Cargo Services BV
	416	Van Der Wilt Techniques
CM	417	NRG Pallas BV
CM	418	Cyclomedica Ltd
CM	419	ABX advanced biochemical compounds
CM	420	AWEX – Wallonia Export & Investment Agency
	420	BioVendor
	420	ELYSIA RAYTEST
	420	IRE ELIT
	420	PHSE
	420	THE ONCIDIUM FOUNDATION




FINAL PROGRAMME | INDUSTRY EXHIBITION

WORLD LEADING MEETING — EANM'26
OCTOBER 17–21, 2026

EXHIBITION HALLS

HALL X5
LEVEL 0

	501	Colibri Isotopes Corporation
CM	502	Urenco Isotopes
CM	503	Jiangsu Huayi Radiopharmaceuticals Co., Ltd.
CM	504	MOLTEK SAĞLIK HİZMETLERİ ÜRETİM VE PAZ. A.Ş.
CM	505	Hermes Medical Solutions AB
CM	506	United Imaging Healthcare Europe B.V.
CM	507	Curium International Managment SAS
CM	508	Lemer Pax
CM	509	Spectrum Dynamics Medical SA
	510	Isotopia Molecular Imaging
	511	Avelion (PMB – ALCEN)
	512	Perceptive
	513	DOSIsoft
	514	Nuclear Medicine Europe
CM	515	GE Healthcare
	516	Hyperion Hybrid Systems GmbH
	517	Bianco Healthcare
	518	Radioprotech
	519	Nuclivision NV
CM	520	Life Couriers
	521	Minerva Imaging ApS
	522	Imaging Endpoints
	523	A.C.O.M. Advanced Center Oncology Macerata S.R.L.
CM	524	Bayer AG
	525	MIM Software
CM	525	GE Healthcare
CM	526	Siemens Healthineers AG
CM	527	Telix Pharmaceuticals
CM	528	Trasis SA
CM	529	Siemens Healthineers AG
CM	530	Polatom
CM	531	Siemens Healthineers AG



FINAL PROGRAMME | INDUSTRY EXHIBITION



RESEARCH4LIFE®

EARL THERANOSTICS CENTRES OF EXCELLENCE

Over 130 centres are now part of the Theranostics Certification - setting the benchmark for quality and patient-focused care.

Join our Centres of Excellence Programme!

COMPANY PROFILES

A.C.O.M. - ADVANCED CENTER ONCOLOGY MACERATA - S.R.L.

LOC. CAVALLINO 39/A-B
62010 MONTECOSARO (MC), Italy

https://www.acompet.it

ACOM S.r.l. is an Italian SME with over 25 years of experience in nuclear medicine, specializing in the research, development and clinical translation of innovative radiopharmaceuticals. The Company develops advanced diagnostic and therapeutic solutions, with a strong focus on oncology and theranostic medicine, bridging scientific research with industrial development.

Alongside its R&D activities, ACOM manufactures and distributes established radiopharmaceuticals for routine clinical practice, providing extensive expertise in GMP manufacturing, quality systems, regulatory affairs and hospital supply chains.

A key area of innovation is the development of Copper-64 chloride ($^{64}CuCl_2$) as a next-generation theranostic radiopharmaceutical for PET imaging and targeted radionuclide therapy. ACOM was the first Company in Europe to commercialise Copper-64 as a radiopharmaceutical precursor and continues to advance its clinical development, including programmes that have received orphan designations for malignant gliomas.

Through its integrated scientific, clinical and industrial capabilities, ACOM is committed to delivering innovative and sustainable radiopharmaceutical solutions that address unmet clinical needs and support the future of precision medicine.

For any further information please visit our stand and our WEB page (www.acompet.it) where you can find the most updated information.

ABSCINT

LegiaPark,
Boulevard Patience et Beaujonc 3
B - 4000 Liege, Belgium

https://abscint.com

ABSCINT is a clinical stage molecular imaging company developing in vivo diagnostics empowered by single-domain antibodies. Our name captures our essence, which is to address unmet medical needs with the development of unique antibodies (AB) providing superior performance in scintigraphy (SCINT). Our mission is to provide more precise, more specific, more convenient and safer diagnostics in the fields of oncology, cardiology and immunology.

ABX
advanced biochemical compounds

Heinrich-Gläser-Str. 10-14
01454 Radeberg, Germany

http://abx.de

ABX – Trusted Excellence from Molecule to Market.
ABX advanced biochemical compounds is a leading global innovator and trusted partner in radiopharmaceuticals, with a focus on PET tracers.
We provide end-to-end expertise across the entire value chain - from research and development to clinical manufacturing, regulatory support, commercialization and global supply.
Based in Germany and with 30 years of experience, we combine scientific excellence, regulatory expertise and operational precision to help customers bring innovative radiopharmaceutical solutions to patients faster.
Our portfolio includes radiopharmaceuticals, CMO/CDMO services and products, enabling customers to simplify processes with one experienced partner.

- We operate a hot lab for R&D and GMP manufacturing of radiopharmaceuticals, cold kits, reagent sets and cassettes.
- Our in-house production of cyclotron-based isotopes, excipients, and sterile disposables makes us independent from external and ensures a reliable supply chain.
- As market leader we developed the ^{177}Lu-PSMA-617 – until clinical phase II (sublicense Novartis) as well as ^{18}F-PSMA-1007 – now approved in selected countries in Europe, Asia and North Africa. A perfect example of theranostics and radioligand therapy (RLT) in action.

Built on GMP-compliant manufacturing, uncompromising quality standards and a collaborative mindset, ABX is a trusted deliverer of reliable solutions for even the most demanding projects.
Trusted Excellence defines how we work - advancing nuclear medicine and improving patient care worldwide.

ABX-CRO advanced pharmaceutical services

Schössergasse 19
01067 Dresden, Germany

https://www.abx-cro.com

ABX-CRO is an international CRO providing standard & specialised clinical and non-clinical studies, with emphasis on neuroscience, oncology and diagnostic imaging. With a unique translational medicine approach, we are happy to develop products from first non-clinical to late-stage multicentre human studies, or to support marketing authorisation.
Our dedicated Molecular and Functional Imaging Core Lab provides comprehensive turn-key solutions covering all aspects of pre-clinical and clinical imaging and dosimetry. We provide solutions for radiolabelling, dosimetry, regulatory issues and the intricacies of functional imaging that are frequently seen as major obstacles in the conduct of oncology and imaging trials.
Whether you represent a clinical trial site or want to find out how your project could benefit from our experience, come over and get an idea of our comprehensive services and expertise!

Advanced Cyclotron Systems Inc.

150-7280River Rd.
V6X 1X5 Richmond, BC, Canada

https://advancedcyclotron.com

Advanced Cyclotron Systems, Inc. (ACSI) is a world leader in the design and manufacturing of cyclotron systems. With over 30 years of experience and more than 60 cyclotron systems installed, ACSI can provide a wide range of equipment and services worldwide. ACSI cyclotrons are used for the commercial production of PET and SPECT nuclides by internationally recognized companies and leading universities and research facilities. ACSI cyclotrons are designed, manufactured, and assembled in Richmond, Canada.ACSI offers a full spectrum of cyclotron systems ranging from PET cyclotrons to medium and high energy accelerators. All ACSI manufactured cyclotrons have variable energy and employ external ion source technology, offering the highest beam current output available on the market. The versatility, high beam current and exceptional quality of ACSI cyclotrons are some of the reasons why many of the world's most prestigious universities and research centres, as well as some of the most successful commercial radioisotope producers have chosen ACSI cyclotrons to meet their radioisotope production needs.For more information, please visit www.advancedcyclotron.com

AI4R

25 rue Marcel Dassault
44980 SAINTE LUCE SUR LOIRE, France

https://www.ai4r.com

AI4R range in digital autoradiography.
We deliver the most sensitive autoradiography range able to detect very low level of radioactivity. With the 2 solutions BeaQuant and BeaQuant-s, all sizes of devices are now available with the same features for radioisotope imaging. With an unrivalled sensitivity and the widest range of radioisotopes on the market, from very low energy emitters like 3H or 99mTc, to high energy emitters like PET tracers as well as alpha emitters for Targeted Alpha Therapy or radioligand therapy, the BeaQuant range suits perfectly your needs in imaging. From neuroscience studies to QWBA for DMPK studies, everything is accessible with only 1 device.

Alliance Medical GmbH

Westring 168
44575 Castrop-Rauxel, Germany

http://www.alliancemedical.eu

Alliance Medical is an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. These combined services allows physicians, pharma industry and academia greater access to established and innovative imaging agents for clinical trials and clinical routine.

Almac Group

20 Seagoe Industrial Estate
BT635QD Craigavon, United Kingdom

https://www.almacgroup.com

Almac has >20 years' experience supplying peptides to both the research community and for clinical trials. Our scientists have developed a high level of technical expertise enabling manufacture of peptides with a wide range of complexity, including high-throughput manufacture, long peptides, conjugation and peptide cocktails. Almac has intimate knowledge of all the required steps to progress a peptide radiopharmaceutical precursor from initial concept to first in human testing, and through the entire clinical journey. We have ongoing programs from Phase 0 through to Process Validation and supported a commercial radiopharmaceutical launch in 2023.

Amber Bridge Isotopes

United Financial Building, Binhu District
Wuxi City, Jiangsu Province, China

https://www.amberbridgeisotope.com

Amber Bridge was founded in 2022 as a key subsidiary of the DWS Group. Dedicated to the isotope industry, we are committed to advancing innovation and reliability, with the aspiration of becoming a leading global supplier of stable isotopes.

Amber Bridge is the global agent for the complete stable isotope portfolio of China National Nuclear Corporation (CNNC), including Ni-64, Zn-68, Mo-100, Xe-124, and Si-28. We provide enriched stable isotopes and customised isotope solutions supporting radiopharmaceutical production, quantum computing, semiconductor manufacturing, scientific research, and other high-tech industries. Most of these isotopes are produced using advanced gas centrifugation technology, enabling high isotopic enrichment, consistent quality, and a scalable supply.

We are committed to building long-term partnerships with our customers. By delivering high-quality stable isotopes and reliable isotope supply solutions, we have established strong relationships with pharmaceutical companies, cyclotron centres, research institutes, universities, and technology companies worldwide.

ARALE Laboratory

200, Wangsan-ro, Dongdaemun-gu
2559 Seoul, Korea, Rep. of South

https://aralelab.com

ARALE lab is pioneering the next generation of intraoperative imaging with the world's first drop-in type miniature gamma camera for robotic surgery.

Our proprietary gamma-ray imaging technology enables real-time visualization of critical anatomical targets during surgery, expanding the capabilities of surgical robotic systems.

The device fits seamlessly into existing surgical workflows, inserted via a 12mm trocar and controlled by robotic forceps.

We are actively engaging with global leaders and companies, positioning ourselves at the forefront of the surgical imaging market.

ArgonSoft Ltd.

H-1133 Budapest, Váci út 76. Capital Square
1133 Budapest, Hungary

https://www.argonsoft.hu/en

ArgonSoft, was established in 2008 with the primary objective of offering custom software development services. Since then, we have successfully completed over 150 projects for more than 30 clients across 9 countries. Our exceptional results can be attributed to the hard work of our team of over 40 IT experts, our client-focused approach, and our strong relationships with our clients. The scope of our projects varies from 100 man-days to 10,000 man-days. Several of our national IT systems have been in continuous use by thousands of users for over a decade. We have developed sophisticated IT solutions for various industries including healthcare, public services, and financial institutions. In addition to our domestic projects, we have collaborated with numerous international companies worldwide. As part of our high-quality service portfolio, we provide our clients with IT consultancy, project management, quality assurance, various outsourcing services, and long-term system support. Based on the knowledge gained from our diverse and large-scale projects, we have also established a product development division. Expanding our service and product portfolio, ArgonSoft has ventured into the healthcare sector and since 2016, we have been actively increasing our involvement in this area, particularly in the field of nuclear medicine. With our extensive development skills, our experience and proficiency in the healthcare sector and our relationships with universities, ASIS.TO LIMS has been developed as a unique, innovative, flexible, production-supporting IT system. By combining ASIS.TO LIMS's capabilities with ArgonSoft's custom software development services and expertise in medical device software, we can offer our clients a unique solution when needed.

AtomVie Global Radiopharma Inc.

10 Aeropark Blvd.
L0R 1W0 Hamilton, Ontario, Canada

https://www.atomvie.com

AtomVie is a lifecycle radiopharmaceutical CDMO supporting partners from process development through clinical production to commercial manufacturing. Built on renowned technical expertise in process & analytical development & a proven track record of reliable global delivery, AtomVie has consistently operated successfully under constrained environments, now amplified by a purpose-built, 72,300 sq. ft., high-capacity commercial facility currently being commissioned & set for operational readiness this year. With over 99% delivery success in reaching patients globally, deep scientific expertise & a flexible partner offering, AtomVie enables seamless progression from early development to commercial manufacturing of radiopharmaceuticals. AtomVie not only helps you succeed in Phase I and II; we scale with you as you excel in Phase III development and reach the marketplace to deliver radiopharmaceuticals to patients. AtomVie offers a wide range of services for development, manufacturing & regulatory approvals. Our highly skilled team boasts a strong track record with results that speak for themselves:

- 125+ Quality & Operations professionals supporting sponsors in cGMP production
- 70+ Clinical Development & Tech Transfer programs spanning Phase I - III
- 1,000+ cGMP batches ordered
- 4,400+ cGMP doses shipped successfully to 28 countries across 6 continents with a 99% success rate
- AtomVie has worked on 50% of the Phase II/III assets currently on the market
- Successfully filed over 525 Regulatory submissions to Health Canada & the US FDA

AVELION (PMB)

Place Sainctelette 2
1080 Brussels, Belgium

https://www.avelion-alcen.com

AVELION (formerly PMB) is a French high-technology company with a long-standing expertise in brazing dissimilar materials and specialized in the design and manufacture of complex assemblies and sub-assemblies (RF and beamline components, components for X-ray tubes, ceramic-metal assemblies…), as well as particle accelerators and disruptive medical systems.
AVELION designs and manufactures the iMiTRACE® 12 MeV cyclotron, specifically engineered for the on-site production of PET radioisotopes, combining a compact architecture, high performance and reliability.
AVELION has also developed radiochemistry room and microfluidic synthesis module, providing key technologies for automated radiopharmaceutical production.

AWEX - Wallonia Trade and Investment Agency

Place Sainctelette 2
1080 Brussels, Belgium

https://www.awex.be/en

The Wallonia Foreign Trade and Investment Agency, also known as AWEX, is Wallonia's - Region of Belgium - government agency in charge of foreign Trade and foreign investment. Wallonia is home to many nuclear medicine companies of various sizes, from SMEs to large companies, such as IBA and IRE, including spinoffs, suppliers and service providers.Our regional government supports the development of existing or newly established innovative activities with regard to R&D and production in the radiopharma and radiotherapy industry. AWEX is a one-stop shop for all foreign companies interested in setting up or expanding their business in Wallonia, as well as a partner for all Walloon companies wishing to develop their activities outside Belgium. If you're interested to know more, we will provide you with tailor-made information.Our partner BioWIN, the Health Cluster of Wallonia since 2006, encourages innovation and international development of Walloon actors active in this sector. BIOWIN connects some 250 key players: universities, research units and centers, R&D as well as manufacturing companies, incubators, capital providers, hospitals. To find out more about BioWIN's activities, please visit https://biowin.org/.

Bayer AG

Kaiser-Wilhelm-Allee 1
51373 Leverkusen , Germany

www.bayer.com

Bayer is committed to delivering SCIENCE FOR A BETTER LIFE and is increasing its commitment to Nuclear Medicine through innovative cancer treatments, molecular imaging agents and PET tracer infusion devices. Its portfolio includes XOFIGO (radium-223 dichloride), a targeted alpha therapy for metastatic castration-resistant prostate cancer with bone metastases*(1) and MEDRAD Intego, an Infusion System for the administration/delivery of 18F-FDG or 18F-Na(2). Bayer continues to actively pursue the expansion of its footprint in radiotheranostics, which includes a pipeline of actinium-225 based targeted radionuclide treatments for oncology as well as PET and SPECT tracers for the diagnosis of cardiac amyloidosis(3) using molecular imaging.

*progressing after ≥2 lines of systemic therapy, or ineligible for systemic treatment for mCRPC

References:

(1) Xofigo (radium Ra 223 dichloride) solution for injection Summary of Product Characteristics (SmPC). 51368 Leverkusen, Germany: Bayer AG; July 2025 https://www.ema.europa.eu/en/documents/product-information/xofigo-epar-product-information_en.pdf Accessed June 2026.

(2) Medrad ® Intego Operation Manual 86472953 Rev.F 2021.

(3) https://www.bayer.com/sites/default/files/ph-rd-pipeline-2026-04-29-final-update.pdf. Accessed June 2026

BE.SURE

VERTS PACAGES 14
1457 Walhain (Tourinnes-Saint-Lambert), Belgium

www.besurerp.be

Be.Sure is an accredited Belgian organisation. Its experts offer services in all areas relating to radioprotection, starting from the initial studies and basic design, through to licence applications, optimisation of working procedures, staff training, monitoring and control during operation, right through to the dismantling and decommissioning of facilities. Be.Sure is the leading organisation in Belgium, highly recommanded by numerous operators, including outside Belgium. We carry out missions in various countries (Luxembourg, France, England, Estonia, the Netherlands, etc.). Be.Sure is at your service to provide practical assistance in translating regulations into concrete applications within your organisation.

Becquerel & Sieveret Co., Ltd

3f-1, NO 56, Ln. 258, RuiGuang Rd.
11491 Taipei City, Taiwan

https://bqsv.com/RWD/htm/en/enindex.html

"Radiation safety and dose accuracy are our primary concerns".
Becquerel & Sievert Co. Ltd (as named BqSv) was established in 1993 and has been constantly devoted to new technology and the innovation of radiation safety and protection equipment, automation and quality control in the application of radiology, nuclear medicine, oncology, radiopharmaceutical GMP facilities, and nuclear industries. We have successfully provided many total solutions and turnkey services from site plan design, radiation safety evaluation, equipment manufacture, and system installation to helping our customers comply with the highest standards and guidelines. Come visit us at Booth 241!

Berthold Technologies GmbH

Goldschlagstrasse 182
1140 Vienna, Austria

https://www.berthold.com

Berthold Technologies is a global technology leader in life sciences, process control and radiation protection. We deliver integrated measuring solutions that have been trusted by scientists, technicians and engineers since more than 70 years.

Best Cyclotron Systems, Inc.

Magdalen CentreOxford Science Park
OX4 4GA Oxford, United Kingdom

https://www.blueearthdiagnostics.com

TeamBest®, through Best Cyclotron Systems, (BCS), offers radioisotopes and production capabilities for nuclear medicine and radiotherapy with its range of cyclotron systems. BCS's mission is to create technology to provide healthcare options for various needs around the world. Our staff assists from the planning stage, detailed design, facility construction, daily production, maintenance and emergency repair through the TeamBest® network. We provide solutions for PET-CT and molecular imaging radiopharmaceuticals with the same excellent customized care as demonstrated in our 40+ year history of radiotherapy support.

Best Medical International, a Team Best company also manufactures and supplies localization needles with Iodine-125 seeds for breast surgery applications, Gamma Probes for I-125 and Tc-99m detection and other products (www.teambest.com). For more information, please visit: www.blueearthdiagnostics.com.

Bianco Healthcare

VOGUE BUSINESS CENTER RUYA SOK.
NO:12
K:12 ATASEHIR ISTANBUL, Türkiye

https://www.biancosaglik.com

Bianco Healthcare is an Imaging Services Provider in Nuclear Medicine, Radiology and Radiation Oncology. The company has been in the Imaging business since 1991 headquartered in Istanbul, Türkiye. We collaborate with public and private hospitals as well as universities to bring innovative and reliable imaging services to these institutions while working with a profit-sharing model. We operate Imaging and Therapy departments with over 500+ expert staff. With our investments in modern technology and our patient-oriented approach, we aim to continuously improve the quality of healthcare services. or more information, please visit: www.blueearthdiagnostics.com.

BIOEMTECH

Kleisthenous 271
15344 Athens, Greece

https://www.bioemtech.com

BIOEMTECH's mission is to accelerate the preclinical development of promising drug candidates and support their translation into the clinic through high-quality services and innovative imaging solutions.

BIOEMTECH operates boutique preclinical laboratories offering comprehensive evaluation of new compounds throughout the preclinical development pathway. The company has also developed the eyes™ series of desktop imaging systems for real-time *in vivo* imaging of radionuclides and optical probes.

The eyes™ systems enable *in vivo* imaging of alpha emitters, including ^{212}Pb and ^{225}Ac, in oncology models, with short acquisition times. Across both its services and products, BIOEMTECH focuses on fast and efficient screening workflows that help accelerate drug development.

Blue Earth Diagnostics Ltd.

Magdalen CentreOxford Science Park
OX4 4GA Oxford, United Kingdom

https://www.blueearthdiagnostics.com

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company's success is driven by its management expertise and supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals. Blue Earth Diagnostics' expanding portfolio encompasses a variety of disease states, including oncology. Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in diagnostic imaging. For more information, please visit: www.blueearthdiagnostics.com.

Boston Scientific International SA

2 Rue René Caudron
78960 Voisins-le-Bretonneux, France

https://www.bostonscientific.eu

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.

Bracco Imaging

Via Egidio Folli, 50
20134 Milan, Italy

https://www.bracco.com/

Bracco group, founded in 1927, is a global leader in diagnostic imaging, committed to advancing healthcare and improving people's lives by shaping the future of prevention and precision medicine.
The company operates in the healthcare sector across more than 100 countries with a workforce of over 4,000 employees and consolidated annual revenues of approximately €2 billion, 88% generated by international markets.
With a strong commitment to innovation - investing around 9% of its reference turnover in Research & Development - Bracco develops and provides a broad portfolio of pharmaceutical products for diagnostic imaging, including contrast agents for X-ray, Computed Tomography (CT), and Magnetic Resonance Imaging (MRI), as well as microbubbles for Contrast Enhanced Ultrasound (CEUS), and Molecular Imaging through radioactive tracers and novel PET imaging agents, alongside AI-based solutions. It is also a global market leader in advanced contrast management technologies for cardiovascular angiography and radiology imaging.
Discover more at www.bracco.com

Brightonix Imaging

#1705, SK V1 Tower, 25, Yeonmujang 5ga-gil, Seongdong-gu
04782 Seoul, Korea, Rep. of South

https://www.brtnx.com/en

Brightonix Imaging is an innovative healthcare company dedicated to providing society with cutting-edge biomedical imaging systems. We currently offer a range of preclinical and clinical PET systems, along with advanced medical imaging AI solutions. PHAROS is a high-performance, multifunctional digital PET system equipped with state-of-the-art detector technology. SimPET is the most compact and reliable MRI-compatible SiPM PET insert, enabling truly simultaneous PET/MRI studies in small animals. BTXBrain is an AI-powered, fully automated software solution for quantification of brain PET and SPECT imaging.
What's new this year is ELIOS, Brightonix Imaging's latest addition to our preclinical product portfolio. ELIOS is a preclinical PET/CT system for small animals, designed to deliver high-quality imaging performance with precision and reliability. We are proud to present ELIOS for the first time at EANM, with a full-scale demonstration system available at our booth. Come visit us to experience it firsthand. vailable at our booth. Come visit us to experience it firsthand.

Bruker

Rudolf-Plank-Str. 23
76275 Ettlingen, Germany

https://www.bruker.com/en/products-and-solutions/preclinical-imaging.html

Bruker BioSpin, a global leader in preclinical imaging solutions, empowers researchers and clinicians with cutting-edge technologies for in vivo imaging. Their comprehensive portfolio supports drug discovery, disease research, and translational medicine. Notably, Bruker acquired MOLECUBES NV, specializing in benchtop preclinical nuclear molecular imaging (NMI) systems. MOLECUBES' modular PET, SPECT, and CT CUBES™ imagers enhance high-throughput research, strengthening Bruker's NMI position. Additionally, Bruker's renowned PMOD™ PET data analysis software aids accurate quantification, image processing, and modeling in preclinical studies and clinical trials. Recently, Bruker expanded their offerings by acquiring Spectral Instruments Imaging LLC, a leader in preclinical optical imaging systems, broadening their solutions for disease research. Collaborating with these partners, Bruker continues to drive scientific advancements and improve patient outcomes.

BV Cyclotron VU

Van der Boechorststraat 6A
1081 BT Amsterdam, Netherlands

https://www.cyclotron.nl

BV Cyclotron VU produces radiopharmaceuticals and radiochemicals for medical diagnostics and research. Strategically located in Amsterdam next to Amsterdam UMC we produce GMP-compliant medical isotopes in our state-of-the-art manufacturing facilities. Our long-standing track record on supplying daily to the customers, our great expertise combined with strong collaborations makes us a reliable partner for hospitals, pharmaceutical companies and research centers all over the world.rmaceutical companies and research centers all over the world.

Cedars-Sinai Medical Center

6500 Wilshire Blvd, 5th floor
90048 Los Angeles, United States of America

https://thecardiacsuite.com

Cedars-Sinai is a nonprofit academic healthcare organization serving the diverse Los Angeles community and beyond. With pioneering medical research achievements, education programs defining the future of healthcare and wide-ranging community benefit activities, we're setting new standards for quality and innovation in patient care.
Today, Cedars-Sinai serves more than 1 million people each year in over 40 locations, with more than 4,500 physicians and nurses and 1,500 research projects in motion.
Cardiac Suite is the result of decades of groundbreaking research in nuclear cardiology, providing highly validated quantitative tools for the analysis of cardiac PET, SPECT, and hybrid PET/CT and SPECT/CT studies. Thousands of publications have investigated the use of QGS+QPS, QPET, and QBS in the assessment of heart disease, both from our institution and independent researchers. Cedars-Sinai Cardiac Suite is in use at tens of thousands of institutions worldwide.
Cedars-SinaiCardiacSuite:DesignedforClinicians,Powered by Research.

Cencora - World Courier

https://www.worldcourier.com

Our full-service logistics and storage solutions help you seamlessly deliver innovation.
We manage the logistics for your most precious innovations. And we don't take that responsibility lightly. Across our global network of dedicated team members, we monitor the safety and integrity of your product proactively, ensuring it reaches patients without delay. We plan for contingencies, so you don't have to, leveraging our global capabilities and local, on-the-ground knowledge to navigate logistics complexities. Our innovative distribution services for medications, including rare, orphan, and gene therapies, are customized and scalable to fit your product's needs.
We go the extra mile to ensure increased supply chain efficiency, maximum return on investment, and enhanced patient care. 4/Ga-68/Zr-89-labeled radiopharmaceuticals to worldwide partners.

CGN Isotope Co., Ltd.

No.9 Kangxin Road, Youxian Street,
Youxian District
621000 Mianyang, China

https://www.cgn-healthcare.com

CGN Isotope is a leading innovator in the R&D, production, and supply of medical isotopes, dedicated to building a complete nuclear medicine value chain and driving next-generation radiopharmaceutical applications. Leveraging both reactor and accelerator technologies, CGN Isotope has the capability to produce and supply a wide range of isotopes, including 68Ge, 68Ge/68Ga generators, 123I, 64Cu, 89Zr, 177Lu, 226Ra, and 18O, among others. We are also committed to developing new products by drawing on the extensive resources of our parent company, CGN Group.

CGN Isotope operates under CGN Healthcare, which specializes in applying nuclear technology to cancer diagnosis and treatment, and is part of CGN Group (China General Nuclear Power Group), the largest nuclear power conglomerate in China and second largest globally.

Our mission is to empower healthcare providers worldwide with cutting-edge nuclear medicine solutions that improve patient outcomes and advance the diagnosis and treatment of cancer.

Champions Oncology

1330 Piccard Drive, Suite 25
MD 20850 Rockville, United States of Americaa

https://www.championsoncology.com

At Champions Oncology, we are passionate about accelerating the development of next-generation oncology therapeutics through end-to-end research and development solutions and strong scientific engagement.
With the largest collection of highly clinically relevant patient-derived models, a broad portfolio of ex vivo and in vivo platforms, advanced analytical solutions, and the richest molecular multi-omic datasets, Champions Oncology is your partner in meeting

CHELATEC

1 rue Aronnax
44800 Saint-Herblain, France

https://www.chelatec.coms

Chelatec was founded in 2000 by seasoned scientists trained in the development of radiopharmaceuticals. Experts in the use of radioactive tracers, they decided to offer their knowledge in preclinical development of targeted radiotherapeutics to pharma and biotech.
With state-of-the-art fully equipped laboratories for radiolabeling, radioanalyses, handling of cells and housing of animals, Chelatec is recognized for its reliable expertise and offers a unique combination of custom radiolabeling, in vitro assays and in vivo investigations capabilities.
Specializing in radiopharmaceutical R&D, Chelatec will provide you with information on your Investigational Medicinal Product to be part of the documentation package. All quality and non-clinical safety data required for translation of a radiopharmaceutical.
Our services include:

- Bioconjugation
- Radioactive labeling (177Lu, 90Y, 111In, 225Ac, 161Tb…)
- Analytical controls (HPLC, iTLC/TLC, SDS-PAGE…)
- Stability studies (storage stability, plasma stability)
- In vitro assays (Binding affinity, IRF, internalization, cytotoxicity, autoradiography on tissue sections)
- In vivo investigations (Pharmacokinetics, biodistribution, efficacy, dosimetry)

CHEMATECH

2 rue Pauline Kergomard
21000 Duon, France

http://www.chematech-mdt.com

CheMatech is a world-leading company specializing in the design and synthesis of bifunctional chelating agents such as DOTA, NOTA and NODAGA derivatives. These molecules are widely used for peptides or antibodies labeling with 67/68Ga, 111In, 64/67Cu, 89Zr, ... for PET/SPECT imaging, 177Lu, 225Ac, 212Pb, 90Y,... for therapy. CheMatech offers a wide range of functionalized and protected chelating agents from milligrams to kilograms scale. CheMatech offers cGMP production, custom syntheses of chelators and bioconjugation services. ction, custom syntheses of chelators and bioconjugation services.

Chengdu NOVEL MEDICAL Equipment Co., Ltd.

Room 101&102,1/F, Unit 1, Block 7, No. 1717 Fenghuang Road, Chengdu Tianfu International Bio-Town,
Shuangliu District, Chengdu, Sichuan Province, P.R.China. 610219 Chengdu, China

https://www.novelmedical.net

Chengdu NOVEL MEDICAL Equipment Ltd. was established in June 2011, co-founded by Hong Kong renowned industrialist Mr. Chao Kuang Piu and Tsinghua University.
NOVEL MEDICAL has cooperated with Tsinghua University to establish "Tsinghua-Novel Medical Nuclear Medicine Imaging Joint Research Center". Leveraging on the world-class medical physics research of Tsinghua University, the company being the first in China has successfully launched clinical SPECT and SPECT/CT, preclinical micro PET/SPECT/CT, and radiation intelligent monitoring system, and remained its leading positions in these fields in China. The series of products have been applied nationwide, providing strong support for the development of radiation detection and molecular imaging industry.

CMR Corporation GmbH

Bldg 638b, Cargo City South
60549 Frankfurt, Germany

https://isotope-cmr.com

Center of Molecular Research (CMR) - one of the leading global suppliers of nuclear medicine products.
CMR Group was established in 2001 and during more than 20 years has been specialized in the development, production and distribution of isotopes, lyophilizates, reagents, peptides and a wide range of other products for radionuclide diagnostic and therapy.
Today, CMR is not only one of the world's largest producers of Oxygen-18 water, but also a qualified supplier of a wide range of products, including STABLE AND RADIOACTIVE ISOTOPICS, CHEMICAL RADIOPHARM PRECURSORS and COLD KITS, which fully cover the needs of medical facilities, scientists and technologists in the field of nuclear medicine and radiochemistry.
Full Product List always available on our website.

CMR Molecular Imaging

2720 Loker Avenue West, Suite O
92010 Carlsbad, United States of America

https://cmr-naviscan.com

CMR Molecular Imaging is a unit of CMR Naviscan Corporation, headquartered in Carlsbad, California, and is US FDA registered. It is a global medical technology company committed to providing peace of mind to patients and physicians alike, offering Molecular Breast Imaging (MBI) and Positron Emission Tomography for the breast (PET), as secondary screening and diagnostic tools.
Compañía Mexicana de Radiología (CMR), headquartered in Querétaro, México, has been a developer and manufacturer of high-quality diagnostic imaging equipment and healthcare IT solutions for more than 50 years. CMR was founded in 1973, and its subsidiaries are CMR Molecular Imaging, CMR X-ray, and CMR Vet.

Colibri Isotopes Corporation

Texas
United States of America

https://www.colibriso.com

Colibri Isotopes Corporation (USA) is a medical isotopes research, development and supply company specializing in therapeutic isotopes production through state-of-the-art target designs and physicochemical separation technologies for nuclear reactor-based and accelerator-based production methods. Colibri is focusing on production of Lu-177, Ac-225, Ra-223, Tb-161 and Pb-212.

Colibri's Lu177 nca proprietary production technology allows to set up the most reliable supply chain for the customers all over the world and to do it in the most cost effective way. Colibri is developing an accelerator-based Ac-225 production route with the use of physicochemical separation technologies providing the purest final product on the market.

Current scope of products / services offered includes:
- Lu-177, Ac-225, Ra224 and Ra223 supply
- RnD collaboration for production facility set up

For more information, please visit our website: colibriso.comFor more information, please visit our website: colibriso.com

COMECER SPA

Via Maestri del Lavoro, 90
48014 Castel Bolognese (RA), Italy

https://www.comecer.com

Comecer, an ATS Company, is a leading provider of advanced technologies for the Radiopharmaceutical, Nuclear Medicine, Pharmaceutical, and Life Sciences industries.
Proudly combining Italian engineering excellence with a global presence, the company develops and manufactures customized solutions supporting the entire radiopharmaceutical workflow, from production and synthesis to dispensing and administration, for both diagnostic and therapeutic applications.
With over 50 years of experience and installations worldwide, Comecer's portfolio includes shielded hot cells, synthesis and dispensing isolators, radiopharmaceutical production systems, solid target solutions, radiopharma injectors, as well as management software and digital solutions designed to enhance process control, data management, traceability, and operational efficiency. Combining expertise in radiochemistry, aseptic processing, containment, automation, and digital innovation, Comecer helps pharmaceutical companies, hospitals, radiopharmacies, and research centers achieve the highest standards of safety, efficiency, and GMP compliance.

Corning SAS

7 Bis Av. de Valvins
77210 Avon, France

https://www.corning.com/worldwide/en/products/advanced-optics/product-materials/specialty-glass-and-glass-ceramics.html

Comecer develops and manufactures high-tech systems in the Radiopharmaceutical field, offering customized equipment and special solutions for Therapeutical, GMP Radiopharmacy, and Nuclear Medicine applications, as well as isolation technology solutions in the field of Aseptic ProcessingandContainmentforthePharmaceuticalindustry.

In particular, Comecer excels in the field of radiochemistry where, on behalf of large industrial groups or research institutes, it manufactures shielding systems for special applications. Radiopharmaceuticals are radioactive substances used to identify a specific part of the body through the emission of radio particles captured by gamma chambers and PET tomographs capable of offering accurate functional morphological images.

In the Nuclear Medicine sector, Comecer products such as shielded hot cells, synthesis and dispensing isolators, solid target systems, and radiopharma injectors, are used in the most advanced and prestigious research centers, universities, hospitals, and pharmaceutical companies worldwide.

C-Ray Therapeutics (Chengdu) Co.,Ltd.

198 haida road, Wenjiang district
Chengdu, Sichuan province, China

https://www.c-raytherapeutics.com

C-Ray is a one-stop CRDMO service provider for radiopharmaceuticals. Since its founding in 2021, C-Ray has established 28, 000+m^2 R&D(with a GLP-like animal facility) and multi-product manufacturing facility in Chengdu, China, which meets the cGMP requirements of the FDA, EMA, and NMPA. Under the Class A Radiation Safety Permit in China,
C-Ray can operate over 30 types of radionuclides and supports your radiopharmaceutical candidates' screening, pre-clinical studies, process development, clinical & commercial-scale manufacturing, and Phase 0 clinical trial in China.
C-Ray is also the leading radiopharmaceutical company. In 2024, its Series A+ financing round exceeded $100 million. Since the launch of CRDMO, (Contract Research,Development, and Manufacturing Organization) services, C-Ray has successfully delivered 5 CDMO projects, 20+ theranostics and molecular imaging CRO projects, and multiple ongoing R&D programs "Lu-177/Ac-225/Cu-64/Ga-68/Zr-89-labeled radiopharmaceuticals to worldwide partners.

CRL - Central Research Laboratories

Hiroshimastrasse, 2
61440 Oberursel, Germany

https://www.crlsolutions.com

CRL (www.crlsolutions.com), a DESTACO Company, has been a leader in remote handling products since 1945.
Our telemanipulators have been trusted by nuclear laboratories and radiopharmaceutical customers on 6 continents. Our complete line of telemanipulators and transfer products are backed by a global organization with sales and customer support throughout Europe, North America and Asia.

Croft Associates Ltd

F4 Culham Campus, Abingdon, Oxfordshire
OX14 3DB, United Kingdom

http://www.croftltd.com

Croft is a leading provider of specialist transport packaging for radioactive materials, offering end-to-end services including design, testing, licensing, supply, maintenance, and technical support. Its packaging solutions comply with international transport regulations, including IAEA SSR-6 and US Nuclear Regulatory Commission (NRC) requirements under 10 CFR Part 71.
Recognised as both a Design Authority and a Competent Authority, Croft combines regulatory expertise, engineering capability, and operational experience to develop safe and compliant packaging solutions.
Within the radiopharmaceutical industry, Croft is an established logistics partner providing solutions tailored to customer needs. Our SAFKEG® range of Type B transport packages are certified by the US NRC and approved for use in multiple international markets, including Canada, Europe, Australia, and China:
SAFKEG® 3977 HS – depleted uranium-shielded package used primarily for transporting medical radioisotopes such as Mo-99 and I-131.
SAFKEG® 3979 LS – lead-shielded package designed for isotopes such as Lu-177, Ac-225, Kr-79 and Xe-133.
We provide cost effective solutions by licensing for additional isotopes/contents in our existing packaging designs and develop bespoke design solutions to meet customer specific requirements.
Croft also provides specialist containment verification services to ISO 12807 and ANSI N14.5 standards. Using its proprietary CALT® leakage tester, the company performs gas pressure-change testing and helium mass spectrometer leak testing, supported by ASNT qualified personnel.

Crystal Photonics GmbH

Albert-Einstein-Straße 16
12489 Berlin, Germany

http://www.crystal-photonics.com

Crystal Photonics is engaged in Nuclear Medicine for highly qualified products of Molecular Imaging and intraoperative and transcutane sentinel lymph node localization (SLNE) since 25 years. The product range includes our excellent mini-USB Hand-Held-Gamma-Camera "CrystalCam", the surgical Gamma Probe System "Crystal Probe - automatic" with various kinds of cable and wireless probes. We are worldwide the first company, who is presenting complete autoclavable gamma probes without compromises! Since this year is also available the very new detection system CrystalGuard for Isolated Limb Perfusion (ILP), as well as the very new CrystalAnalyzer for HPLC-investigation in coincidence mode for any PET-drugs are available. Additionally, we present our very new mini-Laparoscopic gamma probe for robotic-assisted minimal-invasive surgeries, (Drop-in-Probe) special designed for the DaVinci robotic operation system. This probe is very small (D 1 cm x 5 cm) was developed in the course of the new PSMA-technology for Prostate Cancer and has excellent medical-technical properties. The product portfolio is completed by a large variety of miniaturized Gamma- and Beta-detectors for any kind of application, particularly systems for the production and dose-rate controlling of medical radioisotopes with high activities. For more information, please visit our websites: www.crystal-photonics.com

CUP Contract Labs

Carl-Eschbach-Strasse 7
1454 Radeberg, Germany

https://www.cup-contract-labs.com

CUP Contract Labs is an independent GMP-compliant contract laboratory based in Radeberg, Germany, specializing in radiopharmaceutical analytics and complex pharmaceutical testing. We support developers and manufacturers of radiopharmaceuticals and targeted therapeutics across the product lifecycle – from method development and validation to release testing, stability studies and routine QC. Our expertise includes short-lived radionuclides, complex matrices, sterility testing, E&L studies and regulatory-oriented analytical support Independent. GMP-compliant. Experienced.

Curium

12 rue Lord Byron
75008 Paris, France

https://www.curiumpharma.com

Curium is the world's largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for potentially life-threatening diseases to over 15 million patients annually. The name 'Curium' honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com

Cyclomedica

Unit 4, 1 The Crescent, Kingsgrove
2208 New South Wales, Australia

https://www.cyclomedica.com

Cyclomedica is a global leader in nuclear medicine and molecular imaging, redefining respiratory diagnostics through innovation, collaboration, and clinical impact. Since 1986, we have remained at the forefront of nuclear pulmonology with our flagship product, Technegas®, used in over 66 + countries and impacting the lives of millions.

The recent FDA approval of Technegas® in the United States marks a pivotal milestone in our growth, opening new opportunities to support clinicians in diagnosing and managing pulmonary embolism and other respiratory diseases. We are actively expanding its clinical utility through international research, development, and clinical trials-broadening its application across multiple respiratory indications.

At Cyclomedica, we work closely with a network of global partners-including TEMA Sinergie, Jubilant Radiopharma, ROTOP, and ABX-to bring an extended portfolio of innovative solutions to market. These alliances allow us to push boundaries, deliver complementary Nuclear Medicine, PET and theranostic products, and support customers with an integrated, future-ready offering.

Whether in Molecular Imaging, PET, or Theranostics, our mission remains clear: to aspire to better care, inspire scientific progress, and illuminate new pathways in health.

We provide end-to-end support, from early-stage project planning to installation, applications training, and long-term service. Whether introducing a new system or expanding an existing one, our team is committed to helping customers deliver the best in patient care.

As we continue to grow, we remain focused on meaningful progress-aspiring to higher standards, inspiring clinical confidence, and illuminating smarter pathways in nuclear medicine. Learn more about our story and solutions at cyclomedica.com

DC Pharma

No.7 Changbaishan Road,Yantai
Development Zone
264005 Yantai, China

http://www.dcb-group.com

Dongcheng Pharma was founded in 1998 and listed in Shenzhen in 2012. It has now become one of the two largest radiopharmaceutical industry groups in China. Currently, we have more than 32 Chinese radio pharmacies in different provinces, which can support all short half-life radio products local production and distribution. Relying on this extensive radio network, we have commercialized most of PET and SPECT products. As for R&D capabilities, DC pharma acquired Mitro biotech, which can provide customers with molecular imaging research, one-stop-shop R&D services for radio pipelines, and clinical companion diagnostic services. We also pay attention to innovation strategy, through in-house development and external collaboration. On the purpose of business expanding, we have always insisted on opening and collaborative philosophy for the domestic and foreign partners in all kinds of cooperation such as CMO, CRO, license-in or any other investment.

Dec Group

Z. I. Larges Pieces A Chemin du Devent P. O. Box 9
1024 Ecublens, Switzerland

https://www.dec-group.ch

Headquartered in Switzerland with a global footprint, we provide advanced process solutions for the radiopharmaceutical, pharmaceutical, and life sciences industries. Safety, innovation, and reliability are at the heart of every solution we design, supporting the production of highly sensitive and high-value therapies.
Our portfolio includes powder transfer and bulk handling systems, as well as fully integrated high-containment, aseptic, and automated processing technologies. Designed to meet the stringent requirements of radiopharmaceutical manufacturing, our solutions help customers maximize operator safety, ensure product integrity, and achieve compliance with the latest regulatory standards.
Driven by continuous growth and strategic acquisitions, we bring together five specialized divisions with strong engineering expertise to deliver seamless, end-to-end solutions—from raw material handling and isotope processing to sterile filling and finished product.

DiaSource ImmunoAssays

Rue du Bosquet 2
1348 Louvain-la-Neuve, Belgium

https://diasource-diagnostics.com

DiaSource ImmunoAssays® S.A., a BioVendor Group company, is an international diagnostic company based in Belgium with more than 30 years of experience in IVD (kits and instrumentation).
World leader in IVD, Tests & Instrumentation for more than 30 years
Our expertiseis in the development, manufacturing and marketing of clinical diagnostic products in the field of endocrinology, auto-immunity and infectious diseases.
Our RIA and ELISA product range is very comprehensive, ranging from manual assays and instruments for small laboratories (Readers, Washer, Shakers, Gamma Counters) to assays and instruments offering full automatization to medium-sized and high-throughput Clinical laboratories for ELISA Stratec Gemini and Dynex Technologies instruments : e.g. DS2®, DSX® and Agility® and for RIA automation CoNext125 sample Preparation Automate and CLIA system.
With more than 30 years in RIA business and hundreds of customers, DiaSource has become a world leader in this field and has set the standards with commitment to continuously support their customers. With the same dedication and commitment, DiaSource offers to the ELISA market a portfolio of more than 200 ELISA products which has been expanded since the acquisition by the BioVendor Group.

DOSIsoft

45/47 Avenue Carnot
94230 Cachan, France

http://www.dosisoft.com

Founded in 2002, DOSIsoft is a market leader in dosimetry software for radiation oncology and nuclear medicine, dedicated to improving cancer treatment quality and patient safety. With more than 1,000 installations across 800+ hospital centers in 80 countries, DOSIsoft provides advanced solutions for radiation therapy quality assurance, theranostics, and personalized dosimetry.
A spin-off from Gustave Roussy and Institut Curie, DOSIsoft continues to innovate through close collaboration with leading cancer centers worldwide. DOSIsoft is a contributing partner of the European Thera4Care project (Theranostics Ecosystem for Personalized Care).

DSD Pharma GmbH

Schuhmeierstraße 24
1140 Purkersdorf, Austria

https://dsd-pharma.com

DSD Pharma is a GDP-certified distributor of radiopharmaceuticals, medical products and medical-technical equipment in the field of nuclear medicine and radiopharmacy in Austria close to Vienna.

Eckert & Ziegler Medical

Robert-Roessle-Str.10
13125 Berlin, Germany

https://www.ezag.com/products

The Eckert & Ziegler Group (Berlin, Germany) is one of the world's largest providers of isotope technology for medical, scientific and industrial use. Our operating business is divided into two segments:

Eckert & Ziegler Medical draws on more than three decades of experience in nuclear medicine, molecular imaging, radiation therapy and related fields. As a one-stop shop for radiopharmaceutical needs, we offer a comprehensive portfolio for alpha, beta and gamma emitters: radionuclides in radiochemical grade (Ac-225) and radiopharmaceutical grade (Yttriga [Y-90], GalliaPharm® [Ga-68 generator], Theralugand® [Lu-177]), hot cell solutions, radiosynthesis technology (Modular-Lab, KitLab), and radiochromatography equipment.

Our services cover development and contract manufacturing (CDMO/CMC) through a global network of GMP suites - fully licensed radioisotope labs, stable supply arrangements for nearly all pharmaceutical radioisotopes, state-of-the-art logistics infrastructure, and experienced staff available on-site for preclinical and clinical projects.

Eckert & Ziegler Isotope Products (EZIP) complements this portfolio with flood, PET, SPECT and multimodal sources for the nuclear medicine community worldwide, as well as Tc-99m generators and cold-kit compounds for SPECT imaging.

Visit us at Booth #257 to discuss GMP Suites, CDMO/CMC, GalliaPharm®, Ac-225, Lu-177, Y-90, Tc-99m, hot cell solutions, calibration sources, synthesis equipment, quality control and more.

EDL

509 Av. de La Victoire du 8 Mai 1945
13130 Berre-L'Etang, France

https://www.edl.fr

Launched in 1994, EDL's software solutions have already attracted more than 600 medical imaging departments. EDL also publishes integrated applications covering all the modern needs of imaging services such as: RIS, PACS, DACS, VINA, Teleradiology, IA, Radiopharmacy and WEB portals.

Eichrom Technologies

1955 University Lane
60532 Lisle, United States of America

www.eichrom.com

Eichrom is a global leader is nuclear separation chemistry for analytical radiochemistry, isotope geochemistry and nuclear medicine. Eichrom is characterized by integrity, responsive customer service and high standards for product quality. We are a difference-making supplier because of our collaborative approach and the continual growth of our technical competence. Eichrom has an experienced team of radiochemists that continually strives to improve efficiency and lower costs for our customers.

EITA - European Isotopes Transport Association

c/o Vandelanotte Buro & Design Center
Esplanade 1/85
1020 Brussels, Belgium

http://www.eita.org

EITA is a non-profit association, which was founded in 1998 by European logistics providers trained, licensed and specialized in the handling and transport by Road, Air and Sea of radioactive isotopes, which are mainly used for medical purpose.

• Mission

Establishment of harmonized regulations and standards

Aiming for harmonized national and international regulations and legislations to guarantee the free market access in every

state for the EITA members.

• Compliance with applicable regulations

To ensure all EITA member activities are carried out in full compliance with all applicable legal requirements.

• Safety, Security and traceability

To ensure safety and security and full traceability at all times during the complete supply chain.

• Quality

To ensure high quality of handling, packing and transport of radioactive isotopes in accordance with required standards.

• Competence centre

To provide a forum to exchange information and knowledge to

increase awareness..

ELSE Solutions srl

via Carlo Goldoni, 18
20090 Trezzano sul Naviglio (MI), Italy

https://www.elsesolutions.com

ELSE Solutions S.r.l., founded in Italy in 1990, designs and manufactures advanced systems for Nuclear Medicine, Radiopharmacy, Radiotherapy, and industrial applications. The company specializes in radiation detection systems, shielded handling and transfer solutions, automated dispensing systems and integrated production plants.

Its product portfolio includes the SmartEye Platform for radiation monitoring, shielded workstations with energy-saving functions, patented dispensing technologies and PLC-controlled automation systems compliant with international standards. ELSE Solutions also develops innovative equipment for radiotherapy and radiopharmaceutical production, combining safety, reliability, efficiency and environmental responsibility.

With more than 35 years of experience, ELSE Solutions is committed to delivering state-of-the-art technologies that support healthcare professionals and industrial operators worldwide.

ELYSIA S.A.

rue du Sart-Tilman 375 B
4031 Angleur, Belgium

https://www.elysia-raytest.com

Elysia is a provider of hard- and software solutions for the full integrated quality control of your radio-pharmaceutical production. GINA X and SARA offer a user friendly and fully GMP compliant solution to your QC problems. We provide LIMS solutions, services, chromatography and quality control systems to the pharmaceutical, agrochemical and nuclear/PET industries.

We design, manufacture, sell and service instruments used for measurement of radioactivity and quality control. We work in close collaboration with radiopharmaceutical and cyclotron providers to develop new products and improve existing solutions.

In 2015 Elysia has purchased the Raytest Isotopenmessgeräte GmbH to increase the R&D, service and production capacity.

Since the integration of raytest, Elysia has extended the product line with cassette based synthesis module especially for the peptide labelling with Ga68, Lu177 and other radio-metals.

This allows us to plan and offer complete GMP and European Pharmacopeia compliant, turnkey solutions for the quality control of a huge variety of PET and SPECT tracers.

Our mission is to make the measurement of radioactivity, the peptide labelling and quality control of radiopharmaceuticals easier, faster and safer.

Radiopharmaceuticals should be accessible world-wide and affordable. We help our customers accelerate their R&D and to validate QC methods for existing and new molecules.

Our team is customer-oriented and composed of radiochemists, IT and QA specialists.

Their professional background ensures high-efficacy answers for all radiopharmaceutical, software and instrument questions.

For more information about the company and its products, please visit our website at www.elysia-raytest.com

EPSILON RADIOACTIVE SOURCES - (ERS)

Ferhatpasa Mahallesi 15. Sokak No:126-128
3488 Istanbul, Türkiye

www.epsilonsources.com

ERS designs and manufactures a comprehensive portfolio of sealed reference and quality assurance sources compatible with leading OEM systems in PET, PET/CT, PET/MR, and SPECT imaging. The product range includes Ge-68, Na-22, Co-57, and Gd-153 sources in various geometries and activity levels, tailored to system-specific calibration and quality control requirements.

In addition, ERS offers I-125 localization seeds for non-palpable metastasis, as well as radio decontamination solutions including decontamination liquids, soaps, and wipes designed for safe and effective cleanup of radioactive contamination.

Customized configurations are available upon request.

Please get in touch with your local distributor or ERS headquarters for product availability and additional information.

EuroMedical Instruments

1, rue du Centre
93160 Noisy-le-Grand, France

https://www.em-instruments.com/en/home-en

EuroMedical Instruments is the exclusive worldwide sales and marketing company of the Europrobe, a state-of-the-art surgical gamma probe manufactured by Eurorad SA, Strasbourg, France. Founded in 1982, Eurorad is a company specialised in R&D, Service and Production of mono and polycrystalline semiconductors for radiation detectors, and one of the main manufacturers for this type of equipment in the world.

FemtoIsotope GmbH

Jägerstraße 51
D-10117 Berlin, Germany

https://femtoisotope.com

At FemtoIsotope, we supply a diverse selection of radioisotopes suitable for various applications, including diagnostic imaging, cancer therapy, industrial radiography, and more. Our products undergo rigorous quality control measures to ensure purity, stability, and reliability.

for-med.nl

Parallelweg Zuid 33-02
5281LB Boxtel, Netherlands

info@for-med.nl

for-med.nl is a registered trademark of VANDERWILT techniques bv an ISO 13485 engineering company of customized products for daily laboratory and clinical nuclear medicine practice as well as research purposes, using state-of-the-art and innovative production methods. Typically, our customers are universities, hospitals and nuclear medicine departments, as well as radiopharmaceutical and imaging equipment companies.

Full-Life Technologies

London,
United Kingdom

https://www.full-life.com

Full-Life Technologies ("Full-Life") is a fully integrated clinical-stage global radiotherapeutics company with operations globally. We aim to own the entire value chain for radiopharmaceutical research & development, production & commercialization to deliver clinical impact for patients. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and seasoned scientists with a proven history of success in the life sciences, alongside radioisotope research and clinical development.

Gamma Medical Technology

Friesdorfer Straße 194A
53175 Bonn, Germany

http://www.gamma-mt.com

Welcome to Gamma Medical Technology, a pioneering supplier of advanced gamma probes for Sentinel Lymph Node Biopsy (SLNB) and radio-guided surgery. Our objective is to transform cancer treatment with precision-focused surgical tools that elevate patient outcomes and streamline surgical processes.Founded by a team of visionary medical experts and engineers, we are devoted to ongoing innovation, research, and development in radio-guided surgery. Our skilled team is dedicated to designing user-friendly gamma probes that meet the complex demands of modern surgical procedures.Our flagship product, the CENNA-500W, exemplifies our commitment to quality and innovation. This next-gen gamma probe offers unmatched accuracy, sensitivity, and ease of use, enabling surgeons to confidently identify sentinel lymph nodes during SLNB. Its state-of-the-art design ensures precise gamma radiation detection, minimizing false-negative risks and reducing surgery times.Gamma Medical Technology is renowned for quality, reliability, and exceptional customer support. We collaborate with surgeons and medical facilities worldwide, offering training, education, and ongoing assistance to optimize product use.As we expand globally, we remain committed to our core values of innovation, excellence, and customer satisfaction. Discover the difference our products make in radio-guided surgery and join us in revolutionizing cancer treatment worldwide.

GE HealthCare

283 rue de la miniere
78530 Buc, France

http://www.gehealthcare.co.uk

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services and data analytics to make clinicians more effective, therapies more precise, and patients healthier and happier.
Serving patients and providers for more than 100 years, GE HealthCare is advancing connected and compassionate care, while simplifying the patient's journey across the care pathway.
Together, we're creating a world where healthcare has no limits.

Getinge Life Science France (LaCalhene)

1 rue du comte de Donegal
41100 Vendome, France

https://www.lacalhene.com/fr

LaCalhene is part of the Getinge group, a global leader in Life & Science in the pharma industry
Since the 1960s, LaCalhene has been designing equipment for protecting operators and safely handling contaminated materials in the nuclear industry, research, and medecine.
We offer complete solutions for hot cells, and glove boxes:

- Remote manipulators: a wide range of mechanical and electrical remote handling systems for multiple applications allowing work in hot cells of all sizes.
- Transfer systems: safely transfer small, medium, and large volumes of contaminated materials and waste without breaking containment.
- Transport Casks: shielded containers designed for a wide variety of transfers (waste or materials, underwater or in hot cells) and for on-site transport or on public roads.
- Manipulation Devices: a complete range of easy-to-use and safe manipulation solutions for glove boxes.
- LaCalhene is there from A to Z to provide expert advice, safe products, comprehensive training, and maintenance support.
- Learn more about our solutions here: www.lacalhene.com.

Global Morpho Pharma

8 Rue de la Fionie
44240 la Chapelle-sur-Erdre, France

https://morphopharma.com

Global Morpho Pharma is a turnkey technology and service provider specializing in medical radioisotope production and distribution. Its proprietary platform, KaLupso, is a fully automated, GMP-compliant radiochemistry solution engineered for seamless technology transfer, enabling partners to manufacture n.c.a Lutetium-177 and Terbium-161.
Supported by end-to-end supply chain services, Global Morpho Pharma delivers scalable, reliable access to critical isotopes for the rapidly expanding nuclear medicine ecosystem.
Come visit us at booth 508.
Available products: Turnkey technology: KaLupso platform to produce nca Lu-177 and Tb-161.
Isotopes: Lu-177, Tb-161, Ac-225, Th-228, Ra-226, Yb-176, Gd-160 and other difficult-to-find isotopes.
Categories: Automated Synthesis Systems, Radioisotopes, Radiopharmaceuticals.

Glotope Advanced Pharmaceutical Technology Ltd.

Building 8, No.8 East Huigu 1st Road,
Shuangliu District, Chengdu Tianfu
International Bio-Town
610000 ChengDu, China

https://www.glotope.com

A Global Radiopharmaceutical CRDMO Bridging Isotope Supply, Manufacturing, and Clinical Translation.
Reliable execution for radiopharmaceutical innovation.
Glotope is an integrated radiopharmaceutical CRDMO platform supporting global partners from early discovery through clinical development and regulatory submission. With large-scale GMP infrastructure, extensive isotope handling capabilities, and an established translational trial network, we enable efficient progression from preclinical validation to clinical data generation.
Our platform includes:

- Isotope supply platform
- 60,000+ sqm specialized CRDMO facilities
- 110+ hot cells across 3 licensed GMP sites
- GLP facilities for non-clinical study
- 20+ Investigator-Initiated Trial (IIT) execution network
- Clinical and commercial supply

For innovators seeking scalable infrastructure, reliable isotope access, and integrated development execution — Glotope provides a seamless pathway from concept to commrtcial.

Guangzhou Diqi Trading Co., Ltd

Room 503-3, 5th Floor, No.2086,
Kaichuang Avenue, Huangpu District
51000 Guangzhou, China

https://www.diqisohub.com

DiqisoHUB | Established in 2012, is transforming into a 3rd party platform dedifcated to supply Radioisotopes (Lu-177, Tc-99m generator, etc.), enriched stable isotopes (Zn-68, Ni-64, etc.), and High-tech equipment (cyclotrons, Industry CT, etc.) in China and for ROW.
Our DIRLADS digital platform offers unparalleled real-time tracking for logistics/supply chain, enabling global compliance and partnerships with industrial-leading players worldwide.

Hermes Medical Solutions AB

Strandbergsgatan 16
112 51 Stockholm, Sweden

https://www.hermesmedical.com

Hermes Medical Solutions is celebrating 50 years of innovation in nuclear medicine. Since 1976, Hermes Medical Solutions has grown alongside the field—from the early days of analog imaging and manual workflows to today's highly quantitative, data-driven era

Hidex

Lemminkäisenkatu 62
FIN-20520 Turku, Finland

https://www.hidex.com

Hidex is a manufacturer of high-performance analysis equipment for life science research, radiation measurement, and nuclear medicine. As a world leader in detecting alpha, beta, and gamma emitters, Hidex offers optimized gamma counters for molecular imaging isotope energies. Our gamma counters are designed to streamline workflow, sample tracking, and ensure GxP compliance. Hidex liquid scintillation counters are used globally in the development and quality control of radiopharmaceuticals, utilizing isotopes such as actinium, radium, thorium, lutetium, strontium, yttrium, and more.
At EANM 2025, we are showcasing the following solutions:
Hidex Automated gamma counter: The Hidex AMG, equipped with a NaI well detector and onboard sample balance, is ideal for metabolic studies, blood input function curves, Glucomerase filtration rate, and general nuclear medicine applications.
Hidex Radiowater Generator: The Hidex Radiowater Generator is an online system for preparing oxygen-15 labelled water ([O-15]-H2O) infusions. With approximately 50 installations worldwide, Hidex is a pioneer in ^{15}O water technology.
Hidex Sense: The Hidex Sense microplate reader comes equipped with radiometric and non-radiometric detection modes. The multi-well reader is ideal for a multi-user environment and provides uncompromised performance, usability and sensitivity.
Liquid Scintillation Counting: Our Liquid scintillation counters, Hidex 300SL, Hidex 600SL, and Hidex ULLA are used for versatile applications including radiopharmaceutical production facilities for development and quality control of medical use isotopes, detection of impurities, contamination control with wipe tests, as well as activity standardization.
To learn more about our solutions, please book a meeting with our specialists and visit our booth 416!

HiRO (Harvest Integrated Research Organization)

220 Davidson Avenue, Ste.201, Somerset 8873 New Jersey, United States of America

https://harvestiro.com

Harvest Integrated Research Organization (HiRO) is a modern global CRO specializing in the clinical development of diagnostic and therapeutic radiopharmaceuticals. We support sponsors across all phases of development, helping advance innovative nuclear medicine and precision oncology therapies worldwide.

Through integrated clinical operations, biometrics, medical oversight, regulatory strategy, and quality management, HiRO delivers coordinated global execution across North America, Europe, Asia-Pacific, and Japan. Our teams understand the unique operational, regulatory, and logistical challenges of radiopharmaceutical development and provide tailored solutions to support successful clinical programs.

With more than 15 years of radiopharmaceutical experience and over 45 completed clinical trials, HiRO combines scientific expertise with operational excellence to help sponsors accelerate the development of transformative therapies for patients.

HOY Scandinavian ApS

Jacob Møllersgade 4
9560 Hadsund, Denmark

https://www.hoyscandinavian.dk

HOY Scandinavian was founded in 1991 as a supplier and distributor for Nuclear Medicine and radiochemistry departments in Scandinavia
The "HOY Exclusive" product range was launched in 2006. The head officeis located in Hadsund, Denmark, and all the HOY Exclusive products range is produced in Hadsund, Denmark.
Today HOY Scandinavian is an international business that supplies products to nuclear medicine and oncology departments at hospitals and laboratories all over the world. We are known for supplying very high-quality products and are now a market leader in many markets, particularly in Scandinavia and Europe.
Our home market is primarily Denmark and Sweden. We are represented in other markets by a distributor network.
Products and activities:

- At HOY we develop and manufacture "Hoy Exclusive", an all-in-house product design - offering quality products for radiation protection in nuclear medicine and PET departments.

- The "HOY Exclusive" product portfolio has a modern, timeless Scandinavian design, and offers maximum ergonomic comfort aligned too European standards.

Key products are:

- Vial glass Shields
- Syringe Shielding
- Syringe handling
- Syringe Carrier and transports
- Waste Containers
- Tongs for Vials

HTA Co., Ltd.

Beijing,
China

HTA Co., Ltd., a key radiopharmaceutical enterprise within CNNC's isotope and radiopharmaceutical business system and part of the CIRC business platform, which empowers global innovators with bespoke, full-lifecycle import solutions to expedite radiopharmaceutical commercialization and seamlessly integrate advanced therapies into China, is the largest radiopharmaceutical enterprise in China and one of the country's earliest pioneers in the development and industrialization of radiopharmaceuticals. With more than 60 years of dedicated experience in nuclear medicine, HTA has established a strong industry foundation covering radiopharmaceutical R&D, manufacturing, quality control, clinical application support, and market services. Supported by 6 R&D centers and 3 comprehensive production bases, HTA continues to strengthen its capabilities in innovation, industrial transformation, and large-scale supply of radiopharmaceutical products. As a leading force in China's nuclear medicine industry, HTA remains committed to advancing the application of medical radioisotopes and radiopharmaceuticals, and to delivering timely, reliable, and effective healthcare solutions for patients.

Huahe Pharmaceutical Co., Ltd.

No. 5 Factory Building, Phase I, Isotope Industrial Park, Haiyan County, Jiaxing City, Zhejiang Province
314300 Jiaxing, China

http://jxhhyy-001.jz.aitsite.cn

Huahe Pharmaceutical Co., Ltd. is a radiopharmaceutical CRO/CDMO specializing in radiolabeling development, GMP manufacturing, clinical supply, and commercial production support for targeted radiopharmaceuticals.
We provide end-to-end solutions covering radiochemistry development, process optimization, analytical testing, quality control, technology transfer, and regulatory support. Our GMP facilities and experienced team support programs utilizing a variety of therapeutic and diagnostic radionuclides, including Lu-177 and Ac-225.
Huahe works with biotechnology companies, pharmaceutical partners, isotope suppliers, and academic institutions worldwide to accelerate the development and commercialization of innovative radiopharmaceutical products.
We welcome opportunities for isotope supply partnerships, contract development and manufacturing, clinical supply support, and global technology collaboration.

I.M.A. Industria Macchine Automatiche S.p.A.

Via Emilia 428/442
40064 Ozzano dell'Emilia, Bologna , Italy

https://www.imagroup.com

Established in 1961, IMA S.p.A. is world leader in the development and production of automatic machines for the processing and packaging of pharmaceutical, cosmetic, food, tea and coffee products, as well as in the automation of industrial processes.
A leadership acquired thanks to significant investments in research and development, a constant and constructive dialogue with end-users of the reference sectors, to the capability of the Group to internationalise and conquer new markets. Its history is in fact characterised by constant growth, also thanks to the work of highly skilled people working within it, and to a certified, reliable supply chain.
IMA Life is the ideal partner for aseptic processing lines. The product range includes washers, depyrogenation tunnels, liquid and powder fillers, isolation systems, freeze dryers, automatic loaders/unloaders, labellers and track and trace solutions. Blowing machines, depackers, tray loaders and other ancillary equipment are also available.
IMA Life operates out of six production sites, each one specialised in a specific step of the process.
Producing more than 200 machines per year, most of which are integrated into complete processing lines and with over 1000 freeze dryers installed in over 50 different countries, IMA Life can manage large-scale projects, designing and manufacturing customised solutions to meet special end-user requirements.

IBA

Chemin du Cyclotron 3
1348 Louvain la Neuve, Belgium

https://www.iba-radiopharmasolutions.com

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals, and dosimetry. The company is based in Louvain-la-Neuve, Belgium and employs approximately 2000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBC Advanced Technologies, Inc./RadSep, Inc.

856 East Utah Valley Drive
84003 American Fork, United States of America

https://ibcmrt.com

IBC Advanced Technologies, Inc., through its subsidiary RadSep, Inc., provides state-of-the-art purification technology and novel chelators for medical radioisotopes and their precursors, including Ac-225, Ra-224, Ra-225, Ra-226, Ra-228, Th-228, Th-232, Pb-212, Cu-67 and more.
IBC offers proprietary Molecular Recognition Technology® (MRT™) resins featuring:
- Exceptional selectivity and high loading capacities
- First-pass recoveries and purities of 99.9+%
- High chemical and radiolytic stability, enabling multiple reuse cycles
- Simple, scalable processes with minimal manufacturing space and waste
- Maximum usable activity and reduced operating costs

MRT™ makes radioisotope production compatible with radiopharmaceutical manufacturing at scale.
As an award-winning manufacturer, IBC also offers highly selective chelators for a variety of alpha- and beta-emitting radioisotopes.
Learn more at ibcmrt.com and radsep.com

ICPO Foundation

Humboldstrasse 29
65189 Wiesbaden, Germany

https://www.icpo.foundation

The International Centers for Precision Oncology Foundation (ICPO) is a non-profit organization established in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. Recognizing a paradigm shift in cancer care from one size fits all to a personalized approach, the ICPO Foundation is helping to build momentum to scale global patient access to Radiomolecular Precision Oncology to support this shift.
Therefore, the ICPO Foundation aims to develop an international network of physical diagnostic and therapeutic Centers for Precision Oncology organized in a Social Franchise model based on shared know-how, certified education with the ICPO Academy for Theranostics, and design and process standardization that enables best clinical practice globally.
Furthermore, it is the ICPO Foundation's objective to empower its Centers by embedding them in a highly inclusive Community that spearheads its model and lives up to the Precision Oncology promise by making it available to all patients in need, irrespective of country or social status.

Virtual: November 14 & 15, 2024

Register for our ICPO THERANOSTICS VIRTUAL SUMMIT 2024

Join our world-class scientific program with 30+ invited experts from academia and industry in the field of theranostics in precision oncology. The first day will be dedicated to alpha therapies and the second day to new radiopharma-ceuticals, FAP and beyond. Our objective will be to sketch together the contours of a new era in cancer care, ultimately benefiting patients around the globe.
Please register here: www.icpovirtualsummit.com

Germany, Munich, May 15 & 16, 2025

ICPO FORUM 2025 in the Science Center in Garching by Munich

Imaging Endpoints

7150 East Camelback Road, Suite 120
85251 Scottsdale, United States of America

https://imagingendpoints.com

Imaging Endpoints (IE) is the largest oncology focused imaging CRO globally and is widely recognized for conducting the industry's largest, most complex, and most successful imaging trials for both solid and liquid tumor indications.

Institute of Isotopes Co. Ltd.

Konkoly-Thege Miklós u. 29-33.
1121 Budapest, Hungary

https://www.izotop.hu

Institute of Isotopes Co. Ltd. is on the frontline of radioisotope technology collaborating with long-term partners and customers. Over the years we have developed numerous products from diagnostic kits to radioactive sources for various radioactive applications. Our company provides varied and flexible services in this unique field. Our production complies with the highest quality standards: GMP, ISO9001, ISO13485, ISO14001 We are also engaged in product development projects and offer contract manufacturing, OEM services for our customers.

Izotop looking forward to new products to widen our portfolio.

Fields of expertise: Radiopharmaceuticals, radiochemicals, Immunoassay / In vitro products for human diagnosis and life science, Synthesis / Radiosynthesis, Radiation technique

Main products, services: Thyrotop I-131 sodium iodide hard capsules, I-131 sodium iodide sterile solution, I-131 MIBG injection for therapy and for diagnostic use, Radiochemicals /I-125, I-131/, Cold kits for Tc-99m-labelling: DMSA, DTPA, EC, FYTON, MDP, MIBITop, PYRON, , TECHIDA, , Sm-153-labelling MULTIBONE kit

Ready to take part in R&D and manufacturing of active pharmaceutical ingredients, cold kits as well as investigational products for clinical trials.

In Vitro diagnostics (RIA, IRMA), Research Immunoassay kits;

C-14 radiolabeled drug substances, GMP custom radiosynthesis;

Radiation technique solutions for medical, research and industrial applications, Multipurpose irradiators.

Inter Medical Medizintechnik GmbH

Daimlerstr. 34-36
32312 Lübbecke, Germany

http://www.intmed.de

The Inter Medical Medizintechnik GmbH Company is specialized in medicine software and hardware with the focal point in Nuclear Medicine technique.

Long time experience in product innovations, development and production of Nuclear systems makes Inter Medical to a competent partner for all technical requirements in the Nuclear Medicine and other medical departments.

Are you looking for a special camera or software for heart and brain examinations? With the MultiCam 3000 and our in-house software such as AutoCardio 4D, 3D rendering and the 3D neurological brain evaluation package, we offer what you are looking for.

Would you like to evaluate interdisciplinary data? With the Multimodality Fusion software, you can use data from different systems such as ultrasound, PET, MR. We offer the possibility of merging and evaluating data from different manufacturers.

Visit our booth to see how we can enhance your institute with our product portfolio of 1-2-3-n Head Gamma Cameras, partly with MDR Certification.

INVIA Medical Imaging Solutions

8192 Jackson Rd
48103 Ann Arbor, United States of America

http://www.inviasolutions.com

INVIA Medical Imaging Solutions is dedicated to advancing cardiac SPECT, PET and Hybrid-CT imaging through continuous research and innovation. We are the creators of 4DM, a comprehensive application for nuclear cardiac quantification, interpretation, and reporting.

4DM streamlines the entire nuclear cardiology workflow—all within a single, unified application.

Built on decades of peer-reviewed research and clinical validation, clinicians use our advanced imaging tools for perfusion, function, viability, and flow analysis. 4DM integrates seamlessly with leading imaging systems and supports all major tracers.

Originally developed at the University of Michigan, 4DM was designed with one goal: to improve patient care. Today, it's the application of choice for nuclear cardiac imaging for many major hospitals, academic medical centers, and cardiology practices worldwide.

Start a conversation about how we can support your nuclear cardiology needs at conferences@INVIAsolutions.com.

inviscan imaging systems

5 Rue Georges Guynemer
67120 Altorf (near Strasbourg), France

https://www.inviscan.fr

Inviscan imaging systems is a high technology company located in France. inviscan develops and manufactures preclinical imaging systems used in medical research. Products of inviscan include PET/CT and CT systems for imaging rodents and larger animals (NHP), as well as novel MRI compatible PET technology.Inviscan is the original manufacturer of IRIS PET/CT systems and is the leading provider of preclinical PET/CT systems in a number of countries such as France and China. The systems are fully developed by inviscan and manufactured in France. Inviscan is a highly innovative company with several R&D programs on new technologies and applications. Inviscan is partner in several projects with high profile institutions including CNRS, INSERM, Helmholtz Institute in Germany, as well as CNR and University of Pisa in Italy.

iPHASE Technologies

Unit 5/899 Wellington Rd
3178 Rowville, Australia

www.iphase.com.au

IPHASE technologies was created in 2003 and has grown into one of the world class leaders in manufacturing of high quality automated radiopharmaceutical equipment for radiolabelling of F-18, C-11, Ga-68, Lu-177, Zr-89, Cu64, I-124, PB-212 & Ac-225 compounds.
IPHASE also provide cutting edge solution for QC, Dispensing solutions and specialise in developing custom PET & Nuclear Medicine automation solutions.

IRE ELiT

Avenue de l'Espérance, 1
6220 Fleurus, Belgium

https://www.ire.eu/en

IRE ELiT is the innovation subsidiary of the Institute for Radioelements (IRE), dedicated to the development and commercialization of radiopharmaceutical solutions.
A key player in nuclear medicine, IRE ELiT is internationally recognized for its Ge-68/Ga-68 generator, an innovative and reliable solution that provides on-site access to gallium-68, a PET radioisotope widely used for the diagnosis and management of diseases such as neuroendocrine tumors (NETs) and prostate cancer.
Inspired by the proven principles of Tc-99m generators and approved worldwide, IRE ELiT's Ge-68/Ga-68 generator delivers a gallium chloride solution (Ga-68) suitable for radiolabeling a wide range of PET radiopharmaceutical kits.
Designed for both manual and automated workflows, the generator is fully compatible with commercially available synthesis modules, offering flexibility, efficiency, and seamless integration into nuclear medicine departments and radiopharmacies.
Through its commitment to innovation, quality, and patient care, IRE ELiT contributes to advancing precision diagnostics worldwide.

Isotopia Molecular Imaging

Alexander Yanai 39 Petach Tikva
4927735 Petach Tikva, Israel

https://isotopia-global.com

Isotopia is a global radiopharmaceutical company providing innovative diagnostic and therapeutic solutions for nuclear medicine and theranostics. With GMP manufacturing facilities in Israel and the United States, Isotopia supports healthcare providers, radiopharmacies, research institutions, and pharmaceutical partners worldwide.
Our Portfolio:
Lutetium-177 (n.c.a. & c.a.)
- GMP manufactured
- DMF support
- Commercial-scale production
- Dual-site manufacturing for supply security

Isoprotrace®
PSMA-11 radiolabelling kit for the preparation of Ga-68 Gozetotide for PET imaging in prostate cancer.
- Fast, simple preparation
- Multi-dose format
- Streamlined radiopharmacy workflow
- Commercially available in multiple European markets

GMP-Grade Terbium Chloride (Tb-161)
- GMP-grade production
- Long-term supply strategy
- Supporting clinical and translational research
- Partner in the VIOLET clinical trial

Why Meet Isotopia?
- Global GMP manufacturing capabilities
- Reliable supply and operational flexibility
- Expertise in diagnostics and therapeutics
- Support for clinical, research, and commercial programs
- Strong regulatory and quality foundation

Let's Connect at EANM - Whether you are seeking Lutetium-177, exploring Tb-161 opportunities, or interested in implementing Isoprotrace®, our team looks forward to discussing how Isotopia can support your nuclear medicine and theranostics programs.

ITEL Telecomunicazioni SRL

Via Antonio Labriola, snc
70037 Ruvo di Puglia, Italy

https://itelpharma.com

Itelpharma is a dynamic and trusted radiopharmaceutical company, part of the Italian healthcare group ITEL Telecomunicazioni srl. Established as a GMP-certified pharmaceutical facility and authorized by the Italian Medicines Agency (AIFA), Itelpharma specializes in the production of high-quality radiopharmaceuticals for diagnostic imaging in oncology, neurology, and cardiology. With two state-of-the-art production lines operating in parallel, we ensure continuous and efficient output to meet the growing demand in precision diagnostics. Our facility also includes two cyclotrons and a fully integrated in-house microbiological laboratory, both designed and implemented entirely by our expert team.

Recognized among the most reliable manufacturers and suppliers of radiopharmaceuticals, Itelpharma not only develops and markets its own products, but also partners with major pharmaceutical companies as a contract manufacturer and distributor.

Over more than a decade of experience, we have steadily expanded our capabilities in manufacturing, research, and product development, refining our expertise across the scientific, regulatory, technical, and commercial domains.

Driven by a commitment to quality and innovation, we operate in full compliance with the highest standards, continuously expanding our pipeline of molecular products and tailored services to support the evolving needs of modern healthcare.

ITM Isotope Technologies Munich SE

Walther von Dyck Strasse 4
85748 Garching, Germany

https://www.itm-radiopharma.com/home

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.

Jiangsu Huayi Technology Co., Ltd.

18 Fuyu Road, Haiyu Town
215522 Changshu City, China

http://www.huayitec.net

Jiangsu Huayi Radiopharmaceuticals Co., Ltd. is a fully integrated provider of radiopharmaceuticals in China. We develop, manufacture, and distribute high-quality radiopharmaceutical products. CDMO services are offered to our global clients. We support projects from initial research phase to commercial production.One of the divisions, Huayi Isotopes Co. (HIC), manufactures and distributes stable isotopes, PET and SPECT precursors, reagents kits, cassettes, and sterile vials etc. Products of HIC are supplied to clients around the world. We are client-oriented and determined to build and foster long-term partnerships with our clients. Since the company was established in 2001, we have been dedicated to serving the nuclear medicine industry. Since 2014, we have been setting up nuclear medicine manufacturing sites strategically. Our integrated radiopharmaceutical manufacturing and distribution network will enable us to reach most of the patients in China. Follow us on LinkedIn, Twitter, Facebook, for the latest news.

Products and Services:

- Radiopharmaceuticals
- CDMO Services for Radiopharmaceuticals
- O-18 Water
- Total Solutions for PET Consumables
- Biochemicals
- Sterile Vials
- CMO Services (API, Reagents Kit & Cassettes, FIll/ Finish)

Jubilant Radiopharma

790 Township Line Rd, Suite 325
19067 Yardley, United States of America

http://www.jubilantradiopharma.com

Jubilant Radiopharma is a global leader in radiopharmaceuticals, committed to delivering better clinical outcomes through strategic investment in our pipeline, infrastructure, and people. Our team is united by an uncompromising passion for advancing the utility and sustainability of nuclear medicine.

With a mission to "Improve Lives through Nuclear Medicine," we focus on developing, manufacturing, commercializing, and distributing high-quality, sustainable diagnostic and therapeutic agents worldwide. We also recognize the critical and evolving role of Cardiac PET in diagnosing and managing patients with known or suspected coronary artery disease. Through our global partnerships, we're bringing innovative cardiac PET solutions to practices around the world.

Visit Jubilant Radiopharma at Booth #402 during this year's EANM Congress. Explore the latest advancements in Cardiac PET imaging and learn how our innovative solutions can help enhance patient care and support the growth of your cardiac imaging practice.

For more information, please contact our customer service team at customerservice@jdi.jubl.com

Kev Medical Imaging

Sokratous 3
11147 Galatsi, Greece

http://www.kevimaging.gr

KeV Medical Imaging is the proud manufacturer of QDOSE, an advanced dosimetry software designed for radiopharmaceutical dose management in nuclear medicine. With MDR approval, QDOSE ensures compliance with stringent regulatory standards while empowering healthcare providers worldwide, wherever MDR is required, reliable tools to optimize patient diagnostics and therapeutic outcomes.
Primarily based in Greece, KeV Medical Imaging offers comprehensive sales, service, and support for nuclear medicine systems, including planning, system sales, technical support, and upgrades for near-zero downtime and optimal performance. Our 24/7 service model reflects our commitment to excellence, ensuring our clients' success by delivering tailored solutions to nuclear medicine departments in Greece and beyond the region.

LabLogic Systems Limited

Innovation House, 6 Europa View
S9 1XH Sheffield, United Kingdom

https://www.lablogic.com

LabLogic has over 40 years' experience of designing and manufacturing instruments and software for PET and Nuclear Medicine applications. At EANM'25 we will be showcasing our range of market leading products for Radiopharmacy QC, including r-TLC and r-HPLC instruments, plus our single point of control radiochromatography software package – Laura Radiopharma. Furthermore we offer dedicated LIMS systems for PET and Nuclear medicine applications. PETra, a PET LIMS system designed to improve efficiency and compliance, SPECTra, a dedicated Radiopharmacy LIMS, and Orla, an online radiopharmaceutical order communication system. Visit our stand #64 at the show to see demonstrations of these and other products in our nuclear medicine range.

Lantheus

Innovation House, 6 Europa View
S9 1XH Sheffield, United Kingdom

https://www.lantheus.com

LabLogic has over 40 years' experience of designing and manufacturing instruments and software for PET and Nuclear Medicine applications.
At EANM'26 we will be showcasing our range of market leading products for Radiopharmacy QC, including r-TLC and r-HPLC instruments, plus our single point of control radiochromatography software package – Laura Radiopharma.
Furthermore we offer dedicated LIMS systems for PET and Nuclear medicine applications. PETra, a PET LIMS system designed to improve efficiency and compliance, SPECTra, a dedicated Radiopharmacy LIMS, and Orla, an online radiopharmaceutical order communication system.
Visit our stand #262 at the show to see demonstrations of these and other products in our nuclear medicine range.

Lemer Pax

14 avenue Syrma
44470 Carquefou, France

https://www.lemerpax.com/en

A pioneer in radiation protection calculations and the historic manufacturer of the first shielded hot cells for radioisotope production in France in the 1950s, the Lemer Group has continuously expanded this expertise.
With more than 70 years of experience, Lemer Pax offers state-of-the-art solutions, including shielded hot cell production lines for radioisotopes, automated systems for radiopharmaceutical dose preparation and injection, transport containers, and radioactive effluent management systems.
Committed to continuous technological innovation, the company actively contributes to the advancement of practices in Nuclear Medicine.
Come visit us at booth 508

Life Couriers

Alois-Wolfmüller-Straße 8
80939 Munich, Germany

https://lifecouriers.com

Life-saving therapies. Critical diagnostics. Breakthrough clinical trials. Life Couriers places hope in the hands of patients everywhere by being the world's most trusted logistics partner for crucial pharmaceutical and medical products.
The worldwide market leader for radiopharmaceutical and stem cell logistics. We understand a fundamental reality - that missing a delivery can mean losing a life.
Biopharmaceuticals, cell and gene therapies, lab specimens, clinical trials, organ transplant, medical devices and more. We are Life Couriers - Logistics for Life.

Longevous Beamtech Co.Ltd

No.120 Wen Wu Road, Economic Development Zone
621000 Mianyang, China

https://www.long-beam.com

Founded in February 2017, Longevous Beamtech Co.,Ltd (LBT) is China's leading company in the research and development of medical cyclotrons. It provides comprehensive nuclear medicine solutions that include multi-energy level medical cyclotrons ranging from 7MeV to 100 MeV, target irradiation systems, after-processing chemical systems, and full-chain positron drug preparation centers.
We focus on the development of high-end nuclear medicine equipment. LBT has passed CE, ISO13485, ISO9001 certifications, with cyclotron performance indicators reaching internationally advanced levels. Longevous Beamtech provides reliable, flexible, and high-ROI cyclotron products and services to clients globally, including Europe, Southeast Asia, Africa, Latin America etc., covering more than 40 countries worldwide.
Driven by technological innovation, Longevous Beamtech has won more than 20 awards and honors at national levels. Our technical team consists of top-tier experts specializing in nuclear technology, nuclear medicine, and radiochemistry etc.
Currently, the company is actively pursuing various medical isotope technology innovations based on cyclotron production, aiming to achieve large-scale production of isotopes such as 177Lutetium, 211Astatine, and 68Germanium etc.
We will continue to focus on the high-end nuclear medical equipment sector, striving to become a world-class company in the research and manufacturing of nuclear medical equipment.

LYLA B.V.

Molengraaffsingel 12
2629 JD Delft, Netherlands

https://www.lyla.systems

Quality control in Targeted Radionuclide Therapy (TRT) lacks critical and time-constrained insights, risking treatment outcomes. LYLA solves this incomplete quality control with a novel measurement method! This approach provides an extra layer of information to ensure cancer therapies are safer and more effective.
The result: fast, efficient, and user-friendly quality control that integrates seamlessly into routine TRT workflows.
Care about quality in your process? Visit our booth and get in touch!!

Macrocyclics, Inc.

700 Klein Rd.
75074 Plano, United States of America

http://www.macrocyclics.com

Macrocyclics, Inc., founded in 1995 and headquartered in Plano, Texas, is a CDMO specializing in chelating agents for radiopharmaceuticals and nuclear medicine. A subsidiary of Orano Med, the company provides custom synthesis, kilo-scale manufacturing, and bioconjugation services to accelerate early-stage pharmaceutical development. Macrocyclics also offers CMC analytical services, maintains a GMP compliant Quality System, and stocks a catalog of over 90 products available online. With a dedicated team of project managers, the company ensures end-to-end project support while delivering innovative solutions to overcome complex challenges.!

Medhub Arge Sağlık Hizmetleri Sanayi ve Ticaret AŞ

Kerem
34908 Istanbul, Türkiye

https://www.medhubarge.com

A start-up company established in December 2022 and started its activities about radiopharmaceutical/ nuclear medicine field in University of Health Sciences Teknopol İstanbul Campus İstanbul/TURKEY. We are API manufacturer and particularly produce GMP grade radiopharmaceutical peptides such as psma, dotatate and reagent sets for 68Ga, 177Lu and 225Ac. Gmp compliant sterile cold kits for 68Ga, 177lu and 99Tc are also produced at aceptic conditions.

Medicines Discovery Catapult

Block 35, Mereside, Alderley Park, Alderley Edge
SK10 4ZF Macclesfield, United Kingdom

https://md.catapult.org.uk

Medicines Discovery Catapult (MDC) is a Life Sciences service dedicated to turning drug discovery into commercial breakthroughs.
At the frontier of drug discovery, MDC works with entrepreneurial[SP1.1] scientists to make every move count. It validates their ideas, de-risks investments, and feeds insights back into the sector to drive productivity and impact.
MDC creates momentum through its unique blend of discovery expertise, technology, insights, and sector-leading partnerships. Where there is unmet patient need, MDC stimulates innovation through its National Programmes.
MDC has worked with over 397 organisations, who have gone on to raise more than £1.9bn of R&D investment.
Its approach to drug discovery drives game-changing breakthroughs and improves patients' lives.
More information:

- Part of the Innovate UK Catapult Network
- Based in Alderley Park, Cheshire

Connect with us on LinkedIn:
https://www.linkedin.com/company/meddisccat
For more information, visit:
https://md.catapult.org.uk

Medi-Radiopharma Ltd.

Szamos u. 10-12.
2030 Érd, Hungary

https://www.mediradiopharma.com

Medi-Radiopharma (MRP) has more than 25 years of experience in developing, manufacturing, and supplying radiopharmaceutical products to customers around the globe. Our purpose is to serve the healthcare and improve patient outcomes through a wide portfolio of high-quality products. MRP specializes in the production and supply of generic in-vivo kits for Tc99m labelling used in nuclear medicine. By potentially enabling accurate early diagnosis and treatment of cancer, as well as heart, brain and bone diseases, our world-class products – registered in more than 80 countries worldwide - empower our customers with effective treatment and proven patient outcomes. We are also involved in the development of therapeutic radiopharmaceuticals. MRP holds valid Manufacturer's Authorization, Certificate of GMP Compliance of a Manufacturer, Wholesale Distribution Authorization, Certificate of GDP Compliance of a Wholesaler Distributor, GLP and ISO Certificate and relevant authorization for the manufacture and wholesale distribution of radiopharmaceuticals.

Mediso Medical Imaging Systems

Laborc u. 3.
1037 Budapest, Hungary

https://www.mediso.com

Mediso has been active in the field of Nuclear Medicine and Molecular Imaging for more than 35 years with a profile of development, manufacturing, selling and servicing standalone and multi-modality imaging systems. Our company offers complete solutions for both clinical patient care and preclinical research from hardware design to evaluation and quantification software. With more than 1500 clinical and 400 preclinical systems installed in over 100 countries worldwide, Mediso is the only company offering molecular imaging systems for both clinical patient care and scientific research.
Our clinical product portfolio ranges from gamma cameras developed for routine examinations, to three-detector SPECT/CT systems suitable for performing theranostic examinations at the highest level, to complex hybrid devices that uniquely integrate three modalities (SPECT/CT/PET). The latest member of the AnyScan TRIO family, the TheraMAX SPECT/CT features extreme sensitivity with uncompromised PET-like image quality ensuring ultra-fast, quantitative, Total-Body scans for theranostic and diagnostic applications even at high energies.
Our innovative preclinical products serve the highest level of molecular imaging needs. In addition to the market-leading nanoScan PET/CT and SPECT/CT, Mediso also offers standalone MRI and integrated PET/MRI systems based on a cryogen-free magnet with 3T or 7T field strength and a PET insert for simultaneous PET/MRI imaging.

MEDraysintell

76 route de la Demi-lune, Les Collines de l'Arche,
Bâtiment OPERA E
92057 Paris - La Défense, France

https://www.medraysintell.com

MEDraysintell is a team of international experts, created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann, providing first-rate strategic intelligence in nuclear medicine, radiopharmaceutical, cyclotron, proton therapy and brachytherapy. We offer the most comprehensive set of reports and directories, with over 4,900 pages of unrivalled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment.

We offer client-specific intelligence in the field of radiation healthcare, with the utmost knowledge leveraging our extended network of worldwide contacts.

We are proud to support numerous companies globally, helping them better understand the markets, the competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeatedly satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and university research laboratories.

In 2024, MEDraysintell was integrated into NucAdvisor, which is a nuclear consulting company, a subsidiary of Soletanche Freyssinet (VINCI Group), established in France by a group of senior executives from across the nuclear research and industry. Following this acquisition, MEDraysintell has become the nuclear medicine brand of NucAdvisor.

MedTrace Pharma A/S

Agern Allé 5A
2970 Hørsholm, Denmark

https://www.medtracepharma.com

Striving to Make O-15 Water PET practically available - MedTrace Pharma is a development stage radiopharmaceutical and device company with headquarter in Hoersholm, Denmark. We are committed to transforming cardiac diagnostics by making oxygen-15 water (O-15 H_2O) readily available for routine use in PET imaging.

Our O-15 water and automated manufacturing technology is being investigated under a FDA approved Phase 3 clinical trial: the RAPID-WATER-FLOW study (NCT05134012), a multicenter, open-label investigation assessing the diagnostic potential of intravenously administered [15-O]-H_2O for identifying coronary artery disease during pharmacological stress and rest using PET imaging. The study is conducted under FDA IND #135360.

We welcome collaboration and research inquiries, particularly from those exploring novel applications of O-15 water in diagnostic imaging. For more information, please contact our Chief Medical Officer, Dr. Nicholas Borys, at nicholas@medtracepharma.com.

Brands:

MedTrace Pharma, [15-O]-H2O injection, O-15 Water, O-15 H2O for diagnostic PET imaging, [O-15]-Water PET Myocardial Perfusion Imaging (MPI), novel PET imaging agent labeled with the radioisotope [15-O], aQuant quantitative imaging software, P3 System (MT-100).

MIAS Pharma

Suite 1, Stafford House, Strand Road,
Portmarnock
D13 WC83 Dublin, Ireland

https://www.miaspharma.com

MIAS Pharma Ltd was set up in 2016 to enable pharma and bio-pharma companies to manufacture and import products into the EU / EEA in a compliant manner, at optimal cost, with no significant investment in licence application activities or office / personnel costs.

The company focuses on helping small to medium pharma and bio-pharma companies that look to enter the EU market but do not have required Manufacturing and Importation licence or the quality/regulator expertise to comply with complex EU / UK regulations. It also supports CMOs, CROs, Packaging companies and Testing companies with QP solutions to take the burden off internal resources.

MIAS Pharma delivers two main solutions:

1. A licensing framework to enable pharmaceutical importation and batch certification (required before each batch of a medicine can be made available in the EU/EEA marketplace)
2. Qualified Person (QP) services to oversee the release of investigational medicinal product for Clinical Trials and commercial product to the market.

MIAS Pharma also provides the following services to help pharma companies grow their business:

- European Qualified Person (QP) services
- Regulatory compliance of manufacturing activities
- Regulatory compliance of Repackaging / Relabelling services
- Regulatory compliance of Shipment and Transportation activities
- Compliance with responsibilities as a Market Authorisation Holder (MAH)

MIAS operates in a hub and spoke model with a core group of MIAS employee being able to rely on a group of associated to flex up/down capacity depending on clients requirements.

MiE medical imaging electronics GmbH

Hauptstrasse 112
23845 Seth, Germany

https://www.mie-scintron.com

MiE has been a trusted name in the market since 1981, with over 40 years of experience as a leading service provider and partner in the field of nuclear medicine. Based in Germany, we are an established manufacturer of gamma cameras and workstations, offering a comprehensive product portfolio that meets the diverse needs of our customers.

In addition to our hardware, we also develop our own software solutions which are continuously updated to incorporate the latest advancements and ensure optimal performance for our clients.

Our dense service network and long-standing partnerships highlight our commitment to quality and reliability, resulting in strong customer acceptance worldwide.

In 2023, we expanded our solutions by partnering with United Imaging to offer digital PET/CT systems in the D-A-CH region, further reinforcing our position as a key player in the imaging industry.

With extensive expertise in nuclear medicine and a proven track record, MiE remains dedicated to delivering exceptional service and cutting-edge technology to healthcare professionals around the globe.

MILabs

Duwboot 7A
3991CD Houten, Netherlands

https://www.milabs.com

Clarity that advances discovery.
MILabs empowers the nuclear medicine and molecular imaging community with high-resolution preclinical SPECT, PET and CT solutions that transform complex biological processes into quantitative, reproducible evidence.
Built on decades of scientific innovation, MILabs enables researchers to visualize subtle biological changes, accurately quantify tracer distribution, and generate data that translates with confidence from discovery to clinical application. Flexible multimodality configurations, scalable upgrade paths, and integrated workflows support every stage of radiopharmaceutical development, from early target validation to therapy assessment.
At EANM, where innovation in molecular imaging and theranostics drives the future of patient care, MILabs is proud to partner with researchers developing the next generation of precision diagnostics and targeted therapies.

Mindview

Calle Jerónimo de Monsoriu, 92 bajo izq
46022 Valencia, Spain

https://www.mindviewpet.com

MINDVIEW is the new business unit of Oncovision for personalized molecular brain imaging and care. Its first product, CAREMIBRAIN, ULTRA-HIGH RESOLUTION dedicated brain PET, perfected since 2017, has proven clinical outcomes in >600 PATIENTS at leading hospitals in Spain, Germany and the United States, and FDA APPROVAL (since 2023).
ADVANCED, ACCESSIBLE and AFFORDABLE, Caremibrain is combining ultra-high resolution 1,5 mm, 10% sensitivity, powerful quantification / dynamic capabilities, award-winning patient experience, vastly reduced radiotracer dose and very short study time.
Compact, light, energy-efficient, CMB is enabling access to the BEST brain PET that every person deserves, with unequalled productivity, ease of use, seamless multimodal integration, minimum initial / ongoing costs and turnkey options. Unprecedented screening, clinical diagnosis, therapy guidance, treatment results assessment, advanced neurological research and synergy imaging / tracer / therapy opportunities for EVERYONE, EVERYWHERE.

Minerva Imaging

Lyshøjvej 21
3650 Ølstykke, Denmark

http://www.minervaimaging.com

Minerva Imaging is an integrated CRO and CDMO specialised in targeted radionuclide therapies. The company focusses on the use of advanced models within oncology, cardiovascular diseases and in vivo molecular imaging for translational research and drug development. Minerva Imaging engages with its clients to understand their scientific questions and discuss how its methods and capabilities can provide answers. The facility located in Denmark offers best–in–industry fully integrated radiopharmaceutical research, drug development and manufacturing services.
Follow us on LinkedIn for the latest news updates or visit minervaimaging.com for more information.

Mirion Medical

7 Vreeland Rd
7932 Florham Park, United States of America

https://www.mirion.com/products/medical

From diagnosis through treatment, we enhance the delivery and ensure the safety of healthcare. With practitioners and patients as our inspiration, we create advanced technology that improves lives, and for radiopharmaceutical owners and manufacturers, that means solutions built to protect product integrity, staff, and patients at every step of the radiopharmacy workflow. Our innovations power the fields of Medical Imaging, Radiation Therapy, Nuclear Medicine, Radiopharmaceuticals and Occupational Dosimetry, with deep expertise in dose calibration, radiation safety, and quality control for radiopharmaceutical production and distribution. Our solutions are trusted globally by drug owners, providers, and industry leaders, enabling smarter workflows, reduced risk, and harnessed opportunity. Visit Capintec and ec² Software in Mirion Medical booth 410.

MNT Healthcare Services Inc.

19 Mayıs Mah. Dr.Şevkey Bey Sk. No:5 Şişli
34360 Istanbul, Türkiye

http://www.mnt.com.tr

Since 1990, MNT has been providing professional nuclear medicine and radiation oncology solutions to healthcare organizations. Currently, MNT operates 63 centers in Turkey and 9 centers in Europe, offering specialized diagnostic and therapeutic services throughout all stages of nuclear medicine and radiation oncology.With a dynamic and innovative approach, MNT is recognized as one of the most experienced healthcare service providers in the field. Its services reach patients in numerous NM and RT Centers within universities, state hospitals, and private hospitals. MNT also directly caters to cancer patients through its own branded centers, Neolife.Neolife is rapidly expanding its global presence and establishing itself as a formidable international brand. MNT operates 6 Neolife centers in Romania, 1 center in Moldova, and 2 centers in Bulgaria. Additionally, MNT is actively pursuing further projects in Africa, the Balkans, the Middle East, and Central Asia.MNT adheres to the gold standards in medicine and leads in theragnostic applications. By utilizing cutting-edge technology, such as advanced imaging, molecular probes, and minimal radiation doses, MNT enables precise diagnosis and targeted therapies across its centers.

MNT ensures the smooth and timely completion of turn-key projects by offering the following services:

- Project Design and Installation
- Equipment Investment and Maintenance
- Personnel Recruitment
- Radiation Safety and Training
- Project Management

MODELLO ARCHITECTES

MODELLO is an architecture firm, based in Belgium, bringing together 15 architects, with offices in Charleroi and Huy. Depending on the project, MODELLO partners with structural and special techniques design offices. Drawing on its proven expertise in these fields, MODELLO focuses on hospital, nuclear, and pharmaceutical infrastructure projects.

From the initial sketch to final project handover, MODELLO manages every stage of the construction project. This includes permit applications, submission plans to construction companies, bid analysis and site supervision.

At the client's request, a 'design and build' approach can also be considered, in collaboration with a construction company.

MODELLO, which has been active in Wallonia for over 15 years, connects public and private partners from the very first stages of a project. This process includes plot search, analysis of the project's administrative and legal framework, program development and initial sketches, as well as cost and scheduling analysis..

MR Solutions Ltd.

Ashbourne House Old Portsmouth Road
GU3 1LR Guildford, United Kingdom

http://www.mrsolutions.com

MR SOLUTIONS GROUP is a global leader in advanced imaging solutions, offering a comprehensive range of MR, CT, PET, and SPECT products. All scanners are modular, allowing seamless integration for multi-modality imaging.

The company leads in high-field, cryogen-free MR technology, powered by its proprietary dry magnet systems. The MRS*DRYMAG line provides MR up to 9.4T with a bore size up to 42 cm. Unique features include variable, rampable field and a rotating capability. The dry magnet technology eliminates the need for helium lines or shielded rooms, minimizing installation costs.

MR SOLUTIONS' imaging solutions support up to 9.4T simultaneous PET/MR imaging. SPECT can be combined with PET/MR to create a tri-modality scanner for advanced theranostic applications. With our CLIP-ON technology, PET and SPECT scanners can be easily removed from MR systems and reattached to CT systems, conserving space and reducing the need for multiple scanners. Models are available in benchtop, high-resolution, and large-bore sizes for up to 12 kg animals.

Additionally, MR SOLUTIONS can refurbish and upgrade components on any MR system.

The company has received numerous awards, including the prestigious Queen's Awards, the Institute of Physics Innovation Award, and the global R&D 100 Award. MR SOLUTIONS has a worldwide presence with offices and support staff to serve its customers globally.

Nancyclotep

Hôpital de Brabois, 5 rue du Morvan
54500 Vandoeuvre lès Nancy, France

https://www.nancyclotep.com

In Nancy (France), Nancyclotep, Posifit, and Protherium form an ecosystem dedicated to nuclear medicine, from translational research to the production of radiopharmaceuticals and their clinical use.

Created in 2007, Nancyclotep is an economic interest group bringing together the Nancy University Hospital (CHRU de Nancy), the University of Lorraine, and Posifit. Its mission is to promote the transfer of approaches in molecular imaging and theranostics. Its work covers radiochemistry, preclinical and clinical research, as well as the treatment, quantification, and analysis of medical images.

Posifit, a pharmaceutical company, handles the development and production of radiopharmaceuticals for research and clinical applications. Its expertise includes pharmaceutical development, GMP production, and regulatory affairs, from the lab to use in humans.

Protherium represents the industrial scale-up of the Nancy nuclear medicine ecosystem. It is a contract manufacturing organization which develops very large production capacities in Europe to meet the increasing demand for late-stage development and commercial production. It supports pharma companies in setting up production and supply chain, and accessing the European market, including regulatory aspects and logistics. Protherium is creating a network of European industrial centers covering the full value chain.

Their complementarity allows coverage of the entire development path in nuclear medicine, from proof of concept to industrialization, making it easier to access new diagnostic and therapeutic solutions.

Neusoft Medical Systems Co., Ltd.

No. 177-1 Chuangxin Road, Hunnan District
110167 Shenyang, China

https://www.neusoftmedical.com/en

Neusoft Medical Systems, founded in 1998 and headquartered in Shenyang, is a global leader in advancing healthcare through the deep integration of digital intelligence and medical imaging. The company delivers comprehensive diagnostic and therapy solutions, including CT, MRI, DSA, PET/CT, RT, GXR, US and MDaaS (Medical Devices & Data as a Service) imaging platform.

Focusing on breakthroughs in core technologies, Neusoft Medical has strengthened its presence in the high-end segment with globally advanced products such as the world's first wide-coverage photon-counting CT and the world's first 1024-slice ultra-high-definition CT, earning trust for their superior performance and clinical value.

The company has also developed the NeuAI imaging platform. Built on a large-model engine and enriched with clinical knowledge, NeuAI enhances the entire care pathway to deliver greater value from intelligent imaging.

With 16 subsidiaries worldwide, Neusoft Medical serves over 16,000 customers across more than 130 countries and regions, with a historical installed base exceeding 53,000 systems, supporting the advancement of accessible, high-quality healthcare globally.

Niowave, Inc.

1012 N Walnut St
48906 Lansing , United States of America

https://niowaveinc.com

Founded in 2005, Niowave, Inc. is a global leader in developing and operating superconducting electron linear accelerators and advancing radiochemistry procedures for medical isotope production. Headquartered in Lansing, Michigan, the company produces Actinium-225 and other isotopes to support the next generation of cancer treatments, with a mission to accelerate the fight against cancer through reliable, scalable supply.

Nippon Sanso Corporation

Minato Mirai Grand Central Tower 7F 4-6-2 Minatomirai, Nishi-ku 2208561 Yokohama, Japan

https://stableisotope.jp.nipponsanso.com/english/index.html

NIPPON SANSO, established in 1910, is a leading global industrial gas manufacturer. We developed the most energy efficient Oxygen-18O separation process utilizing our cryogenic air separation and ultra-clean technology. Since 2004, we have been supplying Water-18O to the world PET market. To meet the growing demand we completed our 3 plants with capacity of 600kg/year in 2015 by using state-of-the art separation technology. The largest capacity of 600kg/year with these three independent plants and GMP capability enable us to secure the stable supply of the highest and consistent quality of Water-18O, continuing to contribute to the advancement of the PET industry.

Effective April 2026, TAIYO NIPPON SANSO changed its company name to "NIPPON SANSO".

Norroy Bioscience Co., Ltd.

No. 35-208, Changjiang South Road,
Xinwu District,
Wuxi City (Research and Production Center)
214100 Wuxi City, Jiangsu Province, China

https://www.norroybiopharm.com

NORROY is a clinical phase III stage company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals, as well as automated synthesizers and functional modules for radiopharmaceutical production in both R&D and GMP environments.

NORROY has developed over 20 pipeline programs in solid tumors, including urologic cancers, gastrointestinal & pancreatic cancers, lung cancers, etc. NORROY has received 5 IND clearances from the U.S. Food and Drug Administration (FDA) and 5 IND approvals from the National Medical Products Administration (NMPA).

NorthStar

1800 Gateway Blvd.
53511 Beloit, WI, United States of America

https://www.northstarnm.com

NorthStar is a commercial-stage radiopharmaceutical company at the forefront of advancing patient care by utilizing novel technologies to produce commercial-scale radioisotopes that, once attached to a molecule, have the ability to detect and treat cancer and other serious diseases. NorthStar's expanding industry-leading position in the emerging field of radiopharmaceutical therapy is supported by its unique capabilities in the sophisticated production of radioisotopes, proven management team, and state-of-the-art, environmentally preferable technologies. NorthStar produces copper-67 (Cu-67) and is the first commercial-scale producer of no-carrier added actinium-225 (n.c.a. Ac-225) using electron-accelerator technology. The company's Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs.
For more information about NorthStar's comprehensive portfolio and patient-focused services, visit: www.northstarnm.com

Novartis Pharma AG

Forum 1, Novartis Campus
CH-4056 Basel, Switzerland

https://www.novartis.com

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease.
Our medicines reach nearly 300 million people worldwide.
.

NRG PALLAS | Nuclear. For Life.

Westerduinweg 3
1755 LE Petten, Netherlands

https://www.nrgpallas.com/medical-isotope-solutions

BOOMING NUCLEAR MEDICINE MARKET
The field of nuclear medicine is undergoing a revolution. With promising treatments emerging for a wide range of indications, and a robust clinical pipeline filled with new therapies, the market is attracting increasing interest from big pharma. Startups and academic spin-outs are driving innovation, offering fertile ground for partnerships and growth. At first glance, the opportunities seem boundless.
COMPLEX IN PRACTISE
But entering and scaling up in this market is far from straightforward. Behind the scenes, companies face a complex reality. We hear it almost daily: despite the promise, many players struggle to meet their timelines. Operational hurdles mount. Growth slows.
To succeed, companies must navigate a maze of challenges:

- Scaling up production while managing radioactive waste
- Securing critical target materials, often through recycling
- Building resilient supply chains with multi-sourcing strategies
- Operating and maintaining a global fleet of specialised containers for radioactive shipments
- Managing radiation safety and licensing

These are not minor obstacles — they are make-or-break factors. Even established global players have recently exited the market, unable to overcome the operational and logistical demands. The promise of nuclear medicine is real, but so are the risks.

Nuclear Medicine Europe

Avenue Louise 65
1050 Brussels, Belgium

https://www.nuclearmedicineeurope.eu

Nuclear Medicine Europe (ex AIPES) represents many of the major pharmaceutical & Imaging equipment companies in the field of Nuclear Medicine in Europe. The combination of radiopharmaceuticals & state-of-the-art imaging permits noninvasive visualization of organs, function & structure within the body. Nuclear medicine is used in the diagnosis, management, treatment & prognosis of diseases across a broad range of medical specialties, such as oncology, cardiovascular & neurology to name a few, and as such is an integral part of patient care.

Nuclear Shields B.V.

Akkervoortweg 29
5827 AP Vortum-Mullem, Netherlands

http://www.nuclear-shields.com

Nuclear Shields B.V. designs and manufactures radiation shielding solutions for the nuclear medicine, radiopharmaceutical, research, industrial and nuclear sectors. From our headquarters and production facility in the Netherlands, we supply customers worldwide through a network of distributors and direct partnerships.

Our portfolio includes both standard products and fully customized shielding solutions. Standard products include syringe shields, vial shields, L-blocks, waste containers, storage cabinets, transport containers and hot cell accessories. In addition, we develop customer-specific shielding equipment tailored to unique applications, workflows and facility requirements. Our engineering team works closely with customers to translate technical requirements into practical, manufacturable solutions.

We also manufacture Type A transport packaging for the safe transport of radioactive materials. These packaging solutions are developed and tested in accordance with applicable transport regulations and can be adapted to customer-specific contents and operational needs.

All products are designed with a strong focus on radiation protection, usability, quality and long service life. By combining in-house engineering, manufacturing and assembly, we maintain full control over the development and production process, enabling us to deliver reliable solutions for both standard applications and complex custom projects.

Nuclivision NV

Edward Pynaertkaai
87 9000 Ghent, Belgium

https://www.nuclivision.com

Nuclivision is a Belgium-based medtech company transforming nuclear medicine through AI. Founded in Ghent in 2022, the company develops intelligent software solutions that enhance nuclear imaging, making it faster, safer, and more accessible. Its CE-certified software as a medical device, NUCLARITY, reduces the need for radioactive tracers and shortens PET scan times without compromising lesion detectability, addressing key cost, safety, and environmental challenges in nuclear medicine.

Driven by a mission to improve the quality, safety, and accessibility of nuclear imaging, Nuclivision helps patients gain faster access to accurate diagnoses and appropriate treatments. By reducing radiation exposure, costs, and logistical barriers, the company also contributes to a more sustainable healthcare system through more efficient use of radiopharmaceuticals.

The founders' team of Nuclivision is advised by professor-clinicians and seasoned entrepreneurs with deep expertise in AI and nuclear medicine. With a focus on oncology, neurology, and theranostics, the company will expand internationally across Europe and the U.S., enabling earlier, safer detection, interpretation, and prediction of diseases such as cancer and Alzheimer's.

NUVIA Instruments GmbH

Dornblüthstrasse 14 A
01277 Dresden, Germany

https://www.nuviatech-healthcare.com

NUVIA Instruments GmbH, formerly known as MED Nuklear-Medizintechnik Dresden GmbH is a member of the NUVIA Group since 2014. With 2 sites in Dresden and Dülmen, NUVIA Instruments GmbH designs and manufactures laboratory counters and radiation monitoring systems for nuclear medicine, PET-centres and therapy stations, including:

- Dose Calibrators, Well-Counters
- Thyroid Uptake-Counters, Incorporation Counters,
- Waste Water Counters (single and inline)
- Patient and Area Monitoring Systems
- Contamination Monitors (portable and hand-foot)
- Waste and Release Monitors
- Laboratory Furniture (standard and customized)
- Service, maintenance and training

About the NUVIA Group:
NUVIA is the nuclear branch of Soletanche Freyssinet, a subsidiary of Vinci Construction Group. Even though the NUVIA name was created in 2007, its history goes back to the beginning of the French and British nuclear industry. Today, with more than 30 years of experience and approx. 3,000 employees worldwide, the NUVIA Group offers engineering, services and products at all stages of a nuclear facility's lifecycle: design, construction, operations, maintenance, decommissioning. The NUVIATECH HEALTHCARE brand was created in 2017 to offer the Group's complete portfolio of instruments, systems and solutions for healthcare applications.
For more information about the NUVIA Group and its activities in the healthcare sector, please visit: www.nuviatech-healthcare.com.

OmniAb Inc.

5980 Horton St. Ste. 600
94608 Emeryville, United States of America

https://www.omniab.com

OmniAb licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners' drug development efforts.tment overall costs in low-income countries. Come and meet us !

OncoBeta GmbH

Schleißheimer Str. 91
85748 Garching bei München, Germany

https://www.oncobeta.com

OncoBeta® is a global medical technology company dedicated to improving care for patients with non-melanoma skin cancer. The company develops and commercializes Rhenium-SCT®, a lesion-directed radioisotope therapy designed to deliver targeted treatment directly to the skin.
Working closely with clinicians, researchers, and healthcare partners, OncoBeta® is committed to advancing clinical evidence and expanding access to innovative treatment options in skin cancer care.

ONCODESIGN SERVICES

20 rue Jean Mazen
21000 Dijon, France

https://www.oncodesign-services.com

Oncodesign Services partners with biotech and biopharma companies to support the drug development journey from early discovery through preclinical candidate selection.
We offer state-of-the-art pharmaco-imaging services and a robust preclinical research infrastructure, with particular expertise in Oncology, Immuno-oncology, and Inflammatory diseases. Our services also include comprehensive support for the development of novel radiopharmaceuticals and the repositioning of oncology candidates into molecular radiotherapy programs. This is backed by over a decade of experience in molecular radiotherapy and a secured radionuclide supply chain.
Our flexible business models and nimble project execution allow us to deliver high-quality research efficiently, driven by a core commitment to scientific excellence.
With extensive experience collaborating with big pharma, biotech, public research institutions, and investment groups, we are dedicated to advancing the development of innovative therapeutic agents.

ONCOFUSE Med / 3CON Pharma Medical GmbH

Oberndorf 128c
6341 Ebbs, Austria

https://www.oncofuse.com
https://www.3con.com/leistungen/life-science

ONCOFUSE and 3CON Pharma Medical are Austria-based partners dedicated to driving innovation in Radioligand Therapy (RLT). By merging ONCOFUSE's deep understanding of clinical practices with 3CON Pharma Medical's high-end engineering and manufacturing expertise, the cooperation creates next-generation technology for handling radiopharmaceuticals. From specialized syringe shielding to streamlined workflow integration, our joint solutions enhance radiation protection, support healthcare providers, and enable safe, efficient therapy delivery.

PAIRE

29 rue du Faubourg Saint Jacques
75014 PARIS, France

https://www.paire.tech/fr

PAIRE is a MedTech company specializing in AI for nuclear medicine. Founded in 2021, it develops software as a medical device (SaMD) to support nuclear physicians.
Discover PIONUS: Your First AI Assistant for Augmented Nuclear Medicine
Imagine an AI assistant that performs anomaly detection, segmentation, and quantification before you even open the patient's record.
PIONUS integrates seamlessly into your existing viewer. In under 5 minutes, your reading workspace is automatically enriched for PET-CT exams: anomalies are detected and displayed, biomarkers are quantified and key clinical data are generated. Providing a systematic second read, PIONUS supports daily clinical practice by integrating directly into your workflow.
Join us at our booth!
Want to see PIONUS in action? Come visit our stand for a live demo and discover how PAIRE empowers nuclear medicine.

PBL SPA

Via Alessandro Volta, 8
43046 Rubbiano di Solignano, Italy

https://www.pbl.it

PBL was born from an enterpreneurial investment started in 1979, when the first automation solutions for the beverage, chemical and pharmaceutical sectors were designed, built and installed.The experience gained in over 40 years of technological research has allowed PBL to consolidate its position in the markets of interest, gaining the trust of new customers around the world.PBL is investing in three main fields:PHARMA DIVISIONWe offer flexibility, innovation, technical expertise, and value on your investments for pharma, radio-pharma, and cosmetic custom solutions applied to primary and secondary packaging.CONSUMER DIVISIONWe design and supply filling and packaging lines for single-serve coffee pods. These lines can satisfy any client request and promptly react to the continuous market developments.HEALTHCARE DIVISIONOur expertise in Artificial Intelligence and Deep Learning is offered to companies in need of dedicated industrial solutions based on innovative and efficient technologies.

Perceptive

55 Blue Sky Drive
01803 Burlington, United States of America

https://www.perceptive.com

At Perceptive, nuclear medicine is in our DNA. As a trusted research partner to the global radiopharmaceutical industry, we provide an end-to-end approach spanning preclinical and translational research through late-phase clinical trial imaging support.
With deep scientific expertise and significant experience delivering dosimetry, radiochemistry, tracer management, analytics/software, quantitative imaging, and imaging core lab services, Perceptive helps researchers accelerate the discovery and development of life-changing medicines across therapeutic areas, including radiopharmaceuticals, oncology, and the central nervous system.

PHSE s.r.l.

Via del Lavoro snc
26817 lodi, Italy

whttps://phse.com/en

PHSE is a global leader in temperature-controlled and time-critical pharmaceutical logistics.
With proven expertise in the sector, PHSE manages the transportation and shipment of high-value pharmaceutical products, radiopharmaceuticals, biotech, clinical trials, biological samples and advanced therapy medicinal products. The company serves vital delivery channels including hospitals, nuclear medicine departments, home care services and clinical laboratories worldwide.
Our extensive presence spans direct branches across North America, South America, Europe, United Kingdom, Asia, and a qualifed network of certifed agents for seamless worldwide coverage. We operate on a multimodal scale by land, air, and sea, ensuring flexible and reliable temperature-controlled logistics solutions for every critical transportation need.

PI Medical

Forellenweg 7
4941 SJ Raamsdonksveer, Netherlands

http://www.pi-medical.nl

PI Medical offers a wide range of instruments and accessories for the nuclear medicine market. The product range includes FDG dispensing systems, dose calibrators, contamination and radiation monitors, PET and SPECT phantoms, calibration sources and other QA devices, radiation shielding materials, Surgical equipment, Breast cancer localization products, patient positioning devices, etc. PI Medical is stands for high quality products and a high quality service.With our own Service department, all highly trained and educated, we can provide the best service, support and advice to our end users.Together with our partners, we can give you the best products and service for your needs.PI Medical Diagnostic Equipment B.V. – a Medical Imaging Specialist !

piCHEM Forschungs- und Entwicklungs GmbH

Parkring 3
8074 Raaba-Grambach, Austria

http://www.pichem.at

Having more than three decades of experience piCHEM is a reliable partner for the manufacturing of synthetic peptides and peptide related molecules. The company is privately owned and located in Austria. piCHEM provides peptides and complex organic molecules for medical, biochemical and pharmaceutical research as well as full GMP service for peptides used as active pharmaceutical ingredients (APIs).

In addition to basic research and pharmaceutical development piCHEM offers a wide range of value-added services including process scale-up, process validation, analytical services, stability studies and regulatory support.

Picorad

İstanbul
Türkiye

https://www.picorad.com

As Picorad, we are committed to providing the state-of-the-art solutions for the Healthcare Industry with a primary focus on Radiology, Nuclear Medicine and Radiation Oncology. Our expertise covers various areas such as Radiation Protection and Shielding, Nuclear Medicine Hotlab Equipment supply, and we are a manufacturer of Calibration and QA sources for Nuclear Medicine systems. Leveraging over 20 years of industry experience, our team addresses the challenges faced by the healthcare sector by offering diverse solutions. We are proud to consistently provide high-quality, cost-effective, and innovative solutions tailored to our clients' needs.

POLATOM - National Centre for Nuclear Research, Radioisotope Center POLATOM

Andrzeja Sołtana 7
05-400 Otwock, Poland

http://www.polatom.pl

National Centre for Nuclear Research, Radioisotope Center POLATOM is a Polish producer and distributor of isotope preparations used in medicine, science, industry and environmental protection. It also conducts research and development works of an application nature and concern radiopharmacy, chemistry and nuclear technology as well as scientific disciplines such as radiochemistry, biochemistry, and immunology, resulting in development of our own products and technologies.Our offer for nuclear medicine includes:- ready-made radiopharmaceuticals, used in cancer therapy and in the treatment of benign thyroid diseases;- technetium scintigraphy kits used in oncological diagnostics, intended for imaging of: kidneys, liver, bile ducts, spleen, heart, bones;- labeling precursors;- radionuclide generators 99mTc;- accessories necessary in Departments of Nuclear Medicine;- as well as various GMP and GMP compliant products and components for medical research.NCBJ Radioisotope Center POLATOM holds the ISO 9001:2015 Quality System Certificate and the Internal Control System for trade in dual-use goods, as well as a Certificate confirming compliance with the GMP requirements. Moreover, in our Radioactivity Standards Laboratory, a management system compliant with the international standard ISO/IEC 17025:2018 has been implemented and maintained. Our RSL's technical competence – as a calibration laboratory – is confirmed by the accreditation certificate AP 120 granted by the Polish Center for Accreditation.

Positrigo AG

Technoparkstrasse 1
8005 Zurich, Switzerland

http://www.positrigo.com

Positrigo is a pioneer in nuclear medical imaging technologies. Headquartered in Switzerland, the medical device company was founded in 2018. NeuroLF® - the company's first device - is an ultra-compact brain PET scanner which has applications in assessment of causes of dementias, such as Alzheimer's disease and other brain related disorders.

PSI CRO

Baarerstrasse 113a
6300 Zug, Switzerland

http://www.psi-cro.com

PSI is the leading pivotal-stage radiopharmaceutical CRO, currently running over 40% of the industry's registrational nuclear medicine trials.

We specialize in delivering complex diagnostic and theragnostic trials across diverse geographies with precision and reliability. Our strength lies in seamlessly coordinating multidisciplinary site teams, ensuring regulatory and logistical readiness, specialized site support, and developing tailored recruitment strategies to meet the unique demands of radiopharmaceutical research. With deep expertise, unwavering focus, and dedicated RLT teams around the world, PSI successfully supports sponsors embarking on registrational radiopharm trials globally.

In 2025, PSI celebrated its 30th year of business as the only fully independent and privately owned mid-sized CRO. Global headquarters are in Switzerland at Baarerstrasse 113a, 6300 Zug.

For more information, visit www.psi-cro.com

R2PHARMA

6681 Ipiranga Avenue – TECNOPUC - Building 93, Office 201
90619-900 Porto Alegre, Brazil

https://www.r2pharma.com

R2PHARMA was established through the merger of two leading players in the sector — the RPH Group and the R2IBF Group — representing a significant milestone in the advancement of healthcare in Brazil, particularly in the field of Nuclear Medicine.

This union reflects a shared commitment to excellence, innovation, and ethical responsibility, combining strong values and complementary expertise. Together, these forces strengthen our mission to transform access to cutting-edge diagnostic and therapeutic solutions.

With a strong focus on innovation and patient-centered care, R2PHARMA ensures that the latest technologies are rapidly and responsibly brought to market. The company is the leading supplier of cold kits in Brazil, operating a GMP-certified manufacturing facility, two Nuclear Pharmacies, and five cyclotrons strategically located across the country. R2PHARMA is also actively expanding its international presence, already exporting cold kits to approximately 15 countries. With a commitment to regulatory compliance, quality, and long-term partnerships, the company continues to grow its global reach and contribute to the advancement of Nuclear Medicine worldwide.

Radioprotech

1 rue des Vergers
69760 Limonest, Francel

http://www.radioprotech.com

Radiation protection equipment for Nuclear Medicine department.

Designed and made in France. Our products range cover all radiation protection needs from the arrival of the radiopharmaceutical until its disposal.

Radnostix (RadQual)

4137 Commerce Circle
83401 Idaho Falls, United States of America

https://radnostix.com

Radnostix is a U.S.-based manufacturer and global supplier of nuclear medicine products, medical devices, and calibration standards with a nearly three-decade track record of innovation and reliability. Established in 1995 and headquartered in Idaho Falls, Idaho, the company has built a reputation as a trusted partner for hospitals, radiopharmacies, imaging centers, and research institutions worldwide.

Radnostix operates at the intersection of theranostics, nuclear medicine, industrial isotope applications, and radiation safety, addressing growing global demand for diagnostic imaging, targeted cancer therapies, and dependable calibration and shielding solutions.

The company's portfolio spans several synergistic business units: radiopharmaceutical products such as sodium iodide I-131, used in the diagnosis and treatment of thyroid disease; RadQual calibration standards and reference sources, relied upon by nuclear pharmacies and imaging centers to ensure precise and accurate measurements; Cobalt-60 sealed sources used in cancer therapy and industrial sterilization; innovative medical devices like the Swirler® and Tru-Fit™ mouthpieces introduced under its RadVent division; and advanced synthesis modules and shielding products delivered through strategic distribution and joint venture partnerships.

Redberry SAS

850 Boulevard Sébastien Brant
67400 Illkirch-Graffenstaden, France

https://www.redberry.net

Redberry offers rapid testing solution aimed at avoiding long waiting time-to-results for industrial microbiology testing.
Our mission is to help product manufacturers release earlier, increase their in-process controls and avoid injecting at risk.
Based on an automated Solid-Phase Cytometry instrument, our solutions provide results at unprecedented speed and ease of use, with full validation packages in comparison to compendial methods.
Sterility testing is now executed in 4 days against 14 days with compendial methods.
Bioburden and rapid screening are delivering quantitative results on the same day.

Rotem GmbH

Franz-Flemming-Str. 39A
04179 Leipzig, Germany

https://rotem-medical.com

Rotem is a trusted global partner for PET radiopharmaceutical production, delivering comprehensive consumable solutions and supporting customers throughout every stage of the radiotracer lifecycle—from development to commercial production.
Our portfolio includes Oxygen-18 enriched water, disposable cassettes, precursors, reagent kits, and complementary consumables compatible with leading synthesis platforms. Manufactured under cGMP requirements according to EU and PIC/S guidelines in our US FDA-inspected facility, our products are backed by an experienced analytical laboratory providing quality control, method development, technical expertise, and regulatory support.
Collaboration is at the heart of what we do. By working closely with radiopharmaceutical companies, research organizations, and manufacturing partners worldwide, Rotem develops customized consumables that help accelerate innovation and bring new radiotracers to market.
In addition, Rotem provides advanced radiation detection and monitoring technologies, expanding its expertise beyond consumables to support the evolving needs of nuclear medicine worldwide.
Rotem GmbH in Leipzig provides local sales, technical support, and customer service throughout Europe.

ROTOP Pharmaka GmbH

Bautzner Landstraße 400
01328 Dresden, Germany

https://www.rotop-pharmaka.com

ROTOP has strong expertise in product development and application, as well as commercial cGMP production, including distribution. At our facilities, we combine comprehensive know-how in pharmaceutical development, including regulatory affairs, cGMP manufacturing of APIs/ drug substance precursors and sterile drug products, and an independent quality unit with several Qualified Persons (QPs) to release drug products.
For more information about our products and CDMO services, visit us at booth 414c (hall X5) to meet our experts.
We look forward to connecting with you in person!

RoweMed AG - Medical 4 Life

Juri-Gagarin-Ring 4
19370 Parchim, Germany

https://www.rowemed.de

RoweMed AG – Medical 4 Life is an innovative MedTech company. Our focus is on developing and producing customized single use systems for fluid transfer, especially handling of sensitive pharmaceuticals.
R&D: The development of systems is closely coordinated with the customer, from first sketch up to a market-ready product, including CAD construction, prototyping (3D printing), first series and product tests.
Production: We offer injection molding, assembling and packaging under one-roof. In our clean room production facility (ISO class 7) in Parchim our employees carry out single-part, small series and automated mass production. At the assembling department, all common welding and gluing technologies are implemented.
Regulatory Affairs: In addition to the technical services, we offer the complete technical documentation according to international regulations and customer requirements.

RPT Labworks

918 Deming Way, STE 101
53717 Madison, United States of America

http://www.rptlabworks.com

RPT Labworks is a USA-based contract research organization (CRO) that provides preclinical radiopharmaceutical theranostics (RPT) development, optimization and testing services.
From consulting, experimental design, radiochemistry and QC method development, conjugation and radiolabeling, radiochemistry quality control, cell handling and cell culture, in vitro assays, cancer modeling, in vivo imaging, dosimetry, efficacy and pharmacology, non-GLP radiation toxicology, ex vivo biodistribution, tissue preparation/ fixation for histology, and preclinical support for IND submission, we offer end-to-end preclinical services. We are radionuclide- and vector-agnostic and equipped to manage complex and unconventional studies. We focus on speed and quality and we pride ourselves as being an extension of your R&D team.

RQS Alexander Ruffani

Kantstrasse 15
01809 Heidenau, Germany

http://www.rqs-ar.com

RQS Alexander Ruffani was founded in 2017 and has years of experience in radiochemistry, radiopharmacy and analytical instrumentation. A growing team of experienced and motivated professionals with expertise in synthesis development, radiochemistry, GMP-compliant production processes and chromatography instrumentation will help you find the best possible solution for your work application. End of 2023, RQS expanded to the field of nuclear medicine. Our new colleagues already had more than 20 year of experience in that field. The team is ready to support you with all your requests and is looking forward to get in contact with you.
Thanks to deep experience in the various fields of nuclear medicine and radiochemistry, it is possible to offer a wide range of services of the highest quality.

- Support in laboratory planning, construction and commissioning
- Qualification, maintenance and repair of instruments for the production of (radio-)pharmaceuticals
- GMP documentation for radiopharmacy for quality management system
- Method development for various syntheses and quality control processes in radiopharmacy
- Validation of methods in production and quality control acy• Validation of methods in production and quality control

Santenov Dijon Bourgogne

7 boulevard Jeanne D'arc
21000 Dijon, France

http://www.santenov.com

Santenov Dijon Bourgogne, the health sector cluster brings together the health ecosystem of the Dijon Bourgogne area, made up of companies, startups, research labs, academic players, and university hospitals to move health projects forward.
In EANM congress, he will be present with compagny like Oncodesign Premise Medicine, Rivolution, Promethe, CGFL...

SCANNIX

Rue du Mont d'Orcq 3 B
7503 Froyennes, Belgium

https://www.scannix.com

Scannix is specialized in the development and sales of nuclear spectroscopy equipment and radioprotection systems. Scannix offers a wide range of measurement devices in order to maintain safety of staff, assess the health of nuclear facilities and safeguard the public and the environment.

SCINTOMICS Molecular, Applied Theranostics Technologies GmbH

Lindach 4
82256 Fürstenfeldbruck, Germany

https://sci-att.com

SCINTOMICS Molecular, Applied Theranostics Technologies (SCI-att), is a prominent and fast-growing player in the radiopharmaceutical industry. With a strategic focus on ensuring a consistent supply and comprehensive support for proprietary and innovative tracer technology and non-IP protected precursors, such as PSMA I&T and next-generation PSMA inhibitors like [18F]siPSMA-14 and [18F]SiFAlinTATE, SCI-att stands at the forefront of cutting-edge theranostics solutions.

The GRP Module Series is an extremely capable and cost-efficient solution for the production of radiopharmaceuticals. We are dedicated to expanding our portfolio and providing our customers with an unparalleled array of products and services. Additionally, SCI-att offers proprietary cassettes and reagents for the production of [18F], [68Ga], [99mTc] and [177Lu] tracers.

With an extensive network of distributors and partners all over the world, SCI-att ensures broad accessibility and support for our cutting-edge solutions. At SCI-att, we pride ourselves on delivering top-notch quality and exceptional customer support. We invite you to visit us at booth 240, where our knowledgeable team will be delighted to share information about our latest and exciting projects.

SCK CEN

Boeretang 190
2400 Mol, Belgium

https://www.sckcen.be

With more than 70 years of expertise in nuclear research and technology, SCK CEN is one of Belgium's largest research institutions. Every day, over 900 employees dedicate themselves to developing peaceful applications of radioactivity. Our research focuses on three core areas: innovative nuclear systems, nuclear waste management and dismantling, and the resolute fight against cancer.

For decades, SCK CEN has played a key role in the global production of medical radioisotopes by irradiating in its Belgian Reactor 2 (BR2). Today, SCK CEN is evolving into a radiopharmaceutical player, engaged in both pre-clinical research as well as radiochemical purification in its brand-new pilot production facility. SCK CEN is thus actively contributing to the development of radioligand therapy (RLT).

These treatments use carrier molecules to deliver radioactive isotopes directly to tumours, precisely targeting and shrinking tumours while sparing healthy tissues. This approach reduces side effects and offers a more humane alternative to conventional cancer treatments.

We have established our own dedicated preclinical cancer research programme, focusing on glioblastoma (brain cancer), colon cancer, and ovarian cancer. In addition to our internal research efforts, we also actively contribute to external research projects. To reach our goal, we rely on both our unique infrastructure and impactful partnerships with renowned entities in the field. By integrating in-house expertise with external collaborations, SCK CEN aims to be a global leader in nuclear medicine.

SDS Life Sciences Pvt. Ltd.

C2/ 388, Pankha Road, Janakpuri, New Delhi
110058 Delhi, India

https://sdslife.in

SDS Life Sciences Pvt. Ltd. (SDS) is one of India's leading private manufacturers of radiopharmaceuticals. Established in 2015, the company serves over 200 hospitals and diagnostic centres across India and is expanding its presence across South Asia, Southeast Asia, Africa, the Middle East & North Africa (MENA), and the CIS countries.

SDS operates WHO-GMP compliant manufacturing facilities in Gurugram, Haryana, near Delhi, for the production of Technetium-99m generators, Iodine-131 radiopharmaceuticals, and Lutetium-177 PSMA and DOTATATE therapies. The company also operates a state-of-the-art PET radiopharmaceutical production facility in Visakhapatnam, Andhra Pradesh, equipped with an IBA Kiube 300 medical cyclotron for the production of FDG and other PET radiopharmaceuticals.

SDS is establishing two new medical cyclotron facilities near Delhi and Ahmedabad, Gujarat, scheduled for commissioning in 2027. The company is also developing projects for the production of medical isotopes and pursuing strategic collaborations in manufacturing, marketing and new radiopharmaceutical development.

SDS is seeking distribution partners to expand its market presence outside India. The company also welcomes partnerships in radiopharmaceutical manufacturing, CDMO services, contract research and clinical trials (CRO), technology transfer, and the marketing and distribution of complementary nuclear medicine products in India.

SEDECAL MOLECULAR IMAGING S.L.U. (SMI)

C/ Pelaya, 9 2
8110 Algete, Spain

https://www.sedecal.com/molecular-division

Sedecal Molecular Imaging (SMI) develops advanced molecular imaging solutions that make the invisible detectable. Our portfolio spans high-performance preclinical PET/CT systems and next-generation dedicated brain PET technologies, providing researchers and clinicians with innovative tools to visualize and quantify biological processes with exceptional accuracy.

Combining advanced detector technologies, virtual DOI capabilities, real-time imaging, dual-isotope imaging (mPET), and high-resolution CT, SMI delivers flexible and scalable imaging platforms for biomedical research, translational medicine, and neurological imaging. From small animal studies to dedicated brain PET applications, SMI empowers researchers and clinicians with innovative tools to visualize biological processes with unprecedented detail, accelerating scientific discovery and the translation of research into clinical practice.

Stand nº 274- Find our accuracy Solutions to accelerate your Discoveries.

Shanghai Leading Technology Co., Ltd

Area A, Floor 4, Building 1, No. 1355,
Chengbei Road,
Jiading District 201907 Shanghai, China

http://www.leadingmetal.com/en

Shanghai Leading Technology Co., Ltd. has been dedicated to radiation shielding and nuclear medicine solutions for 20 years. From our perspective, nuclear medicine is not only about technology—it is about enabling safer workflows, reliable diagnostics, and confidence for the professionals who work with radiation every day. From our partner's perspective, Leading Technology is a dependable supplier that consistently delivers performance, quality, and stability. We specialize in SPECT/PET collimators, radiopharmaceutical containers, PET protection equipment, and radiation PPE, serving OEMs, hospitals, and radiopharmacies worldwide. These products are engineered to provide effective radiation attenuation, practical ergonomics, and reliable performance in clinical environments.

Over the years, Leading Technology has become a trusted partner to many of the world's leading imaging and healthcare companies. This trust is built on long-term cooperation, technical understanding of nuclear medicine applications, and consistent product quality. We are proud that many customers see us not just as a component supplier, but as a solution partner.

A key strength of Leading Technology is our stable, vertically integrated supply chain, covering raw materials, in-house R&D, precision processing, and quality control. This structure allows us to provide dependable supply, cost stability, and continuous product improvement in a market where material availability and pricing can fluctuate.

SHINE

3400 Innovation Court
53546 Janesville, United States of America

http://www.shinefusion.com

Headquartered in Janesville, Wisconsin, SHINE stands as an industry leader in next-generation nuclear fusion and separation technology. SHINE deploys innovative fusion and fusion-based technology that seamlessly combines safety, cost-efficiency, and environmental responsibility.

Distinguished by its proprietary medical isotope production processes, SHINE is at the forefront of creating n.c.a. lutetium-177—a vital component in cutting-edge medical treatments. Anticipating further advancements, the company's forward-looking vision includes the creation of molybdenum-99, a diagnostic tool that plays a pivotal role in medical procedures aimed at detecting heart disease and cancer.

SHINE's commitment to innovation extends beyond the realms of industry and healthcare. Drawing on its fusion-technology expertise, the company has set its sights on addressing one of energy's most complex challenges—nuclear waste recycling. With a comprehensive and visionary approach, SHINE is steadfastly driving advancements across multiple sectors, leaving an indelible mark on the domains of technology, healthcare, and sustainable energy solutions.

Sidam S.R.L.

Via Statale Sud, 169
41037 Mirandola (MO), Italy

https://www.sidam.it

Sidam is a biomedical company located in the biomedical district of Mirandola (Italy), one of the world's most renowned biomedical districts. With a broad portfolio of healthcare solutions, Sidam develops and manufactures medical devices and disposable products for Radiopharmacy, Radiology, Oncology, Intensive Care, Surgery and Regenerative Medicine as well as secondary pharmaceutical packaging systems. Leveraging extensive expertise in custom development, Sidam supports customers throughout the entire product lifecycle—from design and regulatory compliance to quality assurance and manufacturing—delivering tailored solutions that meet the highest standards of safety, quality, and performance.

Siemens Healthineers

Siemensstr. 3
91301 Forchheim, Germany

https://www.siemens-healthineers.com/molecular-imaging

At Siemens Healthineers, we pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. As a leading medical technology company, we want to advance a world in which breakthroughs in healthcare create new possibilities sustainably. We partner with healthcare providers to address their most pressing challenges so that they can deliver high-quality, patient-centered care, efficiently.

We are active in the areas of imaging, diagnostics, cancer care, and minimally invasive therapies, augmented by digital technologies and artificial intelligence. With our unique combination of strengths in Patient Twinning*, Precision Therapy, as well as Healthcare AI, we take on the greatest challenges in healthcare. We help improve access to healthcare for underserved communities worldwide and overcome the most threatening diseases.

We are a team of around 74,000 Healthineers in over 70 countries passionately pushing the boundaries of what is possible in healthcare so that patients can live with hope, not fear of disease.

- Early detection, accurate diagnosis. individualized therapy selection, simulation and planning, continuous monitoring and aftercare.

SinoUnion Healthcare Inc.

Dongsheng International Science & Technology Park 100072 Beijing, China

https://www.sinounion.com

SinoUnion Healthcare Inc.(Hereafter SinoUnion) is a high-tech industrial company and PET/CT & SPECT/CT manufacturer,headquartered in Beijing backed-up by Tsinghua University In line with the core value concept of "Better Insight", in Peking Union Medical College Hospital.
SinoUnion made a perfect completion of the clinical examination and scientific research projects, we are committed to building a high-end precision cancer diagnosis and treatment industry chain Our mission is "building industry-leading high-end medical products and providing people-oriented innovative medical services".
We have fully mastered the core technology of our products and have launched a number of high-end medical devices with completely independent intellectual property rights. Make It Seen and we believe that the world will see us.

Sirtex Medical Europe GmbH

Joseph-Schumpeter-Allee 33
53227 Bonn, Germany

https://www.sirtex.com/eu

Sirtex Medical is a global healthcare business with offices in the US, Australia, Germany and Singapore, working to improve outcomes in people with cancer.
Sirtex' current lead product is SIR-Spheres® Y-90 resin microspheres, a medical device used in Selective Internal Radiation Therapy (SIRT) for treatment of primary and secondary liver tumors.
Sirtex also distributes EmboCept® S DSM 50 µm, Degradable Starch Microspheres (DSM) used as adjuvant in the intra-arterial treatment of inoperable liver tumours and lung tumours in combination with cytostatic agents.
For further information please visit www.sirtex.com.

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.

EmboCept® is a registered trademark of Magle PharmaCept GmbH.

Skistad Elektroautomasjon AS

Grenseveien 71C
663 Oslo, Norway

https://www.siemens-healthineers.com/molecular-imaging

We are proud to showcase our Target Switch System (TSS), by Skistad. Our mission is to make the transfer of radioactive isotopes from the cyclotron to the patient safer, more reliable and more efficient.
TSS is an automated transfer system that safely transports radioactive isotopes from the cyclotron to hot cells, synthesis modules and ultimately to the patient. Designed specifically for radiopharmaceutical production facilities, TSS provides complete process control, full traceability and intelligent automation to maximize uptime and support GMP compliant production.
Today, Skistad is trusted by hospitals, research institutions and commercial radiopharmaceutical producers across Europe, USA and Asia.
Visit us to discuss your production challenges and explore how Skistad can support your facility.

Southern Scientific

United Kingdom

https://www.southernscientific.co.uk

Southern Scientific manufacture a range of probes and contamination monitors for medical applications. This includes the Care Wise C-Trak Galaxy Gamma Probe System. This system provides accurate and precise detection of gamma radiation and is used during sentinel node biopsies in breast, melanoma and other types of cancer. Our contamination monitor range includes the Radhound and Handhound. TheRadhoundmonitorisavailablewithawiderangeofprobes suitable for detecting Alpha, Gamma and Beta isotopes. The Handhound is a voice-activated hand monitor. All measurements are logged against a user and are easily exported for compliance purposes. Southern Scientific is also a distributor for Mirion Capintec, Hoy, LemerPax and Tracerco. We are actively looking for commercial partners in certain countries, so if you are interested, please visit our stand and speak to one of our team.

Special Cargo Services

Breguetlaan 9
1438BA Oude meer, Netherlands

https://www.specialcargo.com

Special Cargo Services – Experts in Radioactive Logistics.
With over 25 years of experience, Special Cargo Services is a recognized authority and trusted knowledge partner for both government agencies and private companies. We specialize in the safe transport, documentation, packing, logistics, and storage of radioactive materials, always prioritizing quality and safety.
Our strength lies in transforming complex logistical challenges into clear answers and practical solutions. Whether your shipments are national or international, by air, road, or sea – we always go the extra mile. Partnering with Special Cargo Services means contributing to a safer logistics chain.
Our services include:

- Safe Transportation: We adhere to the highest safety standards for transporting radioactive materials.
- Regulatory Compliance: We ensure full compliance with all applicable international and local regulations.
- Timely Deliveries: We guarantee prompt and reliable deliveries, critical for supporting essential medical treatments.
- Customized Solutions: Our logistics services are tailored to meet the specific needs of the nuclear medicine sector and other specialized industries.
- Education and Training: We provide comprehensive training in the safe handling and transportation of radioactive materials.

Choose Special Cargo Services – making the logistics world safer, one shipment at a time.

SpectronRx

9550 Zionsville Road
46268 Indianapolis, United States of America

https://www.spectronrx.com

SpectronRx is a diagnostic and therapeutic radiopharmaceutical developer and manufacturer specializing in Radiopharmaceutical Contract Development (CDMO), Manufacturing (CMO), and Isotope Production. With facilities in the US and Europe, the company supports all stages of development, from early conjugations through scale-up and commercial distribution, and has the capacity to run clinical trials.
Withateamofexperiencedradiochemists,radiopharmacists, scientists and engineers, dozens of qualified clean rooms and more than 400,000 square feet of production space, SpectronRx supplies radiopharmaceuticals and isotopes to more than 29 countries. The company has been EMA and FDA-inspected and can produce or procure any currently used radioisotope.

Spectrum Dynamics Medical

Rue de Lausanne 31
1110 Morges, Switzerland

https://www.spectrum-dynamics.com

Spectrum Dynamics is spearheading the transformation of Nuclear Medicine from analog to digital technology, enabling clinicians to provide superior healthcare services with improved image quality and efficiency at lower doses. Spectrum launched the world's first digital cardiac SPECT system: the D-SPECT® in 2007. It is the world's first digital cardiac SPECT system based on Broadview Technology: swiveling CZT digital detectors. It is the platform for advanced applications such as TruCorr Attenuation Correction, TruFlow 3D dynamic SPECT imaging for Myocardial Flow Reserve (MFR) analysis, Simultaneous Dual Isotope Imaging (SDI).
Spectrum's latest innovation is the VERITON-CT®. It is The world's first digital 360°CZT-based, ring-shaped gantry design SPECT/CT, with high-resolution 16 or 64 slice CT. It's 80cm wide bore accommodates patients of all sizes. VERITON features TruFlow 3D dynamic SPECT/CT imaging for SPECT MFR, bone, renal, and general studies. VERITON-CT continues to evolve with an energy range up to 400 KeV and multiple peak imaging, providing highest quality and quantitation-ready images.

Sumitomo Heavy Industries, Ltd.

ThinkPark Tower, 1-1 Osaki 2-chome,
Shinagawa-ku, 141
6025 Tokyo, Japan

https://www.shi.co.jp/industrial/en/product/medical/index.html

Since its establishment, Sumitomo Heavy Industries, Ltd. has contributed to the society by providing advanced technologies related to industrial machinery and infrastructure equipment to customers in the world. In particular, we have accumulated over 50 years of experience in the manufacture of accelerators, which have been applied to scientific, industrial and medical fields and have earned a high reputation.
In the nuclear medicine, Sumitomo PET radio-tracer production system (incl. cyclotron, target, synthesizer, etc.) were delivered to more than 260 sites in the world and have been contributed for the development of clinical use and new technologies (such as Theranostics).
In EANM 2026 exhibition, CYPRIS MP-30X Cyclotron which has capability to produce large amount of 211At for targeted alpha therapy will be highlighted.
Also, our existing cyclotron such as HM-20, HM-12 and HM-18HC as well as our original solid target system called "SmartTAG-LT" will be exhibited.
We are welcome to you at our booth!

Sykam

Carl-von-Lindestrasse 2
82256 Fürstenfeldbruck, Germany

https://www.sykam.com

Individual solutions tailored to your needs.
Trusted by innovators worldwide, we deliver reliable and tailored solutions that empower labs and industries from analytics to instrumentation excellence.

Syntermed, Inc.

333 Sandy Springs Circle, Suite 107
30328 Atlanta, United States of America

https://www.syntermed.com

Syntermed, Inc. (Stand 73B), is a global leader in providing Cardiac, NeuroRadiology, and Oncology solutions. Syntermed solutions power over 50% of the nuclear medicine departments worldwide. Signature products include NeuroQ™ and Cardiac Toolbox™ (eCTB). We are introducing the next generation of NeuroQ - Version 4. Along with a brand new UI, NeuroQ V4 includes Centiloid calculations for Amyloid studies, significant enhancements for DaTscan, improved diagnostic output, and much more. NeuroQ is one of the most widely used solutions for quantifying NeuroRadiology studies. We will also introduce the VHRisk (Vall d'Hebron in Barcelona) extensions to eCTB's powerful Intelligent Decision Support (IDS), full support for Flyrcado, Longitudinal Strain, and more. Please visit Stand 73B to learn more. Syntermed products and services are available worldwide from leading OEMs, Distributors, and Value-added Resellers. For more information about Syntermed Innovation, please visit www.syntermed.com, or email info@syntermed.com

Synthra GmbH

Albert-Einstein-Ring 21
22761 Hamburg, Germany

http://www.synthra.com

Synthra is a worldwide leading and specialized manufacturer of branded radio synthesizers and concentrates over 40 years of experiences in the field of radiopharmaceutical production, quality control and lab automation. We are committed to automated production of molecular imaging tracers and continuously provide innovative solutions to facilitate and improve the production of tracers for Positron Emission Tomography (PET).
Our portfolio comprises C-11, F-18, N-13, Ga-68, Lu-177 and other radioisotopes. It includes radio synthesizers with self-cleaning systems, customized modules, quality control equipment, spare parts and services.
Our radio synthesizers combine high performance and efficiency with high flexibility that enables the reliable production of radiopharmaceuticals. Moreover, our software and synthesizers are highly user-friendly and meet the latest GMP regulations.
We are happy to present our Synthra Photoreactor and our completely redesigned Synthra MChelate for radiometal syntheses, which enable you to expand your Synthra labeling opportunities.
Meet us at our booth 302.

TELIX

Rue de Hermée 255
4040 Herstal, Belgium

https://telixpharma.com

Telix is a global commercial-stage biopharmaceutical company focused on the development of therapeutic and diagnostic ("theranostic") radiopharmaceuticals and associated medical devices, and a service provider in nuclear medicine, with its European headquarters located in Liège, Belgium. Telix's targeted radiation technologies have potential to transform the way clinicians can find and manage cancer and rare diseases, to inform treatment decisions and deliver personalised therapy in areas of major unmet medical need. With 18 clinical studies underway worldwide (including partnered investigator-led studies), Telix's core pipeline is focused on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Telix also has a growing research pipeline focused on novel targets and technologies. Telix has received regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent (Illuccix®, TLX591-CDx, kit for the preparation of 68Ga-PSMA-11 injection) and is progressing marketing authorisation applications for TLX591-CDx in the European Union and the United Kingdom. The company's manufacturing hub in Brussels South, Belgium, Telix Manufacturing Solutions, recently inaugurated, will deliver significant operational flexibility, R&D capabilities, and support commercial production requirements in Europe.

Tema Sinergie

via Malpighi, 120
48018 Faenza, Italy

http://www.temasinergie.com

Tema Sinergie is a global leader in the design and manufacture of advanced technologies for radiopharmaceutical production, processing and quality control, supporting the evolution of Radioligand Therapy (RLT), theranostics and Nuclear Medicine.

Over 40 years of experience, combined with continuous innovation, have enabled the company to develop a comprehensive range of products and integrated solutions that have become a trusted reference for radiopharmaceutical manufacturers, pharmaceutical companies, hospitals, research institutes and academic centers worldwide.

From automated dispensing systems and hot cells to quality control solutions, aseptic processing technologies, digital workflow management and integrated production systems, Tema Sinergie is the ideal partner for every stage of the radiopharmaceutical lifecycle, helping customers deliver innovative therapies safely, efficiently and in full compliance with the highest regulatory standards.

TerThera b.v.

Minervum 7070
4817ZK Breda, Netherlands

http://www.terthera.com

Therthera was founded in 2021, TerThera strives to meet the growing global demand for radionuclides in cancer healthcare by providing a highly sustainable and uninterrupted supply of Terbium-161 for use in radioligand therapy.

The scarcity of radionuclides for use in radioligand therapy impacts the lives of many cancer patients, with a secured stock of highly enriched gadolinium-160 our team promises to deliver therapeutic quantities of GMP-grade Terbium-161, expanding the options available for patient treatments.

Having resolved the scarcity of Terbium-161, we aim to enable Terbium-161 radioligand therapy by supporting academic partners, preclinical, and clinical research towards patient treatment, ultimately working towards understanding the underlying mechanisms of internal radiation therapy.

THE ONCIDIUM FOUNDATION

av. Herrmann-Debroux, 40 B
1160 Brussels, Belgium

https://www.oncidiumfoundation.org

The Oncidium foundation is a non-profit, public-benefit organization dedicated to advancing targeted radionuclide therapy (TRT) for cancer care worldwide.

We focus on education, awareness, and advocating for equitable access to treatment. Through our initiatives, we bridge care gaps and build an ecosystem that supports people living with cancer, regardless of geographical or financial barriers, offering hope for an improved quality of life. Come and meet us!

Tianjin Nuclear Safety Technology Co., Ltd.

300350 Tianjin, China

Tianjin Nuclear Safety Technology Co., Ltd. (NST) is a high-tech enterprise providing one-stop turnkey solutions for radiopharmaceutical factories and nuclear medicine departments.

We manufacture hot cells, radiopharmaceutical production lines, radiation monitoring devices and supporting instruments, and deliver full services including site planning, construction, compliance application and radiation safety training, fully adhering to global GMP specifications.

We customize planning for PET imaging centers and radiobiology labs, and supply cyclotron precursors & chemical reagents to global nuclear medicine partners.

time:matters

Gutenbergstr. 6, 62362 Neu-Isenburg
63263 Neu-Isenburg, Germany

https://www.time-matters.com

time:matters, a subsidiary of Lufthansa Cargo, is a specialist in providing reliable, time-critical logistics solutions for sensitive medical goods. We offer specialized solutions for one of the most demanding areas of logistics in the healthcare sector: radiopharmaceuticals

Our benefits at a glance:
- Patient-centered supply chain specifically for nuclear medicine
- Specialized processes and extensive experience in handling sensitive and regulated goods
- Fast handling of dangerous goods (DG check < 3 hours) at central hubs (Frankfurt & Munich)
- Direct delivery to the aircraft for maximum reliability during unloading
- 24/7 monitoring and proactive status communication for full transparency
- Cat. 7 trained staff in service and operations
- Own Courier Terminal at Frankfurt Airport for maximum control and flexibility for radiopharma shipments
- Individual backup solutions to minimize risk in the event of irregularities
- Unique airfreight setups with Lufthansa, United Airlines and LATAM Airlines

Responsibility meets precision.
We understand that every transport in the radiopharmaceutical sector is critical - for doctors, clinics and, above all, for patients. time:matters stands for logistical safety, reliability and innovation in a highly sensitive medical environment.

TMC Group Manufacturing Company Inc.

North Vancouver, Canada

hhttps://tmc-group.ca

High-Purity Enriched Stable Isotopes from Canada.
TMC Group manufactures high-purity enriched stable isotopes from our 30,000+ sq. ft. production facility in North Vancouver, Canada. Since 2004, we have supported leading scientific and medical research organizations worldwide, delivering more than 10 kilograms of isotopes with enrichment levels up to 99.9%.
Our proprietary manufacturing processes enable us to respond to evolving market demands while maintaining the highest quality standards. We produce more than two kilograms of Yb-176 annually, are expanding Gd-160 production, and continue to broaden our isotope portfolio.
Available Isotopes for sale:
Ytterbium-176 (Yb-176)
Gadolinium-160 (Gd-160)
Gallium-69 (Ga-69)
Need a stable isotope not listed above? Contact us at info@tmc2.ca. We'd love to explore how we can help!
All isotopes are produced at our Canadian facility and available for worldwide shipment.

Trasis

Rue Gilles Magnée 90
4430 Ans, Belgium

https://www.trasis.com/en

At Trasis, we are dedicated to helping the medical community access new radio-labelled therapeutic and diagnostic substances easily and faster.
We address the entire value chain of radiopharmaceuticals, from early development to production, quality control, dose preparation, and even injection.
To this end, we design, manufacture, sell and support high performance synthesizers (AllinOne, AllinOne mini, AllinOne S and EasyOne), radiopharmaceutical quality control instruments (QC1), sterility testing solution (Sterinow), dose preparation equipment (Unidose and Quickfill dispensers), their shielding and accessories. We also develop customized synthetic methods and instruments. As certified GMP Part I and Part II, we can provide GMP Active Pharmaceutical Ingredients (API) and support our customers with their regulatory affairs.
Our proven radiopharmaceutical expertise, coupled with our high-end instruments, allow us to provide fully integrated solutions for an effective tracer production and faster transition from drug development to marketing authorization.
Brands: AllinOne, Mini-AllinOne, AllinOne S and EasyOne chemistry synthesizers, Shielding Solutions: Unidose & Quickfill dispensers, QC1 for radiopharmaceutical Quality Control, and (radio)chimical Custom Development and manufacturing Services.

TrisKem International

3 rue des Champs Geons
35170 Bruz, France

https://www.triskem-international.com

TrisKem International develops, manufactures and commercializes highly selective resins for the separation and quality control of radionuclides such as Lu-177, Tb-161, Ga-67/8, Zr-89, Cu-61/4/7, Ac-225, Ge-68, Ti-44/5, Sc-43/4/7, Pb-212 and many other radionuclides for use in nuclear medicine – in diagnosis as well as in therapy.Further to its range of resins TrisKem also develops and provides selective thin layer chromatography paper (i.e. DGA Sheets) for quality control of radionuclides and generator effluents (Ra-223, Ac-225, Pb-212, Ga-68,...) with respect to their radionuclidic purity, as well as for the control of presence of free radionuclides after labeling (i.e. CU Sheets). TrisKem's resins are increasingly finding use in the production of radionuclides for radiopharmacy and are employed by leading radionuclide manufacturers worldwide.Our R&D team is constantly working on the development of new resins and methods to help you with your separation needs. If you have a special separation need, need help with your method development, you are interested in participating in R&D projects or you are looking for a partner to commercialize a new technology you have developed, please do not hesitate to contact us!

U.S. National Isotope Development Center

P.O. Box 2008, MS 6158
37830-6158 Oak Ridge, TN, United States of America

https://isotopes.gov

The National Isotope Development Center (NIDC), managed by the U.S. Department of Energy (DOE) Office of Isotope R&D and Production (IRP), serves as the nation's interface for the production, development, and distribution of critical isotopes. The NIDC connects research, medical, and industrial communities with isotopes essential for scientific discovery, advanced medical therapies, and national security. By coordinating production across DOE facilities, including Argonne, Brookhaven, Idaho, Los Alamos, Oak Ridge and Pacific Northwest National Laboratories, as well as with university partners, the NIDC ensures reliable access to both stable and radioactive isotopes in short supply through reactors, accelerators and other advanced production technologies.
Providing essential isotopes and specialized services, the NIDC reduces the nation's reliance on foreign sources and strengthens U.S. leadership in nuclear science, technology, and innovation. Through these efforts, the NIDC enables research and innovation, advances public health, enhances national security and sustains U.S. competitiveness worldwide.

United Imaging Healthcare

2258 Chengbei Rd., Jiading District
201807 Shanghai, China

https://global.united-imaging.com/en

United Imaging Healthcare Technology Group Co., Ltd. (United Imaging Group) is a global leader in healthcare technology. With innovative solutions from prevention to diagnosis, treatment, and rehabilitation, United Imaging Group aims to build an intelligent healthcare ecosystem to benefit patients all over the world. Supported by the Central Research Institute and subsidiaries, United Imaging Group develops and produces a full portfolio of advanced medical imaging and radiotherapy equipment, life science instruments, medical robotics, smart wearables, e-medicine solutions, medical artificial intelligence (AI) solutions, medical 3D printing solutions, as well as medical imaging diagnostic center and health management center. United Imaging Group is committed to creating more value for our customers and constantly improving the global accessibility of high-end medical equipment and services through in-depth cooperation with hospitals, universities, research institutions, and industry partners.

Our vision: Leading Healthcare Innovation

Our mission: To Bring Equal Healthcare for All

Urenco Isotopes

Drienemansweg 1
7601PZ Almelo, Netherlands

https://www.urencoisotopes.com

At Urenco Isotopes, we are on a mission to drive advancements in healthcare, research and beyond. For more than three decades, we have been delivering innovation in stable isotopes across a wide range of medical, industrial and research applications.
As a trusted and reliable manufacturer of advanced isotope products, we are guided by a quality-driven culture, a commitment to operational excellence and a focus on building collaborative industry partnerships.
Based in the Netherlands, we deliver high-quality isotope solutions that support life-saving treatments, enable breakthrough research and fuel progress in cutting-edge industries, making a meaningful impact on people's lives and the world around us.
Leveraging the world's most advanced ultracentrifuge technology, we can enrich materials to greater than 99% purity or below 1%, providing tailored solutions for the most demanding applications.

Von Gahlen Nederland B.V.

Kelvinstraat 9
6902 PW ZEVENAAR, Netherlands

http://www.vongahlen.com

Von Gahlen is excited to be part of the EANM 2026 meeting! Please visit us in Booth 412 to discuss your shielding needs. Von Gahlen designs and manufactures lead shielding products for the radiopharmacy and nuclear medicine industry. Our products range from fully integrated GMP-hot cell production lines for the development or production of radiopharmaceuticals, including automated dispensing systems, to Type A-certified radiopharmaceutical packaging solutions for transport.
Since its founding over 50 years ago, Von Gahlen has become a world leader in these industries. With our strong customer focus, we provide high-quality products that meet or exceed industry standards and safety requirements. Von Gahlen hot cell installations can be found worldwide, including many of the largest turnkey installations in the field. In our approach, we not only focus on developing the best radiation-shielding lead products and solutions but also on optimizing their lifecycle. We are your partner in the development of hot cells (also for special purposes) and complete nuclear medicine laboratory facilities. We understand better than anyone the continuing need to guarantee long-lasting solutions, improve operational management, and control costs.
Our team of professionals includes highly qualified technical designers as well as experienced manufacturing and installation personnel. Von Gahlen is an ISO 9001 Certified Company. Our quality assurance program has been audited and approved by numerous customers. .

VORTAL

44 Rue de le Belle Haie B
1490 Court St Etienne, Belgium

http://www.vortal.com

WHO WE ARE Leader in reusable TYPE A certified transport systemOUR PRODUCTSTransport system for liquid radio pharmaceuticalsShielding material for radiopharma facilitiesWHAT WE DO BETTER TYPE A transport systemsCustomized shielding for pharmaceutical environmentAutomatic closure system for lead containerOUR MAIN REFERENCES Advanced Acceleration Applications, Curium, IBA, IAEA, Siemens, Europet...

VS Medical Mühendislik Danışmanlık İthalat İhracat A.Ş.

Esentepe Mah. Milangaz Cad. No:77/2,
Daire:128
34870 Istanbul, Türkiye

http://www.vsmedical.com.tr

VS Medical Engineering Consultancy Import Export Inc. is one of the leading solution providers in the fields of nuclear medicine and radiopharmaceutical production. Our company offers a comprehensive range of services, including the supply of equipment and instruments for radiopharmaceutical production facilities, as well as maintenance, repair, calibration, validation, and technical support services.

VS Medical provides turnkey solutions for new radiopharmaceutical production facilities, supporting customers throughout the entire project lifecycle, from planning and equipment selection to installation, commissioning, and operational management. In addition, we offer specialized services such as technical training for production personnel, quality management system consultancy, GMP compliance support, and quality control solutions.

Wälischmiller Engineering GmbH

Schießstattweg 16
88677 Markdorf, Germany

http://www.hwm.com

Wälischmiller Engineering is the provider of the nuclear medicine industry most innovative and reliable nuclear telemanipulators. The company has a hard earned international reputation for performance, excellence in engineering and exceptional robotic hardware.

FULL RANGE SUPPLIER:

- mechanical telemanipulators for a wide range of applications (models A100, A200, VNE series and Model 9 - 2.0)
- universal grippers
- robot system LIROB with unique capabilities which includes no wiring outside the arm, and precise movements
- custom solutions ranging from simple tools to custom automation

PRODUCTS FROM A SINGLE SOURCE:

- engineering including product design and development
- high manufacturing including single part assembly
- all required specialised staff available within the company
- installation at sites
- worldwide service and maintenance

By working closely with our specialist engineers and project managers, you can be confident of receiving not just an off-the shelf product, but a custom-tailored solution to your problems that offers highest quality and guarantee of long-term operational safety to even most-demanding customers.

The company is certified according ISO 9001:2015, ISO 19443:2018, ISO 14001:2015, DIN EN 45001:2018, KTA 1401, and CEFRI-E.

Brands: HWM, Wälischmiller Engineering, TELBOT®, LIROB

WuXi AppTec

Am Haag 16
82166 Gräfelfing, Germany

https://www.wuxiapptec.com

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time.

Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd.

No.20 Qianrong Road
214063 Wuxi, China

http://www.jysy.cc

Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd is a high-tech enterprise owned by Jiangsu Institute of Nuclear Medicine and Key Laboratory of Nuclear Medicine of Ministry of Health.

Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd specializes in the R&D and production of radiopharmaceuticals and medical devices. It is a high-tech enterprise integrating positron drugs, radioimmunoassay, single photon drug production and R&D. Advanced equipment such as cyclo-tron, micro-PET/CT, optical imaging and synthesis module are deployed for the re-search and production of positron drugs, undertaking or participating in major research projects of various countries and provinces.

Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd has a large-scale and diverse production base of radiopharma-ceuticals in vivo in China, and has successfully passed GMP certification. The company also produces PET precursors, kits, sterile vacuum vials and accessories. Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd also cooperates with other scientific research institutions to provide the best quality service support.

XEOS Medical NV

Ottergemsesteenweg-Zuid 808 b358
9000 Gent, Belgium

https://www.xeos.care

XEOS wants to tackle the limitations of today's available imaging techniques applied in surgical oncology, by using the transformative power of molecular Imaging intra-operatively.The AURA 10 is the first-ever PET-CT specimen imager for the operating room, offering surgeons and imaging specialists the sensitivity of PET imaging at submillimeter spatial resolution. Thanks to the AURA 10 mobile scanner, a specimen does no longer need to be transported to the radiology or pathology department during surgery. High-quality specimen images can now be obtained in the OR within 10 minutes after excision. Founded in 2019 in Ghent, Belgium, XEOS is an expert in specimen imaging and focuses on improving outcomes in surgical oncology through innovations in intraoperative imaging. The XEOS team is passionate about expanding the use of molecular imaging to optimize clinical workflows and improve patient outcomes. The company has an admirable track record of in-house PET & CT design. XEOS is an ISO 13485 certified company.ss

CORPORATE MEMBERS

We gratefully acknowledge the support of the following companies (in alphabetical order):

- ABX Advanced Biochemical Compounds
- ABX-CRO advanced pharmaceutical services
- Alliance Medical GmbH
- Bayer AG
- Blue Earth Diagnostics
- Bruker BioSpin, Preclinical Imaging Division
- C-Ray Therapeutics (Chengdu)
- CMR (Center of Molecular Research)

- Comecer Group
- Curium
- Cyclomedica Europe
- Debiopharma International
- Eckert & Ziegler
- Eli Lilly and Company
- ELSE Solutions
- GE HealthCare
- Hermes Medical Solutions
- IBA

- ITM Isotope Technologies Munich SE
- Jiangsu Huayi Technology Co.,Ltd.
- Jubilant Radiopharma
- Lantheus
- Lemer Pax
- Medi-Radiopharma Ltd.
- Mediso Medical Imaging Systems
- MIM Software
- Mirion Medical
- MOLTEK SAĞLIK HİZMETLERİ ÜRETİM VE PAZARLAMA A.Ş.
- Narodowe Centrum Badań Jądrowych, Ośrodek Radioizotopów POLATOM
- Novartis Pharma AG

NRG PALLAS

PBL S.P.A.

Perspective Therapeutics

RayzeBio

ROTOP Pharmaka GmbH

RQS Alexander Ruffani

SCK CEN

SHINE Technologies

Siemens Healthineers

SLS Group GmbH

Spectrum Dynamics Medical

Telix Pharmaceuticals

Tema Sinergie

TerThera

Trasis

Triskem International

United Imaging Healthcare

Urenco Stable Isotopes

Von Gahlen

Wallonia Trade & Investment Agency (AWEX)

USEFUL CONTACTS

Scientific Programme

EANM Executive Office
Andrea Csismazia

Schmalzhofgasse 26,
1060 Vienna, Austria
Phone: +43 1 890 44 27
a.csismazia@eanm.org
eanm26.eanm.org

Industry Exhibition

EANM Executive Office
Alexander Berger
Andreas Felser

Schmalzhofgasse 26,
1060 Vienna, Austria
Phone: +43 1 890 44 27
a.berger@eanm.org
eanm26.eanm.org

Registration

EANM Executive Office
Petra Wurzinger

Schmalzhofgasse 26,
1060 Vienna, Austria
Phone: +43 1 890 44 27
registration@eanm.org
eanm26.eanm.org

IMPRINT

Publisher

European Association of Nuclear Medicine
Schmalzhofgasse 26,
1060 Vienna, Austria
Phone: +43 1 890 44 27
E-mail: office@eanm.org
Web: www.eanm.org

Editors

Valentina Garibotto, EANM Scientific Events Council, Chair
Andreas Felser,
Andrea Csismazia,
EANM Executive Office

Layout & Design

Olga Dogadina,
EANM Executive Office

Content

No responsability will be taken by the EANM Executive Office regarding the correctness of the information provided.
Last updated in September 2026.